6PGD,HTM,Up,12757,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
A1CF,HTM,Up,24086,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
A1CF,HTM,Down,24086,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
A1CF,HTM,Down,24086,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
A1CF,HTM,Up,24086,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
A2M,HTM,Down,7,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
A2M,HTM,Up,7,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
A2M,HTM,Up,7,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
A2ML1,HTM,Down,23336,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
AAGAB,HTM,Up,25662,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AAMP,HTM,Down,18,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
AAMP,HTM,Up,18,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
AAMP,HTM,Up,18,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
AAMP,HTM,Up,18,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
AARD,HTM,Down,33842,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
AARD,HTM,Down,33842,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
AARS1,HTM,Up,20,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
AARS1,HTM,Up,20,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
AARS1,HTM,Up,20,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
AARS1,HTM,Up,20,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
AARS1,HTM,Up,20,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
AASS,HTM,Down,17366,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AASS,HTM,Down,17366,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AASS,HTM,Down,17366,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AATK,HTM,Down,21,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ABAT,HTM,Down,23,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ABCA1,HTM,Up,29,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0032,30592142
ABCA1,HTM,Up,29,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ABCA1,HTM,Up,29,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
ABCA1,HTM,Up,29,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0032,30592142
ABCA12,HTM,Up,14637,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,29316740
ABCA12,HTM,Down,14637,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ABCA12,HTM,Down,14637,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ABCA12,HTM,Down,14637,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ABCA12,HTM,Down,14637,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
ABCA12,HTM,Up,14637,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
ABCA12,HTM,Down,14637,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
ABCA4,HTM,Down,34,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ABCA4,HTM,Down,34,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ABCA4,HTM,Down,34,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ABCA5,HTM,Down,35,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ABCA5,HTM,Down,35,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ABCA7,HTM,Up,37,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ABCA9,HTM,Down,39,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ABCA9,HTM,Down,39,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ABCA9-AS1,HTM,Down,39983,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ABCB1,HTM,Up,40,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0604,21618577
ABCB1,HTM,Up,40,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0604,21618577
ABCB1,HTM,Up,40,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0604,22954703
ABCB1,HTM,Up,40,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0604,21618577
ABCB1,HTM,Up,40,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.28,0.0604,21788403
ABCB6,HTM,Up,47,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ABCC1,HTM,Up,51,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0212,25881239
ABCC10,HTM,Down,52,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ABCC2,HTM,Up,53,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0106,25881239
ABCC2,HTM,Up,53,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0106,25881239
ABCC2,HTM,Up,53,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Gene ChIP analysis,0.04,0.0106,18423378
ABCC2,HTM,Up,53,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0106,31709178
ABCC2,HTM,Up,53,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.2,0.0106,34680485
ABCC2,HTM,Up,53,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0106,31709178
ABCC3,HTM,Up,54,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ABCC3,HTM,Up,54,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ABCC3,HTM,Up,54,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
ABCC3,HTM,Down,54,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
ABCC4,HTM,Up,55,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ABCC4,HTM,Up,55,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ABCC4,HTM,Up,55,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
ABCC5,HTM,Up,56,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0053,23820871
ABCC5,HTM,Up,56,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
ABCC6P1,HTM,Down,33352,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ABCC6P1,HTM,Down,33352,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ABCC8,HTM,Up,59,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ABCC9,HTM,Up,60,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ABCC9,HTM,Up,60,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
ABCE1,HTM,Down,69,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ABCF2,HTM,Down,71,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
ABCF2,HTM,Down,71,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
ABCF2,HTM,Down,71,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
ABCF2,HTM,Down,71,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
ABCF2,HTM,Down,71,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
ABCF2,HTM,Down,71,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
ABCF2,HTM,Down,71,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
ABCF2,HTM,Down,71,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
ABCG1,HTM,Up,73,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,35229723
ABCG1,HTM,Down,73,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
ABCG1,HTM,Up,73,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
ABCG2,HTM,Up,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.48,0.1739,25881239
ABCG2,HTM,Up,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.48,0.1739,25881239
ABCG2,HTM,Up,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Gene ChIP analysis,0.48,0.1739,18423378
ABCG2,HTM,Up,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.48,0.1739,18034892
ABCG2,HTM,Up,74,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.12,0.1739,20424609
ABCG2,HTM,Up,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.48,0.1739,31289135
ABHD11,HTM,Down,16407,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ABHD11,HTM,Up,16407,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ABHD14B,HTM,Up,28235,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
ABHD14B,HTM,Up,28235,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
ABHD17B,HTM,Up,24278,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
ABHD17C,HTM,Up,26925,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ABHD17C,HTM,Up,26925,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ABHD2,HTM,Down,18717,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ABHD3,HTM,Down,18718,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ABHD3,HTM,Down,18718,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ABHD4,HTM,Up,20154,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ABHD4,HTM,Down,20154,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ABHD5,HTM,Down,21396,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ABHD6,HTM,Up,21398,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ABHD8,HTM,Up,23759,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ABHD8,HTM,Up,23759,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ABHD8,HTM,Up,23759,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ABI1,HTM,Up,11320,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
ABI1,HTM,Up,11320,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
ABI2,HTM,Down,24011,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ABI3BP,HTM,Up,17265,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0021,26351321
ABI3BP,HTM,Up,17265,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ABLIM1,HTM,Up,78,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ABLIM2,HTM,Down,19195,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ABLIM3,HTM,Down,29132,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ABLIM3,HTM,Down,29132,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ABR,HTM,Down,81,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ABRACL,HTM,Down,21230,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ABRACL,HTM,Down,21230,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ABRAXAS1,HTM,Down,25829,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ABTB2,HTM,Down,23842,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ABTB2,HTM,Down,23842,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
AC013444,HTM,Up,6469,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
AC068538,HTM,Up,28860,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
AC073069,HTM,Up,7506,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
AC073621,HTM,Up,15828,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ACAA1,HTM,Down,82,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ACAA1,HTM,Up,82,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
ACAA2,HTM,Up,83,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ACACA,HTM,Down,84,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ACACB,HTM,Up,85,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ACAD10,HTM,Down,21597,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ACADM,HTM,Up,89,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ACADSB,HTM,Up,91,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ACADSB,HTM,Up,91,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ACADSB,HTM,Down,91,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ACADVL,HTM,Up,92,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ACAN,HTM,NA,319,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
ACAP2,HTM,Up,16469,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ACAT1,HTM,Up,93,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ACAT1,HTM,Down,93,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
ACAT2,HTM,Down,94,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ACAT2,HTM,Down,94,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ACAT2,HTM,Down,94,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ACAT2,HTM,Up,94,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ACAT2,HTM,Up,94,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ACBD3,HTM,Up,15453,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
ACBD3,HTM,Up,15453,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
ACBD5,HTM,Up,23338,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ACCS,HTM,Down,23989,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ACE,HTM,Up,2707,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ACE,HTM,Down,2707,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ACE2,HTM,Down,13557,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ACE2,HTM,Down,13557,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ACER3,HTM,Down,16066,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ACHE,HTM,Up,108,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ACKR3,HTM,Down,23692,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ACLY,HTM,Up,115,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
ACO1,HTM,Down,117,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ACO2,HTM,Down,118,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
ACO2,HTM,Up,118,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
ACO2,HTM,Up,118,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
ACO2,HTM,Up,118,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
ACO2,HTM,Up,118,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
ACO2,HTM,Up,118,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0042,21788403
ACOT11,HTM,Up,18156,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ACOT11,HTM,Up,18156,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ACOT11,HTM,Down,18156,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ACOT11,HTM,Up,18156,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ACOT13,HTM,Up,20999,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ACOT13,HTM,Down,20999,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ACOT2,HTM,Down,18431,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,29316740
ACOT2,HTM,Up,18431,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ACOT7,HTM,Down,24157,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ACOT7,HTM,Up,24157,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ACOT9,HTM,Down,17152,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ACOXL,HTM,Down,25621,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ACP1,HTM,Up,122,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ACP3,HTM,Down,125,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ACP6,HTM,Down,29609,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
ACP6,HTM,Up,29609,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ACP6,HTM,Down,29609,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
ACP7,HTM,Down,33781,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ACSBG1,HTM,Down,29567,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ACSF2,HTM,Down,26101,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ACSF2,HTM,Down,26101,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ACSL1,HTM,Up,3569,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
ACSL1,HTM,Up,3569,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ACSL1,HTM,Up,3569,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
ACSL1,HTM,Up,3569,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
ACSL1,HTM,Up,3569,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
ACSL1,HTM,Up,3569,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0042,21788403
ACSL3,HTM,Up,3570,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
ACSL3,HTM,Down,3570,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
ACSL3,HTM,Up,3570,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
ACSL3,HTM,Up,3570,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
ACSL3,HTM,Up,3570,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
ACSL3,HTM,Down,3570,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
ACSL3,HTM,Up,3570,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
ACSL4,HTM,Down,3571,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ACSL4,HTM,Down,3571,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ACSL4,HTM,Down,3571,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
ACSL4,HTM,Down,3571,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ACSL4,HTM,Down,3571,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ACSL4,HTM,Down,3571,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ACSL5,HTM,Up,16526,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ACSM3,HTM,Up,10522,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ACSM3,HTM,Up,10522,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ACSM3,HTM,Up,10522,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ACSS1,HTM,Down,16091,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ACSS1,HTM,Down,16091,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ACSS1,HTM,Down,16091,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ACSS1,HTM,Up,16091,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ACSS2,HTM,Up,15814,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ACSS2,HTM,Up,15814,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ACSS3,HTM,Up,24723,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ACTA2,HTM,Up,130,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.24,0.0011,31289135
ACTB,HTM,Up,132,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,33670440
ACTB,HTM,Up,132,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,22623141
ACTC1,HTM,Up,143,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,20424609
ACTC1,HTM,Up,143,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,20424609
ACTC1,HTM,Down,143,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ACTG1,HTM,Down,144,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ACTN1,HTM,Down,163,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
ACTN1,HTM,Down,163,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ACTN1,HTM,Down,163,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ACTN1,HTM,Up,163,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
ACTN4,HTM,Up,166,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0074,33670440
ACTN4,HTM,Down,166,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0074,23820871
ACTN4,HTM,Up,166,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
ACTN4,HTM,Up,166,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
ACTN4,HTM,Down,166,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0074,34168259
ACTN4,HTM,Down,166,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0074,34168259
ACTN4,HTM,Down,166,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0074,27746256
ACTN4,HTM,Down,166,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,29340052
ACTN4,HTM,Up,166,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
ACTR1A,HTM,Up,167,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
ACTR1A,HTM,Down,167,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ACTR1A,HTM,Up,167,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ACTR1A,HTM,Up,167,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ACTR3,HTM,Up,170,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,22623141
ACTR3,HTM,Up,170,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
ACTR3,HTM,Up,170,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
ACTR3B,HTM,Up,17256,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ACTR3C,HTM,Up,37282,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ACTR6,HTM,Down,24025,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ACTR6,HTM,Down,24025,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ACVR2B,HTM,Up,174,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
ADA,HTM,Down,186,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ADA,HTM,Down,186,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
ADAM12,HTM,Up,190,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
ADAM12,HTM,Up,190,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ADAM15,HTM,Up,193,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,27965308
ADAM17,HTM,Up,195,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ADAM17,HTM,Up,195,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ADAM17,HTM,Up,195,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ADAM19,HTM,Up,197,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ADAM19,HTM,Down,197,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ADAM22,HTM,Up,201,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ADAM22,HTM,Up,201,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ADAM22,HTM,Up,201,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ADAM22,HTM,Up,201,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ADAM22,HTM,Up,201,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ADAM23,HTM,Up,202,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ADAM23,HTM,Up,202,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ADAM23,HTM,Up,202,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ADAM28,HTM,Down,206,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ADAM28,HTM,Down,206,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ADAM28,HTM,Down,206,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ADAM7,HTM,Up,214,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ADAM7,HTM,Down,214,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ADAMTS1,HTM,Down,217,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ADAMTS1,HTM,Down,217,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ADAMTS1,HTM,Down,217,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ADAMTS1,HTM,Up,217,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ADAMTS1,HTM,Up,217,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ADAMTS1,HTM,Down,217,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
ADAMTS1,HTM,Up,217,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ADAMTS10,HTM,Up,13201,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ADAMTS13,HTM,Down,1366,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ADAMTS14,HTM,Down,14899,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ADAMTS14,HTM,Up,14899,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
ADAMTS17,HTM,Up,17109,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ADAMTS2,HTM,Up,218,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ADAMTS3,HTM,Up,219,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ADAMTS4,HTM,Up,220,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ADAMTS6,HTM,Down,222,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ADAMTS6,HTM,Down,222,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ADAMTS6,HTM,Down,222,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ADAMTS6,HTM,Down,222,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ADAMTS6,HTM,Down,222,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ADAMTS9,HTM,Up,13202,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ADAMTS9,HTM,Up,13202,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
ADAMTSL1,HTM,Up,14632,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ADAMTSL3,HTM,Down,14633,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22740085
ADAMTSL3,HTM,Up,14633,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ADAMTSL3,HTM,Up,14633,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ADAMTSL3,HTM,Up,14633,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ADAMTSL4,HTM,Up,19706,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ADAP1,HTM,Down,16486,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ADAR,HTM,Up,225,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,20424609
ADAR,HTM,Up,225,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,20424609
ADAR,HTM,Up,225,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ADAT2,HTM,Down,21172,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ADCY1,HTM,Down,232,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
ADCY1,HTM,Down,232,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
ADCY1,HTM,Up,232,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
ADCY10,HTM,Down,21285,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ADCY10,HTM,Down,21285,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ADCY3,HTM,Up,234,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ADCY5,HTM,Up,236,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ADCY7,HTM,Down,238,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ADD2,HTM,Up,244,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ADGRA2,HTM,Down,17849,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ADGRA3,HTM,Down,13839,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ADGRB2,HTM,Up,944,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ADGRB3,HTM,Up,945,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
ADGRB3,HTM,Up,945,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
ADGRE2,HTM,Up,3337,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29416721
ADGRE2,HTM,Up,3337,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
ADGRE2,HTM,Up,3337,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
ADGRE2,HTM,Up,3337,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
ADGRF1,HTM,Up,18990,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ADGRF1,HTM,Down,18990,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ADGRF1,HTM,Up,18990,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
ADGRG2,HTM,Up,4516,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ADGRG2,HTM,Up,4516,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ADGRG3,HTM,Down,13728,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ADGRG6,HTM,Up,13841,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ADGRG6,HTM,Down,13841,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
ADGRG6,HTM,Down,13841,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
ADGRG7,HTM,Up,19241,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ADGRL2,HTM,Down,18582,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ADGRL2,HTM,Up,18582,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ADGRL3,HTM,Up,20974,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
ADGRL4,HTM,Down,20822,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ADGRV1,HTM,Up,17416,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
ADGRV1,HTM,Up,17416,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ADH1A,HTM,Up,249,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0011,17932721
ADH1C,HTM,Up,251,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0011,17932721
ADH5,HTM,Down,253,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ADH6,HTM,Up,255,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ADH7,HTM,Up,256,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ADH7,HTM,Up,256,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ADIPOQ,HTM,Up,13633,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ADIRF,HTM,Up,24043,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ADIRF,HTM,Down,24043,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
ADK,HTM,Down,257,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ADK,HTM,Down,257,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ADM,HTM,Down,259,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
ADM,HTM,Up,259,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,24961511
ADM,HTM,Up,259,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,24961511
ADM,HTM,Down,259,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.24,0.0032,24961511
ADM,HTM,Up,259,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.36,0.0032,27746256
ADORA1,HTM,Down,262,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ADORA2B,HTM,Down,264,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ADORA2B,HTM,Down,264,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ADORA2B,HTM,Down,264,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ADPRM,HTM,Down,30925,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ADPRM,HTM,Down,30925,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ADRA1B,HTM,Down,278,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ADRA1B,HTM,Up,278,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
ADRA2A,HTM,Up,281,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0021,17932721
ADRA2A,HTM,Up,281,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ADRB2,HTM,Down,286,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
ADSL,HTM,Up,291,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
ADTRP,HTM,Up,21214,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
AEBP2,HTM,Down,24051,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
AFAP1,HTM,Down,24017,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
AFAP1-AS1,HTM,Up,28141,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AFAP1L2,HTM,Down,25901,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
AFAP1L2,HTM,Down,25901,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
AFDN,HTM,Down,7137,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AFDN,HTM,Down,7137,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AFDN-DT,HTM,Down,21236,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AFDN-DT,HTM,Down,21236,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AFF1,HTM,Up,7135,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
AFF4,HTM,Up,17869,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
AFF4,HTM,Up,17869,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
AFG3L2,HTM,Up,315,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
AFMID,HTM,Down,20910,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AFP,HTM,Down,317,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
AFP,HTM,Down,317,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
AGAP1,HTM,Up,16922,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
AGAP11,HTM,Up,29421,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
AGAP5,HTM,Down,23467,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AGAP5,HTM,Down,23467,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AGAP6,HTM,Down,23466,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AGAP6,HTM,Down,23466,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AGGF1,HTM,Up,24684,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AGGF1,HTM,Up,24684,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AGGF1,HTM,Up,24684,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AGMAT,HTM,Down,18407,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AGO2,HTM,Down,3263,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AGO2,HTM,Down,3263,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AGPAT1,HTM,Up,324,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
AGPAT3,HTM,Down,326,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
AGPAT4,HTM,Up,20885,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0011,34794402
AGPAT4,HTM,Up,20885,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0011,34794402
AGPS,HTM,Down,327,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
AGPS,HTM,Down,327,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
AGPS,HTM,Up,327,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0042,28881576
AGPS,HTM,Up,327,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.16,0.0042,20530554
AGR2,HTM,Up,328,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
AGR2,HTM,Up,328,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
AGR2,HTM,Down,328,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
AGR2,HTM,Down,328,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31729259
AGR2,HTM,Up,328,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
AGR2,HTM,Up,328,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
AGR2,HTM,Up,328,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
AGR2,HTM,Up,328,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
AGR2,HTM,Down,328,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0064,34168259
AGR2,HTM,Down,328,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
AGR2,HTM,Down,328,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31729259
AGR3,HTM,Down,24167,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
AGT,HTM,Up,333,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
AGT,HTM,Up,333,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0032,17932721
AGT,HTM,Up,333,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
AGT,HTM,Up,333,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
AGT,HTM,Up,333,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
AGTR1,HTM,Up,336,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
AHCY,HTM,Up,343,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
AHDC1,HTM,Up,25230,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AHDC1,HTM,Up,25230,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AHDC1,HTM,Up,25230,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AHI1-DT,HTM,Down,32526,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AHNAK,HTM,Down,347,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
AHNAK,HTM,Down,347,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
AHNAK,HTM,Down,347,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
AHNAK,HTM,Down,347,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
AHNAK,HTM,Down,347,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
AHNAK,HTM,Up,347,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
AHNAK2,HTM,Down,20125,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
AHNAK2,HTM,Down,20125,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
AHNAK2,HTM,Down,20125,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
AHRR,HTM,Up,346,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
AHRR,HTM,Up,346,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
AHSA1,HTM,Down,1189,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AHSA1,HTM,Down,1189,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AHSA2P,HTM,Down,20437,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AHSA2P,HTM,Down,20437,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AHSG,HTM,Up,349,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,33670440
AIF1L,HTM,Down,28904,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
AIF1L,HTM,Down,28904,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
AIFM1,HTM,Down,8768,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
AIFM1,HTM,Down,8768,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
AIFM1,HTM,Up,8768,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
AIFM1,HTM,Down,8768,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
AIFM3,HTM,Down,26398,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
AIFM3,HTM,Down,26398,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
AIG1,HTM,Down,21607,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AJM1,HTM,Up,37284,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
AJUBA,HTM,Down,20250,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
AJUBA,HTM,Down,20250,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
AK095600,HTM,Up,20629,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
AK1,HTM,Up,361,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
AK1,HTM,Up,361,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
AK2,HTM,Down,362,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
AK4,HTM,Down,363,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AK4,HTM,Down,363,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AK4,HTM,Down,363,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AK7,HTM,Up,20091,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AK9,HTM,Down,33814,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AK9,HTM,Down,33814,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AKAP1,HTM,Up,367,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AKAP1,HTM,Up,367,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AKAP1,HTM,Up,367,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AKAP12,HTM,Down,370,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
AKAP12,HTM,Down,370,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0053,23820871
AKAP12,HTM,Up,370,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,24961511
AKAP12,HTM,Up,370,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,24961511
AKAP12,HTM,Down,370,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.24,0.0053,24961511
AKAP12,HTM,Up,370,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
AKAP12,HTM,Down,370,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
AKAP12,HTM,Down,370,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
AKAP13,HTM,Up,371,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
AKAP13,HTM,Up,371,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
AKAP8,HTM,Down,378,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AKAP9,HTM,Up,379,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
AKNA,HTM,Down,24108,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
AKR1B1,HTM,Up,381,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
AKR1B1,HTM,Up,381,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
AKR1B1,HTM,Up,381,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
AKR1B1,HTM,Up,381,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
AKR1B10,HTM,Up,382,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,33670440
AKR1B10,HTM,Up,382,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0042,25881239
AKR1B10,HTM,Up,382,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0042,25881239
AKR1B10,HTM,Up,382,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.04,0.0042,27520449
AKR1B10,HTM,Up,382,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
AKR1B10,HTM,Up,382,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
AKR1B10,HTM,Up,382,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
AKR1C1,HTM,Up,384,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.24,0.0085,33670440
AKR1C1,HTM,Up,384,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0085,25881239
AKR1C1,HTM,Up,384,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0085,25881239
AKR1C1,HTM,Up,384,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0085,31709178
AKR1C1,HTM,Up,384,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0085,34168259
AKR1C1,HTM,UP,384,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0085,23108794
AKR1C1,HTM,UP,384,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0085,23108794
AKR1C1,HTM,UP,384,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0085,23108794
AKR1C1,HTM,UP,384,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0085,23108794
AKR1C1,HTM,UP,384,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0085,23108794
AKR1C1,HTM,Down,384,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0085,24098529
AKR1C2,HTM,Up,385,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.24,0.0053,33670440
AKR1C2,HTM,Up,385,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0053,25881239
AKR1C2,HTM,Up,385,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
AKR1C2,HTM,Up,385,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0053,17911267
AKR1C3,HTM,Up,386,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,33670440
AKR1C3,HTM,Up,386,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0042,25881239
AKR1C3,HTM,Up,386,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0042,25881239
AKR1C3,HTM,Up,386,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0042,34794402
AKR1C3,HTM,Up,386,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0042,34794402
AKR1C3,HTM,Up,386,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0042,21788403
AKR1C4,HTM,Up,387,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,33670440
AKR1C4,HTM,Up,387,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
AKR1C4,HTM,Up,387,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
AKR1C4,HTM,Up,387,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
AKR1D1,HTM,Down,388,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AKR1D1,HTM,Down,388,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AKR1E2,HTM,Up,23437,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AKR1E2,HTM,Up,23437,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AKR7A2,HTM,Down,389,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AKT1,HTM,Down,391,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,29352988
AKT1,HTM,Down,391,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0074,29352988
AKT1,HTM,Down,391,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0074,22954703
AKT2,HTM,Down,392,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
AKT2,HTM,Down,392,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
AKT2,HTM,Down,392,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
AKT2,HTM,Down,392,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
AKT3,HTM,Up,393,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
AKT3,HTM,Up,393,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
AKT3,HTM,NA,393,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0021,29352988
AKT3,HTM,Up,393,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
AL117636,HTM,Up,NA,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ALAD,HTM,Down,395,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ALAD,HTM,Down,395,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ALB,HTM,Up,399,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ALB,HTM,Up,399,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ALB,HTM,Up,399,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ALCAM,HTM,Up,400,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.28,0.0583,23903875
ALCAM,HTM,Up,400,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0583,34680485
ALCAM,HTM,Up,400,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0583,17911267
ALDH18A1,HTM,Up,9722,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
ALDH1A1,HTM,Up,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.72,0.6840,33670440
ALDH1A1,HTM,Up,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.72,0.6840,33670440
ALDH1A1,HTM,Up,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.72,0.6840,35229723
ALDH1A1,HTM,Up,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.72,0.6840,25881239
ALDH1A1,HTM,Up,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.72,0.6840,25881239
ALDH1A1,HTM,Up,402,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.28,0.6840,22623141
ALDH1A1,HTM,Up,402,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.4,0.6840,34794402
ALDH1A1,HTM,Up,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.12,0.6840,25881239
ALDH1A1,HTM,Up,402,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.2,0.6840,34794402
ALDH1A1,HTM,Up,402,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.48,0.6840,27520449
ALDH1A1,HTM,Down,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.4,0.6840,34168259
ALDH1A1,HTM,Down,402,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.6840,34168259
ALDH1A1,HTM,Up,402,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.32,0.6840,34414448
ALDH1A1,HTM,Down,402,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.32,0.6840,22954703
ALDH1A1,HTM,Up,402,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.52,0.6840,21788403
ALDH1A2,HTM,Up,15472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.32,0.0117,25881239
ALDH1A3,HTM,Down,409,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.48,0.0201,25881239
ALDH1A3,HTM,Down,409,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.48,0.0201,25881239
ALDH1A3,HTM,Up,409,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.48,0.0201,25881239
ALDH1A3,HTM,Up,409,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.48,0.0201,25881239
ALDH1A3,HTM,Down,409,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0201,25881239
ALDH1A3,HTM,Down,409,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0201,32503348
ALDH1A3,HTM,Down,409,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0201,32503348
ALDH1A3,HTM,Down,409,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.2,0.0201,34680485
ALDH1A3,HTM,Down,409,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0201,34168259
ALDH1A3,HTM,Up,409,Breast Cancer,NA,Primary,NA,Transcriptomics,0.4,0.0201,30559934
ALDH1B1,HTM,Up,407,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.32,0.0032,21788403
ALDH2,HTM,Down,404,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ALDH3A1,HTM,Up,405,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0074,35229723
ALDH3A1,HTM,Down,405,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,34059086
ALDH3A1,HTM,Up,405,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.28,0.0074,32503348
ALDH3A1,HTM,Up,405,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0074,32503348
ALDH3A1,HTM,Up,405,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0074,34680485
ALDH3A1,HTM,Up,405,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0074,34168259
ALDH3A1,HTM,Down,405,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0074,34168259
ALDH3A2,HTM,Up,403,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
ALDH3A2,HTM,Up,403,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
ALDH3A2,HTM,Down,403,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ALDH3B2,HTM,Down,411,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ALDH3B2,HTM,Up,411,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ALDH3B2,HTM,Down,411,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ALDH5A1,HTM,Down,408,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ALDH5A1,HTM,Down,408,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ALDH7A1,HTM,Up,877,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
ALDH7A1,HTM,Up,877,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
ALDH7A1,HTM,Up,877,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ALDOA,HTM,Up,414,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,33670440
ALDOA,HTM,Down,414,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
ALDOA,HTM,Down,414,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
ALDOA,HTM,Down,414,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
ALDOA,HTM,Up,414,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
ALDOC,HTM,Down,418,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ALDOC,HTM,Down,418,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ALDOC,HTM,Up,418,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ALDOC,HTM,Up,418,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ALDOC,HTM,Down,418,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
ALG1,HTM,Up,18294,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ALG10B,HTM,Down,31088,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ALG10B,HTM,Down,31088,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ALG10B,HTM,Up,31088,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
ALG13,HTM,Up,30881,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ALG13,HTM,Up,30881,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ALG13,HTM,Up,30881,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ALG3,HTM,Down,23056,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
ALG3,HTM,Down,23056,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ALG5,HTM,Up,20266,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ALG5,HTM,Up,20266,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ALG5,HTM,Up,20266,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ALG5,HTM,Up,20266,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ALG5,HTM,Up,20266,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ALG8,HTM,Up,23161,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ALKBH2,HTM,Up,32487,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ALKBH2,HTM,Up,32487,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ALKBH2,HTM,Down,32487,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
ALKBH6,HTM,Down,28243,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ALKBH8,HTM,Up,25189,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ALKBH8,HTM,Up,25189,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ALKBH8,HTM,Up,25189,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ALOX12B,HTM,Down,430,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ALOX12B,HTM,Up,430,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ALOX12B,HTM,Down,430,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ALOX12P2,HTM,Down,432,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ALOX15B,HTM,Down,434,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ALOX15B,HTM,Down,434,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ALOX15B,HTM,Down,434,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ALOX15B,HTM,Down,434,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ALOX5,HTM,Down,435,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.24,0.0021,34680485
ALOX5AP,HTM,Up,436,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ALPG,HTM,Up,441,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ALPG,HTM,Up,441,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ALPK2,HTM,Up,20565,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ALPK2,HTM,Up,20565,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ALPK2,HTM,Up,20565,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ALPK2,HTM,Up,20565,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ALPK2,HTM,Down,20565,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
ALPK2,HTM,Up,20565,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ALPL,HTM,Down,438,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ALPL,HTM,Down,438,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ALPP,HTM,Down,439,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ALPP,HTM,Up,439,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
ALS2CL,HTM,Down,20605,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ALX1,HTM,Up,1494,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ALX1,HTM,Up,1494,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ALYREF,HTM,Up,19071,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
AMD1,HTM,Up,457,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AMD1,HTM,Up,457,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AMD1,HTM,Up,457,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AMDHD1,HTM,Up,28577,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
AMDHD1,HTM,Down,28577,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
AMDHD1,HTM,Up,28577,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
AMDHD1,HTM,Down,28577,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
AMDHD1,HTM,Up,28577,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
AMDHD1,HTM,Up,28577,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
AMELX,HTM,Up,461,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
AMH,HTM,Up,464,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
AMH,HTM,Up,464,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
AMIGO1,HTM,Down,20824,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AMIGO2,HTM,Down,24073,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
AMIGO3,HTM,Up,24075,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
AMMECR1,HTM,Up,467,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
AMN1,HTM,Up,27281,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMOT,HTM,Down,17810,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
AMOT,HTM,Up,17810,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
AMOTL1,HTM,Down,17811,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMOTL1,HTM,Down,17811,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMOTL1,HTM,Down,17811,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMPD3,HTM,Down,470,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AMPD3,HTM,Down,470,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
AMY1A,HTM,Up,474,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMY1A,HTM,Up,474,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMY1B,HTM,Up,475,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMY1B,HTM,Up,475,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMY1C,HTM,Up,476,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMY1C,HTM,Up,476,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMY2A,HTM,Up,477,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMY2A,HTM,Up,477,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMY2B,HTM,Up,478,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMY2B,HTM,Up,478,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMY2B,HTM,Up,478,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AMZ1,HTM,Down,22231,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
AMZ1,HTM,Down,22231,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
AMZ2P1,HTM,Up,26491,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ANG,HTM,Up,483,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ANG,HTM,Up,483,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ANG,HTM,Down,483,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ANGPT1,HTM,Up,484,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
ANGPT1,HTM,Down,484,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
ANGPTL4,HTM,Down,16039,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ANGPTL4,HTM,Down,16039,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ANGPTL4,HTM,Up,16039,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ANK1,HTM,Up,492,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
ANK1,HTM,Up,492,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
ANK1,HTM,Up,492,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0032,28881576
ANK2,HTM,Up,493,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ANK3,HTM,Down,494,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ANK3,HTM,Up,494,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
ANKDD1A,HTM,Up,28002,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ANKFY1,HTM,Up,20763,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ANKFY1,HTM,Up,20763,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ANKFY1,HTM,Up,20763,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ANKFY1,HTM,Up,20763,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ANKH,HTM,Up,15492,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ANKH,HTM,Up,15492,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
ANKRD1,HTM,Up,15819,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ANKRD1,HTM,Up,15819,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ANKRD10,HTM,Up,20265,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ANKRD10,HTM,Up,20265,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ANKRD10,HTM,Up,20265,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ANKRD13A,HTM,Down,21268,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ANKRD17,HTM,Up,23575,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ANKRD18B,HTM,Down,23644,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ANKRD20A11P,HTM,Down,42024,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ANKRD20A12P,HTM,Down,43603,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ANKRD20A12P,HTM,Down,43603,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ANKRD20A2P,HTM,Down,31979,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ANKRD20A8P,HTM,Up,23666,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ANKRD20A8P,HTM,Up,23666,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ANKRD22,HTM,Down,28321,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ANKRD22,HTM,Up,28321,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ANKRD22,HTM,Down,28321,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ANKRD27,HTM,Down,25310,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ANKRD28,HTM,Down,29024,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ANKRD31,HTM,Up,26853,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ANKRD34A,HTM,Up,27639,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ANKRD34B,HTM,Up,33736,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ANKRD35,HTM,Up,26323,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ANKRD37,HTM,Down,29593,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
ANKRD49,HTM,Down,25970,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ANKRD49,HTM,Down,25970,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ANKRD50,HTM,Down,29223,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANKRD50,HTM,Down,29223,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANKRD50,HTM,Up,29223,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ANKRD50,HTM,Up,29223,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ANKRD50,HTM,Up,29223,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
ANKRD50,HTM,Up,29223,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ANKRD52,HTM,Down,26614,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ANKRD52,HTM,Down,26614,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ANKRD53,HTM,Down,25691,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ANKS1B,HTM,Up,24600,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ANKS4B,HTM,Up,26795,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,35229723
ANKS6,HTM,Down,26724,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
ANKZF1,HTM,Down,25527,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ANKZF1,HTM,Down,25527,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ANKZF1,HTM,Down,25527,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ANO1,HTM,Down,21625,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANO1,HTM,Down,21625,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANO1,HTM,Down,21625,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANO1,HTM,Down,21625,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ANO1,HTM,Down,21625,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ANO1,HTM,Down,21625,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ANO3,HTM,Up,14004,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
ANO3,HTM,Up,14004,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
ANO4,HTM,Down,23837,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ANO4,HTM,Down,23837,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ANO4,HTM,Down,23837,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ANO5,HTM,Down,27337,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ANO5,HTM,Up,27337,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ANO5,HTM,Up,27337,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ANO7,HTM,Up,31677,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ANO9,HTM,Down,20679,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ANOS1,HTM,Up,6211,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ANP32A,HTM,Up,13233,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ANP32A,HTM,Up,13233,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ANP32A,HTM,Up,13233,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ANP32C,HTM,Down,16675,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ANP32E,HTM,Down,16673,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
ANP32E,HTM,Down,16673,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
ANPEP,HTM,Down,500,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0117,25881239
ANPEP,HTM,Down,500,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0117,25881239
ANPEP,HTM,Down,500,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0117,27746256
ANPEP,HTM,Up,500,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0117,34168259
ANTXR1,HTM,Up,21014,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ANTXR1,HTM,Up,21014,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ANTXR1,HTM,Down,21014,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0042,23820871
ANTXR1,HTM,Down,21014,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
ANTXR1,HTM,Down,21014,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
ANTXR1,HTM,Up,21014,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
ANTXR2,HTM,Down,21732,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
ANTXR2,HTM,Down,21732,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ANTXR2,HTM,Down,21732,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ANTXR2,HTM,Down,21732,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ANTXR2,HTM,Up,21732,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
ANXA1,HTM,Up,533,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,33670440
ANXA1,HTM,Up,533,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,33670440
ANXA1,HTM,Up,533,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,22623141
ANXA1,HTM,Down,533,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0053,34168259
ANXA1,HTM,Up,533,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
ANXA11,HTM,Up,535,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
ANXA11,HTM,Down,535,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ANXA13,HTM,Up,536,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ANXA13,HTM,Up,536,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ANXA13,HTM,Down,536,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ANXA2,HTM,Up,537,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.36,0.0032,22623141
ANXA2,HTM,Up,537,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.36,0.0032,22623141
ANXA2,HTM,Down,537,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
ANXA2,HTM,Down,537,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
ANXA2,HTM,Up,537,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
ANXA3,HTM,Down,541,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0085,25881239
ANXA3,HTM,Down,541,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0085,25881239
ANXA3,HTM,Down,541,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0085,24961511
ANXA3,HTM,Down,541,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0085,24961511
ANXA3,HTM,Down,541,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0085,31709178
ANXA3,HTM,Down,541,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0085,22623141
ANXA3,HTM,Down,541,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0085,26259570
ANXA3,HTM,Down,541,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0085,26259570
ANXA3,HTM,Down,541,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0085,34680485
ANXA3,HTM,Up,541,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0085,34168259
ANXA3,HTM,Down,541,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0085,34414448
ANXA4,HTM,Up,542,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANXA4,HTM,Up,542,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANXA4,HTM,Down,542,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ANXA4,HTM,Down,542,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ANXA4,HTM,Down,542,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
ANXA5,HTM,Up,543,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
ANXA6,HTM,Down,544,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,22623141
ANXA6,HTM,Down,544,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
ANXA6,HTM,Up,544,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
ANXA6,HTM,Up,544,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
ANXA6,HTM,Down,544,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
ANXA6,HTM,Down,544,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
ANXA6,HTM,Up,544,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0053,34414448
ANXA6,HTM,Up,544,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
ANXA7,HTM,Up,545,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ANXA8,HTM,Down,546,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANXA8,HTM,Down,546,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANXA8,HTM,Down,546,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ANXA8,HTM,Down,546,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
ANXA8L1,HTM,Down,23334,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANXA8L1,HTM,Down,23334,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANXA8L1,HTM,Down,23334,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANXA8L1,HTM,Down,23334,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANXA8L1,HTM,Down,23334,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANXA8L1,HTM,Down,23334,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANXA8L1,HTM,Down,23334,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ANXA8L1,HTM,Down,23334,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
ANXA9,HTM,Up,547,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ANXA9,HTM,Down,547,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ANXA9,HTM,Down,547,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
AOC1,HTM,Down,80,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
AOX1,HTM,Down,553,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
AOX1,HTM,Down,553,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
AOX1,HTM,Up,553,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
AOX1,HTM,Down,553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
AOX1,HTM,Down,553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
AP1M2,HTM,Down,558,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
AP1S1,HTM,Up,559,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
AP1S3,HTM,Down,18971,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
AP2B1,HTM,Up,563,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AP2B1,HTM,Up,563,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AP2B1,HTM,Up,563,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
AP2M1,HTM,Down,564,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
AP2M1,HTM,Up,564,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
AP2M1,HTM,Up,564,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
AP3B1,HTM,Up,566,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
AP3B2,HTM,Up,567,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
AP3B2,HTM,Down,567,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
AP3D1,HTM,Down,568,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
AP3S2,HTM,Up,571,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
AP3S2,HTM,Up,571,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
AP3S2,HTM,Up,571,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
AP4B1,HTM,Down,572,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AP5B1,HTM,Down,25104,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AP5S1,HTM,Down,15875,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
APBA1,HTM,Up,578,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
APBA2,HTM,Up,579,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
APBB2,HTM,Down,582,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
APBB2,HTM,Down,582,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
APBB2,HTM,Down,582,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
APC,HTM,Up,583,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,20424609
APC,HTM,Up,583,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,20424609
APC,HTM,Up,583,Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by Transcriptomics and qPCR,0.4,0.0021,26621583
APC2,HTM,Up,24036,Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by Transcriptomics and qPCR,0.4,0.0011,26621583
APCDD1L,HTM,Up,26892,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
APCDD1L-DT,HTM,Up,27152,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
APEH,HTM,Up,586,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
APEH,HTM,Up,586,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
APEH,HTM,Up,586,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
APEX1,HTM,Down,587,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
APEX1,HTM,Down,587,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
APEX1,HTM,Down,587,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
APH1B,HTM,Down,24080,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
API5,HTM,Down,594,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
APLP1,HTM,Up,597,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
APLP2,HTM,Down,598,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
APMAP,HTM,Up,13238,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
APMAP,HTM,Up,13238,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
APMAP,HTM,Down,13238,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
APMAP,HTM,Up,13238,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
APOA1,HTM,Up,600,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
APOB,HTM,Up,603,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
APOBEC3A,HTM,Up,17343,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
APOBEC3B,HTM,Up,17352,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
APOBEC3B,HTM,Down,17352,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
APOBEC3B,HTM,Up,17352,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
APOBEC3B,HTM,Up,17352,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
APOBEC3B,HTM,Up,17352,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
APOBEC3C,HTM,Down,17353,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
APOBEC3F,HTM,Down,17356,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
APOBEC3G,HTM,Down,17357,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
APOC1,HTM,Up,607,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
APOC1,HTM,Up,607,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
APOC1,HTM,Up,607,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
APOC1,HTM,Down,607,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
APOC1,HTM,Down,607,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
APOD,HTM,Up,612,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,35229723
APOD,HTM,Down,612,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
APOD,HTM,Down,612,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
APOD,HTM,Up,612,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
APOE,HTM,Up,613,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
APOH,HTM,Up,616,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
APOH,HTM,Up,616,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
APOL6,HTM,Up,14870,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
APOOL,HTM,Up,24009,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
APP,HTM,Down,620,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
APP,HTM,Down,620,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
APP,HTM,Down,620,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
APP,HTM,Down,620,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
APP,HTM,Up,620,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
APP,HTM,Up,620,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
APP,HTM,Down,620,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
APRT,HTM,Up,626,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
APRT,HTM,Up,626,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
APRT,HTM,Up,626,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
APRT,HTM,Down,626,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
APTR,HTM,Down,44173,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AQP2,HTM,Up,634,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
AQP3,HTM,Down,636,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
AQP3,HTM,Up,636,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
AQP3,HTM,Down,636,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
AQP3,HTM,Up,636,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
AQP3,HTM,Up,636,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
AQP6,HTM,Up,639,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
AR,HTM,Up,644,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
AR,HTM,Up,644,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
AR,HTM,Up,644,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
AR,HTM,Up,644,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
AR,HTM,Up,644,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ARAF,HTM,NA,646,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0011,29352988
ARAP2,HTM,Down,16924,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARAP2,HTM,Down,16924,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ARC,HTM,Up,648,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ARC,HTM,Up,648,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ARC,HTM,Up,648,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ARC,HTM,Up,648,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ARCN1,HTM,Down,649,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
AREG,HTM,Down,651,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,34059086
AREG,HTM,Down,651,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
AREG,HTM,Down,651,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
AREG,HTM,Down,651,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
AREG,HTM,Down,651,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
AREG,HTM,Down,651,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0064,24961511
AREG,HTM,Up,651,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0064,24961511
AREG,HTM,Up,651,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0064,24961511
AREG,HTM,Down,651,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
AREG,HTM,Down,651,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
AREG,HTM,Up,651,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
ARF3,HTM,Up,654,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ARF3,HTM,Up,654,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ARF3,HTM,Down,654,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ARF4,HTM,Up,655,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ARF4,HTM,Up,655,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ARF4,HTM,Down,655,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ARF4,HTM,Up,655,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ARFGEF1,HTM,Up,15772,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ARFGEF1,HTM,Up,15772,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ARFGEF1,HTM,Up,15772,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ARFGEF3,HTM,Up,21213,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARFGEF3,HTM,Up,21213,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ARG1,HTM,Down,663,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ARG1,HTM,Down,663,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ARG2,HTM,Up,664,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,35229723
ARG2,HTM,Down,664,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ARG2,HTM,Down,664,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
ARG2,HTM,Down,664,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
ARG2,HTM,Up,664,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
ARGLU1,HTM,Up,25482,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARGLU1,HTM,Down,25482,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ARGLU1,HTM,Down,25482,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ARHGAP1,HTM,Down,673,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGAP1,HTM,Down,673,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ARHGAP10,HTM,Down,26099,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARHGAP11A,HTM,Down,15783,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ARHGAP11A,HTM,Down,15783,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
ARHGAP12,HTM,Up,16348,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARHGAP18,HTM,Up,21035,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ARHGAP21,HTM,Up,23725,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ARHGAP23,HTM,Down,29293,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARHGAP23,HTM,Down,29293,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARHGAP26,HTM,Up,17073,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGAP26,HTM,Down,17073,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ARHGAP27,HTM,Down,31813,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ARHGAP29,HTM,Down,30207,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGAP29,HTM,Down,30207,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGAP29,HTM,Down,30207,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ARHGAP29,HTM,Down,30207,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ARHGAP30,HTM,Down,27414,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ARHGAP31,HTM,Down,29216,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ARHGAP31,HTM,Up,29216,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ARHGAP32,HTM,Up,17399,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ARHGAP32,HTM,Up,17399,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ARHGAP32,HTM,Up,17399,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ARHGAP32,HTM,Down,17399,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
ARHGAP32,HTM,Up,17399,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ARHGAP36,HTM,Down,26388,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ARHGAP40,HTM,Down,16226,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ARHGAP42,HTM,Up,26545,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGAP42,HTM,Up,26545,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGAP42,HTM,Up,26545,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGAP42,HTM,Up,26545,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGAP42,HTM,Down,26545,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ARHGAP5-AS1,HTM,Up,20279,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ARHGDIA,HTM,UP,678,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
ARHGDIA,HTM,UP,678,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
ARHGDIA,HTM,UP,678,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
ARHGDIA,HTM,UP,678,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
ARHGDIA,HTM,UP,678,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
ARHGDIB,HTM,Down,679,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ARHGDIB,HTM,Down,679,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ARHGDIB,HTM,Down,679,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ARHGDIB,HTM,Down,679,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
ARHGDIB,HTM,Up,679,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
ARHGDIB,HTM,Down,679,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
ARHGDIG,HTM,Down,680,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ARHGEF10,HTM,Up,14103,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ARHGEF10,HTM,Up,14103,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ARHGEF10,HTM,Up,14103,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ARHGEF10,HTM,Up,14103,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ARHGEF11,HTM,Up,14580,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
ARHGEF12,HTM,Up,14193,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ARHGEF12,HTM,Up,14193,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ARHGEF12,HTM,Up,14193,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ARHGEF16,HTM,Down,15515,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ARHGEF16,HTM,Up,15515,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ARHGEF16,HTM,Up,15515,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ARHGEF17,HTM,Down,21726,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ARHGEF17,HTM,Up,21726,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
ARHGEF18,HTM,Down,17090,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ARHGEF19,HTM,Up,26604,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ARHGEF19,HTM,Up,26604,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ARHGEF19,HTM,Down,26604,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ARHGEF19,HTM,Up,26604,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ARHGEF25,HTM,Down,30275,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ARHGEF25,HTM,Down,30275,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ARHGEF3,HTM,Down,683,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ARHGEF3,HTM,Down,683,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
ARHGEF34P,HTM,Down,38086,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ARHGEF35,HTM,Down,33846,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGEF35,HTM,Down,33846,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGEF35,HTM,Down,33846,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ARHGEF37,HTM,Down,34430,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ARHGEF37,HTM,Up,34430,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ARHGEF38,HTM,Up,25968,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARHGEF39,HTM,Down,25909,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ARHGEF5,HTM,Down,13209,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGEF5,HTM,Down,13209,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGEF5,HTM,Down,13209,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGEF5,HTM,Down,13209,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARHGEF5,HTM,Down,13209,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ARHGEF9,HTM,Up,14561,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARID1A,HTM,Down,11110,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ARID1A,HTM,Up,11110,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ARID1B,HTM,Up,18040,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ARID1B,HTM,Up,18040,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ARID1B,HTM,Up,18040,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ARID1B,HTM,Up,18040,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ARID1B,HTM,Up,18040,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ARID2,HTM,Up,18037,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
ARID2,HTM,Up,18037,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
ARID3B,HTM,Down,14350,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARID3B,HTM,Down,14350,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARID4A,HTM,Up,9885,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARID4A,HTM,Up,9885,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARID5A,HTM,Down,17361,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
ARID5A,HTM,Up,17361,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
ARID5A,HTM,Down,17361,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
ARID5A,HTM,Up,17361,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0042,28881576
ARID5B,HTM,Down,17362,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARID5B,HTM,Up,17362,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ARL10,HTM,Up,22042,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ARL13B,HTM,Down,25419,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ARL14,HTM,Down,22974,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ARL17A,HTM,Up,24096,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARL17A,HTM,Up,24096,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARL17A,HTM,Up,24096,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARL17B,HTM,Up,32387,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARL17B,HTM,Up,32387,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARL17B,HTM,Up,32387,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ARL17B,HTM,Up,32387,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ARL3,HTM,Up,694,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
ARL4A,HTM,Up,695,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ARL4C,HTM,Down,698,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ARL4C,HTM,Down,698,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ARL4C,HTM,Down,698,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
ARL4C,HTM,Down,698,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
ARL4C,HTM,Down,698,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
ARL4D,HTM,Down,656,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARL6,HTM,Up,13210,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ARL6IP5,HTM,Up,16937,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ARL9,HTM,Up,23592,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ARL9,HTM,Up,23592,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ARL9,HTM,Up,23592,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ARMC10,HTM,Up,21706,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
ARMCX3,HTM,Down,24065,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ARMCX3,HTM,Down,24065,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ARMCX3,HTM,Up,24065,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ARMCX3,HTM,Up,24065,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ARMH1,HTM,Down,34345,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ARMT1,HTM,Up,17872,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ARMT1,HTM,Up,17872,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ARMT1,HTM,Down,17872,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ARMT1,HTM,Up,17872,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ARNT2,HTM,Up,16876,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ARNTL,HTM,Up,701,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
ARNTL2,HTM,Down,18984,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARNTL2,HTM,Down,18984,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARNTL2,HTM,Down,18984,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARPC2,HTM,Down,705,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ARPC3,HTM,Up,706,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
ARPC3,HTM,Up,706,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.28,0.0021,32503348
ARPC3,HTM,Up,706,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
ARPC5L,HTM,Down,23366,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ARPP19,HTM,Down,16967,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARPP19,HTM,Down,16967,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARR3,HTM,Up,710,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ARRB1,HTM,Up,711,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARRB2,HTM,Up,712,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARRB2,HTM,Up,712,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARRDC1,HTM,Down,28633,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ARRDC3,HTM,Up,29263,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ARRDC3,HTM,Up,29263,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ARRDC3,HTM,Down,29263,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
ARRDC3,HTM,Up,29263,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ARRDC4,HTM,Up,28087,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ARSA,HTM,Up,713,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ARSB,HTM,Up,714,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ARSD,HTM,Down,717,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ARSD,HTM,Up,717,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ARSD,HTM,Up,717,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ARSI,HTM,Down,32521,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ARSJ,HTM,Down,26286,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARSJ,HTM,Down,26286,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARSJ,HTM,Down,26286,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARSK,HTM,Down,25239,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARSL,HTM,Up,719,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ARSL,HTM,Up,719,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ART5,HTM,Down,24049,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ARVCF,HTM,Down,728,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
AS3MT,HTM,Up,17452,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ASAH1,HTM,Down,735,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ASAP2,HTM,Down,2721,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ASAP2,HTM,Down,2721,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ASAP3,HTM,Down,14987,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ASB1,HTM,Down,16011,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ASB11,HTM,Down,17186,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
ASB11,HTM,Up,17186,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ASB3,HTM,Down,16013,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ASB4,HTM,Down,16009,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ASB9,HTM,Up,17184,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ASCC3,HTM,Down,18697,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
ASCC3,HTM,Up,18697,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
ASCC3,HTM,Up,18697,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.16,0.0032,20530554
ASCL2,HTM,Up,739,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.2,0.0053,27520449
ASCL2,HTM,Down,739,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0053,22954703
ASGR1,HTM,Down,742,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ASGR1,HTM,Down,742,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ASGR1,HTM,Up,742,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ASGR1,HTM,Up,742,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ASGR1,HTM,Up,742,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ASIC1,HTM,Up,100,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ASIC1,HTM,Up,100,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
ASIC4,HTM,Down,21263,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ASMTL,HTM,Down,751,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ASNS,HTM,Up,753,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22740085
ASNS,HTM,Up,753,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
ASNS,HTM,Down,753,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
ASNS,HTM,Down,753,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
ASNSD1,HTM,Down,24910,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ASPH,HTM,Up,757,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ASPHD1,HTM,Up,27380,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ASPHD1,HTM,Up,27380,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ASPHD1,HTM,Up,27380,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ASRGL1,HTM,Up,16448,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
ASRGL1,HTM,Up,16448,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,20424609
ASRGL1,HTM,Up,16448,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,20424609
ASRGL1,HTM,NA,16448,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0053,20630067
ASRGL1,HTM,Up,16448,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
ASRGL1,HTM,Up,16448,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
ASRGL1,HTM,Down,16448,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
ASRGL1,HTM,Up,16448,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
ASS1,HTM,Down,758,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
ASS1,HTM,Up,758,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
ASS1,HTM,Up,758,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
ASS1,HTM,Up,758,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
ASS1,HTM,Down,758,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
ASS1,HTM,Down,758,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
ASTE1,HTM,Down,25021,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ASTE1,HTM,Down,25021,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ASTE1,HTM,Down,25021,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ASTE1,HTM,Down,25021,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ASTE1,HTM,Down,25021,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ASTN2,HTM,Up,17021,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ATAD2,HTM,Up,30123,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
ATAD2B,HTM,Up,29230,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATAD3A,HTM,Up,25567,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ATAD3C,HTM,Down,32151,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ATAT1,HTM,Up,21186,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ATAT1,HTM,Up,21186,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ATAT1,HTM,Up,21186,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ATCAY,HTM,Up,779,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
ATF1,HTM,Down,783,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ATF3,HTM,Down,785,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ATF3,HTM,Down,785,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ATF7IP,HTM,Down,20092,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ATF7IP2,HTM,Up,20397,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATG10,HTM,Down,20315,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
ATG10,HTM,Down,20315,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0032,28881576
ATG10,HTM,Up,20315,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.16,0.0032,20530554
ATG16L1,HTM,Down,21498,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ATG16L2,HTM,Up,25464,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ATIC,HTM,Down,794,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ATIC,HTM,Down,794,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ATL3,HTM,Up,24526,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ATM,HTM,Up,795,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ATM,HTM,Up,795,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ATM,HTM,Up,795,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ATOH8,HTM,Down,24126,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ATP10B,HTM,Down,13543,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ATP10D,HTM,Down,13549,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP10D,HTM,Down,13549,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP10D,HTM,Down,13549,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP11B,HTM,Down,13553,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP13A1,HTM,Up,24215,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
ATP13A1,HTM,Up,24215,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.16,0.0032,20530554
ATP13A1,HTM,Down,24215,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
ATP13A3,HTM,Down,24113,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP13A4,HTM,Up,25422,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ATP1A1,HTM,Up,799,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
ATP1A1,HTM,Up,799,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ATP1A1,HTM,Up,799,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ATP1A1,HTM,Up,799,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
ATP1A2,HTM,Up,800,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
ATP1A3,HTM,Up,801,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
ATP1A4,HTM,Down,14073,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ATP1B1,HTM,Up,804,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
ATP1B1,HTM,Up,804,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
ATP1B1,HTM,Up,804,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ATP1B3,HTM,Down,806,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ATP1B3,HTM,Up,806,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
ATP1B3,HTM,Up,806,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
ATP2A1,HTM,Down,811,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ATP2A2,HTM,Down,812,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
ATP2A3,HTM,Up,813,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ATP2B1,HTM,Up,814,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ATP2B1,HTM,Up,814,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ATP2B1,HTM,Up,814,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
ATP2B1-AS1,HTM,Up,27883,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ATP2B2,HTM,Down,815,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ATP2B2,HTM,Down,815,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ATP2B3,HTM,Up,816,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ATP2B4,HTM,Down,817,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP2B4,HTM,Down,817,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP2C2,HTM,Down,29103,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ATP2C2,HTM,Up,29103,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ATP4A,HTM,Up,819,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
ATP5F1A,HTM,Up,823,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
ATP5F1A,HTM,Down,823,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ATP5F1A,HTM,Down,823,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ATP5F1A,HTM,Up,823,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
ATP5F1A,HTM,Down,823,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
ATP5F1B,HTM,Up,830,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ATP5F1B,HTM,Up,830,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ATP5F1B,HTM,Down,830,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ATP5F1B,HTM,Down,830,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
ATP5F1C,HTM,Up,833,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ATP5F1C,HTM,Up,833,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ATP5F1C,HTM,Down,833,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ATP5F1D,HTM,Up,837,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ATP5G1,HTM,Up,841,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP5MC1,HTM,Up,841,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ATP5ME,HTM,Down,846,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ATP5MF,HTM,Down,848,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
ATP5MF,HTM,Down,848,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
ATP5MF,HTM,Down,848,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
ATP5MF,HTM,Up,848,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ATP5MF,HTM,Down,848,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
ATP5MF,HTM,Down,848,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
ATP5PB,HTM,Up,840,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ATP5PB,HTM,Down,840,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ATP5PD,HTM,Up,845,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ATP5PO,HTM,Up,850,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ATP5PO,HTM,Up,850,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ATP5PO,HTM,Down,850,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ATP6AP1,HTM,Up,868,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ATP6V0A4,HTM,Up,866,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ATP6V0D1,HTM,Down,13724,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP6V0D1,HTM,Down,13724,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP6V0E2,HTM,Down,21723,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ATP6V1A,HTM,Down,851,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
ATP6V1B1,HTM,Down,853,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ATP6V1B1,HTM,Down,853,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ATP6V1B1,HTM,Down,853,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ATP6V1B1,HTM,Up,853,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
ATP6V1B1,HTM,Down,853,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ATP6V1C2,HTM,Down,18264,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ATP6V1C2,HTM,Up,18264,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0021,17932721
ATP6V1D,HTM,Down,13527,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP6V1G2,HTM,Down,862,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ATP7A,HTM,Up,869,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP7A,HTM,Up,869,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP7A,HTM,Up,869,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP7B,HTM,Up,870,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP8A1,HTM,Up,13531,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ATP8A2,HTM,Down,13533,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ATP8B1,HTM,Down,3706,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ATP8B2,HTM,Up,13534,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ATP8B4,HTM,Down,13536,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ATP9A,HTM,Up,13540,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ATP9A,HTM,Up,13540,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
ATP9A,HTM,Up,13540,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ATP9A,HTM,Up,13540,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
ATP9A,HTM,Down,13540,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
ATP9A,HTM,Up,13540,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
ATP9B,HTM,Up,13541,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ATP9B,HTM,Up,13541,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ATP9B,HTM,Up,13541,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ATR,HTM,Up,882,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
ATRNL1,HTM,Down,29063,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ATRX,HTM,Up,886,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ATRX,HTM,Up,886,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ATRX,HTM,Up,886,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ATRX,HTM,Up,886,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
ATXN1,HTM,Up,10548,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,27965308
ATXN1,HTM,Down,10548,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0064,22954703
ATXN10,HTM,Down,10549,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ATXN8,HTM,Down,32925,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AURKA,HTM,Down,11393,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
AURKA,HTM,NA,11393,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,29221160
AURKA,HTM,Down,11393,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
AURKB,HTM,Down,11390,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
AURKB8,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
AURKB8,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
AURKB8,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
AVEN,HTM,Down,13509,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AVP,HTM,Up,894,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,35229723
AVPI1,HTM,Up,30898,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
AWAT2,HTM,Up,23251,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
AXIN1,HTM,Down,903,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
AXIN2,HTM,Up,904,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
AXIN2,HTM,Up,904,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
AXIN2,HTM,Up,904,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0064,28927099
AXIN2,HTM,Up,904,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
AXIN2,HTM,Up,904,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0064,24098529
AXL,HTM,Up,905,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22740085
AXL,HTM,Down,905,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
AXL,HTM,Up,905,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
AZGP1,HTM,Up,910,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
AZIN1,HTM,Down,16432,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
B2M,HTM,Up,914,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
B2M,HTM,Up,914,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
B2M,HTM,Down,914,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
B2M,HTM,Up,914,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
B3GALNT1,HTM,Down,918,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
B3GALNT1,HTM,Down,918,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
B3GALT4,HTM,Up,919,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
B3GNT3,HTM,Down,13528,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
B3GNT3,HTM,Down,13528,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
B3GNT3,HTM,Down,13528,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
B3GNT5,HTM,Down,15684,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
B3GNT5,HTM,Down,15684,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
B3GNT5,HTM,Down,15684,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
B3GNT5,HTM,Down,15684,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
B3GNT5,HTM,Down,15684,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
B3GNT5,HTM,Down,15684,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
B3GNT7,HTM,Down,18811,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
B3GNT7,HTM,Up,18811,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
B4GALNT1,HTM,Up,4117,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
B4GALNT2,HTM,Down,24136,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
B4GALNT3,HTM,Down,24137,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
B4GALT4,HTM,Up,927,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
B4GALT4,HTM,Up,927,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
B4GALT5,HTM,Up,928,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
B4GALT5,HTM,Up,928,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
B4GALT5,HTM,Up,928,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
B4GALT6,HTM,Down,929,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
B4GALT6,HTM,Down,929,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
B4GAT1,HTM,Up,15685,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
BAALC,HTM,Up,14333,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
BAAT,HTM,Up,932,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
BAAT,HTM,Up,932,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
BAAT,HTM,Up,932,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
BAAT,HTM,Up,932,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
BAAT,HTM,Up,932,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
BABAM2,HTM,Up,1106,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BACE2,HTM,Down,934,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BACE2,HTM,Down,934,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
BACH2,HTM,Down,14078,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
BAG2,HTM,Up,938,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BAG3,HTM,Down,939,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BAG4,HTM,Up,940,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
BAG6,HTM,Down,13919,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
BAHCC1,HTM,Down,29279,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
BAHD1,HTM,Down,29153,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
BAIAP2,HTM,Up,947,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
BAIAP2,HTM,Up,947,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
BAIAP2L1,HTM,Down,21649,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
BAIAP2L2,HTM,Up,26203,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
BAIAP2L2,HTM,Up,26203,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
BAMBI,HTM,Up,30251,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
BAMBI,HTM,Up,30251,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
BAMBI,HTM,Up,30251,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0032,17932721
BANF1,HTM,Down,17397,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
BANF1,HTM,Down,17397,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
BARX1,HTM,Down,955,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
BARX2,HTM,Down,956,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
BARX2,HTM,Down,956,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
BARX2,HTM,Up,956,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
BASP1,HTM,Up,957,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
BASP1,HTM,Down,957,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
BASP1,HTM,Down,957,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
BASP1,HTM,Up,957,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
BAX,HTM,Down,959,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
BAX,HTM,Down,959,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
BAX,HTM,Down,959,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0053,19451087
BAX,HTM,Up,959,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
BAX,HTM,Up,959,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
BAX,HTM,Up,959,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,29340052
BAX,HTM,Up,959,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
BAX,HTM,Up,959,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0053,21788403
BAZ2A,HTM,Down,962,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
BBIP1,HTM,Down,28093,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
BBIP1,HTM,Down,28093,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
BBS4,HTM,Up,969,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BBS9,HTM,NA,30000,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29221160
BBS9,HTM,Up,30000,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
BCAM,HTM,Up,6722,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
BCAM,HTM,Up,6722,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
BCAM,HTM,Up,6722,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
BCAP29,HTM,Up,24131,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
BCAP29,HTM,Up,24131,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
BCAP29,HTM,Up,24131,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
BCAP31,HTM,Down,8768,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
BCAP31,HTM,Up,16695,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
BCAP31,HTM,Up,16695,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
BCAP31,HTM,Down,16695,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
BCAR3,HTM,Down,973,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BCAR3,HTM,Down,973,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BCAR3,HTM,Down,973,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BCAS1,HTM,Up,974,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BCAS1,HTM,Up,974,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BCAS1,HTM,Down,974,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
BCAS1,HTM,Down,974,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
BCAS2,HTM,Up,975,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BCAS3,HTM,Up,14347,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BCAS3,HTM,Down,14347,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
BCAS4,HTM,Down,14367,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
BCAT1,HTM,Down,976,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BCAT1,HTM,Up,976,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BCAT1,HTM,Up,976,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
BCDIN3D,HTM,Up,27050,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
BCHE,HTM,Down,983,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
BCHE,HTM,Up,983,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
BCHE,HTM,Up,983,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
BCKDHA,HTM,Up,986,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
BCL10,HTM,Down,989,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BCL11A,HTM,Up,13221,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
BCL11A,HTM,Up,13221,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
BCL11A,HTM,Down,13221,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
BCL11B,HTM,NA,13222,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
BCL2A1,HTM,Down,991,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BCL2A1,HTM,Down,991,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BCL2L1,HTM,Down,992,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
BCL2L14,HTM,Down,16657,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
BCL2L14,HTM,Down,16657,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
BCL2L14,HTM,Up,16657,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
BCL2L15,HTM,Up,33624,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BCL2L15,HTM,Up,33624,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BCL2L15,HTM,Up,33624,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
BCL2L15,HTM,Up,33624,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
BCL2L15,HTM,Up,33624,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
BCL3,HTM,Up,998,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
BCL6,HTM,Down,1001,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
BCL6,HTM,Down,1001,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
BCL6,HTM,Up,1001,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
BCL7A,HTM,Down,1004,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BCL9,HTM,Up,1008,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BCLAF1,HTM,Down,16863,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
BCLAF1,HTM,Down,16863,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
BCLAF1,HTM,Down,16863,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
BCO1,HTM,Up,13815,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BCO2,HTM,Down,18503,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
BCOR,HTM,Up,20893,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BCOR,HTM,Up,20893,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BCOR,HTM,Down,20893,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
BCORL1,HTM,Up,25657,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
BCORL1,HTM,Up,25657,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
BCR,HTM,Down,1014,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
BCR,HTM,Down,1014,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BDH1,HTM,Down,1027,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
BDH2,HTM,Up,32389,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
BDKRB1,HTM,Up,1029,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
BDNF,HTM,Up,1033,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
BDNF,HTM,Up,1033,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
BDNF,HTM,Up,1033,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,21826669
BDNF,HTM,Up,1033,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
BDNF,HTM,Up,1033,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0053,19451087
BDNF,HTM,Up,1033,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0053,17932721
BEAN1,HTM,Up,24160,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
BEND4,HTM,Down,23815,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
BEND6,HTM,Down,20871,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
BEND6,HTM,Down,20871,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
BEND6,HTM,Down,20871,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
BEND7,HTM,Up,23514,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BEST3,HTM,Up,17105,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
BEX1,HTM,Up,1036,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
BEX1,HTM,Up,1036,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
BEX3,HTM,Up,13388,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
BFAR,HTM,Down,17613,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
BFAR,HTM,Down,17613,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BFSP1,HTM,Up,1040,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
BGN,HTM,Up,1044,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0032,17932721
BGN,HTM,Down,1044,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
BHLHA15,HTM,Up,22265,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
BHLHB2,HTM,Up,1046,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
BHLHB2,HTM,Up,1046,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
BHLHB2,HTM,Up,1046,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
BHLHB9,HTM,Up,29353,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
BHLHB9,HTM,Up,29353,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
BHLHB9,HTM,Up,29353,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
BHLHE40,HTM,Up,1046,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
BHLHE41,HTM,Up,16617,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
BHLHE41,HTM,Down,16617,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
BHLHE41,HTM,Down,16617,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
BICC1,HTM,Up,19351,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
BICC1,HTM,Up,19351,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
BICC1,HTM,Down,19351,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
BICC1,HTM,Down,19351,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
BICD1,HTM,Up,1049,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
BICDL1,HTM,Down,28095,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
BICDL1,HTM,Up,28095,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
BICDL1,HTM,Up,28095,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
BICDL1,HTM,Down,28095,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
BICDL2,HTM,Down,33584,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
BICDL2,HTM,Up,33584,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
BID,HTM,Down,1050,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
BIK,HTM,Down,1051,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
BIN1,HTM,Down,1052,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
BIRC3,HTM,Down,591,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
BIRC3,HTM,Up,591,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
BIRC3,HTM,Up,591,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
BIRC3,HTM,Down,591,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0053,19451087
BIRC3,HTM,Up,591,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
BIRC3,HTM,Down,591,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
BIRC3,HTM,Down,591,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
BIRC5,HTM,Down,593,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
BIRC51,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
BIRC51,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
BIRC51,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
BIRC6,HTM,Up,13516,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
BIRC6,HTM,Up,13516,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
BLACAT1,HTM,Down,48597,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
BLACAT1,HTM,Up,48597,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
BLID,HTM,Down,33495,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0011,26351321
BLM,HTM,Down,1058,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
BLM,HTM,Up,1058,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
BLM,HTM,Down,1058,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
BLMH,HTM,Up,1059,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,29340052
BLMH,HTM,Down,1059,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
BLMH,HTM,Down,1059,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0053,23820871
BLMH,HTM,Up,1059,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
BLMH,HTM,Down,1059,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
BLNK,HTM,Up,14211,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
BLOC1S2,HTM,Down,20984,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BLOC1S6,HTM,Up,8549,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
BLVRB,HTM,Up,1063,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BMF,HTM,Down,24132,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
BMF,HTM,Down,24132,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
BMF,HTM,Down,24132,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
BMP1,HTM,Up,1067,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,20424609
BMP1,HTM,Up,1067,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,20424609
BMP1,HTM,Down,1067,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
BMP2,HTM,Up,1069,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,20424609
BMP2,HTM,Up,1069,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,20424609
BMP3,HTM,NA,1070,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0021,20630067
BMP4,HTM,Down,1071,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
BMP4,HTM,Down,1071,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
BMP5,HTM,Up,1072,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
BMP6,HTM,Up,1073,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25432175
BMP6,HTM,Up,1073,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0021,25881239
BMP6,HTM,Up,1073,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
BMP7,HTM,Down,1074,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
BMP8B,HTM,Up,1075,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
BMPER,HTM,Down,24154,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
BMPR1B,HTM,Up,1077,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BMPR1B,HTM,Up,1077,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BMPR2,HTM,Down,1078,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
BMT2,HTM,Up,26475,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
BMT2,HTM,Up,26475,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
BNC1,HTM,Down,1081,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BNC1,HTM,Down,1081,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BNC1,HTM,Down,1081,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BNC2,HTM,Up,30988,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
BNC2,HTM,Up,30988,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
BNC2,HTM,Up,30988,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,28588211
BNIP3,HTM,Down,1084,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
BNIP3,HTM,Up,1084,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
BNIP3,HTM,Down,1084,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
BNIPL,HTM,Up,16976,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
BOD1,HTM,Down,25114,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
BOD1L1,HTM,Up,31792,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
BOK,HTM,Up,1087,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
BOK,HTM,Down,1087,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
BOLA1,HTM,Up,24263,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
BOLA1,HTM,Up,24263,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
BOLA1,HTM,Up,24263,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
BOLA2,HTM,Down,29488,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
BOLA2,HTM,Down,29488,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
BOLA2,HTM,Up,29488,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
BOLA3,HTM,Down,24415,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
BOP1,HTM,Up,15519,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
BOP1,HTM,Up,15519,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
BORA,HTM,Up,24724,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
BORA,HTM,Up,24724,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
BORA,HTM,Up,24724,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
BORA,HTM,Up,24724,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
BORCS7-ASMT,HTM,Up,49183,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BPESC1,HTM,Down,13228,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
BPIFA1,HTM,Up,15749,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
BPIFB1,HTM,Up,16108,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
BPIFB1,HTM,Up,16108,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
BPIFB1,HTM,Up,16108,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
BPIFB1,HTM,Up,16108,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
BPIFB1,HTM,Up,16108,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
BPIFB1,HTM,Up,16108,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
BPIFB1,HTM,Up,16108,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
BPIFC,HTM,Up,16503,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
BPNT1,HTM,Up,1096,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BRAF,HTM,Down,1097,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
BRAF,HTM,Down,1097,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
BRCA1,HTM,Down,1100,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
BRCA1,HTM,Down,1100,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
BRCA1,HTM,Down,1100,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
BRCA1,HTM,Down,1100,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
BRCC3,HTM,Down,24185,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
BRD9,HTM,Down,25818,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
BRD9,HTM,Down,25818,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
BRD9,HTM,Down,25818,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
BRINP2,HTM,Up,13746,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
BRIP1,HTM,NA,20473,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29221160
BRIP1,HTM,Down,20473,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
BRP44,HTM,Up,24515,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BRWD1,HTM,Down,12760,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
BRWD1,HTM,Down,12760,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
BRWD1,HTM,Up,12760,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
BRWD1,HTM,Up,12760,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
BRWD1,HTM,Down,12760,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
BRWD1,HTM,Up,12760,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
BSG,HTM,Up,1116,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
BSG,HTM,Down,1116,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
BSPRY,HTM,Down,18232,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
BST2,HTM,Up,1119,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
BTBD10,HTM,Down,21445,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
BTBD11,HTM,Down,23844,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
BTBD6,HTM,Down,19897,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
BTG2,HTM,Down,1131,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
BTN3A2,HTM,Down,1139,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
BUB1,HTM,Down,1148,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
BUB1B,HTM,Down,1149,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
BUB1B,HTM,Up,1149,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
BVES,HTM,Down,1152,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
BVES,HTM,Down,1152,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
BZW1,HTM,Up,18380,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
BZW2,HTM,Down,18808,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
C10ORF35,HTM,Up,23519,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C10ORF35,HTM,Up,23519,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C10ORF35,HTM,Up,23519,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C11ORF1,HTM,Up,1163,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
C11ORF24,HTM,Down,1174,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
C11ORF54,HTM,Up,30204,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
C11orf54,HTM,Up,30204,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
C11orf54,HTM,Up,30204,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
C11ORF54,HTM,Up,30204,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
C11ORF54,HTM,Up,30204,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0053,28881576
C11ORF54,HTM,Up,30204,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.16,0.0053,20530554
C11ORF86,HTM,Down,34442,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
C11ORF86,HTM,Down,34442,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
C11orf96,HTM,Up,38675,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
C12ORF34,HTM,Up,25915,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C12ORF34,HTM,Up,25915,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C12ORF34,HTM,Up,25915,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C12ORF48,HTM,Up,26074,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
C12ORF60,HTM,Up,28726,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C12ORF60,HTM,Up,28726,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C12ORF60,HTM,Up,28726,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C14ORF132,HTM,Down,20346,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
C14ORF132,HTM,Down,20346,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
C14orf132,HTM,Up,20346,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
C14ORF2,HTM,Down,1188,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
C15ORF29,HTM,Up,26199,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C15ORF29,HTM,Up,26199,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C15ORF29,HTM,Up,26199,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C15ORF48,HTM,Down,29898,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
C15ORF48,HTM,Down,29898,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
C15ORF48,HTM,Down,29898,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
C15orf62,HTM,Up,34489,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
C15orf65,HTM,Down,44654,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
C16orf78,HTM,Up,28479,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
C16ORF82,HTM,Down,30755,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
C17ORF107,HTM,Down,37238,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
C17ORF63,HTM,Down,25563,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
C17ORF63,HTM,Down,25563,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
C17ORF63,HTM,Down,25563,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
C17ORF67,HTM,Down,27900,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
C18ORF12,HTM,Down,NA,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
C18ORF54,HTM,Down,13796,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
C18ORF54,HTM,Down,13796,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
C18ORF54,HTM,Up,13796,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
C18ORF54,HTM,Up,13796,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
C18ORF54,HTM,Up,13796,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
C19ORF25,HTM,Up,26711,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
C19ORF33,HTM,Up,16668,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
C19ORF38,HTM,Down,34073,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
C1D,HTM,Down,29911,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
C1D,HTM,Down,29911,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
C1GALT1,HTM,Up,24337,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
C1GALT1,HTM,Up,24337,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
C1GALT1,HTM,Up,24337,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
C1GALT1,HTM,Up,24337,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
C1ORF109,HTM,Up,26039,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C1ORF109,HTM,Up,26039,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C1ORF109,HTM,Up,26039,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C1ORF112,HTM,Down,25565,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
C1ORF115,HTM,Down,25873,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
C1ORF116,HTM,Down,28667,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
C1ORF116,HTM,Down,28667,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
C1ORF116,HTM,Down,28667,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
C1ORF21,HTM,Down,15494,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
C1ORF210,HTM,Down,28755,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
C1ORF210,HTM,Up,28755,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
C1ORF54,HTM,Up,26258,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
C1ORF54,HTM,Up,26258,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
C1ORF54,HTM,Up,26258,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
C1ORF54,HTM,Up,26258,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
C1ORF54,HTM,Up,26258,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
C1ORF54,HTM,Up,26258,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
C1orf9,HTM,Down,1240,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
C1QBP,HTM,Down,1243,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
C1QBP,HTM,Down,1243,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
C1QBP,HTM,Up,1243,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
C1QBP,HTM,Up,1243,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
C1QL3,HTM,Up,19359,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
C1QTNF6,HTM,Down,14343,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
C1QTNF7,HTM,Up,14342,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
C1R,HTM,Up,1246,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
C1R,HTM,Down,1246,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
C1R,HTM,Down,1246,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
C1S,HTM,Up,1247,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
C1S,HTM,Up,1247,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
C1S,HTM,Down,1247,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
C1S,HTM,Down,1247,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
C20orf204,HTM,Up,27655,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
C20orf27,HTM,Down,15873,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
C20ORF96,HTM,Down,16227,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
C21ORF91,HTM,Down,16459,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
C21ORF91,HTM,Down,16459,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
C22ORF13,HTM,Up,14237,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
C2CD4A,HTM,Up,33627,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
C2CD5,HTM,Up,29062,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
C2CD6,HTM,Down,14438,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
C2ORF15,HTM,Up,28436,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
C2ORF49,HTM,Up,28772,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
C2orf72,HTM,Down,27418,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
C2ORF88,HTM,Down,28191,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
C2ORF88,HTM,Down,28191,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
C3,HTM,Down,1318,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0064,30592142
C3,HTM,Down,1318,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
C3,HTM,Up,1318,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0064,24961511
C3,HTM,Up,1318,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0064,24961511
C3,HTM,Down,1318,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
C3,HTM,Down,1318,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
C3,HTM,Up,1318,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
C3,HTM,Down,1318,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
C3,HTM,Down,1318,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0064,30592142
C3ORF14,HTM,Up,25024,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C3ORF14,HTM,Up,25024,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C3ORF14,HTM,Up,25024,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C3ORF18,HTM,Down,24837,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
C3ORF23,HTM,Up,25241,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C3ORF23,HTM,Up,25241,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C3ORF23,HTM,Up,25241,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
C3ORF33,HTM,Down,26434,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
C3ORF80,HTM,Up,40048,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
C4BPA,HTM,Up,1325,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
C4BPA,HTM,Up,1325,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
C4BPB,HTM,Down,1328,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
C4BPB,HTM,Down,1328,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
C4ORF19,HTM,Down,25618,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
C4ORF19,HTM,Down,25618,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
C4ORF33,HTM,Down,27025,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
C4ORF33,HTM,Down,27025,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
C4orf46,HTM,Down,27320,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
C4ORF46,HTM,Down,27320,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
C5,HTM,Up,1331,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
C5,HTM,Up,1331,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
C5AR1,HTM,Up,1338,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
C5AR1,HTM,Down,1338,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
C5ORF34,HTM,Down,24738,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
C5orf46,HTM,Up,33768,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
C6ORF132,HTM,Down,21288,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
C6ORF141,HTM,Up,21351,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
C6ORF15,HTM,Up,13927,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
C8orf37,HTM,Up,27232,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
C8orf37,HTM,Up,27232,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
C8ORF4,HTM,Down,25646,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
C8ORF4,HTM,Down,25646,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
C8ORF4,HTM,Down,25646,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
C8ORF4,HTM,Down,25646,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
C8ORF4,HTM,Down,25646,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
C8ORF88,HTM,Down,44672,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
C9ORF152,HTM,Up,31455,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
C9ORF152,HTM,Up,31455,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
C9ORF152,HTM,Up,31455,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
C9ORF152,HTM,Up,31455,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
C9ORF85,HTM,Down,28784,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
C9ORF92,HTM,Down,19054,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CA12,HTM,Up,1371,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CA12,HTM,Up,1371,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CA12,HTM,Up,1371,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CA13,HTM,Down,14914,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CA13,HTM,Down,14914,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CA13,HTM,Up,14914,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
CA2,HTM,Up,1373,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,35229723
CA2,HTM,Down,1373,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CA2,HTM,Down,1373,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CA2,HTM,Down,1373,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CA2,HTM,Down,1373,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CA5B,HTM,Up,1378,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CA5BP1,HTM,Up,29544,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
CA6,HTM,Down,1380,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
CA8,HTM,Up,1382,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CA8,HTM,Up,1382,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CA9,HTM,Down,1383,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CA9,HTM,Down,1383,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CA9,HTM,Down,1383,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CAB39,HTM,Down,20292,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CAB39,HTM,Down,20292,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CAB39L,HTM,Up,20290,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CAB39L,HTM,Up,20290,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
CAB39L,HTM,Up,20290,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
CABIN1,HTM,Down,24187,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CABIN1,HTM,Down,24187,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CABLES1,HTM,Up,25097,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CABLES1,HTM,Down,25097,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CABLES2,HTM,Down,16143,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CABYR,HTM,Up,15569,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CACFD1,HTM,Up,1365,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CACNA1A,HTM,Up,1388,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
CACNA1B,HTM,Down,1389,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CACNA1C,HTM,Up,1390,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CACNA1D,HTM,Up,1391,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CACNA1D,HTM,Up,1391,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CACNA1G,HTM,Up,1394,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
CACNA1H,HTM,Down,1395,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CACNA1H,HTM,Up,1395,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
CACNA1I,HTM,Up,1396,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
CACNA2D1,HTM,Up,1399,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.4,0.0064,25881239
CACNA2D1,HTM,Up,1399,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.4,0.0064,25881239
CACNA2D1,HTM,Up,1399,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
CACNA2D1,HTM,Up,1399,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0064,34414448
CACNA2D2,HTM,Up,1400,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
CACNA2D3,HTM,Down,15460,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
CACNA2D3,HTM,Down,15460,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
CACNB1,HTM,Up,1401,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CACNB2,HTM,Up,1402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CACNB4,HTM,Up,1404,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CACNB4,HTM,Up,1404,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CACNB4,HTM,Up,1404,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
CACNG4,HTM,Up,1408,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
CACNG6,HTM,Down,13625,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
CACTIN,HTM,Down,29938,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CACYBP,HTM,Down,30423,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CACYBP,HTM,Down,30423,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CACYBP,HTM,Down,30423,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CACYBP,HTM,Down,30423,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CACYBP,HTM,Down,30423,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
CAD,HTM,Down,1424,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CAD,HTM,Up,1424,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CAD,HTM,Up,1424,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CAD,HTM,Up,1424,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
CADM1,HTM,Up,5951,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CADM1,HTM,Up,5951,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CADM1,HTM,Up,5951,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
CADM1,HTM,Down,5951,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
CADM2,HTM,Up,29849,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
CADM3,HTM,Up,17601,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
CADPS,HTM,Up,1426,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CADPS2,HTM,Up,16018,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
CADPS2,HTM,Up,16018,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CADPS2,HTM,Up,16018,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CADPS2,HTM,Up,16018,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
CADPS2,HTM,Up,16018,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
CALB1,HTM,Down,1434,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CALB1,HTM,Up,1434,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
CALB1,HTM,Up,1434,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
CALB1,HTM,Down,1434,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CALB2,HTM,Down,1435,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0053,26351321
CALB2,HTM,Up,1435,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0053,23820871
CALB2,HTM,Down,1435,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
CALB2,HTM,Up,1435,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
CALB2,HTM,Up,1435,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0053,34168259
CALCOCO1,HTM,Down,29306,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CALCOCO1,HTM,Down,29306,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CALCOCO2,HTM,Up,29912,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CALCR,HTM,Down,1440,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CALD1,HTM,Down,1441,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
CALD1,HTM,Down,1441,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
CALD1,HTM,Down,1441,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
CALM1,HTM,Up,442,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
CALM1,HTM,Down,1442,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
CALM3,HTM,Down,1449,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CALML5,HTM,Down,18180,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CALR,HTM,Up,1455,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CALR,HTM,Up,1455,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CALR,HTM,Up,1455,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CALR,HTM,Up,1455,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CALU,HTM,Up,1458,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
CAMK1,HTM,Up,1459,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CAMK1,HTM,Up,1459,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CAMK1D,HTM,Down,19341,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
CAMK1D,HTM,Up,19341,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CAMK1D,HTM,Down,19341,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
CAMK1D,HTM,Down,19341,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
CAMK2A,HTM,Down,1460,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CAMK2B,HTM,Up,1461,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
CAMK2B,HTM,Up,1461,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CAMK2B,HTM,Up,1461,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
CAMK2B,HTM,Up,1461,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
CAMK2B,HTM,Up,1461,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
CAMK2B,HTM,Up,1461,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
CAMK2D,HTM,Up,1462,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CAMK2D,HTM,Up,1462,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CAMK2D,HTM,Down,1462,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
CAMKK1,HTM,Up,1469,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CAMP,HTM,Up,1472,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CAMSAP3,HTM,Down,29307,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CAND1,HTM,Down,30688,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CANX,HTM,Up,1473,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
CANX,HTM,Up,1473,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
CANX,HTM,Up,1473,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
CANX,HTM,Down,1473,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
CANX,HTM,Up,1473,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
CANX,HTM,Up,1473,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
CANX,HTM,Up,1473,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
CANX,HTM,Up,1473,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
CAP1,HTM,Down,20040,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CAP1,HTM,Up,20040,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
CAP1,HTM,Down,20040,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CAP1,HTM,Up,20040,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
CAPG,HTM,Up,1474,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CAPN1,HTM,Down,1476,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CAPN1,HTM,Down,1476,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CAPN11,HTM,Down,1478,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CAPN13,HTM,Down,16663,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CAPN15,HTM,Up,11182,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CAPN15,HTM,Up,11182,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CAPN15,HTM,Up,11182,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CAPN2,HTM,Down,1479,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
CAPN2,HTM,Up,1479,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CAPN5,HTM,Down,1482,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CAPN5,HTM,Up,1482,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CAPN8,HTM,Down,1485,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CAPN8,HTM,Up,1485,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CAPNS1,HTM,Up,1481,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
CAPNS1,HTM,Up,1481,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
CAPNS2,HTM,Down,16371,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CAPRIN1,HTM,Down,6743,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CAPRIN1,HTM,Down,6743,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CAPRIN1,HTM,Down,6743,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
CAPRIN2,HTM,Down,21259,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CAPRIN2,HTM,Up,21259,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CAPRIN2,HTM,Up,21259,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CAPRIN2,HTM,Down,21259,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
CAPRIN2,HTM,Up,21259,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CAPS,HTM,Up,1487,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CAPZB,HTM,Up,1491,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CARD10,HTM,Down,16422,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CARD11,HTM,Down,16393,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CARD6,HTM,Down,16394,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CARD6,HTM,Down,16394,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CARHSP1,HTM,Up,17150,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
CARM1,HTM,Down,23393,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
CARM1,HTM,Down,23393,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
CARMIL1,HTM,Up,21581,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
CARMN,HTM,Down,42872,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CASC15,HTM,Up,28245,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.2,0.0021,34680485
CASC4,HTM,Down,24892,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
CASC9,HTM,Up,48906,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CASD1,HTM,Up,16014,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CASK,HTM,Up,1497,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CASKIN1,HTM,Down,20879,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CASP1,HTM,Up,1499,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CASP1,HTM,Up,1499,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CASP1,HTM,Up,1499,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CASP10,HTM,Down,1500,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CASP14,HTM,Down,1502,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CASP14,HTM,Up,1502,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CASP14,HTM,Down,1502,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CASP2,HTM,Down,1503,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0021,19451087
CASP2,HTM,Up,1503,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
CASP3,HTM,Down,1504,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CASP3,HTM,Down,1504,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
CASP4,HTM,Down,1505,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CASP4,HTM,Down,1505,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CASP4,HTM,Down,1505,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CASP9,HTM,Down,1511,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
CASS4,HTM,Up,15878,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
CAST,HTM,Up,1515,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CAST,HTM,Up,1515,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CAST,HTM,Down,1515,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CAST,HTM,Down,1515,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CAST,HTM,Up,1515,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CASTOR2,HTM,Up,37073,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CASTOR2,HTM,Up,37073,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CASTOR3,HTM,Up,29954,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CASTOR3,HTM,Down,29954,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CASZ1,HTM,Up,26002,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CASZ1,HTM,Up,26002,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
CAT,HTM,Down,1516,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
CAT,HTM,Down,1516,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
CAT,HTM,Up,1516,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
CAT,HTM,Down,1516,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
CAT,HTM,Down,1516,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
CAT,HTM,Down,1516,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
CATSPER1,HTM,Down,17116,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CAV1,HTM,Down,1527,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0117,25881239
CAV1,HTM,NA,1527,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0117,29352988
CAV1,HTM,Down,1527,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0117,25881239
CAV1,HTM,Down,1527,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0117,26259570
CAV1,HTM,Up,1527,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0117,21618577
CAV1,HTM,Down,1527,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0117,26259570
CAV1,HTM,Up,1527,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0117,21618577
CAV1,HTM,Up,1527,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.24,0.0117,31289135
CAV1,HTM,Down,1527,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.24,0.0117,31501409
CAV1,HTM,Up,1527,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0117,34168259
CAV1,HTM,Down,1527,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0117,30696080
CAV1,HTM,Down,1527,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0117,27746256
CAV1,HTM,Down,1527,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0117,30696080
CAV1,HTM,Up,1527,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0117,21618577
CAV2,HTM,Down,1528,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
CAV2,HTM,Down,1528,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
CAV2,HTM,Down,1528,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,29352988
CAV2,HTM,Down,1528,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0074,29352988
CAV2,HTM,Down,1528,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
CAV2,HTM,Down,1528,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0074,26259570
CAV2,HTM,Down,1528,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0074,26259570
CAV2,HTM,Up,1528,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.24,0.0074,31289135
CAV2,HTM,Down,1528,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.24,0.0074,34680485
CAV2,HTM,Down,1528,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.24,0.0074,31501409
CAV2,HTM,Down,1528,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0074,30696080
CAV2,HTM,Down,1528,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0074,30696080
CAVIN1,HTM,Up,9688,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
CAVIN1,HTM,Down,9688,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CAVIN1,HTM,Down,9688,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CAVIN1,HTM,Down,9688,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
CAVIN3,HTM,Down,9400,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CBFA2T2,HTM,NA,1536,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29221160
CBFA2T2,HTM,Up,1536,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
CBFA2T3,HTM,Down,1537,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CBFA2T3,HTM,Down,1537,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CBL,HTM,Down,1541,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
CBL,HTM,Down,1541,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
CBL,HTM,Down,1541,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CBLC,HTM,Down,15961,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CBLC,HTM,Down,15961,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CBR1,HTM,Up,1548,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CBS,HTM,Up,1550,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
CBWD3,HTM,Down,18519,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CBWD3,HTM,Down,18519,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CBX1,HTM,Up,1551,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
CBX2,HTM,Down,1552,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CBX3,HTM,Up,1553,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CBX3,HTM,Up,1553,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CBX3,HTM,Down,1553,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CBX3,HTM,Down,1553,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CBX3,HTM,Up,1553,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CBX4,HTM,Up,1554,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
CBX5,HTM,Down,1555,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
CBX5,HTM,Down,1555,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
CBX8,HTM,Down,15962,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CCAR1,HTM,Up,24236,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
CCAR2,HTM,Down,23360,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CCBE1,HTM,Down,29426,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCBE1,HTM,Down,29426,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCBE1,HTM,Down,29426,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCBL1,HTM,Down,1564,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CCDC120,HTM,Down,28910,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CCDC125,HTM,Up,28924,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CCDC125,HTM,Up,28924,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CCDC125,HTM,Up,28924,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
CCDC130,HTM,Down,28118,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CCDC138,HTM,Down,26531,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CCDC138,HTM,Down,26531,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CCDC138,HTM,Down,26531,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CCDC138,HTM,Down,26531,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CCDC138,HTM,Down,26531,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CCDC144A,HTM,Up,29072,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCDC144A,HTM,Up,29072,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCDC144B,HTM,Up,26704,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCDC144B,HTM,Up,26704,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCDC144CP,HTM,Up,29073,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCDC144CP,HTM,Up,29073,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCDC146,HTM,Up,29296,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CCDC159,HTM,Up,26996,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CCDC169,HTM,Up,34361,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCDC183,HTM,Up,28236,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CCDC183,HTM,Up,28236,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CCDC183,HTM,Up,28236,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CCDC198,HTM,Up,20189,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CCDC198,HTM,Up,20189,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CCDC198,HTM,Down,20189,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CCDC198,HTM,Up,20189,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0032,17932721
CCDC198,HTM,Down,20189,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CCDC22,HTM,Down,28909,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CCDC22,HTM,Down,28909,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
CCDC33,HTM,Down,26552,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CCDC34,HTM,Up,25079,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCDC34,HTM,Up,25079,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCDC43,HTM,Down,26472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CCDC43,HTM,Down,26472,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
CCDC47,HTM,Down,24856,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
CCDC47,HTM,Down,24856,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
CCDC50,HTM,Down,18111,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCDC57,HTM,Down,27564,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CCDC65,HTM,Down,29937,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CCDC66,HTM,Up,27709,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CCDC68,HTM,Up,24350,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCDC7,HTM,Up,26533,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
CCDC71,HTM,Down,25760,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
CCDC71,HTM,Down,25760,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
CCDC71,HTM,Down,25760,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
CCDC71,HTM,Up,25760,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
CCDC74A,HTM,Down,25197,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CCDC77,HTM,Up,28203,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCDC78,HTM,Down,14153,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CCDC80,HTM,Up,30649,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CCDC80,HTM,Up,30649,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CCDC80,HTM,Up,30649,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0032,26351321
CCDC80,HTM,Down,30649,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CCDC80,HTM,Down,30649,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CCDC85A,HTM,Down,29400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CCDC85A,HTM,Down,29400,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CCDC87,HTM,Up,25579,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CCDC88A,HTM,Up,25523,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CCDC88A,HTM,Up,25523,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
CCDC88C,HTM,Down,19967,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCDC89,HTM,Up,26762,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CCDC91,HTM,Up,24855,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
CCDC92,HTM,Down,29563,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CCDC92,HTM,Down,29563,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CCDC97,HTM,Down,28289,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
CCDC9B,HTM,Up,33488,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CCL1,HTM,Up,10609,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CCL2,HTM,Up,10618,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,25432175
CCL2,HTM,Down,10618,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0074,34059086
CCL2,HTM,Up,10618,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0074,25881239
CCL2,HTM,Up,10618,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0074,26351321
CCL2,HTM,Up,10618,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0074,34414448
CCL20,HTM,Up,10619,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0074,35229723
CCL20,HTM,Down,10619,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
CCL20,HTM,Down,10619,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
CCL20,HTM,Up,10619,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0074,24961511
CCL20,HTM,Up,10619,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0074,24961511
CCL20,HTM,Up,10619,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
CCL20,HTM,Up,10619,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
CCL20,HTM,Down,10619,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.2,0.0074,31709178
CCL20,HTM,Down,10619,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0074,22954703
CCL20,HTM,Up,10619,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
CCL22,HTM,Up,10621,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CCL22,HTM,Down,10621,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CCL23,HTM,Down,10622,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CCL28,HTM,Down,17700,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CCL5,HTM,Up,10632,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,25432175
CCL5,HTM,Up,10632,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.24,0.0064,35229723
CCL5,HTM,Up,10632,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
CCL5,HTM,Down,10632,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0064,30696080
CCL5,HTM,Down,10632,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0064,30696080
CCN2,HTM,Up,2500,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,21826669
CCN2,HTM,Up,2500,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
CCN3,HTM,Up,7885,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CCN3,HTM,Up,7885,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CCN3,HTM,Up,7885,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CCN5,HTM,Down,12770,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CCN5,HTM,Down,12770,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CCN6,HTM,Down,12771,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
CCNA1,HTM,Down,1577,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CCNA1,HTM,Down,1577,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CCNA1,HTM,Down,1577,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CCNA2,HTM,Up,1578,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22740085
CCNA2,HTM,Down,1578,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
CCNA2,HTM,Down,1578,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
CCNA2,HTM,Down,1578,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
CCNA2,HTM,Down,1578,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.24,0.0042,31289135
CCNA2,HTM,Down,1578,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.24,0.0042,34680485
CCNB1,HTM,Down,1579,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
CCNB1,HTM,Down,1579,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
CCNB1,HTM,Down,1579,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.24,0.0053,31289135
CCNB1,HTM,Down,1579,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.24,0.0053,19353633
CCNB1,HTM,Down,1579,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0053,22954703
CCNB1,HTM,Down,1579,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
CCND1,HTM,Down,1582,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0201,34059086
CCND1,HTM,Up,1582,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.04,0.0201,27520449
CCND1,HTM,Up,1582,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.2,0.0201,21618577
CCND1,HTM,Up,1582,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0201,21618577
CCND1,HTM,Down,1582,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0201,30696080
CCND1,HTM,Down,1582,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0201,30696080
CCND1,HTM,Up,1582,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0201,21618577
CCND2,HTM,Down,1583,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCND2,HTM,Down,1583,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCND2,HTM,Down,1583,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCND3,HTM,Up,1585,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCNE1,HTM,Up,1589,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCNG2,HTM,Down,1593,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CCNG2,HTM,Down,1593,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CCNG2,HTM,Up,1593,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0032,19451087
CCNG2,HTM,Up,1593,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CCNL1,HTM,Down,20569,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CCNL1,HTM,Down,20569,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CCNL1,HTM,Down,20569,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CCNL1,HTM,Down,20569,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CCNL1,HTM,Down,20569,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CCNT1,HTM,Up,1599,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CCNT2,HTM,Up,1600,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
CCPG1,HTM,Up,24227,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CCPG1,HTM,Up,24227,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0032,19451087
CCPG1,HTM,Down,24227,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CCR1,HTM,Up,1602,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CCR3,HTM,Up,1604,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CCR8,HTM,Up,1609,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
CCSER1,HTM,Up,29349,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CCT2,HTM,Down,1615,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CCT2,HTM,Down,1615,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CCT2,HTM,Down,1615,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CCT2,HTM,Up,1615,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
CCT2,HTM,Down,1615,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CCT3,HTM,Down,1616,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
CCT3,HTM,Down,1616,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CCT3,HTM,Down,1616,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CCT3,HTM,Up,1616,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
CCT4,HTM,Down,1617,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CCT4,HTM,Down,1617,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CCT4,HTM,Down,1617,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CCT4,HTM,Up,1617,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
CCT4,HTM,Up,1617,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CCT5,HTM,Down,1618,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CCT5,HTM,Down,1618,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CCT5,HTM,Up,1618,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
CCT6A,HTM,Down,1620,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
CCT6A,HTM,Down,1620,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
CCT6B,HTM,Down,1621,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CCT6P1,HTM,Down,33094,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CCT6P1,HTM,Down,33094,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CCT7,HTM,Down,1622,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CCT7,HTM,Down,1622,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CCT7,HTM,Down,1622,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CCT7,HTM,Down,1622,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CCT7,HTM,Down,1622,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CCT8,HTM,Up,1623,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
CD109,HTM,Up,21685,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0053,23903875
CD109,HTM,Down,21685,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
CD109,HTM,Up,21685,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
CD109,HTM,Down,21685,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
CD109,HTM,Down,21685,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
CD14,HTM,Up,1628,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CD163,HTM,Up,1631,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
CD1A,HTM,Down,1634,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CD1C,HTM,Down,1636,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CD200,HTM,Down,7203,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
CD200,HTM,Up,7203,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0021,17932721
CD22,HTM,Up,1643,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
CD22,HTM,Up,1643,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
CD22,HTM,Down,1643,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CD24,HTM,Down,1645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.4560,31709178
CD24,HTM,NA,1645,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.4560,25676692
CD24,HTM,Down,1645,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.24,0.4560,26259570
CD24,HTM,Up,1645,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.32,0.4560,27520449
CD24,HTM,Down,1645,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.4,0.4560,26259570
CD24,HTM,Down,1645,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.28,0.4560,30696080
CD24,HTM,Down,1645,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.4560,30696080
CD24,HTM,Down,1645,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.12,0.4560,22954703
CD24P4,HTM,Down,1649,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CD274,HTM,Down,17635,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CD274,HTM,Down,17635,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CD274,HTM,Down,17635,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CD300LB,HTM,Up,30811,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CD300LB,HTM,Up,30811,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CD300LB,HTM,Up,30811,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CD300LB,HTM,Up,30811,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CD300LB,HTM,Up,30811,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CD302,HTM,Down,30843,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CD302,HTM,Down,30843,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CD302,HTM,Up,30843,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CD302,HTM,Up,30843,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CD302,HTM,Up,30843,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CD302,HTM,Down,30843,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
CD36,HTM,Up,1663,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
CD36,HTM,Up,1663,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
CD36,HTM,Up,1663,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CD36,HTM,Down,1663,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
CD36,HTM,Down,1663,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
CD3D,HTM,NA,1673,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
CD4,HTM,NA,1678,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
CD4,HTM,NA,1678,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
CD44,HTM,Up,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.48,1.0000,35229723
CD44,HTM,Down,1681,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,1.0000,25881239
CD44,HTM,Up,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.48,1.0000,27520449
CD44,HTM,Up,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.6,1.0000,34680485
CD44,HTM,Down,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.4,1.0000,34168259
CD44,HTM,Up,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.8,1.0000,35013621
CD46,HTM,Down,6953,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
CD47,HTM,Down,1682,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CD47,HTM,Down,1682,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CD47,HTM,Down,1682,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CD5,HTM,Down,1685,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
CD55,HTM,Up,2665,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CD55,HTM,Up,2665,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CD55,HTM,Up,2665,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CD55,HTM,Down,2665,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
CD55,HTM,Down,2665,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
CD58,HTM,Up,1688,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
CD58,HTM,Down,1688,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CD58,HTM,Down,1688,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CD58,HTM,Up,1688,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
CD59,HTM,Down,1689,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CD59,HTM,Down,1689,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CD59,HTM,Up,1689,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
CD59,HTM,Down,1689,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CD59,HTM,Down,1689,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
CD68,HTM,Down,1693,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CD72,HTM,Down,1696,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CD74,HTM,Down,1697,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CD74,HTM,Down,1697,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CD74,HTM,Up,1697,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0032,19451087
CD74,HTM,Up,1697,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0032,19451087
CD82,HTM,Down,6210,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
CD84,HTM,Up,1704,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
CD8A,HTM,Up,1706,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,20424609
CD8A,HTM,Up,1706,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,20424609
CD8A,HTM,NA,1706,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0021,20630067
CD8B,HTM,Up,1707,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,20424609
CD8B,HTM,Up,1707,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,20424609
CD8B,HTM,NA,1707,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0021,20630067
CD9,HTM,Down,1709,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CD9,HTM,Down,1709,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CD9,HTM,Down,1709,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CD9,HTM,Up,1709,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.28,0.0032,32503348
CD9,HTM,Up,1709,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CD93,HTM,Up,15855,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
CD99,HTM,Down,7082,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CD99,HTM,Down,7082,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CD99L2,HTM,Up,18237,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CD99L2,HTM,Up,18237,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
CD99L2,HTM,Up,18237,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
CD99L2,HTM,Up,18237,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
CDADC1,HTM,Down,20299,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
CDC14A,HTM,Up,1718,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CDC2,HTM,Up,1722,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22740085
CDC2,HTM,Up,1722,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,20424609
CDC2,HTM,Up,1722,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,20424609
CDC2,HTM,Up,1722,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
CDC2,HTM,Up,1722,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
CDC2,HTM,Up,1722,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
CDC20,HTM,Down,1723,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CDC20,HTM,Down,1723,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CDC20,HTM,Down,1723,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CDC20,HTM,Down,1723,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CDC20,HTM,Down,1723,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CDC208,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CDC208,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CDC208,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CDC25A,HTM,Down,1725,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CDC25A,HTM,Down,1725,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CDC25A,HTM,Up,1725,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0032,19451087
CDC25A,HTM,Up,1725,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
CDC25B,HTM,Down,1726,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CDC25C,HTM,Down,1727,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CDC25C7,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CDC25C7,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CDC25C7,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CDC34,HTM,Up,1734,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDC34,HTM,Up,1734,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDC34,HTM,Up,1734,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDC37,HTM,Down,1735,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CDC37,HTM,Down,1735,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CDC37,HTM,Up,1735,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
CDC40,HTM,Up,17350,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CDC42,HTM,Up,1736,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
CDC42,HTM,Up,1736,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
CDC42,HTM,Up,1736,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
CDC42,HTM,Down,1736,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
CDC42,HTM,Down,1736,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
CDC42BPB,HTM,Up,1738,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CDC42BPB,HTM,Up,1738,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CDC42BPB,HTM,Up,1738,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CDC42BPB,HTM,Up,1738,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
CDC42BPG,HTM,Down,29829,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CDC42EP1,HTM,Up,17014,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDC42EP1,HTM,Up,17014,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDC42EP1,HTM,Up,17014,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDC42EP3,HTM,Down,16943,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDC42EP3,HTM,Down,16943,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDC42EP3,HTM,Down,16943,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDC42EP3,HTM,Down,16943,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CDC42EP4,HTM,Up,17147,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
CDC6,HTM,Up,1744,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDCA3,HTM,Down,14624,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CDCA3,HTM,Down,14624,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CDCA3,HTM,Down,14624,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CDCA47,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CDCA47,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CDCA47,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CDCA5,HTM,Down,14626,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CDCA7,HTM,Down,14628,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CDCA7,HTM,Down,14628,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
CDCA7,HTM,Up,14628,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
CDCA7L,HTM,Down,30777,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CDCA7L,HTM,Down,30777,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
CDCP1,HTM,Down,24357,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDCP1,HTM,Down,24357,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDCP1,HTM,Down,24357,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDH1,HTM,Down,1748,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0053,22740085
CDH1,HTM,NA,1748,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0053,29352988
CDH1,HTM,Down,1748,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0053,23903875
CDH1,HTM,Down,1748,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
CDH1,HTM,Down,1748,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.24,0.0053,31289135
CDH1,HTM,Down,1748,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
CDH10,HTM,Down,1749,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
CDH11,HTM,Down,1750,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CDH11,HTM,Down,1750,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CDH11,HTM,Down,1750,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CDH11,HTM,Down,1750,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
CDH11,HTM,Down,1750,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
CDH11,HTM,Down,1750,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
CDH11,HTM,Down,1750,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
CDH11,HTM,Up,1750,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
CDH11,HTM,Down,1750,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
CDH12,HTM,Down,1751,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CDH12,HTM,Down,1751,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CDH12,HTM,Up,1751,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CDH13,HTM,Down,1753,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CDH13,HTM,Down,1753,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CDH13,HTM,Down,1753,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CDH13,HTM,Down,1753,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
CDH13,HTM,Down,1753,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
CDH13,HTM,Down,1753,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
CDH13,HTM,Down,1753,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
CDH13,HTM,Up,1753,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CDH13,HTM,Up,1753,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CDH15,HTM,Up,1754,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDH15,HTM,Up,1754,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDH15,HTM,Up,1754,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDH16,HTM,Up,1755,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
CDH17,HTM,Up,1756,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
CDH17,HTM,Up,1756,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDH17,HTM,Up,1756,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDH18,HTM,Down,1757,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
CDH18,HTM,Down,1757,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
CDH18,HTM,Down,1757,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
CDH18,HTM,Down,1757,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
CDH19,HTM,Up,1758,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
CDH19,HTM,Up,1758,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
CDH2,HTM,Down,1759,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0085,30592142
CDH2,HTM,Up,1759,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0085,22740085
CDH2,HTM,Up,1759,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0085,25881239
CDH2,HTM,NA,1759,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by PCR array assay,0.04,0.0085,20630067
CDH2,HTM,Down,1759,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0085,23820871
CDH2,HTM,Up,1759,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0085,25881239
CDH2,HTM,Up,1759,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0085,31709178
CDH2,HTM,NA,1759,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0085,20630067
CDH2,HTM,Down,1759,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0085,29340052
CDH2,HTM,Down,1759,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0085,30592142
CDH23,HTM,Down,13733,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CDH26,HTM,Up,15902,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CDH26,HTM,Down,15902,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CDH26,HTM,Down,15902,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CDH3,HTM,Down,1762,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDH3,HTM,Down,1762,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDH3,HTM,Down,1762,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDH3,HTM,Down,1762,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CDH6,HTM,Up,1765,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
CDH6,HTM,Up,1765,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
CDH6,HTM,Down,1765,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDH8,HTM,Up,1767,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
CDHR1,HTM,Up,14550,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
CDK11A,HTM,Down,1730,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CDK11A,HTM,Up,1730,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
CDK11B,HTM,Up,1729,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
CDK12,HTM,Down,24224,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CDK14,HTM,Down,8883,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CDK14,HTM,Down,8883,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CDK14,HTM,Down,8883,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CDK14,HTM,Down,8883,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CDK14,HTM,Up,8883,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CDK17,HTM,Down,8750,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDK17,HTM,Down,8750,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDK19,HTM,Up,19338,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDK2,HTM,Down,1771,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CDK6,HTM,Down,1777,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CDK6,HTM,Down,1777,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CDK6,HTM,Down,1777,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
CDK8,HTM,Down,1779,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
CDKL4,HTM,Down,19287,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
CDKL5,HTM,Up,11411,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDKN1A,HTM,Down,1784,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CDKN1A,HTM,Down,1784,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CDKN1A,HTM,Up,1784,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
CDKN1A,HTM,Up,1784,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0042,28927099
CDKN1B,HTM,Up,1785,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDKN1C,HTM,Up,1786,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDKN1C,HTM,Up,1786,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDKN1C,HTM,Up,1786,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDKN2A,HTM,Down,1787,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
CDKN2AIPNL,HTM,Down,30545,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
CDKN2AIPNL,HTM,Down,30545,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
CDKN2AIPNL,HTM,Down,30545,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
CDKN2B,HTM,Down,1788,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
CDKN2B,HTM,Up,1788,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CDKN2B,HTM,Up,1788,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CDKN2B,HTM,Up,1788,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CDKN2B-AS1,HTM,Down,34341,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDKN2B-AS1,HTM,Down,34341,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDKN2B-AS1,HTM,Down,34341,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDKN2B-AS1,HTM,Down,34341,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CDKN2B-AS1,HTM,Down,34341,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CDKN3,HTM,Up,1791,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDKN3,HTM,Up,1791,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDR1,HTM,Up,1798,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDR1,HTM,Up,1798,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDRT1,HTM,Up,14379,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDRT1,HTM,Up,14379,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDRT1,HTM,Up,14379,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDRT1,HTM,Up,14379,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDRT1,HTM,Up,14379,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDRT1,HTM,Up,14379,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDRT1,HTM,Up,14379,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CDRT4,HTM,Up,14383,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDRT4,HTM,Up,14383,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDRT4,HTM,Up,14383,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CDS1,HTM,Down,1800,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDS1,HTM,Down,1800,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CDS1,HTM,Down,1800,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CDSN,HTM,Up,1802,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CDT1,HTM,Down,24576,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CDT1,HTM,Down,24576,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
CDV3,HTM,Down,26928,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
CDYL,HTM,Up,1811,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
CEACAM1,HTM,Up,1814,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.2,0.0064,35229723
CEACAM1,HTM,Up,1814,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.2,0.0064,29416721
CEACAM1,HTM,Up,1814,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.2,0.0064,29416721
CEACAM1,HTM,Up,1814,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.2,0.0064,29416721
CEACAM1,HTM,Up,1814,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.2,0.0064,29416721
CEACAM1,HTM,Down,1814,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
CEACAM1,HTM,Up,1814,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
CEACAM1,HTM,Down,1814,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0064,34168259
CEACAM5,HTM,Up,1817,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CEACAM5,HTM,Up,1817,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CEACAM5,HTM,Up,1817,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
CEACAM6,HTM,Up,1818,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,35229723
CEACAM6,HTM,Up,1818,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CEACAM6,HTM,Up,1818,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CEACAM6,HTM,Up,1818,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
CEACAM6,HTM,Down,1818,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
CEACAM7,HTM,Down,1819,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
CEBPB,HTM,Down,1834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CEBPD,HTM,Up,1835,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
CEBPD,HTM,Up,1835,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
CEBPD,HTM,Up,1835,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.28,0.0042,31501409
CEBPD,HTM,Up,1835,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
CEBPD,HTM,Up,1835,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
CELA3B,HTM,Down,15945,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CELSR2,HTM,Down,3231,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CELSR2,HTM,Up,3231,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CELSR2,HTM,Up,3231,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CELSR2,HTM,Up,3231,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CELSR2,HTM,Up,3231,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
CEMIP,HTM,Up,29213,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
CEMIP,HTM,Up,29213,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0042,17932721
CEMIP,HTM,Up,29213,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
CENPA,HTM,Up,1851,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CENPA,HTM,Up,1851,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
CENPA,HTM,Up,1851,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
CENPA,HTM,Down,1851,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
CENPA,HTM,Up,1851,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
CENPA,HTM,Down,1851,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
CENPA2,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CENPA2,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CENPA2,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CENPB,HTM,Down,1852,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
CENPE,HTM,Down,1856,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CENPE,HTM,Down,1856,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CENPE,HTM,Down,1856,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CENPE,HTM,Down,1856,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
CENPE,HTM,Up,1856,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0032,28881576
CENPH,HTM,Down,17268,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
CENPJ,HTM,Up,17272,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
CENPK,HTM,Down,29479,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
CENPK,HTM,Up,29479,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
CENPL,HTM,Down,17879,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CENPL,HTM,Down,17879,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CENPL,HTM,Down,17879,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CENPM,HTM,Down,18352,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CENPM,HTM,Down,18352,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CENPM,HTM,Down,18352,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CENPO,HTM,Up,28152,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CENPS,HTM,Down,23163,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CENPV,HTM,Up,29920,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CENPV,HTM,Up,29920,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CENPV,HTM,Down,29920,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CENPW,HTM,Down,21488,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CEP104,HTM,Up,24866,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
CEP112,HTM,Up,28514,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CEP112,HTM,Up,28514,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CEP126,HTM,Up,29264,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CEP152,HTM,Down,29298,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
CEP170,HTM,Down,28920,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CEP350,HTM,Up,24238,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
CEP350,HTM,Up,24238,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
CEP55,HTM,Down,1161,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CEP55,HTM,Down,1161,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
CEP83,HTM,Down,17966,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CEP95,HTM,Up,25141,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
CES1,HTM,Up,1863,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CES1,HTM,Up,1863,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CES1,HTM,Down,1863,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CES1,HTM,Down,28817,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
CES2,HTM,Up,1864,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
CETN3,HTM,Down,1868,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
CFAP20DC,HTM,Down,24763,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CFAP20DC,HTM,Down,24763,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CFAP20DC,HTM,Down,24763,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CFAP20DC,HTM,Down,24763,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CFAP251,HTM,Down,28506,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CFAP251,HTM,Down,28506,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CFAP251,HTM,Down,28506,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CFAP251,HTM,Down,28506,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CFAP251,HTM,Down,28506,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CFAP44,HTM,Down,25631,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CFAP44,HTM,Down,25631,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CFAP44,HTM,Up,25631,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CFAP44,HTM,Up,25631,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
CFAP44,HTM,Up,25631,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
CFAP53,HTM,Up,26530,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CFAP53,HTM,Up,26530,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CFAP53,HTM,Up,26530,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CFAP57,HTM,Down,26485,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CFAP58-DT,HTM,Down,45243,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CFAP70,HTM,Up,30726,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
CFAP70,HTM,Up,30726,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
CFAP92,HTM,Up,29231,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CFD,HTM,Down,2771,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
CFI,HTM,Down,5394,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CFI,HTM,Down,5394,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CFL1,HTM,Down,1874,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
CFL1,HTM,Down,1874,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
CFL1,HTM,Down,1874,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
CFL1,HTM,Up,1874,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
CFL1,HTM,Up,1874,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
CFL2,HTM,Up,1875,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CFL2,HTM,Up,1875,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
CFL2,HTM,Up,1875,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31729259
CFL2,HTM,Down,1875,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
CFL2,HTM,Up,1875,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31729259
CGA,HTM,Up,1885,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CGA,HTM,Up,1885,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CGAS,HTM,Down,21367,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CGN,HTM,Up,17429,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CGN,HTM,Down,17429,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CGN,HTM,Up,17429,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CGN,HTM,Up,17429,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CGN,HTM,Up,17429,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CGNL1,HTM,Up,25931,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
CGNL1,HTM,Up,25931,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CGNL1,HTM,Up,25931,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
CGNL1,HTM,Down,25931,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
CGNL1,HTM,Up,25931,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
CH10,HTM,Down,21637,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
CHAC1,HTM,Down,28680,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
CHAC2,HTM,Down,32363,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CHAC2,HTM,Up,32363,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CHAC2,HTM,Up,32363,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CHAC2,HTM,Up,32363,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CHAC2,HTM,Up,32363,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0032,28881576
CHAD,HTM,Down,1909,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CHAF1B,HTM,Down,1911,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CHCHD8,HTM,Down,24604,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CHCHD8,HTM,Down,24604,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CHCHD8,HTM,Down,24604,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CHCHD8,HTM,Down,24604,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CHCHD8,HTM,Down,24604,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CHD1,HTM,Up,1915,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
CHD1L,HTM,Down,1916,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
CHD4,HTM,Down,1919,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CHD4,HTM,Down,1919,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CHD5,HTM,Down,16816,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CHD6,HTM,Up,19057,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CHD7,HTM,Up,20626,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CHD9,HTM,Up,25701,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CHD9,HTM,Down,25701,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
CHEK1,HTM,Down,1925,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.24,0.0011,31289135
CHERP,HTM,Down,16930,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CHGB,HTM,Up,1930,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CHGB,HTM,Up,1930,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
CHGB,HTM,Up,1930,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
CHGB,HTM,Up,1930,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
CHI3L1,HTM,Up,1932,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CHI3L2,HTM,Up,1933,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CHI3L2,HTM,Down,1933,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CHID1,HTM,Down,28474,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CHML,HTM,Up,1941,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CHML,HTM,Down,1941,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CHMP1A,HTM,Down,8740,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CHMP4C,HTM,Down,30599,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CHN1,HTM,Up,1943,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CHN1,HTM,Up,1943,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CHN2,HTM,Up,1944,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CHORDC1,HTM,Up,14525,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CHORDC1,HTM,Up,14525,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
CHP2,HTM,Down,24927,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CHP2,HTM,Down,24927,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CHPF,HTM,Up,24291,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CHPT1,HTM,Up,17852,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CHPT1,HTM,Up,17852,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CHPT1,HTM,Up,17852,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CHPT1,HTM,Up,17852,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CHPT1,HTM,Up,17852,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CHRDL1,HTM,Up,29861,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CHRM1,HTM,Up,1950,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CHRNA5,HTM,Up,1959,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CHRNA5,HTM,Up,1959,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CHRNA5,HTM,Down,1959,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CHRNB1,HTM,Down,1961,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CHRNB1,HTM,Down,1961,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CHRNB1,HTM,Down,1961,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CHRNB1,HTM,Down,1961,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CHST11,HTM,Down,17422,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CHST11,HTM,Up,17422,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CHST12,HTM,Down,17423,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CHST13,HTM,Up,21755,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CHST13,HTM,Up,21755,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CHST13,HTM,Up,21755,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CHST3,HTM,Up,1971,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
CHST3,HTM,Down,1971,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
CHST3,HTM,Down,1971,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
CHSY1,HTM,Down,17198,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CHTF18,HTM,Down,18435,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CHUK,HTM,NA,1974,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0011,29352988
CHURC1,HTM,Down,20099,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CHURC1,HTM,Down,20099,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CHURC1,HTM,Down,20099,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CHURC1,HTM,Down,20099,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CHURC1,HTM,Down,20099,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CIAO3,HTM,Down,14179,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CIDEC,HTM,Down,24229,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CILP,HTM,Up,1980,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CIRBP,HTM,Down,1982,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CISD1,HTM,Up,30880,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
CISD3,HTM,Up,27578,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
CISH,HTM,Down,1984,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CIT,HTM,Down,1985,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CITED1,HTM,Up,1986,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CITED1,HTM,Up,1986,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CITED1,HTM,Up,1986,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CITED1,HTM,Up,1986,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CITED2,HTM,Up,1987,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CITED2,HTM,Down,1987,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,25676692
CITED2,HTM,Down,1987,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,25676692
CITED2,HTM,Down,1987,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
CITED2,HTM,Down,1987,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,25676692
CITED2,HTM,Down,1987,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
CITED2,HTM,Up,1987,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
CITED4,HTM,Down,18696,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CKAP2,HTM,Up,1990,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CKAP2,HTM,Up,1990,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CKAP2,HTM,Up,1990,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CKAP2L,HTM,Up,26877,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
CKAP2L,HTM,Down,26877,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CKAP2L,HTM,Up,26877,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CKAP2L,HTM,Up,26877,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CKAP2L,HTM,Up,26877,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CKAP4,HTM,Up,16991,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
CKB,HTM,Up,1991,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
CKB,HTM,Up,1991,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
CKB,HTM,Up,1991,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
CKB,HTM,Down,1991,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
CKB,HTM,Down,1991,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
CKB,HTM,Up,1991,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
CKB,HTM,Down,1991,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
CKMT1A,HTM,Down,31736,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CKMT1A,HTM,Down,31736,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CKMT1A,HTM,Down,31736,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CKMT1B,HTM,Down,1995,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CKMT1B,HTM,Down,1995,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CKMT1B,HTM,Down,1995,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CKMT2,HTM,Up,1996,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CKS1B,HTM,Down,19083,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CKS1B,HTM,Down,19083,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CKS1B,HTM,Down,19083,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CLASP2,HTM,Up,17078,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
CLCA2,HTM,Down,2016,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CLCA2,HTM,Down,2016,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CLCA2,HTM,Up,2016,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
CLCA2,HTM,Down,2016,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CLCA2,HTM,Up,2016,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CLCA2,HTM,Up,2016,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
CLCA2,HTM,Up,2016,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
CLCA4,HTM,Up,2018,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
CLCC1,HTM,Down,29675,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CLCC1,HTM,Down,29675,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CLCC1,HTM,Down,29675,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CLCN2,HTM,Down,2020,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
CLCN3,HTM,Up,2021,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
CLCN3,HTM,Up,2021,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
CLCN3,HTM,Up,2021,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
CLCN3,HTM,Up,2021,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
CLCN4,HTM,Up,2022,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CLCN5,HTM,Up,2023,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
CLCN6,HTM,Up,2024,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CLDN1,HTM,Up,2032,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CLDN1,HTM,Up,2032,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.04,0.0042,27520449
CLDN1,HTM,Down,2032,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
CLDN1,HTM,Down,2032,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
CLDN1,HTM,Down,2032,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
CLDN10,HTM,Down,2033,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CLDN10,HTM,Up,2033,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
CLDN10,HTM,Down,2033,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CLDN10,HTM,Up,2033,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CLDN11,HTM,Down,8514,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CLDN11,HTM,Down,8514,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CLDN11,HTM,Down,8514,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CLDN11,HTM,Up,8514,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CLDN12,HTM,Down,2034,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CLDN15,HTM,Up,2036,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CLDN15,HTM,Up,2036,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CLDN15,HTM,Up,2036,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CLDN18,HTM,Up,2039,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
CLDN2,HTM,Down,2041,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CLDN2,HTM,Up,2041,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
CLDN2,HTM,Up,2041,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CLDN2,HTM,Up,2041,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CLDN2,HTM,Up,2041,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CLDN23,HTM,Down,17591,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CLDN3,HTM,Down,2045,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CLDN4,HTM,Down,2046,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
CLDN4,HTM,Up,2046,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CLDN4,HTM,Down,2046,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
CLDN4,HTM,Up,2046,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
CLDN4,HTM,Up,2046,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
CLDN5,HTM,Up,2047,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CLDN5,HTM,Up,2047,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CLDN7,HTM,Up,2049,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
CLDN7,HTM,Down,2049,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CLDN9,HTM,Down,2051,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CLDND1,HTM,Down,1322,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CLEC2B,HTM,Up,2053,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0021,30592142
CLEC2B,HTM,Up,2053,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CLEC2B,HTM,Up,2053,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0021,30592142
CLEC2D,HTM,Up,14351,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CLEC2D,HTM,Down,14351,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CLEC3A,HTM,Down,2052,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CLEC3B,HTM,Up,11891,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CLEC4E,HTM,Down,14555,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CLEC5A,HTM,Down,2054,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CLEC7A,HTM,Up,14558,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CLEC7A,HTM,Down,14558,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CLGN,HTM,Up,2060,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CLHC1,HTM,Down,26453,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CLHC1,HTM,Down,26453,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CLIC1,HTM,Down,2062,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CLIC1,HTM,Down,2062,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CLIC1,HTM,Down,2062,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CLIC1,HTM,Down,2062,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CLIC1,HTM,Up,2062,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
CLIC1,HTM,Up,2062,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
CLIC3,HTM,Up,2064,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CLIC3,HTM,Down,2064,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
CLIC3,HTM,Down,2064,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
CLIC3,HTM,Down,2064,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CLIC5,HTM,Up,13517,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
CLIC5,HTM,Up,13517,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
CLIC5,HTM,Up,13517,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
CLIC5,HTM,Down,13517,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
CLIC5,HTM,Up,13517,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
CLIC5,HTM,Up,13517,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
CLIP3,HTM,Down,24314,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CLIP3,HTM,Down,24314,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CLK1,HTM,Down,2068,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CLK1,HTM,Down,2068,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CLMN,HTM,Down,19972,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CLMN,HTM,Up,19972,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CLMP,HTM,Down,24039,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CLMP,HTM,Down,24039,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CLMP,HTM,Down,24039,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CLMP,HTM,Up,24039,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CLN6,HTM,Down,2077,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CLN8,HTM,Up,2079,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
CLOCK,HTM,Down,2082,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0021,25881239
CLOCK,HTM,Down,2082,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0021,25881239
CLPTM1,HTM,Down,2087,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
CLPTM1L,HTM,Down,24308,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CLRN1,HTM,Down,12605,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CLRN3,HTM,Up,20795,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CLRN3,HTM,Up,20795,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CLRN3,HTM,Up,20795,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CLSPN,HTM,Down,19715,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CLSPN,HTM,Down,19715,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CLSTN1,HTM,Down,17447,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CLSTN1,HTM,Down,17447,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CLSTN1,HTM,Down,17447,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CLSTN2,HTM,Up,17448,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CLSTN3,HTM,Up,18371,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CLTA,HTM,Down,2090,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CLTB,HTM,Down,2091,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CLTB,HTM,Down,2091,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CLTC,HTM,Down,2092,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
CLTC,HTM,Up,2092,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
CLTC,HTM,Up,2092,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
CLTC,HTM,Down,2092,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
CLTC,HTM,Up,2092,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
CLTC,HTM,Down,2092,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
CLTCL1,HTM,Down,2093,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
CLU,HTM,Up,2095,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0064,33670440
CLU,HTM,Up,2095,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0064,33670440
CLU,HTM,Up,2095,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0064,25881239
CLU,HTM,Up,2095,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0064,25881239
CLU,HTM,Up,2095,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
CLU,HTM,Down,2095,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0064,30696080
CLU,HTM,Down,2095,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0064,30696080
CLU,HTM,Down,2095,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,29340052
CMAHP,HTM,Down,2098,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CMBL,HTM,Up,25090,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CMC1,HTM,Down,28783,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CMC1,HTM,Down,28783,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CMC1,HTM,Down,28783,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CMC1,HTM,Down,28783,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CMC1,HTM,Down,28783,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
CMPK1,HTM,Up,18170,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
CMPK1,HTM,Up,18170,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CMPK1,HTM,Up,18170,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CMPK1,HTM,Up,18170,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CMPK1,HTM,Down,18170,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CMSS1,HTM,Up,28666,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
CMTM7,HTM,Down,19178,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CMTM7,HTM,Down,19178,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CMTM8,HTM,Down,19179,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CMTM8,HTM,Up,19179,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CMYA5,HTM,Down,14305,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CMYA5,HTM,Up,14305,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CNDP2,HTM,Up,24437,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
CNFN,HTM,Up,30183,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CNGA1,HTM,Up,2148,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CNGA4,HTM,Up,2152,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
CNIH4,HTM,Up,25013,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
CNKSR1,HTM,Down,19700,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CNKSR2,HTM,Up,19701,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CNKSR2,HTM,Up,19701,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CNKSR2,HTM,Down,19701,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
CNKSR3,HTM,Up,23034,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CNKSR3,HTM,Up,23034,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
CNN2,HTM,Down,2156,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CNN2,HTM,Down,2156,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CNN2,HTM,Down,2156,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CNN2,HTM,Down,2156,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
CNN2,HTM,Down,2156,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CNN3,HTM,Down,2157,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CNNM1,HTM,Up,102,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CNNM1,HTM,Up,102,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CNNM2,HTM,Up,103,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CNNM4,HTM,Down,105,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CNNM4,HTM,Down,105,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CNNM4,HTM,Down,105,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CNOT2,HTM,Up,7878,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
CNOT3,HTM,Down,7879,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
CNOT6,HTM,Up,14099,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CNOT6,HTM,Up,14099,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CNOT6,HTM,Up,14099,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CNOT6,HTM,Up,14099,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
CNP,HTM,Up,2158,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CNR1,HTM,Up,2159,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
CNST,HTM,Down,26486,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CNTD1,HTM,Down,26847,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CNTD1,HTM,Down,26847,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CNTLN,HTM,Up,23432,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CNTLN,HTM,Down,23432,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
CNTN1,HTM,Up,2171,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CNTN1,HTM,Up,2171,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CNTN1,HTM,Up,2171,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
CNTN2,HTM,Up,2172,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CNTN3,HTM,Up,2173,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CNTNAP1,HTM,Up,8011,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CNTNAP1,HTM,Down,8011,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CNTNAP1,HTM,Down,8011,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CNTNAP2,HTM,Up,13830,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
CNTNAP2,HTM,Up,13830,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CNTNAP3,HTM,Down,13834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CNTNAP3,HTM,Up,13834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CNTNAP3,HTM,Up,13834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CNTNAP3,HTM,Up,13834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CNTNAP3,HTM,Up,13834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CNTNAP3,HTM,Up,13834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CNTNAP3,HTM,Up,13834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CNTNAP3,HTM,Up,13834,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
CNTNAP3,HTM,Up,13834,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
CNTNAP3B,HTM,Up,32035,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CNTNAP3B,HTM,Up,32035,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CNTNAP4,HTM,Up,18747,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
COA1,HTM,Down,21868,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
COA3,HTM,Up,24990,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
COBL,HTM,Up,22199,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
COBL,HTM,Down,22199,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
COBLL1,HTM,Down,23571,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
COBLL1,HTM,Down,23571,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
COBLL1,HTM,Down,23571,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
COCH,HTM,Up,2180,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
COCH,HTM,Up,2180,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
COCH,HTM,Down,2180,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
COG6,HTM,Up,18621,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
COG7,HTM,Down,18622,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
COL11A2,HTM,Up,2187,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
COL11A2,HTM,Up,2187,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
COL11A2,HTM,Up,2187,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
COL11A2,HTM,Up,2187,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0021,28927099
COL11A2,HTM,Up,2187,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
COL11A2,HTM,Up,2187,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
COL12A1,HTM,Up,2188,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
COL12A1,HTM,Down,2188,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
COL12A1,HTM,Down,2188,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
COL12A1,HTM,Down,2188,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
COL12A1,HTM,Down,2188,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
COL13A1,HTM,Up,2190,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
COL13A1,HTM,Up,2190,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
COL14A1,HTM,Up,2191,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
COL14A1,HTM,Up,2191,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
COL15A1,HTM,Up,2192,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
COL15A1,HTM,Up,2192,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
COL15A1,HTM,Up,2192,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
COL16A1,HTM,Up,2193,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
COL16A1,HTM,Up,2193,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
COL17A1,HTM,Up,2194,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.28,0.0064,29416721
COL17A1,HTM,Down,2194,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0064,25881239
COL17A1,HTM,Down,2194,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0064,25881239
COL17A1,HTM,Down,2194,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
COL17A1,HTM,Down,2194,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
COL17A1,HTM,Up,2194,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
COL18A1,HTM,Up,2195,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
COL18A1,HTM,Up,2195,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
COL18A1,HTM,Down,2195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
COL18A1,HTM,Down,2195,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
COL18A1,HTM,Up,2195,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
COL1A1,HTM,NA,2197,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by PCR array assay,0.04,0.0021,20630067
COL1A1,HTM,Down,2197,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
COL1A1,HTM,Down,2197,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
COL1A2,HTM,Up,2198,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0021,28927099
COL21A1,HTM,Up,17025,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
COL21A1,HTM,Up,17025,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
COL28A1,HTM,Up,22442,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
COL2A1,HTM,NA,2200,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0021,20630067
COL3A1,HTM,Up,2201,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
COL4A1,HTM,Up,2202,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
COL4A1,HTM,Up,2202,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0021,28927099
COL4A2,HTM,Up,2203,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
COL4A3,HTM,Up,2204,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
COL4A3BP,HTM,Down,2205,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
COL4A4,HTM,Down,2206,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
COL4A5,HTM,Up,2207,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
COL4A5,HTM,Up,2207,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
COL4A5,HTM,Up,2207,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
COL4A5,HTM,Down,2207,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
COL4A5,HTM,Up,2207,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
COL4A6,HTM,Up,2208,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
COL5A1,HTM,Up,2209,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
COL5A1,HTM,Down,2209,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
COL5A1,HTM,Up,2209,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
COL5A2,HTM,Up,2210,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
COL6A1,HTM,Up,2211,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
COL6A2,HTM,Down,2212,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
COL6A2,HTM,Down,2212,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
COL6A3,HTM,Down,2213,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
COL6A6,HTM,Up,27023,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
COL7A1,HTM,Up,2214,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
COL7A1,HTM,Up,2214,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
COL7A1,HTM,Up,2214,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
COL7A1,HTM,Up,2214,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
COL8A1,HTM,Up,2215,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
COL8A1,HTM,Up,2215,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
COL9A1,HTM,NA,2217,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
COL9A3,HTM,Up,2219,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
COL9A3,HTM,Down,2219,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
COLEC10,HTM,Down,2220,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
COLEC10,HTM,Up,2220,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
COMMD10,HTM,Up,30201,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
COMMD6,HTM,Up,24015,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
COMMD6,HTM,Up,24015,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
COMMD6,HTM,Up,24015,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
COMMD6,HTM,Up,24015,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
COMMD6,HTM,Up,24015,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
COMMD8,HTM,Up,26036,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
COMMD8,HTM,Up,26036,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
COMMD8,HTM,Up,26036,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
COMTD1,HTM,Down,26309,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
COP1,HTM,Down,17440,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
COPA,HTM,Up,2230,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
COPA,HTM,Up,2230,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
COPA,HTM,Up,2230,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
COPB,HTM,Up,2231,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
COPB2,HTM,Up,2232,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
COPB2,HTM,Down,2232,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
COPE,HTM,Down,2234,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
COPE,HTM,Down,2234,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
COPG1,HTM,Down,2236,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
COPS4,HTM,Up,16702,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
COPS5,HTM,Down,2240,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29511337
COPS5,HTM,Down,2240,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0011,29511337
COPS7A,HTM,Down,16758,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
COPS7A,HTM,Down,16758,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
COPZ1,HTM,Down,2243,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
COPZ2,HTM,Up,19356,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
COPZ2,HTM,Up,19356,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
COPZ2,HTM,Up,19356,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
COQ10B,HTM,Up,25819,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
COQ4,HTM,Down,19693,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CORO1B,HTM,Down,2253,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CORO1B,HTM,Down,2253,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CORO1C,HTM,Down,2254,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CORO2A,HTM,Down,2255,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CORO2A,HTM,Down,2255,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CORO2A,HTM,Down,2255,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CORO2A,HTM,Down,2255,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
COTL1,HTM,Down,18304,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
COTL1,HTM,Down,18304,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
COTL1,HTM,Up,18304,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
COTL1,HTM,Down,18304,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
COX11,HTM,Up,2261,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
COX11,HTM,Up,2261,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
COX11,HTM,Up,2261,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
COX19,HTM,Up,28074,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
COX19,HTM,Up,28074,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
COX19,HTM,Up,28074,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
COX19,HTM,Down,28074,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
COX4I1,HTM,Up,2265,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
COX4I1,HTM,Up,2265,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
COX5A,HTM,Up,2267,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
COX5A,HTM,Up,2267,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
COX5A,HTM,Down,2267,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
COX5A,HTM,Down,2267,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
COX6A1,HTM,Down,2277,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
COX6B1,HTM,Up,2280,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
COX6B2,HTM,Down,24380,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
COX7A2,HTM,Up,2288,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
COX7A2,HTM,Up,2288,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
COX7A2,HTM,Down,2288,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
COX7A2,HTM,Down,2288,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
COX7B,HTM,Up,2291,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CP,HTM,Up,2295,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CP,HTM,Up,2295,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CP,HTM,Up,2295,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CPA3,HTM,Down,2298,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CPA3,HTM,Down,2298,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CPA3,HTM,Down,2298,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CPA4,HTM,Down,15740,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CPA4,HTM,Down,15740,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CPA4,HTM,Up,15740,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
CPA4,HTM,Down,15740,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
CPA4,HTM,Down,15740,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
CPAMD8,HTM,Up,23228,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CPD,HTM,Up,2301,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CPD,HTM,Up,2301,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CPD,HTM,Up,2301,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CPE,HTM,Down,2303,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
CPE,HTM,Up,2303,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CPE,HTM,Up,2303,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
CPE,HTM,Up,2303,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
CPE,HTM,Up,2303,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
CPEB1,HTM,Down,21744,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CPEB1,HTM,Down,21744,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CPEB2,HTM,Up,21745,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CPEB2,HTM,Up,21745,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CPEB2,HTM,Up,21745,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CPEB2,HTM,Up,21745,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CPEB4,HTM,Up,21747,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CPEB4,HTM,Up,21747,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CPEB4,HTM,Up,21747,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
CPED1,HTM,Up,26159,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CPLX1,HTM,Down,2309,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CPLX2,HTM,Up,2310,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CPLX2,HTM,Up,2310,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CPM,HTM,Down,2311,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0053,23820871
CPM,HTM,Down,2311,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
CPM,HTM,Up,2311,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
CPM,HTM,Down,2311,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
CPM,HTM,Down,2311,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
CPM,HTM,Down,2311,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0053,28881576
CPNE2,HTM,Up,2315,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
CPNE4,HTM,Up,2317,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CPNE4,HTM,Up,2317,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CPNE4,HTM,Up,2317,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CPNE7,HTM,Down,2320,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CPOX,HTM,Down,2321,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CPOX,HTM,Down,2321,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CPOX,HTM,Down,2321,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CPOX,HTM,Up,2321,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
CPPED1,HTM,Down,25632,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CPPED1,HTM,Up,25632,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CPPED1,HTM,Up,25632,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CPPED1,HTM,Up,25632,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
CPS1,HTM,Up,2323,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
CPS1,HTM,Up,2323,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
CPS1,HTM,Up,2323,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
CPS1,HTM,Up,2323,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
CPS1,HTM,Down,2323,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
CPS1,HTM,Down,2323,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,29340052
CPS1,HTM,Down,2323,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0053,24098529
CPS1,HTM,Down,2323,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0053,24098529
CPS1,HTM,Down,2323,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0053,24098529
CPSF6,HTM,Down,13871,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CPSF7,HTM,Down,30098,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
CPSF7,HTM,Down,30098,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
CPT1A,HTM,Down,2328,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
CPVL,HTM,Down,14399,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
CPVL,HTM,Down,14399,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CPXM2,HTM,Up,26977,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
CPZ,HTM,Down,2333,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CRABP1,HTM,Down,2338,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CRABP1,HTM,Up,2338,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CRABP2,HTM,Down,2339,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CRABP2,HTM,Down,2339,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CRACR2A,HTM,Up,28657,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CRACR2A,HTM,Up,28657,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CRACR2B,HTM,Down,28703,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CRACR2B,HTM,Up,28703,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CRAT,HTM,Up,2342,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CRAT,HTM,Up,2342,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
CRB3,HTM,Down,20237,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CRBN,HTM,Up,30185,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
CREB3L1,HTM,Up,18856,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CREB3L1,HTM,Up,18856,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
CREB3L1,HTM,Up,18856,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
CREB3L1,HTM,Up,18856,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,28588211
CREB3L3,HTM,Down,18855,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CREB3L3,HTM,Down,18855,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CREB5,HTM,Down,16844,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CREB5,HTM,Down,16844,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CREBBP,HTM,Up,2348,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
CREBBP,HTM,Up,2348,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics,0.04,0.0021,25731617
CREBL2,HTM,Up,2350,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CREBRF,HTM,Down,24050,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
CREBRF,HTM,Up,24050,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CREBZF,HTM,Up,24905,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CREBZF,HTM,Down,24905,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
CREG2,HTM,Down,14272,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CRELD1,HTM,Up,14630,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CRH,HTM,Down,2355,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CRHR1,HTM,Down,2357,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CRIM1,HTM,Down,2359,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
CRIM1,HTM,Down,2359,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
CRIM1,HTM,Down,2359,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
CRIM1,HTM,Down,2359,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
CRIP1,HTM,Up,2360,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CRIP1,HTM,Down,2360,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
CRIP1,HTM,Down,2360,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CRIPT,HTM,Up,14312,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CRISP3,HTM,Up,16904,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CRISPLD1,HTM,Down,18206,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
CRLF1,HTM,Up,2364,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25432175
CRLS1,HTM,Down,16148,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CRLS1,HTM,Down,16148,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CRNDE,HTM,Up,37078,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CROCCP2,HTM,Down,28170,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CROT,HTM,Down,2366,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CROT,HTM,Up,2366,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0021,26351321
CRSP8P,HTM,Down,NA,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CRSP9,HTM,Up,2378,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CRTAP,HTM,Down,2379,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
CRYAA,HTM,Up,2388,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CRYBA1,HTM,Up,2394,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
CRYBG1,HTM,Down,356,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CRYBG1,HTM,Down,356,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CRYBG1,HTM,Down,356,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CRYBG2,HTM,Down,17295,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CRYBG2,HTM,Down,17295,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CRYBG2,HTM,Down,17295,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CRYGS,HTM,Down,2417,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CRYGS,HTM,Down,2417,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CRYGS,HTM,Down,2417,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CRYZ,HTM,Up,2419,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CRYZ,HTM,Up,2419,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CRYZL1,HTM,Down,2420,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CRYZL1,HTM,Down,2420,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CRYZL1,HTM,Down,2420,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
CRYZL1,HTM,Down,2420,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
CS,HTM,Up,2422,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
CS,HTM,Down,2422,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
CSAD,HTM,Down,18966,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CSAD,HTM,Down,18966,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CSAD,HTM,Up,18966,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
CSAG1,HTM,Down,24294,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CSAG2,HTM,Up,16847,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CSAG3,HTM,Up,26237,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CSDE1,HTM,Up,29905,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
CSE1L,HTM,Up,2431,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
CSE1L,HTM,Down,2431,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CSF1,HTM,Down,2432,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0032,26351321
CSF1,HTM,Up,2432,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CSF2,HTM,Up,2434,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25432175
CSF2RA,HTM,Up,2435,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CSF2RA,HTM,Up,2435,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CSF2RA,HTM,Up,2435,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CSF3,HTM,Up,2438,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,25432175
CSF3,HTM,Up,2438,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CSGALNACT1,HTM,Up,24290,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CSGALNACT1,HTM,Up,24290,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
CSGALNACT1,HTM,Down,24290,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
CSGALNACT1,HTM,Up,24290,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
CSGALNACT1,HTM,Up,24290,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
CSGALNACT1,HTM,Up,24290,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
CSGALNACT1,HTM,Down,24290,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
CSGALNACT1,HTM,Up,24290,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
CSK,HTM,Down,2444,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
CSK,HTM,Down,2444,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
CSMD2,HTM,Up,19290,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CSMD3,HTM,Up,19291,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
CSMD3,HTM,Up,19291,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
CSMD3,HTM,Up,19291,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
CSN2,HTM,Down,2447,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CSN2,HTM,Down,2447,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CSN2,HTM,Down,2447,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CSN3,HTM,Down,2446,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CSN3,HTM,Down,2446,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CSN3,HTM,Down,2446,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CSNK1A1,HTM,Up,2451,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics,0.04,0.0021,25731617
CSNK1A1,HTM,Up,2451,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
CSNK1D,HTM,Up,2452,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
CSNK1E,HTM,Down,2453,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CSNK1E,HTM,Down,2453,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CSNK2A1,HTM,Up,2457,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.36,0.0011,22623141
CSPG4,HTM,Down,2466,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
CSPP1,HTM,Up,26193,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CSPP1,HTM,Up,26193,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CSPP1,HTM,Up,26193,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CSRP1,HTM,Down,2469,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CSRP1,HTM,Down,2469,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CSRP1,HTM,Down,2469,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CSRP2,HTM,Down,2470,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CSRP2,HTM,Down,2470,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CSRP2,HTM,Down,2470,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
CST1,HTM,Up,2473,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CST3,HTM,Up,2475,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,33670440
CST6,HTM,Down,2478,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CST6,HTM,Down,2478,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
CSTA,HTM,Down,2481,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CSTA,HTM,Down,2481,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CSTA,HTM,Down,2481,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CSTA,HTM,Down,2481,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
CSTB,HTM,Down,2482,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CSTB,HTM,Up,2482,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CSTB,HTM,Up,2482,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CSTB,HTM,Down,2482,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CSTF3,HTM,Up,2485,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
CT45A2,HTM,Down,28400,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
CTAG2,HTM,Up,2492,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CTAG2,HTM,Up,2492,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CTAG2,HTM,Up,2492,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CTAGE15,HTM,Down,2481,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CTAGE15,HTM,Down,2481,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CTAGE4,HTM,Down,24772,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CTAGE4,HTM,Down,24772,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CTAGE6,HTM,Down,28644,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CTAGE6,HTM,Down,28644,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CTAGE8,HTM,Down,37294,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CTAGE8,HTM,Down,37294,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CTAGE9,HTM,Down,37275,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CTAGE9,HTM,Down,37275,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CTBP1,HTM,Up,2494,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
CTDSP2,HTM,Down,17077,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
CTDSPL,HTM,Up,16890,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CTDSPL,HTM,Down,37294,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CTH,HTM,Down,2501,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CTNNA1,HTM,Up,2509,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
CTNNA1,HTM,Down,2509,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
CTNNA3,HTM,Up,2511,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
CTNNA3,HTM,Up,2511,Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by Transcriptomics and qPCR,0.4,0.0021,26621583
CTNNAL1,HTM,Up,2512,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22740085
CTNNAL1,HTM,Down,2512,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CTNNAL1,HTM,Down,2512,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CTNNAL1,HTM,Down,2512,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
CTNNAL1,HTM,Down,2512,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
CTNNB1,HTM,Down,2514,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0647,34059086
CTNNB1,HTM,Down,2514,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0647,25881239
CTNNB1,HTM,Down,2514,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.28,0.0647,29352988
CTNNB1,HTM,Down,2514,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.28,0.0647,29352988
CTNNB1,HTM,Down,2514,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.28,0.0647,23903875
CTNNB1,HTM,Down,2514,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.28,0.0647,27965308
CTNNB1,HTM,Down,2514,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0647,25881239
CTNNB1,HTM,Up,2514,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics,0.04,0.0647,25731617
CTNNB1,HTM,Down,2514,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0647,29340052
CTNNB1,HTM,Up,2514,Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by Transcriptomics and qPCR,0.4,0.0647,26621583
CTNNB1,HTM,Up,2514,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0647,29959199
CTNNBL1,HTM,Down,15879,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CTNND1,HTM,Down,2515,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
CTNND1,HTM,Up,2515,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CTNND1,HTM,Up,2515,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
CTNND1,HTM,Down,2515,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
CTPS1,HTM,Down,2519,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CTRL,HTM,Up,2524,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CTRL,HTM,Up,2524,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CTRL,HTM,Up,2524,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CTSB,HTM,Down,2527,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
CTSB,HTM,Down,2527,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
CTSB,HTM,Down,2527,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0053,34168259
CTSC,HTM,Up,2528,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CTSC,HTM,Down,2528,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CTSD,HTM,Up,2529,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0053,34794402
CTSD,HTM,Up,2529,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0053,34794402
CTSD,HTM,Up,2529,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.28,0.0053,32503348
CTSD,HTM,Up,2529,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
CTSD,HTM,Down,2529,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0053,34168259
CTSD,HTM,Down,2529,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0053,34168259
CTSD,HTM,Down,2529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.36,0.0053,27746256
CTSD,HTM,Down,2529,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0053,34168259
CTSF,HTM,Down,2531,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
CTSF,HTM,Up,2531,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CTSF,HTM,Up,2531,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
CTSH,HTM,Down,2535,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CTSK,HTM,Down,2536,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CTSL,HTM,Up,2537,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CTSL,HTM,Up,2537,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CTSL,HTM,Up,2537,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CTSO,HTM,Up,2542,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CTSV,HTM,Up,2538,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CTSZ,HTM,Down,2547,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CTSZ,HTM,Down,2547,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CTSZ,HTM,Down,2547,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CTTN,HTM,Down,3338,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
CTTN,HTM,Up,3338,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CTTN,HTM,Up,3338,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CTTNBP2,HTM,Up,15679,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0011,17932721
CTTNBP2NL,HTM,Down,25330,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CTTNBP2NL,HTM,Down,25330,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CTTNBP2NL,HTM,Down,25330,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CUL4A,HTM,Down,2554,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
CUTA,HTM,Up,21101,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CUTA,HTM,Up,21101,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CUTA,HTM,Down,21101,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
CUTC,HTM,Up,24271,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CUTC,HTM,Up,24271,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CUTC,HTM,Up,24271,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CUTC,HTM,Up,24271,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CUTC,HTM,Up,24271,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CUTC,HTM,Up,24271,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
CUX2,HTM,Down,19347,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CUX2,HTM,Down,19347,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CWC22,HTM,Up,29322,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
CWC22,HTM,Down,29322,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
CWC22,HTM,Up,29322,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
CX3CL1,HTM,Up,10647,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CX3CL1,HTM,Up,10647,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CX3CL1,HTM,Up,10647,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
CXADR,HTM,Up,2559,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CXADR,HTM,Up,2559,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CXADR,HTM,Up,2559,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CXADR,HTM,Down,2559,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
CXCL1,HTM,Down,4602,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
CXCL1,HTM,Down,4602,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
CXCL1,HTM,Down,4602,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
CXCL1,HTM,Up,4602,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
CXCL1,HTM,Down,4602,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0064,30696080
CXCL1,HTM,Down,4602,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0064,30696080
CXCL1,HTM,Down,4602,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.12,0.0064,22954703
CXCL11,HTM,Up,10638,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0021,30592142
CXCL11,HTM,Up,10638,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0021,30592142
CXCL11,HTM,UP,10638,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
CXCL11,HTM,UP,10638,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
CXCL11,HTM,UP,10638,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
CXCL11,HTM,UP,10638,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
CXCL11,HTM,UP,10638,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
CXCL119,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CXCL119,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CXCL119,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CXCL12,HTM,Up,10672,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,20424609
CXCL12,HTM,Up,10672,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,20424609
CXCL12,HTM,Down,10672,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CXCL12,HTM,Down,10672,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CXCL12,HTM,Down,10672,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CXCL1210,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CXCL1210,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CXCL1210,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CXCL14,HTM,Up,10640,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
CXCL14,HTM,Up,10640,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
CXCL14,HTM,Down,10640,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0032,19451087
CXCL14,HTM,Up,10640,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CXCL16,HTM,Down,16642,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CXCL17,HTM,Up,19232,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CXCL17,HTM,Up,19232,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CXCL2,HTM,Down,4603,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
CXCL2,HTM,Down,4603,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
CXCL2,HTM,Up,4603,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,30254465
CXCL2,HTM,Up,4603,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,31709178
CXCL2,HTM,Up,4603,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
CXCL2,HTM,Up,4603,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
CXCL2,HTM,Up,4603,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0074,31501409
CXCL2,HTM,Up,4603,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
CXCL2,HTM,Down,4603,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0074,28881576
CXCL3,HTM,Up,4604,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CXCL5,HTM,Down,10642,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CXCL5,HTM,Up,10642,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CXCL6,HTM,Up,10643,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CXCL8,HTM,Up,6025,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,27965308
CXCR1,HTM,Up,6026,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CXCR4,HTM,Down,2561,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.4,0.0498,34059086
CXCR4,HTM,Down,2561,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.4,0.0498,34059086
CXCR4,HTM,Down,2561,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.4,0.0498,34059086
CXCR4,HTM,Up,2561,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0498,19353633
CXCR4,HTM,Up,2561,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0498,24961511
CXCR4,HTM,Up,2561,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0498,24961511
CXCR4,HTM,Down,2561,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.24,0.0498,24961511
CXCR4,HTM,Up,2561,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.24,0.0498,24961511
CXCR4,HTM,Up,2561,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.48,0.0498,34680485
CXCR4,HTM,Up,2561,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.48,0.0498,19353633
CXCR4,HTM,Up,2561,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.48,0.0498,31501409
CXCR4,HTM,Up,2561,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0498,34414448
CXCR4,HTM,Up,2561,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.48,0.0498,19353633
CXCR4,HTM,Up,2561,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.32,0.0498,35013621
CXORF49,HTM,Down,30891,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
CXXC5,HTM,Up,26943,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CXXC5,HTM,Down,26943,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CYB561,HTM,Down,2571,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CYB561,HTM,Down,2571,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CYB561,HTM,Up,2571,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
CYB5A,HTM,Down,2570,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CYB5A,HTM,Up,2570,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
CYB5B,HTM,Up,24374,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CYB5B,HTM,Up,24374,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
CYB5B,HTM,Up,24374,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
CYB5R1,HTM,Down,13397,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CYB5R2,HTM,Down,24376,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CYB5R2,HTM,Down,24376,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CYB5R3,HTM,Up,2873,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CYBRD1,HTM,Up,20797,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CYBRD1,HTM,Up,20797,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CYBRD1,HTM,Up,20797,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CYC1,HTM,Up,2579,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CYC1,HTM,Up,2579,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CYCS,HTM,Down,19986,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
CYCS,HTM,Up,19986,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
CYCS,HTM,Up,19986,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
CYCS,HTM,Up,19986,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
CYFIP2,HTM,Up,13760,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CYFIP2,HTM,Up,13760,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CYFIP2,HTM,Down,13760,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CYFIP2,HTM,Down,13760,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CYGB,HTM,Up,16505,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CYGB,HTM,Up,16505,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CYLD,HTM,Down,2584,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
CYLD,HTM,Up,2584,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
CYP1A1,HTM,Down,2595,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
CYP1A1,HTM,Up,2595,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
CYP1A1,HTM,Up,2595,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CYP1A1,HTM,Up,2595,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
CYP1A1,HTM,Up,2595,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
CYP1B1,HTM,Up,2597,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,29416721
CYP1B1,HTM,Up,2597,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
CYP1B1,HTM,Up,2597,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
CYP1B1,HTM,Up,2597,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
CYP1B1,HTM,Up,2597,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
CYP1B1,HTM,Down,2597,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,29340052
CYP1B1,HTM,Up,2597,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0064,20530554
CYP20A1,HTM,Down,20576,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
CYP24A1,HTM,Up,2602,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CYP24A1,HTM,Up,2602,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CYP24A1,HTM,Down,2602,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CYP24A1,HTM,Down,2602,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CYP26B1,HTM,Up,20581,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
CYP27C1,HTM,Down,33480,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CYP27C1,HTM,Down,33480,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CYP2C19,HTM,Up,2621,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
CYP2C8,HTM,Up,2622,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CYP2C8,HTM,Up,2622,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CYP2C8,HTM,Down,2622,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
CYP2J2,HTM,Up,2634,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CYP2R1,HTM,Down,20580,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CYP3A5,HTM,Down,2638,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CYP3A5,HTM,Up,2638,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CYP3A5,HTM,Up,2638,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CYP3A5,HTM,Up,2638,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CYP3A7,HTM,Down,2640,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
CYP3A7,HTM,Down,2640,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CYP3A7,HTM,Down,51504,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
CYP46A1,HTM,Up,2641,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CYP4B1,HTM,Up,2644,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CYP4F11,HTM,Up,13265,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CYP4F11,HTM,Up,13265,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CYP4F11,HTM,Down,13265,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CYP4F11,HTM,Up,13265,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CYP4F12,HTM,Down,18857,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
CYP4F12,HTM,Up,18857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CYP4F2,HTM,Down,2645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CYP4F2,HTM,Down,2645,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
CYP4F22,HTM,Up,26820,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
CYP4F3,HTM,Up,2646,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
CYP4F3,HTM,Up,2646,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CYP4F3,HTM,Down,2646,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
CYP4V2,HTM,Down,2640,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CYP4V2,HTM,Up,23198,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
CYP4V2,HTM,Down,23198,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
CYP4V2,HTM,Down,51504,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
CYP4Z2P,HTM,Up,24426,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CYP4Z2P,HTM,Up,24426,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CYP4Z2P,HTM,Up,24426,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
CYP51A1,HTM,Up,2649,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
CYP51A1,HTM,Up,2649,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
CYP51A1,HTM,Up,2649,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
CYP51A1,HTM,Up,2649,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
CYP51A1,HTM,Up,2649,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
CYP51A1,HTM,Up,2649,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
CYR61,HTM,Up,2654,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,25432175
CYR61,HTM,Down,2654,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0053,34059086
CYR61,HTM,Down,2654,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0053,25881239
CYR61,HTM,Down,2654,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0053,25881239
CYR61,HTM,Down,2654,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
CYR61,HTM,Up,2654,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
CYR61,HTM,Down,2654,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
CYR61,HTM,Down,2654,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
CYSRT1,HTM,Up,30529,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CYSRT1,HTM,Up,30529,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CYSRT1,HTM,Up,30529,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
CYSRT1,HTM,Up,30529,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
CYSTM1,HTM,Up,30239,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
CYTB,HTM,Up,7427,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
CYTH1,HTM,Down,23198,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CYTH1,HTM,Down,23198,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
CYTL1,HTM,Down,24435,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
CYTOR,HTM,UP,28717,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
CYTOR,HTM,UP,28717,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
CYTOR,HTM,UP,28717,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
CYTOR,HTM,UP,28717,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
CYTOR,HTM,UP,28717,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
DAAM1,HTM,Down,18142,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DAAM1,HTM,Down,18142,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
DAAM2,HTM,Up,18143,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DAB2,HTM,Down,2662,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
DAB2,HTM,Up,2662,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
DAB2,HTM,Up,2662,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
DAB2,HTM,Down,2662,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
DAB2IP,HTM,Down,17294,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DACH1,HTM,Down,2663,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
DAD1,HTM,Up,2664,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
DAGLA,HTM,Up,1165,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
DAP,HTM,Up,2672,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DAPK1,HTM,Up,2674,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
DAPK1,HTM,Up,2674,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
DAPK1,HTM,Down,2674,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
DAPK1,HTM,Up,2674,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
DAPK1,HTM,Down,2674,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
DAPK1,HTM,Up,2674,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
DAPK1,HTM,Down,2674,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
DAPK1,HTM,Up,2674,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
DAPP1,HTM,Down,16500,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
DAPP1,HTM,Down,16500,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DAPP1,HTM,Down,16500,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DAPP1,HTM,Down,16500,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DAPP1,HTM,Down,16500,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
DARS2,HTM,Down,25538,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DBF4,HTM,Up,17364,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DBF4,HTM,Up,17364,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DBF4,HTM,Up,17364,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DBF4B,HTM,Down,17883,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DBI,HTM,Up,2690,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
DBI,HTM,Up,2690,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
DBN1,HTM,Down,2695,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
DBN1,HTM,Up,2695,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
DBNL,HTM,Down,2696,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
DBP,HTM,Down,2697,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DC2,HTM,Up,24448,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
DC2,HTM,Up,24448,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
DC2,HTM,Up,24448,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
DC2,HTM,Up,24448,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
DC2,HTM,Up,24448,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
DC2,HTM,Up,24448,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
DCAF11,HTM,Down,20258,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DCAF11,HTM,Down,20258,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DCAF12,HTM,Down,19911,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DCAF12,HTM,Down,19911,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DCAF13,HTM,Up,24535,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
DCAF13,HTM,Up,24535,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
DCAF13,HTM,Down,24535,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
DCAF13,HTM,Up,24535,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
DCAF13,HTM,Up,24535,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
DCAF17,HTM,Down,25784,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
DCAF6,HTM,Down,30002,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DCAF8,HTM,Down,24891,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
DCBLD1,HTM,Up,21479,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
DCBLD2,HTM,Down,24627,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DCBLD2,HTM,Down,24627,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0021,19451087
DCDC2,HTM,Up,18141,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DCDC2,HTM,Up,18141,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DCDC2,HTM,Down,18141,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
DCLK1,HTM,Up,2700,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0159,25881239
DCLK1,HTM,Up,2700,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0159,34680485
DCLRE1A,HTM,Up,17660,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DCLRE1B,HTM,Down,17641,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DCLRE1B,HTM,Up,17641,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DCLRE1B,HTM,Up,17641,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DCLRE1B,HTM,Up,17641,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DCPS,HTM,Down,29812,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
DCSTAMP,HTM,Down,18549,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
DCSTAMP,HTM,Down,18549,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
DCTN2,HTM,Up,2712,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
DCTN4,HTM,Up,15518,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
DCTPP1,HTM,Down,28777,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DCTPP1,HTM,Down,28777,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
DCTPP1,HTM,Down,28777,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DCTPP1,HTM,Down,28777,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DCTPP1,HTM,Down,28777,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DCTPP1,HTM,Down,28777,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DCUN1D4,HTM,Up,28998,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
DDAH1,HTM,Up,2715,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DDAH1,HTM,Up,2715,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
DDB1,HTM,Down,2717,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
DDB2,HTM,Up,2718,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,29316740
DDC,HTM,Up,2719,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DDHD1,HTM,Up,19714,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DDIAS,HTM,Down,26351,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DDIT3,HTM,Up,2726,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
DDIT3,HTM,Up,2726,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.2,0.0032,19353633
DDIT3,HTM,Up,2726,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
DDIT4,HTM,Up,24944,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DDIT4,HTM,Up,24944,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DDIT4,HTM,Down,24944,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
DDIT4,HTM,Down,24944,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
DDIT4,HTM,Up,24944,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DDIT4L,HTM,Up,30555,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DDOST,HTM,Up,2728,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
DDOST,HTM,Down,2728,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
DDR1,HTM,Up,2730,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
DDR1,HTM,Up,2730,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
DDR1,HTM,Down,2730,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
DDR1,HTM,Up,2730,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
DDR2,HTM,Up,2731,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,34228218
DDR2,HTM,Up,2731,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
DDR2,HTM,Up,2731,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
DDR2,HTM,Up,2731,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
DDR2,HTM,Down,2731,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
DDR2,HTM,Up,2731,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
DDRGK1,HTM,Down,16110,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
DDT,HTM,Down,2732,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
DDX17,HTM,Down,2740,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
DDX17,HTM,Up,2740,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
DDX18,HTM,Down,2741,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
DDX18,HTM,Down,2741,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
DDX21,HTM,Down,2744,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
DDX21,HTM,Up,2744,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
DDX21,HTM,Down,2744,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
DDX21,HTM,Down,2744,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
DDX23,HTM,Up,17347,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DDX31,HTM,Up,16715,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
DDX39B,HTM,Up,13917,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
DDX39B,HTM,Down,13917,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
DDX39B,HTM,Down,13917,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
DDX39B,HTM,Down,13917,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
DDX3X,HTM,Down,2745,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,22623141
DDX3Y,HTM,Down,2699,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DDX5,HTM,Down,2746,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
DDX5,HTM,Down,2746,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
DDX5,HTM,Up,2746,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
DDX55,HTM,Up,20085,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DDX58,HTM,Down,19102,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DDX58,HTM,Down,19102,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DDX58,HTM,Down,19102,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DDX58,HTM,Up,19102,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
DDX60,HTM,Up,25942,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0011,30592142
DDX60,HTM,Up,25942,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0011,30592142
DEDD2,HTM,Up,24450,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
DEF6,HTM,Down,2760,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DEFB123,HTM,Down,18103,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
DEFB136,HTM,Down,34433,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DEGS2,HTM,Up,20113,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DENND10,HTM,Down,31793,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
DENND10,HTM,Down,31793,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
DENND11,HTM,Down,29472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
DENND11,HTM,Up,29472,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DENND1B,HTM,Down,28404,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
DENND1B,HTM,Up,28404,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DENND1B,HTM,Up,28404,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DENND1B,HTM,Down,28404,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
DENND1B,HTM,Down,28404,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
DENND1C,HTM,Down,26225,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DENND2B,HTM,Down,11350,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DENND2B,HTM,Down,11350,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
DENND2B,HTM,Down,11350,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
DENND2B,HTM,Down,11350,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
DENND2C,HTM,Up,24748,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DENND2C,HTM,Up,24748,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DENND2C,HTM,Up,24748,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
DENND2D,HTM,Down,26192,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
DENND2D,HTM,Up,26192,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
DENND5B,HTM,Up,28338,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DENND5B,HTM,Up,28338,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DENND5B,HTM,Up,28338,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
DENND5B,HTM,Up,28338,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DENND5B,HTM,Up,28338,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DENND5B,HTM,Up,28338,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DENR,HTM,Up,2769,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
DEPDC1,HTM,Up,22949,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22740085
DEPDC1,HTM,Down,22949,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
DEPDC1,HTM,Down,22949,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
DEPDC1B,HTM,Down,24902,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
DEPP1,HTM,Down,23355,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
DEPP1,HTM,Down,23355,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
DEPP1,HTM,Up,23355,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
DEPTOR,HTM,Up,22953,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DERL1,HTM,Up,28454,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
DERL1,HTM,Down,28454,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
DET1,HTM,Up,25477,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DET1,HTM,Up,25477,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DET1,HTM,Up,25477,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
DEXI,HTM,Down,13267,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DEXI,HTM,Down,13267,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DFFA,HTM,Up,2772,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DFFA,HTM,Up,2772,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DFFA,HTM,Up,2772,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DFNA5,HTM,Down,2674,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
DFNA5,HTM,Down,2674,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
DFNA5,HTM,Down,2810,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DFNB59,HTM,Down,2810,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
DFNB59,HTM,Down,2810,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
DGAT1,HTM,Down,2843,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DGAT2,HTM,Up,16940,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
DGAT2,HTM,Down,16940,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
DGCR5,HTM,Down,16757,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DGCR5,HTM,Down,16757,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DGCR8,HTM,Up,2847,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
DGCR8,HTM,Up,2847,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DGCR8,HTM,Up,2847,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DGCR8,HTM,Down,2847,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
DGCR8,HTM,Up,2847,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DGKA,HTM,Down,2849,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DGKA,HTM,Down,2849,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DGKA,HTM,Down,2849,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DGKD,HTM,Up,2851,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DGKD,HTM,Up,2851,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DGKH,HTM,Down,2854,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DGKH,HTM,Down,2854,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DHCR24,HTM,Down,2859,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
DHCR24,HTM,Down,2859,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
DHCR24,HTM,Down,2859,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
DHCR24,HTM,Up,2859,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0053,19451087
DHCR24,HTM,Up,2859,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
DHCR24,HTM,Up,2859,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0053,34168259
DHCR24,HTM,Up,2859,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0053,34168259
DHCR7,HTM,Down,2860,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
DHCR7,HTM,Up,2860,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,25676692
DHCR7,HTM,Up,2860,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.24,0.0064,26259570
DHCR7,HTM,Up,2860,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.24,0.0064,26259570
DHCR7,HTM,Up,2860,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
DHCR7,HTM,Up,2860,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
DHCR7,HTM,Up,2860,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0064,28881576
DHDH,HTM,Down,17887,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DHDH,HTM,Down,17887,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DHFR,HTM,Down,2861,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
DHFR,HTM,Up,2861,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
DHFR,HTM,Up,2861,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
DHFR,HTM,Down,2861,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0042,23820871
DHFR,HTM,Down,2861,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
DHH,HTM,NA,2865,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
DHRS1,HTM,Down,16445,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DHRS1,HTM,Down,16445,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DHRS1,HTM,Down,16445,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DHRS1,HTM,Up,16445,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DHRS1,HTM,Up,16445,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DHRS1,HTM,Up,16445,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DHRS2,HTM,Up,18349,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
DHRS3,HTM,Down,17693,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0032,30592142
DHRS3,HTM,Down,17693,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.24,0.0032,31501409
DHRS3,HTM,Down,17693,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0032,30592142
DHRS7,HTM,Up,21524,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
DHRS9,HTM,Down,16888,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0064,22740085
DHRS9,HTM,Down,16888,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,34059086
DHRS9,HTM,Up,16888,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
DHRS9,HTM,Up,16888,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,29340052
DHRS9,HTM,Up,16888,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0064,34168259
DHRS9,HTM,Down,16888,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0064,24098529
DHX38,HTM,Down,17211,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
DHX38,HTM,Up,17211,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
DHX40,HTM,Up,18018,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DHX40,HTM,Up,18018,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DHX57,HTM,Down,20086,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DHX9,HTM,Down,2750,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
DHX9,HTM,Down,2750,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
DHX9,HTM,Up,2750,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
DHX9,HTM,Down,2750,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
DHX9,HTM,Down,2750,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0053,34168259
DHX9,HTM,Up,2750,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
DHX9,HTM,Down,2750,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,29340052
DIAPH1,HTM,Up,2876,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
DIAPH1,HTM,Up,2876,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
DIAPH2,HTM,Up,2877,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DIAPH2-AS1,HTM,Up,16972,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
DICER1-AS1,HTM,Down,43017,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DIDO1,HTM,Up,2680,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
DIO2,HTM,Up,2884,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
DIO2,HTM,Down,2884,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
DIO3,HTM,Down,2885,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DIO3,HTM,Down,2885,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DIO3OS,HTM,Down,20348,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DIPK1A,HTM,Down,32213,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DIPK1A,HTM,Down,32213,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
DIPK2A,HTM,Up,28490,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DIPK2A,HTM,Up,28490,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DIPK2A,HTM,Up,28490,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DIRAS2,HTM,Up,19323,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DIRAS3,HTM,NA,687,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0011,29352988
DIS3,HTM,Down,20604,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
DIS3L,HTM,Up,28698,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DIS3L,HTM,Up,28698,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DIS3L2,HTM,Down,28648,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
DIS3L2,HTM,Down,28648,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
DIXDC1,HTM,Up,23695,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DJ434O11,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
DJ434O11,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
DJ434O11,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
DKK1,HTM,Down,2891,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
DKK1,HTM,Up,2891,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0042,17932721
DKK1,HTM,Down,2891,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
DKK1,HTM,Down,2891,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
DKK3,HTM,Down,2893,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
DKK3,HTM,Down,2893,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
DKK3,HTM,Down,2893,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
DKK3,HTM,Up,2893,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
DKK3,HTM,Down,2893,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
DKK3,HTM,Up,2893,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
DKK3,HTM,Down,2893,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
DKK3,HTM,Up,2893,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
DLAT,HTM,Up,2896,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
DLC1,HTM,Down,2897,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
DLC1,HTM,Down,2897,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
DLC1,HTM,Up,2897,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
DLC1,HTM,Down,2897,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
DLC1,HTM,Up,2897,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0042,17911267
DLD,HTM,Up,2898,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
DLEU1,HTM,Up,13747,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DLEU1,HTM,Up,13747,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DLEU1,HTM,Up,13747,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DLG1,HTM,Down,2900,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DLG1,HTM,Down,2900,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DLG3,HTM,Up,2902,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DLG3,HTM,Down,2902,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
DLG3,HTM,Down,2902,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
DLG4,HTM,Down,2903,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
DLG5,HTM,Down,2904,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DLG5,HTM,Down,2904,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
DLG5,HTM,Up,2904,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
DLGAP1-AS1,HTM,Up,31676,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DLGAP5,HTM,Down,16864,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
DLL1,HTM,NA,2908,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by PCR array assay,0.04,0.0032,20630067
DLL1,HTM,NA,2908,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0032,20630067
DLL1,HTM,Down,2908,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
DLL1,HTM,Up,2908,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,35013621
DLL3,HTM,NA,2909,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
DLL4,HTM,Down,2910,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
DLST,HTM,Up,2911,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
DLST,HTM,Up,2911,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
DLST,HTM,Up,2911,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
DLST,HTM,Down,2911,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
DLST,HTM,Up,2911,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
DLX1,HTM,Down,2914,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
DLX3,HTM,Down,2916,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
DLX3,HTM,Down,2916,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
DLX3,HTM,Down,2916,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
DLX4,HTM,Down,2917,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DLX6-AS1,HTM,Down,37151,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
DLX6-AS1,HTM,Down,37151,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
DMAC2,HTM,Down,25496,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DMACs2L,HTM,Down,18799,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DMACs2L,HTM,Down,18799,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
DMACs2L,HTM,Down,18799,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
DMACs2L,HTM,Down,18799,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DMACs2L,HTM,Down,18799,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DMACs2L,HTM,Down,18799,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DMACs2L,HTM,Down,18799,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DMACs2L,HTM,Down,18799,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
DMBT1,HTM,Up,2926,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DMBT1,HTM,Up,2926,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DMBT1,HTM,Up,2926,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
DMBT1,HTM,Up,2926,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
DMBT1,HTM,Up,2926,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DMC1,HTM,Up,2927,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
DMD,HTM,Up,2928,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
DMGDH,HTM,Down,24475,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
DMKN,HTM,Down,25063,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DMKN,HTM,Down,25063,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DMKN,HTM,Down,25063,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DMKN,HTM,Up,25063,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
DMKN,HTM,Down,25063,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
DMP1,HTM,Up,2932,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DMPK,HTM,Down,2933,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
DMRT2,HTM,Up,2935,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DMRTA1,HTM,Down,13826,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DMRTC1,HTM,Down,13910,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DMTF1,HTM,Up,14603,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
DMTN,HTM,Down,3382,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
DMTN,HTM,Down,3382,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
DMTN,HTM,Up,3382,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
DMXL2,HTM,Up,2938,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DMXL2,HTM,Up,2938,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DNA2,HTM,Up,2939,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DNA2,HTM,Down,2939,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
DNAAF11,HTM,Down,16725,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DNAH1,HTM,Down,2940,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
DNAH11,HTM,Down,2942,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
DNAH11,HTM,Down,2942,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
DNAH12,HTM,Up,2943,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
DNAH14,HTM,Up,2945,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DNAH14,HTM,Up,2945,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
DNAH2,HTM,Down,2948,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DNAH9,HTM,Up,2953,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
DNAJA1,HTM,Up,5229,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
DNAJA4,HTM,Down,14885,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DNAJB11,HTM,Up,14889,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
DNAJB11,HTM,Up,14889,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
DNAJB13,HTM,Down,30718,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
DNAJB6,HTM,Up,14888,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
DNAJC10,HTM,Up,24637,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
DNAJC10,HTM,Up,24637,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
DNAJC10,HTM,Down,24637,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
DNAJC10,HTM,Up,24637,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
DNAJC12,HTM,Up,28908,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DNAJC12,HTM,Up,28908,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DNAJC12,HTM,Up,28908,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
DNAJC12,HTM,Up,28908,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
DNAJC12,HTM,Up,28908,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
DNAJC12,HTM,Up,28908,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
DNAJC14,HTM,Down,24581,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
DNAJC19,HTM,Up,30528,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
DNAJC19,HTM,Up,30528,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DNAJC19,HTM,Up,30528,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DNAJC19,HTM,Up,30528,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DNAJC19,HTM,Up,30528,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DNAJC19,HTM,Up,30528,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
DNAJC21,HTM,Down,27030,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
DNAJC22,HTM,Down,25802,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DNAJC24,HTM,Up,26979,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
DNAJC28,HTM,Down,1297,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
DNAJC28,HTM,Down,1297,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
DNAJC3,HTM,Down,9439,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DNAJC4,HTM,Up,5271,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DNAJC5,HTM,Down,16235,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DNAJC5B,HTM,Down,24138,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
DNASE1L2,HTM,Up,2958,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DND1,HTM,Down,23799,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DNER,HTM,Up,24456,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
DNER,HTM,Up,24456,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
DNER,HTM,Down,24456,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
DNER,HTM,Down,24456,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
DNHD1,HTM,Up,26532,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DNM1,HTM,Up,2972,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DNM1,HTM,Up,2972,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DNM3,HTM,Down,29125,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DNMBP,HTM,Down,30373,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DNMBP,HTM,Down,30373,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
DNMT3B,HTM,Down,2979,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DNPH1,HTM,Up,21218,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DNPH1,HTM,Up,21218,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DNPH1,HTM,Up,21218,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DOC2A,HTM,Up,2985,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
DOCK10,HTM,Up,23479,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
DOCK10,HTM,Up,23479,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
DOCK10,HTM,Down,23479,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
DOCK10,HTM,Down,23479,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
DOCK10,HTM,Down,23479,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0042,28881576
DOCK11,HTM,Up,23483,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DOCK11,HTM,Down,23483,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
DOCK4,HTM,Down,19192,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DOCK4,HTM,Down,19192,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DOCK4,HTM,Up,19192,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
DOCK5,HTM,Up,23476,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
DOCK7,HTM,Down,19190,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DOCK7,HTM,Down,19190,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DOCK8,HTM,Down,19191,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
DOCK8,HTM,Down,19191,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
DOCK9,HTM,Down,14132,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DOCK9,HTM,Down,14132,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DOK1,HTM,Down,2990,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DOK2,HTM,NA,2991,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0011,29352988
DOK4,HTM,Up,19868,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DOK4,HTM,Up,19868,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DOK7,HTM,Up,26594,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DOLK,HTM,Down,23406,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DOLK,HTM,Down,23406,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DOM3Z,HTM,Up,2992,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
DOP1B,HTM,Down,1291,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DOP1B,HTM,Down,1291,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DOP1B,HTM,Down,1291,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DPEP1,HTM,Down,3002,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
DPEP1,HTM,Down,3002,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
DPEP3,HTM,Up,23029,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
DPF3,HTM,Up,17427,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DPH6,HTM,Down,30543,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
DPP10,HTM,Up,20823,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DPP4,HTM,Up,3009,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0085,29416721
DPP4,HTM,Up,3009,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0085,34680485
DPP9,HTM,Down,18648,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DPY19L1,HTM,Up,22205,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DPY19L1,HTM,Up,22205,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DPY19L2,HTM,Up,19414,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
DPY19L2,HTM,Up,19414,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
DPY19L2P1,HTM,Down,22305,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DPY30,HTM,Down,24590,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
DPYD,HTM,Down,3012,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
DPYD,HTM,Down,3012,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
DPYD,HTM,Up,3012,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
DPYD,HTM,Up,3012,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
DPYS,HTM,Down,3013,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
DPYSL2,HTM,Up,3014,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DPYSL2,HTM,Up,3014,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DPYSL2,HTM,Up,3014,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
DPYSL2,HTM,Down,3014,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
DPYSL3,HTM,Down,3015,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DRAP1,HTM,Down,3019,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DRD1,HTM,Up,3020,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DSC1,HTM,Up,3035,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
DSC1,HTM,Up,3035,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
DSC2,HTM,Up,3036,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,29416721
DSC2,HTM,Down,3036,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
DSC2,HTM,Down,3036,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
DSC2,HTM,Down,3036,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
DSC2,HTM,Up,3036,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
DSC2,HTM,Up,3036,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0053,20530554
DSC3,HTM,Down,3037,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DSC3,HTM,Down,3037,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DSC3,HTM,Down,3037,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DSC3,HTM,Down,3037,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
DSCAM,HTM,Down,3039,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DSCAM-AS1,HTM,Down,40197,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DSCR1,HTM,Down,3040,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
DSCR1,HTM,Down,3040,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
DSCR1,HTM,Down,3040,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
DSCR8,HTM,Up,16707,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
DSCR8,HTM,Down,16707,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
DSE,HTM,Down,21144,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DSE,HTM,Down,21144,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DSE,HTM,Down,21144,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DSE,HTM,Down,21144,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
DSE,HTM,Down,21144,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
DSEL,HTM,Down,18144,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DSEL,HTM,Up,18144,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
DSG1,HTM,Up,3048,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DSG2,HTM,Down,3049,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DSG2,HTM,Up,3049,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
DSG3,HTM,Up,3050,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
DSG3,HTM,Down,3050,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DSG3,HTM,Down,3050,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DSG3,HTM,Down,3050,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
DSG3,HTM,Down,3050,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
DSN1,HTM,Down,16165,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
DSP,HTM,Down,3052,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
DSP,HTM,Up,3052,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
DSP,HTM,Down,3052,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
DSP,HTM,Up,3052,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
DSP,HTM,Down,3052,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
DSP,HTM,Down,3052,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
DSP,HTM,Up,3052,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
DST,HTM,Down,1090,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
DST,HTM,Up,1090,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
DST,HTM,Up,1090,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
DST,HTM,Down,1090,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
DST,HTM,Down,1090,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
DSTNP2,HTM,Up,34546,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DTL,HTM,Up,30288,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DTL,HTM,Up,30288,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DTL,HTM,Up,30288,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
DTNA,HTM,Up,3057,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
DTNA,HTM,Down,3057,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
DTNA,HTM,Up,3057,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
DTNA,HTM,Down,3057,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
DTNA,HTM,Up,3057,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
DTNA,HTM,Down,3057,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
DTNA,HTM,Down,3057,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
DTNA,HTM,Up,3057,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
DTX1,HTM,NA,3060,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
DTX1,HTM,NA,3060,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
DTX2,HTM,Down,15973,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DTX3L,HTM,Up,30323,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
DTX4,HTM,Down,29151,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
DTX4,HTM,Down,29151,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
DTX4,HTM,Down,29151,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
DUOX1,HTM,Down,3062,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DUOX1,HTM,Down,3062,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DUOX2,HTM,Down,13273,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DUOX2,HTM,Down,13273,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DUS2,HTM,Down,26014,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DUS3L,HTM,Up,26920,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
DUS3L,HTM,Up,26920,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
DUSP1,HTM,Down,3064,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
DUSP1,HTM,Down,3064,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
DUSP1,HTM,Down,3064,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
DUSP1,HTM,Down,3064,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
DUSP10,HTM,Down,3065,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
DUSP10,HTM,Up,3065,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DUSP10,HTM,Down,3065,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
DUSP10,HTM,Up,3065,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DUSP10,HTM,Up,3065,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DUSP11,HTM,Down,3066,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DUSP13,HTM,Up,19681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
DUSP16,HTM,Up,17909,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DUSP2,HTM,Down,3068,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
DUSP28,HTM,Down,33237,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DUSP4,HTM,Up,3070,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
DUSP4,HTM,Up,3070,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
DUSP5,HTM,Up,3071,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
DUSP5,HTM,Up,3071,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
DUSP6,HTM,Down,3072,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
DUSP6,HTM,Down,3072,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
DUSP6,HTM,Up,3072,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
DUSP6,HTM,Down,3072,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0053,26351321
DUSP6,HTM,Down,3072,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
DUSP6,HTM,Up,3072,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
DUSP6,HTM,Up,3072,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
DUSP6,HTM,Up,3072,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
DUSP6,HTM,Up,3072,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
DUSP7,HTM,Down,3073,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DUSP7,HTM,Down,3073,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DUSP7,HTM,Down,3073,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DUSP8,HTM,Down,3074,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,27965308
DUSP9,HTM,Down,3076,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
DUT,HTM,Down,3078,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
DUT,HTM,Down,3078,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
DUX4,HTM,Down,50800,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DUXAP9,HTM,Up,32188,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DUXAP9,HTM,Up,32188,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DUXAP9,HTM,Up,32188,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DUXAP9,HTM,Up,32188,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
DYM,HTM,Up,21317,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
DYNC1H1,HTM,Up,2961,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
DYNC1H1,HTM,Up,2961,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
DYNC1H1,HTM,Up,2961,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
DYNC1H1,HTM,Up,2961,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
DYNC1H1,HTM,Up,2961,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
DYNC1I1,HTM,Up,2963,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0021,34794402
DYNC1I1,HTM,Up,2963,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0021,34794402
DYNC1I1,HTM,Up,2963,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0021,17932721
DYNC1LI1,HTM,Down,18745,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DYNC1LI1,HTM,Up,18745,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DYNC1LI1,HTM,Up,18745,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DYNC1LI1,HTM,Up,18745,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DYNC2H1,HTM,Up,2962,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
DYNC2H1,HTM,Down,2962,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
DYNC2I1,HTM,Down,21862,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
DYNC2I1,HTM,Up,21862,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DYNC2I1,HTM,Up,21862,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DYNC2I1,HTM,Up,21862,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
DYNLL1,HTM,Down,15476,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
DYNLL1,HTM,Down,15476,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
DYNLL2,HTM,Down,24596,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
DYRK3,HTM,Up,3094,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
DYSF,HTM,Down,3097,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
DYSF,HTM,Up,3097,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
DYX1C1,HTM,Up,21493,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
DYX1C1,HTM,Down,21493,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
DZIP1,HTM,Down,20908,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
DZIP1,HTM,Down,20908,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DZIP1,HTM,Up,20908,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
DZIP3,HTM,Down,30938,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
DZIP3,HTM,Up,30938,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
E2F1,HTM,Down,3113,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
E2F2,HTM,Down,3114,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
E2F5,HTM,Up,3119,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
E2F5,HTM,Up,3119,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
E2F7,HTM,Down,23820,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,29316740
E2F7,HTM,Down,23820,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
E2F7,HTM,Down,23820,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
E2F7,HTM,Down,23820,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
E2F8,HTM,Up,24727,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EAF1,HTM,Up,20907,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
EAPP,HTM,Up,19312,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EBF1,HTM,Up,3126,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EBF1,HTM,Up,3126,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EBI3,HTM,Up,3129,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
EBP,HTM,Down,3133,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
EBP,HTM,Down,3133,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
EBP,HTM,Up,3133,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
EBP,HTM,Up,3133,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
EBP,HTM,Up,3133,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
EBPL,HTM,Up,18061,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EBPL,HTM,Down,18061,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ECEL1,HTM,Down,3147,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ECH1,HTM,Up,3149,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ECH1,HTM,Up,3149,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ECH1,HTM,Up,3149,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ECH1,HTM,Up,3149,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ECH1,HTM,Up,3149,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
ECH1,HTM,Up,3149,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
ECHDC3,HTM,Down,23489,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ECHDC3,HTM,Down,23489,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ECHDC3,HTM,Down,23489,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ECHDC3,HTM,Down,23489,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ECHS1,HTM,Up,3151,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
ECHS1,HTM,Up,3151,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
ECHS1,HTM,Up,3151,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
ECHS1,HTM,Down,3151,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,25081334
ECHS1,HTM,Down,3151,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
ECM1,HTM,Up,3153,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ECM2,HTM,Up,3154,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22740085
ECM2,HTM,Up,3154,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ECM2,HTM,Up,3154,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ECM2,HTM,Up,3154,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ECT2,HTM,Down,3155,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
EDA,HTM,Up,3157,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
EDA,HTM,Up,3157,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
EDA2R,HTM,Up,17756,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EDARADD,HTM,Up,14341,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EDARADD,HTM,Up,14341,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EDARADD,HTM,Up,14341,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EDEM1,HTM,Down,18967,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EDEM1,HTM,Down,18967,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EDEM1,HTM,Down,18967,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EDEM3,HTM,Down,16787,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
EDIL3,HTM,Up,3173,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25432175
EDIL3,HTM,Up,3173,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,34228218
EDN1,HTM,Up,3176,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
EDN1,HTM,Up,3176,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
EDN1,HTM,Down,3176,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
EDN1,HTM,Up,3176,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
EDN1,HTM,Up,3176,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
EDN1,HTM,Down,3176,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
EDN1,HTM,Down,3176,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
EDN1,HTM,Up,3176,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
EDN2,HTM,Down,3177,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
EDN2,HTM,Up,3177,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
EDN2,HTM,Up,3177,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
EDN2,HTM,Up,3177,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
EDN3,HTM,Up,3178,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
EDN3,HTM,Up,3178,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
EDNRA,HTM,Down,3179,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EDNRA,HTM,Down,3179,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EDNRA,HTM,Down,3179,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EEA1,HTM,Down,3185,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EEA1,HTM,Up,3185,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
EEA1,HTM,Up,3185,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
EEA1,HTM,Up,3185,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
EEF1A1,HTM,Down,3189,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
EEF1A1,HTM,Up,3189,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
EEF1A1,HTM,Up,3189,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
EEF1A1P5,HTM,Up,3200,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
EEF1A2,HTM,Down,3192,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
EEF1A2,HTM,Up,3192,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
EEF1A2,HTM,Down,3192,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
EEF1A2,HTM,Up,3192,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
EEF1A2,HTM,Down,3192,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
EEF1A2,HTM,Up,3192,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
EEF1A23,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
EEF1A23,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
EEF1A23,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
EEF1B2,HTM,Down,3208,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
EEF1B2,HTM,Down,3208,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
EEF1B2,HTM,Up,3208,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
EEF1B2,HTM,Up,3208,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
EEF1B2,HTM,Up,3208,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
EEF1D,HTM,Down,3211,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
EEF1D,HTM,Down,3211,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
EEF1D,HTM,Down,3211,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
EEF1D,HTM,Down,3211,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
EEF1D,HTM,Down,3211,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
EEF1D,HTM,Up,3211,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
EEF1G,HTM,Down,3213,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
EEF1G,HTM,Down,3213,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
EEF1G,HTM,Up,3213,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
EEF2,HTM,Down,3214,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,22623141
EEF2,HTM,Down,3214,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
EEF2,HTM,Down,3214,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
EEF2,HTM,Up,3214,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
EEF2,HTM,Up,3214,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
EEF2,HTM,Up,3214,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0053,34168259
EEF2,HTM,Up,3214,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
EEF2K,HTM,Up,24615,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EEF2K,HTM,Up,24615,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EEF2K,HTM,Up,24615,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EEF2KMT,HTM,Up,32221,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
EEF2KMT,HTM,Up,32221,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
EEPD1,HTM,Up,22223,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
EF1A1P5,HTM,Down,3200,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
EF1A1P5,HTM,Down,3200,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
EF1G,HTM,Up,3213,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
EFCC1,HTM,Up,25692,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
EFEMP1,HTM,Down,3218,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
EFEMP1,HTM,Down,3218,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
EFEMP1,HTM,Down,3218,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
EFEMP1,HTM,Down,3218,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0064,24961511
EFEMP1,HTM,Down,3218,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0064,24961511
EFEMP1,HTM,Up,3218,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
EFEMP1,HTM,Up,3218,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
EFEMP1,HTM,Up,3218,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
EFEMP1,HTM,Down,3218,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0064,30696080
EFEMP1,HTM,Down,3218,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0064,34414448
EFEMP1,HTM,Down,3218,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0064,30696080
EFEMP2,HTM,Down,3219,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
EFHC1,HTM,Down,16406,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
EFHD1,HTM,Up,29556,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
EFHD2,HTM,Down,28670,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
EFHD2,HTM,Up,28670,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
EFHD2,HTM,Up,28670,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
EFNA1,HTM,Down,3221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
EFNA1,HTM,Down,3221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
EFNA1,HTM,Down,3221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
EFNA1,HTM,Down,3221,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
EFNA1,HTM,Down,3221,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
EFNA1,HTM,Down,3221,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
EFNB1,HTM,Down,3226,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EFNB2,HTM,Down,3227,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EFNB2,HTM,Down,3227,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EFR3A,HTM,Up,28970,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
EFTUD2,HTM,Up,30858,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EGF,HTM,NA,3229,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0021,29352988
EGF,HTM,Up,3229,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EGFL8,HTM,Down,13944,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
EGFL8,HTM,Down,13944,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
EGFR,HTM,Down,3236,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
EGFR,HTM,Down,3236,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
EGFR,HTM,Down,3236,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,29352988
EGFR,HTM,Down,3236,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0074,29352988
EGFR,HTM,Up,3236,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0074,23903875
EGFR,HTM,Down,3236,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
EGFR,HTM,Down,3236,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0074,30696080
EGFR,HTM,Down,3236,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0074,27746256
EGFR,HTM,Down,3236,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0074,30696080
EGLN1,HTM,Up,1232,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,35013621
EGLN3,HTM,Down,14661,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
EGLN3,HTM,Up,14661,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
EGLN3,HTM,Up,14661,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
EGLN3,HTM,Down,14661,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
EGLN3,HTM,Down,14661,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
EGR1,HTM,Down,3238,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,29340052
EGR1,HTM,Down,3238,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
EGR1,HTM,Up,3238,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,21826669
EGR1,HTM,Up,3238,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0074,23820871
EGR1,HTM,Up,3238,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,24961511
EGR1,HTM,Up,3238,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.24,0.0074,24961511
EGR1,HTM,Up,3238,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0074,34680485
EGR1,HTM,Down,3238,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0074,31501409
EGR2,HTM,Up,3239,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EGR2,HTM,Up,3239,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
EGR3,HTM,Up,3240,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
EHBP1,HTM,Down,29144,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
EHD1,HTM,Down,3242,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
EHD1,HTM,Down,3242,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
EHD1,HTM,Down,3242,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
EHD1,HTM,Down,3242,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
EHD2,HTM,Down,3243,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EHD2,HTM,Down,3243,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
EHD3,HTM,Up,3244,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
EHD4,HTM,Down,3245,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EHD4,HTM,Down,3245,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EHF,HTM,Down,3246,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,29340052
EHF,HTM,Down,3246,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
EHF,HTM,Down,3246,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
EHF,HTM,Up,3246,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0053,19451087
EHF,HTM,Up,3246,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
EHF,HTM,Up,3246,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
EHF,HTM,Up,3246,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
EHF,HTM,Up,3246,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
EHHADH,HTM,Up,3247,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
EHHADH,HTM,Up,3247,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
EID3,HTM,Up,32961,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EID3,HTM,Up,32961,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EID3,HTM,Down,32961,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
EID3,HTM,Down,32961,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
EIF1AY,HTM,Up,3252,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
EIF2AK2,HTM,Down,9437,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
EIF2AK4,HTM,Down,19687,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EIF2AK4,HTM,Down,19687,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EIF2B4,HTM,Up,3260,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EIF2B4,HTM,Up,3260,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EIF2B4,HTM,Up,3260,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EIF2D,HTM,Down,6583,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
EIF2D,HTM,Down,6583,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
EIF2S1,HTM,Down,3265,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
EIF2S3B,HTM,Up,43863,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
EIF3A,HTM,Down,3271,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
EIF3A,HTM,Down,3271,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
EIF3D,HTM,Down,3278,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
EIF3D,HTM,Down,3278,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
EIF3F,HTM,Down,3275,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
EIF3F,HTM,Down,3275,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
EIF3G,HTM,Up,3274,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
EIF3H,HTM,Down,3273,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
EIF3H,HTM,Down,3273,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
EIF3H,HTM,Up,3273,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
EIF3J,HTM,Up,3270,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
EIF3S2,HTM,Up,3272,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,25081334
EIF3S9,HTM,Up,3280,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
EIF3S9,HTM,Up,3280,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
EIF3S9,HTM,Up,3280,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
EIF3S9,HTM,Up,3280,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
EIF3S9,HTM,Up,3280,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
EIF4A1,HTM,Down,3282,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
EIF4A1,HTM,Down,3282,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
EIF4A1,HTM,Up,3282,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
EIF4A1,HTM,Up,3282,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
EIF4A1,HTM,Up,3282,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
EIF4A1,HTM,Up,3282,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
EIF4A1,HTM,Up,3282,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
EIF4A1,HTM,Up,3282,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
EIF4A2,HTM,Up,3284,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
EIF4A2,HTM,Down,3284,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
EIF4A2,HTM,Up,3284,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
EIF4B,HTM,Down,3285,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
EIF4B,HTM,Down,3285,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
EIF4E,HTM,Up,3287,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EIF4E,HTM,Up,3287,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EIF4E,HTM,Up,3287,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EIF4E3,HTM,Down,31837,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EIF4EBP1,HTM,Down,3288,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
EIF4G1,HTM,Down,3296,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
EIF4G1,HTM,Down,3296,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
EIF4G1,HTM,Up,3296,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
EIF4G2,HTM,Down,3297,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
EIF4G2,HTM,Up,3297,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
EIF4G2,HTM,Up,3297,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
EIF4G3,HTM,Up,3298,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
EIF4G3,HTM,Up,3298,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
EIF4H,HTM,Down,12741,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
EIF4H,HTM,Down,12741,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
EIF4H,HTM,Up,12741,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
EIF4H,HTM,Up,12741,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
EIF5,HTM,Down,3299,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
EIF5,HTM,Down,3299,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
EIF5A,HTM,Down,3300,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
EIF5A,HTM,Down,3300,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
EIF5A,HTM,Up,3300,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
EIF5A,HTM,Down,3300,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
EIF5A,HTM,Up,3300,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
EIF5A,HTM,Up,3300,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
EIF5A,HTM,Up,3300,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
EIF5B,HTM,Up,30793,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
EIF6,HTM,Up,6159,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ELAPOR1,HTM,Down,29618,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
ELAPOR1,HTM,Up,29618,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ELAPOR1,HTM,Up,29618,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
ELAPOR2,HTM,Down,21945,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ELAPOR2,HTM,Down,21945,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ELAPOR2,HTM,Up,21945,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ELAVL1,HTM,Down,3312,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ELAVL2,HTM,Down,3313,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ELF3,HTM,Down,3318,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
ELF3,HTM,Up,3318,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ELF3,HTM,Down,3318,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
ELF3,HTM,Down,3318,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
ELF5,HTM,Up,3320,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ELF5,HTM,Up,3320,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ELFN2,HTM,Up,29396,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ELFN2,HTM,Up,29396,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ELFN2,HTM,Up,29396,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ELFN2,HTM,Up,29396,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ELFN2,HTM,Up,29396,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ELFN2,HTM,Up,29396,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ELK1,HTM,Down,3321,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
ELK1,HTM,Down,3321,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
ELK3,HTM,Down,3325,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ELK3,HTM,Down,3325,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ELK4,HTM,Up,3326,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,35013621
ELL2,HTM,Down,17064,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ELL2,HTM,Down,17064,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ELL2,HTM,Down,17064,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ELL2,HTM,Down,17064,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ELL2,HTM,Down,17064,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ELL2,HTM,Up,17064,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ELMO1,HTM,Up,16286,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ELMO1,HTM,Up,16286,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ELMO3,HTM,Down,17289,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ELOA,HTM,Down,11620,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ELOB,HTM,Down,11619,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
ELOB,HTM,Down,11619,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
ELOF1,HTM,Down,28691,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ELOVL1,HTM,Down,14418,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ELOVL1,HTM,Down,14418,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ELOVL2,HTM,Down,14416,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
ELOVL2,HTM,Up,14416,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ELOVL2,HTM,Up,14416,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ELOVL2,HTM,Down,14416,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
ELOVL2,HTM,Down,14416,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
ELOVL2,HTM,Down,14416,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
ELOVL3,HTM,Down,18047,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ELOVL6,HTM,Down,15829,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ELOVL6,HTM,Down,15829,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ELOVL6,HTM,Down,15829,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
ELOVL7,HTM,Down,26292,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ELOVL7,HTM,Down,26292,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ELP1,HTM,Down,5959,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ELP1,HTM,Up,5959,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ELP1,HTM,Up,5959,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ELP1,HTM,Up,5959,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ELP2,HTM,Down,18248,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
EMB,HTM,Down,30465,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EMB,HTM,Down,30465,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EMB,HTM,Down,30465,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EMBP1,HTM,Down,38661,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
EMC1,HTM,Down,28957,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EMC10,HTM,Up,27609,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
EMC6,HTM,Down,28430,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
EMC8,HTM,Down,7864,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
EME1,HTM,Up,24965,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EMG1,HTM,Up,16912,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EMG1,HTM,Up,16912,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EMG1,HTM,Up,16912,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EML1,HTM,Up,3330,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EML1,HTM,Up,3330,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EML1,HTM,Up,3330,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
EML2,HTM,Down,18035,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
EML2,HTM,Up,18035,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
EML4,HTM,Up,1316,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
EML4,HTM,Up,1316,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
EML4,HTM,Up,1316,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
EML4,HTM,Up,1316,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
EML6,HTM,Down,35412,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
EML6,HTM,Down,35412,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
EML6,HTM,Up,35412,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
EMP1,HTM,Down,3333,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
EMP1,HTM,Down,3333,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
EMP1,HTM,Down,3333,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
EMP1,HTM,Down,3333,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
EMP1,HTM,Down,3333,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
EMP2,HTM,Down,3334,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EMP2,HTM,Down,3334,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
EMP3,HTM,Up,3335,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
EMP3,HTM,Down,3335,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
EMP3,HTM,Down,3335,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
EMX1,HTM,Down,3340,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ENC1,HTM,Up,3345,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
ENDOD1,HTM,Down,29129,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ENDOD1,HTM,Down,29129,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ENDOV,HTM,Down,26640,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ENGASE,HTM,Down,24622,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ENKD1,HTM,Up,25246,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ENKD1,HTM,Up,25246,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ENKD1,HTM,Up,25246,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ENO1,HTM,Up,3350,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0095,33670440
ENO1,HTM,Up,3350,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0095,23903875
ENO1,HTM,Up,3350,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0095,22623141
ENO1,HTM,Down,3350,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.08,0.0095,19451087
ENO1,HTM,Up,3350,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0095,34680485
ENO1,HTM,Down,3350,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0095,34168259
ENO1,HTM,Up,3350,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0095,27746256
ENO2,HTM,Down,3353,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
ENO2,HTM,Up,3353,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
ENO2,HTM,Up,3353,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
ENO2,HTM,Down,3353,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
ENO3,HTM,Down,3354,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ENOPH1,HTM,Down,24599,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ENOPH1,HTM,Down,24599,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ENPEP,HTM,Up,3355,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ENPP1,HTM,Up,3356,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ENPP1,HTM,Up,3356,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ENPP1,HTM,Down,3356,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0032,26351321
ENPP1,HTM,Up,3356,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ENPP1,HTM,Down,3356,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ENPP1,HTM,Down,3356,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ENPP2,HTM,Up,3357,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ENPP2,HTM,Up,3357,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ENPP3,HTM,Down,3358,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ENPP5,HTM,Down,13717,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ENPP5,HTM,Down,13717,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ENSA,HTM,Up,3360,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
ENTPD1,HTM,Up,3363,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
ENTPD2,HTM,Down,3364,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ENTPD2,HTM,Up,3364,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ENTPD3,HTM,Down,3365,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ENTPD3,HTM,Down,3365,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ENTPD3,HTM,Down,3365,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ENTPD3,HTM,Down,3365,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ENTPD7,HTM,Down,19745,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ENTPD8,HTM,Down,24860,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ENTPD8,HTM,Up,24860,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ENTPD8,HTM,Down,24860,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
EOGT,HTM,Down,28526,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EOGT,HTM,Down,28526,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EOGT,HTM,Down,28526,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EP400,HTM,Up,11958,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
EP400,HTM,Up,11958,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
EP400,HTM,Up,11958,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
EP400,HTM,Up,11958,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
EPAS1,HTM,Up,3374,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,35013621
EPB41,HTM,Up,3377,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EPB41L1,HTM,Up,3378,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
EPB41L1,HTM,Up,3378,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
EPB41L1,HTM,Down,3378,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
EPB41L1,HTM,Down,3378,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
EPB41L2,HTM,Up,3379,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
EPB41L4A,HTM,Up,13278,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
EPB41L4A-DT,HTM,Down,25643,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
EPB41L4B,HTM,Down,19818,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
EPB41L4B,HTM,Down,19818,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
EPC1,HTM,Up,19876,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
EPC1,HTM,Up,19876,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
EPC2,HTM,Up,24543,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
EPCAM,HTM,Down,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.56,0.2110,25881239
EPCAM,HTM,Down,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.56,0.2110,25881239
EPCAM,HTM,Down,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.56,0.2110,25881239
EPCAM,HTM,Up,11529,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.12,0.2110,25881239
EPCAM,HTM,Down,11529,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.2110,31709178
EPCAM,HTM,Up,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.2110,34168259
EPDR1,HTM,Up,17572,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EPDR1,HTM,Down,17572,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
EPGN,HTM,Up,17470,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
EPGN,HTM,Up,17470,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
EPGN,HTM,Up,17470,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
EPGN,HTM,Up,17470,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
EPGN,HTM,Up,17470,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
EPGN,HTM,Up,17470,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
EPGN,HTM,Up,17470,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
EPHA1,HTM,Down,3385,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
EPHA1,HTM,Up,3385,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
EPHA1,HTM,Up,3385,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
EPHA4,HTM,Down,3388,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
EPHA5,HTM,Down,3389,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
EPHA5,HTM,Up,3389,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
EPHA5,HTM,Up,3389,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
EPHA7,HTM,Up,3390,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EPHB1,HTM,Down,3392,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
EPHB3,HTM,Up,3394,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29416721
EPHB3,HTM,Up,3394,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29416721
EPHB3,HTM,Down,3394,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
EPHB3,HTM,Up,3394,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.04,0.0042,27520449
EPHB3,HTM,Up,3394,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
EPHB4,HTM,Up,3395,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
EPHB6,HTM,Up,3396,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
EPHX1,HTM,Up,3401,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
EPHX1,HTM,Up,3401,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
EPHX1,HTM,Up,3401,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
EPHX1,HTM,Up,3401,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
EPHX1,HTM,Up,3401,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
EPHX1,HTM,Up,3401,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
EPHX1,HTM,Up,3401,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
EPHX4,HTM,Down,23758,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
EPM2AIP1,HTM,Up,19735,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EPM2AIP1,HTM,Up,19735,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EPM2AIP1,HTM,Up,19735,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EPN3,HTM,Down,18235,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
EPO,HTM,Down,3415,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
EPO,HTM,Down,3415,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
EPPIN,HTM,Down,15932,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
EPPK1,HTM,Up,15577,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,19190339
EPPK1,HTM,Down,15577,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
EPPK1,HTM,Down,15577,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
EPPK1,HTM,Up,15577,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,19190339
EPPK1,HTM,Up,15577,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,19190339
EPPK1,HTM,Up,15577,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,19190339
EPPK1,HTM,Up,15577,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,19190339
EPPK1,HTM,Up,15577,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0042,21788403
EPRS1,HTM,Up,3418,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
EPS15L1,HTM,Down,24634,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
EPS15L1,HTM,Up,24634,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
EPS8,HTM,Up,3420,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EPS8,HTM,Down,3420,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
EPS8,HTM,Down,3420,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
EPS8,HTM,Up,3420,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EPS8L1,HTM,Down,21295,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
EPS8L2,HTM,Down,21296,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
EPS8L2,HTM,Down,21296,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ERAP1,HTM,Down,18173,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ERAP1,HTM,Down,18173,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ERAP1,HTM,Down,18173,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ERAP2,HTM,Down,29499,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ERAP2,HTM,Down,29499,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ERAP2,HTM,Down,29499,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ERAS,HTM,Up,5174,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ERBB2,HTM,Down,3430,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,34059086
ERBB2,HTM,Down,3430,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,34059086
ERBB2,HTM,NA,3430,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0074,29352988
ERBB2,HTM,Down,3430,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0074,24961511
ERBB2,HTM,Down,3430,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0074,24961511
ERBB3,HTM,Down,3431,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22740085
ERBB3,HTM,Up,3431,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ERBB3,HTM,Down,3431,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ERBIN,HTM,Down,15842,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ERBIN,HTM,Down,15842,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ERC1,HTM,Down,17072,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ERC2,HTM,Up,31922,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ERC2,HTM,Down,31922,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ERC2-IT1,HTM,Down,1229,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ERCC1,HTM,Down,3433,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
ERCC6,HTM,Down,3438,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ERCC6,HTM,Down,3438,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ERCC6,HTM,Up,3438,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
ERCC6,HTM,Down,3438,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ERCC6L,HTM,Down,20794,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
EREG,HTM,Down,3443,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
EREG,HTM,Up,3443,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
EREG,HTM,Down,3443,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
ERG,HTM,Down,3446,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ERGIC1,HTM,Up,29205,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ERGIC3,HTM,Down,15927,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ERI1,HTM,Down,23994,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ERI2,HTM,Up,30541,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ERICH1,HTM,Down,27234,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ERICH1,HTM,Up,27234,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ERICH1,HTM,Up,27234,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ERICH1,HTM,Up,27234,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ERLEC1,HTM,Up,25222,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ERLEC1,HTM,Up,25222,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ERLIN1,HTM,Down,16947,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ERLIN1,HTM,Up,16947,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
ERLIN2,HTM,Down,1356,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ERMP1,HTM,Down,23703,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ERMP1,HTM,Up,23703,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
ERN1,HTM,Up,3449,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ERN1,HTM,Up,3449,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ERN1,HTM,Up,3449,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ERO1A,HTM,Down,13280,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ERO1A,HTM,Down,13280,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
ERO1A,HTM,Up,13280,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
ERO1A,HTM,Up,13280,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
ERO1A,HTM,Down,13280,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
ERO1B,HTM,Up,14355,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ERP29,HTM,Up,13799,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ERP29,HTM,Up,13799,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ERP29,HTM,Up,13799,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
ERP29,HTM,Down,13799,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
ERP44,HTM,Up,18311,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
ERP44,HTM,Up,18311,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
ERRFI1,HTM,Up,18185,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ERV3-1,HTM,Up,3454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ERVMER34-1,HTM,Up,42970,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ESAM,HTM,Up,17474,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ESAM,HTM,Up,17474,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ESAM,HTM,Up,17474,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ESCO1,HTM,Up,24645,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ESCO2,HTM,Down,27230,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
ESCO2,HTM,Up,27230,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ESCO2,HTM,Down,27230,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
ESD,HTM,Up,3465,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,22623141
ESF1,HTM,Up,15898,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ESF1,HTM,Up,15898,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ESF1,HTM,Down,15898,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
ESF1,HTM,Up,15898,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ESM1,HTM,Up,3466,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ESPN,HTM,Down,13281,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ESPN,HTM,Up,13281,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ESPN,HTM,Down,13281,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ESR1,HTM,Down,3467,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
ESR1,HTM,Down,3467,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
ESR1,HTM,Down,3467,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
ESR1,HTM,Down,3467,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
ESR2,HTM,Up,3468,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ESR2,HTM,Up,3468,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ESR2,HTM,Up,3468,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ESR2,HTM,Up,3468,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ESR2,HTM,Up,3468,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ESR2,HTM,Up,3468,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ESRP1,HTM,Down,25966,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ESRP1,HTM,Down,25966,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ESRP1,HTM,Down,25966,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ESRP2,HTM,Down,26152,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ESRP2,HTM,Down,26152,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ESRRG,HTM,Up,3474,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ESYT1,HTM,Down,29534,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ESYT1,HTM,Down,29534,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
ESYT1,HTM,Down,29534,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ESYT1,HTM,Down,29534,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
ESYT2,HTM,Up,22211,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ESYT3,HTM,Down,24295,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ESYT3,HTM,Down,24295,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ESYT3,HTM,Down,24295,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ETAA1,HTM,Down,24648,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ETAA1,HTM,Down,24648,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ETFA,HTM,NA,3481,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29221160
ETFA,HTM,Up,3481,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ETFA,HTM,Up,3481,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ETFA,HTM,Down,3481,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ETFB,HTM,Up,3482,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ETFB,HTM,Up,3482,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ETFB,HTM,Up,3482,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ETFB,HTM,Up,3482,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
ETFB,HTM,Down,3482,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
ETFBKMT,HTM,Down,28739,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ETFBKMT,HTM,Up,28739,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ETFDH,HTM,Down,3483,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ETFRF1,HTM,Down,27052,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ETFRF1,HTM,Down,27052,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ETHE1,HTM,Down,23287,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ETNK1,HTM,Up,24649,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ETNK1,HTM,Up,24649,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ETNK2,HTM,Down,25575,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ETNPPL,HTM,Up,14404,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ETS1,HTM,Down,3488,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ETS1,HTM,Down,3488,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ETS1,HTM,Down,3488,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ETS1,HTM,Down,3488,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
ETS1,HTM,Down,3488,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
ETS1,HTM,Up,3488,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
ETS2,HTM,Down,3489,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ETV1,HTM,Up,3490,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ETV1,HTM,Up,3490,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ETV1,HTM,Down,3490,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0042,26351321
ETV1,HTM,Up,3490,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ETV1,HTM,Up,3490,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
ETV4,HTM,Up,3493,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ETV4,HTM,Up,3493,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ETV4,HTM,Up,3493,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.48,0.0032,34680485
ETV5,HTM,Up,3494,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ETV5,HTM,Up,3494,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ETV6,HTM,Up,3495,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
EVA1A,HTM,Up,25816,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EVA1A,HTM,Up,25816,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EVA1A,HTM,Up,25816,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
EVA1C,HTM,Up,13239,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EVA1C,HTM,Up,13239,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
EVC,HTM,Up,3497,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
EVPL,HTM,Down,3503,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
EWSR1,HTM,Down,3508,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EWSR1,HTM,Down,3508,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EWSR1,HTM,Down,3508,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EWSR1,HTM,Up,3508,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
EXO1,HTM,Up,3511,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Transcriptomics followed by Western Blotting,0.32,0.0042,24440048
EXO1,HTM,Up,3511,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.32,0.0042,25881239
EXO1,HTM,Down,3511,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
EXO1,HTM,Up,3511,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
EXO5,HTM,Up,26115,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
EXOC2,HTM,Down,24968,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EXOC3L4,HTM,Down,20120,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
EXOC4,HTM,Up,30389,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EXOC6,HTM,Up,23196,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EXOC6,HTM,Up,23196,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EXOC6B,HTM,Down,17085,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EXOSC4,HTM,Down,18189,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
EXOSC5,HTM,Down,24662,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
EXOSC5,HTM,Down,24662,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
EXOSC6,HTM,Down,19055,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
EXPH5,HTM,Up,30578,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
EXPH5,HTM,Up,30578,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
EXPH5,HTM,Up,30578,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
EXPH5,HTM,Up,30578,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
EXT1,HTM,Down,3512,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
EXT1,HTM,Down,3512,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
EXT1,HTM,Up,3512,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.52,0.0032,17911267
EXT2,HTM,Down,3513,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EXTL3,HTM,Down,3518,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EXTL3,HTM,Down,3518,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EYA1,HTM,Down,3519,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EYA1,HTM,Down,3519,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EYA2,HTM,Down,3520,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
EYA3,HTM,Down,3521,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
EYS,HTM,Up,21555,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
EZH2,HTM,Up,3527,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
EZR,HTM,Up,12691,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0064,23903875
EZR,HTM,Down,12691,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0064,22623141
EZR,HTM,Down,12691,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0064,22623141
EZR,HTM,Down,12691,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0064,22623141
EZR,HTM,Down,12691,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0064,22623141
EZR,HTM,Up,12691,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
EZR,HTM,Up,12691,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
EZR,HTM,Down,12691,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0064,34168259
EZR,HTM,Up,12691,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0064,34168259
EZR,HTM,Up,12691,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0064,27746256
F11R,HTM,Down,14685,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
F11R,HTM,Down,14685,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
F11R,HTM,Down,14685,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
F11R,HTM,Down,14685,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
F12,HTM,Down,3530,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
F2,HTM,Down,3535,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
F2,HTM,Up,3535,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0021,17932721
F2R,HTM,Up,3537,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
F2R,HTM,Up,3537,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
F2R,HTM,Down,3537,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
F2R,HTM,Down,3537,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
F2R,HTM,Up,3537,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
F2RL1,HTM,Up,3538,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
F2RL1,HTM,Up,3538,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
F2RL1,HTM,Down,3538,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
F2RL1,HTM,Down,3538,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
F2RL1,HTM,Down,3538,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
F2RL2,HTM,Up,3539,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
F2RL2,HTM,Up,3539,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
F3,HTM,Down,3541,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
F3,HTM,Down,3541,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
F3,HTM,Down,3541,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
F3,HTM,Down,3541,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
F5,HTM,Up,3542,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,35229723
F5,HTM,Up,3542,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
F5,HTM,Up,3542,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
F5,HTM,Up,3542,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
F5,HTM,Up,3542,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
F7,HTM,Up,3544,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
F8A1,HTM,Down,3547,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
F8A1,HTM,Up,3547,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
F8A1,HTM,Up,3547,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
F8A1,HTM,Up,3547,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
F8A1,HTM,Up,3547,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
F8A1,HTM,Up,3547,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
F8A1,HTM,Up,3547,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
F8A1,HTM,Up,31849,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
F8A1,HTM,Up,31849,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
F8A1,HTM,Up,31849,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
F8A1,HTM,Up,31850,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
F8A1,HTM,Up,31850,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
F8A1,HTM,Up,31850,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
F8A2,HTM,Up,31849,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
F8A2,HTM,Up,31849,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
F8A2,HTM,Up,31849,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
F8A3,HTM,Up,31850,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
F8A3,HTM,Up,31850,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
F8A3,HTM,Up,31850,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FA2H,HTM,Up,21197,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
FA2H,HTM,Up,21197,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
FA2H,HTM,Down,21197,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0042,31709178
FA2H,HTM,Down,21197,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0042,31709178
FA2H,HTM,Down,21197,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
FA2H,HTM,Down,21197,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0042,31709178
FA2H,HTM,Down,21197,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0042,31709178
FAAH,HTM,Down,3553,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FAAH,HTM,Down,3553,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FAAH2,HTM,Up,26440,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FAAH2,HTM,Down,26440,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FAAH2,HTM,Up,26440,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
FAAH2,HTM,Down,26440,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FABP5,HTM,Up,3560,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
FABP5,HTM,Up,3560,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
FABP5,HTM,Down,3560,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
FABP5,HTM,Up,3560,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
FABP6,HTM,Up,3561,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FABP6,HTM,Up,3561,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FABP6,HTM,Up,3561,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FABP6,HTM,Up,3561,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FADD,HTM,Up,3573,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
FADS2,HTM,Down,3575,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
FADS2,HTM,Up,3575,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0064,24961511
FADS2,HTM,Up,3575,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0064,24961511
FADS2,HTM,Up,3575,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,25676692
FADS2,HTM,Up,3575,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,25676692
FADS2,HTM,Up,3575,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
FADS2,HTM,Up,3575,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,25676692
FADS2,HTM,Up,3575,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
FADS2,HTM,Down,3575,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
FADS3,HTM,Down,3576,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
FAF2,HTM,Up,24666,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
FAF2,HTM,Up,24666,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
FAHD1,HTM,Down,14169,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FAHD2A,HTM,Up,24252,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FAHD2A,HTM,Up,24252,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FAHD2A,HTM,Up,24252,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FAHD2B,HTM,Down,25318,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FAHD2CP,HTM,Down,44135,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FAIM,HTM,Down,18703,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FAIM2,HTM,Up,17067,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FAM102A,HTM,Down,31419,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
FAM102A,HTM,Down,31419,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
FAM102A,HTM,Down,31419,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
FAM102A,HTM,Up,31419,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM102A,HTM,Up,31419,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM102B,HTM,Up,27637,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FAM102B,HTM,Up,27637,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FAM102B,HTM,Up,27637,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FAM102B,HTM,Up,27637,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
FAM102B,HTM,Up,27637,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
FAM102B,HTM,Up,27637,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
FAM104B,HTM,Down,25085,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
FAM107B,HTM,Up,23726,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM107B,HTM,Up,23726,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM107B,HTM,Up,23726,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FAM110A,HTM,Down,16188,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FAM110B,HTM,Up,28587,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FAM110C,HTM,Down,33340,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
FAM110C,HTM,Down,33340,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FAM117B,HTM,Down,14440,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FAM120A,HTM,NA,13247,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
FAM122B,HTM,Up,30490,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAM124A,HTM,Up,26413,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FAM126A,HTM,Down,24587,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FAM126A,HTM,Down,24587,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FAM126A,HTM,Up,24587,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FAM126A,HTM,Up,24587,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31729259
FAM126A,HTM,Up,24587,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31729259
FAM133B,HTM,Up,28629,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
FAM133B,HTM,Up,28629,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
FAM133B,HTM,Up,28629,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
FAM136A,HTM,Up,25911,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAM13A,HTM,Up,19367,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FAM13B,HTM,Down,1335,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FAM13B,HTM,Down,1335,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FAM155A,HTM,Down,33877,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
FAM160A1,HTM,Down,34237,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM160A1,HTM,Down,34237,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM160A1,HTM,Down,34237,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FAM161A,HTM,Up,25808,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAM167A,HTM,Up,15549,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FAM167A,HTM,Up,15549,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FAM167A,HTM,Up,15549,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FAM167A,HTM,Up,15549,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FAM169A,HTM,Down,29138,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
FAM171A1,HTM,Up,23522,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FAM171B,HTM,Up,29412,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAM171B,HTM,Up,29412,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAM172BP,HTM,Down,34336,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAM174B,HTM,Down,34339,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FAM184A,HTM,Up,20991,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAM185A,HTM,Up,22412,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAM189A1,HTM,Up,29075,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FAM200B,HTM,Down,27740,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FAM200B,HTM,Down,27740,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FAM20B,HTM,Up,23017,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
FAM214A,HTM,Up,25609,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM214A,HTM,Down,25609,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
FAM214A,HTM,Down,25609,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
FAM214B,HTM,Up,25666,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
FAM216A,HTM,Down,30180,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FAM229B,HTM,Up,33858,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
FAM229B,HTM,Down,33858,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
FAM229B,HTM,Down,33858,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
FAM238B,HTM,Down,44917,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FAM27D1,HTM,Down,32015,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
FAM36A,HTM,Up,26970,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAM3A,HTM,Down,13749,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FAM3C,HTM,Down,18664,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM3C,HTM,Down,18664,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM3C,HTM,Down,18664,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM3C,HTM,Down,18664,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM3C,HTM,Down,18664,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
FAM3D,HTM,Down,18665,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
FAM43A,HTM,Down,26888,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FAM43A,HTM,Down,26888,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FAM49B,HTM,Up,25216,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
FAM49B,HTM,Down,25216,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
FAM49B,HTM,Down,25216,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
FAM49B,HTM,Up,25216,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
FAM49B,HTM,Up,25216,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
FAM49B,HTM,Up,25216,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
FAM49B,HTM,Up,25216,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
FAM49B,HTM,Down,25216,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
FAM50B,HTM,Down,18789,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FAM64A,HTM,Down,25483,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FAM64A,HTM,Down,25483,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FAM69B,HTM,Up,28290,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FAM69B,HTM,Up,28290,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FAM69B,HTM,Up,28290,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FAM71E1,HTM,Down,25107,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FAM71E2,HTM,Down,25278,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FAM71F1,HTM,Down,30704,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FAM72A,HTM,Down,24044,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
FAM72B,HTM,Down,24805,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
FAM72D,HTM,Up,33593,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FAM72D,HTM,Up,33593,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FAM72D,HTM,Up,33593,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FAM76A,HTM,Down,28530,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FAM76A,HTM,Down,28530,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FAM81A,HTM,Up,28379,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM81A,HTM,Up,28379,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FAM81A,HTM,Up,28379,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FAM81A,HTM,Up,28379,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FAM83A,HTM,Down,28210,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM83A,HTM,Down,28210,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM83A,HTM,Up,28210,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FAM83A-AS1,HTM,Down,48658,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FAM83B,HTM,Down,21357,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FAM83B,HTM,Down,21357,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FAM83B,HTM,Down,21357,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FAM83B,HTM,Down,21357,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FAM83B,HTM,Up,21357,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
FAM83B,HTM,Up,21357,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
FAM83B,HTM,Up,21357,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
FAM83D,HTM,Down,16122,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FAM83D,HTM,Down,16122,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FAM83D,HTM,Down,16122,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FAM83E,HTM,Up,25972,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FAM83F,HTM,Down,25148,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FAM83H,HTM,Down,24797,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FAM86B1,HTM,Down,28268,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
FAM86B1,HTM,Up,28268,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM86B1,HTM,Up,28268,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAM86C1P,HTM,Up,25561,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAM92A,HTM,Up,30452,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
FAM98A,HTM,Up,24520,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
FAM98B,HTM,Down,26773,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
FAM98B,HTM,Up,26773,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FAM98B,HTM,Up,26773,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FAM98B,HTM,Up,26773,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FAN1,HTM,Down,29170,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FANCB,HTM,Up,3583,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FANCF,HTM,Down,3587,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FAP,HTM,Up,3590,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FAR2,HTM,Down,25531,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAR2,HTM,Down,25531,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAR2,HTM,Up,25531,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FARP1,HTM,Down,3591,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
FARSA,HTM,Down,3592,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,22623141
FARSB,HTM,Down,17800,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
FARSB,HTM,Down,17800,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
FAS,HTM,Down,11920,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FAS,HTM,Down,11920,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FAS,HTM,Down,11920,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FAS,HTM,Up,11920,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
FASN,HTM,Up,3594,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,25676692
FASN,HTM,Up,3594,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.24,0.0074,26259570
FASN,HTM,Up,3594,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.24,0.0074,26259570
FASN,HTM,Up,3594,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0074,32503348
FASN,HTM,Up,3594,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0074,32503348
FASN,HTM,Up,3594,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0074,31501409
FASN,HTM,Up,3594,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0074,34168259
FASN,HTM,Down,3594,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0074,34168259
FAT1,HTM,Down,3595,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FAT2,HTM,Down,3596,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAT2,HTM,Down,3596,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAT2,HTM,Down,3596,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FAT3,HTM,Up,23112,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
FAT3,HTM,Up,23112,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
FAT4,HTM,Down,23109,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FAT4,HTM,Down,23109,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FAT4,HTM,Down,23109,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
FAT4,HTM,Up,23109,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
FAT4,HTM,Up,23109,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
FAU,HTM,Down,3597,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
FAU,HTM,Up,3597,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
FAXDC2,HTM,Up,1334,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FBF1,HTM,Down,24674,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
FBL,HTM,Down,3599,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
FBL,HTM,Down,3599,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
FBL,HTM,Down,3599,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FBLN1,HTM,Down,3600,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
FBLN1,HTM,Down,3600,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
FBLN1,HTM,Down,3600,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
FBLN1,HTM,Down,3600,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FBLN2,HTM,Up,3601,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FBLN2,HTM,Down,3601,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
FBLN5,HTM,Up,3602,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FBN1,HTM,Up,3603,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
FBN1,HTM,Up,3603,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
FBN1,HTM,Down,3603,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
FBN1,HTM,Down,3603,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
FBN2,HTM,Down,3604,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FBN2,HTM,Down,3604,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FBN2,HTM,Down,3604,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
FBN2,HTM,Down,3604,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
FBP1,HTM,Down,3606,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
FBP1,HTM,Down,3606,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31729259
FBP1,HTM,Down,3606,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
FBP1,HTM,Down,3606,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
FBP1,HTM,Down,3606,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
FBP1,HTM,Down,3606,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31729259
FBXL12,HTM,Up,13611,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
FBXL18,HTM,Down,21874,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
FBXL18,HTM,Up,21874,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
FBXL18,HTM,Up,21874,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
FBXL18,HTM,Up,21874,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
FBXL18,HTM,Up,21874,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
FBXL18,HTM,Up,21874,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
FBXL2,HTM,Down,13598,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FBXL20,HTM,Down,24679,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
FBXL20,HTM,Up,24679,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FBXL21P,HTM,Down,13600,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FBXL21P,HTM,Down,13600,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FBXO17,HTM,Up,18754,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FBXO17,HTM,Up,18754,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FBXO2,HTM,Down,13581,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
FBXO2,HTM,Down,13581,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FBXO2,HTM,Up,13581,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
FBXO27,HTM,Down,18753,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FBXO32,HTM,Up,16731,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FBXO32,HTM,Up,16731,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FBXO32,HTM,Up,16731,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FBXO4,HTM,Up,13583,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
FBXO41,HTM,Down,29409,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FBXO42,HTM,Down,29249,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FBXO6,HTM,Down,13585,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FBXO8,HTM,Down,13587,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FBXO8,HTM,Down,13587,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FBXW10,HTM,Up,1211,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FBXW10,HTM,Up,1211,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FBXW10,HTM,Up,1211,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FBXW7,HTM,Down,16712,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FBXW9,HTM,Up,28136,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FBXW9,HTM,Up,28136,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FCAR,HTM,Down,3608,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
FCER1A,HTM,UP,3609,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
FCER1A,HTM,UP,3609,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
FCER1A,HTM,UP,3609,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
FCER1A,HTM,UP,3609,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
FCER1A,HTM,UP,3609,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
FCGBP,HTM,Up,13572,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,35229723
FCGBP,HTM,Down,13572,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
FCHO1,HTM,Up,29002,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FCHO1,HTM,Up,29002,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FCHO1,HTM,Up,29002,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FCMR,HTM,Down,14315,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FCRL2,HTM,Down,14875,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
FCRL5,HTM,Down,18508,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
FCSK,HTM,Down,29500,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FDCSP,HTM,Down,19215,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FDFT1,HTM,Down,3629,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FDFT1,HTM,Down,3629,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FDFT1,HTM,Up,3629,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,25676692
FDFT1,HTM,Up,3629,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,25676692
FDFT1,HTM,Up,3629,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
FDFT1,HTM,Up,3629,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,25676692
FDFT1,HTM,Up,3629,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
FDFT1,HTM,Up,3629,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
FDPS,HTM,Down,3631,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FDPS,HTM,Up,3631,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
FDPS,HTM,Up,3631,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
FDPS,HTM,Up,3631,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
FEM1B,HTM,Up,3649,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
FEN1,HTM,Down,3650,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
FEN1,HTM,Down,3650,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
FER,HTM,Down,3655,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FER1L4,HTM,Down,15801,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FER1L4,HTM,Up,15801,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FER1L6,HTM,Up,28065,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FERMT1,HTM,Down,15889,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
FERMT1,HTM,Down,15889,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FERMT1,HTM,Down,15889,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FERMT1,HTM,Down,15889,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FERMT1,HTM,Down,15889,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
FERMT1,HTM,Down,15889,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
FERMT2,HTM,Up,15767,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FES,HTM,Down,3657,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
FES,HTM,Up,3657,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FES,HTM,Up,3657,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FES,HTM,Up,3657,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FEZ1,HTM,Down,3659,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FEZ1,HTM,Down,3659,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FEZ1,HTM,Down,3659,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FFAR2,HTM,Up,4501,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FFAR2,HTM,Down,4501,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FGA,HTM,Up,3661,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FGA,HTM,Up,3661,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FGB,HTM,Up,3662,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FGB,HTM,Up,3662,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FGD3,HTM,Up,16027,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FGD3,HTM,Up,16027,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FGD3,HTM,Down,16027,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FGD3,HTM,Up,16027,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FGD4,HTM,Down,19125,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FGD4,HTM,Up,19125,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0042,23820871
FGD4,HTM,Down,19125,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
FGD4,HTM,Down,19125,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
FGD5P1,HTM,Down,44498,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FGD6,HTM,Up,21740,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
FGF1,HTM,Up,3665,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,20424609
FGF1,HTM,Up,3665,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,20424609
FGF1,HTM,Up,3665,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FGF1,HTM,NA,3665,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0032,20630067
FGF11,HTM,Down,3667,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FGF11,HTM,Down,3667,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FGF11,HTM,Down,3667,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FGF11,HTM,Down,3667,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
FGF11,HTM,Down,3667,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
FGF12,HTM,Down,3668,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
FGF12,HTM,Down,3668,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
FGF12,HTM,Up,3668,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FGF13,HTM,Up,3670,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FGF13,HTM,Up,3670,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FGF13,HTM,Up,3670,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FGF13,HTM,Up,3670,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FGF2,HTM,Up,3676,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
FGF2,HTM,Up,3676,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
FGF2,HTM,Up,3676,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
FGF2,HTM,Up,3676,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31729259
FGF2,HTM,Up,3676,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31729259
FGF2,HTM,Up,3676,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
FGF2,HTM,Up,3676,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
FGF2,HTM,Down,3676,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
FGF2,HTM,Down,3676,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
FGF2,HTM,Up,3676,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
FGF22,HTM,Up,3679,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0011,28927099
FGF3,HTM,NA,3681,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by PCR array assay,0.04,0.0021,20630067
FGF3,HTM,NA,3681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0021,20630067
FGF3,HTM,Down,3681,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
FGF5,HTM,Down,3683,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FGF5,HTM,Down,3683,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FGF5,HTM,Down,3683,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FGF9,HTM,Down,3687,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
FGFBP1,HTM,Down,19695,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FGFBP1,HTM,Down,19695,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FGFBP1,HTM,Down,19695,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FGFBP1,HTM,Up,19695,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
FGFBP1,HTM,Up,19695,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
FGFBP1,HTM,Down,19695,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
FGFR1,HTM,Up,3688,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
FGFR1,HTM,Up,3688,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
FGFR1,HTM,Up,3688,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0053,26351321
FGFR1,HTM,Up,3688,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
FGFR1,HTM,Up,3688,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
FGFR1,HTM,Up,3688,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
FGFR2,HTM,Down,3689,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FGFR2,HTM,Down,3689,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FGFR2,HTM,Up,3689,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0032,26351321
FGFR2,HTM,Down,3689,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FGFR2,HTM,Down,3689,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FGFR2,HTM,Down,3689,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FGFR4,HTM,Down,3691,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,29316740
FGG,HTM,Up,3694,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FGG,HTM,Up,3694,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FGG,HTM,Up,3694,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FGG,HTM,Up,3694,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FGG,HTM,Up,3694,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FGL1,HTM,Down,3695,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
FGL1,HTM,Up,3695,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FGL1,HTM,Up,3695,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FH,HTM,Down,3700,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
FH,HTM,Down,3700,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
FH,HTM,Down,3700,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
FH,HTM,Down,3700,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
FH,HTM,Down,3700,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
FH,HTM,Down,3700,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
FHAD1,HTM,Down,29408,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FHDC1,HTM,Up,29363,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FHDC1,HTM,Up,29363,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FHDC1,HTM,Up,29363,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FHIT,HTM,Up,3701,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FHL1,HTM,Down,3702,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FHL1,HTM,Up,3702,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
FHL2,HTM,Down,3703,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
FHL2,HTM,Up,3703,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0053,23820871
FHL2,HTM,Down,3703,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
FHL2,HTM,Down,3703,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
FHL2,HTM,Down,3703,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
FHL2,HTM,Down,3703,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
FHOD3,HTM,Down,26178,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FHOD3,HTM,Down,26178,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FHOD3,HTM,Down,26178,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FHOD3,HTM,Down,26178,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
FHOD3,HTM,Down,26178,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
FHOD3,HTM,Down,26178,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
FHOD3,HTM,Down,26178,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
FIGN,HTM,Down,13285,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FILIP1,HTM,Up,21015,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FILIP1,HTM,Up,21015,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FILIP1L,HTM,Down,24589,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FIS1,HTM,Down,21689,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
FITM2,HTM,Up,16135,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FJX1,HTM,Down,17166,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FJX1,HTM,Down,17166,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FKBP10,HTM,Down,18169,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
FKBP10,HTM,Down,18169,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
FKBP11,HTM,Down,18624,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
FKBP14,HTM,Up,18625,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
FKBP15,HTM,Down,23397,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FKBP1A,HTM,Down,3711,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
FKBP1A,HTM,Down,3711,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
FKBP1A,HTM,Down,3711,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
FKBP1A,HTM,Down,3711,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
FKBP2,HTM,Up,3718,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
FKBP2,HTM,Up,3718,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
FKBP2,HTM,Up,3718,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FKBP4,HTM,Up,3720,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FKBP4,HTM,Up,3720,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FKBP4,HTM,Down,3720,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FKBP4,HTM,Up,3720,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FKBP4,HTM,Up,13949,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FKBP4,HTM,Up,13949,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FKBP4,HTM,Up,13949,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FKBP5,HTM,Up,3721,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
FKBP5,HTM,Down,3721,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FKBP5,HTM,Up,3721,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
FKBP5,HTM,Down,3721,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
FKBP5,HTM,Up,3721,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
FKBP5,HTM,Up,3721,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
FKBP7,HTM,Down,3723,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
FKRP,HTM,Down,13949,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FLI1,HTM,Down,3749,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FLI1,HTM,Down,3749,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FLI1,HTM,Down,3749,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FLII,HTM,Down,3750,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FLII,HTM,Down,3750,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
FLJ22536,HTM,Down,NA,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FLJ22536,HTM,Down,NA,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FLJ23867,HTM,Up,17997,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FLJ25865,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FLJ25865,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FLJ25865,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FLJ30092,HTM,Up,NA,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
FLJ46363,HTM,Down,NA,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FLJ46875,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FLNA,HTM,Down,3754,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
FLNA,HTM,Down,3754,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
FLNA,HTM,Down,3754,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
FLNA,HTM,Down,3754,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
FLNA,HTM,Up,3754,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
FLNA,HTM,Down,3754,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
FLNA,HTM,Down,3754,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
FLNB,HTM,Down,3755,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FLNB,HTM,Down,3755,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
FLNC,HTM,Up,3756,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FLOT1,HTM,Up,3757,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
FLOT1,HTM,Up,3757,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
FLOT2,HTM,Down,3758,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
FLOT2,HTM,Down,3758,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
FLOT2,HTM,Up,3758,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
FLOT2,HTM,Up,3758,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
FLRT2,HTM,Down,3761,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FLRT2,HTM,Down,3761,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FLRT2,HTM,Down,3761,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FLRT3,HTM,Up,3762,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
FLRT3,HTM,Up,3762,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
FLRT3,HTM,Up,3762,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
FLRT3,HTM,Up,3762,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
FLRT3,HTM,Up,3762,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
FLT1,HTM,Down,3763,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FLT3LG,HTM,Up,3766,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0011,28927099
FLVCR1,HTM,Down,24682,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
FLVCR1,HTM,Up,24682,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FLVCR1,HTM,Up,24682,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FLVCR2,HTM,Up,20105,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FLVCR2,HTM,Down,20105,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
FLVCR2,HTM,Down,20105,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
FMN2,HTM,Up,14074,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FMN2,HTM,Up,14074,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
FMN2,HTM,Up,14074,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FMNL1,HTM,Down,1212,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FMNL2,HTM,Up,18267,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0011,34794402
FMNL2,HTM,Up,18267,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0011,34794402
FMNL3,HTM,Up,23698,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FMO3,HTM,Up,3771,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FMO3,HTM,Up,3771,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FMO3,HTM,Up,3771,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FMO5,HTM,Up,3773,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FMO5,HTM,Up,3773,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FN1,HTM,Up,3778,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,33670440
FN1,HTM,Up,3778,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.08,0.0053,29416721
FN1,HTM,Up,3778,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.08,0.0053,29416721
FN1,HTM,Up,3778,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.08,0.0053,29416721
FN1,HTM,Up,3778,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.08,0.0053,29416721
FN1,HTM,Up,3778,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
FN1,HTM,Down,3778,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.2,0.0053,34680485
FNDC3B,HTM,Up,24670,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
FNDC4,HTM,Up,20239,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FNIP2,HTM,Up,29280,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FOCAD,HTM,Down,23377,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
FOCAD,HTM,Down,23377,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FOCAD,HTM,Down,23377,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FOLR1,HTM,Up,3791,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
FOLR1,HTM,Up,3791,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
FOLR1,HTM,Up,3791,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
FOLR1,HTM,Up,3791,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
FOLR1,HTM,Up,3791,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
FOLR1,HTM,Down,3791,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
FOLR1,HTM,Up,3791,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
FOS,HTM,Down,3796,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
FOS,HTM,Down,3796,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0053,29352988
FOS,HTM,Up,3796,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,21826669
FOS,HTM,Down,3796,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
FOSB,HTM,Up,3797,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,27965308
FOSB,HTM,Up,3797,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0032,19451087
FOSB,HTM,Up,3797,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
FOSL2,HTM,Up,3798,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
FOXA1,HTM,Up,5021,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FOXA1,HTM,Down,5021,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FOXA1,HTM,Down,5021,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31729259
FOXA1,HTM,Down,5021,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FOXA1,HTM,Down,5021,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31729259
FOXA2,HTM,Up,5022,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FOXA2,HTM,Up,5022,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FOXA2,HTM,Up,5022,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
FOXC2,HTM,Up,3801,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FOXC2,HTM,Up,3801,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FOXD2,HTM,Up,3803,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
FOXE1,HTM,Down,3806,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FOXF1,HTM,Up,3809,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FOXF1,HTM,Down,3809,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
FOXF1,HTM,Down,3809,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
FOXF1,HTM,Up,3809,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FOXF2,HTM,Up,3810,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,28588211
FOXG1,HTM,Down,3811,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FOXH1,HTM,Up,3814,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
FOXI1,HTM,Up,3815,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FOXI1,HTM,Down,3815,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FOXI3,HTM,Up,35123,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FOXK1,HTM,Down,23480,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FOXL1,HTM,Down,3817,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
FOXM1,HTM,Up,3818,Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by Transcriptomics and qPCR,0.4,0.0053,26621583
FOXM17,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FOXM17,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FOXM17,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FOXN2,HTM,Up,5281,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
FOXO1,HTM,Up,3819,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
FOXO3,HTM,Up,3821,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0021,19451087
FOXO4,HTM,Up,7139,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FOXP1,HTM,Down,3823,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FOXP110,HTM,Up,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FOXP110,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FOXP110,HTM,Up,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
FOXP2,HTM,Up,13875,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FOXP3,HTM,Down,6106,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
FOXQ1,HTM,Down,20951,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FPGS,HTM,Down,3824,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
FPGT-TNNI3K,HTM,Down,42952,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
FRA10AC1,HTM,Up,1162,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
FRAS1,HTM,Down,19185,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
FRAS1,HTM,Down,19185,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
FREM1,HTM,Up,23399,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
FREM2,HTM,Down,25396,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FRK,HTM,Up,3955,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FRK,HTM,Down,3955,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FRK,HTM,Up,3955,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
FRMD3,HTM,Up,24125,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FRMD4A,HTM,Up,25491,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FRMD4B,HTM,Down,24886,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FRMD4B,HTM,Down,24886,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FRMD4B,HTM,Down,24886,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FRMD4B,HTM,Down,24886,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FRMD4B,HTM,Up,24886,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
FRMD5,HTM,Down,28214,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FRMD5,HTM,Up,28214,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
FRMD6,HTM,Down,19839,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FRMD6,HTM,Down,19839,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FRMD6,HTM,Down,19839,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FRMD6,HTM,Up,19839,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
FRMD8,HTM,Up,25462,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
FRMPD3,HTM,Up,29382,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FRRS1,HTM,Down,27622,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FRY,HTM,Up,20367,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FRY,HTM,Up,20367,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FRYL,HTM,Down,29127,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FRYL,HTM,Down,29127,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FRYL,HTM,Down,29127,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FRYL,HTM,Down,29127,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FRYL,HTM,Up,29127,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
FRZB,HTM,Up,3959,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FSCN1,HTM,Down,11148,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
FSCN1,HTM,Down,11148,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
FSCN1,HTM,Up,11148,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
FSCN1,HTM,Up,11148,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
FSCN1,HTM,Up,11148,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
FSCN1,HTM,Up,11148,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
FSCN1,HTM,Up,11148,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0064,27746256
FSCN1,HTM,Up,11148,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0064,34168259
FSCN2,HTM,Down,3960,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FSD1,HTM,Up,13745,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FSD1,HTM,Up,13745,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FSD1,HTM,Down,13745,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FSD1,HTM,Up,13745,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
FSIP2,HTM,Up,21675,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FSIP2,HTM,Up,21675,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FSIP2,HTM,Up,21675,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FST,HTM,Down,3971,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FST,HTM,Down,3971,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FST,HTM,Down,3971,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0042,26351321
FST,HTM,Down,3971,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FST,HTM,Up,3971,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
FST,HTM,Up,3971,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
FSTL1,HTM,Down,3972,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FSTL1,HTM,Down,3972,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FSTL1,HTM,Down,3972,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FSTL1,HTM,Down,3972,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
FSTL1,HTM,Down,3972,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
FSTL1,HTM,Up,3972,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
FSTL3,HTM,Down,3973,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
FSTL3,HTM,Down,3973,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
FSTL3,HTM,Down,3973,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
FSTL3,HTM,Down,3973,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
FSTL4,HTM,Up,21389,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FTH1,HTM,Up,3976,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
FTH1,HTM,Up,3976,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
FTH1,HTM,Down,3976,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
FTL,HTM,Up,3999,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FTL,HTM,Up,3999,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
FTL,HTM,Up,3999,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
FTL,HTM,Up,3999,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
FTO,HTM,Up,24678,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FTO,HTM,Up,24678,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
FTSJ1,HTM,Down,13254,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FUBP1,HTM,Down,4004,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
FUBP1,HTM,Down,4004,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
FUBP1,HTM,Up,4004,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0042,17911267
FUBP1,HTM,Up,4004,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
FUBP1,HTM,Down,4004,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
FUCA1,HTM,Down,4006,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FUCA1,HTM,Down,4006,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31729259
FUCA1,HTM,Down,4006,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
FUCA1,HTM,Down,4006,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31729259
FUOM,HTM,Down,24733,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
FUS,HTM,Down,4010,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
FUT1,HTM,Down,4012,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FUT1,HTM,Down,4012,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
FUT11,HTM,Down,19233,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FUT11,HTM,Down,19233,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FUT2,HTM,Down,4013,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
FUT3,HTM,Down,4014,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FUT3,HTM,Down,4014,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FUT9,HTM,Down,4020,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
FUT9,HTM,Down,4020,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FXR1,HTM,Down,4023,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
FXYD2,HTM,Down,4026,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
FXYD2,HTM,Up,4026,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
FXYD3,HTM,Down,4027,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
FXYD3,HTM,Down,4027,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
FXYD3,HTM,Down,4027,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
FXYD3,HTM,Down,4027,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
FXYD3,HTM,Down,4027,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0053,34414448
FXYD4,HTM,Up,4028,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
FXYD5,HTM,Down,4029,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
FYB2,HTM,Down,27295,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FYB2,HTM,Down,27295,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
FZD1,HTM,NA,4038,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by PCR array assay,0.04,0.0042,20630067
FZD1,HTM,NA,4038,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0042,20630067
FZD1,HTM,Up,4038,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics and IF staining and qRT-PCR,0.48,0.0042,25731617
FZD1,HTM,Up,4038,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0042,29959199
FZD10,HTM,Up,4039,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25731617
FZD2,HTM,Up,4040,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25731617
FZD4,HTM,Up,4042,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
FZD4,HTM,Down,4042,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
FZD4,HTM,Down,4042,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
FZD4,HTM,Up,4042,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
FZD5,HTM,Up,4043,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
FZD5,HTM,Down,4043,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
FZD6,HTM,Down,4044,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
FZD6,HTM,Down,4044,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FZD6,HTM,Down,4044,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
FZD6,HTM,Down,4044,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
FZD6,HTM,Down,4044,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
FZD7,HTM,Up,4045,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,34228218
FZD7,HTM,Up,4045,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
FZD7,HTM,Up,4045,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.2,0.0064,30696080
FZD7,HTM,Up,4045,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0064,30696080
FZD8,HTM,Up,4046,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
FZD8,HTM,Down,4046,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
FZR1,HTM,Down,24824,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
G0S2,HTM,Down,30229,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
G0S2,HTM,Down,30229,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
G0S2,HTM,Down,30229,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
G0S2,HTM,Up,30229,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
G0S2,HTM,Up,30229,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
G0S2,HTM,Up,30229,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
G0S2,HTM,Up,30229,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
G3BP1,HTM,Down,30292,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
G3BP1,HTM,Down,30292,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
G3BP1,HTM,Down,30292,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
G6PC3,HTM,Down,24861,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
G6PD,HTM,Up,4057,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
G6PD,HTM,Up,4057,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
G6PD,HTM,Down,4057,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
G6PD,HTM,Down,4057,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
G6PD,HTM,Up,4057,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
GAB1,HTM,Down,4066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GAB1,HTM,Down,4066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GAB1,HTM,Down,4066,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
GAB1,HTM,Down,4066,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
GAB1,HTM,Down,4066,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
GAB2,HTM,Down,14458,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,27965308
GAB2,HTM,Up,14458,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GAB2,HTM,Down,14458,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
GABARAPL1,HTM,Up,4068,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GABARAPL1,HTM,Down,4068,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
GABARAPL1,HTM,Down,4068,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
GABARAPL1,HTM,Up,4068,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
GABPB1,HTM,NA,4074,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
GABPB2,HTM,Down,28441,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GABRA3,HTM,Up,4077,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GABRA5,HTM,Up,4079,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GABRA5,HTM,Up,4079,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GABRB3,HTM,Down,4083,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
GABRB3,HTM,Up,4083,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GABRB3,HTM,Up,4083,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GABRD,HTM,Up,4084,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
GABRP,HTM,Up,4089,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0032,17932721
GABRP,HTM,Down,4089,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
GACAT2,HTM,Up,50516,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GAD1,HTM,Down,4092,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
GADD45A,HTM,Down,4095,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GADD45B,HTM,Down,4096,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GADD45B,HTM,Down,4096,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
GADD45B,HTM,Down,4096,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
GADD45G9,HTM,Up,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GADD45G9,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GADD45G9,HTM,Up,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GAGE1,HTM,Down,4098,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GAGE1,HTM,Down,4098,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GAGE12B,HTM,Down,26779,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GAGE13,HTM,Down,29081,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GAGE2A,HTM,Down,4099,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GAGE2B,HTM,Down,4099,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GAGE2C,HTM,Down,31906,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GAGE2E,HTM,Down,31960,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GAGE8,HTM,Down,4099,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GAL,HTM,Up,4114,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,25432175
GAL,HTM,Down,4114,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
GAL,HTM,Down,4114,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
GAL3ST2,HTM,Up,24869,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GALC,HTM,Up,4115,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GALK1,HTM,Down,4118,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
GALM,HTM,Down,24063,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
GALM,HTM,Up,24063,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
GALM,HTM,Up,24063,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
GALM,HTM,Down,24063,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
GALM,HTM,Down,24063,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
GALNT11,HTM,Up,19875,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GALNT11,HTM,Up,19875,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GALNT11,HTM,Up,19875,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GALNT12,HTM,Up,19877,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GALNT12,HTM,Up,19877,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
GALNT13,HTM,Up,23242,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GALNT13,HTM,Up,23242,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GALNT13,HTM,Up,23242,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GALNT13,HTM,Down,23242,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
GALNT14,HTM,Down,22946,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GALNT16,HTM,Down,23233,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
GALNT16,HTM,Down,23233,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
GALNT3,HTM,Down,4125,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
GALNT3,HTM,Down,4125,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
GALNT3,HTM,Down,4125,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
GALNT3,HTM,Down,4125,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
GALNT4,HTM,Up,4126,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GALNT4,HTM,Up,4126,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GALNT5,HTM,Down,4127,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
GALNT5,HTM,Down,4127,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GALNT5,HTM,Down,4127,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GALNT5,HTM,Up,4127,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
GALNT6,HTM,Down,4128,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
GALNT6,HTM,Down,4128,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
GALNT6,HTM,Down,4128,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
GALNT6,HTM,Up,4128,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
GALNT6,HTM,Down,4128,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
GALNT7,HTM,Up,4129,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GALNT7,HTM,Down,4129,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
GALNT79,HTM,Up,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GALNT79,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GALNT79,HTM,Up,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GANAB,HTM,Up,4138,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
GANAB,HTM,Up,4138,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
GANAB,HTM,Down,4138,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
GAP43,HTM,Up,4140,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
GAPDH,HTM,Up,4141,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,33670440
GAPDH,HTM,Up,4141,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0053,34794402
GAPDH,HTM,Up,4141,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0053,34794402
GAPDH,HTM,Down,4141,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0053,34168259
GAPDH,HTM,Down,4141,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0053,24098529
GAPVD1,HTM,NA,23375,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
GAREM1,HTM,Up,26136,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GART,HTM,Up,4163,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,19190339
GART,HTM,Down,4163,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
GART,HTM,Down,4163,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
GART,HTM,Up,4163,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,19190339
GART,HTM,Up,4163,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,19190339
GART,HTM,Up,4163,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0064,27746256
GART,HTM,Down,4163,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0064,34168259
GART,HTM,Up,4163,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,19190339
GART,HTM,Up,4163,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,19190339
GART,HTM,Down,4163,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,29340052
GART,HTM,Up,4163,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0064,21788403
GAS2L1,HTM,Up,16955,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,33670440
GAS2L1,HTM,Up,16955,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
GAS2L3,HTM,Down,27475,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
GAS2L3,HTM,Up,27475,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GAS2L3,HTM,Up,27475,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GAS2L3,HTM,Up,27475,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GAS5,HTM,Up,16355,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
GAS7,HTM,Down,4169,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GAS8-AS1,HTM,Up,1197,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GASK1B,HTM,Down,25312,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GATA2,HTM,Up,4171,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GATA2,HTM,Up,4171,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GATA2,HTM,Up,4171,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GATA3,HTM,Down,4172,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
GATA3,HTM,Down,4172,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31729259
GATA3,HTM,Down,4172,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31729259
GATA6,HTM,Up,4174,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,28588211
GATB,HTM,Down,8849,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
GATD3A,HTM,Up,1273,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
GATD3A,HTM,Up,1273,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
GATM,HTM,Up,4175,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
GATM,HTM,Up,4175,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
GATM,HTM,Down,4175,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
GATM,HTM,Up,4175,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
GATM,HTM,Down,4175,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
GATM,HTM,Down,4175,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
GBF1,HTM,Down,4181,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GBP1,HTM,Down,4182,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GBP1,HTM,Down,4182,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GBP2,HTM,Up,4183,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GBP2,HTM,Up,4183,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GBP2,HTM,Up,4183,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GBP2,HTM,Up,4183,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GBP3,HTM,Down,4184,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GBP3,HTM,Down,4184,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GBP3,HTM,Down,4184,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GBP3,HTM,Down,4184,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GBP3,HTM,Down,4184,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GBP3,HTM,Up,4184,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
GBP6,HTM,Down,25395,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GBP6,HTM,Down,25395,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GBP6,HTM,Down,25395,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GC,HTM,Down,4187,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
GC,HTM,Down,4187,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
GC,HTM,Down,4187,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
GCA,HTM,Up,15990,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GCA,HTM,Up,15990,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GCHFR,HTM,Up,4194,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GCKR,HTM,Up,4196,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GCLC,HTM,Up,4311,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GCN1,HTM,Down,4199,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
GCN1,HTM,Down,4199,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
GCN1L,HTM,Up,4199,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
GCNA,HTM,Up,15805,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
GCNT1,HTM,Down,4203,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GCNT2,HTM,Up,4204,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GCNT2,HTM,Up,4204,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GCNT3,HTM,Up,4205,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GCNT3,HTM,Up,4205,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GCNT3,HTM,Up,4205,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GCNT3,HTM,Up,4205,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GCNT3,HTM,Up,4205,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GCNT4,HTM,Down,17973,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GCNT4,HTM,Down,17973,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GCNT4,HTM,Down,17973,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GCNT4,HTM,Down,17973,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
GCNT4,HTM,Down,17973,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
GCOM1,HTM,Down,26424,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
GCOM1,HTM,Down,26424,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
GDA,HTM,Down,4212,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0042,23820871
GDA,HTM,Up,4212,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
GDA,HTM,Up,4212,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
GDA,HTM,Down,4212,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
GDA,HTM,Down,4212,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
GDA,HTM,Up,4212,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
GDAP1,HTM,Down,15968,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
GDAP1,HTM,Up,15968,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GDF15,HTM,Up,30142,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
GDF15,HTM,Up,30142,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.2,0.0042,34680485
GDF15,HTM,Up,30142,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.2,0.0042,31501409
GDF159,HTM,Up,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GDF159,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GDF159,HTM,Up,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GDF2,HTM,NA,4217,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
GDF7,HTM,Up,4222,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GDI2,HTM,Down,4227,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
GDI2,HTM,Down,4227,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
GDI2,HTM,Down,4227,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
GDI2,HTM,Down,4227,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
GDPD1,HTM,Up,20883,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GDPD3,HTM,Up,28638,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GDPD3,HTM,Up,28638,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GDPD5,HTM,Up,28804,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GDPGP1,HTM,Down,34360,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GEM,HTM,Up,4234,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GEM,HTM,Down,4234,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
GEM,HTM,Down,4234,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
GEMIN4,HTM,Up,15717,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
GEMIN5,HTM,Down,20043,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GEMIN6,HTM,Up,20044,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GFER,HTM,Down,4236,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GFI1,HTM,Down,4237,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GFI1,HTM,Down,4237,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GFM1,HTM,Down,13780,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
GFM2,HTM,Down,29682,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
GFOD1,HTM,Up,21096,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GFPT1,HTM,Up,4241,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
GFPT1,HTM,Up,4241,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
GFPT2,HTM,Up,4242,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
GFRA1,HTM,Up,4243,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
GFRA1,HTM,Down,4243,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GFRA3,HTM,Up,4245,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GFRA3,HTM,Up,4245,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GGA2,HTM,Down,16064,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GGCX,HTM,Down,4247,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GGT1,HTM,Up,4250,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GGT5,HTM,Up,4260,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GGT6,HTM,Up,26891,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GGT7,HTM,Up,4259,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GGT8P,HTM,Down,33438,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GGTLC1,HTM,Down,16437,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GHR,HTM,Down,4263,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
GHR,HTM,Up,4263,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GHR,HTM,Down,4263,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
GHR,HTM,Up,4263,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GHR,HTM,Up,4263,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GHRL,HTM,Down,18129,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
GID8,HTM,Down,15857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GIGYF2,HTM,Down,11960,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
GIGYF2,HTM,Down,11960,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
GIGYF2,HTM,Down,11960,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
GIN1,HTM,Down,25959,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
GINM1,HTM,Down,21074,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GINS1,HTM,Up,28980,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GINS1,HTM,Up,28980,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
GINS2,HTM,Down,24575,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GINS2,HTM,Down,24575,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GINS2,HTM,Down,24575,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GINS2,HTM,Down,24575,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GINS4,HTM,Up,28226,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GINS4,HTM,Down,28226,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
GINS4,HTM,Down,28226,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
GIPC3,HTM,Up,18183,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
GIPC3,HTM,Up,18183,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
GIPC3,HTM,Up,18183,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
GIPC3,HTM,Up,18183,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
GIPC3,HTM,Up,18183,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
GIT2,HTM,Down,4273,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GJA1,HTM,Down,4274,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
GJA1,HTM,Up,4274,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,20424609
GJA1,HTM,Up,4274,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,20424609
GJA1,HTM,Up,4274,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,34228218
GJA1,HTM,Down,4274,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
GJA1,HTM,Down,4274,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
GJA1,HTM,Down,4274,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
GJA5,HTM,Down,4279,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GJA5,HTM,Down,4279,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GJB1,HTM,Down,4283,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
GJB1,HTM,Down,4283,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
GJB1,HTM,Down,4283,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,20424609
GJB1,HTM,Down,4283,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,20424609
GJB1,HTM,Up,4283,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0042,17932721
GJB1,HTM,Up,4283,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0042,17932721
GJB1,HTM,Down,4283,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
GJB1,HTM,Down,4283,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
GJB2,HTM,Down,4284,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GJB2,HTM,Down,4284,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GJB2,HTM,Down,4284,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GJB2,HTM,Down,4284,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
GJB2,HTM,Down,4284,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
GJB3,HTM,Down,4285,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GJB4,HTM,Down,4286,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GJB5,HTM,Down,4287,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GJB5,HTM,Down,4287,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GJB5,HTM,Down,4287,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GJB5,HTM,Down,4287,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
GJB6,HTM,Down,4288,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GJC1,HTM,Up,4280,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GJC1,HTM,Up,4280,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GJC1,HTM,Up,4280,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
GJC1,HTM,Up,4280,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
GJC2,HTM,Up,17494,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GJC2,HTM,Up,17494,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GK2,HTM,Up,4291,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GKAP1,HTM,Up,17496,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GKAP1,HTM,Up,17496,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GKAP1,HTM,Up,17496,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GKAP1,HTM,Up,17496,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GKAP1,HTM,Up,17496,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GLA,HTM,Up,4296,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GLA,HTM,Up,4296,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GLA,HTM,Down,4296,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GLB1,HTM,Down,4298,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GLB1,HTM,Up,4298,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GLB1,HTM,Up,4298,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GLB1,HTM,Up,4298,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GLB1L2,HTM,Up,25129,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GLCCI1,HTM,Up,18713,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GLCCI1,HTM,Down,18713,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
GLDC,HTM,Up,4313,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GLDC,HTM,Up,4313,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GLDN,HTM,Up,29514,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
GLDN,HTM,Up,29514,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GLG1,HTM,Down,4316,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GLI1,HTM,Up,4317,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0308,34414448
GLI1,HTM,Up,4317,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0308,29959199
GLI2,HTM,Up,4318,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0106,34228218
GLI3,HTM,Down,4319,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GLI3,HTM,Down,4319,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GLI3,HTM,Down,4319,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GLIPR1,HTM,Down,17001,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GLIPR1,HTM,Down,17001,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GLIPR1,HTM,Down,17001,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GLIPR1L1,HTM,Up,28392,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GLIS3,HTM,Up,28510,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GLIS3,HTM,Up,28510,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GLO1,HTM,Up,4323,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
GLO1,HTM,Up,4323,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
GLO1,HTM,Down,4323,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
GLO1,HTM,Up,4323,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
GLP1R,HTM,Down,4324,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GLRA2,HTM,Down,4327,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GLRX,HTM,Up,4330,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GLRX,HTM,Up,4330,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0032,34794402
GLRX,HTM,Up,4330,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0032,34794402
GLRX,HTM,Up,4330,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
GLRX3,HTM,Up,15987,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics and qRT-PCR and Western Blotting,0.56,0.0032,34794402
GLRX3,HTM,Up,15987,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics and qRT-PCR and Western Blotting,0.56,0.0032,34794402
GLRX3,HTM,Up,15987,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GLRX3,HTM,Up,15987,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GLRX3,HTM,Up,15987,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
GLRX3,HTM,Up,15987,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GLS,HTM,Up,4331,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
GLT8D2,HTM,Down,24890,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GLT8D2,HTM,Up,24890,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GLT8D2,HTM,Up,24890,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GLT8D2,HTM,Up,24890,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GLTPD2,HTM,Down,33756,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GLUD1,HTM,Up,4335,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
GLUD1,HTM,Down,4335,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
GLUD1,HTM,Up,4335,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
GLUL,HTM,Down,4341,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GLUL,HTM,Down,4341,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GLUL,HTM,Down,4341,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GLYAT,HTM,Down,13734,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GLYCTK,HTM,Down,24247,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GM2A,HTM,Down,4367,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GM2A,HTM,Down,4367,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GM2A,HTM,Down,4367,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GMIP,HTM,Up,24852,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GMIP,HTM,Up,24852,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GMIP,HTM,Up,24852,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
GMIP,HTM,Up,24852,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GMPPB,HTM,Up,22932,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GMPPB,HTM,Up,22932,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GMPPB,HTM,Up,22932,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GMPR,HTM,Up,4376,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GMPS,HTM,Down,4378,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
GMPS,HTM,Down,4378,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
GNA13,HTM,Down,4381,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
GNA15,HTM,Down,4383,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GNA15,HTM,Down,4383,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GNA15,HTM,Down,4383,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GNAI1,HTM,Up,4384,Luminal A Breast Cancer,,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GNAI1,HTM,Down,4384,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
GNAI2,HTM,Down,4385,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GNAI2,HTM,Down,4385,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GNAI2,HTM,Down,4385,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GNAI3,HTM,Down,4387,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GNAL,HTM,Up,4388,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GNAL,HTM,Up,4388,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GNAL,HTM,Up,4388,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GNAO1,HTM,Up,4389,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GNAQ,HTM,Down,4390,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
GNAS,HTM,Down,4392,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
GNB4,HTM,Down,20731,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GNB4,HTM,Down,20731,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GNB4,HTM,Up,20731,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
GNE,HTM,Up,23657,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
GNE,HTM,Up,23657,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
GNE,HTM,Down,23657,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
GNG11,HTM,Up,4403,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GNG11,HTM,Up,4403,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GNG11,HTM,Up,4403,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
GNG13,HTM,Up,14131,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0011,28927099
GNG2,HTM,Up,4404,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0021,28927099
GNG2,HTM,Down,4404,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
GNG4,HTM,Up,4407,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GNG4,HTM,Down,4407,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GNGT1,HTM,Up,4411,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GNGT1,HTM,Up,4411,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GNGT1,HTM,Up,4411,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0021,28927099
GNGT1,HTM,Up,4411,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GNL3L,HTM,Down,25553,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GNLY,HTM,Down,4414,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GNPDA1,HTM,Up,4417,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,22623141
GNPTAB,HTM,Down,29670,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GNPTAB,HTM,Up,29670,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
GNPTG,HTM,Up,23026,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GNPTG,HTM,Up,23026,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GNPTG,HTM,Up,23026,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GNRH1,HTM,Up,4419,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GNRH1,HTM,Up,4419,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GNRH1,HTM,Up,4419,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GOLGA2P2Y,HTM,Down,16479,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GOLGA2P5,HTM,Down,25315,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
GOLGA2P5,HTM,Down,25315,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
GOLGA2P5,HTM,Up,25315,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
GOLGA4,HTM,Up,4427,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GOLGA4,HTM,Up,4427,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GOLGA4,HTM,Up,4427,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GOLGA8IP,HTM,Down,26660,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GOLGA8IP,HTM,Down,26660,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GOLIM4,HTM,Up,15448,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
GOLM1,HTM,Down,15451,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
GOLPH3,HTM,Down,15452,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GOLPH3L,HTM,Down,24882,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GOLT1B,HTM,Up,20175,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
GOLT1B,HTM,Up,20175,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
GOPC,HTM,Down,17643,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GOSR1,HTM,Down,4430,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GOSR2,HTM,Up,4431,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
GOT1,HTM,Down,4432,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
GOT1,HTM,Down,4432,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
GOT1,HTM,Down,4432,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
GOT2,HTM,Up,4433,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
GOT2,HTM,Up,4433,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
GPALPP1,HTM,Down,20298,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GPAM,HTM,Down,24865,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GPAT3,HTM,Up,28157,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GPAT3,HTM,Up,28157,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GPATCH1,HTM,Up,24658,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GPATCH2,HTM,Up,25499,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
GPATCH2,HTM,Up,25499,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
GPATCH2,HTM,Up,25499,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
GPBP1L1,HTM,NA,28843,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
GPC3,HTM,Up,4451,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0032,17932721
GPC3,HTM,Up,4451,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
GPC4,HTM,Up,4452,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0021,17932721
GPC4,HTM,Up,4452,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GPC6,HTM,Up,4454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GPC6,HTM,Up,4454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GPC6,HTM,Down,4454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GPCPD1,HTM,Up,26957,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GPD1,HTM,Up,4455,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GPD1L,HTM,Up,28956,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GPD1L,HTM,Up,28956,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GPD2,HTM,Up,4456,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
GPD2,HTM,Down,4456,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
GPD2,HTM,Down,4456,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
GPD2,HTM,Down,4456,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
GPER1,HTM,Up,4485,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GPI,HTM,Up,4458,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
GPI,HTM,Up,4458,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
GPI,HTM,Up,4458,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
GPI,HTM,Down,4458,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
GPI,HTM,Down,4458,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
GPM6A,HTM,Up,4460,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
GPNMB,HTM,Up,4462,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
GPNMB6,HTM,Up,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GPNMB6,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GPNMB6,HTM,Up,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GPNNB,HTM,Up,NA,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
GPR141,HTM,Down,19997,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GPR141,HTM,Down,19997,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GPR143,HTM,Up,20145,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GPR155,HTM,Down,22951,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GPR157,HTM,Down,23687,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GPR160,HTM,Down,23693,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
GPR160,HTM,Down,23693,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GPR161,HTM,Up,23694,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GPR179,HTM,Down,31371,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GPR18,HTM,Up,4472,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GPR180,HTM,Up,28899,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
GPR183,HTM,Down,3128,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GPR183,HTM,Down,3128,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GPR20,HTM,Down,4475,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GPR3,HTM,Up,4484,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
GPR37L1,HTM,Down,14923,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
GPR37L1,HTM,Down,14923,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GPR56,HTM,Up,4512,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
GPR68,HTM,Down,4519,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GPR87,HTM,Down,4538,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GPR87,HTM,Down,4538,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GPR87,HTM,Down,4538,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
GPR87,HTM,Up,4538,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GPR87,HTM,Up,4538,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GPR87,HTM,Up,4538,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GPRASP2,HTM,Down,25169,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
GPRC5A,HTM,Down,9836,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
GPRC5A,HTM,Down,9836,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
GPRC5A,HTM,Down,9836,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
GPRC5B,HTM,Up,13308,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GPRIN2,HTM,Down,23730,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GPRIN3,HTM,Up,27733,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GPRIN3,HTM,Up,27733,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GPRIN3,HTM,Up,27733,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GPSM1,HTM,Down,17858,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GPSM2,HTM,Down,29501,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GPSM2,HTM,Down,29501,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GPSM2,HTM,Down,29501,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GPX1,HTM,Up,4553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
GPX1,HTM,Up,4553,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
GPX2,HTM,Up,4554,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GPX2,HTM,Up,4554,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GPX2,HTM,Up,4554,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
GPX2,HTM,Up,4554,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
GPX2,HTM,Up,4554,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
GPX3,HTM,Down,4555,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GPX3,HTM,Down,4555,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GPX3,HTM,Down,4555,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GPX3,HTM,Up,4555,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
GPX3,HTM,Up,4555,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
GPX3,HTM,Up,4555,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GPX3,HTM,Up,4555,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GPX3,HTM,Up,4555,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GPX4,HTM,Up,4556,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
GPX8,HTM,Down,33100,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GRAMD1A,HTM,Down,29305,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GRAMD1B,HTM,Up,29214,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GRAMD1B,HTM,Up,29214,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GRAMD2A,HTM,Down,27287,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GRAMD2B,HTM,Down,24911,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
GRAMD2B,HTM,Down,24911,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
GRAMD2B,HTM,Down,24911,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
GRAMD2B,HTM,Down,24911,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
GRAMD2B,HTM,Up,24911,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
GRAMD2B,HTM,Up,24911,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
GRAMD2B,HTM,Up,24911,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
GRB10,HTM,Up,4564,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
GRB10,HTM,Up,4564,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
GRB14,HTM,Up,4565,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GRB14,HTM,Up,4565,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GRB14,HTM,Up,4565,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GRB2,HTM,Down,4566,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
GRB2,HTM,Down,4566,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
GRB2,HTM,Up,4566,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
GRB7,HTM,Up,4567,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GRB7,HTM,Down,4567,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
GREB1,HTM,Down,24885,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
GREB1,HTM,Down,24885,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GREB1L,HTM,Down,31042,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GREM1,HTM,Up,2001,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
GREM1,HTM,Down,2001,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
GREP1,HTM,Up,27549,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GRHL1,HTM,Up,17923,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GRHL1,HTM,Down,17923,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
GRHL2,HTM,Down,2799,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GRIA4,HTM,Up,4574,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GRIK2,HTM,Up,4580,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GRIK2,HTM,Up,4580,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GRIK2,HTM,Up,4580,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
GRIK2,HTM,Up,4580,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
GRIK2,HTM,Up,4580,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GRIK3,HTM,Up,4581,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GRIK4,HTM,Up,4582,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GRIK4,HTM,Up,4582,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GRIN2A,HTM,Up,4585,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
GRIN3B,HTM,Up,16768,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
GRINA,HTM,Up,4589,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
GRK5,HTM,Down,4544,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GRK5,HTM,Down,4544,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GRK5,HTM,Down,4544,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GRK5,HTM,Down,4544,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
GRK6,HTM,Down,4545,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
GRK6,HTM,Down,4545,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
GRM4,HTM,Down,4596,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
GRM7,HTM,Down,4599,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GRN,HTM,Down,4601,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
GRSF1,HTM,Down,4610,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
GRSF1,HTM,Down,4610,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
GRTP1,HTM,Down,20310,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
GSAP,HTM,Down,28042,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GSAP,HTM,Down,28042,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GSC,HTM,Down,4612,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
GSDMB,HTM,Down,23690,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GSDMB,HTM,Down,23690,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
GSDMC,HTM,Down,7151,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GSDMC,HTM,Down,7151,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GSDMC,HTM,Down,7151,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GSDMC,HTM,Up,7151,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GSE1,HTM,Up,28979,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GSG1L,HTM,Up,28283,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GSG1L,HTM,Up,28283,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GSG1L,HTM,Up,28283,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GSK3B,HTM,Up,4617,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics,0.04,0.0053,25731617
GSK3B,HTM,Down,4617,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0053,29959199
GSN,HTM,Down,4620,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0053,23903875
GSN,HTM,Down,4620,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
GSN,HTM,Up,4620,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
GSN,HTM,Up,4620,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0053,34168259
GSN,HTM,Down,4620,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0053,22954703
GSPT2,HTM,Up,4622,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
GSPT2,HTM,Down,4622,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
GSPT2,HTM,Up,4622,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GSPT2,HTM,Up,4622,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GSPT2,HTM,Up,4622,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
GSR,HTM,Up,4623,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GSR,HTM,Up,4623,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GSR,HTM,Up,4623,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GSR,HTM,Down,4623,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
GSS,HTM,Up,4624,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
GSS,HTM,Up,4624,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
GSTA1,HTM,Up,4626,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GSTA1,HTM,Up,4626,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GSTA2,HTM,Down,4627,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GSTA2,HTM,Down,4627,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GSTA2,HTM,Down,4627,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GSTA4,HTM,Up,4629,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GSTA4,HTM,Up,4629,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
GSTCD,HTM,Down,25806,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GSTM1,HTM,Up,4632,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GSTM1,HTM,Down,4632,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GSTM2,HTM,Up,4634,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GSTM3,HTM,Down,4635,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
GSTM3,HTM,Up,4635,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
GSTM4,HTM,Up,4636,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GSTO1,HTM,Down,13312,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
GSTO1,HTM,Down,13312,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
GSTO1,HTM,Up,13312,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
GSTP1,HTM,Down,4638,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0053,34059086
GSTP1,HTM,Down,4638,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0053,34059086
GSTP1,HTM,Up,4638,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
GSTP1,HTM,Up,4638,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
GSTP1,HTM,Up,4638,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0053,34168259
GSTP1,HTM,Down,4638,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0053,34168259
GSTP1,HTM,Up,4638,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.12,0.0053,31073886
GSTP1,HTM,Down,4638,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0053,34168259
GSTT2,HTM,Down,4642,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GSTT2,HTM,Down,4642,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GSTT2,HTM,Down,4642,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GSTT2B,HTM,Down,33437,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GSTT2B,HTM,Down,33437,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GSTT2B,HTM,Down,33437,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GTDC1,HTM,Down,20887,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
GTF2A2,HTM,Up,4647,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
GTF2E1,HTM,Down,4650,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
GTF2E1,HTM,Up,4650,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
GTF2H2,HTM,Up,4656,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GTF2H2,HTM,Up,4656,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GTF2H2,HTM,Down,4656,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
GTF2H2,HTM,Up,4656,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GTF2H2,HTM,Up,31394,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GTF2H2,HTM,Up,31394,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GTF2H2,HTM,Up,31394,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
GTF2H2C_2,HTM,Down,35418,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GTF2I,HTM,Down,4659,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
GTF3A,HTM,Up,4662,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GTF3C2,HTM,Down,4665,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GTPBP1,HTM,Down,4669,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GTPBP1,HTM,Down,4669,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GTPBP8,HTM,Up,25007,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GTPBP8,HTM,Up,25007,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GTPBP8,HTM,Up,25007,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GTSE13,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GTSE13,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GTSE13,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GUCA1B,HTM,Down,4679,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GUCY1A1,HTM,Up,4685,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GUCY1A2,HTM,Down,4684,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
GUCY1B1,HTM,Up,4687,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
GUCY1B2,HTM,Up,4686,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GULP1,HTM,Up,18649,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GULP1,HTM,Up,18649,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
GULP1,HTM,Up,18649,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
GULP1,HTM,Down,18649,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
GUSB,HTM,Up,4696,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GUSB,HTM,Up,4696,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GUSB,HTM,Up,4696,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
GUSBP1,HTM,Up,13670,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
GUSBP1,HTM,Down,13670,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
GUSBP1,HTM,Down,13670,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
GUSBP2,HTM,Up,18792,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GUSBP2,HTM,Up,18792,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GUSBP2,HTM,Up,18792,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GUSBP3,HTM,Up,37301,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GUSBP3,HTM,Up,37301,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GYG1,HTM,Down,4699,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
GYG2,HTM,Up,4700,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GYG2,HTM,Up,4700,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GYG2P1,HTM,Down,4701,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
GYMAP7,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GYMAP7,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GYMAP7,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
GYS1,HTM,Down,4706,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
GYS1,HTM,Down,4706,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
H1-0,HTM,Up,4714,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
H1-0,HTM,Up,4714,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
H1-0,HTM,Up,4714,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
H1-0,HTM,Up,4714,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
H1-0,HTM,Down,4714,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
H1-0,HTM,Down,4714,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
H1-1,HTM,Down,4715,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
H1-1,HTM,Down,4715,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
H1-1,HTM,Down,4715,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
H1-2,HTM,Down,4716,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
H1-2,HTM,Down,4716,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
H1-2,HTM,Up,4716,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
H1-2,HTM,Down,4716,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
H1-2,HTM,Down,4716,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0053,34168259
H1-2,HTM,Up,4716,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,29340052
H1-3,HTM,Up,4717,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
H1-3,HTM,Down,4717,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
H1-3,HTM,Down,4717,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
H1-3,HTM,Up,4717,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
H1-4,HTM,Down,1863,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
H1-5,HTM,Down,4719,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
H1-5,HTM,Down,4719,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
H1-5,HTM,Down,4719,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
H1-5,HTM,Down,4719,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
H1-5,HTM,Down,4719,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
H19,HTM,Up,4713,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
H19,HTM,Up,4713,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
H19,HTM,Down,4713,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
H19,HTM,Up,4713,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
H19,HTM,Down,4713,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
H19,HTM,Up,4713,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
H19,HTM,Down,4713,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
H19,HTM,Down,4713,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
H19,HTM,Down,4713,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0064,34414448
H19,HTM,Up,4713,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
H195,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
H195,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
H195,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
H2AC1,HTM,Up,18729,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
H2AC15,HTM,Down,4726,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC15,HTM,UP,4726,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC17,HTM,Down,4735,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,29316740
H2AC18,HTM,Down,4736,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
H2AC20,HTM,Up,4738,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
H2AC20,HTM,Up,4738,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
H2AC21,HTM,Up,20508,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
H2AC21,HTM,Down,20508,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
H2AC21,HTM,Down,20508,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
H2AC4,HTM,Up,4734,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
H2AC4,HTM,UP,4734,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC4,HTM,UP,4734,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC4,HTM,UP,4734,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC4,HTM,UP,4734,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC4,HTM,UP,4734,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC4,HTM,UP,4734,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC4,HTM,UP,4734,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC4,HTM,UP,4734,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC4,HTM,UP,4734,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC4,HTM,UP,4734,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2AC6,HTM,Down,4733,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
H2AC8,HTM,Up,4724,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
H2AC8,HTM,Up,4724,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
H2AC8,HTM,Up,4724,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
H2AC8,HTM,Up,4724,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
H2ACP1,HTM,Down,42647,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
H2ACP1,HTM,Down,42647,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
H2ACP1,HTM,Down,42647,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
H2ACP1,HTM,Down,42647,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
H2ACP1,HTM,Down,42647,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
H2ACP1,HTM,Down,42647,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
H2AFY2,HTM,Down,14453,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
H2AX,HTM,Down,4739,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
H2AZ2,HTM,UP,20664,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H2AZ2,HTM,UP,20664,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H2AZ2,HTM,UP,20664,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H2AZ2,HTM,UP,20664,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H2AZ2,HTM,UP,20664,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H2BC12,HTM,Up,13954,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
H2BC12,HTM,Up,13954,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
H2BC12,HTM,Down,13954,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
H2BC13,HTM,Down,4748,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
H2BC18,HTM,Up,24700,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
H2BC18,HTM,Up,24700,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
H2BC21,HTM,Down,4760,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
H2BC21,HTM,Up,4760,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
H2BC21,HTM,Up,4760,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
H2BC21,HTM,Up,4760,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
H2BC21,HTM,Down,4760,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
H2BC3,HTM,Down,4751,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
H2BC3,HTM,Down,4751,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
H2BC3,HTM,Down,4751,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
H2BC3,HTM,Down,4751,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
H2BC3,HTM,Down,4751,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
H2BC3,HTM,Down,4751,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
H2BC3,HTM,UP,4751,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2BC3,HTM,UP,4751,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2BC3,HTM,UP,4751,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2BC3,HTM,UP,4751,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2BC3,HTM,UP,4751,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H2BC8,HTM,Up,4746,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
H2BC9,HTM,Up,4755,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
H2BC9,HTM,Down,4755,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
H2BC9,HTM,Down,4755,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
H2BP1,HTM,Up,20560,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
H2BP1,HTM,Up,20560,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
H2BU1,HTM,UP,20514,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H2BU1,HTM,UP,20514,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H2BU1,HTM,UP,20514,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H2BU1,HTM,UP,20514,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H2BU1,HTM,UP,20514,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H3-3A,HTM,Up,4764,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
H3-4,HTM,Down,4778,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
H3-4,HTM,Down,4778,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
H3C1,HTM,Down,4774,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
H3C10,HTM,Down,4775,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
H3C11,HTM,Down,4771,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
H3C14,HTM,Down,20503,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
H3C2,HTM,Down,4776,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
H3C7,HTM,Down,4773,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
H3C7,HTM,UP,4773,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H3C7,HTM,UP,4773,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H3C7,HTM,UP,4773,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H3C7,HTM,UP,4773,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H3C7,HTM,UP,4773,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
H3C8,HTM,Down,4772,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
H4-16,HTM,Down,20510,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
H4C1,HTM,UP,4781,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H4C1,HTM,UP,4781,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H4C1,HTM,UP,4781,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H4C1,HTM,UP,4781,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H4C1,HTM,UP,4781,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
H4C14,HTM,Down,4794,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
H4C14,HTM,Up,4794,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
H4C14,HTM,Down,4794,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
H4C14,HTM,Down,4794,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
H4C15,HTM,Up,29607,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
H4C5,HTM,Down,4790,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
H4C8,HTM,Up,4788,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
H4C8,HTM,Up,4788,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
H4C8,HTM,Down,4788,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
H4C9,HTM,Down,4793,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
H4C9,HTM,Down,4793,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
HABP2,HTM,Up,4798,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29416721
HABP2,HTM,Down,4798,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,25676692
HABP2,HTM,Down,4798,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,25676692
HABP2,HTM,Down,4798,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
HABP2,HTM,Up,4798,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
HABP2,HTM,Down,4798,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,25676692
HABP2,HTM,Down,4798,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
HABP2,HTM,Up,4798,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
HABP2,HTM,Up,4798,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
HACD3,HTM,Up,24175,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HACD4,HTM,Down,20920,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HACD4,HTM,Down,20920,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HADH,HTM,Up,4799,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HADH,HTM,Up,4799,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HADH,HTM,Up,4799,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HADHA,HTM,Up,4801,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
HADHA,HTM,Up,4801,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
HADHA,HTM,Up,4801,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HADHA,HTM,Up,4801,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HADHA,HTM,Up,4801,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HADHA,HTM,Up,4801,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HADHA,HTM,Down,4801,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HADHA,HTM,Down,4801,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
HADHA,HTM,Up,4801,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HADHA,HTM,Up,4801,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
HADHB,HTM,Up,4803,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HADHB,HTM,Up,4803,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HADHB,HTM,Up,4803,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HADHB,HTM,Up,4803,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HAND1,HTM,Down,4807,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
HAO1,HTM,Down,4809,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
HAP1,HTM,Down,4812,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
HAR1A,HTM,Up,33117,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HAR1B,HTM,Up,33118,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HARS1,HTM,Down,4816,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HAS3,HTM,Down,4820,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
HAS3,HTM,Up,4820,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
HAT1,HTM,NA,4821,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29221160
HAUS1,HTM,Up,25174,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HAUS1,HTM,Up,25174,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HAUS1,HTM,Down,25174,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
HAUS1,HTM,Up,25174,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HAUS3,HTM,Up,28719,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
HAUS5,HTM,Down,29130,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
HAUS6,HTM,Down,25948,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
HAUS6,HTM,Down,25948,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
HAVCR1,HTM,Up,17866,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HAVCR1,HTM,Up,17866,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HAVCR1,HTM,Down,17866,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
HAVCR1,HTM,Down,17866,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
HAVCR1,HTM,Down,17866,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
HBA1,HTM,Up,4823,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
HBA1,HTM,Up,4823,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
HBA2,HTM,Up,4824,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
HBB,HTM,Down,4827,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
HBB,HTM,Up,4827,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
HBB,HTM,Up,4827,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
HBB,HTM,Down,4827,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0032,28881576
HBE1,HTM,Up,4830,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HBE1,HTM,Down,4830,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
HBEGF,HTM,Down,3059,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HBEGF,HTM,Down,3059,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HBEGF,HTM,Down,3059,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HBP1,HTM,Up,23200,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
HBP1,HTM,Up,23200,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
HBP110,HTM,Up,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
HBP110,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
HBP110,HTM,Up,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
HCAR1,HTM,Down,4532,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
HCAR2,HTM,Down,24827,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
HCAR2,HTM,Down,24827,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
HCAR2,HTM,Down,24827,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
HCAR2,HTM,Down,24827,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
HCFC2,HTM,Down,24972,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HCG11,HTM,Down,17707,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
HCG27,HTM,Up,27366,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HCG27,HTM,Up,27366,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HCG27,HTM,Up,27366,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HCG9,HTM,Up,21243,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HCG9,HTM,Up,21243,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HCG9,HTM,Up,21243,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HCK,HTM,Down,4840,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HCLS1,HTM,Down,4844,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HCLS1,HTM,Down,4844,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HCLS1,HTM,Down,4844,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HCMOG,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
HCN1,HTM,Up,4845,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
HCN4,HTM,Up,16882,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
HDAC1,HTM,Down,4852,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
HDAC11,HTM,Down,19086,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
HDAC11,HTM,Up,19086,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
HDAC2,HTM,Up,4853,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,20424609
HDAC2,HTM,Up,4853,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,20424609
HDAC4,HTM,Down,14063,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
HDAC8,HTM,Down,13315,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
HDAC9,HTM,Down,14065,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
HDAC9,HTM,Down,14065,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
HDAC9,HTM,Down,14065,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
HDAC9,HTM,Down,14065,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
HDGF,HTM,Up,4856,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HDGF,HTM,Up,4856,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HDGF,HTM,Down,4856,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
HDGFL3,HTM,Up,24937,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
HDLBP,HTM,Down,4857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
HDLBP,HTM,Up,4857,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
HEATR5A,HTM,Up,20276,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HEATR5A,HTM,Up,20276,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
HEATR5A,HTM,Up,20276,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
HEATR5A,HTM,Up,20276,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
HEATR5B,HTM,Up,29273,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
HECW1,HTM,Up,22195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HECW2,HTM,Up,29853,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
HECW2,HTM,Up,29853,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
HEG1,HTM,Down,29227,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
HEG1,HTM,Down,29227,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
HEG1,HTM,Up,29227,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
HEG1,HTM,Down,29227,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
HEG1,HTM,Down,29227,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
HEG1,HTM,Up,29227,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
HELB,HTM,Up,17196,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HELLS,HTM,Down,4861,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
HELLS,HTM,Down,4861,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
HEMK1,HTM,Down,24923,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HEMK1,HTM,Down,24923,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
HENMT1,HTM,Down,26400,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
HEPACAM,HTM,Up,26361,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
HEPHL1,HTM,Down,30477,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HEPHL1,HTM,Down,30477,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HEPHL1,HTM,Down,30477,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HEPHL1,HTM,Down,30477,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
HEPHL1,HTM,Down,30477,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
HERC1,HTM,Up,4867,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29511337
HERC1,HTM,Up,4867,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0011,29511337
HERC2,HTM,Up,4868,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HERC2,HTM,Up,4868,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HERC2,HTM,Up,4868,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HERC3,HTM,Down,4876,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HERC3,HTM,Down,4876,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HERC3,HTM,Down,4876,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HERC3,HTM,Down,4876,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
HERC4,HTM,Down,24521,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29511337
HERC4,HTM,Up,24521,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
HERC4,HTM,Down,24521,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0021,29511337
HERC5,HTM,Up,24368,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HERC6,HTM,Down,26072,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HERC6,HTM,Down,26072,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
HES1,HTM,Down,5192,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0095,34059086
HES1,HTM,Up,5192,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0095,27965308
HES1,HTM,Up,5192,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0095,31501409
HES2,HTM,Down,16005,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
HES6,HTM,Up,18254,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
HES6,HTM,Up,18254,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
HES6,HTM,Down,18254,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
HEXA,HTM,Up,4878,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HEXA,HTM,Down,4878,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
HEXA,HTM,Down,4878,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
HEXA-AS1,HTM,Down,25810,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
HEXB,HTM,Up,4879,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HEXB,HTM,Down,4879,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HEXB,HTM,Up,4879,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
HEY2,HTM,Down,4881,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
HFE,HTM,Down,4886,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
HFE,HTM,Up,4886,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0032,28881576
HFE,HTM,Down,4886,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
HGD,HTM,Up,4892,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HGD,HTM,Up,4892,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HGD,HTM,Up,4892,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HGD,HTM,Up,4892,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HGF,HTM,Up,4893,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
HGF,HTM,Up,4893,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
HGF,HTM,Up,4893,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
HGH1,HTM,Up,24161,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HGH1,HTM,Up,24161,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HGSNAT,HTM,Down,26527,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
HHEX,HTM,Up,4901,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HHEX,HTM,Up,4901,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HHIP,HTM,Down,14866,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HHIP,HTM,Down,14866,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0021,29959199
HHIPL2,HTM,Up,25842,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HHIPL2,HTM,Up,25842,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HHIPL2,HTM,Up,25842,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
HHLA2,HTM,Down,4905,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HHLA2,HTM,Down,4905,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HIBCH,HTM,Down,4908,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HIBCH,HTM,Down,4908,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
HIC2,HTM,Up,18595,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
HID1,HTM,Down,15736,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HID1,HTM,Down,15736,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
HIF1A,HTM,Up,4910,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.28,0.0106,31501409
HIF1A,HTM,Up,4910,Breast Cancer,NA,Primary,NA,Transcriptomics,0.12,0.0106,30559934
HIF1A,HTM,Up,4910,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0106,35013621
HIF3A,HTM,Down,15825,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HIF3A,HTM,Down,15825,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HIGD1A,HTM,Down,29527,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
HIKESHI,HTM,Up,26938,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HIKESHI,HTM,Up,26938,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HIKESHI,HTM,Up,26938,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HILPDA,HTM,Up,28859,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HILPDA,HTM,Up,28859,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
HILPDA,HTM,Down,28859,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
HIP1,HTM,Down,4913,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HIP1,HTM,Down,4913,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HIP1,HTM,Up,4913,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HIP1,HTM,Up,4913,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HIPK1,HTM,Up,19006,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
HIPK2,HTM,Up,14402,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
HIPK2,HTM,Up,14402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
HIPK2,HTM,Up,14402,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
HIRA,HTM,Up,4916,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
HIRIP3,HTM,Down,4917,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
HIST1H1E,HTM,Down,4718,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HIST1H1E,HTM,Down,4718,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HIST1H4J,HTM,Down,4788,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
HIVEP1,HTM,Up,4920,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
HIVEP1,HTM,Up,4920,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
HIVEP1,HTM,Up,4920,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
HIVEP2,HTM,Down,4921,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HIVEP2,HTM,Down,4921,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HJURP,HTM,Up,25444,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HJURP,HTM,Up,25444,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HJURP,HTM,Up,25444,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HJURP,HTM,Up,25444,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HK1,HTM,Down,4922,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
HK1,HTM,Down,4922,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
HK1,HTM,Up,4922,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HK1,HTM,Up,4922,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HK1,HTM,Down,4922,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
HK2,HTM,Down,4923,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HKDC1,HTM,Up,23302,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HKDC1,HTM,Up,23302,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HLA-A,HTM,Down,4931,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-A,HTM,Down,4931,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-A,HTM,Down,4931,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-A,HTM,Down,4931,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-A,HTM,Down,4931,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-A,HTM,Down,4931,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-A,HTM,Down,4931,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-A,HTM,Up,4931,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HLA-A,HTM,Up,4931,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HLA-B,HTM,Down,4932,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-B,HTM,Down,4932,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-B,HTM,Down,4932,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-B,HTM,Down,4932,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-B,HTM,Down,4932,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-B,HTM,Down,4932,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-B,HTM,Down,4932,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-B,HTM,Down,4932,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-B,HTM,Up,4932,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,25081334
HLA-C,HTM,Down,4933,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HLA-C,HTM,Down,4933,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HLA-C,HTM,Down,4933,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HLA-C,HTM,Down,4933,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HLA-C,HTM,Down,4933,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HLA-DMA,HTM,Down,4934,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HLA-DMA,HTM,Up,4934,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HLA-DMA,HTM,Up,4934,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HLA-DMA,HTM,Up,4934,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HLA-DMB,HTM,Up,4935,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-DMB,HTM,Up,4935,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-DMB,HTM,Up,4935,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0021,17932721
HLA-DQB1,HTM,Down,4944,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HLA-DRA,HTM,Down,4947,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
HLA-DRB1,HTM,Down,4948,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
HLA-DRB1,HTM,Down,4948,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HLA-DRB5,HTM,Down,4953,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HLA-F,HTM,Up,4963,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HLA-F,HTM,Up,4963,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HLA-F,HTM,Up,4963,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HLA-G,HTM,Down,4964,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-G,HTM,Down,4964,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HLA-G,HTM,Up,4964,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HLA-G,HTM,Up,4964,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HLA-G,HTM,Up,4964,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HLA-J,HTM,Down,4967,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HLA-J,HTM,Down,4967,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HLA-J,HTM,Down,4967,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HLF,HTM,Down,4977,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HLF,HTM,Down,4977,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HLTF,HTM,Up,11099,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HLTF,HTM,Up,11099,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HM13,HTM,Down,16435,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HM13,HTM,Down,16435,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HMBS,HTM,Down,4982,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
HMBS,HTM,Down,4982,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
HMCES,HTM,Down,24446,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HMCN1,HTM,Down,19194,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
HMCN2,HTM,Up,21293,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
HMGA1,HTM,Down,5010,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HMGA1,HTM,Down,5010,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HMGA1,HTM,Up,5010,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HMGA2,HTM,Down,5009,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
HMGA2,HTM,Down,5009,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
HMGA2,HTM,Down,5009,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
HMGB1,HTM,Down,4983,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
HMGB1,HTM,Down,4983,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
HMGB1,HTM,Down,4983,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
HMGB2,HTM,Down,5000,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HMGCLL1,HTM,Up,21359,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HMGCR,HTM,Down,5006,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
HMGCR,HTM,Down,5006,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
HMGCR,HTM,Up,5006,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
HMGCR,HTM,Up,5006,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
HMGCR,HTM,Up,5006,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
HMGCR,HTM,Up,5006,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
HMGCR,HTM,Up,5006,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
HMGCR,HTM,Down,5006,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0053,22954703
HMGCR,HTM,Up,5006,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
HMGCS1,HTM,Down,5007,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
HMGCS1,HTM,Down,5007,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
HMGCS1,HTM,Up,5007,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0074,24961511
HMGCS1,HTM,Up,5007,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0074,24961511
HMGCS1,HTM,NA,5007,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,25676692
HMGCS1,HTM,NA,5007,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,25676692
HMGCS1,HTM,Up,5007,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.24,0.0074,26259570
HMGCS1,HTM,Up,5007,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.24,0.0074,21618577
HMGCS1,HTM,Up,5007,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.24,0.0074,26259570
HMGCS1,HTM,Up,5007,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
HMGCS1,HTM,Up,5007,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0074,34680485
HMGCS1,HTM,Up,5007,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0074,31501409
HMGCS1,HTM,Up,5007,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0074,31501409
HMGCS1,HTM,Up,5007,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
HMGCS2,HTM,Up,5008,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HMGCS2,HTM,Up,5008,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HMGN2,HTM,Down,4986,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HMGN2,HTM,Down,4986,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HMGN5,HTM,Up,8013,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HMGN5,HTM,Up,8013,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HMGN5,HTM,Up,8013,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
HMGN5,HTM,Down,8013,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
HMMR,HTM,Down,5012,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
HMMR,HTM,Up,5012,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0032,28881576
HMMR,HTM,Down,5012,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.16,0.0032,20530554
HMMR,HTM,Down,5012,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.16,0.0032,20530554
HMOX1,HTM,Down,5013,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,34059086
HMOX1,HTM,Up,5013,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
HMOX1,HTM,Up,5013,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
HMOX1,HTM,Up,5013,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0064,26351321
HMOX1,HTM,Up,5013,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.2,0.0064,34680485
HMOX1,HTM,Up,5013,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.2,0.0064,31501409
HMOX2,HTM,Down,5014,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HMOX2,HTM,Down,5014,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HNF1A-AS1,HTM,Up,26785,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HNF1A-AS1,HTM,Up,26785,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HNF1B,HTM,Up,11630,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HNF1B,HTM,Up,11630,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HNF4G,HTM,Up,5026,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HNF4G,HTM,Up,5026,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HNMT,HTM,Up,5028,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HNMT,HTM,Down,5028,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
HNRNPA0,HTM,Up,5030,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
HNRNPA1,HTM,Down,5031,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
HNRNPA1,HTM,Down,5031,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
HNRNPA2B1,HTM,Down,4718,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.36,0.0042,27746256
HNRNPA2B1,HTM,Down,5033,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HNRNPA2B1,HTM,Down,5033,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HNRNPA2B1,HTM,Up,5033,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
HNRNPA2B1,HTM,Up,5033,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HNRNPA3,HTM,Down,5033,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
HNRNPA3,HTM,Down,24941,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
HNRNPA3,HTM,Down,24941,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
HNRNPA3,HTM,Down,24941,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
HNRNPAB,HTM,Down,5034,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
HNRNPAB,HTM,Down,5034,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
HNRNPAB,HTM,Down,5034,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.36,0.0032,34168259
HNRNPAB,HTM,Down,5034,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.36,0.0032,34168259
HNRNPAB,HTM,Up,5034,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.36,0.0032,34168259
HNRNPAB,HTM,Down,5034,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.36,0.0032,34168259
HNRNPAB,HTM,Down,11316,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
HNRNPC,HTM,Up,5035,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
HNRNPC,HTM,Down,5035,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
HNRNPC,HTM,Down,5035,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
HNRNPC,HTM,Down,5035,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
HNRNPD,HTM,Down,5036,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HNRNPD,HTM,Down,5036,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HNRNPDL,HTM,Down,5037,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HNRNPDL,HTM,Down,5037,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HNRNPDL,HTM,Down,5037,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HNRNPF,HTM,Down,5039,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HNRNPF,HTM,Down,5039,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HNRNPF,HTM,Up,5039,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HNRNPH1,HTM,Down,5041,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
HNRNPH1,HTM,Up,5041,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
HNRNPH1,HTM,Up,5041,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
HNRNPH1,HTM,Up,5041,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
HNRNPH3,HTM,Up,5043,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,22623141
HNRNPH3,HTM,Down,5043,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
HNRNPK,HTM,Down,5044,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
HNRNPK,HTM,Down,5044,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HNRNPL,HTM,Down,5045,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
HNRNPM,HTM,Down,5046,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HNRNPM,HTM,Down,5046,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HNRNPM,HTM,Down,5046,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
HNRNPR,HTM,Up,5047,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
HNRNPU,HTM,Up,5048,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
HNRNPU,HTM,Up,5048,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
HNRNPU,HTM,Down,5048,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
HNRNPU,HTM,Down,5048,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HNRPA1,HTM,Down,5031,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
HNRPF,HTM,Down,5039,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
HNRPLL,HTM,Up,25127,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HNRPLL,HTM,Up,25127,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HNRPLL,HTM,Up,25127,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HNRPUL1,HTM,Down,17011,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
HOMER1,HTM,Up,17512,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HOMER1,HTM,Up,17512,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
HOMER1,HTM,Up,17512,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
HOMER1,HTM,Down,17512,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
HOMER3,HTM,Up,17514,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HOMER3,HTM,Up,17514,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HOMER3,HTM,Up,17514,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HOOK1,HTM,Up,19884,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
HOOK1,HTM,Up,19884,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HOOK1,HTM,Down,19884,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
HOOK1,HTM,Up,19884,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
HOOK1,HTM,Up,19884,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
HOOK2,HTM,Down,19885,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
HOOK3,HTM,Down,23576,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
HOPX,HTM,Up,24961,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HORMAD1,HTM,Up,25245,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HORMAD1,HTM,Up,25245,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HORMAD2,HTM,Up,28383,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
HORMAD2-AS1,HTM,Down,50729,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
HOXA1,HTM,Up,5099,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
HOXA13,HTM,Up,5102,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HOXA13,HTM,Up,5102,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HOXA13,HTM,Up,5102,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HOXA5,HTM,Up,5106,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,28588211
HOXA-AS3,HTM,Down,43748,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
HOXB2,HTM,Up,5113,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HOXB3,HTM,Up,5114,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,28588211
HOXB3,HTM,Up,5114,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
HOXB6,HTM,Down,5117,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HOXB6,HTM,Up,5117,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HOXB6,HTM,Up,5117,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HOXB-AS3,HTM,Down,40283,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
HOXC10,HTM,Up,5122,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
HOXC13,HTM,Down,5125,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HOXC4,HTM,Up,5126,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
HOXC9,HTM,Up,5130,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HOXC9,HTM,Up,5130,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HOXC9,HTM,Up,5130,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HOXC9,HTM,Down,5130,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
HP1BP3,HTM,Up,24973,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
HP1BP3,HTM,Up,24973,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
HP1BP3,HTM,Down,24973,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
HP1BP3,HTM,Down,24973,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
HP1BP3,HTM,Down,24973,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
HPCAL1,HTM,Up,5145,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
HPCAL1,HTM,Up,5145,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
HPD,HTM,Up,5147,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
HPD,HTM,Up,5147,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
HPD,HTM,Up,5147,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
HPD,HTM,Up,5147,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
HPD,HTM,Up,5147,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
HPD,HTM,Down,5147,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
HPDL,HTM,Down,28242,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
HPGD,HTM,Up,5154,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HPGD,HTM,Up,5154,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HPGD,HTM,Up,5154,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HPGD,HTM,Down,5154,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
HPGD,HTM,Down,5154,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
HPRT1,HTM,Down,5157,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HPS5,HTM,Up,17022,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HPSE,HTM,Down,5164,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HPSE,HTM,Down,5164,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
HPX,HTM,Down,5171,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
HR,HTM,Down,5172,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
HR,HTM,Down,5172,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
HRAS,HTM,Down,5173,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HRAS,HTM,Down,5173,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HRAS,HTM,Down,5173,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HRAS,HTM,Down,5173,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
HRAS,HTM,Down,5173,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
HRCT1,HTM,Down,33872,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
HRK,HTM,Up,5185,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HRK,HTM,Up,5185,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HRK,HTM,Up,5185,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HRNR,HTM,Up,20846,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
HROB,HTM,Down,28460,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
HROB,HTM,Down,28460,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
HROB,HTM,Down,28460,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
HRSP12,HTM,Down,16897,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HRSP12,HTM,Up,16897,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HRSP12,HTM,Up,16897,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HRSP12,HTM,Up,16897,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
HS1BP3,HTM,Up,24979,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HS1BP3,HTM,Up,24979,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HS1BP3,HTM,Up,24979,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HS2ST1,HTM,Down,5193,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
HS3ST3A1,HTM,Down,5196,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
HS3ST3A1,HTM,Down,5196,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
HS3ST3A1,HTM,Down,5196,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
HS3ST6,HTM,Up,14178,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HS6ST2,HTM,Up,19133,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
HS6ST2,HTM,Down,19133,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
HS6ST3,HTM,Up,19134,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HSCB,HTM,Up,28913,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HSCB,HTM,Up,28913,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HSCB,HTM,Up,28913,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
HSD11B1,HTM,Down,5208,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
HSD11B2,HTM,Down,5209,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
HSD17B10,HTM,Up,4800,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
HSD17B10,HTM,Up,4800,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
HSD17B11,HTM,Up,22960,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HSD17B11,HTM,Up,22960,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HSD17B11,HTM,Up,22960,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
HSD17B11,HTM,Up,22960,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
HSD17B12,HTM,Up,18646,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HSD17B12,HTM,Up,18646,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
HSD17B12,HTM,Up,18646,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HSD17B12,HTM,Down,18646,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
HSD17B14,HTM,Up,23238,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
HSD17B14,HTM,Up,23238,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
HSD17B14,HTM,Up,23238,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
HSD17B2,HTM,Down,5211,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
HSD17B2,HTM,Down,5211,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
HSD17B4,HTM,Down,5213,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
HSD3B1,HTM,Up,5217,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
HSH2D,HTM,Down,24920,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
HSH2D,HTM,Up,24920,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
HSP90AA1,HTM,Down,5253,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0064,23903875
HSP90AA1,HTM,Up,5253,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0064,34794402
HSP90AA1,HTM,Up,5253,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0064,34794402
HSP90AA1,HTM,Down,5253,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
HSP90AA1,HTM,Down,5253,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
HSP90AA1,HTM,Down,5253,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0064,34168259
HSP90AA1,HTM,Up,5253,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0064,27746256
HSP90AB1,HTM,Up,5258,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0074,22623141
HSP90AB1,HTM,Up,5258,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0074,34794402
HSP90AB1,HTM,Up,5258,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0074,22623141
HSP90AB1,HTM,Down,5258,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.08,0.0074,19451087
HSP90AB1,HTM,Up,5258,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0074,34794402
HSP90AB1,HTM,Down,5258,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0074,32503348
HSP90AB1,HTM,Down,5258,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0074,32503348
HSP90AB1,HTM,Up,5258,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0074,31501409
HSP90AB1,HTM,Down,5258,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0074,34168259
HSP90AB1,HTM,Down,5258,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0074,34168259
HSP90AB1,HTM,Up,5258,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0074,34168259
HSP90AB1,HTM,Up,5258,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0074,27746256
HSP90AB2P,HTM,Down,32537,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
HSP90AB2P,HTM,Down,32537,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
HSP90B1,HTM,Up,12028,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0042,34794402
HSP90B1,HTM,Down,12028,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
HSP90B1,HTM,Down,12028,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
HSP90B1,HTM,Up,12028,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0042,34794402
HSP90B1,HTM,Up,12028,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HSP90B1,HTM,Up,12028,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HSP90B1,HTM,Up,12028,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HSP90B1,HTM,Up,12028,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HSP90B1,HTM,Down,12028,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HSPA12A,HTM,Up,19022,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0011,17932721
HSPA1A,HTM,Down,5232,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
HSPA1A,HTM,Up,5232,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
HSPA1A,HTM,Down,5232,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,22623141
HSPA1A,HTM,Down,5232,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,22623141
HSPA1A,HTM,Down,5232,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,22623141
HSPA1A,HTM,Up,5232,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
HSPA1A,HTM,Up,5232,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
HSPA1A,HTM,Down,5232,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
HSPA1B,HTM,Up,5233,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
HSPA1B,HTM,Up,5233,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
HSPA1B,HTM,Up,5233,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HSPA1B,HTM,Up,5233,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HSPA1B,HTM,Up,5233,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
HSPA1L,HTM,Up,5234,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
HSPA2,HTM,Up,5235,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
HSPA2,HTM,Down,5235,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
HSPA2,HTM,Up,5235,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
HSPA4,HTM,Down,5237,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HSPA4,HTM,Down,5237,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HSPA4,HTM,Up,5237,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HSPA4,HTM,Up,5237,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0042,21788403
HSPA4L,HTM,Down,17041,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HSPA5,HTM,Up,5238,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0117,34794402
HSPA5,HTM,Up,5238,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0117,34794402
HSPA5,HTM,Up,5238,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0117,34794402
HSPA5,HTM,Up,5238,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0117,34794402
HSPA5,HTM,Up,5238,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0117,32503348
HSPA5,HTM,Up,5238,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0117,32503348
HSPA5,HTM,Up,5238,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.2,0.0117,31501409
HSPA5,HTM,Up,5238,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0117,34168259
HSPA5,HTM,Up,5238,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0117,34168259
HSPA5,HTM,Down,5238,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.36,0.0117,27746256
HSPA5,HTM,Up,5238,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0117,34168259
HSPA5,HTM,Up,5238,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0117,29340052
HSPA6,HTM,Down,5239,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,29340052
HSPA6,HTM,Down,5239,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0053,23903875
HSPA6,HTM,Down,5239,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
HSPA6,HTM,Down,5239,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
HSPA6,HTM,Up,5239,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0053,34168259
HSPA7,HTM,Down,5240,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
HSPA7,HTM,Down,5240,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
HSPA8,HTM,Up,5241,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0085,22623141
HSPA8,HTM,Up,5241,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0085,22623141
HSPA8,HTM,Down,5241,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0085,23903875
HSPA8,HTM,Up,5241,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0085,22623141
HSPA8,HTM,Down,5241,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0085,32503348
HSPA8,HTM,Down,5241,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0085,32503348
HSPA8,HTM,Down,5241,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0085,31501409
HSPA8,HTM,Down,5241,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0085,34168259
HSPA8,HTM,Down,5241,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0085,34168259
HSPA8,HTM,Up,5241,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0085,34168259
HSPA8,HTM,Up,5241,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0085,27746256
HSPA8,HTM,Up,5241,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0085,24098529
HSPA9,HTM,NA,5244,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by PCR array assay,0.04,0.0042,20630067
HSPA9,HTM,Up,5244,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HSPA9,HTM,Up,5244,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HSPA9,HTM,Down,5244,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
HSPA9,HTM,Up,5244,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HSPB1,HTM,Down,5246,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
HSPB1,HTM,Up,5246,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0053,34794402
HSPB1,HTM,Up,5246,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,22623141
HSPB1,HTM,Up,5246,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0053,34794402
HSPB1,HTM,Up,5246,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
HSPB1,HTM,Up,5246,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
HSPB1,HTM,Down,5246,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
HSPB8,HTM,Down,30171,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HSPB8,HTM,Down,30171,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HSPBAP1,HTM,Up,16389,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
HSPD1,HTM,Down,5261,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0064,22623141
HSPD1,HTM,Down,5261,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0064,22623141
HSPD1,HTM,Down,5261,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.08,0.0064,19451087
HSPD1,HTM,Down,5261,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.08,0.0064,19451087
HSPD1,HTM,Down,5261,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
HSPD1,HTM,Down,5261,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
HSPD1,HTM,Down,5261,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
HSPD1,HTM,Up,5261,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0064,34168259
HSPD1,HTM,Down,5261,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0064,27746256
HSPE1,HTM,Up,5269,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
HSPE1,HTM,Up,5269,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
HSPE1,HTM,Up,5269,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
HSPE1,HTM,Down,5269,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
HSPE1,HTM,Down,5269,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
HSPE1,HTM,Down,5269,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0053,34168259
HSPE1,HTM,Up,5269,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
HSPG2,HTM,Down,5273,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
HSPG2,HTM,Down,5273,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
HSPH1,HTM,Up,16969,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
HSPH1,HTM,Up,16969,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
HTATIP2,HTM,Up,16637,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HTATIP2,HTM,Up,16637,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HTR1A,HTM,Up,5286,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
HTR1B,HTM,Up,5287,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
HTR1D,HTM,Up,5289,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
HTR2A,HTM,Down,5293,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
HTR2B,HTM,Down,5294,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HTR2B,HTM,Down,5294,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HTRA1,HTM,Down,9476,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HTRA1,HTM,Up,9476,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
HTRA4,HTM,Down,26909,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HTRA4,HTM,Down,26909,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HTT,HTM,Up,4851,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
HULC,HTM,Down,34232,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HULC,HTM,Down,34232,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
HUWE1,HTM,Down,30892,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
HUWE1,HTM,Up,30892,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
HUWE1,HTM,Down,30892,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,29511337
HUWE1,HTM,Down,30892,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0032,29511337
HYAL1,HTM,Up,5320,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
HYAL1,HTM,Up,5320,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
HYAL1,HTM,Up,5320,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
HYAL1,HTM,Up,5320,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
HYAL1,HTM,Up,5320,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
HYAL1,HTM,Down,5320,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
HYKK,HTM,Up,34403,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HYKK,HTM,Up,34403,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
HYKK,HTM,Down,34403,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
HYOU1,HTM,Down,16931,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
HYOU1,HTM,Up,16931,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HYOU1,HTM,Up,16931,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
HYOU1,HTM,Up,16931,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HYOU1,HTM,Up,16931,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
HYOU1,HTM,Down,16931,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
HYPK,HTM,Up,18418,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ICA1,HTM,Up,5343,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ICAM1,HTM,Up,5344,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
ICAM1,HTM,Up,5344,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
ICAM1,HTM,Up,5344,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
ICAM1,HTM,Up,5344,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0064,27746256
ICAM1,HTM,Up,5344,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
ICAM2,HTM,Up,5345,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ICOSLG,HTM,Down,17087,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ID1,HTM,Down,5360,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
ID1,HTM,Down,5360,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,25676692
ID1,HTM,Down,5360,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,25676692
ID1,HTM,Down,5360,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
ID1,HTM,Down,5360,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0053,25676692
ID1,HTM,Down,5360,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
ID1,HTM,Down,5360,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
ID1,HTM,Down,5360,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
ID1,HTM,Down,5360,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
ID2,HTM,Up,5361,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
ID2,HTM,Up,5361,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
ID2,HTM,Up,5361,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0064,19451087
ID2,HTM,Down,5361,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
ID2,HTM,Down,5361,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
ID2,HTM,Down,5361,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
ID2,HTM,Down,5361,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
ID2,HTM,Up,5361,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0064,30696080
ID2,HTM,Up,5361,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0064,30696080
ID2B,HTM,Up,30656,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0021,19451087
ID2B,HTM,Up,30656,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ID2B,HTM,Up,30656,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ID3,HTM,Up,5362,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ID3,HTM,Up,5362,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ID3,HTM,Down,5362,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
ID3,HTM,Down,5362,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
ID35,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ID35,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ID35,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ID4,HTM,Down,5363,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
ID4,HTM,Down,5363,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
ID4,HTM,Up,5363,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
ID4,HTM,Up,5363,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
ID4,HTM,Down,5363,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
ID4,HTM,Up,5363,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,28588211
IDH1,HTM,Up,5382,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
IDH1,HTM,Up,5382,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
IDH1,HTM,Down,5382,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
IDH1-AS1,HTM,Down,40292,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
IDH2,HTM,Down,5383,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
IDH2,HTM,Down,5383,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
IDH3A,HTM,Down,5384,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IDI1,HTM,Up,5387,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
IDI1,HTM,Up,5387,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
IDI1,HTM,Up,5387,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
IDI1,HTM,Up,5387,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
IDS,HTM,Up,5389,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IER3,HTM,Down,5392,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IER3,HTM,Down,5392,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IER3,HTM,Down,5392,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IER3,HTM,Down,5392,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IER3,HTM,Down,5392,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IER3,HTM,Down,5392,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IER3,HTM,Down,5392,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IER3,HTM,Down,5392,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IER3,HTM,Down,5392,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IER3,HTM,Up,5392,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
IER3,HTM,Up,5392,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
IER3,HTM,Up,5392,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
IER3,HTM,Up,5392,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
IER3,HTM,Up,5392,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
IER5,HTM,Up,5393,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
IER5,HTM,Up,5393,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
IER5L,HTM,Down,23679,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IFFO2,HTM,Down,27006,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IFFO2,HTM,Down,27006,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IFI16,HTM,Down,5395,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IFI16,HTM,Down,5395,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IFI16,HTM,Down,5395,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IFI16,HTM,Up,5395,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
IFI16,HTM,Up,5395,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
IFI16,HTM,Up,5395,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
IFI16,HTM,Up,5395,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
IFI16,HTM,Up,5395,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
IFI16,HTM,Up,5395,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
IFI30,HTM,Down,5398,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
IFI30,HTM,Down,5398,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
IFI30,HTM,Up,5398,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
IFI30,HTM,Up,5398,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
IFI30,HTM,Down,5398,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
IFI30,HTM,Up,5398,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
IFI35,HTM,Down,5399,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
IFI44,HTM,Up,16938,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0021,30592142
IFI44,HTM,Down,16938,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IFI44,HTM,Down,16938,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IFI44,HTM,Down,16938,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IFI44,HTM,Up,16938,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0021,30592142
IFI44L,HTM,Up,17817,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
IFI6,HTM,Down,4054,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
IFI6,HTM,Up,4054,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
IFI6,HTM,Down,4054,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
IFI6,HTM,Up,4054,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
IFI6,HTM,Up,4054,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
IFIT1,HTM,Up,5407,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
IFIT2,HTM,Down,5409,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
IFIT2,HTM,Down,5409,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
IFITM1,HTM,Up,5412,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
IFITM1,HTM,Up,5412,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
IFITM1,HTM,Up,5412,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
IFITM1,HTM,Up,5412,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
IFITM10,HTM,Down,40022,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
IFITM10,HTM,Down,40022,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
IFITM3,HTM,Down,5414,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IFITM3,HTM,Down,5414,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IFITM3,HTM,Down,5414,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IFITM3,HTM,Up,5414,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
IFNE,HTM,Down,18163,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
IFNGR1,HTM,Down,5439,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IFNGR2,HTM,Down,5440,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IFNL1,HTM,Up,18363,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IFNL2,HTM,Down,18364,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
IFNLR1,HTM,Down,18584,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
IFRD2,HTM,Down,5457,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IFT122,HTM,Up,13556,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IFT20,HTM,Up,30989,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IFT57,HTM,Down,17367,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IFT74,HTM,Up,21424,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,25081334
IFT80,HTM,Up,29262,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IFT81,HTM,Up,14313,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IFT81,HTM,Up,14313,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IFTAP,HTM,Down,25142,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
IFTAP,HTM,Down,25142,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
IGF1,HTM,NA,5464,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by PCR array assay,0.04,0.0053,20630067
IGF1,HTM,Up,5464,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,20424609
IGF1,HTM,Up,5464,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,20424609
IGF1,HTM,Up,5464,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
IGF1,HTM,Up,5464,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
IGF1,HTM,Up,5464,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0053,24098529
IGF1R,HTM,Up,5465,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
IGF2,HTM,Down,5466,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
IGF2,HTM,Down,5466,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
IGF2,HTM,Down,5466,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
IGF2,HTM,Up,5466,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0032,17932721
IGF2,HTM,Down,5466,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
IGF2BP1,HTM,Down,28866,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
IGF2BP1,HTM,Down,28866,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
IGF2BP1,HTM,Up,28866,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IGF2BP1,HTM,Up,28866,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IGF2BP1,HTM,Up,28866,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
IGF2BP1,HTM,Up,28866,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
IGF2BP2,HTM,Down,28867,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IGF2BP2,HTM,Down,28867,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IGF2BP2,HTM,Down,28867,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IGF2BP2,HTM,Down,28867,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
IGF2BP2-AS1,HTM,Down,32674,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
IGF2BP2-AS1,HTM,Down,32674,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
IGF2BP3,HTM,Up,28868,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
IGF2BP3,HTM,Up,28868,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
IGF2BP3,HTM,Down,28868,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
IGFBP1,HTM,Down,5469,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,27965308
IGFBP1,HTM,Down,5469,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
IGFBP1,HTM,Down,5469,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
IGFBP2,HTM,Down,5471,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
IGFBP2,HTM,Up,5471,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
IGFBP2,HTM,Down,5471,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
IGFBP2,HTM,Down,5471,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
IGFBP3,HTM,Down,5472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0095,34059086
IGFBP3,HTM,Down,5472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0095,34059086
IGFBP3,HTM,Down,5472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0095,34059086
IGFBP3,HTM,Down,5472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0095,34059086
IGFBP3,HTM,Up,5472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0095,25881239
IGFBP3,HTM,Up,5472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0095,25881239
IGFBP3,HTM,Up,5472,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0095,30254465
IGFBP3,HTM,Down,5472,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0095,24961511
IGFBP3,HTM,Down,5472,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0095,24961511
IGFBP3,HTM,Up,5472,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0095,19451087
IGFBP3,HTM,Up,5472,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0095,19451087
IGFBP3,HTM,NA,5472,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0095,25676692
IGFBP3,HTM,NA,5472,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0095,25676692
IGFBP3,HTM,Down,5472,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.24,0.0095,26259570
IGFBP3,HTM,Down,5472,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.24,0.0095,26259570
IGFBP3,HTM,Up,5472,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0095,34680485
IGFBP3,HTM,Down,5472,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0095,31709178
IGFBP4,HTM,Up,5473,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,33670440
IGFBP4,HTM,Up,5473,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,33670440
IGFBP4,HTM,Up,5473,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0042,25881239
IGFBP4,HTM,Up,5473,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0042,25881239
IGFBP4,HTM,Up,5473,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
IGFBP4,HTM,Down,5473,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
IGFBP46,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
IGFBP46,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
IGFBP46,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
IGFBP5,HTM,Down,5474,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
IGFBP5,HTM,Up,5474,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
IGFBP52,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
IGFBP52,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
IGFBP52,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
IGFBP6,HTM,Down,5475,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
IGFBP6,HTM,Down,5475,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
IGFBP6,HTM,Down,5475,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
IGFBP6,HTM,Down,5475,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
IGFBP7,HTM,Down,5476,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IGFBP7,HTM,Down,5476,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IGFBP7,HTM,Down,5476,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IGFBP7,HTM,Down,5476,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
IGFBP7,HTM,Down,5476,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
IGFBP7,HTM,Down,5476,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
IGFBP7,HTM,Down,5476,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
IGFBP7,HTM,Up,5476,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
IGFBP7,HTM,Up,5476,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
IGFL1,HTM,Up,24093,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IGFL2-AS1,HTM,Up,52559,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IGFLR1,HTM,Down,23620,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
IGFN1,HTM,Up,24607,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
IGIP,HTM,Down,33847,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
IGLL1,HTM,Down,5870,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
IGLL3P,HTM,Down,5872,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
IGLL3P,HTM,Down,5872,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
IGSF1,HTM,Down,5948,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IGSF10,HTM,Up,26384,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IGSF3,HTM,Down,5950,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IGSF3,HTM,Down,5950,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
IGSF9,HTM,Down,18132,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
IKBIP,HTM,Down,26430,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
IKBIP,HTM,Up,26430,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
IKBIP,HTM,Down,26430,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
IKBIP,HTM,Down,26430,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
IKBKB,HTM,Down,5960,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
IKBKB,HTM,Down,5960,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
IKBKE,HTM,NA,14552,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0021,29352988
IKBKG,HTM,Down,5961,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
IKBKG,HTM,Down,5961,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
IKZF2,HTM,Up,13177,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IKZF3,HTM,Up,13178,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
IKZF3,HTM,Down,13178,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,28588211
IL11,HTM,Up,5966,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,25432175
IL11,HTM,Down,5966,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
IL12A,HTM,Up,5969,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,35013621
IL13RA2,HTM,Up,5975,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
IL15,HTM,Up,5977,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
IL16,HTM,Down,5980,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IL16,HTM,Down,5980,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IL16,HTM,Down,5980,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IL17RA,HTM,Down,5985,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
IL17RC,HTM,Up,18358,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IL17RE,HTM,Up,18439,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IL17REL,HTM,Up,33808,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IL18,HTM,Down,5986,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
IL18,HTM,Down,5986,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
IL18R1,HTM,Up,5988,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IL1A,HTM,Down,5991,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
IL1A,HTM,Down,5991,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
IL1A,HTM,Down,5991,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
IL1A,HTM,Down,5991,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
IL1A,HTM,Up,5991,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
IL1A,HTM,Up,5991,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
IL1B,HTM,Up,5992,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0074,35229723
IL1B,HTM,Up,5992,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0074,29416721
IL1B,HTM,Down,5992,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
IL1B,HTM,Down,5992,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
IL1B,HTM,Down,5992,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
IL1B,HTM,Up,5992,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,24961511
IL1B,HTM,Down,5992,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.24,0.0074,24961511
IL1B,HTM,Up,5992,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.24,0.0074,24961511
IL1B,HTM,Up,5992,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.24,0.0074,24961511
IL1B,HTM,Up,5992,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,31709178
IL1R1,HTM,Up,5993,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IL1R1,HTM,Up,5993,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IL1R1,HTM,Down,5993,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
IL1R1,HTM,Down,5993,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
IL1R2,HTM,Down,5994,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
IL1RAP,HTM,Down,5995,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IL1RAP,HTM,Down,5995,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IL1RAP,HTM,Down,5995,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IL1RL1,HTM,Down,5998,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IL1RL1,HTM,Down,5998,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IL1RN,HTM,Down,6000,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,29340052
IL1RN,HTM,Down,6000,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
IL1RN,HTM,Down,6000,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
IL1RN,HTM,Down,6000,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
IL1RN,HTM,Down,6000,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0053,34414448
IL1RN,HTM,Down,6000,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
IL20,HTM,Down,6002,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
IL20RA,HTM,Up,6003,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IL20RB,HTM,Down,6004,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IL20RB,HTM,Down,6004,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IL20RB,HTM,Down,6004,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IL21R,HTM,Down,6006,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
IL23A,HTM,Up,15488,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
IL24,HTM,Up,11346,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0032,30592142
IL24,HTM,Up,11346,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
IL24,HTM,Up,11346,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
IL24,HTM,Up,11346,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
IL24,HTM,Up,11346,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0032,30592142
IL24,HTM,Up,11346,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
IL2RG,HTM,Down,6010,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
IL2RG,HTM,Down,6010,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
IL2RG,HTM,Down,6010,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
IL2RG,HTM,Down,6010,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
IL31RA,HTM,Down,18969,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IL31RA,HTM,Down,18969,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IL31RA,HTM,Down,18969,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IL36G,HTM,Down,15741,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
IL36G,HTM,Down,15741,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
IL36RN,HTM,Down,15561,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
IL36RN,HTM,Down,15561,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
IL37,HTM,Up,15563,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
IL4,HTM,Down,6014,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
IL4R,HTM,Down,6015,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IL4R,HTM,Down,6015,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IL6,HTM,Up,6018,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0191,26351321
IL6,HTM,Up,6018,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0191,31709178
IL6,HTM,Up,6018,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0191,21618577
IL6,HTM,Up,6018,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0191,21618577
IL6,HTM,Up,6018,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0191,28927099
IL6,HTM,Up,6018,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.28,0.0191,31709178
IL6,HTM,Up,6018,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0191,21618577
IL6R,HTM,Up,6019,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0021,18034892
IL6ST,HTM,Down,6021,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
IL6ST,HTM,Up,6021,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
IL7,HTM,Down,6023,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
IL7R,HTM,Up,6024,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0042,30592142
IL7R,HTM,Down,6024,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IL7R,HTM,Down,6024,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IL7R,HTM,Down,6024,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IL7R,HTM,Up,6024,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
IL7R,HTM,Up,6024,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
IL7R,HTM,Up,6024,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0042,30592142
IL8,HTM,Down,6025,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0159,30592142
IL8,HTM,Up,6025,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0159,25432175
IL8,HTM,Down,6025,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0159,25881239
IL8,HTM,Up,6025,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0159,25881239
IL8,HTM,Up,6025,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0159,31709178
IL8,HTM,Up,6025,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.28,0.0159,19451087
IL8,HTM,Down,6025,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0159,26259570
IL8,HTM,Up,6025,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0159,21618577
IL8,HTM,Down,6025,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0159,26259570
IL8,HTM,Up,6025,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0159,21618577
IL8,HTM,Down,6025,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0159,30696080
IL8,HTM,Down,6025,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0159,30696080
IL8,HTM,Down,6025,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0159,30592142
IL8,HTM,Up,6025,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0159,21618577
ILDR1,HTM,Down,28741,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ILDR2,HTM,Down,18131,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ILF2,HTM,Down,6037,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ILF3,HTM,Down,6038,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
ILF3,HTM,Up,6038,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
ILK,HTM,Down,6040,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IMMP1L,HTM,Down,26317,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
IMMP1L,HTM,Down,26317,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
IMMP1L,HTM,Down,26317,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
IMMP1L,HTM,Down,26317,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
IMMP1L,HTM,Down,26317,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
IMMT,HTM,Down,6047,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
IMMT,HTM,Up,6047,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
IMPA1,HTM,Down,6050,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
IMPA2,HTM,Down,6051,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,29316740
IMPAD1,HTM,Up,26019,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
IMPDH2,HTM,Down,6053,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
IMPDH2,HTM,Down,6053,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
IMPDH2,HTM,Down,6053,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
IMPDH2,HTM,Down,6053,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
IMPDH2,HTM,Down,6053,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
INA,HTM,Up,6057,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
INA,HTM,Up,6057,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
INA,HTM,Down,6057,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
INAFM2,HTM,Up,35165,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
INAVA,HTM,Down,25599,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
INAVA,HTM,Down,25599,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
INF2,HTM,Down,23791,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ING1,HTM,Down,6062,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ING2,HTM,Up,6063,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ING2,HTM,Up,6063,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ING2,HTM,Up,6063,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ING3,HTM,Down,14587,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
INHA,HTM,Up,6065,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,25432175
INHA,HTM,Down,6065,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
INHA,HTM,Down,6065,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
INHA,HTM,Down,6065,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
INHA,HTM,Up,6065,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
INHA,HTM,Down,6065,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
INHBA,HTM,Up,6066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,25432175
INHBA,HTM,Up,6066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,25432175
INHBA,HTM,Down,6066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0042,25881239
INHBA,HTM,Down,6066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0042,25881239
INHBA,HTM,Down,6066,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
INHBA,HTM,Up,6066,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
INHBA,HTM,Up,6066,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
INHBA,HTM,Up,6066,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0042,17911267
INHBB,HTM,Up,6067,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,25432175
INHBB,HTM,Down,6067,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
INHBB,HTM,Down,6067,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
INHBB,HTM,Up,6067,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
INHBB,HTM,Down,6067,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
INHBB,HTM,Up,6067,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
INHBB,HTM,Down,6067,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.2,0.0064,34680485
INHBB,HTM,Down,6067,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
INHBB,HTM,Up,6067,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
INHBC,HTM,Up,6068,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25432175
INHBE,HTM,Up,24029,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25432175
INHBE,HTM,Up,24029,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
INHBE,HTM,Up,24029,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
INHBE,HTM,Up,24029,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
INO80D,HTM,Down,25997,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
INPP4B,HTM,Down,6075,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
INPP4B,HTM,Down,6075,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
INPP4B,HTM,Down,6075,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
INPP4B,HTM,Down,6075,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
INPP5A,HTM,Down,6076,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
INPP5D,HTM,Down,6079,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
INPP5D,HTM,Down,6079,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
INPP5D,HTM,Down,6079,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
INPP5D,HTM,Down,6079,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
INPP5E,HTM,Down,21474,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
INPP5F,HTM,Down,17054,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
INPP5F,HTM,Down,17054,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
INPP5F,HTM,Down,17054,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
INSIG1,HTM,Down,6083,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
INSIG1,HTM,Down,6083,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
INSIG1,HTM,Up,6083,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
INSIG1,HTM,Up,6083,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0053,19451087
INSIG1,HTM,Up,6083,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
INSIG2,HTM,Down,20452,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
INSIG2,HTM,Down,20452,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
INSIG2,HTM,Down,20452,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
INS-IGF2,HTM,Down,33527,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
INS-IGF2,HTM,Down,33527,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
INS-IGF2,HTM,Down,33527,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
INSL4,HTM,Up,6087,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
INSL4,HTM,Up,6087,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
INSRR,HTM,Up,6093,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
INTS13,HTM,Up,20174,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
INTS13,HTM,Up,20174,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
INTS13,HTM,Up,20174,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
INTS14,HTM,Down,25372,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
INTS2,HTM,Up,29241,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
INTS2,HTM,Up,29241,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
INTS3,HTM,Up,26153,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
INTS3,HTM,Up,26153,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
INTS3,HTM,Up,26153,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
INTS6,HTM,Up,14879,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
INTS6,HTM,Up,14879,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
INTS6,HTM,Up,14879,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
INTS6,HTM,Up,14879,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
INTS9,HTM,Down,25592,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
IP6K1,HTM,Down,18360,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,27965308
IPO11,HTM,Down,20628,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IPO11,HTM,Up,20628,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
IPO5,HTM,Up,6402,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
IPO7,HTM,Up,9852,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
IQCA1,HTM,Down,26195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IQCA1,HTM,Down,26195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IQCA1,HTM,Down,26195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
IQCA1,HTM,Down,26195,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
IQCE,HTM,Up,29171,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
IQCJ-SCHIP1,HTM,Down,38842,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
IQCJ-SCHIP1,HTM,Down,38842,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
IQGAP1,HTM,Up,6110,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
IQGAP1,HTM,Down,6110,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
IQGAP1,HTM,Up,6110,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
IQGAP1,HTM,Up,6110,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
IQGAP1,HTM,Up,6110,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
IQGAP2,HTM,Up,6111,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IQGAP2,HTM,Up,6111,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IQGAP2,HTM,Up,6111,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IQSEC2,HTM,Down,29059,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
IQSEC2,HTM,Up,29059,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
IRAG2,HTM,Down,6690,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IRAIN,HTM,Down,50365,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
IRAK2,HTM,Up,6113,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
IRAK3,HTM,Down,17020,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IRAK3,HTM,Down,17020,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IRAK3,HTM,Down,17020,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IRAK4,HTM,Down,17967,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,27965308
IRAK4,HTM,Down,17967,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
IRAK4,HTM,Down,17967,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
IREB2,HTM,Up,6115,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IRF5,HTM,Down,6120,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
IRF6,HTM,Down,6121,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
IRF6,HTM,Down,6121,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
IRF6,HTM,Down,6121,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
IRF6,HTM,Down,6121,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
IRF6,HTM,Up,6121,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
IRF6,HTM,Up,6121,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
IRS1,HTM,Down,6125,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
IRX3,HTM,Up,14360,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
IRX5,HTM,Down,14361,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
IRX5,HTM,Up,14361,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ISCA1,HTM,Up,28660,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ISCA1,HTM,Up,28660,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ISCA1,HTM,Up,28660,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ISCA1,HTM,Up,28660,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ISCA1,HTM,Up,28660,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ISG15,HTM,Up,4053,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
ISL1,HTM,Down,6132,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ISL1,HTM,Down,6132,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ISL1,HTM,Down,6132,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ISM1,HTM,Down,16213,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ISOC1,HTM,Down,24254,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ITCH,HTM,Up,13890,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29511337
ITCH,HTM,Up,13890,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0021,29511337
ITCH,HTM,Up,13890,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
ITGA1,HTM,Up,6134,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
ITGA1,HTM,Up,6134,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ITGA10,HTM,Up,6135,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
ITGA10,HTM,Up,6135,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ITGA11,HTM,Up,6136,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
ITGA2,HTM,Down,6137,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0106,25881239
ITGA2,HTM,Down,6137,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0106,25881239
ITGA2,HTM,Up,6137,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0106,23903875
ITGA2,HTM,Down,6137,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0106,25881239
ITGA2,HTM,Down,6137,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0106,26259570
ITGA2,HTM,Down,6137,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0106,26259570
ITGA2,HTM,Up,6137,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0106,32503348
ITGA2,HTM,Up,6137,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0106,32503348
ITGA2,HTM,Up,6137,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0106,34680485
ITGA2,HTM,Up,6137,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0106,31501409
ITGA2,HTM,Up,6137,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0106,31501409
ITGA2,HTM,Down,6137,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0106,30696080
ITGA2,HTM,Down,6137,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0106,27746256
ITGA2,HTM,Down,6137,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0106,30696080
ITGA2,HTM,Up,6137,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0106,24098529
ITGA2B,HTM,Up,6138,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
ITGA3,HTM,Down,6139,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ITGA3,HTM,Down,6139,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ITGA3,HTM,Down,6139,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ITGA3,HTM,Down,6139,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
ITGA5,HTM,Down,6141,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ITGA5,HTM,Down,6141,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ITGA5,HTM,Down,6141,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ITGA5,HTM,Up,6141,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ITGA6,HTM,Down,6142,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0265,25881239
ITGA6,HTM,Down,6142,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0265,25881239
ITGA6,HTM,Up,6142,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.6,0.0265,23903875
ITGA6,HTM,Down,6142,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0265,25881239
ITGA6,HTM,Up,6142,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0265,21618577
ITGA6,HTM,Up,6142,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0265,21618577
ITGA6,HTM,Up,6142,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.2,0.0265,34680485
ITGA6,HTM,Up,6142,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0265,21618577
ITGA7,HTM,Down,6143,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
ITGA7,HTM,Down,6143,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
ITGA7,HTM,Down,6143,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
ITGA7,HTM,Down,6143,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
ITGA7,HTM,Up,6143,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ITGA7,HTM,Up,6143,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ITGAD,HTM,Up,6146,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
ITGAE,HTM,Down,6147,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ITGAE,HTM,Down,6147,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ITGAE,HTM,Down,6147,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ITGAL,HTM,Up,6148,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
ITGAV,HTM,Down,6150,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ITGAV,HTM,Up,6150,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Doxorubicin,SFA followed by single-cell time-of-flight mass cytometry,0.08,0.0032,34831064
ITGAV,HTM,Down,6150,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
ITGAX,HTM,Up,6152,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
ITGB1,HTM,Up,6153,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0180,32503348
ITGB1,HTM,Up,6153,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0180,32503348
ITGB1,HTM,Down,6153,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.36,0.0180,27746256
ITGB1,HTM,Down,6153,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0180,29340052
ITGB2,HTM,Up,6155,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
ITGB2,HTM,Up,6155,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
ITGB3,HTM,Up,6156,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ITGB3,HTM,Up,6156,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ITGB3BP,HTM,Down,6157,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ITGB3BP,HTM,Down,6157,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ITGB4,HTM,Down,6158,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,29340052
ITGB4,HTM,Up,6158,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0074,29416721
ITGB4,HTM,Up,6158,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0074,29416721
ITGB4,HTM,Down,6158,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
ITGB4,HTM,Down,6158,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
ITGB4,HTM,Up,6158,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.36,0.0074,23903875
ITGB4,HTM,Down,6158,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
ITGB4,HTM,Down,6158,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,31709178
ITGB4,HTM,Up,6158,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0074,34168259
ITGB4,HTM,Down,6158,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0074,34168259
ITGB5,HTM,Up,6160,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ITGB5,HTM,Up,6160,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ITGB5,HTM,Down,6160,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
ITGB5,HTM,Down,6160,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
ITGB5,HTM,Up,6160,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ITGB5,HTM,Up,6160,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ITGB5,HTM,Up,6160,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ITGB6,HTM,Down,6161,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ITGB6,HTM,Down,6161,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ITGB6,HTM,Down,6161,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ITGB6,HTM,Down,6161,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
ITGB6,HTM,Up,6161,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
ITGB6,HTM,Down,6161,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
ITGB8,HTM,Up,6163,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,29416721
ITGB8,HTM,Down,6163,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
ITGB8,HTM,Down,6163,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
ITGB8,HTM,Down,6163,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
ITGB8,HTM,Down,6163,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
ITGB8,HTM,Up,6163,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
ITGB8,HTM,Up,6163,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
ITGBL1,HTM,Down,6164,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ITGBL1,HTM,Down,6164,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ITGBL1,HTM,Down,6164,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ITGBL1,HTM,Down,6164,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
ITGBL1,HTM,Down,6164,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
ITLN1,HTM,Down,18259,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ITM2C,HTM,Up,6175,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ITPK1,HTM,Down,6177,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
ITPKA,HTM,Up,6178,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ITPKA,HTM,Up,6178,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ITPKC,HTM,Down,14897,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ITPR1,HTM,Up,6180,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ITPR1,HTM,Up,6180,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
ITPR1,HTM,Up,6180,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
ITPR1,HTM,Up,6180,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ITPR2,HTM,Down,6181,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ITPR2,HTM,Up,6181,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
ITPR2,HTM,Down,6181,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
ITPR3,HTM,Down,6182,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ITPR3,HTM,Down,6182,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ITPRID2,HTM,Down,11319,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
ITPRID2,HTM,Up,11319,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
ITPRIP,HTM,Down,29370,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ITSN1,HTM,Down,6183,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ITSN1,HTM,Up,6183,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ITSN2,HTM,Up,6184,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ITSN2,HTM,Up,6184,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ITSN2,HTM,Down,6184,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
ITSN2,HTM,Up,6184,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ITSN2,HTM,Up,6184,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
IVL,HTM,Down,6187,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22740085
IVL,HTM,Down,6187,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
IVNS1ABP,HTM,Up,16951,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
IVNS1ABP,HTM,Up,16951,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
IVNS1ABP,HTM,Up,16951,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
JADE1,HTM,Up,30027,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
JADE1,HTM,Up,30027,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
JADE2,HTM,Down,22984,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
JADE2,HTM,Up,22984,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
JAG1,HTM,Down,6188,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0117,25881239
JAG1,HTM,Down,6188,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0117,25881239
JAG1,HTM,NA,6188,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by PCR array assay,0.04,0.0117,20630067
JAG1,HTM,Down,6188,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0117,25881239
JAG1,HTM,Down,6188,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0117,22954703
JAG1,HTM,Down,6188,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0117,29959199
JAG1,HTM,Up,6188,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0117,35013621
JAG2,HTM,Up,6189,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0032,29959199
JAK1,HTM,Down,6190,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
JAK1,HTM,Down,6190,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
JAK1,HTM,Down,6190,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
JAK2,HTM,Down,6192,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,29352988
JAK2,HTM,Down,6192,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0053,29352988
JAK2,HTM,Down,6192,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
JAK2,HTM,Down,6192,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
JAK2,HTM,Down,6192,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0053,20530554
JAK3,HTM,Down,6193,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
JAKMIP2,HTM,Down,29067,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
JAM2,HTM,Up,14686,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
JAM2,HTM,Up,14686,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
JAM2,HTM,Up,14686,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
JARID2,HTM,Down,6196,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
JCAD,HTM,Up,29283,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
JCAD,HTM,Up,29283,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
JDP2,HTM,Down,17546,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
JMJD4,HTM,Up,25724,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
JMJD4,HTM,Down,25724,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
JMJD7,HTM,Up,34397,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
JMY,HTM,Up,28916,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
JMY,HTM,Down,28916,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
JPH1,HTM,Down,14201,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
JPH1,HTM,Down,14201,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0042,23820871
JPH1,HTM,Down,14201,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
JPH1,HTM,Up,14201,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
JPH2,HTM,Down,14202,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
JPH2,HTM,Down,14202,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
JPH2,HTM,Down,14202,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
JPH3,HTM,Up,14203,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
JPT1,HTM,Down,14569,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
JPT1,HTM,Down,14569,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
JPT2,HTM,Down,14137,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
JPX,HTM,Up,37191,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
JUN,HTM,Down,6204,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,29352988
JUN,HTM,Down,6204,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0053,29352988
JUN,HTM,Up,6204,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,21826669
JUN,HTM,Up,6204,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,24961511
JUN,HTM,Up,6204,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,24961511
JUNB,HTM,Up,6205,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,21826669
JUP,HTM,Up,6207,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.36,0.0042,22623141
JUP,HTM,Down,6207,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
JUp,HTM,Down,6207,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
JUP,HTM,Up,6207,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
JUP,HTM,Up,6207,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
KAAG1,HTM,Up,21031,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KALRN,HTM,Down,4814,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
KANK3,HTM,Down,24796,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KANSL1L,HTM,Up,26310,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
KARS1,HTM,Up,6215,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
KARS1,HTM,Down,6215,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
KAT2B,HTM,Up,8638,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KAT2B,HTM,Up,8638,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KAT2B,HTM,Down,8638,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
KAT6B,HTM,Up,17582,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
KAT6B,HTM,Up,17582,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
KAT6B,HTM,Up,17582,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
KAT7,HTM,NA,17016,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
KAT8,HTM,NA,17933,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
KATNAL1,HTM,Down,28361,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KATNAL1,HTM,Down,28361,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KATNB1,HTM,Down,6217,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KAZALD1,HTM,Up,25460,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
KAZN,HTM,Down,29173,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
KAZN,HTM,Down,29173,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
KBTBD11,HTM,Down,29104,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KBTBD11,HTM,Down,29104,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KBTBD11-OT1,HTM,Down,49147,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KBTBD11-OT1,HTM,Down,49147,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KBTBD6,HTM,Down,25340,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KBTBD8,HTM,Up,30691,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KBTBD8,HTM,Up,30691,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KBTBD8,HTM,Up,30691,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KCNAB1,HTM,Up,6228,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
KCNAB2,HTM,Up,6229,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KCNAB2,HTM,Up,6229,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KCNB1,HTM,Up,6231,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,34414448
KCNC1,HTM,Up,6233,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KCNC1,HTM,Up,6233,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,34414448
KCNC4,HTM,Down,6236,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KCND1,HTM,Up,6237,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,34414448
KCND3,HTM,Up,6239,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
KCNE1,HTM,Down,6240,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
KCNE2,HTM,Up,6242,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
KCNF1,HTM,Up,6246,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
KCNF1,HTM,Up,6246,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
KCNF1,HTM,Up,6246,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
KCNF1,HTM,Up,6246,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
KCNG1,HTM,Up,6248,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
KCNG3,HTM,Up,18306,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KCNG3,HTM,Up,18306,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
KCNH1,HTM,Up,6250,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
KCNH2,HTM,Up,6251,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KCNH2,HTM,Up,6251,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KCNH2,HTM,Up,6251,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KCNIP1,HTM,Down,15521,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
KCNIP3,HTM,Down,15523,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
KCNIP3,HTM,Down,15523,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
KCNJ12,HTM,Down,6258,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KCNJ15,HTM,Down,6261,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KCNJ15,HTM,Down,6261,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KCNJ15,HTM,Down,6261,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KCNJ15,HTM,Down,6261,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
KCNJ5,HTM,Down,6266,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KCNJ5,HTM,Down,6266,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KCNJ8,HTM,Down,6269,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
KCNK12,HTM,Up,6274,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
KCNK13,HTM,Up,6275,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KCNK13,HTM,Up,6275,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
KCNK2,HTM,Up,6277,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KCNK3,HTM,Up,6278,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KCNK5,HTM,Up,6280,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KCNK5,HTM,Down,6280,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
KCNK59,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
KCNK59,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
KCNK59,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
KCNMA1,HTM,Down,6284,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
KCNMA1,HTM,Down,6284,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
KCNMA1,HTM,Up,6284,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
KCNMA1,HTM,Up,6284,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
KCNMA1,HTM,Up,6284,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
KCNMA1,HTM,Up,6284,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
KCNMA1,HTM,Up,6284,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
KCNMA1,HTM,Up,6284,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
KCNMB2,HTM,Up,6286,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
KCNMB3,HTM,Up,6287,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
KCNN4,HTM,Up,6293,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KCNN4,HTM,Down,6293,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
KCNN4,HTM,Down,6293,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
KCNQ1,HTM,Up,6294,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
KCNQ2,HTM,Up,6296,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
KCNQ5,HTM,Down,6299,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KCNQ5,HTM,Down,6299,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KCNQ5,HTM,Up,6299,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
KCNRG,HTM,Up,18893,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KCNS1,HTM,Down,6300,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
KCNS1,HTM,Down,6300,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
KCNS3,HTM,Up,6302,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KCNT1,HTM,Up,18865,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
KCNT2,HTM,Down,18866,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KCNT2,HTM,Down,18866,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KCP,HTM,Down,17585,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
KCP,HTM,Down,17585,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
KCP,HTM,Down,17585,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
KCTD13,HTM,Up,22234,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
KCTD14,HTM,Down,23295,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KCTD14,HTM,Down,23295,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KCTD15,HTM,Down,23297,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KCTD21,HTM,Down,27452,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KCTD4,HTM,Up,23227,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
KDELC2,HTM,Up,28496,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KDELR3,HTM,Up,6306,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
KDELR3,HTM,Up,6306,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KDF1,HTM,Down,26624,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KDM1B,HTM,Up,21577,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
KDM6A,HTM,Up,12637,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
KDR,HTM,Up,6307,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KDR,HTM,Up,6307,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
KDR,HTM,Up,6307,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
KEAP1,HTM,Down,23177,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KHDRBS1,HTM,Up,18116,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
KHDRBS1,HTM,Down,18116,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
KHSRP,HTM,Down,6316,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
KHSRP,HTM,Down,6316,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
KHSRP,HTM,Down,6316,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
KHSRP,HTM,Down,6316,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
KIAA0040,HTM,Down,28950,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KIAA0040,HTM,Down,28950,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KIAA0040,HTM,Down,28950,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KIAA0040,HTM,Down,28950,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
KIAA0040,HTM,Up,28950,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
KIAA0232,HTM,Down,28992,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
KIAA0256,HTM,Up,28997,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KIAA0256,HTM,Up,28997,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KIAA0256,HTM,Up,28997,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KIAA0319,HTM,Up,21580,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIAA0319,HTM,Up,21580,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIAA0895L,HTM,Up,34408,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
KIAA0930,HTM,Down,1314,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIAA1217,HTM,Down,25428,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIAA1217,HTM,Down,25428,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIAA1217,HTM,Down,25428,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIAA1522,HTM,Down,29301,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KIAA1549,HTM,Up,22219,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KIAA1549,HTM,Up,22219,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KIAA1614,HTM,Down,29327,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIAA1614,HTM,Down,29327,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIAA1958,HTM,Up,23427,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIAA2026,HTM,Up,23378,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KIAA2026,HTM,Up,23378,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KIAA2026,HTM,Up,23378,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KIF12,HTM,Up,21495,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0011,17932721
KIF13A,HTM,Down,14566,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KIF13A,HTM,Down,14566,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
KIF13A,HTM,Down,14566,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
KIF13B,HTM,Up,14405,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIF13B,HTM,Up,14405,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIF14,HTM,Down,19181,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
KIF15,HTM,Down,17273,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
KIF18A,HTM,Up,29441,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIF18A,HTM,Up,29441,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIF1B,HTM,Up,16636,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KIF1B,HTM,Up,16636,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KIF1B,HTM,Up,16636,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KIF20B,HTM,Down,7212,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIF23,HTM,Down,6392,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIF26A,HTM,Down,20226,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
KIF27,HTM,Up,18632,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KIF27,HTM,Up,18632,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KIF27,HTM,Down,18632,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
KIF2A,HTM,Down,6318,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIF3A,HTM,Down,6319,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KIF5C,HTM,Down,6325,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KIF5C,HTM,Down,6325,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KIFAP3,HTM,Up,17060,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KIFAP3,HTM,Up,17060,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KIFAP3,HTM,Down,17060,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
KIFAP3,HTM,Up,17060,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KIRREL1,HTM,Down,15734,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KIRREL1,HTM,Down,15734,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KIRREL1,HTM,Down,15734,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KIRREL1,HTM,Up,15734,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
KIRREL2,HTM,Down,18816,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
KIRREL2,HTM,Up,18816,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
KISS1R,HTM,Up,4510,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KISS1R,HTM,Up,4510,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KIT,HTM,Down,6342,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.12,0.0180,34680485
KITLG,HTM,Up,6343,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KITLG,HTM,Down,6343,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
KL,HTM,Up,6344,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
KLB,HTM,Down,15527,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KLF10,HTM,Down,11810,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
KLF11,HTM,Down,11811,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
KLF12,HTM,Down,6346,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KLF3-AS1,HTM,Up,25796,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
KLF5,HTM,Down,6349,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
KLF5,HTM,Down,6349,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
KLF5,HTM,Down,6349,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
KLF6,HTM,Down,2235,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
KLF6,HTM,Down,2235,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KLF6,HTM,Down,2235,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KLF6,HTM,Down,2235,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KLF6,HTM,Down,2235,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
KLF6,HTM,Down,2235,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
KLF7,HTM,Down,6350,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KLF7,HTM,Down,6350,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KLF7,HTM,Down,6350,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KLF7,HTM,Down,6350,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KLF9,HTM,Down,1123,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.04,0.0032,27520449
KLF9,HTM,Up,1123,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
KLF9,HTM,Up,1123,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
KLF9,HTM,Down,1123,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
KLF9,HTM,Up,1123,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
KLHDC2,HTM,Up,20231,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KLHDC2,HTM,Up,20231,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KLHDC2,HTM,Down,20231,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
KLHDC2,HTM,Down,20231,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
KLHDC3,HTM,Down,20704,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
KLHDC4,HTM,Down,25272,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KLHDC7B,HTM,Down,25145,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KLHDC8B,HTM,Down,28557,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
KLHL1,HTM,Up,6352,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
KLHL1,HTM,Up,6352,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
KLHL11,HTM,Up,19008,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KLHL11,HTM,Up,19008,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KLHL11,HTM,Up,19008,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KLHL13,HTM,Down,22931,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
KLHL13,HTM,Down,22931,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KLHL13,HTM,Down,22931,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
KLHL13,HTM,Down,22931,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
KLHL15,HTM,Up,29347,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KLHL15,HTM,Up,29347,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KLHL15,HTM,Up,29347,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KLHL15,HTM,Up,29347,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KLHL23,HTM,Up,27506,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KLHL23,HTM,Up,27506,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KLHL23,HTM,Up,27506,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KLHL23,HTM,Up,27506,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KLHL29,HTM,Up,29404,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
KLHL36,HTM,Down,17844,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KLHL6-AS1,HTM,Down,40850,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KLK10,HTM,Down,6358,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
KLK10,HTM,Down,6358,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
KLK11,HTM,Down,6359,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
KLK13,HTM,Down,6361,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
KLK3,HTM,Up,6364,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
KLK3,HTM,Up,6364,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
KLK3,HTM,Up,6364,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
KLK3,HTM,Up,6364,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
KLK3,HTM,Up,6364,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
KLK3,HTM,Up,6364,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
KLK4,HTM,Down,6365,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
KLK5,HTM,Down,6366,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KLK6,HTM,Down,6367,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
KLK6,HTM,Down,6367,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
KLK6,HTM,Down,6367,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
KLK7,HTM,Down,6368,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KLK8,HTM,Down,6369,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
KLK8,HTM,Down,6369,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
KLK9,HTM,Down,6370,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KLKB1,HTM,Up,6371,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KLKB1,HTM,Up,6371,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KLKB1,HTM,Up,6371,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KLRC3,HTM,Up,6376,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
KLRF1,HTM,Up,13342,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KLRG2,HTM,Down,24778,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
KLRG2,HTM,Up,24778,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KMO,HTM,Down,6381,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KMO,HTM,Down,6381,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KMT2A,HTM,Up,7132,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
KMT2C,HTM,Up,13726,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KMT2C,HTM,Up,13726,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KMT2C,HTM,Up,13726,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
KMT2C,HTM,Up,13726,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KMT2E,HTM,Down,18541,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
KMT2E,HTM,Up,18541,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
KMT2E-AS1,HTM,Down,40845,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KMT2E-AS1,HTM,Down,40845,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
KMT5A,HTM,Up,29489,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
KMT5B,HTM,Up,24283,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
KMT5B,HTM,Up,24283,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
KMT5B,HTM,Up,24283,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
KNDC1,HTM,Down,29374,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KNG1,HTM,Down,6383,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
KNG1,HTM,Down,6383,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
KNG1,HTM,Down,6383,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
KNG1,HTM,Down,6383,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
KNG1,HTM,Down,6383,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
KNG1,HTM,Down,6383,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
KNOP1,HTM,Up,34404,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KNSTRN,HTM,Up,30767,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KNSTRN,HTM,Up,30767,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KNSTRN,HTM,Up,30767,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
KPNA4,HTM,Down,6397,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
KPNA6,HTM,Down,6399,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KPNB1,HTM,Down,6400,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
KPNB1,HTM,Down,6400,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
KRAS,HTM,NA,6407,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0011,29352988
KREMEN1,HTM,Up,17550,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KREMEN1,HTM,Down,17550,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
KREMEN2,HTM,Down,18797,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
KREMEN2,HTM,Up,18797,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KRR1,HTM,Down,5176,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KRR1,HTM,Down,5176,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KRR1,HTM,Down,5176,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KRT1,HTM,Up,6412,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0042,34794402
KRT1,HTM,Up,6412,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0042,34794402
KRT1,HTM,Up,6412,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
KRT1,HTM,Up,6412,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
KRT1,HTM,Up,6412,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,25081334
KRT10,HTM,Up,6413,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KRT10,HTM,Up,6413,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
KRT10,HTM,Up,6413,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
KRT10,HTM,Up,6413,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
KRT13,HTM,Up,6415,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
KRT14,HTM,Down,6416,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KRT14,HTM,Down,6416,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KRT14,HTM,Down,6416,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KRT14,HTM,Up,6416,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KRT15,HTM,Down,6421,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0053,22740085
KRT15,HTM,Down,6421,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
KRT15,HTM,Down,6421,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
KRT15,HTM,NA,6421,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by PCR array assay,0.04,0.0053,20630067
KRT15,HTM,Down,6421,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
KRT15,HTM,Up,6421,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
KRT16,HTM,Down,6423,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
KRT16,HTM,Up,6423,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
KRT16,HTM,Up,6423,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
KRT16,HTM,Up,6423,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
KRT16,HTM,Up,6423,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
KRT16,HTM,Down,6423,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0064,22954703
KRT16,HTM,UP,6423,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,23108794
KRT16,HTM,UP,6423,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,23108794
KRT16,HTM,UP,6423,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,23108794
KRT16,HTM,UP,6423,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,23108794
KRT16,HTM,UP,6423,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,23108794
KRT16,HTM,Up,6423,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
KRT17,HTM,Down,6427,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
KRT17,HTM,Down,6427,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
KRT17,HTM,Down,6427,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
KRT17,HTM,Down,6427,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
KRT17,HTM,Down,6427,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
KRT17,HTM,Down,6427,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
KRT17,HTM,Up,6427,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,27965308
KRT17,HTM,Down,6427,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
KRT17,HTM,Down,6427,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
KRT17,HTM,Down,6427,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
KRT17,HTM,Down,6427,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
KRT17,HTM,Up,6427,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
KRT17,HTM,Up,6427,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
KRT17,HTM,Down,6427,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0064,22954703
KRT17P2,HTM,Up,6429,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
KRT18,HTM,Up,6430,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
KRT18,HTM,Up,6430,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
KRT18,HTM,Up,6430,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
KRT18,HTM,Up,6430,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
KRT18,HTM,Up,6430,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0074,22623141
KRT18,HTM,Down,6430,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,31709178
KRT18,HTM,Down,6430,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,31729259
KRT18,HTM,Up,6430,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0074,22623141
KRT18,HTM,Down,6430,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0074,32503348
KRT18,HTM,Down,6430,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0074,32503348
KRT18,HTM,Down,6430,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0074,34168259
KRT18,HTM,Down,6430,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0074,34168259
KRT18,HTM,Down,6430,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0074,27746256
KRT18,HTM,Down,6430,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0074,34168259
KRT18,HTM,Down,6430,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,31729259
KRT18P11,HTM,Down,6431,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KRT18P17,HTM,Down,33385,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KRT18P29,HTM,Down,33398,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KRT19,HTM,Down,6436,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
KRT19,HTM,Up,6436,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
KRT19,HTM,Up,6436,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
KRT19,HTM,Down,6436,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0074,34168259
KRT19,HTM,Down,6436,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0074,25081334
KRT19,HTM,Down,6436,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.28,0.0074,27746256
KRT19,HTM,Down,6436,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,31709178
KRT19,HTM,Up,6436,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
KRT2,HTM,Up,6439,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
KRT2,HTM,Up,6439,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
KRT2,HTM,Up,6439,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
KRT2,HTM,Down,6439,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
KRT23,HTM,Down,6438,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
KRT23,HTM,Up,6438,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
KRT23,HTM,Up,6438,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
KRT3,HTM,Up,6440,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
KRT32,HTM,Up,6449,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
KRT34,HTM,Up,6452,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
KRT38,HTM,Up,6456,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
KRT4,HTM,Up,6441,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0032,18034892
KRT4,HTM,Up,6441,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KRT4,HTM,Up,6441,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
KRT5,HTM,Down,6442,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
KRT5,HTM,Down,6442,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
KRT5,HTM,Up,6442,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
KRT5,HTM,Down,6442,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
KRT5,HTM,Up,6442,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
KRT5,HTM,Down,6442,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0064,34414448
KRT6A,HTM,Down,6443,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KRT6A,HTM,Down,6443,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KRT6A,HTM,Down,6443,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KRT6A,HTM,Down,6443,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KRT6A,HTM,Down,6443,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KRT6A,HTM,Down,6443,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
KRT6A,HTM,Down,6443,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
KRT6B,HTM,Up,6444,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
KRT6B,HTM,Down,6444,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
KRT6B,HTM,Down,6444,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
KRT6B,HTM,Down,6444,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
KRT6B,HTM,Down,6444,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
KRT6B,HTM,Down,6444,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
KRT6B,HTM,Down,6444,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
KRT6B,HTM,Up,6444,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
KRT6C,HTM,Down,20406,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
KRT6C,HTM,Down,20406,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
KRT6C,HTM,Up,20406,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
KRT6C,HTM,Down,20406,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
KRT6C,HTM,Down,20406,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
KRT7,HTM,Up,6445,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
KRT7,HTM,Down,6445,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
KRT79,HTM,Up,28930,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KRT79,HTM,Down,28930,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
KRT79,HTM,Down,28930,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
KRT8,HTM,Up,6446,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0074,33670440
KRT8,HTM,Up,6446,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0074,33670440
KRT8,HTM,Up,6446,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0074,25881239
KRT8,HTM,Up,6446,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0074,25881239
KRT8,HTM,Down,6446,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0074,22623141
KRT8,HTM,Down,6446,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0074,23820871
KRT8,HTM,Down,6446,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,31709178
KRT8,HTM,Down,6446,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0074,22623141
KRT8,HTM,Down,6446,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0074,34168259
KRT8,HTM,Down,6446,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0074,25081334
KRT80,HTM,Down,27056,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.04,0.0032,27520449
KRT80,HTM,Down,27056,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
KRT80,HTM,Down,27056,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
KRT80,HTM,Down,27056,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
KRT81,HTM,Down,6458,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
KRT81,HTM,Up,6458,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KRT81,HTM,Up,6458,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KRT81,HTM,Down,6458,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
KRT83,HTM,Down,6460,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
KRT86,HTM,Down,6463,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
KRT8P10,HTM,Down,33364,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KRT8P3,HTM,Down,31056,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KRT8P32,HTM,Down,39866,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KRT8P33,HTM,Down,39867,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KRT8P37,HTM,Down,39871,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
KRT8P45,HTM,Down,39879,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
KRT9,HTM,Up,6447,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0042,34794402
KRT9,HTM,Up,6447,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0042,34794402
KRT9,HTM,Up,6447,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
KRT9,HTM,Up,6447,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
KRT9,HTM,Down,6447,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,25081334
KRT9,HTM,Up,6447,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,25081334
KRT9,HTM,Up,6447,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
KRTAP10-10,HTM,Down,22972,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KRTAP10-10,HTM,Down,22972,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KRTAP1-3,HTM,Down,16771,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KRTAP13-1,HTM,Down,18924,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
KRTAP1-4,HTM,Down,18904,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KRTAP4-1,HTM,Down,18907,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
KRTAP4-7,HTM,Down,18898,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
KRTDAP,HTM,Up,16313,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KRTDAP,HTM,Up,16313,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KRTDAP,HTM,Up,16313,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
KRTDAP,HTM,Up,16313,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
KTI12,HTM,Up,25160,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
KTN1,HTM,Down,6467,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
KTN1,HTM,Up,6467,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
KTN1,HTM,Down,6467,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
KYAT3,HTM,Down,33238,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
KYNU,HTM,Up,6469,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KYNU,HTM,Up,6469,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
KYNU,HTM,Up,6469,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
KYNU,HTM,Up,6469,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
KYNU,HTM,Up,6469,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
L3HYPDH,HTM,Down,20488,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
L3HYPDH,HTM,Down,20488,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
L3MBTL1,HTM,Down,15905,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
L3MBTL1,HTM,Down,15905,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
L3MBTL3,HTM,Down,23035,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
LACTB2,HTM,Down,18512,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
LACTB2,HTM,Up,18512,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LACTB2,HTM,Up,18512,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LACTB2,HTM,Up,18512,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
LAD1,HTM,Down,6472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LAD1,HTM,Down,6472,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
LAD1,HTM,Down,6472,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
LAGE3,HTM,Down,26058,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
LAMA1,HTM,Down,6481,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
LAMA1,HTM,Down,6481,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
LAMA1,HTM,Up,6481,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LAMA1,HTM,Up,6481,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LAMA1,HTM,Up,6481,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LAMA3,HTM,Down,6483,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
LAMA3,HTM,Down,6483,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
LAMA3,HTM,Down,6483,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
LAMA3,HTM,Down,6483,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
LAMA3,HTM,Down,6483,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
LAMA3,HTM,Down,6483,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
LAMA5,HTM,Down,6485,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LAMB1,HTM,Down,6486,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
LAMB2,HTM,Up,6487,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LAMB3,HTM,Up,6490,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,29416721
LAMB3,HTM,Down,6490,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
LAMB3,HTM,Down,6490,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
LAMB3,HTM,Up,6490,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0064,23903875
LAMB3,HTM,Down,6490,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
LAMB3,HTM,Up,6490,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
LAMB3,HTM,Up,6490,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0064,34168259
LAMB3,HTM,Up,6490,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0064,22954703
LAMC2,HTM,Down,6493,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
LAMC2,HTM,Down,6493,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LAMC2,HTM,Down,6493,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LAMC2,HTM,Down,6493,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LAMC2,HTM,Down,6493,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
LAMC2,HTM,Down,6493,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
LAMC3,HTM,Up,6494,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
LAMC3,HTM,Up,6494,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
LAMC3,HTM,Up,6494,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
LAMP2,HTM,Up,6501,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
LAMP2,HTM,Up,6501,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
LAMP2,HTM,Up,6501,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
LAMP3,HTM,Down,14582,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
LAMP3,HTM,Down,14582,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
LANCL1,HTM,Down,6508,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
LANCL1,HTM,Down,6508,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
LAPTM4B,HTM,Up,13646,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LAPTM4B,HTM,Up,13646,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LAPTM4B,HTM,Up,13646,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LAPTM5,HTM,Down,29612,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LAPTM5,HTM,Down,29612,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LAPTM5,HTM,Down,29612,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LARGE2,HTM,Down,16522,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LARP6,HTM,Down,24012,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LARP6,HTM,Down,24012,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LARS2,HTM,Down,17095,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LAS1L,HTM,Up,25726,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LAS1L,HTM,Up,25726,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LASP1,HTM,Down,6513,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
LBP,HTM,Down,6517,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LBR,HTM,Down,6518,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LCA5,HTM,Down,31923,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
LCA5L,HTM,Down,1255,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
LCK,HTM,Up,6524,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
LCLAT1,HTM,Down,26756,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
LCLAT1,HTM,Up,26756,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LCMT2,HTM,Up,17558,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
LCN2,HTM,Up,6526,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0042,26351321
LCN2,HTM,Down,6526,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
LCN2,HTM,Down,6526,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
LCN2,HTM,Up,6526,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
LCP1,HTM,Up,6528,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LCP1,HTM,Down,6528,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
LCP1,HTM,Down,6528,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
LDAF1,HTM,Up,30136,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LDAF1,HTM,Up,30136,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LDAF1,HTM,Up,30136,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LDAH,HTM,Up,26145,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LDB1,HTM,Down,6532,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
LDB3,HTM,Up,15710,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LDHA,HTM,Down,6535,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
LDHA,HTM,Down,6535,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.36,0.0053,34168259
LDHA,HTM,Down,6535,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.36,0.0053,34168259
LDHA,HTM,Up,6535,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.36,0.0053,34168259
LDHA,HTM,Up,6535,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
LDHA,HTM,Down,6535,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.36,0.0053,34168259
LDHA,HTM,Down,6535,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0053,24098529
LDHB,HTM,Up,6541,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
LDHB,HTM,Down,6541,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
LDHB,HTM,Down,6541,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
LDHB,HTM,Up,6541,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
LDHB,HTM,Up,6541,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
LDLR,HTM,Down,6547,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LDLR,HTM,Down,6547,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LDLR,HTM,Down,6547,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LDLRAD3,HTM,Up,27046,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LDOC1,HTM,Down,6548,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LEF1,HTM,Up,6551,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LEF1,HTM,Up,6551,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.24,0.0032,31289135
LEF1,HTM,Up,6551,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics,0.04,0.0032,25731617
LEFTY1,HTM,Up,6552,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
LEG1,HTM,Down,20960,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
LEMD1,HTM,Down,18725,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LENG9,HTM,Down,16306,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LETR1,HTM,Down,49597,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LEXM,HTM,Down,26854,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
LFNG,HTM,Up,6560,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LFNG,HTM,Up,6560,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LGALS1,HTM,Down,6561,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
LGALS1,HTM,Down,6561,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
LGALS1,HTM,Down,6561,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
LGALS1,HTM,Down,6561,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
LGALS1,HTM,Down,6561,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
LGALS1,HTM,Down,6561,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
LGALS1,HTM,Down,6561,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0053,34168259
LGALS1,HTM,Down,6561,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
LGALS14,HTM,Down,30054,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LGALS14,HTM,Down,30054,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LGALS2,HTM,Up,6562,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0011,17932721
LGALS3,HTM,Up,6563,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.36,0.0021,27746256
LGALS3BP,HTM,Up,6564,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29416721
LGALS3BP,HTM,Up,6564,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.28,0.0042,32503348
LGALS3BP,HTM,Up,6564,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
LGALS3BP,HTM,Down,6564,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
LGALS3BP,HTM,Down,6564,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
LGALS3BP,HTM,Down,6564,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
LGALS9,HTM,Down,6570,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LGALSL,HTM,Up,25012,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
LGI4,HTM,Down,18712,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LGI4,HTM,Down,18712,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LGR4,HTM,Up,13299,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LGR4,HTM,Up,13299,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LGR4,HTM,Up,13299,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.04,0.0032,27520449
LGR4,HTM,Up,13299,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
LGR4,HTM,Up,13299,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
LGR4,HTM,Up,13299,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
LGR6,HTM,Up,19719,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,35229723
LGR6,HTM,Down,19719,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
LGR6,HTM,Up,19719,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
LGSN,HTM,Up,21016,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LGSN,HTM,Up,21016,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LGSN,HTM,Down,21016,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
LHFP,HTM,Down,6586,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LHFP,HTM,Down,6586,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LHFP,HTM,Down,6586,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LHFP,HTM,Up,6586,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
LHX2,HTM,Up,6594,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
LHX4,HTM,Up,21734,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LHX4,HTM,Up,21734,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LHX4,HTM,Up,21734,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LHX6,HTM,Up,21735,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
LIF,HTM,Up,6596,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LIFR,HTM,Up,6597,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LIFR,HTM,Up,6597,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LIFR,HTM,Up,6597,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LIFR,HTM,Up,6597,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
LIG1,HTM,Up,6598,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LIG1,HTM,Up,6598,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LIG1,HTM,Up,6598,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LIG4,HTM,Down,6601,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LIG4,HTM,Down,6601,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LIMA1,HTM,Down,24636,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LIMA1,HTM,Down,24636,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LIMA1,HTM,Down,24636,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LIMA1,HTM,Down,24636,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
LIMA1,HTM,Down,24636,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
LIMCH1,HTM,Up,29191,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LIMCH1,HTM,Up,29191,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
LIMCH1,HTM,Up,29191,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
LIMD2,HTM,Up,28142,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
LIMK2,HTM,Down,6614,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LIMK2,HTM,Up,6614,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LIMS2,HTM,Up,16084,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LIN28A,HTM,Down,15986,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0138,24098529
LIN37,HTM,Up,33234,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
LIN7A,HTM,Up,17787,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LIN7A,HTM,Up,17787,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LIN7A,HTM,Up,17787,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LIN9,HTM,Up,30830,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
LINC00240,HTM,Down,18772,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC00261,HTM,Down,16189,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LINC00261,HTM,Down,16189,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LINC00265,HTM,Down,28019,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC00294,HTM,Down,27456,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC00324,HTM,Down,26628,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
LINC00327,HTM,Up,42009,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LINC00473,HTM,Down,8772,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
LINC00473,HTM,Up,21160,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LINC00514,HTM,Down,27549,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LINC00523,HTM,Down,20117,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC00540,HTM,Down,43673,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC00672,HTM,Down,44353,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC00674,HTM,Down,44355,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC00842,HTM,Down,44989,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC00865,HTM,Down,45170,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC00877,HTM,Down,27706,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC00885,HTM,Down,48571,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
LINC00885,HTM,Up,48571,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LINC00905,HTM,Down,26334,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
LINC00905,HTM,Down,26334,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
LINC00905,HTM,Down,26334,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
LINC00963,HTM,Down,48716,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC00963,HTM,Down,48716,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC00989,HTM,Down,48918,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC01000,HTM,Down,38541,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC01006,HTM,Up,48971,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LINC01016,HTM,Down,48991,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
LINC01016,HTM,Down,48991,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LINC01085,HTM,Up,27198,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LINC01116,HTM,Down,49259,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LINC01121,HTM,Down,49266,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC01139,HTM,Down,27924,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LINC01152,HTM,Down,16752,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC01291,HTM,Down,50358,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LINC01304,HTM,Down,50472,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC01433,HTM,Down,50746,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC01475,HTM,Down,51113,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC01488,HTM,Down,51144,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LINC01493,HTM,Down,51150,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC01505,HTM,Up,51186,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
LINC01514,HTM,Down,51207,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC01535,HTM,Down,51282,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC01559,HTM,Down,26598,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LINC02210,HTM,Down,26327,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LINC02210,HTM,Down,26327,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LINC02249,HTM,Down,32351,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LINC02249,HTM,Down,32351,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LINC02395,HTM,Up,53322,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LINC02551,HTM,Up,53586,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
LINC02593,HTM,Down,53933,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LINC02875,HTM,Up,32699,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LINC02908,HTM,Down,31426,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LINC-PINT,HTM,Down,26885,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LINC-PINT,HTM,Down,26885,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LINS1,HTM,Down,30922,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
LINS1,HTM,Down,30922,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
LIPA,HTM,Down,6617,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
LIPA,HTM,Up,6617,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
LIPA,HTM,Up,6617,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
LIPC,HTM,Down,6619,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LIPC,HTM,Down,6619,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LIPG,HTM,Down,6623,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LIPG,HTM,Down,6623,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LIPG,HTM,Down,6623,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LIPG,HTM,Up,6623,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LIPH,HTM,Up,18483,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LIPH,HTM,Up,18483,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LIPH,HTM,Down,18483,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
LIPT1,HTM,Up,29569,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LIPT1,HTM,Up,29569,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LIPT1,HTM,Up,29569,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LIX1L,HTM,Down,28715,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LIX1L,HTM,Up,28715,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
LLGL2,HTM,Down,6629,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LLPH,HTM,Down,28229,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LMAN1L,HTM,Down,6632,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LMAN2,HTM,Down,16986,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
LMAN2,HTM,Down,16986,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
LMCD1,HTM,Down,6633,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
LMCD1,HTM,Up,6633,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LMLN,HTM,Up,15991,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
LMNA,HTM,Up,6636,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
LMNA,HTM,Up,6636,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
LMNA,HTM,Down,6636,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
LMNA,HTM,Down,6636,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
LMNA,HTM,Down,6636,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
LMNA,HTM,Down,6636,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
LMNA,HTM,Up,6636,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
LMNA,HTM,Up,6636,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
LMNA,HTM,Down,6636,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
LMNB1,HTM,Down,6637,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
LMNB1,HTM,Down,6637,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
LMNB1,HTM,Up,6637,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
LMNB1,HTM,Up,6637,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
LMNB2,HTM,Down,6638,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LMNB2,HTM,Down,6638,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
LMO1,HTM,Down,6641,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
LMO1,HTM,Down,6641,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
LMO2,HTM,Down,6642,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LMO2,HTM,Down,6642,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LMO3,HTM,Up,6643,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LMO3,HTM,Up,6643,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
LMO3,HTM,Up,6643,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
LMO4,HTM,Up,6644,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LMO7,HTM,Up,6646,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
LMO7,HTM,Up,6646,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LMO7,HTM,Up,6646,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
LMO7,HTM,Up,6646,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
LMTK3,HTM,Down,19295,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LMX1B,HTM,Down,6654,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LNCAROD,HTM,Down,50913,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LNPEP,HTM,Down,6656,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LNPK,HTM,Down,21610,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
LNX1,HTM,Up,6657,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29511337
LNX1,HTM,Up,6657,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0011,29511337
LNX2,HTM,Down,20421,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LNX2,HTM,Down,20421,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LNX2,HTM,Down,20421,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
LOC124902802,HTM,Down,NA,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LOC344967,HTM,Down,NA,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LOC728392,HTM,Down,NA,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LOC728392,HTM,Down,NA,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LONP1,HTM,Up,9479,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
LONP2,HTM,Down,20598,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
LONP2,HTM,Up,20598,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
LONP2,HTM,Up,20598,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
LONRF2,HTM,Up,24788,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LONRF2,HTM,Up,24788,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LONRF2,HTM,Up,24788,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LONRF3,HTM,Down,21152,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
LONRF3,HTM,Up,21152,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LOX,HTM,Down,6664,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,34059086
LOX,HTM,Up,6664,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,31709178
LOX,HTM,Down,6664,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0074,25676692
LOX,HTM,Down,6664,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0074,25676692
LOX,HTM,Down,6664,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0074,26259570
LOX,HTM,Down,6664,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0074,25676692
LOX,HTM,Down,6664,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0074,26259570
LOX,HTM,Down,6664,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0074,30696080
LOX,HTM,Down,6664,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0074,30696080
LOX,HTM,Up,6664,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0074,20530554
LOXL2,HTM,Down,6666,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
LOXL2,HTM,Down,6666,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
LOXL2,HTM,Up,6666,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,24961511
LOXL2,HTM,Up,6666,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,24961511
LOXL2,HTM,Down,6666,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.24,0.0042,24961511
LOXL2,HTM,Up,6666,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.24,0.0042,24961511
LOXL2,HTM,Up,6666,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.24,0.0042,24961511
LOXL2,HTM,Up,6666,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
LOXL3,HTM,Down,13869,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LOXL4,HTM,Down,17171,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LOXL4,HTM,Down,17171,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LPA,HTM,Down,6667,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LPAR1,HTM,Down,3166,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LPAR1,HTM,Down,3166,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LPAR1,HTM,Down,3166,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
LPAR1,HTM,Up,3166,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
LPAR1,HTM,Down,3166,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
LPAR3,HTM,Down,14298,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LPAR3,HTM,Down,14298,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LPAR3,HTM,Down,14298,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LPAR5,HTM,Down,13307,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LPCAT1,HTM,Down,25718,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LPCAT2,HTM,Down,26032,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
LPCAT2,HTM,Down,26032,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
LPCAT2,HTM,Down,26032,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LPCAT2,HTM,Down,26032,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LPCAT3,HTM,Up,30244,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
LPCAT4,HTM,Down,30059,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LPIN1,HTM,Up,13345,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LPIN2,HTM,Down,14450,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LPIN2,HTM,Down,14450,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LPL,HTM,Down,6677,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LPP,HTM,Down,6679,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LPXN,HTM,Down,14061,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LPXN,HTM,Down,14061,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LPXN,HTM,Down,14061,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRAT,HTM,Down,6685,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
LRAT,HTM,Down,6685,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
LRAT,HTM,Down,6685,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
LRAT,HTM,Up,6685,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
LRAT,HTM,Down,6685,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
LRATD2,HTM,Down,24166,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
LRATD2,HTM,Down,24166,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
LRATD2,HTM,Down,24166,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
LRBA,HTM,Down,1742,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LRBA,HTM,Up,1742,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LRBA,HTM,Up,1742,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LRBA,HTM,Up,1742,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LRCH1,HTM,Down,20309,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
LRCH1,HTM,Up,20309,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LRCH1,HTM,Up,20309,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LRCH1,HTM,Up,20309,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LRFN1,HTM,Down,29290,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LRFN5,HTM,Up,20360,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
LRFN5,HTM,Up,20360,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
LRG1,HTM,Down,29480,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LRIF1,HTM,Up,30299,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
LRIG1,HTM,Down,17360,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
LRIG1,HTM,Down,17360,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
LRIG1,HTM,Down,17360,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
LRIG1,HTM,Down,17360,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
LRIG1,HTM,Down,17360,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
LRIG1,HTM,Up,17360,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
LRIG1,HTM,Up,17360,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
LRIG1,HTM,Up,17360,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
LRIG1,HTM,Up,17360,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
LRIG1,HTM,Up,17360,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
LRIG3,HTM,Down,30991,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LRIG3,HTM,Up,30991,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LRMDA,HTM,Up,23405,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LRMDA,HTM,Up,23405,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LRMDA,HTM,Up,23405,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LRP12,HTM,Down,31708,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
LRP1B,HTM,Up,6693,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LRP5,HTM,Up,6697,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
LRP5,HTM,Up,6697,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,25731617
LRP5L,HTM,Down,25323,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LRP5L,HTM,Down,25323,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LRP6,HTM,Up,6698,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LRP6,HTM,Up,6698,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LRP6,HTM,Up,6698,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25731617
LRP8,HTM,Down,6700,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
LRPPRC,HTM,Up,15714,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0064,18034892
LRPPRC,HTM,Down,15714,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0064,23903875
LRPPRC,HTM,Down,15714,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
LRPPRC,HTM,Down,15714,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
LRPPRC,HTM,Up,15714,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0064,17911267
LRPPRC,HTM,Down,15714,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0064,34168259
LRPPRC,HTM,Down,15714,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0064,27746256
LRR1,HTM,Down,19742,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LRRC1,HTM,Down,14307,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LRRC10B,HTM,Up,37215,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LRRC15,HTM,Up,20818,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LRRC23,HTM,Up,19138,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LRRC23,HTM,Up,19138,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
LRRC3,HTM,Down,14965,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LRRC32,HTM,Down,4161,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LRRC34,HTM,Down,28408,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
LRRC37A2,HTM,Up,32404,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRRC37A2,HTM,Up,32404,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRRC37A2,HTM,Up,32404,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRRC37A2,HTM,Up,32404,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRRC37A3,HTM,Up,32427,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LRRC37A3,HTM,Up,32427,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LRRC37A3,HTM,Up,32427,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LRRC37A3,HTM,Up,32427,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LRRC37A3,HTM,Down,32427,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
LRRC37A3,HTM,Down,32427,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
LRRC37A4P,HTM,Up,25479,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRRC37A4P,HTM,Up,25479,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRRC37A4P,HTM,Up,25479,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRRC37B,HTM,Up,29070,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRRC37BP1,HTM,Down,25390,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LRRC37BP1,HTM,Down,25390,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LRRC4,HTM,Up,15586,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LRRC4,HTM,Down,15586,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
LRRC45,HTM,Up,28302,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LRRC45,HTM,Up,28302,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LRRC45,HTM,Up,28302,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LRRC49,HTM,Down,25965,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LRRC49,HTM,Down,25965,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
LRRC55,HTM,Down,32324,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
LRRC59,HTM,Down,8091,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
LRRC59,HTM,Down,28817,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
LRRC59,HTM,Down,28817,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
LRRC6,HTM,Up,16725,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRRC61,HTM,Down,21704,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
LRRC61,HTM,Up,21704,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
LRRC61,HTM,Down,21704,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
LRRC61,HTM,Down,21704,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
LRRC61,HTM,Down,21704,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
LRRC69,HTM,Down,34303,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
LRRC71,HTM,Down,26556,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
LRRC75B,HTM,Up,33155,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LRRC75B,HTM,Up,33155,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
LRRC8A,HTM,Down,19027,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRRC8A,HTM,Down,19027,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRRC8B,HTM,Down,30692,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
LRRC8B,HTM,Up,30692,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
LRRC8C,HTM,Down,25075,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LRRC8C,HTM,Down,25075,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LRRC8C,HTM,Down,25075,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LRRC8C,HTM,Up,25075,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
LRRC8E,HTM,Down,26272,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
LRRCC1,HTM,Up,29373,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LRRCC1,HTM,Down,29373,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
LRRFIP1,HTM,Down,6702,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
LRRK2,HTM,Up,18618,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRRK2,HTM,Up,18618,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LRRN1,HTM,Down,20980,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
LRRN2,HTM,Up,16914,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
LRRN3,HTM,Up,17200,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
LRRN3,HTM,Up,17200,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
LSAMP,HTM,Up,6705,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
LSAMP,HTM,Up,6705,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
LSAMP,HTM,Down,6705,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
LSAMP,HTM,Down,6705,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
LSM11,HTM,Down,30860,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LSM14A,HTM,Down,24489,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
LSM14A,HTM,Up,24489,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
LSM2,HTM,Down,13940,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LSM3,HTM,Down,17874,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
LSM3,HTM,Down,17874,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
LSM3,HTM,Down,17874,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
LSM3,HTM,Down,17874,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
LSM3,HTM,Down,17874,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
LSM5,HTM,Up,17162,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LSM5,HTM,Up,17162,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LSM5,HTM,Up,17162,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LSM6,HTM,Up,17017,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LSM6,HTM,Up,17017,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LSM6,HTM,Down,17017,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LSM6,HTM,Up,17017,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
LSMEM2,HTM,Up,26781,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
LSR,HTM,Down,29572,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
LSR,HTM,Down,29572,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
LSS,HTM,Down,6708,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
LSS,HTM,Down,6708,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0042,23820871
LSS,HTM,Up,6708,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
LSS,HTM,Up,6708,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
LSS,HTM,Up,6708,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
LSS,HTM,Up,6708,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
LSS,HTM,Up,6708,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
LTA4H,HTM,Up,6710,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
LTA4H,HTM,Up,6710,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
LTA4H,HTM,Up,6710,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
LTB,HTM,Up,6711,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
LTBP1,HTM,Down,6714,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LTBP2,HTM,Down,6715,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LTBP2,HTM,Up,6715,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LTBR,HTM,Up,6718,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
LTO1,HTM,Up,17589,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LTO1,HTM,Up,17589,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LTO1,HTM,Up,17589,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LUC7L2,HTM,Up,21608,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
LUCAT1,HTM,Down,48498,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
LURAP1L,HTM,Up,31452,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
LURAP1L,HTM,Up,31452,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
LURAP1L,HTM,Up,31452,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
LURAP1L,HTM,Up,31452,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
LUZP1,HTM,Down,14985,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LUZP1,HTM,Down,14985,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LUZP1,HTM,Down,14985,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LXN,HTM,Up,13347,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
LXN,HTM,Up,13347,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
LXN,HTM,Down,13347,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
LXN,HTM,Down,13347,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
LXN,HTM,Down,13347,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
LXN,HTM,Down,13347,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0053,34168259
LY6D,HTM,Down,13348,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
LY6E,HTM,Up,6727,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
LY6E,HTM,Up,6727,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
LY6E,HTM,Up,6727,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
LY6E,HTM,Down,6727,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
LY6E,HTM,Down,6727,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
LY6G6C,HTM,Up,13936,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LY75,HTM,Up,6729,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LY75,HTM,Up,6729,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LY75,HTM,Up,6729,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LY75,HTM,Up,6729,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
LY75,HTM,Down,6729,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
LYAR,HTM,Down,26021,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LYAR,HTM,Up,26021,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
LYN,HTM,Down,6735,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
LYN,HTM,Down,6735,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
LYN,HTM,Down,6735,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
LYNX1,HTM,Down,29604,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LYPD2,HTM,Up,25215,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
LYPD3,HTM,Up,24880,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
LYPD3,HTM,Up,24880,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
LYPD6,HTM,Up,28751,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LYPD6,HTM,Up,28751,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LYPD6,HTM,Up,28751,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
LYPD6B,HTM,Up,27018,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
LYPLAL1,HTM,Up,20440,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
LYRM2,HTM,Up,25229,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
LYRM4,HTM,Down,21365,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
LYST,HTM,Up,1968,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
LZTFL1,HTM,Up,6741,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
MAB21L4,HTM,Down,26216,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MACC1,HTM,Up,30215,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MACROD2,HTM,Up,16126,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MACsC1,HTM,Up,30215,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
MACsC1,HTM,Down,30215,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
MACsF1,HTM,Down,13664,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0021,19451087
MACsF1,HTM,Up,13664,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
MACsIR,HTM,Up,25052,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MACsIR,HTM,Up,25052,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MACsO1,HTM,Down,25572,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MACsO1,HTM,Up,25572,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
MACsROD2,HTM,Up,16126,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MACsROH2A1,HTM,Up,4740,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MACsROH2A1,HTM,Up,4740,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MACsROH2A1,HTM,Down,4740,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
MAD1L1,HTM,Up,6762,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
MAD2L1,HTM,Down,6763,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MADD,HTM,Down,6766,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MAF,HTM,Up,6776,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MAF,HTM,Up,6776,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MAF,HTM,Up,6776,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MAFB,HTM,Up,6408,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAFB,HTM,Up,6408,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAFB,HTM,Up,6408,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MAFB,HTM,Down,6408,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MAFB,HTM,Up,6408,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAFF,HTM,Up,6780,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MAGEA1,HTM,Up,6796,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MAGEA1,HTM,Up,6796,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MAGEA1,HTM,Up,6796,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
MAGEA1,HTM,Up,6796,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MAGEA12,HTM,Up,6799,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
MAGEA3,HTM,Down,6801,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
MAGEA6,HTM,Up,6804,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
MAGEA6,HTM,Down,6804,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
MAGEB2,HTM,Down,6809,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.2,0.0021,29340052
MAGED1,HTM,Down,6813,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MAGED2,HTM,Down,16353,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
MAGI1,HTM,Up,946,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
MAGI1,HTM,Up,946,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
MAGI1,HTM,Up,946,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MAGOH,HTM,Up,6815,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
MAGOH,HTM,Up,6815,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
MAGT1,HTM,Up,28880,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
MAL,HTM,Down,6817,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MAL2,HTM,Down,13634,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
MAL2,HTM,Up,13634,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
MAL2,HTM,Down,13634,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
MAL2,HTM,Down,13634,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
MALAT1,HTM,Up,29665,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,24961511
MALAT1,HTM,Up,29665,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,24961511
MALAT1,HTM,Up,29665,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0074,34680485
MALAT1,HTM,Up,29665,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0074,30696080
MALAT1,HTM,Up,29665,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0074,30696080
MALAT1,HTM,Up,29665,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0074,20530554
MALAT1,HTM,Up,29665,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0074,20530554
MALAT1,HTM,Up,29665,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0074,20530554
MALAT1,HTM,Up,29665,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0074,20530554
MALL,HTM,Up,6818,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MALL,HTM,Up,6818,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MALL,HTM,Down,6818,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MALL,HTM,Down,6818,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
MALRD1,HTM,Down,24331,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MAMDC2,HTM,Up,23673,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MAMDC4,HTM,Down,24083,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MAMDC4,HTM,Down,24083,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MAML1,HTM,Up,13632,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0011,29959199
MAML2,HTM,Down,16259,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MAML2,HTM,Up,16259,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MAML3,HTM,Up,16272,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MAML3,HTM,Up,16272,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MAML3,HTM,Up,16272,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
MAMLD1,HTM,Up,2568,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MAN1A1,HTM,Down,6821,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MAN1A2,HTM,Up,6822,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MAN2A1,HTM,Up,6824,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
MAN2A110,HTM,Up,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MAN2A110,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MAN2A110,HTM,Up,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MAN2C1,HTM,Down,6827,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22740085
MANF,HTM,Down,15461,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MANSC1,HTM,Up,25505,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MANSC1,HTM,Up,25505,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MANSC1,HTM,Up,25505,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
MAOA,HTM,Down,6833,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MAOA,HTM,Down,6833,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MAOA,HTM,Down,6833,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MAOA,HTM,Up,6833,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MAP10,HTM,Up,29265,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MAP1B,HTM,Up,6836,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MAP1B,HTM,Up,6836,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MAP1LC3B2,HTM,Down,34390,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MAP1S,HTM,Down,15715,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
MAP2,HTM,Down,6839,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MAP2,HTM,Up,6839,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MAP2K1,HTM,NA,6840,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0021,29352988
MAP2K1,HTM,Up,6840,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Proteomics and Western Blotting,0.36,0.0021,17911267
MAP2K2,HTM,Down,6842,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
MAP2K2,HTM,Down,6842,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
MAP2K4,HTM,Down,6844,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
MAP2K4,HTM,Down,6844,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
MAP2K5,HTM,Up,6845,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MAP2K6,HTM,Up,6846,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MAP2K6,HTM,Up,6846,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MAP2K7,HTM,Down,6847,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
MAP2K7,HTM,Down,6847,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
MAP3K1,HTM,Down,6848,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
MAP3K1,HTM,Down,6848,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
MAP3K1,HTM,Down,6848,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MAP3K12,HTM,Up,6851,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MAP3K14,HTM,Down,6853,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MAP3K14,HTM,Down,6853,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MAP3K14-AS1,HTM,Down,44359,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MAP3K2,HTM,Down,6854,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MAP3K2,HTM,Down,6854,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0021,19451087
MAP3K20,HTM,Down,17797,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
MAP3K20,HTM,Up,17797,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MAP3K20,HTM,Down,17797,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
MAP3K21,HTM,Up,29798,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MAP3K21,HTM,Up,29798,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
MAP3K4,HTM,Up,6856,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MAP3K4,HTM,Up,6856,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MAP3K4,HTM,Up,6856,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MAP3K5,HTM,Down,6857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MAP3K5,HTM,Down,6857,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
MAP3K6,HTM,Up,6858,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MAP3K6,HTM,Up,6858,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MAP3K8,HTM,Down,6860,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MAP3K8,HTM,Down,6860,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
MAP3K8,HTM,Up,6860,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAP3K8,HTM,Down,6860,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
MAP3K8,HTM,Up,6860,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAP3K8,HTM,Up,6860,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAP4,HTM,Up,6862,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MAP4,HTM,Up,6862,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MAP4,HTM,Down,6862,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MAP4K3,HTM,Up,6865,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MAP4K3,HTM,Up,6865,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MAP4K3,HTM,Up,6865,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MAP4K4,HTM,Down,6866,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MAP4K4,HTM,Down,6866,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MAP4K5,HTM,Down,6867,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MAP7,HTM,Down,6869,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MAP7D2,HTM,Up,25899,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MAP7D2,HTM,Up,25899,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MAP7D2,HTM,Up,25899,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAP7D2,HTM,Up,25899,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAP7D2,HTM,Down,25899,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MAP7D2,HTM,Up,25899,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAP9,HTM,Up,26118,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
MAPK1,HTM,Down,6871,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
MAPK1,HTM,Down,6871,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
MAPK10,HTM,Down,6872,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
MAPK10,HTM,Down,6872,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
MAPK10,HTM,Up,6872,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MAPK10,HTM,Up,6872,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MAPK11,HTM,Up,6873,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MAPK12,HTM,Down,6874,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MAPK13,HTM,Down,6875,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MAPK13,HTM,Down,6875,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MAPK13,HTM,Up,6875,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
MAPK13,HTM,Down,6875,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
MAPK14,HTM,Up,6876,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MAPK14,HTM,Up,6876,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MAPK15,HTM,Up,24667,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MAPK3,HTM,Down,6877,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
MAPK3,HTM,Up,6877,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
MAPK3,HTM,Up,6877,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
MAPK4,HTM,Up,6878,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MAPK4,HTM,Down,6878,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MAPK6,HTM,Down,6879,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MAPK8,HTM,Down,6881,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
MAPK8,HTM,Down,6881,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
MAPK8,HTM,Up,6881,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAPK8,HTM,Up,6881,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAPK8,HTM,Up,6881,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAPK8IP2,HTM,Down,6883,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MAPK8IP2,HTM,Down,6883,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MAPK8IP3,HTM,Up,6884,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,35013621
MAPK9,HTM,NA,6886,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0011,29352988
MAPKAP1,HTM,Up,18752,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
MAPKAPK3,HTM,Down,6888,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
MAPKAPK3,HTM,Down,6888,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MAPKAPK3,HTM,Down,6888,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MAPKAPK3,HTM,Down,6888,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
MAPKAPK3,HTM,Up,6888,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAPKAPK3,HTM,Up,6888,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAPKAPK3,HTM,Up,6888,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MAPKAPK5-AS1,HTM,Up,24091,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MAPRE2,HTM,Up,6891,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MARCHF8,HTM,Up,23356,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MARCKS,HTM,Down,6759,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
MARCKS,HTM,Up,6759,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.36,0.0032,27746256
MARCKSL1,HTM,Down,7142,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MARCO,HTM,Down,6895,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MARK1,HTM,Down,6896,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MARK1,HTM,Down,6896,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MARK2,HTM,Up,3332,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MARK2,HTM,Up,3332,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MARK2,HTM,Up,3332,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MARK4,HTM,Up,13538,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
MARS1,HTM,Up,6898,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MARS2,HTM,Down,25133,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
MARVELD2,HTM,Down,26401,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MARVELD3,HTM,Down,30525,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MAST3,HTM,Up,19036,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
MAST4,HTM,Up,19037,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MAST4,HTM,Up,19037,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
MASTL,HTM,Up,19042,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
MAT2A,HTM,Down,6904,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MAT2A,HTM,Down,6904,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MAT2A,HTM,Down,6904,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MAT2B,HTM,Down,6905,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MAT2B,HTM,Down,6905,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MAT2B,HTM,Up,6905,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
MATK,HTM,Up,6906,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MATK,HTM,Up,6906,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MATK,HTM,Down,6906,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MATK,HTM,Down,6906,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MATK,HTM,Up,6906,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MATN2,HTM,Up,6908,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MATN2,HTM,Up,6908,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MATN2,HTM,Up,6908,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MATN3,HTM,Down,6909,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MATR3,HTM,Down,6912,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MATR3,HTM,Down,6912,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MATR3,HTM,Down,6912,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
MATR3,HTM,Up,6912,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
MATR3,HTM,Down,6912,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
MB21D2,HTM,Up,30438,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MB21D2,HTM,Up,30438,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MB21D2,HTM,Down,30438,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MB21D2,HTM,Down,30438,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
MB21D2,HTM,Up,30438,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MBD2,HTM,Down,6917,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MBD2,HTM,Up,6917,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MBD2,HTM,Up,6917,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MBD2,HTM,Up,6917,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MBD4,HTM,Down,6919,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
MBD4,HTM,Down,6919,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
MBD5,HTM,Down,20444,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
MBD6,HTM,Up,20445,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
MBIP,HTM,Up,20427,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MBL2,HTM,Down,6922,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MBL2,HTM,Down,6922,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MBNL1,HTM,Up,6923,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
MBNL1,HTM,Up,6923,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
MBNL1,HTM,Up,6923,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
MBNL2,HTM,Up,16746,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MBNL2,HTM,Up,16746,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
MBNL3,HTM,Down,20564,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MBNL3,HTM,Down,20564,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MBOAT1,HTM,Down,21579,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MBOAT1,HTM,Down,21579,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MBOAT2,HTM,Down,25193,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MBOAT2,HTM,Down,25193,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MBOAT2,HTM,Down,25193,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MBOAT2,HTM,Down,25193,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
MBTD1,HTM,Up,19866,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MBTD1,HTM,Up,19866,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
MBTPS1,HTM,Up,15456,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MBTPS1,HTM,Up,15456,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MBTPS1,HTM,Up,15456,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MBTPS2,HTM,Up,15455,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MBTPS2,HTM,Up,15455,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MC1R,HTM,Up,6929,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MC1R,HTM,Up,6929,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MC1R,HTM,Up,6929,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MCAM,HTM,Down,6934,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
MCAM,HTM,Down,6934,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
MCAM,HTM,Down,6934,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
MCAM,HTM,Up,6934,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
MCAM,HTM,Down,6934,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
MCAM,HTM,Down,6934,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
MCAM,HTM,Up,6934,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.12,0.0064,34680485
MCC,HTM,Down,6935,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MCC,HTM,Down,6935,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MCC,HTM,Down,6935,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MCC,HTM,Down,6935,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
MCC,HTM,Down,6935,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
MCC,HTM,Down,6935,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
MCCC1,HTM,Up,6936,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MCF2L,HTM,Down,14576,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MCF2L,HTM,Up,14576,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MCFD2,HTM,Up,18451,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MCFD2,HTM,Up,18451,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MCFD2,HTM,Up,18451,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
MCFD2,HTM,Up,18451,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MCHR2,HTM,Up,20867,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
MCL1,HTM,Down,6943,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.48,0.0032,25881239
MCL1,HTM,Down,6943,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MCM2,HTM,Down,6944,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MCM2,HTM,Up,6944,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
MCM3,HTM,Down,6945,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MCM3,HTM,Down,6945,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MCM3,HTM,Up,6945,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
MCM4,HTM,Down,6947,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
MCM4,HTM,Down,6947,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
MCM5,HTM,Up,6948,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
MCM59,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MCM59,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MCM59,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MCM6,HTM,Up,6949,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MCM7,HTM,Up,6950,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
MCM7,HTM,Up,6950,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
MCM7,HTM,Down,6950,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
MCM7,HTM,Up,6950,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
MCM8,HTM,Up,16147,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MCM9,HTM,Down,21484,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
MCMBP,HTM,Up,25782,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
MCOLN2,HTM,Up,13357,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
MCOLN3,HTM,Down,13358,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
MCOLN3,HTM,Down,13358,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
MCOLN3,HTM,Up,13358,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
MCOLN3,HTM,Down,13358,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MCPH1,HTM,Down,6954,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MCPH1,HTM,Down,6954,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
MCTP1,HTM,Up,26183,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MCTP1,HTM,Up,26183,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MCTP1,HTM,Up,26183,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MCTP1,HTM,Up,26183,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MCTP2,HTM,Down,25636,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MCTP2,HTM,Down,25636,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MCTS1,HTM,Down,23357,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
MCTS1,HTM,Down,23357,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
MDC1,HTM,Up,21163,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
MDFI,HTM,Down,6967,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MDFIC,HTM,Down,28870,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
MDFIC,HTM,Down,28870,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
MDGA1,HTM,Up,19267,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
MDGA2,HTM,Up,19835,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MDGA2,HTM,Down,19835,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
MDH1,HTM,Down,6970,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,22623141
MDH1,HTM,Down,6970,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
MDH1,HTM,Down,6970,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
MDH1,HTM,Up,6970,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0053,17911267
MDH1,HTM,Down,6970,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0053,34168259
MDH1,HTM,Up,6970,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
MDH1,HTM,Down,6970,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0053,34168259
MDH2,HTM,Up,6971,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
MDH2,HTM,Down,6971,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
MDH2,HTM,Down,6971,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
MDK,HTM,Up,6972,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MDM1,HTM,Down,29917,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
MDM2,HTM,NA,6973,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,29221160
MDM2,HTM,Down,6973,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,29511337
MDM2,HTM,Down,6973,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0042,29511337
MDM2,HTM,Up,6973,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
MDM2,HTM,Up,6973,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
MDM4,HTM,Up,6974,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MDN1,HTM,Up,18302,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MDN1,HTM,Up,18302,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MDN1,HTM,Up,18302,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MDN1,HTM,Up,18302,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
MDN1,HTM,Up,18302,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
ME1,HTM,Up,6983,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ME1,HTM,Up,6983,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ME1,HTM,Up,6983,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
ME1,HTM,Up,6983,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
ME1,HTM,Up,6983,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0042,17911267
ME1,HTM,Up,6983,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.36,0.0042,27746256
ME1,HTM,Up,6983,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
ME2,HTM,Down,6984,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ME2,HTM,Down,6984,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
ME3,HTM,Down,6985,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
ME3,HTM,Up,6985,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
MECOM,HTM,Down,3498,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MED12,HTM,Up,11957,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MED12,HTM,Up,11957,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MED12,HTM,Up,11957,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MED13,HTM,NA,22474,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
MED13L,HTM,Up,22962,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MED13L,HTM,NA,22962,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,29221160
MED13L,HTM,Up,22962,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
MED14,HTM,Down,2370,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
MED15,HTM,Down,14248,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MED21,HTM,Up,11473,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MED21,HTM,Up,11473,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MED21,HTM,Up,11473,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MED22,HTM,Down,11477,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
MED27,HTM,Down,2377,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MED6,HTM,Down,19970,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
MED6,HTM,Up,19970,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
MED9,HTM,Up,25487,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MED9,HTM,Up,25487,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MED9,HTM,Up,25487,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MEF2C,HTM,Up,6996,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MEF2C,HTM,Down,6996,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MEFV,HTM,Down,6998,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MEGF8,HTM,Up,3233,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MEGF9,HTM,Up,3234,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MEGF9,HTM,Up,3234,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MEIOC,HTM,Up,26670,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MEIOC,HTM,Up,26670,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MEIS1,HTM,Down,7000,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MEIS1,HTM,Down,7000,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MEIS1,HTM,Up,7000,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,34228218
MEIS1,HTM,Down,7000,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MEIS3P1,HTM,Up,7002,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MEIS3P2,HTM,Up,17638,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MELK,HTM,Down,16870,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MEMO1,HTM,Up,14014,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MEMO1,HTM,Up,14014,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MEMO1,HTM,Up,14014,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MEP1A,HTM,Up,7015,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MEP1A,HTM,Up,7015,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MERTK,HTM,Up,7027,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MEST,HTM,Up,7028,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MEST,HTM,Up,7028,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MEST,HTM,Down,7028,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MET,HTM,Down,7029,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.2,0.0191,31501409
MET,HTM,Up,7029,Breast Cancer,NA,Primary,NA,Transcriptomics,0.12,0.0191,30559934
METAP1,HTM,Up,15789,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,22623141
METAP1D,HTM,Down,32583,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
METTL13,HTM,Down,24248,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
METTL15,HTM,Down,26606,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
METTL16,HTM,Up,28484,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.16,0.0021,20530554
METTL16,HTM,Up,NA,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
METTL21A,HTM,Down,30476,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
METTL23,HTM,Up,26988,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
METTL5,HTM,Up,25006,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
METTL5,HTM,Up,25006,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
METTL5,HTM,Up,25006,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
METTL6,HTM,Up,28343,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
METTL6,HTM,Up,28343,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
METTL6,HTM,Up,28343,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
METTL6,HTM,Up,28343,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
METTL7A,HTM,Up,24550,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
METTL7A,HTM,Down,24550,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
METTL7B,HTM,Up,28276,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
METTL7B,HTM,Up,28276,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MEX3A,HTM,Down,33482,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MFAP2,HTM,Down,7033,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
MFAP5,HTM,Down,29673,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MFAP5,HTM,Down,29673,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MFAP5,HTM,Up,29673,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
MFAP5,HTM,Down,29673,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MFF,HTM,Up,24858,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MFF,HTM,Down,24858,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
MFGE8,HTM,Up,7036,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MFI2,HTM,Down,7037,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MFN2,HTM,Down,16877,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MFN2,HTM,Down,16877,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MFNG,HTM,Down,7038,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MFNG,HTM,Up,7038,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MFNG,HTM,Up,7038,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MFNG,HTM,Up,7038,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MFSD10,HTM,Down,16894,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MFSD14B,HTM,Down,23376,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MFSD2A,HTM,Down,25897,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MFSD2A,HTM,Down,25897,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MFSD2A,HTM,Down,25897,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MFSD2A,HTM,Up,25897,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MFSD3,HTM,Down,25157,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MFSD6,HTM,Down,24711,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MFSD6,HTM,Up,24711,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MFSD9,HTM,Down,28158,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MGA,HTM,Up,14010,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MGARP,HTM,Up,29969,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MGARP,HTM,Up,29969,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MGARP,HTM,Up,29969,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MGAT1,HTM,Down,7044,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MGAT3,HTM,Down,7046,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MGAT4A,HTM,Up,7047,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MGAT4A,HTM,Down,7047,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MGAT5,HTM,Down,7049,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MGC26963,HTM,Up,28395,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
MGC26963,HTM,Up,28395,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
MGC70870,HTM,Up,NA,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MGLL,HTM,Down,17038,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
MGLL,HTM,Down,17038,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MGLL,HTM,Down,17038,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
MGMT,HTM,Down,7059,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MGP,HTM,Up,7060,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MGST2,HTM,Down,7063,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
MGST2,HTM,Down,7063,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
MGST2,HTM,Down,7063,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
MGST2,HTM,Down,7063,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
MGST2,HTM,Down,7063,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
MGST2,HTM,Up,7063,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0042,21788403
MGST3,HTM,Down,7064,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MGST3,HTM,Up,7064,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
MGST3,HTM,Up,7064,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
MIA2,HTM,Up,18432,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MIA2,HTM,Up,18432,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
MIA3,HTM,Up,24008,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MIB1,HTM,Up,21086,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
MICA,HTM,Up,7090,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
MICAL2,HTM,Down,24693,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MICAL2,HTM,Down,24693,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MICAL2,HTM,Down,24693,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
MICAL2,HTM,Down,24693,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MICAL2,HTM,Down,24693,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
MICAL2,HTM,Down,24693,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
MICALCL,HTM,Down,24693,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MICALCL,HTM,Down,24693,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MICALCL,HTM,Down,24693,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MICALCL,HTM,Down,24693,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MICB,HTM,Up,7091,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
MICB,HTM,Down,7091,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
MICB,HTM,Down,7091,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
MICU1,HTM,Up,1530,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MICU3,HTM,Down,27820,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MID1,HTM,Up,7095,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MID1,HTM,Up,7095,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MID1,HTM,Down,7095,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MID2,HTM,Up,7096,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MID2,HTM,Down,7096,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MIEN1,HTM,Down,28230,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MIEN1,HTM,Up,28230,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MIF,HTM,Down,7097,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
MIF,HTM,Up,7097,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MIF,HTM,Up,7097,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MIF,HTM,Down,7097,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
MIF4GD,HTM,Down,24030,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MILR1,HTM,Up,27570,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MINAR1,HTM,Up,29172,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
MINDY1,HTM,Up,25648,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MIPOL1,HTM,Up,21460,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MIPOL1,HTM,Down,21460,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
MIPOL1,HTM,Down,21460,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
MIR100,HTM,Down,31487,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,21785383
MIR100,HTM,Up,31487,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,25676692
MIR100,HTM,Up,31487,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29407170
MIR101-1,HTM,Down,31488,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31692042
MIR101-1,HTM,Down,31488,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR101-1,HTM,Up,31488,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0032,22180714
MIR103A1,HTM,Up,31490,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
MIR103A1,HTM,Up,31490,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
MIR106A,HTM,Up,31494,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR106B,HTM,Down,31495,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR107,HTM,Up,31496,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
MIR107,HTM,Up,31496,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
MIR1-1,HTM,Down,31499,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29407170
MIR1185-1,HTM,Down,35257,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,33798550
MIR1185-1,HTM,Down,35257,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,32661467
MIR1202,HTM,Up,35268,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR1202,HTM,Up,35268,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR122,HTM,Down,31501,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29407170
MIR122,HTM,Down,31501,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,30188754
MIR122,HTM,Down,31501,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,30188754
MIR122,HTM,Up,31501,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,32661467
MIR1224,HTM,Up,33923,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR1226,HTM,Up,33922,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR1228,HTM,Up,33928,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR1228,HTM,Up,33928,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR1229,HTM,Down,33924,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR1229,HTM,Down,33924,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR1234,HTM,Up,33926,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,29187905
MIR1234,HTM,Up,33926,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,30188754
MIR1234,HTM,Up,33926,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0042,29187905
MIR1234,HTM,Up,33926,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,25117811
MIR1234,HTM,Down,33926,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0042,23007737
MIR1236,HTM,Up,33925,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR1237,HTM,Up,33927,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR1246,HTM,Up,35312,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0021,26711929
MIR1246,HTM,Up,35312,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR1249,HTM,Down,35315,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR1249,HTM,Down,35315,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR1250,HTM,Down,35316,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR1255A,HTM,Down,35320,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR125A,HTM,Up,31505,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,28440445
MIR125A,HTM,Down,31505,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0032,23117485
MIR125A,HTM,Up,31505,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,32661467
MIR125B1,HTM,Down,31506,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0042,23117485
MIR125B1,HTM,Up,31506,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,29187905
MIR125B1,HTM,Up,31506,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0042,29187905
MIR1260B,HTM,Down,38258,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,26711929
MIR1260B,HTM,Up,38258,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,30188754
MIR1260B,HTM,Up,38258,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR1262,HTM,Down,35328,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR1265,HTM,Up,35332,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR1266,HTM,Down,35334,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR1268A,HTM,Up,35336,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR1268A,HTM,Up,35336,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR1269B,HTM,Down,41787,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25676692
MIR1269B,HTM,Down,41787,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25676692
MIR127,HTM,Down,31509,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay followed by Transcriptomics,0.12,0.0042,22285547
MIR1273C,HTM,Down,38173,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR1273C,HTM,Down,38173,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR1276,HTM,Down,35347,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR1277,HTM,Up,35350,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR1280,HTM,Up,35368,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR128-1,HTM,Down,31510,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0011,28580169
MIR1285-1,HTM,Down,35277,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR1285-1,HTM,Down,35277,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR1285-1,HTM,Down,35277,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR1285-1,HTM,Down,35277,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR1285-1,HTM,Down,35277,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR1287,HTM,Up,35280,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR1288,HTM,Up,35363,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR1290,HTM,Up,35283,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR1290,HTM,Up,35283,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR1291,HTM,Up,35284,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR129-1,HTM,Up,31512,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31692042
MIR1292,HTM,Down,35364,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR129-2,HTM,Down,31513,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR1293,HTM,Down,35286,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR1306,HTM,Up,35371,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR1307,HTM,Down,35372,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR130A,HTM,Down,31514,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR130A,HTM,Down,31514,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR130B,HTM,Down,31515,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,26711929
MIR130B,HTM,Up,31515,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29407170
MIR132,HTM,Down,31516,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR134,HTM,Up,31519,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR1343,HTM,Up,41902,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR135B,HTM,Down,31760,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29407170
MIR135B,HTM,Up,31760,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,30188754
MIR135B,HTM,Up,31760,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,30188754
MIR138-1,HTM,Down,31524,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0011,29407170
MIR138-2,HTM,Up,31525,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,22180714
MIR139,HTM,Up,31526,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,28440445
MIR139,HTM,Up,31526,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,30188754
MIR139,HTM,Up,31526,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,30188754
MIR139,HTM,Up,31526,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,32661467
MIR141,HTM,Down,31528,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR142,HTM,Up,31529,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0021,21785383
MIR142,HTM,Up,31529,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0021,21785383
MIR142,HTM,Down,31529,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29407170
MIR143,HTM,Down,31530,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay followed by Transcriptomics,0.12,0.0011,22285547
MIR145,HTM,Down,31532,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0032,28580169
MIR145,HTM,Down,31532,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay followed by Transcriptomics and qRT-PCR,0.4,0.0032,22285547
MIR1469,HTM,Up,35378,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0021,23117485
MIR1469,HTM,Up,35378,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR146A,HTM,Up,31533,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0042,23117485
MIR146A,HTM,Up,31533,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29407170
MIR146A,HTM,Up,31533,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,30188754
MIR146A,HTM,Down,31533,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,25117811
MIR147B,HTM,Down,33655,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR148A,HTM,Down,31535,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR148A,HTM,Down,31535,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR148B,HTM,Up,31761,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.24,0.0021,25117811
MIR149,HTM,Up,31536,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,23117485
MIR149,HTM,Up,31536,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
MIR149,HTM,Up,31536,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
MIR149,HTM,Up,31536,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
MIR150,HTM,Up,31537,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR151A,HTM,Up,31762,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29187905
MIR151A,HTM,Up,31762,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0021,29187905
MIR151B,HTM,Up,41588,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,28440445
MIR151B,HTM,Up,41588,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,32661467
MIR154,HTM,Down,31541,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR154,HTM,Down,31541,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR155,HTM,Up,31542,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0053,28440445
MIR155,HTM,Down,31542,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0053,21785383
MIR155,HTM,Down,31542,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0053,21785383
MIR155,HTM,Down,31542,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,25117811
MIR15B,HTM,Up,31544,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0085,28440445
MIR15B,HTM,Down,31544,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0085,21785383
MIR15B,HTM,Down,31544,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0085,23117485
MIR15B,HTM,Down,31544,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0085,26711929
MIR15B,HTM,Up,31544,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0085,25676692
MIR15B,HTM,Down,31544,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0085,21785383
MIR15B,HTM,Up,31544,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0085,29187905
MIR15B,HTM,Up,31544,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0085,29187905
MIR15B,HTM,Up,31544,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0085,25117811
MIR15B,HTM,Up,31544,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0085,32661467
MIR16-1,HTM,Down,31545,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0032,23117485
MIR16-1,HTM,Down,31545,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,26711929
MIR16-1,HTM,Up,31545,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,29187905
MIR16-1,HTM,Up,31545,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0032,29187905
MIR16-2,HTM,Down,31546,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR17,HTM,Down,31547,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,26711929
MIR17,HTM,Down,31547,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,26711929
MIR17,HTM,Up,31547,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR17,HTM,Up,31547,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0032,22180714
MIR17HG,HTM,Down,23564,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MIR181A1,HTM,Down,31590,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31692042
MIR181A1,HTM,Up,31590,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,28440445
MIR181A1,HTM,Up,31590,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,26711929
MIR181A2,HTM,Down,31549,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR181C,HTM,Up,31552,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
MIR181C,HTM,Up,31552,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
MIR181C,HTM,Up,31552,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
MIR181C,HTM,Down,31552,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,30188754
MIR181D,HTM,Down,32089,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,30188754
MIR181d,HTM,Up,32089,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR181D,HTM,Up,32089,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,32661467
MIR182,HTM,Down,31553,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR1825,HTM,Up,35389,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR183,HTM,Down,31554,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR188,HTM,Up,31559,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR18A,HTM,Down,31548,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR18A,HTM,Up,31548,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,30188754
MIR18A,HTM,Up,31548,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.24,0.0021,30188754
MIR18B,HTM,Down,32025,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR1908,HTM,Up,35392,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR191,HTM,Up,31561,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR1910,HTM,Down,35394,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR1910,HTM,Up,35394,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,32661467
MIR1913,HTM,Up,35397,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR1914,HTM,Up,35398,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR1915,HTM,Up,35399,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0021,23117485
MIR1915,HTM,Up,35399,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR193A,HTM,Down,31563,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,26711929
MIR193A,HTM,Up,31563,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0042,22180714
MIR193B,HTM,Down,32087,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR193B,HTM,Down,32087,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR193B,HTM,Up,32087,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR194-1,HTM,Down,31564,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.24,0.0021,23007737
MIR195,HTM,Down,31566,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0032,21785383
MIR195,HTM,Down,31566,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0032,21785383
MIR195,HTM,Down,31566,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,33798550
MIR196A1,HTM,Up,31567,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,32661467
MIR196B,HTM,Up,31790,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR197,HTM,Up,31569,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR197,HTM,Down,31569,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR1972-1,HTM,Down,37060,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR1972-1,HTM,Down,37060,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR1976,HTM,Down,37064,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR198,HTM,Down,31570,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MIR198,HTM,Down,31570,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MIR198,HTM,Down,31570,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MIR199A1,HTM,Up,31571,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,25676692
MIR199A1,HTM,Up,31571,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,25676692
MIR199A1,HTM,Up,31571,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,25676692
MIR199B,HTM,Up,31573,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
MIR199B,HTM,Up,31573,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
MIR199B,HTM,Up,31573,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
MIR199B,HTM,Down,31573,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay followed by Transcriptomics,0.12,0.0021,22285547
MIR19A,HTM,Down,31574,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.48,0.0064,22301433
MIR19A,HTM,Down,31574,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0064,21785383
MIR19A,HTM,Down,31574,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,26711929
MIR19A,HTM,Down,31574,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0064,21785383
MIR19A,HTM,Up,31574,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,30188754
MIR19A,HTM,Up,31574,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.24,0.0064,30188754
MIR19A,HTM,Up,31574,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0064,22180714
MIR19B1,HTM,Down,31575,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,26711929
MIR19B1,HTM,Up,31575,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,29187905
MIR19B1,HTM,Up,31575,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0042,29187905
MIR19B1,HTM,Up,31575,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,25117811
MIR200A,HTM,Down,31578,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,33959615
MIR200A,HTM,Down,31578,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,33959615
MIR200A,HTM,Down,31578,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR200B,HTM,Down,31579,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29407170
MIR200B,HTM,Down,31579,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29407170
MIR200B,HTM,Down,31579,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR200C,HTM,Down,31580,Skin Cancer,NA,D10,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0074,26208390
MIR200C,HTM,Down,31580,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0074,26711929
MIR200C,HTM,Down,31580,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,29407170
MIR200C,HTM,Down,31580,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0074,29187905
MIR200C,HTM,Down,31580,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0074,30188754
MIR200C,HTM,Down,31580,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0074,29187905
MIR200C,HTM,Up,31580,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0074,25117811
MIR202,HTM,Down,32080,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR203A,HTM,Up,31581,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR204,HTM,Down,31582,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR204,HTM,Down,31582,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR205,HTM,Up,31583,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31692042
MIR205,HTM,Down,31583,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MIR205,HTM,Down,31583,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MIR205,HTM,Down,31583,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MIR205HG,HTM,Down,43562,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MIR208A,HTM,Up,31585,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,33959615
MIR208A,HTM,Up,31585,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,33959615
MIR20A,HTM,Down,31577,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,26711929
MIR20A,HTM,Up,31577,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,29187905
MIR20A,HTM,Up,31577,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0042,29187905
MIR20A,HTM,Up,31577,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0042,22180714
MIR20B,HTM,Down,32024,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0042,22301433
MIR20B,HTM,Down,32024,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0042,23117485
MIR20B,HTM,Down,32024,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,26711929
MIR20B,HTM,Up,32024,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,25117811
MIR21,HTM,Down,31586,Skin Cancer,NA,D10,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0085,26208390
MIR21,HTM,Down,31586,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0085,23117485
MIR21,HTM,Up,31586,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0085,29187905
MIR21,HTM,Up,31586,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0085,29187905
MIR21,HTM,Down,31586,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0085,25117811
MIR210,HTM,Up,31587,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics and RT-PCR   ,0.24,0.0064,22301433
MIR210,HTM,Up,31587,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,26711929
MIR210,HTM,Up,31587,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,25676692
MIR210,HTM,Up,31587,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,25117811
MIR210,HTM,Down,31587,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0064,23007737
MIR211,HTM,Down,31588,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR2114,HTM,Up,37308,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR2116,HTM,Up,37310,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR212,HTM,Up,31589,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29407170
MIR215,HTM,Down,31592,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25676692
MIR217,HTM,Down,31594,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR218-1,HTM,Up,31595,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR22,HTM,Up,31599,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR22,HTM,Up,31599,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR22,HTM,Up,31599,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25676692
MIR221,HTM,Up,31601,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,33959615
MIR221,HTM,Up,31601,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,33959615
MIR221,HTM,Up,31601,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,30188754
MIR221,HTM,Up,31601,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,25117811
MIR221,HTM,Up,31601,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0053,23007737
MIR222,HTM,Up,31602,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,33959615
MIR222,HTM,Up,31602,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,33959615
MIR222,HTM,Up,31602,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR223,HTM,Up,31603,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR224,HTM,Down,31604,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0042,22301433
MIR224,HTM,Down,31604,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29407170
MIR224,HTM,Down,31604,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,29187905
MIR224,HTM,Down,31604,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0042,29187905
MIR224,HTM,Down,31604,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,25117811
MIR2278,HTM,Down,37315,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR22HG,HTM,Down,28219,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MIR22HG,HTM,Down,28219,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MIR2355,HTM,Down,38328,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR2392,HTM,Up,41843,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR23A,HTM,Down,31605,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,22180714
MIR23B,HTM,Down,31606,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0032,23117485
MIR23B,HTM,Up,31606,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,29187905
MIR23B,HTM,Down,31606,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,30188754
MIR23B,HTM,Up,31606,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0032,29187905
MIR23C,HTM,Down,38913,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0032,23117485
MIR23C,HTM,Down,38913,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,30188754
MIR23C,HTM,Down,38913,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,33798550
MIR24-1,HTM,Up,31607,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
MIR24-1,HTM,Up,31607,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
MIR2467,HTM,Down,41881,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR2467,HTM,Down,41881,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR25,HTM,Down,31609,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,26711929
MIR26B,HTM,Down,31612,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics and RT-PCR   ,0.24,0.0032,22301433
MIR26B,HTM,Down,31612,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0032,33959615
MIR26B,HTM,Down,31612,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0032,33959615
MIR26B,HTM,Down,31612,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,33959615
MIR26B,HTM,Down,31612,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,33959615
MIR26B,HTM,Up,31612,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,29187905
MIR26B,HTM,Up,31612,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0032,29187905
MIR27A,HTM,Down,31613,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31692042
MIR27A,HTM,Down,31613,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0053,22301433
MIR27A,HTM,Down,31613,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0053,23117485
MIR27A,HTM,Up,31613,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,30188754
MIR27A,HTM,Up,31613,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.24,0.0053,29187905
MIR27A,HTM,Up,31613,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.24,0.0053,30188754
MIR27A,HTM,Up,31613,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.24,0.0053,30188754
MIR27A,HTM,Up,31613,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0053,29187905
MIR27B,HTM,Down,31614,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0021,22301433
MIR27B,HTM,Up,31614,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29187905
MIR27B,HTM,Up,31614,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0021,29187905
MIR2861,HTM,Up,38221,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0032,23117485
MIR2861,HTM,Up,38221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR299,HTM,Up,31618,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0011,29407170
MIR29A,HTM,Down,31616,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0053,21785383
MIR29A,HTM,Down,31616,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0053,21785383
MIR29A,HTM,Up,31616,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics and RT-PCR,0.24,0.0053,29187905
MIR29A,HTM,Up,31616,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.24,0.0053,30188754
MIR29A,HTM,Up,31616,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.24,0.0053,30188754
MIR29A,HTM,Up,31616,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0053,29187905
MIR29A,HTM,Down,31616,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,25117811
MIR29A,HTM,Up,31616,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0053,23007737
MIR29B1,HTM,Down,31619,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0064,22301433
MIR29B1,HTM,Down,31619,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0064,21785383
MIR29B1,HTM,Down,31619,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0064,21785383
MIR29B1,HTM,Up,31619,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,29187905
MIR29B1,HTM,Up,31619,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0064,29187905
MIR29B1,HTM,Down,31619,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,25117811
MIR29B1,HTM,Up,31619,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,25117811
MIR29B1,HTM,Up,31619,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.24,0.0064,23007737
MIR29B2,HTM,Down,31620,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31692042
MIR29C,HTM,Down,31621,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31692042
MIR29C,HTM,Up,31621,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
MIR29C,HTM,Up,31621,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
MIR29C,HTM,Up,31621,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
MIR29C,HTM,Up,31621,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0032,22180714
MIR301A,HTM,Down,31622,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,26711929
MIR301A,HTM,Down,31622,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR301A,HTM,Up,31622,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0032,22180714
MIR301B,HTM,Down,33667,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR302d,HTM,Down,31765,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR302d,HTM,Down,31765,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR3065,HTM,Down,38234,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR3065,HTM,Down,38234,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR3065,HTM,Up,38234,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR30A,HTM,Down,31624,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.2,0.0085,31692042
MIR30A,HTM,Down,31624,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.2,0.0085,31692042
MIR30A,HTM,Down,31624,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0085,26711929
MIR30A,HTM,Up,31624,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0085,29187905
MIR30A,HTM,Up,31624,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0085,29187905
MIR30A,HTM,Down,31624,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0085,25117811
MIR30A,HTM,Up,31624,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0085,32661467
MIR30A,HTM,Up,31624,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0085,32661467
MIR30B,HTM,Down,31625,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31692042
MIR30B,HTM,Down,31625,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31692042
MIR30B,HTM,Down,31625,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0053,22301433
MIR30B,HTM,Down,31625,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,23117485
MIR30B,HTM,Up,31625,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,32661467
MIR30C1,HTM,Down,31626,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0042,23117485
MIR30C1,HTM,Up,31626,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,32661467
MIR30C2,HTM,Down,31627,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31692042
MIR30D,HTM,Down,31628,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31692042
MIR30D,HTM,Up,31628,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,26711929
MIR30d,HTM,Down,31628,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR30E,HTM,Down,31629,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0032,22301433
MIR30e,HTM,Down,31629,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR30e,HTM,Up,31629,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0032,22180714
MIR31,HTM,Down,31630,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics and RT-PCR   ,0.24,0.0064,22301433
MIR31,HTM,Up,31630,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,25117811
MIR31,HTM,Up,31630,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0064,22180714
MIR31,HTM,Up,31630,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0064,23007737
MIR3116-1,HTM,Down,38200,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR3126,HTM,Down,38225,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR3130-1,HTM,Down,38275,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR3130-1,HTM,Up,38275,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR3131,HTM,Down,38347,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3135B,HTM,Up,41783,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR3141,HTM,Up,38326,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0021,23117485
MIR3141,HTM,Up,38326,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR3145,HTM,Down,38327,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR3147,HTM,Up,38300,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3149,HTM,Down,38251,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR3150B,HTM,Up,38938,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR3154,HTM,Up,38176,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3155B,HTM,Down,50003,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR3158-1,HTM,Down,38196,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR3158-1,HTM,Down,38196,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR3173,HTM,Down,38174,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR3173,HTM,Up,38174,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR3177,HTM,Down,38364,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR3178,HTM,Up,38381,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0021,23117485
MIR3178,HTM,Up,38381,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR3180-1,HTM,Up,38382,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3184,HTM,Up,38182,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3185,HTM,Up,38391,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,28440445
MIR3185,HTM,Up,38391,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0021,23117485
MIR3187,HTM,Up,38319,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR3187,HTM,Up,38319,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR3188,HTM,Down,38226,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3192,HTM,Up,38202,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR3193,HTM,Up,38204,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3194,HTM,Down,38346,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3195,HTM,Up,38250,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR3195,HTM,Up,38250,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR3197,HTM,Up,38366,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR32,HTM,Down,31631,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,26711929
MIR32,HTM,Down,31631,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.24,0.0042,25117811
MIR3200,HTM,Up,38227,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR320A,HTM,Down,31632,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.24,0.0021,28580169
MIR320B,HTM,Down,NA,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0011,28580169
MIR320B1,HTM,Down,35247,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR320D1,HTM,Down,35386,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR323A,HTM,Down,31766,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR324,HTM,Down,31767,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR324,HTM,Up,31767,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR328,HTM,Up,31770,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR330,HTM,Down,31771,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR331,HTM,Down,31772,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR337,HTM,Up,31774,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR338,HTM,Down,31775,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
MIR338,HTM,Down,31775,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
MIR338,HTM,Down,31775,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
MIR338,HTM,Up,31775,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR339,HTM,Up,31776,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR33A,HTM,Up,31634,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR342,HTM,Down,31778,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR342,HTM,Down,31778,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR345,HTM,Down,31779,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR346,HTM,Up,31780,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR34A,HTM,Down,31635,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
MIR34A,HTM,Down,31635,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics and RT-PCR,0.24,0.0011,29187905
MIR34B,HTM,Down,31636,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR34C,HTM,Up,31637,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,33959615
MIR34C,HTM,Up,31637,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,33959615
MIR34C,HTM,Down,31637,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR3605,HTM,Up,38922,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,30188754
MIR3609,HTM,Down,38956,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR361,HTM,Up,31867,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3613,HTM,Up,38964,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,32661467
MIR3615,HTM,Down,38905,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR3615,HTM,Down,38905,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR3619,HTM,Up,38998,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR362,HTM,Up,32022,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29407170
MIR362,HTM,Up,32022,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR3621,HTM,Up,38930,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0021,23117485
MIR3621,HTM,Up,38930,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR3646,HTM,Down,38935,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR3652,HTM,Up,38894,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR365A,HTM,Down,33692,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29407170
MIR365A,HTM,Up,33692,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,29187905
MIR365A,HTM,Up,33692,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0032,29187905
MIR365A,HTM,Up,33692,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0032,23007737
MIR3663,HTM,Down,38958,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
MIR3663,HTM,Down,38958,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
MIR3664,HTM,Down,38899,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR3665,HTM,Up,38939,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3679,HTM,Down,38979,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR3679,HTM,Down,38979,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR3682,HTM,Up,38916,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3688-1,HTM,Down,38986,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR370,HTM,Up,31784,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.24,0.0021,25117811
MIR371A,HTM,Up,31785,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR373,HTM,Up,31787,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR373,HTM,Up,31787,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR374A,HTM,Up,31788,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,22180714
MIR375,HTM,Down,31868,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,25676692
MIR375,HTM,Down,31868,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,25676692
MIR375,HTM,Down,31868,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,25676692
MIR377,HTM,Up,31870,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29407170
MIR378A,HTM,Down,31871,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,26711929
MIR378A,HTM,Down,31871,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,25676692
MIR378A,HTM,Down,31871,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,25676692
MIR378A,HTM,Down,31871,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0053,25676692
MIR378A,HTM,Up,31871,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.24,0.0053,25117811
MIR378A,HTM,Up,31871,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,32661467
MIR378B,HTM,Down,38283,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR378C,HTM,Up,38374,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.24,0.0021,25117811
MIR378D1,HTM,Down,41550,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
MIR378D1,HTM,Down,41550,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
MIR378D1,HTM,Down,41550,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
MIR378D1,HTM,Up,41550,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR378E,HTM,Up,41671,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR378F,HTM,Up,41686,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR378G,HTM,Up,41785,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR378I,HTM,Up,41620,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR379,HTM,Down,31872,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR379,HTM,Down,31872,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR381,HTM,Down,31874,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR384,HTM,Up,31878,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR384,HTM,Up,31878,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR3911,HTM,Up,38962,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,32661467
MIR3912,HTM,Up,38923,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,30188754
MIR3913-1,HTM,Up,38884,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR3917,HTM,Down,38911,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3922,HTM,Down,38895,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR3922,HTM,Up,38895,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR3927,HTM,Down,38901,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR3929,HTM,Down,38945,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29407170
MIR3929,HTM,Up,38945,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR3937,HTM,Up,38970,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3940,HTM,Up,38893,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR3944,HTM,Down,38898,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR3960,HTM,Up,41595,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR409,HTM,Down,32055,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR421,HTM,Down,32793,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR421,HTM,Down,32793,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR421,HTM,Up,32793,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR422A,HTM,Up,31879,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR423,HTM,Down,31880,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,26711929
MIR423,HTM,Up,31880,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR424,HTM,Up,31881,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,28440445
MIR424,HTM,Down,31881,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0064,21785383
MIR424,HTM,Down,31881,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0064,21785383
MIR424,HTM,Down,31881,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,25117811
MIR424,HTM,Up,31881,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,32661467
MIR424,HTM,Up,31881,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0064,22180714
MIR425,HTM,Up,31882,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR425,HTM,Up,31882,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4253,HTM,Up,38231,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR4254,HTM,Down,38193,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR4257,HTM,Up,38312,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR4257,HTM,Up,38312,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4258,HTM,Up,38281,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4259,HTM,Up,38309,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR4261,HTM,Up,38272,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4274,HTM,Up,38194,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR4279,HTM,Up,38195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4281,HTM,Up,38357,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0011,23117485
MIR4284,HTM,Down,38322,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR4284,HTM,Up,38322,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4286,HTM,Up,38186,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,28440445
MIR4286,HTM,Up,38186,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29407170
MIR4286,HTM,Up,38186,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,32661467
MIR4288,HTM,Up,38203,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR429,HTM,Down,13784,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29407170
MIR429,HTM,Up,13784,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,25117811
MIR4319,HTM,Down,38212,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4323,HTM,Down,38394,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR4327,HTM,Up,38355,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR4417,HTM,Down,41535,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,32661467
MIR4428,HTM,Up,41667,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR4428,HTM,Down,41667,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,32661467
MIR4428,HTM,Up,41667,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0032,23007737
MIR4435-1,HTM,Down,41713,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR4436B1,HTM,Up,41587,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR4443,HTM,Up,41830,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR4443,HTM,Up,41830,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29187905
MIR4443,HTM,Up,41830,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0021,29187905
MIR4446,HTM,Up,41700,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR4448,HTM,Up,41604,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR4451,HTM,Up,41858,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR4455,HTM,Up,41536,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR4455,HTM,Down,41536,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4463,HTM,Up,41665,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR4463,HTM,Up,41665,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4465,HTM,Down,41842,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR4465,HTM,Up,41842,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4466,HTM,Up,41726,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4467,HTM,Up,41896,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4470,HTM,Down,41833,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR4470,HTM,Down,41833,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR4474,HTM,Down,41821,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR4476,HTM,Up,41793,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR448,HTM,Down,26069,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR448,HTM,Down,26069,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR4484,HTM,Up,41799,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4485,HTM,Up,41628,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4485,HTM,Down,41628,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,33798550
MIR4487,HTM,Down,41851,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR4487,HTM,Down,41851,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,33798550
MIR4487,HTM,Up,41851,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0032,23007737
MIR4488,HTM,Up,41599,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR4488,HTM,Up,41599,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4492,HTM,Up,41563,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4492,HTM,Down,41563,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,32661467
MIR4497,HTM,Up,41737,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4499,HTM,Up,41739,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR449A,HTM,Down,27645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR449B,HTM,Down,32794,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR449B,HTM,Down,32794,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0032,23007737
MIR449C,HTM,Down,37302,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR4508,HTM,Up,41659,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR450B,HTM,Down,33642,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,25676692
MIR450B,HTM,Down,33642,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,25676692
MIR450B,HTM,Down,33642,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,25676692
MIR4516,HTM,Up,41617,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR4516,HTM,Up,41617,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR451A,HTM,Down,32053,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29407170
MIR451A,HTM,Down,32053,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0021,28580169
MIR452,HTM,Down,32054,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29407170
MIR452,HTM,Down,32054,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR4521,HTM,Down,41813,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29407170
MIR4521,HTM,Down,41813,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,30188754
MIR4521,HTM,Up,41813,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0032,23007737
MIR4524A,HTM,Down,41771,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR4529,HTM,Down,41703,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,33798550
MIR4530,HTM,Up,41764,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29187905
MIR4530,HTM,Up,41764,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0021,29187905
MIR4530,HTM,Up,41764,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4535,HTM,Up,41629,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR455,HTM,Down,32344,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR455,HTM,Down,32344,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR4638,HTM,Up,41841,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4645,HTM,Up,41689,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR4646,HTM,Up,41543,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4649,HTM,Up,41852,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,28440445
MIR4649,HTM,Up,41852,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,32661467
MIR4651,HTM,Up,41647,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR4655,HTM,Up,41754,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4656,HTM,Up,41749,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR4659A,HTM,Down,41857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR4661,HTM,Down,41582,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR4665,HTM,Down,41696,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,30188754
MIR4665,HTM,Up,41696,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR4665,HTM,Down,41696,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,32661467
MIR4669,HTM,Up,41558,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4674,HTM,Up,41729,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4675,HTM,Up,41619,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4676,HTM,Down,41691,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR4685,HTM,Down,41802,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4685,HTM,Up,41802,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4687,HTM,Up,41712,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4687,HTM,Up,41712,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4688,HTM,Down,41897,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29407170
MIR4688,HTM,Up,41897,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR4689,HTM,Up,41895,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4697,HTM,Up,41570,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR4697,HTM,Up,41570,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4701,HTM,Down,41627,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR4706,HTM,Down,41576,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4706,HTM,Down,41576,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,32661467
MIR4707,HTM,Up,41531,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4713,HTM,Up,41899,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4716,HTM,Up,41812,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4721,HTM,Up,41609,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4722,HTM,Down,41782,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR4725,HTM,Up,41608,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4725,HTM,Down,41608,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR4728,HTM,Up,41632,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR4728,HTM,Down,41632,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR4731,HTM,Up,41597,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR4731,HTM,Down,41597,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4732,HTM,Up,41639,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4739,HTM,Up,41801,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR4739,HTM,Up,41801,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4741,HTM,Down,41661,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,32661467
MIR4741,HTM,Up,41661,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR4745,HTM,Up,41868,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4749,HTM,Up,41760,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR4749,HTM,Up,41760,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,32661467
MIR4750,HTM,Up,41765,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4758,HTM,Up,41836,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4763,HTM,Up,41677,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR4763,HTM,Down,41677,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR4769,HTM,Down,41694,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR4778,HTM,Up,41648,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR4783,HTM,Up,41874,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4784,HTM,Up,41580,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR4787,HTM,Up,41653,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4787,HTM,Up,41653,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR4788,HTM,Up,41676,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR4791,HTM,Down,41704,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR4800,HTM,Up,41877,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR483,HTM,Up,32340,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics,0.04,0.0053,23117485
MIR483,HTM,Up,32340,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,26711929
MIR483,HTM,Up,32340,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,25117811
MIR484,HTM,Down,32341,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR485,HTM,Up,32067,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR485,HTM,Up,32067,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR486-1,HTM,Down,32342,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,29407170
MIR486-1,HTM,Up,32342,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,30188754
MIR486-1,HTM,Up,32342,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,30188754
MIR486-1,HTM,Up,32342,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.24,0.0053,25117811
MIR486-1,HTM,Up,32342,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0053,23007737
MIR487A,HTM,Up,32343,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR487B,HTM,Up,32533,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29407170
MIR487B,HTM,Down,32533,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR487B,HTM,Up,32533,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0032,22180714
MIR489,HTM,Up,32074,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR489,HTM,Up,32074,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR491,HTM,Down,32076,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR493,HTM,Up,32082,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,22180714
MIR494,HTM,Up,32084,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,29187905
MIR494,HTM,Up,32084,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0032,29187905
MIR494,HTM,Down,32084,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,33798550
MIR497,HTM,Down,32088,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0053,31692042
MIR497,HTM,Down,32088,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0053,21785383
MIR497,HTM,Down,32088,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0053,21785383
MIR497,HTM,Down,32088,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0053,22180714
MIR498,HTM,Up,32092,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR498,HTM,Up,32092,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR499A,HTM,Up,32133,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR5000,HTM,Down,43464,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR5006,HTM,Up,43495,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR500A,HTM,Down,32134,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR500A,HTM,Up,32134,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR500B,HTM,Up,38223,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR501,HTM,Up,32135,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,33959615
MIR501,HTM,Up,32135,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,33959615
MIR5010,HTM,Up,43484,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR504,HTM,Down,32139,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,33959615
MIR504,HTM,Down,32139,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,33959615
MIR512-1,HTM,Down,32090,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR512-1,HTM,Down,32090,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR513C,HTM,Up,33934,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR516A1,HTM,Down,32130,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR517B,HTM,Down,32115,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR517B,HTM,Down,32115,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR518B,HTM,Down,32106,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR518e,HTM,Down,32119,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR518e,HTM,Down,32119,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR5194,HTM,Up,43498,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR519A1,HTM,Up,32128,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,22180714
MIR522,HTM,Up,32127,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,22180714
MIR524,HTM,Down,32110,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,22180714
MIR526B,HTM,Up,32100,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR526B,HTM,Up,32100,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR532,HTM,Up,32795,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR532,HTM,Up,32795,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR542,HTM,Up,32534,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,22180714
MIR548AC,HTM,Up,41626,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR548Ad,HTM,Down,41683,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR548Ad,HTM,Down,41683,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR548Ah,HTM,Down,41605,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR548Ap,HTM,Down,43465,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR548AP,HTM,Down,43465,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR548H1,HTM,Up,35342,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR548l,HTM,Up,35292,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR548l,HTM,Up,35292,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR548y,HTM,Down,38980,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR548y,HTM,Down,38980,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR549A,HTM,Up,32803,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0021,21785383
MIR549A,HTM,Up,32803,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0021,21785383
MIR549A,HTM,Down,32803,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR551A,HTM,Up,32806,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR551A,HTM,Up,32806,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR557,HTM,Down,32813,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR5582,HTM,Down,43461,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR559,HTM,Up,32815,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR559,HTM,Up,32815,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR561,HTM,Down,32817,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,22180714
MIR573,HTM,Down,32829,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR5739,HTM,Down,49977,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,32661467
MIR574,HTM,Up,32830,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,26711929
MIR574,HTM,Up,32830,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29407170
MIR574,HTM,Down,32830,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0032,23007737
MIR575,HTM,Down,32831,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR575,HTM,Down,32831,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR582,HTM,Down,32838,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.2,0.0064,22301433
MIR582,HTM,Down,32838,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,26711929
MIR582,HTM,Up,32838,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,29407170
MIR582,HTM,Up,32838,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0064,22180714
MIR584,HTM,Up,32840,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR584,HTM,Up,32840,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR584,HTM,Up,32840,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,22180714
MIR590,HTM,Up,32846,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR590,HTM,Up,32846,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,22180714
MIR593,HTM,Up,32849,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR599,HTM,Down,32855,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR599,HTM,Down,32855,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR600HG,HTM,Down,23642,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MIR6087,HTM,Up,50045,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
MIR6087,HTM,Up,50045,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
MIR6088,HTM,Up,50164,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
MIR6088,HTM,Up,50164,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
MIR6126,HTM,Down,50099,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,32661467
MIR614,HTM,Down,32870,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MIR614,HTM,Down,32870,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MIR614,HTM,Up,32870,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR615,HTM,Down,32871,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR616,HTM,Up,32872,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR622,HTM,Up,32878,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MIR622,HTM,Up,32878,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MIR622,HTM,Down,32878,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR624,HTM,Up,32880,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR625,HTM,Down,32881,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR625,HTM,Down,32881,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR627,HTM,Up,32883,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR629,HTM,Up,32885,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR630,HTM,Up,32886,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR630,HTM,Up,32886,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR641,HTM,Up,32897,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR641,HTM,Up,32897,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR642B,HTM,Up,38902,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR645,HTM,Down,32901,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR645,HTM,Down,32901,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics,0.04,0.0011,21785383
MIR6501,HTM,Down,50033,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR6505,HTM,Up,50104,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR6511B1,HTM,Down,50228,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR6516,HTM,Up,50233,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,30188754
MIR652,HTM,Up,32908,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR658,HTM,Up,32914,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR660,HTM,Down,32916,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29407170
MIR660,HTM,Up,32916,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR663A,HTM,Down,32919,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR663A,HTM,Up,32919,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR664B,HTM,Down,43501,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR664B,HTM,Down,43501,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29407170
MIR665,HTM,Up,33662,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR668,HTM,Down,33135,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,33798550
MIR668,HTM,Down,33135,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,32661467
MIR670,HTM,Down,37304,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR671,HTM,Up,33134,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR6723,HTM,Down,50152,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MIR6732,HTM,Down,50066,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,32661467
MIR6733,HTM,Up,50239,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR675,HTM,Up,33351,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MIR675,HTM,Up,33351,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MIR675,HTM,Down,33351,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,30188754
MIR675,HTM,Up,33351,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR6756,HTM,Down,49974,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR6768,HTM,Down,50264,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,32661467
MIR6788,HTM,Down,50078,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR6794,HTM,Down,50117,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,32661467
MIR6805,HTM,Down,50215,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR6820,HTM,Down,50095,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR708,HTM,Up,33654,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR7-1,HTM,Down,31638,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,30188754
MIR7-1,HTM,Down,31638,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,30188754
MIR7-1,HTM,Up,31638,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,25117811
MIR7-1,HTM,Down,31638,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0042,28580169
MIR7-1,HTM,Up,31638,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0042,23007737
MIR7110,HTM,Up,50024,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR7110,HTM,Down,50024,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,32661467
MIR7154,HTM,Down,49972,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,32661467
MIR718,HTM,Up,37317,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR720,HTM,Up,NA,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR7-3HG,HTM,Down,30049,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0011,28580169
MIR760,HTM,Down,33666,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,25676692
MIR760,HTM,Down,33666,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,25676692
MIR760,HTM,Down,33666,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,25676692
MIR762,HTM,Up,37303,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR7641-1,HTM,Up,49995,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR766,HTM,Up,33139,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR766,HTM,Down,33139,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,23007737
MIR7704,HTM,Down,50089,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR7704,HTM,Up,50089,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR7705,HTM,Up,50143,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,30188754
MIR8073,HTM,Down,50131,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,32661467
MIR8075,HTM,Down,50172,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,33798550
MIR873,HTM,Down,33663,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR874,HTM,Up,33643,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR874,HTM,Up,33643,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0021,22180714
MIR876,HTM,Up,33653,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,22180714
MIR877,HTM,Down,33660,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR877,HTM,Up,33660,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR885,HTM,Up,33659,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,23007737
MIR887,HTM,Up,33661,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR9-1,HTM,Down,31641,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR9-1,HTM,Down,31641,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR920,HTM,Down,33670,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR921,HTM,Down,33671,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR92A1,HTM,Down,31643,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR92B,HTM,Up,32920,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
MIR93,HTM,Down,31645,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,26711929
MIR93,HTM,Down,31645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0032,28580169
MIR93,HTM,Down,31645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0032,28580169
MIR936,HTM,Down,33679,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR939,HTM,Down,33682,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,30188754
MIR939,HTM,Down,33682,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR9-3HG,HTM,Up,27388,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MIR940,HTM,Down,33683,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MIR940,HTM,Down,33683,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MIR940,HTM,Up,33683,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIR942,HTM,Up,33688,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29407170
MIR944,HTM,Down,33690,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
MIR944,HTM,Down,33690,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29407170
MIR95,HTM,Down,31647,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,26711929
MIR96,HTM,Down,31648,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,25117811
MIR96,HTM,Up,31648,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0032,22180714
MIR98,HTM,Down,31649,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0021,28580169
MIRLET7A1,HTM,Down,31476,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0032,22301433
MIRLET7A1,HTM,Down,31476,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0032,28580169
MIRLET7A1,HTM,Down,31476,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0032,28580169
MIRLET7A2,HTM,Down,31477,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0011,26351321
MIRLET7B,HTM,Down,31479,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,23117485
MIRLET7B,HTM,Down,31479,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,29187905
MIRLET7B,HTM,Down,31479,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0042,29187905
MIRLET7B,HTM,Down,31479,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0042,28580169
MIRLET7B,HTM,Down,31479,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0042,28580169
MIRLET7B,HTM,Down,31479,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay followed by Transcriptomics,0.12,0.0042,22285547
MIRLET7C,HTM,Down,31480,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics and RT-PCR   ,0.24,0.0042,22301433
MIRLET7C,HTM,Down,31480,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0042,28580169
MIRLET7C,HTM,Down,31480,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0042,28580169
MIRLET7C,HTM,Down,31480,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay followed by Transcriptomics,0.12,0.0042,22285547
MIRLET7D,HTM,Down,31481,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0021,22301433
MIRLET7D,HTM,Down,31481,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0021,28580169
MIRLET7D,HTM,Down,31481,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0021,28580169
MIRLET7E,HTM,Down,31482,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics and RT-PCR   ,0.24,0.0032,22301433
MIRLET7E,HTM,Down,31482,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0032,28580169
MIRLET7E,HTM,Down,31482,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0032,28580169
MIRLET7F1,HTM,Down,31483,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.2,0.0053,31692042
MIRLET7F1,HTM,Up,31483,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,25117811
MIRLET7F1,HTM,Down,31483,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0053,28580169
MIRLET7F1,HTM,Down,31483,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0053,28580169
MIRLET7F2,HTM,Down,31484,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0021,22301433
MIRLET7F2,HTM,Down,31484,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0021,28580169
MIRLET7G,HTM,Down,31485,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.2,0.0032,22301433
MIRLET7G,HTM,Down,31485,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0032,28580169
MIRLET7G,HTM,Down,31485,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0032,28580169
MIRLET7I,HTM,Up,31486,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
MIRLET7I,HTM,Down,31486,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0021,28580169
MIRLET7I,HTM,Down,31486,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics,0.04,0.0021,28580169
MIS18A,HTM,Down,1286,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
MISP,HTM,Down,27000,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MITF,HTM,Up,7105,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MITF,HTM,Down,7105,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MIX23,HTM,Up,31136,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MIX23,HTM,Up,31136,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MIX23,HTM,Up,31136,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MKI67,HTM,Down,7107,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.24,0.0021,31289135
MKI67,HTM,Down,7107,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
MKKS,HTM,Down,7108,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MKKS,HTM,Down,7108,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MKNK2,HTM,Down,7111,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,27965308
MLANA,HTM,Down,7124,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MLKL,HTM,Down,26617,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MLKL,HTM,Up,26617,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
MLLT10,HTM,Up,16063,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
MLLT10,HTM,Down,16063,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
MLLT11,HTM,Up,16997,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MLLT3,HTM,Down,7136,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
MLLT3,HTM,Up,7136,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MLLT3,HTM,Up,7136,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MLLT3,HTM,Down,7136,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MLPH,HTM,Up,29643,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MLXIP,HTM,Down,17055,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
MLXIP,HTM,Down,17055,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MLXIP,HTM,Up,17055,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
MLYCD,HTM,Down,7150,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MMAA,HTM,Down,18871,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MMAA,HTM,Up,18871,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
MMD,HTM,Up,7153,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MMD,HTM,Up,7153,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MMD,HTM,Down,7153,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
MMD,HTM,Down,7153,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
MME,HTM,NA,7154,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.12,0.0053,20630067
MME,HTM,Up,7154,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
MMP1,HTM,Down,7155,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MMP1,HTM,Down,7155,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MMP1,HTM,Down,7155,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MMP1,HTM,Down,7155,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
MMP1,HTM,Down,7155,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
MMP10,HTM,Down,7156,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MMP10,HTM,Down,7156,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MMP10,HTM,Down,7156,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MMP14,HTM,Up,7160,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,35229723
MMP14,HTM,Down,7160,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MMP14,HTM,Down,7160,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MMP14,HTM,Down,7160,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MMP16,HTM,Up,7162,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MMP2,HTM,Down,7166,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MMP2,HTM,Down,7166,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MMP2,HTM,Up,7166,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MMP2,HTM,Up,7166,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MMP23B,HTM,Up,7171,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MMP23B,HTM,Up,7171,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MMP23B,HTM,Up,7171,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MMP24-AS1,HTM,Down,NA,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MMP25,HTM,Up,14246,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MMP25,HTM,Up,14246,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MMP25,HTM,Up,14246,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MMP25-AS1,HTM,Down,51372,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MMP25-AS1,HTM,Down,51372,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MMP28,HTM,Up,14366,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0011,28927099
MMP7,HTM,Down,7174,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22740085
MMP7,HTM,Up,7174,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,35229723
MMP7,HTM,Up,7174,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0042,17932721
MMP7,HTM,Down,7174,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
MMP9,HTM,Up,7176,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0021,28927099
MMRN1,HTM,Up,7178,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MN1,HTM,Up,7180,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MND1,HTM,Up,24839,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MND1,HTM,Up,24839,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MND1,HTM,Up,24839,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MNS1,HTM,Up,29636,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MOB3B,HTM,Down,23825,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MOB3B,HTM,Down,23825,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MOB4,HTM,Up,17261,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
MOCS1,HTM,Down,7190,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
MOGS,HTM,Up,24862,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
MOGS,HTM,Up,24862,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MOGS,HTM,Up,24862,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MOGS,HTM,Up,24862,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
MOGS,HTM,Up,24862,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
MON2,HTM,Up,29177,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
MORC3,HTM,Down,23572,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MORC3,HTM,Down,23572,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MORC3,HTM,Down,23572,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MORC4,HTM,Up,23485,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MORC4,HTM,Up,23485,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MORC4,HTM,Up,23485,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MORC4,HTM,Up,23485,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MORN2,HTM,Down,30166,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MOSMO,HTM,Up,27087,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
MOSPD3,HTM,Down,25078,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MOSPD3,HTM,Down,25078,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MOXD1,HTM,Down,21063,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MOXD1,HTM,Down,21063,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MPC1,HTM,Down,21606,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MPHOSPH6,HTM,Up,7214,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MPHOSPH6,HTM,Up,7214,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MPHOSPH6,HTM,Up,7214,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MPHOSPH8,HTM,Up,29810,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
MPHOSPH9,HTM,Up,7215,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MPI,HTM,Down,7216,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
MPI,HTM,Up,7216,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MPI,HTM,Up,7216,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MPI,HTM,Up,7216,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MPI,HTM,Up,7216,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MPI,HTM,Up,7216,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MPP1,HTM,Up,7219,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MPP1,HTM,Up,7219,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MPP2,HTM,Down,7220,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MPP7,HTM,Down,26542,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MPP7,HTM,Up,26542,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MPP7,HTM,Up,26542,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MPP7,HTM,Down,26542,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
MPP7,HTM,Down,26542,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MPP7,HTM,Up,26542,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MPV17,HTM,Up,7224,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MPV17,HTM,Up,7224,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MPV17,HTM,Up,7224,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MPZL2,HTM,Down,3496,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
MPZL2,HTM,Down,3496,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
MPZL2,HTM,Down,3496,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
MPZL2,HTM,Down,3496,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
MPZL2,HTM,Down,3496,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
MPZL2,HTM,Down,3496,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
MPZL2,HTM,Up,3496,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
MPZL2,HTM,Up,3496,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
MPZL2,HTM,Down,3496,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0064,34414448
MPZL3,HTM,Up,27279,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
MPZL3,HTM,Down,27279,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MR1,HTM,Down,4975,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MRAS,HTM,Down,7227,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
MRAS,HTM,Down,7227,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
MRC2,HTM,Up,16875,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MREG,HTM,Down,25478,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MREG,HTM,Down,25478,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MREG,HTM,Down,25478,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
MROH1,HTM,Down,26958,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MROH1,HTM,Down,26958,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MROH1,HTM,Down,26958,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MROH6,HTM,Down,27814,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MRPL11,HTM,Down,14042,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MRPL12,HTM,Down,10378,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MRPL12,HTM,Down,10378,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MRPL12,HTM,Down,10378,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MRPL2,HTM,Up,14056,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
MRPL28,HTM,Down,14484,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
MRPL30,HTM,Up,14036,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MRPL33,HTM,Up,14487,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MRPL33,HTM,Up,14487,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MRPL33,HTM,Up,14487,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MRPL33,HTM,Up,14487,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MRPL38,HTM,Down,14033,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MRPL4,HTM,Down,14276,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MRPL41,HTM,Up,14492,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL41,HTM,Up,14492,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL41,HTM,Up,14492,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL41,HTM,Up,14492,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL41,HTM,Up,14492,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL42,HTM,Up,14493,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL42,HTM,Up,14493,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL42,HTM,Up,14493,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL42,HTM,Up,14493,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL42,HTM,Up,14493,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL44,HTM,Down,16650,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
MRPL47,HTM,Up,16652,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
MRPL47,HTM,Up,16652,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MRPL47,HTM,Up,16652,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MRPL47,HTM,Up,16652,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
MRPL47,HTM,Up,16652,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
MRPL47,HTM,Up,16652,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
MRPL47,HTM,Up,16652,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
MRPL47,HTM,Up,16652,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MRPL48,HTM,Up,16653,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MRPL48,HTM,Up,16653,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MRPL48,HTM,Up,16653,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MRPL49,HTM,Up,1176,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MRPL49,HTM,Up,1176,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MRPL50,HTM,Up,16654,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MRPL51,HTM,Up,14044,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
MRPL54,HTM,Up,16685,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL54,HTM,Up,16685,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL54,HTM,Up,16685,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL54,HTM,Up,16685,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPL54,HTM,Up,16685,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPS14,HTM,Down,14049,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
MRPS18B,HTM,Up,14516,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
MRPS23,HTM,Up,14509,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPS23,HTM,Up,14509,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPS23,HTM,Up,14509,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPS23,HTM,Up,14509,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPS23,HTM,Up,14509,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
MRPS25,HTM,Up,14511,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
MRPS27,HTM,Up,14512,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
MRPS27,HTM,Down,14512,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
MRPS27,HTM,Up,14512,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
MRPS35,HTM,Up,16635,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MRTFA,HTM,Down,14334,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MS4A14,HTM,Down,30706,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MS4A2,HTM,Down,7316,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
MSANTD3,HTM,Down,23370,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MSANTD3-TMEFF1,HTM,Down,38838,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MSH2,HTM,Up,7325,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Transcriptomics followed by Western Blotting,0.32,0.0021,24440048
MSH3,HTM,Down,7326,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MSH3,HTM,Down,7326,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MSH3,HTM,Down,7326,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MSH3,HTM,Down,7326,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MSH5,HTM,Down,7328,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MSL1,HTM,Up,27905,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
MSL1,HTM,Up,27905,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
MSL1,HTM,Down,27905,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
MSL3P1,HTM,Up,17837,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MSL3P1,HTM,Down,17837,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MSLN,HTM,Down,7371,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MSLN,HTM,Down,7371,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
MSMB,HTM,Up,7372,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MSMB,HTM,Up,7372,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MSMB,HTM,Up,7372,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MSMO1,HTM,Down,10545,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MSMO1,HTM,Down,10545,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MSMO1,HTM,Up,10545,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
MSN,HTM,Up,7373,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
MSN,HTM,Down,7373,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MSN,HTM,Up,7373,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
MSN,HTM,Up,7373,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
MSRB3,HTM,Up,27375,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MSRB3,HTM,Up,27375,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MSRB3,HTM,Up,27375,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MSRB3,HTM,Up,27375,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MST1,HTM,Up,7380,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,35229723
MST1,HTM,Down,7380,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
MST1,HTM,Down,7380,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
MST1L,HTM,Down,7390,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MST1L,HTM,Down,7390,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MST1P2,HTM,Down,7383,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MST1P2,HTM,Down,7383,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MST1R,HTM,Down,7381,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MST1R,HTM,Down,7381,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MST1R,HTM,Down,7381,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MSTO2P,HTM,Up,26329,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MSX1,HTM,NA,7391,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
MT1DP,HTM,Down,7396,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MT1DP,HTM,Down,7396,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MT1DP,HTM,Down,7396,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MT1E,HTM,Down,7397,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MT1E,HTM,Down,7397,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MT1E,HTM,Down,7397,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MT1F,HTM,Down,7398,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT1F,HTM,Down,7398,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT1F,HTM,Down,7398,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MT1G,HTM,Down,7399,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MT1G,HTM,Down,7399,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MT1G,HTM,Down,7399,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MT1L,HTM,Down,7404,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT1L,HTM,Down,7404,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT1L,HTM,Down,7404,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT1L,HTM,Down,7404,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MT1M,HTM,Up,14296,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
MT1P3,HTM,Down,16120,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MT1P3,HTM,Down,16120,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MT1P3,HTM,Down,16120,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MT1X,HTM,Up,7405,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
MT1X,HTM,Down,7405,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
MT1X,HTM,Down,7405,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
MT1X,HTM,Down,7405,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
MT1X,HTM,Down,7405,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
MT1X,HTM,Down,7405,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
MT2A,HTM,Down,7406,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT2A,HTM,Down,7406,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT2A,HTM,Down,7406,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT2A,HTM,Down,7406,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT2A,HTM,Down,7406,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT2A,HTM,Down,7406,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT2A,HTM,Down,7406,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT2A,HTM,Down,7406,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT2A,HTM,Down,7406,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MT2A,HTM,Up,7406,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
MTAP,HTM,Down,7413,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MTAP,HTM,Down,7413,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MTAP,HTM,Down,7413,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MTAP,HTM,Up,7413,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
MTCH2,HTM,Up,17587,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
MT-CO2,HTM,Up,7421,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
MT-CO2,HTM,Down,7421,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
MTERF4,HTM,Down,28785,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
MTERF4,HTM,Up,28785,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
MTERFD3,HTM,Down,30779,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MTERFD3,HTM,Down,30779,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MTFP1,HTM,Down,26945,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MTHFD1,HTM,Down,7432,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MTHFD1,HTM,Down,7432,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MTHFD1,HTM,Up,7432,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
MTHFD1,HTM,Up,7432,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
MTHFD1L,HTM,Down,21055,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MTHFD2,HTM,Up,7434,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MTHFD2,HTM,Up,7434,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MTHFD2,HTM,Up,7434,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MTHFD2L,HTM,Up,31865,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MTMR10,HTM,Down,25999,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MTMR9,HTM,Down,14596,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MT-ND1,HTM,Up,7455,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
MTRF1,HTM,Up,7469,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MTRF1L,HTM,Down,21051,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
MTRNR2L2,HTM,Down,37156,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MTSS1,HTM,Down,20443,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
MTSS1,HTM,Down,20443,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
MTSS1,HTM,Down,20443,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
MTSS1,HTM,Up,20443,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
MTSS1,HTM,Down,20443,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
MTSS1,HTM,Up,20443,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0042,17932721
MTSS1,HTM,Down,20443,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
MT-TE,HTM,Down,7479,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MT-TL1,HTM,Down,7490,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MT-TS1,HTM,Down,7497,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MT-TT,HTM,Down,7499,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MT-TY,HTM,Down,7502,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MTUS1,HTM,Down,29789,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
MTUS1,HTM,Up,29789,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MTUS1,HTM,Up,29789,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MTUS1,HTM,Down,29789,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MUC1,HTM,Down,7508,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,29352988
MUC1,HTM,Down,7508,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0042,29352988
MUC1,HTM,Down,7508,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
MUC1,HTM,Down,7508,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31729259
MUC1,HTM,Down,7508,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31729259
MUC13,HTM,Down,7511,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
MUC13,HTM,Up,7511,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
MUC13,HTM,Up,7511,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
MUC13,HTM,Up,7511,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
MUC13,HTM,Up,7511,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
MUC13,HTM,Up,7511,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
MUC13,HTM,Down,7511,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0053,22954703
MUC13,HTM,Up,7511,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0053,22954703
MUC15,HTM,Up,14956,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
MUC15,HTM,Up,14956,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
MUC16,HTM,Down,15582,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
MUC16,HTM,Down,15582,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MUC16,HTM,Down,15582,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
MUC2,HTM,Down,7512,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MUC4,HTM,Down,7514,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
MUC4,HTM,Up,7514,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MUC4,HTM,Up,7514,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MUC5AC,HTM,Up,7515,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
MUC5B,HTM,Up,7516,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
MUC5B,HTM,Up,7516,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
MUC5B,HTM,Up,7516,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MUC5B,HTM,Up,7516,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MVD,HTM,Up,7529,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,25676692
MVD,HTM,Up,7529,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.24,0.0042,26259570
MVD,HTM,Up,7529,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.24,0.0042,26259570
MVD,HTM,Up,7529,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
MVD,HTM,Down,7529,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
MVP,HTM,Up,7531,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
MVP,HTM,Up,7531,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
MVP,HTM,Up,7531,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
MVP,HTM,Up,7531,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
MVP,HTM,Down,7531,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
MVP,HTM,Up,7531,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
MVP,HTM,Up,7531,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
MVP,HTM,Up,7531,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
MX1,HTM,Down,7532,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MX1,HTM,Up,7532,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MX1,HTM,Up,7532,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MX1,HTM,Up,7532,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
MX2,HTM,Up,7533,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MX2,HTM,Up,7533,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MXD1,HTM,Up,6761,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0021,19451087
MXD1,HTM,Up,6761,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MXD1,HTM,Up,6761,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MXD1,HTM,Up,6761,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MXI1,HTM,Up,7534,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MYADM,HTM,Down,7544,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MYB,HTM,Up,7545,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MYB,HTM,Down,7545,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MYBBP1A,HTM,Down,1689,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
MYBBP1A,HTM,Down,7546,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
MYBBP1A,HTM,Up,7546,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
MYBBP1A,HTM,Up,7546,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
MYBL1,HTM,Down,7547,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MYBL2,HTM,Down,7548,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MYBL2,HTM,Down,7548,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
MYBL21,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MYBL21,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MYBL21,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
MYC,HTM,Down,7553,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.28,0.1304,29352988
MYC,HTM,Down,7553,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.28,0.1304,29352988
MYC,HTM,Up,7553,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.12,0.1304,20424609
MYC,HTM,Up,7553,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.6,0.1304,27520449
MYC,HTM,Down,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.48,0.1304,34680485
MYC,HTM,Down,7553,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.1304,29340052
MYC,HTM,Up,7553,Breast Cancer,NA,Primary,NA,Transcriptomics,0.36,0.1304,30559934
MYCL,HTM,Up,7555,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.04,0.0021,27520449
MYCL,HTM,Down,7555,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MYCN,HTM,Up,7559,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,21826669
MYCN,HTM,Up,7559,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
MYCT1,HTM,Up,23172,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
MYEF2,HTM,Up,17940,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MYEF2,HTM,Up,17940,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MYEF2,HTM,Up,17940,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
MYEOV,HTM,Up,7563,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MYEOV,HTM,Up,7563,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MYH10,HTM,Down,7568,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MYH10,HTM,Up,7568,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
MYH11,HTM,Down,7569,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MYH14,HTM,Down,23212,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MYH14,HTM,Up,23212,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MYH3,HTM,Down,7573,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
MYH3,HTM,Down,7573,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
MYH3,HTM,Up,7573,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
MYH4,HTM,Up,7574,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
MYH9,HTM,Down,7579,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.4,0.0064,34059086
MYH9,HTM,Down,7579,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.4,0.0064,25881239
MYH9,HTM,Up,7579,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
MYH9,HTM,Up,7579,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
MYH9,HTM,Down,7579,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0064,34168259
MYH9,HTM,Up,7579,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0064,27746256
MYL12A,HTM,Up,16701,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MYL12A,HTM,Up,16701,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
MYL12A,HTM,Down,16701,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
MYL12A,HTM,Up,16701,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
MYL5,HTM,Down,7586,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
MYL5,HTM,Down,7586,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
MYL6,HTM,Up,7587,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MYL6,HTM,Up,7587,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
MYL6,HTM,Up,7587,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
MYL9,HTM,Up,15754,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
MYLIP,HTM,Up,21155,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MYLIP,HTM,Up,21155,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
MYLK,HTM,Up,7590,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MYLK,HTM,Up,7590,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MYLK,HTM,Up,7590,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31729259
MYLK,HTM,Up,7590,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MYLK,HTM,Up,7590,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31729259
MYLK2,HTM,Down,16243,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
MYLK3,HTM,Down,29826,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MYLK3,HTM,Down,29826,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
MYLPF,HTM,Down,29824,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
MYNN,HTM,Up,14955,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
MYO10,HTM,Up,7593,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MYO10,HTM,Down,7593,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
MYO10,HTM,Down,7593,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
MYO15B,HTM,Up,14083,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MYO1B,HTM,Down,7596,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
MYO1B,HTM,Down,7596,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
MYO1B,HTM,Down,7596,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
MYO1B,HTM,Down,7596,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0053,22954703
MYO1B,HTM,Up,7596,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0053,24098529
MYO1D,HTM,Down,7598,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MYO1D,HTM,Down,7598,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MYO1D,HTM,Down,7598,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MYO1D,HTM,Up,7598,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
MYO1E,HTM,Up,7599,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MYO1E,HTM,Up,7599,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MYO3A,HTM,Down,7601,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
MYO5A,HTM,Down,7602,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MYO5B,HTM,Up,7603,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MYO5B,HTM,Down,7603,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
MYO5B,HTM,Up,7603,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
MYO5C,HTM,Down,7604,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MYO5C,HTM,Down,7604,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
MYO6,HTM,Down,7605,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
MYO6,HTM,Down,7605,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
MYO7A,HTM,Up,7606,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
MYO9A,HTM,Down,7608,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
MYO9A,HTM,Up,7608,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
MYO9A,HTM,Up,7608,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MYO9A,HTM,Up,7608,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MYO9A,HTM,Up,7608,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
MYO9A,HTM,Up,7608,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
MYO9A,HTM,Up,7608,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
MYO9B,HTM,NA,7609,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
MYOCD,HTM,Up,16067,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MYOCD,HTM,Up,16067,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
MYOD1,HTM,NA,7611,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0011,20630067
MYOF,HTM,Down,3656,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
MYOF,HTM,Down,3656,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
MYOF,HTM,Down,3656,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
MYORG,HTM,Down,19918,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
MYPN,HTM,Up,23246,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MYPN,HTM,Up,23246,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MYPN,HTM,Down,23246,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
MYPN,HTM,Up,23246,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
MYRF,HTM,Up,1181,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MYRF,HTM,Up,1181,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MYRF,HTM,Up,1181,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
MYZAP,HTM,Down,43444,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
MYZAP,HTM,Down,43444,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
MZF1,HTM,Up,13108,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
MZF1,HTM,Up,13108,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
N4BP1,HTM,Up,29850,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
N4BP1,HTM,Up,29850,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
N4BP1,HTM,Up,29850,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
N4BP2L2-IT2,HTM,Down,25038,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
N4BP2L2-IT2,HTM,Down,25038,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NA11,HTM,Down,28125,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
NAA16,HTM,Down,26164,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
NAALADL1,HTM,Up,23536,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NAALADL1,HTM,Up,23536,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NAALADL2,HTM,Up,23219,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NAB1,HTM,Up,7626,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NAB1,HTM,Up,7626,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NAB1,HTM,Up,7626,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NABP1,HTM,Down,26232,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NABP1,HTM,Down,26232,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NABP1,HTM,Down,26232,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NABP1,HTM,Up,26232,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
NABP1,HTM,Up,26232,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
NABP1,HTM,Down,26232,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
NABP1,HTM,Down,26232,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
NABP2,HTM,Up,28412,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
NACA,HTM,Down,7629,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NACA,HTM,Down,7629,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NACA,HTM,Down,7629,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NACA,HTM,Down,7629,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NACA,HTM,Down,7629,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NACA4P,HTM,Up,24688,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NACA4P,HTM,Up,24688,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NACA4P,HTM,Up,24688,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NAGK,HTM,Up,17174,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NAGS,HTM,Up,17996,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NAGS,HTM,Up,17996,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NAGS,HTM,Up,17996,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NAMPT,HTM,Up,30092,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
NANOG,HTM,Up,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,DIM,Single-cell time-of-flight mass cytometry,0.52,0.5461,34464674
NANOG,HTM,Up,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Doxorubicin,SFA followed by single-cell time-of-flight mass cytometry,0.48,0.5461,34831064
NANOG,HTM,Up,20857,Breast Cancer,NA,Primary,NA,Transcriptomics,0.68,0.5461,30559934
NANOS1,HTM,Down,23044,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
NANS,HTM,Up,19237,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
NANS,HTM,Up,19237,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
NANS,HTM,Down,19237,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
NAP1L1,HTM,Down,7637,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
NAP1L1,HTM,Down,7637,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
NAP1L1,HTM,Down,7637,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
NAP1L1,HTM,Up,7637,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
NAP1L2,HTM,Up,7638,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NAP1L2,HTM,Up,7638,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NAP1L5,HTM,Down,19968,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NAP1L5,HTM,Down,19968,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NAPA-AS1,HTM,Down,44118,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NAPB,HTM,Down,15751,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NAPB,HTM,Down,15751,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NAPEPLD,HTM,Up,21683,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NAPRT,HTM,Up,30450,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NAPRT,HTM,Up,30450,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NAPRT,HTM,Down,30450,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
NARG2,HTM,Up,29885,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NARG2,HTM,Up,29885,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NASP,HTM,Down,7644,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
NASP,HTM,Down,7644,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
NASP,HTM,Up,7644,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
NAT1,HTM,Down,7645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NAT1,HTM,Down,7645,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NAT1,HTM,Down,7645,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NAT8L,HTM,Down,26742,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NAV1,HTM,Down,15989,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NAV1,HTM,Down,15989,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NAV1,HTM,Down,15989,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NAV2,HTM,Down,15997,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
NAV2,HTM,Down,15997,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
NAV2,HTM,Down,15997,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
NAV2,HTM,Down,15997,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
NAV2,HTM,Down,15997,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
NAV2,HTM,Up,15997,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
NAV3,HTM,Down,15998,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
NAV3,HTM,Down,15998,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
NAV3,HTM,Down,15998,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
NAV3,HTM,Down,15998,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
NAV3,HTM,Down,15998,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
NAV3,HTM,Up,15998,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
NAV3,HTM,Down,15998,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
NAV3,HTM,Down,15998,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
NAXE,HTM,Down,18453,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
NBAS,HTM,Up,15625,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
NBEA,HTM,Up,7648,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NBEAL1,HTM,Down,20681,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
NBPF1,HTM,Down,26088,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
NBPF1,HTM,Up,26088,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
NBPF10,HTM,Up,31992,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
NBPF11,HTM,Up,31993,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
NBPF12,HTM,Up,24297,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
NBPF14,HTM,Up,25232,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
NBPF15,HTM,Up,28791,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
NBPF20,HTM,Up,32000,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
NBPF8,HTM,Up,31990,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
NBPF9,HTM,Up,31991,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
NBR2,HTM,Up,20691,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NBR2,HTM,Up,20691,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NBR2,HTM,Up,20691,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NCALD,HTM,Up,7655,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
NCALD,HTM,Up,7655,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
NCAM1,HTM,Up,7656,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.36,0.0074,29416721
NCAM1,HTM,Up,7656,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.36,0.0074,29416721
NCAM1,HTM,Up,7656,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0074,23903875
NCAM1,HTM,NA,7656,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by PCR array assay,0.04,0.0074,20630067
NCAM1,HTM,NA,7656,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0074,20630067
NCAPD2,HTM,Down,24305,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NCAPD3,HTM,Down,28952,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
NCAPG,HTM,Down,24304,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
NCAPH,HTM,Down,1112,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NCAPH,HTM,Down,1112,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NCAPH,HTM,Down,1112,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NCCRP1,HTM,Down,33739,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
NCEH1,HTM,Down,29260,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NCEH1,HTM,Down,29260,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NCEH1,HTM,Down,29260,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
NCEH1,HTM,Up,29260,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
NCEH1,HTM,Down,29260,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
NCF2,HTM,Down,7661,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NCF2,HTM,Down,7661,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NCK1,HTM,Down,7664,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
NCK1,HTM,Down,7664,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
NCK2,HTM,Down,7665,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NCKAP5,HTM,Up,29847,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NCL,HTM,Down,7667,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
NCL,HTM,Down,7667,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
NCL,HTM,Down,7667,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
NCL,HTM,Up,7667,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
NCL,HTM,Down,24941,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
NCOA1,HTM,Up,7668,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NCOA1,HTM,Up,7668,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NCOA2,HTM,Up,7669,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NCOA2,HTM,Up,7669,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
NCOA2,HTM,Up,7669,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
NCOA2,HTM,Up,7669,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
NCOA3,HTM,Up,7670,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NCOA3,HTM,Up,7670,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NCOA7,HTM,Up,21081,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NCOA7,HTM,Down,21081,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
NCOR1,HTM,Up,7672,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NCOR1,HTM,Up,7672,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
NCOR1P1,HTM,Up,16724,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NCR3LG1,HTM,Up,42400,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NCR3LG1,HTM,Up,42400,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NCR3LG1,HTM,Up,42400,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NCR3LG1,HTM,Up,42400,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NCRNA00250,HTM,Down,NA,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NCRNA00250,HTM,Down,NA,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NCS1,HTM,Down,3953,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NDC1,HTM,Down,25525,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NDE1,HTM,Down,17619,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NDFIP2,HTM,Down,18537,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NDFIP2,HTM,Up,18537,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
NDGG1,HTM,NA,NA,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25676692
NDGG1,HTM,NA,NA,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25676692
NDRG1,HTM,Down,7679,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
NDRG1,HTM,Down,7679,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
NDRG1,HTM,Down,7679,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
NDRG1,HTM,Down,7679,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
NDRG1,HTM,Down,7679,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
NDRG1,HTM,Up,7679,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.28,0.0064,32503348
NDRG1,HTM,Up,7679,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
NDRG1,HTM,Down,7679,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
NDRG1,HTM,Up,7679,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0064,22954703
NDRG19,HTM,Up,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NDRG19,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NDRG19,HTM,Up,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NDRG2,HTM,Down,14460,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NDST1,HTM,Down,7680,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NDST1,HTM,Down,7680,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NDUFA11,HTM,Up,20371,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
NDUFA2,HTM,Down,7685,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NDUFA2,HTM,Down,7685,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NDUFA2,HTM,Down,7685,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NDUFA2,HTM,Down,7685,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NDUFA2,HTM,Down,7685,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NDUFA3,HTM,Up,7686,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NDUFA5,HTM,Up,7688,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
NDUFA5,HTM,Up,7688,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
NDUFAB1,HTM,Down,7694,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
NDUFAB1,HTM,Down,7694,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
NDUFAF4,HTM,Up,21034,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NDUFAF4,HTM,Up,21034,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NDUFAF4,HTM,Up,21034,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NDUFB1,HTM,Up,7695,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
NDUFB3,HTM,Up,7698,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
NDUFS1,HTM,Up,7707,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
NDUFS3,HTM,Up,7710,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
NDUFS6,HTM,Up,7713,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NDUFS6,HTM,Up,7713,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NDUFS6,HTM,Up,7713,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NEAT1,HTM,Up,30815,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
NEAT1,HTM,Up,30815,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
NEB,HTM,Up,7720,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NEBL,HTM,Up,16932,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NEBL,HTM,Up,16932,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
NEBL,HTM,Up,16932,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
NECAB1,HTM,Down,20983,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NECAB2,HTM,Up,23746,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
NECAP1,HTM,Down,24539,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NECAP2,HTM,Down,25528,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NECTIN1,HTM,Down,9706,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NECTIN1,HTM,Down,9706,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NECTIN1,HTM,Down,9706,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NECTIN2,HTM,Down,9707,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
NECTIN3,HTM,Down,17664,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NECTIN3,HTM,Up,17664,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NECTIN4,HTM,Down,19688,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NEDD1,HTM,Down,7723,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NEDD1,HTM,Up,7723,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
NEDD4,HTM,Up,7727,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
NEDD4,HTM,Down,7727,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NEDD4,HTM,Up,7727,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
NEDD4,HTM,Up,7727,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
NEDD4L,HTM,Up,7728,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NEDD4L,HTM,Up,7728,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NEDD4L,HTM,Up,7728,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NEDD8,HTM,Up,7732,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
NEDD9,HTM,Up,7733,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NEDD9,HTM,Up,7733,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NEDD9,HTM,Down,7733,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
NEDD9,HTM,Down,7733,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
NEFH,HTM,Down,7737,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
NEFL,HTM,Down,7739,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NEFM,HTM,Down,7734,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NEIL2,HTM,Up,18956,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NEIL2,HTM,Up,18956,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NEIL3,HTM,Up,24573,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NEK1,HTM,Down,7744,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NEK1,HTM,Down,7744,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NEK1,HTM,Down,7744,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NEK2,HTM,Up,7745,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NEK5,HTM,Up,7748,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NEK7,HTM,Down,13386,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
NELFA,HTM,Up,12768,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
NELFB,HTM,Down,24324,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NELL2,HTM,Up,7751,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
NELL2,HTM,Up,7751,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
NEO1,HTM,Up,7754,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NEO1,HTM,Up,7754,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NES,HTM,Down,7756,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.32,0.0573,27746256
NETO1,HTM,Down,13823,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NETO1,HTM,Down,13823,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NETO1,HTM,Down,13823,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NETO2,HTM,Up,14644,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
NEU1,HTM,Up,7758,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NEU1,HTM,Up,7758,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NEU1,HTM,Up,7758,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
NEURL1,HTM,Down,7761,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NEURL1,HTM,Up,7761,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
NEURL1B,HTM,Down,35422,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
NEURL1B,HTM,Up,35422,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
NEURL3,HTM,Down,25162,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NEURL4,HTM,Down,34410,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
NEURL4,HTM,Up,34410,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
NEURL4,HTM,Up,34410,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
NEURL4,HTM,Up,34410,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
NEUROG1,HTM,Up,7764,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,20424609
NEUROG1,HTM,Up,7764,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,20424609
NEUROG2,HTM,NA,13805,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by PCR array assay,0.24,0.0021,20630067
NEUROG2,HTM,NA,13805,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0021,20630067
NEXMIF,HTM,Up,29433,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
NEXMIF,HTM,Up,29433,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
NEXMIF,HTM,Up,29433,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
NEXN,HTM,Down,29557,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NEXN,HTM,Down,29557,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NF1,HTM,Down,7765,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22740085
NF1,HTM,Up,7765,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
NF1,HTM,Up,7765,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
NF1,HTM,Up,7765,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
NF1,HTM,Up,7765,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,35013621
NF1,HTM,Up,7765,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,35013621
NF2,HTM,Down,7773,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NF2,HTM,Down,7773,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
NFASC,HTM,Up,29866,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NFASC,HTM,Up,29866,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
NFAT5,HTM,Down,7774,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NFATC2,HTM,Up,7776,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NFATC2,HTM,Up,7776,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NFATC2,HTM,Down,7776,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NFATC4,HTM,Down,7778,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NFE2,HTM,Down,7780,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NFE2L1,HTM,Down,7781,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NFIB,HTM,Up,7785,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
NFIB,HTM,Up,7785,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
NFIB,HTM,Up,7785,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
NFIB,HTM,Up,7785,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
NFIB,HTM,Up,7785,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
NFIB,HTM,Up,7785,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
NFIC,HTM,Down,7786,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NFIX,HTM,Down,7788,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NFIX,HTM,Up,7788,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
NFIX,HTM,Up,7788,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0032,28881576
NFKB1,HTM,Down,7794,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
NFKB1,HTM,Down,7794,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
NFKB1,HTM,Down,7794,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,29352988
NFKB1,HTM,Down,7794,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0064,29352988
NFKB1,HTM,Down,7794,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
NFKB1,HTM,Up,7794,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0064,19451087
NFKB2,HTM,Down,7795,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
NFKB2,HTM,Down,7795,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
NFKB2,HTM,Up,7795,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0032,19451087
NFKB2,HTM,Up,7795,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,35013621
NFKBIA,HTM,Up,7797,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
NFKBIZ,HTM,Down,29805,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NFKBIZ,HTM,Down,29805,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NFKBIZ,HTM,Down,29805,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NFKBIZ,HTM,Up,29805,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
NFRKB,HTM,Down,7802,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NFS1,HTM,Down,15910,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NFS1,HTM,Down,15910,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NFYC,HTM,Down,7806,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
NGEF,HTM,Down,7807,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NGEF,HTM,Down,7807,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NGEF,HTM,Down,7807,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NGRN,HTM,Down,18077,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NHS,HTM,Up,7820,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NHSL1,HTM,Down,21021,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NHSL2,HTM,Up,33737,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NIBAN1,HTM,Down,16784,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
NIBAN1,HTM,Up,16784,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
NIBAN1,HTM,Up,16784,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
NIBAN1,HTM,Up,16784,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
NIBAN1,HTM,Up,16784,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
NIBAN1,HTM,Up,16784,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
NIBAN1,HTM,Up,16784,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
NIBAN1,HTM,Up,16784,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
NIBAN1,HTM,Up,16784,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
NIBAN2,HTM,Up,25282,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
NIBAN2,HTM,Up,25282,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
NICN1,HTM,Down,18317,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NID1,HTM,Up,7821,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NIFK-AS1,HTM,Down,27385,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NIN,HTM,Up,14906,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
NIN,HTM,Down,14906,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
NINL,HTM,Down,29163,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NIP7,HTM,Up,24328,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
NIPAL1,HTM,Down,27194,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NIPAL1,HTM,Down,27194,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NIPAL1,HTM,Down,27194,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NIPAL1,HTM,Up,27194,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
NIPAL2,HTM,Down,25854,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NIPAL2,HTM,Down,25854,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NIPAL2,HTM,Down,25854,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NIPAL3,HTM,Down,25233,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NIPAL4,HTM,Down,28018,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NIPAL4,HTM,Down,28018,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NIPAL4,HTM,Down,28018,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NIPSNAP1,HTM,Up,7827,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NIPSNAP1,HTM,Up,7827,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NIPSNAP1,HTM,Up,7827,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
NIPSNAP1,HTM,Up,7827,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
NIPSNAP3A,HTM,Down,23619,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NIPSNAP3A,HTM,Down,23619,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
NKAIN1,HTM,Up,25743,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
NKAIN1,HTM,Up,25743,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
NKAIN1,HTM,Down,25743,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
NKAIN1,HTM,Down,25743,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
NKAP,HTM,Up,29873,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NKD1,HTM,Down,17045,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NKD1,HTM,Down,17045,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NKD2,HTM,Up,17046,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NKD2,HTM,Up,17046,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NKG7,HTM,Up,7830,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
NKILA,HTM,Down,51599,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NKRF,HTM,Down,19374,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NKX3-1,HTM,Up,7838,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NKX6-1,HTM,Up,7839,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NLE1,HTM,Up,19889,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NLE1,HTM,Up,19889,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NLGN1,HTM,Up,14291,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
NLGN1,HTM,Up,14291,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
NLN,HTM,Down,16058,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
NLN,HTM,Down,16058,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
NLN,HTM,Down,16058,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
NLN,HTM,Up,16058,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
NLRC5,HTM,Up,29933,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NLRP1,HTM,Down,14374,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NLRP1,HTM,Down,14374,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NLRP1,HTM,Down,14374,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NLRP2,HTM,Up,22948,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NLRP2,HTM,Up,22948,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NLRP7,HTM,Down,22947,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
NLRP8,HTM,Down,22940,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NLRP8,HTM,Down,22940,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NMB,HTM,Down,7842,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NMB,HTM,Down,7842,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NME1,HTM,Down,7849,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NME1,HTM,Down,7849,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NME1,HTM,Down,7849,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
NME2,HTM,Down,7850,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
NME2,HTM,Down,7850,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
NME2,HTM,Down,7850,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
NME2,HTM,Down,7850,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
NME2,HTM,Down,7850,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
NME4,HTM,Up,7852,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NME4,HTM,Up,7852,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NME5,HTM,Down,7853,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NME5,HTM,Down,7853,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NME6,HTM,Up,20567,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NME6,HTM,Up,20567,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NME6,HTM,Up,20567,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NMI,HTM,Down,7854,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NMNAT1,HTM,Down,17877,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NMRK1,HTM,Up,26057,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NMRK1,HTM,Up,26057,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NMRK1,HTM,Up,26057,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NMRK2,HTM,Up,17871,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NMRK2,HTM,Up,17871,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NMRK2,HTM,Up,17871,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NNMT,HTM,Up,7861,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
NNMT,HTM,Up,7861,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
NNMT,HTM,Down,7861,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
NNMT,HTM,Down,7861,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
NNMT,HTM,Down,7861,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0053,22954703
NNMT,HTM,Up,7861,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0053,20530554
NOC3L,HTM,Down,24034,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NOC4L,HTM,Down,28461,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NOCT,HTM,Up,14254,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
NOD1,HTM,Up,16390,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NOD1,HTM,Up,16390,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NOD1,HTM,Up,16390,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NOD2,HTM,Down,5331,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NODAL,HTM,Up,7865,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25432175
NOG,HTM,Up,7866,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NOG,HTM,Up,7866,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NOG,HTM,Up,7866,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NOL10,HTM,Up,25862,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
NOL12,HTM,Up,28585,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NOL12,HTM,Up,28585,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NOL12,HTM,Up,28585,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NOL3,HTM,Up,7869,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
NOL4L,HTM,Down,16106,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NOL6,HTM,Up,19910,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NOL6,HTM,Up,19910,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NOL6,HTM,Down,19910,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
NOLC1,HTM,Up,15608,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
NOLC1,HTM,Down,15608,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
NOLC1,HTM,Down,15608,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
NOLC1,HTM,Down,15608,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
NOMO1,HTM,Up,30060,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.36,0.0011,23903875
NONO,HTM,Down,7871,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
NONO,HTM,Down,7871,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
NOP16,HTM,Up,26934,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NOP16,HTM,Up,26934,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NOP53,HTM,Up,4333,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,29316740
NOP56,HTM,Down,15911,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
NOP9,HTM,Down,19826,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NOS1AP,HTM,Up,16859,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
NOSTRIN,HTM,Up,20203,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NOSTRIN,HTM,Up,20203,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NOTCH1,HTM,NA,7881,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by PCR array assay,0.04,0.0477,20630067
NOTCH1,HTM,NA,7881,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by PCR array assay,0.32,0.0477,20630067
NOTCH1,HTM,Up,7881,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0477,29959199
NOTCH1,HTM,Up,7881,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0477,35013621
NOTCH2,HTM,Down,7882,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0117,34059086
NOTCH2,HTM,Up,7882,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0117,20424609
NOTCH2,HTM,Up,7882,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0117,20424609
NOTCH2,HTM,NA,7882,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by PCR array assay,0.04,0.0117,20630067
NOTCH3,HTM,Up,7883,Breast Cancer,NA,Primary,NA,Transcriptomics,0.12,0.0085,30559934
NOTCH4,HTM,Down,7884,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0042,29959199
NOV,HTM,Down,7885,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
NOV,HTM,Down,7885,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
NOV,HTM,Up,7885,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
NOX4,HTM,Down,7891,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NOX4,HTM,Down,7891,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NOX4,HTM,Down,7891,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
NOX4,HTM,Down,7891,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
NOX5,HTM,Down,14874,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NOXA1,HTM,Up,10668,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,35229723
NOXA1,HTM,Down,10668,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NPAS2,HTM,Up,7895,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NPAS2,HTM,Up,7895,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NPAS3,HTM,Up,19311,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
NPC1,HTM,Down,7897,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NPC1,HTM,Down,7897,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NPC1,HTM,Down,7897,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NPC1,HTM,Up,7897,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
NPC1,HTM,Up,7897,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
NPC1L1,HTM,Up,7898,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NPC1L1,HTM,Up,7898,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
NPC2,HTM,Down,14537,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NPC2,HTM,Down,14537,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NPEPL1,HTM,Down,16244,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NPEPPS,HTM,Up,7900,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
NPEPPS,HTM,Up,7900,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
NPHP4,HTM,Up,19104,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
NPM1,HTM,Down,7910,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
NPM1,HTM,Down,7910,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
NPM1,HTM,Down,7910,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
NPM1,HTM,Down,7910,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
NPM1,HTM,Down,7910,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
NPNT,HTM,Up,27405,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
NPNT,HTM,Up,27405,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
NPNT,HTM,Up,27405,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
NPNT,HTM,Down,27405,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
NPNT,HTM,Down,27405,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
NPNT,HTM,Up,27405,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
NPPA,HTM,Down,7939,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NPPA-AS1,HTM,Up,37635,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NPR3,HTM,Up,7945,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NPR3,HTM,Up,7945,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NPR3,HTM,Up,7945,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NPR3,HTM,Up,7945,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NPR3,HTM,Up,7945,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NPR3,HTM,Up,7945,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NPR3,HTM,Up,7945,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NPRL3,HTM,Down,14124,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
NPTN,HTM,Up,17867,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
NPTX1,HTM,Up,7952,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
NPTX1,HTM,Up,7952,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
NPTX1,HTM,Down,7952,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
NPTX1,HTM,Up,7952,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
NPW,HTM,Down,30509,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
NPW,HTM,Down,30509,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
NPY4R,HTM,Up,9329,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NPY4R,HTM,Up,9329,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NQO1,HTM,Up,2874,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
NQO1,HTM,Up,2874,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
NQO1,HTM,Up,2874,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
NQO1,HTM,Up,2874,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
NQO1,HTM,Up,2874,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
NQO1,HTM,Up,2874,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
NQO1,HTM,Up,2874,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
NQO2,HTM,Up,7856,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NR0B1,HTM,Up,7960,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NR0B1,HTM,Up,7960,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0021,18034892
NR1D1,HTM,Up,7962,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
NR1D1,HTM,Up,7962,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NR1D1,HTM,Up,7962,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NR1H2,HTM,Up,7965,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
NR1H4,HTM,Down,7967,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
NR1H4,HTM,Down,7967,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
NR1H4,HTM,Down,7967,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NR1H4,HTM,Down,7967,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
NR1H4,HTM,Down,7967,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NR2E3,HTM,Down,7974,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NR2F1,HTM,Down,7975,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
NR2F2,HTM,Up,7976,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NR2F2,HTM,Up,7976,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NR2F2,HTM,Up,7976,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NR3C1,HTM,Up,7978,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
NR3C1,HTM,Up,7978,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
NR3C1,HTM,Up,7978,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
NR3C2,HTM,Down,7979,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
NR4A1,HTM,Up,7980,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,21826669
NR4A1,HTM,Up,7980,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
NR4A1,HTM,Up,7980,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
NR4A1,HTM,Up,7980,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
NR4A1,HTM,Up,7980,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
NR4A2,HTM,Up,7981,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
NR4A2,HTM,Up,7981,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
NR4A2,HTM,Up,7981,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
NR4A3,HTM,Down,7982,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NR5A2,HTM,Up,7984,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
NR5A2,HTM,Up,7984,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
NR5A2,HTM,Down,7984,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
NR6A1,HTM,Up,7985,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0011,29959199
NRAD1,HTM,Down,26981,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
NRAD1,HTM,Down,26981,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
NRAD1,HTM,Down,26981,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
NRARP,HTM,Down,33843,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
NRARP,HTM,Down,33843,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NRAS,HTM,Down,7989,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
NRAS,HTM,Down,7989,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
NRCAM,HTM,Up,7994,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NRCAM,HTM,Up,7994,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NRCAM,HTM,Down,7994,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
NRDC,HTM,Up,7995,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
NREP,HTM,Up,16834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NREP,HTM,Up,16834,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
NREP,HTM,Up,16834,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
NRG1,HTM,Down,7997,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
NRG1,HTM,Down,7997,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NRG1,HTM,Down,7997,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NRG2,HTM,Down,7998,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NRG4,HTM,Up,29862,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NRG4,HTM,Up,29862,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NRIP1,HTM,Down,8001,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NRIP2,HTM,Down,23078,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
NRK,HTM,Up,25391,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NRN1,HTM,Down,17972,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
NRN1,HTM,Up,17972,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NRP1,HTM,Up,8004,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
NRP1,HTM,Down,8004,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.48,0.0053,34680485
NRP2,HTM,Down,8005,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NRP2,HTM,Down,8005,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NRSN2,HTM,Up,16229,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NRSN2,HTM,Down,16229,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
NRTN,HTM,Up,8007,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NRTN,HTM,Up,8007,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NRTN,HTM,Up,8007,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NRXN2,HTM,Down,8009,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
NRXN3,HTM,Down,8010,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
NRXN3,HTM,Down,8010,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
NRXN3,HTM,Down,8010,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
NRXN3,HTM,Down,8010,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
NSFL1C,HTM,Down,15912,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
NSMAF,HTM,Down,8017,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
NSUN2,HTM,Down,25994,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
NSUN2,HTM,Down,25994,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
NSUN6,HTM,Down,23529,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
NSUN6,HTM,Up,23529,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
NSUN6,HTM,Up,23529,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
NSUN6,HTM,Up,23529,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
NSUN7,HTM,Up,25857,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NSUN7,HTM,Down,25857,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
NT5C2,HTM,Up,8022,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NT5C2,HTM,Up,8022,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
NT5C3B,HTM,Up,28300,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
NT5DC2,HTM,Down,25717,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NT5DC3,HTM,Down,30826,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NT5E,HTM,Up,8021,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0095,22740085
NT5E,HTM,Down,8021,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0095,25881239
NT5E,HTM,Down,8021,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0095,25881239
NT5E,HTM,Up,8021,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0095,23903875
NT5E,HTM,Up,8021,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0095,31709178
NT5E,HTM,Down,8021,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0095,34680485
NT5E,HTM,Up,8021,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0095,31501409
NT5E,HTM,Up,8021,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0095,17911267
NT5E,HTM,Down,8021,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0095,30696080
NT5E,HTM,Down,8021,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0095,30696080
NTAN1,HTM,Down,29909,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NTF3,HTM,Up,8023,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
NTF4,HTM,Down,8024,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NTF4,HTM,Down,8024,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NTM,HTM,Down,17941,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NTM,HTM,Down,17941,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NTM,HTM,Down,17941,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NTN1,HTM,Up,8029,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
NTN1,HTM,Up,8029,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
NTN1,HTM,Up,8029,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
NTN1,HTM,Down,8029,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
NTN4,HTM,Up,13658,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NTN4,HTM,Down,13658,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
NTN4,HTM,Down,13658,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
NTN4,HTM,Down,13658,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
NTRK2,HTM,Up,8032,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
NTRK3,HTM,Down,8033,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
NTRK3,HTM,Down,8033,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
NTRK3,HTM,Up,8033,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NTRK3,HTM,Up,8033,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NTS,HTM,Up,8038,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,35229723
NTS,HTM,Up,8038,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NTS,HTM,Up,8038,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
NTS,HTM,Down,8038,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
NTSR1,HTM,Up,8039,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NUAK1,HTM,Down,14311,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
NUAK1,HTM,Down,14311,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NUAK1,HTM,Down,14311,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NUAK2,HTM,Up,29558,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NUAK2,HTM,Up,29558,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NUAK2,HTM,Up,29558,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NUBPL,HTM,Down,20278,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
NUCB2,HTM,Up,8044,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
NUCB2,HTM,Up,8044,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
NUCB2,HTM,Up,8044,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
NUCB2,HTM,Up,8044,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
NUCB2,HTM,Up,8044,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
NUCB2,HTM,Up,8044,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
NUCKS1,HTM,Up,29923,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
NUCKS1,HTM,Up,29923,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
NUCKS1,HTM,Up,29923,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
NUCKS1,HTM,Down,29923,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
NUDT1,HTM,Down,8048,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
NUDT11,HTM,Down,18011,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NUDT11,HTM,Down,18011,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NUDT13,HTM,Down,18827,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
NUDT14,HTM,Down,20141,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NUDT16L2P,HTM,Up,27189,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
NUDT6,HTM,Up,8053,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NUDT6,HTM,Up,8053,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NUDT6,HTM,Up,8053,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
NUDT6,HTM,Up,8053,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
NUDT6,HTM,Up,8053,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
NUDT7,HTM,Down,8054,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
NUDT7,HTM,Down,8054,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
NUFIP1,HTM,Down,8057,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NUMA1,HTM,Up,8059,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,27965308
NUMA1,HTM,Down,8059,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
NUMB,HTM,Down,8060,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0021,29959199
NUP107,HTM,Down,29914,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NUP155,HTM,Down,8063,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
NUP160,HTM,Up,18017,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
NUP210,HTM,Down,30052,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
NUP210,HTM,Up,30052,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NUP210,HTM,Up,30052,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NUP210,HTM,Up,30052,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
NUP214,HTM,Up,8064,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NUP214,HTM,Up,8064,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NUP214,HTM,Up,8064,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NUP35,HTM,Up,29797,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NUP35,HTM,Up,29797,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NUP35,HTM,Up,29797,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
NUP37,HTM,Up,29929,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NUP37,HTM,Up,29929,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NUP37,HTM,Up,29929,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NUP37,HTM,Up,29929,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NUP37,HTM,Up,29929,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
NUP50-DT,HTM,Down,50502,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
NUP62CL,HTM,Up,25960,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NUP62CL,HTM,Up,25960,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NWD1,HTM,Up,27619,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NXF2,HTM,Down,8072,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
NXF2B,HTM,Down,23984,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
NXF3,HTM,Up,8073,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
NXNL2,HTM,Down,30482,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
NXT2,HTM,Up,18151,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
NYNRIN,HTM,Up,20165,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NYNRIN,HTM,Up,20165,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
NYNRIN,HTM,Down,20165,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
OAS1,HTM,Up,8086,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
OAS1,HTM,Up,8086,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
OAS1,HTM,Down,8086,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
OAS1,HTM,Up,8086,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
OAS1,HTM,Up,8086,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
OAS2,HTM,Down,8087,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
OAS2,HTM,Down,8087,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
OAT,HTM,Down,8091,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
OAT,HTM,Down,8091,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
OAT,HTM,Down,8091,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
OAT,HTM,Down,8091,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
OAT,HTM,Down,8091,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
OAT,HTM,Up,8091,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
OAT,HTM,Down,8091,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
OBSL1,HTM,Down,29092,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
OBSL1,HTM,Up,29092,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
OCIAD2,HTM,Down,28685,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
OCIAD2,HTM,Down,28685,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
OCIAD2,HTM,Down,28685,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
OCIAD2,HTM,Down,28685,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
OCIAD2,HTM,Down,28685,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
OCIAD2,HTM,Down,28685,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
OCLN,HTM,Up,8104,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
OCLN,HTM,Down,8104,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
OCLN,HTM,Down,8104,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
OCRL,HTM,Up,8108,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ODAM,HTM,Down,26043,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ODC1,HTM,Up,8109,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25676692
ODC1,HTM,Up,8109,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.24,0.0021,26259570
ODC1,HTM,Up,8109,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.24,0.0021,26259570
ODC19,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ODC19,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ODC19,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ODF2,HTM,Down,8114,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ODF2L,HTM,Down,29225,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ODR4,HTM,Up,24299,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,29316740
ODR4,HTM,Up,24299,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
OGDH,HTM,Down,8124,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OGFOD3,HTM,Down,26174,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
OGFRL1,HTM,Up,21378,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
OGN,HTM,Down,8126,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
OGT,HTM,Up,8127,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OIP5,HTM,Down,20300,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
OIP58,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
OIP58,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
OIP58,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
OLA1,HTM,Down,28833,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
OLA1,HTM,Down,28833,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
OLA1,HTM,NA,28833,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29221160
OLFM1,HTM,Up,17187,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
OLFM4,HTM,Down,17190,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
OLFM4,HTM,Up,17190,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
OLFML2A,HTM,Down,27270,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
OLFML2A,HTM,Down,27270,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
OLFML2A,HTM,Up,27270,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
OLFML3,HTM,Up,24956,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
OLMALINC,HTM,Up,28060,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
OLR1,HTM,Up,8133,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
OLR1,HTM,Up,8133,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
OLR1,HTM,Down,8133,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
OLR1,HTM,Down,8133,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
OLR1,HTM,Down,8133,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
OLR1,HTM,Up,8133,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
OMA1,HTM,Down,29661,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ONECUT1,HTM,Down,8138,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ONECUT2,HTM,Down,8139,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
OPA1,HTM,Down,8140,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
OPA1,HTM,Down,8140,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
OPA6,HTM,Down,33170,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
OPHN1,HTM,Up,8148,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OPLAH,HTM,Up,8149,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
OPN3,HTM,Up,14007,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
OPN3,HTM,Down,14007,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
OPRD1,HTM,Up,8153,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
OPTN,HTM,Down,1941,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OPTN,HTM,Down,17142,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OR10G9,HTM,Down,15129,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
OR10H4,HTM,Up,15388,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
OR10Z1,HTM,Down,14996,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
OR13H1,HTM,Up,17142,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OR1D4,HTM,UP,8185,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
OR1D4,HTM,UP,8185,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
OR1D4,HTM,UP,8185,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
OR1D4,HTM,UP,8185,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
OR1D4,HTM,UP,8185,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
OR1D4,HTM,UP,8186,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
OR1D4,HTM,UP,8186,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
OR1D4,HTM,UP,8186,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
OR1D4,HTM,UP,8186,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
OR1D4,HTM,UP,8186,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
OR1K1,HTM,Down,8212,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
OR2A4,HTM,Down,14729,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OR2A4,HTM,Down,14729,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OR2A7,HTM,Down,8234,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OR2A7,HTM,Down,8234,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OR2A7,HTM,Down,8234,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OR2A7,HTM,Down,8234,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OR2T27,HTM,Up,31252,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
OR4C16,HTM,Down,15172,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
OR5AK2,HTM,Down,15251,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
OR5P2,HTM,Down,14783,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
OR6A2,HTM,Up,15301,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
OR7E14P,HTM,Up,8234,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OR7E156P,HTM,Down,31311,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
OR8B8,HTM,Down,8477,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
OR8J1,HTM,Up,14855,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
OR9A3P,HTM,Up,15094,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ORAI2,HTM,Down,21667,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ORAI3,HTM,Down,28185,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ORC1,HTM,Down,8487,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ORC2L,HTM,Down,8488,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ORC6L2,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ORC6L2,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ORC6L2,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ORM1,HTM,Up,8498,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ORM1,HTM,Up,8498,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ORM1,HTM,Up,8498,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ORMDL1,HTM,Up,16036,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ORMDL1,HTM,Up,16036,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ORMDL1,HTM,Up,16036,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ORMDL2,HTM,Down,8385,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ORMDL3,HTM,Down,16038,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ORMDL3,HTM,Down,16038,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
OSBPL10,HTM,Down,16037,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OSBPL11,HTM,Up,16397,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
OSBPL1A,HTM,Up,16395,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OSBPL6,HTM,Up,16388,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
OSBPL6,HTM,Up,16388,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
OSBPL8,HTM,Down,16398,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OSCP1,HTM,Up,29971,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
OSCP1,HTM,Up,29971,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
OSCP1,HTM,Up,29971,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
OSGEPL1,HTM,Down,23075,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
OSGEPL1-AS1,HTM,Down,41009,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
OSGIN1,HTM,Up,30093,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
OSGIN2,HTM,Up,1355,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
OSGIN2,HTM,Up,1355,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
OSGIN2,HTM,Down,1355,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
OSMR,HTM,Up,1355,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
OSTF1,HTM,Down,8510,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OSTF1,HTM,Down,8510,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OSTM1,HTM,Up,21652,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
OTUB2,HTM,Down,20351,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
OTUD4,HTM,Up,24949,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
OTUD4,HTM,Up,24949,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
OTUD4,HTM,Up,24949,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
OTULINL,HTM,Down,25629,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
OTULINL,HTM,Down,25629,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
OVGP1,HTM,Down,8524,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
OVGP1,HTM,Down,8524,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
OVOL1,HTM,Down,8525,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
OVOL1,HTM,Down,8525,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
OVOL1,HTM,Down,8525,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
OVOL1,HTM,Down,8525,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
OVOL2,HTM,Down,15804,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
OVOL2,HTM,Down,15804,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
OVOL2,HTM,Down,15804,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
OVOS2,HTM,Down,NA,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
OVOS2,HTM,Down,NA,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
OXCT1,HTM,Down,8527,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OXCT1,HTM,Down,8527,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OXCT1,HTM,Down,8527,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OXGR1,HTM,Up,4531,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
OXSR1,HTM,Down,8508,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
OXTR,HTM,Up,8529,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
P2RX3,HTM,Down,8534,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
P2RX4,HTM,Up,8535,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
P2RX5,HTM,Down,8536,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
P2RY1,HTM,Up,8539,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
P2RY1,HTM,Up,8539,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
P2RY11,HTM,Up,8540,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
P2RY11,HTM,Up,8540,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
P2RY11,HTM,Up,8540,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
P2RY6,HTM,Up,8543,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
P3H2,HTM,Up,19317,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
P3H2,HTM,Up,19317,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
P3H2,HTM,Down,19317,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
P3H2,HTM,Down,19317,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
P3H3,HTM,Up,19318,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0011,17932721
P4HA1,HTM,Down,8546,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
P4HA1,HTM,Down,8546,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
P4HA1,HTM,Up,8546,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
P4HA1,HTM,Up,8546,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
P4HA2,HTM,Down,8547,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
P4HA2,HTM,Down,8547,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
P4HA2,HTM,Down,8547,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
P4HB,HTM,Down,8548,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
P4HB,HTM,Up,8548,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
P4HB,HTM,Up,8548,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
P4HB,HTM,Up,8548,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
P4HB,HTM,Down,8548,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
PA2G4,HTM,Down,8550,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PA2G4,HTM,Down,8550,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PABPC1,HTM,Down,8554,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PABPC1,HTM,Down,8554,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PABPC1,HTM,Down,8554,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PABPC1,HTM,Down,8554,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
PABPC1L,HTM,Down,15797,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PABPC1L,HTM,Down,15797,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PABPC1L,HTM,Up,15797,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PABPC3,HTM,Down,8556,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PABPC4,HTM,Down,8547,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PABPC4L,HTM,Down,31955,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PABPC4L,HTM,Down,31955,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PABPN1,HTM,Up,8565,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PABPN1,HTM,Up,8565,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PACS1,HTM,Down,30032,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PACSIN1,HTM,Down,8570,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PADI1,HTM,Down,18367,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PADI1,HTM,Down,18367,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.04,0.0021,27520449
PADI2,HTM,Down,18341,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PADI2,HTM,Up,18341,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PADI2,HTM,Down,18341,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PAEP,HTM,Down,8573,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PAEP,HTM,Up,8573,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
PAF1,HTM,Down,25459,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
PAFAH1B2,HTM,Down,8575,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
PAFAH1B2,HTM,Up,8575,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PAFAH1B2,HTM,Up,8575,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PAFAH1B2,HTM,Down,8575,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PAFAH1B2,HTM,Down,8575,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PAG1,HTM,Up,30043,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,30592142
PAG1,HTM,Down,30043,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0042,23820871
PAG1,HTM,Up,30043,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
PAG1,HTM,Up,30043,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
PAG1,HTM,Up,30043,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0042,30592142
PAGM5,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PAGM5,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PAGM5,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PAICS,HTM,Down,8587,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PAICS,HTM,Down,8587,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PAICS,HTM,Down,8587,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PAICS,HTM,Down,8587,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PAK1,HTM,Down,8590,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
PAK1,HTM,Down,8590,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
PAK1,HTM,Down,8590,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PAK1IP1,HTM,Up,20882,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PAK1IP1,HTM,Up,20882,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PAK1IP1,HTM,Up,20882,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PAK2,HTM,Down,8591,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PAK2,HTM,Down,8591,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PAK2,HTM,Up,8591,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
PAK3,HTM,Down,8592,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PAK3,HTM,Down,8592,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PAK3,HTM,Down,8592,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PAK6,HTM,Down,16061,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PAK6,HTM,Up,16061,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
PALLD,HTM,Down,17068,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PALLD,HTM,Down,17068,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PALM,HTM,Up,8594,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PALM3,HTM,Up,33274,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PALMD,HTM,Down,15846,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PALMD,HTM,Down,15846,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PALMD,HTM,Down,15846,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PALMD,HTM,Up,15846,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
PALMD,HTM,Down,15846,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0042,28881576
PALMD,HTM,Down,15846,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.16,0.0042,20530554
PAM,HTM,Up,8596,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PAN3,HTM,NA,29991,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
PANK2,HTM,Down,15894,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
PANK3,HTM,Up,19365,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
PANX1,HTM,Down,8599,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PANX1,HTM,Down,8599,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PANX1,HTM,Down,8599,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PANX2,HTM,Up,8600,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PANX2,HTM,Up,8600,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PAPLN,HTM,Down,19262,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
PAPPA,HTM,Up,8602,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PAPPA,HTM,Up,8602,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PAPPA,HTM,Up,8602,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PAPPA,HTM,Down,8602,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PAPPA,HTM,Down,8602,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PAPSS1,HTM,Down,8603,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PAPSS2,HTM,Up,8604,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PAPSS2,HTM,Up,8604,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PAQR4,HTM,Down,26386,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PAQR5,HTM,Up,29645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PAQR5,HTM,Up,29645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PAQR5,HTM,Up,29645,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PAQR5,HTM,Up,29645,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PAQR5,HTM,Up,29645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PAQR5,HTM,Up,29645,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PAQR6,HTM,Down,30132,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PAQR6,HTM,Down,30132,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PAQR7,HTM,Up,23146,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PAQR9,HTM,Up,30131,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PAQR9,HTM,Up,30131,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PAQR9,HTM,Up,30131,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PARD3,HTM,Up,29645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PARD3B,HTM,Up,16051,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PARD6A,HTM,Down,15943,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,20424609
PARD6A,HTM,Down,15943,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,20424609
PARD6A,HTM,NA,15943,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by PCR array assay,0.04,0.0032,20630067
PARD6A,HTM,Up,15943,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
PARD6B,HTM,Up,16245,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PARD6B,HTM,Down,16245,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PARK7,HTM,Down,16369,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
PARK7,HTM,Up,16369,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
PARK7,HTM,Down,16369,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
PARM1,HTM,Up,16245,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PARM1,HTM,Down,24536,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
PARM1,HTM,Up,24536,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PARP1,HTM,Down,270,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PARP1,HTM,Down,270,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PARP1,HTM,Down,270,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
PARP14,HTM,Down,29232,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PARP4,HTM,Up,271,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PARP4,HTM,Up,271,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PARP4,HTM,Up,271,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PARVA,HTM,Down,24536,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PATJ,HTM,Down,28881,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
PATJ,HTM,Up,28881,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
PATJ,HTM,Up,28881,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
PATZ1,HTM,Down,14652,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PAX8-AS1,HTM,Down,49271,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PAX9,HTM,Up,8623,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PAX9,HTM,Up,8623,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PAX9,HTM,Up,8623,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PAX9,HTM,Up,8623,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PAXIP1-DT,HTM,Down,27328,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PBOV1,HTM,Up,21079,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PBX1,HTM,Down,8632,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
PBX1,HTM,Up,8632,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PBX1,HTM,Up,8632,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PBX1,HTM,Up,8632,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
PBX1,HTM,Up,8632,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
PBX1,HTM,Up,8632,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
PBX1,HTM,Up,8632,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
PBX3,HTM,Down,8634,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PBXIP1,HTM,Up,21199,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PC,HTM,Up,8636,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PCBD1,HTM,Up,8646,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PCBD1,HTM,Up,8646,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PCBP1,HTM,Down,8647,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PCBP1,HTM,Down,8647,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PCBP2,HTM,Down,8648,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PCBP2,HTM,Up,8648,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
PCCA,HTM,Up,8653,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PCCA,HTM,Up,8653,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PCCA,HTM,Up,8653,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PCDH1,HTM,Down,8655,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PCDH10,HTM,Down,13404,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
PCDH17,HTM,Down,14267,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PCDH17,HTM,Down,14267,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PCDH20,HTM,Up,14257,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PCDH20,HTM,Down,14257,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
PCDH20,HTM,Down,14257,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
PCDH20,HTM,Down,14257,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
PCDH20,HTM,Down,14257,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
PCDH20,HTM,Up,14257,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
PCDH20,HTM,Up,14257,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
PCDH20,HTM,Down,14257,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
PCDH20,HTM,Up,14257,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
PCDH7,HTM,Down,8659,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
PCDH7,HTM,Up,8659,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PCDH8,HTM,Up,8660,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PCDH9,HTM,Up,8661,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PCDH9,HTM,Up,8661,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PCDH9,HTM,Up,8661,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PCDH9,HTM,Up,8661,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
PCDH9,HTM,Up,8661,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
PCDHA1,HTM,Up,8663,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
PCDHA1,HTM,Up,8663,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
PCDHA4,HTM,Down,8670,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PCDHA7,HTM,Up,8673,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PCDHA7,HTM,Up,8673,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PCDHAC2,HTM,Up,8677,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PCDHB16,HTM,Down,14546,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PCDHB16,HTM,Down,14546,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PCDHB17P,HTM,Up,14547,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PCDHB17P,HTM,Up,14547,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PCDHB17P,HTM,Up,14547,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PCDHB2,HTM,Up,8687,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PCDHB2,HTM,Up,8687,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PCDHB2,HTM,Up,8687,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PCDHB2,HTM,Up,8687,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PCDHB2,HTM,Up,8688,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PCDHB2,HTM,Up,8688,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PCDHB2,HTM,Up,8688,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PCDHB5,HTM,Up,8690,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PCDHB5,HTM,Up,8690,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PCDHB5,HTM,Up,8690,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PCDHGA1,HTM,Up,8696,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PCDHGA9,HTM,Up,8707,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
PCDHGC4,HTM,Up,8717,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
PCED1A,HTM,Down,16212,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PCED1B,HTM,Down,28255,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PCF11,HTM,Down,30097,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PCGF6,HTM,Up,21156,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PCGF6,HTM,Up,21156,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PCGF6,HTM,Up,21156,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PCID2,HTM,Up,25653,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PCIF1,HTM,Up,16200,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
PCK2,HTM,Down,8725,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
PCK2,HTM,Down,8725,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
PCK2,HTM,Up,8725,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
PCK2,HTM,Up,8725,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
PCK2,HTM,Down,8725,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
PCLAF,HTM,Down,28961,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PCLAF,HTM,Up,28961,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PCLAF,HTM,Down,28961,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PCLO,HTM,Down,13406,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PCMT1,HTM,Down,8728,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PCMTD1,HTM,Up,30483,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
PCMTD2,HTM,Up,15882,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PCMTD2,HTM,Down,15882,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PCMTD2,HTM,Down,15882,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PCNA,HTM,Down,8729,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PCNA,HTM,Up,8729,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PCNP,HTM,Up,30023,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,22623141
PCNX1,HTM,Up,19740,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PCNX1,HTM,Up,19740,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PCNX1,HTM,Up,19740,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PCNX1,HTM,Up,19740,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PCNX1,HTM,Up,19740,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PCOLCE2,HTM,Up,8739,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PCOLCE2,HTM,Up,8739,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PCSK1,HTM,Down,8743,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
PCSK2,HTM,Up,8744,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PCSK5,HTM,Down,8747,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PCSK5,HTM,Down,8747,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PCSK5,HTM,Down,8747,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
PCSK6,HTM,Up,8569,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PCSK6,HTM,Up,8569,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PCSK6,HTM,Up,8569,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PCSK9,HTM,Up,20001,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
PCSK9,HTM,Up,20001,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
PCSK9,HTM,Down,20001,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
PCSK9,HTM,Down,20001,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
PCYT1A,HTM,Down,8754,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PCYT1A,HTM,Down,8754,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDCD10,HTM,Down,8761,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PDCD10,HTM,Down,8761,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PDCD10,HTM,Down,8761,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PDCD10,HTM,Down,8761,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PDCD10,HTM,Down,8761,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PDCD11,HTM,Up,13408,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PDCD11,HTM,Up,13408,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PDCD1LG2,HTM,Down,18731,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDCD1LG2,HTM,Down,18731,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDCD1LG2,HTM,Down,18731,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDCD2L,HTM,Down,28194,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PDCD4,HTM,Up,8763,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
PDCD5,HTM,Down,8764,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
PDCD5,HTM,Down,8764,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
PDCD5,HTM,Down,8764,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
PDCD5,HTM,Down,8764,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
PDCD5,HTM,Down,8764,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
PDCD5,HTM,Down,8764,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
PDE10A,HTM,Up,8772,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDE10A,HTM,Up,8772,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDE10A,HTM,Down,8772,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PDE11A,HTM,Down,8773,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
PDE1A,HTM,Up,8774,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PDE1A,HTM,Down,8774,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
PDE1C,HTM,Up,8776,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDE1C,HTM,Up,8776,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDE3A,HTM,Up,8778,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PDE3A,HTM,Up,8778,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PDE3A,HTM,Down,8778,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
PDE3A,HTM,Down,8778,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
PDE3B,HTM,Up,8779,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDE3B,HTM,Up,8779,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDE3B,HTM,Down,8779,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
PDE4A,HTM,Up,8780,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PDE4B,HTM,Up,8781,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDE4B,HTM,Up,8781,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDE4B,HTM,Down,8781,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PDE4C,HTM,Down,8782,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PDE4C,HTM,Down,8782,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PDE4D,HTM,Down,8783,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
PDE4D,HTM,Up,8783,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PDE4D,HTM,Up,8783,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PDE4D,HTM,Down,8783,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
PDE4D,HTM,Up,8783,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
PDE4DIP,HTM,Down,15580,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDE4DIP,HTM,Up,15580,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDE4DIP,HTM,Up,15580,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
PDE5A,HTM,Down,8784,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
PDE5A,HTM,Up,8784,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PDE5A,HTM,Down,8784,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
PDE5A,HTM,Down,8784,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
PDE7B,HTM,Up,8792,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDE7B,HTM,Up,8792,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDE7B,HTM,Up,8792,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PDE7B,HTM,Up,8792,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PDE7B,HTM,Up,8792,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PDE8A,HTM,Up,8793,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDE8A,HTM,Up,8793,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDE8B,HTM,Up,8794,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDE8B,HTM,Up,8794,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDE9A,HTM,Down,8795,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PDGFA,HTM,Up,8799,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25432175
PDGFA,HTM,Down,8799,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0021,25881239
PDGFA,HTM,Down,8799,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDGFB,HTM,Up,8800,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,25432175
PDGFB,HTM,Down,8800,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
PDGFC,HTM,Up,8801,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
PDGFC,HTM,Down,8801,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDGFC,HTM,Down,8801,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDGFC,HTM,Down,8801,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDGFD,HTM,Up,30620,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDGFD,HTM,Up,30620,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDGFRA,HTM,Down,8803,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PDGFRA,HTM,Up,8803,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PDGFRA,HTM,Down,8803,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PDGFRA,HTM,Up,8803,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PDGFRA,HTM,Up,8803,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PDGFRL,HTM,Up,8805,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDGFRL,HTM,Up,8805,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDGFRL,HTM,Down,8805,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PDHA1,HTM,Up,8806,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,22623141
PDHA1,HTM,Down,8806,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
PDHB,HTM,Up,8808,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PDIA3,HTM,Up,4606,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PDIA3,HTM,Up,4606,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PDIA3,HTM,Up,4606,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PDIA3,HTM,Down,4606,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PDIA3,HTM,Down,4606,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
PDIA4,HTM,Down,30167,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,22623141
PDIA4,HTM,Down,30167,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0053,23903875
PDIA4,HTM,Up,30167,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
PDIA4,HTM,Up,30167,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
PDIA4,HTM,Up,30167,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0053,34168259
PDIA4,HTM,Up,30167,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0053,21788403
PDIA6,HTM,Down,30168,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
PDIA6,HTM,Up,30168,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PDIA6,HTM,Up,30168,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PDIA6,HTM,Up,30168,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PDIA6,HTM,Down,30168,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PDK1,HTM,Down,8809,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
PDK1,HTM,Down,8809,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
PDK1,HTM,Down,8809,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0053,22954703
PDK2,HTM,Up,8810,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDK3,HTM,Up,8811,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PDK4,HTM,Up,8812,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PDK4,HTM,Up,8812,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PDK4,HTM,Up,8812,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
PDK4,HTM,Up,8812,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
PDLIM1,HTM,Down,2067,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDLIM1,HTM,Down,2067,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PDLIM4,HTM,Down,16501,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
PDLIM5,HTM,Up,17468,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
PDLIM7,HTM,Down,22958,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
PDLIM7,HTM,Down,22958,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
PDP1,HTM,Down,9279,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDP1,HTM,Down,9279,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PDPK1,HTM,Up,8816,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
PDPK1,HTM,Down,8816,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
PDPK1,HTM,Down,8816,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
PDPN,HTM,Up,29602,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
PDPN,HTM,Down,29602,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PDPN,HTM,Down,29602,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PDPN,HTM,Down,29602,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PDXDC1,HTM,Down,28995,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PDXDC1,HTM,Up,28995,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
PDXDC2P,HTM,Up,27559,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
PDZD2,HTM,Up,18486,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PDZD2,HTM,Up,18486,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PDZD2,HTM,Up,18486,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PDZD2,HTM,Down,18486,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
PDZD2,HTM,Up,18486,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PDZD7,HTM,Up,26257,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PDZK1,HTM,Down,8821,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PDZK1,HTM,Down,8821,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PEA15,HTM,Down,8822,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PEA15,HTM,Up,8822,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PEA15,HTM,Up,8822,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PEA15,HTM,Up,8822,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PEAK1,HTM,Up,29431,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PEBP1,HTM,Up,8630,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
PEBP1,HTM,Up,8630,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PEBP1,HTM,Up,8630,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PEBP1,HTM,Down,8630,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PECAM1,HTM,Up,8823,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
PECR,HTM,Up,18281,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PECR,HTM,Up,18281,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PECR,HTM,Up,18281,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PEG10,HTM,Up,14005,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PEG10,HTM,Up,14005,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PEG13,HTM,Up,19969,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PELI1,HTM,Down,8827,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PELI1,HTM,Down,8827,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PELI1,HTM,Up,8827,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,29511337
PELI1,HTM,Up,8827,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0032,29511337
PELI1,HTM,Up,8827,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
PELI2,HTM,Up,8828,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PELI2,HTM,Up,8828,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PELO,HTM,Up,8829,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
PELO,HTM,Up,8829,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
PEPD,HTM,Down,8840,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PEPD,HTM,Down,8840,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
PEPD,HTM,Down,8840,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PER2,HTM,Up,8846,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PER3,HTM,Up,8847,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PER3,HTM,Up,8847,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PER3,HTM,Up,8847,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PERM1,HTM,Down,28208,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PERP,HTM,Down,17637,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PERP,HTM,Down,17637,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
PERP,HTM,Up,17637,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PEX1,HTM,Up,8850,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PEX11A,HTM,Down,8852,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PEX11G,HTM,Down,20208,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PEX11G,HTM,Down,20208,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PEX2,HTM,Down,9717,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PEX2,HTM,Down,9717,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PEX3,HTM,Down,8858,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PFAS,HTM,Up,8863,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PFAS,HTM,Up,8863,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PFAS,HTM,Down,8863,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PFDN1,HTM,Down,8866,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PFDN4,HTM,Down,8868,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PFDN4,HTM,Down,8868,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PFKFB3,HTM,Up,8874,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PFKFB3,HTM,Down,8874,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PFKM,HTM,Up,8877,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
PFKP,HTM,Down,8878,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PFN1,HTM,Up,8881,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,33670440
PFN1,HTM,Down,8881,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
PFN1,HTM,Down,8881,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
PFN1,HTM,Up,8881,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
PFN1,HTM,Up,8881,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
PFN1P2,HTM,Down,24298,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PFN1P2,HTM,Down,24298,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PFN2,HTM,Up,8882,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PFN2,HTM,Up,8882,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PFN2,HTM,Down,8882,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PFN2,HTM,Down,8882,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PFN2,HTM,Up,8882,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PGAM1,HTM,Down,8888,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PGAM1,HTM,Down,8888,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PGAM1,HTM,Down,8888,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PGAM1,HTM,Up,8888,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,25081334
PGAM1,HTM,Up,8888,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
PGAM1,HTM,Down,8888,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
PGAM4,HTM,Down,21731,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PGAM4,HTM,Down,21731,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PGAM4,HTM,Down,21731,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PGAM5,HTM,Up,28763,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PGAM5,HTM,Up,28763,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PGAP3,HTM,Up,23719,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PGBD3,HTM,Down,19400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PGBD3,HTM,Down,19400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PGBD3,HTM,Down,19400,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PGD,HTM,Down,8891,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
PGD,HTM,Up,8891,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
PGD,HTM,Up,8891,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
PGD,HTM,Down,8891,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
PGD,HTM,Up,8891,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
PGD,HTM,Up,8891,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
PGD,HTM,Up,8891,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0053,34168259
PGD,HTM,Down,8891,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0053,24098529
PGDP2,HTM,Down,39144,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
PGK1,HTM,Up,8896,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PGK1,HTM,Up,8896,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PGK1,HTM,Down,8896,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PGK2,HTM,Up,8898,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PGK2,HTM,Up,8898,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PGLS,HTM,Up,8903,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PGLS,HTM,Up,8903,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PGLYRP2,HTM,Up,30013,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PGLYRP4,HTM,Down,30015,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PGM1,HTM,Up,8905,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PGM1,HTM,Up,8905,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PGM1,HTM,Up,8905,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
PGM2,HTM,Down,8906,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PGM2,HTM,Down,8906,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PGM2,HTM,Down,8906,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
PGM2L1,HTM,Up,20898,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PGM2L1,HTM,Up,20898,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PGM2L1,HTM,Down,20898,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PGM2L1,HTM,Up,20898,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PGM3,HTM,Down,8907,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PGM5-AS1,HTM,Up,44181,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
PGR,HTM,Down,8910,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.44,0.0021,34680485
PGRMC1,HTM,Up,16090,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PGRMC1,HTM,Up,16090,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PGRMC2,HTM,Down,16089,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PGS1,HTM,Down,30029,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PHACTR2,HTM,Down,20956,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PHACTR2,HTM,Up,20956,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
PHACTR3,HTM,Down,15833,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
PHB,HTM,Up,8912,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PHB,HTM,Up,8912,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PHB,HTM,Down,8912,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PHB,HTM,Down,8912,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
PHB2,HTM,Up,30306,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
PHB2,HTM,Up,30306,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
PHB2,HTM,Down,30306,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
PHB2,HTM,Down,30306,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
PHC3,HTM,Up,15682,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
PHF11,HTM,Down,17024,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PHF16,HTM,Up,22982,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PHF16,HTM,Up,22982,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
PHF21A,HTM,Up,24156,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PHF21B,HTM,Down,25161,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PHF6,HTM,Down,18145,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
PHGDH,HTM,Down,8923,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
PHGDH,HTM,Up,8923,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
PHGDH,HTM,Down,8923,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
PHIP,HTM,NA,15673,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
PHKA2,HTM,Down,8926,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PHKA2,HTM,Down,8926,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PHKA2,HTM,Down,8926,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
PHLDA1,HTM,Down,8933,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PHLDA1,HTM,Down,8933,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PHLDA1,HTM,Down,8933,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PHLDA1,HTM,Up,8933,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.24,0.0042,31501409
PHLDA1,HTM,Down,8933,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
PHLDA1,HTM,Down,8933,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
PHLDA2,HTM,Up,12385,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PHLDA2,HTM,Up,12385,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
PHLDA2,HTM,Down,12385,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
PHLDA2,HTM,Down,12385,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
PHLDB1,HTM,Down,23697,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PHLDB2,HTM,Down,29573,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
PHLDB2,HTM,Down,29573,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PHLDB2,HTM,Down,29573,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
PHLDB2,HTM,Down,29573,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
PHOSPHO1,HTM,Down,16815,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PHOSPHO1,HTM,Up,16815,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PHOSPHO2,HTM,Up,28316,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PHOSPHO2,HTM,Down,28316,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
PHTF1,HTM,Down,8939,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PHTF2,HTM,Down,13411,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
PHYH,HTM,Up,8940,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PI3,HTM,Up,8947,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0064,30592142
PI3,HTM,Down,8947,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,34059086
PI3,HTM,Up,8947,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0064,24961511
PI3,HTM,Up,8947,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0064,24961511
PI3,HTM,Down,8947,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
PI3,HTM,Up,8947,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
PI3,HTM,Up,8947,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0064,30592142
PI3,HTM,Up,8947,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0064,20530554
PI4K2A,HTM,Down,30031,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PI4K2B,HTM,Down,18215,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PI4KA,HTM,Down,8983,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PICALM,HTM,Up,15514,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PICALM,HTM,Up,15514,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PID1,HTM,Down,26084,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PID1,HTM,Down,26084,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PIEZO1,HTM,Down,28993,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
PIEZO2,HTM,Down,26270,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PIEZO2,HTM,Down,26270,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PIF1,HTM,Up,26220,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
PIGM,HTM,Down,18858,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PIGR,HTM,Down,8968,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PIGR,HTM,Down,8968,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PIGU,HTM,Down,15791,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PIGW,HTM,Up,23213,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
PIK3AP1,HTM,Down,30034,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
PIK3C2A,HTM,Down,8971,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
PIK3C2A,HTM,Down,8971,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
PIK3C2B,HTM,NA,8972,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0032,29352988
PIK3C2B,HTM,Up,8972,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PIK3C2B,HTM,Down,8972,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
PIK3C2B,HTM,Down,8972,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
PIK3C3,HTM,Up,8974,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PIK3C3,HTM,Up,8974,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PIK3C3,HTM,Up,8974,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PIK3CA,HTM,Down,8975,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
PIK3CA,HTM,Down,8975,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
PIK3CA,HTM,Up,8975,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0032,34794402
PIK3CA,HTM,Up,8975,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0032,34794402
PIK3CB,HTM,NA,8976,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0011,29352988
PIK3CD,HTM,Down,8977,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PIK3CD,HTM,Down,8977,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
PIK3CD,HTM,Down,8977,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
PIK3IP1,HTM,Down,24942,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PIK3IP1,HTM,Down,24942,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PIK3IP1,HTM,Down,24942,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PIK3R1,HTM,Down,8979,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,29352988
PIK3R1,HTM,Down,8979,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0042,29352988
PIK3R1,HTM,Up,8979,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
PIK3R1,HTM,Up,8979,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0042,17911267
PIK3R1,HTM,Down,8979,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
PIK3R2,HTM,Down,8980,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
PIK3R2,HTM,Down,8980,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
PIK3R2,HTM,Up,8980,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
PIK3R3,HTM,Up,8981,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PIK3R5,HTM,Down,30035,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PIKC1,HTM,Up,NA,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,35013621
PILRA,HTM,Down,20396,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PILRA,HTM,Down,20396,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PILRB,HTM,Down,18297,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
PIM1,HTM,Down,8986,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PIMREG,HTM,Down,25483,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PIN4,HTM,Up,8992,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
PINK1,HTM,Down,14581,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PIP,HTM,Down,8993,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PIP,HTM,Up,8993,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
PIP,HTM,Up,8993,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
PIP,HTM,Up,8993,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
PIP4K2A,HTM,Down,8997,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PIP4K2B,HTM,Down,8998,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PIP4K2C,HTM,Down,23786,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PIP4P2,HTM,Down,25452,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PIP5K1A,HTM,Up,8994,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,27965308
PIP5K1A,HTM,Up,8994,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
PIPOX,HTM,Down,17804,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PIR,HTM,Up,30048,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PIR,HTM,Up,30048,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PIR,HTM,Down,30048,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
PITPNM2,HTM,Up,21044,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
PITPNM3,HTM,Up,21043,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PITPNM3,HTM,Down,21043,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PITX1,HTM,Up,9004,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PITX1,HTM,Up,9004,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PJA2,HTM,Up,17481,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29511337
PJA2,HTM,Up,17481,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0011,29511337
PJVK,HTM,Down,29502,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PKD1,HTM,Down,9008,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,27965308
PKD1L2,HTM,Down,21715,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PKDCC,HTM,Down,25123,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PKDCC,HTM,Down,25123,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
PKDREJ,HTM,Up,9015,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
PKIB,HTM,Up,9018,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0021,17932721
PKIB,HTM,Down,9018,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PKIG,HTM,Up,9019,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PKLR,HTM,Up,9020,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PKLR,HTM,Up,9020,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PKM,HTM,Up,9021,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PKM,HTM,Up,9021,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PKM,HTM,Up,9021,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
PKM,HTM,Up,9021,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
PKM2,HTM,Down,9021,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
PKN1,HTM,Down,9405,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PKNOX2,HTM,Up,16714,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PKP1,HTM,Down,9023,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PKP1,HTM,Down,9023,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PKP1,HTM,Up,9023,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PKP1,HTM,Down,9023,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
PKP2,HTM,Down,9024,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PKP2,HTM,Down,9024,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PKP2,HTM,Down,9024,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
PKP2,HTM,Down,9024,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
PKP2,HTM,Down,9024,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
PKP2,HTM,Down,9024,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
PKP3,HTM,Down,9025,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PKP4,HTM,Down,9026,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PKP4,HTM,Down,9026,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
PLA1A,HTM,Down,17661,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PLA1A,HTM,Down,17661,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PLA2G10,HTM,Up,9029,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLA2G2A,HTM,Down,9031,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PLA2G3,HTM,Up,17934,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
PLA2G4A,HTM,Down,9035,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
PLA2G4A,HTM,Up,9035,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PLA2G4A,HTM,Up,9035,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PLA2G4A,HTM,Up,9035,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,35013621
PLA2G4C,HTM,Up,9037,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
PLA2G4C,HTM,Down,9037,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
PLA2G4C,HTM,Up,9037,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
PLA2G4C,HTM,Down,9037,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
PLA2G4C,HTM,Up,9037,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
PLA2G4C,HTM,Up,9037,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
PLA2G4E,HTM,Down,24791,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PLA2G4F,HTM,Up,27396,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PLA2R1,HTM,Down,9042,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PLA2R1,HTM,Up,9042,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PLAAT1,HTM,Up,14922,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
PLAAT3,HTM,Up,17825,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PLAAT3,HTM,Up,17825,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PLAAT3,HTM,Down,17825,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PLAAT3,HTM,Down,17825,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
PLAC8,HTM,Up,19254,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PLAC8,HTM,Up,19254,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PLAC8,HTM,Down,19254,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
PLAC8,HTM,Up,19254,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PLAG1,HTM,Up,9045,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
PLAG1,HTM,Up,9045,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
PLAGL1,HTM,Down,9046,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
PLAT,HTM,Down,9051,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
PLAT,HTM,Down,9051,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
PLAT,HTM,Up,9051,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
PLAT,HTM,Up,9051,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
PLAT,HTM,Up,9051,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
PLAT,HTM,Up,9051,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
PLAT,HTM,Up,9051,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
PLAT,HTM,Down,9051,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0064,34414448
PLAU,HTM,Down,9052,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
PLAU,HTM,Down,9052,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PLAU,HTM,Down,9052,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PLAU,HTM,Down,9052,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PLAU,HTM,Down,9052,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
PLAU,HTM,Down,9052,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
PLAUR,HTM,Down,9053,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0085,25881239
PLBD1,HTM,Up,26215,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PLBD1,HTM,Down,26215,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
PLBD1,HTM,Down,26215,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
PLBD1,HTM,Down,26215,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
PLCB1,HTM,Up,15917,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLCB1,HTM,Up,15917,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLCB3,HTM,Down,9056,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PLCB3,HTM,Down,9056,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
PLCB4,HTM,Up,9059,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PLCB4,HTM,Up,9059,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PLCD3,HTM,Down,9061,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PLCE1,HTM,Up,17175,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLCE1,HTM,Up,17175,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLCG1,HTM,Down,9065,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
PLCG1,HTM,Down,9065,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
PLCH1,HTM,Up,29185,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PLCH1,HTM,Up,29185,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PLCH1,HTM,Down,29185,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PLCL1,HTM,Up,9063,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
PLCXD3,HTM,Down,31822,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PLCXD3,HTM,Up,31822,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PLCXD3,HTM,Down,31822,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PLCXD3,HTM,Up,31822,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PLCXD3,HTM,Up,31822,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PLD1,HTM,Up,9067,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLD1,HTM,Up,9067,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLD5,HTM,Up,26879,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLD5,HTM,Up,26879,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLEC,HTM,Down,9069,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0053,23903875
PLEC,HTM,Up,9069,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
PLEC,HTM,Up,9069,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
PLEC,HTM,Up,9069,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
PLEC,HTM,Down,9069,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
PLEK2,HTM,Down,19238,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLEK2,HTM,Down,19238,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLEK2,HTM,Down,19238,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLEKHA1,HTM,Down,14335,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLEKHA2,HTM,Down,14336,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
PLEKHA2,HTM,Up,14336,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
PLEKHA4,HTM,Up,14339,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PLEKHA5,HTM,Up,30036,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
PLEKHA6,HTM,Up,17053,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLEKHA7,HTM,Up,27049,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PLEKHA7,HTM,Down,27049,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PLEKHB1,HTM,Down,19079,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PLEKHB1,HTM,Down,19079,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PLEKHB1,HTM,Up,19079,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PLEKHG1,HTM,Up,20884,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PLEKHG1,HTM,Up,20884,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PLEKHG1,HTM,Down,20884,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
PLEKHG3,HTM,Down,20364,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PLEKHG4,HTM,Up,24501,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PLEKHG6,HTM,Down,25562,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PLEKHH2,HTM,Up,30506,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PLEKHH2,HTM,Up,30506,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PLEKHM1,HTM,Down,29017,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PLEKHO2,HTM,Up,30026,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PLGLA,HTM,Up,9074,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
PLGLA,HTM,Up,9074,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
PLGLB2,HTM,Up,9073,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
PLIN2,HTM,Up,248,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
PLIN2,HTM,Up,248,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
PLIN2,HTM,Down,248,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
PLIN2,HTM,Down,248,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
PLIN2,HTM,Down,248,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
PLIN2,HTM,Up,248,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
PLIN4,HTM,Down,29393,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PLK13,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PLK13,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PLK13,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PLK2,HTM,Up,19699,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PLK3,HTM,Up,2154,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PLLP,HTM,Up,18553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PLOD1,HTM,Down,9081,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
PLOD1,HTM,Down,9081,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
PLOD1,HTM,Down,9081,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PLOD1,HTM,Down,9081,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
PLOD2,HTM,Down,9082,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0074,23903875
PLOD2,HTM,Down,9082,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
PLOD2,HTM,Up,9082,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,31709178
PLOD2,HTM,Down,9082,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0074,25676692
PLOD2,HTM,Down,9082,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0074,25676692
PLOD2,HTM,Down,9082,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0074,26259570
PLOD2,HTM,Down,9082,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0074,25676692
PLOD2,HTM,Down,9082,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0074,26259570
PLOD2,HTM,Down,9082,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0074,34680485
PLOD2,HTM,Up,9082,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0074,35013621
PLOD3,HTM,Down,9083,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
PLPBP,HTM,Up,9457,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
PLPBP,HTM,Up,9457,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PLPBP,HTM,Up,9457,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PLPBP,HTM,Down,9457,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PLPP1,HTM,Up,9228,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLPP2,HTM,Up,9230,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PLPP3,HTM,Up,9229,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PLPPR1,HTM,Up,25993,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLPPR2,HTM,Up,29566,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PLPPR4,HTM,Down,23496,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PLS1,HTM,Down,9090,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PLS3,HTM,Up,9091,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
PLS3-AS1,HTM,Down,50343,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PLSCR3,HTM,Down,16495,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLSCR3,HTM,Down,16495,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLSCR4,HTM,Up,16497,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PLSCR4,HTM,Down,16497,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
PLSCR4,HTM,Down,16497,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
PLSCR4,HTM,Down,16497,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
PLSCR4,HTM,Down,16497,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
PLXDC2,HTM,Up,21013,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PLXDC2,HTM,Up,21013,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PLXDC2,HTM,Down,21013,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PLXNA1,HTM,Down,9099,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLXNA1,HTM,Down,9099,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLXNA1,HTM,Down,9099,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PLXNA2,HTM,Down,9100,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PLXNA2,HTM,Down,9100,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PLXNA2,HTM,Down,9100,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PLXNA2,HTM,Down,9100,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PLXNA3,HTM,Up,9101,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PLXNA4,HTM,Down,9102,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0021,26351321
PLXNA4,HTM,Down,9102,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
PLXNB1,HTM,Down,9103,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22740085
PLXNB1,HTM,Down,9103,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
PLXNB1,HTM,Up,9103,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PLXNB2,HTM,Up,9104,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
PLXNB3,HTM,Up,9105,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PLXNC1,HTM,Up,9106,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
PLXNC1,HTM,Up,9106,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
PLXND1,HTM,Up,9107,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0011,17932721
PLXND1,HTM,Up,9107,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0011,17932721
PM20D2,HTM,Down,21408,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PMAIP1,HTM,Up,9108,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PMAIP1,HTM,Up,9108,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PMAIP1,HTM,Up,9108,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PMEL,HTM,Down,10880,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PMEPA1,HTM,Down,14107,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PMFBP1,HTM,Down,17728,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PMFBP1,HTM,Down,17728,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PMP2,HTM,Up,9117,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
PMP22,HTM,Up,9118,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PMP22,HTM,Up,9118,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PMS1,HTM,Down,9121,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
PNCK,HTM,Down,13415,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PNLDC1,HTM,Up,21185,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
PNLIPRP3,HTM,Down,23492,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PNMA2,HTM,Up,9159,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
PNMA8A,HTM,Down,25578,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PNP,HTM,Down,7892,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PNPLA10P,HTM,Up,32928,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PNPLA10P,HTM,Up,32928,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PNPLA10P,HTM,Up,32928,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PNPLA2,HTM,Down,30802,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PNPLA2,HTM,Up,30802,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
PNPLA2,HTM,Down,30802,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PNPLA2,HTM,Up,30802,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
PNPLA2,HTM,Up,30802,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
PNPLA2,HTM,Up,30802,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
PNPLA2,HTM,Up,30802,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
PNPLA4,HTM,Down,24887,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
PNPLA7,HTM,Up,24768,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PNPLA7,HTM,Up,24768,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PNPLA7,HTM,Up,24768,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PNPLA7,HTM,Up,24768,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PNRC2,HTM,Down,23158,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PNRC2,HTM,Down,23158,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POC1A,HTM,Down,24488,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
POC1B,HTM,Up,30836,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
POC1B,HTM,Up,30836,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
POC1B,HTM,Down,30836,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PODXL,HTM,Up,9171,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PODXL,HTM,Up,9171,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PODXL,HTM,Up,9171,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
PODXL,HTM,Up,9171,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31729259
PODXL,HTM,Up,9171,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31729259
POF1B,HTM,Up,13711,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POF1B,HTM,Up,13711,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POGLUT2,HTM,Up,19350,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
POGLUT2,HTM,Down,19350,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
POGLUT3,HTM,Up,28496,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
POLA1,HTM,Up,9173,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POLA2,HTM,Down,30073,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
POLA2,HTM,Down,30073,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
POLD1,HTM,Down,9175,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
POLD2,HTM,Down,9176,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
POLD2,HTM,Down,9176,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
POLD4,HTM,Down,14106,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
POLDIP2,HTM,Up,23781,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,22623141
POLH,HTM,Down,9181,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POLH,HTM,Down,9181,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POLH,HTM,Down,9181,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POLI,HTM,Down,9182,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
POLK,HTM,Down,9183,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
POLM,HTM,Down,9185,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
POLQ,HTM,Up,9186,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POLR1A,HTM,Down,17264,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
POLR1D,HTM,Down,20422,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POLR1E,HTM,Up,17631,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
POLR1E,HTM,Up,17631,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
POLR1E,HTM,Down,17631,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
POLR1G,HTM,Down,24219,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
POLR1G,HTM,Down,24219,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
POLR1G,HTM,Up,24219,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
POLR1G,HTM,Up,24219,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
POLR1G,HTM,Up,24219,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
POLR2A,HTM,Down,9187,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POLR2C,HTM,Down,9189,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
POLR2D,HTM,Down,9191,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
POLR2E,HTM,Down,9192,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
POLR2F,HTM,Down,9193,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
POLR2G,HTM,Down,9194,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
POLR2L,HTM,Down,9199,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
POLR3A,HTM,Down,30074,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POLR3C,HTM,Up,30076,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
POLR3C,HTM,Up,30076,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
POLR3C,HTM,Up,30076,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
POLR3D,HTM,Up,1080,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
POLR3D,HTM,Up,1080,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
POLR3G,HTM,Up,30075,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
POLR3G,HTM,Up,30075,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
POLR3G,HTM,Down,30075,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
POLR3G,HTM,Up,30075,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
POM121,HTM,Up,19702,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
POM121,HTM,Up,19702,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
POM121,HTM,Up,19702,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PON2,HTM,Up,9205,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PON2,HTM,Up,9205,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PON3,HTM,Up,9206,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PON3,HTM,Up,9206,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POP1,HTM,Down,30129,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
POP1,HTM,Up,30129,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
POP1,HTM,Up,30129,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PORCN,HTM,Down,17652,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PORCN,HTM,Down,17652,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PORCN,HTM,Down,17652,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POSTN,HTM,Up,16953,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,34228218
POSTN,HTM,Down,16953,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
POSTN,HTM,Up,16953,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
POSTN,HTM,Up,16953,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
POT1,HTM,Up,17284,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
POTEB,HTM,Up,33734,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POTEC,HTM,Down,33894,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
POTEE,HTM,Up,33895,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
POTEE,HTM,Up,33895,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
POTEE,HTM,UP,33895,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
POTEE,HTM,UP,33895,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
POTEE,HTM,UP,33895,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
POTEE,HTM,UP,33895,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
POTEE,HTM,UP,33895,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
POTEF,HTM,Up,33895,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
POTEF,HTM,Down,33905,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
POTEF,HTM,Up,33905,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
POTEG,HTM,Up,33896,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POTEG,HTM,Up,33896,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POTEH,HTM,Up,133,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POTEM,HTM,Up,37096,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
POU2F2,HTM,Up,9213,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
POU2F3,HTM,Up,19864,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
POU4F1,HTM,Down,9218,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
POU4F2,HTM,Down,9219,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
POU4F2,HTM,Down,9219,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
POU4F2,HTM,Down,9219,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
POU5F1,HTM,Up,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.52,0.6448,35229723
POU5F1,HTM,Up,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,DIM,Single-cell time-of-flight mass cytometry,0.52,0.6448,34464674
POU5F1,HTM,Up,9221,Breast Cancer,NA,Primary,NA,Transcriptomics,0.6,0.6448,30559934
POU6F2,HTM,Up,21694,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPA1,HTM,Down,9226,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,22623141
PPA2,HTM,Down,28883,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PPAP2A,HTM,Down,9228,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
PPARA,HTM,Up,9232,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
PPARD,HTM,Down,9235,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PPARD,HTM,Down,9235,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PPARD,HTM,Down,9235,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PPARG,HTM,Up,9236,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPARG,HTM,Up,9236,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPARGC1A,HTM,Down,9237,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PPARGC1A,HTM,Down,9237,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PPBP,HTM,Down,9240,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PPFIA2,HTM,Up,9246,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
PPFIA4,HTM,Down,9248,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PPFIBP1,HTM,Up,9249,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PPFIBP2,HTM,Up,9250,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PPFIBP2,HTM,Up,9250,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PPFIBP2,HTM,Down,9250,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
PPFIBP2,HTM,Down,9250,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
PPFIBP2,HTM,Up,9250,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PPIA,HTM,Up,9253,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
PPIB,HTM,Up,9255,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PPIB,HTM,Up,9255,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PPIB,HTM,Up,9255,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PPIB,HTM,Down,9255,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
PPID,HTM,Up,9257,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
PPID,HTM,Up,9257,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
PPIEL,HTM,Down,33195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PPIF,HTM,Down,9259,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
PPIL4,HTM,Down,15702,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PPIL6,HTM,Down,21557,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PPIP5K1,HTM,Up,29023,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PPIP5K1,HTM,Up,29023,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PPIP5K1,HTM,Up,29023,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PPIP5K2,HTM,Down,29035,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
PPL,HTM,Down,9273,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PPL,HTM,Down,9273,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
PPM1B,HTM,Down,9276,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PPM1B,HTM,Down,9276,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PPM1B,HTM,Up,9276,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PPM1D,HTM,Up,9277,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
PPM1E,HTM,Up,19322,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PPM1L,HTM,Up,16381,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PPME1,HTM,Down,30178,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PPP1CA,HTM,Down,9281,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PPP1CB,HTM,Down,9282,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PPP1CB,HTM,Up,9282,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PPP1R10,HTM,Down,9284,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PPP1R11,HTM,Down,9285,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PPP1R13L,HTM,Down,18838,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PPP1R14A,HTM,Down,14871,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PPP1R14A,HTM,Up,14871,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PPP1R14C,HTM,Down,14952,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PPP1R15A,HTM,Up,14375,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PPP1R15A,HTM,Up,14375,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PPP1R15A,HTM,Up,14375,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PPP1R16A,HTM,Up,14941,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
PPP1R18,HTM,Down,29413,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP1R18,HTM,Down,29413,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP1R18,HTM,Down,29413,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP1R1B,HTM,Up,9287,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PPP1R1C,HTM,Down,14940,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PPP1R1C,HTM,Down,14940,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PPP1R2,HTM,Up,9288,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
PPP1R21,HTM,Down,30595,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PPP1R21,HTM,Down,30595,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PPP1R26,HTM,Down,29089,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PPP1R3C,HTM,Up,9293,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
PPP1R3C,HTM,Up,9293,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PPP1R3C,HTM,Up,9293,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PPP1R3C,HTM,Down,9293,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
PPP1R3C,HTM,Up,9293,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PPP1R3F,HTM,Down,14944,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
PPP1R9A,HTM,Up,14946,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP1R9A,HTM,Up,14946,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP1R9B,HTM,Down,9298,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
PPP2R2A,HTM,Down,9304,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PPP2R2C,HTM,Up,9306,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP2R2C,HTM,Up,9306,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP2R2D,HTM,Up,23732,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PPP2R2D,HTM,Up,23732,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PPP2R2D,HTM,Up,23732,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PPP2R3A,HTM,Down,9307,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP2R3A,HTM,Down,9307,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP2R3A,HTM,Down,9307,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP3CA,HTM,Up,9314,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
PPP3CB,HTM,Down,9315,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP3CC,HTM,Down,9316,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP4R1,HTM,Down,9320,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP4R1,HTM,Down,9320,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP4R1,HTM,Down,9320,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP4R4,HTM,Down,23788,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP4R4,HTM,Down,23788,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP4R4,HTM,Down,23788,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PPP6R2,HTM,Down,19253,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PPRC1,HTM,Up,30025,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
PQLC2,HTM,Down,26001,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PQLC2,HTM,Down,26001,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PRAG1,HTM,Up,25438,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PRAME,HTM,Up,9336,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PRAME,HTM,Up,9336,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PRAME,HTM,Up,9336,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
PRDM5,HTM,Down,9349,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
PRDX1,HTM,Up,9352,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PRDX1,HTM,Up,9352,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
PRDX1,HTM,Down,9352,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
PRDX1,HTM,Down,9352,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
PRDX1,HTM,Up,9352,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
PRDX2,HTM,Down,9353,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0074,32503348
PRDX2,HTM,Down,9353,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0074,32503348
PRDX2,HTM,Down,9353,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0074,31501409
PRDX2,HTM,Down,9353,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0074,34168259
PRDX2,HTM,Down,9353,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0074,34168259
PRDX2,HTM,Down,9353,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0074,24098529
PRDX3,HTM,Up,9354,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PRDX3,HTM,Down,9354,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PRDX4,HTM,Up,17169,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,22623141
PRDX5,HTM,Up,9355,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PRDX5,HTM,Up,9355,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PRDX5,HTM,Up,9355,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PRDX5,HTM,Up,9355,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PRDX5,HTM,Down,9355,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PRDX5,HTM,Up,9355,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
PRDX6,HTM,Up,16753,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
PRDX6,HTM,Up,16753,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
PRDX6,HTM,Up,16753,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
PRDX6,HTM,Up,16753,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
PRELID2,HTM,Down,28306,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PRELID3B,HTM,Down,15892,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
PREP,HTM,Down,9358,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PREP,HTM,Down,9358,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PREP,HTM,Down,9358,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PREX1,HTM,Down,32594,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
PREX1,HTM,Up,32594,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
PREX1,HTM,Down,32594,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PREX1,HTM,Down,32594,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
PREX1,HTM,Down,32594,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
PREX2,HTM,Up,22950,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRG2,HTM,Down,9362,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PRG2,HTM,Down,9362,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PRG4,HTM,Up,9364,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRICKLE1,HTM,Down,17019,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRICKLE2,HTM,Down,20340,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PRICKLE2,HTM,Down,20340,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PRICKLE2,HTM,Up,20340,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PRICKLE2-AS1,HTM,Up,40916,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PRIM1,HTM,Up,9369,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRKAA2,HTM,Up,9377,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRKAA2,HTM,Up,9377,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRKAB2,HTM,Down,9379,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PRKAB2,HTM,Down,9379,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PRKAB2,HTM,Down,9379,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
PRKACB,HTM,Up,9381,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PRKAG1,HTM,Down,9385,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PRKAG1,HTM,Down,9385,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
PRKAR1B,HTM,Down,9390,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PRKAR2A,HTM,Up,9391,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
PRKAR2B,HTM,Up,9392,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRKAR2B,HTM,Up,9392,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRKAR2B,HTM,Up,9392,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRKCA,HTM,Up,9393,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PRKCA,HTM,Up,9393,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PRKCA,HTM,NA,9393,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0042,29352988
PRKCA,HTM,Down,9393,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0042,23820871
PRKCA,HTM,Up,9393,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
PRKCA,HTM,Up,9393,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
PRKCB,HTM,NA,9395,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0032,29352988
PRKCB,HTM,Down,9395,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
PRKCB,HTM,Down,9395,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
PRKCD,HTM,Down,9399,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
PRKCD,HTM,Down,9399,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
PRKCD,HTM,Down,9399,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PRKCE,HTM,Down,9401,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PRKCE,HTM,Down,9401,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
PRKCE,HTM,Down,9401,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
PRKCG,HTM,NA,9402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0021,29352988
PRKCG,HTM,Up,9402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PRKCQ,HTM,NA,9410,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0011,29352988
PRKCSH,HTM,Up,9411,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PRKCSH,HTM,Up,9411,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PRKCSH,HTM,Down,9411,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
PRKCZ,HTM,Up,9412,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
PRKCZ,HTM,Up,9412,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
PRKD1,HTM,Up,9407,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PRKD1,HTM,Up,9407,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PRKD1,HTM,Up,9407,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PRKD1,HTM,Up,9407,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PRKDC,HTM,Down,9413,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
PRKDC,HTM,Down,9413,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
PRKDC,HTM,Up,9413,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
PRKG1,HTM,Up,9414,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRKRA,HTM,Down,9438,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
PRLR,HTM,Down,9446,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PRLR,HTM,Down,9446,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PRLR,HTM,Up,9446,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PRMT1,HTM,Up,5187,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PRMT2,HTM,Up,5186,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
PRMT3,HTM,Down,30163,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
PRMT5,HTM,Up,10894,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
PRMT6,HTM,Down,18241,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRMT6,HTM,Down,18241,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PROCR,HTM,Down,9452,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PROCR,HTM,Down,9452,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PRODH,HTM,Up,9453,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PRODH,HTM,Up,9453,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PRODH,HTM,Up,9453,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PROM1,HTM,Up,9454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,DIM,Single-cell time-of-flight mass cytometry,0.48,0.7582,34464674
PROM1,HTM,Up,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Doxorubicin,SFA and FACs followed by single-cell time-of-flight mass cytometry,0.48,0.7582,34831064
PROM1,HTM,Up,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.48,0.7582,22954703
PROM1,HTM,Up,9454,Breast Cancer,NA,Primary,NA,Transcriptomics,0.6,0.7582,30559934
PROM1,HTM,Up,9454,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.6,0.7582,20530554
PROM2,HTM,Down,20685,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PROM2,HTM,Down,20685,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PROS1,HTM,Up,9456,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PROS1,HTM,Up,9456,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PROS1,HTM,Up,9456,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PROS1,HTM,Up,9456,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PROSER2,HTM,Up,23728,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PROSER2,HTM,Up,23728,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PROSER2,HTM,Down,23728,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PROSER2,HTM,Down,23728,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
PROSER2,HTM,Down,23728,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
PROSER2,HTM,Up,23728,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PRPF19,HTM,Down,17896,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PRPF19,HTM,Down,17896,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PRPF39,HTM,Down,20314,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PRPF39,HTM,Down,20314,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PRPF39,HTM,Down,20314,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PRPF39,HTM,Down,20314,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PRPF39,HTM,Down,20314,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PRPF4B,HTM,Down,17346,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PRPF4B,HTM,Down,17346,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PRPF4B,HTM,Down,17346,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PRPF4B,HTM,Down,17346,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PRPF4B,HTM,Down,17346,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PRPF8,HTM,Up,17340,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
PRPS1,HTM,Up,9462,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PRPS1,HTM,Down,9462,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PRPS1,HTM,Down,9462,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PRR11,HTM,Down,25619,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
PRR11,HTM,Down,25619,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
PRR12,HTM,Down,29217,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PRR14,HTM,Down,28458,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PRR15,HTM,Down,22310,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PRR15,HTM,Up,22310,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PRR15L,HTM,Up,28149,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
PRR5,HTM,Down,31682,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PRR7,HTM,Up,28130,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PRR7,HTM,Up,28130,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PRRC2B,HTM,Down,28121,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PRRC2B,HTM,Down,28121,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PRRC2B,HTM,Down,28121,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PRRG1,HTM,Down,9469,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
PRRG2,HTM,Down,9470,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PRRG4,HTM,Down,30799,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PRRT2,HTM,Down,30500,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
PRRT4,HTM,Up,37280,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PRRX1,HTM,Up,9142,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PRRX1,HTM,Up,9142,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PRRX1,HTM,Up,9142,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
PRRX1,HTM,Up,9142,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PRRX1,HTM,Up,9142,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,28588211
PRSS1,HTM,Up,9475,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,33670440
PRSS1,HTM,Down,9475,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0032,25881239
PRSS1,HTM,Down,9475,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0032,25881239
PRSS1,HTM,Down,9475,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PRSS1,HTM,Down,9475,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PRSS1,HTM,Down,9475,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
PRSS12,HTM,Down,9477,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRSS12,HTM,Down,9477,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRSS16,HTM,Down,9480,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PRSS2,HTM,Down,9483,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PRSS2,HTM,Down,9483,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PRSS2,HTM,Down,9483,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PRSS2,HTM,Down,9483,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0032,26351321
PRSS2,HTM,Down,9483,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PRSS2,HTM,Down,9483,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PRSS2,HTM,Down,9483,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PRSS2,HTM,Down,9483,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
PRSS22,HTM,Down,14368,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PRSS23,HTM,Down,14370,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0042,23820871
PRSS23,HTM,Up,14370,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
PRSS23,HTM,Down,14370,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
PRSS23,HTM,Down,14370,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
PRSS23,HTM,Down,14370,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
PRSS27,HTM,Down,15475,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PRSS27,HTM,Down,15475,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PRSS3,HTM,Up,9486,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,33670440
PRSS3,HTM,Down,9486,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0021,25881239
PRSS3,HTM,Down,9486,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0021,25881239
PRSS3,HTM,Down,9486,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0021,25881239
PRSS3,HTM,Down,9486,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PRSS3,HTM,Down,9486,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PRSS3,HTM,Down,9486,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PRSS3P2,HTM,Down,43788,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PRSS3P2,HTM,Down,43788,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PRSS3P2,HTM,Down,43788,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
PRSS48,HTM,Up,24635,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRSS53,HTM,Up,34407,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PRSS53,HTM,Up,34407,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PRSS53,HTM,Up,34407,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PRSS56,HTM,Down,39433,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
PRSS56,HTM,Down,39433,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
PRSS8,HTM,Down,9491,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PRTFDC1,HTM,Up,23333,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PRTFDC1,HTM,Up,23333,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PRTFDC1,HTM,Up,23333,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PRTFDC1,HTM,Up,23333,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
PRTFDC1,HTM,Up,23333,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
PRTFDC1,HTM,Up,23333,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
PRTFDC1,HTM,Down,23333,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
PRTFDC1,HTM,Up,23333,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
PRTG,HTM,Up,26373,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRTG,HTM,Up,26373,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PRXL2A,HTM,Up,28651,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PRXL2A,HTM,Up,28651,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PRXL2A,HTM,Down,28651,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PRXL2C,HTM,Down,16881,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PSAP,HTM,Up,9498,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PSAP,HTM,Down,9498,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PSAP,HTM,Down,9498,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PSAPL1,HTM,Up,33131,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PSAT1,HTM,Down,19129,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
PSAT1,HTM,Up,19129,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
PSAT1,HTM,Down,19129,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
PSAT1,HTM,Down,19129,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
PSCA,HTM,Up,9500,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
PSCA,HTM,Up,9500,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PSCA,HTM,Up,9500,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PSCA,HTM,Up,9500,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
PSCA,HTM,Up,9500,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
PSCA,HTM,Up,9500,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
PSD4,HTM,Down,19096,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PSG5,HTM,Up,9522,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PSIP1,HTM,Up,9527,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PSIP1,HTM,Up,9527,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
PSMA1,HTM,Down,9530,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PSMA1,HTM,Down,9530,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PSMA2,HTM,Down,9531,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PSMA2,HTM,Down,9531,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PSMA3,HTM,Down,9532,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PSMA4,HTM,Down,9533,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PSMA4,HTM,Down,9533,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PSMA5,HTM,Down,9534,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PSMA5,HTM,Down,9534,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PSMA5,HTM,Down,9534,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PSMA5,HTM,Down,9534,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PSMA5,HTM,Down,9534,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PSMA7,HTM,Down,9536,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PSMA7,HTM,Down,9536,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PSMA7,HTM,Down,9536,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
PSMB1,HTM,Down,9537,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PSMB10,HTM,Down,9538,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PSMB7,HTM,Down,9544,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PSMB7,HTM,Down,9544,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PSMB7,HTM,Down,9544,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PSMB8,HTM,Down,9545,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PSMB9,HTM,Down,9546,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
PSMB9,HTM,Down,9546,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PSMB9,HTM,Down,9546,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PSMC3,HTM,Up,9549,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
PSMC4,HTM,Up,9551,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PSMC4,HTM,Up,9551,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PSMC4,HTM,Down,9551,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PSMC4,HTM,Down,9551,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PSMC4,HTM,Up,9551,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
PSMC5,HTM,Down,9552,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PSMC5,HTM,Up,9552,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PSMC6,HTM,Down,9553,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,22623141
PSMC6,HTM,Up,9553,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PSMC6,HTM,Up,9553,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PSMC6,HTM,Up,9553,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
PSMD14,HTM,Down,16889,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PSMD14,HTM,Down,16889,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PSMD2,HTM,Down,9559,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PSMD2,HTM,Down,9559,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PSMD2,HTM,Down,9559,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PSMD2,HTM,Down,9559,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PSMD8,HTM,Up,9566,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
PSME1,HTM,Up,9568,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PSME1,HTM,Up,9568,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PSME1,HTM,Down,9568,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PSME1,HTM,Up,9568,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
PSME1,HTM,Down,9568,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PSME2,HTM,Down,9569,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
PSME3,HTM,Down,9570,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PSME3,HTM,Down,9570,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29511337
PSME3,HTM,Down,9570,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0021,29511337
PSME4,HTM,Down,20635,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PSMF1,HTM,Down,9571,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PSMF1,HTM,Down,9571,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PSORS1C1,HTM,Up,17202,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PSORS1C2,HTM,Up,17199,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PSORS1C2,HTM,Up,17199,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PSORS1C2,HTM,Up,17199,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PSORS1C2,HTM,Up,17199,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PSORS1C2,HTM,Up,17199,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
PSPC1,HTM,Up,20320,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
PSPH,HTM,Down,9577,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PSPH,HTM,Down,9577,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PSPH,HTM,Up,9577,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
PSPH,HTM,Up,9577,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
PSTK,HTM,Up,28578,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PSTK,HTM,Up,28578,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PSTK,HTM,Up,28578,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PSTPIP2,HTM,Down,9581,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PSTPIP2,HTM,Down,9581,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PSTPIP2,HTM,Down,9581,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PTAFR,HTM,Down,9582,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTAFR,HTM,Down,9582,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTAFR,HTM,Down,9582,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTAFR,HTM,Down,9582,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PTAFR,HTM,Down,9582,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PTBP1,HTM,Down,9583,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
PTCH1,HTM,Up,9585,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PTCH1,HTM,Up,9585,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PTCH1,HTM,Up,9585,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0032,29959199
PTCHD1,HTM,Down,26392,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
PTDSS2,HTM,Up,15463,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PTDSS2,HTM,Up,15463,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PTEN,HTM,Up,9588,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0053,20530554
PTER,HTM,Up,9590,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PTGER2,HTM,Up,9594,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PTGES,HTM,Down,9599,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PTGES,HTM,Down,9599,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PTGES3,HTM,Down,16049,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PTGES3,HTM,Down,16049,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PTGES3L-AARSD1,HTM,Down,43946,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PTGES3L-AARSD1,HTM,Down,43946,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PTGFRN,HTM,Down,9601,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTGFRN,HTM,Down,9601,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTGFRN,HTM,Down,9601,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTGFRN,HTM,Down,9601,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PTGIS,HTM,Down,9603,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PTGIS,HTM,Down,9603,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PTGR1,HTM,Up,18429,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTGR1,HTM,Up,18429,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTGR1,HTM,Down,18429,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
PTGR1,HTM,Down,18429,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
PTGR1,HTM,Down,18429,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
PTGR2,HTM,Up,20149,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTGR2,HTM,Up,20149,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTGR2,HTM,Down,20149,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
PTGS1,HTM,Down,9604,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
PTGS1,HTM,Down,9604,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PTGS2,HTM,Down,9605,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,29340052
PTGS2,HTM,Down,9605,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
PTGS2,HTM,Up,9605,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,24961511
PTGS2,HTM,Up,9605,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,24961511
PTGS2,HTM,Up,9605,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.24,0.0064,24961511
PTGS2,HTM,Up,9605,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.24,0.0064,24961511
PTGS2,HTM,Down,9605,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
PTGS2,HTM,Up,9605,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
PTGS2,HTM,Up,9605,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0064,28927099
PTGS2,HTM,Down,9605,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
PTGS2,HTM,Down,9605,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,29340052
PTH2R,HTM,Up,9609,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PTHLH,HTM,Up,9607,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,25432175
PTHLH,HTM,Down,9607,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0042,25881239
PTHLH,HTM,Down,9607,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.24,0.0042,25881239
PTHLH,HTM,Up,9607,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0042,23820871
PTHLH,HTM,Down,9607,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PTHLH,HTM,Down,9607,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
PTHLH,HTM,Down,9607,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
PTK2,HTM,NA,9611,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0032,29352988
PTK2,HTM,Down,9611,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
PTK2,HTM,Down,9611,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
PTK2,HTM,Up,9611,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
PTK2B,HTM,Down,9612,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTK2B,HTM,Up,9612,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PTK7,HTM,Up,9618,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.2,0.0032,23903875
PTK7,HTM,Down,9618,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
PTMA,HTM,Down,9623,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PTMA,HTM,Down,9623,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
PTMA,HTM,Down,9623,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
PTMA,HTM,Down,9623,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
PTMS,HTM,Up,9629,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PTMS,HTM,Up,9629,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PTOV1,HTM,Down,9632,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
PTP4A2,HTM,Down,9635,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
PTP4A3,HTM,Up,9636,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PTP4A3,HTM,Up,9636,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PTPLA9,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PTPLA9,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PTPLA9,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
PTPN13,HTM,Down,9646,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PTPN13,HTM,Down,9646,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PTPN14,HTM,Down,9647,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTPN14,HTM,Down,9647,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTPN14,HTM,Down,9647,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTPN14,HTM,Down,9647,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
PTPN18,HTM,Down,9649,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PTPN2,HTM,Up,9650,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
PTPN20,HTM,Up,23423,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
PTPN20,HTM,Down,23423,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PTPN3,HTM,Down,9655,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PTPN4,HTM,Up,9656,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
PTPN6,HTM,Down,9658,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PTPRD,HTM,Up,9668,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
PTPRD,HTM,Down,12839,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
PTPRE,HTM,Down,9669,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PTPRE,HTM,Down,9669,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PTPRE,HTM,Down,9669,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PTPRE,HTM,Up,9669,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.24,0.0032,34680485
PTPRF,HTM,Up,9670,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
PTPRG,HTM,Down,9671,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PTPRG,HTM,Down,9671,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PTPRG,HTM,Down,9671,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PTPRH,HTM,Down,9672,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PTPRH,HTM,Down,9672,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
PTPRJ,HTM,Down,9673,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PTPRJ,HTM,Up,9673,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTPRJ,HTM,Up,9673,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTPRK,HTM,Down,9674,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTPRK,HTM,Down,9674,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTPRK,HTM,Down,9674,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PTPRK,HTM,Down,9674,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PTPRK,HTM,Down,9674,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
PTPRM,HTM,Up,9675,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PTPRM,HTM,Up,9675,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
PTPRM,HTM,Down,9675,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
PTPRM,HTM,Down,9675,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
PTPRM,HTM,Down,9675,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
PTPRM,HTM,Down,9675,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
PTPRM,HTM,Down,9675,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
PTPRN2,HTM,Up,9677,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PTPRT,HTM,Up,9682,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PTPRU,HTM,Down,9683,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PTPRZ1,HTM,Down,9685,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PTPRZ1,HTM,Down,9685,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PTPRZ1,HTM,Down,9685,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PTTG1IP,HTM,Down,13524,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PTX3,HTM,Up,9692,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PTX3,HTM,Up,9692,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31729259
PTX3,HTM,Up,9692,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31729259
PUDP,HTM,Down,16818,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PUF60,HTM,Down,17042,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PUF60,HTM,Down,17042,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
PURG,HTM,Down,17930,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
PUS1,HTM,Up,15508,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PUS1,HTM,Up,15508,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
PUS1,HTM,Down,15508,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PUS7,HTM,NA,26033,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
PUS7L,HTM,Down,25276,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
PVR,HTM,Down,9705,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PVRIG,HTM,Down,32190,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PVRIG,HTM,Down,32190,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
PVT1,HTM,Down,9709,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
PVT1,HTM,Down,9709,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
PWP2,HTM,Down,9711,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
PWWP2A,HTM,Up,29406,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
PWWP3A,HTM,Up,29641,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
PXDN,HTM,Down,14966,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PXDN,HTM,Down,14966,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PXDN,HTM,Down,14966,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
PXDN,HTM,Down,14966,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
PXDN,HTM,Down,14966,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
PXDN,HTM,Down,14966,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
PXDN,HTM,Down,14966,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
PXMP4,HTM,Up,15920,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
PXN,HTM,NA,9718,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0011,29352988
PXT1,HTM,Down,18312,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
PYCARD,HTM,Down,16608,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PYCARD,HTM,Down,16608,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
PYCARD,HTM,Down,16608,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
PYGB,HTM,Up,9723,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
PYGB,HTM,Up,9723,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
PYGB,HTM,Up,9723,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
PYGL,HTM,Down,9725,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
PYGL,HTM,Down,9725,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
PYGO1,HTM,Up,30256,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PYGO1,HTM,Up,30256,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
PYROXD2,HTM,Up,23517,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PYROXD2,HTM,Up,23517,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PYROXD2,HTM,Up,23517,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
PZP,HTM,Up,9750,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
QARS1,HTM,Down,9751,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
QARS1,HTM,Up,9751,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
QKI,HTM,Down,21100,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
QKI,HTM,Down,21100,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
QKI,HTM,Up,21100,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
QPCT,HTM,Up,9753,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
QPCT,HTM,Up,9753,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
QRFPR,HTM,Down,15565,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
QRICH2,HTM,Up,25326,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
QRICH2,HTM,Up,25326,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
QSOX1,HTM,Down,9756,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
QSOX1,HTM,Down,9756,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
QSOX1,HTM,Up,9756,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
QSOX1,HTM,Up,9756,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
R3HDM1,HTM,Up,9757,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
R3HDM1,HTM,Up,9757,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
R3HDM1,HTM,Up,9757,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
R3HDM2,HTM,Down,29167,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RAB10,HTM,Up,9759,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RAB10,HTM,Up,9759,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RAB11A,HTM,Up,9760,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RAB11A,HTM,Up,9760,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RAB11A,HTM,Up,9760,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RAB11FIP1,HTM,Down,30265,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
RAB11FIP1,HTM,Up,30265,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RAB11FIP1,HTM,Down,30265,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
RAB11FIP3,HTM,Down,17224,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RAB11FIP4,HTM,Down,30267,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RAB11FIP4,HTM,Up,30267,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
RAB15,HTM,Up,20150,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RAB15,HTM,Up,20150,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RAB15,HTM,Down,20150,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RAB17,HTM,Down,16523,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RAB17,HTM,Down,16523,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RAB18,HTM,Down,14244,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RAB1A,HTM,Up,9758,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RAB1A,HTM,Up,9758,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RAB1A,HTM,Up,9758,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RAB20,HTM,Down,18260,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RAB20,HTM,Down,18260,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
RAB21,HTM,Up,18263,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
RAB25,HTM,Down,18238,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RAB25,HTM,Down,18238,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RAB27A,HTM,Down,9766,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
RAB27B,HTM,Up,9767,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
RAB27B,HTM,Up,9767,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RAB27B,HTM,Up,9767,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
RAB27B,HTM,Up,9767,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
RAB27B,HTM,Up,9767,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
RAB2B,HTM,Down,20246,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RAB30,HTM,Up,9770,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RAB31,HTM,Down,9771,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RAB31,HTM,Down,9771,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RAB31,HTM,Down,9771,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RAB31,HTM,Down,9771,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
RAB31,HTM,Down,9771,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
RAB31,HTM,Down,9771,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
RAB32,HTM,Down,9772,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RAB33B,HTM,Up,16075,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RAB37,HTM,Down,30268,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RAB38,HTM,Down,9776,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RAB38,HTM,Down,9776,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RAB38,HTM,Down,9776,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RAB39A,HTM,Down,16521,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RAB3B,HTM,Down,9778,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RAB3D,HTM,Up,9779,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RAB3IL1,HTM,Up,9780,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RAB3IL1,HTM,Up,9780,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RAB3IL1,HTM,Up,9780,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RAB3IL1,HTM,Up,9780,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RAB3IP,HTM,Down,16508,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
RAB40B,HTM,Up,18284,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RAB40B,HTM,Up,18284,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RAB40B,HTM,Up,18284,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RAB42,HTM,Down,28702,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RAB4B,HTM,Down,9782,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RAB5A,HTM,Down,9783,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
RAB5A,HTM,Down,9783,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
RAB6A,HTM,Up,9786,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RAB6A,HTM,Up,9786,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RAB6A,HTM,Up,9786,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RAB6C,HTM,Up,16525,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22740085
RAB7A,HTM,Up,9788,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RAB7A,HTM,Up,9788,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RAB7A,HTM,Up,9788,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RAB8B,HTM,Down,30273,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RAB9B,HTM,Down,14090,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RABEP2,HTM,Down,24817,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RABGAP1L,HTM,Down,24663,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
RABL2A,HTM,Down,9799,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RABL2B,HTM,Down,9800,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
RAC1,HTM,Down,9801,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
RAC1,HTM,Down,9801,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
RAC1,HTM,Down,9801,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
RAC1,HTM,Down,9801,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
RAC2,HTM,Down,9802,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RAC2,HTM,Down,9802,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RAC2,HTM,Down,9802,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RACK1,HTM,Down,4399,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RACK1,HTM,Down,4399,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RACK1,HTM,Up,4399,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
RACK1,HTM,Up,4399,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RAD1,HTM,Up,9806,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22740085
RAD17,HTM,Down,9807,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
RAD21,HTM,Down,9811,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
RAD21L1,HTM,Down,16271,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RAD23B,HTM,Up,9813,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RAD23B,HTM,Up,9813,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RAD50,HTM,Down,9816,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RAD51,HTM,Up,9817,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Transcriptomics followed by Western Blotting,0.32,0.0032,24440048
RAD51,HTM,Down,9817,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
RAD51,HTM,Down,9817,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
RAD51,HTM,Down,9817,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
RAD51B,HTM,Up,9822,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RAD51B,HTM,Up,9822,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RAD51B,HTM,Up,9822,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RAD51B,HTM,Up,9822,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RAD51B,HTM,Up,9822,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RAD54B,HTM,Up,17228,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RAD54B,HTM,Down,17228,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RAD54L,HTM,Down,9826,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RAET1E,HTM,Down,16793,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RAET1L,HTM,Up,16798,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RAF1,HTM,Down,9829,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RAF1,HTM,Down,9829,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RAF1,HTM,Down,9829,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RAF1,HTM,Down,9829,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
RAF1,HTM,Down,9829,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
RAI14,HTM,Down,14873,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RAI14,HTM,Down,14873,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
RALA,HTM,Down,9839,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RALB,HTM,Down,9840,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
RALB,HTM,Down,9840,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RALB,HTM,Down,9840,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
RALB,HTM,Down,9840,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
RALGAPA1,HTM,Up,17770,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
RALGAPA1,HTM,Down,17770,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
RALGAPA2,HTM,Up,16207,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RALGAPB,HTM,Up,29221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
RALGPS1,HTM,Down,16851,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RALGPS1,HTM,Down,16851,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
RALGPS1,HTM,Down,16851,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
RALY,HTM,Down,15921,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RALYL,HTM,Down,27036,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RAMP3,HTM,Down,9845,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RAN,HTM,Down,9846,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RAN,HTM,Down,9846,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RANBP1,HTM,Down,9847,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RANBP1,HTM,Down,9847,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RANBP1,HTM,Up,9847,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RANBP17,HTM,Down,14428,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
RANBP2,HTM,Down,9848,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
RANBP2,HTM,Up,9848,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
RANBP3,HTM,Up,9850,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
RANBP3L,HTM,Up,26353,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
RAP1A,HTM,Up,9855,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RAP1A,HTM,Up,9855,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RAP1A,HTM,Down,9855,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RAP1B,HTM,Down,9857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
RAP1GDS1,HTM,Down,9859,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RAP1GDS1,HTM,Down,9859,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RAP2A,HTM,Down,9861,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RAPGEF2,HTM,Up,16854,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
RAPGEF5,HTM,Up,16862,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RAPGEF5,HTM,Down,16862,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
RAPGEF5,HTM,Up,16862,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
RAPGEF6,HTM,Up,20655,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RAPGEF6,HTM,Up,20655,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RAPGEF6,HTM,Up,20655,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RAPGEFL1,HTM,Up,17428,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RAPGEFL1,HTM,Down,17428,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
RAPGEFL1,HTM,Down,17428,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
RAPH1,HTM,Up,14436,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
RAPH1,HTM,Up,14436,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
RAPH1,HTM,Up,14436,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
RAPH1,HTM,Up,14436,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RARA,HTM,Down,9864,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RARA,HTM,Down,9864,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RARB,HTM,Down,9865,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
RARB,HTM,Down,9865,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
RARB,HTM,Up,9865,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RARB,HTM,Up,9865,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RARB,HTM,Up,9865,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RARB,HTM,Down,9865,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
RARB,HTM,Down,9865,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
RARRES1,HTM,Up,9867,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RARRES1,HTM,Down,9867,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RARS1,HTM,Down,9870,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RARS1,HTM,Down,9870,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RARS1,HTM,Up,9870,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
RASA1,HTM,Down,9871,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
RASA1,HTM,Down,9871,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
RASA2,HTM,Down,9872,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RASA3,HTM,Up,20331,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RASA4,HTM,Up,23181,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RASAL1,HTM,Down,9873,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RASAL2,HTM,Down,9874,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RASAL2,HTM,Down,9874,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RASAL2,HTM,Up,9874,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
RASD1,HTM,Down,15828,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RASD1,HTM,Down,15828,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RASD1,HTM,Down,15828,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RASD1,HTM,Up,15828,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RASEF,HTM,Up,26464,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
RASEF,HTM,Up,26464,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
RASEF,HTM,Up,26464,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
RASEF,HTM,Up,26464,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RASGEF1B,HTM,Up,24881,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RASGRF2,HTM,Down,9876,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
RASGRP1,HTM,Down,9878,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RASGRP3,HTM,Up,14545,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RASL11A,HTM,Down,23802,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RASL11A,HTM,Down,23802,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RASSF1,HTM,Up,9882,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
RASSF2,HTM,Up,9883,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RASSF3,HTM,Up,14271,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RASSF5,HTM,Down,17609,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RASSF5,HTM,Down,17609,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RASSF6,HTM,Down,20796,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RASSF6,HTM,Down,20796,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RASSF6,HTM,Up,20796,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
RASSF8,HTM,Down,13232,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RASSF8,HTM,Up,13232,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
RASSF8,HTM,Up,13232,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
RASSF8-AS1,HTM,Up,48637,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RAVER2,HTM,Up,25577,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
RB1CC1,HTM,Up,15574,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
RBAK,HTM,Up,17680,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
RBBP4,HTM,Down,9887,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RBBP5,HTM,Up,9888,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RBBP6,HTM,Up,9889,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RBBP6,HTM,Up,9889,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RBBP6,HTM,Up,9889,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RBBP7,HTM,Down,9890,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RBBP7,HTM,Down,9890,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RBBP7,HTM,Down,9890,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RBBP7,HTM,Up,9890,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RBBP8,HTM,Down,9891,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RBBP8,HTM,Down,9891,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RBFA,HTM,Down,26120,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RBFOX3,HTM,Up,27097,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RBIS,HTM,Down,32235,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RBIS,HTM,Down,32235,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RBIS,HTM,Down,32235,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RBIS,HTM,Down,32235,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RBIS,HTM,Down,32235,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RBM12,HTM,Down,9898,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
RBM15,HTM,Up,14959,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RBM15,HTM,Up,14959,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RBM15,HTM,Up,14959,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RBM15,HTM,Up,14959,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RBM15,HTM,Up,14959,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RBM17,HTM,Up,16944,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
RBM18,HTM,Up,28413,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
RBM24,HTM,Up,21539,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RBM24,HTM,Up,21539,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RBM24,HTM,Down,21539,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
RBM24,HTM,Down,21539,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
RBM25,HTM,Down,23244,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
RBM25,HTM,Up,23244,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
RBM39,HTM,Down,15923,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RBM39,HTM,Up,15923,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
RBM42,HTM,Down,28117,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
RBM43,HTM,Down,24790,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RBM43,HTM,Down,24790,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RBM47,HTM,Down,30358,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RBM47,HTM,Up,30358,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RBM48,HTM,Up,21785,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
RBM5-AS1,HTM,Up,48871,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics,0.04,0.0011,27520449
RBMS1,HTM,Down,9907,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RBMS1,HTM,Down,9907,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
RBMS2,HTM,Down,9909,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RBMS3,HTM,Down,13427,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RBMS3,HTM,Down,13427,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
RBMX,HTM,Down,9910,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RBMXL1,HTM,Down,25073,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RBP1,HTM,Down,9919,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RBP1,HTM,Down,9919,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RBP1,HTM,Down,9919,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RBP1,HTM,Down,9919,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RBP2,HTM,Down,9920,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
RBP4,HTM,Up,9922,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RBP4,HTM,Up,9922,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RBP4,HTM,Up,9922,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
RBP7,HTM,Down,30316,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
RBP7,HTM,Down,30316,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
RBP7,HTM,Down,30316,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
RBPJ,HTM,Down,5724,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0011,29959199
RBPMS,HTM,Up,19097,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RBPMS,HTM,Up,19097,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RBPMS,HTM,Down,19097,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
RBPMS,HTM,Down,19097,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
RBX1,HTM,Down,9928,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RC3H2,HTM,Down,21461,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RC3H2,HTM,Up,21461,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
RCAN1,HTM,Up,3040,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
RCAN3,HTM,Up,3042,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
RCC1,HTM,Down,1913,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RCCD1,HTM,Up,30457,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RCE1,HTM,Up,13721,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
RCHY1,HTM,Up,17479,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RCL1,HTM,Down,17687,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0011,29352988
RCN1,HTM,Up,9934,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RCN1,HTM,Up,9934,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RCN3,HTM,Up,21145,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RCN3,HTM,Up,21145,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
RDH10,HTM,Up,19975,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0042,30592142
RDH10,HTM,Down,19975,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
RDH10,HTM,Up,19975,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
RDH10,HTM,Down,19975,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
RDH10,HTM,Up,19975,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0042,30592142
RDH13,HTM,Up,19978,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
RDX,HTM,Up,9944,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
REC114,HTM,Up,25065,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RECQL,HTM,Down,9948,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
RECQL4,HTM,Down,9949,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RECQL4,HTM,Up,9949,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
RECQL4,HTM,Up,9949,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
REEP2,HTM,Up,17975,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
REEP2,HTM,Up,17975,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
REEP2,HTM,Up,17975,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
REEP3,HTM,Down,23711,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
REEP3,HTM,Down,23711,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
REG4,HTM,Down,22977,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
REL,HTM,Down,9954,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
REL,HTM,Down,9954,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
RELA,HTM,Down,9955,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
RELA,HTM,Down,9955,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
RELB,HTM,Down,9956,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
RELB,HTM,Down,9956,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
RELB,HTM,Up,9956,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
REPIN1,HTM,Down,17922,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
REPIN1,HTM,Up,17922,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
REPS2,HTM,Up,9963,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RERG,HTM,Up,15980,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RERG,HTM,Up,15980,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RESF1,HTM,Up,25559,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RET,HTM,Up,9967,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
RETREG1,HTM,Down,25964,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RETREG1,HTM,Up,25964,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RETREG2,HTM,Down,28450,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
REV1,HTM,Down,14060,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
REV3L,HTM,Up,9968,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
REV3L,HTM,Up,9968,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
REV3L,HTM,Up,9968,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
REX1BD,HTM,Down,26098,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
REXO2,HTM,Down,17851,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
REXO4,HTM,Up,12820,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
REXO4,HTM,Up,12820,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
REXO4,HTM,Up,12820,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RFC1,HTM,Down,9969,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RFC1,HTM,Up,9969,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
RFC2,HTM,Down,9970,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
RFC2,HTM,Down,9970,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
RFC2,HTM,Down,9970,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
RFC3,HTM,Down,9971,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RFC5,HTM,Up,9973,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RFC5,HTM,Down,9973,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RFESD,HTM,Up,29587,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RFESD,HTM,Up,29587,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RFESD,HTM,Up,29587,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RFK,HTM,Up,30324,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RFLNA,HTM,Down,27051,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
RFLNA,HTM,Down,27051,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
RFLNB,HTM,Up,28705,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
RFPL1,HTM,Down,9977,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RFPL2,HTM,Down,9979,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RFPL3S,HTM,Up,9981,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RFPL3S,HTM,Up,9981,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RFPL3S,HTM,Up,9981,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RFTN1,HTM,Down,30278,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RFTN1,HTM,Down,30278,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RFTN1,HTM,Down,30278,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RFTN1,HTM,Up,30278,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RFX6,HTM,Down,21478,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
RGCC,HTM,Down,20369,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RGCC,HTM,Up,20369,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RGCC,HTM,Down,20369,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RGL1,HTM,Up,30281,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RGL1,HTM,Up,30281,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RGL4,HTM,Down,31911,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RGL4,HTM,Down,31911,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RGMA,HTM,Down,30308,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RGMB,HTM,Up,26896,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RGMB-AS1,HTM,Up,48666,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RGPD1,HTM,Down,32414,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
RGPD2,HTM,Down,32415,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
RGPD3,HTM,Down,32416,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
RGPD4,HTM,Down,32417,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
RGPD5,HTM,Down,32418,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
RGPD6,HTM,Down,32419,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
RGR,HTM,Up,9990,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RGR,HTM,Up,9990,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RGR,HTM,Up,9990,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RGS10,HTM,Down,9992,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RGS12,HTM,Up,9994,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RGS12,HTM,Up,9994,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RGS12,HTM,Up,9994,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RGS2,HTM,Down,9998,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RGS2,HTM,Down,9998,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RGS2,HTM,Up,9998,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
RGS20,HTM,Up,14600,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
RGS5,HTM,Up,10001,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RGS6,HTM,Up,10002,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RGS8,HTM,Down,16810,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
RHBDD2,HTM,Up,23082,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RHBDF1,HTM,Up,20561,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
RHBDF2,HTM,Up,20788,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RHBDF2,HTM,Up,20788,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RHBDF2,HTM,Up,20788,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RHBDL2,HTM,Down,16083,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RHBDL2,HTM,Down,16083,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RHBDL3,HTM,Up,16502,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RHBG,HTM,Down,14572,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RHCE,HTM,Up,10008,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RHCG,HTM,Down,18140,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
RHCG,HTM,Up,18140,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
RHCG,HTM,Down,18140,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
RHNO1,HTM,Down,28206,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RHOA,HTM,Down,667,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
RHOA,HTM,Down,667,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
RHOB,HTM,Down,668,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,29352988
RHOB,HTM,Down,668,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0042,29352988
RHOB,HTM,Down,668,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
RHOB,HTM,Down,668,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
RHOB,HTM,Down,668,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
RHOB,HTM,Up,668,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
RHOB,HTM,Down,668,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
RHOB,HTM,Up,668,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
RHOB,HTM,Up,668,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
RHOBTB1,HTM,Up,18738,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RHOBTB1,HTM,Up,18738,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RHOBTB1,HTM,Down,18738,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
RHOBTB3,HTM,Down,18757,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.24,0.0032,31501409
RHOC,HTM,Down,669,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
RHOC,HTM,Down,669,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
RHOC,HTM,Down,669,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RHOD,HTM,Down,670,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RHOD,HTM,Down,670,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RHOD,HTM,Down,670,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
RHOD,HTM,Down,670,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
RHOD,HTM,Down,670,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
RHOF,HTM,Down,15703,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RHOG,HTM,Down,672,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
RHOG,HTM,Down,672,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
RHOQ,HTM,Up,17736,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RHOT1,HTM,Down,21168,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RHOT1,HTM,Up,21168,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RHOT1,HTM,Up,21168,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RHOU,HTM,Up,17794,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RHOU,HTM,Down,17794,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
RHOV,HTM,Down,18313,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RHOV,HTM,Up,18313,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RHPN1,HTM,Down,19973,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RHPN2,HTM,Up,19974,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RHPN2,HTM,Up,19974,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RHPN2,HTM,Up,19974,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RHPN2,HTM,Down,19974,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RIC3,HTM,Down,30338,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RIC8A,HTM,Down,29550,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RIC8B,HTM,Up,25555,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
RICTOR,HTM,Up,28611,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RICTOR,HTM,Up,28611,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RICTOR,HTM,Up,28611,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RIF1,HTM,Down,23207,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
RILPL1,HTM,Up,26814,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RILPL1,HTM,Up,26814,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RILPL1,HTM,Up,26814,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RIMKLA,HTM,Up,28725,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
RIMKLA,HTM,Up,28725,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RIMS1,HTM,Down,17282,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
RIMS2,HTM,Up,17283,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RIMS2,HTM,Up,17283,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RIMS3,HTM,Down,21292,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RIMS3,HTM,Down,21292,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
RIMS4,HTM,Down,16183,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RIN1,HTM,Up,18749,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RIN1,HTM,Up,18749,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RIN2,HTM,Down,18750,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
RIOK3,HTM,Down,11451,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RIPK1,HTM,Up,10019,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
RIPK2,HTM,Up,10020,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RIPK3,HTM,Up,10021,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RIPK3,HTM,Up,10021,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RIPK3,HTM,Up,10021,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RIPK4,HTM,Up,496,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RIPK4,HTM,Up,496,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RIPK4,HTM,Down,496,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RIPK4,HTM,Up,496,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RIPOR1,HTM,Up,25836,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RIPOR1,HTM,Up,25836,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RIPOR1,HTM,Up,25836,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RIPPLY3,HTM,Down,3047,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RIT1,HTM,Up,10023,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RLIM,HTM,Down,13429,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RLN2,HTM,Down,10027,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RMDN1,HTM,Down,24285,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RMDN1,HTM,Down,24285,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RMDN1,HTM,Down,24285,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RMDN1,HTM,Down,24285,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RMDN1,HTM,Down,24285,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
RMI1,HTM,Up,25764,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RMI2,HTM,Down,28349,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RMND1,HTM,Down,21176,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
RN7SK,HTM,Up,10037,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RN7SK,HTM,Up,10037,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RN7SK,HTM,Up,10037,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RN7SK,HTM,Up,10037,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RNASE2,HTM,Down,10045,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RNASE2,HTM,Down,10045,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RNASE4,HTM,Up,10047,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
RNASE4,HTM,Down,10047,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
RNASE4,HTM,Up,10047,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
RNASEH1,HTM,Up,18466,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RNASEH1,HTM,Up,18466,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RNASEH1,HTM,Up,18466,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RNASEH2A,HTM,Up,18518,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
RNASEH2B,HTM,Up,25671,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RNASEH2B,HTM,Up,25671,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RNASEH2B,HTM,Up,25671,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RNASEH2C,HTM,Down,24116,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
RNASEH2C,HTM,Up,24116,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RNASEH2C,HTM,Up,24116,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RNASEH2C,HTM,Up,24116,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RNASET2,HTM,Up,21686,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RND1,HTM,Up,18314,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RND1,HTM,Up,18314,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RND1,HTM,Up,18314,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RND1,HTM,Up,18314,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RND3,HTM,Down,671,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
RND3,HTM,Up,671,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
RNF103,HTM,Up,12859,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RNF11,HTM,Down,10056,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RNF111,HTM,Up,17384,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RNF111,HTM,Up,17384,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RNF111,HTM,Up,17384,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
RNF111,HTM,Up,17384,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RNF114,HTM,Down,13094,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RNF121,HTM,Up,21070,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
RNF122,HTM,Down,21147,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RNF125,HTM,Up,21150,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RNF125,HTM,Up,21150,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RNF125,HTM,Up,21150,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RNF125,HTM,Up,21150,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RNF128,HTM,Down,21153,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RNF130,HTM,Up,18280,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
RNF144A,HTM,Down,20457,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RNF144B,HTM,Down,21578,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RNF144B,HTM,Down,21578,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
RNF144B,HTM,Down,21578,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
RNF144B,HTM,Up,21578,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
RNF144B,HTM,Up,21578,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
RNF144B,HTM,Up,21578,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
RNF145,HTM,Up,20853,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RNF148,HTM,Down,20351,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RNF149,HTM,Up,23137,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RNF149,HTM,Up,23137,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RNF149,HTM,Up,23137,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RNF149,HTM,Up,23137,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
RNF152,HTM,Down,26811,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RNF152,HTM,Down,26811,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RNF152,HTM,Down,26811,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RNF157,HTM,Down,29402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
RNF157,HTM,Up,29402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
RNF157,HTM,Up,29402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
RNF157,HTM,Up,29402,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
RNF157,HTM,Up,29402,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0042,28881576
RNF182,HTM,Up,28522,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
RNF186,HTM,Down,25978,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RNF187,HTM,Down,27146,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
RNF19B,HTM,Down,26886,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RNF19B,HTM,Down,26886,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RNF213,HTM,Down,14539,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RNF213,HTM,Up,14539,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RNF213,HTM,Up,14539,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RNF213,HTM,Up,14539,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RNF213,HTM,Up,14539,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RNF213,HTM,Up,14539,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RNF213,HTM,Up,14539,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RNF217,HTM,Down,21487,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RNF217,HTM,Down,21487,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
RNF217,HTM,Down,21487,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
RNF217-AS1,HTM,Down,50866,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RNF223,HTM,Down,40020,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RNF223,HTM,Down,40020,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RNF224,HTM,Up,41912,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RNF32-DT,HTM,Down,48971,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RNF39,HTM,Down,18064,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RNF41,HTM,Up,18401,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
RNF43,HTM,Up,18505,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RNF7,HTM,Up,10070,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
RNF7,HTM,Down,10070,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
RNF7,HTM,Down,10070,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
RNF7,HTM,Up,10070,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
RNF7,HTM,Up,10070,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
RNF7,HTM,Up,10070,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
RNF7,HTM,Up,10070,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
RNFT1,HTM,Up,30206,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RNFT1,HTM,Up,30206,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RNFT1,HTM,Up,30206,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RNFT2,HTM,Up,25905,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RNFT2,HTM,Up,25905,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RNFT2,HTM,Down,25905,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
RNH1,HTM,Down,10074,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RNLS,HTM,Up,25641,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RNLS,HTM,Up,25641,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RNLS,HTM,Up,25641,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RNPEP,HTM,Down,10078,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RNPEP,HTM,Down,10078,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
RNR1,HTM,Down,10082,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RNR2,HTM,Down,10083,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RNU1-1,HTM,Up,10120,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RNU1-1,HTM,Up,10120,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RNU1-1,HTM,Up,10120,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RNU1-1,HTM,Up,10120,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RNU1-1,HTM,Up,10120,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RNU6ATAC,HTM,Down,34017,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RNU6ATAC5P,HTM,Up,34095,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,29316740
RNY4P8,HTM,Up,34057,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ROBO2,HTM,Down,10250,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ROBO2,HTM,Down,10250,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
ROBO2,HTM,Down,10250,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ROBO2,HTM,Up,10250,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
ROGDI,HTM,Down,29478,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ROPN1L,HTM,Up,24060,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ROR1,HTM,Up,10256,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ROR1,HTM,Up,10256,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ROR2,HTM,Down,10257,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0011,26351321
RORA,HTM,Up,10258,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RORC,HTM,Up,10260,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RORC,HTM,Down,10260,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RP1,HTM,Up,10263,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RP1,HTM,Down,10263,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
RP11-78J21.1,HTM,Down,27067,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RP11-78J21.1,HTM,Down,27067,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
RP2,HTM,Down,10274,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RPAIN,HTM,Up,28641,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RPAIN,HTM,Up,28641,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RPAIN,HTM,Up,28641,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
RPE,HTM,Down,10293,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
RPF2,HTM,Down,20870,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RPGR,HTM,Up,10295,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RPIA,HTM,Down,10297,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RPL10,HTM,Down,10298,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPL10,HTM,Down,10298,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPL10A,HTM,Down,10299,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL10A,HTM,Down,10299,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL10A,HTM,Up,10299,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL11,HTM,Down,10301,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPL12,HTM,Down,10302,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RPL12,HTM,Down,10302,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL13,HTM,Down,10303,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPL13,HTM,Up,10303,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPL13A,HTM,Up,10304,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
RPL13A,HTM,Down,10304,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
RPL13A,HTM,Down,10304,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
RPL13A,HTM,Down,10304,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
RPL13A,HTM,Down,10304,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
RPL13A,HTM,Up,10304,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
RPL13A,HTM,Up,10304,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
RPL13A,HTM,Up,10304,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0053,34168259
RPL13A,HTM,Down,10304,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0053,34168259
RPL13AP20,HTM,Down,35709,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RPL14,HTM,Down,10305,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL14,HTM,Down,10305,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL14,HTM,Up,10305,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL14,HTM,Up,10305,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL14,HTM,Down,10305,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL15,HTM,Up,10306,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL15,HTM,Down,10306,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
RPL17,HTM,Down,10307,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL17,HTM,Down,10307,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL17,HTM,Down,10307,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL17,HTM,Up,10307,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL17,HTM,Down,10307,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL18,HTM,Down,10310,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL18,HTM,Down,10310,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL18,HTM,Up,10310,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL18A,HTM,Down,10311,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RPL19,HTM,Up,10312,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPL21,HTM,Down,10313,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RPL22,HTM,Down,10315,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL22,HTM,Down,10315,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL22,HTM,Up,10315,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL23,HTM,Down,10316,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPL23,HTM,Down,10316,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPL23,HTM,Up,10316,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPL23,HTM,Down,10316,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
RPL23A,HTM,Down,10317,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPL23A,HTM,Down,10317,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPL23A,HTM,Down,10317,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
RPL23A,HTM,Down,10317,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPL23A,HTM,Up,10317,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPL23AP64,HTM,Up,36552,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RPL24,HTM,Down,10325,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL24,HTM,Down,10325,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL24,HTM,Down,10325,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL26,HTM,Down,10327,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPL26L1,HTM,Up,17050,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPL27,HTM,Down,10328,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPL27A,HTM,Up,10329,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPL27A,HTM,Up,10329,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPL29,HTM,Down,10331,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL29,HTM,Down,10331,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL29,HTM,Down,10331,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL3,HTM,Down,10332,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RPL3,HTM,Up,10332,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL30,HTM,Down,10333,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPL30,HTM,Down,10333,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPL31,HTM,Up,10334,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL31,HTM,Up,10334,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
RPL31P11,HTM,Down,35849,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RPL32,HTM,Down,10336,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL32,HTM,Down,10336,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL32,HTM,Up,10336,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL32P31,HTM,Down,37035,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
RPL34,HTM,Down,10340,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPL34,HTM,Down,10340,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPL35,HTM,Down,10344,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPL35,HTM,Up,10344,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPL35A,HTM,Up,10345,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
RPL35A,HTM,Down,10345,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL35A,HTM,Up,10345,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL36,HTM,Down,13631,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPL36,HTM,Down,13631,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPL36A,HTM,Up,10359,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RPL36A,HTM,Up,10359,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RPL36A,HTM,Up,10359,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RPL37,HTM,Up,10347,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
RPL37A,HTM,Down,10348,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RPL37A,HTM,Up,10348,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
RPL38,HTM,Down,10349,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPL38,HTM,Down,10349,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPL39L,HTM,Down,17094,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RPL4,HTM,Down,10353,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPL4,HTM,Up,10353,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPL4,HTM,Down,10353,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPL5,HTM,Down,10360,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPL6,HTM,Up,10362,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
RPL6,HTM,Up,10362,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
RPL6,HTM,Down,10362,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPL6,HTM,Down,10362,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPL6,HTM,Up,10362,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPL6,HTM,Down,10362,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPL6,HTM,Up,10362,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
RPL7,HTM,Down,10363,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
RPL7,HTM,Down,10363,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPL7,HTM,Down,10363,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPL7,HTM,Down,10363,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPL7A,HTM,Down,10364,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL7A,HTM,Down,10364,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL7A,HTM,Down,10364,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL7A,HTM,Up,10364,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL7A,HTM,Down,10364,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL8,HTM,Down,10368,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL8,HTM,Down,10368,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPL8,HTM,Down,10368,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL8,HTM,Up,10368,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPL9,HTM,Down,10369,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
RPL9,HTM,Down,10369,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
RPL9,HTM,Down,10369,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
RPL9,HTM,Up,10369,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
RPL9,HTM,Up,10369,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
RPL9,HTM,Down,10369,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
RPLP0,HTM,Down,10371,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPLP0,HTM,Down,10371,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPLP0,HTM,Up,10371,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
RPLP0,HTM,Up,10371,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPLP1,HTM,Down,10372,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPLP1,HTM,Down,10372,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPLP1,HTM,Down,10372,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPLP2,HTM,Down,10377,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPLP2,HTM,Down,10377,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPLP2,HTM,Up,10377,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPN1,HTM,Down,10381,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
RPN1,HTM,Up,10381,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
RPN1,HTM,Up,10381,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
RPN1,HTM,Up,10381,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
RPN1,HTM,Down,10381,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
RPN1,HTM,Down,10381,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
RPN2,HTM,Up,10382,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
RPN2,HTM,Down,10382,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPN2,HTM,Up,10382,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPN2,HTM,Down,10382,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPN2,HTM,Up,10382,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPP14,HTM,Down,30327,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RPP25,HTM,Down,30361,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RPP25L,HTM,Down,19909,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RPPH1,HTM,Up,19273,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RPRD1B,HTM,Down,16209,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RPRD1B,HTM,Down,16209,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RPRM,HTM,Up,24201,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RPS10,HTM,Down,10383,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS10,HTM,Down,10383,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS10,HTM,Down,10383,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS11,HTM,Down,10384,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS11,HTM,Down,10384,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS11,HTM,Down,10384,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS12,HTM,Up,10385,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,29316740
RPS12,HTM,Down,10385,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPS12,HTM,Down,10385,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPS12,HTM,Up,10385,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPS13,HTM,Down,10386,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS13,HTM,Down,10386,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS13,HTM,Down,10386,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS14,HTM,Down,10387,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS14,HTM,Down,10387,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS14,HTM,Down,10387,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS14,HTM,Down,10387,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS14,HTM,Up,10387,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS15,HTM,Down,10388,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPS15,HTM,Down,10388,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPS15A,HTM,Down,10389,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPS15A,HTM,Down,10389,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPS16,HTM,Down,10396,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPS16,HTM,Up,10396,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPS16,HTM,Down,10396,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPS17,HTM,Down,10397,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS17,HTM,Down,10397,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS17,HTM,Up,10397,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
RPS18,HTM,Down,10401,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPS18,HTM,Down,10401,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPS19,HTM,Down,10402,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS19,HTM,Down,10402,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS19,HTM,Down,10402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS19,HTM,Down,10402,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS19,HTM,Up,10402,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS2,HTM,Down,10404,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPS2,HTM,Down,10404,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPS2,HTM,Up,10404,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
RPS2,HTM,Down,10404,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPS20,HTM,Down,10405,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPS20,HTM,Down,10405,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPS21,HTM,Down,10409,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPS23,HTM,Down,10410,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPS23,HTM,Up,10410,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPS25,HTM,Up,10413,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
RPS25,HTM,Down,10413,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPS25,HTM,Down,10413,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPS25,HTM,Down,10413,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPS25,HTM,Up,10413,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPS26,HTM,Down,10414,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS26,HTM,Down,10414,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS26,HTM,Down,10414,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS26,HTM,Up,10414,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS26P11,HTM,Up,31817,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPS27A,HTM,Down,10417,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RPS27L,HTM,Up,18476,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RPS27L,HTM,Up,18476,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RPS28,HTM,Down,10418,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS28,HTM,Down,10418,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS28,HTM,Down,10418,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS28,HTM,Up,10418,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS29,HTM,Down,10419,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RPS29,HTM,Down,10419,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS29,HTM,Down,10419,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS3,HTM,Down,10420,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPS3,HTM,Down,10420,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPS3,HTM,Down,10420,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
RPS3,HTM,Up,10420,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPS3,HTM,Up,10420,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPS3A,HTM,Down,10421,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPS3A,HTM,Down,10421,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPS3A,HTM,Down,10421,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
RPS3A,HTM,Up,10421,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPS3A,HTM,Down,10421,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPS4X,HTM,Down,10424,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPS4X,HTM,Down,10424,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RPS4Y1,HTM,Down,10425,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RPS5,HTM,Down,10426,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS5,HTM,Down,10426,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RPS5,HTM,Up,10426,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS6,HTM,Up,10429,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RPS6,HTM,Down,10429,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
RPS6KA1,HTM,Down,10430,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RPS6KA2,HTM,Up,10431,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
RPS6KA3,HTM,Up,10432,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RPS6KA5,HTM,Up,10434,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
RPS6KA5,HTM,Up,10434,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RPS6KA5,HTM,Up,10434,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
RPS6KA5,HTM,Up,10434,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
RPS6KA6,HTM,Down,10435,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RPS6KA6,HTM,Up,10435,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RPS6KA6,HTM,Up,10435,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RPS6KC1,HTM,Up,10439,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
RPS7,HTM,Up,10440,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
RPS7,HTM,Up,10440,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
RPS7,HTM,Down,10440,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPS7,HTM,Down,10440,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RPS7,HTM,Down,10440,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPS7,HTM,Up,10440,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPS7,HTM,Up,10440,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPS7,HTM,Down,10440,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
RPS7,HTM,Up,10440,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
RPS8,HTM,Up,10441,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPS9,HTM,Up,10442,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RPSA,HTM,Up,6502,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0053,23903875
RPSA,HTM,Down,6502,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
RPSA,HTM,Down,6502,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
RPSA,HTM,Down,6502,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
RPSA,HTM,Up,6502,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0053,34168259
RPSA,HTM,UP,6502,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,23108794
RPSA,HTM,UP,6502,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,23108794
RPSA,HTM,UP,6502,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,23108794
RPSA,HTM,UP,6502,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,23108794
RPSA,HTM,UP,6502,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,23108794
RPSAP58,HTM,Down,36809,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RPUSD3,HTM,Up,28437,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RQCD1,HTM,Down,10445,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
RRAD,HTM,Up,10446,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RRAGA,HTM,Down,16963,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
RRAGB,HTM,Up,19901,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RRAGB,HTM,Up,19901,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RRAGB,HTM,Up,19901,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RRAGC,HTM,Down,19902,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RRAGD,HTM,Up,19903,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
RRAGD,HTM,Up,19903,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RRAGD,HTM,Up,19903,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
RRAGD,HTM,Up,19903,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
RRAS,HTM,Down,10447,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
RRAS,HTM,Down,10447,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
RRAS,HTM,Down,10447,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RRAS2,HTM,Down,17271,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29352988
RRAS2,HTM,Down,17271,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0011,29352988
RRBP1,HTM,Down,10448,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
RRBP1,HTM,Up,10448,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RRBP1,HTM,Up,10448,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
RRBP1,HTM,Down,10448,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
RRM2,HTM,Up,10452,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RRM2,HTM,Up,10452,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RRM2,HTM,Up,10452,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RRNAD1,HTM,Down,24273,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RRP12,HTM,Up,29100,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RRP12,HTM,Up,29100,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RRP7A,HTM,Down,24286,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
RRP7A,HTM,Down,24286,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
RRP7BP,HTM,Up,30454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,29316740
RRP9,HTM,Up,16829,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
RRP9,HTM,Up,16829,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RRP9,HTM,Up,16829,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
RRP9,HTM,Up,16829,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RRP9,HTM,Up,16829,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RRS1,HTM,Up,17083,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
RS3,HTM,Up,20367,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
RSAD2,HTM,Up,30908,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RSBN1,HTM,Up,25642,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
RSBN1L,HTM,Up,24765,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RSBN1L,HTM,Down,24765,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
RSF1,HTM,Up,18118,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
RSF1,HTM,Up,18118,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
RSF1,HTM,Up,18118,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
RSF1,HTM,Up,18118,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
RSKR,HTM,Up,26314,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RSL1D1,HTM,Down,24534,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
RSL1D1,HTM,Down,24534,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
RSN,HTM,Up,10461,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
RSPO3,HTM,Up,20866,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RSPO3,HTM,Up,20866,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RSPO3,HTM,Down,20866,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RSRC1,HTM,Up,24152,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RSU1,HTM,Down,10464,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
RTCB,HTM,Up,26935,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RTCB,HTM,Up,26935,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
RTKN,HTM,Down,10466,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RTKN2,HTM,Up,19364,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RTKN2,HTM,Up,19364,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RTL10,HTM,Down,26112,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
RTL5,HTM,Up,29430,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RTL8C,HTM,Up,2569,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RTL8C,HTM,Up,2569,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RTL8C,HTM,Up,2569,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
RTN1,HTM,Up,10467,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
RTN3,HTM,Down,10469,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RTN4,HTM,Up,14085,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
RTN4IP1,HTM,Down,18647,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RTN4IP1,HTM,Down,18647,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RTN4IP1,HTM,Down,18647,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RTN4R,HTM,Up,18601,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RTN4R,HTM,Up,18601,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RTP1,HTM,Up,28580,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
RTP4,HTM,Down,23992,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RTRAF,HTM,Up,23169,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RTRAF,HTM,Up,23169,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RUBCNL,HTM,Down,20420,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RUFY2,HTM,Up,19761,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
RUNDC3A,HTM,Up,16984,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RUNDC3A-AS1,HTM,Up,51344,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RUNX1,HTM,Up,10471,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RUNX1,HTM,Up,10471,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RUNX1,HTM,Up,10471,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
RUNX1,HTM,Up,10471,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
RUNX1-IT1,HTM,UP,16623,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
RUNX1-IT1,HTM,UP,16623,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
RUNX1-IT1,HTM,UP,16623,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
RUNX1-IT1,HTM,UP,16623,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
RUNX1-IT1,HTM,UP,16623,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
RUNX1T1,HTM,Up,1535,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RUNX2,HTM,Down,10472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RUNX2,HTM,Down,10472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
RUNX2,HTM,Down,10472,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
RUNX3,HTM,Down,10473,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
RUSC1-AS1,HTM,Up,26680,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
RUVBL1,HTM,Down,10474,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RUVBL1,HTM,Down,10474,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
RWDD2A,HTM,Down,21385,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RWDD2A,HTM,Down,21385,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RWDD3,HTM,Down,21393,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RWDD3,HTM,Down,21393,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
RXRG,HTM,Down,10479,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
RYBP,HTM,Up,10480,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
RYR1,HTM,Down,10483,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
RYR1,HTM,Up,10483,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
S100A10,HTM,Up,10487,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
S100A11,HTM,Down,10488,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
S100A11,HTM,Down,10488,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
S100A11,HTM,Up,10488,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
S100A11,HTM,Up,10488,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
S100A11,HTM,Up,10488,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
S100A11,HTM,Up,10488,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
S100A14,HTM,Up,18901,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,35229723
S100A14,HTM,Down,18901,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
S100A14,HTM,Down,18901,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
S100A14,HTM,Down,18901,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
S100A14,HTM,Down,18901,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
S100A14,HTM,Up,18901,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
S100A14,HTM,Down,18901,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
S100A16,HTM,Down,20441,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
S100A16,HTM,Down,20441,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
S100A16,HTM,Down,20441,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
S100A16,HTM,Up,20441,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
S100A16,HTM,Up,20441,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
S100A16,HTM,Up,20441,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
S100A16,HTM,Down,20441,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
S100A2,HTM,Down,10492,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
S100A2,HTM,Down,10492,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
S100A2,HTM,Down,10492,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
S100A2,HTM,Down,10492,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
S100A4,HTM,Up,10494,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
S100A4,HTM,Up,10494,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
S100A4,HTM,Up,10494,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0074,34680485
S100A4,HTM,Down,10494,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0074,31501409
S100A4,HTM,Down,10494,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0074,34168259
S100A4,HTM,Down,10494,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,29340052
S100A6,HTM,Up,10496,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,33670440
S100A6,HTM,Up,10496,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
S100A6,HTM,Up,10496,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
S100A6,HTM,Up,10496,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
S100A6,HTM,Down,10496,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0053,34168259
S100A6,HTM,Up,10496,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
S100A7,HTM,Down,10497,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
S100A7,HTM,Down,10497,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
S100A7L2,HTM,Up,21655,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
S100A7L2,HTM,Up,21655,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
S100A7L2,HTM,Up,21655,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
S100A8,HTM,Down,10498,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,34059086
S100A8,HTM,Up,10498,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,29416721
S100A8,HTM,Down,10498,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
S100A8,HTM,Down,10498,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
S100A8,HTM,Down,10498,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
S100A8,HTM,Down,10498,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0064,24961511
S100A8,HTM,Down,10498,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
S100A8,HTM,Up,10498,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.28,0.0064,32503348
S100A8,HTM,Up,10498,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
S100A9,HTM,Up,10499,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29416721
S100A9,HTM,Down,10499,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
S100A9,HTM,Up,10499,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.28,0.0042,32503348
S100A9,HTM,Up,10499,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
S100A9,HTM,Up,10499,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
S100B,HTM,NA,10500,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0021,20630067
S100P,HTM,Down,10504,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0106,34059086
S100P,HTM,Up,10504,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0106,25881239
S100P,HTM,Up,10504,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0106,19353633
S100P,HTM,Up,10504,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0106,25881239
S100P,HTM,Down,10504,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0106,31709178
S100P,HTM,Up,10504,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0106,32503348
S100P,HTM,Up,10504,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0106,32503348
S100P,HTM,Up,10504,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0106,19353633
S100P,HTM,Down,10504,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0106,31501409
S100P,HTM,Down,10504,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0106,34168259
S100P,HTM,Down,10504,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0106,34414448
S100P,HTM,Down,10504,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0106,29340052
S100P,HTM,Up,10504,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0106,19353633
S1PR1,HTM,Up,3165,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
S1PR1,HTM,Up,3165,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
S1PR3,HTM,Up,3167,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
S1PR5,HTM,Down,14299,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SAA1,HTM,Down,10513,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SAA1,HTM,Down,10513,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SAA1,HTM,Down,10513,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SAA1,HTM,Down,10513,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SAA2,HTM,Down,10514,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SAA2,HTM,Up,10514,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SACS,HTM,Down,10519,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
SACS,HTM,Down,10519,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SACS,HTM,Down,10519,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SACS,HTM,Up,10519,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SALL2,HTM,Up,10526,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SALL2,HTM,Up,10526,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
SALL4,HTM,Up,15924,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SAMD1,HTM,Down,17958,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SAMD11,HTM,Down,28706,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SAMD12,HTM,Up,31750,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SAMD4B,HTM,Down,25492,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
SAMD9,HTM,Down,1348,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SAMD9,HTM,Down,1348,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SAMD9,HTM,Down,1348,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SAMD9,HTM,Down,1348,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SAMD9,HTM,Down,1348,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SAP30,HTM,Up,10532,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SAR1A,HTM,Down,10534,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SAR1B,HTM,Up,10535,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SARS1,HTM,Up,10537,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SARS2,HTM,Up,17697,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SARS2,HTM,Up,17697,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SARS2,HTM,Down,17697,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
SART1,HTM,Up,10538,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SAT1,HTM,Down,10540,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0064,22740085
SAT1,HTM,Down,10540,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,34059086
SAT1,HTM,Up,10540,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0064,19353633
SAT1,HTM,Up,10540,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
SAT1,HTM,Up,10540,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,19353633
SAT1,HTM,Up,10540,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
SAT1,HTM,Down,10540,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0064,30696080
SAT1,HTM,Down,10540,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0064,30696080
SAT1,HTM,Up,10540,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0064,19353633
SATB1,HTM,Up,10541,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SATB2,HTM,Up,21637,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SATB2,HTM,Up,21637,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SAV1,HTM,Down,17795,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SAV1,HTM,Down,17795,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SAYSD1,HTM,Down,21025,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SBK1,HTM,Down,17699,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SC5DL,HTM,Down,10547,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SC5DL,HTM,Down,10547,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SC5DL,HTM,Up,10547,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SC5DL,HTM,Up,10547,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SC5DL,HTM,Up,10547,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SCAF4,HTM,Down,19304,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SCAMP2,HTM,Down,10564,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SCARA3,HTM,Up,19000,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SCARA3,HTM,Down,19000,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SCARA5,HTM,Down,28701,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SCARA5,HTM,Down,28701,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SCARB1,HTM,Down,1664,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SCARB2,HTM,Up,1665,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SCARNA14,HTM,Up,32571,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SCARNA20,HTM,Up,32578,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SCARNA9,HTM,Up,32566,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SCARNA9,HTM,Down,32566,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SCARNA9,HTM,Down,32566,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SCCPDH,HTM,Up,24275,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SCCPDH,HTM,Up,24275,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SCCPDH,HTM,Up,24275,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SCD,HTM,Up,10571,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0127,30592142
SCD,HTM,Up,10571,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.48,0.0127,24961511
SCD,HTM,Up,10571,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.48,0.0127,24961511
SCD,HTM,Up,10571,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.48,0.0127,34680485
SCD,HTM,Up,10571,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.48,0.0127,31501409
SCD,HTM,Up,10571,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0127,30592142
SCD5,HTM,Up,21088,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SCD5,HTM,Up,21088,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
SCDP1,HTM,Up,10572,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SCEL,HTM,Up,10573,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SCEL,HTM,Down,10573,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SCEL,HTM,Down,10573,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
SCFD1,HTM,Down,20726,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
SCFD1,HTM,Up,20726,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
SCFD2,HTM,Down,30676,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,29316740
SCG2,HTM,Up,10575,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SCG2,HTM,Up,10575,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
SCGB1A1,HTM,Down,12523,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SCGB1A1,HTM,Up,12523,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SCGB1A1,HTM,Down,12523,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SCGB1D29,HTM,Up,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SCGB1D29,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SCGB1D29,HTM,Up,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SCGB2A1,HTM,Up,7051,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SCGB2A1,HTM,Up,7051,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SCGB2A1,HTM,Up,7051,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SCGB3A1,HTM,Down,18384,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SCGB3A1,HTM,Down,18384,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SCIN,HTM,Up,21695,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
SCIN,HTM,Up,21695,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
SCIN,HTM,Down,21695,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
SCIN,HTM,Down,21695,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
SCIN,HTM,Down,21695,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
SCIN,HTM,Up,21695,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
SCIN,HTM,Up,21695,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
SCML1,HTM,Down,10580,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SCML2,HTM,Up,10581,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SCML2,HTM,Up,10581,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SCML4,HTM,Down,21397,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SCML4,HTM,Down,21397,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SCML4,HTM,Down,21397,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,28588211
SCN1B,HTM,Down,10586,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SCN2A,HTM,Down,10588,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SCN2A,HTM,Down,10588,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SCN3B,HTM,Up,20665,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
SCN8A,HTM,Up,10596,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
SCN8A,HTM,Down,10596,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SCN9A,HTM,Up,10597,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SCN9A,HTM,Up,10597,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
SCNN1A,HTM,Down,10599,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SCNN1A,HTM,Up,10599,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SCNN1A,HTM,Down,10599,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
SCNN1A,HTM,Down,10599,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31729259
SCNN1A,HTM,Down,10599,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
SCNN1A,HTM,Down,10599,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31729259
SCNN1A,HTM,Down,10599,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0053,22954703
SCNN1D,HTM,Up,10601,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SCNN1D,HTM,Up,10601,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SCNN1D,HTM,Up,10601,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SCO1,HTM,Up,10603,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SCO2,HTM,Up,10604,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SCOTIN,HTM,Down,30376,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
SCPEP1,HTM,Down,29507,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SCRIB,HTM,Up,30377,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SCRIB,HTM,Up,30377,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SCRN1,HTM,Up,22192,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SCRN1,HTM,Up,22192,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SCRN1,HTM,Up,22192,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SCRN3,HTM,Down,30382,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SCUBE2,HTM,Down,30425,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SCUBE3,HTM,Up,13655,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
SCUBE3,HTM,Up,13655,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
SCYL2,HTM,Down,19286,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SCYL3,HTM,Up,19285,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
SDC2,HTM,Up,10659,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SDC2,HTM,Down,10659,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
SDC2,HTM,Up,10659,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
SDC2,HTM,Up,10659,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
SDC3,HTM,Up,10660,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SDC4,HTM,Down,10661,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SDC4,HTM,Down,10661,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SDC4P,HTM,Down,18903,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SDCBP2,HTM,Down,15756,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SDF2,HTM,Down,10675,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SDF2,HTM,Up,10675,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SDF2,HTM,Up,10675,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SDHA,HTM,Down,10680,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,34059086
SDHA,HTM,Up,10680,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0064,23903875
SDHA,HTM,Up,10680,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0064,22623141
SDHA,HTM,Down,10680,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0064,34168259
SDHA,HTM,Up,10680,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0064,21788403
SDHA,HTM,Down,10680,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0064,24098529
SDHAF3,HTM,Up,21752,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SDHB,HTM,Up,10681,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
SDK1,HTM,Down,19307,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SDR16C5,HTM,Down,30311,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SDR42E1,HTM,Down,29834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SDR42E1,HTM,Down,29834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SEBOX,HTM,Up,32942,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
SEC13,HTM,Down,10697,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SEC14L1,HTM,Up,10698,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SEC14L2,HTM,Down,10699,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SEC14L2,HTM,Down,10699,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SEC14L2,HTM,Down,10699,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SEC14L2,HTM,Down,10699,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
SEC16A,HTM,Down,29006,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SEC16A,HTM,Up,29006,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SEC16A,HTM,Up,29006,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SEC16A,HTM,Up,29006,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SEC16B,HTM,Down,30301,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SEC22C,HTM,Down,16828,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SEC23A,HTM,Up,10701,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
SEC23A,HTM,Down,10701,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SEC24D,HTM,Down,10706,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SEC31A,HTM,Up,17052,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SEC61B,HTM,Up,16993,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SEC62,HTM,Up,11846,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
SECISBP2,HTM,Up,30972,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SECISBP2,HTM,Up,30972,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SECISBP2,HTM,Up,30972,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SECISBP2L,HTM,Up,28997,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SECTM1,HTM,Down,10707,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
SECTM1,HTM,Down,10707,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
SECTM1,HTM,Up,10707,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SECTM1,HTM,Up,10707,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
SEL1L3,HTM,Down,29108,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SELENBP1,HTM,Up,10719,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
SELENBP1,HTM,Up,10719,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
SELENBP1,HTM,Up,10719,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SELENBP1,HTM,Down,10719,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
SELENOF,HTM,Up,17705,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
SELENOH,HTM,Up,18251,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
SELENOM,HTM,Up,30397,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SELENON,HTM,Down,15999,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SELENOP,HTM,Down,10751,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
SELENOP,HTM,Up,10751,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SELENOP,HTM,Down,10751,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
SELENOP,HTM,Down,10751,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
SELENOV,HTM,Down,30399,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SELENOW,HTM,Down,10752,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SELENOW,HTM,Down,10752,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SELL,HTM,Up,10720,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SELL,HTM,Up,10720,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SELL,HTM,Down,10720,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SELL,HTM,Up,10720,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SELPLG,HTM,Up,10722,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
SEMA3A,HTM,Down,10723,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SEMA3A,HTM,Down,10723,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SEMA3A,HTM,Down,10723,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SEMA3D,HTM,Down,10726,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SEMA3E,HTM,Up,10727,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SEMA3F,HTM,Up,10728,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SEMA3F,HTM,Up,10728,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SEMA4A,HTM,Down,10729,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SEMA4B,HTM,Down,10730,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SEMA4F,HTM,Down,10734,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SEMA4F,HTM,Down,10734,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SEMA4G,HTM,Up,10735,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SEMA5B,HTM,Down,10737,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SEMA5B,HTM,Down,10737,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SEMA6B,HTM,Down,10739,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SEMA6D,HTM,Up,16770,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SEMA6D,HTM,Up,16770,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SEMA6D,HTM,Up,16770,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SEMA7A,HTM,Down,10741,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SEMA7A,HTM,Down,10741,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SEMA7A,HTM,Down,10741,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SEMA7A,HTM,Down,10741,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
SEMA7A,HTM,Down,10741,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
SEMA7A,HTM,Down,10741,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SENP3,HTM,Down,17862,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SEPHS1,HTM,Down,19685,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
SEPHS2,HTM,Down,19686,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SEPHS2,HTM,Down,19686,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SEPTIN2,HTM,Up,7729,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,22623141
SEPTIN2,HTM,Up,7729,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SEPTIN2,HTM,Up,7729,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SEPTIN5,HTM,Up,9164,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
SEPTIN6,HTM,Down,15848,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SEPTIN7,HTM,Down,1717,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SEPTIN7,HTM,Down,1717,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SEPTIN7P2,HTM,Down,32339,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SEPTIN7P2,HTM,Down,32339,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SEPTIN9,HTM,Up,7323,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SEPTIN9,HTM,Up,7323,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SERBP1,HTM,Up,17860,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
SERF1A,HTM,Down,10755,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SERHL2,HTM,Up,29446,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SERINC1,HTM,Up,13464,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SERINC1,HTM,Up,13464,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SERINC1,HTM,Up,13464,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SERINC2,HTM,Down,23231,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SERINC2,HTM,Down,23231,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SERINC2,HTM,Down,23231,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SERINC2,HTM,Down,23231,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SERINC2,HTM,Up,23231,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SERINC5,HTM,Down,18825,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SERINC5,HTM,Down,18825,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SERPINA1,HTM,Up,8941,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
SERPINA1,HTM,Up,8941,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,21826669
SERPINA1,HTM,Up,8941,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SERPINA3,HTM,Down,16,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SERPINA5,HTM,Down,8723,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SERPINA5,HTM,Down,8723,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SERPINA6,HTM,Up,1540,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0011,17932721
SERPINB1,HTM,Up,3311,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SERPINB1,HTM,Down,3311,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
SERPINB1,HTM,Up,3311,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
SERPINB1,HTM,Up,3311,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
SERPINB1,HTM,Down,3311,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
SERPINB10,HTM,Down,8942,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SERPINB11,HTM,Down,14221,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
SERPINB11,HTM,Down,14221,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
SERPINB2,HTM,Down,8584,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SERPINB2,HTM,Down,8584,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SERPINB2,HTM,Down,8584,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SERPINB2,HTM,Down,8584,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
SERPINB2,HTM,Down,8584,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
SERPINB2,HTM,Down,8584,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
SERPINB2,HTM,UP,8584,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,23108794
SERPINB2,HTM,UP,8584,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,23108794
SERPINB2,HTM,UP,8584,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,23108794
SERPINB2,HTM,UP,8584,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,23108794
SERPINB2,HTM,UP,8584,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,23108794
SERPINB3,HTM,Down,10569,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
SERPINB3,HTM,Up,10569,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0053,23903875
SERPINB3,HTM,Up,10569,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
SERPINB3,HTM,Up,10569,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
SERPINB3,HTM,Up,10569,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
SERPINB3,HTM,Down,10569,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
SERPINB4,HTM,Down,10570,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SERPINB5,HTM,Down,8949,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
SERPINB5,HTM,Down,8949,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
SERPINB5,HTM,Down,8949,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0064,23903875
SERPINB5,HTM,Down,8949,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
SERPINB5,HTM,Down,8949,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
SERPINB5,HTM,Up,8949,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
SERPINB5,HTM,Down,8949,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0064,34414448
SERPINB5,HTM,Down,8949,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0064,31709178
SERPINB5,HTM,Down,8949,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0064,22954703
SERPINB7,HTM,Down,13902,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SERPINB7,HTM,Down,13902,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SERPINB8,HTM,Down,8952,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SERPINB8,HTM,Down,8952,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SERPINB8,HTM,Down,8952,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SERPINB8,HTM,Up,8952,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SERPINB9,HTM,Up,8955,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SERPINB9,HTM,Up,8955,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SERPINB9,HTM,Down,8955,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SERPINB9P1,HTM,Down,28590,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SERPINE1,HTM,Down,8583,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SERPINE1,HTM,Down,8583,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SERPINE1,HTM,Down,8583,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SERPINE1,HTM,Up,8583,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
SERPINE1,HTM,Up,8583,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
SERPINE1,HTM,Up,8583,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
SERPINE1,HTM,Up,8583,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
SERPINE1,HTM,Down,8583,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
SERPINE1,HTM,Down,8583,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
SERPINE1,HTM,Up,8583,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
SERPINE1,HTM,Up,8583,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
SERPINE1,HTM,Up,8583,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
SERPINE2,HTM,Down,8951,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SERPINE2,HTM,Down,8951,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SERPINE2,HTM,Down,8951,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SERPINE2,HTM,Up,8951,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
SERPINE2,HTM,Up,8951,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31729259
SERPINE2,HTM,Up,8951,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
SERPINE2,HTM,Up,8951,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
SERPINE2,HTM,Up,8951,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31729259
SERPINF1,HTM,Down,8824,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SERPINF1,HTM,Down,8824,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SERPINF1,HTM,Down,8824,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SERPINF1,HTM,Down,8824,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SERPINF1,HTM,Down,8824,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SERPING1,HTM,Down,1228,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
SERPING1,HTM,Down,1228,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
SERPING1,HTM,Down,1228,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SERPING1,HTM,Down,1228,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
SERPING1,HTM,Down,1228,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SERPINH1,HTM,Down,1546,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0042,23903875
SERPINH1,HTM,Down,1546,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SERPINH1,HTM,Up,1546,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
SERPINH1,HTM,Up,1546,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
SERPINH1,HTM,Up,1546,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
SERTAD1,HTM,Down,17932,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SERTAD4,HTM,Down,25236,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SERTAD4,HTM,Up,25236,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SERTAD4,HTM,Up,25236,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SERTAD4,HTM,Up,25236,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SESN1,HTM,Down,21595,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SESN1,HTM,Up,21595,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SESN1,HTM,Up,21595,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SESN1,HTM,Up,21595,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SESN2,HTM,Up,20746,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SESN3,HTM,Down,23060,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SESN3,HTM,Down,23060,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SESTD1,HTM,Up,18379,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SESTD1,HTM,Down,18379,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SET,HTM,Down,10760,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SETBP1,HTM,Up,15573,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SETD1A,HTM,Down,29010,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SETD5,HTM,Up,25566,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
SETD5,HTM,Down,25566,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SETSIP,HTM,Up,42937,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SETSIP,HTM,Down,42937,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SEZ6L2,HTM,Up,30844,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SEZ6L2,HTM,Up,30844,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SF3A1,HTM,Down,10765,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SF3B1,HTM,Down,10768,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
SF3B1,HTM,Down,10768,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
SF3B1,HTM,Down,10768,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
SF3B1,HTM,Down,10768,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
SF3B1,HTM,Up,10768,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0042,21788403
SF3B2,HTM,Down,10769,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
SF3B3,HTM,Down,10770,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SF3B3,HTM,Down,10770,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SF3B6,HTM,Up,30096,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SF3B6,HTM,Up,30096,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SF3B6,HTM,Up,30096,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SFI1,HTM,Down,29064,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SFMBT2,HTM,Up,20256,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SFMBT2,HTM,Up,20256,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SFMBT2,HTM,Up,20256,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
SFMBT2,HTM,Down,20256,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
SFMBT2,HTM,Down,20256,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
SFN,HTM,Down,10773,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SFN,HTM,Down,10773,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SFN,HTM,Down,10773,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SFN,HTM,Down,10773,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
SFN,HTM,Up,10773,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,25676692
SFN,HTM,Up,10773,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,25676692
SFN,HTM,Up,10773,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
SFN,HTM,Up,10773,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0053,25676692
SFN,HTM,Up,10773,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
SFPQ,HTM,Down,10774,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
SFPQ,HTM,Down,10774,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
SFPQ,HTM,Up,10774,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
SFPQ,HTM,Down,10774,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
SFPQ,HTM,Down,10774,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
SFPQ,HTM,Up,10774,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0042,21788403
SFRP1,HTM,Down,10776,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SFRP1,HTM,Down,10776,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SFRP1,HTM,Down,10776,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SFRP4,HTM,Up,10778,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SFRP5,HTM,Down,10779,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SFRS1810,HTM,Up,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SFRS1810,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SFRS1810,HTM,Up,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SFRS3,HTM,Up,10785,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0032,18034892
SFRS3,HTM,Up,10785,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
SFRS3,HTM,Up,10785,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
SFT2D1,HTM,Down,21102,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SFXN1,HTM,Down,16085,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SFXN1,HTM,Up,16085,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SFXN1,HTM,Down,16085,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SFXN2,HTM,Up,16086,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SFXN2,HTM,Up,16086,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SFXN2,HTM,Down,16086,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SFXN2,HTM,Up,16086,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SFXN3,HTM,Up,16087,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SGCA,HTM,Down,10805,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SGCB,HTM,Down,10806,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SGCB,HTM,Up,10806,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SGCD,HTM,Up,10807,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SGCD,HTM,Up,10807,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SGCE,HTM,Up,10808,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SGCE,HTM,Up,10808,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SGCG,HTM,Up,10809,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SGK1,HTM,Up,10810,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0053,27965308
SGK1,HTM,Down,10810,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SGK1,HTM,Up,10810,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
SGK1,HTM,Down,10810,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
SGK1,HTM,Down,10810,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
SGK1,HTM,Up,10810,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0053,24098529
SGK3,HTM,Down,10812,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SGMS2,HTM,Down,28395,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SGO2,HTM,Down,30812,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
SGO2,HTM,Down,30812,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
SGPP1,HTM,Down,17720,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SGPP2,HTM,Down,19953,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SGPP2,HTM,Up,19953,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SGPP2,HTM,Down,19953,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
SGSH,HTM,Up,10818,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SGSH,HTM,Up,10818,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SGSH,HTM,Up,10818,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SGSH,HTM,Up,10818,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SGSH,HTM,Up,10818,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SGSM1,HTM,Up,29410,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SH2D1A,HTM,Down,10820,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
SH2D3A,HTM,Down,16885,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SH2D4A,HTM,Down,26102,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
SH2D4A,HTM,Up,26102,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SH2D4A,HTM,Up,26102,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SH2D4A,HTM,Up,26102,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SH2D4A,HTM,Up,26102,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SH2D5,HTM,Down,28819,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SH2D5,HTM,Up,28819,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SH2D5,HTM,Up,28819,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SH3BGRL,HTM,Up,10823,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SH3BGRL,HTM,Up,10823,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SH3BGRL,HTM,Up,10823,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
SH3BGRL,HTM,Up,10823,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
SH3BGRL,HTM,Up,10823,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
SH3BGRL,HTM,Down,10823,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
SH3BGRL2,HTM,Up,15567,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SH3BGRL2,HTM,Up,15567,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SH3BGRL2,HTM,Up,15567,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SH3BGRL2,HTM,Up,15567,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SH3BGRL3,HTM,Down,15568,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SH3BGRL3,HTM,Up,15568,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
SH3BGRL3,HTM,Up,15568,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
SH3BGRL4,HTM,Up,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SH3BGRL4,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SH3BGRL4,HTM,Up,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SH3BP1,HTM,Down,10824,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SH3BP2,HTM,Down,10825,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SH3BP4,HTM,Up,10826,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SH3BP4,HTM,Down,10826,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
SH3BP4,HTM,Down,10826,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
SH3BP4,HTM,Down,10826,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
SH3BP5,HTM,Down,10827,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SH3BP5-AS1,HTM,Up,44501,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SH3BP5L,HTM,Up,29360,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SH3BP5L,HTM,Up,29360,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SH3BP5L,HTM,Up,29360,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SH3GLB1,HTM,Down,10833,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SH3PXD2A,HTM,Down,23664,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
SH3PXD2A,HTM,Down,23664,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SH3PXD2A,HTM,Down,23664,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SH3PXD2A,HTM,Down,23664,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
SH3PXD2A,HTM,Up,23664,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
SH3PXD2A,HTM,Down,23664,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
SH3PXD2B,HTM,Up,29242,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SH3RF2,HTM,Down,26299,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SH3RF2,HTM,Down,26299,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SH3RF2,HTM,Down,26299,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SH3RF2,HTM,Down,26299,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SH3RF3,HTM,Up,24699,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SH3RF3,HTM,Down,24699,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
SH3TC2,HTM,Up,29427,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SH3TC2,HTM,Down,29427,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SH3YL1,HTM,Down,29546,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SHANK2,HTM,Up,14295,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SHANK2,HTM,Down,14295,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SHARPIN,HTM,Down,25321,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SHC1,HTM,NA,10840,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0021,29352988
SHC1,HTM,Down,10840,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SHC3,HTM,NA,18181,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0021,29352988
SHC3,HTM,Up,18181,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SHC4,HTM,Up,16743,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SHCBP1,HTM,Down,29547,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SHCBP1,HTM,Down,29547,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SHH,HTM,Down,10848,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.28,0.0201,34680485
SHISA2,HTM,Up,20366,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SHISA7,HTM,Down,35409,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SHKBP1,HTM,Down,19214,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
SHMT2,HTM,Down,10852,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
SHMT2,HTM,Down,10852,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SHMT2,HTM,Up,10852,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
SHMT2,HTM,Up,10852,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
SHOC1,HTM,Up,26535,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SHOC1,HTM,Up,26535,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SHOC1,HTM,Up,26535,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SHOX2,HTM,Up,10854,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SHPK,HTM,Up,1492,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SHPK,HTM,Up,1492,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SHPK,HTM,Up,1492,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SHROOM2,HTM,Down,630,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SHROOM3,HTM,Down,30422,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SHROOM3,HTM,Up,30422,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SHROOM3,HTM,Down,30422,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
SIDT1,HTM,Up,25967,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SIDT1,HTM,Up,25967,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SIDT1,HTM,Up,25967,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SIGLEC11,HTM,Up,15622,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
SIGLEC15,HTM,Down,27596,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SIGLEC16,HTM,Up,24851,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
SIGLEC6,HTM,Up,10875,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SIK3,HTM,Up,29165,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SIK3,HTM,Up,29165,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
SIKE1,HTM,Up,26119,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SIL1,HTM,Up,24624,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SIMC1,HTM,Down,24779,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SIN3A,HTM,Up,19353,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
SINHCAF,HTM,Down,30702,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SINHCAF,HTM,Down,30702,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
SINHCAF,HTM,Up,30702,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
SIPA1L1,HTM,Down,20284,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SIPA1L1,HTM,Down,20284,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SIPA1L2,HTM,Up,23800,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SIPA1L2,HTM,Up,23800,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SIRPA,HTM,Down,9662,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SIRPB2,HTM,Down,16247,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SIRPB2,HTM,Down,16247,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
SIRPG,HTM,Up,15757,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.48,0.0021,29416721
SIRPG-AS1,HTM,Down,51229,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SIRPG-AS1,HTM,Down,51229,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SIRT1,HTM,Up,14929,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SIRT1,HTM,Up,14929,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SIRT2,HTM,Up,10886,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SIRT3,HTM,Down,14931,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SIRT5,HTM,Down,14933,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SIRT5,HTM,Down,14933,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SIRT6,HTM,Down,14934,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SIRT7,HTM,Down,14935,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SIX2,HTM,Down,10888,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SKAP2,HTM,Up,15687,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SKAP2,HTM,Up,15687,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SKAP2,HTM,Up,15687,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SKAP2,HTM,Up,15687,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SKAP2,HTM,Up,15687,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SKI,HTM,Down,10896,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SKIL,HTM,Down,10897,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SKP1,HTM,Down,10899,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SKP1,HTM,Down,10899,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SKP2,HTM,Down,10901,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SKP2,HTM,Down,10901,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
SLAIN1,HTM,Up,26387,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLAIN1,HTM,Up,26387,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC10A7,HTM,Down,23088,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC10A7,HTM,Down,23088,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC10A7,HTM,Down,23088,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC12A1,HTM,Up,10910,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC12A2,HTM,Up,10911,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SLC12A2,HTM,Up,10911,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
SLC12A2,HTM,Up,10911,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
SLC12A2,HTM,Up,10911,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
SLC12A2,HTM,Up,10911,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
SLC12A2,HTM,Down,10911,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0053,34168259
SLC12A2,HTM,Up,10911,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
SLC12A2,HTM,Up,10911,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0053,21788403
SLC12A4,HTM,Up,10913,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC12A9,HTM,Down,40807,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SLC13A3,HTM,Down,14430,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLC14A1,HTM,Up,10918,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0021,30592142
SLC14A1,HTM,Down,10918,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics,0.04,0.0021,26351321
SLC14A1,HTM,Up,10918,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0021,30592142
SLC15A4,HTM,Down,23090,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC16A13,HTM,Down,31037,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLC16A14,HTM,Up,26417,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC16A2,HTM,Down,10923,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC16A2,HTM,Down,10923,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC16A2,HTM,Down,10923,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC16A3,HTM,Down,10924,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
SLC16A3,HTM,Down,10924,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SLC16A4,HTM,Up,10925,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC16A5,HTM,Down,10926,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLC16A6,HTM,Down,10927,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC16A6,HTM,Down,10927,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SLC16A6,HTM,Down,10927,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SLC16A9,HTM,Down,23520,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC17A3,HTM,Up,10931,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC17A3,HTM,Up,10931,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC17A3,HTM,Up,10931,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC17A5,HTM,Up,10933,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SLC18A1,HTM,Up,10934,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
SLC18A2,HTM,Up,10935,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SLC19A3,HTM,Up,16266,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SLC1A1,HTM,Up,10939,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC1A3,HTM,Down,10941,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SLC1A3,HTM,Up,10941,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
SLC1A3,HTM,Up,10941,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
SLC1A3,HTM,Down,10941,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
SLC1A3,HTM,Down,10941,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
SLC1A3,HTM,Up,10941,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
SLC1A5,HTM,Down,10943,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SLC20A1,HTM,Down,10946,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC20A1,HTM,Down,10946,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC20A1,HTM,Down,10946,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC20A1,HTM,Up,10946,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SLC20A2,HTM,Down,10947,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC20A2,HTM,Down,10947,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC20A2,HTM,Down,10947,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC22A15,HTM,Down,20301,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC22A15,HTM,Down,20301,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SLC22A15,HTM,Down,20301,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SLC22A17,HTM,Up,23095,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLC22A18,HTM,Up,10964,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC22A23,HTM,Down,21106,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SLC22A23,HTM,Up,21106,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SLC22A23,HTM,Down,21106,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SLC22A23,HTM,Up,21106,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SLC22A23,HTM,Up,21106,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SLC22A3,HTM,Up,10967,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC22A3,HTM,Up,10967,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC22A31,HTM,Down,27091,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLC22A4,HTM,Up,10968,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SLC22A4,HTM,Up,10968,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC23A1,HTM,Up,10974,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC23A1,HTM,Up,10974,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC23A2,HTM,Up,10973,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC23A2,HTM,Up,10973,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC25A1,HTM,Down,10979,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SLC25A1,HTM,Up,10979,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SLC25A1,HTM,Down,10979,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SLC25A10,HTM,Up,10980,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SLC25A10,HTM,Down,10980,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SLC25A12,HTM,Down,10982,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SLC25A18,HTM,Up,10988,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC25A19,HTM,Up,14409,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC25A19,HTM,Up,14409,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC25A19,HTM,Up,14409,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC25A2,HTM,Down,22921,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SLC25A2,HTM,Down,22921,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SLC25A2,HTM,Down,22921,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
SLC25A21,HTM,Up,14411,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC25A24,HTM,Down,20662,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC25A26,HTM,Down,20661,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
SLC25A29,HTM,Up,20116,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC25A3,HTM,Up,10989,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SLC25A3,HTM,Down,10989,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SLC25A3,HTM,Up,10989,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SLC25A30,HTM,Down,27371,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC25A30,HTM,Down,27371,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC25A30,HTM,Up,27371,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
SLC25A35,HTM,Up,31921,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC25A38,HTM,Down,26054,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SLC25A42,HTM,Down,28380,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SLC25A45,HTM,Up,27442,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC25A47,HTM,Up,20115,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SLC25A47,HTM,Up,20115,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SLC25A5,HTM,Down,10991,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
SLC25A5,HTM,Down,10991,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
SLC25A5,HTM,Up,10991,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
SLC25A5,HTM,Up,10991,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
SLC25A5,HTM,Down,10991,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
SLC25A6,HTM,Down,10992,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
SLC25A6,HTM,Down,10992,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
SLC25A6,HTM,Down,10992,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
SLC25A6,HTM,Up,10992,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
SLC25A6,HTM,Up,10992,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
SLC25A6,HTM,Down,10992,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
SLC26A10,HTM,Up,14470,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC26A2,HTM,Down,10994,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC26A2,HTM,Up,10994,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC26A6,HTM,Up,14472,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SLC26A9,HTM,Down,14469,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLC27A2,HTM,Up,10996,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SLC27A2,HTM,Up,10996,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SLC27A2,HTM,Down,10996,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SLC27A2,HTM,Down,10996,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SLC27A2,HTM,Down,10996,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
SLC28A2,HTM,Up,11002,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,35229723
SLC28A3,HTM,Down,16484,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SLC28A3,HTM,Up,16484,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC28A3,HTM,Down,16484,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SLC29A1,HTM,Down,11003,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SLC29A1,HTM,Down,11003,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC29A3,HTM,Down,23096,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC2A1,HTM,Down,11005,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SLC2A1,HTM,Down,11005,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SLC2A1,HTM,Up,11005,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
SLC2A1,HTM,Up,11005,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
SLC2A1,HTM,Up,11005,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
SLC2A1,HTM,Up,11005,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
SLC2A10,HTM,Up,13444,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC2A10,HTM,Down,13444,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SLC2A12,HTM,Down,18067,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SLC2A12,HTM,Down,18067,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SLC2A12,HTM,Down,18067,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SLC2A14,HTM,Up,18301,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SLC2A2,HTM,Down,11006,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SLC2A2,HTM,Down,11006,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SLC2A3,HTM,Up,11007,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SLC2A3,HTM,Up,11007,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SLC2A3,HTM,Up,11007,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
SLC2A4,HTM,Up,11009,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
SLC2A6,HTM,Up,11011,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC2A6,HTM,Down,11011,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
SLC2A9,HTM,Down,13446,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC2A9,HTM,Down,13446,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SLC30A10,HTM,Down,25355,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SLC30A10,HTM,Down,25355,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SLC30A4,HTM,Down,11015,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC30A7,HTM,Down,19306,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC30A7,HTM,Down,19306,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC31A1,HTM,Up,11016,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
SLC31A2,HTM,Down,11017,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC31A2,HTM,Down,11017,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC33A1,HTM,Down,95,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SLC34A3,HTM,Up,20305,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC35C1,HTM,Down,20197,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC35D1,HTM,Down,20800,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC35D2,HTM,Down,20799,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC35D2,HTM,Down,20799,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SLC35F2,HTM,Down,23615,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC35F6,HTM,Up,26055,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC35F6,HTM,Up,26055,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC35F6,HTM,Up,26055,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC37A1,HTM,Down,11024,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLC37A2,HTM,Down,20644,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC37A2,HTM,Down,20644,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC37A2,HTM,Down,20644,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC37A2,HTM,Up,20644,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC38A10,HTM,Up,28237,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SLC38A2,HTM,Up,13448,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
SLC38A2,HTM,Up,13448,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SLC38A2,HTM,Up,13448,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
SLC38A2,HTM,Up,13448,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
SLC38A2,HTM,Up,13448,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
SLC38A2,HTM,Up,13448,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
SLC38A5,HTM,Down,18070,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC38A5,HTM,Down,18070,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC38A6,HTM,Up,19863,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC38A6,HTM,Up,19863,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC38A6,HTM,Down,19863,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
SLC39A10,HTM,Down,20861,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SLC39A11,HTM,Up,14463,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC39A13,HTM,Up,20859,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SLC39A4,HTM,Up,17129,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SLC39A4,HTM,Up,17129,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SLC39A6,HTM,Up,18607,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC39A6,HTM,Down,18607,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SLC39A8,HTM,Up,20862,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC39A8,HTM,Up,20862,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC39A8,HTM,Up,20862,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC3A2,HTM,Up,11026,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0085,23903875
SLC3A2,HTM,Down,11026,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0085,32503348
SLC3A2,HTM,Down,11026,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0085,32503348
SLC3A2,HTM,Down,11026,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0085,31501409
SLC3A2,HTM,Down,11026,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0085,27746256
SLC3A2,HTM,Up,11026,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0085,34168259
SLC40A1,HTM,Up,10909,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC40A1,HTM,Up,10909,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC40A1,HTM,Up,10909,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC41A2,HTM,Up,31045,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC41A2,HTM,Up,31045,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC41A2,HTM,Up,31045,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC43A1,HTM,Down,9225,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SLC43A2,HTM,Up,23087,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
SLC43A2,HTM,Up,23087,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
SLC43A2,HTM,Up,23087,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
SLC43A2,HTM,Up,23087,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
SLC43A2,HTM,Up,23087,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
SLC43A2,HTM,Up,23087,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
SLC43A3,HTM,Down,17466,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC43A3,HTM,Down,17466,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC43A3,HTM,Down,17466,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC44A1,HTM,Down,18798,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SLC44A2,HTM,Down,17292,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC44A2,HTM,Down,17292,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC44A2,HTM,Down,17292,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SLC44A3,HTM,Up,28689,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC44A3,HTM,Down,28689,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SLC44A3-AS1,HTM,Down,49057,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SLC44A4,HTM,Up,13941,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC44A4,HTM,Up,13941,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC44A5,HTM,Up,28524,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC45A1,HTM,Up,17939,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC45A4,HTM,Up,29196,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC45A4,HTM,Up,29196,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC47A1,HTM,Up,25588,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SLC47A1,HTM,Up,25588,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SLC47A1,HTM,Down,25588,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
SLC47A1,HTM,Up,25588,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SLC47A1,HTM,Up,25588,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SLC47A1,HTM,Up,25588,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SLC49A4,HTM,Up,16628,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC49A4,HTM,Up,16628,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC49A4,HTM,Up,16628,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC4A11,HTM,Down,16438,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLC4A11,HTM,Down,16438,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLC4A2,HTM,Down,11028,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SLC4A3,HTM,Down,11029,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SLC4A4,HTM,Down,11030,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
SLC4A4,HTM,Up,11030,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SLC4A4,HTM,Up,11030,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SLC4A4,HTM,Up,11030,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0032,17932721
SLC4A4,HTM,Up,11030,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0032,17932721
SLC4A7,HTM,Down,11033,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC4A8,HTM,Up,11034,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC4A9,HTM,Down,11035,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SLC51A,HTM,Down,29955,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLC52A2,HTM,Down,30224,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SLC52A3,HTM,Down,16187,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SLC52A3,HTM,Up,16187,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC5A1,HTM,Down,11036,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLC5A1,HTM,Down,11036,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLC5A11,HTM,Down,23091,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SLC5A11,HTM,Down,23091,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SLC5A11,HTM,Up,23091,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SLC5A11,HTM,Up,23091,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SLC5A3,HTM,Up,11038,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SLC5A3,HTM,Down,11038,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
SLC5A6,HTM,Down,11041,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SLC5A6,HTM,Down,11041,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SLC5A6,HTM,Up,11041,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC5A8,HTM,Up,19119,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC66A3,HTM,Up,28503,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC6A10P,HTM,Down,11043,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC6A10P,HTM,Down,11043,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC6A11,HTM,Down,11044,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC6A11,HTM,Down,11044,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC6A11,HTM,Down,11044,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC6A11,HTM,Down,11044,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SLC6A12,HTM,Down,11045,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
SLC6A12,HTM,Up,11045,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
SLC6A12,HTM,Down,11045,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
SLC6A12,HTM,Up,11045,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
SLC6A12,HTM,Up,11045,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
SLC6A12,HTM,Down,11045,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
SLC6A12,HTM,Up,11045,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
SLC6A14,HTM,Down,11047,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SLC6A14,HTM,Down,11047,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SLC6A14,HTM,Down,11047,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SLC6A15,HTM,Down,13621,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC6A15,HTM,Down,13621,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SLC6A15,HTM,Down,13621,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SLC6A16,HTM,Up,13622,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC6A20,HTM,Down,30927,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SLC6A20,HTM,Down,30927,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SLC6A20,HTM,Up,30927,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
SLC6A6,HTM,Up,11052,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC6A6,HTM,Up,11052,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC6A6,HTM,Up,11052,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC6A8,HTM,Down,11055,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC6A8,HTM,Down,11055,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC6A8,HTM,Down,11055,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SLC7A11,HTM,Up,11059,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC7A2,HTM,Up,11060,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC7A2,HTM,Up,11060,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC7A2,HTM,Down,11060,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
SLC7A5,HTM,Up,11063,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
SLC7A5,HTM,Up,11063,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
SLC7A5,HTM,Down,11063,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
SLC7A5,HTM,Down,11063,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
SLC7A5P2,HTM,Up,24951,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31692042
SLC7A7,HTM,Up,11065,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC7A7,HTM,Up,11065,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC7A8,HTM,Down,11066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SLC7A8,HTM,Up,11066,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SLC7A8,HTM,Up,11066,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SLC7A8,HTM,Up,11066,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SLC7A8,HTM,Up,11066,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SLC8A1,HTM,Down,11068,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SLC8A1,HTM,Down,11068,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SLC8A1,HTM,Down,11068,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
SLC8A1,HTM,Down,11068,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
SLC8A1,HTM,Up,11068,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SLC8A2,HTM,Down,11069,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SLC9A1,HTM,Down,11071,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC9A1,HTM,Down,11071,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC9A1,HTM,Down,11071,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLC9A1,HTM,Up,11071,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
SLC9A2,HTM,Up,11072,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC9A2,HTM,Up,11072,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC9A3R1,HTM,Down,11075,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SLC9A3R2,HTM,Up,11076,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC9A4,HTM,Up,11077,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLC9A7,HTM,Up,17123,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLC9A7,HTM,Up,17123,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
SLC9B2,HTM,Down,25143,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC9B2,HTM,Down,25143,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLC9B2,HTM,Up,25143,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC9B2,HTM,Up,25143,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLC9B2,HTM,Up,25143,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SLCO1A2,HTM,Up,10956,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLCO1A2,HTM,Up,10956,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SLCO1B3,HTM,Up,10961,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLCO1B3,HTM,Up,10961,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLCO2A1,HTM,Down,10955,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLCO3A1,HTM,Down,10952,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLCO4A1,HTM,Up,10953,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
SLCO4A1,HTM,Up,10953,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
SLCO4A1,HTM,Up,10953,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
SLCO4A1,HTM,Up,10953,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
SLCO4C1,HTM,Up,23612,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLCO4C1,HTM,Up,23612,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLCO5A1,HTM,Up,19046,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
SLF1,HTM,Up,25408,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLF1,HTM,Up,25408,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLFN12,HTM,Down,25500,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLFN12,HTM,Down,25500,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLFN13,HTM,Up,26481,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SLFN13,HTM,Down,26481,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SLFN5,HTM,Down,28286,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SLIT1,HTM,Up,11085,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SLIT1,HTM,Up,11085,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLIT2,HTM,Up,11086,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SLIT2,HTM,Down,11086,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SLIT3,HTM,Down,11087,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLITRK1,HTM,Up,20297,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SLITRK4,HTM,Down,23502,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SLITRK5,HTM,Down,20295,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
SLITRK5,HTM,Up,20295,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SLITRK6,HTM,Up,23503,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Transcriptomics,0.04,0.0011,30592142
SLITRK6,HTM,Up,23503,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Transcriptomics,0.04,0.0011,30592142
SLMAP,HTM,Down,16643,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SLMAP,HTM,Up,16643,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
SLPI,HTM,Down,11092,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,34059086
SLPI,HTM,Up,11092,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
SLPI,HTM,Down,11092,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,31709178
SLPI,HTM,Up,11092,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0074,34680485
SLPI,HTM,Up,11092,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0074,31501409
SLPI,HTM,Down,11092,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0074,34414448
SLPI,HTM,UP,11092,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,23108794
SLPI,HTM,UP,11092,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,23108794
SLPI,HTM,UP,11092,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,23108794
SLPI,HTM,UP,11092,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,23108794
SLPI,HTM,UP,11092,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,23108794
SLX1A,HTM,Down,20922,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
SLX4IP,HTM,Down,16225,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SLX4IP,HTM,Up,16225,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SMAD2,HTM,Down,6768,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SMAD3,HTM,Down,6769,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SMAD3,HTM,Up,6769,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,35013621
SMAD5,HTM,Down,6771,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SMAD6,HTM,Up,6772,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SMAD6,HTM,Up,6772,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SMAD6,HTM,Up,6772,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SMAD6,HTM,Down,6772,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
SMAD6,HTM,Up,6772,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SMAD6,HTM,Up,6772,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SMAD7,HTM,Down,6773,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
SMAD7,HTM,Down,6773,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
SMAD7,HTM,Down,6773,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SMAD9,HTM,Up,6774,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SMAD9,HTM,Down,6774,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SMAP1,HTM,Up,19651,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SMAP1,HTM,Up,19651,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SMAP1,HTM,Up,19651,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SMARCA1,HTM,Up,11097,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SMARCA1,HTM,Up,11097,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SMARCA1,HTM,Up,11097,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SMARCA4,HTM,Down,11100,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SMARCC1,HTM,Up,11104,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
SMARCD1,HTM,Down,11106,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SMC1A,HTM,Up,11111,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SMC1A,HTM,Up,11111,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SMC1A,HTM,Up,11111,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SMCHD1,HTM,Up,29090,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SMCR6,HTM,Down,NA,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SMG1P1,HTM,Up,44186,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31692042
SMG9,HTM,Down,25763,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
SMG9,HTM,Down,25763,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
SMG9,HTM,Up,25763,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SMG9,HTM,Up,25763,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SMG9,HTM,Up,25763,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SMIM14,HTM,Up,27321,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SMIM14,HTM,Up,27321,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SMIM24,HTM,Up,37244,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SMIM24,HTM,Up,37244,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SMIM31,HTM,Down,49638,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SMIM32,HTM,Down,53640,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SMIM5,HTM,Up,40030,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SMN1,HTM,Up,11117,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SMN1,HTM,Up,11117,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SMN1,HTM,Up,11117,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SMO,HTM,Down,11119,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0212,31709178
SMOC1,HTM,Up,20318,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SMOC2,HTM,Up,20323,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SMOC2,HTM,Down,20323,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
SMOX,HTM,Up,15862,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SMOX,HTM,Up,15862,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SMOX,HTM,Up,15862,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SMPD3,HTM,Down,14240,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SMPDL3B,HTM,Down,21416,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SMTN,HTM,Down,11126,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SMU1,HTM,Down,18247,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
SMUG1,HTM,Down,17148,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
SMURF2,HTM,Down,16809,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SMURF2,HTM,Down,16809,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SMURF2,HTM,Down,16809,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SMURF2,HTM,Up,16809,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
SNAI1,HTM,Up,11128,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.24,0.0212,34680485
SNAI2,HTM,Down,11094,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0159,25881239
SNAI2,HTM,Down,11094,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0159,25881239
SNAI2,HTM,Down,11094,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0159,25881239
SNAI2,HTM,Up,11094,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0159,21618577
SNAI2,HTM,Up,11094,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0159,21618577
SNAI2,HTM,Down,11094,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.28,0.0159,34680485
SNAI2,HTM,Down,11094,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.28,0.0159,31501409
SNAI2,HTM,Up,11094,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0159,21618577
SNAI2,HTM,Up,11094,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0159,28588211
SNAP23,HTM,Down,11131,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SNAP23,HTM,Up,11131,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SNAP23,HTM,Up,11131,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SNAP23,HTM,Up,11131,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SNAP25,HTM,Up,11132,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SNAP25,HTM,Up,11132,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SNAP25,HTM,Down,11132,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SNAP25,HTM,Down,11132,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SNAP25-AS1,HTM,Down,44312,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SNAPC1,HTM,Up,11134,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SNAPC1,HTM,Down,11134,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SNAPC1,HTM,Down,11134,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
SNAPC5,HTM,Up,15484,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SNAPC5,HTM,Up,15484,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SNAPC5,HTM,Down,15484,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
SNCA,HTM,Down,11138,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SNCA,HTM,Down,11138,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SNCA,HTM,Down,11138,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SNCA,HTM,Down,11138,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SNCA,HTM,Down,11138,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SNCG,HTM,Down,11141,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SND1,HTM,Up,30646,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SND1,HTM,Up,30646,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SND1,HTM,Up,30646,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SND1-IT1,HTM,Up,24158,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SND1-IT1,HTM,Up,24158,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SND1-IT1,HTM,Up,24158,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SNED1,HTM,Up,24696,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
SNHG11,HTM,Down,25046,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SNHG12,HTM,Down,30062,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SNHG29,HTM,Down,28619,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SNHG5,HTM,Up,21026,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SNHG5,HTM,Up,21026,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SNHG5,HTM,Up,21026,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SNHG6,HTM,Down,32965,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SNHG6,HTM,Down,32965,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SNORA11,HTM,Up,32599,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,29316740
SNORA12,HTM,Up,32600,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SNORA21,HTM,Up,32611,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SNORA23,HTM,Up,32613,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SNORA25,HTM,Up,32615,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SNORA25,HTM,Up,32615,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SNORA25,HTM,Up,32615,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SNORA50A,HTM,Up,32643,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SNORA61,HTM,Down,32655,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SNORA63,HTM,Up,10106,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SNORA70D,HTM,Down,34356,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SNORA71A,HTM,Up,10232,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SNORA75,HTM,Down,32661,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SNORA78,HTM,Down,32664,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SNORA78,HTM,Down,32664,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SNORD104,HTM,Up,32768,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SNORD111B,HTM,Up,33579,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,25117811
SNORD13,HTM,Up,32711,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SNORD138,HTM,Up,50420,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,26711929
SNORD138,HTM,Down,50420,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,25117811
SNORD13P2,HTM,Up,10111,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SNORD14C,HTM,Down,30352,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SNORD33,HTM,Up,10160,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SNORD36B,HTM,Up,10164,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SNORD41,HTM,Down,10179,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,29316740
SNORD42B,HTM,Down,10181,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SNORD42B,HTM,Up,10181,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SNORD4A,HTM,Down,10097,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SNORD4B,HTM,Up,10098,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SNORD4B,HTM,Up,10098,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SNORD4B,HTM,Up,10098,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SNORD5,HTM,Up,32702,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SNORD5,HTM,Down,32702,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SNORD50A,HTM,Down,10200,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
SNORD50A,HTM,Down,10200,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
SNORD50A,HTM,Down,10200,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
SNORD50A,HTM,Down,10200,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
SNORD50A,HTM,Down,10200,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
SNORD75,HTM,Down,32735,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SNORD91A,HTM,Down,32752,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SNRK,HTM,Down,30598,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SNRK,HTM,Up,30598,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
SNRNP200,HTM,Down,30859,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SNRNP200,HTM,Down,30859,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SNRNP25,HTM,Down,14161,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SNRPA,HTM,Up,11151,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SNRPA,HTM,Up,11151,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SNRPD1,HTM,Down,11158,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SNRPD2,HTM,Down,11159,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SNRPD2,HTM,Down,11159,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SNRPD3,HTM,Down,11160,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SNRPD3,HTM,Down,11160,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SNTB1,HTM,Up,11168,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SNTB1,HTM,Up,11168,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SNTB2,HTM,Up,11169,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
SNX10,HTM,Down,14974,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SNX10,HTM,Down,14974,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SNX13,HTM,Up,21335,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SNX15,HTM,Down,14978,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
SNX24,HTM,Up,21533,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SNX24,HTM,Up,21533,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SNX24,HTM,Up,21533,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SNX27,HTM,NA,20073,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
SNX29,HTM,Down,30542,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SNX3,HTM,Up,11174,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
SNX4,HTM,Down,11175,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SOBP,HTM,Down,29256,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
SOCS2,HTM,Up,19382,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0053,23820871
SOCS2,HTM,Down,19382,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0053,19451087
SOCS2,HTM,Down,19382,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
SOCS2,HTM,Down,19382,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
SOCS2,HTM,Down,19382,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
SOCS3,HTM,Down,19391,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SOCS3,HTM,Down,19391,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SOCS3,HTM,Up,19391,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
SOCS4,HTM,Up,19392,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SOCS4,HTM,Up,19392,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SOCS4,HTM,Up,19392,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SOCS6,HTM,Up,16833,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SOCS6,HTM,Up,16833,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SOD1,HTM,Up,11179,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
SOD1,HTM,Up,11179,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
SOD1,HTM,Down,11179,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
SOD1,HTM,Up,11179,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
SOD2,HTM,Down,11180,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.28,0.0064,24961511
SOD2,HTM,Up,11180,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.28,0.0064,24961511
SOD2,HTM,Up,11180,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.28,0.0064,24961511
SOD2,HTM,Up,11180,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
SOD2,HTM,Up,11180,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0064,32503348
SOD2,HTM,Up,11180,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
SOD2,HTM,Up,11180,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0064,31501409
SOD2,HTM,Down,11180,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0064,34168259
SOD2,HTM,Down,11180,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0064,34168259
SOGA1,HTM,NA,16111,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
SOGA3,HTM,Down,21494,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SOHLH2,HTM,Up,26026,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SON,HTM,Up,11183,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SON,HTM,Up,11183,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
SORBS1,HTM,Up,14565,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
SORBS1,HTM,Down,14565,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SORBS2,HTM,Down,24098,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
SORBS2,HTM,Up,24098,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SORBS2,HTM,Down,24098,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
SORCS1,HTM,Up,16697,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SORCS2,HTM,Down,16698,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SORD,HTM,Down,11184,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SORD,HTM,Down,11184,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SORL1,HTM,Down,11185,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SORL1,HTM,Down,11185,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SORL1,HTM,Down,11185,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SORL1,HTM,Down,11185,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SORT1,HTM,Down,11186,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SORT1,HTM,Down,11186,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SOS1,HTM,Down,11187,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
SOS1,HTM,Down,11187,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
SOS2,HTM,Down,11188,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
SOS2,HTM,Down,11188,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
SOWAHB,HTM,Down,32958,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SOWAHC,HTM,Down,17148,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
SOWAHC,HTM,Down,26149,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SOWAHC,HTM,Down,26149,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SOWAHC,HTM,Down,26149,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SOWAHC,HTM,Up,26149,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SOX1,HTM,Up,11189,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20424609
SOX1,HTM,Down,11189,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
SOX1,HTM,NA,11189,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by PCR array assay,0.04,0.0042,20630067
SOX13,HTM,Up,11192,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SOX15,HTM,Down,11196,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SOX2,HTM,Up,11195,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.12,0.5695,20424609
SOX2,HTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by PCR array assay,0.48,0.5695,20630067
SOX2,HTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.6,0.5695,20630067
SOX2,HTM,Up,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.52,0.5695,31289135
SOX2,HTM,Up,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,DIM,Single-cell time-of-flight mass cytometry,0.52,0.5695,34464674
SOX2,HTM,Up,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.52,0.5695,34680485
SOX2,HTM,Up,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.52,0.5695,17911267
SOX2,HTM,Up,11195,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.5695,34414448
SOX2,HTM,Up,11195,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.5695,34414448
SOX2,HTM,Up,11195,Breast Cancer,NA,Primary,NA,Transcriptomics,0.36,0.5695,30559934
SOX21,HTM,Up,11197,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,35229723
SOX3,HTM,Down,11200,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SOX4,HTM,Up,11200,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
SOX4,HTM,Up,11200,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
SOX4,HTM,Up,11200,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
SOX8,HTM,Up,11203,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,35229723
SOX9,HTM,Up,11204,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.52,0.0244,35229723
SOX9,HTM,Up,11204,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.52,0.0244,29416721
SOX9,HTM,Up,11204,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.52,0.0244,29416721
SOX9,HTM,Down,11204,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0244,31709178
SOX9,HTM,Up,11204,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0244,21618577
SOX9,HTM,Up,11204,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0244,21618577
SOX9,HTM,Up,11204,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.48,0.0244,34680485
SOX9,HTM,Up,11204,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Doxorubicin,SFA followed by single-cell time-of-flight mass cytometry,0.28,0.0244,34831064
SOX9,HTM,Down,11204,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0244,30696080
SOX9,HTM,Down,11204,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0244,30696080
SOX9,HTM,Down,11204,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0244,31709178
SOX9,HTM,Up,11204,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0244,21618577
SOX9-AS1,HTM,Up,49321,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SP1,HTM,Down,11205,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SP100,HTM,Down,11206,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SP110,HTM,Down,5401,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SP140,HTM,Down,17133,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,28588211
SP140L,HTM,Up,25105,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SP2,HTM,Down,11207,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SP6,HTM,Down,14530,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SP6,HTM,Up,14530,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SP8,HTM,Down,19196,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SP8,HTM,Down,19196,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SPA17,HTM,Up,11210,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SPACA5,HTM,Down,31353,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
SPACA6,HTM,Down,27113,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SPACA6,HTM,Down,27113,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SPAG1,HTM,Up,11212,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SPAG1,HTM,Up,11212,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SPAG1,HTM,Up,11212,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SPAG5,HTM,Up,13452,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPANXA1,HTM,Up,11218,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPANXA1,HTM,Up,11218,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPANXA2,HTM,Up,14328,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPANXA2,HTM,Up,14331,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPANXC,HTM,Up,14331,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPANXC,HTM,Up,14331,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPANXC,HTM,Up,14331,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPANXC,HTM,Up,14331,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPANXC,HTM,Up,14331,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPANXD,HTM,Up,14332,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPANXD,HTM,Up,14332,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPANXD,HTM,Up,14332,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPARC,HTM,Down,11219,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SPARC,HTM,Down,11219,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SPARC,HTM,Down,11219,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SPARC,HTM,Up,11219,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
SPARC,HTM,Down,11219,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
SPAST,HTM,Down,11233,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SPATA17,HTM,Up,25184,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPATA18,HTM,Down,29579,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SPATA18,HTM,Up,29579,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SPATA2,HTM,Up,14681,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SPATA2,HTM,Up,14681,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SPATA2,HTM,Up,14681,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SPATA20,HTM,Down,26125,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SPATA25,HTM,Up,16158,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
SPATA6L,HTM,Down,25472,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SPATA9,HTM,Down,22988,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SPATS2L,HTM,Down,24574,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SPC24,HTM,Down,26913,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SPCS3,HTM,Down,26212,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPCS3,HTM,Down,26212,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPCS3,HTM,Down,26212,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPDEF,HTM,Up,17257,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SPDYE1,HTM,Up,16408,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SPDYE1,HTM,Up,16408,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SPDYE1,HTM,Up,16408,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SPDYE1,HTM,Down,16408,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SPDYE1,HTM,Down,16408,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SPDYE2,HTM,Up,33841,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPDYE5,HTM,Up,35464,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPDYE5,HTM,Up,35464,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPDYE5,HTM,Up,35464,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPDYE7P,HTM,Up,35466,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPDYE7P,HTM,Up,35466,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPDYE7P,HTM,Up,35466,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPEN,HTM,Down,17575,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SPEN,HTM,Up,17575,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
SPG11,HTM,Up,11226,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SPG11,HTM,Up,11226,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SPG11,HTM,Up,11226,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SPHK1,HTM,Up,11240,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SPHK1,HTM,Down,11240,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SPHK1,HTM,Down,11240,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SPHK2,HTM,Down,18859,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SPIDR,HTM,Down,28971,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SPIDR,HTM,Down,28971,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SPIN3,HTM,Up,27272,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SPINK1,HTM,Up,11244,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
SPINK1,HTM,Up,11244,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
SPINK1,HTM,Up,11244,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0032,17932721
SPINK1,HTM,Up,11244,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
SPINK13,HTM,Down,27200,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SPINK4,HTM,Up,16646,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SPINK6,HTM,Up,29486,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,30254465
SPINK6,HTM,Up,29486,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
SPINK6,HTM,Up,29486,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
SPINK6,HTM,Down,29486,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
SPINK6,HTM,Up,29486,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
SPINT1,HTM,Down,11246,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SPINT1,HTM,Down,11246,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SPINT1,HTM,Down,11246,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SPINT2,HTM,Down,11247,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SPIRE2,HTM,Up,30623,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SPNS2,HTM,Down,26992,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SPNS2,HTM,Up,26992,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SPOCK1,HTM,Down,11251,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SPOCK1,HTM,Down,11251,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SPOCK1,HTM,Up,11251,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
SPOCK1,HTM,Down,11251,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
SPOCK1,HTM,Down,11251,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
SPOCK1,HTM,Down,11251,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
SPOCK2,HTM,Down,13564,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SPOCK2,HTM,Down,13564,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SPON1,HTM,Up,11252,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
SPP1,HTM,Up,11255,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
SPP1,HTM,Up,11255,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SPP1,HTM,Up,11255,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
SPP1,HTM,Up,11255,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SPR,HTM,Down,11257,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SPR,HTM,Up,11257,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SPRR1A,HTM,Up,11259,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SPRR1B,HTM,Down,11260,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,29340052
SPRR1B,HTM,Down,11260,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SPRR1B,HTM,Down,11260,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SPRR1B,HTM,Down,11260,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SPRR1B,HTM,Up,11260,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
SPRR1B,HTM,Up,11260,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
SPRR1B,HTM,Up,11260,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
SPRR1B,HTM,Up,11260,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
SPRR2A,HTM,Down,11261,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SPRR2A,HTM,Down,11261,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SPRR2D,HTM,Down,11264,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SPRR2D,HTM,Down,11264,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SPRR2E,HTM,Down,11265,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
SPRR2E,HTM,Up,11265,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
SPRR2E,HTM,Down,11265,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SPRR2F,HTM,Down,11266,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SPRR3,HTM,Up,11268,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SPRR3,HTM,Up,11268,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SPRY1,HTM,Up,11269,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SPRY2,HTM,Up,11270,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SPRY4,HTM,Up,15533,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SPRY4,HTM,Up,15533,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SPRY4,HTM,Up,15533,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SPRY4,HTM,Up,15533,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SPTBN2,HTM,Up,11276,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SPTBN2,HTM,Up,11276,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SPTLC1,HTM,Down,11277,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SPTLC3,HTM,Down,16253,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SPTLC3,HTM,Down,16253,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SPTLC3,HTM,Up,16253,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
SPTLC3,HTM,Down,16253,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
SPTLC3,HTM,Up,16253,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
SPTSSA,HTM,Down,20361,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
SPTSSA,HTM,Up,20361,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SPTSSA,HTM,Up,20361,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SPTSSA,HTM,Up,20361,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SPTSSA,HTM,Up,20361,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
SPTSSB,HTM,Up,24045,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SPTSSB,HTM,Up,24045,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SPTSSB,HTM,Up,24045,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SPTSSB,HTM,Up,24045,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SPTY2D1,HTM,Up,26818,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SPX,HTM,Up,28139,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SPX,HTM,Down,28139,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SPX,HTM,Down,28139,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
SQLE,HTM,Down,11279,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SQLE,HTM,Up,11279,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
SQLE,HTM,Up,11279,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
SQLE,HTM,Up,11279,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
SQLE,HTM,Up,11279,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
SQLE,HTM,Up,11279,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
SQLE,HTM,Up,11279,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
SQLE,HTM,Down,11279,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
SQOR,HTM,Down,20390,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SQOR,HTM,Down,20390,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SQOR,HTM,Down,20390,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SQOR,HTM,Up,20390,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
SQOR,HTM,Down,20390,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
SQSTM1,HTM,Down,11280,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
SQSTM1,HTM,Up,11280,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
SQSTM1,HTM,Up,11280,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
SQSTM1,HTM,Up,11280,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
SRC,HTM,Down,11283,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,29352988
SRC,HTM,Down,11283,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0032,29352988
SRCIN1,HTM,Up,29506,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
SRCIN1,HTM,Up,29506,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SRD5A1,HTM,Up,11284,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
SRD5A1,HTM,Up,11284,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
SREBF2,HTM,Up,11290,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SREBF2,HTM,Up,11290,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SREK1IP1,HTM,Down,26716,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SREK1IP1,HTM,Down,26716,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SREK1IP1,HTM,Down,26716,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SREK1IP1,HTM,Down,26716,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SRFBP1,HTM,Down,26333,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SRGAP3,HTM,Up,19744,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SRGN,HTM,Up,9361,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SRGN,HTM,Up,9361,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SRGN,HTM,Up,9361,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SRGN,HTM,Up,9361,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
SRGN,HTM,Up,9361,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SRI,HTM,Down,11292,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SRMS,HTM,Up,11298,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SRMS,HTM,Down,11298,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SRP14,HTM,Down,11299,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SRP14,HTM,Down,11299,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SRP14,HTM,Up,11299,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SRP14,HTM,Down,11299,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SRP54,HTM,Up,11301,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SRP54,HTM,Up,11301,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
SRP9,HTM,Down,11304,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SRPK2,HTM,Up,11306,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SRPK2,HTM,Up,11306,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SRPK2,HTM,Up,11306,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SRPX,HTM,Down,11309,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SRPX,HTM,Down,11309,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SRPX,HTM,Down,11309,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SRPX,HTM,Down,11309,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
SRPX,HTM,Down,11309,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
SRPX,HTM,Down,11309,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
SRPX,HTM,Down,11309,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
SRPX,HTM,Down,11309,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
SRPX2,HTM,Up,30668,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
SRR,HTM,Up,14398,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SRRT,HTM,Down,24101,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
SRSF1,HTM,Down,10780,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SRSF1,HTM,Down,10780,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
SRSF10,HTM,Down,16713,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SRSF2,HTM,Down,10783,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SRSF2,HTM,Down,10783,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SRSF2,HTM,Down,10783,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SRSF7,HTM,Down,10789,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
SRSF7,HTM,Down,10789,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
SRSF7,HTM,Down,10789,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
SRSF7,HTM,Up,10789,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SRSF7,HTM,Down,10789,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
SRSF7,HTM,Down,10789,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
SRXN1,HTM,Up,16132,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SRXN1,HTM,Up,16132,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SRXN1,HTM,Up,16132,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SRXN1,HTM,Up,16132,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SRXN1,HTM,Up,16132,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
SRXN1,HTM,Up,16132,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0032,28881576
SSB,HTM,Down,7546,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
SSBP1,HTM,Up,11317,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SSBP2,HTM,Up,15831,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SSBP2,HTM,Down,15831,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
SSBP3,HTM,Down,15674,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SSH2,HTM,Down,30580,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SSH2,HTM,Up,30580,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SSH2,HTM,Up,30580,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SSH2,HTM,Up,30580,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
SSH3,HTM,Down,30581,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SSH3,HTM,Down,30581,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31729259
SSH3,HTM,Down,30581,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31729259
SSPN,HTM,Up,11322,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SSPN,HTM,Down,11322,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SSR1,HTM,Up,11323,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SSR1,HTM,Up,11323,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
SSR1,HTM,Up,11323,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SSR1,HTM,Down,11323,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SSR3,HTM,Down,11325,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SSRP1,HTM,Up,11327,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
SSTR5,HTM,Up,11334,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SSTR5,HTM,Up,11334,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SSX1,HTM,Up,11335,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SSX1,HTM,Up,11335,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SSX1,HTM,Up,11335,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SSX2IP,HTM,Down,16509,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SSX8P,HTM,UP,19654,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
SSX8P,HTM,UP,19654,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
SSX8P,HTM,UP,19654,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
SSX8P,HTM,UP,19654,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
SSX8P,HTM,UP,19654,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
ST13,HTM,Up,11343,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
ST13,HTM,Up,11343,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
ST14,HTM,Down,11344,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ST14,HTM,Down,11344,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ST20,HTM,Down,33520,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ST20,HTM,Down,33520,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ST3GAL1,HTM,Up,10862,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ST3GAL2,HTM,Up,10863,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ST3GAL2,HTM,Up,10863,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ST3GAL3,HTM,Up,10866,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ST3GAL3,HTM,Up,10866,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ST3GAL3,HTM,Up,10866,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ST3GAL3,HTM,Up,10866,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ST3GAL3,HTM,Up,10866,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
ST3GAL5,HTM,Up,10872,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,30254465
ST3GAL5,HTM,Down,10872,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ST3GAL6,HTM,Down,18080,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ST3GAL6,HTM,Down,18080,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ST3GAL6,HTM,Down,18080,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ST6GAL1,HTM,Down,10860,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ST6GAL1,HTM,Up,10860,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0021,17932721
ST6GAL1,HTM,Down,10860,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ST6GAL2,HTM,Up,10861,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ST6GAL2,HTM,Up,10861,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ST6GALNAC1,HTM,Up,23614,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ST6GALNAC2,HTM,Down,10867,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ST6GALNAC2,HTM,Down,10867,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ST6GALNAC2,HTM,Down,10867,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ST6GALNAC2,HTM,Up,10867,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ST6GALNAC4,HTM,Up,17846,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ST6GALNAC5,HTM,Down,19342,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ST7,HTM,Down,11351,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ST8SIA1,HTM,Up,10869,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ST8SIA4,HTM,Up,10871,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ST8SIA4,HTM,Up,10871,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
ST8SIA4,HTM,Up,10871,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
ST8SIA4,HTM,Down,10871,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
ST8SIA4,HTM,Up,10871,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0042,20530554
ST8SIA6,HTM,Up,23317,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
STAB1,HTM,Up,18628,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
STAM2,HTM,Down,11358,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
STAP2,HTM,Down,30430,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
STARD10,HTM,Down,10666,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
STARD3,HTM,Down,17579,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
STARD4,HTM,Down,18058,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
STARD4,HTM,Down,18058,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
STARD4,HTM,Down,18058,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
STARD4,HTM,Up,18058,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
STARD4,HTM,Up,18058,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
STARD4,HTM,Down,18058,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0042,22954703
STARD5,HTM,Down,18065,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
STARD5,HTM,Down,18065,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
STARD5,HTM,Down,18065,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
STARD5,HTM,Down,18065,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
STARD8,HTM,Up,19161,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
STARD8,HTM,Up,19161,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
STARD8,HTM,Up,19161,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
STARD9,HTM,Up,19162,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
STAT1,HTM,Up,11362,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
STAT1,HTM,Down,11362,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
STAT1,HTM,Down,11362,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
STAT3,HTM,Up,11364,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0223,29352988
STAT3,HTM,Up,11364,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Proteomics and Western Blotting,0.36,0.0223,17911267
STAT3,HTM,Up,11364,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.36,0.0223,34680485
STAT4,HTM,Down,11365,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
STAT6,HTM,Down,11368,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STBD1,HTM,Down,24854,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
STBD1,HTM,Down,24854,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
STC1,HTM,Down,11373,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
STC1,HTM,Up,11373,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
STC1,HTM,Up,11373,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
STC1,HTM,Up,11373,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
STC2,HTM,Down,11374,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,34680485
STEAP1,HTM,Down,11378,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
STEAP1,HTM,Up,11378,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
STEAP1,HTM,Up,11378,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
STEAP1,HTM,Up,11378,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
STEAP1,HTM,Up,11378,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0053,24961511
STEAP1,HTM,Up,11378,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0053,24961511
STEAP1,HTM,Up,11378,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
STEAP1,HTM,Up,11378,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
STEAP1,HTM,Up,11378,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0053,19353633
STEAP1B,HTM,Up,41907,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
STEAP2,HTM,Up,17885,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
STEAP2,HTM,Up,17885,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
STEAP2,HTM,Up,17885,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
STEAP2,HTM,Up,17885,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
STEAP2,HTM,Up,17885,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
STEAP2,HTM,Up,17885,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
STEAP4,HTM,Up,21923,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
STEAP4,HTM,Down,21923,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
STIMATE,HTM,Down,30526,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
STING1,HTM,Down,27962,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STIP1,HTM,Down,11387,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
STIP1,HTM,Down,11387,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
STIP1,HTM,Down,11387,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
STIP1,HTM,Down,11387,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
STIP1,HTM,Up,11387,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
STK10,HTM,Down,11388,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STK11,HTM,Down,11389,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
STK11,HTM,Down,11389,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
STK17A,HTM,Down,11395,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STK17A,HTM,Down,11395,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STK17A,HTM,Down,11395,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STK25,HTM,Down,11404,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
STK26,HTM,Down,18174,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
STK32B,HTM,Up,14217,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STK32B,HTM,Up,14217,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STK33,HTM,Down,14568,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
STK33,HTM,Down,14568,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
STK35,HTM,Down,16254,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
STK39,HTM,Down,17717,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
STMN1,HTM,Down,6510,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
STMN1,HTM,Down,6510,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
STMN1,HTM,Down,6510,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
STMN1,HTM,Down,6510,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
STMN3,HTM,Up,15926,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
STMN3,HTM,Down,15926,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
STN1,HTM,Down,26200,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
STOM,HTM,Down,3383,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
STOM,HTM,Down,3383,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
STOM,HTM,Down,3383,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
STOML2,HTM,Down,14559,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
STOML2,HTM,Down,14559,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
STOML2,HTM,Down,14559,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
STOML2,HTM,Up,14559,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
STOML2,HTM,Down,14559,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
STOX1,HTM,Down,23508,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
STOX2,HTM,Down,25450,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
STRA6,HTM,Down,30650,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
STRADB,HTM,Up,13205,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STRBP,HTM,Up,16462,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STRIP2,HTM,Down,22209,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
STRN,HTM,Down,11424,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
STRN3,HTM,Up,15720,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
STS,HTM,Down,11425,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
STT3A,HTM,Up,6172,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
STUB1,HTM,Down,11427,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29511337
STUB1,HTM,Down,11427,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29511337
STUM,HTM,Up,30491,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
STX11,HTM,Up,11429,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
STX11,HTM,Up,11429,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
STX11,HTM,Up,11429,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
STX2,HTM,Down,3403,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
STX2,HTM,Up,3403,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
STX3,HTM,Up,11438,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STX6,HTM,Down,11441,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STX6,HTM,Down,11441,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STXBP1,HTM,Down,11444,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STXBP4,HTM,Up,19694,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STXBP4,HTM,Up,19694,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STXBP5,HTM,Down,19665,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
STXBP5-AS1,HTM,Down,44183,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
STXBP6,HTM,Down,19666,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
STYK1,HTM,Down,18889,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
STYXL1,HTM,Down,18165,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SUB1,HTM,Up,19985,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SUB1,HTM,Down,19985,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SUCLA2,HTM,Down,11448,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SUCLG2,HTM,Up,11450,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SUCO,HTM,Up,1240,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SUFU,HTM,Up,16466,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0011,29959199
SUGP2,HTM,Down,18641,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SULF1,HTM,Down,20391,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,34680485
SULF2,HTM,Down,20392,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SULF2,HTM,Down,20392,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SULF2,HTM,Down,20392,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SULF2,HTM,Up,20392,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SULT1A1,HTM,Down,11453,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SULT1A2,HTM,Up,11454,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SULT1A2,HTM,Up,11454,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
SULT1C2,HTM,Down,11456,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
SULT1C2,HTM,Up,11456,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
SULT1E1,HTM,Up,11377,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SULT2B1,HTM,Down,11459,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SUMF1,HTM,Down,20376,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SUMF2,HTM,Down,20415,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SUMO1,HTM,Down,12502,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
SUMO3,HTM,Down,11124,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SUMO4,HTM,Down,21181,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
SUPT16H,HTM,Up,11465,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
SUPT5H,HTM,Down,11469,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
SUPT6H,HTM,Up,11470,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SURF4,HTM,Down,11476,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SUSD1,HTM,Down,25413,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SUSD1,HTM,Down,25413,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
SUSD2,HTM,Down,30667,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SUSD2,HTM,Up,30667,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SUSD3,HTM,Down,28391,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
SUSD3,HTM,Down,28391,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SUSD3,HTM,Down,28391,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
SUSD3,HTM,Down,28391,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SUSD3,HTM,Down,28391,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
SVEP1,HTM,Up,15985,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SVEP1,HTM,Down,15985,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
SVIP,HTM,Up,25238,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SWAP70,HTM,Down,17070,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
SWAP70,HTM,Down,17070,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
SX2,HTM,Down,NA,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SYBU,HTM,Down,26011,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SYBU,HTM,Down,26011,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
SYBU,HTM,Down,26011,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
SYBU,HTM,Up,26011,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SYBU,HTM,Down,26011,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SYCP2,HTM,Up,11490,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SYCP2,HTM,Up,11490,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
SYCP2,HTM,Up,11490,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
SYCP2,HTM,Up,11490,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
SYCP2,HTM,Up,11490,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
SYCP2,HTM,Down,11490,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
SYCP2L,HTM,Up,21537,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SYDE1,HTM,Up,25824,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
SYDE2,HTM,Up,25841,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SYDE2,HTM,Down,25841,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SYK,HTM,Down,11491,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SYK,HTM,Down,11491,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SYN3,HTM,Up,11496,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SYNC,HTM,Up,28897,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SYNCRIP,HTM,Down,16918,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,22623141
SYNCRIP,HTM,Down,16918,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0053,23820871
SYNCRIP,HTM,Down,16918,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
SYNCRIP,HTM,Down,16918,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
SYNCRIP,HTM,Down,16918,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
SYNCRIP,HTM,Down,16918,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0053,34168259
SYNE2,HTM,Up,17084,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
SYNE2,HTM,Up,17084,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
SYNE2,HTM,Up,17084,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
SYNE3,HTM,Down,19861,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SYNE3,HTM,Down,19861,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SYNE3,HTM,Up,19861,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
SYNE4,HTM,Down,26703,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SYNE4,HTM,Up,26703,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SYNE4,HTM,Up,26703,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
SYNE4,HTM,Down,26703,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SYNGR1,HTM,Up,11498,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SYNGR3,HTM,Up,11501,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
SYNGR4,HTM,Up,11502,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SYNGR4,HTM,Up,11502,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SYNGR4,HTM,Up,11502,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
SYNJ2BP,HTM,Up,18955,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
SYNJ2BP-COX16,HTM,Down,48350,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SYNM,HTM,Up,24466,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SYNM,HTM,Up,24466,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SYPL1,HTM,Up,11507,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SYPL1,HTM,Down,11507,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
SYPL1,HTM,Down,11507,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
SYT1,HTM,Up,11509,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SYT1,HTM,Up,11509,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SYT10,HTM,Down,19266,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SYT12,HTM,Down,18381,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
SYT13,HTM,Up,14962,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0021,17932721
SYT13,HTM,Up,14962,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SYT14,HTM,Up,23143,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SYT14,HTM,Down,23143,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
SYT17,HTM,Up,24119,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SYT17,HTM,Up,24119,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
SYT3,HTM,Down,11511,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
SYT5,HTM,Down,11513,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
SYT7,HTM,Down,11514,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
SYT7,HTM,Down,11514,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SYT7,HTM,Up,11514,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SYTL1,HTM,Up,15584,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0042,35229723
SYTL1,HTM,Down,15584,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
SYTL1,HTM,Up,15584,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
SYTL1,HTM,Up,15584,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0042,24961511
SYTL1,HTM,Down,15584,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
SYTL2,HTM,Up,15585,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
SYTL2,HTM,Down,15585,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
SYTL2,HTM,Up,15585,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
SYTL2,HTM,Up,15585,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
SYTL2,HTM,Up,15585,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
SYTL4,HTM,Down,15588,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
SYTL5,HTM,Up,15589,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
SYTL5,HTM,Down,15589,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
SZRD1,HTM,Down,30232,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TAC3,HTM,Up,11521,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,35229723
TACC1,HTM,Down,11522,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TACC2,HTM,Up,11523,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TACO1,HTM,Down,24316,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TACSTD2,HTM,Down,11530,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
TACSTD2,HTM,Down,11530,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
TACSTD2,HTM,Down,11530,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
TACSTD2,HTM,Down,11530,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
TAF11,HTM,Up,11544,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
TAF13,HTM,Up,11546,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
TAF15,HTM,Down,11547,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
TAF15,HTM,Down,11547,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
TAF15,HTM,Up,11547,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
TAF15,HTM,Up,11547,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0042,21788403
TAF15,HTM,Up,11547,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.16,0.0042,20530554
TAF1A,HTM,Up,11532,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAF1A,HTM,Up,11532,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAF1A,HTM,Up,11532,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAF1B,HTM,Down,11533,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
TAF1D,HTM,Up,28759,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TAF1D,HTM,Up,28759,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
TAF1D,HTM,Up,28759,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
TAF3,HTM,Up,17303,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
TAF4B,HTM,Down,11538,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TAF4B,HTM,Down,11538,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
TAF5,HTM,Down,11539,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TAF5L,HTM,Up,17304,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAF5L,HTM,Up,17304,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAF5L,HTM,Up,17304,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAF9,HTM,Up,11542,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAF9,HTM,Up,11542,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAF9,HTM,Up,11542,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAGLN2,HTM,Up,11554,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TAGLN2,HTM,Up,11554,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TAGLN2,HTM,Down,11554,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
TAGLN3,HTM,Down,29868,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TAGLN3,HTM,Down,29868,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TAGLN3,HTM,Down,29868,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TAGLN3,HTM,Up,29868,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
TALDO1,HTM,Up,11559,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
TALDO1,HTM,Up,11559,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
TALDO1,HTM,Up,11559,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
TALDO1,HTM,Down,11559,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
TANC1,HTM,Down,29364,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
TANC2,HTM,Down,30212,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TANC2,HTM,Down,30212,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TANC2,HTM,Down,30212,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TANK,HTM,Down,11562,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
TAOK1,HTM,Down,29259,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TAOK1,HTM,Up,29259,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
TAOK3,HTM,Up,18133,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TAOK3,HTM,Down,18133,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TAOK3,HTM,Up,18133,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TAOK3,HTM,Up,18133,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TAP1,HTM,Down,43,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TAPBP,HTM,Down,11566,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,22623141
TARDBP,HTM,Down,11571,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TARDBP,HTM,Down,11571,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TARDBP,HTM,Down,11571,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
TARP,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TARS1,HTM,Down,11572,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,22623141
TAS2R14,HTM,Up,14920,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,19190339
TAS2R14,HTM,Up,14920,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TAS2R14,HTM,Up,14920,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
TAS2R14,HTM,Up,14920,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
TAS2R14,HTM,Up,14920,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,19190339
TAS2R14,HTM,Up,14920,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,19190339
TAS2R14,HTM,Up,14920,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,19190339
TAS2R14,HTM,Up,14920,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,19190339
TAS2R14,HTM,Up,14920,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
TAS2R41,HTM,Down,18883,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
TAS2R5,HTM,Up,14912,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAS2R5,HTM,Up,14912,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAS2R5,HTM,Up,14912,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAS2R8,HTM,Up,14915,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
TASOR2,HTM,Up,23484,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
TASOR2,HTM,Up,23484,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
TASOR2,HTM,Up,23484,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
TATDN1,HTM,Up,24220,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TATDN1,HTM,Up,24220,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TATDN1,HTM,Up,24220,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TATDN3,HTM,Up,27010,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TATDN3,HTM,Up,27010,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TATDN3,HTM,Up,27010,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAX1BP3,HTM,Up,30684,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAX1BP3,HTM,Up,30684,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAX1BP3,HTM,Up,30684,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TAZ,HTM,Down,11577,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
TBC1D1,HTM,Down,11578,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TBC1D1,HTM,Down,11578,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TBC1D15,HTM,Up,25694,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TBC1D15,HTM,Up,25694,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TBC1D15,HTM,Up,25694,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TBC1D15,HTM,Up,25694,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TBC1D2,HTM,Down,18026,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TBC1D2,HTM,Down,18026,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TBC1D2,HTM,Down,18026,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TBC1D2,HTM,Up,18026,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
TBC1D23,HTM,Down,25622,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TBC1D30,HTM,Up,29164,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TBC1D30,HTM,Up,29164,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TBC1D30,HTM,Down,29164,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TBC1D30,HTM,Up,29164,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
TBC1D31,HTM,Up,30888,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TBC1D31,HTM,Up,30888,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TBC1D31,HTM,Up,30888,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
TBC1D4,HTM,Up,19165,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TBC1D8,HTM,Up,17791,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TBC1D9,HTM,Up,21710,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TBCA,HTM,Down,11579,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
TBCA,HTM,Down,11579,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
TBL1X,HTM,Up,11585,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TBR1,HTM,Down,11590,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
TBX18,HTM,Up,11595,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TBX18,HTM,Up,11595,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TBX2,HTM,Up,11597,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TBX2,HTM,Up,11597,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TBX20,HTM,Down,11598,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
TBX20,HTM,Down,11598,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TBX3,HTM,Down,11602,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
TBX3,HTM,Up,11602,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0032,19451087
TBX3,HTM,Down,11602,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.24,0.0032,31289135
TBX4,HTM,Up,11603,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TBX5,HTM,Down,11604,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
TBX5,HTM,Up,11604,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,28588211
TBXAS1,HTM,Up,11609,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TBXAS1,HTM,Up,11609,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TC2N,HTM,Up,19859,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TCAF2,HTM,Up,26878,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TCEA1,HTM,Up,11612,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TCEA1,HTM,Up,11612,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TCEA3,HTM,Up,11615,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TCEA3,HTM,Up,11615,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TCEA3,HTM,Up,11615,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TCEAL4,HTM,Up,26121,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
TCEAL9,HTM,Down,30084,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TCEAL9,HTM,Up,30084,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
TCF15,HTM,Up,11627,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
TCF4,HTM,Up,11634,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,34228218
TCF4,HTM,Up,11634,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
TCF7,HTM,Down,11639,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TCF7,HTM,Up,11639,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TCF7L1,HTM,Down,11640,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TCF7L1,HTM,Down,11640,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TCF7L1,HTM,Down,11640,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TCF7L1,HTM,Down,11640,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TCF7L1,HTM,Down,11640,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TCF7l2,HTM,Up,11641,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics,0.04,0.0011,25731617
TCHP,HTM,Down,28135,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
TCIM,HTM,Up,1357,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TCIM,HTM,Up,1357,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TCN1,HTM,Up,11652,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TCOF1,HTM,Down,11654,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
TCOF1,HTM,Up,11654,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TCOF1,HTM,Up,11654,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TCOF1,HTM,Down,11654,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
TCP1,HTM,Down,11655,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,22623141
TCP1,HTM,Up,11655,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0053,23903875
TCP1,HTM,Down,11655,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
TCP1,HTM,Down,11655,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
TCP1,HTM,Down,11655,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0053,34168259
TCP1,HTM,Up,11655,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
TCP11L2,HTM,Up,28627,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TCP11L2,HTM,Down,28627,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TCP11L2,HTM,Down,28627,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TCTA,HTM,Up,11692,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TCTE3,HTM,Up,11695,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
TDG,HTM,Up,11700,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
TDP2,HTM,Up,17768,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TDP2,HTM,Up,17768,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TDP2,HTM,Up,17768,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
TDP2,HTM,Up,17768,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TDRD12,HTM,Down,25044,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
TDRD7,HTM,Down,30831,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TEAD2,HTM,Up,11715,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
TEAD4,HTM,Down,11717,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TEAD4,HTM,Down,11717,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TEC,HTM,Up,11719,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TEC,HTM,Up,11719,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TECPR1,HTM,Up,22214,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TECR,HTM,Up,4551,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
TECR,HTM,Down,4551,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
TECTA,HTM,Down,11720,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TEDC1,HTM,Up,20127,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TEDC1,HTM,Up,20127,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TEDC1,HTM,Up,20127,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
TEDC2,HTM,Down,25849,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TEKT4P2,HTM,Down,40046,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TENM2,HTM,Down,29943,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TENM2,HTM,Down,29943,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TENM2,HTM,Down,29943,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TENM3,HTM,Down,29944,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
TENM4,HTM,Up,29945,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.28,0.0021,34680485
TENT2,HTM,Up,26776,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
TENT5A,HTM,Up,18345,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TENT5A,HTM,Up,18345,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TENT5A,HTM,Up,18345,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TENT5A,HTM,Up,18345,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TENT5C,HTM,Up,24712,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TERC,HTM,Up,11727,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TERF2,HTM,Up,11729,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TERT,HTM,Down,11730,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
TERT,HTM,Down,11730,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
TES,HTM,Down,14620,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TESC,HTM,Up,26065,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TESC,HTM,Up,26065,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TESC,HTM,Up,26065,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TESK1,HTM,Down,11731,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TET1,HTM,Up,29484,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TEX13B,HTM,Down,11736,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TEX15,HTM,Up,11738,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TEX19,HTM,Up,33802,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
TEX41,HTM,Down,48667,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TEX9,HTM,Up,29585,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TF,HTM,Up,11740,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0021,34794402
TF,HTM,Down,11740,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TF,HTM,Up,11740,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0021,34794402
TF,HTM,Down,11740,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TFAP2A,HTM,Down,11742,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TFAP2C,HTM,Up,11744,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TFAP2C,HTM,Down,11744,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
TFAP2C,HTM,Down,11744,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
TFAP4,HTM,Down,11745,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TFCP2L1,HTM,Down,17925,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TFDP1,HTM,Down,11749,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TFDP1,HTM,Down,11749,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
TFDP2,HTM,Up,11751,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TFF1,HTM,Up,11755,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TFF1,HTM,NA,11755,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by PCR array assay,0.04,0.0021,20630067
TFF2,HTM,Up,11756,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TFF2,HTM,Up,11756,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TFF2,HTM,Up,11756,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TFF3,HTM,Up,11757,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
TFF3,HTM,Up,11757,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
TFF3,HTM,Up,11757,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
TFF3,HTM,Up,11757,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
TFF3,HTM,Up,11757,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
TFF3,HTM,Up,11757,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0042,21618577
TFF3,HTM,Down,11757,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
TFG,HTM,Down,11758,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TFPI,HTM,Up,11760,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TFPI,HTM,Up,11760,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TFPI,HTM,Down,11760,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
TFPI,HTM,Down,11760,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
TFPI,HTM,Up,11760,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
TFPI2,HTM,Down,11761,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
TFPI2,HTM,Down,11761,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
TFPI2,HTM,Up,11761,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0042,23820871
TFPI2,HTM,Down,11761,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
TFPI2,HTM,Up,11761,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
TFPI2,HTM,Up,11761,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
TFR2,HTM,Up,11762,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TFR2,HTM,Up,11762,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TFR2,HTM,Up,11762,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TFRC,HTM,Up,11763,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,29340052
TFRC,HTM,Up,11763,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0053,23903875
TFRC,HTM,Up,11763,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
TFRC,HTM,Up,11763,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
TFRC,HTM,Down,11763,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
TFRC,HTM,Down,11763,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
TFRC,HTM,Down,11763,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0053,34168259
TFRC,HTM,Down,11763,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0053,34168259
TG,HTM,Down,11764,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TGFA,HTM,Down,11765,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TGFA,HTM,Down,11765,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TGFA,HTM,Down,11765,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TGFA,HTM,Up,11765,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TGFB1,HTM,Up,11766,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.28,0.0138,25432175
TGFB1,HTM,Down,11766,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0138,34059086
TGFB1,HTM,Down,11766,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0138,34059086
TGFB1,HTM,Up,11766,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0138,31709178
TGFB1,HTM,NA,11766,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0138,25676692
TGFB1,HTM,NA,11766,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0138,25676692
TGFB1,HTM,Up,11766,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0138,34680485
TGFB1,HTM,Up,11766,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0138,20530554
TGFB1I1,HTM,Up,11767,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TGFB1I1,HTM,Up,11767,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0032,19451087
TGFB1I1,HTM,Up,11767,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
TGFB2,HTM,Up,11768,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,25432175
TGFB2,HTM,Down,11768,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0074,26259570
TGFB2,HTM,Down,11768,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0074,26259570
TGFB2,HTM,Up,11768,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.24,0.0074,31289135
TGFB2,HTM,Down,11768,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.24,0.0074,34680485
TGFB2,HTM,Up,11768,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0074,20530554
TGFB2-OT1,HTM,Up,50629,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29187905
TGFB3,HTM,Up,11769,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25432175
TGFB3,HTM,Up,11769,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TGFBI,HTM,Up,11771,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TGFBI,HTM,Down,11771,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TGFBI,HTM,Down,11771,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TGFBI,HTM,Down,11771,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
TGFBR1,HTM,Down,11772,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TGFBR2,HTM,Down,11773,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TGFBR2,HTM,Up,11773,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0032,31709178
TGFBR2,HTM,Up,11773,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0032,31709178
TGFBR2,HTM,Up,11773,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0032,31709178
TGFBR2,HTM,Up,11773,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.24,0.0032,31709178
TGFBR3,HTM,Up,11774,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TGFBR3,HTM,Up,11774,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TGIF2,HTM,Down,15764,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TGM1,HTM,Down,11777,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TGM2,HTM,Up,11778,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
TGM2,HTM,Up,11778,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
TGM2,HTM,Up,11778,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
THAP5,HTM,Up,23188,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
THAP5P1,HTM,Down,22340,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
THAP6,HTM,Down,23189,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
THAP6,HTM,Down,23189,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
THAP9,HTM,Up,23192,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
THBD,HTM,Up,11784,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
THBD,HTM,Down,11784,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
THBS1,HTM,Down,11785,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
THBS1,HTM,Down,11785,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
THBS1,HTM,Down,11785,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0042,23820871
THBS1,HTM,Down,11785,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
THBS1,HTM,Down,11785,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
THBS1,HTM,Down,11785,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
THBS1,HTM,Down,11785,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
THBS1,HTM,Down,11785,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0042,30696080
THBS2,HTM,Up,11786,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
THBS3,HTM,Down,11787,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
THBS3,HTM,Down,11787,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
THBS3,HTM,Down,11787,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
THBS3,HTM,Down,11787,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0011,24961511
THBS4,HTM,Down,11788,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
THBS4,HTM,Down,11788,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
THEG,HTM,Up,13706,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
THEM5,HTM,Up,26755,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
THEX1,HTM,Up,23994,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
THIC,HTM,Up,NA,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
THNSL2,HTM,Down,25602,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
THOC2,HTM,Up,19073,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
THOC3,HTM,Down,19072,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
THOC3,HTM,Down,19072,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
THOC5,HTM,Down,19074,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
THOP1,HTM,Up,11793,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
THRA,HTM,Up,11796,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
THRA,HTM,Up,11796,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
THRAP3,HTM,Down,22964,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
THRB,HTM,Down,11799,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
THRSP,HTM,Down,11800,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
THSD4,HTM,Up,25835,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
THSD4,HTM,Down,25835,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
THSD4,HTM,Down,25835,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
THSD4,HTM,Up,25835,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
THSD7A,HTM,Up,22207,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
THSD7A,HTM,Up,22207,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
THUMPD3,HTM,Down,24493,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
THY1,HTM,Up,11801,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.12,0.0371,34228218
THY1,HTM,Up,11801,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Doxorubicin,SFA followed by single-cell time-of-flight mass cytometry,0.2,0.0371,34831064
THYN1,HTM,Up,29560,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
TIAM1,HTM,Up,11805,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TIAM2,HTM,Down,11806,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TIAM2,HTM,Down,11806,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TICRR,HTM,Up,28704,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TICRR,HTM,Up,28704,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TICRR,HTM,Up,28704,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TICRR,HTM,Up,28704,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TIGD1,HTM,Up,14523,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TIGD1,HTM,Up,14523,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TIGD1,HTM,Down,14523,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
TIGD2,HTM,Up,18333,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
TIGD2,HTM,Up,18333,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
TIGD5,HTM,Down,18336,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TIGD6,HTM,Down,18332,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TIMELESS,HTM,Up,11813,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TIMM10,HTM,Up,11814,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TIMM22,HTM,Down,17317,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TIMM23,HTM,Down,17312,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TIMM44,HTM,Down,17316,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
TIMM50,HTM,Down,23656,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
TIMM50,HTM,Up,23656,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
TIMM8B,HTM,Down,11818,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,27965308
TIMMDC1,HTM,Up,1321,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
TIMP1,HTM,Down,11820,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TIMP1,HTM,Down,11820,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TIMP1,HTM,Down,11820,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TIMP1,HTM,Up,11820,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0053,34794402
TIMP1,HTM,Up,11820,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
TIMP1,HTM,Up,11820,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
TIMP1,HTM,Up,11820,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
TIMP1,HTM,Up,11821,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0053,34794402
TIMP2,HTM,Up,11821,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TIMP2,HTM,Up,11821,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TIMP2,HTM,Down,11821,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
TIMP2,HTM,Down,11821,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0032,24961511
TIMP3,HTM,Down,11822,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TIMP3,HTM,Down,11822,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TIMP3,HTM,Down,11822,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TIMP3,HTM,Down,11822,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TIMP3,HTM,Down,11822,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TIMP3,HTM,Down,11822,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TIMP3,HTM,Down,11822,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
TIMP3,HTM,Up,11822,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
TIMP3,HTM,Down,11822,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
TIMP3,HTM,Down,11822,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0053,34414448
TIMP4,HTM,Up,11823,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TIMP4,HTM,Up,11823,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TIMP4,HTM,Up,11823,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TIMP4,HTM,Up,11823,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TINAG,HTM,Up,14599,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
TINAG,HTM,Up,14599,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
TINAGL1,HTM,Down,19168,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TINAGL1,HTM,Down,19168,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TINAGL1,HTM,Down,19168,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TINAGL1,HTM,Down,19168,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TINAGL1,HTM,Down,19168,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TINAGL1,HTM,Down,19168,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TINCR,HTM,Down,14607,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TIPARP,HTM,Down,23696,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TIPARP,HTM,Down,23696,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TIPARP,HTM,Down,23696,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TIPARP,HTM,Down,23696,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TIPIN,HTM,Up,30750,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TJP2,HTM,Down,11828,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TJP2,HTM,Up,11828,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
TJP3,HTM,Down,11829,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TK19,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TK19,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TK19,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TKFC,HTM,Up,24552,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
TKFC,HTM,Up,24552,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
TKT,HTM,Down,11834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
TKT,HTM,Up,11834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TKT,HTM,Up,11834,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
TKT,HTM,Up,11834,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0053,26259570
TKT,HTM,Up,11834,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
TKT,HTM,Up,11834,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
TKT,HTM,Up,11834,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
TLCD1,HTM,Up,25177,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TLCD1,HTM,Up,25177,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TLCD2,HTM,Down,33522,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TLCD4,HTM,Up,26477,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TLCD4,HTM,Up,26477,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TLE1,HTM,Up,11837,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TLE1,HTM,Up,11837,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TLE2,HTM,Up,11838,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TLE4,HTM,Down,11840,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TLE4,HTM,Up,11840,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TLE4,HTM,Up,11840,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
TLE6,HTM,Up,30788,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TLE6,HTM,Up,30788,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TLE6,HTM,Up,30788,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TLK1,HTM,Down,11841,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
TLL1,HTM,Up,11843,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TLNRD1,HTM,Down,13519,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TLR3,HTM,Down,11849,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TLR4,HTM,Down,11850,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TLR4,HTM,Down,11850,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TLR4,HTM,Down,11850,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TLR5,HTM,Down,11851,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TLR5,HTM,Down,11851,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TLR6,HTM,Up,16711,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TLR6,HTM,Up,16711,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TM2D2,HTM,Down,24127,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TM2D3,HTM,Down,24128,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TM2D3,HTM,Down,24128,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TM4SF1,HTM,Up,11853,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TM4SF1,HTM,Up,11853,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TM4SF1,HTM,Up,11853,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0053,18034892
TM4SF1,HTM,Up,11853,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0053,18034892
TM4SF1,HTM,Up,11853,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0053,23820871
TM4SF1,HTM,Up,11853,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0053,34680485
TM4SF1,HTM,Down,11853,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
TM4SF1,HTM,Down,11853,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0053,30696080
TM4SF18,HTM,Up,25181,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TM4SF18,HTM,Up,25181,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TM4SF18,HTM,Down,25181,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
TM4SF20,HTM,Up,26230,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TM4SF20,HTM,Up,26230,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TM4SF4,HTM,Up,11856,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0032,25881239
TM4SF4,HTM,Up,11856,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0032,25881239
TM4SF4,HTM,Down,11856,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TM4SF4,HTM,Down,11856,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TM4SF5,HTM,Up,11857,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TM4SF5,HTM,Up,11857,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TM4SF5,HTM,Up,11857,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TM7SF2,HTM,Up,11863,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
TM7SF2,HTM,Up,11863,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
TM7SF2,HTM,Up,11863,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
TM7SF2,HTM,Up,11863,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Transcriptomics,0.04,0.0021,24961511
TM7SF2,HTM,Up,11863,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TM7SF3,HTM,Down,23049,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TMA16,HTM,Down,25638,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TMBIM1,HTM,Down,23410,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TMBIM1,HTM,Up,23410,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TMBIM1,HTM,Up,23410,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TMBIM1,HTM,Up,23410,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TMC2,HTM,Up,16527,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TMC4,HTM,Up,22998,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TMC4,HTM,Down,22998,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TMC5,HTM,Up,22999,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TMC5,HTM,Down,22999,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TMC5,HTM,Up,22999,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
TMC6,HTM,Down,18021,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TMC7,HTM,Down,23000,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMC7,HTM,Down,23000,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMC8,HTM,Down,20474,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TMCC1,HTM,Up,29116,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TMCC1-AS1,HTM,Up,49060,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TMCC2,HTM,Up,24239,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TMCC3,HTM,Down,29199,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TMCC3,HTM,Down,29199,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TMCC3,HTM,Down,29199,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TMCO2,HTM,Up,23312,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TMCO3,HTM,Down,20329,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TMCO4,HTM,Down,27393,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TMED10,HTM,Up,16998,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TMED10,HTM,Up,16998,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TMED10,HTM,Down,16998,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
TMED10,HTM,Up,16998,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TMED10P1,HTM,Down,30754,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TMED10P1,HTM,Down,30754,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TMED3,HTM,Up,28889,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TMED5,HTM,Up,24251,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
TMED7,HTM,Down,24253,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEFF1,HTM,Up,11866,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TMEFF2,HTM,Up,11867,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM101,HTM,Down,28653,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TMEM102,HTM,Down,26722,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TMEM104,HTM,Up,25984,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
TMEM106B,HTM,Up,22407,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM109,HTM,Up,28771,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
TMEM114,HTM,Up,33227,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
TMEM115,HTM,Down,30055,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TMEM120B,HTM,Up,32008,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM123,HTM,Down,30138,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TMEM125,HTM,Down,28275,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TMEM126B,HTM,Up,30883,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TMEM126B,HTM,Up,30883,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TMEM126B,HTM,Down,30883,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
TMEM126B,HTM,Up,30883,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TMEM128,HTM,Up,28201,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TMEM128,HTM,Up,28201,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TMEM128,HTM,Up,28201,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TMEM131L,HTM,Up,29146,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TMEM131L,HTM,Up,29146,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TMEM131L,HTM,Up,29146,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TMEM132D,HTM,Down,29411,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TMEM132D,HTM,Down,29411,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TMEM132D,HTM,Down,29411,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TMEM138,HTM,Down,26944,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
TMEM139,HTM,Down,22058,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
TMEM141,HTM,Down,28211,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
TMEM141,HTM,Up,28211,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
TMEM141,HTM,Down,28211,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
TMEM141,HTM,Down,28211,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
TMEM141,HTM,Down,28211,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
TMEM141,HTM,Down,28211,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
TMEM144,HTM,Down,25633,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TMEM145,HTM,Down,26912,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TMEM145,HTM,UP,26912,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
TMEM145,HTM,UP,26912,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
TMEM145,HTM,UP,26912,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
TMEM145,HTM,UP,26912,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
TMEM145,HTM,UP,26912,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
TMEM147,HTM,Up,30414,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TMEM147,HTM,Down,30414,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
TMEM14B,HTM,Up,21384,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM150C,HTM,Up,37263,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TMEM150C,HTM,Up,37263,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
TMEM154,HTM,Down,26489,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM154,HTM,Down,26489,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM154,HTM,Down,26489,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM155,HTM,Down,55077,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
TMEM156,HTM,Down,26260,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TMEM156,HTM,Up,26260,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TMEM158,HTM,Up,30293,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
TMEM158,HTM,Up,30293,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31729259
TMEM158,HTM,Up,30293,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
TMEM158,HTM,Up,30293,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
TMEM158,HTM,Up,30293,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31729259
TMEM167B,HTM,Down,30187,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM167B,HTM,Down,30187,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM169,HTM,Down,25130,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TMEM170B,HTM,Down,34244,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
TMEM171,HTM,Down,27031,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TMEM171,HTM,Down,27031,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TMEM176B,HTM,Down,29596,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TMEM176B,HTM,Down,29596,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TMEM181,HTM,NA,20958,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
TMEM184A,HTM,Down,28797,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TMEM184B,HTM,Down,1310,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM184B,HTM,Down,1310,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM185B,HTM,Down,18896,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TMEM198,HTM,Up,33704,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TMEM198B,HTM,Down,43629,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TMEM2,HTM,Up,11869,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM200B,HTM,Down,33785,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TMEM201,HTM,Down,33719,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
TMEM205,HTM,Up,29631,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TMEM205,HTM,Up,29631,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
TMEM205,HTM,Up,29631,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
TMEM214,HTM,Up,25983,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
TMEM214,HTM,Up,25983,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
TMEM225B,HTM,Down,53075,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TMEM229B,HTM,Up,20130,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TMEM230,HTM,Up,15876,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM242,HTM,Down,17206,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
TMEM245,HTM,Up,1363,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
TMEM251,HTM,Up,20218,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
TMEM256,HTM,Up,28618,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TMEM256,HTM,Up,28618,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TMEM256,HTM,Up,28618,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TMEM258,HTM,Up,1164,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
TMEM263,HTM,Down,28281,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TMEM263,HTM,Down,28281,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TMEM268,HTM,Up,24513,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TMEM268,HTM,Up,24513,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TMEM268,HTM,Up,24513,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TMEM30B,HTM,Down,27254,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TMEM30B,HTM,Down,27254,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TMEM30B,HTM,Up,27254,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
TMEM33,HTM,Down,25541,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
TMEM38A,HTM,Down,28462,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TMEM40,HTM,Down,25620,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TMEM40,HTM,Down,25620,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TMEM40,HTM,Down,25620,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TMEM40,HTM,Down,25620,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TMEM43,HTM,Down,28472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TMEM43,HTM,Down,28472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TMEM43,HTM,Down,28472,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TMEM44,HTM,Up,25120,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TMEM45A,HTM,Down,25480,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TMEM45A,HTM,Down,25480,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TMEM45A,HTM,Up,25480,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0053,23820871
TMEM45A,HTM,Down,25480,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TMEM45A,HTM,Down,25480,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0053,31709178
TMEM45A,HTM,Up,25480,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
TMEM45B,HTM,Down,25194,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
TMEM45B,HTM,Up,25194,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
TMEM45B,HTM,Down,25194,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
TMEM45B,HTM,Up,25194,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
TMEM489,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TMEM489,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TMEM489,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TMEM50B,HTM,Down,1280,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM51,HTM,Down,25488,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TMEM51,HTM,Down,25488,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TMEM54,HTM,Down,24143,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TMEM54,HTM,Down,24143,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TMEM60,HTM,Up,21754,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM63A,HTM,Up,29118,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM63B,HTM,Down,17735,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM63C,HTM,Down,23787,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TMEM63C,HTM,Up,23787,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
TMEM64,HTM,Down,25441,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TMEM75,HTM,Up,32295,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMEM79,HTM,Up,28196,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TMEM79,HTM,Up,28196,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TMEM79,HTM,Up,28196,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TMEM79,HTM,Up,28196,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TMEM82,HTM,Up,32350,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TMEM82,HTM,Up,32350,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TMEM87A,HTM,Down,24522,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TMEM87A,HTM,Up,24522,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TMEM87A,HTM,Up,24522,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TMEM87A,HTM,Up,24522,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TMEM97,HTM,Down,28106,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
TMEM97,HTM,Up,28106,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TMEM97,HTM,Up,28106,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TMEM97,HTM,Up,28106,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TMEM97,HTM,Up,28106,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TMEM97,HTM,Up,28106,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TMEM98,HTM,Down,24529,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TMEM98,HTM,Down,24529,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TMEM98,HTM,Down,24529,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
TMEM98,HTM,Down,24529,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
TMIE,HTM,Down,30800,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TMPO,HTM,Up,11875,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TMPO,HTM,Down,11875,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
TMPO,HTM,Down,11875,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
TMPO,HTM,Down,11875,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
TMPO,HTM,Down,11875,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
TMPO,HTM,Down,11875,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
TMPO8,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TMPO8,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TMPO8,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TMPRSS11D,HTM,Down,24059,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMPRSS11D,HTM,Down,24059,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMPRSS11D,HTM,Down,24059,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMPRSS11E,HTM,Up,24465,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TMPRSS13,HTM,Down,29808,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TMPRSS3,HTM,Down,11877,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TMPRSS4,HTM,Up,11878,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
TMPRSS4,HTM,Up,11878,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
TMPRSS4,HTM,Down,11878,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
TMPRSS7,HTM,Down,30846,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TMSB10,HTM,Up,11879,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,33670440
TMSB15A,HTM,Down,30744,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
TMSB15B,HTM,Down,28612,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
TMSB4X,HTM,Up,11881,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,33670440
TMSB4X,HTM,Up,11881,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
TMTC2,HTM,Down,25440,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TMTC2,HTM,Up,25440,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TMTC3,HTM,Down,26899,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMTC4,HTM,Up,25904,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TMUB2,HTM,Down,28459,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TNC,HTM,Down,5318,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TNC,HTM,Down,5318,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TNC,HTM,Down,5318,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TNC,HTM,Up,5318,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TNC,HTM,Up,5318,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TNC,HTM,Up,5318,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
TNC,HTM,Up,5318,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TNC,HTM,Up,5318,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TNF,HTM,Down,11892,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TNFAIP1,HTM,Down,11894,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TNFAIP1,HTM,Down,11894,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TNFAIP2,HTM,Down,11895,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
TNFAIP2,HTM,Down,11895,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
TNFAIP2,HTM,Down,11895,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TNFAIP3,HTM,Down,11896,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
TNFAIP3,HTM,Down,11896,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
TNFAIP3,HTM,Up,11896,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0064,27965308
TNFAIP3,HTM,Down,11896,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0064,25881239
TNFAIP3,HTM,Up,11896,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0064,19451087
TNFAIP3,HTM,Down,11896,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
TNFAIP3,HTM,Up,11896,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
TNFAIP3,HTM,Down,11896,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0064,26259570
TNFAIP3,HTM,Up,11896,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
TNFAIP3,HTM,Up,11896,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0064,34680485
TNFAIP3,HTM,Up,11896,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0064,21618577
TNFAIP6,HTM,Up,11898,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TNFAIP6,HTM,Up,11898,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
TNFAIP8,HTM,Down,17260,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TNFRSF10A,HTM,Down,11904,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TNFRSF10B,HTM,Up,11905,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
TNFRSF10C,HTM,Up,11906,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TNFRSF11B,HTM,Down,11909,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TNFRSF11B,HTM,Up,11909,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
TNFRSF11B,HTM,Up,11909,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
TNFRSF11B,HTM,Up,11909,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,34680485
TNFRSF11B,HTM,Down,11909,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TNFRSF11B,HTM,Up,11909,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
TNFRSF12A,HTM,Up,18152,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TNFRSF12A,HTM,Up,18152,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TNFRSF12A,HTM,Up,18152,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TNFRSF13C,HTM,Up,17755,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TNFRSF13C,HTM,Up,17755,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TNFRSF13C,HTM,Up,17755,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TNFRSF19,HTM,Up,11915,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
TNFRSF1A,HTM,Up,11916,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TNFRSF21,HTM,Down,13469,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TNFRSF25,HTM,Up,11910,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
TNFRSF4,HTM,Down,11918,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TNFRSF8,HTM,Down,11923,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TNFRSF9,HTM,Up,11924,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
TNFSF10,HTM,Down,11925,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22740085
TNFSF10,HTM,Down,11925,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TNFSF10,HTM,Down,11925,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TNFSF10,HTM,Down,11925,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TNFSF10,HTM,Down,11925,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TNFSF13,HTM,Down,11928,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TNFSF14,HTM,Down,11930,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TNFSF15,HTM,Up,11931,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TNFSF15,HTM,Up,11931,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TNFSF15,HTM,Up,11931,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
TNFSF4,HTM,Down,11934,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TNFSF4,HTM,Down,11934,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TNFSF9,HTM,Down,11939,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TNFSF9,HTM,Up,11939,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
TNIK,HTM,Up,30765,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TNIK,HTM,Up,30765,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
TNIK,HTM,Up,30765,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
TNIK,HTM,Up,30765,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
TNIK,HTM,Down,30765,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
TNIK,HTM,Down,30765,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0053,22954703
TNIK,HTM,Up,30765,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0053,21618577
TNIP1,HTM,Down,16903,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TNIP1,HTM,Down,16903,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TNIP1,HTM,Down,16903,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TNIP3,HTM,Down,19315,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
TNK1,HTM,Down,11940,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TNKS1BP1,HTM,Up,19081,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TNKS1BP1,HTM,Up,19081,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TNKS1BP1,HTM,Up,19081,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TNKS2,HTM,Up,15677,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
TNNC1,HTM,Down,11943,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TNNC1,HTM,Down,11943,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TNNC1,HTM,Down,11943,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TNNC1,HTM,Down,11943,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TNNT1,HTM,Up,11948,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TNNT1,HTM,Up,11948,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TNNT1,HTM,Down,11948,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TNNT1,HTM,Down,11948,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TNP1,HTM,Up,11951,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0011,33670440
TNPO1,HTM,Down,6401,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
TNPO2,HTM,Up,19998,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
TNRC6A,HTM,Up,11969,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TNRC6C-AS1,HTM,Down,NA,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TNRC6C-AS1,HTM,Up,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TNS1,HTM,Down,11973,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
TNS1,HTM,Down,11973,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
TNS1,HTM,Down,11973,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TNS1,HTM,Down,11973,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,25676692
TNS1,HTM,Down,11973,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TNS1,HTM,Up,11973,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
TNS2,HTM,Up,19737,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TNS2,HTM,Down,19737,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
TNS3,HTM,Up,21616,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TNS3,HTM,Up,21616,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TNS3,HTM,Down,21616,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
TNS3,HTM,Down,21616,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
TNS3,HTM,Down,21616,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0032,30696080
TNS4,HTM,Down,24352,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
TNS4,HTM,Down,24352,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
TNS4,HTM,Down,24352,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
TNS4,HTM,Down,24352,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
TNS4,HTM,Up,24352,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
TNS4,HTM,Down,24352,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
TNXB,HTM,Down,11976,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TOM1L1,HTM,Up,11983,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TOMM20,HTM,Down,20947,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
TOMM20,HTM,Down,20947,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
TOMM22,HTM,Down,18002,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TOMM34,HTM,Down,15746,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TOMM40,HTM,Down,18001,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
TOMM40,HTM,Up,18001,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
TOMM40,HTM,Down,18001,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
TONSL,HTM,Up,7801,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TONSL,HTM,Up,7801,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TONSL,HTM,Down,7801,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
TOP1,HTM,Down,11986,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TOP1,HTM,Down,11986,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TOP1,HTM,Up,11986,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
TOP1MT,HTM,Down,29787,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TOP2B,HTM,Down,11990,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TOR4A,HTM,Up,25981,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TOR4A,HTM,Up,25981,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TOX2,HTM,Up,16095,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TOX2,HTM,Up,16095,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TOX2,HTM,Down,16095,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
TOX2,HTM,Down,16095,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
TOX2,HTM,Up,16095,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TOX3,HTM,Down,11972,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
TOX3,HTM,Up,11972,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TOX3,HTM,Up,11972,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TOX3,HTM,Up,11972,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
TP11,HTM,Up,NA,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0011,34794402
TP11,HTM,Up,NA,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0011,34794402
TP53,HTM,Up,11998,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TP53,HTM,Down,11998,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TP53BP2,HTM,Down,12000,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,27965308
TP53I11,HTM,Down,16842,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
TP53I3,HTM,Down,19373,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,29316740
TP53I3,HTM,Down,19373,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
TP53I3,HTM,Down,19373,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TP53INP1,HTM,Up,18022,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,29316740
TP53INP1,HTM,Down,18022,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TP53INP1,HTM,Down,18022,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TP53INP1,HTM,Down,18022,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TP53RK,HTM,Up,16197,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TP63,HTM,Down,15979,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TP63,HTM,Down,15979,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TP63,HTM,Down,15979,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TP63,HTM,Down,15979,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
TP73-AS1,HTM,Down,29052,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TPBG,HTM,Up,12004,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
TPBG,HTM,Up,12004,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29416721
TPBG,HTM,Up,12004,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
TPD52,HTM,Down,12005,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TPD52,HTM,Up,12005,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
TPD52L1,HTM,Down,12006,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
TPD52L1,HTM,Up,12006,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
TPD52L1,HTM,Down,12006,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
TPD52L1,HTM,Down,12006,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
TPD52L110,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TPD52L110,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TPD52L110,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TPD52L2,HTM,Down,12007,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TPD52L2,HTM,Up,12007,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TPD52L2,HTM,Up,12007,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TPD52L3,HTM,Up,23382,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
TPI1,HTM,Up,12009,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
TPI1,HTM,Up,12009,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
TPI1,HTM,Up,12009,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,25081334
TPI1,HTM,Up,12009,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
TPI1,HTM,Up,12009,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
TPI1,HTM,Down,12009,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
TPM1,HTM,Down,12010,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0042,23820871
TPM1,HTM,Down,12010,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0042,19451087
TPM1,HTM,Down,12010,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
TPM1,HTM,Down,12010,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0042,26259570
TPM1,HTM,Down,12010,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
TPM2,HTM,Up,12011,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TPM3,HTM,Down,12012,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
TPM3,HTM,Up,12012,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,25081334
TPM4,HTM,Down,12013,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,34059086
TPM4,HTM,Down,12013,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
TPM4,HTM,Down,12013,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
TPM4,HTM,Up,12013,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0053,31501409
TPM4,HTM,Up,12013,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
TPMT,HTM,UP,12014,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
TPMT,HTM,UP,12014,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
TPMT,HTM,UP,12014,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
TPMT,HTM,UP,12014,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
TPMT,HTM,UP,12014,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
TPP1,HTM,Up,2073,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TPP1,HTM,Up,2073,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TPP1,HTM,Up,2073,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TPP1,HTM,Down,2073,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
TPR,HTM,Down,12017,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0032,23903875
TPR,HTM,Up,12017,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
TPR,HTM,Up,12017,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
TPR,HTM,Down,12017,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
TPR,HTM,Up,12017,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
TPRG1,HTM,Down,24759,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TPRG1L,HTM,Down,27007,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TPRG1L,HTM,Up,27007,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
TPRKB,HTM,Down,24259,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TPRKB,HTM,Up,24259,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TPRKB,HTM,Down,24259,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TPRKB,HTM,Up,24259,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TPRKB,HTM,Up,24259,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TPRXL,HTM,Up,32178,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
TPRXL,HTM,Up,32178,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
TPRXL,HTM,Up,32178,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
TPRXL,HTM,Up,32178,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
TPRXL,HTM,Up,32178,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
TPST1,HTM,Down,12020,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TPST1,HTM,Down,12020,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TPST1,HTM,Down,12020,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TPST1,HTM,Up,12020,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TPST1,HTM,Up,12020,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TPST1,HTM,Up,12020,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TPT1,HTM,Up,12022,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,22623141
TPT1,HTM,Down,12022,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TPT1,HTM,Down,12022,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TPX2,HTM,Down,1249,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TRA2B,HTM,Up,10781,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
TRABD,HTM,Up,28805,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
TRABD2A,HTM,Up,27013,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TRAF3IP2,HTM,Down,1343,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TRAF3IP2,HTM,Down,1343,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TRAF3IP2,HTM,Down,1343,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TRAF3IP2,HTM,Down,1343,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TRAF3IP3,HTM,Down,30766,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TRAF4,HTM,Down,12034,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TRAF4,HTM,Down,12034,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TRAF5,HTM,Up,12035,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TRAF7,HTM,Up,20456,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRAF7,HTM,Up,20456,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRAF7,HTM,Up,20456,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRAK1,HTM,Down,29947,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TRAK2,HTM,Down,13206,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
TRAM2,HTM,Down,16855,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TRAM2,HTM,Down,16855,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TRAM2,HTM,Up,16855,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TRAM2,HTM,Down,16855,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
TRAP1,HTM,Up,16264,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
TRAP1,HTM,Up,16264,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
TRAP1,HTM,Down,16264,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0053,34680485
TRAP1,HTM,Down,16264,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0053,34168259
TRAP1,HTM,Down,16264,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,25081334
TRAP1,HTM,Up,16264,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0053,21788403
TRAPPC1,HTM,Down,19894,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TRAPPC11,HTM,Up,25751,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
TRAPPC2,HTM,Up,23068,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRAPPC2,HTM,Up,23068,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRAPPC2,HTM,Up,23068,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRAPPC9,HTM,Up,30832,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TRAPPC9,HTM,Up,30832,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TRDMT1,HTM,Up,2977,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TREM1,HTM,Up,17760,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
TREM1,HTM,Down,17760,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
TRERF1,HTM,Down,18273,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TRERF1,HTM,Up,18273,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
TRERF1,HTM,Up,18273,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
TRIB1,HTM,Up,16891,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TRIB2,HTM,Up,30809,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TRIB3,HTM,Up,16228,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0011,19451087
TRIM13,HTM,Up,9976,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TRIM14,HTM,Down,16283,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TRIM15,HTM,Up,16284,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
TRIM15,HTM,Up,16284,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
TRIM15,HTM,Up,16284,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TRIM15,HTM,Up,16284,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,25676692
TRIM15,HTM,Up,16284,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TRIM16,HTM,Up,17241,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TRIM16,HTM,Up,17241,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TRIM16,HTM,Down,17241,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TRIM16,HTM,Down,17241,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
TRIM16L,HTM,Up,32670,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TRIM16L,HTM,Up,32670,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TRIM16L,HTM,Down,32670,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TRIM2,HTM,Up,15974,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TRIM2,HTM,Up,15974,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
TRIM2,HTM,Down,15974,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
TRIM22,HTM,Down,16379,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TRIM23,HTM,Up,660,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TRIM24,HTM,Up,11812,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TRIM25,HTM,Down,12932,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TRIM26,HTM,Up,12962,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TRIM28,HTM,Down,16384,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TRIM28,HTM,Down,16384,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TRIM28,HTM,Down,16384,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
TRIM29,HTM,Down,17274,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
TRIM29,HTM,Down,17274,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
TRIM29,HTM,Down,17274,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0074,25881239
TRIM29,HTM,Down,17274,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,31709178
TRIM29,HTM,Up,17274,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
TRIM29,HTM,Up,17274,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
TRIM29,HTM,Up,17274,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0074,32503348
TRIM29,HTM,Up,17274,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0074,32503348
TRIM29,HTM,Up,17274,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0074,34680485
TRIM29,HTM,Down,17274,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0074,31501409
TRIM29,HTM,Down,17274,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0074,31501409
TRIM29,HTM,Down,17274,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0074,34414448
TRIM29,HTM,Up,17274,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0074,21618577
TRIM31,HTM,Down,16289,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TRIM31,HTM,Down,16289,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TRIM31,HTM,Down,16289,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TRIM33,HTM,Up,16290,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TRIM33,HTM,Up,16290,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
TRIM37,HTM,Up,7523,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRIM37,HTM,Up,7523,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRIM37,HTM,Up,7523,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRIM4,HTM,Up,16275,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRIM4,HTM,Up,16275,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRIM4,HTM,Up,16275,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRIM5,HTM,Up,16276,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
TRIM5,HTM,Up,16276,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
TRIM5,HTM,Down,16276,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
TRIM58,HTM,Down,24150,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TRIM58,HTM,Down,24150,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
TRIM66,HTM,Down,29005,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TRIM7,HTM,Up,16278,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TRIM7,HTM,Up,16278,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TRIM7,HTM,Up,16278,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TRIM7,HTM,Up,16278,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
TRIM73,HTM,Up,18162,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
TRIM73,HTM,Up,18162,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
TRIM9,HTM,Down,16288,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TRIM9,HTM,Down,16288,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
TRIML2,HTM,Up,26378,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TRIML2,HTM,Up,26378,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TRIML2,HTM,Down,26378,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
TRIML2,HTM,Down,26378,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TRIOBP,HTM,Down,17009,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TRIP10,HTM,Down,12304,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
TRIP10,HTM,Down,12304,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
TRIP13,HTM,Down,12307,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
TRIP13,HTM,Down,12307,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
TRIP13,HTM,Down,12307,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
TRIP138,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TRIP138,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TRIP138,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TRIP6,HTM,Down,12311,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TRIQK,HTM,Down,27828,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
TRMT10A,HTM,Down,28403,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TRMT10A,HTM,Down,28403,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TRMT10A,HTM,Down,28403,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
TRMT10C,HTM,Down,26022,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TRMT10C,HTM,Down,26022,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TRMT13,HTM,Up,25502,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
TRMT61B,HTM,Up,26070,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRMT61B,HTM,Up,26070,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRMT61B,HTM,Up,26070,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TRNT1,HTM,NA,17341,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29221160
TRNT1,HTM,Up,17341,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
TRO,HTM,Up,12326,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29416721
TROAP8,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TROAP8,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TROAP8,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TROVE2,HTM,Up,11313,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
TRPA1,HTM,Up,497,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TRPA1,HTM,Up,497,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TRPC1,HTM,Up,12333,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
TRPC4,HTM,Up,12336,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
TRPM2,HTM,Down,12339,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TRPM2-AS,HTM,Down,50758,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TRPM4,HTM,Up,17993,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR and Western Blotting and IF staining,0.76,0.0011,34680485
TRPM6,HTM,Down,17995,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
TRPM7,HTM,Up,17994,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
TRPM8,HTM,Up,17961,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
TRPS1,HTM,Down,12340,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TRPS1,HTM,Down,12340,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TRPV2,HTM,Up,18082,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TRPV2,HTM,Up,18082,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TRPV2,HTM,Up,18082,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
TRPV2,HTM,Up,18082,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TRPV3,HTM,Up,18084,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TRPV4,HTM,Down,18083,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TRPV4,HTM,Down,18083,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TRPV6,HTM,Up,14006,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
TRRAP,HTM,Up,12347,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
TSC2,HTM,Down,12363,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TSC22D1,HTM,Up,16826,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,28588211
TSC22D3,HTM,Down,3051,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TSC22D4,HTM,Down,21696,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TSGA10IP,HTM,Up,26555,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TSHR,HTM,Down,12373,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TSHZ2,HTM,Up,13010,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TSHZ2,HTM,Down,13010,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
TSKU,HTM,Up,28850,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TSKU,HTM,Down,28850,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TSLP,HTM,Up,30743,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
TSPAN1,HTM,Down,20657,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TSPAN1,HTM,Down,20657,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TSPAN1,HTM,Down,20657,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TSPAN1,HTM,Up,20657,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
TSPAN10,HTM,Up,29942,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TSPAN10,HTM,Up,29942,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TSPAN10,HTM,Up,29942,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TSPAN12,HTM,Up,21641,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
TSPAN14,HTM,Down,23303,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TSPAN15,HTM,Up,23298,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TSPAN15,HTM,Down,23298,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TSPAN2,HTM,Up,20659,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TSPAN3,HTM,Up,17752,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TSPAN3,HTM,Down,17752,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
TSPAN33,HTM,Down,28743,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TSPAN5,HTM,Down,17753,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TSPAN5,HTM,Down,17753,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TSPAN5,HTM,Down,17753,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TSPAN5,HTM,Down,17753,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TSPAN6,HTM,Down,11858,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
TSPAN6,HTM,Up,11858,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TSPAN7,HTM,Up,11854,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TSPAN8,HTM,Up,11855,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TSPAN8,HTM,Down,11855,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
TSPEAR,HTM,Up,1268,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TSPEAR-AS1,HTM,Up,1271,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TSPEAR-AS2,HTM,Up,16428,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TSPO,HTM,Up,1158,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
TSPOAP1,HTM,Down,16831,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TSPYL1,HTM,Down,12382,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TSPYL2,HTM,Up,24358,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TSPYL2,HTM,Up,24358,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
TSPYL5,HTM,Up,29367,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0032,25881239
TSPYL5,HTM,Up,29367,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TSPYL5,HTM,Down,29367,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TST,HTM,Up,12388,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
TST,HTM,Up,12388,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
TST,HTM,Up,12388,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
TST,HTM,Down,12388,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
TST,HTM,Up,12388,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
TSTD1,HTM,Down,35410,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TSTD1,HTM,Down,35410,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TSTD1,HTM,Down,35410,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TTBK2,HTM,Down,19141,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TTBK2,HTM,Down,19141,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TTC12,HTM,Up,23700,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TTC12,HTM,Up,23700,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TTC12,HTM,Up,23700,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TTC17,HTM,Up,25596,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
TTC22,HTM,Down,26067,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TTC27,HTM,Up,25986,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TTC27,HTM,Up,25986,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TTC27,HTM,Up,25986,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TTC28,HTM,Up,29179,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TTC3,HTM,Up,12393,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TTC3,HTM,Up,12393,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TTC3,HTM,Up,12393,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TTC30A,HTM,Down,25853,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TTC39A,HTM,Down,18657,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TTC39B,HTM,Down,23704,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TTC39B,HTM,Down,23704,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TTC39C,HTM,Down,26595,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TTC39C,HTM,Down,26595,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
TTC39C,HTM,Up,26595,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
TTC39C,HTM,Down,26595,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
TTC9,HTM,Down,20267,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TTC9B,HTM,Down,26395,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TTLL1,HTM,Up,1312,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
TTLL12,HTM,Up,28974,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TTLL12,HTM,Up,28974,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TTLL12,HTM,Up,28974,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
TTLL3,HTM,Up,24483,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TTLL3,HTM,Up,24483,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TTLL3,HTM,Up,24483,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TTLL7,HTM,Down,26242,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TTN,HTM,Up,12403,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
TTN,HTM,Up,12403,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0021,21788403
TTR,HTM,Up,12405,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics,0.04,0.0011,17932721
TTYH2,HTM,Up,13877,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
TUB,HTM,Up,12406,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
TUBA1A,HTM,Up,20766,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,22623141
TUBA1A,HTM,Up,20766,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
TUBA1A,HTM,Down,20766,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
TUBA1A,HTM,Down,20766,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
TUBA1B,HTM,Down,18809,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
TUBA1B,HTM,Down,18809,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
TUBA1B,HTM,Down,18809,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
TUBA1B,HTM,Down,18809,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
TUBA1B,HTM,Up,18809,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
TUBA1B,HTM,Up,18809,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
TUBA1B,HTM,Down,18809,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0042,19353633
TUBA1C,HTM,Down,20768,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TUBA1C,HTM,Down,20768,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TUBA1C,HTM,Up,20768,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
TUBA4A,HTM,Down,12407,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TUBA4A,HTM,Down,12407,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TUBA4A,HTM,Up,12407,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
TUBB,HTM,Down,20778,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
TUBB,HTM,Down,20778,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
TUBB,HTM,Up,20778,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
TUBB2A,HTM,Down,12412,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TUBB2B,HTM,Down,30829,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TUBB2B,HTM,Up,30829,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
TUBB3,HTM,Up,20772,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0011,34794402
TUBB3,HTM,Up,20772,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0011,34794402
TUBB4A,HTM,Up,20774,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TUBB4A,HTM,Up,20774,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TUBB4B,HTM,Up,20771,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0021,22623141
TUBB4B,HTM,Down,20771,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TUBB4B,HTM,Down,20771,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TUBB6,HTM,Down,20776,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TUBB6,HTM,Down,20776,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
TUBB6,HTM,Down,20776,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TUBB8,HTM,Down,20773,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
TUBB8,HTM,Down,20773,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
TUBD1,HTM,Up,16811,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TUBD1,HTM,Up,16811,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TUBG2,HTM,Up,12419,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TUBGCP4,HTM,Down,16691,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TUBGCP6,HTM,Down,18127,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TUBGCP6,HTM,Down,18127,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
TUFM,HTM,Up,12420,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,22623141
TUFM,HTM,Down,12420,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
TUFM,HTM,Down,12420,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
TUFM,HTM,Up,12420,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0042,34168259
TUFM,HTM,Up,12420,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
TUFM,HTM,Down,12420,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
TUNAR,HTM,Up,44088,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TUSC3,HTM,Up,30242,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TUT4,HTM,Up,28981,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
TUT7,HTM,Up,25817,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TUT7,HTM,Up,25817,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TUT7,HTM,Up,25817,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
TVP23B,HTM,Up,20399,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
TWIST1,HTM,Up,12428,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0191,34228218
TWIST1,HTM,Up,12428,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0191,31709178
TWIST1,HTM,Up,12428,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.28,0.0191,28588211
TWIST1,HTM,Up,12428,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0191,24098529
TXK,HTM,Up,12434,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
TXLNB,HTM,Up,21617,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
TXN,HTM,Down,12435,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TXN,HTM,Down,12435,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
TXN,HTM,Up,12435,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
TXNDC16,HTM,Up,19965,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
TXNDC16,HTM,Up,19965,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
TXNDC16,HTM,Up,19965,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
TXNDC16,HTM,Up,19965,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
TXNDC16,HTM,Up,19965,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
TXNDC16,HTM,Up,19965,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
TXNDC16,HTM,Up,19965,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
TXNDC17,HTM,Down,28218,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
TXNDC9,HTM,Down,24110,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TXNDC9,HTM,Up,24110,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TXNDC9,HTM,Down,24110,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
TXNDC9,HTM,Up,24110,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TXNDC9,HTM,Up,24110,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
TXNIP,HTM,Up,16952,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,35229723
TXNRD1,HTM,Up,12437,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TXNRD1,HTM,Up,12437,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TXNRD1,HTM,Up,12437,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
TYSND1,HTM,Up,28531,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TYSND1,HTM,Up,28531,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TYSND1,HTM,Up,28531,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
TYW5,HTM,Down,26754,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
TYW5,HTM,Down,26754,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
TYW5,HTM,Down,26754,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
TYW5,HTM,Down,26754,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
TYW5,HTM,Down,26754,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
U2AF1L4,HTM,Up,23020,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
U2AF2,HTM,Down,23156,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
U2AF2,HTM,Up,23156,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
UAP1,HTM,Down,12457,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UAP1,HTM,Down,12457,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UBA1,HTM,Down,12469,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0042,34059086
UBA1,HTM,Up,12469,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
UBA1,HTM,Up,12469,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
UBA1,HTM,Down,12469,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0042,34168259
UBA1,HTM,Up,12469,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0042,27746256
UBA2,HTM,Up,30661,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
UBA2,HTM,Up,30661,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
UBA2,HTM,Down,30661,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0032,23820871
UBA2,HTM,Up,30661,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
UBA2,HTM,Up,30661,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
UBA2,HTM,Up,30661,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
UBA52,HTM,Up,12458,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
UBA52,HTM,Up,12458,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
UBA6,HTM,Down,25581,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UBA6,HTM,Down,25581,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UBALD2,HTM,Down,28438,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
UBALD2,HTM,Up,28438,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
UBAP2L,HTM,Up,29877,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UBAP2L,HTM,Up,29877,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UBAP2L,HTM,Up,29877,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UBASH3A,HTM,Down,12462,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
UBASH3B,HTM,Down,29884,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
UBASH3B,HTM,Up,29884,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
UBASH3B,HTM,Down,29884,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
UBB,HTM,Up,12463,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UBC,HTM,Up,12468,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
UBD,HTM,Down,18795,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
UBD,HTM,Down,18795,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
UBE2C,HTM,Down,15937,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
UBE2C7,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
UBE2C7,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
UBE2C7,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
UBE2D1,HTM,Down,12474,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
UBE2D3,HTM,Down,12476,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29511337
UBE2D3,HTM,Up,12476,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
UBE2D3,HTM,Down,12476,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0021,29511337
UBE2E1,HTM,Down,12477,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
UBE2E3,HTM,Down,12479,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
UBE2E3,HTM,Up,12479,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
UBE2H,HTM,Up,12484,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
UBE2H,HTM,Up,12484,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
UBE2K,HTM,Up,4914,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
UBE2L3,HTM,Down,12488,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
UBE2L3,HTM,Down,12488,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
UBE2Q2,HTM,Up,19248,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UBE2Q2,HTM,Up,19248,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UBE2Q2,HTM,Up,19248,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UBE2QL1,HTM,Down,37269,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
UBE2S8,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
UBE2S8,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
UBE2S8,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
UBE2T7,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
UBE2T7,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
UBE2T7,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
UBE3A,HTM,Down,12496,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
UBE3A,HTM,Up,12496,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
UBE3B,HTM,Down,13478,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UBE3C,HTM,Up,16803,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
UBE3D,HTM,Up,21381,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UBE3D,HTM,Up,21381,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UBE3D,HTM,Up,21381,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UBL3,HTM,Up,12504,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UBL5,HTM,Up,13736,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
UBL5,HTM,Up,13736,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
UBL5,HTM,Up,13736,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
UBL5,HTM,Up,13736,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
UBL5,HTM,Up,13736,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
UBN2,HTM,Up,21931,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UBQLN1,HTM,Up,12508,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
UBQLN4,HTM,UP,1237,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
UBQLN4,HTM,UP,1237,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
UBQLN4,HTM,UP,1237,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
UBQLN4,HTM,UP,1237,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
UBQLN4,HTM,UP,1237,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
UBR1,HTM,Down,16808,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UBR4,HTM,Up,30313,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
UBTF,HTM,Down,12511,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
UBTF,HTM,Up,12511,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
UBXN11,HTM,Down,30600,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UBXN2A,HTM,Up,27265,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UBXN2A,HTM,Up,27265,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UBXN2A,HTM,Up,27265,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UCA1,HTM,Down,37126,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
UCA1,HTM,Down,37126,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
UCA1,HTM,Down,37126,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
UCA1,HTM,Down,37126,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0032,34414448
UCHL1,HTM,Up,12513,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
UCHL1,HTM,Down,12513,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
UCHL3,HTM,Down,12515,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UCK2,HTM,Down,12562,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
UCN,HTM,Up,12516,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UCN,HTM,Up,12516,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UCN,HTM,Up,12516,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UCN2,HTM,Down,18414,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
UCP2,HTM,Up,12518,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UCP2,HTM,Up,12518,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UCP2,HTM,Up,12518,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UEVLD,HTM,Up,30866,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
UFSP1,HTM,Down,33821,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
UGCG,HTM,Down,12524,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
UGCG,HTM,Down,12524,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
UGCG,HTM,Down,12524,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
UGCG,HTM,Down,12524,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
UGDH,HTM,Up,12525,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0053,25881239
UGDH,HTM,Up,12525,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,22623141
UGDH,HTM,Down,12525,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by Proteomics,0.08,0.0053,22623141
UGDH,HTM,Up,12525,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0053,34168259
UGDH,HTM,Up,12525,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0053,21788403
UGG2,HTM,Up,15664,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
UGGT1,HTM,Up,15663,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
UGGT1,HTM,Down,15663,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0021,23903875
UGGT1,HTM,Up,15663,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
UGGT1,HTM,Up,15663,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
UGGT1,HTM,Up,15663,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
UGGT1,HTM,Up,15663,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
UGP2,HTM,Up,12527,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
UGP2,HTM,Up,12527,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
UGT1A1,HTM,Up,12530,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
UGT1A1,HTM,Up,12530,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
UGT1A1,HTM,Up,12530,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
UGT1A1,HTM,Up,12530,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
UGT1A1,HTM,Up,12530,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
UGT1A10,HTM,Up,12531,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
UGT1A10,HTM,Up,12531,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
UGT1A10,HTM,Down,12531,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
UGT1A10,HTM,Up,12531,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
UGT1A6,HTM,Up,12538,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
UGT1A6,HTM,Up,12538,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
UGT1A6,HTM,Up,12538,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
UGT1A6,HTM,Up,12538,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
UGT1A7,HTM,Up,12539,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
UGT2B10,HTM,Up,12544,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
UGT2B10,HTM,Up,12544,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
UGT2B7,HTM,Up,12554,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UGT2B7,HTM,Up,12554,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UGT8,HTM,Down,12555,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UGT8,HTM,Down,12555,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UHRF1,HTM,Up,12556,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
UHRF1BP1,HTM,Up,21216,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UHRF2,HTM,NA,12557,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
ULBP2,HTM,Down,14894,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ULBP2,HTM,Down,14894,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ULK1,HTM,Down,12558,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
UMPK9,HTM,Down,NA,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
UMPK9,HTM,Down,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
UMPK9,HTM,Down,NA,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
UMPS,HTM,Up,12563,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UMPS,HTM,Up,12563,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UMPS,HTM,Up,12563,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UNC13A,HTM,Up,23150,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
UNC13A,HTM,Up,23150,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
UNC13A,HTM,Up,23150,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
UNC13C,HTM,Down,23149,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
UNC13D,HTM,Down,23147,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
UNC13D,HTM,Down,23147,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
UNC5A,HTM,Down,12567,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
UNC5B,HTM,Down,12568,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
UNC80,HTM,Down,26582,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
UNC80,HTM,Down,26582,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
UNC93B1,HTM,Down,13481,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
UNG,HTM,Up,12572,Bladder Cancer,Carcinoma,5637,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
UNG,HTM,Up,12572,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
UPF3B,HTM,Up,20439,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UPK1A,HTM,Up,12577,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
UPK1B,HTM,Up,12578,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UPK1B,HTM,Up,12578,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UPK2,HTM,Up,12579,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
UpK3B,HTM,Down,21444,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
UPK3B,HTM,Up,21444,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
UPP1,HTM,Down,12576,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
UPP1,HTM,Down,12576,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
UPP1,HTM,Down,12576,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
UpP1,HTM,Down,12576,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
UQCC1,HTM,Down,15891,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
UQCR10,HTM,Down,30863,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
UQCR11,HTM,Up,30862,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UQCR11,HTM,Up,30862,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UQCR11,HTM,Up,30862,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
UQCRB,HTM,Up,12582,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
UQCRC1,HTM,Up,12585,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0011,34168259
UQCRC1,HTM,Up,12585,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0011,34168259
UQCRFS1,HTM,Up,12587,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UQCRFS1,HTM,Up,12587,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
URB1,HTM,Up,17344,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
URG4,HTM,Up,30890,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
URI1,HTM,Down,13236,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
URI1,HTM,Up,13236,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
USF3,HTM,Up,30494,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
USP11,HTM,Down,12609,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
USP11,HTM,Up,12609,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
USP11,HTM,Up,12609,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
USP11,HTM,Down,12609,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
USP12-AS1,HTM,Down,39961,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
USP15,HTM,Up,12613,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
USP15,HTM,Up,12613,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
USP15,HTM,Up,12613,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
USP15,HTM,Up,12613,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
USP15,HTM,Up,12613,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
USP2,HTM,Up,12618,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
USP22,HTM,Up,12621,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
USP25,HTM,Up,12624,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
USP3,HTM,Up,12626,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
USP3,HTM,Up,12626,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
USP34,HTM,Up,20066,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
USP34,HTM,Up,20066,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
USP34,HTM,Up,20066,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
USP35,HTM,Down,20061,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
USP4,HTM,Down,12627,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0021,25881239
USP4,HTM,Down,12627,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.28,0.0021,25881239
USP43,HTM,Down,20072,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
USP45,HTM,Up,20080,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
USP49,HTM,Down,20078,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
USP49,HTM,Down,20078,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
USP5,HTM,Down,12628,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
USP5,HTM,Down,12628,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
USP5,HTM,Up,12628,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
USP5,HTM,Down,12628,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0032,21788403
USP53,HTM,Up,29255,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
USP6,HTM,UP,12629,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
USP6,HTM,UP,12629,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
USP6,HTM,UP,12629,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
USP6,HTM,UP,12629,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
USP6,HTM,UP,12629,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
USP6NL,HTM,Up,16858,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
USP7,HTM,Down,12630,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
USP9Y,HTM,Down,12633,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
UTP15,HTM,Down,25758,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
UTP15,HTM,Up,25758,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,20530554
UTP25,HTM,Up,28440,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
UTS2,HTM,Up,12636,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
UTS2,HTM,Up,12636,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
UVRAG,HTM,Up,12640,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
UXS1,HTM,Up,17729,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
VAC14-AS1,HTM,Down,48605,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
VAMP1,HTM,Up,12642,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
VAMP1,HTM,Up,12642,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
VAMP1,HTM,Up,12642,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
VAMP1,HTM,Up,12642,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
VAMP3,HTM,Down,12644,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
VAMP4,HTM,Down,12645,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
VAMP5,HTM,Down,12646,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
VAMP8,HTM,Down,12647,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
VAMP8,HTM,Down,12647,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
VAMP8,HTM,Up,12647,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0032,20530554
VANGL2,HTM,Down,15511,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
VAPA,HTM,Down,12648,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
VAPA,HTM,Up,12648,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
VAPA,HTM,Up,12648,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
VARS,HTM,Up,12651,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
VARS1,HTM,Down,12651,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
VARS1,HTM,Down,12651,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0011,32503348
VARS2,HTM,Down,21642,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
VASP,HTM,Down,12652,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
VASP,HTM,Down,12652,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
VAT1,HTM,Down,16919,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
VAT1,HTM,Up,16919,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
VAT1,HTM,Up,16919,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
VAT1,HTM,Up,16919,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
VAT1L,HTM,Down,29315,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
VAV1,HTM,NA,12657,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.04,0.0011,29352988
VAV2,HTM,Down,12658,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VAV2,HTM,Down,12658,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
VAV2,HTM,Down,12658,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
VAV2,HTM,Down,12658,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VAV3,HTM,Down,12659,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29352988
VAV3,HTM,Down,12659,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay,0.24,0.0021,29352988
VAV3,HTM,Down,12659,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
VAV3,HTM,Down,12659,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
VCAM1,HTM,Up,12663,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0011,34228218
VCAN,HTM,Up,2464,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29416721
VCAN,HTM,Up,2464,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VCAN,HTM,Up,2464,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VCL,HTM,Down,12665,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
VCL,HTM,Up,12665,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0032,34168259
VCL,HTM,Up,12665,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.36,0.0032,27746256
VCL,HTM,Up,12665,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
VCP,HTM,Down,12666,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
VCP,HTM,Up,12666,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
VCP,HTM,Up,12666,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
VCP,HTM,Down,12666,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0042,34168259
VCP,HTM,Up,12666,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0042,34168259
VCPIP1,HTM,Down,30897,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
VCPIP1,HTM,Down,30897,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
VCX3B,HTM,Up,31838,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
VCX3B,HTM,Up,31838,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
VCX3B,HTM,Up,31838,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
VDAC1,HTM,Down,12669,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0021,19451087
VDAC1,HTM,Up,12669,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0021,34168259
VDAC1,HTM,Up,12669,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
VDAC1,HTM,Down,12669,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
VDAC2,HTM,Up,12672,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.36,0.0011,34168259
VDAC2,HTM,Up,12672,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.36,0.0011,34168259
VDAC2,HTM,Down,12672,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.36,0.0011,34168259
VDAC2,HTM,Up,12672,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.36,0.0011,34168259
VDAC3,HTM,Down,12674,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0011,34168259
VDR,HTM,Down,12679,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
VDR,HTM,Down,12679,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VEGFA,HTM,Down,12680,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
VEGFA,HTM,Down,12680,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
VEGFA,HTM,Down,12680,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0032,19451087
VEGFC,HTM,Down,12682,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VEGFC,HTM,Down,12682,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VEGFC,HTM,Down,12682,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VEGFC,HTM,Up,12682,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0021,34414448
VEPH1,HTM,Down,25735,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
VEPH1,HTM,Down,25735,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
VEZT,HTM,Down,18258,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
VGF,HTM,Up,12684,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
VGF,HTM,Up,12684,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
VGF,HTM,Up,12684,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
VGF,HTM,Up,12684,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
VGF,HTM,Up,12684,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
VGLL1,HTM,Up,20985,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VGLL1,HTM,Down,20985,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
VGLL3,HTM,Up,24327,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VGLL3,HTM,Up,24327,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VGLL3,HTM,Down,24327,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
VHL,HTM,Up,12687,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29511337
VHL,HTM,Up,12687,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0011,29511337
VHLL,HTM,Up,30666,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
VIL1,HTM,Up,12690,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,35229723
VIL1,HTM,Up,12690,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
VILL,HTM,Up,30906,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
VIM,HTM,Up,12692,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0170,22740085
VIM,HTM,Up,12692,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Proteomics,0.08,0.0170,34794402
VIM,HTM,Down,12692,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0170,25881239
VIM,HTM,Up,12692,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0170,31709178
VIM,HTM,Up,12692,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0170,31729259
VIM,HTM,Down,12692,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0170,19451087
VIM,HTM,Up,12692,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Proteomics,0.08,0.0170,34794402
VIM,HTM,Down,12692,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0170,32503348
VIM,HTM,Down,12692,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0170,32503348
VIM,HTM,Up,12692,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Docetaxel,Transcriptomics followed by qRT-PCR,0.28,0.0170,31289135
VIM,HTM,Up,12692,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Doxorubicin,SFA followed by single-cell time-of-flight mass cytometry,0.2,0.0170,34831064
VIM,HTM,Down,12692,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.36,0.0170,27746256
VIM,HTM,Up,12692,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0170,31729259
VIPR1,HTM,Up,12694,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
VIPR2,HTM,Down,12695,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
VKORC1L1,HTM,Up,21492,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0011,34168259
VLDLR,HTM,Up,12698,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
VLDLR,HTM,Up,12698,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
VLDLR,HTM,Up,12698,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
VN1R2,HTM,Down,19872,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
VN1R2,HTM,Down,19872,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
VNN3,HTM,Down,16431,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
VNN3,HTM,Down,16431,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
VNN3,HTM,Down,16431,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
VPS13C,HTM,Up,23594,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
VPS35,HTM,Up,13487,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
VPS37B,HTM,Down,25754,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
VPS37D,HTM,Up,18287,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
VPS37D,HTM,Up,18287,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
VPS37D,HTM,Up,18287,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
VPS50,HTM,Up,25956,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
VPS9D1,HTM,Up,13526,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
VRK1,HTM,NA,12718,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29221160
VRK2,HTM,Up,12719,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
VRK2,HTM,Up,12719,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
VRK2,HTM,Up,12719,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
VSIG10L,HTM,Up,27111,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
VSIG2,HTM,Up,17149,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
VSIG2,HTM,Up,17149,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
VSIG2,HTM,Up,17149,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
VSIG8,HTM,Down,32063,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
VSNL1,HTM,Down,12722,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VSNL1,HTM,Down,12722,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VSNL1,HTM,Down,12722,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
VSNL1,HTM,Down,12722,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
VSTM2A,HTM,Down,28499,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
VTCN1,HTM,Up,28873,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
VTI1A,HTM,Down,17792,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
VTI1B,HTM,Down,17793,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
VTN,HTM,Up,12724,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
VTN,HTM,Down,12724,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
VTN,HTM,Up,12724,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
VTRNA2-1,HTM,Down,37054,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,22180714
VTRNA2-1,HTM,Down,37054,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics,0.04,0.0011,22180714
VWA1,HTM,Down,30910,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
VWA1,HTM,Up,30910,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
VWA1,HTM,Up,30910,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
VWA1,HTM,Up,30910,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
VWA1,HTM,Up,30910,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
VWA5B2,HTM,Up,25144,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
VWA7,HTM,Up,13939,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
VWA8,HTM,Down,29071,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
VWDE,HTM,Down,21897,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
VWF,HTM,Down,12726,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
WARS1,HTM,Up,12729,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
WARS1,HTM,Up,12729,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
WARS1,HTM,Up,12729,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
WASF1,HTM,Down,12732,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
WASF1,HTM,Down,12732,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
WASF1,HTM,Down,12732,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
WASF1,HTM,Down,12732,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
WASF1,HTM,Down,12732,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0032,19353633
WASF2,HTM,Down,12733,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
WASH2P,HTM,Up,33145,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
WASH3P,HTM,Up,24362,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
WASH4P,HTM,Up,14126,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
WASH6P,HTM,Up,31685,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
WASHC1,HTM,Up,24361,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
WASHC5,HTM,Down,28984,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
WASHC5,HTM,Down,28984,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
WBP2,HTM,Up,12738,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
WDCP,HTM,Down,26157,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
WDCP,HTM,Up,26157,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
WDFY1,HTM,Down,20451,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
WDFY2,HTM,Down,20482,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
WDFY2,HTM,Down,20482,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
WDFY2,HTM,Down,20482,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
WDR1,HTM,Up,12754,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
WDR12,HTM,Down,14098,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
WDR17,HTM,Up,16661,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
WDR17,HTM,Up,16661,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
WDR20,HTM,Up,19667,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
WDR3,HTM,Down,12755,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
WDR31,HTM,Down,21421,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
WDR35,HTM,Up,29250,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
WDR35,HTM,Up,29250,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
WDR35,HTM,Up,29250,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
WDR4,HTM,Down,12756,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
WDR41,HTM,Up,25601,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
WDR45,HTM,Down,28912,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
WDR47,HTM,Down,29141,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
WDR47,HTM,Down,29141,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
WDR47,HTM,Down,29141,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
WDR47,HTM,Up,29141,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
WDR53,HTM,Down,28786,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
WDR53,HTM,Down,28786,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
WDR53,HTM,Down,28786,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
WDR53,HTM,Down,28786,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
WDR53,HTM,Down,28786,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
WDR5B,HTM,Down,17826,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
WDR5B,HTM,Down,17826,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
WDR64,HTM,Down,26570,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
WDR72,HTM,Up,26790,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
WDR72,HTM,Up,26790,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
WDR72,HTM,Down,26790,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
WDR72,HTM,Down,26790,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
WDR77,HTM,Down,29652,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
WDR77,HTM,Down,29652,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
WDR86,HTM,Down,28020,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
WDR90,HTM,Up,26960,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
WDR91,HTM,Down,24997,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
WDSUB1,HTM,Down,26697,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
WDSUB1,HTM,Down,26697,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
WDSUB1,HTM,Down,26697,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
WDTC1,HTM,Up,29175,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
WEE1,HTM,Up,12761,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
WEE1,HTM,Up,12761,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
WEE1,HTM,Up,12761,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
WEE2,HTM,Down,19684,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
WFDC1,HTM,Up,15466,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
WFDC2,HTM,Up,15939,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0042,25881239
WFDC2,HTM,Down,15939,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
WFDC2,HTM,Up,15939,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0042,34680485
WFDC2,HTM,Down,15939,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0042,34414448
WFDC2,HTM,Down,15939,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0042,31709178
WFDC21P,HTM,Up,50357,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
WFS1,HTM,UP,12762,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
WFS1,HTM,UP,12762,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
WFS1,HTM,UP,12762,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
WFS1,HTM,UP,12762,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
WFS1,HTM,UP,12762,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,23108794
WHAMMP2,HTM,Down,32360,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
WHAMMP2,HTM,Down,32360,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
WIPF1,HTM,Down,12736,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
WIPF2,HTM,Up,30923,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
WIPI1,HTM,Down,25471,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
WLS,HTM,Down,30238,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
WLS,HTM,Down,30238,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
WLS,HTM,Down,30238,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
WLS,HTM,Up,30238,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
WLS,HTM,Up,30238,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,29340052
WNK1,HTM,Down,14540,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,31501409
WNK1,HTM,Up,14540,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0032,17911267
WNK1,HTM,UP,14540,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,23108794
WNK1,HTM,UP,14540,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,23108794
WNK1,HTM,UP,14540,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,23108794
WNK1,HTM,UP,14540,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,23108794
WNK1,HTM,UP,14540,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,23108794
WNK2,HTM,Down,14542,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
WNK3,HTM,Up,14543,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
WNT1,HTM,Up,12774,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0074,20424609
WNT1,HTM,Up,12774,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay and FACs for CSC marker followed by Transcriptomics,0.04,0.0074,20424609
WNT10A,HTM,Down,13829,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
WNT10A,HTM,Down,13829,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
WNT10B,HTM,Up,12775,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0011,28927099
WNT11,HTM,Up,12776,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs for CSCs marker and SFA followed by Transcriptomics,0.04,0.0021,28927099
WNT11,HTM,Down,12776,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
WNT2,HTM,Down,12780,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,25731617
WNT2B,HTM,Up,12781,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
WNT3,HTM,Up,12782,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.12,0.0011,29959199
WNT3A,HTM,Down,15983,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25731617
WNT5A,HTM,Up,12784,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
WNT5A,HTM,Up,12784,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25731617
WNT5B,HTM,Up,16265,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
WNT6,HTM,Down,12785,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
WNT6,HTM,Down,12785,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
WNT6,HTM,Down,12785,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
WNT7A,HTM,Down,12786,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
WNT7A,HTM,Down,12786,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
WNT7A,HTM,Down,12786,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
WNT7A,HTM,Down,12786,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
WNT7A,HTM,Up,12786,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,25731617
WNT7B,HTM,Up,12787,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,25731617
WNT7B,HTM,Up,12787,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0042,24098529
WNT9A,HTM,Down,12778,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
WSB1,HTM,Up,19221,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
WSB2,HTM,Down,19222,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
WSB2,HTM,Down,19222,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
WSCD1,HTM,Up,29060,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
WT1,HTM,Down,12796,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
WT1,HTM,Down,12796,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
WWC2,HTM,Down,24148,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
WWOX,HTM,Up,12799,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
WWOX,HTM,Up,12799,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
WWOX,HTM,Up,12799,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
WWOX,HTM,Up,12799,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
WWOX,HTM,Up,12799,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,19190339
WWP2,HTM,Up,16804,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,29511337
WWP2,HTM,Up,16804,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0011,29511337
WWTR1,HTM,Down,24042,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
XAB2,HTM,Down,14089,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
XAF1,HTM,Up,30932,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
XAGE1A,HTM,Up,4111,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
XAGE1A,HTM,Up,4111,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
XBP1,HTM,Up,12801,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
XDH,HTM,Down,12805,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
XDH,HTM,Down,12805,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
XDH,HTM,Down,12805,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
XDH,HTM,Down,12805,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
XG,HTM,Up,12806,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
XIAP,HTM,Up,592,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics,0.04,0.0021,19451087
XIAP,HTM,Up,592,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,29511337
XIAP,HTM,Up,592,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Transcriptomics,0.04,0.0021,29511337
XIST,HTM,Up,12810,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
XK,HTM,Down,12811,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
XK,HTM,Up,12811,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
XKR6,HTM,Down,27806,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
XPC,HTM,Down,12816,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
XPNPEP3,HTM,Down,28052,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
XPO1,HTM,Down,12825,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
XPO1,HTM,Down,12825,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
XPO1,HTM,NA,12825,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0032,29221160
XPO1,HTM,Down,12825,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
XPO5,HTM,Down,17675,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
XPO6,HTM,Down,19733,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
XPO7,HTM,Down,14108,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
XPO7,HTM,Down,14108,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
XRCC3,HTM,Down,12830,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
XRCC3,HTM,Up,12830,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
XRCC3,HTM,Up,12830,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
XRCC5,HTM,Down,12833,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
XRCC5,HTM,Down,12833,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
XRCC5,HTM,Down,12833,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
XRCC5,HTM,Down,12833,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0032,34168259
XRCC5,HTM,Down,12833,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0032,27746256
XRCC5,HTM,Down,12833,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
XRCC6,HTM,Up,4055,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Transcriptomics followed by Western Blotting,0.32,0.0053,24440048
XRCC6,HTM,Down,4055,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
XRCC6,HTM,Down,4055,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0053,32503348
XRCC6,HTM,Down,4055,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0053,27746256
XRCC6,HTM,Down,4055,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0053,34168259
XXYLT1,HTM,Up,26639,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
XXYLT1,HTM,Up,26639,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0011,30696080
XYLB,HTM,Down,12839,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
XYLT1,HTM,Up,15516,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
YAF2,HTM,Up,17363,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
YAF2,HTM,Down,17363,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
YAF2,HTM,Down,17363,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
YAP1,HTM,Up,16262,Bladder Cancer,Carcinoma,T24,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0117,29340052
YARS1,HTM,Up,12840,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0011,27746256
YBX1,HTM,Up,8014,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics,0.08,0.0021,34168259
YBX2,HTM,Down,17948,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
YBX2,HTM,Down,17948,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics,0.08,0.0021,34168259
YBX2,HTM,Down,17948,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
YES1,HTM,Up,12841,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
YIPF1,HTM,Down,25231,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
YKT6,HTM,Down,16959,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
YLPM1,HTM,Up,17798,Colon Cancer,NA,Primary,NA,SFA followed by Proteomics,0.16,0.0011,21788403
YPEL2,HTM,Up,18326,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
YPEL2,HTM,Up,18326,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
YPEL2,HTM,Up,18326,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
YPEL2,HTM,Up,18326,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
YTHDC1,HTM,Up,30626,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
YTHDC1,HTM,Up,30626,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
YTHDC1,HTM,Up,30626,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
YTHDC2,HTM,Up,24721,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
YWHAB,HTM,Up,12849,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,33670440
YWHAB,HTM,Down,12849,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.08,0.0032,34059086
YWHAB,HTM,Down,12849,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics,0.08,0.0032,34168259
YWHAE,HTM,Up,12851,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.36,0.0021,27746256
YWHAE,HTM,Up,12851,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
YWHAG,HTM,Up,12852,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
YWHAG,HTM,Up,12852,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0021,32503348
YWHAG,HTM,Up,12852,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0021,34168259
YWHAH,HTM,Down,12853,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
YWHAH,HTM,Down,12853,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
YWHAQ,HTM,Up,12854,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,33670440
YWHAQ,HTM,Down,12854,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
YWHAQ,HTM,Down,12854,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0032,32503348
YWHAQ,HTM,Up,12854,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics,0.08,0.0032,34168259
YWHAZ,HTM,Up,12855,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by Proteomics,0.08,0.0042,33670440
YWHAZ,HTM,Up,12855,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
YWHAZ,HTM,Up,12855,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6sl,NA,SFA followed by Proteomics,0.08,0.0042,32503348
YWHAZ,HTM,Up,12855,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0042,31501409
YWHAZ,HTM,Up,12855,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.36,0.0042,27746256
ZACN,HTM,Up,29504,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by Transcriptomics,0.04,0.0011,34414448
ZBED2,HTM,Down,20710,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZBED2,HTM,Down,20710,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZBED2,HTM,Down,20710,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZBED6CL,HTM,Up,21720,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ZBED6CL,HTM,Down,21720,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ZBTB11,HTM,Down,16740,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ZBTB18,HTM,Down,13030,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZBTB18,HTM,Down,13030,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZBTB2,HTM,Down,20868,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ZBTB20,HTM,Up,13503,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZBTB20,HTM,Up,13503,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZBTB20,HTM,Up,13503,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZBTB20,HTM,Up,13503,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZBTB20,HTM,Up,13503,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZBTB21,HTM,Down,13083,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZBTB3,HTM,Up,22918,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ZBTB38,HTM,Down,26636,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZBTB38,HTM,Down,26636,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZBTB43,HTM,Up,17908,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ZBTB45,HTM,Up,23715,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ZBTB48,HTM,Down,4930,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZBTB49,HTM,Up,19883,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZBTB5,HTM,Up,23836,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZBTB5,HTM,Up,23836,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZBTB5,HTM,Up,23836,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZBTB7A,HTM,Up,18078,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ZBTB7C,HTM,Up,31700,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ZBTB8OS,HTM,Up,24094,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZBTB8OS,HTM,Up,24094,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZBTB8OS,HTM,Up,24094,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZC2HC1A,HTM,Down,24277,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ZC2HC1C,HTM,Down,20354,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZC3H10,HTM,Up,25893,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZC3H11A,HTM,Up,29093,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ZC3H12A,HTM,Up,26259,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZC3H12A,HTM,Up,26259,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZC3H12A,HTM,Up,26259,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ZC3H12A,HTM,Up,26259,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZC3H13,HTM,Up,20368,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ZC3H13,HTM,Up,20368,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ZC3H13,HTM,Up,20368,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0011,19353633
ZC3H6,HTM,Up,24762,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZC3H8,HTM,Up,30941,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZC3H8,HTM,Up,30941,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZC3H8,HTM,Up,30941,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZC3HAV1,HTM,Down,23721,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZC3HAV1,HTM,Down,23721,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZC3HC1,HTM,Up,29913,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics,0.08,0.0011,23903875
ZCCHC24,HTM,Up,26911,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ZCCHC7,HTM,Up,26209,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ZCCHC9,HTM,Down,25424,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZCCHC9,HTM,Down,25424,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZCWPW1,HTM,Up,23486,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZCWPW1,HTM,Up,23486,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZCWPW1,HTM,Up,23486,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZDBF2,HTM,Up,29313,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZDHHC13,HTM,Down,18413,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ZDHHC13,HTM,Down,18413,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ZDHHC13,HTM,Down,18413,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ZDHHC16,HTM,Down,20714,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZDHHC2,HTM,Down,18469,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZDHHC2,HTM,Down,18469,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZDHHC21,HTM,Down,20750,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZDHHC23,HTM,Down,28654,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ZDHHC24,HTM,Down,27387,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZDHHC3,HTM,Down,18470,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZDHHC3,HTM,Down,18470,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZDHHC3,HTM,Up,18470,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ZDHHC4,HTM,Up,18471,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0011,22954703
ZEB1,HTM,Up,11642,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.2,0.0074,25881239
ZEB1,HTM,Up,11642,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.2,0.0074,25881239
ZEB1,HTM,Up,11642,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0074,34228218
ZEB1,HTM,Up,11642,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0074,31709178
ZEB2,HTM,Up,14881,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ZFAND3,HTM,Up,18019,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
ZFAND5,HTM,Up,13008,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZFAND5,HTM,Up,13008,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZFAND6,HTM,Up,30164,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZFC3H1,HTM,Up,28328,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZFC3H1,HTM,Up,28328,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZFC3H1,HTM,Up,28328,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
ZFC3H1,HTM,Up,28328,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZFHX3,HTM,Up,777,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ZFHX3,HTM,Up,777,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZFHX3,HTM,Up,777,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ZFHX3,HTM,Up,777,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ZFHX4,HTM,Up,30939,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZFHX4,HTM,Up,30939,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZFHX4,HTM,Down,30939,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
ZFP1,HTM,Up,23328,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
ZFP28,HTM,Down,17801,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZFP3,HTM,Up,12861,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZFP36,HTM,Up,12862,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ZFP36L1,HTM,Down,1107,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ZFP36L1,HTM,Down,1107,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZFP36L2,HTM,Down,1108,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZFP36L2,HTM,Down,1108,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZFP41,HTM,Down,26786,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ZFP41,HTM,Up,26786,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
ZFP41,HTM,Up,26786,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
ZFP41,HTM,Up,26786,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
ZFP41,HTM,Up,26786,Breast Cancer,Carcinoma,SKBR7,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
ZFP41,HTM,Up,26786,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,19190339
ZFP82,HTM,Down,28682,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ZFPL1,HTM,Down,12868,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZFPM1,HTM,Down,19762,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZFTA,HTM,Down,28449,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZFX,HTM,Up,12869,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
ZFX,HTM,Up,12869,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZFY,HTM,Down,12870,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZFYVE1,HTM,Up,13180,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ZFYVE16,HTM,Down,20756,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
ZFYVE16,HTM,Up,20756,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZFYVE21,HTM,Up,20760,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZFYVE21,HTM,Up,20760,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZFYVE21,HTM,Up,20760,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZFYVE26,HTM,Up,20761,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZFYVE26,HTM,Up,20761,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZFYVE26,HTM,Up,20761,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZFYVE28,HTM,Down,29334,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZG16B,HTM,Up,30456,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ZHX1,HTM,Up,12871,Bladder Cancer,Carcinoma,HT-1376,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,29340052
ZIC4,HTM,Down,20393,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZIC4,HTM,Down,20393,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZIK1,HTM,Up,33104,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZKSCAN2,HTM,Down,25677,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZMAT1,HTM,Up,29377,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ZMAT1,HTM,Up,29377,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ZMAT1,HTM,Up,29377,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ZMYM1,HTM,Down,26253,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZMYM2,HTM,Up,12989,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZMYM4,HTM,Up,13055,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
ZNF114,HTM,Down,12894,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ZNF121,HTM,Up,12904,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF121,HTM,Up,12904,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF121,HTM,Up,12904,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF124,HTM,Down,12907,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF124,HTM,Down,12907,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF136,HTM,Up,12920,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ZNF14,HTM,Up,12924,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
ZNF140,HTM,Down,12925,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ZNF140,HTM,Up,12925,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ZNF140,HTM,Down,12925,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ZNF140,HTM,Up,12925,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ZNF140,HTM,Up,12925,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ZNF140,HTM,Up,12925,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
ZNF146,HTM,Up,12931,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF146,HTM,Up,12931,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF146,HTM,Down,12931,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
ZNF165,HTM,Down,12953,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ZNF165,HTM,Up,12953,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ZNF17,HTM,Up,12958,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF17,HTM,Up,12958,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF17,HTM,Up,12958,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF181,HTM,Up,12971,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF185,HTM,Down,12976,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
ZNF185,HTM,Down,12976,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ZNF185,HTM,Down,12976,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ZNF185,HTM,Down,12976,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
ZNF189,HTM,Down,12980,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ZNF189,HTM,Down,12980,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ZNF189,HTM,Up,12980,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0021,28881576
ZNF20,HTM,Down,12992,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF20,HTM,Down,12992,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF20,HTM,Down,12992,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF200,HTM,Up,12993,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ZNF204P,HTM,Down,12995,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ZNF211,HTM,Up,13003,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF212,HTM,Up,13004,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF212,HTM,Up,13004,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF215,HTM,Down,13007,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF215,HTM,Up,13007,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ZNF222,HTM,Up,13015,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ZNF222,HTM,Up,13015,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ZNF222,HTM,Up,13015,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ZNF222,HTM,Up,13015,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ZNF223,HTM,Up,13016,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF230,HTM,Up,13024,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF250,HTM,Up,13044,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF252P,HTM,Up,13046,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ZNF253,HTM,Down,13497,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF26,HTM,Up,13053,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
ZNF260,HTM,Up,13499,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF267,HTM,Up,13060,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0011,18034892
ZNF271P,HTM,Up,13065,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF271P,HTM,Up,13065,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF271P,HTM,Up,13065,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF275,HTM,Down,13069,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF277,HTM,Down,13070,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF277,HTM,Down,13070,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF28,HTM,Down,13073,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF280A,HTM,Up,18597,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF280A,HTM,Up,18597,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF280B,HTM,Up,23022,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF280C,HTM,Up,25955,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF283,HTM,Up,13077,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF286A,HTM,Up,13501,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ZNF287,HTM,Down,13502,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF287,HTM,Down,13502,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF295-AS1,HTM,Up,23130,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF295-AS1,HTM,Up,23130,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF295-AS1,HTM,Up,23130,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF3,HTM,Up,13089,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF30,HTM,Up,13090,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF30,HTM,Up,13090,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF302,HTM,Up,13848,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF302,HTM,Up,13848,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF302,HTM,Down,13848,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ZNF302,HTM,Down,13848,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ZNF304,HTM,Up,13505,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF304,HTM,Up,13505,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF304,HTM,Up,13505,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF304,HTM,Up,13505,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZNF32,HTM,Up,13095,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0021,22954703
ZNF320,HTM,Down,13842,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ZNF320,HTM,Up,13842,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZNF323,HTM,Up,14097,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF324,HTM,Up,14096,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF324,HTM,Up,14096,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF324,HTM,Up,14096,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF331,HTM,Up,15489,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF331,HTM,Down,15489,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ZNF331,HTM,Down,15489,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ZNF334,HTM,Down,15806,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF334,HTM,Down,15806,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF33B,HTM,Up,13097,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF33B,HTM,Up,13097,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF33B,HTM,Up,13097,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF33B,HTM,Up,13097,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZNF343,HTM,Up,16017,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Proteomics,0.16,0.0011,28881576
ZNF35,HTM,Up,13099,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF35,HTM,Up,13099,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF35,HTM,Up,13099,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF354A,HTM,Up,11628,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF354C,HTM,Down,16736,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF354C,HTM,Down,16736,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF365,HTM,Up,18194,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ZNF37A,HTM,Up,13102,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF37BP,HTM,Down,13103,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ZNF383,HTM,Up,18609,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF385A,HTM,Down,17521,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZNF385B,HTM,Up,26332,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF385B,HTM,Up,26332,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF385B,HTM,Up,26332,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF397,HTM,Down,18818,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,34059086
ZNF397,HTM,Up,18818,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ZNF397,HTM,Up,18818,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ZNF397,HTM,Up,18818,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ZNF397,HTM,Down,18818,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
ZNF408,HTM,Up,20041,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF417,HTM,Up,20646,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF417,HTM,Up,20646,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF417,HTM,Up,20646,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF420,HTM,Up,20649,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
ZNF420,HTM,Up,20649,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZNF426,HTM,Down,20725,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF426,HTM,Down,20725,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF428,HTM,Down,20804,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0011,23820871
ZNF431,HTM,Up,20809,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF432,HTM,Down,20810,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF432,HTM,Down,20810,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF436,HTM,Up,20814,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ZNF436,HTM,Up,20814,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ZNF436,HTM,Up,20814,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by Transcriptomics,0.04,0.0021,30696080
ZNF439,HTM,Up,20873,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF443,HTM,Up,20878,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF443,HTM,Up,20878,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF443,HTM,Up,20878,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF451,HTM,Down,21091,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ZNF461,HTM,Up,21629,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF462,HTM,Down,21684,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF462,HTM,Down,21684,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF468,HTM,Down,33105,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF468,HTM,Down,33105,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF468,HTM,Down,33105,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ZNF473,HTM,Up,23239,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF484,HTM,Up,23385,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF485,HTM,Up,23440,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF486,HTM,Down,20807,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF486,HTM,Down,20807,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF486,HTM,Down,20807,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF486,HTM,Up,20807,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZNF493,HTM,Up,23708,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF496,HTM,Down,23713,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZNF503,HTM,Up,23589,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ZNF503,HTM,Up,23589,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,28588211
ZNF503-AS2,HTM,Up,23525,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ZNF507,HTM,Up,23783,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF507,HTM,Up,23783,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF512,HTM,Up,29380,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF512,HTM,Down,29380,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
ZNF518A,HTM,Down,29009,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZNF518A,HTM,Down,29009,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZNF528,HTM,Down,29384,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF528,HTM,Down,29384,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF529,HTM,Up,29328,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
ZNF530,HTM,Up,29297,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF532,HTM,Down,30940,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZNF542P,HTM,Down,25393,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF543,HTM,Up,25281,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF543,HTM,Up,25281,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF543,HTM,Up,25281,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF543,HTM,Up,25281,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZNF546,HTM,Up,28671,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF555,HTM,Down,28382,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZNF558,HTM,Up,26422,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF561,HTM,Down,28684,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF561,HTM,Down,28684,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF561,HTM,Up,28684,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
ZNF563,HTM,Down,30498,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ZNF564,HTM,Up,31106,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF566,HTM,Up,25919,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF566,HTM,Up,25919,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF567,HTM,Up,28696,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics,0.04,0.0021,18034892
ZNF567,HTM,Up,28696,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
ZNF569,HTM,Up,24737,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF570,HTM,Up,26416,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF571,HTM,Up,25000,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
ZNF571,HTM,Up,25000,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZNF574,HTM,Down,26166,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZNF578,HTM,Up,26449,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF580,HTM,Up,29473,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF580,HTM,Up,29473,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF580,HTM,Up,29473,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF581,HTM,Up,25017,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF581,HTM,Up,25017,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF581,HTM,Up,25017,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF585A,HTM,Down,26305,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Transcriptomics,0.04,0.0021,23820871
ZNF585A,HTM,Up,26305,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF585A,HTM,Up,26305,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF585A,HTM,Up,26305,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF586,HTM,Down,25949,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZNF588,HTM,Up,12887,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF608,HTM,Down,29238,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ZNF609,HTM,Up,29003,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
ZNF613,HTM,Up,25827,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF614,HTM,Down,24722,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ZNF614,HTM,Down,24722,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0021,26259570
ZNF614,HTM,Down,24722,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,29340052
ZNF615,HTM,Up,24740,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF618,HTM,Up,29416,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF618,HTM,Down,29416,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ZNF619,HTM,Up,26910,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ZNF624,HTM,Up,29254,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF625,HTM,Down,30571,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF625,HTM,Down,30571,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF625,HTM,Down,30571,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF625,HTM,Up,30571,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZNF626,HTM,Down,30461,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF627,HTM,Up,30570,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF627,HTM,Up,30570,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF627,HTM,Up,30570,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF627,HTM,Up,30570,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZNF630,HTM,Down,28855,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ZNF630,HTM,Up,28855,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF630,HTM,Up,28855,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF630,HTM,Up,28855,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF638,HTM,Up,17894,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ZNF638,HTM,Up,17894,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ZNF638,HTM,Up,17894,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0021,17911267
ZNF638,HTM,Up,17894,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Transcriptomics,0.04,0.0021,19353633
ZNF641,HTM,Down,31834,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ZNF641,HTM,Down,31834,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ZNF644,HTM,Up,29222,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics,0.04,0.0011,17911267
ZNF649,HTM,Down,25741,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ZNF649,HTM,Down,25741,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ZNF649,HTM,Down,25741,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0032,26259570
ZNF649,HTM,Up,25741,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
ZNF652,HTM,Up,29147,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF658,HTM,Up,25226,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF665,HTM,Up,25885,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF670,HTM,Up,28167,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF671,HTM,Down,26279,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ZNF671,HTM,Up,26279,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF671,HTM,Up,26279,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF671,HTM,Up,26279,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF676,HTM,Up,20429,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF681,HTM,Up,26457,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF681,HTM,Down,26457,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ZNF688,HTM,Down,30489,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZNF69,HTM,Down,13138,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF69,HTM,Down,13138,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF695,HTM,Up,30954,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF695,HTM,Up,30954,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF695,HTM,Up,30954,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF695,HTM,Up,30954,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0021,21618577
ZNF696,HTM,Down,25872,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZNF70,HTM,Up,13140,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ZNF703,HTM,Down,25883,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ZNF703,HTM,Up,25883,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZNF711,HTM,Up,13128,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF724,HTM,Down,32460,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF724,HTM,Down,32460,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF728,HTM,Down,32463,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZNF740,HTM,Up,27465,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF740,HTM,Up,27465,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF740,HTM,Up,27465,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF750,HTM,Up,25843,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
ZNF750,HTM,Down,25843,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ZNF75A,HTM,Up,13146,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ZNF75A,HTM,Up,13146,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ZNF75A,HTM,Down,13146,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs for CSC marker and CFA followed by Transcriptomics,0.04,0.0032,22954703
ZNF75A,HTM,Up,13146,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0032,21618577
ZNF75A,HTM,Up,13146,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0032,24098529
ZNF75D,HTM,Down,13145,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF75D,HTM,Down,13145,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF766,HTM,Up,28063,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF767P,HTM,Up,21884,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF771,HTM,Up,29653,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF771,HTM,Up,29653,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF771,HTM,Up,29653,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF773,HTM,Up,30487,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF777,HTM,Up,22213,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF777,HTM,Up,22213,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF777,HTM,Up,22213,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF780A,HTM,Up,27603,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF780A,HTM,Up,27603,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF780A,HTM,Up,27603,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZNF784,HTM,Up,33111,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF784,HTM,Up,33111,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF784,HTM,Up,33111,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF785,HTM,Up,26496,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0011,20530554
ZNF787,HTM,Down,26998,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZNF79,HTM,Up,13153,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF79,HTM,Up,13153,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF790,HTM,Down,33114,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF790,HTM,Down,33114,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF790,HTM,Down,33114,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF804A,HTM,Up,21711,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ZNF805,HTM,Up,23272,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF805,HTM,Up,23272,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF805,HTM,Up,23272,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF808,HTM,Down,33230,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF808,HTM,Down,33230,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF81,HTM,Up,13156,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF81,HTM,Up,13156,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF81,HTM,Up,13156,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF813,HTM,Up,33257,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF814,HTM,Down,33258,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF814,HTM,Down,33258,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics,0.04,0.0011,26259570
ZNF83,HTM,Down,13158,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF83,HTM,Down,13158,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF83,HTM,Down,13158,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF831,HTM,Down,16167,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ZNF831,HTM,Down,16167,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.0021,28588211
ZNF841,HTM,Up,27611,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ZNF841,HTM,Up,27611,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZNF85,HTM,Up,13160,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZNF852,HTM,Up,27713,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ZNF853,HTM,Up,21767,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ZNF860,HTM,Down,34513,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ZNF860,HTM,Down,34513,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0032,25881239
ZNF860,HTM,Up,34513,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0032,34680485
ZNF860,HTM,Down,34513,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0032,31709178
ZNF875,HTM,Up,4928,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF875,HTM,Up,4928,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF875,HTM,Up,4928,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZNF90,HTM,Down,13165,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF90,HTM,Down,13165,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF91,HTM,Down,13166,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF91,HTM,Down,13166,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF91,HTM,Down,13166,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,31709178
ZNF92,HTM,Up,13168,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZNF92,HTM,Up,13168,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZNF93,HTM,Down,13169,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNF93,HTM,Down,13169,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZNRF4,HTM,Up,17726,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0011,24098529
ZP3,HTM,Up,13189,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZP3,HTM,Up,13189,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZP3,HTM,Up,13189,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and Transcriptomics,0.04,0.0011,21618577
ZRSR2,HTM,Up,23019,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0021,31501409
ZRSR2,HTM,UP,23019,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
ZRSR2,HTM,UP,23019,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
ZRSR2,HTM,UP,23019,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
ZRSR2,HTM,UP,23019,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
ZRSR2,HTM,UP,23019,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0021,23108794
ZSCAN12P1,HTM,Down,13850,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ZSCAN2,HTM,Up,20994,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics,0.04,0.0011,31501409
ZSCAN20,HTM,Down,13093,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,34059086
ZSCAN20,HTM,Up,13093,Skin Cancer,NA,Primary,NA,SP assay and CFA followed by Transcriptomics,0.12,0.0021,24098529
ZSCAN21,HTM,Up,13104,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by Transcriptomics,0.04,0.0011,25881239
ZSWIM8,HTM,Up,23528,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0011,34680485
ZSWIM9,HTM,Down,34495,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZXDB,HTM,Down,13199,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZYG11A,HTM,Down,32058,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.04,0.0011,31709178
ZYX,HTM,Down,13200,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0021,25881239
ZYX,HTM,Up,13200,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics,0.08,0.0021,27746256
ZZEF1,HTM,Down,29027,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
ZZEF1,HTM,Down,29027,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Transcriptomics,0.04,0.0011,34059086
AMIGO2,HTM  ,Up,24073,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
ANKRD1,HTM  ,Up,15819,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
AP1S3,HTM  ,Up,18971,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
ARHGEF10,HTM  ,Up,14103,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0032,30397177
ASAP1,HTM  ,Up,2720,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0011,30397177
ATP2A2,HTM  ,Up,812,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
ATP8B1,HTM  ,Up,3706,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
ATXN1,HTM  ,Up,10548,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0064,30397177
CD24,HTM  ,Up,1645,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.12,0.4560,30397177
CDC42BPA,HTM  ,Up,1737,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0011,30397177
CEMIP,HTM  ,Up,29213,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0042,30397177
CHD6,HTM  ,Up,19057,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
CLSPN,HTM  ,Up,19715,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0032,30397177
CSE1L,HTM  ,Up,2431,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0032,30397177
ENDOD1,HTM  ,Up,29129,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0032,30397177
FAM13A,HTM  ,Up,19367,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
FAT1,HTM  ,Up,3595,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
FHL2,HTM  ,Up,3703,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0053,30397177
FOS,HTM  ,Up,3796,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0053,30397177
GNE,HTM  ,Up,23657,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0042,30397177
HAT1,HTM  ,Up,4821,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
INSIG1,HTM  ,Up,6083,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0053,30397177
KDELC2,HTM  ,Up,28496,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
LAMB1,HTM  ,Up,6486,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
LAMC1,HTM  ,Up,6492,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0011,30397177
LATS1,HTM  ,Up,6514,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0011,30397177
MACC1,HTM  ,Up,30215,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
MAN1A1,HTM  ,Up,6821,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
MB,HTM  ,Up,6915,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0011,30397177
MSH6,HTM  ,Up,7329,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0011,30397177
ORC1,HTM  ,Up,8487,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
PALLD,HTM  ,Up,17068,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
PDGFB,HTM  ,Up,8800,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.28,0.0032,30397177
PDK1,HTM  ,Up,8809,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0053,30397177
PLIN2,HTM  ,Up,248,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0064,30397177
PRKCB,HTM  ,Up,9395,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0032,30397177
RAPGEF4,HTM  ,Up,16626,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0011,30397177
RHOBTB3,HTM  ,Up,18757,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0032,30397177
RNASE4,HTM  ,Up,10047,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0042,30397177
RRM2,HTM  ,Up,10452,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
S100A10,HTM  ,Up,10487,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
SASS6,HTM  ,Up,25403,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0011,30397177
SLC16A7,HTM  ,Up,10928,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0011,30397177
SOX17,HTM  ,Up,18122,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0011,30397177
SOX9,HTM  ,Up,11204,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0244,30397177
TACC1,HTM  ,Up,11522,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
TEAD1,HTM  ,Up,11714,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0011,30397177
TJP3,HTM  ,Up,11829,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0021,30397177
TOR1AIP1,HTM  ,Up,29456,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.04,0.0011,30397177
YAP1,HTM  ,Up,16262,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics,0.52,0.0117,30397177
ABCG2,HTM/LTM,Up,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics and qRT-PCR,0.48,0.1739,17911267
ACAT2,HTM/LTM,Up,94,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0032,27746256
ADM,HTM/LTM,Up,259,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0032,27746256
AKR1C1,HTM/LTM,Up,384,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics and qRT-PCR,0.24,0.0085,18034892
AKR1C2,HTM/LTM,Up,385,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by Transcriptomics and qRT-PCR,0.24,0.0053,18034892
AKR1C2,HTM/LTM,Up,385,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,26351321
ALDH1A3,HTM/LTM,Up,409,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0201,35053617
ALDH3A1,HTM/LTM,Up,405,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics and qRT-PCR,0.28,0.0074,32503348
ALOX5,HTM/LTM,Up,435,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0021,31666201
ALOX5,HTM/LTM,Up,435,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0021,31666201
ALPI,HTM/LTM,Up,437,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0011,19451087
ANXA1,HTM/LTM,Up,533,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics and Western Blotting,0.36,0.0053,22623141
ANXA1,HTM/LTM,Down,533,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.36,0.0053,21826669
ANXA2,HTM/LTM,Up,537,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics and Western Blotting,0.36,0.0032,22623141
ARPC3,HTM/LTM,Up,706,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics and qRT-PCR,0.28,0.0021,32503348
ASCL2,HTM/LTM,Up,739,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0053,19451087
AXIN1,HTM/LTM,Up,903,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0021,19451087
B3GNT2,HTM/LTM,Up,15629,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by PCR array assay and qRT-PCR,0.24,0.0011,30466404
B3GNT2,HTM/LTM,Up,15629,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by PCR array assay and qRT-PCR,0.24,0.0011,30466404
B3GNT3,HTM/LTM,Up,13528,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by PCR array assay and qRT-PCR,0.24,0.0042,30466404
B3GNT3,HTM/LTM,Up,13528,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by PCR array assay and qRT-PCR,0.24,0.0042,30466404
BAMBI,HTM/LTM,Down,30251,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,34680485
BGN,HTM/LTM,Up,1044,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR and Western Blotting,0.76,0.0032,35053617
BIK,HTM/LTM,Down,1051,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0021,21826669
BMI1,HTM/LTM,Up,1066,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and RT-PCR and Western Blotting,0.52,0.1135,24719318
BMP1,HTM/LTM,Up,1067,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0032,19451087
BMP3,HTM/LTM,Up,1070,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0021,19451087
BMP4,HTM/LTM,Up,1071,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and RT-PCR,0.24,0.0021,24719318
BMP7,HTM/LTM,Down,1074,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,21826669
BMP7,HTM/LTM,Up,1074,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,34680485
BST2,HTM/LTM,Up,1119,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0032,31666201
BST2,HTM/LTM,Up,1119,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and RT-PCR,0.24,0.0032,24719318
BTG1,HTM/LTM,Up,1130,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and RT-PCR,0.24,0.0011,24719318
BTRC,HTM/LTM,Up,1144,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0011,19451087
C16ORF46,HTM/LTM,Down,26525,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,17911267
CAPZA1,HTM/LTM,Up,1488,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,21455326
CAV1,HTM/LTM,Down,1527,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0117,34680485
CCL11,HTM/LTM,Up,10610,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0011,35053617
CCL2,HTM/LTM,Up,10618,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0074,35053617
CCL5,HTM/LTM,Up,10632,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0064,35053617
CCL7,HTM/LTM,Up,10634,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0011,35053617
CCNH,HTM/LTM,Down,1594,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0011,27932392
CD24,HTM/LTM,NA,1645,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.4560,25676692
CD24,HTM/LTM,NA,1645,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.4,0.4560,25676692
CD24,HTM/LTM,NA,1645,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.4560,25676692
CD44,HTM/LTM,Up,1681,Large Cell Lung Cancer,Carcinoma,Primary,NA,Proteomics followed by IHC staining,0.48,1.0000,21888658
CD44,HTM/LTM,Up,1681,Large Cell Lung Cancer,Carcinoma,Primary,NA,Proteomics followed by IHC staining,0.48,1.0000,21888658
CD9,HTM/LTM,Up,1709,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics and qRT-PCR,0.28,0.0032,32503348
CDC2,HTM/LTM,Up,1722,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0042,19451087
CDC42,HTM/LTM,Up,1736,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0042,21826669
CDK7,HTM/LTM,Down,1778,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0011,27932392
CLIC1,HTM/LTM,Up,2062,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0042,21455326
CMKLR1,HTM/LTM,Up,2121,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0011,31666201
COL17A1,HTM/LTM,Up,2194,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0064,35053617
COL1A2,HTM/LTM,Up,2198,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0021,35053617
COL2A1,HTM/LTM,Up,2200,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0021,35053617
COL3A1,HTM/LTM,Up,2201,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0021,35053617
COL6A1,HTM/LTM,Up,2211,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0021,35053617
COL7A1,HTM/LTM,Up,2214,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0032,35053617
COPE,HTM/LTM,Up,2234,Colon Cancer,NA,Primary,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.4,0.0021,20530554
CP,HTM/LTM,Up,2295,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0021,26850699
CSNK2A1,HTM/LTM,Up,2457,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics and Western Blotting,0.36,0.0011,22623141
CTNNA1,HTM/LTM,Up,2509,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0032,19451087
CTNNB1,HTM/LTM,Up,2514,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics and Western Blotting,0.36,0.0647,22623141
CTSD,HTM/LTM,Up,2529,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics and qRT-PCR,0.28,0.0053,32503348
CTSD,HTM/LTM,Down,2529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0053,27746256
CXCL2,HTM/LTM,Up,4603,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0074,21826669
CXCR1,HTM/LTM,Up,6026,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,19190339
CXCR1,HTM/LTM,Up,6026,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,19190339
CXCR1,HTM/LTM,Up,6026,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,19190339
CYCS,HTM/LTM,Down,19986,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,17911267
DCN,HTM/LTM,Up,2705,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0011,35053617
DDB1,HTM/LTM,Down,2717,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0021,27932392
DDB2,HTM/LTM,Up,2718,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0021,27932392
DHCR7,HTM/LTM,Up,2860,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,25676692
DHCR7,HTM/LTM,Up,2860,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,25676692
DHCR7,HTM/LTM,Up,2860,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,25676692
DHRS3,HTM/LTM,Down,17693,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,34680485
DUSP16,HTM/LTM,Up,17909,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,17911267
EDN1,HTM/LTM,Up,3176,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0053,21826669
EEF1D,HTM/LTM,Up,3211,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0042,21455326
EGR4,HTM/LTM,Up,3241,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0011,31666201
EME1,HTM/LTM,Up,24965,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0021,27932392
ENC1,HTM/LTM,Up,3345,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0021,34680485
ENO1,HTM/LTM,Up,3350,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0095,25081334
EP300,HTM/LTM,Up,3373,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0011,19451087
ERCC2,HTM/LTM,Up,3434,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0011,27932392
ERCC3,HTM/LTM,Down,3435,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0011,27932392
EXT1,HTM/LTM,Up,3512,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,Transcriptomics followed by qRT-PCR and Western Blotting,0.52,0.0032,29050299
EZR,HTM/LTM,Up,12691,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0064,25081334
FA2H,HTM/LTM,Up,21197,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0042,31729259
FA2H,HTM/LTM,Up,21197,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0042,31729259
FASN,HTM/LTM,Up,3594,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0074,27746256
FASN,HTM/LTM,Up,3594,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,25676692
FASN,HTM/LTM,Up,3594,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,25676692
FASN,HTM/LTM,Up,3594,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,25676692
FAXDC2,HTM/LTM,Up,1334,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0021,34680485
FBXO21,HTM/LTM,Up,13592,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,19190339
FBXO21,HTM/LTM,Up,13592,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,19190339
FBXO21,HTM/LTM,Up,13592,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,19190339
FGF4,HTM/LTM,Up,3682,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0011,19451087
FGF9,HTM/LTM,Down,3687,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0021,21826669
FGFR1,HTM/LTM,Up,3688,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0053,19451087
FOLR1,HTM/LTM,Up,3791,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and RT-PCR and Western Blotting,0.52,0.0053,24719318
FOXQ1,HTM/LTM,Up,20951,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and RT-PCR and Western Blotting,0.52,0.0021,24719318
GALNT12,HTM/LTM,Up,19877,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by PCR array assay and qRT-PCR,0.24,0.0032,30466404
GALNT12,HTM/LTM,Up,19877,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by PCR array assay and qRT-PCR,0.24,0.0032,30466404
GALNT16,HTM/LTM,Up,23233,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by PCR array assay and qRT-PCR,0.24,0.0021,30466404
GALNT16,HTM/LTM,Up,23233,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by PCR array assay and qRT-PCR,0.24,0.0021,30466404
GALNT3,HTM/LTM,Up,4125,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by PCR array assay and qRT-PCR,0.24,0.0042,30466404
GALNT3,HTM/LTM,Up,4125,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by PCR array assay and qRT-PCR,0.24,0.0042,30466404
GAPDH,HTM/LTM,Up,4141,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0053,21455326
GATA2,HTM/LTM,Down,4171,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0021,21826669
HDHA,HTM/LTM,Up,NA,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,34168259
HDHA,HTM/LTM,Up,NA,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,34168259
HDHA,HTM/LTM,Up,NA,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,34168259
HDHA,HTM/LTM,Up,NA,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,34168259
HMGCS1,HTM/LTM,NA,5007,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,25676692
HMGCS1,HTM/LTM,NA,5007,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,25676692
HMGCS1,HTM/LTM,NA,5007,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0074,25676692
HNRNPA2B1,HTM/LTM,Down,5033,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0042,27746256
HNRNPAB,HTM/LTM,Down,5034,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0032,34168259
HNRNPAB,HTM/LTM,Down,5034,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0032,34168259
HNRNPAB,HTM/LTM,Down,5034,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0032,34168259
HNRNPAB,HTM/LTM,Down,5034,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0032,34168259
HSPA5,HTM/LTM,Down,5238,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0117,27746256
HSPA8,HTM/LTM,Up,5241,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics and Western Blotting,0.36,0.0085,25081334
IGFBP3,HTM/LTM,NA,5472,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0095,25676692
IGFBP3,HTM/LTM,NA,5472,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0095,25676692
IGFBP3,HTM/LTM,NA,5472,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0095,25676692
IL6,HTM/LTM,Up,6018,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0191,31729259
IL6,HTM/LTM,Up,6018,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.28,0.0191,31729259
IL8,HTM/LTM,Up,6025,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0159,19190339
IL8,HTM/LTM,Up,6025,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0159,19190339
IL8,HTM/LTM,Up,6025,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0159,19190339
ITGA6,HTM/LTM,Up,6142,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics and Western Blotting,0.6,0.0265,23903875
ITGA6,HTM/LTM,Up,6142,Head and Neck Cancer,Squamous Cell Carcinoma,HN12,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0265,23903875
ITGA6,HTM/LTM,Up,6142,Head and Neck Cancer,Squamous Cell Carcinoma,HN13,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0265,23903875
ITGA6,HTM/LTM,Up,6142,Head and Neck Cancer,Squamous Cell Carcinoma,HN6,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0265,23903875
ITGB1,HTM/LTM,Down,6153,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0180,27746256
ITGB4,HTM/LTM,Up,6158,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0074,23903875
ITGB4,HTM/LTM,Up,6158,Head and Neck Cancer,Squamous Cell Carcinoma,HN12,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0074,23903875
ITGB4,HTM/LTM,Up,6158,Head and Neck Cancer,Squamous Cell Carcinoma,HN13,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0074,23903875
ITGB4,HTM/LTM,Up,6158,Head and Neck Cancer,Squamous Cell Carcinoma,HN6,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0074,23903875
JUP,HTM/LTM,Up,6207,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics and Western Blotting,0.36,0.0042,22623141
KCNE4,HTM/LTM,Up,6244,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,34680485
KRT20,HTM/LTM,Up,20412,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,34680485
KRT5,HTM/LTM,Up,6442,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0064,35053617
LAMA3,HTM/LTM,Up,6483,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0053,35053617
LDHA,HTM/LTM,Down,6535,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0053,34168259
LDHA,HTM/LTM,Down,6535,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0053,34168259
LDHA,HTM/LTM,Down,6535,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0053,34168259
LDHA,HTM/LTM,Down,6535,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0053,34168259
LGALS1,HTM/LTM,Down,6561,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0053,27746256
LGALS3,HTM/LTM,Up,6563,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0021,26850699
LGALS3BP,HTM/LTM,Up,6564,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics and qRT-PCR,0.28,0.0042,32503348
LIG1,HTM/LTM,Up,6598,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0021,27932392
LINGO2,HTM/LTM,NA,21207,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA and Transcriptomics followed by RT-PCR and Western Blotting,0.52,0.0011,30696080
LINGO2,HTM/LTM,NA,21207,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA and Transcriptomics followed by RT-PCR and Western Blotting,0.52,0.0011,30696080
LRP8,HTM/LTM,Down,6700,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,17911267
MAOB,HTM/LTM,Up,6834,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,34680485
MARCKS,HTM/LTM,Up,6759,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0032,26850699
MARCKS,HTM/LTM,Up,6759,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0032,27746256
MBD4,HTM/LTM,Up,6919,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0021,27932392
ME1,HTM/LTM,Up,6983,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0042,27746256
MGAT4A,HTM/LTM,Up,7047,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by PCR array assay and qRT-PCR,0.24,0.0032,30466404
MGAT4A,HTM/LTM,Up,7047,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by PCR array assay and qRT-PCR,0.24,0.0032,30466404
MIR100,HTM/LTM,Up,31487,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,25676692
MIR100,HTM/LTM,Down,31487,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,21785383
MIR100,HTM/LTM,Up,31487,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,25676692
MIR100,HTM/LTM,Up,31487,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,25676692
MIR105-1,HTM/LTM,Up,31492,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,21130073
MIR106A,HTM/LTM,Down,31494,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21785383
MIR106A,HTM/LTM,Down,31494,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21785383
MIR1-1,HTM/LTM,Up,31499,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29975934
MIR122,HTM/LTM,Up,31501,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics and RT-PCR,0.24,0.0042,28440445
MIR1231,HTM/LTM,Down,33921,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,22180714
MIR125B1,HTM/LTM,Down,31506,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,21785383
MIR125B1,HTM/LTM,Down,31506,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,21785383
MIR125B1,HTM/LTM,Up,31506,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,24734907
MIR1269A,HTM/LTM,Down,35337,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25676692
MIR1269A,HTM/LTM,Down,35337,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25676692
MIR1269A,HTM/LTM,Down,35337,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25676692
MIR1269B,HTM/LTM,Down,41787,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25676692
MIR1269B,HTM/LTM,Down,41787,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25676692
MIR1269B,HTM/LTM,Down,41787,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25676692
MIR127,HTM/LTM,Down,31509,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,29975934
MIR130B,HTM/LTM,Up,31515,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,28534939
MIR132,HTM/LTM,Up,31516,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,29407170
MIR132,HTM/LTM,Up,31516,Gastric Cancer,Adenocarcinoma,MKN28,NA,SFA followed by Transcriptomics and qPCR,0.24,0.0032,28383763
MIR132,HTM/LTM,Up,31516,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Transcriptomics and qPCR,0.24,0.0032,28383763
MIR134,HTM/LTM,Down,31519,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29975934
MIR137,HTM/LTM,Up,31523,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,29407170
MIR138-1,HTM/LTM,Down,31524,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,29407170
MIR140,HTM/LTM,Up,31527,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,29407170
MIR141,HTM/LTM,Down,31528,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0021,29407170
MIR147B,HTM/LTM,Up,33655,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,26323893
MIR147B,HTM/LTM,Up,33655,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,26323893
MIR148A,HTM/LTM,Up,31535,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29975934
MIR148B,HTM/LTM,Up,31761,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29975934
MIR151A,HTM/LTM,Down,31762,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21130073
MIR151A,HTM/LTM,Down,31762,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21130073
MIR155,HTM/LTM,Up,31542,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics and RT-PCR,0.24,0.0053,28440445
MIR155,HTM/LTM,Up,31542,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,21130073
MIR15B,HTM/LTM,Up,31544,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0085,25676692
MIR15B,HTM/LTM,Up,31544,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0085,25676692
MIR15B,HTM/LTM,Up,31544,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0085,25676692
MIR16-2,HTM/LTM,Up,31546,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21130073
MIR181B1,HTM/LTM,Up,31550,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0021,28534939
MIR181B1,HTM/LTM,Up,31550,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21130073
MIR185,HTM/LTM,Up,31556,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21130073
MIR185,HTM/LTM,Down,31556,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29975934
MIR192,HTM/LTM,Up,31562,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21785383
MIR192,HTM/LTM,Up,31562,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21785383
MIR192,HTM/LTM,Up,31562,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics and qPCR,0.24,0.0021,22180714
MIR193A,HTM/LTM,Down,31563,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,29975934
MIR194-1,HTM/LTM,Up,31564,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics and qPCR,0.24,0.0021,22180714
MIR196A1,HTM/LTM,Up,31567,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics and RT-PCR,0.24,0.0021,28440445
MIR1976,HTM/LTM,Up,37064,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,26323893
MIR1976,HTM/LTM,Up,37064,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,26323893
MIR200A,HTM/LTM,Down,31578,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,29407170
MIR203A,HTM/LTM,Down,31581,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0021,29407170
MIR20A,HTM/LTM,Up,31577,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,29975934
MIR210,HTM/LTM,Up,31587,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,25676692
MIR210,HTM/LTM,Up,31587,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,25676692
MIR210,HTM/LTM,Up,31587,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,30188754
MIR210,HTM/LTM,Up,31587,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,25676692
MIR215,HTM/LTM,Down,31592,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25676692
MIR215,HTM/LTM,Down,31592,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25676692
MIR215,HTM/LTM,Down,31592,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25676692
MIR215,HTM/LTM,Up,31592,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics and qPCR,0.24,0.0021,22180714
MIR22,HTM/LTM,Up,31599,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25676692
MIR22,HTM/LTM,Up,31599,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25676692
MIR22,HTM/LTM,Up,31599,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25676692
MIR221,HTM/LTM,Down,31601,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,21130073
MIR223,HTM/LTM,Down,31603,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0021,29407170
MIR25,HTM/LTM,Up,31609,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,28534939
MIR2682,HTM/LTM,Up,41688,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,29407170
MIR299,HTM/LTM,Up,31618,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,29407170
MIR29B1,HTM/LTM,Up,31619,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics and qPCR,0.24,0.0064,22180714
MIR302A,HTM/LTM,Up,31623,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,28534939
MIR302C,HTM/LTM,Up,31764,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0021,28534939
MIR302C,HTM/LTM,Down,31764,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs for CSC marker followed by qRT-PCR,0.2,0.0021,32617772
MIR302C,HTM/LTM,Down,31764,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs for CSC marker followed by qRT-PCR,0.2,0.0021,32617772
MIR30A,HTM/LTM,Up,31624,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics and RT-PCR,0.24,0.0085,28440445
MIR30A,HTM/LTM,Down,31624,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0085,24734907
MIR30B,HTM/LTM,Up,31625,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics and RT-PCR,0.24,0.0053,28440445
MIR30C1,HTM/LTM,Up,31626,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by Transcriptomics and RT-PCR,0.24,0.0042,28440445
MIR30C1,HTM/LTM,Down,31626,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,24734907
MIR31,HTM/LTM,Down,31630,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,21130073
MIR3182,HTM/LTM,Up,38317,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29975934
MIR32,HTM/LTM,Up,31631,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,29975934
MIR32,HTM/LTM,Up,31631,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics and qPCR,0.24,0.0042,22180714
MIR320A,HTM/LTM,Down,31632,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29975934
MIR320D1,HTM/LTM,Down,35386,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21130073
MIR335,HTM/LTM,Up,31773,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,24734907
MIR33A,HTM/LTM,Up,31634,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics and qPCR,0.24,0.0021,22180714
MIR340,HTM/LTM,Up,31777,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29975934
MIR3622A,HTM/LTM,Up,38934,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,26323893
MIR3622A,HTM/LTM,Up,38934,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,26323893
MIR370,HTM/LTM,Down,31784,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29975934
MIR374A,HTM/LTM,Up,31788,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29975934
MIR377,HTM/LTM,Down,31870,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29975934
MIR378A,HTM/LTM,Down,31871,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,29975934
MIR378C,HTM/LTM,Down,38374,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,29975934
MIR3916,HTM/LTM,Down,38912,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,29407170
MIR3935,HTM/LTM,Down,38918,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,29407170
MIR411,HTM/LTM,Up,32792,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29975934
MIR423,HTM/LTM,Up,31880,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,21130073
MIR424,HTM/LTM,Down,31881,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,26323893
MIR424,HTM/LTM,Down,31881,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0064,26323893
MIR429,HTM/LTM,Up,13784,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,21785383
MIR429,HTM/LTM,Up,13784,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,21785383
MIR429,HTM/LTM,Down,13784,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,21130073
MIR449B,HTM/LTM,Down,32794,Dukes Type A Colon Cancer,Adenocarcinoma,SW1117,NA,FACs for CSC marker followed by Gene ChIP assay and RT-PCR,0.24,0.0032,23674142
MIR455,HTM/LTM,Up,32344,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21130073
MIR455,HTM/LTM,Up,32344,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21130073
MIR4730,HTM/LTM,Down,41880,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,26323893
MIR4730,HTM/LTM,Down,41880,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,26323893
MIR483,HTM/LTM,Down,32340,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0053,29407170
MIR486-1,HTM/LTM,Down,32342,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,29975934
MIR494,HTM/LTM,Up,32084,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,21130073
MIR497,HTM/LTM,Up,32088,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0053,28534939
MIR548D1,HTM/LTM,Down,32801,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,21130073
MIR636,HTM/LTM,Down,32892,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,21130073
MIR671,HTM/LTM,Up,33134,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0021,28534939
MIR6823,HTM/LTM,Down,49952,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,29407170
MIR6836,HTM/LTM,Down,50067,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,26323893
MIR6836,HTM/LTM,Down,50067,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,26323893
MIR6873,HTM/LTM,Down,50231,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,26323893
MIR6873,HTM/LTM,Down,50231,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,26323893
MIR7152,HTM/LTM,Down,50257,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,26323893
MIR7152,HTM/LTM,Down,50257,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,26323893
MIR744,HTM/LTM,Up,33658,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21130073
MIR889,HTM/LTM,Up,33651,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,29975934
MIR93,HTM/LTM,Down,31645,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,22180714
MIR96,HTM/LTM,Down,31648,Non Small Cell Lung Cancer,NA,LC021,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,29407170
MIR98,HTM/LTM,Down,31649,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0021,33798550
MIR99A,HTM/LTM,Down,31650,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21785383
MIR99A,HTM/LTM,Down,31650,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,21785383
MIRLET7A1,HTM/LTM,Down,31476,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,26323893
MIRLET7A1,HTM/LTM,Down,31476,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,FACs for CSC marker and SFA followed by Transcriptomics and qRT-PCR,0.24,0.0032,26323893
MIRLET7E,HTM/LTM,Down,31482,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,28534939
MIRLET7F1,HTM/LTM,Down,31483,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,24734907
MIRLET7FI,HTM/LTM,Down,31483,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,24734907
MLH1,HTM/LTM,Up,7127,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0011,27932392
MSH2,HTM/LTM,Up,7325,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0021,27932392
MVD,HTM/LTM,Up,7529,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,25676692
MVD,HTM/LTM,Up,7529,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,25676692
MVD,HTM/LTM,Up,7529,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0042,25676692
NDGG1,HTM/LTM,NA,NA,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25676692
NDGG1,HTM/LTM,NA,NA,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25676692
NDGG1,HTM/LTM,NA,NA,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,25676692
NDRG1,HTM/LTM,Up,7679,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics and qRT-PCR,0.28,0.0064,32503348
NEUROG2,HTM/LTM,Up,13805,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0021,19451087
NFYA,HTM/LTM,Up,7804,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,19190339
NFYA,HTM/LTM,Up,7804,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,19190339
NFYA,HTM/LTM,Up,7804,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,19190339
NLK,HTM/LTM,Up,29858,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,17911267
NOMO1,HTM/LTM,Up,30060,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,23903875
NOMO1,HTM/LTM,Up,30060,Head and Neck Cancer,Squamous Cell Carcinoma,HN12,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,23903875
NOMO1,HTM/LTM,Up,30060,Head and Neck Cancer,Squamous Cell Carcinoma,HN13,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,23903875
NOMO1,HTM/LTM,Up,30060,Head and Neck Cancer,Squamous Cell Carcinoma,HN6,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,23903875
NOTCH2,HTM/LTM,Up,7882,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0117,19190339
NOTCH2,HTM/LTM,Up,7882,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0117,19190339
NOTCH2,HTM/LTM,Up,7882,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0117,19190339
NR4A2,HTM/LTM,Up,7981,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0042,21826669
ODC1,HTM/LTM,Up,8109,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25676692
ODC1,HTM/LTM,Up,8109,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25676692
ODC1,HTM/LTM,Up,8109,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,25676692
PARD1,HTM/LTM,Down,NA,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,27746256
PGK1,HTM/LTM,Up,8896,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0032,27746256
PGK1,HTM/LTM,Up,8896,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0032,27746256
PHB,HTM/LTM,Down,8912,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Proteomics,0.08,0.0032,25081334
PHLDA1,HTM/LTM,Up,8933,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0042,34680485
PIAS2,HTM/LTM,Up,17311,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,17911267
PIK3C2A,HTM/LTM,Up,8971,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,17911267
POLE,HTM/LTM,Up,9177,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0011,27932392
POLL,HTM/LTM,Up,9184,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0011,27932392
POSTN,HTM/LTM,Up,16953,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0042,35053617
PPARD,HTM/LTM,Up,9235,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0021,19451087
PPP3R1,HTM/LTM,Up,9317,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,17911267
PRKAR1A,HTM/LTM,Up,9388,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and RT-PCR,0.24,0.0011,24719318
PTPRE,HTM/LTM,Up,9669,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0032,31666201
RAD51,HTM/LTM,Up,9817,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0032,27932392
RAD51L11,HTM/LTM,Up,NA,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,19190339
RAD51L11,HTM/LTM,Up,NA,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,19190339
RAD51L11,HTM/LTM,Up,NA,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0011,19190339
RAD52,HTM/LTM,Up,9824,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0011,27932392
RFC1,HTM/LTM,Up,9969,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0032,27932392
RHOBTB3,HTM/LTM,Down,18757,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,34680485
S100A8,HTM/LTM,Up,10498,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics and qRT-PCR,0.28,0.0064,32503348
S100A9,HTM/LTM,Up,10499,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by Proteomics and qRT-PCR,0.28,0.0042,32503348
S100B,HTM/LTM,Up,10500,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0021,19451087
S100P,HTM/LTM,Up,10504,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0106,21826669
SCD,HTM/LTM,Up,10571,Gastric Cancer,NA,Primary,NA,SFA followed by Proteomics and Western Blotting,0.52,0.0127,32350414
SFN,HTM/LTM,Up,10773,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0053,21455326
SMAD7,HTM/LTM,Up,6773,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,21826669
SMUG1,HTM/LTM,Up,17148,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0021,27932392
SNAI1,HTM/LTM,Up,11128,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0212,31666201
SNAI1,HTM/LTM,Up,11128,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.28,0.0212,31666201
SNAI2,HTM/LTM,Up,11094,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.28,0.0159,31666201
SOCS2,HTM/LTM,Down,19382,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0053,21826669
SOS1,HTM/LTM,Up,11187,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,17911267
SOS2,HTM/LTM,Up,11188,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics and qRT-PCR,0.24,0.0021,17911267
SOX4,HTM/LTM,Up,11200,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and RT-PCR,0.24,0.0042,24719318
SPARC,HTM/LTM,Up,11219,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0042,31666201
SRSF3,HTM/LTM,Up,10785,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs for CSC marker followed by Proteomics and Western Blotting,0.36,0.0011,22623141
STAT3,HTM/LTM,Up,11364,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs for CSC marker followed by SFA and PCR array assay and qRT-PCR,0.24,0.0223,29352988
SUV39H1,HTM/LTM,NA,11479,Bladder Cancer,NA,Primary,NA,SFA followed by Transcriptomics and qRT-PCR,0.4,0.0011,28765327
SYNJ1,HTM/LTM,Up,11503,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and CFA followed by Transcriptomics and qRT-PCR,0.24,0.0011,17911267
TACSTD2,HTM/LTM,Up,11530,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and RT-PCR,0.24,0.0042,24719318
TEK,HTM/LTM,Up,11724,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker and SP assay followed by Transcriptomics and qRT-PCR,0.24,0.0011,17932721
TGFB1,HTM/LTM,NA,11766,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0138,25676692
TGFB1,HTM/LTM,NA,11766,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0138,25676692
TGFB1,HTM/LTM,NA,11766,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0138,25676692
TGFB2,HTM/LTM,Up,11768,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0074,31666201
TGFBR2,HTM/LTM,Up,11773,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0032,31729259
TGFBR2,HTM/LTM,Up,11773,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics and qPCR,0.24,0.0032,31729259
TGM2,HTM/LTM,Down,11778,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0032,34680485
TMEM45A,HTM/LTM,Up,25480,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by Transcriptomics and qRT-PCR,0.24,0.0053,26351321
TNFRSF19,HTM/LTM,Up,11915,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics ,0.04,0.0021,34680485
TNFRSF8,HTM/LTM,Up,11923,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker and SFA followed by Transcriptomics and RT-PCR,0.24,0.0021,19451087
TOP3A,HTM/LTM,Up,11992,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0011,27932392
TP63,HTM/LTM,Up,15979,Breast Cancer,NA,Primary,NA,FACs for CSC marker and Transcriptomics followed by qRT-PCR  ,0.4,0.0032,35053617
TUBB,HTM/LTM,Up,20778,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0032,21455326
UFD1,HTM/LTM,Up,12520,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,21455326
UGDH,HTM/LTM,Down,12525,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs for CSC marker followed by Transcriptomics and qRT-PCR,0.24,0.0053,34680485
UNG,HTM/LTM,Up,12572,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0032,27932392
VCL,HTM/LTM,Up,12665,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0032,27746256
VDAC2,HTM/LTM,Up,12672,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,34168259
VDAC2,HTM/LTM,Up,12672,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,34168259
VDAC2,HTM/LTM,Up,12672,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,34168259
VDAC2,HTM/LTM,Up,12672,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0011,34168259
VIM,HTM/LTM,Down,12692,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0170,27746256
WNT3A,HTM/LTM,Up,15983,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Transcriptomics and RT-PCR,0.24,0.0021,24719318
XPC,HTM/LTM,Up,12816,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0021,27932392
XRCC6,HTM/LTM,Up,4055,Colon Cancer,Adenocarcinoma,HT-29,NA,Transcriptomics followed by qPCR,0.24,0.0053,27932392
YAP1,HTM/LTM,NA,16262,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by Transcriptomics and RT-PCR and Western Blotting,0.52,0.0117,30397177
YAP1,HTM/LTM,NA,16262,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Transcriptomics and RT-PCR and Western Blotting,0.52,0.0117,30397177
YWHAE,HTM/LTM,Up,12851,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0021,27746256
YWHAZ,HTM/LTM,Up,12855,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Proteomics and Western Blotting,0.36,0.0042,27746256
A2B5,LTM,NA,NA,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting and Sedimentation field flow fractionation(SdFFF) ,0.28,0.0011,31179686
ABCA2,LTM,NA,32,Bladder Cancer,Carcinoma,253JB-V,NA,SP assay followed by RT-PCR,0.2,0.0021,23226356
ABCA2,LTM,NA,32,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by invasion assay and RT-PCR,0.2,0.0021,17510412
ABCA2,LTM,NA,32,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SP assay followed by invasion assay and RT-PCR,0.2,0.0021,17510412
ABCA2,LTM,NA,32,Bladder Cancer,Carcinoma,J-82,NA,SP assay followed by RT-PCR,0.2,0.0021,23226356
ABCA2,LTM,NA,32,Bladder Cancer,Carcinoma,RT-112,NA,SP assay followed by RT-PCR,0.2,0.0021,23226356
ABCA2,LTM,NA,32,Bladder Cancer,Transitional Cell Papilloma,RT-4,NA,SP assay followed by RT-PCR,0.2,0.0021,23226356
ABCA2,LTM,NA,32,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,SK-MES-1,NA,SP assay followed by invasion assay and RT-PCR,0.2,0.0021,17510412
ABCB1,LTM,NA,40,Bladder Cancer,Carcinoma,5637,NA,SFA followed by qRT-PCR,0.2,0.0604,30592142
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and qRT-PCR,0.32,0.0604,34400945
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.32,0.0604,33980809
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.32,0.0604,22900142
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR,0.32,0.0604,22615765
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR,0.32,0.0604,22855139
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SP assay and Tumorigenicity assay,0.32,0.0604,26940223
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by FACs and SFA,0.32,0.0604,26081992
ABCB1,LTM,NA,40,Gastric Cancer,Adenocarcinoma,AGS,NA,Four-dimensional (4D) culture model by a magnetic responsive alginate-based hydrogel to rotating magnets followed by RT-PCR and IF staining,0.44,0.0604,33836517
ABCB1,LTM,NA,40,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Western Blotting,0.28,0.0604,30853342
ABCB1,LTM,NA,40,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by Western Blotting,0.28,0.0604,30853342
ABCB1,LTM,NA,40,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by qRT-PCR,0.28,0.0604,29048549
ABCB1,LTM,NA,40,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.2,0.0604,27380877
ABCB1,LTM,NA,40,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,qRT-PCR followed by SFA and CFA,0.2,0.0604,27380877
ABCB1,LTM,NA,40,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Docetaxel,qRT-PCR followed by SFA and CFA,0.2,0.0604,27380877
ABCB1,LTM,NA,40,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.28,0.0604,30853342
ABCB1,LTM,NA,40,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,Gemcitabine,CFA followed by SFA and qRT-PCR,0.28,0.0604,19598259
ABCB1,LTM,NA,40,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SP assay followed by qRT-PCR,0.28,0.0604,20372854
ABCB1,LTM,NA,40,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SP assay followed by qRT-PCR,0.28,0.0604,20372854
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA and qRT-PCR,0.2,0.0604,26351321
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.28,0.0604,33980809
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Carcinoma,H1299,Docetaxel,RT-PCR,0.28,0.0604,28959367
ABCB1,LTM,NA,40,Small Cell Lung Cancer,Carcinoma,H1417,NA,FACs followed by CFA,0.12,0.0604,17327908
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1781,Afatinib,qRT-PCR followed by SFA,0.2,0.0604,29532558
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay followed by SFA and RT-PCR,0.2,0.0604,28440478
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,Afatinib,qRT-PCR followed by SFA,0.2,0.0604,29532558
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SP assay followed by invasion assay and RT-PCR,0.2,0.0604,17510412
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,SP assay followed by invasion assay and RT-PCR,0.2,0.0604,17510412
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0604,27706681
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SP assay followed by invasion assay and RT-PCR,0.48,0.0604,17510412
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SP assay followed by RT-PCR,0.48,0.0604,22855139
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Adenocarcinoma,HCC4006,Afatinib,Western Blotting and CFA,0.28,0.0604,26202045
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Adenocarcinoma,HCC4006,Docetaxel,RT-PCR,0.28,0.0604,28959367
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Afatinib,Western Blotting and CFA,0.28,0.0604,26202045
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Docetaxel,RT-PCR,0.28,0.0604,28959367
ABCB1,LTM,NA,40,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR,0.2,0.0604,26206183
ABCB1,LTM,NA,40,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR,0.2,0.0604,29902974
ABCB1,LTM,NA,40,Head and Neck Cancer,Carcinoma,HEp-2,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.2,0.0604,27380877
ABCB1,LTM,NA,40,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,qRT-PCR followed by SFA and CFA,0.2,0.0604,27380877
ABCB1,LTM,NA,40,Head and Neck Cancer,Carcinoma,HEp-2,Docetaxel,qRT-PCR followed by SFA and CFA,0.2,0.0604,27380877
ABCB1,LTM,NA,40,Pancreatic Cancer,Adenocarcinoma,HPAC,Gemcitabine,CFA followed by SFA and qRT-PCR,0.2,0.0604,19598259
ABCB1,LTM,NA,40,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,SFA followed by Western Blotting,0.28,0.0604,30853342
ABCB1,LTM,NA,40,Bladder Cancer,Carcinoma,HT-1376,NA,SFA followed by qRT-PCR,0.2,0.0604,26452033
ABCB1,LTM,NA,40,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR,0.2,0.0604,26206183
ABCB1,LTM,NA,40,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR,0.2,0.0604,29902974
ABCB1,LTM,NA,40,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by RT-PCR,0.2,0.0604,30209760
ABCB1,LTM,NA,40,Bladder Cancer,Carcinoma,J-82,Cisplatin,RT-PCR,0.2,0.0604,26647959
ABCB1,LTM,NA,40,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),qRT-PCR followed by Western Blotting,0.48,0.0604,28627611
ABCB1,LTM,NA,40,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),qRT-PCR followed by Western Blotting and SFA,0.48,0.0604,29956726
ABCB1,LTM,NA,40,Dukes Type B Colon Cancer,Adenocarcinoma,LS180,NA,RT-PCR,0.2,0.0604,29902974
ABCB1,LTM,NA,40,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,qRT-PCR followed by SFA and Western Blotting,0.48,0.0604,29050299
ABCB1,LTM,NA,40,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.0604,31604679
ABCB1,LTM,NA,40,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,Western Blotting,0.48,0.0604,29028589
ABCB1,LTM,NA,40,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,Western Blotting,0.48,0.0604,29635751
ABCB1,LTM,NA,40,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Paclitaxel,qRT-PCR,0.48,0.0604,31628941
ABCB1,LTM,NA,40,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.48,0.0604,30188754
ABCB1,LTM,NA,40,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0604,31756533
ABCB1,LTM,NA,40,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,IF staining,0.28,0.0604,35084278
ABCB1,LTM,NA,40,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR,0.28,0.0604,29036915
ABCB1,LTM,NA,40,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Paclitaxel,FACs and SP assay followed by SFA and qRT-PCR,0.32,0.0604,30572639
ABCB1,LTM,NA,40,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.32,0.0604,31604679
ABCB1,LTM,NA,40,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.32,0.0604,31756533
ABCB1,LTM,NA,40,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.2,0.0604,33110235
ABCB1,LTM,NA,40,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.2,0.0604,31508487
ABCB1,LTM,NA,40,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by qRT-PCR,0.2,0.0604,18240351
ABCB1,LTM,NA,40,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by RT-PCR,0.2,0.0604,18240351
ABCB1,LTM,NA,40,Pancreatic Cancer,Carcinoma,PANC-1,Cisplatin,SFA followed by FACs,0.2,0.0604,34123574
ABCB1,LTM,NA,40,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by FACs,0.2,0.0604,34123574
ABCB1,LTM,NA,40,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR,0.2,0.0604,31508487
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR,0.2,0.0604,34771484
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR,0.2,0.0604,34771484
ABCB1,LTM,NA,40,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,Four-dimensional (4D) culture model by a magnetic responsive alginate-based hydrogel to rotating magnets followed by RT-PCR and IF staining,0.44,0.0604,33836517
ABCB1,LTM,NA,40,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,SK-MES-1,NA,SP assay followed by invasion assay and RT-PCR,0.2,0.0604,17510412
ABCB1,LTM,NA,40,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR,0.2,0.0604,31508487
ABCB1,LTM,NA,40,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by qRT-PCR,0.2,0.0604,20372854
ABCB1,LTM,NA,40,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by qRT-PCR,0.2,0.0604,20372854
ABCB1,LTM,NA,40,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by qRT-PCR and Western Blotting,0.48,0.0604,24926880
ABCB1,LTM,NA,40,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,SP assay followed by CFA and RT-PCR,0.2,0.0604,18787416
ABCB1,LTM,NA,40,Bladder Cancer,Carcinoma,T24,Cisplatin,RT-PCR,0.2,0.0604,26647959
ABCB1,LTM,NA,40,Bladder Cancer,Carcinoma,T24,Cisplatin,RT-PCR,0.2,0.0604,27474203
ABCB1,LTM,NA,40,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.2,0.0604,30592142
ABCB1,LTM,NA,40,Bladder Cancer,Carcinoma,T24,NA,SP assay followed by RT-PCR and SFA,0.2,0.0604,25020236
ABCB1,LTM,NA,40,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR,0.2,0.0604,26452033
ABCB1,LTM,NA,40,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SP assay followed by RT-PCR and SFA,0.2,0.0604,25020236
ABCB1,LTM,NA,40,Colon Cancer,NA,Primary,NA,SFA and qPCR,0.28,0.0604,24944672
ABCB1,LTM,NA,40,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.28,0.0604,19450560
ABCB1,LTM,NA,40,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by RT-PCR,0.28,0.0604,21292542
ABCB1,LTM,NA,40,Hepatic Cancer,Carcinoma,Primary,NA,SP assay followed by IHC staining,0.32,0.0604,26592953
ABCB1,LTM,NA,40,Lung Cancer,NA,Primary,NA,IHC staining followed by FACs,0.52,0.0604,19536353
ABCB1,LTM,NA,40,Pancreatic Cancer,NA,Primary,NA,IF staining,0.32,0.0604,33110235
ABCB1,LTM,NA,40,Pancreatic Cancer,Adenocarcinoma,Primary,NA,SP assay followed by IHC staining,0.32,0.0604,24069258
ABCB5,LTM,NA,46,Skin Cancer,NA,A-375,NA,SFA followed by Western Blotting,0.28,0.0085,26693692
ABCB5,LTM,NA,46,Glioblastoma Multiforme,NA,GBM8401,NA,SP assay and SFA followed by RT-PCR,0.2,0.0085,25359730
ABCB5,LTM,NA,46,Skin Cancer,NA,HBL,NA,Label retainig using GFP tag and SFA followed by FACs,0.12,0.0085,25223735
ABCB5,LTM,NA,46,Hepatic Cancer,Carcinoma,Hep3B,NA,FACs followed by CFA,0.12,0.0085,22194816
ABCB5,LTM,NA,46,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by CFA,0.12,0.0085,22194816
ABCB5,LTM,NA,46,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by FACs,0.12,0.0085,34123574
ABCB5,LTM,NA,46,Skin Cancer,NA,SK-MEL-28,NA,Label retainig using GFP tag and SFA followed by FACs,0.12,0.0085,25223735
ABCB5,LTM,NA,46,Skin Cancer,NA,WM793,NA,SFA followed by Western Blotting,0.28,0.0085,26693692
ABCB5,LTM,NA,46,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by RT-PCR,0.28,0.0085,21292542
ABCB5,LTM,NA,46,Hepatic Cancer,NA,Primary,NA,FACs,0.2,0.0085,26942873
ABCB5,LTM,NA,46,Skin Cancer,NA,Primary,NA,IHC staining and FACs,0.52,0.0085,23146306
ABCC1,LTM,NA,51,Bladder Cancer,Carcinoma,253JB-V,NA,SP assay followed by RT-PCR,0.2,0.0212,23226356
ABCC1,LTM,NA,51,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.28,0.0212,33980809
ABCC1,LTM,NA,51,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.28,0.0212,25683371
ABCC1,LTM,NA,51,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,Gemcitabine,CFA followed by SFA and qRT-PCR,0.2,0.0212,19598259
ABCC1,LTM,NA,51,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SP assay followed by qRT-PCR,0.2,0.0212,20372854
ABCC1,LTM,NA,51,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SP assay followed by qRT-PCR,0.2,0.0212,20372854
ABCC1,LTM,NA,51,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.28,0.0212,33980809
ABCC1,LTM,NA,51,Non Small Cell Lung Cancer,Adenocarcinoma,H1658,Erlotinib,RT-PCR followed by CFA and SFA,0.2,0.0212,31069016
ABCC1,LTM,NA,51,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0212,27706681
ABCC1,LTM,NA,51,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR,0.2,0.0212,26206183
ABCC1,LTM,NA,51,Hepatic Cancer,Carcinoma,Hep3B,NA,FACs followed by CFA,0.12,0.0212,22194816
ABCC1,LTM,NA,51,Pancreatic Cancer,Adenocarcinoma,HPAC,Gemcitabine,CFA followed by SFA and qRT-PCR,0.2,0.0212,19598259
ABCC1,LTM,NA,51,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR,0.2,0.0212,26206183
ABCC1,LTM,NA,51,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by CFA,0.12,0.0212,22194816
ABCC1,LTM,NA,51,Bladder Cancer,Carcinoma,J-82,Cisplatin,RT-PCR,0.2,0.0212,26647959
ABCC1,LTM,NA,51,Bladder Cancer,Carcinoma,J-82,NA,SP assay followed by RT-PCR,0.2,0.0212,23226356
ABCC1,LTM,NA,51,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,Western Blotting,0.28,0.0212,29028589
ABCC1,LTM,NA,51,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.28,0.0212,30175027
ABCC1,LTM,NA,51,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0212,34451892
ABCC1,LTM,NA,51,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR,0.28,0.0212,29036915
ABCC1,LTM,NA,51,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.2,0.0212,28893318
ABCC1,LTM,NA,51,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by RT-PCR,0.2,0.0212,24573253
ABCC1,LTM,NA,51,Pancreatic Cancer,Carcinoma,PANC-1,Cisplatin,SFA followed by FACs,0.12,0.0212,34123574
ABCC1,LTM,NA,51,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by FACs,0.12,0.0212,34123574
ABCC1,LTM,NA,51,Bladder Cancer,Carcinoma,RT-112,NA,SP assay followed by RT-PCR,0.2,0.0212,23226356
ABCC1,LTM,NA,51,Bladder Cancer,Transitional Cell Papilloma,RT-4,NA,SP assay followed by RT-PCR,0.2,0.0212,23226356
ABCC1,LTM,NA,51,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by qRT-PCR,0.2,0.0212,20372854
ABCC1,LTM,NA,51,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by qRT-PCR,0.2,0.0212,20372854
ABCC1,LTM,NA,51,Bladder Cancer,Carcinoma,T24,Cisplatin,RT-PCR,0.2,0.0212,26647959
ABCC1,LTM,NA,51,Glioblastoma Multiforme,NA,Primary,NA,SFA followed by IHC staining,0.32,0.0212,22798502
ABCC1,LTM,NA,51,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.28,0.0212,19450560
ABCC2,LTM,NA,53,Hepatic Cancer,Carcinoma,Hep-G2,NA,SFA followed by qRT-PCR,0.2,0.0106,28554132
ABCC2,LTM,NA,53,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.2,0.0106,30175027
ABCC2,LTM,NA,53,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.2,0.0106,28893318
ABCC2,LTM,NA,53,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-26,NA,qRT-PCR followed by SP assay,0.2,0.0106,24913304
ABCC2,LTM,NA,53,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.28,0.0106,22426199
ABCC2,LTM,NA,53,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by RT-PCR,0.28,0.0106,23876835
ABCC2,LTM,NA,53,Hepatic Cancer,NA,Primary,NA,IHC staining followed by qRT-PCR,0.6,0.0106,28554132
ABCC3,LTM,NA,54,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.2,0.0042,28893318
ABCC4,LTM,NA,55,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by qRT-PCR,0.2,0.0042,25104726
ABCC4,LTM,NA,55,Head and Neck Cancer,Carcinoma,KB,NA,SFA followed by qRT-PCR,0.2,0.0042,25104726
ABCC4,LTM,NA,55,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.2,0.0042,28893318
ABCC5,LTM,NA,56,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.2,0.0053,28893318
ABCC5,LTM,NA,56,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by RT-PCR,0.2,0.0053,24573253
ABCC5,LTM,NA,56,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.28,0.0053,22426199
ABCC6,LTM,NA,57,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.28,0.0011,22426199
ABCF1,LTM,NA,70,Hepatic Cancer,Carcinoma,Hep3B,NA,Western Blotting followed by CFA,0.28,0.0011,31100412
ABCF1,LTM,NA,70,Hepatic Cancer,Carcinoma,Hep-G2,NA,Western Blotting followed by CFA,0.28,0.0011,31100412
ABCF1,LTM,NA,70,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting followed by CFA,0.28,0.0011,31100412
ABCG2,LTM,NA,74,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Western Blotting,0.28,0.1739,29559853
ABCG2,LTM,NA,74,Bladder Cancer,Carcinoma,253JB-V,NA,SP assay followed by RT-PCR,0.2,0.1739,23226356
ABCG2,LTM,NA,74,Skin Cancer,NA,A-375,NA,FACs,0.12,0.1739,26208390
ABCG2,LTM,NA,74,Skin Cancer,NA,A-375,NA,FACs,0.12,0.1739,27476721
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.1739,28861158
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,Western Blotting and qRT-PCR,0.48,0.1739,25200103
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting and SP assay followed by qRT-PCR,0.48,0.1739,23009336
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,MACs followed by Western Blotting,0.48,0.1739,31819528
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,5-fluorouracil,FACs followed by qRT-PCR,0.48,0.1739,22416214
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,Methotrexate,FACs followed by qRT-PCR,0.48,0.1739,22416214
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,FACs followed by RT-PCR,0.48,0.1739,24356998
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SP assay followed by FACs and RT-PCR,0.48,0.1739,24009622
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by FACs and RT-PCR,0.48,0.1739,25988710
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by SFA and Western Blotting,0.48,0.1739,33707423
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.1739,33980809
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay and Western Blotting,0.48,0.1739,31871777
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,IF staining followed by SP assay,0.48,0.1739,25810011
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by IHC staining and Tumorigenicity assay,0.48,0.1739,29552128
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR,0.48,0.1739,33068069
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by SFA and SP assay,0.48,0.1739,26468775
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA,0.48,0.1739,31368411
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.1739,22900142
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by qRT-PCR,0.48,0.1739,24961511
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by RT-PCR,0.48,0.1739,24961511
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.48,0.1739,28951614
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.48,0.1739,29414668
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by qRT-PCR,0.48,0.1739,27911857
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR,0.48,0.1739,21347385
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR,0.48,0.1739,22615765
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR,0.48,0.1739,22855139
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by FACs and SFA,0.48,0.1739,26081992
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SP assay followed by FACs and Tumorigenicity assay,0.48,0.1739,22844424
ABCG2,LTM,NA,74,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qPCR,0.2,0.1739,29559846
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Western Blotting,0.28,0.1739,30853342
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by Western Blotting,0.28,0.1739,30853342
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by IHC staining,0.24,0.1739,23903875
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by qRT-PCR,0.24,0.1739,24112466
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.24,0.1739,27380877
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,qRT-PCR followed by SFA and CFA,0.24,0.1739,27380877
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Docetaxel,qRT-PCR followed by SFA and CFA,0.24,0.1739,27380877
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by qRT-PCR,0.2,0.1739,30819221
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by SFA and qRT-PCR,0.2,0.1739,30466404
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,Capan-2,NA,SFA followed by Western Blotting,0.28,0.1739,33934523
ABCG2,LTM,NA,74,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SP assay followed by qRT-PCR and Western Blotting,0.48,0.1739,20372854
ABCG2,LTM,NA,74,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SP assay followed by Western Blotting and qRT-PCR,0.48,0.1739,20372854
ABCG2,LTM,NA,74,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.48,0.1739,30853342
ABCG2,LTM,NA,74,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,Gemcitabine,CFA followed by SFA and qRT-PCR,0.48,0.1739,19598259
ABCG2,LTM,NA,74,Skin Cancer,NA,D10,NA,FACs followed by SFA,0.12,0.1739,26208390
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by qRT-PCR,0.2,0.1739,26351321
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Cisplatin,SP assay followed by Western Blotting,0.28,0.1739,29228308
ABCG2,LTM,NA,74,Glioblastoma Multiforme,NA,GBM8401,NA,SP assay and SFA followed by RT-PCR,0.2,0.1739,25359730
ABCG2,LTM,NA,74,Lung Cancer,Adenocarcinoma,GLC-82,NA,SP assay followed by Tumorigenicity assay and FACs,0.12,0.1739,28920265
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,Gun-1,NA,SFA followed by IF staining and FACs,0.36,0.1739,19027347
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H1299,Cisplatin,MACs and IF staining followed by qRT-PCR,0.56,0.1739,31819528
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,MACs followed by qPCR,0.56,0.1739,24008862
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.56,0.1739,33980809
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SP assay and Western Blotting,0.56,0.1739,31871777
ABCG2,LTM,NA,74,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay followed by FACs and Tumorigenicity assay,0.12,0.1739,20424609
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,SP assay and SFA followed by Western Blotting and qRT-PCR,0.48,0.1739,23009336
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Adenocarcinoma,H1658,Erlotinib,RT-PCR followed by CFA and SFA,0.2,0.1739,31069016
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H1703,NA,qRT-PCR followed by SFA and SP assay,0.2,0.1739,26468775
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay and SFA followed by Western Blotting and qRT-PCR,0.48,0.1739,23009336
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay followed by SFA and RT-PCR,0.48,0.1739,28440478
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SP assay followed by invasion assay and RT-PCR,0.2,0.1739,17510412
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Adenocarcinoma,H23,Cisplatin,SFA followed by Western Blotting,0.28,0.1739,26872057
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,SP assay followed by invasion assay and RT-PCR,0.28,0.1739,17510412
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Western Blotting,0.28,0.1739,31100681
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Western Blotting and SP assay,0.28,0.1739,26911281
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,SFA followed by RT-PCR,0.2,0.1739,29414668
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,SP assay followed by invasion assay and RT-PCR,0.2,0.1739,17510412
ABCG2,LTM,NA,74,Small Cell Lung Cancer,Carcinoma,H446,Cisplatin,RT-PCR followed by FACs,0.32,0.1739,21174061
ABCG2,LTM,NA,74,Small Cell Lung Cancer,Carcinoma,H446,Taxinol,RT-PCR followed by FACs,0.32,0.1739,21174061
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.1739,28861158
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SP assay followed by Western Blotting and qRT-PCR,0.48,0.1739,27911857
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,Western Blotting and qRT-PCR,0.48,0.1739,25200103
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,Ciprofloxacin,SFA followed by Western Blotting,0.48,0.1739,26947806
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,0.1739,28259926
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,0.1739,31100681
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting and SP assay,0.48,0.1739,26911281
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR,0.48,0.1739,33068069
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by qRT-PCR and Tumorigenicity assay,0.48,0.1739,24961511
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by RT-PCR and Tumorigenicity assay,0.48,0.1739,24961511
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SP assay followed by invasion assay and RT-PCR,0.48,0.1739,17510412
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SP assay followed by RT-PCR,0.48,0.1739,22855139
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SP assay followed by Tumorigenicity assay and RT-PCR,0.48,0.1739,22428030
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by SP assay and FACs,0.48,0.1739,26387547
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,FACs for CSC marker followed by SFA and Western Blotting,0.28,0.1739,33707423
ABCG2,LTM,NA,74,Hepatic Cancer,NA,HAK-1B,NA,SP assay followed by qRT-PCR,0.2,0.1739,24325739
ABCG2,LTM,NA,74,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.1739,35155201
ABCG2,LTM,NA,74,Colon Cancer,Carcinoma,HCT116,Oxaliplatin,SFA followed by Western Blotting,0.48,0.1739,24330852
ABCG2,LTM,NA,74,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil+Oxaliplatin,Western Blotting followed by SFA,0.48,0.1739,21161336
ABCG2,LTM,NA,74,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR,0.48,0.1739,26206183
ABCG2,LTM,NA,74,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qPCR,0.48,0.1739,28825721
ABCG2,LTM,NA,74,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by RT-PCR,0.48,0.1739,21750907
ABCG2,LTM,NA,74,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SFA followed by Western Blotting,0.28,0.1739,27997180
ABCG2,LTM,NA,74,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,SP assay followed by Western Blotting,0.28,0.1739,29228308
ABCG2,LTM,NA,74,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by qRT-PCR,0.28,0.1739,25104726
ABCG2,LTM,NA,74,Head and Neck Cancer,Carcinoma,HEp-2,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.28,0.1739,27380877
ABCG2,LTM,NA,74,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,qRT-PCR followed by SFA and CFA,0.28,0.1739,27380877
ABCG2,LTM,NA,74,Head and Neck Cancer,Carcinoma,HEp-2,Docetaxel,qRT-PCR followed by SFA and CFA,0.28,0.1739,27380877
ABCG2,LTM,NA,74,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by qPCR,0.2,0.1739,29559846
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,HPAC,Gemcitabine,CFA followed by SFA and qRT-PCR,0.2,0.1739,19598259
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,SFA followed by Western Blotting,0.28,0.1739,30853342
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,FACs,0.28,0.1739,22948659
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-2,NA,FACs followed by Western Blotting and qRT-PCR,0.6,0.1739,23992541
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-4,NA,SP assay followed by qRT-PCR and IHC staining ,0.44,0.1739,20651344
ABCG2,LTM,NA,74,Bladder Cancer,Carcinoma,HT-1376,NA,SFA followed by qRT-PCR,0.2,0.1739,26452033
ABCG2,LTM,NA,74,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,qRT-PCR,0.2,0.1739,30772447
ABCG2,LTM,NA,74,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR,0.2,0.1739,26206183
ABCG2,LTM,NA,74,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.2,0.1739,21130073
ABCG2,LTM,NA,74,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and qRT-PCR,0.2,0.1739,27556511
ABCG2,LTM,NA,74,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qPCR,0.2,0.1739,28825721
ABCG2,LTM,NA,74,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.2,0.1739,27556511
ABCG2,LTM,NA,74,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.1739,33825221
ABCG2,LTM,NA,74,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and qRT-PCR,0.48,0.1739,21618577
ABCG2,LTM,NA,74,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by qRT-PCR and SFA,0.48,0.1739,29792038
ABCG2,LTM,NA,74,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by FACs,0.48,0.1739,25997710
ABCG2,LTM,NA,74,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by qRT-PCR,0.2,0.1739,35116788
ABCG2,LTM,NA,74,Bladder Cancer,Carcinoma,J-82,NA,SP assay followed by RT-PCR,0.2,0.1739,23226356
ABCG2,LTM,NA,74,Head and Neck Cancer,Carcinoma,KB,NA,SFA followed by qRT-PCR,0.2,0.1739,25104726
ABCG2,LTM,NA,74,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.1739,21618577
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,KP-1NL,NA,SP assay followed by qRT-PCR,0.2,0.1739,19296540
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,KUMA-1,NA,FACs followed by Western Blotting and qRT-PCR,0.6,0.1739,23992541
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,Cisplatin,FACs,0.12,0.1739,34123574
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,Gemcitabine,FACs,0.12,0.1739,34123574
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,Gemcitabine,SP assay followed by Tumorigenicity assay and FACs,0.12,0.1739,24950733
ABCG2,LTM,NA,74,Hepatic Cancer,Carcinoma,Mahlavu,NA,SP assay followed by Western Blotting,0.28,0.1739,29792038
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.1739,34249423
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.1739,28935760
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.1739,31604679
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.1739,31695364
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by Western Blotting and SFA ,0.48,0.1739,30274780
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,Western Blotting,0.48,0.1739,29028589
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by IF staining,0.48,0.1739,34718182
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.48,0.1739,34486791
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR,0.48,0.1739,31762819
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.48,0.1739,29982992
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.48,0.1739,30175027
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.48,0.1739,30188754
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by FACs,0.48,0.1739,18951337
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by SFA and FACs,0.48,0.1739,17881900
ABCG2,LTM,NA,74,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.1739,34249423
ABCG2,LTM,NA,74,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR followed by Western Blotting,0.48,0.1739,28760736
ABCG2,LTM,NA,74,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.1739,34789263
ABCG2,LTM,NA,74,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.48,0.1739,34770867
ABCG2,LTM,NA,74,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.1739,31756533
ABCG2,LTM,NA,74,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qPCR followed by SFA,0.48,0.1739,29907642
ABCG2,LTM,NA,74,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.1739,29103027
ABCG2,LTM,NA,74,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Paclitaxel,FACs and SP assay followed by SFA and qRT-PCR,0.32,0.1739,30572639
ABCG2,LTM,NA,74,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.32,0.1739,34789263
ABCG2,LTM,NA,74,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Doxorubicin,SFA followed by Western Blotting,0.32,0.1739,29750424
ABCG2,LTM,NA,74,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.32,0.1739,31604679
ABCG2,LTM,NA,74,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-705,NA,SFA followed by Western Blotting,0.28,0.1739,31756533
ABCG2,LTM,NA,74,Skin Cancer,NA,Me67,NA,FACs,0.12,0.1739,26208390
ABCG2,LTM,NA,74,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.2,0.1739,28893318
ABCG2,LTM,NA,74,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by RT-PCR,0.2,0.1739,24573253
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.2,0.1739,33110235
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,qRT-PCR,0.2,0.1739,23073476
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Cisplatin,SFA followed by FACs,0.2,0.1739,34123574
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by FACs,0.2,0.1739,34123574
ABCG2,LTM,NA,74,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR,0.2,0.1739,25081334
ABCG2,LTM,NA,74,Skin Cancer,NA,NA8-MEL,NA,FACs,0.12,0.1739,26208390
ABCG2,LTM,NA,74,Gastric Cancer,Carcinoma,NCI-N88,5-Fluorouracil,SFA followed by FACs and qRT-PCR,0.32,0.1739,28847472
ABCG2,LTM,NA,74,Gastric Cancer,Adenocarcinoma,OCUM-12,NA,SP assay followed by qRT-PCR,0.2,0.1739,34667215
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by qRT-PCR and Western Blotting,0.48,0.1739,24040121
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,0.1739,33934523
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,0.1739,22923052
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting followed by SFA,0.48,0.1739,30819221
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.48,0.1739,26335012
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.48,0.1739,31508487
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by qRT-PCR,0.48,0.1739,18240351
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by qRT-PCR,0.48,0.1739,19296540
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by RT-PCR,0.48,0.1739,18240351
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,PANC-1,Cisplatin,SFA followed by FACs,0.48,0.1739,34123574
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by FACs,0.48,0.1739,34123574
ABCG2,LTM,NA,74,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,0.1739,22948659
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR,0.2,0.1739,31508487
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR,0.2,0.1739,34771484
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR,0.2,0.1739,34771484
ABCG2,LTM,NA,74,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SFA followed by qRT-PCR,0.2,0.1739,22773665
ABCG2,LTM,NA,74,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SP assay followed by FACs and SFA,0.2,0.1739,25997710
ABCG2,LTM,NA,74,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SP assay followed by FACs,0.2,0.1739,25997710
ABCG2,LTM,NA,74,Bladder Cancer,Carcinoma,RT-112,NA,SP assay followed by RT-PCR,0.2,0.1739,23226356
ABCG2,LTM,NA,74,Bladder Cancer,Transitional Cell Papilloma,RT-4,NA,SFA followed by qRT-PCR,0.2,0.1739,35116788
ABCG2,LTM,NA,74,Bladder Cancer,Transitional Cell Papilloma,RT-4,NA,SP assay followed by RT-PCR,0.2,0.1739,23226356
ABCG2,LTM,NA,74,Small Cell Lung Cancer,Carcinoma,SBC-5,NA,SFA followed by RT-PCR,0.2,0.1739,28248963
ABCG2,LTM,NA,74,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by Western Blotting,0.28,0.1739,18083101
ABCG2,LTM,NA,74,Hepatic Cancer,Adenocarcinoma,SK-Hep-1,NA,SP assay followed by Western Blotting,0.28,0.1739,29792038
ABCG2,LTM,NA,74,Skin Cancer,NA,SK-MEL-1,NA,FACs,0.12,0.1739,26208390
ABCG2,LTM,NA,74,Skin Cancer,NA,SK-MEL-1,NA,FACs,0.12,0.1739,27476721
ABCG2,LTM,NA,74,Skin Cancer,NA,SK-MEL-28,NA,FACs,0.12,0.1739,27476721
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,SK-MES-1,NA,SP assay followed by invasion assay and RT-PCR,0.2,0.1739,17510412
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SP assay followed by RT-PCR and Tumorigenicity assay,0.2,0.1739,22862169
ABCG2,LTM,NA,74,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by RT-PCR,0.2,0.1739,21455326
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by qRT-PCR and Western Blotting,0.48,0.1739,20372854
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting and qRT-PCR,0.48,0.1739,20372854
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR,0.48,0.1739,31508487
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by qRT-PCR,0.48,0.1739,30819221
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by SFA and qRT-PCR,0.48,0.1739,30466404
ABCG2,LTM,NA,74,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by qRT-PCR and Western Blotting,0.48,0.1739,24450541
ABCG2,LTM,NA,74,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA and qRT-PCR,0.48,0.1739,29693155
ABCG2,LTM,NA,74,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.48,0.1739,28212529
ABCG2,LTM,NA,74,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.48,0.1739,29805588
ABCG2,LTM,NA,74,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs followed by SFA,0.12,0.1739,29805588
ABCG2,LTM,NA,74,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,SP assay followed by CFA and RT-PCR,0.2,0.1739,18787416
ABCG2,LTM,NA,74,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,SP assay followed by RT-PCR and SFA,0.2,0.1739,25031712
ABCG2,LTM,NA,74,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Western Blotting,0.28,0.1739,29559853
ABCG2,LTM,NA,74,Bladder Cancer,Carcinoma,T24,Cisplatin,RT-PCR,0.28,0.1739,27474203
ABCG2,LTM,NA,74,Bladder Cancer,Carcinoma,T24,NA,SP assay followed by CFA and RT-PCR,0.28,0.1739,19589244
ABCG2,LTM,NA,74,Bladder Cancer,Carcinoma,T24,NA,SP assay followed by RT-PCR,0.28,0.1739,24337040
ABCG2,LTM,NA,74,Bladder Cancer,Carcinoma,T24,NA,SP assay followed by RT-PCR and SFA,0.28,0.1739,25020236
ABCG2,LTM,NA,74,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Western Blotting,0.28,0.1739,28935760
ABCG2,LTM,NA,74,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR,0.2,0.1739,19232461
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-10B,NA,SP assay and SFA followed by Western Blotting and qRT-PCR,0.48,0.1739,21344428
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-46,NA,SP assay followed by qRT-PCR,0.2,0.1739,25379016
ABCG2,LTM,NA,74,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,Cisplatin,qRT-PCR,0.2,0.1739,31239709
ABCG2,LTM,NA,74,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR,0.2,0.1739,26452033
ABCG2,LTM,NA,74,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SP assay followed by RT-PCR and SFA,0.2,0.1739,25020236
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-26,NA,qRT-PCR followed by SP assay,0.2,0.1739,24913304
ABCG2,LTM,NA,74,Colon Cancer,Adenocarcinoma,WIDR,NA,SFA followed by RT-PCR,0.2,0.1739,25625841
ABCG2,LTM,NA,74,Skin Cancer,NA,WM115,NA,FACs,0.12,0.1739,26208390
ABCG2,LTM,NA,74,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.1739,21618577
ABCG2,LTM,NA,74,Breast Cancer,NA,Primary,Chemotherapy,SFA followed by Western Blotting,0.36,0.1739,28835684
ABCG2,LTM,NA,74,Colon Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.36,0.1739,29110645
ABCG2,LTM,NA,74,Colon Cancer,Adenocarcinoma,Primary,NA,SP assay followed by SFA and Western Blotting,0.36,0.1739,25997915
ABCG2,LTM,NA,74,Colon Cancer,NA,Primary,NA,IHC staining,0.36,0.1739,31186779
ABCG2,LTM,NA,74,Colon Cancer,NA,Primary,NA,IHC staining,0.36,0.1739,31516883
ABCG2,LTM,NA,74,Colon Cancer,NA,Primary,NA,qRT-PCR,0.36,0.1739,24492635
ABCG2,LTM,NA,74,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.1739,28404967
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.28,0.1739,19450560
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by RT-PCR,0.28,0.1739,21292542
ABCG2,LTM,NA,74,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by RT-PCR,0.28,0.1739,23876835
ABCG2,LTM,NA,74,Hepatic Cancer,Carcinoma,Primary,NA,SP assay followed by IHC staining,0.32,0.1739,26592953
ABCG2,LTM,NA,74,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay and Western Blotting followed by RT-PCR and SFA,0.64,0.1739,26416062
ABCG2,LTM,NA,74,Lung Cancer,NA,Primary,NA,FACs followed by SFA,0.64,0.1739,34929442
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,MACs followed by FACs and Migration assay,0.4,0.1739,18612434
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,MACs followed by FACs and Migration assay,0.4,0.1739,18612434
ABCG2,LTM,NA,74,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.4,0.1739,22199321
ABCG2,LTM,NA,74,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.32,0.1739,21922151
ABCG2,LTM,NA,74,Pancreatic Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.32,0.1739,26609473
ABCG2,LTM,NA,74,Pancreatic Cancer,NA,Primary,NA,FACs,0.32,0.1739,23029396
ABCG2,LTM,NA,74,Skin Cancer,NA,Primary,NA,IHC staining,0.32,0.1739,27870003
ABCG2,LTM,NA,74,Skin Cancer,NA,Primary,NA,FACs,0.32,0.1739,21203549
ABCG2,LTM,NA,74,Skin Cancer,NA,Primary,NA,SFA followed by FACs,0.32,0.1739,20236249
ABCG2-,LTM,NA,74,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by qRT-PCR,0.32,0.0011,29444383
ABCG5,LTM,NA,13886,Skin Cancer,NA,A-375,NA,FACs,0.12,0.0021,27476721
ABCG5,LTM,NA,13886,Skin Cancer,NA,SK-MEL-1,NA,FACs,0.12,0.0021,27476721
ABCG5,LTM,NA,13886,Skin Cancer,NA,SK-MEL-28,NA,FACs,0.12,0.0021,27476721
ABCG5,LTM,NA,13886,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.32,0.0021,24346092
ACBD3,LTM,NA,15453,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,RT-PCR and Western Blotting followed by SP assay and SFA,0.48,0.0032,29307786
ACBD3,LTM,NA,15453,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,RT-PCR and Western Blotting followed by SP assay and SFA,0.48,0.0032,29307786
ACTN4,LTM,NA,166,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs and RT-PCR,0.32,0.0074,29197410
ACVR1,LTM,NA,171,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by qRT-PCR,0.2,0.0011,30819221
ACVR1,LTM,NA,171,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting followed by SFA,0.28,0.0011,30819221
ACVR1,LTM,NA,171,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by qRT-PCR,0.2,0.0011,30819221
ADORA2B,LTM,NA,264,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and qRT-PCR followed by SFA,0.48,0.0042,29218545
ADORA2B,LTM,NA,264,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and FACs,0.48,0.0042,30242135
ADORA2B,LTM,NA,264,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and qRT-PCR followed by SFA,0.48,0.0042,29218545
ADORA2B,LTM,NA,264,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.0042,35401817
ADORA2B,LTM,NA,264,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by qRT-PCR and FACs,0.32,0.0042,30242135
ADORA2B,LTM,NA,264,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by Western Blotting,0.28,0.0042,35401817
AFF4,LTM,NA,17869,Bladder Cancer,Carcinoma,5637,NA,qRT-PCR followed by Western Blotting,0.48,0.0032,32676121
AFF4,LTM,NA,17869,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,qRT-PCR followed by Western Blotting,0.48,0.0032,32676121
AFP,LTM,NA,317,Hepatic Cancer,NA,Primary,NA,SP assay followed by qRT-PCR and SFA,0.28,0.0021,23104270
AKR1C1,LTM,NA,384,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0085,35155201
AKT1,LTM,NA,391,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Western Blotting,0.28,0.0074,29088759
AKT1,LTM,NA,391,Colon Cancer,Carcinoma,HCT116,NA,SFA and Western Blotting,0.28,0.0074,26399781
AKT1,LTM,NA,391,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0074,29088759
AKT1,LTM,NA,391,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0074,31308814
AKT1,LTM,NA,391,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and qRT-PCR,0.2,0.0074,24719318
AKT1,LTM,NA,391,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by RT-PCR,0.2,0.0074,24734907
ALCAM,LTM,NA,400,Skin Cancer,NA,A-375,NA,FACs,0.12,0.0583,27476721
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,IF staining followed by SFA and FACs,0.36,0.0583,31024010
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining,0.36,0.0583,23947765
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.36,0.0583,31582014
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs,0.36,0.0583,33068069
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.36,0.0583,33995625
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.36,0.0583,33670440
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.36,0.0583,33707423
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs,0.36,0.0583,33631674
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,A549,Curcumin+Cisplatin,FACs followed by SFA,0.36,0.0583,26531053
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.36,0.0583,29868483
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by FACs,0.36,0.0583,32655321
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and Tumorigenicity assay,0.36,0.0583,25881239
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and Tumorigenicity assay,0.36,0.0583,29187584
ALCAM,LTM,NA,400,Colon Cancer,Adenocarcinoma,CACO-2,5-Fluorouracil,qPCR,0.2,0.0583,33946505
ALCAM,LTM,NA,400,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Western Blotting,0.28,0.0583,23903875
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,CALU-1,NA,SFA followed by FACs,0.12,0.0583,27577075
ALCAM,LTM,NA,400,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.2,0.0583,23418515
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs and RT-PCR,0.32,0.0583,29651165
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA and FACs,0.32,0.0583,33631674
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,H1299,Cisplatin,SFA followed by FACs,0.32,0.0583,32655321
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA followed by FACs,0.12,0.0583,27577075
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,FACs followed by SFA,0.12,0.0583,33670440
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,Curcumin+Cisplatin,FACs followed by SFA,0.12,0.0583,26531053
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,FACs followed by SFA,0.12,0.0583,29868483
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by IF staining,0.24,0.0583,23947765
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,H460,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs,0.24,0.0583,33068069
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs and Tumorigenicity assay,0.24,0.0583,29187584
ALCAM,LTM,NA,400,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by Western Blotting and SFA,0.48,0.0583,21596996
ALCAM,LTM,NA,400,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil+Oxaliplatin,FACs followed by RT-PCR,0.48,0.0583,19956394
ALCAM,LTM,NA,400,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil+Oxaliplatin,SFA followed by Western Blotting,0.48,0.0583,22761031
ALCAM,LTM,NA,400,Colon Cancer,Carcinoma,HCT116,Docetaxel,qRT-PCR,0.48,0.0583,27748801
ALCAM,LTM,NA,400,Colon Cancer,Carcinoma,HCT116,Docetaxel,qRT-PCR,0.48,0.0583,27748801
ALCAM,LTM,NA,400,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil+Oxaliplatin,qRT-PCR and SFA,0.48,0.0583,21161336
ALCAM,LTM,NA,400,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil+Oxaliplatin,RT-PCR,0.48,0.0583,21774804
ALCAM,LTM,NA,400,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qPCR,0.48,0.0583,26506839
ALCAM,LTM,NA,400,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and Tumorigenicity assay,0.48,0.0583,19451087
ALCAM,LTM,NA,400,Colon Cancer,Carcinoma,HCT116,NA,SFA and FACs,0.48,0.0583,25804133
ALCAM,LTM,NA,400,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.48,0.0583,23345327
ALCAM,LTM,NA,400,Head and Neck Cancer,Squamous Cell Carcinoma,HN12,NA,SFA followed by Western Blotting,0.28,0.0583,23903875
ALCAM,LTM,NA,400,Head and Neck Cancer,Squamous Cell Carcinoma,HN13,NA,SFA and Western Blotting followed by qRT-PCR,0.48,0.0583,28279658
ALCAM,LTM,NA,400,Head and Neck Cancer,Squamous Cell Carcinoma,HN13,NA,SFA followed by Western Blotting,0.48,0.0583,23903875
ALCAM,LTM,NA,400,Head and Neck Cancer,Squamous Cell Carcinoma,HN6,NA,SFA followed by Western Blotting,0.28,0.0583,23903875
ALCAM,LTM,NA,400,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by Western Blotting and SFA,0.48,0.0583,21596996
ALCAM,LTM,NA,400,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil+Oxaliplatin,SFA followed by Western Blotting,0.48,0.0583,22761031
ALCAM,LTM,NA,400,Colon Cancer,Adenocarcinoma,HT-29,Docetaxel,qRT-PCR,0.48,0.0583,27748801
ALCAM,LTM,NA,400,Colon Cancer,Adenocarcinoma,HT-29,Docetaxel,qRT-PCR,0.48,0.0583,27748801
ALCAM,LTM,NA,400,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,qRT-PCR,0.48,0.0583,27748801
ALCAM,LTM,NA,400,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,qRT-PCR,0.48,0.0583,27748801
ALCAM,LTM,NA,400,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,qRT-PCR,0.48,0.0583,30772447
ALCAM,LTM,NA,400,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and RT-PCR,0.48,0.0583,28464221
ALCAM,LTM,NA,400,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qPCR,0.48,0.0583,26506839
ALCAM,LTM,NA,400,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and SFA,0.48,0.0583,27520449
ALCAM,LTM,NA,400,Pancreatic Cancer,NA,Insulinoma,NA,FACs,0.12,0.0583,27049037
ALCAM,LTM,NA,400,Gastric Cancer,Carcinoma,KATO-III,NA,FACs,0.12,0.0583,19415765
ALCAM,LTM,NA,400,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),RT-PCR,0.2,0.0583,30552676
ALCAM,LTM,NA,400,Dukes Type B Colon Cancer,Adenocarcinoma,LS174T,NA,SFA and FACs,0.12,0.0583,25804133
ALCAM,LTM,NA,400,Gastric Cancer,Adenocarcinoma,MKN28,NA,FACs,0.12,0.0583,19415765
ALCAM,LTM,NA,400,Skin Cancer,NA,SK-MEL-1,NA,FACs,0.12,0.0583,27476721
ALCAM,LTM,NA,400,Skin Cancer,NA,SK-MEL-28,NA,FACs,0.12,0.0583,27476721
ALCAM,LTM,NA,400,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA and RT-PCR,0.2,0.0583,28464221
ALCAM,LTM,NA,400,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA and FACs,0.2,0.0583,25804133
ALCAM,LTM,NA,400,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN30,NA,SFA and Western Blotting followed by qRT-PCR,0.48,0.0583,28279658
ALCAM,LTM,NA,400,Bladder Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0583,32424373
ALCAM,LTM,NA,400,Colon Cancer,NA,Primary,NA,IHC staining followed by RT-PCR,0.6,0.0583,19010307
ALCAM,LTM,NA,400,Colon Cancer,NA,Primary,NA,IHC staining,0.6,0.0583,22670157
ALCAM,LTM,NA,400,Colon Cancer,NA,Primary,NA,FACs followed by CFA,0.6,0.0583,18757407
ALCAM,LTM,NA,400,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.6,0.0583,18765800
ALCAM,LTM,NA,400,Colon Cancer,NA,Primary,NA,SFA followed by FACs and Tumorigenicity assay,0.6,0.0583,29110645
ALCAM,LTM,NA,400,Gastric Cancer,NA,Primary,NA,FACs followed by SFA,0.2,0.0583,27620279
ALCAM,LTM,NA,400,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0583,25963795
ALCAM,LTM,NA,400,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0583,25963795
ALCAM,LTM,NA,400,Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by FACs and qPCR,0.48,0.0583,26621583
ALCAM,LTM,NA,400,Lung Cancer,NA,Primary,NA,SFA followed by IF staining,0.48,0.0583,25955492
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining followed by Western Blotting,0.68,0.0583,24501004
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.68,0.0583,24346092
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,NA,Primary,NA,qRT-PCR followed by SFA,0.68,0.0583,29568370
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,NA,Primary,NA,FACs followed by SFA,0.68,0.0583,22225612
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,NA,Primary,NA,FACs followed by SFA and Tumorigenicity assay,0.68,0.0583,26846105
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by FACs,0.68,0.0583,28416482
ALCAM,LTM,NA,400,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by FACs and Tumorigenicity assay,0.68,0.0583,26513225
ALCAM,LTM,NA,400,Small Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0583,25963795
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,5637,NA,ALDEFLUOR assay followed by Western Blotting,0.4,0.6840,30349299
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,5637,Paclitaxel,SFA followed by Western Blotting,0.4,0.6840,35008872
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,5637,NA,SFA followed by qRT-PCR,0.4,0.6840,30592142
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,5637,NA,ALDEFLUOR assay,0.4,0.6840,28445934
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,5637,Cisplatin,ALDEFLUOR assay followed by CFA,0.4,0.6840,22399585
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,5637,NA,ALDEFLUOR assay followed by SFA,0.4,0.6840,32676121
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,A-253,NA,RT-PCR followed by CFA,0.2,0.6840,24612587
ALDH1A1,LTM,NA,402,Skin Cancer,NA,A-375,NA,Western Blotting and ALDEFLUOR assay followed by SFA,0.4,0.6840,29408459
ALDH1A1,LTM,NA,402,Skin Cancer,NA,A-375,NA,ALDEFLUOR assay and SFA,0.4,0.6840,27566591
ALDH1A1,LTM,NA,402,Skin Cancer,NA,A-375,NA,ALDEFLUOR assay followed by CFA,0.4,0.6840,29049740
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and qRT-PCR followed by Western Blotting and IF staining,0.72,0.6840,32396269
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay and SFA followed by RT-PCR and Western Blotting,0.72,0.6840,27836546
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,qRT-PCR and Western Blotting,0.72,0.6840,32319573
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by Western Blotting,0.72,0.6840,30878308
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.6840,25955300
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.6840,28431267
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.6840,29344850
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.6840,31891569
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.72,0.6840,28861158
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Irradiation,SFA and ALDEFLUOR assay followed by Western Blotting,0.72,0.6840,34163000
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay followed by Western Blotting,0.72,0.6840,29254164
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay followed by Western Blotting and CFA,0.72,0.6840,24928671
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and Western Blotting,0.72,0.6840,30737252
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,ALDEFLUOR assay followed by SFA and qRT-PCR,0.72,0.6840,33784109
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay and qRT-PCR,0.72,0.6840,32308544
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by FACs,0.72,0.6840,25906011
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Irradiation,CFA followed by Western Blotting,0.72,0.6840,33924205
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.72,0.6840,33980809
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.72,0.6840,23583374
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.72,0.6840,24247269
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.72,0.6840,26517679
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.72,0.6840,27836540
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.72,0.6840,28198062
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by Western Blotting,0.72,0.6840,31207300
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.72,0.6840,31263095
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting,0.72,0.6840,29235568
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Erlotinib,ALDEFLUOR assay followed by FACs,0.72,0.6840,25125655
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay followed by FACs,0.72,0.6840,26278043
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay followed by FACs,0.72,0.6840,26278043
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Afatinib,ALDEFLUOR assay followed by FACs,0.72,0.6840,30885551
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,ALDEFLUOR assay followed by FACs,0.72,0.6840,30885551
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Osimertinib,ALDEFLUOR assay followed by FACs,0.72,0.6840,30885551
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay followed by FACs and SFA,0.72,0.6840,28321046
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay followed by FACs and SFA,0.72,0.6840,28830450
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA and ALDEFLUOR assay,0.72,0.6840,29845263
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and ICC staining,0.72,0.6840,31939436
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR,0.72,0.6840,34400945
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and SFA,0.72,0.6840,34246759
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.72,0.6840,33468994
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.72,0.6840,34277782
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qPCR,0.72,0.6840,26675547
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.72,0.6840,29138851
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Tumorigenicity assay,0.72,0.6840,32124474
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by RT-PCR,0.72,0.6840,27009878
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay followed by SFA,0.72,0.6840,33721187
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay followed by SFA,0.72,0.6840,33783940
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay followed by SFA,0.72,0.6840,33784109
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay,0.72,0.6840,33539684
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay,0.72,0.6840,34546848
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay,0.72,0.6840,35044041
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay,0.72,0.6840,35229723
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,ALDEFLUOR assay,0.72,0.6840,23349823
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay,0.72,0.6840,32655789
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay followed by SFA,0.72,0.6840,24607842
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ALDEFLUOR assay followed by SFA and Tumorigenicity assay,0.72,0.6840,21600232
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,ALDEFLUOR assay followed by SFA and Tumorigenicity assay,0.72,0.6840,26779808
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,CFA and SFA followed by ALDEFLUOR assay,0.72,0.6840,28406482
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay,0.72,0.6840,28400280
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by ALDEFLUOR assay,0.72,0.6840,28850563
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Sorafenib,SFA followed by ALDEFLUOR assay,0.72,0.6840,28850563
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay,0.72,0.6840,30555330
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay,0.72,0.6840,31466290
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay,0.72,0.6840,31582014
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay,0.72,0.6840,31928533
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay,0.72,0.6840,31928533
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay,0.72,0.6840,32033067
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay,0.72,0.6840,32401390
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay,0.72,0.6840,32612672
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ALDEFLUOR assay and Tumorigenicity assay,0.72,0.6840,24013232
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by FACs,0.72,0.6840,27035162
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.72,0.6840,29416721
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.72,0.6840,31121479
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by ALDEFLUOR assay,0.72,0.6840,22825470
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.28,0.6840,35117718
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by ALDEFLUOR assay,0.28,0.6840,32707998
ALDH1A1,LTM,NA,402,Breast Cancer,NA,AS-B145,NA,SFA followed by Western Blotting,0.28,0.6840,29100291
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Western Blotting,0.28,0.6840,30853342
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qPCR,0.28,0.6840,31440741
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.28,0.6840,27996162
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.28,0.6840,27996162
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and qRT-PCR followed by Western Blotting ,0.48,0.6840,34427968
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.48,0.6840,34090492
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by Western Blotting,0.48,0.6840,30624124
ALDH1A1,LTM,NA,402,Breast Cancer,Carcinoma,BrCa-Mz-01,NA,ALDEFLUOR assay,0.12,0.6840,19190339
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,BT-20,NA,SFA followed by Western Blotting and FACs,0.4,0.6840,33924995
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,BT-20,NA,SFA followed by ALDEFLUOR assay,0.4,0.6840,29073729
ALDH1A1,LTM,NA,402,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,34775489
ALDH1A1,LTM,NA,402,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,29075110
ALDH1A1,LTM,NA,402,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,29080749
ALDH1A1,LTM,NA,402,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,29620216
ALDH1A1,LTM,NA,402,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,30206184
ALDH1A1,LTM,NA,402,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,29100291
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Paclitaxel,Western Blotting and SFA,0.28,0.6840,31308076
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Cyclophosphamide,qRT-PCR,0.28,0.6840,33090711
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by qRT-PCR,0.28,0.6840,33090711
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by RT-PCR,0.28,0.6840,30038266
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by RT-PCR,0.28,0.6840,30038266
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,ALDEFLUOR assay followed by SFA,0.28,0.6840,33221681
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Carboplatin,ALDEFLUOR assay followed by SFA,0.28,0.6840,33221681
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Paclitaxel,ALDEFLUOR assay followed by SFA,0.28,0.6840,33221681
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,ALDEFLUOR assay followed by SFA,0.28,0.6840,33674749
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,ALDEFLUOR assay followed by SFA,0.28,0.6840,35064101
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by ALDEFLUOR assay,0.28,0.6840,33510281
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by ALDEFLUOR assay,0.28,0.6840,35277657
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,ALDEFLUOR assay,0.28,0.6840,29197410
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,ALDEFLUOR assay,0.28,0.6840,30460610
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,ALDEFLUOR assay and SFA,0.28,0.6840,31296961
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,ALDEFLUOR assay followed by SFA,0.28,0.6840,28817737
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by ALDEFLUOR assay,0.28,0.6840,28817737
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by ALDEFLUOR assay,0.28,0.6840,29352988
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by ALDEFLUOR assay,0.28,0.6840,29352988
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.6840,30802827
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.6840,30802827
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by Western Blotting,0.48,0.6840,30853342
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,qRT-PCR,0.48,0.6840,26035122
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by qRT-PCR,0.48,0.6840,29048549
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,ALDEFLUOR assay followed by CFA,0.48,0.6840,32550888
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,ALDEFLUOR assay,0.48,0.6840,30747824
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,ALDEFLUOR assay,0.48,0.6840,31388092
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,ALDEFLUOR assay followed by SFA,0.48,0.6840,27748818
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SFA,0.48,0.6840,27748818
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SFA,0.48,0.6840,27999190
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Ca9-22,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,24475244
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,CACO-2,NA,Western Blotting,0.28,0.6840,29235568
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,CACO-2,NA,qRT-PCR,0.28,0.6840,28565875
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs and CFA,0.28,0.6840,25154976
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs and CFA,0.28,0.6840,25154976
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,CACO-2,NA,SFA followed by FACs,0.28,0.6840,26995228
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,Western Blotting followed by SFA,0.28,0.6840,31399556
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,Western Blotting followed by SFA,0.28,0.6840,34795388
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and Western Blotting,0.28,0.6840,27108536
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by ALDEFLUOR assay,0.28,0.6840,34502158
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,5-Fluorouracil,FACs followed by SFA and CFA,0.28,0.6840,27380877
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,FACs followed by SFA and CFA,0.28,0.6840,27380877
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Docetaxel,FACs followed by SFA and CFA,0.28,0.6840,27380877
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,CAL51,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,30450530
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Oral Squamous Cell Carcinoma,CaLH3,NA,SFA followed by qRT-PCR,0.2,0.6840,25212757
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,CALU-1,NA,SFA followed by qRT-PCR,0.2,0.6840,29138851
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,CALU-1,NA,ALDEFLUOR assay followed by CFA,0.2,0.6840,24907115
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay and ALDEFLUOR assay followed by Western Blotting and SFA,0.4,0.6840,32781084
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,ALDEFLUOR assay,0.4,0.6840,30747824
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,Migration and Invasion assay followed by FACs,0.4,0.6840,22109279
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.28,0.6840,30853342
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,qRT-PCR,0.28,0.6840,26035122
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,ALDEFLUOR assay,0.28,0.6840,24194908
ALDH1A1,LTM,NA,402,Lung Cancer,Adenocarcinoma,CL-1-1,NA,SFA followed by FACs,0.12,0.6840,29416721
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,CL-141,NA,SFA followed by Western Blotting,0.28,0.6840,31319622
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,CL-141,NA,SFA followed by ALDEFLUOR assay,0.28,0.6840,31638335
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,CL-141,NA,SP assay followed by FACs and SFA,0.28,0.6840,23024022
ALDH1A1,LTM,NA,402,Lung Cancer,Adenocarcinoma,CL1-5,NA,SFA followed by qRT-PCR,0.2,0.6840,26447186
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,CL-152,NA,SP assay followed by FACs,0.12,0.6840,23024022
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,CNE2,NA,ALDEFLUOR assay,0.12,0.6840,25015320
ALDH1A1,LTM,NA,402,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-201,NA,Western Blotting,0.28,0.6840,29235568
ALDH1A1,LTM,NA,402,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-201,NA,FACs,0.28,0.6840,23354547
ALDH1A1,LTM,NA,402,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6840,24212669
ALDH1A1,LTM,NA,402,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,Western Blotting,0.48,0.6840,29235568
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,COLO-320,NA,Western Blotting,0.28,0.6840,29235568
ALDH1A1,LTM,NA,402,Breast Cancer,Carcinoma,CRL2334,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,28817737
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,ALDEFLUOR assay followed by FACs and SFA,0.24,0.6840,21694723
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.24,0.6840,23418515
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,ALDEFLUOR assay followed by SFA and Tumorigenicity assay,0.24,0.6840,22074823
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SP assay followed by ALDEFLUOR assay and Tumorigenicity assay,0.24,0.6840,21720213
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by qRT-PCR,0.2,0.6840,26351321
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6840,28870814
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6840,32661469
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.6840,31180522
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,EJ-28,Benzidine,SFA followed by Western Blotting,0.48,0.6840,33552265
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by Western Blotting,0.48,0.6840,33552265
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.6840,31382448
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Dasatinib,Western Blotting followed by qRT-PCR,0.48,0.6840,31382448
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Saracatinib,Western Blotting followed by qRT-PCR,0.48,0.6840,31382448
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,Western Blotting followed by SFA,0.48,0.6840,31399556
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Cisplatin,SP assay followed by Western Blotting,0.48,0.6840,29228308
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR,0.48,0.6840,32708734
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Irradiation,ALDEFLUOR assay,0.48,0.6840,28844650
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by ALDEFLUOR assay,0.48,0.6840,34502158
ALDH1A1,LTM,NA,402,Glioblastoma Multiforme,NA,GBM8401,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,31035045
ALDH1A1,LTM,NA,402,Glioblastoma Multiforme,NA,GBM8401,NA,SP assay and SFA followed by ALDEFLUOR assay,0.12,0.6840,25359730
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Carcinoma,GNM,NA,ALDEFLUOR assay and SFA,0.12,0.6840,32357409
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,SFA followed by FACs and Western Blotting,0.4,0.6840,30717421
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,ALDEFLUOR assay followed by FACs,0.4,0.6840,19276181
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,ALDEFLUOR assay followed by Migration assay,0.4,0.6840,19276181
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,ALDEFLUOR assay followed by SFA,0.4,0.6840,24928671
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6840,28431267
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,RT-PCR followed by FACs,0.48,0.6840,25906011
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.6840,33980809
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.6840,23583374
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.6840,26518146
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.6840,27836540
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.6840,28198062
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,ALDEFLUOR assay followed by FACs,0.48,0.6840,24595209
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,ALDEFLUOR assay followed by FACs and CFA,0.48,0.6840,27542268
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,CFA followed by IF staining,0.48,0.6840,25831148
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.6840,33468994
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qPCR,0.48,0.6840,26675547
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.6840,32051483
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,Cisplatin,ALDEFLUOR assay followed by CFA,0.48,0.6840,33550205
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,ALDEFLUOR assay followed by SFA,0.48,0.6840,33783940
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by ALDEFLUOR assay,0.48,0.6840,33539684
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by ALDEFLUOR assay,0.48,0.6840,34546848
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,Paclitaxel,ALDEFLUOR assay followed by SFA,0.48,0.6840,24278179
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs followed by CFA,0.48,0.6840,21827695
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs followed by SFA,0.48,0.6840,24091605
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,Gefitinib,SFA followed by ALDEFLUOR assay,0.48,0.6840,28850563
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,Sorafenib,SFA followed by ALDEFLUOR assay,0.48,0.6840,28850563
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by ALDEFLUOR assay,0.48,0.6840,30555330
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by ALDEFLUOR assay,0.48,0.6840,32401390
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by ALDEFLUOR assay,0.48,0.6840,32612672
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H157,NA,SFA followed by qPCR,0.2,0.6840,26675547
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H157,Cisplatin,SFA followed by RT-PCR,0.2,0.6840,27009878
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,FACs followed by SFA and Tumorigenicity assay,0.12,0.6840,24091605
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,FACs followed by SFA and Tumorigenicity assay,0.12,0.6840,28819374
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,SP assay and ALDEFLUOR assay followed by SFA and Tumorigenicity assay,0.12,0.6840,23418490
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,SP assay followed by ALDEFLUOR assay and SFA,0.12,0.6840,23418490
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,SP assay followed by SFA and ALDEFLUOR assay,0.12,0.6840,26297432
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1781,Afatinib,Western Blotting and qRT-PCR followed by SFA,0.48,0.6840,29532558
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,Osimertinib,SFA followed by Western Blotting,0.28,0.6840,30910592
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,Afatinib,ALDEFLUOR assay followed by FACs,0.28,0.6840,30885551
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,Gefitinib,ALDEFLUOR assay followed by FACs,0.28,0.6840,30885551
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,Osimertinib,ALDEFLUOR assay followed by FACs,0.28,0.6840,30885551
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,ALDEFLUOR assay followed by FACs and SFA,0.28,0.6840,28830450
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,ALDEFLUOR assay followed by FACs and SFA,0.28,0.6840,28927099
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA followed by qRT-PCR,0.28,0.6840,26447186
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay followed by SFA and RT-PCR,0.28,0.6840,28440478
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,ALDEFLUOR assay followed by SFA,0.28,0.6840,24607842
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay followed by ALDEFLUOR assay,0.28,0.6840,23418490
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay followed by ALDEFLUOR assay,0.28,0.6840,23418490
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay followed by SFA and ALDEFLUOR assay,0.28,0.6840,26297432
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.28,0.6840,35229723
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H1993,NA,ALDEFLUOR assay followed by CFA,0.12,0.6840,24907115
ALDH1A1,LTM,NA,402,Small Cell Lung Cancer,NA,H20,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.48,0.6840,33969609
ALDH1A1,LTM,NA,402,Small Cell Lung Cancer,NA,H20,Etopside,SFA followed by qRT-PCR and Western Blotting,0.48,0.6840,33969609
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H2009,NA,ALDEFLUOR assay followed by CFA,0.12,0.6840,24907115
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H2087,NA,ALDEFLUOR assay and  FACs followed by IF staining and Tumorigenicity assay,0.48,0.6840,22617249
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H2087,NA,ALDEFLUOR assay followed by CFA,0.48,0.6840,24907115
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,31466290
ALDH1A1,LTM,NA,402,Small Cell Lung Cancer,Carcinoma,H2227,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.48,0.6840,33969609
ALDH1A1,LTM,NA,402,Small Cell Lung Cancer,Carcinoma,H2227,Etopside,SFA followed by qRT-PCR and Western Blotting,0.48,0.6840,33969609
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,SFA followed by Western Blotting,0.28,0.6840,32509180
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H23,Cisplatin,SFA followed by FACs,0.28,0.6840,26872057
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Western Blotting and IF staining,0.52,0.6840,25411331
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,FACs followed by RT-PCR,0.52,0.6840,27694834
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Western Blotting,0.52,0.6840,34059086
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Western Blotting,0.52,0.6840,31100681
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H322,NA,SFA followed by ELISA,0.28,0.6840,26088878
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H322,NA,SFA followed by ELISA,0.28,0.6840,26088878
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H322,NA,ALDEFLUOR assay followed by FACs,0.28,0.6840,19276181
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H322,NA,ALDEFLUOR assay followed by Migration assay,0.28,0.6840,19276181
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,ALDEFLUOR assay and  FACs followed by IF staining and Tumorigenicity assay,0.48,0.6840,19276181
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,Erlotinib,ALDEFLUOR assay followed by FACs,0.48,0.6840,25125655
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,ALDEFLUOR assay followed by FACs and SFA,0.48,0.6840,28927099
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,SFA followed by RT-PCR,0.48,0.6840,26546046
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,ALDEFLUOR assay,0.48,0.6840,34530236
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,ALDEFLUOR assay followed by CFA,0.48,0.6840,24907115
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,ALDEFLUOR assay followed by Migration assay,0.48,0.6840,19276181
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,SFA followed by ELISA,0.28,0.6840,26088878
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,SFA followed by RT-PCR,0.28,0.6840,26546046
ALDH1A1,LTM,NA,402,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Western Blotting,0.28,0.6840,27633248
ALDH1A1,LTM,NA,402,Small Cell Lung Cancer,Carcinoma,H446,NA,SP assay followed by ALDEFLUOR assay,0.28,0.6840,22825470
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,ALDEFLUOR assay followed by Western Blotting  and RT-PCR,0.6,0.6840,28931539
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting and IF staining,0.6,0.6840,25411331
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by RT-PCR and Western Blotting,0.6,0.6840,28861158
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,Gefitinib,SFA and ALDEFLUOR assay followed by Western Blotting,0.6,0.6840,34163000
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs and Western Blotting,0.6,0.6840,30737252
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA and Western Blotting,0.6,0.6840,34832867
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.6840,34195288
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.6840,26339272
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,Ciprofloxacin,SFA followed by Western Blotting,0.6,0.6840,26947806
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.6840,28122729
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.6840,28179308
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.6840,28259926
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.6840,28677037
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.6840,28931539
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.6840,30111255
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.6840,31100681
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.6840,32509180
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,ALDEFLUOR assay followed by FACs,0.6,0.6840,19276181
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,ALDEFLUOR assay followed by FACs,0.6,0.6840,24595209
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,ALDEFLUOR assay followed by FACs and CFA,0.6,0.6840,27542268
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,qRT-PCR and SFA,0.6,0.6840,34246759
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,ALDEFLUOR assay followed by CFA,0.6,0.6840,33550205
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,ALDEFLUOR assay,0.6,0.6840,23349823
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,ALDEFLUOR assay followed by Migration assay,0.6,0.6840,19276181
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,Paclitaxel,ALDEFLUOR assay followed by SFA,0.6,0.6840,24278179
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,24309934
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,28797843
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,CFA and SFA followed by ALDEFLUOR assay,0.6,0.6840,28406482
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs followed by Tumorigenicity assay,0.6,0.6840,21827695
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,25276790
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,Gefitinib,SFA followed by ALDEFLUOR assay,0.6,0.6840,28850563
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,Sorafenib,SFA followed by ALDEFLUOR assay,0.6,0.6840,28850563
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,31466290
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs,0.6,0.6840,22592563
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,33721187
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,Cisplatin,SFA followed by FACs,0.12,0.6840,27035162
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,H522,NA,ALDEFLUOR assay followed by FACs and Tumorigenicity assay,0.24,0.6840,18952074
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,HCC1143,Doxorubicin,ALDEFLUOR assay followed by SFA,0.12,0.6840,33221681
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,HCC1143,Carboplatin,ALDEFLUOR assay followed by SFA,0.12,0.6840,33221681
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,HCC1143,Paclitaxel,ALDEFLUOR assay followed by SFA,0.12,0.6840,33221681
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,HCC1395,Doxorubicin,ALDEFLUOR assay followed by SFA,0.12,0.6840,33221681
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,HCC1395,Carboplatin,ALDEFLUOR assay followed by SFA,0.12,0.6840,33221681
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,HCC1395,Paclitaxel,ALDEFLUOR assay followed by SFA,0.12,0.6840,33221681
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA followed by ALDEFLUOR assay and qRT-PCR,0.32,0.6840,26711929
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,SFA followed by qRT-PCR,0.2,0.6840,34023418
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,ALDEFLUOR assay followed by SFA,0.2,0.6840,34718356
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,ALDEFLUOR assay followed by SFA,0.2,0.6840,35504883
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,SFA followed by ALDEFLUOR assay,0.2,0.6840,33510281
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,SFA followed by FACs,0.2,0.6840,33672732
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,ALDEFLUOR assay,0.2,0.6840,30091683
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,SFA followed by qRT-PCR,0.2,0.6840,34023418
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,ALDEFLUOR assay,0.2,0.6840,31273285
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,35220209
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,NA,ALDEFLUOR assay,0.12,0.6840,19190339
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,ALDEFLUOR assay followed by SFA,0.12,0.6840,29895705
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,ALDEFLUOR assay followed by SFA,0.12,0.6840,29895705
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,HCC-38,NA,ALDEFLUOR assay,0.12,0.6840,19190339
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC4006,Afatinib,Western Blotting and CFA,0.28,0.6840,26202045
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC4006,Erlotinib,ALDEFLUOR assay followed by FACs,0.28,0.6840,25125655
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC44,NA,ALDEFLUOR assay followed by CFA,0.12,0.6840,24907115
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by Western Blotting,0.28,0.6840,33955683
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Afatinib,Western Blotting and CFA,0.28,0.6840,26202045
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Erlotinib,ALDEFLUOR assay followed by FACs and SFA,0.28,0.6840,25125655
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,qRT-PCR,0.28,0.6840,33764690
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,qPCR,0.28,0.6840,24489728
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Docetaxel,RT-PCR,0.28,0.6840,28959367
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by RT-PCR,0.28,0.6840,28787001
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,SP assay followed by qRT-PCR and CFA,0.28,0.6840,25871388
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,ALDEFLUOR assay and SFA,0.28,0.6840,31765940
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,ALDEFLUOR assay followed by CFA,0.28,0.6840,24907115
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,FACs followed by SFA and Tumorigenicity assay,0.28,0.6840,24091605
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,FACs followed by SFA and Tumorigenicity assay,0.28,0.6840,28819374
ALDH1A1,LTM,NA,402,Lung Cancer,Squamous Cell Carcinoma,HCC95,NA,ALDEFLUOR assay followed by CFA,0.12,0.6840,24907115
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,qRT-PCR followed by Western Blotting and SFA,0.48,0.6840,30912138
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR and Western Blotting followed by SFA,0.48,0.6840,32037723
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by Western Blotting and SFA,0.48,0.6840,21596996
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qPCR and ALDEFLUOR assay,0.48,0.6840,31349708
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by RT-PCR and ALDEFLUOR assay,0.48,0.6840,30774996
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.48,0.6840,26785732
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.48,0.6840,27997180
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,ALDEFLUOR assay followed by FACs and SFA,0.48,0.6840,21694723
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,IHC staining,0.48,0.6840,31810923
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.48,0.6840,35242031
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.48,0.6840,35392530
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR,0.48,0.6840,29902974
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by CFA,0.48,0.6840,26840024
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,ALDEFLUOR assay,0.48,0.6840,19923910
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,Paclitaxel,ALDEFLUOR assay,0.48,0.6840,23327190
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,ALDEFLUOR assay,0.48,0.6840,24122993
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,ALDEFLUOR assay followed by SFA and Tumorigenicity assay,0.48,0.6840,22074823
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,FACs and CFA,0.48,0.6840,25154976
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,FACs and CFA,0.48,0.6840,25154976
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,HCT116,NA,SP assay followed by ALDEFLUOR assay,0.48,0.6840,21720213
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SFA followed by Western Blotting,0.28,0.6840,27997180
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HCT-15,Cisplatin,SFA and qPCR,0.28,0.6840,34921482
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,RT-PCR followed by SFA,0.28,0.6840,28946619
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SP assay followed by Tumorigenicity assay and RT-PCR,0.28,0.6840,21435460
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,ALDEFLUOR assay,0.28,0.6840,19923910
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SP assay followed by ALDEFLUOR assay,0.28,0.6840,21720213
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,SP assay followed by Western Blotting,0.28,0.6840,29228308
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by qRT-PCR,0.28,0.6840,25104726
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Carcinoma,HEp-2,5-Fluorouracil,FACs followed by SFA and CFA,0.28,0.6840,27380877
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,FACs followed by SFA and CFA,0.28,0.6840,27380877
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Carcinoma,HEp-2,Docetaxel,FACs followed by SFA and CFA,0.28,0.6840,27380877
ALDH1A1,LTM,NA,402,Hepatic Cancer,Carcinoma,Hep-G2,NA,IHC staining followed by qRT-PCR,0.44,0.6840,30023612
ALDH1A1,LTM,NA,402,Gastric Cancer,Carcinoma,HGC-27,NA,ALDEFLUOR assay followed by SFA and qRT-PCR,0.32,0.6840,34628473
ALDH1A1,LTM,NA,402,Gastric Cancer,Carcinoma,HGC-27,NA,Western Blotting followed by SFA,0.32,0.6840,31213895
ALDH1A1,LTM,NA,402,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by FACs,0.32,0.6840,31879364
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,HN-1,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,25024430
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,HN13,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,23527004
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,HN4,Cisplatin,Western Blotting followed by SFA,0.28,0.6840,34795388
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,HN6,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,23527004
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,HONE1,NA,ALDEFLUOR assay,0.12,0.6840,25015320
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by qRT-PCR,0.2,0.6840,27891685
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,ALDEFLUOR assay followed by SFA,0.2,0.6840,27748818
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,FACs followed by SFA,0.2,0.6840,27748818
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,HPAF-II,Gemcitabine,qPCR,0.2,0.6840,31440741
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by qRT-PCR,0.2,0.6840,28976208
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,ALDEFLUOR assay followed by SFA,0.2,0.6840,34344863
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,FACs,0.2,0.6840,29162703
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,ALDEFLUOR assay,0.12,0.6840,29515788
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,ALDEFLUOR assay followed by CFA,0.12,0.6840,22847005
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,26448762
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,FACs followed by SFA,0.12,0.6840,27002147
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-4,NA,ALDEFLUOR assay,0.12,0.6840,29515788
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,HT-1197,NA,Western Blotting,0.28,0.6840,35008872
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,HT-1376,NA,SFA followed by qRT-PCR,0.2,0.6840,26452033
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR and Western Blotting followed by SFA,0.48,0.6840,32037723
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by Western Blotting and SFA,0.48,0.6840,21596996
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,ALDEFLUOR assay followed by SFA and RT-PCR,0.48,0.6840,28464221
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR and ALDEFLUOR assay,0.48,0.6840,30774996
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.48,0.6840,33667839
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.48,0.6840,30144515
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,Western Blotting,0.48,0.6840,29235568
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,ALDEFLUOR assay followed by FACs and SFA,0.48,0.6840,21694723
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker followed by qRT-PCR,0.48,0.6840,33744851
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.48,0.6840,35392530
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,qRT-PCR,0.48,0.6840,28565875
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,qRT-PCR,0.48,0.6840,30772447
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR,0.48,0.6840,29902974
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by Tumorigenicity assay and RT-PCR,0.48,0.6840,21435460
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,Paclitaxel,ALDEFLUOR assay,0.48,0.6840,23327190
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,ALDEFLUOR assay followed by CFA,0.48,0.6840,32108197
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,ALDEFLUOR assay followed by SFA,0.48,0.6840,27927191
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,ALDEFLUOR assay followed by SFA,0.48,0.6840,30410666
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.48,0.6840,25154976
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and CFA,0.48,0.6840,25154976
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by ALDEFLUOR assay,0.48,0.6840,26634106
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs and SP assay,0.48,0.6840,21670985
ALDH1A1,LTM,NA,402,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by ALDEFLUOR assay,0.48,0.6840,21720213
ALDH1A1,LTM,NA,402,Bladder Cancer,Transitional Cell Papilloma,HTB-2,NA,ALDEFLUOR assay,0.12,0.6840,20142235
ALDH1A1,LTM,NA,402,Bladder Cancer,Transitional Cell Papilloma,HTB-4,NA,ALDEFLUOR assay,0.12,0.6840,20142235
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,HTB-9,NA,ALDEFLUOR assay,0.12,0.6840,20142235
ALDH1A1,LTM,NA,402,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by Western Blotting,0.4,0.6840,32221015
ALDH1A1,LTM,NA,402,Hepatic Cancer,Carcinoma,Huh7,NA,ALDEFLUOR assay,0.4,0.6840,34405006
ALDH1A1,LTM,NA,402,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,ALDEFLUOR assay,0.12,0.6840,34215226
ALDH1A1,LTM,NA,402,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,34775489
ALDH1A1,LTM,NA,402,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,29080749
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Carcinoma,KB,NA,SFA followed by qRT-PCR,0.2,0.6840,25104726
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,KM12SM,NA,FACs,0.12,0.6840,31505062
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,qRT-PCR,0.2,0.6840,26035122
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR,0.2,0.6840,23917223
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,ALDEFLUOR assay followed by SFA and Migration assay,0.2,0.6840,32004866
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,FACs followed by SFA and Tumorigenicity assay,0.2,0.6840,21695188
ALDH1A1,LTM,NA,402,Breast Cancer,Ductal Carcinoma,LCC2,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,30450766
ALDH1A1,LTM,NA,402,Lung Cancer,Adenocarcinoma,LHK2,NA,SP assay followed by qRT-PCR and CFA,0.2,0.6840,27418136
ALDH1A1,LTM,NA,402,Lung Cancer,Adenocarcinoma,LHK2,Trichostatin,SP assay followed by ALDEFLUOR assay and SFA,0.2,0.6840,27418136
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,Western Blotting,0.28,0.6840,29235568
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,qRT-PCR,0.28,0.6840,30284085
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),RT-PCR,0.28,0.6840,30552676
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,FACs,0.28,0.6840,21701559
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,LS180,NA,RT-PCR,0.2,0.6840,29902974
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,CFA followed by IF staining and Western Blotting,0.52,0.6840,28839461
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Adriamycin,SFA followed by qRT-PCR and Western Blotting,0.52,0.6840,33866606
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6840,34249423
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by SFA and qRT-PCR,0.52,0.6840,34528694
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR and Western Blotting followed by SFA,0.52,0.6840,30541574
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,IHC staining followed by qRT-PCR,0.52,0.6840,30023612
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and IF staining,0.52,0.6840,30188754
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay and Western Blotting,0.52,0.6840,35004266
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay followed by SFA and Western Blotting,0.52,0.6840,29923726
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay and Western Blotting,0.52,0.6840,31497349
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay and IF staining,0.52,0.6840,28935760
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,ALDEFLUOR assay followed by qRT-PCR and SFA,0.52,0.6840,30622340
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,ALDEFLUOR assay followed by SFA and qRT-PCR,0.52,0.6840,31756890
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6840,33305893
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6840,34830821
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.52,0.6840,35078507
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6840,29243835
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6840,29356693
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6840,30080291
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6840,31501409
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6840,31695775
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6840,31760908
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,Western Blotting,0.52,0.6840,31286834
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by SFA,0.52,0.6840,29869379
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by SFA,0.52,0.6840,31283068
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,Western Blotting followed by SFA,0.52,0.6840,31690832
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by IF staining,0.52,0.6840,34718182
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by IF staining,0.52,0.6840,35134607
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,IF staining followed by SFA,0.52,0.6840,31591823
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,IF staining followed by SFA,0.52,0.6840,31595560
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay and FACs,0.52,0.6840,31658701
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by IHC staining,0.52,0.6840,30627418
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR,0.52,0.6840,33634797
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.6840,33603536
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.6840,34680485
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Paclitaxel,qRT-PCR,0.52,0.6840,31628941
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and SFA,0.52,0.6840,30239174
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and qRT-PCR,0.52,0.6840,31728117
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.6840,29179185
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.6840,30188754
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.6840,31693936
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by RT-PCR,0.52,0.6840,30579251
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay and SFA,0.52,0.6840,34298877
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,33791297
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,34315857
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Adriamycin,ALDEFLUOR assay followed by SFA,0.52,0.6840,34403222
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,35508987
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.52,0.6840,34073849
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and ALDEFLUOR assay,0.52,0.6840,34234874
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay,0.52,0.6840,33940518
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay,0.52,0.6840,35047440
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDREFLUOR assay,0.52,0.6840,33419140
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay,0.52,0.6840,19190339
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay,0.52,0.6840,30478301
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay and SFA,0.52,0.6840,31296961
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,28802057
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,29027990
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,ALDEFLUOR assay followed by SFA,0.52,0.6840,29050299
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,29229606
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,29679903
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,30206184
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,30214607
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,30450766
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,31756890
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,ALDEFLUOR assay followed by SFA,0.52,0.6840,31760402
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,ALDEFLUOR assay followed by SFA and SP assay,0.52,0.6840,27974826
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.52,0.6840,31666201
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.52,0.6840,29434914
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.52,0.6840,29602199
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.52,0.6840,30335523
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and CFA followed by ALDEFLUOR assay,0.52,0.6840,29187905
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay,0.52,0.6840,21062983
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay,0.52,0.6840,28823831
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay,0.52,0.6840,28930649
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay,0.52,0.6840,29093680
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay,0.52,0.6840,29348189
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,SFA followed by ALDEFLUOR assay,0.52,0.6840,29363524
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay,0.52,0.6840,29383157
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Fructose,SFA followed by ALDEFLUOR assay,0.52,0.6840,29796188
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay,0.52,0.6840,29964299
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay,0.52,0.6840,30032164
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by ALDEFLUOR assay,0.52,0.6840,31308814
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.52,0.6840,30242135
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.52,0.6840,31726667
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,MDA-1986,Cisplatin,ALDEFLUOR assay and SFA,0.12,0.6840,29121598
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,MDA-MB-157,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,34848450
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,MDA-MB-157,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,28966724
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,MDA-MB-157,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,30559934
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,ALDEFLUOR assay and SFA followed by Western Blotting and qPCR,0.6,0.6840,28703802
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,CFA followed by IF staining and Western Blotting,0.6,0.6840,28839461
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.6,0.6840,33866606
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.6,0.6840,34249423
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA and qRT-PCR,0.6,0.6840,34528694
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and Western Blotting followed by SFA,0.6,0.6840,29848346
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and Western Blotting,0.6,0.6840,30541574
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR followed by Western Blotting,0.6,0.6840,28760736
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay and Western Blotting,0.6,0.6840,35004266
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting and FACs,0.6,0.6840,33924995
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA followed by ALDEFLUOR assay,0.6,0.6840,33797754
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,ALDEFLUOR assay and Western Blotting followed by SFA,0.6,0.6840,29880481
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by Western Blotting and SFA,0.6,0.6840,29316250
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Radiotherapy,FACs followed by Western Blotting,0.6,0.6840,30272295
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,MACs followed by Western Blotting,0.6,0.6840,29228728
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay and Western Blotting,0.6,0.6840,31497349
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qPCR and SFA followed by ALDEFLUOR assay,0.6,0.6840,31745977
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and ALDEFLUOR assay and SFA,0.6,0.6840,30513573
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay and RT-PCR,0.6,0.6840,30131941
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.6,0.6840,29353288
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.6,0.6840,31695775
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.6,0.6840,29869379
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.6,0.6840,31283068
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay and FACs,0.6,0.6840,31658701
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR,0.6,0.6840,33634797
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by qRT-PCR,0.6,0.6840,33845139
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cyclophosphamide,qRT-PCR,0.6,0.6840,33090711
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.6,0.6840,33090711
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Lapatinib,SFA followed by qRT-PCR,0.6,0.6840,34435487
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.6,0.6840,35017469
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and SFA,0.6,0.6840,30239174
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR followed by SFA,0.6,0.6840,31850822
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and qRT-PCR,0.6,0.6840,31728117
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.6,0.6840,29179185
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,8 Gy Radiation,SFA followed by RT-PCR,0.6,0.6840,30579251
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay and SFA,0.6,0.6840,34298877
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Doxorubicin,ALDEFLUOR assay followed by SFA,0.6,0.6840,33221681
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Carboplatin,ALDEFLUOR assay followed by SFA,0.6,0.6840,33221681
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,ALDEFLUOR assay followed by SFA,0.6,0.6840,33221681
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,34311079
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,34344863
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,34451892
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,34770867
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,34944852
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,35135840
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,35171381
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,35216080
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,35216080
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,35504883
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Irradiation,CFA followed by ALDEFLUOR assay,0.6,0.6840,34708581
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.6,0.6840,34073849
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and ALDEFLUOR assay,0.6,0.6840,34234874
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA and ALDEFLUOR assay,0.6,0.6840,35401817
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,33057995
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,33510281
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,33525605
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,33672732
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,34123797
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,34146553
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,34178639
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,34420298
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,34445421
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,34990518
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,35195687
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,35277657
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDREFLUOR assay,0.6,0.6840,33419140
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay,0.6,0.6840,29207686
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay,0.6,0.6840,29290211
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay,0.6,0.6840,29374148
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay,0.6,0.6840,29500278
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay,0.6,0.6840,30301222
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay,0.6,0.6840,30322103
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay,0.6,0.6840,30478301
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay and SFA,0.6,0.6840,27976692
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay and SFA,0.6,0.6840,29197410
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Docetaxel,ALDEFLUOR assay and SFA,0.6,0.6840,29921732
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by CFA,0.6,0.6840,18681906
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Bevacizumab,ALDEFLUOR assay followed by Migration and Invasion assay,0.6,0.6840,31497360
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,28817737
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,29027990
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,29601799
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,29907642
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,30052635
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,30460610
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,30542507
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,30587555
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,31534364
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,31619923
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,ALDEFLUOR assay followed by SFA and SP assay,0.6,0.6840,27974826
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.6,0.6840,29162703
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.6,0.6840,31666201
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.6,0.6840,31545416
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and CFA followed by ALDEFLUOR assay,0.6,0.6840,29187905
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,28817737
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,28823831
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by ALDEFLUOR assay,0.6,0.6840,28835684
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,29073729
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,29106390
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,29137219
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,29383157
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Fructose,SFA followed by ALDEFLUOR assay,0.6,0.6840,29796188
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,30032164
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,30149665
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,30639386
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,30647871
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,30971005
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,31529195
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.6,0.6840,31726667
ALDH1A1,LTM,NA,402,Luminal B Breast Cancer,Adenocarcinoma,MDA-MB-361,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,29075110
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Ductal Carcinoma,MDA-MB-435,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,31534364
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,Irradiation,CFA followed by ALDEFLUOR assay,0.12,0.6840,34708581
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,Docetaxel,SFA followed by ALDEFLUOR assay,0.12,0.6840,28978427
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,Doxorubicin,SFA followed by ALDEFLUOR assay,0.12,0.6840,28978427
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,Paclitaxel,SFA followed by ALDEFLUOR assay,0.12,0.6840,28978427
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,31337967
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,35220209
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,30647871
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,31529195
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,ALDEFLUOR assay followed by SFA and qRT-PCR,0.32,0.6840,34718356
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,ALDEFLUOR assay followed by SFA,0.32,0.6840,34311079
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,ALDEFLUOR assay followed by SFA,0.32,0.6840,34848450
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,ALDEFLUOR assay followed by SFA,0.32,0.6840,35135840
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,ALDEFLUOR assay followed by SFA,0.32,0.6840,35220209
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,Culture of cells in electrospun scaffolds followed by ALDEFLUOR assay,0.32,0.6840,34841239
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,ALDEFLUOR assay followed by CFA,0.32,0.6840,18681906
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Bevacizumab,ALDEFLUOR assay followed by Migration and Invasion assay,0.32,0.6840,31497360
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,ALDEFLUOR assay followed by SFA,0.32,0.6840,28817737
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,ALDEFLUOR assay followed by SFA,0.32,0.6840,28966724
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,ALDEFLUOR assay followed by SFA,0.32,0.6840,30559934
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs and SFA,0.32,0.6840,31745977
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by ALDEFLUOR assay,0.32,0.6840,28817737
ALDH1A1,LTM,NA,402,Skin Cancer,NA,Mel-RM,NA,Western Blotting and ALDEFLUOR assay followed by SFA,0.4,0.6840,29408459
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MGC-803,NA,ALDEFLUOR assay followed by qRT-PCR and Western Blotting,0.6,0.6840,32638620
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting,0.6,0.6840,27524415
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting,0.6,0.6840,28337375
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting,0.6,0.6840,28336807
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by ALDEFLUOR assay and Western Blotting,0.4,0.6840,20940707
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by ALDEFLUOR assay and qRT-PCR,0.4,0.6840,33110235
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,ALDEFLUOR assay followed by qRT-PCR,0.4,0.6840,23073476
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA and Western Blotting,0.4,0.6840,35428310
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,CFA followed by Western Blotting,0.4,0.6840,25015789
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Western Blotting,0.4,0.6840,26458814
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,Western Blotting,0.4,0.6840,24676703
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting,0.4,0.6840,31106493
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting,0.4,0.6840,29179494
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting followed by SFA,0.4,0.6840,28490735
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA and CFA followed by ALDEFLUOR assay and  FACs,0.4,0.6840,20940707
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,ALDEFLUOR assay followed by CFA,0.4,0.6840,32550888
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,ALDEFLUOR assay,0.4,0.6840,31312365
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,ALDEFLUOR assay,0.4,0.6840,24194908
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by SFA,0.4,0.6840,27999190
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by ALDEFLUOR assay,0.4,0.6840,20664924
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MKN45,NA,ALDEFLUOR assay followed by qRT-PCR and Western Blotting,0.6,0.6840,32638620
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MKN45,Acetylcholine,SFA followed by qRT-PCR and IF staining,0.6,0.6840,30207200
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by ALDEFLUOR assay and IF staining,0.6,0.6840,32707998
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MKN45,NA,ALDEFLUOR assay followed by SFA and qRT-PCR,0.6,0.6840,34628473
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and FACs,0.6,0.6840,27157616
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting,0.6,0.6840,34646768
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.6,0.6840,28337375
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MKN45,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,27279633
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MKN45,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,29212193
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.6,0.6840,27620279
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,34173116
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,32863948
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by FACs,0.6,0.6840,31879364
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,MOR,Cisplatin,ALDEFLUOR assay,0.12,0.6840,23349823
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,MU-PK-1,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,25075094
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Carcinoma,NCI-H1915,NA,SFA followed by FACs,0.12,0.6840,23418195
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,22692956
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,SFA and ALDEFLUOR assay,0.12,0.6840,20979610
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,SFA and ALDEFLUOR assay,0.12,0.6840,22422628
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,21169409
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,OHSU-974,NA,ALDEFLUOR assay,0.12,0.6840,25340704
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,OM-1,NA,ALDEFLUOR assay followed by qRT-PCR and SFA,0.32,0.6840,26399460
ALDH1A1,LTM,NA,402,Colon Cancer,Carcinoma,OUMS-23,NA,qRT-PCR,0.2,0.6840,30284085
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and IF staining followed by FACs and qRT-PCR,0.56,0.6840,28580169
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR and Western Blotting,0.56,0.6840,30802827
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR and Western Blotting,0.56,0.6840,30802827
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by qRT-PCR and Western Blotting,0.56,0.6840,24040121
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by qRT-PCR,0.56,0.6840,29444383
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and Western Blotting,0.56,0.6840,35428310
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.56,0.6840,33359649
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,CFA followed by Western Blotting,0.56,0.6840,25015789
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.56,0.6840,26458814
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.56,0.6840,28802012
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting,0.56,0.6840,29179494
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,ALDEFLUOR assay and  FACs followed by SFA,0.56,0.6840,24489910
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by ALDEFLUOR assay,0.56,0.6840,29656202
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by ALDEFLUOR assay,0.56,0.6840,30954649
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,Migration and Invasion assay followed by RT-PCR and SFA,0.56,0.6840,30852389
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qPCR,0.56,0.6840,31440741
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.56,0.6840,26918054
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.56,0.6840,29975934
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.56,0.6840,31508487
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,ALDEFLUOR assay followed by CFA,0.56,0.6840,32550888
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,ALDEFLUOR assay followed by SFA,0.56,0.6840,34551785
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,ALDEFLUOR assay,0.56,0.6840,21062983
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,ALDEFLUOR assay,0.56,0.6840,24575144
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,ALDEFLUOR assay,0.56,0.6840,28864067
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,ALDEFLUOR assay,0.56,0.6840,31312365
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,ALDEFLUOR assay,0.56,0.6840,31669811
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,ALDEFLUOR assay followed by SFA,0.56,0.6840,27748818
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.56,0.6840,27748818
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.56,0.6840,27999190
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by ALDEFLUOR assay,0.56,0.6840,30954649
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.56,0.6840,26887043
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR,0.2,0.6840,31508487
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,SFA followed by RT-PCR and Western Blotting,0.48,0.6840,31233201
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,ALDEFLUOR assay and  FACs followed by SFA and RT-PCR,0.48,0.6840,22935675
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,SFA followed by Western Blotting,0.48,0.6840,33955683
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Osimertinib,SFA followed by Western Blotting,0.48,0.6840,30910592
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Osimertinib+Gefitinib,SFA followed by Western Blotting,0.48,0.6840,30910592
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Afatinib,ALDEFLUOR assay followed by FACs,0.48,0.6840,28521301
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,ALDEFLUOR assay followed by FACs and SFA,0.48,0.6840,28927099
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Erlotinib,FACs followed by ALDEFLUOR assay and SFA,0.48,0.6840,24047698
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qRT-PCR,0.48,0.6840,33764690
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qPCR followed by SFA and Tumorigenicity assay,0.48,0.6840,24489728
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,ALDEFLUOR assay and SFA,0.48,0.6840,31765940
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,ALDEFLUOR assay followed by SP assay and Tumorigenicity assay,0.48,0.6840,25871388
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Carcinoma,PK59,NA,ALDEFLUOR assay followed by SFA and qRT-PCR,0.32,0.6840,34414448
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,RT-112,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,26681916
ALDH1A1,LTM,NA,402,Breast Cancer,Carcinoma,S-68,NA,ALDEFLUOR assay,0.12,0.6840,19190339
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,ALDEFLUOR assay,0.12,0.6840,29515788
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,22692956
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,24475244
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,ALDEFLUOR assay,0.12,0.6840,25217518
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,ALDEFLUOR assay and SFA,0.12,0.6840,32357409
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,ALDEFLUOR assay followed by SP assay,0.12,0.6840,23843890
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SFA and ALDEFLUOR assay,0.12,0.6840,20979610
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SFA and ALDEFLUOR assay,0.12,0.6840,22422628
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,21169409
ALDH1A1,LTM,NA,402,Small Cell Lung Cancer,Carcinoma,SBC-5,NA,SFA followed by RT-PCR,0.2,0.6840,28248963
ALDH1A1,LTM,NA,402,Bladder Cancer,Squamous Cell Carcinoma,SCaBER,NA,ALDEFLUOR assay,0.12,0.6840,28445934
ALDH1A1,LTM,NA,402,Bladder Cancer,Squamous Cell Carcinoma,SCaBER,NA,FACs,0.12,0.6840,30349299
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,Cisplatin,Western Blotting followed by SFA,0.28,0.6840,34795388
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,ALDEFLUOR assay,0.28,0.6840,29515788
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and qRT-PCR followed by Western Blotting ,0.48,0.6840,34427968
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.48,0.6840,34090492
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.48,0.6840,34646768
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.6840,30624124
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,ALDEFLUOR assay followed by SFA,0.48,0.6840,27279633
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by ALDEFLUOR assay,0.48,0.6840,34173116
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by ALDEFLUOR assay,0.48,0.6840,34802261
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,RT-PCR and Western Blotting,0.48,0.6840,30541574
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,RT-PCR and Western Blotting,0.48,0.6840,30541574
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,RT-PCR followed by Western Blotting,0.48,0.6840,31545416
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,RT-PCR followed by Western Blotting,0.48,0.6840,31545416
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by ALDEFLUOR assay and FACs,0.48,0.6840,31726667
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,ALDEFLUOR assay followed by SFA,0.48,0.6840,33389402
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,ALDEFLUOR assay followed by SFA,0.48,0.6840,35220209
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by ALDEFLUOR assay,0.48,0.6840,32859993
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,ALDEFLUOR assay,0.48,0.6840,19190339
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,ALDEFLUOR assay,0.48,0.6840,19190339
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,ALDEFLUOR assay,0.48,0.6840,29080749
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,ALDEFLUOR assay,0.48,0.6840,29080749
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,ALDEFLUOR assay followed by SFA,0.48,0.6840,29620216
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,ALDEFLUOR assay followed by SFA,0.48,0.6840,29620216
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,ALDEFLUOR assay followed by SP assay and SFA,0.48,0.6840,30613295
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,ALDEFLUOR assay followed by SP assay and SFA,0.48,0.6840,30613295
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,Fructose,SFA followed by ALDEFLUOR assay,0.48,0.6840,29796188
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,Fructose,SFA followed by ALDEFLUOR assay,0.48,0.6840,29796188
ALDH1A1,LTM,NA,402,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs,0.48,0.6840,31726667
ALDH1A1,LTM,NA,402,Breast Cancer,Carcinoma,SKBR7,NA,ALDEFLUOR assay,0.12,0.6840,19190339
ALDH1A1,LTM,NA,402,Skin Cancer,NA,SK-MEL-1,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,31582018
ALDH1A1,LTM,NA,402,Skin Cancer,NA,SK-MEL-1,NA,SFA followed by SP assay and FACs,0.12,0.6840,33052601
ALDH1A1,LTM,NA,402,Skin Cancer,NA,SK-MEL-28,NA,Western Blotting and ALDEFLUOR assay,0.4,0.6840,29408459
ALDH1A1,LTM,NA,402,Skin Cancer,NA,SK-MEL-28,NA,ALDEFLUOR assay and SFA,0.4,0.6840,27566591
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,SK-MES-1,Cisplatin,ALDEFLUOR assay followed by CFA,0.12,0.6840,33550205
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,32863948
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,ALDEFLUOR assay,0.12,0.6840,32655789
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,22807978
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,SQ20B,NA,SP assay followed by FACs and SFA,0.12,0.6840,23955575
ALDH1A1,LTM,NA,402,Gastric Cancer,Adenocarcinoma,ST2957,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,32863948
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,Paclitaxel,ALDEFLUOR assay and SFA followed by Western Blotting and qPCR,0.6,0.6840,28703802
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,33674749
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,35135840
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,35508987
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by FACs,0.6,0.6840,35357654
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,ALDEFLUOR assay  followed by SFA,0.6,0.6840,19190339
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,29027990
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,30052635
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,30344009
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,ALDEFLUOR assay followed by Tumorigenicity assay,0.6,0.6840,30632269
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,28978083
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,29471829
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by FACs,0.6,0.6840,30242135
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,Western Blotting and SFA followed by ALDEFLUOR assay,0.4,0.6840,33797754
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,ALDEFLUOR assay followed by RT-PCR and  SFA,0.4,0.6840,31850822
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by Western Blotting,0.4,0.6840,29243835
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by Western Blotting,0.4,0.6840,29356693
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,ALDEFLUOR assay followed by SFA,0.4,0.6840,35064101
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,ALDEFLUOR assay followed by SFA,0.4,0.6840,35110528
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,ALDEFLUOR assay followed by SFA,0.4,0.6840,35512572
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,Paclitaxel,SFA and ALDEFLUOR assay,0.4,0.6840,35401817
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by ALDEFLUOR assay,0.4,0.6840,33057995
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.4,0.6840,35357654
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,ALDEFLUOR assay  followed by SFA,0.4,0.6840,19190339
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,Docetaxel,ALDEFLUOR assay and SFA,0.4,0.6840,29921732
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,ALDEFLUOR assay followed by SFA,0.4,0.6840,29620216
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,ALDEFLUOR assay followed by SFA,0.4,0.6840,30344009
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,ALDEFLUOR assay followed by SFA,0.4,0.6840,30460610
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,ALDEFLUOR assay followed by SFA,0.4,0.6840,31619923
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by ALDEFLUOR assay,0.4,0.6840,28054666
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,Docetaxel,SFA followed by ALDEFLUOR assay,0.4,0.6840,28978427
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,Doxorubicin,SFA followed by ALDEFLUOR assay,0.4,0.6840,28978427
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,Paclitaxel,SFA followed by ALDEFLUOR assay,0.4,0.6840,28978427
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,Paclitaxel,SFA followed by ALDEFLUOR assay,0.4,0.6840,30482914
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by ALDEFLUOR assay,0.4,0.6840,31337967
ALDH1A1,LTM,NA,402,Breast Cancer,Carcinoma,SUM190PT,Paclitaxel,ALDEFLUOR assay and SFA followed by Western Blotting and qPCR,0.6,0.6840,28703802
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay and ALDEFLUOR assay followed by Western Blotting and SFA,0.4,0.6840,32781084
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting,0.4,0.6840,33288882
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Tumorigenicity assay and Western Blotting,0.4,0.6840,25003666
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR,0.4,0.6840,31508487
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.4,0.6840,28947139
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,ALDEFLUOR assay,0.4,0.6840,30954649
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by FACs,0.4,0.6840,26439804
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,SW403,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,33489876
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,ALDEFLUOR assay followed by SFA and RT-PCR,0.32,0.6840,28464221
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA and qRT-PCR,0.32,0.6840,29693155
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by qPCR and ALDEFLUOR assay,0.32,0.6840,31349708
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by RT-PCR and ALDEFLUOR assay,0.32,0.6840,30774996
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by Western Blotting,0.32,0.6840,26785732
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by Western Blotting,0.32,0.6840,30144515
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,ALDEFLUOR assay followed by FACs and SFA,0.32,0.6840,21694723
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,IHC staining,0.32,0.6840,31810923
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs for CSC marker followed by qRT-PCR,0.32,0.6840,33744851
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,ALDEFLUOR assay,0.32,0.6840,19923910
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,ALDEFLUOR assay,0.32,0.6840,24122993
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,ALDEFLUOR assay followed by SFA,0.32,0.6840,27927191
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,ALDEFLUOR assay followed by SFA,0.32,0.6840,29805588
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,ALDEFLUOR assay followed by SFA,0.32,0.6840,30410666
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,ALDEFLUOR assay followed by SFA and Tumorigenicity assay,0.32,0.6840,22074823
ALDH1A1,LTM,NA,402,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by ALDEFLUOR assay and Tumorigenicity assay,0.32,0.6840,21720213
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by qPCR and ALDEFLUOR assay,0.32,0.6840,31349708
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by RT-PCR and ALDEFLUOR assay,0.32,0.6840,30774996
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,5-fluorouracil,FACs followed by SFA and ALDEFLUOR assay,0.32,0.6840,27659530
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,ALDEFLUOR assay followed by SFA,0.32,0.6840,33489876
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,ALDEFLUOR assay,0.32,0.6840,19923910
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,ALDEFLUOR assay followed by SFA,0.32,0.6840,29805588
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs,0.32,0.6840,25154976
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs,0.32,0.6840,32635858
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs and CFA,0.32,0.6840,25154976
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by CFA and ALDEFLUOR assay,0.32,0.6840,30115896
ALDH1A1,LTM,NA,402,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SP assay followed by ALDEFLUOR assay and Tumorigenicity assay,0.32,0.6840,21720213
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,T24,Cisplatin,RT-PCR,0.2,0.6840,27474203
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.2,0.6840,28895409
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.2,0.6840,30592142
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.2,0.6840,31187490
ALDH1A1,LTM,NA,402,Bladder Cancer,Carcinoma,T24,Cisplatin,ALDEFLUOR assay followed by CFA,0.2,0.6840,22399585
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by ALDEFLUOR assay and Western Blotting,0.4,0.6840,31497349
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by ALDEFLUOR assay and IF staining,0.4,0.6840,28935760
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by ALDEFLUOR assay and RT-PCR,0.4,0.6840,30131941
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,IF staining followed by SFA,0.4,0.6840,31591823
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,IF staining followed by SFA,0.4,0.6840,31595560
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,ALDEFLUOR assay,0.4,0.6840,34315857
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,ALDEFLUOR assay followed by SFA,0.4,0.6840,34944852
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by ALDEFLUOR assay,0.4,0.6840,33144693
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,ALDEFLUOR assay followed by SFA,0.4,0.6840,28802057
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Tamoxifen,FACs followed by SFA,0.4,0.6840,29602199
ALDH1A1,LTM,NA,402,Glioblastoma,NA,T98G,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,28685346
ALDH1A1,LTM,NA,402,Bladder Cancer,Transitional Cell Carcinoma,TCCSUP,Cisplatin,ALDEFLUOR assay followed by CFA,0.12,0.6840,22399585
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,TR146,NA,FACs followed by SFA,0.12,0.6840,25471937
ALDH1A1,LTM,NA,402,Glioblastoma,NA,U-87MG,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,31035045
ALDH1A1,LTM,NA,402,Glioblastoma,NA,U-87MG,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,28685346
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-1,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,21304586
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-2,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,23585151
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,34689150
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,Cisplatin,FACs followed by SFA,0.12,0.6840,34689150
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,24533098
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,FACs,0.12,0.6840,29028842
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,Cisplatin,FACs,0.12,0.6840,29861860
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,FACs,0.12,0.6840,32066820
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-103,NA,SFA followed by FACs and qRT-PCR,0.32,0.6840,25428916
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-103,NA,FACs followed by SFA,0.32,0.6840,23558285
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-104,NA,ALDEFLUOR assay followed by Tumorigenicity assay,0.12,0.6840,22162267
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-11B,NA,FACs followed by SFA,0.12,0.6840,27780858
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-11B,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,21304586
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,qRT-PCR followed by SFA,0.2,0.6840,32773768
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,SFA followed by RT-PCR,0.2,0.6840,31742606
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-14B,NA,SFA followed by FACs and qRT-PCR,0.32,0.6840,25428916
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-17A,NA,FACs,0.12,0.6840,32066820
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-17B,NA,FACs followed by SFA,0.12,0.6840,25471937
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-2,NA,ALDEFLUOR assay,0.12,0.6840,24382806
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,34689150
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,Cisplatin,FACs followed by SFA,0.12,0.6840,34689150
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,NA,FACs,0.12,0.6840,32066820
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,NA,FACs followewd by SFA,0.12,0.6840,22014666
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,Cisplatin,ALDEFLUOR assay and SFA,0.12,0.6840,29121598
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,Cisplatin,ALDEFLUOR assay followed by SFA,0.12,0.6840,24709421
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,34689150
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,NA,FACs followed by SFA,0.12,0.6840,27780858
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,Cisplatin,FACs followed by SFA,0.12,0.6840,34689150
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,Cisplatin,FACs,0.12,0.6840,29861860
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,NA,FACs followewd by SFA,0.12,0.6840,22014666
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-29,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,23585151
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,qRT-PCR followed by SFA,0.2,0.6840,32773768
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,ALDEFLUOR assay followed by SFA,0.2,0.6840,23585151
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-47,NA,ALDEFLUOR assay,0.12,0.6840,24382806
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-47,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,23585151
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-47,NA,FACs,0.12,0.6840,29028842
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-47,NA,FACs,0.12,0.6840,32066820
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-58,NA,FACs followed by SFA,0.12,0.6840,25471937
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-74A,NA,ALDEFLUOR assay followed by SFA,0.12,0.6840,26742076
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-74A,NA,SFA followed by FACs,0.12,0.6840,22791367
ALDH1A1,LTM,NA,402,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6840,28870814
ALDH1A1,LTM,NA,402,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6840,32661469
ALDH1A1,LTM,NA,402,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.6840,31180522
ALDH1A1,LTM,NA,402,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,Benzidine,SFA followed by Western Blotting,0.48,0.6840,33552265
ALDH1A1,LTM,NA,402,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting,0.48,0.6840,33552265
ALDH1A1,LTM,NA,402,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR,0.48,0.6840,26452033
ALDH1A1,LTM,NA,402,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,ALDEFLUOR assay followed by SFA,0.48,0.6840,34405274
ALDH1A1,LTM,NA,402,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,ALDEFLUOR assay,0.48,0.6840,27769244
ALDH1A1,LTM,NA,402,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,ALDEFLUOR assay followed by SFA,0.48,0.6840,32676121
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UPCI-SCC-090,NA,FACs,0.12,0.6840,32066820
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UPCI-SCC-154,NA,FACs,0.12,0.6840,32066820
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,ALDEFLUOR assay,0.12,0.6840,23108794
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,ALDEFLUOR assay,0.12,0.6840,23108794
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-22,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,21304586
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,ALDEFLUOR assay,0.12,0.6840,23108794
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,ALDEFLUOR assay,0.12,0.6840,23108794
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,ALDEFLUOR assay,0.12,0.6840,23108794
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-38,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.6840,31382448
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,ALDEFLUOR assay followed by SFA and Tumorigenicity assay,0.12,0.6840,26323893
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,21304586
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,VU-1131,NA,ALDEFLUOR assay and SFA,0.12,0.6840,25340704
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,VU-1365,NA,ALDEFLUOR assay and SFA followed by RT-PCR,0.32,0.6840,25340704
ALDH1A1,LTM,NA,402,Skin Cancer,NA,WM793,NA,ALDEFLUOR assay followed by CFA,0.12,0.6840,29049740
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN19,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,25024430
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN26,NA,SFA followed by ALDEFLUOR assay,0.12,0.6840,25024430
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,ZR-75-1,NA,ALDEFLUOR assay followed by SP assay and SFA,0.12,0.6840,30613295
ALDH1A1,LTM,NA,402,Luminal A Breast Cancer,Ductal Carcinoma,ZR-75-1,Fructose,SFA followed by ALDEFLUOR assay,0.12,0.6840,29796188
ALDH1A1,LTM,NA,402,Breast Cancer,Ductal Carcinoma,ZR-75-30,NA,FACs followed by SFA,0.12,0.6840,30478301
ALDH1A1,LTM,NA,402,Bladder Cancer,NA,Primary,NA,IHC staining,0.32,0.6840,34101386
ALDH1A1,LTM,NA,402,Bladder Cancer,NA,Primary,NA,IHC staining,0.32,0.6840,20142235
ALDH1A1,LTM,NA,402,Bladder Cancer,NA,Primary,NA,IHC staining,0.32,0.6840,25843691
ALDH1A1,LTM,NA,402,Bladder Cancer,NA,Primary,NA,FACs followed by SFA,0.32,0.6840,32019566
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,Western Blotting and IF staining followed by qRT-PCR,0.96,0.6840,30622340
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,qPCR followed by IHC staining,0.96,0.6840,29660692
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,ALDEFLUOR assay followed by SFA and qRT-PCR,0.96,0.6840,31728117
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,IHC staining,0.96,0.6840,35083162
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,IHC staining,0.96,0.6840,34644211
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,IHC staining,0.96,0.6840,27994520
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,IHC staining,0.96,0.6840,28766688
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,IHC staining,0.96,0.6840,29306324
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,IHC staining,0.96,0.6840,29336465
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,IHC staining,0.96,0.6840,29416796
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,IHC staining,0.96,0.6840,29843115
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,IHC staining,0.96,0.6840,29845398
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,IHC staining,0.96,0.6840,30364293
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,IHC staining,0.96,0.6840,31516750
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by qRT-PCR,0.96,0.6840,33799422
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.96,0.6840,28746471
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.96,0.6840,30587593
ALDH1A1,LTM,NA,402,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen,SFA followed by qRT-PCR,0.96,0.6840,31693936
ALDH1A1,LTM,NA,402,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen+Fulvestrant,SFA followed by qRT-PCR,0.96,0.6840,31693936
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,ALDEFLUOR assay,0.96,0.6840,34476645
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,ALDEFLUOR assay,0.96,0.6840,34778599
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,ALDEFLUOR assay,0.96,0.6840,33471244
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,ALDEFLUOR assay,0.96,0.6840,28588211
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,ALDEFLUOR assay followed by CFA,0.96,0.6840,34377198
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,Doxorubicin,ALDEFLUOR assay followed by SFA,0.96,0.6840,33221681
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,Carboplatin,ALDEFLUOR assay followed by SFA,0.96,0.6840,33221681
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,Paclitaxel,ALDEFLUOR assay followed by SFA,0.96,0.6840,33221681
ALDH1A1,LTM,NA,402,Breast Cancer,Ductal Carcinoma,Primary,NA,ALDEFLUOR assay followed by SFA,0.96,0.6840,30050081
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,FACs,0.96,0.6840,34073849
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,FACs,0.96,0.6840,34572409
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,SFA followed by ALDEFLUOR assay,0.96,0.6840,35053617
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,Chemotherapy,SFA followed by ALDEFLUOR assay,0.96,0.6840,28835684
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,SFA followed by ALDEFLUOR assay,0.96,0.6840,28935760
ALDH1A1,LTM,NA,402,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.96,0.6840,30359767
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,SFA followed by ALDEFLUOR assay and IF staining,0.52,0.6840,23642368
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,SFA followed by FACs and IF staining,0.52,0.6840,27077950
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,Oxaliplatin,SFA followed by Western Blotting,0.52,0.6840,30091203
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,Oxaliplatin,SFA followed by Western Blotting,0.52,0.6840,30091203
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,IHC staining,0.52,0.6840,34609414
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,IHC staining,0.52,0.6840,22670157
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,IHC staining,0.52,0.6840,29102042
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,IHC staining,0.52,0.6840,29328371
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,IHC staining,0.52,0.6840,31000786
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,IHC staining,0.52,0.6840,31186779
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,IHC staining,0.52,0.6840,31516883
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,IHC staining followed by Tumorigenicity assay,0.52,0.6840,22902411
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,SFA and IHC staining,0.52,0.6840,24953984
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,Tumorigenicity assay followed by IHC staining and SFA,0.52,0.6840,19808966
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,qRT-PCR,0.52,0.6840,35392530
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,qRT-PCR,0.52,0.6840,24492635
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,ALDEFLUOR assay,0.52,0.6840,22902411
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,ALDEFLUOR assay,0.52,0.6840,27448961
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,30738331
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,ALDEFLUOR assay followed byTumorigenicity assay,0.52,0.6840,28881576
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,FACs,0.52,0.6840,22871210
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,SFA followed by ALDEFLUOR assay,0.52,0.6840,27197176
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,5-Fluorouracil,SFA followed by FACs,0.52,0.6840,30091203
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,Oxaliplatin,SFA followed by FACs,0.52,0.6840,30091203
ALDH1A1,LTM,NA,402,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.52,0.6840,23643941
ALDH1A1,LTM,NA,402,Gastric Cancer,NA,Primary,5-Fluorouracil,RT-PCR and IF staining,0.6,0.6840,31960523
ALDH1A1,LTM,NA,402,Gastric Cancer,NA,Primary,NA,Western Blotting followed by SFA,0.6,0.6840,31309567
ALDH1A1,LTM,NA,402,Gastric Cancer,Submucosal,Primary,NA,IHC staining,0.6,0.6840,33450435
ALDH1A1,LTM,NA,402,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,0.6840,33118117
ALDH1A1,LTM,NA,402,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,0.6840,30240769
ALDH1A1,LTM,NA,402,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,0.6840,31611965
ALDH1A1,LTM,NA,402,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,0.6840,28046028
ALDH1A1,LTM,NA,402,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,0.6840,28952294
ALDH1A1,LTM,NA,402,Gastric Cancer,NA,Primary,NA,FACs followed by SFA,0.6,0.6840,27620279
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by FACs and IF staining,0.52,0.6840,22791367
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.52,0.6840,35140342
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.52,0.6840,26622836
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.52,0.6840,25871396
ALDH1A1,LTM,NA,402,Head and Neck Cancer,NA,Primary,NA,IHC staining,0.52,0.6840,26556875
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.52,0.6840,31811857
ALDH1A1,LTM,NA,402,Head and Neck Cancer,NA,Primary,NA,IHC staining,0.52,0.6840,32816856
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IF staining,0.52,0.6840,25320014
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.52,0.6840,22333601
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,ALDEFLUOR assay,0.52,0.6840,20073073
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,ALDEFLUOR assay,0.52,0.6840,22361100
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,ALDEFLUOR assay,0.52,0.6840,30067878
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,ALDEFLUOR assay,0.52,0.6840,27424180
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,21292542
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,24382806
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,ALDEFLUOR assay followed by Tumorigenicity assay and SFA,0.52,0.6840,19450560
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,ALDEFLUOR assay followed by Tumorigenicity assay and SFA,0.52,0.6840,20036608
ALDH1A1,LTM,NA,402,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,ALDEFLUOR assay followed by Tumorigenicity assay and SFA,0.52,0.6840,20936121
ALDH1A1,LTM,NA,402,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.6840,25963795
ALDH1A1,LTM,NA,402,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.6840,25963795
ALDH1A1,LTM,NA,402,Lung Cancer,Adenocarcinoma,Primary,NA,SFA and FACs followed by IHC staining and IF staining,0.84,0.6840,28855609
ALDH1A1,LTM,NA,402,Lung Cancer,NA,Primary,NA,FACs followed by IHC staining,0.84,0.6840,32500024
ALDH1A1,LTM,NA,402,Lung Cancer,NA,Primary,NA,IHC staining followed by ALDEFLUOR assay,0.84,0.6840,19536353
ALDH1A1,LTM,NA,402,Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by ALDEFLUOR assay and qPCR,0.84,0.6840,26621583
ALDH1A1,LTM,NA,402,Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.84,0.6840,23252868
ALDH1A1,LTM,NA,402,Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.84,0.6840,24235845
ALDH1A1,LTM,NA,402,Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.84,0.6840,26046383
ALDH1A1,LTM,NA,402,Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.84,0.6840,28476825
ALDH1A1,LTM,NA,402,Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.84,0.6840,30303135
ALDH1A1,LTM,NA,402,Lung Cancer,NA,Primary,NA,SFA followed by IF staining,0.84,0.6840,25955492
ALDH1A1,LTM,NA,402,Lung Cancer,Adenocarcinoma,Primary,Erlotinib,RT-PCR followed by SFA,0.84,0.6840,28347243
ALDH1A1,LTM,NA,402,Lung Cancer,NA,Primary,PD98059,SFA followed by qRT-PCR,0.84,0.6840,33867839
ALDH1A1,LTM,NA,402,Lung Cancer,NA,Primary,NA,ALDEFLUOR assay,0.84,0.6840,31930020
ALDH1A1,LTM,NA,402,Lung Cancer,NA,Primary,NA,FACs followed by SFA,0.84,0.6840,32391123
ALDH1A1,LTM,NA,402,Lung Cancer,Adenocarcinoma,Primary,NA,SFA and Tumorigenicity assay followed by ALDEFLUOR assay,0.84,0.6840,25034785
ALDH1A1,LTM,NA,402,Lung Cancer,Large Cell Neuroendocrine Carcinoma,Primary,NA,SFA and Tumorigenicity assay followed by ALDEFLUOR assay,0.84,0.6840,25034785
ALDH1A1,LTM,NA,402,Lung Cancer,Squamous Cell Carcinoma,Primary,NA,SFA and Tumorigenicity assay followed by ALDEFLUOR assay,0.84,0.6840,25034785
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining followed by qRT-PCR,0.6,0.6840,26770215
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,NA,Primary,NA,qRT-PCR followed by IHC staining,0.6,0.6840,25881507
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,ALDEFLUOR assay followed by IHC staining,0.6,0.6840,31921651
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,ALDEFLUOR assay followed by IHC staining,0.6,0.6840,31921651
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,FACs followed by qRT-PCR and SFA,0.6,0.6840,28855609
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,IF staining,0.6,0.6840,27920206
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.6,0.6840,33036771
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.6,0.6840,22115706
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.6,0.6840,23878161
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.6,0.6840,24346092
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,NA,Primary,NA,qRT-PCR followed by SFA,0.6,0.6840,29568370
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.6,0.6840,28416482
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.6,0.6840,31506430
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,NA,Primary,NA,ALDEFLUOR assay,0.6,0.6840,33868998
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,NA,Primary,NA,ALDEFLUOR assay followed by CFA and Tumorigenicity assay,0.6,0.6840,30305380
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,NA,Primary,NA,ALDEFLUOR assay followed by SFA,0.6,0.6840,24309934
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,27343631
ALDH1A1,LTM,NA,402,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by ALDEFLUOR assay,0.6,0.6840,27343631
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining followed by FACs,0.52,0.6840,21695188
ALDH1A1,LTM,NA,402,Pancreatic Cancer,NA,Primary,NA,IF staining,0.52,0.6840,33110235
ALDH1A1,LTM,NA,402,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.52,0.6840,33672734
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.52,0.6840,21922151
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.52,0.6840,25240521
ALDH1A1,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,Primary,NA,ALDEFLUOR assay followed by SFA,0.52,0.6840,26691441
ALDH1A1,LTM,NA,402,Skin Cancer,NA,Primary,NA,IHC staining,0.32,0.6840,26391478
ALDH1A1,LTM,NA,402,Skin Cancer,NA,Primary,NA,IHC staining,0.32,0.6840,27870003
ALDH1A1,LTM,NA,402,Skin Cancer,NA,Primary,NA,SFA followed by FACs,0.32,0.6840,20236249
ALDH1A1,LTM,NA,402,Small Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.6840,25963795
ALDH1A1,LTM,NA,402,Triple Negative Breast Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.36,0.6840,33924995
ALDH1A2,LTM,NA,15472,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and qRT-PCR  followed by SFA and Tumorigenicity assay,0.32,0.0117,29262597
ALDH1A2,LTM,NA,15472,Non Small Cell Lung Cancer,Carcinoma,A549,Pemetrexed,ALDEFLUOR assay,0.32,0.0117,26181204
ALDH1A2,LTM,NA,15472,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,Pemetrexed,ALDEFLUOR assay,0.12,0.0117,26181204
ALDH1A2,LTM,NA,15472,Non Small Cell Lung Cancer,Carcinoma,H460,Pemetrexed,ALDEFLUOR assay,0.12,0.0117,26181204
ALDH1A2,LTM,NA,15472,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.28,0.0117,29348560
ALDH1A2,LTM,NA,15472,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by CFA,0.28,0.0117,26840024
ALDH1A2,LTM,NA,15472,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qPCR,0.28,0.0117,28825721
ALDH1A2,LTM,NA,15472,Hepatic Cancer,Carcinoma,Hep3B,NA,ALDEFLUOR assay,0.12,0.0117,34405006
ALDH1A2,LTM,NA,15472,Bladder Cancer,Carcinoma,HT-1376,NA,SFA followed by qRT-PCR,0.2,0.0117,26452033
ALDH1A2,LTM,NA,15472,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qPCR,0.2,0.0117,28825721
ALDH1A2,LTM,NA,15472,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.2,0.0117,34486791
ALDH1A2,LTM,NA,15472,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR,0.2,0.0117,26452033
ALDH1A2,LTM,NA,15472,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,ALDEFLUOR assay followed by SFA and Tumorigenicity assay,0.12,0.0117,26323893
ALDH1A2,LTM,NA,15472,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.32,0.0117,24770634
ALDH1A3,LTM,NA,409,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0201,27836546
ALDH1A3,LTM,NA,409,Non Small Cell Lung Cancer,Carcinoma,A549,Irradiation,SFA and Western Blotting,0.48,0.0201,34163000
ALDH1A3,LTM,NA,409,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting,0.48,0.0201,29235568
ALDH1A3,LTM,NA,409,Colon Cancer,Adenocarcinoma,CACO-2,NA,Western Blotting,0.28,0.0201,29235568
ALDH1A3,LTM,NA,409,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-201,NA,Western Blotting,0.28,0.0201,29235568
ALDH1A3,LTM,NA,409,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,Western Blotting,0.28,0.0201,29235568
ALDH1A3,LTM,NA,409,Dukes Type C Colon Cancer,Adenocarcinoma,COLO-320,NA,Western Blotting,0.28,0.0201,29235568
ALDH1A3,LTM,NA,409,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,FACs for CSC marker followed by qRT-PCR,0.2,0.0201,34530236
ALDH1A3,LTM,NA,409,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,IF staining followed by ALDEFLUOR assay ,0.36,0.0201,30647492
ALDH1A3,LTM,NA,409,Colon Cancer,Adenocarcinoma,HT-29,NA,Western Blotting,0.28,0.0201,29235568
ALDH1A3,LTM,NA,409,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and FACs,0.28,0.0201,24039918
ALDH1A3,LTM,NA,409,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,Western Blotting,0.28,0.0201,29235568
ALDH1A3,LTM,NA,409,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR,0.2,0.0201,30615901
ALDH1A3,LTM,NA,409,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Irradiation,CFA followed by Western Blotting,0.28,0.0201,34708581
ALDH1A3,LTM,NA,409,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR followed by SFA,0.28,0.0201,31850822
ALDH1A3,LTM,NA,409,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.28,0.0201,31545416
ALDH1A3,LTM,NA,409,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cisplatin,SFA followed by ALDEFLUOR assay,0.28,0.0201,28871147
ALDH1A3,LTM,NA,409,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by ALDEFLUOR assay,0.28,0.0201,28871147
ALDH1A3,LTM,NA,409,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,Irradiation,CFA followed by Western Blotting,0.28,0.0201,34708581
ALDH1A3,LTM,NA,409,Pancreatic Cancer,Ductal Adenocarcinoma,PaCa-44,NA,Prolonged exposure to simulated microgravity followed by qRT-PCR,0.2,0.0201,35391557
ALDH1A3,LTM,NA,409,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,RT-PCR followed by Western Blotting,0.48,0.0201,31545416
ALDH1A3,LTM,NA,409,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,RT-PCR followed by Western Blotting,0.48,0.0201,31545416
ALDH1A3,LTM,NA,409,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,RT-PCR followed by SFA,0.2,0.0201,31850822
ALDH1A3,LTM,NA,409,Triple Negative Breast Cancer,Carcinoma,SUM159,Paclitaxel,SFA followed by FACs,0.2,0.0201,30482914
ALDH1B1,LTM,NA,407,Colon Cancer,NA,Primary,NA,IHC staining,0.32,0.0032,22670157
ALDH1B1,LTM,NA,407,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.32,0.0032,26383537
ALDH3A1,LTM,NA,405,Non Small Cell Lung Cancer,Adenocarcinoma,HCC4006,NA,Western Blotting and qRT-PCR followed by SFA,0.48,0.0074,31817719
ALDH3A1,LTM,NA,405,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by qRT-PCR and Western Blotting,0.48,0.0074,27279633
ALDH3A1,LTM,NA,405,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,FACs for CSC marker followed by qRT-PCR and Western Blotting,0.48,0.0074,27279633
ALDH3A1,LTM,NA,405,Skin Cancer,NA,WM266-4,NA,Western Blotting followed by RT-PCR and SFA,0.48,0.0074,31817719
ALK,LTM,NA,427,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA and FACs followed by RT-PCR and Migration assay,0.32,0.0021,25735977
ALK,LTM,NA,427,Non Small Cell Lung Cancer,Adenocarcinoma,H2228,NA,SFA followed by Western Blotting and  FACs,0.4,0.0021,26517679
ALK,LTM,NA,427,Non Small Cell Lung Cancer,Adenocarcinoma,H3122,NA,SFA followed by Western Blotting and  FACs,0.4,0.0021,26517679
ANPEP,LTM,NA,500,Hepatic Cancer,NA,HAK-1B,NA,SFA followed by FACs and qRT-PCR,0.32,0.0117,24325739
ANPEP,LTM,NA,500,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.2,0.0117,28554132
ANPEP,LTM,NA,500,Hepatic Cancer,Carcinoma,Huh7,NA,FACs,0.2,0.0117,21879266
ANPEP,LTM,NA,500,Hepatic Cancer,Carcinoma,Huh7,NA,FACs,0.2,0.0117,25404478
ANPEP,LTM,NA,500,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by FACs and SFA,0.2,0.0117,20697159
ANPEP,LTM,NA,500,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and Transcriptomics,0.2,0.0117,21618577
ANPEP,LTM,NA,500,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,FACs,0.12,0.0117,21879266
ANPEP,LTM,NA,500,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SP assay followed by FACs and SFA,0.12,0.0117,20697159
ANPEP,LTM,NA,500,Hepatic Cancer,Carcinoma,Primary,NA,FACs,0.2,0.0117,22969999
ANPEP,LTM,NA,500,Hepatic Cancer,NA,Primary,NA,SP assay followed by FACs,0.2,0.0117,23104270
ANTXR2,LTM,NA,21732,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,FACs and qRT-PCR followed by Western Blotting and SFA,0.6,0.0042,29662192
ANTXR2,LTM,NA,21732,Gastric Cancer,NA,XN0422,NA,FACs and qRT-PCR followed by Western Blotting and SFA,0.6,0.0042,29662192
APBB1,LTM,NA,581,Non Small Cell Lung Cancer,Carcinoma,H460,NA,RT-PCR and Western Blotting followed by SFA and Migration Invasion assay,0.48,0.0011,27836546
ASCL1,LTM,NA,738,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,qRT-PCR,0.2,0.0011,31273285
ASCL2,LTM,NA,739,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by SFA,0.24,0.0053,32037723
ASCL2,LTM,NA,739,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.24,0.0053,31544978
ASCL2,LTM,NA,739,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.2,0.0053,32037723
ASCL2,LTM,NA,739,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.2,0.0053,31544978
ATF4,LTM,NA,786,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by RT-PCR,0.2,0.0011,29601799
ATF4,LTM,NA,786,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR,0.2,0.0011,29601799
ATF6,LTM,NA,791,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by RT-PCR,0.2,0.0011,29601799
ATF6,LTM,NA,791,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR,0.2,0.0011,29601799
ATXN1,LTM,NA,10548,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining,0.24,0.0064,21520032
ATXN1,LTM,NA,10548,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining,0.24,0.0064,26261505
ATXN1,LTM,NA,10548,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by SFA and FACs,0.12,0.0064,17881900
AXIN2,LTM,NA,904,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by qPCR,0.2,0.0064,29449559
AXIN2,LTM,NA,904,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.2,0.0064,29383157
AXIN2,LTM,NA,904,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen,SFA followed by qRT-PCR,0.28,0.0064,31693936
AXIN2,LTM,NA,904,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen+Fulvestrant,SFA followed by qRT-PCR,0.28,0.0064,31693936
B3GALT5,LTM,NA,920,Breast Cancer,NA,Primary,NA,qRT-PCR,0.28,0.0011,33413566
B4GALNT1,LTM,NA,4117,Luminal A Breast Cancer,Ductal Carcinoma,HCC1395,NA,qRT-PCR,0.2,0.0042,33722905
B4GALNT1,LTM,NA,4117,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,qRT-PCR,0.2,0.0042,33722905
B4GALNT1,LTM,NA,4117,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR,0.2,0.0042,33722905
B4GALNT1,LTM,NA,4117,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,qRT-PCR,0.2,0.0042,33722905
B4GALNT1,LTM,NA,4117,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,FACs,0.12,0.0042,29221154
B4GALNT1,LTM,NA,4117,Breast Cancer,NA,Primary,NA,qRT-PCR followed by ELISA,0.64,0.0042,35321364
B4GALNT1,LTM,NA,4117,Breast Cancer,NA,Primary,NA,IHC staining,0.64,0.0042,33722905
B4GALT1,LTM,NA,924,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.2,0.0011,31717588
BACH1,LTM,NA,935,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.28,0.0011,34949193
BACH1,LTM,NA,935,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Western Blotting,0.28,0.0011,34949193
BAG3,LTM,NA,939,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0021,28703799
BAG3,LTM,NA,939,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0021,28703799
BAG3,LTM,NA,939,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0021,28703799
BCL2,LTM,NA,990,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.2,0.0011,33603536
BCL6,LTM,NA,1001,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.2,0.0032,35357654
BCL6,LTM,NA,1001,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by qRT-PCR,0.2,0.0032,35357654
BCL6,LTM,NA,1001,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by qRT-PCR,0.2,0.0032,35357654
BCRP1,LTM,NA,39073,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by SFA and FACs,0.12,0.0011,17881900
BGN,LTM,NA,1044,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by Western Blotting,0.28,0.0032,35053617
BHLHA15,LTM,NA,22265,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.32,0.0021,33109579
BHMT,LTM,NA,1047,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR,0.2,0.0011,32065779
BHMT,LTM,NA,1047,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.2,0.0011,32065779
BIRC5,LTM,NA,593,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.2,0.0053,27380877
BIRC5,LTM,NA,593,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,qRT-PCR followed by SFA and CFA,0.2,0.0053,27380877
BIRC5,LTM,NA,593,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Docetaxel,qRT-PCR followed by SFA and CFA,0.2,0.0053,27380877
BIRC5,LTM,NA,593,Head and Neck Cancer,Carcinoma,HEp-2,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.2,0.0053,27380877
BIRC5,LTM,NA,593,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,qRT-PCR followed by SFA and CFA,0.2,0.0053,27380877
BIRC5,LTM,NA,593,Head and Neck Cancer,Carcinoma,HEp-2,Docetaxel,qRT-PCR followed by SFA and CFA,0.2,0.0053,27380877
BIRC5,LTM,NA,593,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and RT-PCR followed by SFA,0.48,0.0053,29383157
BIRC5,LTM,NA,593,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.48,0.0053,29197410
BIRC5,LTM,NA,593,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.2,0.0053,28893318
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,A-253,NA,RT-PCR followed by CFA,0.2,0.1135,24612587
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,A-253,NA,RT-PCR followed by CFA,0.2,0.1135,24612587
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.1135,30555330
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by Western Blotting and RT-PCR,0.48,0.1135,24333218
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by CFA and Western Blotting,0.48,0.1135,32637578
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by Western Blotting,0.48,0.1135,22370645
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,Pemetrexed,SFA followed by Western Blotting,0.48,0.1135,32726929
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.1135,32782570
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,Western Blotting followed by SFA,0.48,0.1135,29299167
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.48,0.1135,34681614
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.48,0.1135,34681614
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.1135,29138851
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.48,0.1135,21520032
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.48,0.1135,29414668
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.48,0.1135,21124918
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,A549,Dexamethasone+Pemetrexed,FACs followed by SFA,0.48,0.1135,29753869
BMI1,LTM,NA,1066,Breast Cancer,NA,AS-B145,NA,SFA followed by Western Blotting,0.28,0.1135,29100291
BMI1,LTM,NA,1066,Triple Negative Breast Cancer,NA,AS-B244,NA,SFA followed by Western Blotting and RT-PCR,0.48,0.1135,28914785
BMI1,LTM,NA,1066,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Western Blotting,0.28,0.1135,25811929
BMI1,LTM,NA,1066,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,Western Blotting,0.28,0.1135,23437065
BMI1,LTM,NA,1066,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Western Blotting,0.28,0.1135,29100291
BMI1,LTM,NA,1066,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Paclitaxel,Western Blotting and SFA,0.28,0.1135,31308076
BMI1,LTM,NA,1066,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.1135,27576197
BMI1,LTM,NA,1066,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,Western Blotting,0.48,0.1135,23437065
BMI1,LTM,NA,1066,Colon Cancer,Adenocarcinoma,CACO-2,NA,SFA followed by RT-PCR,0.2,0.1135,29312609
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,Western Blotting followed by SFA,0.28,0.1135,34795388
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and Western Blotting,0.28,0.1135,27108536
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and Western Blotting,0.28,0.1135,32194902
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,CALU-1,NA,SFA followed by qRT-PCR,0.2,0.1135,29138851
BMI1,LTM,NA,1066,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,Western Blotting,0.28,0.1135,23437065
BMI1,LTM,NA,1066,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.28,0.1135,25811929
BMI1,LTM,NA,1066,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,RT-PCR followed by SFA,0.2,0.1135,32066912
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.1135,30555330
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by CFA and Western Blotting,0.48,0.1135,32637578
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,H1299,Docetaxel,SFA followed by qRT-PCR,0.48,0.1135,25279705
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs,0.48,0.1135,21124918
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Adenocarcinoma,H1355,Pemetrexed,Western Blotting,0.28,0.1135,32726929
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Adenocarcinoma,H1648,NA,FACs,0.12,0.1135,21124918
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,SFA followed by qPCR and Western Blotting,0.48,0.1135,29702194
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,FACs,0.48,0.1135,21124918
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,Dexamethasone+Pemetrexed,FACs followed by SFA,0.48,0.1135,29753869
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Adenocarcinoma,H1658,Erlotinib,RT-PCR followed by CFA and SFA,0.2,0.1135,31069016
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,FACs,0.12,0.1135,21124918
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,SFA followed by RT-PCR,0.2,0.1135,29414668
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,FACs,0.2,0.1135,21124918
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.28,0.1135,34195288
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by CFA and Western Blotting,0.28,0.1135,32637578
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.28,0.1135,30111255
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.28,0.1135,32782570
BMI1,LTM,NA,1066,Hepatic Cancer,NA,HAK-1B,NA,SP assay followed by qRT-PCR,0.2,0.1135,24325739
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Adenocarcinoma,HCC1833,NA,FACs,0.12,0.1135,21124918
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,SP assay followed by qRT-PCR and CFA,0.2,0.1135,25871388
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,FACs,0.2,0.1135,21124918
BMI1,LTM,NA,1066,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil,SFA followed by Western Blotting and qRT-PCR,0.48,0.1135,28990068
BMI1,LTM,NA,1066,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.48,0.1135,27997180
BMI1,LTM,NA,1066,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by SFA,0.48,0.1135,32066912
BMI1,LTM,NA,1066,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by RT-PCR,0.48,0.1135,23174018
BMI1,LTM,NA,1066,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SFA followed by Western Blotting,0.28,0.1135,27997180
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,HN-1,NA,SFA followed by Western Blotting,0.28,0.1135,25024430
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,HN4,Cisplatin,Western Blotting followed by SFA,0.28,0.1135,34795388
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,HN4,NA,SFA and Western Blotting,0.28,0.1135,32194902
BMI1,LTM,NA,1066,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,Western Blotting followed by SFA,0.28,0.1135,34294320
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-2,NA,qRT-PCR,0.2,0.1135,23992541
BMI1,LTM,NA,1066,Bladder Cancer,Carcinoma,HT-1376,NA,SFA and IF staining,0.24,0.1135,33920080
BMI1,LTM,NA,1066,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by Western Blotting and RT-PCR,0.6,0.1135,22384170
BMI1,LTM,NA,1066,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,qRT-PCR,0.6,0.1135,30772447
BMI1,LTM,NA,1066,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.6,0.1135,21130073
BMI1,LTM,NA,1066,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and qRT-PCR,0.6,0.1135,27556511
BMI1,LTM,NA,1066,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.6,0.1135,27556511
BMI1,LTM,NA,1066,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.6,0.1135,29312609
BMI1,LTM,NA,1066,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting and SFA,0.28,0.1135,32229502
BMI1,LTM,NA,1066,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting followed by SFA and CFA,0.28,0.1135,30908631
BMI1,LTM,NA,1066,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by IHC staining,0.28,0.1135,18829528
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,JLO-1,Metformin,qPCR,0.2,0.1135,30621095
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,KUMA-1,NA,qRT-PCR,0.2,0.1135,23992541
BMI1,LTM,NA,1066,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR,0.2,0.1135,26840266
BMI1,LTM,NA,1066,Dukes Type B Colon Cancer,Adenocarcinoma,LS174T,NA,FACs followed by Western Blotting and RT-PCR,0.6,0.1135,22384170
BMI1,LTM,NA,1066,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by IF staining and SFA,0.52,0.1135,29982992
BMI1,LTM,NA,1066,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.1135,31308814
BMI1,LTM,NA,1066,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.1135,31672029
BMI1,LTM,NA,1066,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.1135,34486791
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,MDA-1986,Cisplatin,Western Blotting and SFA,0.28,0.1135,29121598
BMI1,LTM,NA,1066,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting and RT-PCR,0.48,0.1135,28914785
BMI1,LTM,NA,1066,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.1135,34789263
BMI1,LTM,NA,1066,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.48,0.1135,34294320
BMI1,LTM,NA,1066,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.1135,31308814
BMI1,LTM,NA,1066,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting,0.48,0.1135,29394261
BMI1,LTM,NA,1066,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.1135,35195687
BMI1,LTM,NA,1066,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,SFA followed by qRT-PCR,0.2,0.1135,31337967
BMI1,LTM,NA,1066,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.28,0.1135,34789263
BMI1,LTM,NA,1066,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.1135,28415621
BMI1,LTM,NA,1066,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.1135,32229502
BMI1,LTM,NA,1066,Hepatic Cancer,Carcinoma,MHCC97-H,NA,Western Blotting followed by SFA and CFA,0.48,0.1135,30908631
BMI1,LTM,NA,1066,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.52,0.1135,26840266
BMI1,LTM,NA,1066,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Western Blotting,0.28,0.1135,27279633
BMI1,LTM,NA,1066,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.28,0.1135,27644439
BMI1,LTM,NA,1066,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR followed by SFA,0.28,0.1135,30543303
BMI1,LTM,NA,1066,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR,0.28,0.1135,25081334
BMI1,LTM,NA,1066,Gastric Cancer,Carcinoma,NCI-N87,NA,RT-PCR followed by SFA,0.2,0.1135,30543303
BMI1,LTM,NA,1066,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.28,0.1135,33115754
BMI1,LTM,NA,1066,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.28,0.1135,28802012
BMI1,LTM,NA,1066,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting,0.28,0.1135,23815678
BMI1,LTM,NA,1066,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,Western Blotting followed by SFA,0.28,0.1135,30486896
BMI1,LTM,NA,1066,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,Western Blotting followed by SFA,0.28,0.1135,30486896
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs followed by SFA and RT-PCR,0.32,0.1135,22935675
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qRT-PCR,0.32,0.1135,33764690
BMI1,LTM,NA,1066,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SP assay followed by IHC staining,0.24,0.1135,18829528
BMI1,LTM,NA,1066,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SFA followed by qRT-PCR,0.24,0.1135,22773665
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,Cisplatin,Western Blotting followed by SFA,0.28,0.1135,34795388
BMI1,LTM,NA,1066,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.1135,28415621
BMI1,LTM,NA,1066,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,FACs for CSC marker followed by Western Blotting,0.48,0.1135,27279633
BMI1,LTM,NA,1066,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.1135,27644439
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by qPCR and Western Blotting,0.48,0.1135,29702194
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,Docetaxel,SFA followed by qRT-PCR,0.48,0.1135,25279705
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,SQ20B,NA,SP assay followed by qRT-PCR and SFA,0.2,0.1135,23955575
BMI1,LTM,NA,1066,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by qRT-PCR,0.2,0.1135,31337967
BMI1,LTM,NA,1066,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,RT-PCR followed by SFA,0.2,0.1135,23674142
BMI1,LTM,NA,1066,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.1135,27576197
BMI1,LTM,NA,1066,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,5-Fluorouracil,SFA followed by Western Blotting and qRT-PCR,0.48,0.1135,28990068
BMI1,LTM,NA,1066,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,SP assay followed by CFA and RT-PCR,0.2,0.1135,18787416
BMI1,LTM,NA,1066,Bladder Cancer,Carcinoma,T24,NA,SP assay followed by Western Blotting and IF staining,0.52,0.1135,24337040
BMI1,LTM,NA,1066,Bladder Cancer,Carcinoma,T24,Cisplatin,SFA and SP assay followed by RT-PCR and Western Blotting,0.52,0.1135,22343321
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,TR146,NA,SFA followed by qRT-PCR,0.2,0.1135,25471937
BMI1,LTM,NA,1066,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR,0.2,0.1135,19232461
BMI1,LTM,NA,1066,Glioblastoma,NA,U-251,NA,CFA followed by qRT-PCR,0.2,0.1135,19324493
BMI1,LTM,NA,1066,Glioblastoma,NA,U-87MG,Temozolomide,SFA followed by Western Blotting,0.28,0.1135,33691197
BMI1,LTM,NA,1066,Glioblastoma,NA,U-87MG,NA,Western Blotting and SFA,0.28,0.1135,31717924
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,Western Blotting followed by SFA,0.28,0.1135,34689150
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,Cisplatin,Western Blotting followed by SFA,0.28,0.1135,34689150
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-10B,NA,SP assay and SFA followed by Western Blotting and qRT-PCR,0.48,0.1135,21344428
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.1135,32773768
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,SFA followed by RT-PCR,0.48,0.1135,31742606
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-17B,NA,SFA followed by qRT-PCR,0.2,0.1135,25471937
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,Cisplatin,SFA followed by Western Blotting,0.28,0.1135,24709421
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,NA,Western Blotting followed by SFA,0.28,0.1135,34689150
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,Cisplatin,Western Blotting followed by SFA,0.28,0.1135,34689150
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,Cisplatin,SFA followed by Western Blotting,0.28,0.1135,24709421
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,NA,Western Blotting followed by SFA,0.28,0.1135,34689150
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,Cisplatin,Western Blotting followed by SFA,0.28,0.1135,34689150
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.1135,32773768
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-46,NA,SP assay followed by qRT-PCR,0.2,0.1135,25379016
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-58,NA,SFA followed by qRT-PCR,0.2,0.1135,25471937
BMI1,LTM,NA,1066,Colon Cancer,Adenocarcinoma,WIDR,NA,SFA followed by RT-PCR,0.2,0.1135,25625841
BMI1,LTM,NA,1066,Skin Cancer,NA,WM266-4,NA,SFA followed by RT-PCR,0.2,0.1135,26554153
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN19,NA,SFA followed by Western Blotting,0.28,0.1135,25024430
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN26,NA,SFA followed by Western Blotting,0.28,0.1135,25024430
BMI1,LTM,NA,1066,Bladder Cancer,NA,Primary,NA,IHC staining followed by qRT-PCR and Western Blotting,0.96,0.1135,26489630
BMI1,LTM,NA,1066,Bladder Cancer,Carcinoma,Primary,NA,IHC staining,0.96,0.1135,22343321
BMI1,LTM,NA,1066,Breast Cancer,NA,Primary,NA,IHC staining,0.32,0.1135,18269588
BMI1,LTM,NA,1066,Colon Cancer,NA,Primary,NA,qRT-PCR,0.28,0.1135,24492635
BMI1,LTM,NA,1066,Colon Cancer,NA,Primary,NA,RT-PCR,0.28,0.1135,31057717
BMI1,LTM,NA,1066,Colon Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.1135,23643941
BMI1,LTM,NA,1066,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.28,0.1135,27197180
BMI1,LTM,NA,1066,Gastric Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.1135,33986804
BMI1,LTM,NA,1066,Glioblastoma,NA,Primary,NA,Western Blotting followed by SFA,0.36,0.1135,19427293
BMI1,LTM,NA,1066,Glioblastoma Multiforme,NA,Primary,NA,Isolation of autofluorescence cells followed by SFA and qRT-PCR,0.28,0.1135,33669350
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by Western Blotting,0.36,0.1135,21292542
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,Western Blotting,0.36,0.1135,20036608
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.36,0.1135,34689150
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IF staining,0.36,0.1135,27619333
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IF staining,0.36,0.1135,25320014
BMI1,LTM,NA,1066,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.36,0.1135,19450560
BMI1,LTM,NA,1066,Lung Cancer,NA,Primary,NA,RT-PCR,0.28,0.1135,19536353
BMI1,LTM,NA,1066,Lung Cancer,Adenocarcinoma,Primary,Erlotinib,RT-PCR followed by SFA,0.28,0.1135,28347243
BMI1,LTM,NA,1066,Lung Cancer,NA,Primary,NA,SFA followed by RT-PCR,0.28,0.1135,24019906
BMI1,LTM,NA,1066,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.1135,28416482
BMI1,LTM,NA,1066,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.32,0.1135,26840020
BMP2,LTM,NA,1069,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,Western Blotting,0.28,0.0042,34277708
BMP2,LTM,NA,1069,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting and Migartion Invasion assay,0.28,0.0042,26124007
BMP2,LTM,NA,1069,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs and SFA followed by Migration Invasion assay,0.12,0.0042,28725489
BMP2,LTM,NA,1069,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by FACs,0.12,0.0042,26124007
BOP1,LTM,NA,15519,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.28,0.0021,33797754
BOP1,LTM,NA,15519,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,Western Blotting and SFA,0.28,0.0021,33797754
BOP1,LTM,NA,15519,Triple Negative Breast Cancer,NA,Primary,NA,qRT-PCR followed by SFA,0.28,0.0021,33797754
BRCA1,LTM,NA,1100,Breast Cancer,NA,Primary,NA,MACs followed by CFA,0.2,0.0021,34377198
C5,LTM,NA,1331,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,NA,FACs for CSC marker followed by IF staining,0.24,0.0021,35220209
C5,LTM,NA,1331,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs for CSC marker followed by IF staining,0.24,0.0021,35220209
C5,LTM,NA,1331,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs for CSC marker followed by IF staining,0.24,0.0021,35220209
C5,LTM,NA,1331,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs for CSC marker followed by IF staining,0.24,0.0021,35220209
CACNA2D1,LTM,NA,1399,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by Tumorigenicity assay and SFA and Western Blotting,0.4,0.0064,33707423
CACNA2D1,LTM,NA,1399,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by qPCR and SFA,0.4,0.0064,30464601
CACNA2D1,LTM,NA,1399,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs followed by qPCR and SFA,0.32,0.0064,30464601
CACNA2D1,LTM,NA,1399,Small Cell Lung Cancer,NA,H1408,Etoposide,SFA followed by FACs,0.12,0.0064,29437792
CACNA2D1,LTM,NA,1399,Small Cell Lung Cancer,NA,H1408,NA,SFA followed by FACs and Tumorigenicity assay,0.12,0.0064,29437792
CACNA2D1,LTM,NA,1399,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,FACs for CSC marker followed by SFA and Western Blotting,0.28,0.0064,33707423
CACNA2D1,LTM,NA,1399,Gastric Cancer,Carcinoma,HGC-27,NA,FACs followed by SFA,0.12,0.0064,31213895
CACNA2D1,LTM,NA,1399,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs followed by qPCR and SFA,0.32,0.0064,30464601
CACNA2D1,LTM,NA,1399,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,FACs followed by SFA,0.12,0.0064,31213895
CACNA2D1,LTM,NA,1399,Gastric Cancer,NA,Primary,NA,FACs,0.2,0.0064,31213895
CALR,LTM,NA,1455,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.12,0.0032,33835973
CAMK2G,LTM,NA,1463,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.28,0.0021,25965829
CAMK2G,LTM,NA,1463,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.28,0.0021,25965829
CAMK2G,LTM,NA,1463,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.28,0.0021,34195288
CASC15,LTM,NA,28245,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.2,0.0021,35235236
CAV1,LTM,NA,1527,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0117,25963795
CAV1,LTM,NA,1527,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0117,25963795
CAV1,LTM,NA,1527,Small Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0117,25963795
CBX7,LTM,NA,1557,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.28,0.0011,29422082
CBX7,LTM,NA,1557,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.0011,29422082
CCL15,LTM,NA,10613,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
CCL15,LTM,NA,10613,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
CCL15,LTM,NA,10613,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
CCL15,LTM,NA,10613,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
CCL2,LTM,NA,10618,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0074,30397177
CCL2,LTM,NA,10618,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0074,30397177
CCL20,LTM,NA,10619,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA,0.2,0.0074,30052635
CCL20,LTM,NA,10619,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,qRT-PCR followed by SFA,0.2,0.0074,30052635
CCL24,LTM,NA,10623,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
CCL24,LTM,NA,10623,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
CCL3,LTM,NA,10627,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
CCL3,LTM,NA,10627,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
CCL4,LTM,NA,10630,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
CCL4,LTM,NA,10630,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
CCL5,LTM,NA,10632,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0064,30397177
CCL5,LTM,NA,10632,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0064,30397177
CCNB1,LTM,NA,1579,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qPCR,0.2,0.0053,34168259
CCNB1,LTM,NA,1579,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by qPCR,0.2,0.0053,34168259
CCNB1,LTM,NA,1579,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by qPCR,0.2,0.0053,34168259
CCNB1,LTM,NA,1579,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by qPCR,0.2,0.0053,34168259
CCND1,LTM,NA,1582,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.28,0.0201,33980809
CCND1,LTM,NA,1582,Glioblastoma Multiforme,NA,GBM8401,NA,SP assay and SFA followed by RT-PCR,0.2,0.0201,25359730
CCND1,LTM,NA,1582,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.28,0.0201,33980809
CCND1,LTM,NA,1582,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA followed by Western Blotting,0.28,0.0201,33922104
CCND1,LTM,NA,1582,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,RT-PCR and SFA,0.2,0.0201,29895705
CCND1,LTM,NA,1582,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,RT-PCR and SFA,0.2,0.0201,29895705
CCND1,LTM,NA,1582,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by qRT-PCR,0.2,0.0201,25104726
CCND1,LTM,NA,1582,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by qRT-PCR and SFA,0.2,0.0201,29792038
CCND1,LTM,NA,1582,Head and Neck Cancer,Carcinoma,KB,NA,SFA followed by qRT-PCR,0.2,0.0201,25104726
CCND1,LTM,NA,1582,Hepatic Cancer,Carcinoma,Mahlavu,NA,SP assay followed by Western Blotting,0.28,0.0201,29792038
CCND1,LTM,NA,1582,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.0201,31595560
CCND1,LTM,NA,1582,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.0201,31604679
CCND1,LTM,NA,1582,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.0201,31604679
CCND1,LTM,NA,1582,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.48,0.0201,29982992
CCND1,LTM,NA,1582,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.28,0.0201,27976692
CCND1,LTM,NA,1582,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.28,0.0201,29197410
CCND1,LTM,NA,1582,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.28,0.0201,29383157
CCND1,LTM,NA,1582,Hepatic Cancer,Adenocarcinoma,SK-Hep-1,NA,SP assay followed by Western Blotting,0.28,0.0201,29792038
CCND1,LTM,NA,1582,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,Western Blotting,0.28,0.0201,23674142
CCND1,LTM,NA,1582,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.0201,31595560
CCND1,LTM,NA,1582,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen,SFA followed by qRT-PCR,0.28,0.0201,31693936
CCND1,LTM,NA,1582,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen+Fulvestrant,SFA followed by qRT-PCR,0.28,0.0201,31693936
CCND1,LTM,NA,1582,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay and RT-PCR followed by SFA,0.28,0.0201,26416062
CCR5,LTM,NA,1606,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs and Tumorigenicity assay,0.12,0.0011,29358169
CCR6,LTM,NA,1607,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA,0.2,0.0011,30052635
CCR6,LTM,NA,1607,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,qRT-PCR followed by SFA,0.2,0.0011,30052635
CD24,LTM,NA,1645,Bladder Cancer,Carcinoma,5637,NA,Western Blotting followed by SFA,0.28,0.4560,30327565
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,A-253,NA,FACs followed by CFA,0.12,0.4560,24612587
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.12,0.4560,34277782
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by Tumorigenicity assay,0.12,0.4560,33707423
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qPCR and FACs,0.32,0.4560,29559846
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.32,0.4560,28461325
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,AGS,Adriamycin,FACs,0.32,0.4560,31261030
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by FACs,0.32,0.4560,31261030
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by IF staining and FACs,0.36,0.4560,26709750
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qPCR,0.36,0.4560,31440741
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.36,0.4560,27996162
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.36,0.4560,27996162
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.36,0.4560,30119228
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,AsPC1,Triptolide,SP assay followed by FACs,0.36,0.4560,26597727
CD24,LTM,NA,1645,Bladder Cancer,Carcinoma,BFTC-905,NA,Western Blotting followed by SFA,0.28,0.4560,30327565
CD24,LTM,NA,1645,Bladder Cancer,Carcinoma,BFTC-909,NA,Western Blotting followed by SFA,0.28,0.4560,30327565
CD24,LTM,NA,1645,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by FACs,0.12,0.4560,34775489
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs followed by SFA,0.12,0.4560,35064101
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,MACs followed by SFA,0.12,0.4560,34715882
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by FACs,0.12,0.4560,35277657
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by FACs,0.12,0.4560,35526049
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.4560,30802827
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.4560,30802827
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,CFA and  FACs followed by qRT-PCR,0.48,0.4560,21826251
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by IF staining,0.48,0.4560,26709750
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,qRT-PCR,0.48,0.4560,26035122
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs,0.48,0.4560,22948659
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs,0.48,0.4560,31856088
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs and CFA followed by SFA and Tumorigenicity assay,0.48,0.4560,23017870
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SFA,0.48,0.4560,27748818
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SFA,0.48,0.4560,27748818
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SFA,0.48,0.4560,27999190
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SP assay,0.48,0.4560,22963768
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by FACs,0.48,0.4560,30853342
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by FACs,0.48,0.4560,29719602
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,Western Blotting followed by FACs,0.4,0.4560,28775772
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by Western Blotting and SFA,0.4,0.4560,32781084
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Capan-1,Gemcitabine,qRT-PCR,0.4,0.4560,23026911
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs,0.4,0.4560,22948659
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs followed by SP assay,0.4,0.4560,22963768
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,Migration and Invasion assay followed by FACs,0.4,0.4560,22109279
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,Migration assay followed by FACs,0.4,0.4560,31856088
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by FACs,0.4,0.4560,30819221
CD24,LTM,NA,1645,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,qRT-PCR,0.2,0.4560,26035122
CD24,LTM,NA,1645,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,FACs,0.2,0.4560,26398277
CD24,LTM,NA,1645,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by FACs,0.2,0.4560,30853342
CD24,LTM,NA,1645,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by FACs,0.2,0.4560,29100320
CD24,LTM,NA,1645,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SP assay followed by FACs,0.2,0.4560,20372854
CD24,LTM,NA,1645,Pancreatic Cancer,Adenosquamous Cell Carcinoma,COLO-357,NA,FACs followed by SFA,0.12,0.4560,26840020
CD24,LTM,NA,1645,Small Cell Lung Cancer,Carcinoma,DMS273,NA,IF staining followed by FACs,0.36,0.4560,31446534
CD24,LTM,NA,1645,Small Cell Lung Cancer,Carcinoma,DMS53,NA,IF staining followed by FACs,0.36,0.4560,31446534
CD24,LTM,NA,1645,Small Cell Lung Cancer,Carcinoma,GLC14,NA,IF staining followed by FACs,0.36,0.4560,31446534
CD24,LTM,NA,1645,Small Cell Lung Cancer,Carcinoma,H69,NA,IF staining followed by FACs,0.36,0.4560,31446534
CD24,LTM,NA,1645,Hepatic Cancer,NA,HAK-1B,NA,SP assay followed by qRT-PCR,0.2,0.4560,24325739
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,FACs followed by SFA,0.12,0.4560,34718356
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,FACs followed by SFA,0.12,0.4560,35504883
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,SFA followed by FACs,0.12,0.4560,33672732
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,SFA followed by FACs,0.12,0.4560,34023418
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,SFA and FACs,0.12,0.4560,33390847
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,SFA followed by FACs,0.12,0.4560,34023418
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,NA,FACs followed by SFA,0.12,0.4560,35220209
CD24,LTM,NA,1645,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs and qRT-PCR,0.32,0.4560,35242031
CD24,LTM,NA,1645,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil,FACs,0.32,0.4560,34151658
CD24,LTM,NA,1645,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.32,0.4560,35116403
CD24,LTM,NA,1645,Colon Cancer,Carcinoma,HCT116,Paclitaxel,CFA followed by FACs,0.32,0.4560,23624503
CD24,LTM,NA,1645,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.32,0.4560,31641961
CD24,LTM,NA,1645,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and Tumorigenicity assay,0.32,0.4560,22329848
CD24,LTM,NA,1645,Colon Cancer,Carcinoma,HCT116,NA,SFA and FACs,0.32,0.4560,26399781
CD24,LTM,NA,1645,Colon Cancer,Carcinoma,HCT116,NA,SFA and MACs,0.32,0.4560,24696849
CD24,LTM,NA,1645,Colon Cancer,Adenocarcinoma,HCT-15,Cisplatin,SFA and qPCR,0.2,0.4560,34921482
CD24,LTM,NA,1645,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by qRT-PCR,0.2,0.4560,25104726
CD24,LTM,NA,1645,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by qPCR and FACs,0.32,0.4560,29559846
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by IF staining and qRT-PCR,0.44,0.4560,27891685
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by FACs,0.44,0.4560,34794402
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,FACs followed by SFA,0.44,0.4560,26284537
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,FACs followed by SFA,0.44,0.4560,27748818
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,FACs followed by SFA,0.44,0.4560,27748818
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by FACs,0.44,0.4560,26284537
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,HPAF-II,Gemcitabine,qPCR,0.2,0.4560,31440741
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,FACs,0.2,0.4560,22948659
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,SFA followed by FACs,0.2,0.4560,30853342
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,FACs followed by SFA,0.12,0.4560,34294320
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,FACs followed by SFA,0.12,0.4560,34344863
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,MACs followed by SFA,0.12,0.4560,34715882
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,FACs,0.12,0.4560,30029671
CD24,LTM,NA,1645,Bladder Cancer,Carcinoma,HT-1197,NA,FACs,0.12,0.4560,35008872
CD24,LTM,NA,1645,Colon Cancer,Adenocarcinoma,HT-29,NA,qRT-PCR followed by FACs,0.32,0.4560,29158786
CD24,LTM,NA,1645,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,FACs,0.32,0.4560,34151658
CD24,LTM,NA,1645,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.32,0.4560,22329848
CD24,LTM,NA,1645,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,FACs,0.32,0.4560,24323901
CD24,LTM,NA,1645,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.32,0.4560,24760019
CD24,LTM,NA,1645,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and SFA,0.32,0.4560,27520449
CD24,LTM,NA,1645,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.32,0.4560,30770752
CD24,LTM,NA,1645,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs and SP assay,0.32,0.4560,30770752
CD24,LTM,NA,1645,Hepatic Cancer,Carcinoma,Huh7,NA,MACs followed by Western Blotting and SFA,0.4,0.4560,29602239
CD24,LTM,NA,1645,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by FACs and qRT-PCR,0.4,0.4560,32128906
CD24,LTM,NA,1645,Hepatic Cancer,Carcinoma,Huh7,NA,MACs followed by SFA,0.4,0.4560,31732298
CD24,LTM,NA,1645,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,FACs,0.12,0.4560,34215226
CD24,LTM,NA,1645,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,SFA followed by FACs,0.12,0.4560,34775489
CD24,LTM,NA,1645,Gastric Cancer,Carcinoma,KATO-III,NA,FACs,0.12,0.4560,19415765
CD24,LTM,NA,1645,Head and Neck Cancer,Carcinoma,KB,NA,SFA followed by qRT-PCR,0.2,0.4560,25104726
CD24,LTM,NA,1645,Pancreatic Cancer,Ductal Carcinoma,KLM-1,NA,SFA and FACs,0.12,0.4560,34628696
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,KMP5,NA,SFA and FACs,0.12,0.4560,34628696
CD24,LTM,NA,1645,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by IF staining and Western Blotting,0.52,0.4560,32457900
CD24,LTM,NA,1645,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,Western Blotting followed by FACs and SFA,0.52,0.4560,28775772
CD24,LTM,NA,1645,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,qRT-PCR,0.52,0.4560,26035122
CD24,LTM,NA,1645,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR,0.52,0.4560,26840266
CD24,LTM,NA,1645,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,Cisplatin,FACs,0.52,0.4560,34123574
CD24,LTM,NA,1645,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,Gemcitabine,FACs,0.52,0.4560,34123574
CD24,LTM,NA,1645,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,5-Fluorouracil,SP assay followed by Tumorigenicity assay and FACs,0.52,0.4560,24950733
CD24,LTM,NA,1645,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,Gemcitabine,SP assay followed by Tumorigenicity assay and FACs,0.52,0.4560,24950733
CD24,LTM,NA,1645,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),qRT-PCR followed by Western Blotting and SFA,0.48,0.4560,29956726
CD24,LTM,NA,1645,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,qRT-PCR,0.48,0.4560,30284085
CD24,LTM,NA,1645,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),RT-PCR,0.48,0.4560,30552676
CD24,LTM,NA,1645,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,SFA followed by FACs,0.48,0.4560,35242031
CD24,LTM,NA,1645,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,SFA and MACs,0.48,0.4560,24696849
CD24,LTM,NA,1645,Dukes Type B Colon Cancer,Adenocarcinoma,LS174T,NA,FACs,0.12,0.4560,27520449
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by Western Blotting,0.4,0.4560,33731668
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA and IF staining,0.4,0.4560,33274565
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.4,0.4560,31497349
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by IF staining,0.4,0.4560,34718182
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.4,0.4560,34073849
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.4,0.4560,35053617
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs and SFA,0.4,0.4560,35078507
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by CFA,0.4,0.4560,35235236
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.4,0.4560,33919234
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.4,0.4560,34217266
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.4,0.4560,34315857
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Adriamycin,FACs followed by SFA,0.4,0.4560,34403222
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.4,0.4560,35134607
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.4,0.4560,35205696
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.4,0.4560,35254725
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.4,0.4560,35413424
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.4,0.4560,35508987
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,MACs followed by SFA,0.4,0.4560,34715882
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,MACs followed by SFA,0.4,0.4560,35109743
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs,0.4,0.4560,33262438
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs,0.4,0.4560,34234874
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.4,0.4560,33305893
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.4,0.4560,33419140
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.4,0.4560,33511560
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.4,0.4560,33603536
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Adriamycin,SFA followed by FACs,0.4,0.4560,33866606
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.4,0.4560,33940518
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.4,0.4560,34249423
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.4,0.4560,34486791
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.4,0.4560,34680485
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.4,0.4560,34830821
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.4,0.4560,34884742
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.4,0.4560,35047440
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by MACs,0.4,0.4560,34803458
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA and IF staining,0.36,0.4560,33274565
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA and IF staining,0.36,0.4560,34311079
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.36,0.4560,31497349
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,MACs and FACs,0.36,0.4560,34235281
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Lapatinib,SFA followed by qRT-PCR,0.36,0.4560,34435487
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.36,0.4560,33433838
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.36,0.4560,33731668
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.36,0.4560,34665934
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.36,0.4560,35055160
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.36,0.4560,35084278
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by CFA,0.36,0.4560,34502547
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.36,0.4560,32482103
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.36,0.4560,34294320
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.36,0.4560,34344863
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.36,0.4560,34451892
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.36,0.4560,34944852
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.36,0.4560,35135840
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.36,0.4560,35205696
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.36,0.4560,35413424
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.36,0.4560,35504883
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,MACs followed by SFA,0.36,0.4560,33845139
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and FACs,0.36,0.4560,33390847
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and FACs,0.36,0.4560,34234874
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.36,0.4560,33419140
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.36,0.4560,33511560
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.36,0.4560,33866606
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.36,0.4560,34052833
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.36,0.4560,34123797
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.36,0.4560,34130123
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.36,0.4560,34146553
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.36,0.4560,34249423
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.36,0.4560,34445421
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.36,0.4560,34608584
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.36,0.4560,35017469
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.36,0.4560,35277657
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.36,0.4560,35526049
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,MACs and FACs,0.24,0.4560,34235281
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Irradiation,CFA followed by Western Blotting and FACs,0.4,0.4560,34708581
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA and IF staining,0.4,0.4560,34311079
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,Culture of cells in electrospun scaffolds followed by FACs,0.4,0.4560,34841239
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA,0.4,0.4560,35135840
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,MACs followed by SFA,0.4,0.4560,33845139
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by FACs and Western Blotting,0.4,0.4560,27432228
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting followed by FACs,0.4,0.4560,28775772
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting followed by FACs and SFA,0.4,0.4560,29179494
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by IHC staining and SFA,0.4,0.4560,31510100
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by SP assay and Western Blotting,0.4,0.4560,23864708
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Western Blotting,0.4,0.4560,26673007
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,qRT-PCR,0.4,0.4560,24726912
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.4,0.4560,26840266
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by FACs,0.4,0.4560,34123574
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Cisplatin,SFA followed by FACs and Imaging FACs,0.4,0.4560,34123574
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs,0.4,0.4560,22948659
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs,0.4,0.4560,26546043
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs and CFA followed by SFA and Tumorigenicity assay,0.4,0.4560,23017870
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by SFA,0.4,0.4560,27999190
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by Tumorigenicity assay,0.4,0.4560,20940707
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by FACs,0.4,0.4560,29719602
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Triptolide,SP assay followed by FACs,0.4,0.4560,26597727
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,MKN28,NA,FACs,0.12,0.4560,19415765
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.28,0.4560,28461325
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.28,0.4560,27620279
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.28,0.4560,29212193
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.28,0.4560,19415765
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,MKN74,NA,FACs followed by SFA,0.12,0.4560,19415765
CD24,LTM,NA,1645,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.4560,28461325
CD24,LTM,NA,1645,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by FACs,0.28,0.4560,28404967
CD24,LTM,NA,1645,Gastric Cancer,Carcinoma,NCI-N87,NA,FACs followed by SFA,0.28,0.4560,19415765
CD24,LTM,NA,1645,Colon Cancer,Carcinoma,OUMS-23,NA,qRT-PCR,0.2,0.4560,30284085
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.4560,29937934
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.4560,30802827
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.4560,30802827
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting followed by FACs and SFA,0.48,0.4560,29179494
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting followed by FACs and SFA and Tumorigenicity assay,0.48,0.4560,28775772
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by IHC staining and SFA,0.48,0.4560,31510100
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,IHC staining followed by FACs,0.48,0.4560,30272287
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs and qRT-PCR,0.48,0.4560,29975934
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by SP assay and Western Blotting,0.48,0.4560,23864708
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,0.4560,26673007
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,Western Blotting followed by SFA,0.48,0.4560,30486896
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,Microplate array followed by IF staining,0.48,0.4560,23815678
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by IF staining,0.48,0.4560,26709750
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,Modified transwell lower chamber assay and SFA followed by qRT-PCR,0.48,0.4560,24689055
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qPCR,0.48,0.4560,31440741
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qRT-PCR,0.48,0.4560,23026911
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR,0.48,0.4560,24726912
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.48,0.4560,29434962
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.48,0.4560,31027735
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.48,0.4560,31508487
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,0.4560,33011221
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,0.4560,34551785
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,0.4560,33835973
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,0.4560,33934523
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,0.4560,34885233
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,0.4560,22948659
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,0.4560,26261532
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,0.4560,26398277
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,0.4560,27734340
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,0.4560,27764163
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,0.4560,28864067
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,0.4560,29697746
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by Migration and Invasion assay,0.48,0.4560,22335271
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,0.4560,22570653
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,0.4560,24521357
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,0.4560,25852272
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,0.4560,27748818
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,0.4560,27748818
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,0.4560,27999190
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,Doxycycline,FACs followed by SFA,0.48,0.4560,28984401
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,0.4560,29656202
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,0.4560,29727019
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,0.4560,32351328
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA and Tumorigenicity assay,0.48,0.4560,23872274
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SP assay,0.48,0.4560,23815678
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by Tumorigenicity assay,0.48,0.4560,22111082
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and SP assay followed by FACs,0.48,0.4560,29985062
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,0.4560,23815678
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by FACs,0.48,0.4560,25117811
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,0.4560,26689865
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,0.4560,26918054
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,0.4560,28984791
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by FACs,0.48,0.4560,30819221
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,Western Blotting followed by SFA,0.28,0.4560,30486896
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR,0.28,0.4560,31508487
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,FACs followed by SFA,0.28,0.4560,27996162
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,FACs followed by SFA,0.28,0.4560,28244691
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,FACs followed by SFA,0.28,0.4560,28244691
CD24,LTM,NA,1645,Pancreatic Cancer,Ductal Adenocarcinoma,PK-1,NA,SFA followed by qRT-PCR,0.2,0.4560,31027735
CD24,LTM,NA,1645,Head and Neck Cancer,NA,QLL-1,NA,SFA followed by Western Blotting,0.28,0.4560,32327629
CD24,LTM,NA,1645,Pancreatic Cancer,Ductal Adenocarcinoma,S2-013,Triptolide,SP assay followed by FACs,0.12,0.4560,26597727
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,SFA followed by Western Blotting,0.28,0.4560,32327629
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.28,0.4560,29422082
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by FACs,0.28,0.4560,31261030
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by FACs,0.28,0.4560,34802261
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by SFA,0.12,0.4560,35205696
CD24,LTM,NA,1645,Pancreatic Cancer,Ductal Adenocarcinoma,Su86.86,NA,FACs followed by SP assay,0.12,0.4560,22963768
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs followed by SFA,0.12,0.4560,35508987
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.12,0.4560,35526049
CD24,LTM,NA,1645,Colon Cancer,Adenocarcinoma,SW1222,Paclitaxel,CFA followed by FACs,0.12,0.4560,23624503
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting and SFA,0.28,0.4560,32781084
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR,0.28,0.4560,31508487
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,FACs,0.28,0.4560,22322379
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,FACs,0.28,0.4560,27734340
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,FACs followed by SP assay,0.28,0.4560,22963768
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by FACs,0.28,0.4560,20372854
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by FACs,0.28,0.4560,20372854
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by FACs,0.28,0.4560,30819221
CD24,LTM,NA,1645,Dukes Type C Colon Cancer,Adenocarcinoma,SW48,Regorafenib,qRT-PCR,0.2,0.4560,35197754
CD24,LTM,NA,1645,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs,0.12,0.4560,27520449
CD24,LTM,NA,1645,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs,0.12,0.4560,31505062
CD24,LTM,NA,1645,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.12,0.4560,29805588
CD24,LTM,NA,1645,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA and Tumorigenicity assay,0.12,0.4560,22329848
CD24,LTM,NA,1645,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA and MACs,0.12,0.4560,24696849
CD24,LTM,NA,1645,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs followed by SFA,0.12,0.4560,29805588
CD24,LTM,NA,1645,Pancreatic Cancer,Ductal Adenocarcinoma,T3M4,NA,FACs,0.12,0.4560,26546043
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,Western Blotting and SFA,0.28,0.4560,31497349
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs,0.28,0.4560,34315857
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs followed by CFA,0.28,0.4560,35235236
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs followed by SFA,0.28,0.4560,34944852
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by FACs,0.28,0.4560,33144693
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,TR146,NA,SFA followed by qRT-PCR,0.2,0.4560,25471937
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-17B,NA,SFA followed by qRT-PCR,0.2,0.4560,25471937
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-58,NA,SFA followed by qRT-PCR,0.2,0.4560,25471937
CD24,LTM,NA,1645,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,FACs,0.12,0.4560,29221154
CD24,LTM,NA,1645,Bladder Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.4560,32424373
CD24,LTM,NA,1645,Breast Cancer,Ductal Carcinoma,Primary,NA,qRT-PCR and  FACs followed by SFA,0.48,0.4560,30050081
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,IHC staining,0.48,0.4560,35083162
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,IHC staining,0.48,0.4560,33274565
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,IHC staining,0.48,0.4560,33731668
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,IHC staining,0.48,0.4560,27994520
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,IHC staining,0.48,0.4560,28766688
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,IHC staining,0.48,0.4560,28977854
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,IHC staining,0.48,0.4560,29416796
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,IHC staining,0.48,0.4560,29434947
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,IHC staining,0.48,0.4560,29843115
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,IHC staining,0.48,0.4560,31516750
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by qRT-PCR,0.48,0.4560,33799422
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,FACs,0.48,0.4560,34476645
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,FACs,0.48,0.4560,34778599
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,FACs,0.48,0.4560,34073849
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,FACs,0.48,0.4560,34572409
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,FACs,0.48,0.4560,33471244
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,FACs,0.48,0.4560,31555258
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,FACs,0.48,0.4560,18685093
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,FACs,0.48,0.4560,31555258
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,FACs,0.48,0.4560,31555258
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,FACs followed by SFA,0.48,0.4560,34195201
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,FACs followed by SFA,0.48,0.4560,30587593
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,MACs,0.48,0.4560,29344258
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.48,0.4560,33340428
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.48,0.4560,18083101
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.48,0.4560,28746471
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,Chemotherapy,SFA followed by FACs,0.48,0.4560,28835684
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.48,0.4560,29925435
CD24,LTM,NA,1645,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.48,0.4560,30359767
CD24,LTM,NA,1645,Colon Cancer,NA,Primary,NA,IHC staining,0.32,0.4560,34609414
CD24,LTM,NA,1645,Colon Cancer,NA,Primary,NA,IHC staining,0.32,0.4560,24696849
CD24,LTM,NA,1645,Colon Cancer,NA,Primary,NA,FACs followed by SFA,0.32,0.4560,26745821
CD24,LTM,NA,1645,Colon Cancer,NA,Primary,NA,FACs followed by SFA and Tumorigenicity assay,0.32,0.4560,30790680
CD24,LTM,NA,1645,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.32,0.4560,18765800
CD24,LTM,NA,1645,Gastric Cancer,NA,Primary,NA,FACs followed by SFA,0.2,0.4560,27620279
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IF staining,0.32,0.4560,32327629
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.32,0.4560,31811857
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.32,0.4560,22333601
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs followed by SFA,0.32,0.4560,19450560
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by FACs,0.32,0.4560,27619333
CD24,LTM,NA,1645,Lung Cancer,Adenocarcinoma,Primary,NA,FACs followed by CFA,0.2,0.4560,33135338
CD24,LTM,NA,1645,Lung Cancer,Adenocarcinoma,Primary,Erlotinib,FACs followed by SFA,0.2,0.4560,28347243
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.32,0.4560,24346092
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,FACs,0.32,0.4560,34277782
CD24,LTM,NA,1645,Pancreatic Cancer,NA,Primary,NA,CFA followed by qRT-PCR and ICC staining,0.6,0.4560,26199979
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining followed by FACs,0.6,0.4560,27414409
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.6,0.4560,25240521
CD24,LTM,NA,1645,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.6,0.4560,25081383
CD24,LTM,NA,1645,Pancreatic Cancer,NA,Primary,NA,FACs,0.6,0.4560,33188841
CD24,LTM,NA,1645,Pancreatic Cancer,NA,Primary,NA,FACs,0.6,0.4560,23029396
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Primary,NA,FACs,0.6,0.4560,30074477
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Primary,NA,FACs followed by Tumorigenicity assay,0.6,0.4560,17283135
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Primary,NA,SP assay followed by FACs,0.6,0.4560,32132023
CD24,LTM,NA,1645,Small Cell Lung Cancer,NA,Primary,NA,IF staining followed by FACs,0.52,0.4560,31446534
CD24,LTM,NA,1645,Triple Negative Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.2,0.4560,28883001
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,MACs followed by SFA and ICC staining,0.36,0.4560,31939436
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA and FACs,0.36,0.4560,25003810
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ICC staining,0.36,0.4560,31582014
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by qRT-PCR,0.36,0.4560,24961511
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by RT-PCR,0.36,0.4560,24961511
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture and  FACs followed by SFA and Tumorigenicity assay,0.36,0.4560,29017078
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.36,0.4560,26278043
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.36,0.4560,26278043
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.36,0.4560,28789457
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,MACs followed by Tumorigenicity assay,0.36,0.4560,31796785
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.36,0.4560,30555330
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by FACs,0.36,0.4560,22825470
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,BT-20,NA,FACs followed by SFA,0.12,0.4560,29249690
CD24,LTM,NA,1645,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by qPCR,0.2,0.4560,30224376
CD24,LTM,NA,1645,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,FACs,0.2,0.4560,29500278
CD24,LTM,NA,1645,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,FACs followed by SFA,0.2,0.4560,29080749
CD24,LTM,NA,1645,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,FACs followed by SFA,0.2,0.4560,31599500
CD24,LTM,NA,1645,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by FACs,0.2,0.4560,27966906
CD24,LTM,NA,1645,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,Trastuzumab,SFA followed by FACs,0.2,0.4560,28722778
CD24,LTM,NA,1645,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by FACs,0.2,0.4560,29088759
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,Western Blotting and IF staining,0.52,0.4560,29100426
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs,0.52,0.4560,29262622
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs,0.52,0.4560,30246563
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs,0.52,0.4560,30460610
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs followed by SFA,0.52,0.4560,28817737
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs followed by SFA,0.52,0.4560,29197410
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs followed by SFA,0.52,0.4560,31296961
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs followed by SFA,0.52,0.4560,31599500
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by FACs,0.52,0.4560,27995747
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by FACs,0.52,0.4560,28817737
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by FACs,0.52,0.4560,29352988
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by FACs,0.52,0.4560,29352988
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by FACs,0.52,0.4560,30002443
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,CAL51,NA,FACs followed by SFA,0.12,0.4560,30450530
CD24,LTM,NA,1645,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs followed by Tumorigenicity assay,0.12,0.4560,22111082
CD24,LTM,NA,1645,Breast Cancer,Carcinoma,CRL2334,NA,FACs followed by SFA,0.12,0.4560,28817737
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,FACs,0.12,0.4560,24201869
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs,0.12,0.4560,30555330
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,Erlotinib,qRT-PCR,0.2,0.4560,30480362
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Adenocarcinoma,H23,Cisplatin,SFA followed by IF staining and Western Blotting,0.52,0.4560,26872057
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,FACs followed by RT-PCR,0.32,0.4560,27694834
CD24,LTM,NA,1645,Small Cell Lung Cancer,Carcinoma,H446,NA,SP assay followed by FACs,0.12,0.4560,22825470
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by qRT-PCR,0.2,0.4560,24961511
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by RT-PCR and Tumorigenicity assay,0.2,0.4560,24961511
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,H460,SAHA,FACs,0.2,0.4560,26839308
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs,0.2,0.4560,22592563
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Adenocarcinoma,H522,NA,FACs,0.12,0.4560,18952074
CD24,LTM,NA,1645,Breast Cancer,Ductal Carcinoma,HC1500,NA,FACs followed by SFA,0.12,0.4560,29249690
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,FACs,0.12,0.4560,29679903
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,FACs,0.12,0.4560,30091683
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,FACs followed by SFA,0.12,0.4560,31612865
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,qRT-PCR,0.2,0.4560,31273285
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs,0.2,0.4560,29197410
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs,0.2,0.4560,29249690
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs,0.2,0.4560,31709178
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs,0.2,0.4560,31729259
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs followed by SFA,0.2,0.4560,29679903
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs followed by SFA,0.2,0.4560,30227220
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.2,0.4560,31709178
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,MK-0752,FACs,0.12,0.4560,29027990
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,MK-0752,FACs,0.12,0.4560,29027990
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,NA,FACs followed by SFA,0.12,0.4560,30326469
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,SFA followed by FACs,0.12,0.4560,29895705
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,SFA followed by FACs,0.12,0.4560,29895705
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC-38,Docetaxel,FACs followed by SFA,0.12,0.4560,29190901
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,HCC-38,NA,FACs followed by SFA,0.12,0.4560,31599500
CD24,LTM,NA,1645,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.12,0.4560,30429213
CD24,LTM,NA,1645,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.12,0.4560,31883392
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SP assay followed by SFA and IHC staining,0.24,0.4560,29981340
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by qPCR,0.24,0.4560,30224376
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,FACs,0.24,0.4560,29162703
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,Invasion assay followed by SP assay and FACs,0.24,0.4560,18386134
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by FACs,0.24,0.4560,28951456
CD24,LTM,NA,1645,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,FACs followed by Western Blotting,0.4,0.4560,30620624
CD24,LTM,NA,1645,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,FACs followed by SFA,0.4,0.4560,29080749
CD24,LTM,NA,1645,Dukes Type B Colon Cancer,Adenocarcinoma,LS180,Doxorubicin,FACs followed by SFA,0.12,0.4560,30344742
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and IF staining,0.44,0.4560,30188754
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and Western Blotting,0.44,0.4560,29100426
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and Western Blotting,0.44,0.4560,31672029
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by IHC staining and SFA,0.44,0.4560,31579408
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by qRT-PCR and SFA,0.44,0.4560,30239174
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA and qRT-PCR,0.44,0.4560,31501409
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR followed by FACs and SFA,0.44,0.4560,30615901
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and qRT-PCR,0.44,0.4560,30188754
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and qRT-PCR,0.44,0.4560,31300015
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,CFA followed by FACs,0.44,0.4560,28839461
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs,0.44,0.4560,29028589
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.44,0.4560,29323439
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.44,0.4560,29422957
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.44,0.4560,29509055
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.44,0.4560,29526821
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs,0.44,0.4560,29635751
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.44,0.4560,29848346
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.44,0.4560,30206184
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.44,0.4560,30233203
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Radiotherapy,FACs,0.44,0.4560,30272295
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs,0.44,0.4560,31286834
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.44,0.4560,31286834
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs,0.44,0.4560,31627418
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Paclitaxel,FACs,0.44,0.4560,31627418
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.44,0.4560,31762819
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.44,0.4560,31781916
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs and SFA,0.44,0.4560,29185119
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by CFA,0.44,0.4560,18681906
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,28725489
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,MK-0752,FACs followed by SFA,0.44,0.4560,29027990
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,RO49097,FACs followed by SFA,0.44,0.4560,29027990
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs followed by SFA,0.44,0.4560,29050299
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,29218545
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,29229606
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,29355544
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,29601799
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,29602199
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,29797562
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,30076320
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,30335523
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,30442981
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,30450766
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,31283068
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,31296961
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,31599500
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,31695364
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,31695775
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,31695775
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.44,0.4560,31736268
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs followed by SFA,0.44,0.4560,31756890
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA and SP assay,0.44,0.4560,27974826
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,MACs,0.44,0.4560,30482232
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and CFA followed by MACs,0.44,0.4560,29187905
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,21062983
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,28003747
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Paclitaxel,SFA followed by FACs,0.44,0.4560,28718813
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,28823831
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,28930649
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,29088759
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,29093680
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,29187406
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,29221160
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,29228728
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,SFA followed by FACs,0.44,0.4560,29301415
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,SFA followed by FACs,0.44,0.4560,29363524
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,29464036
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,29746865
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,29749438
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Fructose,SFA followed by FACs,0.44,0.4560,29796188
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,29846560
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,29923726
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,29976159
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Adrimycin,SFA followed by FACs,0.44,0.4560,30055109
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,30170097
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,30188754
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,30238818
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,30579251
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,30628646
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,31273952
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,31308814
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,31452727
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,31579408
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,31658701
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,31726667
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.44,0.4560,31756890
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and Tumorigenicity assay,0.44,0.4560,28938607
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,SFA followed by SP assay and FACs,0.44,0.4560,31756890
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Fulvestrant,SFA followed by SP assay and FACs,0.44,0.4560,31756890
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Leptin,SFA followed by SP assay and FACs,0.44,0.4560,31756890
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,SFA followed by SP assay and FACs,0.44,0.4560,31756890
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by FACs,0.44,0.4560,18466993
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by SFA and FACs,0.44,0.4560,17881900
CD24,LTM,NA,1645,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by SFA and FACs,0.44,0.4560,18506619
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and IF staining,0.52,0.4560,29100426
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by IF staining,0.52,0.4560,29207686
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by qRT-PCR and SFA,0.52,0.4560,30239174
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,IF staining,0.52,0.4560,28760736
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SP assay followed by SFA and IHC staining,0.52,0.4560,29981340
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.52,0.4560,29103027
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,CFA followed by FACs,0.52,0.4560,28839461
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,18366788
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,29036915
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,29162703
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,29262622
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,29290211
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,29323439
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,29374148
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,29526821
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,29552056
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,29552056
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,29653746
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,29848346
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,30191610
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,30191610
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,30233203
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,30246563
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Radiotherapy,FACs,0.52,0.4560,30272295
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,30584335
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.52,0.4560,31729259
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,FACs and SFA,0.52,0.4560,28703802
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Docetaxel,FACs and SFA,0.52,0.4560,29921732
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by CFA,0.52,0.4560,18681906
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cisplatin,FACs followed by CFA,0.52,0.4560,30255421
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,27976692
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,28817737
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Docetaxel,FACs followed by SFA,0.52,0.4560,29190901
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,29197410
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,29218545
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,29249663
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,29316250
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,29353288
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,29601799
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Epirubicin,FACs followed by SFA,0.52,0.4560,29792857
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,29797562
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,30021199
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,30450530
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,30460610
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,30479839
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,30542507
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,30587555
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,31283068
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,31501409
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,31545416
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,31599500
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,31612865
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,31619923
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,31695436
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,31695775
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.52,0.4560,31695775
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA and Migration assay,0.52,0.4560,31756533
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cisplatin,FACs followed by SP assay and SFA,0.52,0.4560,30361903
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by Tumorigenicity assay,0.52,0.4560,29658391
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by Tumorigenicity assay,0.52,0.4560,30050079
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,MACs followed by SFA,0.52,0.4560,29301945
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and CFA followed by MACs,0.52,0.4560,29187905
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,28817737
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,28823831
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by FACs,0.52,0.4560,28835684
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,28923385
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,28928832
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,28951456
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,28991374
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,29053396
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,29228728
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,29405062
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Fructose,SFA followed by FACs,0.52,0.4560,29796188
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,29895705
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,29964299
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,29975921
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,30002443
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,30149665
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,30170097
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,30564555
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,6 Gy Radiation,SFA followed by FACs,0.52,0.4560,30579251
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,30647871
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,31273952
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,31308814
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,31452727
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,31462709
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,31658701
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,31726667
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.52,0.4560,31784862
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,MDA-MB-435,NA,FACs followed by CFA,0.12,0.4560,18681906
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,FACs,0.12,0.4560,31729259
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,FACs followed by SFA,0.12,0.4560,29249690
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,FACs followed by SFA,0.12,0.4560,30479839
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs followed by SFA,0.12,0.4560,30021199
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs followed by SFA,0.12,0.4560,31599500
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,SFA followed by FACs,0.12,0.4560,30647871
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Paclitaxel,FACs and SP assay followed by SFA and qRT-PCR,0.32,0.4560,30572639
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by qPCR,0.32,0.4560,30224376
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs,0.32,0.4560,30091683
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs,0.32,0.4560,30191610
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Doxorubicin,FACs,0.32,0.4560,31627418
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Paclitaxel,FACs,0.32,0.4560,31627418
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by CFA,0.32,0.4560,18681906
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA,0.32,0.4560,28817737
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA,0.32,0.4560,29249663
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA,0.32,0.4560,29249690
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA,0.32,0.4560,30021199
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA,0.32,0.4560,31599500
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA and Migration assay,0.32,0.4560,31756533
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs,0.32,0.4560,28817737
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs,0.32,0.4560,28978427
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs,0.32,0.4560,29895705
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs,0.32,0.4560,30628646
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Doxorubicin,SFA followed by FACs,0.32,0.4560,31784862
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and FACs,0.12,0.4560,20940707
CD24,LTM,NA,1645,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs and qRT-PCR,0.32,0.4560,32203224
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,FACs,0.12,0.4560,24201869
CD24,LTM,NA,1645,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.12,0.4560,29201179
CD24,LTM,NA,1645,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qRT-PCR,0.2,0.4560,30480362
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by Western Blotting,0.4,0.4560,30620624
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by Western Blotting,0.4,0.4560,30620624
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs and Western Blotting,0.4,0.4560,29100426
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs and Western Blotting,0.4,0.4560,29100426
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by IHC staining and SFA,0.4,0.4560,31579408
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by IHC staining and SFA,0.4,0.4560,31579408
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs,0.4,0.4560,29080749
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs,0.4,0.4560,29080749
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,5-Fluorouracil,FACs,0.4,0.4560,29371950
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,5-Fluorouracil,FACs,0.4,0.4560,29371950
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs,0.4,0.4560,31729259
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by SFA,0.4,0.4560,31599500
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by SFA,0.4,0.4560,31599500
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by SFA,0.4,0.4560,31695436
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by SFA,0.4,0.4560,31695436
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,Epirubicin,SFA followed  by FACs and SP assay,0.4,0.4560,18083101
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs,0.4,0.4560,18083101
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,TGF-Beta,SFA followed by FACs,0.4,0.4560,28702892
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,Fructose,SFA followed by FACs,0.4,0.4560,29796188
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,Fructose,SFA followed by FACs,0.4,0.4560,29796188
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs,0.4,0.4560,31579408
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs,0.4,0.4560,31579408
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs,0.4,0.4560,31726667
CD24,LTM,NA,1645,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs,0.4,0.4560,31726667
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM1315,NA,FACs,0.12,0.4560,18366788
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Ductal Carcinoma,SUM1315MO2,NA,FACs,0.12,0.4560,31729259
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs,0.12,0.4560,29620216
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs,0.12,0.4560,31709178
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs,0.12,0.4560,31729259
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,Paclitaxel,FACs and SFA,0.12,0.4560,28703802
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs followed by CFA,0.12,0.4560,18366788
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,MK-0752,FACs followed by SFA,0.12,0.4560,29027990
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,RO49097,FACs followed by SFA,0.12,0.4560,29027990
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs followed by SFA,0.12,0.4560,30227220
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs followed by SFA,0.12,0.4560,30542507
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs followed by Tumorigenicity assay,0.12,0.4560,30050079
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by FACs,0.12,0.4560,28951456
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by FACs,0.12,0.4560,28978083
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by FACs,0.12,0.4560,29975921
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.12,0.4560,31709178
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by Western Blotting,0.28,0.4560,30262865
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs,0.28,0.4560,31729259
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM159,Docetaxel,FACs and SFA,0.28,0.4560,29921732
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs followed by CFA,0.28,0.4560,18366788
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs followed by SFA,0.28,0.4560,29249663
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs followed by SFA,0.28,0.4560,30460610
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.28,0.4560,28054666
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.28,0.4560,28951456
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.28,0.4560,28978427
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.28,0.4560,28991374
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.28,0.4560,29358169
CD24,LTM,NA,1645,Triple Negative Breast Cancer,Carcinoma,SUM159,Paclitaxel,SFA followed by FACs,0.28,0.4560,30482914
CD24,LTM,NA,1645,Breast Cancer,Carcinoma,SUM190PT,Paclitaxel,FACs and SFA,0.12,0.4560,28703802
CD24,LTM,NA,1645,Triple Negative Breast Cancer,NA,SUM225,NA,FACs,0.12,0.4560,18366788
CD24,LTM,NA,1645,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs,0.12,0.4560,30429213
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by FACs and qRT-PCR,0.32,0.4560,31300015
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,5-Fluorouracil,FACs,0.32,0.4560,29371950
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs,0.32,0.4560,30076320
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Tamoxifen,FACs followed by SFA,0.32,0.4560,29602199
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs followed by SFA,0.32,0.4560,30326469
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs followed by SFA,0.32,0.4560,31599500
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs followed by SFA,0.32,0.4560,31736268
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Paclitaxel,FACs followed by SP assay and SFA,0.32,0.4560,30361903
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by FACs,0.32,0.4560,31619923
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by FACs and Tumorigenicity assay,0.32,0.4560,28938607
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-1,NA,SFA followed by FACs,0.12,0.4560,21304586
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-11B,NA,SFA followed by FACs,0.12,0.4560,21304586
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-22,NA,SFA followed by FACs,0.12,0.4560,21304586
CD24,LTM,NA,1645,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,SFA followed by FACs,0.12,0.4560,21304586
CD24,LTM,NA,1645,Luminal A Breast Cancer,Ductal Carcinoma,ZR-75-1,Fructose,SFA followed by FACs,0.12,0.4560,29796188
CD274,LTM,NA,17635,Gastric Cancer,Adenocarcinoma,BGC-823,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,33579380
CD274,LTM,NA,17635,Gastric Cancer,Adenocarcinoma,SGC-7901,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,33579380
CD274,LTM,NA,17635,Non Small Cell Lung Cancer,NA,Primary,NA,FACs,0.2,0.0032,32808188
CD274,LTM,NA,17635,Non Small Cell Lung Cancer,NA,Primary,NA,FACs,0.2,0.0032,32808188
CD34,LTM,NA,1662,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.2,0.0053,30981768
CD34,LTM,NA,1662,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.2,0.0053,21520032
CD34,LTM,NA,1662,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by FACs,0.2,0.0053,22370645
CD34,LTM,NA,1662,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.2,0.0053,30981768
CD34,LTM,NA,1662,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,FACs,0.12,0.0053,21124918
CD34,LTM,NA,1662,Non Small Cell Lung Cancer,Adenocarcinoma,HCC1833,NA,FACs,0.12,0.0053,21124918
CD34,LTM,NA,1662,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,FACs,0.12,0.0053,21124918
CD34,LTM,NA,1662,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,Cisplatin,qRT-PCR,0.2,0.0053,31239709
CD38-,LTM,NA,1667,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs,0.12,0.0011,22592563
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Western Blotting,0.28,1.0000,29559853
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,5637,NA,SFA followed by qRT-PCR,0.28,1.0000,30327565
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,5637,NA,FACs,0.28,1.0000,29340052
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,5637,NA,FACs followed by SFA,0.28,1.0000,21964864
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,5637,NA,MACs,0.28,1.0000,32192892
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,5637,NA,SFA followed by FACs,0.28,1.0000,32388699
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,253JB-V,NA,SFA followed by qRT-PCR,0.2,1.0000,34101386
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,A-253,NA,FACs followed by CFA,0.12,1.0000,24612587
CD44,LTM,NA,1681,Skin Cancer,NA,A-375,NA,SFA followed by qPCR and Western Blotting,0.48,1.0000,29693169
CD44,LTM,NA,1681,Skin Cancer,NA,A-375,NA,SFA followed by qRT-PCR and Western Blotting,0.48,1.0000,29693169
CD44,LTM,NA,1681,Skin Cancer,NA,A-375,NA,SFA and Western Blotting,0.48,1.0000,30717768
CD44,LTM,NA,1681,Skin Cancer,NA,A-375,NA,FACs,0.48,1.0000,26208390
CD44,LTM,NA,1681,Skin Cancer,NA,A-375,NA,FACs,0.48,1.0000,27476721
CD44,LTM,NA,1681,Skin Cancer,NA,A-375,NA,FACs,0.48,1.0000,29049740
CD44,LTM,NA,1681,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,IHC staining and FACs,0.36,1.0000,22740085
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,qRT-PCR and Western Blotting,0.48,1.0000,34065942
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,1.0000,25955300
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,1.0000,28431267
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,1.0000,32655789
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining and RT-PCR,0.48,1.0000,21520032
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Irradiation,SFA and FACs followed by Western Blotting,0.48,1.0000,34163000
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and Western Blotting,0.48,1.0000,34949193
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and Western Blotting followed by SFA,0.48,1.0000,28259998
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by IF staining,0.48,1.0000,34527268
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,IF staining followed by FACs and SFA,0.48,1.0000,31781681
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,IF staining followed by SFA and FACs,0.48,1.0000,31024010
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,MACs followed by SFA and ICC staining,0.48,1.0000,31939436
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and qRT-PCR,0.48,1.0000,34400945
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA and RT-PCR,0.48,1.0000,28854941
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA and FACs,0.48,1.0000,25003810
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and qRT-PCR,0.48,1.0000,30816208
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Irradiation,CFA followed by Western Blotting,0.48,1.0000,33924205
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,1.0000,33980809
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting followed by SFA,0.48,1.0000,35278461
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by CFA and Western Blotting,0.48,1.0000,32637578
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,1.0000,23773734
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,1.0000,24247269
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,1.0000,27836540
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,1.0000,28198062
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,1.0000,28741092
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Pemetrexed,SFA followed by Western Blotting,0.48,1.0000,32726929
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,1.0000,32782570
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,1.0000,33125096
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting,0.48,1.0000,29254164
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting,0.48,1.0000,29552200
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by ICC staining,0.48,1.0000,31582014
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining,0.48,1.0000,23947765
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining,0.48,1.0000,26261505
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and SFA,0.48,1.0000,34246759
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,1.0000,33437165
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,1.0000,34832951
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Pemetrexed +Cisplatin,RT-PCR,0.48,1.0000,26895954
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR,0.48,1.0000,31201845
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and qPCR followed by Tumorigenicity assay,0.48,1.0000,31796785
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by qRT-PCR,0.48,1.0000,24961511
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,1.0000,29044153
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Tumorigenicity assay,0.48,1.0000,32124474
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by RT-PCR,0.48,1.0000,24961511
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.48,1.0000,28951614
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,CFA followed by FACs,0.48,1.0000,34816662
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs,0.48,1.0000,33068069
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.48,1.0000,33784109
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,FACs followed by SFA,0.48,1.0000,33784109
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.48,1.0000,34277782
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by FACs,0.48,1.0000,35267489
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture and  FACs followed by SFA and Tumorigenicity assay,0.48,1.0000,29017078
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.48,1.0000,22498113
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,FACs,0.48,1.0000,23349823
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.48,1.0000,26278043
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.48,1.0000,26278043
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.48,1.0000,28516515
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.48,1.0000,28789457
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.48,1.0000,31352088
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.48,1.0000,32466428
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and Tumorigenicity assay,0.48,1.0000,27485114
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.48,1.0000,29144562
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Dexamethasone+Pemetrexed,FACs followed by SFA,0.48,1.0000,29753869
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.48,1.0000,29868483
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA and CFA,0.48,1.0000,29845263
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.48,1.0000,25965829
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by FACs,0.48,1.0000,27035162
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.48,1.0000,30555330
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by FACs,0.48,1.0000,32655321
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and Tumorigenicity assay,0.48,1.0000,25881239
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay and SFA followed by FACs and Tumorigenicity assay,0.48,1.0000,20949018
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by FACs,0.48,1.0000,22825470
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting and IF staining,0.52,1.0000,33288885
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR and Western Blotting,0.52,1.0000,31261030
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,Four-dimensional (4D) culture model by a magnetic responsive alginate-based hydrogel to rotating magnets followed by RT-PCR and IF staining,0.52,1.0000,33836517
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qPCR and FACs,0.52,1.0000,29559846
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.52,1.0000,28461325
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.52,1.0000,32606358
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.52,1.0000,27735991
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.52,1.0000,29512256
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.52,1.0000,28822889
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by RT-PCR,0.52,1.0000,32051395
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,FACs,0.52,1.0000,30485589
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,Adriamycin,FACs,0.52,1.0000,31261030
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by FACs,0.52,1.0000,32707998
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,FACs,0.52,1.0000,33273858
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,AGS,NA,FACs followed by SFA,0.52,1.0000,33061365
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA and FACs followed by Western Blotting,0.4,1.0000,27996162
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by IF staining and FACs,0.4,1.0000,26709750
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qRT-PCR and FACs,0.4,1.0000,27996162
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qPCR,0.4,1.0000,31440741
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,FACs and SFA,0.4,1.0000,33728488
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,FACs followed by SFA,0.4,1.0000,32575925
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.4,1.0000,30119228
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.4,1.0000,30853342
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,AsPC1,Triptolide,SP assay followed by FACs,0.4,1.0000,26597727
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,BFTC-905,NA,SFA followed by qRT-PCR,0.2,1.0000,30327565
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,BFTC-909,NA,SFA followed by qRT-PCR,0.2,1.0000,30327565
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,BGC-823,NA,CFA and IHC staining followed by FACs and Western Blotting,0.64,1.0000,26276718
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by FACs and qRT-PCR and Western Blotting ,0.64,1.0000,33731207
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs and SFA followed by RT-PCR and Western Blotting,0.64,1.0000,28440445
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by FACs and Western Blotting,0.64,1.0000,31517391
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.64,1.0000,34090492
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.64,1.0000,34350176
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by Western Blotting,0.64,1.0000,30624124
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs,0.64,1.0000,32926650
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs followed by SFA,0.64,1.0000,31073886
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,BT-20,NA,FACs followed by SFA,0.12,1.0000,29249690
CD44,LTM,NA,1681,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by qPCR,0.2,1.0000,30224376
CD44,LTM,NA,1681,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by FACs,0.2,1.0000,34775489
CD44,LTM,NA,1681,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,FACs,0.2,1.0000,29500278
CD44,LTM,NA,1681,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,Medrooxyprogesterone Acetate,FACs followed by SFA,0.2,1.0000,28744156
CD44,LTM,NA,1681,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,FACs followed by SFA,0.2,1.0000,29080749
CD44,LTM,NA,1681,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,FACs followed by SFA,0.2,1.0000,31599500
CD44,LTM,NA,1681,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by FACs,0.2,1.0000,27966906
CD44,LTM,NA,1681,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,Trastuzumab,SFA followed by FACs,0.2,1.0000,28722778
CD44,LTM,NA,1681,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by FACs,0.2,1.0000,29088759
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,Western Blotting and IF staining,0.52,1.0000,29100426
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Paclitaxel,Western Blotting and SFA,0.52,1.0000,31308076
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,FACs followed by SFA,0.52,1.0000,33221681
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Carboplatin,FACs followed by SFA,0.52,1.0000,33221681
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Paclitaxel,FACs followed by SFA,0.52,1.0000,33221681
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs followed by SFA,0.52,1.0000,35064101
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,MACs followed by SFA,0.52,1.0000,34715882
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by FACs,0.52,1.0000,35277657
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by FACs,0.52,1.0000,35526049
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs,0.52,1.0000,29262622
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs,0.52,1.0000,30246563
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs,0.52,1.0000,30460610
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs followed by SFA,0.52,1.0000,29197410
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs followed by SFA,0.52,1.0000,31296961
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,FACs followed by SFA,0.52,1.0000,31599500
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by FACs,0.52,1.0000,27995747
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by FACs,0.52,1.0000,28817737
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by FACs,0.52,1.0000,29352988
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Doxorubicin,SFA followed by FACs,0.52,1.0000,29352988
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by FACs,0.52,1.0000,30002443
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,IF staining followed by Western Blotting,0.52,1.0000,31388092
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by RT-PCR and Western Blotting,0.52,1.0000,30802827
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by RT-PCR and Western Blotting,0.52,1.0000,30802827
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,Western Blotting and SFA followed by FACs,0.52,1.0000,33082357
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,CFA and  FACs followed by qRT-PCR,0.52,1.0000,21826251
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,Western Blotting,0.52,1.0000,29970519
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by IF staining,0.52,1.0000,26709750
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,qRT-PCR,0.52,1.0000,26035122
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,qRT-PCR,0.52,1.0000,26035122
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by qRT-PCR,0.52,1.0000,29048549
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs,0.52,1.0000,22948659
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,FACs,0.52,1.0000,31713003
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs,0.52,1.0000,31713003
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs,0.52,1.0000,31856088
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs and CFA followed by SFA and Tumorigenicity assay,0.52,1.0000,23017870
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,FACs followed by SFA,0.52,1.0000,27576197
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SFA,0.52,1.0000,27748818
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SFA,0.52,1.0000,27748818
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SFA,0.52,1.0000,27999190
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SP assay,0.52,1.0000,22963768
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by FACs,0.52,1.0000,30853342
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by FACs,0.52,1.0000,29719602
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CA1,NA,FACs,0.12,1.0000,29568372
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Ca9-22,NA,FACs followed by SFA,0.12,1.0000,24475244
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs followed by IF staining and SFA,0.36,1.0000,31285270
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs and CFA followed by SFA and RT-PCR,0.36,1.0000,29312609
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,CACO-2,NA,qRT-PCR,0.36,1.0000,28565875
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs,0.36,1.0000,25154976
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs,0.36,1.0000,25154976
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,IF staining and Western Blotting followed by SFA,0.52,1.0000,31399556
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,Western Blotting followed by IF staining and SFA,0.52,1.0000,29575240
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,qRT-PCR and IF staining followed by CFA,0.52,1.0000,23627635
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,Western Blotting and FACs followed by SFA,0.52,1.0000,34795388
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by Western Blotting and  FACs,0.52,1.0000,31585633
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Western Blotting,0.52,1.0000,34502158
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and Western Blotting,0.52,1.0000,32194902
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Western Blotting,0.52,1.0000,23903875
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by qRT-PCR,0.52,1.0000,24112466
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,5-Fluorouracil,FACs followed by SFA and CFA,0.52,1.0000,27380877
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,FACs followed by SFA and CFA,0.52,1.0000,27380877
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Docetaxel,FACs followed by SFA and CFA,0.52,1.0000,27380877
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs,0.52,1.0000,27108536
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,5-Fluorouracil,SFA followed by FACs,0.52,1.0000,27108536
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by FACs,0.52,1.0000,27108536
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Docetaxel,SFA followed by FACs,0.52,1.0000,27108536
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,CAL51,NA,FACs followed by SFA,0.12,1.0000,30450530
CD44,LTM,NA,1681,Head and Neck Cancer,Oral Squamous Cell Carcinoma,CaLH3,NA,SFA followed by qRT-PCR,0.2,1.0000,25212757
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,CALU-1,NA,SFA followed by FACs,0.12,1.0000,27577075
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by Western Blotting and SFA,0.28,1.0000,32781084
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Capan-1,Gemcitabine,qRT-PCR,0.28,1.0000,23026911
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by SFA and qRT-PCR,0.28,1.0000,30466404
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by SFA and qRT-PCR,0.28,1.0000,30466404
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs,0.28,1.0000,22948659
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs,0.28,1.0000,24231729
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs followed by SFA,0.28,1.0000,27349387
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs followed by SP assay,0.28,1.0000,22963768
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs followed by Tumorigenicity assay,0.28,1.0000,22111082
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,Migration and Invasion assay followed by FACs,0.28,1.0000,22109279
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,Migration assay followed by FACs,0.28,1.0000,31856088
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by FACs,0.28,1.0000,30819221
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Capan-2,NA,SFA followed by FACs,0.12,1.0000,33934523
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,Gemcitabine,qRT-PCR,0.2,1.0000,26035122
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,qRT-PCR,0.2,1.0000,26035122
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,Gemcitabine,CFA followed by SFA and  FACs,0.2,1.0000,19598259
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,FACs,0.2,1.0000,26398277
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by FACs,0.2,1.0000,30853342
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by FACs,0.2,1.0000,29100320
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SP assay followed by FACs,0.2,1.0000,20372854
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,CL-141,NA,SFA followed by Western Blotting,0.28,1.0000,31638335
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,CL-141,NA,SP assay followed by SFA and Western Blotting,0.28,1.0000,23024022
CD44,LTM,NA,1681,Lung Cancer,Adenocarcinoma,CL-97,NA,SP assay followed by SFA and Western Blotting,0.28,1.0000,23024022
CD44,LTM,NA,1681,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-201,NA,FACs,0.12,1.0000,23354547
CD44,LTM,NA,1681,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,FACs followed by IF staining and SFA,0.36,1.0000,31285270
CD44,LTM,NA,1681,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,FACs,0.36,1.0000,21701559
CD44,LTM,NA,1681,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,SFA followed by FACs,0.36,1.0000,22310487
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,COLO-320,NA,FACs,0.12,1.0000,21701559
CD44,LTM,NA,1681,Pancreatic Cancer,Adenosquamous Cell Carcinoma,COLO-357,NA,FACs followed by SFA,0.12,1.0000,26840020
CD44,LTM,NA,1681,Breast Cancer,Carcinoma,CRL2334,NA,FACs followed by SFA,0.12,1.0000,28817737
CD44,LTM,NA,1681,Skin Cancer,NA,D10,NA,FACs followed by SFA,0.12,1.0000,26208390
CD44,LTM,NA,1681,Head and Neck Cancer,Carcinoma,Detroit-562,NA,SFA followed by FACs,0.12,1.0000,24874475
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,FACs followed by IF staining and SFA,0.36,1.0000,31285270
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,RT-PCR and FACs followed by SFA,0.36,1.0000,32066912
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by qPCR,0.36,1.0000,29449559
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,FACs,0.36,1.0000,24760019
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,FACs followed by SFA,0.36,1.0000,21701559
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by FACs,0.36,1.0000,20630067
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,5-Fluorouracil,SP assay followed by FACs,0.36,1.0000,30005681
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,DMS114,NA,IF staining followed by FACs,0.36,1.0000,31446534
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,DMS153,NA,IF staining followed by FACs,0.36,1.0000,31446534
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,DMS273,NA,IF staining followed by FACs,0.36,1.0000,31446534
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,EBC-1,PHA-665752,SFA followed by qRT-PCR,0.2,1.0000,26351321
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR and Western Blotting and FACs,0.6,1.0000,32661469
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR and Western Blotting,0.6,1.0000,28870814
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by Western Blotting and qRT-PCR,0.6,1.0000,31180522
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,EJ-28,Benzidine,SFA followed by Western Blotting,0.6,1.0000,33552265
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by Western Blotting,0.6,1.0000,33552265
CD44,LTM,NA,1681,Lung Cancer,Adenocarcinoma,EKVX,NA,FACs followed by IHC staining,0.36,1.0000,23738757
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,IF staining and Western Blotting followed by SFA,0.52,1.0000,31399556
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR and Western Blotting,0.52,1.0000,32708734
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Cisplatin,SP assay followed by Western Blotting and FACs,0.52,1.0000,29228308
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by Western Blotting,0.52,1.0000,34502158
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Cisplatin,SFA followed by qRT-PCR,0.52,1.0000,32206093
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Irradiation,FACs,0.52,1.0000,28844650
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by FACs,0.52,1.0000,24874475
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,FACs,0.52,1.0000,24201869
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA and FACs,0.52,1.0000,27108536
CD44,LTM,NA,1681,Glioblastoma Multiforme,NA,GBM8401,NA,SFA followed by IF staining,0.24,1.0000,31035045
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,GLC14,NA,SFA followed by IF staining,0.24,1.0000,33607458
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,GLC16,NA,SFA  and qRT-PCR followed by Western Blotting and IF staining,0.72,1.0000,33607458
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,GLC19,NA,SFA  and qRT-PCR followed by Western Blotting and IF staining,0.72,1.0000,33607458
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Gun-1,NA,SFA followed by IF staining and FACs,0.36,1.0000,19027347
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Gun-1,NA,FACs,0.36,1.0000,20848440
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and Western Blotting,0.48,1.0000,28431267
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs followed by Western Blotting and SFA,0.48,1.0000,24838270
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs followed by IHC staining and SFA,0.48,1.0000,21124918
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs and qRT-PCR,0.48,1.0000,30816208
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs and RT-PCR,0.48,1.0000,29651165
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and FACs,0.48,1.0000,25669973
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,1.0000,33980809
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,Western Blotting followed by SFA,0.48,1.0000,35278461
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by CFA and Western Blotting,0.48,1.0000,32637578
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,1.0000,27836540
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,1.0000,28198062
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,1.0000,33125096
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,Western Blotting,0.48,1.0000,29552200
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,1.0000,34832951
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,Cisplatin,FACs followed by CFA,0.48,1.0000,33550205
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs,0.48,1.0000,24595209
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs,0.48,1.0000,31585300
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs followed by SFA,0.48,1.0000,24091605
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs followed by SFA,0.48,1.0000,29144562
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs,0.48,1.0000,25965829
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs,0.48,1.0000,30555330
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,Cisplatin,SFA followed by FACs,0.48,1.0000,32655321
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SP assay and SFA followed by FACs and Tumorigenicity assay,0.48,1.0000,20949018
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,H1417,NA,FACs followed by CFA,0.12,1.0000,17327908
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,H1437,NA,FACs,0.12,1.0000,22498113
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay followed by FACs and Tumorigenicity assay,0.12,1.0000,20424609
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay followed by FACs and Tumorigenicity assay,0.12,1.0000,20424609
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,SFA followed by qPCR and Western Blotting,0.48,1.0000,29702194
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,FACs followed by IHC staining and SFA,0.48,1.0000,21124918
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,RT-PCR and FACs followed by SFA,0.48,1.0000,28819374
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,Erlotinib,qRT-PCR,0.48,1.0000,30480362
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,Dexamethasone+Pemetrexed,FACs followed by SFA,0.48,1.0000,29753869
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,FACs followed by SFA and Tumorigenicity assay,0.48,1.0000,24091605
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1781,Afatinib,qRT-PCR followed by SFA,0.2,1.0000,29532558
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA followed by Western Blotting,0.28,1.0000,33922104
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay followed by SFA and RT-PCR,0.28,1.0000,28440478
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA followed by FACs,0.28,1.0000,27577075
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,Osimertinib,SFA followed by FACs,0.28,1.0000,30910592
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,H2122,NA,FACs,0.12,1.0000,22498113
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H226,NA,FACs,0.12,1.0000,22498113
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,H23,Cisplatin,SFA followed by IF staining and Western Blotting,0.52,1.0000,26872057
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,FACs followed by IHC staining and SFA,0.52,1.0000,21124918
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,SFA followed by FACs,0.52,1.0000,29190547
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,Western Blotting followed by FACs,0.4,1.0000,30754694
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,FACs followed by RT-PCR,0.4,1.0000,27694834
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Western Blotting,0.4,1.0000,34059086
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,H3122,NA,SFA followed by FACs and qRT-PCR,0.32,1.0000,29950868
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,H357,NA,qRT-PCR and IF staining followed by CFA,0.44,1.0000,23627635
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,SFA followed by Western Blotting,0.28,1.0000,23773734
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,H446,NA,FACs followed by SFA and IF staining,0.36,1.0000,23681228
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Western Blotting,0.36,1.0000,27633248
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Tumorigenicity assay and IF staining,0.36,1.0000,22521544
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,H446,NA,SP assay followed by FACs,0.36,1.0000,22825470
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,Western Blotting followed by RT-PCR,0.48,1.0000,28931539
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,Gefitinib,SFA and FACs followed by Western Blotting,0.48,1.0000,34163000
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs followed by SFA and Western Blotting,0.48,1.0000,26901847
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs followed by Western Blotting,0.48,1.0000,31074646
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,IF staining followed by FACs and SFA,0.48,1.0000,31781681
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA and Western Blotting,0.48,1.0000,34635641
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,1.0000,34195288
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by CFA and Western Blotting,0.48,1.0000,32637578
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,Ciprofloxacin,SFA followed by Western Blotting,0.48,1.0000,26947806
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,1.0000,28179308
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,1.0000,28677037
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,1.0000,28741092
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,1.0000,28931539
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,1.0000,30111255
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,1.0000,32782570
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by IF staining,0.48,1.0000,23947765
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,qRT-PCR and SFA,0.48,1.0000,34246759
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by RT-PCR and Tumorigenicity assay,0.48,1.0000,24961511
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs,0.48,1.0000,33068069
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,FACs followed by CFA,0.48,1.0000,33550205
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by FACs,0.48,1.0000,35267489
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,FACs,0.48,1.0000,23349823
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs,0.48,1.0000,24595209
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Carcinoma,H460,SAHA,FACs,0.48,1.0000,26839308
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,FACs followed by IHC staining,0.36,1.0000,23738757
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,Cisplatin,SFA followed by FACs,0.36,1.0000,27035162
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,H522,NA,FACs,0.12,1.0000,18952074
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,H524,NA,SFA followed by qRT-PCR,0.2,1.0000,35028858
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Giant Cell Carcinoma,H661,Cisplatin,IF staining followed by FACs and SFA,0.36,1.0000,31781681
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,H69,NA,IF staining followed by FACs,0.36,1.0000,31446534
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA followed by qRT-PCR,0.36,1.0000,34832951
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA followed by FACs,0.36,1.0000,34228218
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,H82,NA,SFA followed by FACs,0.12,1.0000,34228218
CD44,LTM,NA,1681,Hepatic Cancer,NA,HAK-1B,NA,SP assay followed by qRT-PCR,0.2,1.0000,24325739
CD44,LTM,NA,1681,Breast Cancer,Ductal Carcinoma,HC1500,NA,FACs followed by SFA,0.12,1.0000,29249690
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,HCC1143,Doxorubicin,FACs followed by SFA,0.12,1.0000,33221681
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,HCC1143,Carboplatin,FACs followed by SFA,0.12,1.0000,33221681
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,HCC1143,Paclitaxel,FACs followed by SFA,0.12,1.0000,33221681
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,HCC1395,Doxorubicin,FACs followed by SFA,0.12,1.0000,33221681
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,HCC1395,Carboplatin,FACs followed by SFA,0.12,1.0000,33221681
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,HCC1395,Paclitaxel,FACs followed by SFA,0.12,1.0000,33221681
CD44,LTM,NA,1681,Breast Cancer,Carcinoma,HCC1569,NA,SFA followed by FACs,0.12,1.0000,34889737
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,FACs followed by SFA and IF staining,0.36,1.0000,31612865
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,SFA followed by qRT-PCR and FACs,0.36,1.0000,34023418
CD44,LTM,NA,1681,Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,SFA followed by FACs,0.36,1.0000,34889737
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,FACs followed by SFA,0.36,1.0000,34718356
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,FACs followed by SFA,0.36,1.0000,35504883
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,SFA followed by FACs,0.36,1.0000,33672732
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,FACs,0.36,1.0000,29679903
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,FACs,0.36,1.0000,30091683
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,SFA followed by qRT-PCR and FACs,0.32,1.0000,34023418
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs followed by qRT-PCR,0.32,1.0000,31273285
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,Western Blotting,0.32,1.0000,30139970
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,SFA and FACs,0.32,1.0000,33390847
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs,0.32,1.0000,29197410
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs,0.32,1.0000,29249690
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs,0.32,1.0000,31709178
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs,0.32,1.0000,31729259
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs followed by SFA,0.32,1.0000,29679903
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs followed by SFA,0.32,1.0000,30227220
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,FACs for CSC marker followed by Transcriptomics,0.32,1.0000,31709178
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,NA,Western Blotting,0.28,1.0000,30139970
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,NA,FACs followed by SFA,0.28,1.0000,35220209
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,MK-0752,FACs,0.28,1.0000,29027990
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,MK-0752,FACs,0.28,1.0000,29027990
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,NA,FACs followed by SFA,0.28,1.0000,30326469
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,SFA followed by FACs,0.28,1.0000,29895705
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,SFA followed by FACs,0.28,1.0000,29895705
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,HCC-38,Docetaxel,FACs followed by SFA,0.12,1.0000,29190901
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,HCC-38,NA,FACs followed by SFA,0.12,1.0000,31599500
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,FACs followed by IHC staining and SFA,0.36,1.0000,21124918
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,FACs followed by SFA and Tumorigenicity assay,0.36,1.0000,24091605
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,FACs followed by SFA and Tumorigenicity assay,0.36,1.0000,28819374
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by FACs,0.36,1.0000,25965829
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,qRT-PCR followed by Western Blotting and SFA,0.48,1.0000,30912138
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by Western Blotting and SFA,0.48,1.0000,21596996
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil,SFA followed by Western Blotting and qRT-PCR,0.48,1.0000,28990068
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting and qRT-PCR,0.48,1.0000,31544978
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs and SFA followed by IF staining,0.48,1.0000,33819194
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by IF staining and FACs,0.48,1.0000,22745705
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by CFA and SFA and qRT-PCR,0.48,1.0000,35392530
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs and qRT-PCR,0.48,1.0000,35242031
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs and RT-PCR followed by CFA,0.48,1.0000,26840024
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil+Oxaliplatin,FACs followed by RT-PCR,0.48,1.0000,19956394
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by RT-PCR,0.48,1.0000,30788057
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR and FACs followed by SFA,0.48,1.0000,32066912
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil+Oxaliplatin,RT-PCR followed by FACs,0.48,1.0000,21774804
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA and FACs followed by RT-PCR,0.48,1.0000,21750907
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs and qPCR,0.48,1.0000,26506839
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil+Oxaliplatin,SFA followed by Western Blotting,0.48,1.0000,22761031
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.48,1.0000,26785732
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.48,1.0000,27894099
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.48,1.0000,29348560
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.48,1.0000,29354056
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,Western Blotting,0.48,1.0000,22319203
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil+Oxaliplatin,Western Blotting followed by SFA,0.48,1.0000,22072622
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,IHC staining,0.48,1.0000,31810923
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA and IF staining,0.48,1.0000,27207017
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil+Oxaliplatin,qRT-PCR and SFA,0.48,1.0000,21161336
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by SFA,0.48,1.0000,32037723
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA and qRT-PCR,0.48,1.0000,25368233
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,1.0000,33419797
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil,FACs,0.48,1.0000,34151658
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by CFA,0.48,1.0000,33958701
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,Paclitaxel,CFA followed by FACs,0.48,1.0000,23624503
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,1.0000,19734943
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,1.0000,20433742
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,1.0000,22842824
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,1.0000,24760019
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,1.0000,25154976
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,1.0000,25154976
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,1.0000,25941936
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,1.0000,29740695
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,1.0000,29928431
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,1.0000,31641961
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,1.0000,32729895
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.48,1.0000,21701559
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.48,1.0000,22329848
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.48,1.0000,27455311
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.48,1.0000,30451890
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.48,1.0000,31950022
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.48,1.0000,33209130
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and Tumorigenicity assay,0.48,1.0000,19451087
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and Tumorigenicity assay,0.48,1.0000,31120140
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by Tumorigenicity assay and SFA,0.48,1.0000,21454414
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,MACs and SFA followed by CFA and Tumorigenicity assay,0.48,1.0000,27600678
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA and FACs,0.48,1.0000,26399781
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA and MACs,0.48,1.0000,24696849
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.48,1.0000,20630067
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.48,1.0000,23345327
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.48,1.0000,23592893
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.48,1.0000,31883392
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs and Tumorigenicity assay,0.48,1.0000,19737148
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil,SP assay followed by FACs,0.48,1.0000,30005681
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,FACs followed by qRT-PCR and Western Blotting,0.6,1.0000,24145190
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,FACs followed by qRT-PCR and SFA,0.6,1.0000,28755485
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HCT-15,Cisplatin,SFA and qPCR,0.6,1.0000,34921482
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,FACs,0.6,1.0000,26136074
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,Oxaliplatin,FACs,0.6,1.0000,26136074
CD44,LTM,NA,1681,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by qPCR and Western Blotting,0.48,1.0000,29228308
CD44,LTM,NA,1681,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by IF staining and qRT-PCR,0.48,1.0000,25104726
CD44,LTM,NA,1681,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,SP assay followed by Western Blotting and FACs,0.48,1.0000,29228308
CD44,LTM,NA,1681,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by RT-PCR,0.48,1.0000,26021266
CD44,LTM,NA,1681,Head and Neck Cancer,Carcinoma,HEp-2,NA,FACs followed by Migration assay,0.48,1.0000,30210931
CD44,LTM,NA,1681,Head and Neck Cancer,Carcinoma,HEp-2,5-Fluorouracil,FACs followed by SFA and CFA,0.48,1.0000,27380877
CD44,LTM,NA,1681,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,FACs followed by SFA and CFA,0.48,1.0000,27380877
CD44,LTM,NA,1681,Head and Neck Cancer,Carcinoma,HEp-2,Docetaxel,FACs followed by SFA and CFA,0.48,1.0000,27380877
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,Hep3B,NA,FACs followed by CFA,0.12,1.0000,22194816
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by FACs,0.12,1.0000,25676692
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,Hep-G2,NA,IHC staining followed by qRT-PCR,0.44,1.0000,30023612
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,Hep-G2,NA,FACs,0.44,1.0000,31888685
CD44,LTM,NA,1681,Gastric Cancer,NA,HFE-145,NA,SFA followed by Western Blotting and IF staining,0.52,1.0000,33288885
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,HGC-27,NA,FACs followed by SFA and Western Blotting,0.4,1.0000,31213895
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by qPCR and FACs,0.4,1.0000,29559846
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by FACs,0.4,1.0000,31879364
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HN12,NA,SFA followed by Western Blotting and IF staining,0.52,1.0000,25749385
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HN12,NA,SFA followed by Western Blotting,0.52,1.0000,23903875
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HN13,NA,SFA and Western Blotting,0.28,1.0000,28279658
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HN13,NA,SFA followed by Western Blotting,0.28,1.0000,23903875
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HN13,NA,FACs followed by Migration assay,0.28,1.0000,30210931
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HN4,NA,SFA followed by Western Blotting and IF staining,0.52,1.0000,25749385
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HN4,Cisplatin,Western Blotting and FACs followed by SFA,0.52,1.0000,34795388
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HN4,NA,SFA and Western Blotting,0.52,1.0000,32194902
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HN6,NA,SFA followed by Western Blotting,0.28,1.0000,23903875
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,CFA followed by IF staining,0.24,1.0000,30395429
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by IF staining,0.24,1.0000,27891685
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by FACs,0.24,1.0000,34794402
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,HPAC,Gemcitabine,CFA followed by SFA and  FACs,0.24,1.0000,19598259
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,FACs followed by SFA,0.24,1.0000,27748818
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,FACs followed by SFA,0.24,1.0000,27748818
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,HPAF-II,Gemcitabine,qPCR,0.2,1.0000,31440741
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,FACs,0.2,1.0000,22948659
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,SFA followed by FACs,0.2,1.0000,30853342
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SP assay followed by SFA and IHC staining,0.24,1.0000,29981340
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by qPCR,0.24,1.0000,30224376
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,FACs followed by SFA,0.24,1.0000,34294320
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,FACs followed by SFA followed by,0.24,1.0000,34344863
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,MACs followed by SFA,0.24,1.0000,34715882
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,FACs,0.24,1.0000,29162703
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,FACs and SFA,0.24,1.0000,29183891
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,FACs followed by SFA,0.24,1.0000,29048610
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,Invasion assay followed by SP assay and FACs,0.24,1.0000,18386134
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by FACs,0.24,1.0000,28951456
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-2,NA,FACs followed by Western Blotting and qRT-PCR,0.6,1.0000,23992541
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,FACs,0.12,1.0000,29515788
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,FACs followed by CFA,0.12,1.0000,22847005
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,FACs followed by SFA,0.12,1.0000,26448762
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,FACs followed by SFA,0.12,1.0000,27002147
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,FACs,0.12,1.0000,30029671
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-4,NA,SP assay followed by qRT-PCR and IHC staining ,0.44,1.0000,20651344
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-4,NA,FACs,0.44,1.0000,29515788
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,HT-1197,NA,FACs,0.12,1.0000,35008872
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,HT-1376,NA,SFA followed by IF staining and qRT-PCR,0.44,1.0000,26452033
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,HT-1376,NA,SFA and IF staining,0.44,1.0000,33920080
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,HT-1376,NA,FACs,0.44,1.0000,29340052
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by Western Blotting and SFA,0.48,1.0000,21596996
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting and qRT-PCR,0.48,1.0000,31544978
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and SFA followed by IF staining,0.48,1.0000,33819194
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by IF staining and SFA,0.48,1.0000,31285270
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA and IHC staining,0.48,1.0000,26918725
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by IF staining and FACs,0.48,1.0000,22745705
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by CFA and SFA and qRT-PCR,0.48,1.0000,35392530
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and CFA followed by SFA and RT-PCR,0.48,1.0000,29312609
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by qRT-PCR and SFA,0.48,1.0000,28755485
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,qRT-PCR followed by FACs,0.48,1.0000,29158786
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs and qPCR,0.48,1.0000,26506839
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil+Oxaliplatin,SFA followed by Western Blotting,0.48,1.0000,22761031
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.48,1.0000,27894099
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil+Oxaliplatin,Western Blotting followed by SFA,0.48,1.0000,22072622
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker followed by qRT-PCR,0.48,1.0000,33744851
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,qRT-PCR,0.48,1.0000,28565875
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,qRT-PCR,0.48,1.0000,30772447
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.48,1.0000,32037723
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.48,1.0000,27556511
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.48,1.0000,29457276
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,FACs,0.48,1.0000,34151658
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.48,1.0000,33667839
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.48,1.0000,21701559
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil+Oxaliplatin,FACs,0.48,1.0000,21774804
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.48,1.0000,22329848
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,FACs,0.48,1.0000,24323901
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.48,1.0000,24760019
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.48,1.0000,25154976
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.48,1.0000,25154976
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.48,1.0000,26136074
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,FACs,0.48,1.0000,26136074
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.48,1.0000,32729895
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and SFA,0.48,1.0000,24970802
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and SFA,0.48,1.0000,27520449
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA,0.48,1.0000,31662289
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA,0.48,1.0000,31904143
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA and Tumorigenicity assay,0.48,1.0000,31120140
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,MACs,0.48,1.0000,27932392
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and FACs,0.48,1.0000,27556511
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.48,1.0000,20630067
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.48,1.0000,26634106
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.48,1.0000,27556511
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.48,1.0000,28825721
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.48,1.0000,28825721
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.48,1.0000,30770752
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs and SP assay,0.48,1.0000,21670985
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs and SP assay,0.48,1.0000,30770752
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs and Tumorigenicity assay,0.48,1.0000,30250604
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by FACs,0.48,1.0000,30209760
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Papilloma,HTB-2,NA,FACs,0.12,1.0000,20142235
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Papilloma,HTB-4,NA,FACs,0.12,1.0000,20142235
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,HTB-9,NA,FACs,0.12,1.0000,20142235
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,HTB-9,NA,FACs followed by SFA,0.12,1.0000,26054707
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by Western Blotting,0.4,1.0000,32221015
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,Huh7,NA,MACs followed by Western Blotting and SFA,0.4,1.0000,29602239
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Western Blotting,0.4,1.0000,33825221
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting followed by SFA and CFA,0.4,1.0000,30908631
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by CFA,0.4,1.0000,22194816
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by FACs and SFA,0.4,1.0000,25997710
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,Huh7,NA,MACs followed by SFA,0.4,1.0000,31732298
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by FACs,0.4,1.0000,25676692
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by FACs,0.4,1.0000,25997710
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by FACs and IF staining and RT-PCR,0.56,1.0000,30397177
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by qRT-PCR,0.56,1.0000,35116788
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by FACs,0.56,1.0000,31176734
CD44,LTM,NA,1681,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,FACs followed by Western Blotting,0.4,1.0000,30620624
CD44,LTM,NA,1681,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,FACs,0.4,1.0000,34215226
CD44,LTM,NA,1681,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,SFA followed by FACs,0.4,1.0000,34775489
CD44,LTM,NA,1681,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,FACs followed by SFA,0.4,1.0000,29080749
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,JLO-1,Metformin,qPCR,0.2,1.0000,30621095
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,JMSU-1,NA,MACs,0.12,1.0000,32192892
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,JTC-30,NA,FACs followed by SFA,0.12,1.0000,21964864
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by Western Blotting and IF staining,0.52,1.0000,33288885
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by Western Blotting,0.52,1.0000,32606358
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,KATO-III,NA,FACs,0.52,1.0000,30485589
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,KATO-III,NA,FACs,0.52,1.0000,19415765
CD44,LTM,NA,1681,Head and Neck Cancer,Carcinoma,KB,NA,SFA followed by IF staining and qRT-PCR,0.44,1.0000,25104726
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Carcinoma,KLM-1,NA,SFA and FACs,0.12,1.0000,34628696
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,KM12SM,NA,FACs,0.12,1.0000,31505062
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,KMBC-2,NA,SFA followed by qRT-PCR,0.2,1.0000,34101386
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,KMP5,NA,SFA and FACs,0.12,1.0000,34628696
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,KUMA-1,NA,FACs followed by Western Blotting and qRT-PCR,0.6,1.0000,23992541
CD44,LTM,NA,1681,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR and FACs,0.32,1.0000,23917223
CD44,LTM,NA,1681,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,Gemcitabine,qRT-PCR,0.32,1.0000,26035122
CD44,LTM,NA,1681,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,qRT-PCR,0.32,1.0000,26035122
CD44,LTM,NA,1681,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR,0.32,1.0000,26840266
CD44,LTM,NA,1681,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,Cisplatin,FACs,0.32,1.0000,34123574
CD44,LTM,NA,1681,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,Gemcitabine,FACs,0.32,1.0000,34123574
CD44,LTM,NA,1681,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.7,NA,FACs followed by Tumorigenicity assay,0.12,1.0000,26880805
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,NA,LC006,NA,FACs,0.12,1.0000,29407170
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,NA,LC021,NA,FACs,0.12,1.0000,29407170
CD44,LTM,NA,1681,Lung Cancer,NA,LC-42,NA,FACs followed by IHC staining,0.36,1.0000,23738757
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,LK0827,NA,FACs,0.12,1.0000,23049743
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,LK0863,NA,FACs,0.12,1.0000,23049743
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,LK0923,NA,FACs,0.12,1.0000,23049743
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),qRT-PCR followed by Western Blotting,0.48,1.0000,28627611
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),qRT-PCR followed by Western Blotting and SFA,0.48,1.0000,29956726
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,SP assay followed by FACs and IF staining,0.48,1.0000,35326523
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),RT-PCR,0.48,1.0000,30552676
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,SFA followed by FACs,0.48,1.0000,35242031
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,FACs,0.48,1.0000,32729895
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,FACs and SFA,0.48,1.0000,24970802
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,SFA and MACs,0.48,1.0000,24696849
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,LS174T,NA,FACs,0.12,1.0000,27520449
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,LS180,Doxorubicin,FACs followed by SFA,0.12,1.0000,30344742
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Carcinoma,LS411N,5-fluorouracil,FACs followed by SFA,0.12,1.0000,27659530
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,LUC4,5 Fluorouracil,FACs,0.12,1.0000,25169655
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Luc4,NA,FACs,0.12,1.0000,29568372
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs followed by Western Blotting and qRT-PCR,0.6,1.0000,29464036
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and qPCR and Western Blotting,0.6,1.0000,29846560
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by IF staining and SFA,0.6,1.0000,29982992
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,IHC staining followed by qRT-PCR,0.6,1.0000,30023612
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and IF staining,0.6,1.0000,30188754
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs and Western Blotting followed by SFA,0.6,1.0000,35078507
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by Western Blotting,0.6,1.0000,33731668
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs followed by SFA and Western Blotting,0.6,1.0000,29050299
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and Western Blotting,0.6,1.0000,29100426
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and Western Blotting,0.6,1.0000,31672029
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA and IF staining,0.6,1.0000,33274565
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA and IF staining,0.6,1.0000,35134607
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA and IF staining,0.6,1.0000,35413424
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by IHC staining and SFA,0.6,1.0000,31579408
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and qRT-PCR,0.6,1.0000,34486791
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs and qRT-PCR,0.6,1.0000,31762819
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by qRT-PCR and SFA,0.6,1.0000,30239174
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA and qRT-PCR,0.6,1.0000,31501409
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR followed by FACs and SFA,0.6,1.0000,30615901
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and qRT-PCR,0.6,1.0000,30188754
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and qRT-PCR,0.6,1.0000,31300015
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.6,1.0000,29243835
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.6,1.0000,29356693
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Lithium Chloride,Western Blotting and SFA,0.6,1.0000,29356693
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Purmorphamine,Western Blotting and SFA,0.6,1.0000,29356693
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.6,1.0000,31497349
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,Western Blotting followed by SFA,0.6,1.0000,31690832
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by IF staining,0.6,1.0000,34718182
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,IF staining followed by SFA,0.6,1.0000,31591823
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by IF staining and Tumorigenicity assay,0.6,1.0000,29176652
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and qRT-PCR,0.6,1.0000,31728117
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.6,1.0000,29044153
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.6,1.0000,29179185
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.6,1.0000,34073849
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.6,1.0000,35053617
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by CFA,0.6,1.0000,35235236
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs followed by SFA,0.6,1.0000,33221681
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Carboplatin,FACs followed by SFA,0.6,1.0000,33221681
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Paclitaxel,FACs followed by SFA,0.6,1.0000,33221681
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,33919234
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,34217266
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,34315857
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Adriamycin,FACs followed by SFA,0.6,1.0000,34403222
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,35205696
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,35254725
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,35508987
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,MACs followed by SFA,0.6,1.0000,34715882
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,MACs followed by SFA,0.6,1.0000,35109743
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs,0.6,1.0000,33262438
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and FACs,0.6,1.0000,34234874
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,33305893
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,33419140
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,33511560
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,33603536
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Adriamycin,SFA followed by FACs,0.6,1.0000,33866606
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,33940518
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,34249423
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,34680485
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,34830821
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,34884742
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,35047440
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by MACs,0.6,1.0000,34803458
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,CFA followed by FACs,0.6,1.0000,28839461
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs,0.6,1.0000,29028589
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.6,1.0000,29323439
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.6,1.0000,29422957
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.6,1.0000,29509055
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.6,1.0000,29526821
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs,0.6,1.0000,29635751
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.6,1.0000,29848346
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.6,1.0000,30206184
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.6,1.0000,30233203
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Radiotherapy,FACs,0.6,1.0000,30272295
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs,0.6,1.0000,31286834
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.6,1.0000,31286834
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs,0.6,1.0000,31627418
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Paclitaxel,FACs,0.6,1.0000,31627418
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.6,1.0000,31781916
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs and SFA,0.6,1.0000,29185119
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by CFA,0.6,1.0000,18681906
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,28725489
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,MK-0752,FACs followed by SFA,0.6,1.0000,29027990
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,RO49097,FACs followed by SFA,0.6,1.0000,29027990
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,29048610
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,29073103
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,29218545
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,29229606
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,29355544
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,29601799
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,29602199
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs followed by SFA,0.6,1.0000,29750424
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,29797562
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,30076320
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,30335523
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,30442981
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,30450766
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,31283068
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,31296961
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,31599500
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,31695364
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,31695775
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,31695775
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.6,1.0000,31736268
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Fulvestrant,FACs followed by SFA,0.6,1.0000,31756890
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA and SP assay,0.6,1.0000,27974826
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,MACs,0.6,1.0000,30482232
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and CFA followed by MACs,0.6,1.0000,29187905
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,21062983
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,28003747
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Paclitaxel,SFA followed by FACs,0.6,1.0000,28718813
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,28823831
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,28930649
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,29088759
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,29093680
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,29187406
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,29221160
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,29228728
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,SFA followed by FACs,0.6,1.0000,29301415
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,SFA followed by FACs,0.6,1.0000,29363524
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,29746865
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,29749438
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Fructose,SFA followed by FACs,0.6,1.0000,29796188
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,29923726
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,29976159
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Adrimycin,SFA followed by FACs,0.6,1.0000,30055109
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,30170097
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,30188754
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,30238818
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,30579251
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,30628646
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,31273952
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,31308814
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,31452727
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,31579408
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,31658701
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,31726667
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.6,1.0000,31756890
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and SP assay,0.6,1.0000,31604679
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and Tumorigenicity assay,0.6,1.0000,28938607
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,SFA followed by SP assay and FACs,0.6,1.0000,31756890
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Fulvestrant,SFA followed by SP assay and FACs,0.6,1.0000,31756890
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Leptin,SFA followed by SP assay and FACs,0.6,1.0000,31756890
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,SFA followed by SP assay and FACs,0.6,1.0000,31756890
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by FACs,0.6,1.0000,18466993
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by SFA and FACs,0.6,1.0000,17881900
CD44,LTM,NA,1681,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by SFA and FACs,0.6,1.0000,18506619
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,MDA-1986,Cisplatin,FACs and SFA,0.12,1.0000,29121598
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by Western Blotting and IF staining,0.64,1.0000,29207686
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,RH-1,qRT-PCR followed by FACs and Western Blotting ,0.64,1.0000,31336714
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and IF staining,0.64,1.0000,29100426
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA followed by Western Blotting,0.64,1.0000,34451892
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by Western Blotting and SFA,0.64,1.0000,29316250
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA and IF staining,0.64,1.0000,33274565
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA and IF staining,0.64,1.0000,34311079
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA and IF staining,0.64,1.0000,35413424
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA and IF staining,0.64,1.0000,31612865
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs and qRT-PCR,0.64,1.0000,34146553
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs and qRT-PCR,0.64,1.0000,34445421
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs and qRT-PCR,0.64,1.0000,35195687
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by qPCR and SFA,0.64,1.0000,31745977
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by qRT-PCR and SFA,0.64,1.0000,30239174
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Gemcitabine,CFA and SFA followed by Western Blotting,0.64,1.0000,28036386
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.64,1.0000,30262865
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.64,1.0000,31497349
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,MACs and FACs,0.64,1.0000,34235281
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,IF staining,0.64,1.0000,28760736
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SP assay followed by SFA and IHC staining,0.64,1.0000,29981340
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Lapatinib,SFA followed by qRT-PCR,0.64,1.0000,34435487
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and SFA,0.64,1.0000,30513573
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and qRT-PCR,0.64,1.0000,31728117
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.64,1.0000,29103027
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.64,1.0000,29179185
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,33433838
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,33731668
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,34073849
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,34665934
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,35055160
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,35084278
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by CFA,0.64,1.0000,34502547
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,32482103
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Doxorubicin,FACs followed by SFA,0.64,1.0000,33221681
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Carboplatin,FACs followed by SFA,0.64,1.0000,33221681
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,FACs followed by SFA,0.64,1.0000,33221681
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,34294320
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,34770867
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,34944852
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,35135840
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,35171381
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,35205696
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,35504883
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA followed by,0.64,1.0000,34344863
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,MACs followed by SFA,0.64,1.0000,33845139
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and FACs,0.64,1.0000,33390847
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and FACs,0.64,1.0000,34234874
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,33419140
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,33511560
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,33866606
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,34052833
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,34123797
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,34130123
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,34249423
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,34608584
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,35017469
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,35277657
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,35526049
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,CFA followed by FACs,0.64,1.0000,28839461
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,18366788
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,29036915
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,29162703
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,29262622
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,29290211
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,29323439
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,29374148
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,29394261
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,29526821
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,29552056
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,29552056
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,29653746
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,29848346
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,30191610
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,30191610
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,30233203
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,30246563
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Radiotherapy,FACs,0.64,1.0000,30272295
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,30584335
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.64,1.0000,31729259
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,FACs and SFA,0.64,1.0000,28703802
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Docetaxel,FACs and SFA,0.64,1.0000,29921732
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by CFA,0.64,1.0000,18681906
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cisplatin,FACs followed by CFA,0.64,1.0000,30255421
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,27976692
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,28817737
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,29048610
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Docetaxel,FACs followed by SFA,0.64,1.0000,29190901
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,29197410
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,29218545
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,29249663
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,29353288
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,29601799
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Epirubicin,FACs followed by SFA,0.64,1.0000,29792857
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,29797562
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,30021199
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,30450530
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,30460610
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,30479839
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,30542507
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,30587555
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,31283068
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,31501409
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,31545416
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,31545416
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,31599500
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,31619923
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,31695436
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,31695775
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.64,1.0000,31695775
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA and Migration assay,0.64,1.0000,31756533
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cisplatin,FACs followed by SP assay and SFA,0.64,1.0000,30361903
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by Tumorigenicity assay,0.64,1.0000,29658391
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by Tumorigenicity assay,0.64,1.0000,30050079
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,MACs followed by SFA,0.64,1.0000,29301945
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and CFA followed by MACs,0.64,1.0000,29187905
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Doxorubicin,SFA followed by FACs,0.64,1.0000,28817737
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,28817737
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,28823831
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by FACs,0.64,1.0000,28835684
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,28923385
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,28928832
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,28951456
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,28991374
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,29053396
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,29228728
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,29405062
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Fructose,SFA followed by FACs,0.64,1.0000,29796188
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,29895705
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,29964299
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,29975921
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,30002443
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,30149665
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,30170097
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,30564555
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,7 Gy Radiation,SFA followed by FACs,0.64,1.0000,30579251
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,30647871
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,31273952
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,31308814
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,31452727
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,31462709
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,31658701
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,31726667
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.64,1.0000,31784862
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,MDA-MB-435,NA,FACs followed by CFA,0.12,1.0000,18681906
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,MACs and FACs,0.24,1.0000,34235281
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,FACs,0.24,1.0000,31729259
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,FACs followed by SFA,0.24,1.0000,29249690
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,FACs followed by SFA,0.24,1.0000,30479839
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs followed by SFA,0.12,1.0000,30021199
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,FACs followed by SFA,0.12,1.0000,31599500
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,SFA followed by FACs,0.12,1.0000,30647871
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Irradiation,CFA followed by Western Blotting and FACs,0.4,1.0000,34708581
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA and IF staining,0.4,1.0000,34311079
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Paclitaxel,FACs and SP assay followed by SFA and qRT-PCR,0.4,1.0000,30572639
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.4,1.0000,30262865
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by qPCR,0.4,1.0000,30224376
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,Culture of cells in electrospun scaffolds followed by FACs,0.4,1.0000,34841239
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA,0.4,1.0000,35135840
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,MACs followed by SFA,0.4,1.0000,33845139
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs,0.4,1.0000,34889737
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs,0.4,1.0000,30091683
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs,0.4,1.0000,30191610
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Doxorubicin,FACs,0.4,1.0000,31627418
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Paclitaxel,FACs,0.4,1.0000,31627418
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by CFA,0.4,1.0000,18681906
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA,0.4,1.0000,28817737
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA,0.4,1.0000,29249663
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA,0.4,1.0000,29249690
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Doxorubicin,FACs followed by SFA,0.4,1.0000,29750424
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA,0.4,1.0000,30021199
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA,0.4,1.0000,31599500
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA and Migration assay,0.4,1.0000,31756533
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs,0.4,1.0000,28817737
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs,0.4,1.0000,28978427
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs,0.4,1.0000,29895705
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs,0.4,1.0000,30628646
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Doxorubicin,SFA followed by FACs,0.4,1.0000,31784862
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs and SP assay,0.4,1.0000,31604679
CD44,LTM,NA,1681,Skin Cancer,NA,Me67,NA,FACs,0.12,1.0000,26208390
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA and FACs followed by qRT-PCR and Western Blotting,0.6,1.0000,33608016
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qPCR and Western Blotting,0.6,1.0000,28428713
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.6,1.0000,28893318
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.6,1.0000,32142918
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by RT-PCR,0.6,1.0000,24573253
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA and FACs,0.6,1.0000,34075691
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,MHCC97-H,NA,Western Blotting followed by SFA and CFA,0.28,1.0000,30908631
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,MHCC97-H,NA,FACs followed by SFA,0.28,1.0000,31888685
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by FACs and Western Blotting,0.4,1.0000,27432228
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting followed by FACs and SFA,0.4,1.0000,29179494
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by IHC staining and SFA,0.4,1.0000,31510100
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,IF staining followed by FACs,0.4,1.0000,19714243
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,IF staining followed by FACs,0.4,1.0000,19714243
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA and Western Blotting,0.4,1.0000,35428310
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by SP assay and Western Blotting,0.4,1.0000,23864708
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Western Blotting,0.4,1.0000,26458814
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Western Blotting,0.4,1.0000,26673007
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting,0.4,1.0000,31106493
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting followed by SFA,0.4,1.0000,28490735
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,IF staining followed by SFA,0.4,1.0000,29107110
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and IF staining,0.4,1.0000,24719318
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,qRT-PCR,0.4,1.0000,23073476
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,qRT-PCR,0.4,1.0000,24726912
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.4,1.0000,26840266
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by FACs,0.4,1.0000,34123574
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Cisplatin,SFA followed by FACs and Imaging FACs,0.4,1.0000,34123574
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs,0.4,1.0000,22948659
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs,0.4,1.0000,26302089
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs,0.4,1.0000,26546043
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs and CFA followed by SFA and Tumorigenicity assay,0.4,1.0000,23017870
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by SFA,0.4,1.0000,24719318
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by SFA,0.4,1.0000,32575925
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by SFA,0.4,1.0000,27999190
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by SFA and Migration assay,0.4,1.0000,24734907
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by Tumorigenicity assay,0.4,1.0000,22111082
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by Tumorigenicity assay,0.4,1.0000,20940707
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and FACs,0.4,1.0000,20940707
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by FACs,0.4,1.0000,29719602
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Triptolide,SP assay followed by FACs,0.4,1.0000,26597727
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN28,NA,SFA followed by IF staining,0.24,1.0000,29178392
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN28,NA,SFA and IF staining,0.24,1.0000,28383763
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by IF staining and Western Blotting,0.52,1.0000,28430578
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting and IF staining,0.52,1.0000,33288885
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.52,1.0000,30843262
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,Acetylcholine,SFA followed by qRT-PCR and IF staining,0.52,1.0000,30207200
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by Western Blotting and SFA,0.52,1.0000,29212193
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs and SFA followed by Western Blotting,0.52,1.0000,28186678
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by FACs and  IF staining,0.52,1.0000,32707998
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by RT-PCR and SFA,0.52,1.0000,30543303
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and FACs,0.52,1.0000,27157616
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs and qRT-PCR,0.52,1.0000,32203224
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by RT-PCR,0.52,1.0000,25081334
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by RT-PCR and SFA,0.52,1.0000,28692437
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.52,1.0000,27644439
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.52,1.0000,28461325
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.52,1.0000,28970066
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,Western Blotting,0.52,1.0000,27878307
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,IF staining,0.52,1.0000,31489619
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by IF staining,0.52,1.0000,29178392
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SP assay followed by SFA and IF staining,0.52,1.0000,31345097
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and IF staining,0.52,1.0000,28383763
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for SFA followed by qRT-PCR,0.52,1.0000,27511210
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,1.0000,27735991
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,1.0000,29512256
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by RT-PCR,0.52,1.0000,33725258
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,qRT-PCR,0.52,1.0000,32099405
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,1.0000,28822889
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,Cisplatin,FACs,0.52,1.0000,30250614
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs,0.52,1.0000,30485589
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.52,1.0000,27620279
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.52,1.0000,31213895
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and FACs,0.52,1.0000,34075691
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and FACs,0.52,1.0000,34646768
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.52,1.0000,19415765
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.52,1.0000,31073886
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.52,1.0000,26155313
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,MACs followed by SFA,0.52,1.0000,31048191
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by FACs,0.52,1.0000,31879364
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by FACs,0.52,1.0000,32863948
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN74,NA,SFA followed by FACs and qRT-PCR,0.32,1.0000,33566246
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN74,NA,IF staining,0.32,1.0000,31489619
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN74,NA,SFA followed by qRT-PCR,0.32,1.0000,28822889
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN74,Cisplatin,FACs,0.32,1.0000,30250614
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,MKN74,NA,FACs followed by SFA,0.32,1.0000,19415765
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,MOR,Cisplatin,FACs,0.12,1.0000,23349823
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MU-PK-1,NA,SFA followed by FACs,0.12,1.0000,25075094
CD44,LTM,NA,1681,Skin Cancer,NA,NA8-MEL,NA,FACs,0.12,1.0000,26208390
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,NCI-N87,Trastuzumab,SFA and FACs followed by RT-PCR and Western Blotting,0.6,1.0000,25669984
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,NCI-N87,NA,FACs followed by RT-PCR and SFA,0.6,1.0000,30543303
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.6,1.0000,28461325
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.6,1.0000,32606358
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by FACs,0.6,1.0000,28404967
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,NCI-N87,NA,FACs followed by SFA,0.6,1.0000,19415765
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,NCI-N87,NA,FACs followed by SFA,0.6,1.0000,31073886
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,NCI-N87,NA,MACs followed by SFA,0.6,1.0000,31048191
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,FACs followed by SFA,0.12,1.0000,22692956
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,FACs,0.12,1.0000,24201869
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,OM-1,NA,FACs followed by SFA,0.12,1.0000,26399460
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,PAMC82,NA,Western Blotting and SFA,0.28,1.0000,33067426
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,PAMC82,NA,FACs followed by SFA,0.28,1.0000,31073886
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR and Western Blotting,0.48,1.0000,30802827
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR and Western Blotting,0.48,1.0000,30802827
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting followed by FACs and SFA,0.48,1.0000,29179494
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by IHC staining and SFA,0.48,1.0000,31510100
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,IHC staining followed by FACs,0.48,1.0000,30272287
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by qRT-PCR,0.48,1.0000,29444383
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs and qRT-PCR,0.48,1.0000,29975934
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR and FACs,0.48,1.0000,23917223
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR and FACs,0.48,1.0000,26439804
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and Western Blotting,0.48,1.0000,35428310
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,1.0000,33359649
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting and SFA,0.48,1.0000,34349642
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by SP assay and Western Blotting,0.48,1.0000,23864708
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,1.0000,26458814
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,1.0000,26673007
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,1.0000,27996162
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,1.0000,28802012
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,1.0000,32395477
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting,0.48,1.0000,29947365
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by IF staining,0.48,1.0000,33915247
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,Microplate array followed by IF staining,0.48,1.0000,23815678
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by IF staining,0.48,1.0000,26709750
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qPCR,0.48,1.0000,31440741
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qRT-PCR,0.48,1.0000,23026911
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR,0.48,1.0000,24726912
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.48,1.0000,26335012
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.48,1.0000,26840266
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.48,1.0000,27996162
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.48,1.0000,28580169
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.48,1.0000,29434962
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.48,1.0000,31027735
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,1.0000,33011221
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,1.0000,33708436
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs and SFA,0.48,1.0000,33728488
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by CFA,0.48,1.0000,34556996
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,1.0000,34551785
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,1.0000,33835973
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,1.0000,33934523
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,1.0000,34885233
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,1.0000,22948659
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,1.0000,26261532
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,1.0000,26398277
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,1.0000,27734340
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,1.0000,27764163
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,1.0000,28864067
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,1.0000,29201179
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.48,1.0000,29697746
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs and CFA followed by SFA and Tumorigenicity assay,0.48,1.0000,25849939
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by Migration and Invasion assay,0.48,1.0000,22335271
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,1.0000,22570653
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,1.0000,24521357
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,1.0000,25852272
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,1.0000,27748818
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,1.0000,27748818
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,1.0000,27999190
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,1.0000,28507102
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,Doxycycline,FACs followed by SFA,0.48,1.0000,28984401
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,1.0000,29656202
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,1.0000,29727019
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,1.0000,29937934
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.48,1.0000,32351328
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SP assay,0.48,1.0000,23815678
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by Tumorigenicity assay,0.48,1.0000,22111082
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,Modified transwell lower chamber assay and SFA followed by FACs,0.48,1.0000,24689055
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and SP assay followed by FACs,0.48,1.0000,29985062
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,1.0000,23815678
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,1.0000,23872274
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by FACs,0.48,1.0000,25117811
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,1.0000,25502497
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,1.0000,26689865
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,1.0000,26918054
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.48,1.0000,28984791
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by FACs,0.48,1.0000,30819221
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,SFA followed by RT-PCR and Western Blotting,0.48,1.0000,31233201
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,Western Blotting followed by SFA,0.48,1.0000,29285189
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by IF staining,0.48,1.0000,31966561
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by IF staining,0.48,1.0000,31966561
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qRT-PCR,0.48,1.0000,30480362
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Osimertinib,SFA followed by FACs,0.48,1.0000,30910592
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Osimertinib+Gefitinib,SFA followed by FACs,0.48,1.0000,30910592
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Adenocarcinoma,PK-1,NA,SFA followed by qRT-PCR,0.2,1.0000,31027735
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PK-45H,NA,FACs and CFA followed by SFA,0.12,1.0000,25849939
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PK-45P,NA,FACs followed by CFA,0.12,1.0000,34556996
CD44,LTM,NA,1681,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by qRT-PCR,0.2,1.0000,34414448
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SP assay followed by FACs and SFA,0.12,1.0000,25997710
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SP assay followed by FACs,0.12,1.0000,25997710
CD44,LTM,NA,1681,Head and Neck Cancer,NA,QLL-1,NA,SFA followed by Western Blotting and IF staining,0.52,1.0000,32327629
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,RKO,NA,SFA followed by IF staining,0.24,1.0000,29721049
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,RT-112,NA,SFA followed by qRT-PCR,0.2,1.0000,34101386
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Papilloma,RT-4,NA,SFA followed by qRT-PCR,0.2,1.0000,35116788
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Papilloma,RT-4,NA,FACs followed by SFA,0.2,1.0000,29340052
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Adenocarcinoma,S2-013,Triptolide,SP assay followed by FACs,0.12,1.0000,26597727
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,FACs,0.12,1.0000,29515788
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,FACs followed by SFA,0.12,1.0000,22692956
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,FACs followed by SFA,0.12,1.0000,24475244
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-131,NA,Western Blotting followed by IF staining and SFA,0.52,1.0000,29575240
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-131,Cisplatin,SFA followed by Western Blotting and  FACs,0.52,1.0000,31585633
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-15,NA,FACs followed by Western Blotting,0.4,1.0000,35013621
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-15,NA,SFA followed by Western Blotting,0.4,1.0000,32327629
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,SFA followed by Western Blotting and IF staining,0.52,1.0000,32327629
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,Cisplatin,Western Blotting and FACs followed by SFA,0.52,1.0000,34795388
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,FACs,0.52,1.0000,29515788
CD44,LTM,NA,1681,Lung Cancer,NA,SELS,NA,FACs followed by IHC staining,0.36,1.0000,23738757
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,CFA and IHC staining followed by FACs and Western Blotting,0.64,1.0000,26276718
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and FACs followed by qRT-PCR and Western Blotting,0.64,1.0000,33608016
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by FACs and qRT-PCR and Western Blotting ,0.64,1.0000,33731207
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR and Western Blotting,0.64,1.0000,30843262
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR and Western Blotting,0.64,1.0000,31261030
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,Four-dimensional (4D) culture model by a magnetic responsive alginate-based hydrogel to rotating magnets followed by RT-PCR and IF staining,0.64,1.0000,33836517
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting followed by FACs,0.64,1.0000,34657624
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by FACs and Western Blotting,0.64,1.0000,31517391
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting and  FACs,0.64,1.0000,30624124
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,FACs followed by IF staining and SFA,0.64,1.0000,29662192
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.64,1.0000,34090492
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.64,1.0000,34350176
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.64,1.0000,27644439
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.64,1.0000,29422082
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR,0.64,1.0000,32142918
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by RT-PCR,0.64,1.0000,32051395
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and FACs,0.64,1.0000,34646768
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by FACs,0.64,1.0000,34802261
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,FACs,0.64,1.0000,32926650
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by Western Blotting,0.4,1.0000,30620624
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by Western Blotting,0.4,1.0000,30620624
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs and Western Blotting,0.4,1.0000,29100426
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs and Western Blotting,0.4,1.0000,29100426
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by IHC staining and SFA,0.4,1.0000,31579408
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by IHC staining and SFA,0.4,1.0000,31579408
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by SFA,0.4,1.0000,35205696
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs,0.4,1.0000,29080749
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs,0.4,1.0000,29080749
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,5-Fluorouracil,FACs,0.4,1.0000,29371950
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,5-Fluorouracil,FACs,0.4,1.0000,29371950
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs,0.4,1.0000,31729259
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by SFA,0.4,1.0000,31599500
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by SFA,0.4,1.0000,31599500
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by SFA,0.4,1.0000,31695436
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by SFA,0.4,1.0000,31695436
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by SP assay and SFA,0.4,1.0000,30613295
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by SP assay and SFA,0.4,1.0000,30613295
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,Epirubicin,SFA followed  by FACs and SP assay,0.4,1.0000,18083101
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs,0.4,1.0000,18083101
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,TGF-Beta,SFA followed by FACs,0.4,1.0000,28702892
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,Fructose,SFA followed by FACs,0.4,1.0000,29796188
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,Fructose,SFA followed by FACs,0.4,1.0000,29796188
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs,0.4,1.0000,31579408
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs,0.4,1.0000,31579408
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs,0.4,1.0000,31726667
CD44,LTM,NA,1681,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by FACs,0.4,1.0000,31726667
CD44,LTM,NA,1681,Skin Cancer,NA,SK-MEL-1,NA,FACs,0.12,1.0000,26208390
CD44,LTM,NA,1681,Skin Cancer,NA,SK-MEL-1,NA,FACs,0.12,1.0000,27476721
CD44,LTM,NA,1681,Skin Cancer,NA,SK-MEL-1,NA,SFA followed by FACs,0.12,1.0000,31582018
CD44,LTM,NA,1681,Skin Cancer,NA,SK-MEL-1,NA,SFA followed by SP assay and FACs,0.12,1.0000,33052601
CD44,LTM,NA,1681,Skin Cancer,NA,SK-MEL-28,NA,SFA and Western Blotting,0.28,1.0000,30717768
CD44,LTM,NA,1681,Skin Cancer,NA,SK-MEL-28,NA,FACs,0.28,1.0000,27476721
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,SK-MES-1,Cisplatin,FACs followed by CFA,0.12,1.0000,33550205
CD44,LTM,NA,1681,Hepatic Cancer,Adenocarcinoma,SMMC-7721,NA,SFA followed by Western Blotting,0.28,1.0000,30866863
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,SNU16,NA,Western Blotting and SFA,0.28,1.0000,33067426
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,SNU16,NA,FACs followed by SFA,0.28,1.0000,31073886
CD44,LTM,NA,1681,Hepatic Cancer,Carcinoma,SNU-398,NA,MACs followed by SFA,0.12,1.0000,31888685
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SNU-410,NA,FACs,0.12,1.0000,22111082
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by IF staining,0.24,1.0000,30284938
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,SNU5,NA,FACs and SFA followed by RT-PCR and Western Blotting,0.6,1.0000,28440445
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,SNU5,NA,FACs followed by SFA and Western Blotting,0.6,1.0000,33798550
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,SNU5,NA,FACs,0.6,1.0000,32661467
CD44,LTM,NA,1681,Gastric Cancer,Carcinoma,SNU5,NA,FACs followed by SFA,0.6,1.0000,31073886
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by Western Blotting,0.28,1.0000,28970066
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by IF staining,0.28,1.0000,30284938
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,SNU-668,NA,SFA followed by Western Blotting,0.28,1.0000,32606358
CD44,LTM,NA,1681,Gastric Cancer,Tubular Adenocarcinoma,SNU-719,NA,FACs followed by SFA,0.12,1.0000,32338409
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by qPCR and Western Blotting,0.48,1.0000,29702194
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by FACs and Western Blotting,0.48,1.0000,34949193
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,SQ20B,NA,SP assay followed by FACs and SFA,0.12,1.0000,23955575
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,ST2957,NA,SFA followed by FACs,0.12,1.0000,32863948
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Adenocarcinoma,Su86.86,NA,FACs followed by SP assay,0.12,1.0000,22963768
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM1315,NA,FACs,0.12,1.0000,18366788
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Ductal Carcinoma,SUM1315MO2,NA,FACs,0.12,1.0000,31729259
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,Paclitaxel,FACs and SFA followed by Western Blotting,0.4,1.0000,28703802
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs followed by SFA,0.4,1.0000,35508987
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by FACs,0.4,1.0000,35357654
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs,0.4,1.0000,29620216
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs,0.4,1.0000,31709178
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs,0.4,1.0000,31729259
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs followed by CFA,0.4,1.0000,18366788
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,MK-0752,FACs followed by SFA,0.4,1.0000,29027990
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,RO49097,FACs followed by SFA,0.4,1.0000,29027990
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs followed by SFA,0.4,1.0000,30227220
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs followed by SFA,0.4,1.0000,30542507
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs followed by Tumorigenicity assay,0.4,1.0000,30050079
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by FACs,0.4,1.0000,28951456
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by FACs,0.4,1.0000,28978083
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by FACs,0.4,1.0000,29975921
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs for CSC marker followed by Transcriptomics,0.4,1.0000,31709178
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by Western Blotting,0.28,1.0000,29243835
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by Western Blotting,0.28,1.0000,29356693
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by Western Blotting,0.28,1.0000,30262865
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,Lithium Chloride,Western Blotting and SFA,0.28,1.0000,29356693
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,Purmorphamine,Western Blotting and SFA,0.28,1.0000,29356693
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs followed by SFA,0.28,1.0000,35512572
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.28,1.0000,35357654
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.28,1.0000,35526049
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs,0.28,1.0000,31729259
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,Docetaxel,FACs and SFA,0.28,1.0000,29921732
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs followed by CFA,0.28,1.0000,18366788
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs followed by SFA,0.28,1.0000,29249663
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs followed by SFA,0.28,1.0000,30460610
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.28,1.0000,28054666
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.28,1.0000,28951456
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.28,1.0000,28978427
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.28,1.0000,28991374
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.28,1.0000,29358169
CD44,LTM,NA,1681,Triple Negative Breast Cancer,Carcinoma,SUM159,Paclitaxel,SFA followed by FACs,0.28,1.0000,30482914
CD44,LTM,NA,1681,Breast Cancer,Carcinoma,SUM190PT,Paclitaxel,FACs and SFA followed by Western Blotting,0.4,1.0000,28703802
CD44,LTM,NA,1681,Triple Negative Breast Cancer,NA,SUM225,NA,FACs,0.12,1.0000,18366788
CD44,LTM,NA,1681,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs followed by IF staining and SFA,0.36,1.0000,31285270
CD44,LTM,NA,1681,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs followed by RT-PCR and SFA,0.36,1.0000,23674142
CD44,LTM,NA,1681,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs,0.36,1.0000,32617772
CD44,LTM,NA,1681,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs followed by SFA,0.36,1.0000,23007737
CD44,LTM,NA,1681,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs followed by SFA,0.36,1.0000,23007737
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,SW1222,Paclitaxel,CFA followed by FACs,0.12,1.0000,23624503
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting,0.28,1.0000,33288882
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting and SFA,0.28,1.0000,32781084
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.28,1.0000,28947139
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.28,1.0000,26439804
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by SFA and qRT-PCR,0.28,1.0000,30466404
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by SFA and qRT-PCR,0.28,1.0000,30466404
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,FACs,0.28,1.0000,22322379
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,FACs,0.28,1.0000,27734340
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,FACs followed by SFA,0.28,1.0000,27576197
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,FACs followed by SP assay,0.28,1.0000,22963768
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by FACs,0.28,1.0000,20372854
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by FACs,0.28,1.0000,20372854
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by FACs,0.28,1.0000,30819221
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,SW48,Regorafenib,qRT-PCR,0.2,1.0000,35197754
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,SW48,Doxorubicin,FACs,0.2,1.0000,27517620
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by qRT-PCR and Western Blotting,0.48,1.0000,24926880
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by Western Blotting,0.48,1.0000,31139149
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by IF staining and SFA,0.48,1.0000,31285270
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA and IF staining,0.48,1.0000,29693155
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by Western Blotting,0.48,1.0000,26785732
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,Western Blotting,0.48,1.0000,22319203
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,IHC staining,0.48,1.0000,31810923
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs for CSC marker followed by qRT-PCR,0.48,1.0000,33744851
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs,0.48,1.0000,32617772
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs,0.48,1.0000,25154976
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs,0.48,1.0000,25154976
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs,0.48,1.0000,27520449
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs,0.48,1.0000,31505062
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs,0.48,1.0000,32729895
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs and SFA,0.48,1.0000,24970802
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.48,1.0000,21454414
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.48,1.0000,22329848
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.48,1.0000,29805588
CD44,LTM,NA,1681,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA and MACs,0.48,1.0000,24696849
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,5-Fluorouracil,SFA followed by Western Blotting and qRT-PCR,0.48,1.0000,28990068
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs followed by Western Blotting,0.48,1.0000,31139149
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs followed by IF staining and SFA,0.48,1.0000,31285270
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by Western Blotting,0.48,1.0000,27894099
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs,0.48,1.0000,25154976
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs,0.48,1.0000,25154976
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,5-fluorouracil,FACs followed by SFA,0.48,1.0000,27659530
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs followed by SFA,0.48,1.0000,29805588
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,MACs followed by SFA,0.48,1.0000,31824193
CD44,LTM,NA,1681,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by CFA and FACs,0.48,1.0000,30115896
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs,0.12,1.0000,25748177
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs,0.12,1.0000,29340052
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,SFA followed by FACs,0.12,1.0000,23226620
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,T24,Cisplatin,SFA and SP assay followed by Western Blotting and IF staining,0.52,1.0000,22343321
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR and Western Blotting,0.52,1.0000,24012496
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Western Blotting,0.52,1.0000,29559853
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Western Blotting,0.52,1.0000,31222373
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,T24,NA,SP assay followed by Western Blotting,0.52,1.0000,25020236
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.52,1.0000,28895409
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.52,1.0000,31187490
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,T24,NA,FACs followed by SFA,0.52,1.0000,21964864
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,T24,NA,FACs followed by SFA,0.52,1.0000,29340052
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,T24,NA,MACs,0.52,1.0000,32192892
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,T24,NA,MACs followed by SFA,0.52,1.0000,32626701
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,T24,NA,SFA followed by FACs,0.52,1.0000,31176734
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,T25,NA,qRT-PCR followed by Western Blotting and SFA,0.48,1.0000,34407043
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Adenocarcinoma,T3M4,NA,FACs,0.12,1.0000,26546043
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Tamoxifen,FACs and SFA followed by Western Blotting and RT-PCR,0.6,1.0000,29602199
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by FACs and qRT-PCR,0.6,1.0000,31300015
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,Western Blotting and SFA,0.6,1.0000,31497349
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,IF staining followed by SFA,0.6,1.0000,31591823
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs,0.6,1.0000,34315857
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs followed by CFA,0.6,1.0000,35235236
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Doxorubicin,FACs followed by SFA,0.6,1.0000,33221681
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Carboplatin,FACs followed by SFA,0.6,1.0000,33221681
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Paclitaxel,FACs followed by SFA,0.6,1.0000,33221681
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs followed by SFA,0.6,1.0000,34944852
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by FACs,0.6,1.0000,33144693
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,5-Fluorouracil,FACs,0.6,1.0000,29371950
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs,0.6,1.0000,30076320
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Medrooxyprogesterone Acetate,FACs followed by SFA,0.6,1.0000,28744156
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs followed by SFA,0.6,1.0000,29048610
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs followed by SFA,0.6,1.0000,30326469
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs followed by SFA,0.6,1.0000,31599500
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,FACs followed by SFA,0.6,1.0000,31736268
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Paclitaxel,FACs followed by SP assay and SFA,0.6,1.0000,30361903
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Tamoxifen,SFA followed by FACs,0.6,1.0000,29363524
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by FACs,0.6,1.0000,31619923
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by FACs and Tumorigenicity assay,0.6,1.0000,28938607
CD44,LTM,NA,1681,Colon Cancer,Carcinoma,T84,NA,FACs followed by IF staining and SFA,0.36,1.0000,31285270
CD44,LTM,NA,1681,Glioblastoma Multiforme,NA,T98G,NA,CFA followed by FACs,0.12,1.0000,34408983
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Carcinoma,TCCSUP,NA,FACs,0.12,1.0000,29340052
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,TR146,NA,SFA followed by FACs and qRT-PCR,0.32,1.0000,25471937
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,TR146,NA,FACs followed by SFA,0.32,1.0000,25471937
CD44,LTM,NA,1681,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR and Western Blotting,0.48,1.0000,34424812
CD44,LTM,NA,1681,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR and FACs,0.48,1.0000,33575080
CD44,LTM,NA,1681,Glioblastoma,NA,U-251,NA,CFA followed by IF staining and SFA,0.48,1.0000,19324493
CD44,LTM,NA,1681,Glioblastoma,NA,U-87MG,NA,FACs and SFA followed by Western blotting and qRT-PCR,0.6,1.0000,34408983
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-1,NA,SFA followed by FACs,0.12,1.0000,21304586
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,Cisplatin,Western Blotting followed by SFA,0.28,1.0000,34689150
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,Western Blotting followed by CFA,0.28,1.0000,28423495
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,FACs followed by SFA,0.28,1.0000,26098778
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,FACs,0.28,1.0000,29028842
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,Cisplatin,FACs,0.28,1.0000,29861860
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,FACs,0.28,1.0000,32066820
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-103,NA,FACs followed by IF staining and SFA ,0.36,1.0000,23558285
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-103,NA,FACs followed by Migration assay,0.36,1.0000,24415402
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-103,NA,SFA followed by FACs,0.36,1.0000,25428916
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-10B,NA,Western Blotting followed by CFA,0.28,1.0000,28423495
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-11B,NA,FACs followed by SFA,0.12,1.0000,27780858
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-11B,NA,SFA followed by FACs,0.12,1.0000,21304586
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,FACs followed by SFA,0.12,1.0000,32773768
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,FACs followed by SFA,0.12,1.0000,31742606
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-14B,NA,SFA followed by FACs,0.12,1.0000,25428916
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-17A,NA,FACs,0.12,1.0000,32066820
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-17B,NA,SFA followed by FACs and qRT-PCR,0.32,1.0000,25471937
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-17B,NA,FACs followed by SFA,0.32,1.0000,25471937
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,Cisplatin,SFA followed by Western Blotting,0.28,1.0000,24709421
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,Cisplatin,FACs followed by SFA,0.28,1.0000,34689150
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,NA,FACs,0.28,1.0000,32066820
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,NA,FACs followewd by SFA,0.28,1.0000,22014666
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,Cisplatin,FACs followed by SFA and Western Blotting,0.4,1.0000,24709421
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,Cisplatin,FACs and SFA,0.4,1.0000,29121598
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,NA,FACs followed by SFA,0.4,1.0000,27780858
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,Cisplatin,FACs followed by SFA,0.4,1.0000,34689150
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,Cisplatin,FACs,0.4,1.0000,29861860
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,NA,FACs followewd by SFA,0.4,1.0000,22014666
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,FACs followed by SFA,0.12,1.0000,32773768
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,FACs followed by SFA,0.12,1.0000,31742606
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-47,NA,FACs,0.12,1.0000,29028842
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-47,NA,FACs,0.12,1.0000,32066820
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-47,NA,FACs followed by Migration assay,0.12,1.0000,24415402
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-58,NA,SFA followed by FACs and qRT-PCR,0.32,1.0000,25471937
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-58,NA,FACs followed by SFA,0.32,1.0000,25471937
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-74A,NA,FACs followed by SFA,0.12,1.0000,26742076
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-74A,NA,SFA followed by FACs,0.12,1.0000,22791367
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR and Western Blotting and FACs,0.6,1.0000,32661469
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by FACs and IF staining and RT-PCR,0.6,1.0000,30397177
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR and Western Blotting,0.6,1.0000,28870814
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting and qRT-PCR,0.6,1.0000,31180522
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by IF staining and qRT-PCR,0.6,1.0000,26452033
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,Benzidine,SFA followed by Western Blotting,0.6,1.0000,33552265
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting,0.6,1.0000,33552265
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,FACs,0.6,1.0000,29221154
CD44,LTM,NA,1681,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,FACs,0.6,1.0000,29340052
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,UM-UC-6,NA,SFA followed by qRT-PCR,0.2,1.0000,34101386
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UPCI-SCC-090,NA,FACs,0.12,1.0000,32066820
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UPCI-SCC-154,NA,FACs,0.12,1.0000,32066820
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-14,NA,FACs,0.12,1.0000,23108794
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-16A,NA,FACs,0.12,1.0000,23108794
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-22,NA,SFA followed by FACs,0.12,1.0000,21304586
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-24A,NA,FACs,0.12,1.0000,23108794
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-30,NA,FACs,0.12,1.0000,23108794
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,FACs,0.12,1.0000,23108794
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-60A,NA,FACs,0.12,1.0000,24387977
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-60B,NA,FACs,0.12,1.0000,24387977
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,SFA followed by FACs,0.12,1.0000,21304586
CD44,LTM,NA,1681,Skin Cancer,NA,WM115,NA,FACs,0.12,1.0000,26208390
CD44,LTM,NA,1681,Skin Cancer,NA,WM793,NA,FACs,0.12,1.0000,29049740
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN30,NA,SFA and Western Blotting,0.28,1.0000,28279658
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN30,Deferoxamine,RT-PCR,0.28,1.0000,35313655
CD44,LTM,NA,1681,Gastric Cancer,NA,XN0422,NA,FACs followed by IF staining and SFA,0.36,1.0000,29662192
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,ZR-75-1,NA,FACs followed by SP assay and SFA,0.12,1.0000,30613295
CD44,LTM,NA,1681,Luminal A Breast Cancer,Ductal Carcinoma,ZR-75-1,Fructose,SFA followed by FACs,0.12,1.0000,29796188
CD44,LTM,NA,1681,Bladder Cancer,NA,Primary,NA,IHC staining,0.32,1.0000,34101386
CD44,LTM,NA,1681,Bladder Cancer,NA,Primary,NA,IHC staining,0.32,1.0000,20142235
CD44,LTM,NA,1681,Bladder Cancer,NA,Primary,NA,IHC staining,0.32,1.0000,28607587
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,Primary,NA,IHC staining,0.32,1.0000,30128900
CD44,LTM,NA,1681,Bladder Cancer,NA,Primary,NA,IHC staining,0.32,1.0000,31718471
CD44,LTM,NA,1681,Bladder Cancer,Carcinoma,Primary,NA,IHC staining,0.32,1.0000,32424373
CD44,LTM,NA,1681,Bladder Cancer,NA,Primary,NA,IHC staining followed by SP assay and CFA,0.32,1.0000,18608209
CD44,LTM,NA,1681,Bladder Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.32,1.0000,28765327
CD44,LTM,NA,1681,Bladder Cancer,NA,Primary,NA,FACs,0.32,1.0000,32065779
CD44,LTM,NA,1681,Bladder Cancer,NA,Primary,NA,FACs followed by SFA,0.32,1.0000,26143634
CD44,LTM,NA,1681,Bladder Cancer,NA,Primary,NA,FACs followed by SFA,0.32,1.0000,32019566
CD44,LTM,NA,1681,Bladder Cancer,NA,Primary,NA,SFA followed by FACs,0.32,1.0000,28765327
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,qPCR followed by IHC staining,0.6,1.0000,29660692
CD44,LTM,NA,1681,Breast Cancer,Ductal Carcinoma,Primary,NA,qRT-PCR and  FACs followed by SFA,0.6,1.0000,30050081
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,Doxorubicin,FACs followed by ALDEFLUOR assay,0.6,1.0000,33221681
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,Carboplatin,FACs followed by ALDEFLUOR assay,0.6,1.0000,33221681
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,Paclitaxel,FACs followed by ALDEFLUOR assay,0.6,1.0000,33221681
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,35083162
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,33274565
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,33731668
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,19385591
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,27994520
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,28766688
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,28977854
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,29306324
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,29416796
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,29434947
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,29843115
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,29845398
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,30364293
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,31516750
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by qRT-PCR,0.6,1.0000,33799422
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.6,1.0000,31728117
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,FACs,0.6,1.0000,34476645
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,FACs,0.6,1.0000,34778599
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,FACs,0.6,1.0000,34073849
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,FACs,0.6,1.0000,34572409
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,FACs,0.6,1.0000,33471244
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,FACs,0.6,1.0000,18685093
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,FACs,0.6,1.0000,31555258
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,FACs,0.6,1.0000,31555258
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,FACs followed by SFA,0.6,1.0000,34195201
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,FACs followed by SFA,0.6,1.0000,30587593
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,MACs,0.6,1.0000,29344258
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.6,1.0000,33340428
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.6,1.0000,18083101
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.6,1.0000,28746471
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,Chemotherapy,SFA followed by FACs,0.6,1.0000,28835684
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.6,1.0000,29925435
CD44,LTM,NA,1681,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.6,1.0000,30359767
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,qRT-PCR and Western Blotting followed by SFA,0.64,1.0000,34271345
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,IHC staining followed by qRT-PCR,0.64,1.0000,33819194
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,IHC staining followed by RT-PCR,0.64,1.0000,19010307
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,qRT-PCR followed by IHC staining,0.64,1.0000,25625240
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,RT-PCR and IHC staining,0.64,1.0000,25625240
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,SFA followed by FACs and IF staining,0.64,1.0000,23642368
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,Tumorigenicity assay and SFA followed by IHC staining and  FACs,0.64,1.0000,19808966
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,Blebbistatin,SFA followed by Western Blotting,0.64,1.0000,23002207
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,IHC staining,0.64,1.0000,35249490
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,IHC staining,0.64,1.0000,34609414
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,IHC staining,0.64,1.0000,22740326
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,IHC staining,0.64,1.0000,24696849
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,IHC staining,0.64,1.0000,25109336
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,IHC staining,0.64,1.0000,29102042
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,IHC staining,0.64,1.0000,31000786
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,IHC staining,0.64,1.0000,31578584
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,SFA and IF staining,0.64,1.0000,24607406
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,qRT-PCR,0.64,1.0000,35392530
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,qRT-PCR,0.64,1.0000,24492635
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,FACs,0.64,1.0000,27354640
CD44,LTM,NA,1681,Colon Cancer,Adenocarcinoma,Primary,NA,FACs,0.64,1.0000,29580161
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,FACs,0.64,1.0000,31973205
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,FACs followed by CFA,0.64,1.0000,18757407
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,FACs followed by SFA,0.64,1.0000,26745821
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,FACs followed by SFA and Tumorigenicity assay,0.64,1.0000,30790680
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.64,1.0000,18765800
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.64,1.0000,26383537
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.64,1.0000,23643941
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,ROCK inhibitor,SFA followed by FACs and Tumorigenicity assay,0.64,1.0000,23002207
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,Y-27632,SFA followed by FACs and Tumorigenicity assay,0.64,1.0000,23002207
CD44,LTM,NA,1681,Colon Cancer,NA,Primary,NA,SFA followed by FACs and Tumorigenicity assay,0.64,1.0000,29110645
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining and RT-PCR,0.6,1.0000,28053963
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,SFA followed by qRT-PCR and IF staining,0.6,1.0000,33986804
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,Western Blotting followed by SFA,0.6,1.0000,31309567
CD44,LTM,NA,1681,Gastric Cancer,Submucosal,Primary,NA,IHC staining,0.6,1.0000,33450435
CD44,LTM,NA,1681,Gastric Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.6,1.0000,34027868
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,33288885
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,33118117
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,31489619
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,30240769
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,31632151
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,28261336
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,28337375
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,28828692
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,29445738
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,27931044
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,27055559
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,24910454
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,28952294
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,SFA followed by IHC staining,0.6,1.0000,21727908
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,FACs followed by SFA,0.6,1.0000,27620279
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,SFA followed by FACs,0.6,1.0000,32350414
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,SFA followed by FACs,0.6,1.0000,29178392
CD44,LTM,NA,1681,Gastric Cancer,NA,Primary,NA,SFA followed by FACs,0.6,1.0000,30641083
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs followed by qRT-PCR and IF staining,0.8,1.0000,23627635
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR and Western Blotting,0.8,1.0000,30651721
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR and IF staining,0.8,1.0000,22426199
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by FACs and IF staining,0.8,1.0000,22791367
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by Western Blotting,0.8,1.0000,22640830
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IF staining,0.8,1.0000,23563306
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IF staining,0.8,1.0000,32327629
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.8,1.0000,35140342
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.8,1.0000,22847005
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.8,1.0000,27077749
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.8,1.0000,26622836
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.8,1.0000,25751671
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.8,1.0000,21514878
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.8,1.0000,23523931
CD44,LTM,NA,1681,Head and Neck Cancer,Oropharyngeal Squamous Cell Carcinoma,Primary,NA,IHC staining,0.8,1.0000,24315751
CD44,LTM,NA,1681,Head and Neck Cancer,NA,Primary,NA,IHC staining,0.8,1.0000,26556875
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.8,1.0000,31811857
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IF staining,0.8,1.0000,27619333
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IF staining,0.8,1.0000,25320014
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,Cisplatin,SFA followed by qRT-PCR,0.8,1.0000,32206093
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.8,1.0000,22333601
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs,0.8,1.0000,26757432
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs,0.8,1.0000,20073073
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs,0.8,1.0000,22361100
CD44,LTM,NA,1681,Head and Neck Cancer,NA,Primary,NA,FACs,0.8,1.0000,21322081
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,FACs followed by SFA,0.8,1.0000,19450560
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by FACs,0.8,1.0000,26239260
CD44,LTM,NA,1681,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by FACs,0.8,1.0000,23876835
CD44,LTM,NA,1681,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.48,1.0000,25963795
CD44,LTM,NA,1681,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.48,1.0000,25963795
CD44,LTM,NA,1681,Lung Cancer,NA,Primary,NA,IHC staining followed by FACs,0.52,1.0000,19536353
CD44,LTM,NA,1681,Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by FACs and qPCR,0.52,1.0000,26621583
CD44,LTM,NA,1681,Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.52,1.0000,23252868
CD44,LTM,NA,1681,Lung Cancer,NA,Primary,NA,IHC staining,0.52,1.0000,25335738
CD44,LTM,NA,1681,Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.52,1.0000,28286162
CD44,LTM,NA,1681,Lung Cancer,NA,Primary,NA,SFA and IF staining,0.52,1.0000,33531664
CD44,LTM,NA,1681,Lung Cancer,Squamous Cell Carcinoma,Primary,NA,RT-PCR,0.52,1.0000,27698819
CD44,LTM,NA,1681,Lung Cancer,Adenocarcinoma,Primary,NA,FACs followed by CFA,0.52,1.0000,33135338
CD44,LTM,NA,1681,Lung Cancer,Adenocarcinoma,Primary,Erlotinib,FACs followed by SFA,0.52,1.0000,28347243
CD44,LTM,NA,1681,Lung Cancer,NA,Primary,NA,FACs followed by SFA,0.52,1.0000,32391123
CD44,LTM,NA,1681,Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by FACs,0.52,1.0000,29720480
CD44,LTM,NA,1681,Lung Cancer,NA,Primary,NA,SFA followed by FACs and Tumorigenicity assay,0.52,1.0000,24019906
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by IF staining and Western Blotting,0.68,1.0000,31506430
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.68,1.0000,33036771
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.68,1.0000,24346092
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.68,1.0000,33109579
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IF staining,0.68,1.0000,33925297
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by IF staining,0.68,1.0000,33925297
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,NA,Primary,NA,qRT-PCR followed by SFA,0.68,1.0000,29568370
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.68,1.0000,31506430
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,FACs,0.68,1.0000,34277782
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,NA,Primary,NA,FACs,0.68,1.0000,19464919
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,NA,Primary,NA,FACs,0.68,1.0000,22225612
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,FACs,0.68,1.0000,31921651
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,FACs,0.68,1.0000,31921651
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by FACs,0.68,1.0000,27343631
CD44,LTM,NA,1681,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by FACs,0.68,1.0000,27343631
CD44,LTM,NA,1681,Pancreatic Cancer,NA,Primary,NA,CFA followed by qRT-PCR and ICC staining,0.6,1.0000,26199979
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining followed by FACs,0.6,1.0000,27414409
CD44,LTM,NA,1681,Pancreatic Cancer,NA,Primary,NA,MACs followed by SFA and qRT-PCR,0.6,1.0000,26609473
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Adenocarcinoma,Primary,NA,IHC staining,0.6,1.0000,33836674
CD44,LTM,NA,1681,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,33672734
CD44,LTM,NA,1681,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,19598259
CD44,LTM,NA,1681,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,22783415
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.6,1.0000,25240521
CD44,LTM,NA,1681,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,24839953
CD44,LTM,NA,1681,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.6,1.0000,25081383
CD44,LTM,NA,1681,Pancreatic Cancer,NA,Primary,NA,FACs,0.6,1.0000,33188841
CD44,LTM,NA,1681,Pancreatic Cancer,NA,Primary,NA,FACs,0.6,1.0000,23029396
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Primary,NA,FACs,0.6,1.0000,30074477
CD44,LTM,NA,1681,Pancreatic Cancer,Adenocarcinoma,Primary,NA,FACs followed by Tumorigenicity assay,0.6,1.0000,17283135
CD44,LTM,NA,1681,Pancreatic Cancer,Ductal Adenocarcinoma,Primary,NA,SFA followed by FACs,0.6,1.0000,33240436
CD44,LTM,NA,1681,Skin Cancer,NA,Primary,NA,IHC staining,0.32,1.0000,26391478
CD44,LTM,NA,1681,Skin Cancer,NA,Primary,NA,IHC staining,0.32,1.0000,27870003
CD44,LTM,NA,1681,Small Cell Lung Cancer,NA,Primary,NA,IF staining followed by FACs,0.52,1.0000,31446534
CD44,LTM,NA,1681,Small Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.52,1.0000,25963795
CD44,LTM,NA,1681,Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.52,1.0000,27363902
CD44,LTM,NA,1681,Triple Negative Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.2,1.0000,28883001
CD47,LTM,NA,1682,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0021,31273952
CD47,LTM,NA,1682,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0021,31273952
CD70,LTM,NA,11937,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.12,0.0021,30175027
CD70,LTM,NA,11937,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA and Tumorigenicity assay,0.12,0.0021,29953653
CDH2,LTM,NA,1759,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.2,0.0085,26862521
CDK1,LTM,NA,1722,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting followed by SFA,0.28,0.0011,33721187
CDK1,LTM,NA,1722,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,Western Blotting followed by SFA,0.28,0.0011,33721187
CDKN1A,LTM,NA,1784,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0042,31506430
CEACAM1,LTM,NA,1814,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR,0.2,0.0064,22855139
CEACAM1,LTM,NA,1814,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by Western Blotting,0.4,0.0011,32221015
CEBPD,LTM,NA,1835,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0042,30262865
CLOCK,LTM,NA,2082,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.28,0.0021,33125096
CLOCK,LTM,NA,2082,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.28,0.0021,33125096
CLSPN,LTM,NA,19715,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.2,0.0032,30240769
CLSPN,LTM,NA,19715,Gastric Cancer,Adenocarcinoma,MKN74,NA,SFA followed by qRT-PCR,0.2,0.0032,30240769
CLSPN,LTM,NA,19715,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.0032,30240769
CLU,LTM,NA,2095,Gastric Cancer,NA,Primary,NA,SFA followed by Western Blotting and IHC staining,0.68,0.0064,30745823
COL17A1,LTM,NA,2194,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.28,0.0064,31928533
COX7B2,LTM,NA,24381,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR,0.2,0.0011,32065779
COX7B2,LTM,NA,24381,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.2,0.0011,32065779
CSF1,LTM,NA,2432,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0032,30397177
CSF1,LTM,NA,2432,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0032,30397177
CSF2,LTM,NA,2434,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0021,30397177
CSF2,LTM,NA,2434,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0021,30397177
CSF3,LTM,NA,2438,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0032,30397177
CSF3,LTM,NA,2438,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0032,30397177
CSPG4,LTM,NA,2466,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by RT-PCR,0.2,0.0032,28093940
CSPG4,LTM,NA,2466,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR,0.2,0.0032,28093940
CSPG4,LTM,NA,2466,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR and SFA,0.2,0.0032,28692437
CSPG4,LTM,NA,2466,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR followed by SFA,0.2,0.0011,30543303
CSPG4,LTM,NA,2466,Gastric Cancer,Carcinoma,NCI-N87,NA,RT-PCR followed by SFA,0.2,0.0011,30543303
CTAG1B,LTM,NA,2491,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by IF staining and SFA,0.36,0.0011,31579408
CTAG1B,LTM,NA,2491,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by IHC staining and SFA,0.36,0.0011,31579408
CTAG1B,LTM,NA,2491,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by IF staining and SFA,0.36,0.0011,31579408
CTAG1B,LTM,NA,2491,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by IF staining and SFA,0.36,0.0011,31579408
CTAG1B,LTM,NA,2491,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by IHC staining and SFA,0.36,0.0011,31579408
CTAG1B,LTM,NA,2491,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,FACs followed by IHC staining and SFA,0.36,0.0011,31579408
CTNNB1,LTM,NA,2514,Bladder Cancer,Carcinoma,5637,Paclitaxel,SFA followed by Western Blotting,0.28,0.0647,35008872
CTNNB1,LTM,NA,2514,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,Western Blotting and SFA,0.28,0.0647,25966742
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.28,0.0647,33980809
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.28,0.0647,24013232
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.28,0.0647,27836540
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,Western Blotting,0.28,0.0647,31819528
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,Western Blotting followed by Migration assay,0.28,0.0647,20074550
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,qRT-PCR and SFA,0.28,0.0647,34246759
CTNNB1,LTM,NA,2514,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Western Blotting,0.28,0.0647,25811929
CTNNB1,LTM,NA,2514,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,Western Blotting,0.28,0.0647,29100426
CTNNB1,LTM,NA,2514,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by Western Blotting,0.28,0.0647,31585633
CTNNB1,LTM,NA,2514,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by Western Blotting and SFA,0.28,0.0647,32781084
CTNNB1,LTM,NA,2514,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.28,0.0647,25811929
CTNNB1,LTM,NA,2514,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by RT-PCR,0.28,0.0647,29100320
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Adenocarcinoma,CL-141,NA,SFA followed by Western Blotting,0.28,0.0647,31638335
CTNNB1,LTM,NA,2514,Glioblastoma Multiforme,NA,GBM8401,NA,SP assay and SFA followed by RT-PCR,0.2,0.0647,25359730
CTNNB1,LTM,NA,2514,Small Cell Lung Cancer,Carcinoma,GLC14,NA,SFA followed by Western Blotting,0.28,0.0647,33607458
CTNNB1,LTM,NA,2514,Small Cell Lung Cancer,Carcinoma,GLC16,NA,SFA followed by Western Blotting,0.28,0.0647,33607458
CTNNB1,LTM,NA,2514,Small Cell Lung Cancer,Carcinoma,GLC19,NA,SFA followed by Western Blotting,0.28,0.0647,33607458
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.28,0.0647,33980809
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.28,0.0647,27836540
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Carcinoma,H1299,Cisplatin,Western Blotting,0.28,0.0647,31819528
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.28,0.0647,25669973
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,qRT-PCR and SFA,0.2,0.0647,34246759
CTNNB1,LTM,NA,2514,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.28,0.0647,35392530
CTNNB1,LTM,NA,2514,Colon Cancer,Carcinoma,HCT116,NA,SFA and Western Blotting,0.28,0.0647,24039918
CTNNB1,LTM,NA,2514,Colon Cancer,Carcinoma,HCT116,NA,SFA and Western Blotting,0.28,0.0647,24039918
CTNNB1,LTM,NA,2514,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qPCR,0.28,0.0647,31349708
CTNNB1,LTM,NA,2514,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by Western Blotting,0.28,0.0647,25104726
CTNNB1,LTM,NA,2514,Hepatic Cancer,Carcinoma,Hep3B,NA,FACs followed by CFA,0.12,0.0647,22194816
CTNNB1,LTM,NA,2514,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-4,NA,SP assay followed by qRT-PCR and CFA,0.2,0.0647,20651344
CTNNB1,LTM,NA,2514,Bladder Cancer,Carcinoma,HT-1197,Paclitaxel,Western Blotting,0.28,0.0647,35008872
CTNNB1,LTM,NA,2514,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.28,0.0647,35392530
CTNNB1,LTM,NA,2514,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.28,0.0647,29457276
CTNNB1,LTM,NA,2514,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay and qRT-PCR followed by SFA and IF staining,0.44,0.0647,29792038
CTNNB1,LTM,NA,2514,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by CFA,0.44,0.0647,22194816
CTNNB1,LTM,NA,2514,Head and Neck Cancer,Carcinoma,KB,NA,SFA followed by Western Blotting,0.28,0.0647,25024430
CTNNB1,LTM,NA,2514,Hepatic Cancer,Carcinoma,Mahlavu,NA,SP assay followed by Western Blotting,0.28,0.0647,29792038
CTNNB1,LTM,NA,2514,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0647,29100426
CTNNB1,LTM,NA,2514,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0647,31604679
CTNNB1,LTM,NA,2514,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Lithium Chloride,Western Blotting and SFA,0.28,0.0647,29356693
CTNNB1,LTM,NA,2514,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by IF staining,0.28,0.0647,33511560
CTNNB1,LTM,NA,2514,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and RT-PCR followed by SFA,0.48,0.0647,29383157
CTNNB1,LTM,NA,2514,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Western Blotting,0.48,0.0647,34502547
CTNNB1,LTM,NA,2514,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.0647,34451892
CTNNB1,LTM,NA,2514,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting,0.48,0.0647,29100426
CTNNB1,LTM,NA,2514,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.48,0.0647,27976692
CTNNB1,LTM,NA,2514,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by IF staining,0.48,0.0647,33511560
CTNNB1,LTM,NA,2514,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.28,0.0647,31604679
CTNNB1,LTM,NA,2514,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.28,0.0647,32863948
CTNNB1,LTM,NA,2514,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by RT-PCR,0.2,0.0647,30696080
CTNNB1,LTM,NA,2514,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR,0.2,0.0647,30272287
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by IF staining and qRT-PCR,0.44,0.0647,31966561
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by IF staining and qPCR,0.44,0.0647,31966561
CTNNB1,LTM,NA,2514,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SFA followed by qRT-PCR,0.2,0.0647,22773665
CTNNB1,LTM,NA,2514,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-131,Cisplatin,SFA followed by Western Blotting,0.28,0.0647,31585633
CTNNB1,LTM,NA,2514,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by Western Blotting,0.28,0.0647,29100426
CTNNB1,LTM,NA,2514,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by Western Blotting,0.28,0.0647,29100426
CTNNB1,LTM,NA,2514,Hepatic Cancer,Adenocarcinoma,SK-Hep-1,NA,SP assay followed by Western Blotting,0.28,0.0647,29792038
CTNNB1,LTM,NA,2514,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by Western Blotting,0.28,0.0647,32863948
CTNNB1,LTM,NA,2514,Gastric Cancer,Adenocarcinoma,ST2957,NA,SFA followed by Western Blotting,0.28,0.0647,32863948
CTNNB1,LTM,NA,2514,Triple Negative Breast Cancer,Carcinoma,SUM159,Lithium Chloride,Western Blotting and SFA,0.28,0.0647,29356693
CTNNB1,LTM,NA,2514,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting and SFA,0.28,0.0647,32781084
CTNNB1,LTM,NA,2514,Dukes Type C Colon Cancer,Adenocarcinoma,SW48,Doxorubicin,Western Blotting,0.28,0.0647,27517620
CTNNB1,LTM,NA,2514,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by SFA and Western Blotting,0.28,0.0647,28560069
CTNNB1,LTM,NA,2514,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by qPCR,0.28,0.0647,31349708
CTNNB1,LTM,NA,2514,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,MACs followed by RT-PCR and Tumorigenicity assay,0.32,0.0647,20587144
CTNNB1,LTM,NA,2514,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SP assay followed by SFA and Western Blotting,0.32,0.0647,28560069
CTNNB1,LTM,NA,2514,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by qPCR,0.32,0.0647,31349708
CTNNB1,LTM,NA,2514,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Tamoxifen,Western Blotting,0.28,0.0647,29602199
CTNNB1,LTM,NA,2514,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR,0.2,0.0647,19232461
CTNNB1,LTM,NA,2514,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen,SFA followed by qRT-PCR,0.28,0.0647,31693936
CTNNB1,LTM,NA,2514,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen+Fulvestrant,SFA followed by qRT-PCR,0.28,0.0647,31693936
CTNNB1,LTM,NA,2514,Colon Cancer,NA,Primary,NA,IHC staining followed by Tumorigenicity assay,0.36,0.0647,22902411
CTNNB1,LTM,NA,2514,Hepatic Cancer,NA,Primary,NA,FACs,0.2,0.0647,26942873
CTNNB1,LTM,NA,2514,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay and Western Blotting followed by SFA,0.4,0.0647,26416062
CTNNB1,LTM,NA,2514,Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.4,0.0647,23252868
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0647,31506430
CTNNB1,LTM,NA,2514,Colon Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.36,0.0647,33500430
CTNNB1,LTM,NA,2514,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0647,28416482
CTSB,LTM,NA,2527,Head and Neck Cancer,Cutaneous Squamous Cell Carcinoma,Primary,NA,IF staining and Western Blotting,0.68,0.0053,32983794
CTSB,LTM,NA,2527,Pancreatic Cancer,Ductal Adenocarcinoma,Primary,NA,SFA followed by Western Blotting and FACs,0.56,0.0053,33240436
CTSD,LTM,NA,2529,Head and Neck Cancer,Cutaneous Squamous Cell Carcinoma,Primary,NA,IF staining and Western Blotting,0.68,0.0053,32983794
CTSG,LTM,NA,2532,Head and Neck Cancer,Cutaneous Squamous Cell Carcinoma,Primary,NA,IF staining and Western Blotting,0.68,0.0011,32983794
CXCL1,LTM,NA,4602,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA and FACs followed by Migration assay,0.12,0.0064,30115896
CXCL1,LTM,NA,4602,Breast Cancer,NA,Primary,NA,FACs and IHC staining followed by SFA,0.52,0.0064,34195201
CXCL13,LTM,NA,10639,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
CXCL13,LTM,NA,10639,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
CXCL5,LTM,NA,10642,Bladder Cancer,Carcinoma,T24,NA,qRT-PCR followed by Western Blotting and SFA,0.48,0.0032,34407043
CXCL9,LTM,NA,7098,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
CXCL9,LTM,NA,7098,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
CXCR1,LTM,NA,6026,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.32,0.0032,25081383
CXCR2,LTM,NA,6027,Breast Cancer,NA,Primary,NA,FACs followed by SFA,0.2,0.0011,34195201
CXCR3,LTM,NA,4540,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qPCR and Western Blotting,0.48,0.0011,31619923
CXCR3,LTM,NA,4540,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,qRT-PCR,0.2,0.0011,31619923
CXCR3,LTM,NA,4540,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by FACs,0.12,0.0011,31619923
CXCR4,LTM,NA,2561,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by FACs and Western Blotting,0.4,0.0498,22370645
CXCR4,LTM,NA,2561,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,SFA and Western Blotting,0.4,0.0498,26779808
CXCR4,LTM,NA,2561,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs,0.4,0.0498,33068069
CXCR4,LTM,NA,2561,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and CFA,0.4,0.0498,32329414
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Western Blotting,0.28,0.0498,30853342
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qPCR,0.28,0.0498,31440741
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,IF staining followed by Western Blotting,0.52,0.0498,31388092
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,CFA and  FACs followed by qRT-PCR,0.52,0.0498,21826251
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by Western Blotting,0.52,0.0498,30853342
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by Tumorigenicity assay,0.52,0.0498,23338123
CXCR4,LTM,NA,2561,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.28,0.0498,30853342
CXCR4,LTM,NA,2561,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and FACs,0.32,0.0498,25669973
CXCR4,LTM,NA,2561,Non Small Cell Lung Cancer,Carcinoma,H460,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs,0.24,0.0498,33068069
CXCR4,LTM,NA,2561,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,FACs followed by IHC staining,0.36,0.0498,23738757
CXCR4,LTM,NA,2561,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,qRT-PCR,0.2,0.0498,33764690
CXCR4,LTM,NA,2561,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,qPCR,0.2,0.0498,24489728
CXCR4,LTM,NA,2561,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.28,0.0498,27894099
CXCR4,LTM,NA,2561,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR,0.28,0.0498,22871210
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,CFA followed by IF staining,0.24,0.0498,30395429
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,Migration and Invasion assay followed by qRT-PCR,0.24,0.0498,23592398
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,SFA followed by Western Blotting,0.28,0.0498,30853342
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,HPAF-II,Gemcitabine,qPCR,0.28,0.0498,31440741
CXCR4,LTM,NA,2561,Gastric Cancer,Adenocarcinoma,HSC-60,NA,RT-PCR and IHC staining,0.44,0.0498,26110809
CXCR4,LTM,NA,2561,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.28,0.0498,27894099
CXCR4,LTM,NA,2561,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,qRT-PCR,0.28,0.0498,30772447
CXCR4,LTM,NA,2561,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.28,0.0498,21130073
CXCR4,LTM,NA,2561,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,FACs,0.28,0.0498,24323901
CXCR4,LTM,NA,2561,Colon Cancer,Adenocarcinoma,HT-29,NA,MACs followed by SFA,0.28,0.0498,30337351
CXCR4,LTM,NA,2561,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by qRT-PCR,0.2,0.0498,31233198
CXCR4,LTM,NA,2561,Pancreatic Cancer,Carcinoma,KP-2,NA,qRT-PCR,0.2,0.0498,20564084
CXCR4,LTM,NA,2561,Non Small Cell Lung Cancer,Adenocarcinoma,LT73,Cisplatin,FACs,0.12,0.0498,26020124
CXCR4,LTM,NA,2561,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0498,28703799
CXCR4,LTM,NA,2561,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.0498,34052833
CXCR4,LTM,NA,2561,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by Western Blotting and SFA,0.48,0.0498,30274780
CXCR4,LTM,NA,2561,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.48,0.0498,34680485
CXCR4,LTM,NA,2561,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0498,34070538
CXCR4,LTM,NA,2561,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0498,28703799
CXCR4,LTM,NA,2561,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.48,0.0498,29353288
CXCR4,LTM,NA,2561,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.48,0.0498,35413424
CXCR4,LTM,NA,2561,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs and SFA,0.48,0.0498,31745977
CXCR4,LTM,NA,2561,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.48,0.0498,31545416
CXCR4,LTM,NA,2561,Gastric Cancer,Adenocarcinoma,MGC-803,NA,FACs followed by SFA,0.12,0.0498,27524415
CXCR4,LTM,NA,2561,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and FACs,0.12,0.0498,20940707
CXCR4,LTM,NA,2561,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by FACs,0.12,0.0498,32863948
CXCR4,LTM,NA,2561,Pancreatic Cancer,Carcinoma,PANC-1,NA,Migration and Invasion assay followed by qRT-PCR,0.2,0.0498,23592398
CXCR4,LTM,NA,2561,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qPCR,0.2,0.0498,31440741
CXCR4,LTM,NA,2561,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.2,0.0498,31508487
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR,0.2,0.0498,31508487
CXCR4,LTM,NA,2561,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qRT-PCR,0.2,0.0498,33764690
CXCR4,LTM,NA,2561,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qPCR followed by SFA and Tumorigenicity assay,0.2,0.0498,24489728
CXCR4,LTM,NA,2561,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs and CFA,0.2,0.0498,32329414
CXCR4,LTM,NA,2561,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by FACs,0.12,0.0498,32863948
CXCR4,LTM,NA,2561,Gastric Cancer,Adenocarcinoma,ST2957,NA,SFA followed by FACs,0.12,0.0498,32863948
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,SUIT-2,NA,qRT-PCR,0.2,0.0498,20564084
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR,0.2,0.0498,31508487
CXCR4,LTM,NA,2561,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by Western Blotting,0.28,0.0498,27894099
CXCR4,LTM,NA,2561,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0498,28703799
CXCR4,LTM,NA,2561,Colon Cancer,NA,Primary,NA,FACs,0.2,0.0498,22871210
CXCR4,LTM,NA,2561,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.32,0.0498,25240521
CXCR4,LTM,NA,2561,Glioblastoma Multiforme,NA,Primary,NA,Isolation of autofluorescence cells followed by SFA and FACs,0.2,0.0498,33669350
CXCR4,LTM,NA,2561,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IF staining,0.32,0.0498,23563306
CXCR6,LTM,NA,16647,Skin Cancer,NA,Primary,NA,FACs,0.2,0.0011,21203549
CYP3A4,LTM,NA,2637,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0011,24212669
DCLK1,LTM,NA,1681,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by FACs,0.28,0.0159,26673007
DCLK1,LTM,NA,2700,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qPCR,0.2,0.0159,31440741
DCLK1,LTM,NA,2700,Triple Negative Breast Cancer,Carcinoma,BT-20,NA,SFA followed by Western Blotting and FACs,0.4,0.0159,33924995
DCLK1,LTM,NA,2700,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,Western Blotting followed by SFA,0.28,0.0159,31964531
DCLK1,LTM,NA,2700,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.28,0.0159,26785732
DCLK1,LTM,NA,2700,Colon Cancer,Carcinoma,HCT116,NA,Western Blotting,0.28,0.0159,22319203
DCLK1,LTM,NA,2700,Pancreatic Cancer,Adenocarcinoma,HPAF-II,Gemcitabine,qPCR,0.2,0.0159,31440741
DCLK1,LTM,NA,2700,Colon Cancer,Adenocarcinoma,HT-29,NA,MACs followed by qPCR and Western Blotting,0.6,0.0159,30337351
DCLK1,LTM,NA,2700,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.6,0.0159,30144515
DCLK1,LTM,NA,2700,Colon Cancer,Adenocarcinoma,HT-29,NA,Western Blotting followed by SFA,0.6,0.0159,31964531
DCLK1,LTM,NA,2700,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting and FACs,0.4,0.0159,33924995
DCLK1,LTM,NA,2700,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Western Blotting,0.28,0.0159,26317547
DCLK1,LTM,NA,2700,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qPCR,0.2,0.0159,31440741
DCLK1,LTM,NA,2700,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.2,0.0159,26673007
DCLK1,LTM,NA,2700,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.0159,28244691
DCLK1,LTM,NA,2700,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by Western Blotting,0.4,0.0159,22319203
DCLK1,LTM,NA,2700,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by Western Blotting,0.4,0.0159,26785732
DCLK1,LTM,NA,2700,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by Western Blotting,0.4,0.0159,30144515
DCLK1,LTM,NA,2700,Colon Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.32,0.0159,28414327
DCLK1,LTM,NA,2700,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.32,0.0159,31706685
DCLK1,LTM,NA,2700,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.32,0.0159,28351564
DCLK1,LTM,NA,2700,Triple Negative Breast Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.36,0.0159,33924995
DDIT3,LTM,NA,2726,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by RT-PCR,0.2,0.0032,29601799
DDIT3,LTM,NA,2726,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR,0.2,0.0032,29601799
DDIT3,LTM,NA,2726,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,32189359
DDR1,LTM,NA,2730,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qPCR,0.2,0.0032,28336807
DDX27,LTM,NA,15837,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0011,34362383
DDX27,LTM,NA,15837,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Western Blotting,0.28,0.0011,34362383
DDX27,LTM,NA,15837,Breast Cancer,NA,Primary,NA,Western Blotting followed by IHC staining,0.68,0.0011,34362383
DLGAP5,LTM,NA,16864,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and SFA,0.2,0.0021,30513573
DLL4,LTM,NA,2910,Gastric Cancer,Carcinoma,KATO-III,NA,Western Blotting followed by CFA,0.28,0.0042,27891816
DLL4,LTM,NA,2910,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.0042,27891816
DLL4,LTM,NA,2910,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0042,31506430
DLL4,LTM,NA,2910,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.0042,34410967
DLL4,LTM,NA,2910,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.0042,27891816
DNAJB8,LTM,NA,23699,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SP assay followed by RT-PCR,0.2,0.0021,24450541
DNAJB8,LTM,NA,23699,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by RT-PCR and SFA,0.2,0.0021,24450541
DNAJB8,LTM,NA,23699,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by RT-PCR,0.2,0.0021,24145190
DNMT1,LTM,NA,2976,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.2,0.0011,29044153
DNMT1,LTM,NA,2976,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.2,0.0011,29044153
DPP4,LTM,NA,3009,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0085,31285270
DPP4,LTM,NA,3009,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0085,31285270
DPP4,LTM,NA,3009,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0085,31285270
DPP4,LTM,NA,3009,Colon Cancer,Carcinoma,HCT116,NA,Western Blotting,0.28,0.0085,25884645
DPP4,LTM,NA,3009,Colon Cancer,Carcinoma,HCT116,Docetaxel,qRT-PCR,0.28,0.0085,27748801
DPP4,LTM,NA,3009,Colon Cancer,Carcinoma,HCT116,Docetaxel,qRT-PCR,0.28,0.0085,27748801
DPP4,LTM,NA,3009,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0085,31285270
DPP4,LTM,NA,3009,Colon Cancer,Adenocarcinoma,HT-29,NA,Western Blotting,0.64,0.0085,25884645
DPP4,LTM,NA,3009,Colon Cancer,Adenocarcinoma,HT-29,Docetaxel,qRT-PCR,0.64,0.0085,27748801
DPP4,LTM,NA,3009,Colon Cancer,Adenocarcinoma,HT-29,Docetaxel,qRT-PCR,0.64,0.0085,27748801
DPP4,LTM,NA,3009,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,qRT-PCR,0.64,0.0085,27748801
DPP4,LTM,NA,3009,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,qRT-PCR,0.64,0.0085,27748801
DPP4,LTM,NA,3009,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,FACs,0.64,0.0085,25884645
DPP4,LTM,NA,3009,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,RH-1,qRT-PCR,0.2,0.0085,31336714
DPP4,LTM,NA,3009,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting,0.28,0.0085,27524415
DPP4,LTM,NA,3009,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0085,31285270
DPP4,LTM,NA,3009,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0085,31285270
DPP4,LTM,NA,3009,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0085,31285270
DPP4,LTM,NA,3009,Colon Cancer,Carcinoma,T84,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0085,31285270
DPP4,LTM,NA,3009,Colon Cancer,NA,Primary,NA,IHC staining,0.32,0.0085,34609414
DRD2,LTM,NA,3023,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.12,0.0011,27920206
DRD2,LTM,NA,3023,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,FACs,0.12,0.0011,27920206
DRD2,LTM,NA,3023,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,IF staining,0.32,0.0011,27920206
DROSHA,LTM,NA,17904,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0011,32859993
DUSP9,LTM,NA,3076,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0021,29880481
DUSP9,LTM,NA,3076,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by Western Blotting,0.28,0.0021,29880481
E2F1,LTM,NA,3113,Gastric Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0021,33986804
E2F2,LTM,NA,3114,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.2,0.0021,30021199
E2F3,LTM,NA,3115,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,Western Blotting,0.28,0.0011,23674142
EGFR,LTM,NA,3236,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.0074,29464036
EGFR,LTM,NA,3236,Head and Neck Cancer,Squamous Cell Carcinoma,OM-1,NA,SFA followed by RT-PCR,0.2,0.0074,26399460
EIF2AK3,LTM,NA,3255,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by RT-PCR,0.2,0.0011,29601799
EIF2AK3,LTM,NA,3255,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR,0.2,0.0011,29601799
EML4,LTM,NA,1316,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA and FACs followed by RT-PCR and Migration assay,0.32,0.0042,25735977
EML4,LTM,NA,1316,Non Small Cell Lung Cancer,Adenocarcinoma,H3122,NA,SFA followed by Western Blotting and  FACs,0.4,0.0042,26517679
EML4,LTM,NA,1316,Non Small Cell Lung Cancer,Adenocarcinoma,H2228,NA,SFA followed by Western Blotting and  FACs,0.4,0.0011,26517679
ENG,LTM,NA,3349,Skin Cancer,NA,NA8-MEL,NA,FACs followed by SFA,0.12,0.0021,23915418
ENG,LTM,NA,3349,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN30,Deferoxamine,RT-PCR,0.2,0.0021,35313655
ENO1,LTM,NA,3350,Gastric Cancer,Carcinoma,PAMC82,NA,SFA followed by Western Blotting,0.28,0.0095,33067426
ENO1,LTM,NA,3350,Gastric Cancer,Carcinoma,SNU16,NA,SFA followed by Western Blotting,0.28,0.0095,33067426
ENO2,LTM,NA,3353,Small Cell Lung Cancer,Carcinoma,H209,NA,SFA followed by Western Blotting,0.28,0.0042,35487890
ENO2,LTM,NA,3353,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Western Blotting,0.28,0.0042,35487890
ENO2,LTM,NA,3353,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA followed by Western Blotting,0.28,0.0042,35487890
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by qRT-PCR,0.2,0.2110,27766570
EPCAM,LTM,NA,11529,Skin Cancer,NA,A-375,NA,SFA and Western Blotting,0.28,0.2110,30717768
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by IF staining and RT-PCR,0.56,0.2110,21738704
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.56,0.2110,33539684
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and IF staining followed by FACs,0.56,0.2110,28534939
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA and RT-PCR,0.56,0.2110,25678473
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA and RT-PCR,0.56,0.2110,28854941
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qPCR and FACs,0.56,0.2110,26299367
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.56,0.2110,27766570
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR,0.56,0.2110,22855139
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.56,0.2110,33995625
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.56,0.2110,33670440
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.56,0.2110,34277782
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by Tumorigenicity assay,0.56,0.2110,33707423
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture and  FACs followed by SFA and Tumorigenicity assay,0.56,0.2110,29017078
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.56,0.2110,22498113
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.56,0.2110,31692042
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,Curcumin+Cisplatin,FACs followed by SFA,0.56,0.2110,26531053
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.56,0.2110,29868483
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA and CFA,0.56,0.2110,29845263
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and Tumorigenicity assay,0.56,0.2110,25881239
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by IF staining and FACs,0.36,0.2110,26709750
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Western Blotting,0.36,0.2110,27996162
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qPCR,0.36,0.2110,31440741
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qRT-PCR,0.36,0.2110,27996162
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,FACs and SFA,0.36,0.2110,33728488
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.36,0.2110,30119228
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.36,0.2110,30853342
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,AsPC1,Triptolide,SP assay followed by FACs,0.36,0.2110,26597727
EPCAM,LTM,NA,11529,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.28,0.2110,34350176
EPCAM,LTM,NA,11529,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs followed by SFA,0.28,0.2110,31073886
EPCAM,LTM,NA,11529,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,FACs,0.12,0.2110,29500278
EPCAM,LTM,NA,11529,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by FACs,0.12,0.2110,29088759
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,IF staining followed by Western Blotting,0.52,0.2110,31388092
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by IF staining,0.52,0.2110,26709750
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs,0.52,0.2110,22948659
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SFA,0.52,0.2110,27999190
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SP assay,0.52,0.2110,22963768
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by FACs,0.52,0.2110,30853342
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by FACs,0.52,0.2110,29719602
EPCAM,LTM,NA,11529,Head and Neck Cancer,Squamous Cell Carcinoma,CA1,NA,FACs,0.12,0.2110,29568372
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.2110,31285270
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,CACO-2,NA,SP assay followed by qPCR and SFA,0.64,0.2110,32367652
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,CACO-2,NA,SFA followed by FACs,0.64,0.2110,26995228
EPCAM,LTM,NA,11529,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by IHC staining,0.24,0.2110,23903875
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,Western Blotting followed by FACs,0.4,0.2110,28775772
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by Western Blotting and SFA,0.4,0.2110,32781084
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,Capan-1,Gemcitabine,qRT-PCR,0.4,0.2110,23026911
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by SFA and qRT-PCR,0.4,0.2110,30466404
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs,0.4,0.2110,22948659
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs followed by SP assay,0.4,0.2110,22963768
EPCAM,LTM,NA,11529,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,FACs,0.12,0.2110,26398277
EPCAM,LTM,NA,11529,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,FACs,0.12,0.2110,29029495
EPCAM,LTM,NA,11529,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by FACs,0.12,0.2110,30853342
EPCAM,LTM,NA,11529,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by FACs,0.12,0.2110,29100320
EPCAM,LTM,NA,11529,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.2110,31285270
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenosquamous Cell Carcinoma,COLO-357,NA,FACs followed by SFA,0.12,0.2110,26840020
EPCAM,LTM,NA,11529,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.2110,31285270
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.2110,33539684
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,H1299,Docetaxel,FACs followed by SFA and Tumorigenicity assay,0.48,0.2110,25279705
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Tumorigenicity assay and FACs,0.48,0.2110,23820871
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Adenocarcinoma,H1437,NA,FACs,0.12,0.2110,22498113
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,FACs followed by SFA and RT-PCR,0.32,0.2110,25678473
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,SFA followed by qPCR and FACs,0.32,0.2110,26299367
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,FACs followed by SFA and RT-PCR,0.32,0.2110,25678473
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Adenocarcinoma,H2122,NA,FACs,0.12,0.2110,22498113
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,FACs followed by SFA,0.12,0.2110,33670440
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,Curcumin+Cisplatin,FACs followed by SFA,0.12,0.2110,26531053
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,FACs followed by SFA,0.12,0.2110,29868483
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,FACs followed by CFA,0.12,0.2110,33550205
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs,0.12,0.2110,22592563
EPCAM,LTM,NA,11529,Hepatic Cancer,NA,HAK-1B,NA,SP assay followed by qRT-PCR,0.2,0.2110,24325739
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,HCCLM3,NA,CFA followed by SFA and qRT-PCR,0.2,0.2110,27783993
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,HCCLM3,NA,SFA followed by qRT-PCR,0.2,0.2110,25676692
EPCAM,LTM,NA,11529,Colon Cancer,Carcinoma,HCT116,NA,qRT-PCR followed by Western Blotting and SFA,0.48,0.2110,30912138
EPCAM,LTM,NA,11529,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.48,0.2110,27997180
EPCAM,LTM,NA,11529,Colon Cancer,Carcinoma,HCT116,NA,Western Blotting,0.48,0.2110,29354056
EPCAM,LTM,NA,11529,Colon Cancer,Carcinoma,HCT116,NA,IHC staining,0.48,0.2110,31810923
EPCAM,LTM,NA,11529,Colon Cancer,Carcinoma,HCT116,NA,SFA and qRT-PCR,0.48,0.2110,25368233
EPCAM,LTM,NA,11529,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,0.2110,31641961
EPCAM,LTM,NA,11529,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.48,0.2110,33209130
EPCAM,LTM,NA,11529,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by Tumorigenicity assay and SFA,0.48,0.2110,21454414
EPCAM,LTM,NA,11529,Colon Cancer,Carcinoma,HCT116,NA,SFA and FACs,0.48,0.2110,25804133
EPCAM,LTM,NA,11529,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.48,0.2110,26124007
EPCAM,LTM,NA,11529,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs and Tumorigenicity assay,0.48,0.2110,19737148
EPCAM,LTM,NA,11529,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,FACs followed by qRT-PCR and SFA,0.32,0.2110,28755485
EPCAM,LTM,NA,11529,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SFA followed by Western Blotting,0.32,0.2110,27997180
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by FACs and qRT-PCR,0.32,0.2110,27773936
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Hep3B,NA,CFA followed by SFA and qRT-PCR,0.32,0.2110,27783993
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by qRT-PCR,0.32,0.2110,25676692
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Hep3B,NA,FACs followed by CFA,0.32,0.2110,22194816
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by IF staining,0.24,0.2110,27891685
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by FACs,0.24,0.2110,34794402
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,HPAF-II,Gemcitabine,qPCR,0.2,0.2110,31440741
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,FACs,0.2,0.2110,22948659
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,SFA followed by FACs,0.2,0.2110,30853342
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by FACs,0.12,0.2110,28951456
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.2110,31285270
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,HT-29,NA,MACs followed by qPCR and Western Blotting,0.64,0.2110,30337351
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by qRT-PCR and SFA,0.64,0.2110,28755485
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,HT-29,Docetaxel,qRT-PCR,0.64,0.2110,27748801
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,HT-29,Docetaxel,qRT-PCR,0.64,0.2110,27748801
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,qRT-PCR,0.64,0.2110,27748801
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,qRT-PCR,0.64,0.2110,27748801
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,qRT-PCR,0.64,0.2110,30772447
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and qRT-PCR,0.64,0.2110,27556511
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.64,0.2110,27556511
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and SFA,0.64,0.2110,24970802
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.64,0.2110,26634106
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Huh1,NA,FACs,0.12,0.2110,19585654
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by Western Blotting,0.4,0.2110,32221015
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Huh7,NA,MACs followed by Western Blotting and SFA,0.4,0.2110,29602239
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by FACs and qRT-PCR,0.4,0.2110,27773936
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by FACs and qRT-PCR,0.4,0.2110,32128906
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting followed by SFA and CFA,0.4,0.2110,30908631
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.4,0.2110,25676692
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by CFA,0.4,0.2110,22194816
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by FACs and SFA,0.4,0.2110,25997710
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Huh7,NA,FACs,0.4,0.2110,19585654
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Huh7,NA,FACs,0.4,0.2110,25404478
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Huh7,NA,MACs followed by SFA,0.4,0.2110,31732298
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by FACs,0.4,0.2110,25997710
EPCAM,LTM,NA,11529,Gastric Cancer,Carcinoma,KATO-III,NA,qRT-PCR and SFA,0.2,0.2110,31233198
EPCAM,LTM,NA,11529,Pancreatic Cancer,Ductal Carcinoma,KLM-1,NA,SFA and FACs,0.12,0.2110,34628696
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,KMP5,NA,SFA and FACs,0.12,0.2110,34628696
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,Western Blotting followed by FACs and SFA,0.4,0.2110,28775772
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR and FACs,0.4,0.2110,23917223
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR,0.4,0.2110,26840266
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,NA,LC31,NA,FACs followed by IF staining and RT-PCR,0.56,0.2110,21738704
EPCAM,LTM,NA,11529,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),qRT-PCR followed by Western Blotting and SFA,0.48,0.2110,29956726
EPCAM,LTM,NA,11529,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),RT-PCR,0.48,0.2110,30552676
EPCAM,LTM,NA,11529,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,FACs and SFA,0.48,0.2110,24970802
EPCAM,LTM,NA,11529,Dukes Type B Colon Cancer,Adenocarcinoma,LS174T,NA,SFA and FACs,0.12,0.2110,25804133
EPCAM,LTM,NA,11529,Head and Neck Cancer,Squamous Cell Carcinoma,Luc4,NA,FACs,0.12,0.2110,29568372
EPCAM,LTM,NA,11529,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Cobalt Chloride,Western Blotting followed by SFA,0.28,0.2110,31584203
EPCAM,LTM,NA,11529,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR and SFA,0.28,0.2110,35413424
EPCAM,LTM,NA,11529,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.28,0.2110,34073849
EPCAM,LTM,NA,11529,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.28,0.2110,33511560
EPCAM,LTM,NA,11529,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.28,0.2110,21062983
EPCAM,LTM,NA,11529,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.28,0.2110,29088759
EPCAM,LTM,NA,11529,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.28,0.2110,31452727
EPCAM,LTM,NA,11529,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by SFA and FACs,0.28,0.2110,17881900
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.28,0.2110,29353288
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cobalt Chloride,Western Blotting followed by SFA,0.28,0.2110,31584203
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.28,0.2110,35413424
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qPCR followed by SFA,0.28,0.2110,29907642
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.28,0.2110,35055160
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.28,0.2110,33511560
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.28,0.2110,35017469
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.28,0.2110,18366788
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.28,0.2110,29552056
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.28,0.2110,29552056
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.28,0.2110,30584335
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs and SFA,0.28,0.2110,29197410
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Docetaxel,FACs and SFA,0.28,0.2110,29921732
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.28,0.2110,31501409
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.28,0.2110,31545416
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.28,0.2110,31695775
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.28,0.2110,31695775
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA and Migration assay,0.28,0.2110,31756533
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA and SP assay,0.28,0.2110,27974826
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.28,0.2110,28951456
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.28,0.2110,29137219
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.28,0.2110,31452727
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by SFA and Migration assay,0.12,0.2110,31756533
EPCAM,LTM,NA,11529,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA and FACs,0.12,0.2110,33608016
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,MHCC97-H,NA,Western Blotting followed by SFA and CFA,0.28,0.2110,30908631
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,MHCC97-H,NA,CFA followed by SFA and qRT-PCR,0.28,0.2110,27783993
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by qRT-PCR,0.28,0.2110,25676692
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by FACs and Western Blotting,0.4,0.2110,27432228
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting followed by FACs,0.4,0.2110,28775772
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by IHC staining and SFA,0.4,0.2110,31510100
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Western Blotting,0.4,0.2110,26673007
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting,0.4,0.2110,31106493
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and IF staining,0.4,0.2110,24719318
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.4,0.2110,26840266
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Cisplatin,SFA followed by FACs,0.4,0.2110,34123574
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by FACs,0.4,0.2110,34123574
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs,0.4,0.2110,22948659
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs,0.4,0.2110,26302089
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs,0.4,0.2110,26546043
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by SFA,0.4,0.2110,24719318
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by SFA,0.4,0.2110,27999190
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by SFA and Migration assay,0.4,0.2110,24734907
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and FACs,0.4,0.2110,20940707
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by FACs,0.4,0.2110,29719602
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Triptolide,SP assay followed by FACs,0.4,0.2110,26597727
EPCAM,LTM,NA,11529,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by IF staining and Western Blotting,0.52,0.2110,28430578
EPCAM,LTM,NA,11529,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.2110,28959362
EPCAM,LTM,NA,11529,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.52,0.2110,31073886
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,MU-PK-1,NA,SFA followed by FACs,0.12,0.2110,25075094
EPCAM,LTM,NA,11529,Gastric Cancer,Carcinoma,NCI-N87,NA,FACs followed by SFA,0.12,0.2110,31073886
EPCAM,LTM,NA,11529,Pancreatic Cancer,Ductal Adenocarcinoma,PaCa-44,NA,Prolonged exposure to simulated microgravity followed by qRT-PCR,0.2,0.2110,35391557
EPCAM,LTM,NA,11529,Gastric Cancer,Carcinoma,PAMC82,NA,FACs followed by SFA,0.12,0.2110,31073886
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting followed by  FACs and SFA and Tumorigenicity assay,0.4,0.2110,28775772
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by IHC staining and SFA,0.4,0.2110,31510100
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,IHC staining followed by FACs,0.4,0.2110,30272287
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs and qRT-PCR,0.4,0.2110,29975934
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR and FACs,0.4,0.2110,26439804
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.4,0.2110,26673007
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.4,0.2110,27996162
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,Microplate array followed by IF staining,0.4,0.2110,23815678
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by IF staining,0.4,0.2110,26709750
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.4,0.2110,34446696
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,Modified transwell lower chamber assay and SFA followed by qRT-PCR,0.4,0.2110,24689055
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qPCR,0.4,0.2110,31440741
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qRT-PCR,0.4,0.2110,23026911
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.4,0.2110,27996162
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.4,0.2110,31508487
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs and SFA,0.4,0.2110,33728488
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by CFA,0.4,0.2110,34556996
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.4,0.2110,33835973
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.4,0.2110,34885233
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.4,0.2110,22948659
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.4,0.2110,26261532
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.4,0.2110,26398277
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.4,0.2110,27764163
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.4,0.2110,28864067
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs and CFA followed by SFA and Tumorigenicity assay,0.4,0.2110,25849939
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.4,0.2110,22570653
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.4,0.2110,24521357
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.4,0.2110,27999190
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,Doxycycline,FACs followed by SFA,0.4,0.2110,28984401
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.4,0.2110,29656202
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.4,0.2110,29727019
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.4,0.2110,29937934
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.4,0.2110,32351328
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA and Tumorigenicity assay,0.4,0.2110,23872274
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SP assay,0.4,0.2110,23815678
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and SP assay followed by FACs,0.4,0.2110,29985062
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.4,0.2110,23815678
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.4,0.2110,25502497
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.4,0.2110,26918054
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR,0.2,0.2110,31508487
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PK-45H,NA,FACs and CFA followed by SFA,0.12,0.2110,25849939
EPCAM,LTM,NA,11529,Pancreatic Cancer,Carcinoma,PK-45P,NA,FACs followed by CFA,0.12,0.2110,34556996
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SP assay followed by FACs and SFA,0.12,0.2110,25997710
EPCAM,LTM,NA,11529,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SP assay followed by FACs,0.12,0.2110,25997710
EPCAM,LTM,NA,11529,Pancreatic Cancer,Ductal Adenocarcinoma,S2-013,Triptolide,SP assay followed by FACs,0.12,0.2110,26597727
EPCAM,LTM,NA,11529,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.28,0.2110,34350176
EPCAM,LTM,NA,11529,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and FACs,0.28,0.2110,33608016
EPCAM,LTM,NA,11529,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,RT-PCR followed by Western Blotting,0.48,0.2110,31545416
EPCAM,LTM,NA,11529,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,RT-PCR followed by Western Blotting,0.48,0.2110,31545416
EPCAM,LTM,NA,11529,Skin Cancer,NA,SK-MEL-28,NA,SFA and Western Blotting,0.28,0.2110,30717768
EPCAM,LTM,NA,11529,Gastric Cancer,Carcinoma,SNU16,NA,FACs followed by SFA,0.12,0.2110,31073886
EPCAM,LTM,NA,11529,Gastric Cancer,Carcinoma,SNU5,NA,FACs followed by SFA,0.12,0.2110,31073886
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,Docetaxel,FACs followed by SFA and Tumorigenicity assay,0.12,0.2110,25279705
EPCAM,LTM,NA,11529,Pancreatic Cancer,Ductal Adenocarcinoma,Su86.86,NA,FACs followed by SP assay,0.12,0.2110,22963768
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Carcinoma,SUM1315,NA,FACs,0.12,0.2110,18366788
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,FACs followed by CFA,0.12,0.2110,18366788
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,SFA followed by FACs,0.12,0.2110,28951456
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Carcinoma,SUM159,Docetaxel,FACs and SFA,0.12,0.2110,29921732
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs followed by CFA,0.12,0.2110,18366788
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.12,0.2110,28951456
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs,0.12,0.2110,29358169
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,NA,SUM225,NA,FACs,0.12,0.2110,18366788
EPCAM,LTM,NA,11529,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.2110,31285270
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting,0.28,0.2110,33288882
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting and SFA,0.28,0.2110,32781084
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR,0.28,0.2110,31508487
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.28,0.2110,26439804
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by SFA and qRT-PCR,0.28,0.2110,30466404
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,FACs followed by SP assay,0.28,0.2110,22963768
EPCAM,LTM,NA,11529,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.2110,31285270
EPCAM,LTM,NA,11529,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA and qRT-PCR,0.64,0.2110,29693155
EPCAM,LTM,NA,11529,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,IHC staining,0.64,0.2110,31810923
EPCAM,LTM,NA,11529,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs and SFA,0.64,0.2110,24970802
EPCAM,LTM,NA,11529,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.64,0.2110,21454414
EPCAM,LTM,NA,11529,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA and FACs,0.64,0.2110,25804133
EPCAM,LTM,NA,11529,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.2110,31285270
EPCAM,LTM,NA,11529,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by CFA and FACs,0.64,0.2110,30115896
EPCAM,LTM,NA,11529,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by FACs,0.64,0.2110,26124007
EPCAM,LTM,NA,11529,Pancreatic Cancer,Ductal Adenocarcinoma,T3M4,NA,FACs,0.12,0.2110,26546043
EPCAM,LTM,NA,11529,Colon Cancer,Carcinoma,T84,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.2110,31285270
EPCAM,LTM,NA,11529,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,Western Blotting followed by CFA,0.28,0.2110,28423495
EPCAM,LTM,NA,11529,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-10B,NA,Western Blotting followed by CFA,0.28,0.2110,28423495
EPCAM,LTM,NA,11529,Breast Cancer,Adenocarcinoma,Primary,NA,IF staining,0.32,0.2110,31791269
EPCAM,LTM,NA,11529,Breast Cancer,NA,Primary,NA,FACs,0.32,0.2110,28588211
EPCAM,LTM,NA,11529,Colon Cancer,NA,Primary,NA,IHC staining followed by RT-PCR,0.6,0.2110,19010307
EPCAM,LTM,NA,11529,Colon Cancer,NA,Primary,NA,Tumorigenicity assay and SFA followed by IHC staining and  FACs,0.6,0.2110,19808966
EPCAM,LTM,NA,11529,Colon Cancer,NA,Primary,NA,IHC staining,0.6,0.2110,22670157
EPCAM,LTM,NA,11529,Colon Cancer,NA,Primary,NA,IHC staining,0.6,0.2110,31491003
EPCAM,LTM,NA,11529,Colon Cancer,NA,Primary,NA,FACs,0.6,0.2110,27354640
EPCAM,LTM,NA,11529,Colon Cancer,Adenocarcinoma,Primary,NA,FACs,0.6,0.2110,29580161
EPCAM,LTM,NA,11529,Colon Cancer,NA,Primary,NA,FACs,0.6,0.2110,31057717
EPCAM,LTM,NA,11529,Colon Cancer,NA,Primary,NA,FACs followed by CFA,0.6,0.2110,18757407
EPCAM,LTM,NA,11529,Colon Cancer,NA,Primary,NA,SFA and FACs,0.6,0.2110,24944672
EPCAM,LTM,NA,11529,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.6,0.2110,20332776
EPCAM,LTM,NA,11529,Colon Cancer,NA,Primary,NA,SFA followed by FACs and Tumorigenicity assay,0.6,0.2110,19454726
EPCAM,LTM,NA,11529,Hepatic Cancer,NA,Primary,NA,FACs,0.2,0.2110,26942873
EPCAM,LTM,NA,11529,Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by FACs and qPCR,0.48,0.2110,26621583
EPCAM,LTM,NA,11529,Lung Cancer,NA,Primary,NA,FACs,0.48,0.2110,30397852
EPCAM,LTM,NA,11529,Lung Cancer,Adenocarcinoma,Primary,Erlotinib,FACs followed by SFA,0.48,0.2110,28347243
EPCAM,LTM,NA,11529,Lung Cancer,NA,Primary,NA,FACs followed by SFA,0.48,0.2110,32391123
EPCAM,LTM,NA,11529,Lung Cancer,Adenocarcinoma,Primary,NA,SFA and FACs,0.48,0.2110,28855609
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,NA,Primary,NA,FACs,0.2,0.2110,19464919
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,NA,Primary,NA,FACs,0.2,0.2110,19805294
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,NA,Primary,NA,FACs,0.2,0.2110,22225612
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining followed by FACs,0.52,0.2110,27414409
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.52,0.2110,25240521
EPCAM,LTM,NA,11529,Pancreatic Cancer,NA,Primary,NA,FACs,0.52,0.2110,23029396
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,Primary,NA,FACs followed by Tumorigenicity assay,0.52,0.2110,17283135
EPCAM,LTM,NA,11529,Triple Negative Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.2,0.2110,28883001
EPCAM,LTM,NA,11529,Breast Cancer,NA,Primary,NA,FACs,0.32,0.2110,33799422
EPCAM,LTM,NA,11529,Breast Cancer,NA,Primary,NA,FACs,0.32,0.2110,34073849
EPCAM,LTM,NA,11529,Breast Cancer,NA,Primary,NA,FACs,0.32,0.2110,34572409
EPCAM,LTM,NA,11529,Colon Cancer,NA,Primary,NA,IF staining,0.6,0.2110,35008827
EPCAM,LTM,NA,11529,Gastric Cancer,NA,Primary,NA,FACs,0.2,0.2110,31213895
EPCAM,LTM,NA,11529,Gastric Cancer,NA,Primary,NA,SFA followed by FACs,0.2,0.2110,30641083
EPCAM,LTM,NA,11529,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by FACs,0.2,0.2110,27619333
EPCAM,LTM,NA,11529,Hepatic Cancer,NA,Primary,NA,SP assay followed by FACs,0.2,0.2110,23104270
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,FACs,0.2,0.2110,34277782
EPCAM,LTM,NA,11529,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,FACs followed by SFA,0.2,0.2110,28855609
EPCAM,LTM,NA,11529,Pancreatic Cancer,Ductal Adenocarcinoma,Primary,NA,IHC staining,0.52,0.2110,33836674
EPCAM,LTM,NA,11529,Pancreatic Cancer,NA,Primary,NA,FACs,0.52,0.2110,33188841
EPCAM,LTM,NA,11529,Pancreatic Cancer,Adenocarcinoma,Primary,NA,SP assay followed by FACs,0.52,0.2110,32132023
EPHB2,LTM,NA,3393,Colon Cancer,Carcinoma,HCT116,Docetaxel,qRT-PCR,0.2,0.0011,27748801
EPHB2,LTM,NA,3393,Colon Cancer,Adenocarcinoma,HT-29,Docetaxel,qRT-PCR,0.2,0.0011,27748801
EPHB2,LTM,NA,3393,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,qRT-PCR,0.2,0.0011,27748801
ERBB2,LTM,NA,3430,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,Cisplatin,FACs,0.12,0.0074,34123574
ERBB2,LTM,NA,3430,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,Gemcitabine,FACs,0.12,0.0074,34123574
ERBB2,LTM,NA,3430,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.0074,29464036
ERBB2,LTM,NA,3430,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by Tumorigenicity assay,0.28,0.0074,29290211
ERBB2,LTM,NA,3430,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by FACs and Imaging FACs,0.12,0.0074,34123574
ERBB2,LTM,NA,3430,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Cisplatin,SFA followed by FACs and Imaging FACs,0.12,0.0074,34123574
ERBB2,LTM,NA,3430,Gastric Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0074,32974199
ERN1,LTM,NA,3449,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by RT-PCR,0.2,0.0021,29601799
ERN1,LTM,NA,3449,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR,0.2,0.0021,29601799
ESM1,LTM,NA,3466,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Western Blotting,0.28,0.0021,34502547
ESR1,LTM,NA,3467,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.2,0.0042,19353633
ESR1,LTM,NA,3467,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by qRT-PCR,0.2,0.0042,19353633
ESR1,LTM,NA,3467,Breast Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0042,31728117
ETV1,LTM,NA,3490,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.2,0.0042,34052833
ETV1,LTM,NA,3490,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.2,0.0042,34052833
ETV4,LTM,NA,3493,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,34052833
ETV4,LTM,NA,3493,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.2,0.0032,34052833
EZH2,LTM,NA,3527,Skin Cancer,NA,A-375,NA,SFA followed by Western Blotting,0.28,0.0074,26693692
EZH2,LTM,NA,3527,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting and qRT-PCR followed by CFA and Migration Invasion assay,0.48,0.0074,29156731
EZH2,LTM,NA,3527,Triple Negative Breast Cancer,NA,AS-B244,NA,SFA followed by Western Blotting,0.28,0.0074,28914785
EZH2,LTM,NA,3527,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0074,28914785
EZH2,LTM,NA,3527,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by RT-PCR and IHC staining,0.44,0.0074,24734907
EZH2,LTM,NA,3527,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and IF staining,0.44,0.0074,24719318
EZH2,LTM,NA,3527,Skin Cancer,NA,WM793,NA,SFA followed by Western Blotting,0.28,0.0074,26693692
EZH2,LTM,NA,3527,Lung Cancer,NA,Primary,NA,RT-PCR,0.28,0.0074,19536353
FADS2,LTM,NA,3575,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0064,34486791
FAM83A,LTM,NA,28210,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,Western Blotting followed by SFA and SP assay and Tumorigenicity assay,0.28,0.0011,28287611
FAM83A,LTM,NA,28210,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting followed by SFA and SP assay and Tumorigenicity assay,0.28,0.0011,28287611
FAS,LTM,NA,11920,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,34486791
FASLG,LTM,NA,11936,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.2,0.0011,32128906
FASN,LTM,NA,3594,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Culture of cells in electrospun scaffolds followed by Western Blotting,0.28,0.0074,34841239
FASN,LTM,NA,3594,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,Culture of cells in electrospun scaffolds followed by Western Blotting,0.28,0.0074,34841239
FEZF1-AS1,LTM,NA,41001,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and RT-PCR followed by Migration assay,0.2,0.0021,29797562
FEZF1-AS1,LTM,NA,41001,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and RT-PCR followed by Migration assay,0.2,0.0021,29797562
FEZF1-AS1,LTM,NA,41001,Gastric Cancer,Adenocarcinoma,MGC-803,NA,qRT-PCR,0.2,0.0021,32638620
FEZF1-AS1,LTM,NA,41001,Gastric Cancer,Adenocarcinoma,MKN45,NA,qRT-PCR,0.2,0.0021,32638620
FGFR3,LTM,NA,3690,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR and SFA,0.2,0.0011,35413424
FGFR4,LTM,NA,3691,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR and SFA,0.2,0.0021,35413424
FIT3,LTM,NA,NA,Gastric Cancer,Carcinoma,KATO-III,NA,FACs,0.12,0.0011,19415765
FIT3,LTM,NA,NA,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs,0.12,0.0011,19415765
FIT3,LTM,NA,NA,Gastric Cancer,Adenocarcinoma,MKN74,NA,FACs,0.12,0.0011,19415765
FIT3,LTM,NA,NA,Gastric Cancer,Carcinoma,NCI-N87,NA,FACs,0.12,0.0011,19415765
FLOT2,LTM,NA,3758,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs,0.12,0.0032,31856088
FLOT2,LTM,NA,3758,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,Migration assay followed by FACs,0.12,0.0032,31856088
FLT1,LTM,NA,3763,Skin Cancer,NA,A-375,NA,FACs,0.12,0.0021,27476721
FLT1,LTM,NA,3763,Skin Cancer,NA,SK-MEL-1,NA,FACs,0.12,0.0021,27476721
FLT1,LTM,NA,3763,Skin Cancer,NA,SK-MEL-28,NA,FACs,0.12,0.0021,27476721
FN1,LTM,NA,3778,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.2,0.0053,34486791
FOS,LTM,NA,3796,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,Western Blotting and SFA,0.28,0.0053,27965308
FOXD2-AS1,LTM,NA,44256,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.2,0.0011,30628646
FOXD2-AS1,LTM,NA,44256,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by qRT-PCR,0.2,0.0011,30628646
FOXF1,LTM,NA,3809,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and IF staining followed by SFA and Tumorigenicity assay,0.44,0.0032,32319573
FOXF1,LTM,NA,3809,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,qRT-PCR and IF staining followed by SFA and Tumorigenicity assay,0.44,0.0032,32319573
FOXM1,LTM,NA,3818,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.28,0.0053,30111255
FOXM1,LTM,NA,3818,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.28,0.0053,32782570
FOXM1,LTM,NA,3818,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Paclitaxel,Western Blotting and SFA,0.28,0.0053,30572639
FOXM1,LTM,NA,3818,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.28,0.0053,28802012
FOXO3,LTM,NA,3821,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by qPCR,0.2,0.0021,30224376
FOXO3,LTM,NA,3821,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by qPCR,0.2,0.0021,30224376
FOXO3,LTM,NA,3821,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by qPCR,0.2,0.0021,30224376
FSCN1,LTM,NA,11148,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay followed by qRT-PCR and Western Blotting,0.64,0.0064,22285547
FSTL1,LTM,NA,3972,Triple Negative Breast Cancer,Ductal Carcinoma,HCC-38,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0042,30336071
FSTL1,LTM,NA,3972,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0042,30336071
FSTL1,LTM,NA,3972,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0042,30336071
FURIN,LTM,NA,8568,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.2,0.0011,35267511
FURIN,LTM,NA,8568,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.2,0.0011,35267511
FURIN,LTM,NA,8568,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by qRT-PCR,0.2,0.0011,35267511
FUT3,LTM,NA,4014,Gastric Cancer,Adenocarcinoma,MKN28,NA,FACs,0.12,0.0021,19415765
FUT4,LTM,NA,4015,Gastric Cancer,Carcinoma,KATO-III,NA,FACs,0.12,0.0085,19415765
FUT4,LTM,NA,4015,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,FACs followed by SFA,0.12,0.0085,26840266
FUT4,LTM,NA,4015,Gastric Cancer,Adenocarcinoma,MKN28,NA,FACs,0.12,0.0085,19415765
FUT4,LTM,NA,4015,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs,0.12,0.0085,19415765
FUT4,LTM,NA,4015,Gastric Cancer,Adenocarcinoma,MKN74,NA,FACs,0.12,0.0085,19415765
FUT4,LTM,NA,4015,Non Small Cell Lung Cancer,Carcinoma,NCI-H1915,NA,SFA followed by FACs,0.12,0.0085,23418195
FUT4,LTM,NA,4015,Gastric Cancer,Carcinoma,NCI-N87,NA,FACs,0.12,0.0085,19415765
FUT4,LTM,NA,4015,Glioblastoma,NA,Primary,NA,IHC staining and FACs followed by CFA,0.52,0.0085,19427293
FUT4,LTM,NA,4015,Glioblastoma,NA,Primary,NA,SFA followed by IF staining,0.52,0.0085,19956386
FUT4,LTM,NA,4015,Glioblastoma,NA,Primary,NA,SFA and FACs,0.52,0.0085,28881826
FUT4,LTM,NA,4015,Skin Cancer,NA,Primary,NA,IHC staining,0.32,0.0085,26290260
FUT4,LTM,NA,4015,Glioblastoma Multiforme,NA,Primary,NA,Isolation of autofluorescence cells followed by SFA and FACs,0.2,0.0085,33669350
FUT7,LTM,NA,4018,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-103,NA,SFA followed by FACs and IF staining,0.36,0.0011,23558285
FXYD3,LTM,NA,4027,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by FACs and RT-PCR,0.32,0.0053,30206184
FXYD3,LTM,NA,4027,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and RT-PCR,0.32,0.0053,30206184
FZD1,LTM,NA,4038,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qRT-PCR,0.2,0.0042,31966561
FZD1,LTM,NA,4038,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qPCR,0.2,0.0042,31966561
FZD10,LTM,NA,4039,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qRT-PCR,0.2,0.0021,31966561
FZD10,LTM,NA,4039,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qPCR,0.2,0.0021,31966561
FZD2,LTM,NA,4040,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qPCR,0.2,0.0021,34168259
FZD2,LTM,NA,4040,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by qPCR,0.2,0.0021,34168259
FZD2,LTM,NA,4040,Pancreatic Cancer,Ductal Adenocarcinoma,MIA-PaCa-44,NA,SFA followed by qPCR,0.2,0.0021,34168259
FZD2,LTM,NA,4040,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by qPCR,0.2,0.0021,34168259
FZD7,LTM,NA,4045,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qPCR and Western Blotting,0.48,0.0064,29559846
FZD7,LTM,NA,4045,Pancreatic Cancer,Adenocarcinoma,Capan-2,NA,SFA followed by Western Blotting,0.28,0.0064,33934523
FZD7,LTM,NA,4045,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by qPCR and Western Blotting,0.48,0.0064,29559846
FZD7,LTM,NA,4045,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by RT-PCR,0.2,0.0064,30696080
FZD7,LTM,NA,4045,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.28,0.0064,33934523
FZD7,LTM,NA,4045,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.32,0.0064,33109579
GABRP,LTM,NA,4089,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,34023418
GABRP,LTM,NA,4089,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,SFA followed by Western Blotting,0.28,0.0032,34023418
GATA6,LTM,NA,4174,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR and CFA,0.2,0.0021,31544978
GATA6,LTM,NA,4174,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR and CFA,0.2,0.0021,31544978
GBA,LTM,NA,4177,Pancreatic Cancer,NA,Insulinoma,NA,FACs,0.12,0.0011,27049037
GCLC,LTM,NA,4311,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,35155201
GCLC,LTM,NA,4311,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0032,31672029
GDF15,LTM,NA,30142,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.2,0.0042,34486791
GJA3,LTM,NA,4277,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by IF staining and SFA,0.52,0.0011,34830485
GJB2,LTM,NA,4284,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qPCR and Western Blotting followed by SFA and Tumorigenicity assay,0.48,0.0032,29422613
GLDC,LTM,NA,4313,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0021,28416482
GLI1,LTM,NA,4317,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,CFA and Western Blotting,0.28,0.0308,29914183
GLI1,LTM,NA,4317,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by qPCR and Western Blotting,0.48,0.0308,34424425
GLI1,LTM,NA,4317,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by IF staining,0.24,0.0308,33061365
GLI1,LTM,NA,4317,Gastric Cancer,Adenocarcinoma,BGC-823,NA,CFA followed by qPCR and Western Blotting,0.48,0.0308,26276718
GLI1,LTM,NA,4317,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.48,0.0308,34350176
GLI1,LTM,NA,4317,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by Western Blotting,0.48,0.0308,30624124
GLI1,LTM,NA,4317,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by Western Blotting,0.28,0.0308,33552265
GLI1,LTM,NA,4317,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Cisplatin,SFA followed by qRT-PCR,0.2,0.0308,32206093
GLI1,LTM,NA,4317,Glioblastoma Multiforme,NA,GBM8401,NA,SP assay and SFA followed by RT-PCR,0.2,0.0308,25359730
GLI1,LTM,NA,4317,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,Western Blotting followed by CFA and SFA,0.28,0.0308,32509180
GLI1,LTM,NA,4317,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs for CSC marker followed by qPCR and Western Blotting,0.48,0.0308,34424425
GLI1,LTM,NA,4317,Non Small Cell Lung Cancer,Carcinoma,H460,NA,Western Blotting followed by CFA and SFA,0.48,0.0308,32509180
GLI1,LTM,NA,4317,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by qRT-PCR and SFA,0.2,0.0308,29792038
GLI1,LTM,NA,4317,Hepatic Cancer,Carcinoma,Mahlavu,NA,SP assay followed by Western Blotting,0.28,0.0308,29792038
GLI1,LTM,NA,4317,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0308,34052833
GLI1,LTM,NA,4317,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qPCR,0.28,0.0308,29846560
GLI1,LTM,NA,4317,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.28,0.0308,34445421
GLI1,LTM,NA,4317,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.28,0.0308,32863948
GLI1,LTM,NA,4317,Gastric Cancer,Carcinoma,NCI-N87,5-Fluorouracil,SFA followed by qRT-PCR,0.2,0.0308,28847472
GLI1,LTM,NA,4317,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by RT-PCR,0.2,0.0308,30696080
GLI1,LTM,NA,4317,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0308,22923052
GLI1,LTM,NA,4317,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,0.0308,29697746
GLI1,LTM,NA,4317,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR,0.48,0.0308,26918054
GLI1,LTM,NA,4317,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,CFA followed by qPCR and Western Blotting,0.48,0.0308,26276718
GLI1,LTM,NA,4317,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.48,0.0308,34350176
GLI1,LTM,NA,4317,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.0308,30624124
GLI1,LTM,NA,4317,Hepatic Cancer,Adenocarcinoma,SK-Hep-1,NA,SP assay followed by Western Blotting,0.28,0.0308,29792038
GLI1,LTM,NA,4317,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by Western Blotting,0.28,0.0308,32863948
GLI1,LTM,NA,4317,Gastric Cancer,Adenocarcinoma,ST2957,NA,SFA followed by Western Blotting,0.28,0.0308,32863948
GLI1,LTM,NA,4317,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR,0.2,0.0308,19232461
GLI1,LTM,NA,4317,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,qRT-PCR followed by SFA,0.2,0.0308,32773768
GLI1,LTM,NA,4317,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,SFA followed by RT-PCR,0.2,0.0308,31742606
GLI1,LTM,NA,4317,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,qRT-PCR followed by SFA,0.2,0.0308,32773768
GLI1,LTM,NA,4317,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting,0.28,0.0308,33552265
GLI1,LTM,NA,4317,Skin Cancer,Squamous Cell Carcinoma,UW-BCC1,NA,CFA and Western Blotting,0.28,0.0308,29914183
GLI1,LTM,NA,4317,Bladder Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0308,28765327
GLI1,LTM,NA,4317,Breast Cancer,Ductal Carcinoma,Primary,NA,IHC staining,0.32,0.0308,28965964
GLI1,LTM,NA,4317,Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0308,28286162
GLI1,LTM,NA,4317,Pancreatic Cancer,NA,Primary,NA,qRT-PCR and Western Blotting,0.64,0.0308,23029396
GLI1,LTM,NA,4317,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,Cisplatin,SFA followed by qRT-PCR,0.28,0.0308,32206093
GLI2,LTM,NA,4318,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.28,0.0106,34350176
GLI2,LTM,NA,4318,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.28,0.0106,34350176
GLI2,LTM,NA,4318,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by Western Blotting,0.28,0.0106,30624124
GLI2,LTM,NA,4318,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by Western Blotting,0.28,0.0106,33552265
GLI2,LTM,NA,4318,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.28,0.0106,34445421
GLI2,LTM,NA,4318,Gastric Cancer,Carcinoma,NCI-N87,5-Fluorouracil,SFA followed by qRT-PCR,0.2,0.0106,28847472
GLI2,LTM,NA,4318,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0106,22923052
GLI2,LTM,NA,4318,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,0.0106,29697746
GLI2,LTM,NA,4318,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.28,0.0106,30624124
GLI2,LTM,NA,4318,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting,0.28,0.0106,33552265
GLI2,LTM,NA,4318,Pancreatic Cancer,NA,Primary,NA,qRT-PCR and Western Blotting,0.64,0.0106,23029396
GLI2,LTM,NA,4318,Pancreatic Cancer,NA,Primary,NA,CFA followed by qRT-PCR,0.64,0.0106,26199979
GLI3,LTM,NA,4319,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.28,0.0021,29697746
GLO1,LTM,NA,4323,Triple Negative Breast Cancer,Carcinoma,MDA-MB-157,NA,Western Blotting followed by SFA,0.28,0.0042,30559934
GLRX3,LTM,NA,15987,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.32,0.0032,34794402
GPC3,LTM,NA,4451,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.0032,21618577
GPC3,LTM,NA,4451,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.0032,21618577
GPC3,LTM,NA,4451,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.0032,21618577
GPER1,LTM,NA,4485,Breast Cancer,Ductal Carcinoma,ZR-75-30,NA,SFA followed by FACs,0.12,0.0021,30478301
GPNMB,LTM,NA,4462,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by qPCR,0.2,0.0021,30224376
GPSM2,LTM,NA,29501,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR and Western Blotting,0.48,0.0021,30774366
GPT2,LTM,NA,18062,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,CFA followed by IF staining and Western Blotting,0.52,0.0011,28839461
GPT2,LTM,NA,18062,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,CFA followed by IF staining and Western Blotting,0.52,0.0011,28839461
GPX4,LTM,NA,4556,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting and SFA followed by Migration and Invasion assay,0.28,0.0021,30535490
GRN,LTM,NA,4601,Hepatic Cancer,Carcinoma,Hep3B,NA,FACs followed by CFA,0.12,0.0032,22194816
GRN,LTM,NA,4601,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by CFA,0.12,0.0032,22194816
GRN,LTM,NA,4601,Hepatic Cancer,NA,Primary,NA,FACs and CFA followed by SFA and Tumorigenicity assay,0.2,0.0032,26942873
GSK3B,LTM,NA,4617,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and RT-PCR followed by SFA,0.48,0.0053,29383157
GSK3B,LTM,NA,4617,Head and Neck Cancer,Squamous Cell Carcinoma,OM-1,NA,FACs and RT-PCR followed by SFA,0.32,0.0053,26399460
GSK3B,LTM,NA,4617,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0053,31506430
GSTP1,LTM,NA,4638,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.28,0.0053,34840986
HDAC1,LTM,NA,4852,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by Western Blotting,0.28,0.0032,26000099
HDAC1,LTM,NA,4852,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR,0.2,0.0032,30050079
HDAC1,LTM,NA,4852,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-2,Cisplatin,SFA followed by Western Blotting,0.28,0.0032,26000099
HDAC2,LTM,NA,4853,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by Western Blotting,0.28,0.0021,26000099
HDAC2,LTM,NA,4853,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-2,Cisplatin,SFA followed by Western Blotting,0.28,0.0021,26000099
HES1,LTM,NA,5192,Triple Negative Breast Cancer,Carcinoma,BT-20,NA,SFA followed by Western Blotting,0.28,0.0095,33924995
HES1,LTM,NA,5192,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,SFA and Western Blotting,0.28,0.0095,33390847
HES1,LTM,NA,5192,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.28,0.0095,33390847
HES1,LTM,NA,5192,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0095,33924995
HES1,LTM,NA,5192,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0095,28959362
HES1,LTM,NA,5192,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by RT-PCR,0.2,0.0095,30696080
HES1,LTM,NA,5192,Hepatic Cancer,Carcinoma,SNU-398,NA,Western Blotting and SFA,0.28,0.0095,31888685
HES1,LTM,NA,5192,Colon Cancer,NA,Primary,NA,qRT-PCR and Tumorigenicity assay,0.28,0.0095,24492635
HES1,LTM,NA,5192,Breast Cancer,NA,Primary,NA,IHC staining,0.32,0.0095,33390847
HES1,LTM,NA,5192,Triple Negative Breast Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.36,0.0095,33924995
HEY1,LTM,NA,4880,Triple Negative Breast Cancer,Carcinoma,BT-20,NA,SFA followed by Western Blotting,0.28,0.0021,33924995
HEY1,LTM,NA,4880,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0021,33924995
HEY1,LTM,NA,4880,Hepatic Cancer,Carcinoma,SNU-398,NA,Western Blotting and SFA,0.28,0.0021,31888685
HEY1,LTM,NA,4880,Triple Negative Breast Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.36,0.0021,33924995
HEY2,LTM,NA,4881,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,RT-PCR and SFA,0.2,0.0021,29895705
HEY2,LTM,NA,4881,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,RT-PCR and SFA,0.2,0.0021,29895705
HIF1A,LTM,NA,4910,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting followed by SFA and CFA,0.28,0.0106,30908631
HIF1A,LTM,NA,4910,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0106,34830821
HIF1A,LTM,NA,4910,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0106,31308814
HIF1A,LTM,NA,4910,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Western Blotting,0.28,0.0106,34502547
HIF1A,LTM,NA,4910,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cobalt Chloride,Western Blotting followed by SFA,0.28,0.0106,31584203
HIF1A,LTM,NA,4910,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cobalt Chloride,Western Blotting followed by SFA,0.28,0.0106,31584203
HIF1A,LTM,NA,4910,Hepatic Cancer,Carcinoma,MHCC97-H,NA,Western Blotting followed by SFA and CFA,0.28,0.0106,30908631
HIF1A,LTM,NA,4910,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and qRT-PCR,0.2,0.0106,24719318
HIF1A,LTM,NA,4910,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-15,NA,qPCR followed by Western Blotting and SFA,0.48,0.0106,35013621
HIF1A,LTM,NA,4910,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,qPCR followed by Western Blotting and SFA,0.48,0.0106,35013621
HIF1A,LTM,NA,4910,Glioblastoma,NA,U-373MG,NA,SFA followed by Western Blotting,0.28,0.0106,29115404
HIF1A,LTM,NA,4910,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting,0.28,0.0106,29115404
HMGA1,LTM,NA,5010,Colon Cancer,Adenocarcinoma,CACO-2,NA,Western Blotting,0.28,0.0042,24833610
HMGA1,LTM,NA,5010,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,Western Blotting,0.28,0.0042,24833610
HMGA1,LTM,NA,5010,Glioblastoma,NA,U-251,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.0042,21300033
HMGA1,LTM,NA,5010,Colon Cancer,NA,Primary,NA,SFA and Western Blotting,0.36,0.0042,24833610
HMGA1,LTM,NA,5010,Colon Cancer,NA,Primary,NA,Western Blotting,0.36,0.0042,24833610
HMGA2,LTM,NA,5009,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR and SFA,0.2,0.0042,35413424
HMGA2,LTM,NA,5009,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.2,0.0042,35413424
HMGA2,LTM,NA,5009,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0042,28337375
HMGA2,LTM,NA,5009,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0042,28337375
HMGA2,LTM,NA,5009,Gastric Cancer,Adenocarcinoma,MKN45,NA,Western Blotting,0.48,0.0042,27878307
HMGA2,LTM,NA,5009,Gastric Cancer,NA,Primary,NA,IHC staining followed by Western Blotting,0.68,0.0042,27878307
HMGA2,LTM,NA,5009,Gastric Cancer,NA,Primary,NA,IHC staining,0.68,0.0042,28337375
HMGB1,LTM,NA,4983,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.28,0.0032,31255531
HMOX1,LTM,NA,5013,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by RT-PCR,0.2,0.0064,30238818
HMOX1,LTM,NA,5013,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,CORM-A1,SFA followed by RT-PCR,0.2,0.0064,30238818
HOTAIR,LTM,NA,33510,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by qRT-PCR,0.2,0.0011,33737813
HOTAIR,LTM,NA,33510,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.2,0.0011,33737813
HOTTIP,LTM,NA,37461,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.2,0.0011,28947139
HOXD8,LTM,NA,5139,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR and Western Blotting followed by SFA,0.48,0.0011,27748920
HOXD9,LTM,NA,5140,Glioblastoma,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0011,21600039
HSF1,LTM,NA,5224,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Western Blotting,0.28,0.0032,29088759
HSF1,LTM,NA,5224,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,FACs for CSC marker followed by IHC staining and SFA,0.28,0.0032,34775489
HSF1,LTM,NA,5224,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,FACs for CSC marker followed by IHC staining and SFA,0.24,0.0032,34775489
HSF1,LTM,NA,5224,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0032,29088759
HSF1,LTM,NA,5224,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,35158144
HSF1,LTM,NA,5224,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,35158144
HSP90AA1,LTM,NA,5253,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by Western Blotting,0.28,0.0064,34775489
HSP90AA1,LTM,NA,5253,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,SFA followed by Western Blotting,0.28,0.0064,34775489
HSPA4,LTM,NA,5237,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,FACs for CSC marker followed by IHC staining and SFA,0.24,0.0042,34775489
HSPA4,LTM,NA,5237,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,FACs for CSC marker followed by IHC staining and SFA,0.24,0.0042,34775489
HSPA5,LTM,NA,5238,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,FACs followed by Western Blotting,0.4,0.0117,24201869
HSPA5,LTM,NA,5238,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by RT-PCR,0.2,0.0117,29601799
HSPA5,LTM,NA,5238,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR,0.2,0.0117,29601799
HSPA5,LTM,NA,5238,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,FACs followed by Western Blotting,0.4,0.0117,24201869
HSPA5,LTM,NA,5238,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,SFA followed by Western Blotting and  FACs,0.4,0.0117,20979610
HSPA5,LTM,NA,5238,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SFA followed by Western Blotting and  FACs,0.4,0.0117,20979610
HSPA5,LTM,NA,5238,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,Cisplatin,FACs followed by SFA,0.4,0.0117,25217518
HSPA5,LTM,NA,5238,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,FACs followed by SP assay,0.4,0.0117,23843890
HSPA6,LTM,NA,5239,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by qRT-PCR,0.2,0.0053,35158144
HSPA6,LTM,NA,5239,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.2,0.0053,35158144
HSPA9,LTM,NA,5244,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0042,34249423
HSPA9,LTM,NA,5244,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0042,34249423
HSPA9,LTM,NA,5244,Breast Cancer,NA,Primary,NA,IHC staining,0.32,0.0042,34249423
HSPE1,LTM,NA,5269,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by qRT-PCR,0.2,0.0053,35158144
HSPE1,LTM,NA,5269,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.2,0.0053,35158144
HSPH1,LTM,NA,16969,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by qRT-PCR,0.2,0.0021,35158144
HSPH1,LTM,NA,16969,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.2,0.0021,35158144
ICAM1,LTM,NA,5344,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0064,30397177
ICAM1,LTM,NA,5344,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0064,30397177
ICAM1,LTM,NA,5344,Gastric Cancer,NA,Primary,NA,SFA followed by IHC staining,0.32,0.0064,21727908
ICAM1,LTM,NA,5344,Gastric Cancer,NA,Primary,NA,SFA followed by FACs,0.32,0.0064,30641083
ID1,LTM,NA,5360,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting,0.28,0.0053,28529558
ID1,LTM,NA,5360,Gastric Cancer,Adenocarcinoma,MKN28,NA,SFA followed by Western Blotting,0.28,0.0053,28529558
IFNG ,LTM,NA,5438,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
IFNG ,LTM,NA,5438,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
IGF1,LTM,NA,5464,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and qRT-PCR,0.2,0.0053,24719318
IKBKE,LTM,NA,14552,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and Western Blotting followed by FACs and SFA,0.6,0.0021,30615901
IKZF3,LTM,NA,13178,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and Western Blotting followed by SFA and Tumorigenicity assay,0.48,0.0032,30816208
IKZF3,LTM,NA,13178,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,qRT-PCR and Western Blotting followed by SFA and Tumorigenicity assay,0.48,0.0032,30816208
IL10,LTM,NA,5962,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL10,LTM,NA,5962,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL11,LTM,NA,5966,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0032,30397177
IL11,LTM,NA,5966,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0032,30397177
IL12B,LTM,NA,5970,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL12B,LTM,NA,5970,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL12B,LTM,NA,5970,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL12B,LTM,NA,5970,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL13,LTM,NA,5973,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL13,LTM,NA,5973,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL15,LTM,NA,5977,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0021,30397177
IL15,LTM,NA,5977,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0021,30397177
IL16,LTM,NA,5980,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0021,30397177
IL16,LTM,NA,5980,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0021,30397177
IL17A,LTM,NA,5981,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL17A,LTM,NA,5981,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL1A,LTM,NA,5991,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0032,30397177
IL1A,LTM,NA,5991,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0032,30397177
IL1B,LTM,NA,5992,Colon Cancer,Carcinoma,HCT116,NA,SFA and RT-PCR followed by Migration assay,0.2,0.0074,23174018
IL1B,LTM,NA,5992,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0074,30397177
IL1B,LTM,NA,5992,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0074,30397177
IL1RN,LTM,NA,6000,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0053,30397177
IL1RN,LTM,NA,6000,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0053,30397177
IL2,LTM,NA,6001,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL2,LTM,NA,6001,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL33,LTM,NA,16028,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting and RT-PCR,0.48,0.0011,28249897
IL4,LTM,NA,6014,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0021,30397177
IL4,LTM,NA,6014,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0021,30397177
IL5,LTM,NA,6016,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL5,LTM,NA,6016,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
IL6,LTM,NA,6018,Non Small Cell Lung Cancer,Carcinoma,A549,NA,ELISA and qPCR followed by SFA and Migration Invasion assay,0.48,0.0191,26675547
IL6,LTM,NA,6018,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by qRT-PCR and Tumorigenicity assay,0.48,0.0191,27009878
IL6,LTM,NA,6018,Triple Negative Breast Cancer,Carcinoma,BT-20,NA,SFA followed by qPCR,0.2,0.0191,29073729
IL6,LTM,NA,6018,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,ELISA followed by Western Blotting,0.56,0.0191,28978005
IL6,LTM,NA,6018,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H157,NA,ELISA and qPCR followed by SFA and Migration Invasion assay,0.48,0.0191,26675547
IL6,LTM,NA,6018,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H157,Cisplatin,SFA followed by qRT-PCR,0.48,0.0191,27009878
IL6,LTM,NA,6018,Non Small Cell Lung Cancer,Adenocarcinoma,H23,5-fluorouracil,FACs followed by qRT-PCR,0.32,0.0191,22416214
IL6,LTM,NA,6018,Non Small Cell Lung Cancer,Adenocarcinoma,H23,Methotrexate,FACs followed by qRT-PCR,0.32,0.0191,22416214
IL6,LTM,NA,6018,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by qRT-PCR and ELISA,0.48,0.0191,35116788
IL6,LTM,NA,6018,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.48,0.0191,30397177
IL6,LTM,NA,6018,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.48,0.0191,30397177
IL6,LTM,NA,6018,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting and ELISA assay,0.56,0.0191,31497349
IL6,LTM,NA,6018,Luminal A Breast Cancer,Adenocarcinoma,MCF7,MK-0752,Western Blotting followed by SFA,0.56,0.0191,29027990
IL6,LTM,NA,6018,Luminal A Breast Cancer,Adenocarcinoma,MCF7,RO49097,Western Blotting followed by SFA,0.56,0.0191,29027990
IL6,LTM,NA,6018,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.2,0.0191,34146553
IL6,LTM,NA,6018,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,qPCR followed by SFA,0.2,0.0191,28703802
IL6,LTM,NA,6018,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qPCR,0.2,0.0191,29073729
IL6,LTM,NA,6018,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and qRT-PCR,0.2,0.0191,24719318
IL6,LTM,NA,6018,Bladder Cancer,Transitional Cell Papilloma,RT-4,NA,SFA followed by qRT-PCR and ELISA,0.48,0.0191,35116788
IL6,LTM,NA,6018,Triple Negative Breast Cancer,Carcinoma,SUM149PT,MK-0752,Western Blotting followed by SFA,0.28,0.0191,29027990
IL6,LTM,NA,6018,Triple Negative Breast Cancer,Carcinoma,SUM149PT,RO49097,Western Blotting followed by SFA,0.28,0.0191,29027990
IL6,LTM,NA,6018,Triple Negative Breast Cancer,Carcinoma,SUM149PT,Paclitaxel,qPCR followed by SFA,0.28,0.0191,28703802
IL6,LTM,NA,6018,Breast Cancer,Carcinoma,SUM190PT,Paclitaxel,qPCR followed by SFA,0.2,0.0191,28703802
IL6,LTM,NA,6018,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-74A,NA,ELISA followed by Western Blotting,0.56,0.0191,28978005
IL6,LTM,NA,6018,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0191,30397177
IL6,LTM,NA,6018,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0191,30397177
IL6,LTM,NA,6018,Colon Cancer,Adenocarcinoma,WIDR,NA,SFA followed by RT-PCR,0.2,0.0191,25625841
IL6R,LTM,NA,6019,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,Western Blotting followed by SFA,0.28,0.0021,34689150
IL6R,LTM,NA,6019,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,NA,Western Blotting followed by SFA,0.28,0.0021,34689150
IL6R,LTM,NA,6019,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,NA,Western Blotting followed by SFA,0.28,0.0021,34689150
IL7,LTM,NA,6023,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0021,30397177
IL7,LTM,NA,6023,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0021,30397177
IL8,LTM,NA,6025,Triple Negative Breast Cancer,Carcinoma,BT-20,NA,SFA followed by qPCR,0.2,0.0159,29073729
IL8,LTM,NA,6025,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by qRT-PCR and Migration and Invasion assay,0.2,0.0159,30254465
IL8,LTM,NA,6025,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,NA,qRT-PCR followed by SFA,0.2,0.0159,19190339
IL8,LTM,NA,6025,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by Western Blotting,0.28,0.0159,30305725
IL8,LTM,NA,6025,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by Western Blotting,0.28,0.0159,30305725
IL8,LTM,NA,6025,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.28,0.0159,30305725
IL8,LTM,NA,6025,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0159,30397177
IL8,LTM,NA,6025,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.2,0.0159,34146553
IL8,LTM,NA,6025,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,qPCR followed by SFA,0.2,0.0159,28703802
IL8,LTM,NA,6025,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qPCR,0.2,0.0159,29073729
IL8,LTM,NA,6025,Triple Negative Breast Cancer,Carcinoma,SUM149PT,Paclitaxel,qPCR followed by SFA,0.2,0.0159,28703802
IL8,LTM,NA,6025,Breast Cancer,Carcinoma,SUM190PT,Paclitaxel,qPCR followed by SFA,0.2,0.0159,28703802
IL8,LTM,NA,6025,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0159,30397177
INHBB,LTM,NA,6067,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR and SFA,0.2,0.0064,35413424
INHBB,LTM,NA,6067,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.2,0.0064,35413424
ITGA2,LTM,NA,6137,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by FACs,0.2,0.0106,27619333
ITGA3,LTM,NA,6139,Pancreatic Cancer,Ductal Adenocarcinoma,PaCa-44,NA,Prolonged exposure to simulated microgravity followed by qRT-PCR,0.2,0.0032,35391557
ITGA6,LTM,NA,6142,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by qRT-PCR and FACs and Western Blotting,0.6,0.0265,24112466
ITGA6,LTM,NA,6142,Breast Cancer,Carcinoma,HCC1569,NA,SFA followed by FACs,0.12,0.0265,34889737
ITGA6,LTM,NA,6142,Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,SFA followed by FACs,0.12,0.0265,34889737
ITGA6,LTM,NA,6142,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,SFA followed by FACs,0.12,0.0265,33672732
ITGA6,LTM,NA,6142,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,SFA followed by PCR array assay,0.12,0.0265,33510281
ITGA6,LTM,NA,6142,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR,0.2,0.0265,33634797
ITGA6,LTM,NA,6142,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay and SFA followed by FACs and qRT-PCR,0.2,0.0265,17935134
ITGA6,LTM,NA,6142,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SP assay followed by SFA and FACs,0.2,0.0265,17881900
ITGA6,LTM,NA,6142,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Culture of cells in electrospun scaffolds followed by qRT-PCR,0.2,0.0265,34841239
ITGA6,LTM,NA,6142,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR,0.2,0.0265,33634797
ITGA6,LTM,NA,6142,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.2,0.0265,29137219
ITGA6,LTM,NA,6142,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,Culture of cells in electrospun scaffolds followed by qRT-PCR,0.2,0.0265,34841239
ITGA6,LTM,NA,6142,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs,0.2,0.0265,34889737
ITGA6,LTM,NA,6142,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,FACs followed by SFA,0.12,0.0265,35512572
ITGA6,LTM,NA,6142,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.12,0.0265,29805588
ITGA6,LTM,NA,6142,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs followed by SFA,0.12,0.0265,29805588
ITGA6,LTM,NA,6142,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,FACs,0.12,0.0265,25748177
ITGA6,LTM,NA,6142,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,SFA followed by FACs,0.12,0.0265,23226620
ITGA6,LTM,NA,6142,Breast Cancer,Ductal Carcinoma,Primary,NA,qRT-PCR and  FACs followed by SFA,0.48,0.0265,30050081
ITGA6,LTM,NA,6142,Breast Cancer,NA,Primary,NA,FACs,0.48,0.0265,31555258
ITGA6,LTM,NA,6142,Breast Cancer,NA,Primary,NA,FACs,0.48,0.0265,31555258
ITGA6,LTM,NA,6142,Colon Cancer,NA,Primary,NA,FACs followed by CFA,0.2,0.0265,18757407
ITGA6,LTM,NA,6142,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0265,31506430
ITGA6,LTM,NA,6142,Non Small Cell Lung Cancer,NA,Primary,NA,FACs followed by SFA,0.28,0.0265,28416482
ITGA6,LTM,NA,6142,Triple Negative Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.2,0.0265,28883001
ITGA6,LTM,NA,6142,Breast Cancer,NA,Primary,NA,FACs,0.48,0.0265,34572409
ITGA6,LTM,NA,6142,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by FACs,0.2,0.0265,27619333
ITGA6,LTM,NA,6142,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by FACs,0.28,0.0265,28416482
ITGB1,LTM,NA,6153,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,IHC staining and FACs,0.36,0.0180,22740085
ITGB1,LTM,NA,6153,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and Western Blotting  followed by Tumorigenicity assay,0.28,0.0180,30485693
ITGB1,LTM,NA,6153,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by IHC staining,0.24,0.0180,23903875
ITGB1,LTM,NA,6153,Colon Cancer,Carcinoma,HCT116,Docetaxel,qRT-PCR,0.2,0.0180,27748801
ITGB1,LTM,NA,6153,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.2,0.0180,22329848
ITGB1,LTM,NA,6153,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,FACs,0.12,0.0180,30029671
ITGB1,LTM,NA,6153,Colon Cancer,Adenocarcinoma,HT-29,Docetaxel,qRT-PCR,0.2,0.0180,27748801
ITGB1,LTM,NA,6153,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,qRT-PCR,0.2,0.0180,27748801
ITGB1,LTM,NA,6153,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.2,0.0180,22329848
ITGB1,LTM,NA,6153,Lung Cancer,Large Cell Carcinoma,L9981,NA,SFA and Western Blotting  followed by Tumorigenicity assay,0.28,0.0180,30485693
ITGB1,LTM,NA,6153,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.12,0.0180,31545416
ITGB1,LTM,NA,6153,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by FACs and RT-PCR,0.32,0.0180,21455326
ITGB1,LTM,NA,6153,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.12,0.0180,22329848
ITGB1,LTM,NA,6153,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-103,NA,SFA followed by FACs,0.12,0.0180,25428916
ITGB1,LTM,NA,6153,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-14B,NA,SFA followed by FACs,0.12,0.0180,25428916
ITGB1,LTM,NA,6153,Colon Cancer,NA,Primary,NA,IHC staining,0.32,0.0180,22670157
ITGB1,LTM,NA,6153,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.28,0.0180,22333601
ITGB1,LTM,NA,6153,Non Small Cell Lung Cancer,NA,Primary,NA,FACs,0.2,0.0180,19464919
ITGB1,LTM,NA,6153,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.2,0.0180,35053617
ITGB1,LTM,NA,6153,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by FACs,0.28,0.0180,27619333
ITGB3,LTM,NA,6156,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs and SFA,0.12,0.0032,31745977
ITGB3,LTM,NA,6156,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.2,0.0032,35053617
ITGB4,LTM,NA,6158,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by FACs,0.2,0.0074,28416482
JADE3,LTM,NA,22982,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.2,0.0011,29660380
JADE3,LTM,NA,22982,Dukes Type C Colon Cancer,Adenocarcinoma,SW1417,NA,RT-PCR followed by SFA,0.2,0.0011,29660380
JAG1,LTM,NA,6188,Triple Negative Breast Cancer,Carcinoma,BT-20,NA,SFA followed by Western Blotting,0.28,0.0117,33924995
JAG1,LTM,NA,6188,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,FACs followed by SFA,0.12,0.0117,29895705
JAG1,LTM,NA,6188,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,FACs followed by SFA,0.12,0.0117,29895705
JAG1,LTM,NA,6188,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.2,0.0117,31835579
JAG1,LTM,NA,6188,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Lapatinib,FACs followed by SFA,0.12,0.0117,29895705
JAG1,LTM,NA,6188,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Lapatinib,FACs followed by RT-PCR and SFA,0.32,0.0117,29895705
JAG1,LTM,NA,6188,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.32,0.0117,33924995
JAG1,LTM,NA,6188,Gastric Cancer,Adenocarcinoma,MKN45,Trastuzumab,RT-PCR,0.2,0.0117,25669984
JAG1,LTM,NA,6188,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0117,31506430
JAG1,LTM,NA,6188,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.32,0.0117,21922151
JAG1,LTM,NA,6188,Triple Negative Breast Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.36,0.0117,33924995
JAG2,LTM,NA,6189,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by RT-PCR,0.2,0.0032,30696080
JAG2,LTM,NA,6189,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.32,0.0032,21922151
JAK2,LTM,NA,6192,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0053,31658701
JAK2,LTM,NA,6192,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.28,0.0053,31850822
JAK2,LTM,NA,6192,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,Western Blotting and SFA,0.28,0.0053,31850822
JARID2,LTM,NA,6196,Bladder Cancer,Carcinoma,5637,NA,qRT-PCR,0.2,0.0032,28445934
JARID2,LTM,NA,6196,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,qRT-PCR and Western Blotting and SFA,0.48,0.0032,34246759
JARID2,LTM,NA,6196,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,qRT-PCR and Western Blotting and SFA,0.48,0.0032,34246759
JARID2,LTM,NA,6196,Bladder Cancer,Squamous Cell Carcinoma,SCaBER,NA,qRT-PCR,0.2,0.0032,28445934
JPT2,LTM,NA,14137,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by Western Blotting,0.28,0.0021,29249663
JUN,LTM,NA,6204,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0053,31604679
JUN,LTM,NA,6204,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR and SFA,0.28,0.0053,35413424
JUN,LTM,NA,6204,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.2,0.0053,35413424
JUN,LTM,NA,6204,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.28,0.0053,31604679
JUNB,LTM,NA,6205,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0021,31506430
KBM1A,LTM,NA,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by SFA,0.28,0.0011,31627418
KBM1A,LTM,NA,NA,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,Western Blotting followed by SFA,0.28,0.0011,31627418
KCNK3,LTM,NA,6278,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting followed by SFA and Migration assay,0.28,0.0021,29387193
KDM1A,LTM,NA,29079,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0021,33057995
KDM1A,LTM,NA,29079,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0021,33057995
KDM1A,LTM,NA,29079,Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0021,28286162
KDM1B,LTM,NA,21577,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs and ALDEFLUOR assay,0.24,0.0021,29137219
KDM5B,LTM,NA,18039,Skin Cancer,NA,Primary,NA,IHC staining and FACs,0.52,0.0032,23146306
KDM5B,LTM,NA,18039,Skin Cancer,NA,Primary,NA,IF staining,0.52,0.0032,20478252
KDM5B,LTM,NA,18039,Skin Cancer,NA,Primary,NA,IHC staining,0.52,0.0032,22669717
KIF11,LTM,NA,6388,Triple Negative Breast Cancer,Ductal Carcinoma,HCC-38,Docetaxel,qRT-PCR followed by SFA,0.2,0.0011,29190901
KIF11,LTM,NA,6388,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Docetaxel,qRT-PCR followed by SFA,0.2,0.0011,29190901
KIT,LTM,NA,6342,Skin Cancer,NA,A-375,NA,SFA and Western Blotting,0.28,0.0180,30717768
KIT,LTM,NA,6342,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.2,0.0180,21520032
KIT,LTM,NA,6342,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.2,0.0180,20028869
KIT,LTM,NA,6342,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.2,0.0180,20028869
KIT,LTM,NA,6342,Non Small Cell Lung Cancer,Carcinoma,H460,Doxorubicin+Cisplatin+Etiopside,SP assay and SFA followed by IF staining and Tumorigenicity assay,0.24,0.0180,18728788
KIT,LTM,NA,6342,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs,0.24,0.0180,20028869
KIT,LTM,NA,6342,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs,0.24,0.0180,20028869
KIT,LTM,NA,6342,Head and Neck Cancer,Carcinoma,HEp-2,NA,FACs followed by Migration assay,0.12,0.0180,30210931
KIT,LTM,NA,6342,Head and Neck Cancer,Squamous Cell Carcinoma,HN13,NA,FACs followed by Migration assay,0.12,0.0180,30210931
KIT,LTM,NA,6342,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.0180,21618577
KIT,LTM,NA,6342,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.0180,21618577
KIT,LTM,NA,6342,Non Small Cell Lung Cancer,NA,LC31,NA,RT- PCR followed by Western Blotting and SFA,0.48,0.0180,21738704
KIT,LTM,NA,6342,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.12,0.0180,30175027
KIT,LTM,NA,6342,Skin Cancer,NA,NA8-MEL,NA,FACs followed by SFA,0.12,0.0180,23915418
KIT,LTM,NA,6342,Skin Cancer,NA,SK-MEL-28,NA,SFA and Western Blotting,0.28,0.0180,30717768
KIT,LTM,NA,6342,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.0180,21618577
KIT,LTM,NA,6342,Lung Cancer,Adenocarcinoma,Primary,NA,SFA and Tumorigenicity assay followed by FACs,0.2,0.0180,25034785
KIT,LTM,NA,6342,Lung Cancer,Squamous Cell Carcinoma,Primary,NA,SFA and Tumorigenicity assay followed by FACs,0.2,0.0180,25034785
KIT,LTM,NA,6342,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.32,0.0180,22199321
KIT,LTM,NA,6342,Non Small Cell Lung Cancer,Large Cell Neuroendocrine Carcinoma,Primary,NA,SFA and Tumorigenicity assay followed by FACs,0.32,0.0180,25034785
KIT,LTM,NA,6342,Pancreatic Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0180,26609473
KIT,LTM,NA,6342,Skin Cancer,NA,Primary,NA,IHC staining,0.32,0.0180,23958542
KIT,LTM,NA,6342,Skin Cancer,NA,Primary,NA,IHC staining,0.32,0.0180,26290260
KIT,LTM,NA,6342,Skin Cancer,NA,Primary,NA,FACs,0.32,0.0180,19491215
KIT,LTM,NA,6342,Hepatic Cancer,NA,Primary,NA,SP assay followed by qRT-PCR and SFA,0.28,0.0180,23104270
KLF4,LTM,NA,6348,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Western Blotting,0.28,0.0891,29559853
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by SP assay and RT-PCR,0.2,0.0891,30477473
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0891,34873829
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR  followed by Western Blotting,0.48,0.0891,28179999
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0891,30555330
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR,0.48,0.0891,33995625
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by SFA,0.48,0.0891,33670440
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR,0.48,0.0891,25906011
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.48,0.0891,28456659
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA and Western Blotting,0.28,0.0891,34278502
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.28,0.0891,29512256
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.28,0.0891,32633423
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.28,0.0891,28822889
KLF4,LTM,NA,6348,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,qRT-PCR,0.2,0.0891,34163012
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,Western Blotting,0.28,0.0891,29287960
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Cyclophosphamide,qRT-PCR,0.28,0.0891,33090711
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by qRT-PCR,0.28,0.0891,33090711
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by RT-PCR,0.28,0.0891,30038266
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by RT-PCR,0.28,0.0891,30038266
KLF4,LTM,NA,6348,Colon Cancer,Adenocarcinoma,CACO-2,NA,SP assay followed by qPCR and SFA,0.2,0.0891,32367652
KLF4,LTM,NA,6348,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,Western Blotting followed by IF staining and SFA,0.52,0.0891,29575240
KLF4,LTM,NA,6348,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by Western Blotting,0.52,0.0891,31585633
KLF4,LTM,NA,6348,Lung Cancer,Adenocarcinoma,CL1-0,NA,CFA and SFA followed by Western Blotting,0.28,0.0891,35163585
KLF4,LTM,NA,6348,Skin Cancer,NA,D10,NA,SFA and CFA followed by qRT-PCR,0.2,0.0891,26208390
KLF4,LTM,NA,6348,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by RT-PCR and IF staining,0.44,0.0891,23418515
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0891,34873829
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0891,30555330
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,RT-PCR,0.48,0.0891,25906011
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR,0.48,0.0891,29651165
KLF4,LTM,NA,6348,Small Cell Lung Cancer,NA,H20,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.48,0.0891,33969609
KLF4,LTM,NA,6348,Small Cell Lung Cancer,NA,H20,Etopside,SFA followed by qRT-PCR and Western Blotting,0.48,0.0891,33969609
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,qRT-PCR followed by SFA,0.2,0.0891,33670440
KLF4,LTM,NA,6348,Small Cell Lung Cancer,Carcinoma,H2227,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.48,0.0891,33969609
KLF4,LTM,NA,6348,Small Cell Lung Cancer,Carcinoma,H2227,Etopside,SFA followed by qRT-PCR and Western Blotting,0.48,0.0891,33969609
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Adenocarcinoma,H2228,NA,SFA followed by Western Blotting,0.28,0.0891,26517679
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Adenocarcinoma,H3122,NA,SFA followed by Western Blotting,0.28,0.0891,26517679
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.2,0.0891,28456659
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,CFA and SFA followed by Western Blotting,0.28,0.0891,35163585
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,SFA followed by FACs and SP assay,0.28,0.0891,30092824
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.2,0.0891,31658996
KLF4,LTM,NA,6348,Breast Cancer,Carcinoma,HCC1569,NA,Western Blotting followed by SFA,0.28,0.0891,34889737
KLF4,LTM,NA,6348,Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,Western Blotting followed by SFA,0.28,0.0891,34889737
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,FACs,0.28,0.0891,30091683
KLF4,LTM,NA,6348,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,NA,Western Blotting followed by SFA,0.28,0.0891,30326469
KLF4,LTM,NA,6348,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0891,35155201
KLF4,LTM,NA,6348,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and RT-PCR,0.48,0.0891,31120140
KLF4,LTM,NA,6348,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.48,0.0891,27997180
KLF4,LTM,NA,6348,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by SFA,0.48,0.0891,32037723
KLF4,LTM,NA,6348,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.48,0.0891,31544978
KLF4,LTM,NA,6348,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SFA followed by Western Blotting,0.28,0.0891,27997180
KLF4,LTM,NA,6348,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,qRT-PCR,0.28,0.0891,24145190
KLF4,LTM,NA,6348,Head and Neck Cancer,Squamous Cell Carcinoma,HN-1,NA,SFA followed by RT-PCR,0.2,0.0891,25024430
KLF4,LTM,NA,6348,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,qPCR and SFA,0.2,0.0891,26448762
KLF4,LTM,NA,6348,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA and RT-PCR,0.32,0.0891,31120140
KLF4,LTM,NA,6348,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,qRT-PCR,0.32,0.0891,30772447
KLF4,LTM,NA,6348,Colon Cancer,Adenocarcinoma,HT-29,NA,qRT-PCR followed by SFA,0.32,0.0891,32037723
KLF4,LTM,NA,6348,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.32,0.0891,31544978
KLF4,LTM,NA,6348,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.32,0.0891,26634106
KLF4,LTM,NA,6348,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by RT-PCR,0.2,0.0891,30397177
KLF4,LTM,NA,6348,Lung Cancer,Adenocarcinoma,LHK2,NA,SP assay followed by qRT-PCR and CFA,0.2,0.0891,27418136
KLF4,LTM,NA,6348,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by qRT-PCR and SFA,0.48,0.0891,33791297
KLF4,LTM,NA,6348,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.0891,31595560
KLF4,LTM,NA,6348,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.0891,33305893
KLF4,LTM,NA,6348,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.0891,33419140
KLF4,LTM,NA,6348,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting,0.48,0.0891,31591207
KLF4,LTM,NA,6348,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,Western Blotting and SFA,0.48,0.0891,29185119
KLF4,LTM,NA,6348,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.48,0.0891,29287960
KLF4,LTM,NA,6348,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR followed by SFA,0.48,0.0891,30214607
KLF4,LTM,NA,6348,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR,0.48,0.0891,30615901
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by qRT-PCR and Western Blotting,0.48,0.0891,35401817
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and IHC staining,0.48,0.0891,30131941
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.0891,34451892
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.0891,29137219
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.0891,30262865
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.48,0.0891,29287960
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.48,0.0891,29316250
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,Western Blotting followed by SFA,0.48,0.0891,29880481
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cyclophosphamide,qRT-PCR,0.48,0.0891,33090711
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.0891,33090711
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.28,0.0891,30262865
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.2,0.0891,32142918
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting and IF staining,0.52,0.0891,32160650
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting,0.52,0.0891,34278502
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.0891,27157616
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.0891,29512256
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.0891,32633423
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by RT-PCR,0.52,0.0891,33725258
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,MKN45,Acetylcholine,SFA followed by qRT-PCR,0.52,0.0891,30207200
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.0891,28822889
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,MKN74,NA,SFA followed by qRT-PCR,0.2,0.0891,28822889
KLF4,LTM,NA,6348,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR,0.2,0.0891,34163012
KLF4,LTM,NA,6348,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.2,0.0891,26298849
KLF4,LTM,NA,6348,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.2,0.0891,31508487
KLF4,LTM,NA,6348,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR,0.2,0.0891,31508487
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,CFA and SFA followed by IF staining and RT-PCR,0.44,0.0891,25960639
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs followed by SFA and RT-PCR,0.44,0.0891,22935675
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qRT-PCR,0.44,0.0891,31966561
KLF4,LTM,NA,6348,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-131,NA,Western Blotting followed by IF staining and SFA,0.52,0.0891,29575240
KLF4,LTM,NA,6348,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-131,Cisplatin,SFA followed by Western Blotting,0.52,0.0891,31585633
KLF4,LTM,NA,6348,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR,0.2,0.0891,32142918
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,CFA and SFA followed by IF staining and RT-PCR,0.44,0.0891,25960639
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Carcinoma,SUM159,Paclitaxel,SFA followed by qRT-PCR and Western Blotting,0.48,0.0891,35401817
KLF4,LTM,NA,6348,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs and RT-PCR,0.48,0.0891,29249663
KLF4,LTM,NA,6348,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR,0.2,0.0891,31508487
KLF4,LTM,NA,6348,Dukes Type C Colon Cancer,Adenocarcinoma,SW48,Doxorubicin,Western Blotting,0.28,0.0891,27517620
KLF4,LTM,NA,6348,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Western Blotting,0.28,0.0891,29559853
KLF4,LTM,NA,6348,Bladder Cancer,Carcinoma,T24,NA,SP assay followed by RT-PCR and SFA,0.28,0.0891,25020236
KLF4,LTM,NA,6348,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.0891,30326469
KLF4,LTM,NA,6348,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.0891,31595560
KLF4,LTM,NA,6348,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by RT-PCR and IHC staining,0.48,0.0891,30131941
KLF4,LTM,NA,6348,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR,0.2,0.0891,33575080
KLF4,LTM,NA,6348,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by RT-PCR,0.2,0.0891,30397177
KLF4,LTM,NA,6348,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SP assay followed by RT-PCR and SFA,0.2,0.0891,25020236
KLF4,LTM,NA,6348,Colon Cancer,Adenocarcinoma,WIDR,NA,SFA followed by RT-PCR,0.2,0.0891,25625841
KLF4,LTM,NA,6348,Skin Cancer,NA,WM266-4,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0891,31817719
KLF4,LTM,NA,6348,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN19,NA,SFA followed by RT-PCR,0.2,0.0891,25024430
KLF4,LTM,NA,6348,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN26,NA,SFA followed by RT-PCR,0.2,0.0891,25024430
KLF4,LTM,NA,6348,Breast Cancer,Ductal Carcinoma,ZR-75-30,NA,qRT-PCR followed by SFA,0.2,0.0891,30478301
KLF4,LTM,NA,6348,Breast Cancer,NA,Primary,NA,Western Blotting,0.36,0.0891,29185119
KLF4,LTM,NA,6348,Colon Cancer,NA,Primary,NA,IHC staining followed by qRT-PCR,0.6,0.0891,31491003
KLF4,LTM,NA,6348,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining and IF staining followed by SFA,0.92,0.0891,32019273
KLF4,LTM,NA,6348,Head and Neck Cancer,NA,Primary,NA,IHC staining followed by IF staining and SFA,0.92,0.0891,32019273
KLF4,LTM,NA,6348,Head and Neck Cancer,NA,Primary,NA,IF staining and SFA,0.92,0.0891,32019273
KLF4,LTM,NA,6348,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.92,0.0891,30528285
KLF4,LTM,NA,6348,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.92,0.0891,19450560
KLF4,LTM,NA,6348,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0891,31506430
KLF4,LTM,NA,6348,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.0891,28356964
KLF4,LTM,NA,6348,Glioblastoma Multiforme,NA,Primary,NA,Isolation of autofluorescence cells followed by SFA and qRT-PCR,0.28,0.0891,33669350
KLF4,LTM,NA,6348,Head and Neck Cancer,Cutaneous Squamous Cell Carcinoma,Primary,NA,IHC staining and IF staining followed by qRT-PCR,0.92,0.0891,32850316
KLF4,LTM,NA,6348,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by Western Blotting,0.92,0.0891,21292542
KLF5,LTM,NA,6349,Colon Cancer,Adenocarcinoma,CACO-2,NA,SFA followed by RT-PCR,0.2,0.0042,29312609
KLF5,LTM,NA,6349,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.2,0.0042,29312609
KLF5,LTM,NA,6349,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qPCR,0.2,0.0042,31966561
KLK10,LTM,NA,6358,Bladder Cancer,NA,Primary,NA,SFA followed by IF staining,0.32,0.0032,19961489
KRT19,LTM,NA,6436,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by qRT-PCR,0.2,0.0074,30819221
KRT19,LTM,NA,6436,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting followed by SFA,0.28,0.0074,30819221
KRT19,LTM,NA,6436,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by qRT-PCR,0.2,0.0074,30819221
KRT5,LTM,NA,6442,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.28,0.0064,21167769
LDHA,LTM,NA,6535,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0053,34178639
LGR5,LTM,NA,4504,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,IF staining and  FACs followed by SFA,0.36,0.0753,25966742
LGR5,LTM,NA,4504,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by CFA and Western Blotting,0.28,0.0753,32637578
LGR5,LTM,NA,4504,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and SFA,0.28,0.0753,34246759
LGR5,LTM,NA,4504,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qPCR,0.28,0.0753,31796785
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0753,31285270
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,CACO-2,5-Fluorouracil,qPCR,0.64,0.0753,33946505
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,CACO-2,NA,SP assay followed by qPCR and SFA,0.64,0.0753,32367652
LGR5,LTM,NA,4504,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0753,31285270
LGR5,LTM,NA,4504,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0753,31285270
LGR5,LTM,NA,4504,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,Western Blotting followed by SFA,0.64,0.0753,31964531
LGR5,LTM,NA,4504,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,RT-PCR followed by SFA,0.64,0.0753,32066912
LGR5,LTM,NA,4504,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by qPCR,0.64,0.0753,29449559
LGR5,LTM,NA,4504,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.64,0.0753,23418515
LGR5,LTM,NA,4504,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by CFA and Western Blotting,0.28,0.0753,32637578
LGR5,LTM,NA,4504,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by CFA and Western Blotting,0.28,0.0753,32637578
LGR5,LTM,NA,4504,Non Small Cell Lung Cancer,Carcinoma,H460,NA,qRT-PCR and SFA,0.28,0.0753,34246759
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,qRT-PCR followed by Western Blotting and SFA,0.48,0.0753,30912138
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR and Western Blotting followed by SFA,0.48,0.0753,32037723
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by IF staining and FACs,0.48,0.0753,22745705
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and qRT-PCR,0.48,0.0753,29307822
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.48,0.0753,27894099
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,Western Blotting,0.48,0.0753,29354056
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,SFA and IF staining,0.48,0.0753,26745821
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR,0.48,0.0753,29902974
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by CFA,0.48,0.0753,26840024
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by SFA,0.48,0.0753,32066912
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qPCR,0.48,0.0753,28825721
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.48,0.0753,22925500
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.48,0.0753,22329848
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,SFA and FACs,0.48,0.0753,24039918
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.48,0.0753,23345327
LGR5,LTM,NA,4504,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,qRT-PCR,0.2,0.0753,24145190
LGR5,LTM,NA,4504,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SP assay followed by Tumorigenicity assay and RT-PCR,0.2,0.0753,21435460
LGR5,LTM,NA,4504,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by Western Blotting,0.28,0.0753,28446252
LGR5,LTM,NA,4504,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by qRT-PCR,0.28,0.0753,34628473
LGR5,LTM,NA,4504,Gastric Cancer,Carcinoma,HGC-27,NA,RT-PCR,0.28,0.0753,32724313
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0753,31285270
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by Western Blotting and RT-PCR,0.64,0.0753,22384170
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,MACs followed by qPCR and Western Blotting,0.64,0.0753,30337351
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR and Western Blotting followed by SFA,0.64,0.0753,32037723
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs and IF staining,0.64,0.0753,24789370
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by IF staining and FACs,0.64,0.0753,22745705
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and Western Blotting,0.64,0.0753,24039918
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.64,0.0753,27894099
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,Western Blotting followed by SFA,0.64,0.0753,31964531
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and IF staining,0.64,0.0753,26745821
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker followed by qRT-PCR,0.64,0.0753,33744851
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.64,0.0753,35267511
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,qRT-PCR,0.64,0.0753,30772447
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR,0.64,0.0753,29902974
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.64,0.0753,29660380
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and RT-PCR,0.64,0.0753,28464221
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qPCR,0.64,0.0753,28825721
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by Tumorigenicity assay and RT-PCR,0.64,0.0753,21435460
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.64,0.0753,22329848
LGR5,LTM,NA,4504,Gastric Cancer,Carcinoma,KATO-III,NA,FACs followed by CFA,0.12,0.0753,27891816
LGR5,LTM,NA,4504,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR,0.2,0.0753,26840266
LGR5,LTM,NA,4504,Dukes Type B Colon Cancer,Adenocarcinoma,LS174T,NA,FACs followed by Western Blotting and RT-PCR,0.6,0.0753,22384170
LGR5,LTM,NA,4504,Dukes Type B Colon Cancer,Adenocarcinoma,LS180,NA,RT-PCR,0.2,0.0753,29902974
LGR5,LTM,NA,4504,Gastric Cancer,Adenocarcinoma,MGC-803,NA,RT-PCR,0.2,0.0753,32724313
LGR5,LTM,NA,4504,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.2,0.0753,26840266
LGR5,LTM,NA,4504,Gastric Cancer,Adenocarcinoma,MKN28,NA,FACs followed by SFA and IF staining,0.36,0.0753,28383763
LGR5,LTM,NA,4504,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA and IF staining,0.36,0.0753,28383763
LGR5,LTM,NA,4504,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.36,0.0753,28970066
LGR5,LTM,NA,4504,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.36,0.0753,34628473
LGR5,LTM,NA,4504,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.36,0.0753,32863948
LGR5,LTM,NA,4504,Gastric Cancer,Adenocarcinoma,MKN45,Cisplatin,FACs,0.36,0.0753,30250614
LGR5,LTM,NA,4504,Gastric Cancer,Adenocarcinoma,MKN74,Cisplatin,FACs,0.12,0.0753,30250614
LGR5,LTM,NA,4504,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.0753,28446252
LGR5,LTM,NA,4504,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.2,0.0753,27531902
LGR5,LTM,NA,4504,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by IF staining,0.24,0.0753,29689047
LGR5,LTM,NA,4504,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by Western Blotting,0.28,0.0753,28970066
LGR5,LTM,NA,4504,Gastric Cancer,Adenocarcinoma,ST2957,NA,SFA followed by qRT-PCR,0.2,0.0753,32863948
LGR5,LTM,NA,4504,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0753,31285270
LGR5,LTM,NA,4504,Dukes Type C Colon Cancer,Adenocarcinoma,SW1417,NA,RT-PCR followed by SFA,0.2,0.0753,29660380
LGR5,LTM,NA,4504,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0753,31285270
LGR5,LTM,NA,4504,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA and qRT-PCR,0.64,0.0753,29307822
LGR5,LTM,NA,4504,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by SFA and Western Blotting,0.64,0.0753,28560069
LGR5,LTM,NA,4504,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs for CSC marker followed by qRT-PCR,0.64,0.0753,33744851
LGR5,LTM,NA,4504,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA and RT-PCR,0.64,0.0753,28464221
LGR5,LTM,NA,4504,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by Tumorigenicity assay and RT-PCR,0.64,0.0753,21435460
LGR5,LTM,NA,4504,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0753,31285270
LGR5,LTM,NA,4504,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,IHC staining followed by SFA and qRT-PCR,0.64,0.0753,21412503
LGR5,LTM,NA,4504,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by Western Blotting,0.64,0.0753,27894099
LGR5,LTM,NA,4504,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SP assay followed by SFA and Western Blotting,0.64,0.0753,28560069
LGR5,LTM,NA,4504,Colon Cancer,Carcinoma,T84,NA,FACs and Western Blotting followed by IF staining and SFA,0.64,0.0753,31285270
LGR5,LTM,NA,4504,Colon Cancer,Adenocarcinoma,WIDR,NA,SFA followed by RT-PCR,0.2,0.0753,25625841
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,RT-PCR followed by Western Blotting,0.64,0.0753,28249897
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,SFA followed by FACs and IHC staining,0.64,0.0753,18765800
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,IHC staining,0.64,0.0753,29102042
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,IHC staining,0.64,0.0753,29328371
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,IHC staining,0.64,0.0753,31000786
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,IHC staining,0.64,0.0753,31186779
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,SFA and IF staining,0.64,0.0753,26745821
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,RT-PCR,0.64,0.0753,21125339
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,RT-PCR,0.64,0.0753,31057717
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.64,0.0753,25483065
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.64,0.0753,27197180
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.64,0.0753,23643941
LGR5,LTM,NA,4504,Gastric Cancer,NA,Primary,NA,IHC staining and RT-PCR,0.6,0.0753,28053963
LGR5,LTM,NA,4504,Gastric Cancer,NA,Primary,NA,IF staining,0.6,0.0753,29604141
LGR5,LTM,NA,4504,Non Small Cell Lung Cancer,NA,Primary,NA,qRT-PCR followed by IHC staining,0.6,0.0753,25881507
LGR5,LTM,NA,4504,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.6,0.0753,33109579
LGR5,LTM,NA,4504,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.32,0.0753,23438436
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,IF staining,0.64,0.0753,35008827
LGR5,LTM,NA,4504,Colon Cancer,NA,Primary,NA,IHC staining,0.64,0.0753,34657081
LGR5,LTM,NA,4504,Gastric Cancer,NA,Primary,NA,Western Blotting followed by SFA,0.6,0.0753,31309567
LGR5,LTM,NA,4504,Gastric Cancer,NA,Primary,NA,IHC staining,0.6,0.0753,34160355
LGR5,LTM,NA,4504,Gastric Cancer,NA,Primary,NA,SFA followed by FACs,0.6,0.0753,32350414
LGR5,LTM,NA,4504,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.32,0.0753,35123536
LGR6,LTM,NA,19719,Lung Cancer,Adenocarcinoma,Primary,NA,FACs followed by CFA and Tumorigenicity assay,0.2,0.0042,27197183
LIN28A,LTM,NA,15986,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR  followed by Western Blotting,0.48,0.0138,28179999
LIN28A,LTM,NA,15986,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and qRT-PCR  followed by SFA and Tumorigenicity assay,0.48,0.0138,29262597
LIN28A,LTM,NA,15986,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qRT-PCR followed by Western Blotting,0.48,0.0138,28703793
LIN28A,LTM,NA,15986,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qRT-PCR,0.48,0.0138,27996162
LIN28A,LTM,NA,15986,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.0138,28703793
LIN28A,LTM,Up,15986,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,BME based 3D culture followed by SFA and qRT-PCR,0.2,0.0138,34277782
LIN28A,LTM,Up,15986,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,BME based 3D culture followed by SFA and qRT-PCR,0.2,0.0138,34277782
LIN28A,LTM,NA,15986,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,qRT-PCR,0.2,0.0138,24145190
LIN28A,LTM,NA,15986,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0138,29106390
LIN28A,LTM,NA,15986,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and Tumorigenicity assay,0.28,0.0138,28938607
LIN28A,LTM,NA,15986,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0138,29106390
LIN28A,LTM,NA,15986,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qRT-PCR followed by Western Blotting,0.48,0.0138,28703793
LIN28A,LTM,NA,15986,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.48,0.0138,27996162
LIN28A,LTM,NA,15986,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,Epirubicin,SFA followed  by FACs and SP assay,0.12,0.0138,18083101
LIN28A,LTM,NA,15986,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.2,0.0138,28947139
LIN28A,LTM,NA,15986,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by FACs and Tumorigenicity assay,0.12,0.0138,28938607
LIN28A,LTM,NA,15986,Breast Cancer,NA,Primary,NA,FACs,0.2,0.0138,28588211
LIN28A,LTM,NA,15986,Head and Neck Cancer,NA,Primary,NA,FACs,0.2,0.0138,21322081
LIN28A,LTM,Up,15986,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,FACs for CSC marker followed by Western Blotting,0.36,0.0138,34277782
LIN28A-,LTM,NA,15986,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and CFA followed by MACs,0.12,0.0011,29187905
LIN28A-,LTM,NA,15986,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and CFA followed by MACs,0.12,0.0011,29187905
LIN28B,LTM,NA,32207,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0032,34052833
LIN28B,LTM,NA,32207,Pancreatic Cancer,NA,Primary,NA,MACs followed by SFA and qRT-PCR,0.48,0.0032,26609473
LIN28B,LTM,NA,32207,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0032,28416482
LINC00324,LTM,NA,26628,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.2,0.0021,32128906
LINC00511,LTM,NA,43564,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.28,0.0011,30482236
LINC01133,LTM,NA,49447,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.12,0.0011,31283068
LINC01133,LTM,NA,49447,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.28,0.0011,31283068
LINC01619,LTM,NA,27409,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,qRT-PCR and Western Blotting followed by SFA and Tumorigenicity assay,0.48,0.0011,32655789
LINC01638,LTM,NA,52425,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,qRT-PCR followed by SFA and Migration Invasion assay,0.2,0.0011,30002443
LINC01638,LTM,NA,52425,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA and Migration Invasion assay,0.2,0.0011,30002443
LINC-ROR,LTM,NA,43773,Non Small Cell Lung Cancer,Adenocarcinoma,H3122,NA,SFA followed by FACs and qRT-PCR,0.32,0.0021,29950868
LINC-ROR,LTM,NA,43773,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.2,0.0021,28580169
LncCCAT1,LTM,NA,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and SFA and Migration Invasion assay,0.2,0.0011,31695775
LncCCAT1,LTM,NA,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFAand Migration assay,0.2,0.0011,31695775
LncCCAT1,LTM,NA,NA,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and SFA and Migration Invasion assay,0.2,0.0011,31695775
LncCCAT1,LTM,NA,NA,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFAand Migration assay,0.2,0.0011,31695775
LOX,LTM,NA,6664,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Western Blotting,0.28,0.0074,34502547
LPAR3,LTM,NA,14298,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by qPCR,0.2,0.0021,35216080
LPAR6,LTM,NA,15520,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by qPCR,0.2,0.0011,35216080
LRIG1,LTM,NA,17360,Colon Cancer,Adenocarcinoma,HT-29,NA,MACs followed by qPCR and Western Blotting,0.6,0.0053,30337351
LRP1,LTM,NA,6692,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0011,27706681
LRP5,LTM,NA,6697,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.2,0.0042,31835579
LRP5,LTM,NA,6697,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qRT-PCR,0.2,0.0042,31966561
LRP5,LTM,NA,6697,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qPCR,0.2,0.0042,31966561
LTA,LTM,NA,6709,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0011,30397177
LTA,LTM,NA,6709,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0011,30397177
LUCAT1,LTM,NA,48498,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and FACs,0.32,0.0021,31300015
LUCAT1,LTM,NA,48498,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by qRT-PCR and FACs,0.32,0.0021,31300015
MACsC1,LTM,NA,30215,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil,SFA followed by Western Blotting and qRT-PCR,0.48,0.0042,28990068
MACsC1,LTM,NA,30215,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0042,30082743
MACsC1,LTM,NA,30215,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,5-Fluorouracil,SFA followed by Western Blotting and qRT-PCR,0.48,0.0042,28990068
MACsC1-AS1,LTM,NA,41257,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.2,0.0011,32401390
MACsC1-AS1,LTM,NA,41257,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.2,0.0011,32401390
MAGEA3,LTM,NA,6801,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,SP assay followed by RT-PCR and Western Blotting,0.48,0.0021,25031712
MAGEB2,LTM,NA,6809,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR,0.2,0.0021,32065779
MAGEB2,LTM,NA,6809,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.2,0.0021,32065779
MALAT1,LTM,NA,29665,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,FACs,0.12,0.0074,25811929
MALAT1,LTM,NA,29665,Hepatic Cancer,Carcinoma,Hep-G2,NA,SFA followed by qRT-PCR,0.2,0.0074,32626943
MALAT1,LTM,NA,29665,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.2,0.0074,32626943
MALAT1,LTM,NA,29665,Gastric Cancer,Adenocarcinoma,MKN45,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.0074,31037832
MALAT1,LTM,NA,29665,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.0074,31037832
MAPK3,LTM,NA,6877,Glioblastoma,NA,U-373MG,NA,SFA followed by Western Blotting,0.28,0.0032,29115404
MAPK3,LTM,NA,6877,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting,0.28,0.0032,29115404
MAPK8,LTM,NA,6881,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR followed by SFA,0.2,0.0032,30190333
MCAM,LTM,NA,6934,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.12,0.0064,30175027
MCAM,LTM,NA,6934,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.12,0.0064,35055160
MCL1,LTM,NA,6943,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR and Western Blotting,0.48,0.0032,23418490
MCL1,LTM,NA,6943,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,SP assay followed by RT-PCR and Western Blotting,0.48,0.0032,23418490
MCL1,LTM,NA,6943,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay followed by RT-PCR and Western Blotting,0.48,0.0032,23418490
MCL1,LTM,NA,6943,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting and FACs,0.4,0.0032,28978427
MDM2,LTM,NA,6973,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0042,31506430
MET,LTM,NA,402,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.2,0.0191,27996162
MET,LTM,NA,7029,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qRT-PCR,0.2,0.0191,26391180
MET,LTM,NA,7029,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.2,0.0191,27996162
MET,LTM,NA,7029,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.2,0.0191,30119228
MET,LTM,NA,7029,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,qRT-PCR,0.2,0.0191,26035122
MET,LTM,NA,7029,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,qRT-PCR,0.2,0.0191,26035122
MET,LTM,NA,7029,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by RT-PCR,0.2,0.0191,29100320
MET,LTM,NA,7029,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,Migration and Invasion assay followed by qRT-PCR,0.2,0.0191,23592398
MET,LTM,NA,7029,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,qRT-PCR,0.2,0.0191,26035122
MET,LTM,NA,7029,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR and SFA,0.2,0.0191,35413424
MET,LTM,NA,7029,Triple Negative Breast Cancer,Carcinoma,MDA-MB-157,NA,Western Blotting,0.28,0.0191,28966724
MET,LTM,NA,7029,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.2,0.0191,35413424
MET,LTM,NA,7029,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,Western Blotting,0.28,0.0191,28966724
MET,LTM,NA,7029,Gastric Cancer,Adenocarcinoma,MKN45,NA,qRT-PCR,0.2,0.0191,32099405
MET,LTM,NA,7029,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting and SFA,0.28,0.0191,34349642
MET,LTM,NA,7029,Pancreatic Cancer,Carcinoma,PANC-1,NA,Migration and Invasion assay followed by qRT-PCR,0.28,0.0191,23592398
MET,LTM,NA,7029,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.28,0.0191,26298849
MET,LTM,NA,7029,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR,0.2,0.0191,26391180
MET,LTM,NA,7029,Glioblastoma,NA,U-373MG,NA,SFA followed by Western Blotting,0.28,0.0191,29115404
MET,LTM,NA,7029,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting,0.28,0.0191,29115404
MET,LTM,NA,7029,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IF staining,0.32,0.0191,25320014
MET,LTM,NA,7029,Lung Cancer,NA,Primary,NA,IHC staining followed by FACs,0.52,0.0191,19536353
MET,LTM,NA,7029,Skin Cancer,NA,Primary,NA,SFA followed by FACs,0.2,0.0191,20236249
MET,LTM,NA,7029,Glioblastoma Multiforme,NA,Primary,NA,SFA and qPCR followed by Western Blotting and IHC staining,0.96,0.0191,29963265
METTL3,LTM,NA,17563,Bladder Cancer,Carcinoma,5637,NA,qRT-PCR followed by Western Blotting,0.48,0.0011,32676121
METTL3,LTM,NA,17563,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,qRT-PCR followed by Western Blotting,0.48,0.0011,32676121
MICA,LTM,NA,7090,Glioblastoma,NA,U-251,NA,SFA followed by FACs,0.12,0.0021,31288857
MICA,LTM,NA,7090,Glioblastoma,NA,U-87MG,NA,SFA followed by FACs,0.12,0.0021,31288857
MIR127,LTM,NA,31509,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker followed by qRT-PCR,0.2,0.0042,33744851
MIR127,LTM,NA,31509,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,SFA followed by qPCR and Tumorigenicity assay,0.2,0.0042,27869168
MIR127,LTM,NA,31509,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs for CSC marker followed by qRT-PCR,0.2,0.0042,33744851
MIR135B,LTM,NA,31760,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR,0.2,0.0032,32351328
MIR145,LTM,Down,31532,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture followed by qRT-PCR,0.2,0.0032,34277782
MIR155,LTM,NA,31542,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.2,0.0053,29103027
MIR181A1,LTM,NA,31590,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.2,0.0042,35029026
MIR181A1,LTM,NA,31590,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.2,0.0042,35029026
MIR181C,LTM,Down,31552,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture followed by qRT-PCR,0.2,0.0032,34277782
MIR193A,LTM,NA,31563,Gastric Cancer,Adenocarcinoma,AGS,NA,FACs for CSC marker followed by RT-PCR,0.2,0.0042,30485589
MIR193A,LTM,NA,31563,Gastric Cancer,Carcinoma,KATO-III,NA,FACs for CSC marker followed by RT-PCR,0.2,0.0042,30485589
MIR193A,LTM,NA,31563,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by RT-PCR,0.2,0.0042,30485589
MIR195,LTM,Down,31566,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,SFA followed by qRT-PCR,0.2,0.0032,33109220
MIR195,LTM,Down,31566,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by qRT-PCR,0.2,0.0032,33109220
MIR196B,LTM,Up,31790,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture followed by qRT-PCR,0.2,0.0021,34277782
MIR19A,LTM,NA,31574,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0064,28431267
MIR19A,LTM,NA,31574,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0064,28431267
MIR19B1,LTM,NA,31575,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0042,28431267
MIR19B1,LTM,NA,31575,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0042,28431267
MIR200B,LTM,NA,31579,Gastric Cancer,Adenocarcinoma,BGC-823,NA,qRT-PCR,0.2,0.0032,32926650
MIR200B,LTM,NA,31579,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,qRT-PCR,0.2,0.0032,32926650
MIR200C,LTM,NA,31580,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.2,0.0074,32633423
MIR200C,LTM,NA,31580,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.2,0.0074,32633423
MIR205,LTM,NA,31583,Breast Cancer,Ductal Carcinoma,Primary,NA,qRT-PCR followed by Invasion assay and Tumorigenicity assay,0.28,0.0032,30050081
MIR21,LTM,NA,31586,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.2,0.0085,23894315
MIR21,LTM,NA,31586,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR and Tumorigenicity assay,0.2,0.0085,22072622
MIR21,LTM,NA,31586,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.2,0.0085,23894315
MIR21,LTM,NA,31586,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR,0.2,0.0085,27644439
MIR21,LTM,NA,31586,Glioblastoma,NA,U-87MG,NA,SFA followed by RT-PCR,0.2,0.0085,25394756
MIR212,LTM,Up,31589,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture followed by qRT-PCR,0.2,0.0021,34277782
MIR25,LTM,NA,31609,Gastric Cancer,Adenocarcinoma,MKN28,NA,FACs for CSC marker followed by qRT-PCR,0.2,0.0032,29178392
MIR25,LTM,NA,31609,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by qRT-PCR,0.2,0.0032,29178392
MIR25,LTM,NA,31609,Gastric Cancer,NA,Primary,NA,FACs for CSC marker followed by qRT-PCR,0.28,0.0032,29178392
MIR2861,LTM,NA,38221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs and qRT-PCR,0.32,0.0032,29620443
MIR2861,LTM,NA,38221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs and qRT-PCR,0.32,0.0032,29620443
MIR30A,LTM,Down,31624,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture followed by qRT-PCR,0.2,0.0085,34277782
MIR31,LTM,Up,31630,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture followed by qRT-PCR,0.24,0.0064,34277782
MIR3120,LTM,NA,38295,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and qRT-PCR,0.32,0.0011,29307822
MIR3120,LTM,NA,38295,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA and qRT-PCR,0.32,0.0011,29307822
MIR410,LTM,NA,32065,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by SFA and Tumorigenicity assay,0.2,0.0011,28076327
MIR410,LTM,NA,32065,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,qRT-PCR followed by SFA and Tumorigenicity assay,0.2,0.0011,28076327
MIR483,LTM,NA,32340,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.2,0.0053,27511210
MIR490,LTM,Down,32075,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture followed by qRT-PCR,0.2,0.0011,34277782
MIR497,LTM,Down,32088,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,SFA followed by qRT-PCR,0.2,0.0053,33109220
MIR497,LTM,Down,32088,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by qRT-PCR,0.2,0.0053,33109220
MIR5100,LTM,NA,43540,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by FACs and SFA,0.32,0.0011,29144562
MIR5100,LTM,NA,43540,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,qRT-PCR followed by FACs and SFA,0.32,0.0011,29144562
MIR5188,LTM,NA,43502,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR and IF staining followed by SFA and Migration assay,0.44,0.0011,31604679
MIR5188,LTM,NA,43502,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,RT-PCR and IF staining followed by SFA and Migration assay,0.44,0.0011,31604679
MIR520C,LTM,NA,32108,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.2,0.0011,32633423
MIR520C,LTM,NA,32108,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.2,0.0011,32633423
MIR582,LTM,Up,32838,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture followed by qRT-PCR,0.2,0.0064,34277782
MIR582,LTM,NA,32838,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and Tumorigenicity assay followed by SFA,0.2,0.0064,26468775
MIR582,LTM,NA,32838,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H1703,NA,qRT-PCR and Tumorigenicity assay followed by SFA,0.2,0.0064,26468775
MIR655,LTM,NA,32911,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR and IF staining followed by SFA and Migration Invasion assay,0.44,0.0011,29321644
MIR655,LTM,NA,32911,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,RT-PCR and IF staining followed by SFA and Migration Invasion assay,0.44,0.0011,29321644
MIR655,LTM,NA,32911,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,RT-PCR and IF staining followed by SFA and Migration Invasion assay,0.44,0.0011,29321644
MIR744,LTM,NA,33658,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qRT-PCR and FACs,0.32,0.0021,26485754
MIR744,LTM,NA,33658,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR and FACs and Tumorigenicity assay,0.32,0.0021,26485754
MIR873,LTM,Up,33663,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture followed by qRT-PCR,0.2,0.0021,34277782
MIR99A,LTM,Down,31650,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture followed by qRT-PCR,0.2,0.0021,34277782
MIRLET7C,LTM,Down,31480,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture followed by qRT-PCR,0.24,0.0042,34277782
MIRLET7C,LTM,Down,31480,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,BME based 3D culture followed by SFA and qRT-PCR,0.2,0.0042,34277782
MIRLET7C,LTM,Down,31480,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,BME based 3D culture followed by SFA and qRT-PCR,0.2,0.0042,34277782
MIRLET7C,LTM,Down,31480,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,FACs for CSC marker followed by qRT-PCR,0.28,0.0042,34277782
MIRLET7F1,LTM,Down,31483,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture followed by qRT-PCR,0.2,0.0053,34277782
MIRLET7F1,LTM,Down,31483,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,BME based 3D culture followed by SFA and qRT-PCR,0.2,0.0053,34277782
MIRLET7F1,LTM,Down,31483,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,BME based 3D culture followed by SFA and qRT-PCR,0.2,0.0053,34277782
MIRLET7F1,LTM,Down,31483,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,FACs for CSC marker followed by qRT-PCR,0.28,0.0053,34277782
MIRLET7G,LTM,Down,31485,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture followed by qRT-PCR,0.2,0.0032,34277782
MIRLET7G,LTM,Down,31485,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,BME based 3D culture followed by SFA and qRT-PCR,0.2,0.0032,34277782
MIRLET7G,LTM,Down,31485,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,BME based 3D culture followed by SFA and qRT-PCR,0.2,0.0032,34277782
MIRLET7G,LTM,Down,31485,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,FACs for CSC marker followed by qRT-PCR,0.28,0.0032,34277782
MME,LTM,NA,7154,Head and Neck Cancer,Carcinoma,Detroit-562,NA,SFA followed by FACs,0.12,0.0053,24874475
MME,LTM,NA,7154,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by FACs,0.12,0.0053,24874475
MME,LTM,NA,7154,Colon Cancer,Carcinoma,HCT116,NA,qRT-PCR followed by Western Blotting and SFA,0.48,0.0053,30912138
MME,LTM,NA,7154,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.48,0.0053,22329848
MME,LTM,NA,7154,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.12,0.0053,22329848
MMP9,LTM,NA,7176,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0021,31506430
MS4A1,LTM,NA,7315,Skin Cancer,NA,A-375,NA,FACs,0.12,0.0085,27476721
MS4A1,LTM,NA,7315,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SP assay,0.12,0.0085,22963768
MS4A1,LTM,NA,7315,Skin Cancer,NA,HS 294T,NA,SFA followed by FACs,0.12,0.0085,34703819
MS4A1,LTM,NA,7315,Skin Cancer,NA,SK-MEL-1,NA,FACs,0.12,0.0085,27476721
MS4A1,LTM,NA,7315,Skin Cancer,NA,SK-MEL-1,NA,SFA followed by FACs,0.12,0.0085,31582018
MS4A1,LTM,NA,7315,Skin Cancer,NA,SK-MEL-1,NA,SFA followed by SP assay and FACs,0.12,0.0085,33052601
MS4A1,LTM,NA,7315,Skin Cancer,NA,SK-MEL-28,NA,FACs,0.12,0.0085,27476721
MS4A1,LTM,NA,7315,Skin Cancer,NA,WM115,NA,Culture on polydimethylsiloxane plate followed by SFA and  FACs,0.12,0.0085,21917310
MS4A1,LTM,NA,7315,Skin Cancer,NA,WM266-4,NA,SFA followed by FACs and RT-PCR,0.32,0.0085,26554153
MS4A1,LTM,NA,7315,Skin Cancer,NA,Primary,NA,SFA followed by FACs,0.2,0.0085,20236249
MSI1,LTM,NA,7330,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by Western Blotting,0.28,0.0201,22370645
MSI1,LTM,NA,7330,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.28,0.0201,23715514
MSI1,LTM,NA,7330,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.28,0.0201,28461325
MSI1,LTM,NA,7330,Gastric Cancer,Adenocarcinoma,BGC-823,NA,CFA and IHC staining followed by FACs and Western Blotting,0.64,0.0201,26276718
MSI1,LTM,NA,7330,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,SFA followed by Western Blotting,0.28,0.0201,23715514
MSI1,LTM,NA,7330,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,qRT-PCR,0.2,0.0201,31273285
MSI1,LTM,NA,7330,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.2,0.0201,22925500
MSI1,LTM,NA,7330,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and qRT-PCR,0.2,0.0201,27556511
MSI1,LTM,NA,7330,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.2,0.0201,27556511
MSI1,LTM,NA,7330,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,RH-1,qRT-PCR,0.2,0.0201,31336714
MSI1,LTM,NA,7330,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs and RT-PCR,0.32,0.0201,29249690
MSI1,LTM,NA,7330,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.28,0.0201,28461325
MSI1,LTM,NA,7330,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.0201,28461325
MSI1,LTM,NA,7330,Head and Neck Cancer,NA,QLL-1,NA,SFA followed by Western Blotting,0.28,0.0201,32327629
MSI1,LTM,NA,7330,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-15,NA,SFA followed by Western Blotting,0.28,0.0201,32327629
MSI1,LTM,NA,7330,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,SFA followed by Western Blotting,0.28,0.0201,32327629
MSI1,LTM,NA,7330,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,CFA and IHC staining followed by FACs and Western Blotting,0.64,0.0201,26276718
MSI1,LTM,NA,7330,Glioblastoma,NA,U-251,NA,CFA followed by qRT-PCR,0.2,0.0201,19324493
MSI1,LTM,NA,7330,Colon Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.36,0.0201,29110645
MSI1,LTM,NA,7330,Gastric Cancer,NA,Primary,NA,IHC staining,0.68,0.0201,24151393
MSI1,LTM,NA,7330,Glioblastoma,NA,Primary,NA,SFA followed by ICC staining,0.32,0.0201,23143002
MSI1,LTM,NA,7330,Glioblastoma,NA,Primary,NA,SFA and FACs,0.32,0.0201,28881826
MSI1,LTM,NA,7330,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IF staining,0.32,0.0201,32327629
MSI1,LTM,NA,7330,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,qRT-PCR,0.32,0.0201,20036608
MSI1,LTM,NA,7330,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0201,25963795
MSI1,LTM,NA,7330,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0201,25963795
MSI1,LTM,NA,7330,Small Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0201,25963795
MSI1,LTM,NA,7330,Gastric Cancer,NA,Primary,NA,Western Blotting followed by IHC staining,0.68,0.0201,28521458
MSI1,LTM,NA,7330,Glioblastoma Multiforme,NA,Primary,NA,SFA and qPCR followed by Western Blotting and IHC staining,0.96,0.0201,29963265
MSI2,LTM,NA,18585,Hepatic Cancer,Carcinoma,MHCC97-H,NA,Western Blotting and IF staining followed by SFA,0.52,0.0011,31888685
MSI2,LTM,NA,18585,Hepatic Cancer,Carcinoma,SNU-398,NA,Western Blotting and IF staining followed by SFA,0.52,0.0011,31888685
MST1,LTM,NA,7380,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and Tumorigenicity assay,0.12,0.0032,28938607
MST1,LTM,NA,7380,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by FACs and Tumorigenicity assay,0.12,0.0032,28938607
MST1R,LTM,NA,7381,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and Tumorigenicity assay,0.12,0.0032,28938607
MST1R,LTM,NA,7381,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by FACs and Tumorigenicity assay,0.12,0.0032,28938607
MTDH,LTM,NA,29608,Gastric Cancer,Adenocarcinoma,MGC-803,NA,Western Blotting followed by CFA,0.28,0.0011,31632151
MTDH,LTM,NA,29608,Gastric Cancer,Adenocarcinoma,MKN45,NA,Western Blotting followed by CFA,0.28,0.0011,31632151
MTDH,LTM,NA,29608,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.0011,31632151
MTOR1,LTM,NA,3942,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR,0.2,0.0011,30050079
MUC1,LTM,NA,7508,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.28,0.0042,29353288
MUC5AC,LTM,NA,7515,Gastric Cancer,Adenocarcinoma,HSC-60,NA,RT-PCR and IHC staining,0.44,0.0021,26110809
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.1304,30485693
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.1304,30555330
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR and Western Blotting,0.48,0.1304,22615765
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.1304,33980809
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by Western Blotting,0.48,0.1304,22370645
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.48,0.1304,34681614
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA,0.48,0.1304,29225473
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.1304,32033067
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.48,0.1304,28456659
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.28,0.1304,28461325
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.28,0.1304,32606358
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.28,0.1304,33288885
MYC,LTM,NA,7553,Triple Negative Breast Cancer,NA,AS-B244,NA,SFA followed by Western Blotting,0.28,0.1304,28914785
MYC,LTM,NA,7553,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Western Blotting,0.28,0.1304,25811929
MYC,LTM,NA,7553,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,qRT-PCR,0.28,0.1304,34163012
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,BGC-823,NA,Western Blotting followed by SFA,0.28,0.1304,31517391
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,Western Blotting,0.28,0.1304,29287960
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,IF staining followed by SFA,0.28,0.1304,34889737
MYC,LTM,NA,7553,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.1304,24305593
MYC,LTM,NA,7553,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by qRT-PCR,0.48,0.1304,29048549
MYC,LTM,NA,7553,Colon Cancer,Adenocarcinoma,CACO-2,NA,SFA followed by RT-PCR,0.2,0.1304,29312609
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,Western Blotting followed by IF staining and SFA,0.52,0.1304,29575240
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by Western Blotting,0.52,0.1304,31585633
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by RT-PCR,0.52,0.1304,28093940
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Carcinoma,CAL51,NA,qRT-PCR followed by SFA,0.2,0.1304,30450530
MYC,LTM,NA,7553,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.28,0.1304,25811929
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Adenocarcinoma,CL-141,NA,SFA followed by Western Blotting,0.28,0.1304,31638335
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR,0.2,0.1304,28093940
MYC,LTM,NA,7553,Glioblastoma Multiforme,NA,GBM8401,NA,SFA followed by IF staining,0.24,0.1304,31035045
MYC,LTM,NA,7553,Small Cell Lung Cancer,Carcinoma,GLC14,NA,SFA followed by IF staining,0.24,0.1304,33607458
MYC,LTM,NA,7553,Small Cell Lung Cancer,Carcinoma,GLC16,NA,SFA  and qRT-PCR followed by Western Blotting and IF staining,0.72,0.1304,33607458
MYC,LTM,NA,7553,Small Cell Lung Cancer,Carcinoma,GLC19,NA,SFA  and qRT-PCR followed by Western Blotting and IF staining,0.72,0.1304,33607458
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.1304,30555330
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.1304,33980809
MYC,LTM,NA,7553,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay followed by FACs and Tumorigenicity assay,0.12,0.1304,20424609
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,qRT-PCR followed by SFA,0.2,0.1304,32922547
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Adenocarcinoma,H2228,NA,SFA followed by Western Blotting,0.28,0.1304,26517679
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Adenocarcinoma,H3122,NA,SFA followed by Western Blotting,0.28,0.1304,26517679
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.2,0.1304,28456659
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,SFA followed by FACs and SP assay,0.12,0.1304,30092824
MYC,LTM,NA,7553,Breast Cancer,Carcinoma,HCC1569,NA,Western Blotting followed by SFA and IF staining,0.52,0.1304,34889737
MYC,LTM,NA,7553,Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,Western Blotting followed by SFA and IF staining,0.52,0.1304,34889737
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,Western Blotting and SFA,0.52,0.1304,35504883
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,SFA followed by PCR array assay,0.52,0.1304,33510281
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,IF staining followed by SFA,0.24,0.1304,34889737
MYC,LTM,NA,7553,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,NA,Western Blotting followed by SFA,0.28,0.1304,30326469
MYC,LTM,NA,7553,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,RT-PCR and SFA,0.28,0.1304,29895705
MYC,LTM,NA,7553,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,RT-PCR and SFA,0.28,0.1304,29895705
MYC,LTM,NA,7553,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by CFA,0.2,0.1304,26840024
MYC,LTM,NA,7553,Colon Cancer,Carcinoma,HCT116,NA,SFA and qRT-PCR,0.2,0.1304,33209130
MYC,LTM,NA,7553,Hepatic Cancer,Carcinoma,Hep-G2,NA,SFA followed by Western Blotting,0.28,0.1304,32626943
MYC,LTM,NA,7553,Gastric Cancer,NA,HFE-145,NA,SFA followed by Western Blotting,0.28,0.1304,33288885
MYC,LTM,NA,7553,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by Western Blotting,0.28,0.1304,28446252
MYC,LTM,NA,7553,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by Western Blotting,0.28,0.1304,30007956
MYC,LTM,NA,7553,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by qRT-PCR,0.28,0.1304,34628473
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,HN13,NA,SFA and Western Blotting,0.28,0.1304,28279658
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,Western Blotting and RT-PCR followed by SFA,0.48,0.1304,28951456
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,IF staining followed by SFA,0.48,0.1304,34889737
MYC,LTM,NA,7553,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by Western Blotting and RT-PCR,0.6,0.1304,22384170
MYC,LTM,NA,7553,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.6,0.1304,30944638
MYC,LTM,NA,7553,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by IHC staining,0.6,0.1304,26918725
MYC,LTM,NA,7553,Colon Cancer,Adenocarcinoma,HT-29,Docetaxel,qRT-PCR,0.6,0.1304,27748801
MYC,LTM,NA,7553,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,qRT-PCR,0.6,0.1304,27748801
MYC,LTM,NA,7553,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.6,0.1304,21130073
MYC,LTM,NA,7553,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.6,0.1304,26634106
MYC,LTM,NA,7553,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.6,0.1304,29312609
MYC,LTM,NA,7553,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Western Blotting,0.28,0.1304,27312708
MYC,LTM,NA,7553,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by Western Blotting,0.28,0.1304,32606358
MYC,LTM,NA,7553,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by Western Blotting,0.28,0.1304,33288885
MYC,LTM,NA,7553,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR,0.2,0.1304,26840266
MYC,LTM,NA,7553,Lung Cancer,Large Cell Carcinoma,L9981,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.1304,30485693
MYC,LTM,NA,7553,Breast Cancer,Ductal Carcinoma,LCC2,NA,SFA followed by Western Blotting,0.28,0.1304,30450766
MYC,LTM,NA,7553,Dukes Type B Colon Cancer,Adenocarcinoma,LS174T,NA,FACs followed by Western Blotting and RT-PCR,0.6,0.1304,22384170
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR followed by Western Blotting and SFA,0.48,0.1304,31736268
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.1304,30149665
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.1304,33305893
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.48,0.1304,35078507
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.1304,29106390
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,SFA followed by Western Blotting,0.48,0.1304,29750424
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.1304,30450766
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.1304,31604679
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,Western Blotting and SFA,0.48,0.1304,29185119
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.48,0.1304,29287960
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Lithium Chloride,Western Blotting and SFA,0.48,0.1304,29356693
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by SFA,0.48,0.1304,30335523
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and SFA,0.48,0.1304,34298877
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR and SFA,0.48,0.1304,35413424
MYC,LTM,NA,7553,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Paclitaxel,SFA followed by qRT-PCR,0.48,0.1304,30340507
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.1304,32859993
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.1304,30149665
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and RT-PCR followed by SFA,0.48,0.1304,28951456
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and IHC staining,0.48,0.1304,30131941
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.1304,34789263
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.48,0.1304,35504883
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.1304,28914785
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.1304,29106390
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.1304,30262865
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.1304,30647871
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.48,0.1304,29287960
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qPCR followed by SFA,0.48,0.1304,35135840
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and SFA,0.48,0.1304,34298877
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.48,0.1304,35413424
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.1304,34146553
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.1304,34445421
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.1304,35326667
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA,0.48,0.1304,30450530
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA,0.48,0.1304,31658701
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.48,0.1304,29197410
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.48,0.1304,29383157
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by qPCR,0.48,0.1304,28703802
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Doxorubicin,SFA followed by FACs,0.48,0.1304,28817737
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,SFA followed by qRT-PCR,0.2,0.1304,35326667
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,SFA followed by Western Blotting,0.28,0.1304,30647871
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting and FACs,0.4,0.1304,28978427
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,Western Blotting followed by FACs and SFA,0.4,0.1304,28817737
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.4,0.1304,34789263
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Doxorubicin,SFA followed by Western Blotting,0.4,0.1304,29750424
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.4,0.1304,30262865
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.4,0.1304,31604679
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,qPCR followed by SFA,0.4,0.1304,35135840
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting,0.28,0.1304,28337375
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.28,0.1304,32142918
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qPCR,0.28,0.1304,28336807
MYC,LTM,NA,7553,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.2,0.1304,26840266
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.28,0.1304,28337375
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.28,0.1304,28461325
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.28,0.1304,33288885
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,MKN45,NA,Western Blotting,0.28,0.1304,28186678
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR followed by SFA,0.28,0.1304,30543303
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.28,0.1304,34628473
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,MKN45,NA,qRT-PCR,0.28,0.1304,32099405
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR and SFA,0.28,0.1304,28692437
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.28,0.1304,26862521
MYC,LTM,NA,7553,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.1304,28446252
MYC,LTM,NA,7553,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.1304,28461325
MYC,LTM,NA,7553,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.1304,32606358
MYC,LTM,NA,7553,Gastric Cancer,Carcinoma,NCI-N87,NA,RT-PCR followed by SFA,0.28,0.1304,30543303
MYC,LTM,NA,7553,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.1304,24305593
MYC,LTM,NA,7553,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by qRT-PCR and Western Blotting,0.48,0.1304,24040121
MYC,LTM,NA,7553,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,0.1304,29975934
MYC,LTM,NA,7553,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,0.1304,30535490
MYC,LTM,NA,7553,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR,0.48,0.1304,34163012
MYC,LTM,NA,7553,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR,0.48,0.1304,30272287
MYC,LTM,NA,7553,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.48,0.1304,26298849
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qRT-PCR,0.2,0.1304,31966561
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qPCR,0.2,0.1304,31966561
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,SFA followed by RT-PCR,0.2,0.1304,31233201
MYC,LTM,NA,7553,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SFA followed by Western Blotting,0.28,0.1304,27312708
MYC,LTM,NA,7553,Head and Neck Cancer,NA,QLL-1,NA,SFA followed by Western Blotting,0.28,0.1304,32327629
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-131,NA,Western Blotting followed by IF staining and SFA,0.52,0.1304,29575240
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-131,Cisplatin,SFA followed by Western Blotting,0.52,0.1304,31585633
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-15,NA,Western Blotting followed by SFA,0.28,0.1304,35013621
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-15,NA,SFA followed by Western Blotting,0.28,0.1304,32327629
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,Western Blotting followed by SFA,0.28,0.1304,35013621
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,SFA followed by Western Blotting,0.28,0.1304,32327629
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.28,0.1304,30007956
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,Western Blotting followed by SFA,0.28,0.1304,31517391
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR,0.28,0.1304,32142918
MYC,LTM,NA,7553,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by qRT-PCR,0.2,0.1304,35326667
MYC,LTM,NA,7553,Gastric Cancer,Adenocarcinoma,SNU-668,NA,SFA followed by Western Blotting,0.28,0.1304,32606358
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,qPCR followed by SFA,0.2,0.1304,35135840
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Carcinoma,SUM149PT,Paclitaxel,SFA followed by qPCR,0.2,0.1304,28703802
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,Western Blotting and RT-PCR followed by SFA,0.48,0.1304,28951456
MYC,LTM,NA,7553,Triple Negative Breast Cancer,Carcinoma,SUM159,Lithium Chloride,Western Blotting and SFA,0.48,0.1304,29356693
MYC,LTM,NA,7553,Breast Cancer,Carcinoma,SUM190PT,Paclitaxel,SFA followed by qPCR,0.2,0.1304,28703802
MYC,LTM,NA,7553,Dukes Type C Colon Cancer,Adenocarcinoma,SW48,Doxorubicin,Western Blotting,0.28,0.1304,27517620
MYC,LTM,NA,7553,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.1304,30326469
MYC,LTM,NA,7553,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,qRT-PCR followed by Western Blotting and SFA,0.48,0.1304,31736268
MYC,LTM,NA,7553,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Tamoxifen,Western Blotting and RT-PCR,0.48,0.1304,29602199
MYC,LTM,NA,7553,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by RT-PCR and IHC staining,0.48,0.1304,30131941
MYC,LTM,NA,7553,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR,0.2,0.1304,33575080
MYC,LTM,NA,7553,Glioblastoma,NA,U-87MG,NA,SFA followed by IF staining,0.24,0.1304,31035045
MYC,LTM,NA,7553,Skin Cancer,NA,WM266-4,NA,SFA followed by RT-PCR,0.2,0.1304,26554153
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN30,NA,SFA and Western Blotting,0.28,0.1304,28279658
MYC,LTM,NA,7553,Breast Cancer,NA,Primary,NA,Western Blotting,0.36,0.1304,29185119
MYC,LTM,NA,7553,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen,SFA followed by qRT-PCR,0.36,0.1304,31693936
MYC,LTM,NA,7553,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen+Fulvestrant,SFA followed by qRT-PCR,0.36,0.1304,31693936
MYC,LTM,NA,7553,Colon Cancer,NA,Primary,NA,IHC staining followed by qRT-PCR,0.6,0.1304,31491003
MYC,LTM,NA,7553,Colon Cancer,NA,Primary,NA,RT-PCR,0.6,0.1304,21125339
MYC,LTM,NA,7553,Gastric Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.32,0.1304,26862521
MYC,LTM,NA,7553,Glioblastoma,NA,Primary,NA,SFA and qRT-PCR followed by IF staining,0.6,0.1304,19020659
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining and IF staining followed by SFA,0.92,0.1304,32019273
MYC,LTM,NA,7553,Head and Neck Cancer,NA,Primary,NA,IHC staining followed by IF staining and SFA,0.92,0.1304,32019273
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IF staining,0.92,0.1304,32327629
MYC,LTM,NA,7553,Head and Neck Cancer,NA,Primary,NA,IF staining and SFA,0.92,0.1304,32019273
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.92,0.1304,30528285
MYC,LTM,NA,7553,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,qRT-PCR,0.92,0.1304,20036608
MYC,LTM,NA,7553,Lung Cancer,NA,Primary,NA,IHC staining,0.32,0.1304,32500024
MYC,LTM,NA,7553,Pancreatic Cancer,NA,Primary,NA,SFA and qRT-PCR followed by Western Blotting and IHC staining,0.96,0.1304,26451606
MYC,LTM,NA,7553,Pancreatic Cancer,NA,Primary,NA,CFA followed by qRT-PCR,0.96,0.1304,26199979
MYC,LTM,NA,7553,Pancreatic Cancer,NA,Primary,NA,qRT-PCR,0.96,0.1304,21796625
MYC,LTM,NA,7553,Breast Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.36,0.1304,33340428
MYC,LTM,NA,7553,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.1304,28356964
MYC,LTM,NA,7553,Head and Neck Cancer,Cutaneous Squamous Cell Carcinoma,Primary,NA,IHC staining and IF staining followed by qRT-PCR,0.92,0.1304,32850316
MYC,LTM,NA,7553,Head and Neck Cancer,Cutaneous Squamous Cell Carcinoma,Primary,NA,IF staining,0.92,0.1304,32983794
MYC,LTM,NA,7553,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.1304,28416482
MYCN,LTM,NA,7559,Small Cell Lung Cancer,Carcinoma,GLC14,NA,SFA followed by Western Blotting,0.28,0.0032,33607458
MYH9,LTM,NA,7579,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and Western Blotting,0.4,0.0064,34635641
MYH9,LTM,NA,7579,Lung Cancer,Adenocarcinoma,GLC-82,NA,SFA followed by FACs and Western Blotting,0.4,0.0064,34635641
MYH9,LTM,NA,7579,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs and Western Blotting,0.4,0.0064,34635641
MYH9,LTM,NA,7579,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H226,NA,SFA followed by FACs and Western Blotting,0.4,0.0064,34635641
MYH9,LTM,NA,7579,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs and Western Blotting,0.4,0.0064,34635641
MYH9,LTM,NA,7579,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by FACs and Western Blotting,0.4,0.0064,34635641
NAMPT,LTM,NA,30092,Colon Cancer,Carcinoma,HCT116,NA,qRT-PCR followed by SFA and CFA,0.2,0.0032,29203587
NAMPT,LTM,NA,30092,Dukes Type B Colon Cancer,Adenocarcinoma,LS180,NA,qRT-PCR followed by SFA and CFA,0.2,0.0032,29203587
NAMPT,LTM,NA,30092,Glioblastoma,NA,SF268,NA,SFA and CFA followed by FACs,0.12,0.0032,29245920
NAMPT,LTM,NA,30092,Glioblastoma,NA,U-251,NA,SFA and CFA followed by FACs,0.12,0.0032,29245920
NANOG,LTM,NA,9221,Pancreatic Cancer,NA,Primary,NA,SFA and qRT-PCR followed by Western Blotting and IHC staining,0.96,0.5461,26451606
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,5637,NA,SFA followed by qRT-PCR,0.2,0.5461,30592142
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by qRT-PCR,0.2,0.5461,27766570
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by RT-PCR,0.2,0.5461,27556038
NANOG,LTM,NA,20857,Glioblastoma,NA,A-172,Temozolomide,Western Blotting and CFA,0.28,0.5461,34036375
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,A-253,NA,RT-PCR followed by CFA,0.2,0.5461,24612587
NANOG,LTM,NA,20857,Skin Cancer,NA,A-375,NA,SFA followed by qPCR and Western Blotting,0.48,0.5461,29693169
NANOG,LTM,NA,20857,Skin Cancer,NA,A-375,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,29693169
NANOG,LTM,NA,20857,Skin Cancer,NA,A-375,NA,Western Blotting and SFA,0.48,0.5461,27566591
NANOG,LTM,NA,20857,Skin Cancer,NA,A-375,NA,SFA followed by qRT-PCR,0.48,0.5461,30558661
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and Western Blotting,0.48,0.5461,34063628
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,qRT-PCR and Western Blotting,0.48,0.5461,34065942
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,35229723
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,CFA and SFA followed by RT-PCR and Western Blotting,0.48,0.5461,28406482
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR  followed by Western Blotting,0.48,0.5461,28179999
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and qRT-PCR followed by Western Blotting,0.48,0.5461,32396269
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,28431267
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,29344850
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,29888108
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,30485693
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,32655789
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,30555330
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by Western Blotting and RT-PCR,0.48,0.5461,24333218
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining and RT-PCR,0.48,0.5461,21520032
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and qRT-PCR  followed by SFA and Tumorigenicity assay,0.48,0.5461,29262597
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,FACs followed by RT-PCR,0.48,0.5461,24356998
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA and RT-PCR,0.48,0.5461,28854941
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and qRT-PCR,0.48,0.5461,28534939
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,SFA followed by FACs and qRT-PCR,0.48,0.5461,29860718
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and qRT-PCR,0.48,0.5461,30816208
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qPCR and FACs,0.48,0.5461,26299367
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by SFA and Western Blotting,0.48,0.5461,33707423
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.5461,33980809
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.5461,34949193
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by Western Blotting,0.48,0.5461,35267489
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting followed by SFA,0.48,0.5461,33721187
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,SFA and Western Blotting,0.48,0.5461,26779808
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and Western Blotting,0.48,0.5461,29387193
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by CFA and Western Blotting,0.48,0.5461,32637578
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.5461,21425153
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.5461,21802163
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by Western Blotting,0.48,0.5461,22370645
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.5461,26517679
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.5461,27836540
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.5461,28198062
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.5461,29416721
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.5461,31928533
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.5461,32782570
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.48,0.5461,33125096
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,Western Blotting,0.48,0.5461,23349823
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,Western Blotting,0.48,0.5461,30341415
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining,0.48,0.5461,26261505
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IHC staining,0.48,0.5461,24668028
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR,0.48,0.5461,33068069
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR,0.48,0.5461,33995625
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR,0.48,0.5461,34400945
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,qRT-PCR and SFA,0.48,0.5461,33784109
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by SFA,0.48,0.5461,33670440
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,33437165
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,33468994
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,34209829
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,34277782
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,34832951
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,35044041
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture and SFA followed by qRT-PCR,0.48,0.5461,29017078
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Pemetrexed,qPCR,0.48,0.5461,26181204
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR,0.48,0.5461,24646078
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by SFA and SP assay,0.48,0.5461,26468775
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Pemetrexed +Cisplatin,RT-PCR,0.48,0.5461,26895954
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR,0.48,0.5461,31201845
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA,0.48,0.5461,25003810
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA,0.48,0.5461,29225473
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA,0.48,0.5461,31368411
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qPCR,0.48,0.5461,26675547
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qPCR,0.48,0.5461,31796785
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,22900142
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,5-Fluorouracil,SFA followed by qRT-PCR,0.48,0.5461,25683371
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,25683371
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,27766570
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,28035349
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,29138851
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,29448000
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,31024010
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,32033067
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,32401390
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.48,0.5461,32612672
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by qRT-PCR,0.48,0.5461,32655321
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.48,0.5461,23370278
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.48,0.5461,26546046
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by RT-PCR,0.48,0.5461,27009878
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.48,0.5461,28787001
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.48,0.5461,31582014
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay and SFA followed by qRT-PCR,0.48,0.5461,31871777
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by qRT-PCR,0.48,0.5461,23009336
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR,0.48,0.5461,22615765
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR,0.48,0.5461,22825470
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,31261030
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.48,0.5461,28461325
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.48,0.5461,32606358
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.48,0.5461,33288885
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.48,0.5461,35117718
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qPCR,0.48,0.5461,29559846
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.48,0.5461,29512256
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.48,0.5461,34173116
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qRT-PCR followed by Western Blotting,0.48,0.5461,28703793
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qPCR and Western Blotting,0.48,0.5461,32575925
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,27996162
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Western Blotting,0.48,0.5461,25811929
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,qRT-PCR,0.48,0.5461,34163012
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,qRT-PCR and SFA,0.48,0.5461,33728488
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qRT-PCR,0.48,0.5461,27996162
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qRT-PCR,0.48,0.5461,30119228
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and qRT-PCR and Western Blotting ,0.48,0.5461,33731207
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,BGC-823,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,33579380
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,28440445
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.48,0.5461,34350176
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by Western Blotting,0.48,0.5461,30624124
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,BGC-823,NA,Western Blotting followed by SFA,0.48,0.5461,31517391
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by qRT-PCR,0.48,0.5461,33798550
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by qRT-PCR,0.48,0.5461,34173116
NANOG,LTM,NA,20857,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by qRT-PCR,0.2,0.5461,35195687
NANOG,LTM,NA,20857,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,Trastuzumab,SFA followed by qPCR,0.2,0.5461,28722778
NANOG,LTM,NA,20857,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by qPCR,0.2,0.5461,30224376
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Cyclophosphamide,qRT-PCR and Western Blotting,0.48,0.5461,33090711
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,33090711
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,IF staining followed by SFA,0.48,0.5461,34889737
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA and qRT-PCR,0.48,0.5461,35064101
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,RT-PCR,0.48,0.5461,29262622
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.5461,27576197
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.5461,28703793
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by Western Blotting,0.48,0.5461,31713003
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,Western Blotting and SFA,0.48,0.5461,33082357
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by Western Blotting,0.48,0.5461,32766132
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,Western Blotting,0.48,0.5461,29970519
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by qRT-PCR,0.48,0.5461,29048549
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,FACs,0.48,0.5461,31713003
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,Ca9-22,NA,SFA and RT-PCR and Western Blotting,0.48,0.5461,24475244
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,CACO-2,NA,SP assay followed by qPCR and SFA,0.2,0.5461,32367652
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,25588898
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by Western Blotting,0.48,0.5461,26000099
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,Western Blotting and SFA,0.48,0.5461,25871396
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,Western Blotting followed by SFA,0.48,0.5461,34795388
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by IHC staining,0.48,0.5461,23903875
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by qRT-PCR,0.48,0.5461,24112466
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by RT-PCR,0.48,0.5461,28093940
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,CALU-1,NA,SFA followed by qRT-PCR,0.2,0.5461,29138851
NANOG,LTM,NA,20857,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,33737813
NANOG,LTM,NA,20857,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.48,0.5461,25811929
NANOG,LTM,NA,20857,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.48,0.5461,29100320
NANOG,LTM,NA,20857,Lung Cancer,Adenocarcinoma,CL1-0,NA,CFA and SFA followed by Western Blotting,0.28,0.5461,35163585
NANOG,LTM,NA,20857,Lung Cancer,Adenocarcinoma,CL-1-1,NA,SFA followed by Western Blotting,0.28,0.5461,29416721
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,CL-141,NA,SFA followed by Western Blotting,0.28,0.5461,31319622
NANOG,LTM,NA,20857,Lung Cancer,Adenocarcinoma,CL1-5,NA,SFA followed by qRT-PCR,0.2,0.5461,35154481
NANOG,LTM,NA,20857,Skin Cancer,NA,D10,NA,SFA and CFA followed by qRT-PCR,0.2,0.5461,26208390
NANOG,LTM,NA,20857,Glioblastoma,NA,DBTRG-05MG,NA,SFA and Western Blotting,0.28,0.5461,33317545
NANOG,LTM,NA,20857,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.2,0.5461,23418515
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,28870814
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,32661469
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,EJ-28,Benzidine,SFA followed by Western Blotting,0.48,0.5461,33552265
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by Western Blotting,0.48,0.5461,33552265
NANOG,LTM,NA,20857,Lung Cancer,Adenocarcinoma,EKVX,NA,SFA followed by IHC staining,0.24,0.5461,24668028
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by qPCR and Western Blotting,0.48,0.5461,29228308
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Dasatinib,Western Blotting followed by qRT-PCR,0.48,0.5461,31382448
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Saracatinib,Western Blotting followed by qRT-PCR,0.48,0.5461,31382448
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,Western Blotting and SFA,0.48,0.5461,25871396
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Cisplatin,SFA followed by qRT-PCR,0.48,0.5461,32206093
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR,0.48,0.5461,28093940
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR,0.48,0.5461,32708734
NANOG,LTM,NA,20857,Glioblastoma Multiforme,NA,GBM8401,NA,SP assay and SFA followed by RT-PCR,0.2,0.5461,25359730
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,SFA followed by Western Blotting,0.28,0.5461,30717421
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,qRT-PCR,0.28,0.5461,24646078
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,SFA followed by RT-PCR,0.28,0.5461,23370278
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,28431267
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,30555330
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs and Western Blotting,0.48,0.5461,27542268
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,MACs followed by qPCR,0.48,0.5461,24008862
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs and qRT-PCR,0.48,0.5461,30816208
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and FACs,0.48,0.5461,25669973
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.5461,33980809
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by CFA and Western Blotting,0.48,0.5461,32637578
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.5461,27836540
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.5461,28198062
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.5461,33125096
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.5461,33468994
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.5461,34832951
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by and qRT-PCR,0.48,0.5461,29620443
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qPCR,0.48,0.5461,26675547
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.5461,32051483
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.5461,32401390
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.5461,32612672
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,Cisplatin,SFA followed by qRT-PCR,0.48,0.5461,32655321
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR,0.48,0.5461,25735977
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR,0.48,0.5461,27556038
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR,0.48,0.5461,29651165
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SP assay and SFA followed by qRT-PCR,0.48,0.5461,31871777
NANOG,LTM,NA,20857,Small Cell Lung Cancer,NA,H1408,NA,SFA followed by FACs and RT-PCR,0.32,0.5461,29437792
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H157,NA,SFA followed by qPCR,0.2,0.5461,26675547
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H157,Cisplatin,SFA followed by RT-PCR,0.2,0.5461,27009878
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Giant Cell Carcinoma,H1581,NA,SFA followed by qRT-PCR,0.2,0.5461,26936993
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,FACs followed by SFA and qPCR,0.32,0.5461,24091605
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,SFA followed by qPCR and FACs,0.32,0.5461,26299367
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,Erlotinib,qRT-PCR,0.32,0.5461,30480362
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H1658,Erlotinib,RT-PCR followed by CFA and SFA,0.2,0.5461,31069016
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H1703,NA,qRT-PCR followed by SFA and SP assay,0.2,0.5461,26468775
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,29888108
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,Western Blotting,0.48,0.5461,34475041
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,qRT-PCR followed by SFA,0.48,0.5461,32922547
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA and qRT-PCR,0.48,0.5461,29980786
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay followed by qRT-PCR,0.48,0.5461,23009336
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay followed by SFA and RT-PCR,0.48,0.5461,28440478
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.48,0.5461,35229723
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H1993,NA,RT-PCR followed by CFA,0.2,0.5461,29995950
NANOG,LTM,NA,20857,Small Cell Lung Cancer,Carcinoma,H209,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,32953511
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,qRT-PCR followed by SFA,0.2,0.5461,33670440
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H2228,NA,SFA followed by Western Blotting,0.28,0.5461,26517679
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H23,Cisplatin,SFA followed by IF staining and Western Blotting,0.52,0.5461,26872057
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,qRT-PCR and Western Blotting,0.52,0.5461,34063628
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,SFA and qRT-PCR,0.52,0.5461,29980786
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by qRT-PCR,0.2,0.5461,34209829
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H3122,NA,SFA followed by Western Blotting,0.28,0.5461,26517679
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H3122,NA,SFA followed by qRT-PCR,0.28,0.5461,29950868
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H322,NA,SFA followed by Western Blotting,0.28,0.5461,26837769
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,Pemetrexed,qPCR,0.2,0.5461,26181204
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,CFA and SFA followed by Western Blotting,0.28,0.5461,35163585
NANOG,LTM,NA,20857,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,30254465
NANOG,LTM,NA,20857,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,32953511
NANOG,LTM,NA,20857,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Western Blotting,0.48,0.5461,27633248
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,qRT-PCR and Western Blotting,0.48,0.5461,34063628
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,CFA and SFA followed by RT-PCR and Western Blotting,0.48,0.5461,28406482
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA and Western Blotting,0.48,0.5461,34635641
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA and Western Blotting,0.48,0.5461,34832867
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,0.5461,34195288
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Western Blotting,0.48,0.5461,35267489
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by CFA and Western Blotting,0.48,0.5461,32637578
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,0.5461,27281614
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,0.5461,28677037
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,0.5461,30111255
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,0.5461,32782570
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.48,0.5461,26885450
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.48,0.5461,30305725
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,Western Blotting,0.48,0.5461,23349823
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,Western Blotting followed by SFA,0.48,0.5461,26901847
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR,0.48,0.5461,33068069
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,FACs for CSC marker followed by qRT-PCR,0.48,0.5461,33550205
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.48,0.5461,34209829
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.48,0.5461,34349823
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,Pemetrexed,qPCR,0.48,0.5461,26181204
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by and qRT-PCR,0.48,0.5461,29620443
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qPCR and Tumorigenicity assay,0.48,0.5461,30305725
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.48,0.5461,25276790
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by qRT-PCR,0.48,0.5461,28406482
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.48,0.5461,31397494
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.48,0.5461,31658996
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.48,0.5461,31717588
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by RT-PCR,0.48,0.5461,24309934
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs,0.48,0.5461,34044271
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,FACs for CSC marker followed by SFA and Western Blotting,0.28,0.5461,33707423
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,Western Blotting followed by SFA,0.28,0.5461,33721187
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,SFA followed by qRT-PCR,0.28,0.5461,26936993
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,SFA followed by qRT-PCR,0.28,0.5461,32863772
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,H522,NA,RT-PCR,0.2,0.5461,18952074
NANOG,LTM,NA,20857,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA followed by qRT-PCR,0.2,0.5461,34832951
NANOG,LTM,NA,20857,Hepatic Cancer,NA,HAK-1B,NA,SP assay followed by qRT-PCR,0.2,0.5461,24325739
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,HB-CLS-1,NA,MACs,0.12,0.5461,30746788
NANOG,LTM,NA,20857,Breast Cancer,Carcinoma,HCC1569,NA,Western Blotting followed by SFA and IF staining,0.52,0.5461,34889737
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA followed by qRT-PCR,0.2,0.5461,26711929
NANOG,LTM,NA,20857,Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,Western Blotting followed by SFA and IF staining,0.52,0.5461,34889737
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,Western Blotting followed by SFA,0.52,0.5461,29679903
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,SFA and Western Blotting,0.28,0.5461,33390847
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,Western Blotting followed by SFA,0.28,0.5461,29679903
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,IF staining followed by SFA,0.28,0.5461,34889737
NANOG,LTM,NA,20857,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,MK-0752,qRT-PCR,0.2,0.5461,29027990
NANOG,LTM,NA,20857,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,MK-0752,qRT-PCR,0.2,0.5461,29027990
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Ductal Carcinoma,HCC-38,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,30336071
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,FACs followed by SFA and qPCR,0.32,0.5461,24091605
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by Western Blotting,0.32,0.5461,30305725
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,qRT-PCR,0.32,0.5461,33764690
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,qPCR,0.32,0.5461,24489728
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by RT-PCR,0.32,0.5461,28787001
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,SP assay followed by qRT-PCR and CFA,0.32,0.5461,25871388
NANOG,LTM,NA,20857,Lung Cancer,Squamous Cell Carcinoma,HCC95,NA,SFA followed by qRT-PCR,0.2,0.5461,32863772
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,HCCLM3,NA,CFA followed by SFA and qRT-PCR,0.2,0.5461,27783993
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,HCCLM3,NA,SFA followed by qRT-PCR,0.2,0.5461,25676692
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,30774996
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil,SFA followed by Western Blotting and qRT-PCR,0.48,0.5461,28990068
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and RT-PCR,0.48,0.5461,31120140
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by SFA and Western Blotting,0.48,0.5461,33819194
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,SFA and Western Blotting,0.48,0.5461,27207017
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.48,0.5461,30305725
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.48,0.5461,35242031
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,qRT-PCR,0.48,0.5461,29426374
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR,0.48,0.5461,29902974
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by SFA,0.48,0.5461,32037723
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,SFA and qRT-PCR,0.48,0.5461,25368233
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,SFA and qRT-PCR,0.48,0.5461,26241688
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,SFA and qRT-PCR,0.48,0.5461,33209130
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qPCR,0.48,0.5461,31349708
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.48,0.5461,29307822
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.48,0.5461,31544978
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by RT-PCR,0.48,0.5461,23174018
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,0.5461,31641961
NANOG,LTM,NA,20857,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,qRT-PCR,0.2,0.5461,24145190
NANOG,LTM,NA,20857,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,RT-PCR followed by SFA,0.2,0.5461,28946619
NANOG,LTM,NA,20857,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by qPCR and Western Blotting,0.48,0.5461,29228308
NANOG,LTM,NA,20857,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by RT-PCR,0.48,0.5461,26021266
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by qRT-PCR,0.2,0.5461,34405006
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,Hep3B,NA,CFA followed by SFA and qRT-PCR,0.2,0.5461,27783993
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by qRT-PCR,0.2,0.5461,25676692
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,Hep3B,NA,FACs followed by CFA,0.2,0.5461,22194816
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,Hep-G2,NA,SFA followed by Western Blotting,0.28,0.5461,29033320
NANOG,LTM,NA,20857,Gastric Cancer,NA,HFE-145,NA,SFA followed by Western Blotting,0.28,0.5461,33288885
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by Western Blotting,0.28,0.5461,30007956
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by qPCR,0.28,0.5461,29559846
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by qRT-PCR,0.28,0.5461,34628473
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,HN-1,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,25024430
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,HN4,Cisplatin,Western Blotting followed by SFA,0.28,0.5461,34795388
NANOG,LTM,NA,20857,Lung Cancer,Adenocarcinoma,HOP-62,NA,SFA followed by qRT-PCR,0.2,0.5461,35154481
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by qRT-PCR,0.2,0.5461,27891685
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,IF staining followed by SFA,0.24,0.5461,34889737
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by qPCR,0.24,0.5461,30224376
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-2,NA,qRT-PCR,0.2,0.5461,23992541
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,SFA followed by Western Blotting,0.28,0.5461,27002147
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,qPCR and SFA,0.28,0.5461,26448762
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,qRT-PCR followed by CFA,0.28,0.5461,22847005
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-4,NA,SP assay followed by qRT-PCR and CFA,0.2,0.5461,20651344
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,HT-1376,NA,SFA followed by qRT-PCR,0.2,0.5461,26452033
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,NA,MACs followed by qPCR and Western Blotting,0.6,0.5461,30337351
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR and Western Blotting,0.6,0.5461,30774996
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA and RT-PCR,0.6,0.5461,31120140
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker followed by SFA and Western Blotting,0.6,0.5461,33819194
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by IHC staining,0.6,0.5461,26918725
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.6,0.5461,35267511
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,qRT-PCR,0.6,0.5461,30772447
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,NA,qRT-PCR followed by SFA,0.6,0.5461,32037723
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR,0.6,0.5461,29902974
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.6,0.5461,21130073
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.6,0.5461,27556511
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.6,0.5461,31544978
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.6,0.5461,26634106
NANOG,LTM,NA,20857,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by RT-PCR,0.6,0.5461,30209760
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,HTB-9,NA,ICC staining followed by SFA,0.24,0.5461,26054707
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Western Blotting,0.28,0.5461,27312708
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting and SFA,0.28,0.5461,32229502
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting followed by SFA and CFA,0.28,0.5461,30908631
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and qRT-PCR,0.28,0.5461,21618577
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.28,0.5461,25676692
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.28,0.5461,32128906
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by CFA,0.28,0.5461,22194816
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by qRT-PCR,0.2,0.5461,35116788
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by RT-PCR,0.2,0.5461,30397177
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,J-82,Cisplatin,RT-PCR,0.2,0.5461,26647959
NANOG,LTM,NA,20857,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,Western Blotting followed by SFA,0.28,0.5461,30620624
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,JLO-1,Metformin,qPCR,0.2,0.5461,30621095
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by Western Blotting,0.28,0.5461,32606358
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by Western Blotting,0.28,0.5461,33288885
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by qRT-PCR,0.28,0.5461,31233198
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.5461,21618577
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,KUMA-1,NA,qRT-PCR,0.2,0.5461,23992541
NANOG,LTM,NA,20857,Head and Neck Cancer,Esophageal Squamous Cell Carcinoma,KYSE70,NA,qRT-PCR,0.2,0.5461,25351876
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR,0.2,0.5461,26840266
NANOG,LTM,NA,20857,Lung Cancer,Large Cell Carcinoma,L9981,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,30485693
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,NA,LC31,NA,RT- PCR followed by SFA,0.2,0.5461,21738704
NANOG,LTM,NA,20857,Lung Cancer,Adenocarcinoma,LHK2,NA,SP assay followed by qRT-PCR and CFA,0.2,0.5461,27418136
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,LK0923,NA,qRT-PCR,0.2,0.5461,23049743
NANOG,LTM,NA,20857,Glioblastoma,NA,LN-18,NA,SFA and qRT-PCR,0.2,0.5461,29069805
NANOG,LTM,NA,20857,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.28,0.5461,33109220
NANOG,LTM,NA,20857,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,qRT-PCR,0.28,0.5461,30284085
NANOG,LTM,NA,20857,Dukes Type B Colon Cancer,Adenocarcinoma,LS180,NA,RT-PCR,0.2,0.5461,29902974
NANOG,LTM,NA,20857,Skin Cancer,NA,MA-MEL-66A,NA,SFA followed by qRT-PCR,0.2,0.5461,30558661
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by IF staining and SFA,0.52,0.5461,29982992
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and Western Blotting followed by CFA,0.52,0.5461,35235236
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Adriamycin,SFA followed by qRT-PCR and Western Blotting,0.52,0.5461,33866606
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5461,34052833
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5461,34249423
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5461,34755264
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by qRT-PCR and SFA,0.52,0.5461,33791297
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR followed by Western Blotting and SFA,0.52,0.5461,31736268
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5461,31300015
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,SFA followed by qRT-PCR and Western Blotting,0.52,0.5461,31760402
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by RT-PCR and Western Blotting,0.52,0.5461,28703799
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and RT-PCR followed by SFA,0.52,0.5461,29601799
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and IF staining,0.52,0.5461,30188754
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and IF staining,0.52,0.5461,30188754
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by SP assay and Western Blotting,0.52,0.5461,35004266
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5461,33305893
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5461,33419140
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5461,34830821
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.52,0.5461,35078507
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,CFA followed by Western Blotting,0.52,0.5461,28839461
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5461,28802057
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5461,28823831
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5461,29243835
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5461,29356693
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5461,29797562
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5461,31501409
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5461,31604679
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5461,31695775
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5461,31760908
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.52,0.5461,29287960
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Lithium Chloride,Western Blotting and SFA,0.52,0.5461,29356693
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Purmorphamine,Western Blotting and SFA,0.52,0.5461,29356693
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.52,0.5461,29956731
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.52,0.5461,29956731
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.52,0.5461,30482236
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by SFA,0.52,0.5461,30335523
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Cobalt Chloride,Western Blotting followed by SFA,0.52,0.5461,31584203
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and SFA,0.52,0.5461,34217266
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and SFA,0.52,0.5461,34298877
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5461,33511560
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5461,34486791
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5461,34803458
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR,0.52,0.5461,31762819
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,MK-0752,qRT-PCR followed by SFA,0.52,0.5461,29027990
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR,0.52,0.5461,30615901
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5461,30175027
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Paclitaxel,SFA followed by qRT-PCR,0.52,0.5461,30340507
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5461,30628646
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5461,31693936
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by RT-PCR,0.52,0.5461,30579251
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cyclophosphamide,qRT-PCR and Western Blotting,0.48,0.5461,33090711
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and Western Blotting,0.48,0.5461,35055160
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,32859993
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,33090711
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,33866606
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,34070538
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,34249423
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,35401817
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.5461,29848346
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,28703799
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,29601799
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,30336071
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and IHC staining,0.48,0.5461,30131941
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Irradiation,CFA followed by Western Blotting,0.48,0.5461,34708581
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.48,0.5461,33390847
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.48,0.5461,33530373
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by SP assay and Western Blotting,0.48,0.5461,35004266
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5461,34178639
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.48,0.5461,34770867
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,CFA followed by Western Blotting,0.48,0.5461,28839461
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and SP assay followed by Western Blotting,0.48,0.5461,28903350
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5461,28823831
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5461,29137219
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5461,29422613
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5461,29797562
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5461,29981340
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5461,30262865
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5461,31695775
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.48,0.5461,30482236
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.48,0.5461,31501409
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,Western Blotting followed by SFA,0.48,0.5461,29880481
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cobalt Chloride,Western Blotting followed by SFA,0.48,0.5461,31584203
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Culture of cells in electrospun scaffolds followed by qRT-PCR,0.48,0.5461,34841239
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by RT-PCR,0.48,0.5461,34235281
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and SFA,0.48,0.5461,34298877
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5461,33511560
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5461,34052833
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5461,34146553
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5461,34420298
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5461,34445421
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5461,34990518
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5461,35017469
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5461,35195687
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5461,35326667
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qPCR and SFA,0.48,0.5461,31745977
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR,0.48,0.5461,30021199
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR,0.48,0.5461,30542507
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA,0.48,0.5461,30052635
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA,0.48,0.5461,31658701
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.48,0.5461,29197410
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and qRT-PCR,0.48,0.5461,28991374
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and RT-PCR,0.48,0.5461,29964299
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by qPCR,0.48,0.5461,28703802
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cisplatin,SFA followed by qRT-PCR,0.48,0.5461,28871147
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by qRT-PCR,0.48,0.5461,28871147
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5461,30587555
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,9 Gy Radiation,SFA followed by RT-PCR,0.48,0.5461,30579251
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SP assay followed by qPCR,0.48,0.5461,30110679
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Doxorubicin,SFA followed by FACs,0.48,0.5461,28817737
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,Irradiation,CFA followed by Western Blotting,0.28,0.5461,34708581
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,FACs for CSC marker followed by RT-PCR,0.28,0.5461,34235281
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,SFA followed by qRT-PCR,0.28,0.5461,35326667
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,SFA followed by qRT-PCR,0.28,0.5461,31337967
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,30336071
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs and RT-PCR,0.48,0.5461,29249690
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Irradiation,CFA followed by Western Blotting,0.48,0.5461,34708581
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.48,0.5461,30262865
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.48,0.5461,31604679
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,Culture of cells in electrospun scaffolds followed by qRT-PCR,0.48,0.5461,34841239
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by qPCR,0.48,0.5461,30224376
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by qRT-PCR,0.48,0.5461,30628646
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR and Western Blotting and IF staining,0.72,0.5461,28076840
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.5461,32189359
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MGC-803,NA,qRT-PCR and Western Blotting,0.72,0.5461,32638620
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting and qRT-PCR,0.72,0.5461,28415621
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting,0.72,0.5461,27524415
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting,0.72,0.5461,28529558
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qPCR,0.72,0.5461,28428713
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by RT-PCR,0.72,0.5461,24573253
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MGC-803,NA,FACs followed by SFA,0.72,0.5461,28893318
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,32229502
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,MHCC97-H,NA,Western Blotting and SFA,0.48,0.5461,31888685
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,MHCC97-H,NA,Western Blotting followed by SFA and CFA,0.48,0.5461,30908631
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,MHCC97-H,NA,CFA followed by SFA and qRT-PCR,0.48,0.5461,27783993
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by qRT-PCR,0.48,0.5461,25676692
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qPCR and Western Blotting,0.48,0.5461,34168259
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,35158144
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qPCR and Western Blotting,0.48,0.5461,32575925
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA and Western Blotting,0.48,0.5461,35428310
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Western Blotting,0.48,0.5461,26458814
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by Western Blotting,0.48,0.5461,30341797
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by Western Blotting,0.48,0.5461,30341797
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting,0.48,0.5461,29179494
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,qRT-PCR,0.48,0.5461,23073476
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and qRT-PCR,0.48,0.5461,24719318
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.48,0.5461,24734907
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.48,0.5461,26840266
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by FACs,0.48,0.5461,29719602
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by qPCR and Western Blotting,0.48,0.5461,34168259
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN28,NA,SFA followed by Western Blotting,0.28,0.5461,28529558
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by IF staining and Western Blotting,0.52,0.5461,28430578
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by qRT-PCR and Western Blotting,0.52,0.5461,27602437
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,qRT-PCR and Western Blotting followed by SFA,0.52,0.5461,31037832
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting and qRT-PCR,0.52,0.5461,34173116
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5461,28959362
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5461,31345097
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,qRT-PCR and Western Blotting,0.52,0.5461,32638620
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Western Blotting,0.52,0.5461,27279633
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting,0.52,0.5461,34646768
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.52,0.5461,27644439
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.52,0.5461,28461325
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.52,0.5461,33288885
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR followed by SFA,0.52,0.5461,30543303
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.5461,27511210
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.5461,29512256
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.5461,34628473
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by RT-PCR,0.52,0.5461,33725258
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR,0.52,0.5461,25081334
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR and SFA,0.52,0.5461,28692437
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.5461,26862521
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.5461,32863948
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.5461,28461325
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.5461,32606358
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,NCI-N87,NA,RT-PCR followed by SFA,0.28,0.5461,30543303
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by RT-PCR,0.28,0.5461,30696080
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,OCUM-12,NA,SP assay followed by qRT-PCR,0.2,0.5461,34667215
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,22692956
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,SFA and Western Blotting,0.48,0.5461,22422628
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,OM-1,NA,RT-PCR followed by SFA,0.2,0.5461,26399460
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,OSC19,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,25588898
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,OUMS-23,NA,qRT-PCR,0.2,0.5461,30284085
NANOG,LTM,NA,20857,Pancreatic Cancer,Ductal Adenocarcinoma,PaCa-44,NA,SFA followed by qPCR and Western Blotting,0.48,0.5461,34168259
NANOG,LTM,NA,20857,Pancreatic Cancer,Ductal Adenocarcinoma,PaCa-44,NA,Prolonged exposure to simulated microgravity followed by qRT-PCR,0.48,0.5461,35391557
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,PAMC82,NA,Western Blotting and SFA,0.28,0.5461,33067426
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and qRT-PCR followed by Western Blotting and IF staining,0.72,0.5461,29975934
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR and Western Blotting,0.72,0.5461,35158144
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qRT-PCR followed by Western Blotting,0.72,0.5461,28703793
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.5461,27996162
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.5461,29937934
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR and Western Blotting,0.72,0.5461,31508487
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR and Western Blotting,0.72,0.5461,23872274
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by qRT-PCR and Western Blotting,0.72,0.5461,24040121
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA and qPCR,0.72,0.5461,30954649
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and Western Blotting,0.72,0.5461,35428310
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.72,0.5461,33115754
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.72,0.5461,34551785
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.72,0.5461,26458814
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by Western Blotting,0.72,0.5461,30341797
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by Western Blotting,0.72,0.5461,30341797
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.72,0.5461,30535490
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.72,0.5461,32766132
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting,0.72,0.5461,29179494
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting,0.72,0.5461,29947365
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR,0.72,0.5461,34163012
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR and SFA,0.72,0.5461,33728488
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5461,34446696
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,Migration and Invasion assay followed by RT-PCR and SFA,0.72,0.5461,30852389
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qPCR,0.72,0.5461,32605166
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5461,24521357
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5461,26298849
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5461,26439804
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5461,26840266
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5461,26918054
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5461,27996162
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5461,28580169
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5461,30045656
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5461,30954649
NANOG,LTM,NA,20857,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5461,31027735
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.5461,27996162
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.5461,28244691
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.5461,28244691
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR followed by Western Blotting,0.48,0.5461,31508487
NANOG,LTM,NA,20857,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by qPCR and Western Blotting,0.48,0.5461,34168259
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,CFA and SFA followed by IF staining and RT-PCR,0.44,0.5461,25960639
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs followed by SFA and RT-PCR,0.44,0.5461,22935675
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR,0.44,0.5461,34771484
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR,0.44,0.5461,34771484
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qRT-PCR,0.44,0.5461,33764690
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qRT-PCR,0.44,0.5461,31966561
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qPCR followed by SFA and Tumorigenicity assay,0.44,0.5461,24489728
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qRT-PCR,0.44,0.5461,30480362
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qPCR,0.44,0.5461,31966561
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,SP assay followed by RT-PCR and Tumorigenicity assay,0.44,0.5461,25871388
NANOG,LTM,NA,20857,Pancreatic Cancer,Ductal Adenocarcinoma,PK-1,NA,SFA followed by qRT-PCR,0.2,0.5461,31027735
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SFA followed by Western Blotting,0.28,0.5461,27312708
NANOG,LTM,NA,20857,Head and Neck Cancer,NA,QLL-1,NA,SFA followed by Western Blotting,0.28,0.5461,32327629
NANOG,LTM,NA,20857,Colon Cancer,Carcinoma,RKO,NA,SFA followed by qPCR,0.2,0.5461,29721049
NANOG,LTM,NA,20857,Bladder Cancer,Transitional Cell Papilloma,RT-4,NA,SFA followed by qRT-PCR,0.2,0.5461,35116788
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SFA and RT-PCR and Western Blotting,0.48,0.5461,24475244
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,22692956
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,Cisplatin,SFA followed by Western Blotting,0.48,0.5461,33238517
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SFA and Western Blotting,0.48,0.5461,22422628
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SP assay and Western Blotting,0.48,0.5461,23843890
NANOG,LTM,NA,20857,Small Cell Lung Cancer,Carcinoma,SBC-5,NA,SFA followed by qRT-PCR,0.2,0.5461,29448000
NANOG,LTM,NA,20857,Small Cell Lung Cancer,Carcinoma,SBC-5,NA,SFA followed by RT-PCR,0.2,0.5461,28248963
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-15,NA,Western Blotting followed by SFA,0.28,0.5461,35013621
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-15,NA,SFA followed by Western Blotting,0.28,0.5461,32327629
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,Cisplatin,Western Blotting followed by SFA,0.28,0.5461,34795388
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,Western Blotting followed by SFA,0.28,0.5461,35013621
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,SFA followed by Western Blotting,0.28,0.5461,32327629
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR and Western Blotting and IF staining,0.72,0.5461,28076840
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,qRT-PCR and Western Blotting followed by SFA,0.72,0.5461,31037832
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and qRT-PCR and Western Blotting ,0.72,0.5461,33731207
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting and qRT-PCR,0.72,0.5461,34173116
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.5461,31261030
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.72,0.5461,33579380
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting and qRT-PCR,0.72,0.5461,28415621
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,FACs for CSC marker followed by Western Blotting,0.72,0.5461,27279633
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.72,0.5461,34350176
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.72,0.5461,34646768
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.72,0.5461,34657624
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.72,0.5461,27644439
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.72,0.5461,30007956
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.72,0.5461,34802261
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.72,0.5461,30624124
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,Western Blotting followed by SFA,0.72,0.5461,31517391
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,qRT-PCR followed by SFA,0.72,0.5461,29662192
NANOG,LTM,NA,20857,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,Western Blotting followed by SFA,0.28,0.5461,30620624
NANOG,LTM,NA,20857,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,Western Blotting followed by SFA,0.28,0.5461,30620624
NANOG,LTM,NA,20857,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by qRT-PCR,0.28,0.5461,35326667
NANOG,LTM,NA,20857,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,qRT-PCR followed by SP assay and SFA,0.28,0.5461,30613295
NANOG,LTM,NA,20857,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,qRT-PCR followed by SP assay and SFA,0.28,0.5461,30613295
NANOG,LTM,NA,20857,Skin Cancer,NA,SK-MEL-28,NA,Western Blotting and SFA,0.28,0.5461,27566591
NANOG,LTM,NA,20857,Skin Cancer,NA,SK-MEL-28,NA,SFA followed by qRT-PCR,0.28,0.5461,30558661
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,SNU16,NA,Western Blotting and SFA,0.28,0.5461,33067426
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,SNU16,NA,RT-PCR followed by SFA,0.28,0.5461,31073886
NANOG,LTM,NA,20857,Hepatic Cancer,Carcinoma,SNU-398,NA,Western Blotting and SFA,0.28,0.5461,31888685
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by qPCR and Western Blotting,0.48,0.5461,30284938
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Western Blotting and qRT-PCR,0.48,0.5461,33798550
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,SNU5,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,28440445
NANOG,LTM,NA,20857,Gastric Cancer,Carcinoma,SNU5,NA,RT-PCR followed by SFA,0.48,0.5461,31073886
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by qPCR and Western Blotting,0.48,0.5461,30284938
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by qRT-PCR,0.48,0.5461,32863948
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,SNU-668,NA,SFA followed by Western Blotting,0.28,0.5461,32606358
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,CFA and SFA followed by IF staining and RT-PCR,0.44,0.5461,25960639
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by FACs and qPCR,0.44,0.5461,25731617
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Western Blotting,0.44,0.5461,34949193
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by qRT-PCR,0.44,0.5461,28035349
NANOG,LTM,NA,20857,Gastric Cancer,Adenocarcinoma,ST2957,NA,SFA followed by qRT-PCR,0.2,0.5461,32863948
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,qRT-PCR and Western Blotting,0.48,0.5461,30542507
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM149PT,MK-0752,qRT-PCR followed by SFA,0.48,0.5461,29027990
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,RT-PCR followed by SFA,0.48,0.5461,29471829
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM149PT,Paclitaxel,SFA followed by qPCR,0.48,0.5461,28703802
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM159,Paclitaxel,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,35401817
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA and Western Blotting,0.48,0.5461,33530373
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by Western Blotting,0.48,0.5461,29243835
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by Western Blotting,0.48,0.5461,29356693
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM159,Lithium Chloride,Western Blotting and SFA,0.48,0.5461,29356693
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM159,Purmorphamine,Western Blotting and SFA,0.48,0.5461,29356693
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA and qRT-PCR,0.48,0.5461,35064101
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,qRT-PCR and SFA,0.48,0.5461,31850822
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA and qRT-PCR,0.48,0.5461,28991374
NANOG,LTM,NA,20857,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by qRT-PCR,0.48,0.5461,31337967
NANOG,LTM,NA,20857,Breast Cancer,Carcinoma,SUM190PT,Paclitaxel,SFA followed by qPCR,0.2,0.5461,28703802
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,33737813
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.5461,27576197
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR followed by Western Blotting,0.48,0.5461,31508487
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,FACs followed by SFA and qPCR,0.48,0.5461,30954649
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting,0.48,0.5461,33288882
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.48,0.5461,30954649
NANOG,LTM,NA,20857,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.48,0.5461,26439804
NANOG,LTM,NA,20857,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by qRT-PCR and Western Blotting,0.48,0.5461,24926880
NANOG,LTM,NA,20857,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by Western Blotting,0.48,0.5461,30774996
NANOG,LTM,NA,20857,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by SFA and Western Blotting,0.48,0.5461,28560069
NANOG,LTM,NA,20857,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,qRT-PCR,0.48,0.5461,29426374
NANOG,LTM,NA,20857,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by qPCR,0.48,0.5461,31349708
NANOG,LTM,NA,20857,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by qRT-PCR,0.48,0.5461,29307822
NANOG,LTM,NA,20857,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,30774996
NANOG,LTM,NA,20857,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,5-Fluorouracil,SFA followed by Western Blotting and qRT-PCR,0.48,0.5461,28990068
NANOG,LTM,NA,20857,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.48,0.5461,33109220
NANOG,LTM,NA,20857,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SP assay followed by SFA and Western Blotting,0.48,0.5461,28560069
NANOG,LTM,NA,20857,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by CFA and qRT-PCR,0.48,0.5461,30115896
NANOG,LTM,NA,20857,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by qPCR,0.48,0.5461,31349708
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,T24,Cisplatin,SFA and SP assay followed by RT-PCR and Western Blotting,0.48,0.5461,22343321
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,T24,Cisplatin,RT-PCR,0.48,0.5461,26647959
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.48,0.5461,30592142
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.48,0.5461,31187490
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,T24,NA,SP assay followed by RT-PCR and SFA,0.48,0.5461,25020236
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,qRT-PCR and Western Blotting followed by CFA,0.48,0.5461,35235236
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,qRT-PCR followed by Western Blotting and SFA,0.48,0.5461,31736268
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,31300015
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,28703799
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Tamoxifen,Western Blotting and RT-PCR,0.48,0.5461,29602199
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by RT-PCR and IHC staining,0.48,0.5461,30131941
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Western Blotting,0.48,0.5461,28802057
NANOG,LTM,NA,20857,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR,0.2,0.5461,33575080
NANOG,LTM,NA,20857,Glioblastoma,NA,U-251,NA,SFA and qRT-PCR,0.2,0.5461,28881826
NANOG,LTM,NA,20857,Glioblastoma,NA,U-373MG,NA,SFA followed by Western Blotting,0.28,0.5461,29115404
NANOG,LTM,NA,20857,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.5461,34408983
NANOG,LTM,NA,20857,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting,0.48,0.5461,29115404
NANOG,LTM,NA,20857,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting,0.48,0.5461,32578777
NANOG,LTM,NA,20857,Glioblastoma,NA,U-87MG,NA,SFA and Western Blotting,0.48,0.5461,32360621
NANOG,LTM,NA,20857,Glioblastoma,NA,U-87MG,NA,SFA followed by qRT-PCR,0.48,0.5461,30175027
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-1,NA,SFA followed by qPCR,0.2,0.5461,21304586
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-2,Cisplatin,SFA followed by Western Blotting,0.28,0.5461,26000099
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,SFA followed by qRT-PCR,0.2,0.5461,24533098
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-103,NA,SFA followed by qRT-PCR,0.2,0.5461,25428916
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-11B,NA,SFA followed by qPCR,0.2,0.5461,21304586
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-11B,NA,SFA followed by qRT-PCR,0.2,0.5461,26323460
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-14B,NA,SFA followed by qRT-PCR,0.2,0.5461,25428916
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,NA,Western Blotting,0.28,0.5461,25379016
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,NA,Western Blotting,0.28,0.5461,25379016
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,Western Blotting,0.28,0.5461,25379016
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-46,NA,SP assay followed by Western Blotting and qRT-PCR,0.48,0.5461,25379016
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-47,NA,SFA followed by qRT-PCR,0.2,0.5461,24533098
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-9,NA,SFA followed by qRT-PCR,0.2,0.5461,26323460
NANOG,LTM,NA,20857,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,28870814
NANOG,LTM,NA,20857,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5461,32661469
NANOG,LTM,NA,20857,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.5461,31180522
NANOG,LTM,NA,20857,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,Benzidine,SFA followed by Western Blotting,0.48,0.5461,33552265
NANOG,LTM,NA,20857,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting,0.48,0.5461,33552265
NANOG,LTM,NA,20857,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by RT-PCR,0.48,0.5461,30397177
NANOG,LTM,NA,20857,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,Cisplatin,qRT-PCR,0.48,0.5461,31239709
NANOG,LTM,NA,20857,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR,0.48,0.5461,26452033
NANOG,LTM,NA,20857,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SP assay followed by RT-PCR and SFA,0.48,0.5461,25020236
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-22,NA,SFA followed by qPCR,0.2,0.5461,21304586
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,SFA followed by qRT-PCR,0.2,0.5461,26323460
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-38,Dasatinib,Western Blotting followed by qRT-PCR,0.48,0.5461,31382448
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-38,Saracatinib,Western Blotting followed by qRT-PCR,0.48,0.5461,31382448
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,qRT-PCR followed by SFA,0.2,0.5461,26323893
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,qRT-PCR followed by SFA,0.2,0.5461,26323893
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,SFA followed by qPCR,0.2,0.5461,21304586
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,VU-1365,NA,RT-PCR followed by SFA,0.2,0.5461,25340704
NANOG,LTM,NA,20857,Skin Cancer,NA,WM266-4,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,31817719
NANOG,LTM,NA,20857,Skin Cancer,NA,WM266-4,NA,SFA followed by RT-PCR,0.48,0.5461,26554153
NANOG,LTM,NA,20857,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.5461,21618577
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN19,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,25024430
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN26,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5461,25024430
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN30,Deferoxamine,RT-PCR,0.2,0.5461,35313655
NANOG,LTM,NA,20857,Gastric Cancer,NA,XN0422,NA,qRT-PCR followed by SFA,0.2,0.5461,29662192
NANOG,LTM,NA,20857,Luminal A Breast Cancer,Ductal Carcinoma,ZR-75-1,NA,qRT-PCR followed by SP assay and SFA,0.2,0.5461,30613295
NANOG,LTM,NA,20857,Breast Cancer,Ductal Carcinoma,ZR-75-30,NA,qRT-PCR followed by SFA,0.2,0.5461,30478301
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.5461,22343321
NANOG,LTM,NA,20857,Bladder Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.5461,32424373
NANOG,LTM,NA,20857,Breast Cancer,NA,Primary,NA,qPCR followed by IHC staining,0.68,0.5461,29660692
NANOG,LTM,NA,20857,Breast Cancer,NA,Primary,Chemotherapy,SFA followed by Western Blotting,0.68,0.5461,28835684
NANOG,LTM,NA,20857,Breast Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.68,0.5461,30587593
NANOG,LTM,NA,20857,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen,SFA followed by qRT-PCR,0.68,0.5461,31693936
NANOG,LTM,NA,20857,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen+Fulvestrant,SFA followed by qRT-PCR,0.68,0.5461,31693936
NANOG,LTM,NA,20857,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.68,0.5461,30359767
NANOG,LTM,NA,20857,Colon Cancer,NA,Primary,NA,RT-PCR followed by Western Blotting,0.64,0.5461,28249897
NANOG,LTM,NA,20857,Colon Cancer,NA,Primary,NA,IHC staining followed by qRT-PCR,0.64,0.5461,31491003
NANOG,LTM,NA,20857,Colon Cancer,NA,Primary,5-Fluorouracil,SFA followed by Western Blotting,0.64,0.5461,30091203
NANOG,LTM,NA,20857,Colon Cancer,NA,Primary,Oxaliplatin,SFA followed by Western Blotting,0.64,0.5461,30091203
NANOG,LTM,NA,20857,Colon Cancer,NA,Primary,NA,qRT-PCR,0.64,0.5461,24492635
NANOG,LTM,NA,20857,Colon Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.64,0.5461,23643941
NANOG,LTM,NA,20857,Colon Cancer,NA,Primary,5-Fluorouracil,SFA followed by FACs,0.64,0.5461,30091203
NANOG,LTM,NA,20857,Colon Cancer,NA,Primary,Oxaliplatin,SFA followed by FACs,0.64,0.5461,30091203
NANOG,LTM,NA,20857,Gastric Cancer,NA,Primary,NA,qPCR,0.32,0.5461,26870231
NANOG,LTM,NA,20857,Gastric Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.32,0.5461,26862521
NANOG,LTM,NA,20857,Glioblastoma,NA,Primary,NA,SFA and FACs,0.2,0.5461,28881826
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining and IF staining followed by SFA,0.92,0.5461,32019273
NANOG,LTM,NA,20857,Head and Neck Cancer,NA,Primary,NA,IHC staining followed by IF staining and SFA,0.92,0.5461,32019273
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR and Western Blotting,0.92,0.5461,30651721
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IF staining,0.92,0.5461,32327629
NANOG,LTM,NA,20857,Head and Neck Cancer,NA,Primary,NA,IF staining and SFA,0.92,0.5461,32019273
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.92,0.5461,30528285
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IHC staining,0.92,0.5461,22640830
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,qRT-PCR,0.92,0.5461,20036608
NANOG,LTM,NA,20857,Head and Neck Cancer,Hypopharyngeal Carcinoma,Primary,NA,qRT-PCR,0.92,0.5461,23626764
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qPCR,0.92,0.5461,23876835
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.92,0.5461,19450560
NANOG,LTM,NA,20857,Hepatic Cancer,NA,Primary,NA,FACs,0.28,0.5461,26942873
NANOG,LTM,NA,20857,Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining and IF staining followed by qRT-PCR,0.92,0.5461,31894290
NANOG,LTM,NA,20857,Lung Cancer,NA,Primary,NA,IHC staining,0.92,0.5461,32500024
NANOG,LTM,NA,20857,Lung Cancer,Adenocarcinoma,Primary,NA,qRT-PCR,0.92,0.5461,21159654
NANOG,LTM,NA,20857,Lung Cancer,NA,Primary,NA,RT-PCR,0.92,0.5461,24018162
NANOG,LTM,NA,20857,Lung Cancer,Squamous Cell Carcinoma,Primary,NA,RT-PCR,0.92,0.5461,27698819
NANOG,LTM,NA,20857,Lung Cancer,Adenocarcinoma,Primary,Erlotinib,RT-PCR followed by SFA,0.92,0.5461,28347243
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by IF staining and Western Blotting,0.68,0.5461,31506430
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,RT-PCR,0.68,0.5461,31921651
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,RT-PCR,0.68,0.5461,31921651
NANOG,LTM,NA,20857,Pancreatic Cancer,NA,Primary,NA,SFA followed by qRT-PCR and IF staining,0.96,0.5461,26609473
NANOG,LTM,NA,20857,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.96,0.5461,23438436
NANOG,LTM,NA,20857,Pancreatic Cancer,NA,Primary,NA,CFA followed by qRT-PCR,0.96,0.5461,26199979
NANOG,LTM,NA,20857,Pancreatic Cancer,NA,Primary,NA,qPCR followed by SFA,0.96,0.5461,24785258
NANOG,LTM,NA,20857,Pancreatic Cancer,NA,Primary,NA,qRT-PCR,0.96,0.5461,21796625
NANOG,LTM,NA,20857,Skin Cancer,NA,Primary,NA,IHC staining followed by IF staining,0.64,0.5461,30626524
NANOG,LTM,NA,20857,Breast Cancer,NA,Primary,NA,SFA followed by Western Blotting and ICC staining,0.68,0.5461,33340428
NANOG,LTM,NA,20857,Colon Cancer,NA,Primary,NA,qRT-PCR and Western Blotting followed by SFA,0.64,0.5461,34271345
NANOG,LTM,NA,20857,Colon Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.64,0.5461,33500430
NANOG,LTM,NA,20857,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.5461,28356964
NANOG,LTM,NA,20857,Gastric Cancer,NA,Primary,NA,qRT-PCR,0.32,0.5461,30628031
NANOG,LTM,NA,20857,Gastric Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.32,0.5461,33986804
NANOG,LTM,NA,20857,Gastric Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.32,0.5461,32350414
NANOG,LTM,NA,20857,Glioblastoma Multiforme,NA,Primary,NA,IHC staining and IF staining followed by Western Blotting,1,0.5461,27617262
NANOG,LTM,NA,20857,Glioblastoma Multiforme,NA,Primary,NA,Isolation of autofluorescence cells followed by SFA and qRT-PCR,1,0.5461,33669350
NANOG,LTM,NA,20857,Head and Neck Cancer,Cutaneous Squamous Cell Carcinoma,Primary,NA,IHC staining and IF staining followed by qRT-PCR,0.92,0.5461,32850316
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by Western Blotting,0.92,0.5461,21292542
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.92,0.5461,22847005
NANOG,LTM,NA,20857,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,Cisplatin,SFA followed by qRT-PCR,0.92,0.5461,32206093
NANOG,LTM,NA,20857,Hepatic Cancer,NA,Primary,NA,SP assay followed by qRT-PCR and SFA,0.28,0.5461,23104270
NANOG,LTM,NA,20857,Lung Cancer,NA,Primary,NA,SFA and IF staining,0.92,0.5461,33531664
NANOG,LTM,NA,20857,Lung Cancer,NA,Primary,PD98059,SFA followed by qRT-PCR,0.92,0.5461,33867839
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.68,0.5461,33036771
NANOG,LTM,NA,20857,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,qRT-PCR followed by SFA,0.68,0.5461,28855609
NANOGP8,LTM,NA,23106,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qPCR,0.2,0.0011,29689047
NANOGP8,LTM,NA,23106,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qPCR,0.2,0.0011,29689047
NANOGP8,LTM,NA,23106,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qPCR and IF staining,0.44,0.0011,29689047
NCAM1,LTM,NA,7656,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by IF staining,0.36,0.0074,34527268
NCAM1,LTM,NA,7656,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.36,0.0074,32466428
NCAM1,LTM,NA,7656,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-103,NA,SFA followed by FACs and qRT-PCR,0.32,0.0074,25428916
NCAM1,LTM,NA,7656,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-14B,NA,SFA followed by FACs and qRT-PCR,0.32,0.0074,25428916
NCAM1,LTM,NA,7656,Hepatic Cancer,NA,Primary,NA,SP assay followed by qRT-PCR and SFA,0.28,0.0074,23104270
NDRG1,LTM,NA,7679,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.2,0.0064,28456659
NDRG1,LTM,NA,7679,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.2,0.0064,28456659
NES,LTM,NA,7756,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,SFA followed by FACs and qRT-PCR,0.32,0.0573,29860718
NES,LTM,NA,7756,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by IF staining and FACs,0.36,0.0573,26709750
NES,LTM,NA,7756,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qPCR,0.36,0.0573,31440741
NES,LTM,NA,7756,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by IF staining,0.24,0.0573,26709750
NES,LTM,NA,7756,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by IHC staining,0.24,0.0573,23903875
NES,LTM,NA,7756,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by qRT-PCR,0.2,0.0573,30819221
NES,LTM,NA,7756,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,SP assay followed by qRT-PCR and CFA,0.2,0.0573,25871388
NES,LTM,NA,7756,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by RT-PCR,0.2,0.0573,26021266
NES,LTM,NA,7756,Pancreatic Cancer,Adenocarcinoma,HPAF-II,Gemcitabine,qPCR,0.2,0.0573,31440741
NES,LTM,NA,7756,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by qRT-PCR,0.2,0.0573,31233198
NES,LTM,NA,7756,Gastric Cancer,Carcinoma,KATO-III,NA,FACs followed by CFA,0.2,0.0573,27891816
NES,LTM,NA,7756,Glioblastoma,NA,LN-229,NA,SFA and Western Blotting,0.28,0.0573,29228694
NES,LTM,NA,7756,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR,0.2,0.0573,33634797
NES,LTM,NA,7756,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR,0.2,0.0573,33634797
NES,LTM,NA,7756,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.2,0.0573,35413424
NES,LTM,NA,7756,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qPCR followed by SFA,0.2,0.0573,29907642
NES,LTM,NA,7756,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR,0.2,0.0573,25081334
NES,LTM,NA,7756,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0573,22692956
NES,LTM,NA,7756,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,SFA and Western Blotting,0.48,0.0573,22422628
NES,LTM,NA,7756,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by qRT-PCR,0.32,0.0573,29444383
NES,LTM,NA,7756,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting,0.32,0.0573,29947365
NES,LTM,NA,7756,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting followed by SFA,0.32,0.0573,30819221
NES,LTM,NA,7756,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by IF staining,0.32,0.0573,26709750
NES,LTM,NA,7756,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qPCR,0.32,0.0573,31440741
NES,LTM,NA,7756,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.32,0.0573,26335012
NES,LTM,NA,7756,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.32,0.0573,27531902
NES,LTM,NA,7756,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.32,0.0573,29434962
NES,LTM,NA,7756,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.32,0.0573,31027735
NES,LTM,NA,7756,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.32,0.0573,26689865
NES,LTM,NA,7756,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs followed by SFA and RT-PCR,0.32,0.0573,22935675
NES,LTM,NA,7756,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0573,22692956
NES,LTM,NA,7756,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SFA and Western Blotting,0.48,0.0573,22422628
NES,LTM,NA,7756,Glioblastoma,NA,SHG44,NA,SP assay and SFA followed by qRT-PCR and Western Blotting,0.48,0.0573,26617845
NES,LTM,NA,7756,Glioblastoma,NA,SHG-44,NA,SFA followed by IF staining,0.24,0.0573,33889875
NES,LTM,NA,7756,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by qRT-PCR,0.2,0.0573,30819221
NES,LTM,NA,7756,Glioblastoma,NA,U-251,NA,SFA followed by IHC staining,0.24,0.0573,19232461
NES,LTM,NA,7756,Glioblastoma,NA,U-251,NA,CFA followed by IF staining and SFA,0.24,0.0573,19324493
NES,LTM,NA,7756,Glioblastoma,NA,U-251,NA,IF staining followed by SFA,0.24,0.0573,26170223
NES,LTM,NA,7756,Glioblastoma,NA,U-251,NA,Suspended cell culturing and SFA followed by IF staining,0.24,0.0573,23258424
NES,LTM,NA,7756,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR,0.24,0.0573,33575080
NES,LTM,NA,7756,Glioblastoma,NA,U-251,NA,SFA followed by RT-PCR,0.24,0.0573,31288857
NES,LTM,NA,7756,Glioblastoma,NA,U-251,NA,SFA and qRT-PCR,0.24,0.0573,28881826
NES,LTM,NA,7756,Glioblastoma,NA,U-87MG,NA,SFA and Western Blotting,0.28,0.0573,28394339
NES,LTM,NA,7756,Glioblastoma,NA,U-87MG,NA,SFA and Western Blotting,0.28,0.0573,29228694
NES,LTM,NA,7756,Glioblastoma,NA,U-87MG,NA,SFA followed by IF staining,0.28,0.0573,33889875
NES,LTM,NA,7756,Glioblastoma,NA,U-87MG,NA,SFA followed by IF staining,0.28,0.0573,34235925
NES,LTM,NA,7756,Glioblastoma,NA,U-87MG,NA,IF staining followed by SFA,0.28,0.0573,21193962
NES,LTM,NA,7756,Glioblastoma,NA,U-87MG,NA,SFA followed by RT-PCR,0.28,0.0573,31288857
NES,LTM,NA,7756,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.0573,27891816
NES,LTM,NA,7756,Glioblastoma,NA,Primary,NA,IHC staining and Western Blotting followed by SFA,0.68,0.0573,19427293
NES,LTM,NA,7756,Glioblastoma,NA,Primary,NA,SFA and qRT-PCR followed by IF staining,0.68,0.0573,19020659
NES,LTM,NA,7756,Glioblastoma,NA,Primary,NA,SFA and IF staining,0.68,0.0573,26683773
NES,LTM,NA,7756,Glioblastoma,NA,Primary,NA,SFA followed by ICC staining,0.68,0.0573,23143002
NES,LTM,NA,7756,Glioblastoma,NA,Primary,NA,SFA followed by IF staining,0.68,0.0573,19956386
NES,LTM,NA,7756,Glioblastoma,NA,Primary,NA,SFA and qRT-PCR,0.68,0.0573,30280197
NES,LTM,NA,7756,Glioblastoma,NA,Primary,NA,SFA and FACs,0.68,0.0573,28881826
NES,LTM,NA,7756,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,qRT-PCR,0.6,0.0573,20036608
NES,LTM,NA,7756,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.6,0.0573,19450560
NES,LTM,NA,7756,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining followed by IF staining,0.64,0.0573,21293543
NES,LTM,NA,7756,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.32,0.0573,32197003
NES,LTM,NA,7756,Skin Cancer,NA,Primary,NA,FACs,0.32,0.0573,19491215
NES,LTM,NA,7756,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.0573,27891816
NES,LTM,NA,7756,Glioblastoma Multiforme,NA,Primary,NA,SFA and qPCR followed by Western Blotting and IHC staining,0.96,0.0573,29963265
NES,LTM,NA,7756,Glioblastoma Multiforme,NA,Primary,NA,IF staining followed by SFA,0.96,0.0573,29137258
NES,LTM,NA,7756,Glioblastoma Multiforme,NA,Primary,NA,Isolation of autofluorescence cells followed by SFA and qRT-PCR,0.96,0.0573,33669350
NES,LTM,NA,7756,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR and IF staining,0.6,0.0573,21167769
NES,LTM,NA,7756,Skin Cancer,NA,Primary,NA,IHC staining,0.32,0.0573,25339000
NES,LTM,NA,7756,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IF staining,0.32,0.0573,33925297
NES,LTM,NA,7756,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by IF staining,0.32,0.0573,33925297
NFE2L2,LTM,NA,7782,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Cisplatin,SFA followed by IF staining,0.24,0.0042,32206093
NFE2L2,LTM,NA,7782,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0042,35155201
NFE2L2,LTM,NA,7782,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting and IHC staining,0.52,0.0042,31672029
NFE2L2,LTM,NA,7782,Luminal A Breast Cancer,Adenocarcinoma,MCF8,Paclitaxel,SFA followed by Western Blotting,0.28,0.0042,28718813
NFE2L2,LTM,NA,7782,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,Cisplatin,SFA followed by IF staining,0.32,0.0042,32206093
NFKB1,LTM,NA,7794,Triple Negative Breast Cancer,Carcinoma,BT-20,NA,SFA followed by Western Blotting,0.28,0.0064,29073729
NFKB1,LTM,NA,7794,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0064,34755264
NFKB1,LTM,NA,7794,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qPCR and Western Blotting,0.48,0.0064,29846560
NFKB1,LTM,NA,7794,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0064,29073729
NGFR,LTM,NA,7809,Head and Neck Cancer,Squamous Cell Carcinoma,5PT,NA,FACs followed by CFA and SFA,0.12,0.0180,25212757
NGFR,LTM,NA,7809,Skin Cancer,NA,A-375,NA,SFA followed by Western Blotting,0.28,0.0180,26693692
NGFR,LTM,NA,7809,Skin Cancer,NA,A-375,NA,FACs,0.28,0.0180,27476721
NGFR,LTM,NA,7809,Head and Neck Cancer,Oral Squamous Cell Carcinoma,CaLH3,NA,FACs followed by CFA and SFA,0.12,0.0180,25212757
NGFR,LTM,NA,7809,Skin Cancer,NA,HBL,NA,Label retainig using GFP tag and SFA followed by FACs,0.12,0.0180,25223735
NGFR,LTM,NA,7809,Head and Neck Cancer,Esophageal Squamous Cell Carcinoma,KYSE70,NA,FACs followed by qRT-PCR and SFA,0.32,0.0180,25351876
NGFR,LTM,NA,7809,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0180,34755264
NGFR,LTM,NA,7809,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs,0.48,0.0180,30175027
NGFR,LTM,NA,7809,Skin Cancer,NA,MeWo,Etoposide,Western Blotting followed by FACs,0.4,0.0180,28112719
NGFR,LTM,NA,7809,Skin Cancer,NA,NA8-MEL,NA,FACs followed by SFA,0.12,0.0180,23915418
NGFR,LTM,NA,7809,Skin Cancer,NA,SK-MEL-1,NA,FACs,0.12,0.0180,27476721
NGFR,LTM,NA,7809,Skin Cancer,NA,SK-MEL-28,NA,FACs,0.12,0.0180,27476721
NGFR,LTM,NA,7809,Skin Cancer,NA,SK-MEL-28,NA,Label retainig using GFP tag and SFA followed by FACs,0.12,0.0180,25223735
NGFR,LTM,NA,7809,Glioblastoma,NA,U-87MG,NA,SFA followed by FACs,0.12,0.0180,30175027
NGFR,LTM,NA,7809,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,FACs followed by SFA,0.12,0.0180,32773768
NGFR,LTM,NA,7809,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,FACs followed by SFA,0.12,0.0180,31742606
NGFR,LTM,NA,7809,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,FACs followed by SFA,0.12,0.0180,32773768
NGFR,LTM,NA,7809,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,FACs followed by SFA,0.12,0.0180,31742606
NGFR,LTM,NA,7809,Skin Cancer,NA,WM115,NA,Culture on polydimethylsiloxane plate followed by SFA and  FACs,0.12,0.0180,21917310
NGFR,LTM,NA,7809,Skin Cancer,NA,WM793,NA,SFA followed by Western Blotting,0.28,0.0180,26693692
NGFR,LTM,NA,7809,Glioblastoma,NA,Primary,NA,SFA followed by qRT-PCR and Western Blotting,0.64,0.0180,24519935
NGFR,LTM,NA,7809,Head and Neck Cancer,Hypopharyngeal Carcinoma,Primary,NA,IHC staining,0.32,0.0180,23626764
NGFR,LTM,NA,7809,Skin Cancer,NA,Primary,NA,IHC staining,0.32,0.0180,23958542
NGFR,LTM,NA,7809,Skin Cancer,NA,Primary,NA,FACs,0.32,0.0180,19491215
NGFR,LTM,NA,7809,Skin Cancer,NA,Primary,NA,SFA followed by FACs,0.32,0.0180,20236249
NME2,LTM,NA,7850,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0042,34628473
NME2,LTM,NA,7850,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0042,34628473
NNMT,LTM,NA,7861,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by RT-PCR,0.2,0.0053,26021266
NOLC1,LTM,NA,15608,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA,0.2,0.0042,34789263
NOLC1,LTM,NA,15608,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,qRT-PCR followed by SFA,0.2,0.0042,34789263
NOLC1,LTM,NA,15608,Breast Cancer,NA,Primary,NA,qPCR,0.28,0.0042,34789263
NOTCH1,LTM,NA,7881,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0477,30555330
NOTCH1,LTM,NA,7881,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0477,31939436
NOTCH1,LTM,NA,7881,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR and Western Blotting,0.48,0.0477,22615765
NOTCH1,LTM,NA,7881,Non Small Cell Lung Cancer,Carcinoma,A549,Pemetrexed,SFA followed by Western Blotting,0.48,0.0477,32726929
NOTCH1,LTM,NA,7881,Triple Negative Breast Cancer,Carcinoma,BT-20,NA,SFA followed by Western Blotting,0.28,0.0477,33924995
NOTCH1,LTM,NA,7881,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,Western Blotting,0.28,0.0477,34277708
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Western Blotting,0.28,0.0477,25588898
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.28,0.0477,27380877
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,qRT-PCR followed by SFA and CFA,0.28,0.0477,27380877
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Docetaxel,qRT-PCR followed by SFA and CFA,0.28,0.0477,27380877
NOTCH1,LTM,NA,7881,Triple Negative Breast Cancer,Carcinoma,CAL51,NA,qRT-PCR followed by SFA,0.2,0.0477,30450530
NOTCH1,LTM,NA,7881,Glioblastoma Multiforme,NA,GBM8401,NA,SP assay and SFA followed by RT-PCR,0.2,0.0477,25359730
NOTCH1,LTM,NA,7881,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0477,30555330
NOTCH1,LTM,NA,7881,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR,0.48,0.0477,29651165
NOTCH1,LTM,NA,7881,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA followed by Western Blotting,0.28,0.0477,33922104
NOTCH1,LTM,NA,7881,Non Small Cell Lung Cancer,Adenocarcinoma,H322,NA,SFA followed by ELISA,0.28,0.0477,26088878
NOTCH1,LTM,NA,7881,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,RT-PCR and SFA,0.2,0.0477,29895705
NOTCH1,LTM,NA,7881,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,Lapatinib,RT-PCR and SFA,0.2,0.0477,29895705
NOTCH1,LTM,NA,7881,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and RT-PCR,0.32,0.0477,19451087
NOTCH1,LTM,NA,7881,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.32,0.0477,35392530
NOTCH1,LTM,NA,7881,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qPCR,0.32,0.0477,26506839
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Carcinoma,HEp-2,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.2,0.0477,27380877
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,qRT-PCR followed by SFA and CFA,0.2,0.0477,27380877
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Carcinoma,HEp-2,Docetaxel,qRT-PCR followed by SFA and CFA,0.2,0.0477,27380877
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-2,NA,qRT-PCR,0.2,0.0477,23992541
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-4,NA,SP assay followed by qRT-PCR and CFA,0.2,0.0477,20651344
NOTCH1,LTM,NA,7881,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.2,0.0477,35392530
NOTCH1,LTM,NA,7881,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.2,0.0477,21130073
NOTCH1,LTM,NA,7881,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qPCR,0.2,0.0477,26506839
NOTCH1,LTM,NA,7881,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.2,0.0477,31835579
NOTCH1,LTM,NA,7881,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting followed by SFA and CFA,0.28,0.0477,30908631
NOTCH1,LTM,NA,7881,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.28,0.0477,32128906
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,KUMA-1,NA,qRT-PCR,0.2,0.0477,23992541
NOTCH1,LTM,NA,7881,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and Western Blotting,0.28,0.0477,33262438
NOTCH1,LTM,NA,7881,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,IF staining followed by SFA,0.28,0.0477,31595560
NOTCH1,LTM,NA,7881,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Lapatinib,RT-PCR,0.28,0.0477,29895705
NOTCH1,LTM,NA,7881,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0477,33924995
NOTCH1,LTM,NA,7881,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA,0.28,0.0477,30450530
NOTCH1,LTM,NA,7881,Hepatic Cancer,Carcinoma,MHCC97-H,NA,Western Blotting followed by SFA and CFA,0.28,0.0477,30908631
NOTCH1,LTM,NA,7881,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,CFA followed by Western Blotting,0.28,0.0477,25015789
NOTCH1,LTM,NA,7881,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Western Blotting,0.28,0.0477,20940707
NOTCH1,LTM,NA,7881,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and IF staining,0.28,0.0477,24719318
NOTCH1,LTM,NA,7881,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by RT-PCR,0.28,0.0477,24734907
NOTCH1,LTM,NA,7881,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0477,28959362
NOTCH1,LTM,NA,7881,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting,0.48,0.0477,34845198
NOTCH1,LTM,NA,7881,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.48,0.0477,32863948
NOTCH1,LTM,NA,7881,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.48,0.0477,32633423
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,OSC19,NA,SFA followed by Western Blotting,0.28,0.0477,25588898
NOTCH1,LTM,NA,7881,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by qRT-PCR and Western Blotting,0.48,0.0477,24040121
NOTCH1,LTM,NA,7881,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,CFA followed by Western Blotting,0.48,0.0477,25015789
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-15,NA,qPCR followed by Western Blotting and SFA,0.48,0.0477,35013621
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,qPCR followed by Western Blotting and SFA,0.48,0.0477,35013621
NOTCH1,LTM,NA,7881,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.28,0.0477,34845198
NOTCH1,LTM,NA,7881,Hepatic Cancer,Carcinoma,SNU-398,NA,Western Blotting and SFA,0.28,0.0477,31888685
NOTCH1,LTM,NA,7881,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by Western Blotting,0.28,0.0477,32863948
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,SQ20B,NA,SP assay followed by qRT-PCR and SFA,0.2,0.0477,23955575
NOTCH1,LTM,NA,7881,Gastric Cancer,Adenocarcinoma,ST2957,NA,SFA followed by Western Blotting,0.28,0.0477,32863948
NOTCH1,LTM,NA,7881,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,IF staining followed by SFA,0.24,0.0477,31595560
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,qRT-PCR followed by SFA,0.2,0.0477,32773768
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,SFA followed by RT-PCR,0.2,0.0477,31742606
NOTCH1,LTM,NA,7881,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,qRT-PCR followed by SFA,0.2,0.0477,32773768
NOTCH1,LTM,NA,7881,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0477,25963795
NOTCH1,LTM,NA,7881,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0477,25963795
NOTCH1,LTM,NA,7881,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0477,31506430
NOTCH1,LTM,NA,7881,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.32,0.0477,21922151
NOTCH1,LTM,NA,7881,Small Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0477,25963795
NOTCH1,LTM,NA,7881,Glioblastoma,NA,Primary,NA,SFA and Western Blotting,0.36,0.0477,30701538
NOTCH1,LTM,NA,7881,Triple Negative Breast Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.36,0.0477,33924995
NOTCH2,LTM,NA,7882,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.28,0.0117,24013232
NOTCH2,LTM,NA,7882,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting,0.28,0.0117,29254164
NOTCH2,LTM,NA,7882,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,Western Blotting,0.28,0.0117,34277708
NOTCH2,LTM,NA,7882,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,Western Blotting,0.28,0.0117,29100426
NOTCH2,LTM,NA,7882,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0117,29100426
NOTCH2,LTM,NA,7882,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting,0.28,0.0117,29100426
NOTCH2,LTM,NA,7882,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs and SFA,0.28,0.0117,31745977
NOTCH2,LTM,NA,7882,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by Western Blotting,0.28,0.0117,29100426
NOTCH2,LTM,NA,7882,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by Western Blotting,0.28,0.0117,29100426
NOTCH2,LTM,NA,7882,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR,0.2,0.0117,19232461
NOTCH2,LTM,NA,7882,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.32,0.0117,21922151
NOTCH3,LTM,NA,7883,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA followed by qRT-PCR,0.2,0.0085,26711929
NOTCH3,LTM,NA,7883,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.28,0.0085,29956731
NOTCH3,LTM,NA,7883,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by RT-PCR,0.2,0.0085,30696080
NOTCH3,LTM,NA,7883,Colon Cancer,Adenocarcinoma,WIDR,NA,SFA followed by RT-PCR,0.2,0.0085,25625841
NOTCH3,LTM,NA,7883,Colon Cancer,NA,Primary,NA,RT-PCR followed by Western Blotting,0.64,0.0085,28249897
NOTCH3,LTM,NA,7883,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0085,31506430
NOTCH3,LTM,NA,7883,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.32,0.0085,21922151
NOTCH4,LTM,NA,7884,Skin Cancer,NA,A-375,NA,SFA followed by Western Blotting and IF staining,0.52,0.0042,27234159
NOTCH4,LTM,NA,7884,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by qPCR and SFA,0.32,0.0042,31745977
NOTCH4,LTM,NA,7884,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Radiotherapy,Western Blotting,0.32,0.0042,30272295
NPTX1,LTM,NA,7952,Breast Cancer,NA,Primary,NA,FACs and qRT-PCR followed by SFA,0.48,0.0032,30587593
NQO1,LTM,NA,2874,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0042,35155201
NR5A2,LTM,NA,7984,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qRT-PCR,0.2,0.0042,27996162
NR5A2,LTM,NA,7984,Colon Cancer,Carcinoma,HCT116,NA,qRT-PCR and  FACs followed by SFA,0.32,0.0042,32037723
NR5A2,LTM,NA,7984,Colon Cancer,Adenocarcinoma,HT-29,NA,qRT-PCR and  FACs followed by SFA,0.32,0.0042,32037723
NR5A2,LTM,NA,7984,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.2,0.0042,27996162
NRP1,LTM,NA,8004,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and SFA followed by qRT-PCR,0.32,0.0053,29138851
NRP1,LTM,NA,8004,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,CALU-1,NA,FACs and SFA followed by qRT-PCR,0.32,0.0053,29138851
NRP1,LTM,NA,8004,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0053,29179185
NRP1,LTM,NA,8004,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0053,29179185
NRP1,LTM,NA,8004,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs and SFA,0.48,0.0053,31745977
NT5E,LTM,NA,8021,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR,0.2,0.0095,32708734
NTRK2,LTM,NA,8032,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H226,NA,SFA followed by qRT-PCR,0.2,0.0021,35006496
NTRK3,LTM,NA,8033,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H226,NA,SFA followed by qRT-PCR,0.2,0.0032,35006496
NUMB,LTM,NA,8060,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,IF staining followed by SFA,0.24,0.0021,31595560
NUMB,LTM,NA,8060,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,IF staining followed by SFA,0.24,0.0021,31595560
OLFM4,LTM,NA,17190,Colon Cancer,Adenocarcinoma,CACO-2,5-Fluorouracil,qPCR,0.2,0.0032,33946505
OTUB2,LTM,NA,20351,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting,0.28,0.0021,34646768
OTUB2,LTM,NA,20351,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.28,0.0021,34646768
OV6,LTM,NA,NA,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by FACs and IF staining,0.36,0.0011,30397177
OV6,LTM,NA,NA,Bladder Cancer,Transitional Cell Papilloma,RT-4,NA,SFA followed by FACs,0.12,0.0011,30397177
OV6,LTM,NA,NA,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,SFA followed by FACs,0.12,0.0011,30397177
OV6,LTM,NA,NA,Bladder Cancer,Carcinoma,T24,NA,SFA followed by FACs,0.12,0.0011,30397177
OV6,LTM,NA,NA,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by FACs and IF staining,0.36,0.0011,30397177
PAF1,LTM,NA,25459,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by Western Blotting and SFA,0.28,0.0032,32781084
PAF1,LTM,NA,25459,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting and SFA,0.28,0.0032,32781084
PAF1,LTM,NA,25459,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Tumorigenicity assay and Western Blotting,0.28,0.0032,25003666
PAF1,LTM,NA,25459,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting,0.28,0.0032,25003666
PAK1,LTM,NA,8590,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0032,31658701
PAK1,LTM,NA,8590,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0032,31658701
PAK1,LTM,NA,8590,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting and Migartion Invasion assay,0.28,0.0032,31658701
PAK4,LTM,NA,16059,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting,0.28,0.0011,26546043
PAK4,LTM,NA,16059,Pancreatic Cancer,Ductal Adenocarcinoma,T3M4,NA,Western Blotting,0.28,0.0011,26546043
PAX6,LTM,NA,8620,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting and RT-PCR followed by SFA and Migration Invasion assay,0.48,0.0021,31024010
PAX6,LTM,NA,8620,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA followed by qRT-PCR and Western Blotting and Tumorigenicity assay,0.48,0.0021,29980786
PAX6,LTM,NA,8620,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,SFA followed by qRT-PCR and Western Blotting and Tumorigenicity assay,0.48,0.0021,29980786
PAX6,LTM,NA,8620,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,Western Blotting and RT-PCR followed by SFA and Migration Invasion assay,0.48,0.0021,31024010
PCNA,LTM,NA,8729,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.28,0.0032,31255531
PCNA,LTM,NA,8729,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.0032,24151393
PCSK6,LTM,NA,8569,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.2,0.0021,35267511
PCSK6,LTM,NA,8569,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.2,0.0021,35267511
PCSK6,LTM,NA,8569,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by qRT-PCR,0.2,0.0021,35267511
PCSK7,LTM,NA,8748,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.2,0.0011,35267511
PCSK7,LTM,NA,8748,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.2,0.0011,35267511
PCSK7,LTM,NA,8748,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by qRT-PCR,0.2,0.0011,35267511
PDGFB,LTM,NA,8800,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0032,30397177
PDGFB,LTM,NA,8800,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0032,30397177
PDGFRB,LTM,NA,8804,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by qRT-PCR,0.2,0.0011,33845139
PDK1,LTM,NA,8809,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0053,29106390
PDK1,LTM,NA,8809,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.28,0.0053,34052833
PDK1,LTM,NA,8809,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0053,29106390
PDK1,LTM,NA,8809,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.28,0.0053,34052833
PDPN,LTM,NA,29602,Head and Neck Cancer,Oral Squamous Cell Carcinoma,CaLH3,NA,SFA followed by qRT-PCR,0.2,0.0032,25212757
PELP1,LTM,NA,30134,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.0011,29348189
PGR,LTM,Down,8910,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by qRT-PCR and IHC staining,0.44,0.0021,19353633
PGR,LTM,Down,8910,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and IHC staining,0.44,0.0021,19353633
PGR,LTM,Down,8910,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by qRT-PCR and IHC staining,0.44,0.0021,19353633
PGR,LTM,Down,8910,Luminal A Breast Cancer,Ductal Carcinoma,ZR-75-1,NA,SFA followed by qRT-PCR and IHC staining,0.44,0.0021,19353633
PHC3,LTM,NA,15682,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by qPCR and Western Blotting,0.48,0.0021,34424425
PHC3,LTM,NA,15682,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs for CSC marker followed by qPCR and Western Blotting,0.48,0.0021,34424425
PHF5A,LTM,NA,18000,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by Western Blotting and SFA,0.28,0.0011,32781084
PHF5A,LTM,NA,18000,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting and SFA,0.28,0.0011,32781084
PIK3CA,LTM,NA,8975,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by qRT-PCR,0.2,0.0032,28976208
PIM3,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting and qRT-PCR,0.48,0.0011,28775772
PiRNA-823,LTM,NA,NA,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by qRT-PCR and SFA,0.2,0.0011,33791297
PiRNA-823,LTM,NA,NA,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by qRT-PCR and SFA,0.28,0.0011,33791297
PLAU,LTM,NA,9052,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by SP assay and RT-PCR,0.2,0.0042,30477473
PLAUR,LTM,NA,9053,Small Cell Lung Cancer,Carcinoma,H1417,NA,FACs followed by CFA,0.12,0.0085,17327908
PLAUR,LTM,NA,9053,Small Cell Lung Cancer,Carcinoma,H1688,NA,FACs,0.12,0.0085,17327908
PLAUR,LTM,NA,9053,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by FACs and qRT-PCR,0.32,0.0085,30254465
PLAUR,LTM,NA,9053,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Western Blotting,0.32,0.0085,30015975
PLAUR,LTM,NA,9053,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Tumorigenicity assay and IF staining,0.32,0.0085,22521544
PLAUR,LTM,NA,9053,Small Cell Lung Cancer,Carcinoma,H446,NA,FACs,0.32,0.0085,27167619
PLAUR,LTM,NA,9053,Small Cell Lung Cancer,Carcinoma,H69,NA,FACs,0.12,0.0085,17327908
PLAUR,LTM,NA,9053,Small Cell Lung Cancer,Carcinoma,SBC-4,NA,RT-PCR followed by FACs,0.32,0.0085,23066953
PLAUR,LTM,NA,9053,Small Cell Lung Cancer,Carcinoma,SBC-7,NA,RT-PCR followed by FACs,0.32,0.0085,23066953
PLAUR,LTM,NA,9053,Small Cell Lung Cancer,Carcinoma,SBC-9,NA,RT-PCR followed by FACs,0.32,0.0085,23066953
PLAUR,LTM,NA,9053,Lung Cancer,NA,Primary,NA,FACs,0.2,0.0085,19536353
PLEC,LTM,NA,9069,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,FACs for CSC marker followed by qRT-PCR,0.2,0.0053,34530236
PMP22,LTM,NA,9118,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qPCR and Western Blotting and  FACs,0.6,0.0011,28336807
POU5F1,LTM,NA,7553,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting and qRT-PCR,0.72,0.6448,28775772
POU5F1,LTM,NA,7553,Pancreatic Cancer,NA,Primary,NA,SFA and qRT-PCR followed by Western Blotting and IHC staining,0.96,0.6448,26451606
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,5637,Paclitaxel,SFA followed by Western Blotting,0.28,0.6448,35008872
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Western Blotting,0.28,0.6448,29559853
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,5637,NA,SFA followed by qRT-PCR,0.28,0.6448,30592142
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by FACs and Western Blotting,0.4,0.6448,30628703
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by qRT-PCR,0.4,0.6448,27766570
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by RT-PCR,0.4,0.6448,27556038
POU5F1,LTM,NA,9221,Glioblastoma,NA,A-172,Temozolomide,Western Blotting and CFA,0.28,0.6448,34036375
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,A-253,NA,RT-PCR followed by CFA,0.2,0.6448,24612587
POU5F1,LTM,NA,9221,Skin Cancer,NA,A-375,NA,SFA followed by qPCR and Western Blotting,0.48,0.6448,29693169
POU5F1,LTM,NA,9221,Skin Cancer,NA,A-375,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,29693169
POU5F1,LTM,NA,9221,Skin Cancer,NA,A-375,NA,SFA and Western Blotting,0.48,0.6448,30717768
POU5F1,LTM,NA,9221,Skin Cancer,NA,A-375,NA,SFA followed by qRT-PCR,0.48,0.6448,30558661
POU5F1,LTM,NA,9221,Skin Cancer,NA,A-375,NA,SP assay followed by RT-PCR,0.48,0.6448,30522558
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,IF staining followed by Western Blotting,0.52,0.6448,34168463
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,5-Fluorouracil,IF staining followed by Western Blotting,0.52,0.6448,34168463
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and Western Blotting,0.52,0.6448,34063628
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and Western Blotting followed by SFA,0.52,0.6448,33783940
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,33539684
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,34873829
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,35229723
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,CFA and SFA followed by RT-PCR and Western Blotting,0.52,0.6448,28406482
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR  followed by Western Blotting,0.52,0.6448,28179999
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,qRT-PCR and Western Blotting,0.52,0.6448,32319573
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by Western Blotting,0.52,0.6448,30878308
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,28431267
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,29344850
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,29888108
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,30485693
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,32655789
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.52,0.6448,28861158
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.52,0.6448,30555330
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by Western Blotting and RT-PCR,0.52,0.6448,24333218
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining and RT-PCR,0.52,0.6448,21520032
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and IF staining,0.52,0.6448,24101104
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and IF staining,0.52,0.6448,26239272
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by IF staining,0.52,0.6448,21124918
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and qRT-PCR  followed by SFA and Tumorigenicity assay,0.52,0.6448,29262597
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,FACs followed by RT-PCR,0.52,0.6448,24356998
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA and RT-PCR,0.52,0.6448,28854941
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and qRT-PCR,0.52,0.6448,28534939
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,SFA followed by FACs and qRT-PCR,0.52,0.6448,29860718
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and qRT-PCR,0.52,0.6448,30816208
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by SFA and Western Blotting,0.52,0.6448,33707423
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Irradiation,SFA and Western Blotting,0.52,0.6448,34163000
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.6448,33980809
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.6448,34949193
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting,0.52,0.6448,34803670
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting followed by SFA,0.52,0.6448,33721187
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,SFA and Western Blotting,0.52,0.6448,26779808
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and Western Blotting,0.52,0.6448,29387193
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by CFA and Western Blotting,0.52,0.6448,32637578
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.6448,21425153
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.6448,21802163
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by Western Blotting,0.52,0.6448,22370645
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.6448,23583374
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.6448,24013232
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.6448,24386189
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.6448,26517679
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,SFA followed by Western Blotting,0.52,0.6448,29299167
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,SFA followed by Western Blotting,0.52,0.6448,29299167
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.6448,29416721
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by Western Blotting,0.52,0.6448,31207300
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.6448,31263095
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.6448,31928533
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.6448,33125096
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,SP assay followed by Western Blotting,0.52,0.6448,23022172
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,Western Blotting,0.52,0.6448,23349823
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting,0.52,0.6448,29254164
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,Western Blotting,0.52,0.6448,30341415
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,Western Blotting,0.52,0.6448,31282010
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,Western Blotting followed by Migration assay,0.52,0.6448,20074550
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,Western Blotting followed by SFA,0.52,0.6448,29299167
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining,0.52,0.6448,24668028
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining,0.52,0.6448,26261505
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Irradiation,CFA followed by qRT-PCR,0.52,0.6448,33924205
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR,0.52,0.6448,33068069
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR,0.52,0.6448,33995625
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR,0.52,0.6448,34400945
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,qRT-PCR and SFA,0.52,0.6448,33784109
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by SFA,0.52,0.6448,33670440
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,33437165
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,33468994
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,34209829
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,34277782
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,34832951
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,35044041
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.52,0.6448,34681614
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture and SFA followed by qRT-PCR,0.52,0.6448,29017078
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Pemetrexed,qPCR,0.52,0.6448,26181204
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Pemetrexed,qPCR,0.52,0.6448,26181204
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR,0.52,0.6448,24646078
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and SFA,0.52,0.6448,29144562
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by SFA and SP assay,0.52,0.6448,26468775
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR,0.52,0.6448,22300949
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Pemetrexed +Cisplatin,RT-PCR,0.52,0.6448,26895954
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR,0.52,0.6448,26940223
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR,0.52,0.6448,26940223
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR,0.52,0.6448,31201845
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by CFA,0.52,0.6448,29995950
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA,0.52,0.6448,25003810
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA,0.52,0.6448,29225473
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA,0.52,0.6448,31368411
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA and CFA followed by RT-PCR,0.52,0.6448,28850563
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Regorafenib,SFA and CFA followed by RT-PCR,0.52,0.6448,28850563
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Sorafenib,SFA and CFA followed by RT-PCR,0.52,0.6448,28850563
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qPCR,0.52,0.6448,26675547
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,22900142
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,24101104
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,27766570
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,28035349
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,29044153
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,29138851
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,29448000
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,31024010
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,32401390
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.6448,32612672
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by qRT-PCR,0.52,0.6448,32655321
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.52,0.6448,26546046
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by RT-PCR,0.52,0.6448,27009878
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.52,0.6448,28787001
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.52,0.6448,31582014
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.52,0.6448,28456659
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay and SFA followed by qRT-PCR,0.52,0.6448,31871777
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by qRT-PCR,0.52,0.6448,23009336
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR,0.52,0.6448,22615765
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR,0.52,0.6448,22825470
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.52,0.6448,21947321
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,Dexamethasone+Pemetrexed,FACs followed by SFA,0.52,0.6448,29753869
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay and SFA followed by FACs and Tumorigenicity assay,0.52,0.6448,20949018
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by FACs and SFA,0.52,0.6448,26081992
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,31261030
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA and Western Blotting,0.48,0.6448,34278502
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.48,0.6448,28461325
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.48,0.6448,32606358
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.48,0.6448,33288885
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qPCR,0.48,0.6448,29559846
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.48,0.6448,27735991
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.48,0.6448,29512256
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.48,0.6448,32633423
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.48,0.6448,34173116
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qRT-PCR followed by Western Blotting,0.48,0.6448,28703793
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qPCR and Western Blotting,0.48,0.6448,32575925
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,27996162
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Western Blotting,0.48,0.6448,30853342
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,qRT-PCR,0.48,0.6448,34163012
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,qRT-PCR and SFA,0.48,0.6448,33728488
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA and qRT-PCR,0.48,0.6448,35241126
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qRT-PCR,0.48,0.6448,26391180
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qRT-PCR,0.48,0.6448,27996162
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qRT-PCR,0.48,0.6448,30119228
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and qRT-PCR and Western Blotting ,0.48,0.6448,33731207
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and qRT-PCR followed by Western Blotting ,0.48,0.6448,34427968
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,BGC-823,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,33579380
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.6448,28440445
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.48,0.6448,34090492
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.48,0.6448,34350176
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by Western Blotting,0.48,0.6448,30624124
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,BGC-823,NA,Western Blotting followed by SFA,0.48,0.6448,31517391
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by qRT-PCR,0.48,0.6448,33798550
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by qRT-PCR,0.48,0.6448,34173116
POU5F1,LTM,NA,9221,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by qRT-PCR,0.2,0.6448,35195687
POU5F1,LTM,NA,9221,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,Trastuzumab,SFA followed by qPCR,0.2,0.6448,28722778
POU5F1,LTM,NA,9221,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by qPCR,0.2,0.6448,30224376
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Cyclophosphamide,qRT-PCR and Western Blotting,0.48,0.6448,33090711
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,33090711
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,Western Blotting,0.48,0.6448,29100426
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,IF staining followed by SFA,0.48,0.6448,34889737
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA and qRT-PCR,0.48,0.6448,35064101
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by qPCR,0.48,0.6448,35277657
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,RT-PCR,0.48,0.6448,29262622
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.6448,28703793
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.6448,24305593
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by Western Blotting,0.48,0.6448,31713003
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,Western Blotting and SFA,0.48,0.6448,33082357
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by Western Blotting,0.48,0.6448,30853342
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by Western Blotting,0.48,0.6448,32766132
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by qRT-PCR,0.48,0.6448,29048549
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,FACs,0.48,0.6448,31713003
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SP assay,0.48,0.6448,22963768
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by FACs,0.48,0.6448,29719602
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Ca9-22,NA,SFA and RT-PCR and Western Blotting,0.48,0.6448,24475244
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,CACO-2,NA,SFA followed by RT-PCR,0.2,0.6448,29312609
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,Western Blotting followed by IF staining and SFA,0.52,0.6448,29575240
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Western Blotting,0.52,0.6448,34502158
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,Western Blotting and SFA,0.52,0.6448,25871396
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,Western Blotting followed by SFA,0.52,0.6448,31399556
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,Western Blotting followed by SFA,0.52,0.6448,34795388
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and Western Blotting,0.52,0.6448,32194902
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by Western Blotting,0.52,0.6448,31585633
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by qRT-PCR,0.52,0.6448,24112466
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by RT-PCR,0.52,0.6448,28093940
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.52,0.6448,27380877
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,qRT-PCR followed by SFA and CFA,0.52,0.6448,27380877
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Docetaxel,qRT-PCR followed by SFA and CFA,0.52,0.6448,27380877
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,CAL51,NA,qRT-PCR followed by SFA,0.2,0.6448,30450530
POU5F1,LTM,NA,9221,Head and Neck Cancer,Oral Squamous Cell Carcinoma,CaLH3,NA,SFA followed by qRT-PCR,0.2,0.6448,25212757
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,CALU-1,NA,SFA followed by qRT-PCR,0.2,0.6448,29138851
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,Capan-1,Gemcitabine,qRT-PCR followed by IHC staining,0.44,0.6448,23026911
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by Western Blotting and SFA,0.44,0.6448,32781084
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by qRT-PCR,0.44,0.6448,30819221
POU5F1,LTM,NA,9221,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,33737813
POU5F1,LTM,NA,9221,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.48,0.6448,30853342
POU5F1,LTM,NA,9221,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.48,0.6448,29100320
POU5F1,LTM,NA,9221,Lung Cancer,Adenocarcinoma,CL1-0,NA,CFA and SFA followed by Western Blotting,0.28,0.6448,35163585
POU5F1,LTM,NA,9221,Lung Cancer,Adenocarcinoma,CL-1-1,NA,SFA followed by Western Blotting,0.28,0.6448,29416721
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,CL-141,NA,SFA followed by Western Blotting,0.28,0.6448,31638335
POU5F1,LTM,NA,9221,Lung Cancer,Adenocarcinoma,CL1-5,NA,SFA followed by qRT-PCR,0.2,0.6448,35154481
POU5F1,LTM,NA,9221,Skin Cancer,NA,D10,NA,SFA and CFA followed by qRT-PCR,0.2,0.6448,26208390
POU5F1,LTM,NA,9221,Glioblastoma,NA,DBTRG-05MG,NA,SFA and Western Blotting,0.28,0.6448,33317545
POU5F1,LTM,NA,9221,Head and Neck Cancer,Carcinoma,Detroit-562,NA,SFA followed by FACs,0.12,0.6448,24874475
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.2,0.6448,23418515
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,Carcinoma,DMS53,NA,Western Blotting,0.28,0.6448,31446534
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,28870814
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,32661469
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.6448,31180522
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,EJ-28,Benzidine,SFA followed by Western Blotting,0.48,0.6448,33552265
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by Western Blotting,0.48,0.6448,33552265
POU5F1,LTM,NA,9221,Lung Cancer,Adenocarcinoma,EKVX,NA,SFA followed by IF staining,0.24,0.6448,24668028
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by qPCR and Western Blotting,0.48,0.6448,29228308
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.6448,32708734
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Dasatinib,Western Blotting followed by qRT-PCR,0.48,0.6448,31382448
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Saracatinib,Western Blotting followed by qRT-PCR,0.48,0.6448,31382448
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by Western Blotting,0.48,0.6448,34502158
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,Western Blotting and SFA,0.48,0.6448,25871396
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,Western Blotting followed by SFA,0.48,0.6448,31399556
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,Western Blotting,0.48,0.6448,24201869
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Cisplatin,SFA followed by qRT-PCR,0.48,0.6448,32206093
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR,0.48,0.6448,28093940
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by FACs,0.48,0.6448,24874475
POU5F1,LTM,NA,9221,Glioblastoma Multiforme,NA,GBM8401,NA,SFA followed by IF staining,0.24,0.6448,31035045
POU5F1,LTM,NA,9221,Glioblastoma Multiforme,NA,GBM8401,NA,SP assay and SFA followed by RT-PCR,0.24,0.6448,25359730
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,SFA followed by Western Blotting,0.28,0.6448,30717421
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,qRT-PCR,0.28,0.6448,24646078
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.6448,33783940
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,33539684
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,34873829
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,28431267
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.6448,30555330
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs and Western Blotting,0.48,0.6448,27542268
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs followed by IF staining,0.48,0.6448,21124918
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,MACs followed by qPCR,0.48,0.6448,24008862
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs and qRT-PCR,0.48,0.6448,30816208
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and FACs,0.48,0.6448,25669973
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.6448,33980809
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,Western Blotting,0.48,0.6448,34803670
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by CFA and Western Blotting,0.48,0.6448,32637578
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.6448,23583374
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.6448,27836540
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.6448,27836540
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.6448,28198062
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.6448,33125096
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,RT-PCR and SFA,0.48,0.6448,34681614
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.6448,33468994
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.6448,34832951
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,qRT-PCR and SFA,0.48,0.6448,29144562
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,RT-PCR,0.48,0.6448,22300949
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,Gefitinib,SFA and CFA followed by RT-PCR,0.48,0.6448,28850563
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,Regorafenib,SFA and CFA followed by RT-PCR,0.48,0.6448,28850563
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,Sorafenib,SFA and CFA followed by RT-PCR,0.48,0.6448,28850563
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qPCR,0.48,0.6448,26675547
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,Docetaxel,SFA followed by qRT-PCR,0.48,0.6448,25279705
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.6448,32051483
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.6448,32401390
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.6448,32612672
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,Cisplatin,SFA followed by qRT-PCR,0.48,0.6448,32655321
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR,0.48,0.6448,25735977
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR,0.48,0.6448,27556038
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SP assay and SFA followed by qRT-PCR,0.48,0.6448,31871777
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SP assay and SFA followed by FACs and Tumorigenicity assay,0.48,0.6448,20949018
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,NA,H1408,NA,SFA followed by FACs and RT-PCR,0.32,0.6448,29437792
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H157,NA,SFA followed by qPCR,0.2,0.6448,26675547
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H157,Cisplatin,SFA followed by RT-PCR,0.2,0.6448,27009878
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Giant Cell Carcinoma,H1581,NA,SFA followed by qRT-PCR,0.2,0.6448,26936993
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H1648,NA,FACs followed by IF staining,0.36,0.6448,21124918
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,SFA followed by qPCR and Western Blotting,0.48,0.6448,29702194
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,FACs followed by IF staining,0.48,0.6448,21124918
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,FACs followed by SFA and qPCR,0.48,0.6448,24091605
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,Western Blotting,0.48,0.6448,34803670
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,Erlotinib,qRT-PCR,0.48,0.6448,30480362
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,Dexamethasone+Pemetrexed,FACs followed by SFA,0.48,0.6448,29753869
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H1658,Erlotinib,RT-PCR followed by CFA and SFA,0.2,0.6448,31069016
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H1703,NA,qRT-PCR followed by SFA and SP assay,0.2,0.6448,26468775
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1781,Afatinib,qRT-PCR followed by SFA,0.2,0.6448,29532558
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,29888108
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA followed by Western Blotting,0.48,0.6448,33922104
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,Western Blotting,0.48,0.6448,34475041
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,qRT-PCR followed by SFA,0.48,0.6448,32922547
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay followed by qRT-PCR,0.48,0.6448,23009336
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.48,0.6448,35229723
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H1993,NA,RT-PCR followed by CFA,0.2,0.6448,29995950
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,NA,H20,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,33969609
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,NA,H20,Etopside,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,33969609
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,Carcinoma,H209,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,32953511
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,qRT-PCR followed by SFA,0.2,0.6448,33670440
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,Carcinoma,H2227,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,33969609
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,Carcinoma,H2227,Etopside,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,33969609
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H2228,NA,SFA followed by Western Blotting,0.28,0.6448,26517679
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H226,Cisplatin,IF staining followed by Western Blotting,0.52,0.6448,34168463
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H226,5-Fluorouracil,IF staining followed by Western Blotting,0.52,0.6448,34168463
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H23,Cisplatin,SFA followed by IF staining and Western Blotting,0.52,0.6448,26872057
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,qRT-PCR and Western Blotting,0.52,0.6448,34063628
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,FACs followed by IF staining,0.52,0.6448,21124918
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,SFA followed by Western Blotting,0.52,0.6448,32509180
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,SFA and qRT-PCR,0.52,0.6448,29980786
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by qRT-PCR,0.2,0.6448,34209829
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H3122,NA,SFA followed by Western Blotting,0.28,0.6448,26517679
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H3122,NA,SFA followed by qRT-PCR,0.28,0.6448,29950868
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H322,NA,SFA followed by Western Blotting,0.28,0.6448,26837769
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H322,NA,SFA followed by Western Blotting,0.28,0.6448,26837769
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,Carcinoma,H345,NA,Western Blotting,0.28,0.6448,24436149
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,Pemetrexed,qPCR,0.2,0.6448,26181204
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.2,0.6448,28456659
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,FACs,0.2,0.6448,21947321
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,FACs followed by IF staining,0.36,0.6448,21124918
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,CFA and SFA followed by Western Blotting,0.36,0.6448,35163585
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,32953511
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Western Blotting,0.48,0.6448,27633248
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by IF staining,0.48,0.6448,24101104
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA and Western Blotting followed by IF staining,0.52,0.6448,34832867
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,qRT-PCR and Western Blotting,0.52,0.6448,34063628
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,CFA and SFA followed by RT-PCR and Western Blotting,0.52,0.6448,28406482
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by RT-PCR and Western Blotting,0.52,0.6448,28861158
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA and Western Blotting,0.52,0.6448,34635641
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by CFA and Western Blotting,0.52,0.6448,32637578
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.52,0.6448,27281614
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.52,0.6448,28677037
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.52,0.6448,30111255
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.52,0.6448,32509180
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.52,0.6448,26885450
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.52,0.6448,30305725
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,Paclitaxel,SP assay followed by Western Blotting and Tumorigenicity assay,0.52,0.6448,23022172
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,Western Blotting,0.52,0.6448,23349823
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,Western Blotting followed by SFA,0.52,0.6448,26901847
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by RT-PCR,0.52,0.6448,33068069
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,FACs for CSC marker followed by qRT-PCR,0.52,0.6448,33550205
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.52,0.6448,34209829
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.52,0.6448,34349823
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,Pemetrexed,qPCR,0.52,0.6448,26181204
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,RT-PCR,0.52,0.6448,22300949
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,Gefitinib,SFA and CFA followed by RT-PCR,0.52,0.6448,28850563
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,Regorafenib,SFA and CFA followed by RT-PCR,0.52,0.6448,28850563
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,Sorafenib,SFA and CFA followed by RT-PCR,0.52,0.6448,28850563
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qPCR and Tumorigenicity assay,0.52,0.6448,30305725
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.52,0.6448,25276790
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.52,0.6448,31397494
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.52,0.6448,31658996
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.52,0.6448,31717588
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by RT-PCR,0.52,0.6448,24309934
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,FACs for CSC marker followed by SFA and Western Blotting,0.28,0.6448,33707423
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,Western Blotting followed by SFA,0.28,0.6448,33721187
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,SFA followed by qRT-PCR,0.28,0.6448,26936993
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,SFA followed by qRT-PCR,0.28,0.6448,32863772
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,H522,NA,RT-PCR,0.2,0.6448,18952074
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,Carcinoma,H69,NA,Western Blotting,0.28,0.6448,24436149
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA followed by qRT-PCR,0.28,0.6448,34832951
POU5F1,LTM,NA,9221,Breast Cancer,Carcinoma,HCC1569,NA,Western Blotting followed by SFA and IF staining,0.52,0.6448,34889737
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA followed by qRT-PCR,0.2,0.6448,26711929
POU5F1,LTM,NA,9221,Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,Western Blotting followed by SFA and IF staining,0.52,0.6448,34889737
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,Western Blotting and SFA,0.52,0.6448,35504883
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,HCC1833,NA,FACs followed by IF staining,0.36,0.6448,21124918
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,SFA and Western Blotting,0.28,0.6448,33390847
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,IF staining followed by SFA,0.28,0.6448,34889737
POU5F1,LTM,NA,9221,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,NA,Western Blotting followed by SFA,0.28,0.6448,30326469
POU5F1,LTM,NA,9221,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,MK-0752,qRT-PCR,0.28,0.6448,29027990
POU5F1,LTM,NA,9221,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,MK-0752,qRT-PCR,0.28,0.6448,29027990
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,FACs followed by IF staining,0.36,0.6448,21124918
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,FACs followed by SFA and qPCR,0.36,0.6448,24091605
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by Western Blotting,0.36,0.6448,33955683
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by Western Blotting,0.36,0.6448,30305725
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,qRT-PCR,0.36,0.6448,33764690
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,qPCR,0.36,0.6448,24489728
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by RT-PCR,0.36,0.6448,28787001
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,SP assay followed by qRT-PCR and CFA,0.36,0.6448,25871388
POU5F1,LTM,NA,9221,Lung Cancer,Squamous Cell Carcinoma,HCC95,NA,SFA followed by qRT-PCR,0.2,0.6448,32863772
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,HCCLM3,NA,CFA followed by SFA and qRT-PCR,0.2,0.6448,27783993
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,HCCLM3,NA,SFA followed by qRT-PCR,0.2,0.6448,25676692
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.6448,30774996
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil,SFA followed by Western Blotting and qRT-PCR,0.48,0.6448,28990068
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and RT-PCR,0.48,0.6448,19451087
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and RT-PCR,0.48,0.6448,31120140
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by SFA and Western Blotting,0.48,0.6448,33819194
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,Oxaliplatin,SFA followed by Western Blotting,0.48,0.6448,24330852
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.48,0.6448,27997180
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.48,0.6448,30305725
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,SFA and IF staining,0.48,0.6448,26745821
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.48,0.6448,35242031
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,Docetaxel,qRT-PCR,0.48,0.6448,27748801
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,qRT-PCR,0.48,0.6448,29426374
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by SFA,0.48,0.6448,32037723
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,SFA and qRT-PCR,0.48,0.6448,25368233
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,SFA and qRT-PCR,0.48,0.6448,33209130
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.48,0.6448,29307822
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.48,0.6448,31544978
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by RT-PCR,0.48,0.6448,21750907
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,0.6448,31641961
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,qRT-PCR and Western Blotting,0.48,0.6448,24145190
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SFA followed by Western Blotting,0.48,0.6448,27997180
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HCT-15,Cisplatin,SFA and qPCR,0.48,0.6448,34921482
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,RT-PCR followed by SFA,0.48,0.6448,28946619
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SP assay followed by Tumorigenicity assay and RT-PCR,0.48,0.6448,21435460
POU5F1,LTM,NA,9221,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by qPCR and Western Blotting,0.48,0.6448,29228308
POU5F1,LTM,NA,9221,Head and Neck Cancer,Carcinoma,HEp-2,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.48,0.6448,27380877
POU5F1,LTM,NA,9221,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,qRT-PCR followed by SFA and CFA,0.48,0.6448,27380877
POU5F1,LTM,NA,9221,Head and Neck Cancer,Carcinoma,HEp-2,Docetaxel,qRT-PCR followed by SFA and CFA,0.48,0.6448,27380877
POU5F1,LTM,NA,9221,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by RT-PCR,0.48,0.6448,26021266
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by qRT-PCR,0.2,0.6448,27773936
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by qRT-PCR,0.2,0.6448,34405006
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Hep3B,NA,CFA followed by SFA and qRT-PCR,0.2,0.6448,27783993
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by qRT-PCR,0.2,0.6448,25676692
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Hep3B,NA,FACs followed by CFA,0.2,0.6448,22194816
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Hep-G2,NA,SFA followed by Western Blotting,0.28,0.6448,29033320
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Hep-G2,NA,SFA followed by Western Blotting,0.28,0.6448,32626943
POU5F1,LTM,NA,9221,Gastric Cancer,NA,HFE-145,NA,SFA followed by Western Blotting,0.28,0.6448,33288885
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by Western Blotting,0.28,0.6448,30007956
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by qPCR,0.28,0.6448,29559846
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,HN-1,NA,SFA followed by Western Blotting,0.28,0.6448,25024430
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,HN4,Cisplatin,Western Blotting followed by SFA,0.28,0.6448,34795388
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,HN4,NA,SFA and Western Blotting,0.28,0.6448,32194902
POU5F1,LTM,NA,9221,Lung Cancer,Adenocarcinoma,HOP-62,NA,SFA followed by qRT-PCR,0.2,0.6448,35154481
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,CFA followed by IF staining,0.24,0.6448,30395429
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,SFA followed by Western Blotting,0.28,0.6448,30853342
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,IF staining followed by SFA,0.24,0.6448,34889737
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by qPCR,0.24,0.6448,30224376
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-2,NA,qRT-PCR,0.2,0.6448,23992541
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,SFA followed by Western Blotting,0.28,0.6448,27002147
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,qPCR and SFA,0.28,0.6448,26448762
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,qRT-PCR followed by CFA,0.28,0.6448,22847005
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-4,NA,SP assay followed by qRT-PCR and CFA,0.2,0.6448,20651344
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,HT-1197,NA,Western Blotting,0.28,0.6448,35008872
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,HT-1376,NA,SFA followed by qRT-PCR,0.2,0.6448,26452033
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by Western Blotting and RT-PCR,0.6,0.6448,22384170
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR and Western Blotting,0.6,0.6448,30774996
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA and RT-PCR,0.6,0.6448,31120140
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker followed by SFA and Western Blotting,0.6,0.6448,33819194
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.6,0.6448,33667839
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.6,0.6448,30944638
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and IF staining,0.6,0.6448,26745821
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by IHC staining,0.6,0.6448,26918725
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.6,0.6448,35267511
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,Docetaxel,qRT-PCR,0.6,0.6448,27748801
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,Docetaxel,qRT-PCR,0.6,0.6448,27748801
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,qRT-PCR,0.6,0.6448,27748801
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,qRT-PCR,0.6,0.6448,27748801
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,qRT-PCR followed by SFA,0.6,0.6448,32037723
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.6,0.6448,21130073
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and qRT-PCR,0.6,0.6448,27556511
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.6,0.6448,27556511
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.6,0.6448,31544978
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.6,0.6448,26634106
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.6,0.6448,29312609
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by RT-PCR,0.6,0.6448,30209760
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by Tumorigenicity assay and RT-PCR,0.6,0.6448,21435460
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,HTB-9,NA,ICC staining followed by SFA,0.24,0.6448,26054707
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay and qRT-PCR followed by SFA and IF staining,0.44,0.6448,29792038
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Western Blotting,0.44,0.6448,27312708
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting and SFA,0.44,0.6448,32229502
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting followed by SFA and CFA,0.44,0.6448,30908631
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.44,0.6448,27773936
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and qRT-PCR,0.44,0.6448,21618577
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.44,0.6448,25676692
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.44,0.6448,32128906
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by CFA,0.44,0.6448,22194816
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,J-82,NA,Western Blotting,0.28,0.6448,24649144
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by qRT-PCR,0.28,0.6448,35116788
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,J-82,Cisplatin,RT-PCR,0.28,0.6448,26647959
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,JLO-1,Metformin,qPCR,0.2,0.6448,30621095
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by Western Blotting,0.28,0.6448,32606358
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by Western Blotting,0.28,0.6448,33288885
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by qRT-PCR,0.28,0.6448,31233198
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.6448,21618577
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,KUMA-1,NA,qRT-PCR,0.2,0.6448,23992541
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR,0.2,0.6448,26840266
POU5F1,LTM,NA,9221,Lung Cancer,Large Cell Carcinoma,L9981,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,30485693
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,NA,LC31,NA,RT- PCR followed by SFA,0.2,0.6448,21738704
POU5F1,LTM,NA,9221,Lung Cancer,NA,LC-42,NA,IHC staining and SFA followed by SP assay and RT-PCR,0.44,0.6448,23738757
POU5F1,LTM,NA,9221,Breast Cancer,Ductal Carcinoma,LCC2,NA,SFA followed by Western Blotting,0.28,0.6448,30450766
POU5F1,LTM,NA,9221,Glioblastoma,NA,LN-18,NA,SFA and qRT-PCR,0.2,0.6448,29069805
POU5F1,LTM,NA,9221,Glioblastoma,NA,LN-229,NA,SFA and Western Blotting,0.28,0.6448,29228694
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.28,0.6448,33109220
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,qRT-PCR,0.28,0.6448,30284085
POU5F1,LTM,NA,9221,Dukes Type B Colon Cancer,Adenocarcinoma,LS174T,NA,FACs followed by Western Blotting and RT-PCR,0.6,0.6448,22384170
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,Mahlavu,NA,SP assay followed by Western Blotting,0.28,0.6448,29792038
POU5F1,LTM,NA,9221,Skin Cancer,NA,MA-MEL-66A,NA,SFA followed by qRT-PCR,0.2,0.6448,30558661
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting and IF staining,0.52,0.6448,29100426
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting and IHC staining,0.52,0.6448,29749438
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and Western Blotting followed by CFA,0.52,0.6448,35235236
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,34052833
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,34249423
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,35029026
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by qRT-PCR and SFA,0.52,0.6448,33791297
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR followed by Western Blotting and SFA,0.52,0.6448,31736268
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,31300015
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,31760402
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and RT-PCR,0.52,0.6448,29511337
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and RT-PCR followed by SFA,0.52,0.6448,29601799
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qPCR and IF staining,0.52,0.6448,29846560
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and IF staining,0.52,0.6448,30188754
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and IF staining,0.52,0.6448,30188754
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by Western Blotting,0.52,0.6448,33731668
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6448,33305893
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.52,0.6448,34362383
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by SFA,0.52,0.6448,34528694
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,CFA followed by Western Blotting,0.52,0.6448,28839461
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6448,28802057
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6448,28823831
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6448,29106390
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6448,29243835
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6448,29356693
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,SFA followed by Western Blotting,0.52,0.6448,29750424
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6448,29797562
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6448,30080291
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6448,30450766
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6448,31501409
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6448,31604679
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.6448,31695775
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,Western Blotting,0.52,0.6448,31286834
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,Western Blotting and SFA,0.52,0.6448,29185119
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.52,0.6448,29287960
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.52,0.6448,30482236
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by SFA,0.52,0.6448,29218545
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by SFA,0.52,0.6448,30335523
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Cobalt Chloride,Western Blotting followed by SFA,0.52,0.6448,31584203
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR,0.52,0.6448,33634797
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and SFA,0.52,0.6448,34217266
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and SFA,0.52,0.6448,34298877
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR followed by SFA,0.52,0.6448,34830485
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.6448,33511560
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.6448,34486791
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.6448,34803458
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR,0.52,0.6448,31762819
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and SFA,0.52,0.6448,30239174
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,MK-0752,qRT-PCR followed by SFA,0.52,0.6448,29027990
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR followed by SFA,0.52,0.6448,30214607
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA and qRT-PCR,0.52,0.6448,31728117
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.6448,29044153
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.6448,30175027
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Paclitaxel,SFA followed by qRT-PCR,0.52,0.6448,30340507
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.6448,30628646
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.6448,31693936
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by RT-PCR,0.52,0.6448,30579251
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.52,0.6448,29509055
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cyclophosphamide,qRT-PCR and Western Blotting,0.48,0.6448,33090711
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,32859993
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,33090711
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,34070538
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,34249423
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,35029026
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,35401817
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.6448,29848346
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.6448,29601799
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and RT-PCR,0.48,0.6448,29511337
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,MACs followed by Western Blotting,0.48,0.6448,29228728
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Irradiation,CFA followed by Western Blotting,0.48,0.6448,34708581
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Western Blotting,0.48,0.6448,33731668
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.48,0.6448,33390847
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.48,0.6448,33530373
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.6448,34178639
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.48,0.6448,35504883
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.48,0.6448,34528694
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.48,0.6448,34770867
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Gemcitabine,CFA and SFA followed by Western Blotting,0.48,0.6448,28036386
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,CFA followed by Western Blotting,0.48,0.6448,28839461
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and SP assay followed by Western Blotting,0.48,0.6448,28903350
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.6448,28823831
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.6448,29106390
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.6448,29137219
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.6448,29422613
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.6448,29797562
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.6448,29981340
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.6448,30647871
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.6448,31695775
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting,0.48,0.6448,29100426
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Radiotherapy,Western Blotting,0.48,0.6448,30272295
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.48,0.6448,30482236
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.48,0.6448,31501409
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.48,0.6448,29218545
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,Western Blotting followed by SFA,0.48,0.6448,29880481
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cobalt Chloride,Western Blotting followed by SFA,0.48,0.6448,31584203
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR,0.48,0.6448,33634797
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by RT-PCR,0.48,0.6448,34235281
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qPCR followed by SFA,0.48,0.6448,35135840
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and SFA,0.48,0.6448,34298877
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.6448,33511560
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.6448,34052833
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.6448,34146553
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.6448,34420298
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.6448,34445421
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.6448,34990518
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.6448,35195687
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.6448,35326667
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qPCR and SFA,0.48,0.6448,31745977
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR,0.48,0.6448,30021199
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR,0.48,0.6448,30542507
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and SFA,0.48,0.6448,30239174
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA,0.48,0.6448,30052635
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA,0.48,0.6448,30450530
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA,0.48,0.6448,31658701
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.48,0.6448,29197410
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and qRT-PCR,0.48,0.6448,28991374
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and qRT-PCR,0.48,0.6448,31728117
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and RT-PCR,0.48,0.6448,29964299
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by qPCR,0.48,0.6448,28703802
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cisplatin,SFA followed by qRT-PCR,0.48,0.6448,28871147
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by qRT-PCR,0.48,0.6448,28871147
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.6448,30587555
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR,0.48,0.6448,30149665
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,10 Gy Radiation,SFA followed by RT-PCR,0.48,0.6448,30579251
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SP assay followed by qPCR,0.48,0.6448,30110679
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,Irradiation,CFA followed by Western Blotting,0.28,0.6448,34708581
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,FACs for CSC marker followed by RT-PCR,0.28,0.6448,34235281
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,SFA followed by qRT-PCR,0.28,0.6448,35326667
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,SFA followed by qRT-PCR,0.28,0.6448,31337967
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,MDA-MB-453,NA,SFA followed by Western Blotting,0.28,0.6448,30647871
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs and RT-PCR,0.32,0.6448,29249690
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Irradiation,CFA followed by Western Blotting,0.32,0.6448,34708581
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Doxorubicin,SFA followed by Western Blotting,0.32,0.6448,29750424
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.32,0.6448,31604679
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,qPCR followed by SFA,0.32,0.6448,35135840
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by qPCR,0.32,0.6448,30224376
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by qRT-PCR,0.32,0.6448,30628646
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,28076840
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,32189359
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MGC-803,NA,qRT-PCR and Western Blotting,0.48,0.6448,32638620
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MGC-803,NA,qRT-PCR and Western Blotting,0.48,0.6448,32638620
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.6448,28415621
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting,0.48,0.6448,27524415
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting,0.48,0.6448,28337375
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting,0.48,0.6448,28529558
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qPCR,0.48,0.6448,28428713
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.48,0.6448,28893318
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,32229502
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,MHCC97-H,NA,Western Blotting and SFA,0.48,0.6448,31888685
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,MHCC97-H,NA,Western Blotting followed by SFA and CFA,0.48,0.6448,30908631
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,MHCC97-H,NA,CFA followed by SFA and qRT-PCR,0.48,0.6448,27783993
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by qRT-PCR,0.48,0.6448,25676692
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,35158144
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qPCR and Western Blotting,0.48,0.6448,32575925
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA and Western Blotting,0.48,0.6448,35428310
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,CFA followed by Western Blotting,0.48,0.6448,25015789
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by Western Blotting,0.48,0.6448,30341797
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by Western Blotting,0.48,0.6448,30341797
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting,0.48,0.6448,29179494
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting followed by SFA,0.48,0.6448,28490735
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qPCR,0.48,0.6448,34168259
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,qRT-PCR,0.48,0.6448,23073476
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and qRT-PCR,0.48,0.6448,24719318
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.48,0.6448,24734907
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.48,0.6448,26840266
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by FACs,0.48,0.6448,29719602
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by qPCR,0.2,0.6448,34168259
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN28,NA,SFA followed by Western Blotting,0.28,0.6448,28529558
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN28,NA,Western Blotting and CFA,0.28,0.6448,31632151
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by IF staining and Western Blotting,0.52,0.6448,28430578
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting and IF staining,0.52,0.6448,32160650
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by qRT-PCR and Western Blotting,0.52,0.6448,27602437
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting and qRT-PCR,0.52,0.6448,34173116
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,30843262
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.6448,31345097
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Western Blotting,0.52,0.6448,27279633
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Western Blotting,0.52,0.6448,29212193
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting,0.52,0.6448,34278502
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting,0.52,0.6448,34646768
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting,0.52,0.6448,34845198
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.52,0.6448,27644439
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.52,0.6448,28337375
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.52,0.6448,28461325
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.52,0.6448,33288885
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,Western Blotting,0.52,0.6448,27878307
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR followed by SFA,0.52,0.6448,30543303
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.6448,27511210
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.6448,27735991
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.6448,29512256
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.6448,32633423
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by RT-PCR,0.52,0.6448,33725258
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,qRT-PCR,0.52,0.6448,32203224
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,qRT-PCR,0.52,0.6448,32099405
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR,0.52,0.6448,25081334
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,Trastuzumab,RT-PCR,0.52,0.6448,25669984
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR and SFA,0.52,0.6448,28692437
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.6448,32863948
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,MOR,Cisplatin,Western Blotting,0.28,0.6448,23349823
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,Carcinoma,N417,NA,FACs,0.12,0.6448,21947321
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.6448,28461325
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.6448,32606358
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,NCI-N87,Trastuzumab,SFA and Western Blotting,0.28,0.6448,25669984
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,NCI-N87,NA,RT-PCR followed by SFA,0.28,0.6448,30543303
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by RT-PCR,0.28,0.6448,30696080
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,22692956
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,SFA and Western Blotting,0.48,0.6448,22422628
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,Western Blotting,0.48,0.6448,24201869
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,OM-1,NA,RT-PCR followed by SFA,0.2,0.6448,26399460
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,OUMS-23,NA,qRT-PCR,0.2,0.6448,30284085
POU5F1,LTM,NA,9221,Pancreatic Cancer,Ductal Adenocarcinoma,PaCa-44,NA,Prolonged exposure to simulated microgravity followed by qRT-PCR,0.2,0.6448,35391557
POU5F1,LTM,NA,9221,Pancreatic Cancer,Ductal Adenocarcinoma,PaCa-44,NA,SFA followed by qPCR,0.2,0.6448,34168259
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,PAMC82,NA,Western Blotting and SFA,0.28,0.6448,33067426
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and qRT-PCR followed by Western Blotting and IF staining,0.72,0.6448,29975934
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR and Western Blotting,0.72,0.6448,35158144
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qRT-PCR followed by Western Blotting,0.72,0.6448,28703793
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.6448,27996162
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.6448,29937934
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR and Western Blotting,0.72,0.6448,23872274
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR and Western Blotting,0.72,0.6448,24305593
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by qRT-PCR and Western Blotting,0.72,0.6448,24040121
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qRT-PCR followed by IHC staining,0.72,0.6448,23026911
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by qRT-PCR,0.72,0.6448,29444383
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA and qPCR,0.72,0.6448,30954649
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA and qRT-PCR,0.72,0.6448,29444383
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and Western Blotting,0.72,0.6448,35428310
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.72,0.6448,34551785
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting,0.72,0.6448,33708436
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,CFA followed by Western Blotting,0.72,0.6448,25015789
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by Western Blotting,0.72,0.6448,30341797
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by Western Blotting,0.72,0.6448,30341797
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.72,0.6448,30535490
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.72,0.6448,32766132
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting,0.72,0.6448,29179494
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting followed by SFA,0.72,0.6448,30819221
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by IF staining,0.72,0.6448,33915247
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR,0.72,0.6448,34163012
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR and SFA,0.72,0.6448,33728488
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and qRT-PCR,0.72,0.6448,35241126
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.6448,34446696
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,Modified transwell lower chamber assay and SFA followed by qRT-PCR,0.72,0.6448,24689055
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,5-fluorouracil,qRT-PCR followed by SFA,0.72,0.6448,22993328
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qPCR,0.72,0.6448,32605166
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.6448,24521357
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.6448,26298849
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.6448,26840266
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.6448,27505247
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.6448,27996162
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.6448,29434962
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.6448,30045656
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.6448,30954649
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.6448,31027735
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.72,0.6448,31508487
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SP assay,0.72,0.6448,23815678
POU5F1,LTM,NA,9221,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.72,0.6448,26689865
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR,0.2,0.6448,31508487
POU5F1,LTM,NA,9221,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by qPCR,0.2,0.6448,34168259
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,SFA followed by RT-PCR and Western Blotting,0.48,0.6448,31233201
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qRT-PCR and IF staining,0.48,0.6448,33764690
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by IF staining and qRT-PCR,0.48,0.6448,31966561
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,CFA and SFA followed by IF staining and RT-PCR,0.48,0.6448,25960639
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by IF staining and qPCR,0.48,0.6448,31966561
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Erlotinib,FACs followed by qRT-PCR,0.48,0.6448,28901474
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,SFA followed by Western Blotting,0.48,0.6448,33955683
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR,0.48,0.6448,34771484
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR,0.48,0.6448,34771484
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qPCR followed by SFA and Tumorigenicity assay,0.48,0.6448,24489728
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qRT-PCR,0.48,0.6448,30480362
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,SP assay followed by RT-PCR and Tumorigenicity assay,0.48,0.6448,25871388
POU5F1,LTM,NA,9221,Pancreatic Cancer,Ductal Adenocarcinoma,PK-1,NA,SFA followed by qRT-PCR,0.2,0.6448,31027735
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SFA followed by Western Blotting,0.28,0.6448,27312708
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SFA followed by qRT-PCR,0.28,0.6448,22773665
POU5F1,LTM,NA,9221,Head and Neck Cancer,NA,QLL-1,NA,SFA followed by Western Blotting,0.28,0.6448,32327629
POU5F1,LTM,NA,9221,Colon Cancer,Carcinoma,RKO,NA,SFA followed by qPCR,0.2,0.6448,29721049
POU5F1,LTM,NA,9221,Bladder Cancer,Transitional Cell Papilloma,RT-4,NA,SFA followed by qRT-PCR,0.2,0.6448,35116788
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SFA and RT-PCR and Western Blotting,0.48,0.6448,24475244
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,22692956
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,Cisplatin,SFA followed by Western Blotting,0.48,0.6448,33238517
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SFA and Western Blotting,0.48,0.6448,22422628
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SP assay and Western Blotting,0.48,0.6448,23843890
POU5F1,LTM,NA,9221,Small Cell Lung Cancer,Carcinoma,SBC-5,NA,SFA followed by qRT-PCR,0.2,0.6448,29448000
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-131,NA,Western Blotting followed by IF staining and SFA,0.52,0.6448,29575240
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-131,Cisplatin,SFA followed by Western Blotting,0.52,0.6448,31585633
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-15,NA,Western Blotting followed by SFA,0.28,0.6448,35013621
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-15,NA,SFA followed by Western Blotting,0.28,0.6448,32327629
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,Cisplatin,Western Blotting followed by SFA,0.28,0.6448,34795388
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,Western Blotting followed by SFA,0.28,0.6448,35013621
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,SFA followed by Western Blotting,0.28,0.6448,32327629
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and qRT-PCR and Western Blotting ,0.48,0.6448,33731207
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and qRT-PCR followed by Western Blotting ,0.48,0.6448,34427968
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting and qRT-PCR,0.48,0.6448,34173116
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,28076840
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,30843262
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,31261030
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,33579380
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.6448,28415621
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,FACs for CSC marker followed by Western Blotting,0.48,0.6448,27279633
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.48,0.6448,34090492
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.48,0.6448,34350176
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.48,0.6448,34646768
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.48,0.6448,34657624
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.48,0.6448,34845198
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.6448,27644439
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.6448,29422082
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.6448,30007956
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.6448,34802261
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.6448,30624124
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,Western Blotting followed by SFA,0.48,0.6448,31517391
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,qRT-PCR followed by SFA,0.48,0.6448,29662192
POU5F1,LTM,NA,9221,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by Western Blotting and IF staining,0.52,0.6448,29100426
POU5F1,LTM,NA,9221,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by Western Blotting and IF staining,0.52,0.6448,29100426
POU5F1,LTM,NA,9221,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by Western Blotting,0.52,0.6448,18083101
POU5F1,LTM,NA,9221,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by qRT-PCR,0.52,0.6448,35326667
POU5F1,LTM,NA,9221,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,qRT-PCR followed by SP assay and SFA,0.52,0.6448,30613295
POU5F1,LTM,NA,9221,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,qRT-PCR followed by SP assay and SFA,0.52,0.6448,30613295
POU5F1,LTM,NA,9221,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,Epirubicin,SFA followed by qRT-PCR,0.52,0.6448,18083101
POU5F1,LTM,NA,9221,Hepatic Cancer,Adenocarcinoma,SK-Hep-1,NA,SP assay followed by Western Blotting,0.28,0.6448,29792038
POU5F1,LTM,NA,9221,Skin Cancer,NA,SK-MEL-28,NA,SFA and Western Blotting,0.28,0.6448,30717768
POU5F1,LTM,NA,9221,Skin Cancer,NA,SK-MEL-28,NA,SFA followed by qRT-PCR,0.28,0.6448,30558661
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,SNU16,NA,Western Blotting and SFA,0.28,0.6448,33067426
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,SNU16,NA,RT-PCR followed by SFA,0.28,0.6448,31073886
POU5F1,LTM,NA,9221,Hepatic Cancer,Carcinoma,SNU-398,NA,Western Blotting and SFA,0.28,0.6448,31888685
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by qPCR and Western Blotting,0.48,0.6448,30284938
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Western Blotting and qRT-PCR,0.48,0.6448,33798550
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,SNU5,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.6448,28440445
POU5F1,LTM,NA,9221,Gastric Cancer,Carcinoma,SNU5,NA,RT-PCR followed by SFA,0.48,0.6448,31073886
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by qPCR and Western Blotting,0.48,0.6448,30284938
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by qRT-PCR,0.48,0.6448,32863948
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,SNU-668,NA,SFA followed by Western Blotting,0.28,0.6448,32606358
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by qPCR and Western Blotting,0.48,0.6448,29702194
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,CFA and SFA followed by IF staining and RT-PCR,0.48,0.6448,25960639
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by IF staining and qRT-PCR,0.48,0.6448,25731617
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Western Blotting,0.48,0.6448,34949193
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,Docetaxel,SFA followed by qRT-PCR,0.48,0.6448,25279705
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by qRT-PCR,0.48,0.6448,28035349
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SP assay followed by RT-PCR and Tumorigenicity assay,0.48,0.6448,22862169
POU5F1,LTM,NA,9221,Gastric Cancer,Adenocarcinoma,ST2957,NA,SFA followed by qRT-PCR,0.2,0.6448,32863948
POU5F1,LTM,NA,9221,Pancreatic Cancer,Ductal Adenocarcinoma,Su86.86,NA,FACs followed by SP assay,0.12,0.6448,22963768
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,qRT-PCR and Western Blotting,0.48,0.6448,30542507
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM149PT,Paclitaxel,SFA followed by qPCR and Western Blotting,0.48,0.6448,28703802
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,qPCR followed by SFA,0.48,0.6448,35135840
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM149PT,MK-0752,qRT-PCR followed by SFA,0.48,0.6448,29027990
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,RT-PCR followed by SFA,0.48,0.6448,29471829
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM159,Paclitaxel,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,35401817
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs and RT-PCR,0.48,0.6448,29249663
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA and Western Blotting,0.48,0.6448,33530373
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by Western Blotting,0.48,0.6448,29243835
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by Western Blotting,0.48,0.6448,29356693
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA and qRT-PCR,0.48,0.6448,35064101
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,qRT-PCR and SFA,0.48,0.6448,31850822
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA and qRT-PCR,0.48,0.6448,28991374
POU5F1,LTM,NA,9221,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by qRT-PCR,0.48,0.6448,31337967
POU5F1,LTM,NA,9221,Breast Cancer,Carcinoma,SUM190PT,Paclitaxel,SFA followed by qPCR and Western Blotting,0.48,0.6448,28703802
POU5F1,LTM,NA,9221,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,RT-PCR followed by SFA,0.2,0.6448,23674142
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,33737813
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,FACs followed by SFA and qPCR,0.48,0.6448,30954649
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting and SFA,0.48,0.6448,32781084
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Tumorigenicity assay and Western Blotting,0.48,0.6448,25003666
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR,0.48,0.6448,26391180
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR,0.48,0.6448,31508487
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.48,0.6448,30954649
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by qRT-PCR,0.48,0.6448,30819221
POU5F1,LTM,NA,9221,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,FACs followed by SP assay,0.48,0.6448,22963768
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,SW48,Doxorubicin,Western Blotting,0.28,0.6448,27517620
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,SW48,NA,Western Blotting followed by SFA,0.28,0.6448,30802541
POU5F1,LTM,NA,9221,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by qRT-PCR and Western Blotting,0.48,0.6448,24926880
POU5F1,LTM,NA,9221,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by Western Blotting,0.48,0.6448,30774996
POU5F1,LTM,NA,9221,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,Western Blotting followed by SFA,0.48,0.6448,30802541
POU5F1,LTM,NA,9221,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by qRT-PCR,0.48,0.6448,35267511
POU5F1,LTM,NA,9221,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,qRT-PCR,0.48,0.6448,29426374
POU5F1,LTM,NA,9221,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by qRT-PCR,0.48,0.6448,29307822
POU5F1,LTM,NA,9221,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by Tumorigenicity assay and RT-PCR,0.48,0.6448,21435460
POU5F1,LTM,NA,9221,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.48,0.6448,28212529
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.6448,30774996
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,5-Fluorouracil,SFA followed by Western Blotting and qRT-PCR,0.48,0.6448,28990068
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.48,0.6448,33109220
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by qRT-PCR,0.48,0.6448,35267511
POU5F1,LTM,NA,9221,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by CFA and qRT-PCR,0.48,0.6448,30115896
POU5F1,LTM,NA,9221,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,SP assay followed by CFA and RT-PCR,0.2,0.6448,18787416
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,T24,Cisplatin,SFA and SP assay followed by RT-PCR and Western Blotting,0.48,0.6448,22343321
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Western Blotting,0.48,0.6448,29559853
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,T24,Cisplatin,RT-PCR,0.48,0.6448,26647959
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.48,0.6448,30592142
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,T24,NA,SP assay followed by RT-PCR,0.48,0.6448,24337040
POU5F1,LTM,NA,9221,Bladder Cancer,Carcinoma,T24,NA,SP assay followed by RT-PCR and SFA,0.48,0.6448,25020236
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,qRT-PCR and Western Blotting followed by CFA,0.48,0.6448,35235236
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.6448,30326469
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,qRT-PCR followed by Western Blotting and SFA,0.48,0.6448,31736268
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,31300015
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,Western Blotting and SFA,0.48,0.6448,34362383
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Western Blotting,0.48,0.6448,28802057
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Tamoxifen,Western Blotting,0.48,0.6448,29602199
POU5F1,LTM,NA,9221,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR,0.2,0.6448,33575080
POU5F1,LTM,NA,9221,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.6448,34408983
POU5F1,LTM,NA,9221,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting,0.48,0.6448,32578777
POU5F1,LTM,NA,9221,Glioblastoma,NA,U-87MG,Temozolomide,SFA followed by Western Blotting,0.48,0.6448,33691197
POU5F1,LTM,NA,9221,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting and Sedimentation field flow fractionation(SdFFF) ,0.48,0.6448,31179686
POU5F1,LTM,NA,9221,Glioblastoma,NA,U-87MG,NA,SFA and Western Blotting,0.48,0.6448,28394339
POU5F1,LTM,NA,9221,Glioblastoma,NA,U-87MG,NA,SFA and Western Blotting,0.48,0.6448,29228694
POU5F1,LTM,NA,9221,Glioblastoma,NA,U-87MG,NA,SFA and Western Blotting,0.48,0.6448,32360621
POU5F1,LTM,NA,9221,Glioblastoma,NA,U-87MG,NA,SFA followed by IF staining,0.48,0.6448,34235925
POU5F1,LTM,NA,9221,Glioblastoma,NA,U-87MG,NA,SFA followed by qRT-PCR,0.48,0.6448,30175027
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-1,NA,SFA followed by qPCR,0.2,0.6448,21304586
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-1,NA,SFA followed by qRT-PCR,0.2,0.6448,26323460
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,Western Blotting followed by CFA,0.28,0.6448,28423495
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,SFA followed by qRT-PCR,0.28,0.6448,24533098
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-103,NA,SFA followed by qRT-PCR,0.2,0.6448,25428916
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-10B,NA,Western Blotting followed by CFA,0.28,0.6448,28423495
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-11B,NA,SFA followed by qPCR,0.2,0.6448,21304586
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-11B,NA,SFA followed by qRT-PCR,0.2,0.6448,26323460
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.6448,32773768
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,SFA followed by RT-PCR,0.48,0.6448,31742606
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-14B,NA,SFA followed by qRT-PCR,0.2,0.6448,25428916
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,NA,Western Blotting,0.28,0.6448,25379016
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,Cisplatin,SFA followed by Western Blotting,0.28,0.6448,24709421
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,NA,Western Blotting,0.28,0.6448,25379016
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.6448,32773768
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,Western Blotting,0.48,0.6448,25379016
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-46,NA,SP assay followed by Western Blotting and qRT-PCR,0.48,0.6448,25379016
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-47,NA,SFA followed by qRT-PCR,0.2,0.6448,24533098
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-9,NA,SFA followed by qRT-PCR,0.2,0.6448,26323460
POU5F1,LTM,NA,9221,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,28870814
POU5F1,LTM,NA,9221,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.6448,32661469
POU5F1,LTM,NA,9221,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.6448,31180522
POU5F1,LTM,NA,9221,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,Benzidine,SFA followed by Western Blotting,0.48,0.6448,33552265
POU5F1,LTM,NA,9221,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting,0.48,0.6448,33552265
POU5F1,LTM,NA,9221,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,Cisplatin,qRT-PCR,0.48,0.6448,31239709
POU5F1,LTM,NA,9221,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR,0.48,0.6448,26452033
POU5F1,LTM,NA,9221,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SP assay followed by RT-PCR and SFA,0.48,0.6448,25020236
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-22,NA,SFA followed by qPCR,0.2,0.6448,21304586
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-38,Dasatinib,Western Blotting followed by qRT-PCR,0.48,0.6448,31382448
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-38,Saracatinib,Western Blotting followed by qRT-PCR,0.48,0.6448,31382448
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,qRT-PCR followed by SFA,0.2,0.6448,26323893
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,qRT-PCR followed by SFA,0.2,0.6448,26323893
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,SFA followed by qPCR,0.2,0.6448,21304586
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,VU-1365,NA,RT-PCR followed by SFA,0.2,0.6448,25340704
POU5F1,LTM,NA,9221,Colon Cancer,Adenocarcinoma,WIDR,NA,SFA followed by RT-PCR,0.2,0.6448,25625841
POU5F1,LTM,NA,9221,Skin Cancer,NA,WM115,NA,qRT-PCR,0.2,0.6448,23915418
POU5F1,LTM,NA,9221,Skin Cancer,NA,WM266-4,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.6448,31817719
POU5F1,LTM,NA,9221,Skin Cancer,NA,WM266-4,NA,SFA followed by RT-PCR,0.48,0.6448,26554153
POU5F1,LTM,NA,9221,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.6448,21618577
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN19,NA,SFA followed by Western Blotting,0.28,0.6448,25024430
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN26,NA,SFA followed by Western Blotting,0.28,0.6448,25024430
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN30,Deferoxamine,RT-PCR,0.2,0.6448,35313655
POU5F1,LTM,NA,9221,Gastric Cancer,NA,XN0422,NA,qRT-PCR followed by SFA,0.2,0.6448,29662192
POU5F1,LTM,NA,9221,Luminal A Breast Cancer,Ductal Carcinoma,ZR-75-1,NA,qRT-PCR followed by SP assay and SFA,0.2,0.6448,30613295
POU5F1,LTM,NA,9221,Breast Cancer,Ductal Carcinoma,ZR-75-30,NA,qRT-PCR followed by SFA,0.2,0.6448,30478301
POU5F1,LTM,NA,9221,Bladder Cancer,NA,Primary,NA,RT-PCR and IHC staining,0.6,0.6448,17205510
POU5F1,LTM,NA,9221,Bladder Cancer,NA,Primary,NA,SFA followed by IF staining,0.6,0.6448,19961489
POU5F1,LTM,NA,9221,Breast Cancer,NA,Primary,NA,qPCR followed by IHC staining,0.6,0.6448,29660692
POU5F1,LTM,NA,9221,Breast Cancer,NA,Primary,Chemotherapy,SFA followed by Western Blotting,0.6,0.6448,28835684
POU5F1,LTM,NA,9221,Breast Cancer,NA,Primary,NA,Western Blotting,0.6,0.6448,29185119
POU5F1,LTM,NA,9221,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen,SFA followed by qRT-PCR,0.6,0.6448,31693936
POU5F1,LTM,NA,9221,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen+Fulvestrant,SFA followed by qRT-PCR,0.6,0.6448,31693936
POU5F1,LTM,NA,9221,Breast Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.6,0.6448,31728117
POU5F1,LTM,NA,9221,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.6,0.6448,30359767
POU5F1,LTM,NA,9221,Colon Cancer,NA,Primary,NA,RT-PCR followed by Western Blotting,0.64,0.6448,28249897
POU5F1,LTM,NA,9221,Colon Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.64,0.6448,29110645
POU5F1,LTM,NA,9221,Colon Cancer,NA,Primary,5-Fluorouracil,SFA followed by Western Blotting,0.64,0.6448,30091203
POU5F1,LTM,NA,9221,Colon Cancer,NA,Primary,Oxaliplatin,SFA followed by Western Blotting,0.64,0.6448,30091203
POU5F1,LTM,NA,9221,Colon Cancer,NA,Primary,NA,IHC staining,0.64,0.6448,30177970
POU5F1,LTM,NA,9221,Colon Cancer,NA,Primary,NA,IHC staining,0.64,0.6448,31491003
POU5F1,LTM,NA,9221,Colon Cancer,NA,Primary,NA,SFA and IF staining,0.64,0.6448,26745821
POU5F1,LTM,NA,9221,Colon Cancer,NA,Primary,NA,RT-PCR,0.64,0.6448,23545848
POU5F1,LTM,NA,9221,Colon Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.64,0.6448,23643941
POU5F1,LTM,NA,9221,Colon Cancer,NA,Primary,5-Fluorouracil,SFA followed by FACs,0.64,0.6448,30091203
POU5F1,LTM,NA,9221,Colon Cancer,NA,Primary,Oxaliplatin,SFA followed by FACs,0.64,0.6448,30091203
POU5F1,LTM,NA,9221,Gastric Cancer,NA,Primary,NA,SFA and RT-PCR followed by Western Blotting and IHC ataining,0.96,0.6448,32788883
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining and IF staining followed by SFA,0.92,0.6448,32019273
POU5F1,LTM,NA,9221,Head and Neck Cancer,NA,Primary,NA,IHC staining followed by IF staining and SFA,0.92,0.6448,32019273
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qPCR and Western Blotting,0.92,0.6448,23876835
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR and IF staining,0.92,0.6448,22426199
POU5F1,LTM,NA,9221,Head and Neck Cancer,NA,Primary,NA,IF staining and SFA,0.92,0.6448,32019273
POU5F1,LTM,NA,9221,Head and Neck Cancer,NA,Primary,NA,IHC staining,0.92,0.6448,26556875
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.92,0.6448,30528285
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IHC staining,0.92,0.6448,22640830
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,qRT-PCR,0.92,0.6448,20036608
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.92,0.6448,19450560
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.92,0.6448,22333601
POU5F1,LTM,NA,9221,Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining and IF staining followed by qRT-PCR,0.92,0.6448,31894290
POU5F1,LTM,NA,9221,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay and Western Blotting followed by RT-PCR and SFA,0.92,0.6448,26416062
POU5F1,LTM,NA,9221,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay followed by qRT-PCR and Western Blotting,0.92,0.6448,22285547
POU5F1,LTM,NA,9221,Lung Cancer,NA,Primary,NA,IHC staining,0.92,0.6448,32500024
POU5F1,LTM,NA,9221,Lung Cancer,NA,Primary,NA,SFA followed by IF staining,0.92,0.6448,25955492
POU5F1,LTM,NA,9221,Lung Cancer,NA,Primary,NA,SFA followed by IF staining,0.92,0.6448,25955492
POU5F1,LTM,NA,9221,Lung Cancer,Adenocarcinoma,Primary,NA,qRT-PCR,0.92,0.6448,21159654
POU5F1,LTM,NA,9221,Lung Cancer,NA,Primary,NA,RT-PCR,0.92,0.6448,19536353
POU5F1,LTM,NA,9221,Lung Cancer,NA,Primary,NA,SFA followed by RT-PCR,0.92,0.6448,24019906
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.32,0.6448,22300949
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.32,0.6448,24346092
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.32,0.6448,29158791
POU5F1,LTM,NA,9221,Pancreatic Cancer,NA,Primary,NA,SFA followed by qRT-PCR and IF staining,0.96,0.6448,26609473
POU5F1,LTM,NA,9221,Pancreatic Cancer,NA,Primary,NA,qPCR followed by SFA,0.96,0.6448,24785258
POU5F1,LTM,NA,9221,Skin Cancer,NA,Primary,NA,IHC staining followed by IF staining,0.64,0.6448,30626524
POU5F1,LTM,NA,9221,Breast Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.6,0.6448,33340428
POU5F1,LTM,NA,9221,Breast Cancer,NA,Primary,NA,IF staining,0.6,0.6448,35402219
POU5F1,LTM,NA,9221,Breast Cancer,NA,Primary,NA,IHC staining,0.6,0.6448,35506041
POU5F1,LTM,NA,9221,Colon Cancer,NA,Primary,NA,qRT-PCR and Western Blotting followed by SFA,0.64,0.6448,34271345
POU5F1,LTM,NA,9221,Colon Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.64,0.6448,33500430
POU5F1,LTM,NA,9221,Gastric Cancer,NA,Primary,NA,IHC staining,0.96,0.6448,29422082
POU5F1,LTM,NA,9221,Gastric Cancer,NA,Primary,NA,IHC staining,0.96,0.6448,28356964
POU5F1,LTM,NA,9221,Gastric Cancer,NA,Primary,NA,qRT-PCR,0.96,0.6448,30628031
POU5F1,LTM,NA,9221,Gastric Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.96,0.6448,33986804
POU5F1,LTM,NA,9221,Gastric Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.96,0.6448,32350414
POU5F1,LTM,NA,9221,Glioblastoma,NA,Primary,NA,SFA and Western Blotting,0.36,0.6448,30701538
POU5F1,LTM,NA,9221,Glioblastoma Multiforme,NA,Primary,NA,IHC staining and IF staining followed by Western Blotting,1,0.6448,27617262
POU5F1,LTM,NA,9221,Glioblastoma Multiforme,NA,Primary,NA,Isolation of autofluorescence cells followed by SFA and qRT-PCR,1,0.6448,33669350
POU5F1,LTM,NA,9221,Head and Neck Cancer,Cutaneous Squamous Cell Carcinoma,Primary,NA,IHC staining and IF staining followed by qRT-PCR,0.92,0.6448,32850316
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR and IF staining,0.92,0.6448,21167769
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by Western Blotting,0.92,0.6448,26239260
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by Western Blotting,0.92,0.6448,21292542
POU5F1,LTM,NA,9221,Head and Neck Cancer,Cutaneous Squamous Cell Carcinoma,Primary,NA,IF staining,0.92,0.6448,32983794
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.92,0.6448,35140342
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.92,0.6448,22847005
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.92,0.6448,25871396
POU5F1,LTM,NA,9221,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,Cisplatin,SFA followed by qRT-PCR,0.92,0.6448,32206093
POU5F1,LTM,NA,9221,Hepatic Cancer,NA,Primary,NA,SP assay followed by qRT-PCR and SFA,0.28,0.6448,23104270
POU5F1,LTM,NA,9221,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,qRT-PCR followed by SFA,0.32,0.6448,28855609
POU5F1,LTM,NA,9221,Skin Cancer,NA,Primary,NA,IHC staining,0.64,0.6448,34433195
PPARA,LTM,NA,9232,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by IF staining,0.24,0.0021,33525605
PRDX2,LTM,NA,9353,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,Western Blotting followed by ICC staining,0.52,0.0074,30341415
PRDX2,LTM,NA,9353,Non Small Cell Lung Cancer,Carcinoma,H460,Gefitinib,Western Blotting,0.28,0.0074,30341415
PRDX2,LTM,NA,9353,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,Western Blotting,0.28,0.0074,30341415
PRDX2,LTM,NA,9353,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by Western Blotting and SFA and Tumorigenicity assay,0.4,0.0074,27894099
PRDX2,LTM,NA,9353,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by IF staining,0.4,0.0074,33819194
PRDX2,LTM,NA,9353,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by Western Blotting and SFA,0.4,0.0074,27894099
PRDX2,LTM,NA,9353,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by IF staining,0.4,0.0074,33819194
PRDX2,LTM,NA,9353,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs followed by Western Blotting and SFA,0.4,0.0074,27894099
PRDX2,LTM,NA,9353,Colon Cancer,NA,Primary,NA,IHC staining followed by qRT-PCR,0.6,0.0074,33819194
PRDX6,LTM,NA,16753,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,IF staining followed by Western Blotting,0.52,0.0042,31819528
PRDX6,LTM,NA,16753,Non Small Cell Lung Cancer,Carcinoma,H1299,Cisplatin,IF staining followed by Western Blotting,0.52,0.0042,31819528
PRKAA1,LTM,NA,9376,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.28,0.0011,34195288
PRKCD,LTM,NA,9399,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,31261030
PRKCD,LTM,NA,9399,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,31261030
PRMT5,LTM,NA,10894,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,Western Blotting and SFA,0.28,0.0021,29185119
PRMT8,LTM,NA,5188,Colon Cancer,Adenocarcinoma,HCT-8,NA,SFA followed by qRT-PCR and Western Blotting and Invasion assay,0.48,0.0011,29721049
PRMT8,LTM,NA,5188,Colon Cancer,Carcinoma,RKO,NA,FACs followed by CFA and Migration assay,0.12,0.0011,29721049
PROCR,LTM,NA,9452,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by SFA,0.12,0.0021,31545416
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,5637,NA,SFA followed by Western Blotting,0.28,0.7582,29559853
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,5637,NA,SFA followed by qRT-PCR,0.28,0.7582,30592142
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,5637,NA,MACs,0.28,0.7582,30746788
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,5637,NA,SFA followed by FACs,0.28,0.7582,32388699
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95C,NA,MACs,0.12,0.7582,24008862
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by FACs and Western Blotting,0.4,0.7582,30628703
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by SP assay and RT-PCR,0.4,0.7582,30477473
PROM1,LTM,NA,9454,Glioblastoma,NA,A-172,NA,FACs followed by SFA and SP assay,0.12,0.7582,19232461
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,A-253,NA,RT-PCR followed by CFA,0.2,0.7582,24612587
PROM1,LTM,NA,9454,Skin Cancer,NA,A-375,NA,SFA followed by qPCR and Western Blotting,0.48,0.7582,29693169
PROM1,LTM,NA,9454,Skin Cancer,NA,A-375,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,29693169
PROM1,LTM,NA,9454,Skin Cancer,NA,A-375,NA,Western Blotting and FACs followed by SFA,0.48,0.7582,29408459
PROM1,LTM,NA,9454,Skin Cancer,NA,A-375,NA,SFA followed by qRT-PCR,0.48,0.7582,30558661
PROM1,LTM,NA,9454,Skin Cancer,NA,A-375,NA,FACs,0.48,0.7582,27476721
PROM1,LTM,NA,9454,Skin Cancer,NA,A-375,NA,FACs,0.48,0.7582,29049740
PROM1,LTM,NA,9454,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,MACs,0.12,0.7582,29458573
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and qRT-PCR followed by Western Blotting and IF staining,0.72,0.7582,32396269
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by qPCR and Western Blotting,0.72,0.7582,26782458
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,MACs and IF staining followed by qRT-PCR,0.72,0.7582,31819528
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR and FACs followed by IF staining,0.72,0.7582,21947321
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,IHC staining and CFA followed by SFA and Western Blotting,0.72,0.7582,29299167
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,Western Blotting followed by ICC staining,0.72,0.7582,30341415
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,Western Blotting followed by IHC staining and SFA,0.72,0.7582,29299167
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and Western Blotting followed by SFA,0.72,0.7582,33783940
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.7582,33539684
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.7582,25955300
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.7582,28431267
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.7582,30485693
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.7582,31891569
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.72,0.7582,32655789
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,MACs and FACs followed by qRT-PCR,0.72,0.7582,28619508
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,MACs followed by FACs and qPCR,0.72,0.7582,26675547
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining and RT-PCR,0.72,0.7582,21520032
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and IF staining,0.72,0.7582,26239272
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and IF staining,0.72,0.7582,26261505
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA and Western Blotting,0.72,0.7582,31263095
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by FACs and Western Blotting,0.72,0.7582,22370645
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and Western Blotting,0.72,0.7582,28198062
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and Western Blotting,0.72,0.7582,30737252
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting and  FACs,0.72,0.7582,33125096
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by IF staining,0.72,0.7582,34527268
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,IHC staining followed by MACs,0.72,0.7582,33887368
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,IF staining followed by SFA and FACs,0.72,0.7582,31024010
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,MACs followed by IF staining,0.72,0.7582,26690309
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,MACs followed by IF staining and CFA,0.72,0.7582,28000861
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,MACs followed by SFA and IF staining,0.72,0.7582,23456479
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and IF staining followed by FACs,0.72,0.7582,28534939
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and qRT-PCR,0.72,0.7582,34400945
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and qRT-PCR  followed by SFA and Tumorigenicity assay,0.72,0.7582,29262597
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and RT-PCR followed by SFA and Tumorigenicity assay,0.72,0.7582,29225473
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,FACs followed by RT-PCR,0.72,0.7582,24356998
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by RT-PCR,0.72,0.7582,25783528
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA and RT-PCR,0.72,0.7582,25678473
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA and FACs,0.72,0.7582,25003810
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,SFA and FACs followed by qRT-PCR and Tumorigenicity assay,0.72,0.7582,29860718
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and qRT-PCR,0.72,0.7582,24101104
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and qRT-PCR,0.72,0.7582,30816208
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and RT-PCR,0.72,0.7582,23370278
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and RT-PCR,0.72,0.7582,23715514
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qPCR and FACs,0.72,0.7582,26299367
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Irradiation,CFA followed by Western Blotting,0.72,0.7582,33924205
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.72,0.7582,33980809
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting,0.72,0.7582,34803670
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting followed by SFA,0.72,0.7582,33721187
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and Western Blotting,0.72,0.7582,29387193
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.72,0.7582,23583374
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.72,0.7582,24247269
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.72,0.7582,27836540
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by Western Blotting,0.72,0.7582,31207300
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.72,0.7582,32782570
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,MACs and FACs followed by SFA,0.72,0.7582,28854941
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,MACs and FACs followed by SFA,0.72,0.7582,30542415
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and SFA,0.72,0.7582,34246759
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.72,0.7582,33437165
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.72,0.7582,33468994
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.72,0.7582,34832951
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.72,0.7582,35044041
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR,0.72,0.7582,24646078
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and SFA,0.72,0.7582,29144562
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by SFA and SP assay,0.72,0.7582,26468775
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR,0.72,0.7582,25906011
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Pemetrexed +Cisplatin,RT-PCR,0.72,0.7582,26895954
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR,0.72,0.7582,31201845
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.72,0.7582,29044153
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.72,0.7582,29138851
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.72,0.7582,30981768
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.72,0.7582,30981768
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Tumorigenicity assay,0.72,0.7582,32124474
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by RT-PCR,0.72,0.7582,24961511
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.72,0.7582,26546046
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by RT-PCR,0.72,0.7582,27009878
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.72,0.7582,28787001
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.72,0.7582,28951614
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.72,0.7582,29414668
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by qRT-PCR,0.72,0.7582,27911857
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR,0.72,0.7582,21347385
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR,0.72,0.7582,22855139
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,CFA followed by FACs,0.72,0.7582,34816662
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs,0.72,0.7582,33068069
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.72,0.7582,27920206
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.72,0.7582,33959615
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.72,0.7582,34827096
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.72,0.7582,35337095
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and SFA,0.72,0.7582,34063628
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and FACs,0.72,0.7582,33631674
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.72,0.7582,34349823
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.72,0.7582,34424425
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by FACs,0.72,0.7582,35267489
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,CFA and SFA followed by FACs,0.72,0.7582,28406482
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,FACs,0.72,0.7582,23349823
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.72,0.7582,24440048
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.72,0.7582,27542268
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.72,0.7582,28484448
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.72,0.7582,28516515
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.72,0.7582,28789457
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.72,0.7582,31352088
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.72,0.7582,32466428
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and CFA,0.72,0.7582,32329414
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and Tumorigenicity assay,0.72,0.7582,27485114
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.72,0.7582,24903381
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.72,0.7582,26572130
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.72,0.7582,26782458
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.72,0.7582,27276704
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.72,0.7582,28179999
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.72,0.7582,29144562
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,Dexamethasone+Pemetrexed,FACs followed by SFA,0.72,0.7582,29753869
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.72,0.7582,31368411
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA,0.72,0.7582,31466290
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA and CFA,0.72,0.7582,29845263
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by SFA and Tumorigenicity assay,0.72,0.7582,21600232
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,MACs,0.72,0.7582,24008862
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,MACs followed by SFA,0.72,0.7582,22900142
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Modified PLGA magnetic SFA followed by FACs,0.72,0.7582,29843871
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.72,0.7582,20028869
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.72,0.7582,20028869
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.72,0.7582,24101104
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.72,0.7582,25965829
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.72,0.7582,28580971
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.72,0.7582,31121479
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.72,0.7582,32549341
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.72,0.7582,32676335
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and Tumorigenicity assay,0.72,0.7582,28202526
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay and  FACs,0.72,0.7582,19464919
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay and SFA followed by FACs and Tumorigenicity assay,0.72,0.7582,20949018
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by FACs and SFA,0.72,0.7582,22825470
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by FACs and SFA,0.72,0.7582,25007054
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,31261030
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,AGS,NA,Four-dimensional (4D) culture model by a magnetic responsive alginate-based hydrogel to rotating magnets followed by RT-PCR and IF staining,0.48,0.7582,33836517
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.48,0.7582,28461325
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,AGS,NA,Western Blotting and CFA,0.48,0.7582,31632151
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qPCR,0.48,0.7582,29559846
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by IF staining and FACs,0.36,0.7582,26709750
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA and FACs followed by qRT-PCR,0.36,0.7582,35241126
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,FACs followed by SFA and qPCR,0.36,0.7582,32575925
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qPCR,0.36,0.7582,31440741
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,FACs,0.36,0.7582,34163012
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,FACs,0.36,0.7582,26391180
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,FACs followed by SFA,0.36,0.7582,25811929
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.36,0.7582,30119228
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by FACs,0.36,0.7582,30853342
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SP assay followed by FACs,0.36,0.7582,22030254
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,AsPC1,Triptolide,SP assay followed by FACs,0.36,0.7582,26597727
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,BGC-823,NA,MAC followed by qRT-PCR and Western Blotting,0.6,0.7582,28218426
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,BGC-823,Cisplatin,FACs and Western Blotting,0.6,0.7582,33635343
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by FACs and Western Blotting,0.6,0.7582,34350176
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by Western Blotting,0.6,0.7582,30624124
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs followed by SFA,0.6,0.7582,31073886
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Carcinoma,BT-20,NA,SFA followed by Western Blotting and FACs,0.4,0.7582,33924995
PROM1,LTM,NA,9454,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by qPCR,0.2,0.7582,30224376
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Cyclophosphamide,qRT-PCR,0.2,0.7582,33090711
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by qRT-PCR,0.2,0.7582,33090711
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.7582,30802827
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.7582,30802827
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by IF staining,0.48,0.7582,26709750
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,qRT-PCR,0.48,0.7582,26035122
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by qRT-PCR,0.48,0.7582,29048549
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs and SFA,0.48,0.7582,33537082
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,FACs,0.48,0.7582,31713003
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs,0.48,0.7582,31713003
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs,0.48,0.7582,31856088
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,FACs followed by SFA,0.48,0.7582,27576197
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by Tumorigenicity assay,0.48,0.7582,23338123
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by FACs,0.48,0.7582,24305593
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by FACs,0.48,0.7582,30853342
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CACO-2,NA,RT-PCR and Western Blotting followed by FACs,0.6,0.7582,26002465
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs followed by Western Blotting,0.6,0.7582,22623141
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CACO-2,NA,Western Blotting followed by FACs,0.6,0.7582,20023382
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs and CFA followed by SFA and RT-PCR,0.6,0.7582,29312609
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CACO-2,5-Fluorouracil,qPCR,0.6,0.7582,33946505
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CACO-2,NA,RT-PCR,0.6,0.7582,28578295
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CACO-2,NA,SP assay followed by FACs and SFA,0.6,0.7582,32367652
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs,0.6,0.7582,25154976
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs,0.6,0.7582,32729895
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs and CFA,0.6,0.7582,25154976
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs and Tumorigenicity assay followed by SP assay,0.6,0.7582,21826669
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CACO-2,NA,FACs followed by SFA,0.6,0.7582,31285270
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CACO-2,NA,SFA followed by FACs,0.6,0.7582,26995228
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by qRT-PCR and FACs and Western Blotting,0.6,0.7582,24112466
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,IF staining and Western Blotting followed by SFA,0.6,0.7582,31399556
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by RT-PCR,0.6,0.7582,28093940
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.6,0.7582,27380877
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,qRT-PCR followed by SFA and CFA,0.6,0.7582,27380877
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Docetaxel,qRT-PCR followed by SFA and CFA,0.6,0.7582,27380877
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by qRT-PCR,0.6,0.7582,25588898
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,FACs followed by SFA,0.6,0.7582,34795388
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by FACs,0.6,0.7582,27965308
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and FACs,0.6,0.7582,27108536
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,5-Fluorouracil,SFA followed by FACs,0.6,0.7582,27108536
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,SFA followed by FACs,0.6,0.7582,27108536
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Docetaxel,SFA followed by FACs,0.6,0.7582,27108536
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,CALU-1,NA,SFA and FACs followed by SP assay and IHC staining,0.36,0.7582,19464919
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,CALU-1,NA,SFA followed by qRT-PCR,0.36,0.7582,29138851
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Capan-1,Gemcitabine,qRT-PCR followed by IHC staining,0.44,0.7582,23026911
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Capan-1,Gemcitabine,FACs followed by SFA and IF staining,0.44,0.7582,22320450
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by qRT-PCR,0.44,0.7582,30819221
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs,0.44,0.7582,22948659
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Capan-1,Gemcitabine,FACs,0.44,0.7582,27349387
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs,0.44,0.7582,24231729
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs followed by Migration and Invasion assay,0.44,0.7582,27367674
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs followed by SFA,0.44,0.7582,27349387
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs followed by SP assay,0.44,0.7582,22963768
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs followed by Tumorigenicity assay,0.44,0.7582,22111082
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,Migration and Invasion assay followed by FACs,0.44,0.7582,22109279
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,Migration assay followed by FACs,0.44,0.7582,31856088
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,CAR-1,NA,FACs followed by SP assay and RT-PCR,0.32,0.7582,17932721
PROM1,LTM,NA,9454,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,qRT-PCR,0.2,0.7582,26035122
PROM1,LTM,NA,9454,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by RT-PCR,0.2,0.7582,29100320
PROM1,LTM,NA,9454,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,FACs,0.2,0.7582,29029495
PROM1,LTM,NA,9454,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,FACs followed by SFA,0.2,0.7582,25811929
PROM1,LTM,NA,9454,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by FACs,0.2,0.7582,30853342
PROM1,LTM,NA,9454,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SP assay followed by FACs,0.2,0.7582,18829528
PROM1,LTM,NA,9454,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SP assay followed by FACs,0.2,0.7582,20372854
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,CL1-0,NA,CFA and SFA followed by Western Blotting,0.28,0.7582,35163585
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,CL-141,NA,SFA followed by Western Blotting,0.28,0.7582,31319622
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,CL-141,NA,SFA followed by Western Blotting,0.28,0.7582,31638335
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,CL-141,NA,SP assay followed by SFA and Western Blotting,0.28,0.7582,23024022
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,CL1-5,NA,SFA followed by qRT-PCR,0.2,0.7582,26447186
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,CL-97,NA,SP assay followed by SFA and Western Blotting,0.28,0.7582,23024022
PROM1,LTM,NA,9454,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-201,NA,Western Blotting followed by FACs,0.4,0.7582,20023382
PROM1,LTM,NA,9454,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-201,NA,FACs followed by SP assay and RT-PCR,0.4,0.7582,17932721
PROM1,LTM,NA,9454,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-201,NA,Western Blotting,0.4,0.7582,19621338
PROM1,LTM,NA,9454,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-201,NA,FACs,0.4,0.7582,20711432
PROM1,LTM,NA,9454,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,24212669
PROM1,LTM,NA,9454,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,Western Blotting followed by FACs,0.48,0.7582,20023382
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,COLO-205,NA,FACs,0.48,0.7582,35155201
PROM1,LTM,NA,9454,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,FACs,0.48,0.7582,20711432
PROM1,LTM,NA,9454,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,FACs followed by SFA,0.48,0.7582,31285270
PROM1,LTM,NA,9454,Dukes Type D Colon Cancer,Adenocarcinoma,COLO-205,NA,SFA followed by FACs,0.48,0.7582,22310487
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,COLO-320,NA,MACs and IHC staining,0.36,0.7582,31390540
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenosquamous Cell Carcinoma,COLO-357,NA,MACs followed by FACs and SFA,0.24,0.7582,26840020
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,COLO-741,NA,MACs and IHC staining,0.36,0.7582,31390540
PROM1,LTM,NA,9454,Skin Cancer,NA,D10,NA,FACs followed by SFA and qRT-PCR,0.32,0.7582,26208390
PROM1,LTM,NA,9454,Glioblastoma,NA,DBTRG-05MG,NA,SFA and Western Blotting,0.28,0.7582,33317545
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,FACs and Western Blotting followed by SFA,0.4,0.7582,31964531
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by qPCR,0.4,0.7582,29449559
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.4,0.7582,23418515
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,FACs,0.4,0.7582,24760019
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,FACs followed by SFA,0.4,0.7582,21694723
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,FACs followed by SFA,0.4,0.7582,31285270
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,FACs followed by SFA and Tumorigenicity assay,0.4,0.7582,22074823
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,FACs followed by Tumorigenicity assay,0.4,0.7582,20711432
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by FACs,0.4,0.7582,20630067
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SP assay followed by FACs,0.4,0.7582,21720213
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,DMS53,NA,IF staining followed by FACs,0.36,0.7582,31446534
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,28870814
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,32661469
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.7582,31180522
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,EJ-28,Benzidine,SFA followed by Western Blotting,0.48,0.7582,33552265
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by Western Blotting,0.48,0.7582,33552265
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR,0.48,0.7582,32065779
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,EKVX,NA,FACs followed by IHC staining,0.36,0.7582,23738757
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,IF staining and Western Blotting followed by SFA,0.52,0.7582,31399556
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR and Western Blotting,0.52,0.7582,32708734
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Cisplatin,SP assay followed by Western Blotting,0.52,0.7582,29228308
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR,0.52,0.7582,28093940
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA and FACs,0.52,0.7582,27108536
PROM1,LTM,NA,9454,Glioblastoma Multiforme,NA,GBM8401,NA,SFA followed by IF staining,0.24,0.7582,31035045
PROM1,LTM,NA,9454,Glioblastoma Multiforme,NA,GBM8401,NA,SP assay and SFA followed by RT-PCR,0.24,0.7582,25359730
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,GLC-82,NA,SP assay followed by Tumorigenicity assay and FACs,0.12,0.7582,28920265
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,Gun-1,NA,SFA followed by IF staining and FACs,0.36,0.7582,19027347
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,FACs followed by IF staining,0.36,0.7582,19276181
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,SFA followed by FACs and RT-PCR,0.36,0.7582,23370278
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.7582,33783940
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,33539684
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,28431267
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,MACs followed by FACs and qPCR,0.48,0.7582,26675547
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs and Western Blotting,0.48,0.7582,28198062
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting and  FACs,0.48,0.7582,33125096
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,MACs and IF staining,0.48,0.7582,31819528
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs and qRT-PCR,0.48,0.7582,30816208
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs and RT-PCR,0.48,0.7582,29651165
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and FACs,0.48,0.7582,25669973
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.7582,33980809
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,Western Blotting,0.48,0.7582,34803670
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.7582,23583374
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.7582,26518146
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.48,0.7582,27836540
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,CFA followed by IF staining,0.48,0.7582,25831148
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,MACs followed by FACs,0.48,0.7582,30880491
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.7582,33468994
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.7582,34832951
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,qRT-PCR and SFA,0.48,0.7582,29144562
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,RT-PCR,0.48,0.7582,25906011
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.48,0.7582,32051483
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR,0.48,0.7582,23370278
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs,0.48,0.7582,33959615
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs,0.48,0.7582,35337095
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA and FACs,0.48,0.7582,33631674
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs,0.48,0.7582,24440048
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs,0.48,0.7582,24595209
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs,0.48,0.7582,27542268
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs,0.48,0.7582,31585300
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs followed by SFA,0.48,0.7582,25735977
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs followed by SFA,0.48,0.7582,29144562
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,Docetaxel,FACs followed by SFA and Tumorigenicity assay,0.48,0.7582,25279705
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,MACs followed by SFA and Tumorigenicity assay,0.48,0.7582,24008862
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs,0.48,0.7582,25965829
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SP assay and SFA followed by FACs and Tumorigenicity assay,0.48,0.7582,20949018
PROM1,LTM,NA,9454,Small Cell Lung Cancer,NA,H1408,Etoposide,SFA followed by FACs,0.12,0.7582,29437792
PROM1,LTM,NA,9454,Small Cell Lung Cancer,NA,H1408,NA,SFA followed by FACs and Tumorigenicity assay,0.12,0.7582,29437792
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay followed by FACs and Tumorigenicity assay,0.12,0.7582,20424609
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay followed by FACs and Tumorigenicity assay,0.12,0.7582,20424609
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H157,NA,MACs followed by FACs and qPCR,0.44,0.7582,26675547
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H157,Cisplatin,SFA followed by RT-PCR,0.44,0.7582,27009878
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H157,NA,FACs followed by SFA,0.44,0.7582,26572130
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Giant Cell Carcinoma,H1581,NA,SFA followed by qRT-PCR,0.2,0.7582,26936993
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,SFA followed by qPCR and Western Blotting,0.48,0.7582,29702194
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,FACs followed by SFA and RT-PCR,0.48,0.7582,25678473
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,SFA followed by qPCR and FACs,0.48,0.7582,26299367
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,Western Blotting,0.48,0.7582,34803670
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,Erlotinib,qRT-PCR,0.48,0.7582,30480362
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,Dexamethasone+Pemetrexed,FACs followed by SFA,0.48,0.7582,29753869
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H1658,Erlotinib,RT-PCR followed by CFA and SFA,0.2,0.7582,31069016
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H1703,NA,qRT-PCR followed by SFA and SP assay,0.2,0.7582,26468775
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1781,Afatinib,qRT-PCR followed by SFA,0.2,0.7582,29532558
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,FACs followed by SFA and RT-PCR,0.32,0.7582,25678473
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA followed by qRT-PCR,0.32,0.7582,26447186
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay followed by SFA and RT-PCR,0.32,0.7582,28440478
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,FACs,0.32,0.7582,29958884
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,Osimertinib,SFA followed by FACs,0.32,0.7582,30910592
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,FACs,0.12,0.7582,34827096
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,FACs followed by SFA,0.12,0.7582,31466290
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H226,NA,SFA followed by FACs,0.12,0.7582,35006496
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H23,Cisplatin,SFA followed by IF staining and Western Blotting,0.52,0.7582,26872057
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,FACs,0.52,0.7582,27920206
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,FACs and SFA,0.52,0.7582,34063628
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,SFA followed by FACs,0.52,0.7582,34349823
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Western Blotting and IF staining,0.52,0.7582,25411331
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,Cisplatin,Western Blotting followed by FACs,0.52,0.7582,30754694
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,FACs followed by RT-PCR,0.52,0.7582,27694834
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Western Blotting,0.52,0.7582,34059086
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Western Blotting,0.52,0.7582,34059086
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Western Blotting,0.52,0.7582,31100681
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by Western Blotting and SP assay,0.52,0.7582,26911281
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,RT-PCR,0.52,0.7582,32090054
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H3122,NA,SFA followed by FACs and qRT-PCR,0.32,0.7582,29950868
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H322,NA,FACs followed by IF staining,0.36,0.7582,19276181
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H345,NA,FACs followed by CFA and Tumorigenicity assay,0.12,0.7582,24436149
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,RT-PCR and FACs followed by IF staining,0.56,0.7582,21947321
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,FACs followed by IF staining,0.56,0.7582,19276181
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,CFA and SFA followed by Western Blotting,0.28,0.7582,35163585
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,SFA followed by RT-PCR,0.28,0.7582,29414668
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,FACs followed by SFA,0.28,0.7582,27276704
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,SFA followed by FACs and SP assay,0.28,0.7582,30092824
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H446,NA,FACs followed by SFA and IF staining,0.36,0.7582,23681228
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H446,NA,MACs followed by SFA and IF staining,0.36,0.7582,23456479
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H446,Cisplatin,RT-PCR and FACs,0.36,0.7582,21174061
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H446,Taxinol,RT-PCR and FACs,0.36,0.7582,21174061
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Western Blotting,0.36,0.7582,30015975
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H446,NA,MACs and FACs followed by SFA,0.36,0.7582,30542415
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by Tumorigenicity assay and IF staining,0.36,0.7582,22521544
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H446,NA,MACs followed by SFA and Tumorigenicity assay,0.36,0.7582,27633248
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by FACs,0.36,0.7582,26871945
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H446,NA,SP assay followed by FACs and SFA,0.36,0.7582,22825470
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs followed by Western Blotting  and RT-PCR,0.6,0.7582,28931539
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA and Western Blotting followed by IF staining,0.6,0.7582,34832867
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting and IF staining,0.6,0.7582,25411331
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,MACs and FACs followed by qRT-PCR,0.6,0.7582,28619508
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs followed by Western Blotting,0.6,0.7582,31074646
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs and Western Blotting,0.6,0.7582,30737252
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs followed by IF staining,0.6,0.7582,19276181
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,5-fluorouracil,FACs followed by qRT-PCR,0.6,0.7582,22416214
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,Methotrexate,FACs followed by qRT-PCR,0.6,0.7582,22416214
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA and Western Blotting,0.6,0.7582,34635641
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.7582,34195288
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.7582,26339272
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,Ciprofloxacin,SFA followed by Western Blotting,0.6,0.7582,26947806
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.7582,28122729
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.7582,28179308
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.7582,28259926
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.7582,28677037
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.7582,28931539
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.7582,30111255
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.7582,31100681
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.6,0.7582,32782570
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting and SP assay,0.6,0.7582,26911281
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,Gefitinib,Western Blotting,0.6,0.7582,30341415
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,Doxorubicin+Cisplatin+Etiopside,SP assay and SFA followed by IF staining and Tumorigenicity assay,0.6,0.7582,18728788
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,FACs for CSC marker followed by qRT-PCR,0.6,0.7582,33550205
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,qRT-PCR and SFA,0.6,0.7582,34246759
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by qRT-PCR and Tumorigenicity assay,0.6,0.7582,24961511
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by RT-PCR,0.6,0.7582,22552503
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by RT-PCR and Tumorigenicity assay,0.6,0.7582,24961511
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SP assay followed by qRT-PCR,0.6,0.7582,27911857
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SP assay followed by RT-PCR,0.6,0.7582,22855139
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,Culture on collagen films functionalized with glucose (Glc?collagen) followed by FACs,0.6,0.7582,33068069
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs,0.6,0.7582,34827096
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs,0.6,0.7582,35337095
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs and SFA,0.6,0.7582,34063628
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs,0.6,0.7582,34044271
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs,0.6,0.7582,34349823
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs,0.6,0.7582,34424425
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by FACs,0.6,0.7582,35267489
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,CFA and SFA followed by FACs,0.6,0.7582,28406482
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,FACs,0.6,0.7582,23349823
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs,0.6,0.7582,24595209
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,SAHA,FACs,0.6,0.7582,26839308
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs followed by SFA,0.6,0.7582,26901847
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs followed by SFA,0.6,0.7582,31466290
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs,0.6,0.7582,20028869
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs,0.6,0.7582,20028869
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,Taxol,SFA followed by FACs,0.6,0.7582,27281614
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by FACs,0.6,0.7582,28580971
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,FACs followed by IHC staining,0.36,0.7582,23738757
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,SFA followed by FACs and RT-PCR,0.36,0.7582,23715514
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,Western Blotting followed by SFA,0.36,0.7582,33721187
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,SFA followed by qRT-PCR,0.36,0.7582,26936993
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,SFA followed by qRT-PCR,0.36,0.7582,32863772
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,FACs,0.36,0.7582,28484448
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H524,NA,SFA followed by qRT-PCR,0.2,0.7582,35028858
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA followed by qRT-PCR,0.2,0.7582,34832951
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,H69,NA,FACs followed by CFA,0.2,0.7582,24436149
PROM1,LTM,NA,9454,Hepatic Cancer,NA,HAK-1B,NA,SFA followed by FACs and qRT-PCR,0.32,0.7582,24325739
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,HCC1833,NA,FACs followed by IHC staining and SFA,0.36,0.7582,21124918
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Ductal Carcinoma,HCC-38,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.7582,30336071
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by Western Blotting,0.28,0.7582,33955683
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,Western Blotting,0.28,0.7582,30341415
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,qRT-PCR,0.28,0.7582,33764690
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,qPCR,0.28,0.7582,24489728
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by RT-PCR,0.28,0.7582,28787001
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by FACs,0.28,0.7582,25965829
PROM1,LTM,NA,9454,Lung Cancer,Squamous Cell Carcinoma,HCC95,NA,SFA followed by qRT-PCR,0.2,0.7582,32863772
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,HCCLM3,NA,CFA followed by SFA and qRT-PCR,0.2,0.7582,27783993
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs and SFA followed by qRT-PCR and Western Blotting,0.6,0.7582,35155201
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA and FACs followed by RT-PCR and Western Blotting,0.6,0.7582,21750907
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,qRT-PCR followed by Western Blotting and SFA,0.6,0.7582,30912138
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by Western Blotting and SFA,0.6,0.7582,21596996
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil,SFA followed by Western Blotting and qRT-PCR,0.6,0.7582,28990068
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and Western Blotting,0.6,0.7582,34798428
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by Western Blotting,0.6,0.7582,21123622
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by Western Blotting,0.6,0.7582,22623141
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by Western Blotting,0.6,0.7582,29928431
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,MACs followed by SFA and Western Blotting,0.6,0.7582,27894099
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting and FACs,0.6,0.7582,26124007
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,Western Blotting followed by FACs and Tumorigenicity assay,0.6,0.7582,20023382
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs and SFA followed by IF staining,0.6,0.7582,33819194
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,MACs and IHC staining,0.6,0.7582,31390540
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by IF staining and FACs,0.6,0.7582,22745705
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by CFA and SFA and qRT-PCR,0.6,0.7582,35392530
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs and qRT-PCR,0.6,0.7582,35242031
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs and RT-PCR followed by CFA,0.6,0.7582,26840024
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by RT-PCR,0.6,0.7582,30788057
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and qRT-PCR,0.6,0.7582,29307822
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil+Oxaliplatin,RT-PCR followed by FACs,0.6,0.7582,21774804
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.6,0.7582,27997180
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.6,0.7582,29354056
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,Western Blotting,0.6,0.7582,22319203
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA and IF staining,0.6,0.7582,24039918
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by IF staining,0.6,0.7582,28188489
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by IHC staining,0.6,0.7582,22487097
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by IHC staining,0.6,0.7582,22487097
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,Docetaxel,qRT-PCR,0.6,0.7582,27748801
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR,0.6,0.7582,22871210
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR,0.6,0.7582,29902974
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by SFA,0.6,0.7582,32037723
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA and qRT-PCR,0.6,0.7582,26241688
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.6,0.7582,31544978
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil,FACs,0.6,0.7582,34151658
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by CFA,0.6,0.7582,33958701
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.6,0.7582,34815662
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.6,0.7582,35116403
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.6,0.7582,19734943
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,5-Fluorouracil+Oxaliplatin,FACs,0.6,0.7582,19956394
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.6,0.7582,20433742
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.6,0.7582,20711432
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.6,0.7582,22842824
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.6,0.7582,24122993
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.6,0.7582,24760019
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.6,0.7582,25154976
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.6,0.7582,25941936
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.6,0.7582,29740695
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.6,0.7582,30429213
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.6,0.7582,31812723
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.6,0.7582,32729895
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs and CFA,0.6,0.7582,25154976
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs and SFA,0.6,0.7582,21694723
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs and Tumorigenicity assay,0.6,0.7582,21826669
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.6,0.7582,22329848
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.6,0.7582,26745821
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.6,0.7582,27455311
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA,0.6,0.7582,31950022
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and Tumorigenicity assay,0.6,0.7582,19451087
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and Tumorigenicity assay,0.6,0.7582,22074823
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and Tumorigenicity assay,0.6,0.7582,31120140
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by Tumorigenicity assay and SFA,0.6,0.7582,21454414
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,MACs and SFA followed by CFA and Tumorigenicity assay,0.6,0.7582,27600678
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA and FACs,0.6,0.7582,25804133
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA and FACs,0.6,0.7582,26399781
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.6,0.7582,20630067
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.6,0.7582,23345327
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.6,0.7582,26506839
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.6,0.7582,28825721
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs,0.6,0.7582,31883392
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by FACs and Tumorigenicity assay,0.6,0.7582,19737148
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,HCT116,NA,SP assay followed by FACs,0.6,0.7582,21720213
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SFA followed by Western Blotting,0.28,0.7582,27997180
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SP assay followed by FACs,0.28,0.7582,21720213
PROM1,LTM,NA,9454,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by qPCR and Western Blotting,0.48,0.7582,29228308
PROM1,LTM,NA,9454,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,SP assay followed by Western Blotting,0.48,0.7582,29228308
PROM1,LTM,NA,9454,Head and Neck Cancer,Carcinoma,HEp-2,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.48,0.7582,27380877
PROM1,LTM,NA,9454,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,qRT-PCR followed by SFA and CFA,0.48,0.7582,27380877
PROM1,LTM,NA,9454,Head and Neck Cancer,Carcinoma,HEp-2,Docetaxel,qRT-PCR followed by SFA and CFA,0.48,0.7582,27380877
PROM1,LTM,NA,9454,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by RT-PCR,0.48,0.7582,26021266
PROM1,LTM,NA,9454,Head and Neck Cancer,Carcinoma,HEp-2,NA,FACs followed by Migration assay,0.48,0.7582,30210931
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by FACs and qRT-PCR,0.32,0.7582,27773936
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Hep3B,NA,CFA followed by SFA and qRT-PCR,0.32,0.7582,27783993
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Hep3B,NA,FACs followed by CFA,0.32,0.7582,22194816
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by FACs,0.32,0.7582,25676692
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Hep-G2,NA,IHC staining followed by qRT-PCR,0.44,0.7582,30023612
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Hep-G2,NA,FACs followed by SFA and Western Blotting,0.44,0.7582,29033320
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Hep-G2,NA,SFA followed by Western Blotting,0.44,0.7582,32626943
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Hep-G2,NA,RT-PCR and SFA,0.44,0.7582,31140684
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Hep-G2,NA,SFA followed by qRT-PCR,0.44,0.7582,28554132
PROM1,LTM,NA,9454,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by qPCR,0.2,0.7582,29559846
PROM1,LTM,NA,9454,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by FACs,0.2,0.7582,32572790
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,HN13,NA,FACs followed by Migration assay,0.12,0.7582,30210931
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by IF staining and qRT-PCR,0.44,0.7582,27891685
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,FACs followed by SFA,0.44,0.7582,26284537
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,FACs followed by MACs and Tumorigenicity assay,0.24,0.7582,27602113
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,HPAF-II,Gemcitabine,qPCR,0.24,0.7582,31440741
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,SFA followed by FACs,0.24,0.7582,30853342
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,HPAF-II,Gemcitabine,SFA followed by FACs,0.24,0.7582,19501590
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HRT-18,NA,SFA followed by IF staining,0.24,0.7582,28188489
PROM1,LTM,NA,9454,Skin Cancer,NA,HS 294T,NA,SFA followed by FACs,0.12,0.7582,34703819
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,Western Blotting followed by SFA,0.28,0.7582,34294320
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by qPCR,0.28,0.7582,30224376
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by Western Blotting and RT-PCR,0.6,0.7582,22384170
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR and Western Blotting followed by FACs,0.6,0.7582,26002465
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by Western Blotting and SFA,0.6,0.7582,21596996
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA and Western Blotting,0.6,0.7582,34798428
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and Western Blotting followed by SFA,0.6,0.7582,31964531
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA and Western Blotting,0.6,0.7582,30944638
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by Western Blotting,0.6,0.7582,22623141
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,MACs followed by SFA and Western Blotting,0.6,0.7582,27894099
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,Western Blotting followed by FACs,0.6,0.7582,20023382
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and SFA followed by IF staining,0.6,0.7582,33819194
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA and IHC staining,0.6,0.7582,26918725
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,MACs followed by IF staining,0.6,0.7582,30758710
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by IF staining and FACs,0.6,0.7582,22745705
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by CFA and SFA and qRT-PCR,0.6,0.7582,35392530
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and CFA followed by SFA and RT-PCR,0.6,0.7582,29312609
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and RT-PCR followed by SFA and Tumorigenicity assay,0.6,0.7582,21130073
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by qRT-PCR,0.6,0.7582,20333645
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SP assay and qRT-PCR and Tumorigenicity assay,0.6,0.7582,17932721
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,Western Blotting,0.6,0.7582,35115900
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and IF staining,0.6,0.7582,24039918
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by IF staining,0.6,0.7582,28188489
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,Docetaxel,qRT-PCR,0.6,0.7582,27748801
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,Docetaxel,qRT-PCR,0.6,0.7582,27748801
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,qRT-PCR,0.6,0.7582,27748801
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,qRT-PCR,0.6,0.7582,27748801
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,qRT-PCR,0.6,0.7582,29158786
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,qRT-PCR,0.6,0.7582,30772447
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,RT-PCR,0.6,0.7582,24323901
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR,0.6,0.7582,29902974
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.6,0.7582,32037723
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and qRT-PCR,0.6,0.7582,27556511
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.6,0.7582,27556511
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.6,0.7582,31544978
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.6,0.7582,31835579
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.6,0.7582,33744851
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,FACs,0.6,0.7582,34151658
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,MACs,0.6,0.7582,33568147
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.6,0.7582,33667839
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by FACs and SFA,0.6,0.7582,32367652
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil+Oxaliplatin,FACs,0.6,0.7582,21774804
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.6,0.7582,22329848
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.6,0.7582,22329848
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.6,0.7582,24760019
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.6,0.7582,30947381
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,FACs,0.6,0.7582,32108197
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,Oxaliplatin,FACs,0.6,0.7582,32108197
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs,0.6,0.7582,32729895
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and SFA,0.6,0.7582,21694723
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and SFA,0.6,0.7582,27520449
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs and Tumorigenicity assay followed by SP assay,0.6,0.7582,21826669
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA,0.6,0.7582,26745821
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA,0.6,0.7582,30603407
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA,0.6,0.7582,31285270
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA,0.6,0.7582,31662289
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA,0.6,0.7582,31904143
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by SFA and Tumorigenicity assay,0.6,0.7582,31120140
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,MACs,0.6,0.7582,19699770
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,MACs followed by SFA,0.6,0.7582,30337351
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,5-Fluorouracil,SFA and FACs,0.6,0.7582,26527315
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.6,0.7582,20630067
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.6,0.7582,26506839
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.6,0.7582,28825721
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs,0.6,0.7582,30770752
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs and SP assay,0.6,0.7582,21670985
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by FACs and SP assay,0.6,0.7582,30770752
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by SP assay and FACs,0.6,0.7582,31255531
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by FACs,0.6,0.7582,21720213
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by FACs,0.6,0.7582,30209760
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,33825221
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by Western Blotting and SFA,0.48,0.7582,22773665
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by Western Blotting,0.48,0.7582,32221015
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,MACs followed by Western Blotting and SFA,0.48,0.7582,29602239
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,SFA and FACs followed by Western Blotting,0.48,0.7582,32229502
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by FACs and qRT-PCR,0.48,0.7582,27773936
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by FACs and qRT-PCR,0.48,0.7582,32128906
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.48,0.7582,28554132
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and qRT-PCR,0.48,0.7582,21618577
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by qRT-PCR and SFA,0.48,0.7582,29792038
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by CFA,0.48,0.7582,22194816
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by FACs and SFA,0.48,0.7582,25997710
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,FACs,0.48,0.7582,21879266
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,FACs,0.48,0.7582,25404478
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,MACs followed by SFA,0.48,0.7582,31732298
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by FACs,0.48,0.7582,25676692
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by FACs,0.48,0.7582,20697159
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by FACs,0.48,0.7582,25997710
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by FACs and RT-PCR,0.32,0.7582,30397177
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by qRT-PCR,0.32,0.7582,35116788
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,J-82,NA,MACs followed by Tumorigenicity assay,0.32,0.7582,24649144
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by FACs,0.32,0.7582,31176734
PROM1,LTM,NA,9454,Breast Cancer,Ductal Carcinoma,JIMT-1,NA,Western Blotting followed by SFA,0.28,0.7582,30620624
PROM1,LTM,NA,9454,Gastric Cancer,Carcinoma,KATO-III,NA,FACs,0.12,0.7582,19415765
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,KMC14,NA,FACs followed by IHC staining,0.36,0.7582,24278411
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.7582,21618577
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,KP-2,NA,FACs followed by qRT-PCR and Migration assay,0.32,0.7582,20564084
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,qRT-PCR,0.2,0.7582,26035122
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR,0.2,0.7582,23917223
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,FACs followed by SFA,0.2,0.7582,26840266
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,FACs followed by Tumorigenicity assay and SFA,0.2,0.7582,18371365
PROM1,LTM,NA,9454,Lung Cancer,Large Cell Carcinoma,L9981,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,30485693
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,LC31,NA,RT- PCR followed by Western Blotting and SFA,0.48,0.7582,21738704
PROM1,LTM,NA,9454,Lung Cancer,NA,LC-42,NA,FACs and SFA followed by SP assay and Tumorigenicity assay,0.12,0.7582,23738757
PROM1,LTM,NA,9454,Glioblastoma,NA,LN-18,NA,SFA and FACs,0.12,0.7582,29069805
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),qRT-PCR followed by Western Blotting,0.48,0.7582,28627611
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),qRT-PCR followed by Western Blotting and SFA,0.48,0.7582,29956726
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,FACs followed by SP assay and RT-PCR,0.48,0.7582,17932721
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,Western Blotting,0.48,0.7582,19621338
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,qRT-PCR,0.48,0.7582,30284085
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,Irinotecan (CPT?11),RT-PCR,0.48,0.7582,30552676
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,SFA followed by FACs,0.48,0.7582,35242031
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,FACs,0.48,0.7582,20711432
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,FACs,0.48,0.7582,31393941
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,FACs and Tumorigenicity assay followed by SP assay,0.48,0.7582,21826669
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,FACs followed by Tumorigenicity assay,0.48,0.7582,21601882
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,LS174T,NA,FACs followed by Western Blotting and RT-PCR,0.6,0.7582,22384170
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,LS174T,NA,SFA and FACs,0.6,0.7582,25804133
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,LS180,NA,RT-PCR,0.2,0.7582,29902974
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,LT73,Cisplatin,FACs followed by IF staining,0.36,0.7582,26020124
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,LT73,NA,FACs,0.36,0.7582,35337095
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,Mahlavu,NA,SP assay followed by Western Blotting,0.28,0.7582,29792038
PROM1,LTM,NA,9454,Skin Cancer,NA,MA-MEL-66A,NA,SFA followed by qRT-PCR,0.2,0.7582,30558661
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.7582,31595560
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,IHC staining followed by qRT-PCR,0.48,0.7582,30023612
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.48,0.7582,34830821
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by SFA,0.48,0.7582,29869379
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,IF staining and SFA,0.48,0.7582,35413424
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Cisplatin,IF staining followed by SFA,0.48,0.7582,31595560
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by IF staining,0.48,0.7582,28935760
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by IF staining and Tumorigenicity assay,0.48,0.7582,29176652
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.48,0.7582,29044153
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.48,0.7582,29073103
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.48,0.7582,29434914
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by FACs and SP assay,0.48,0.7582,31604679
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,34070538
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.7582,30336071
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting and FACs,0.48,0.7582,33924995
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA followed by FACs,0.48,0.7582,33797754
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.48,0.7582,34294320
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.48,0.7582,29869379
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,IF staining and SFA,0.48,0.7582,35413424
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cyclophosphamide,qRT-PCR,0.48,0.7582,33090711
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.7582,33090711
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Lapatinib,SFA followed by qRT-PCR,0.48,0.7582,34435487
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR,0.48,0.7582,30021199
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SP assay followed by qPCR,0.48,0.7582,30110679
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs,0.48,0.7582,35055160
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SP assay followed by FACs,0.48,0.7582,29907642
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.7582,30336071
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Irradiation,CFA followed by Western Blotting,0.48,0.7582,34708581
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Doxorubicin,SFA followed by Western Blotting,0.48,0.7582,29750424
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by qPCR,0.48,0.7582,30224376
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs,0.48,0.7582,30091683
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,FACs followed by CFA,0.48,0.7582,18681906
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by FACs and SP assay,0.48,0.7582,31604679
PROM1,LTM,NA,9454,Skin Cancer,NA,Mel-RM,NA,Western Blotting and FACs followed by SFA,0.4,0.7582,29408459
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,32189359
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MGC-803,NA,qRT-PCR and Western Blotting,0.48,0.7582,32638620
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.7582,28415621
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA and FACs,0.48,0.7582,34075691
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,MHCC97-H,NA,CFA followed by SFA and qRT-PCR,0.2,0.7582,27783993
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting followed by FACs and SFA,0.4,0.7582,29179494
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,IF staining followed by FACs,0.4,0.7582,19714243
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,IF staining followed by FACs,0.4,0.7582,19714243
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by SFA and qPCR,0.4,0.7582,32575925
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Western Blotting,0.4,0.7582,26317547
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Western Blotting,0.4,0.7582,26458814
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,MACs followed by FACs and SFA,0.4,0.7582,25551472
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.4,0.7582,33110235
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,qRT-PCR,0.4,0.7582,24726912
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs,0.4,0.7582,22948659
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs,0.4,0.7582,26302089
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by SFA,0.4,0.7582,24719318
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,FACs followed by SFA and Migration assay,0.4,0.7582,24734907
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and FACs,0.4,0.7582,20940707
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Triptolide,SP assay followed by FACs,0.4,0.7582,26597727
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN28,NA,SFA followed by IF staining,0.24,0.7582,29178392
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by IF staining and qRT-PCR and Western Blotting,0.84,0.7582,27602437
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by IF staining and Western Blotting,0.84,0.7582,28430578
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.84,0.7582,30843262
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,qRT-PCR and Western Blotting,0.84,0.7582,32638620
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Western Blotting,0.84,0.7582,29212193
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.84,0.7582,27644439
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.84,0.7582,28461325
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.84,0.7582,28970066
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by IF staining,0.84,0.7582,29178392
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.84,0.7582,32633423
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and FACs,0.84,0.7582,34075691
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and FACs,0.84,0.7582,34646768
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by FACs,0.84,0.7582,32572790
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.84,0.7582,31073886
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.84,0.7582,31438772
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,MACs followed by SFA,0.84,0.7582,31048191
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by FACs,0.84,0.7582,32863948
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,MOR,Cisplatin,FACs,0.12,0.7582,23349823
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,N417,NA,RT-PCR and FACs followed by IF staining,0.56,0.7582,21947321
PROM1,LTM,NA,9454,Skin Cancer,NA,NA8-MEL,NA,FACs followed by SFA,0.12,0.7582,23915418
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Carcinoma,NCI-H1915,NA,SFA followed by FACs,0.12,0.7582,23418195
PROM1,LTM,NA,9454,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.7582,28461325
PROM1,LTM,NA,9454,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by FACs,0.28,0.7582,28404967
PROM1,LTM,NA,9454,Gastric Cancer,Carcinoma,NCI-N87,NA,FACs followed by SFA,0.28,0.7582,31073886
PROM1,LTM,NA,9454,Gastric Cancer,Carcinoma,NCI-N87,NA,MACs followed by SFA,0.28,0.7582,31048191
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,OECM1,NA,SFA and FACs,0.12,0.7582,20979610
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,OSC19,NA,SFA followed by qRT-PCR,0.2,0.7582,25588898
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,OUMS-23,NA,qRT-PCR,0.2,0.7582,30284085
PROM1,LTM,NA,9454,Gastric Cancer,Carcinoma,PAMC82,NA,FACs followed by SFA,0.12,0.7582,31073886
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and IF staining followed by FACs and qRT-PCR,0.56,0.7582,28580169
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR and Western Blotting,0.56,0.7582,30802827
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR and Western Blotting,0.56,0.7582,30802827
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by qRT-PCR and Western Blotting,0.56,0.7582,24040121
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qRT-PCR followed by IHC staining,0.56,0.7582,23026911
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting followed by FACs and SFA,0.56,0.7582,29179494
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,MACs followed by IHC staining,0.56,0.7582,31595775
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and FACs followed by qRT-PCR,0.56,0.7582,35241126
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.56,0.7582,33359649
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting and SFA,0.56,0.7582,34349642
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.56,0.7582,26458814
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.56,0.7582,28802012
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting,0.56,0.7582,29947365
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting followed by SFA,0.56,0.7582,30819221
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by IF staining,0.56,0.7582,33915247
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by IF staining,0.56,0.7582,26709750
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.56,0.7582,34446696
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,Migration and Invasion assay followed by RT-PCR and SFA,0.56,0.7582,30852389
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qPCR,0.56,0.7582,31440741
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR,0.56,0.7582,24726912
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR,0.56,0.7582,27531902
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.56,0.7582,29975934
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.56,0.7582,33708436
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs,0.56,0.7582,34163012
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.56,0.7582,33115754
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.56,0.7582,22570653
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA,0.56,0.7582,27505247
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by Tumorigenicity assay,0.56,0.7582,30774366
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,Modified transwell lower chamber assay and SFA followed by FACs,0.56,0.7582,24689055
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.56,0.7582,22923052
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.56,0.7582,24305593
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.56,0.7582,26284537
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.56,0.7582,26689865
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by FACs,0.56,0.7582,30045656
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Patu8988,NA,FACs,0.12,0.7582,31558702
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,FACs followed by SFA,0.12,0.7582,27996162
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,FACs followed by SFA,0.12,0.7582,28244691
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,FACs followed by SFA,0.12,0.7582,28244691
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qRT-PCR and IF staining,0.44,0.7582,33764690
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,FACs followed by Western Blotting,0.44,0.7582,27690301
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Erlotinib,FACs followed by qRT-PCR,0.44,0.7582,28901474
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,SFA followed by Western Blotting,0.44,0.7582,33955683
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,Western Blotting followed by SFA,0.44,0.7582,29285189
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by IF staining,0.44,0.7582,31966561
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by IF staining,0.44,0.7582,31966561
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qPCR followed by SFA and Tumorigenicity assay,0.44,0.7582,24489728
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qRT-PCR,0.44,0.7582,30480362
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs and CFA,0.44,0.7582,32329414
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Osimertinib,SFA followed by FACs,0.44,0.7582,30910592
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Osimertinib+Gefitinib,SFA followed by FACs,0.44,0.7582,30910592
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,PK59,NA,SFA followed by qRT-PCR,0.2,0.7582,34414448
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,FACs followed by Western Blotting and SFA,0.4,0.7582,22773665
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SP assay followed by FACs and SFA,0.4,0.7582,25997710
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,FACs,0.4,0.7582,21879266
PROM1,LTM,NA,9454,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SP assay followed by FACs,0.4,0.7582,25997710
PROM1,LTM,NA,9454,Head and Neck Cancer,NA,QLL-1,NA,SFA followed by Western Blotting,0.28,0.7582,32327629
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,RCM-1,NA,FACs,0.12,0.7582,20711432
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,RKO,NA,SFA followed by IF staining,0.24,0.7582,29721049
PROM1,LTM,NA,9454,Bladder Cancer,Transitional Cell Papilloma,RT-4,NA,SFA followed by qRT-PCR,0.2,0.7582,35116788
PROM1,LTM,NA,9454,Pancreatic Cancer,Ductal Adenocarcinoma,S2-013,Triptolide,SP assay followed by FACs,0.12,0.7582,26597727
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,Cisplatin,FACs followed by SFA,0.12,0.7582,25217518
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,FACs followed by SP assay,0.12,0.7582,23843890
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SFA and FACs,0.12,0.7582,20979610
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,SBC-4,NA,RT-PCR followed by FACs,0.32,0.7582,23066953
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,SBC-7,NA,RT-PCR followed by FACs,0.32,0.7582,23066953
PROM1,LTM,NA,9454,Small Cell Lung Cancer,Carcinoma,SBC-9,NA,RT-PCR followed by FACs,0.32,0.7582,23066953
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,Cisplatin,FACs followed by SFA,0.12,0.7582,34795388
PROM1,LTM,NA,9454,Lung Cancer,NA,SELS,NA,FACs followed by IHC staining,0.36,0.7582,23738757
PROM1,LTM,NA,9454,Glioblastoma,NA,SF-295,NA,SFA and MACs,0.12,0.7582,28881826
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,30843262
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,31261030
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.7582,28415621
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,Four-dimensional (4D) culture model by a magnetic responsive alginate-based hydrogel to rotating magnets followed by RT-PCR and IF staining,0.48,0.7582,33836517
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by FACs and Western Blotting,0.48,0.7582,34350176
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.7582,27644439
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.7582,30624124
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and FACs,0.48,0.7582,34646768
PROM1,LTM,NA,9454,Glioblastoma,NA,SHG44,NA,SP assay and SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,26617845
PROM1,LTM,NA,9454,Glioblastoma,NA,SHG-44,NA,SFA followed by IF staining,0.24,0.7582,33889875
PROM1,LTM,NA,9454,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,Western Blotting followed by SFA,0.28,0.7582,30620624
PROM1,LTM,NA,9454,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,Western Blotting followed by SFA,0.28,0.7582,30620624
PROM1,LTM,NA,9454,Hepatic Cancer,Adenocarcinoma,SK-Hep-1,NA,SP assay followed by Western Blotting,0.28,0.7582,29792038
PROM1,LTM,NA,9454,Skin Cancer,NA,SK-MEL-1,NA,FACs,0.12,0.7582,27476721
PROM1,LTM,NA,9454,Skin Cancer,NA,SK-MEL-28,NA,Western Blotting and FACs,0.4,0.7582,29408459
PROM1,LTM,NA,9454,Skin Cancer,NA,SK-MEL-28,NA,SFA followed by qRT-PCR,0.4,0.7582,30558661
PROM1,LTM,NA,9454,Skin Cancer,NA,SK-MEL-28,NA,FACs,0.4,0.7582,27476721
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,SK-MES-1,Cisplatin,FACs for CSC marker followed by qRT-PCR,0.2,0.7582,33550205
PROM1,LTM,NA,9454,Hepatic Cancer,Adenocarcinoma,SMMC-7721,NA,SFA followed by Western Blotting,0.28,0.7582,30866863
PROM1,LTM,NA,9454,Glioblastoma,NA,SNB-19,NA,SFA and qRT-PCR,0.2,0.7582,20082319
PROM1,LTM,NA,9454,Gastric Cancer,Carcinoma,SNU16,NA,FACs followed by SFA,0.12,0.7582,31073886
PROM1,LTM,NA,9454,Gastric Cancer,Carcinoma,SNU5,NA,FACs followed by SFA,0.12,0.7582,31073886
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by Western Blotting,0.28,0.7582,28970066
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by qPCR and Western Blotting,0.48,0.7582,29702194
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,Docetaxel,FACs followed by SFA and Tumorigenicity assay,0.48,0.7582,25279705
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,MACs,0.48,0.7582,24008862
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by FACs,0.48,0.7582,32676335
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,ST2957,NA,SFA followed by FACs,0.12,0.7582,32863948
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,SUIT-2,NA,FACs followed by qRT-PCR and Migration assay,0.32,0.7582,20564084
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,Western Blotting and SFA followed by FACs,0.4,0.7582,33797754
PROM1,LTM,NA,9454,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs followed by RT-PCR and SFA,0.32,0.7582,23674142
PROM1,LTM,NA,9454,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,SFA followed by FACs and RT-PCR,0.32,0.7582,21455326
PROM1,LTM,NA,9454,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs,0.32,0.7582,32617772
PROM1,LTM,NA,9454,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs followed by SFA,0.32,0.7582,23007737
PROM1,LTM,NA,9454,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs followed by SFA,0.32,0.7582,23007737
PROM1,LTM,NA,9454,Dukes Type A Colon Cancer,Adenocarcinoma,SW1116,NA,FACs followed by SFA,0.32,0.7582,31285270
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Tumorigenicity assay and Western Blotting,0.28,0.7582,25003666
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.28,0.7582,28947139
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by qRT-PCR,0.28,0.7582,30819221
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,FACs,0.28,0.7582,26391180
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,FACs,0.28,0.7582,29344263
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,FACs,0.28,0.7582,31669811
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,FACs followed by SFA,0.28,0.7582,27576197
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by FACs,0.28,0.7582,26439804
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by FACs,0.28,0.7582,20372854
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by FACs,0.28,0.7582,20372854
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by FACs,0.28,0.7582,22030254
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW403,NA,FACs followed by SFA,0.12,0.7582,33489876
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW48,Regorafenib,qRT-PCR,0.2,0.7582,35197754
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW48,Doxorubicin,FACs,0.2,0.7582,27517620
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by qRT-PCR and Western Blotting,0.48,0.7582,24926880
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA and Western Blotting,0.48,0.7582,34798428
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by Western Blotting,0.48,0.7582,22319203
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by Western Blotting,0.48,0.7582,31139149
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA and qRT-PCR,0.48,0.7582,29307822
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,RT-PCR followed by FACs,0.48,0.7582,29899829
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs,0.48,0.7582,32617772
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs,0.48,0.7582,33744851
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.48,0.7582,34815662
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs,0.48,0.7582,24122993
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs,0.48,0.7582,30429213
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs and SFA,0.48,0.7582,21694723
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.48,0.7582,21454414
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.48,0.7582,28212529
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.48,0.7582,29805588
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA,0.48,0.7582,31285270
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA and Tumorigenicity assay,0.48,0.7582,22074823
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA and FACs,0.48,0.7582,25804133
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by MACs,0.48,0.7582,30941956
PROM1,LTM,NA,9454,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by FACs,0.48,0.7582,21720213
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,5-Fluorouracil,SFA followed by Western Blotting and qRT-PCR,0.48,0.7582,28990068
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs followed by Western Blotting,0.48,0.7582,31139149
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,MACs followed by SFA and Western Blotting,0.48,0.7582,27894099
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by Western Blotting and  FACs,0.48,0.7582,26124007
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,MACs followed by RT-PCR and Tumorigenicity assay,0.48,0.7582,20587144
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,RT-PCR followed by FACs,0.48,0.7582,29899829
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,IHC staining followed by SFA,0.48,0.7582,21412503
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs followed by SFA,0.48,0.7582,33489876
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs,0.48,0.7582,21123622
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs,0.48,0.7582,25154976
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs,0.48,0.7582,32635858
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs and CFA,0.48,0.7582,25154976
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs followed by CFA and Tumorigenicity assay,0.48,0.7582,23577199
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,5-fluorouracil,FACs followed by SFA,0.48,0.7582,27659530
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs followed by SFA,0.48,0.7582,29805588
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs followed by SFA,0.48,0.7582,31285270
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,FACs followed by Tumorigenicity assay and SFA,0.48,0.7582,22954703
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,MACs followed by SFA,0.48,0.7582,31824193
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by CFA and FACs,0.48,0.7582,30115896
PROM1,LTM,NA,9454,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SP assay followed by FACs,0.48,0.7582,21720213
PROM1,LTM,NA,9454,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,SP assay followed by RT-PCR and SFA,0.2,0.7582,25031712
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,T24,NA,SFA followed by Western Blotting,0.28,0.7582,29559853
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.28,0.7582,30592142
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.28,0.7582,31187490
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.28,0.7582,32065779
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,T24,NA,SFA followed by FACs,0.28,0.7582,31176734
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.7582,31595560
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Cisplatin,IF staining followed by SFA,0.48,0.7582,31595560
PROM1,LTM,NA,9454,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by IF staining,0.48,0.7582,28935760
PROM1,LTM,NA,9454,Colon Cancer,Carcinoma,T84,NA,FACs followed by SFA,0.12,0.7582,31285270
PROM1,LTM,NA,9454,Glioblastoma,NA,T98G,NA,SFA and qRT-PCR,0.2,0.7582,20082319
PROM1,LTM,NA,9454,Glioblastoma,NA,T98G,NA,FACs followed by SFA,0.2,0.7582,28685346
PROM1,LTM,NA,9454,Glioblastoma Multiforme,NA,T98G,NA,SFA followed by FACs,0.2,0.7582,33582558
PROM1,LTM,NA,9454,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,34424812
PROM1,LTM,NA,9454,Glioblastoma,NA,U-251,NA,FACs followed by SFA and SP assay and IHC staining,0.48,0.7582,19232461
PROM1,LTM,NA,9454,Glioblastoma,NA,U-251,NA,SFA and MACs and qRT-PCR,0.48,0.7582,28881826
PROM1,LTM,NA,9454,Glioblastoma,NA,U-251,BIX01294,SFA and Western Blotting,0.48,0.7582,24833465
PROM1,LTM,NA,9454,Glioblastoma,NA,U-251,NA,SFA and Western Blotting,0.48,0.7582,28394339
PROM1,LTM,NA,9454,Glioblastoma,NA,U-251,NA,CFA followed by IF staining and SFA,0.48,0.7582,19324493
PROM1,LTM,NA,9454,Glioblastoma,NA,U-251,NA,Suspended cell culturing and SFA followed by IF staining,0.48,0.7582,23258424
PROM1,LTM,NA,9454,Glioblastoma,NA,U-251,NA,SFA followed by RT-PCR,0.48,0.7582,31288857
PROM1,LTM,NA,9454,Glioblastoma,NA,U-251,NA,SFA followed by FACs,0.48,0.7582,33575080
PROM1,LTM,NA,9454,Glioblastoma,NA,U-251,NA,FACs followed by SFA,0.48,0.7582,21300033
PROM1,LTM,NA,9454,Glioblastoma,NA,U-373,NA,SFA and IF staining followed by qRT-PCR and FACs,0.56,0.7582,26030909
PROM1,LTM,NA,9454,Glioblastoma,NA,U-373MG,NA,SFA followed by Western Blotting,0.28,0.7582,29115404
PROM1,LTM,NA,9454,Glioblastoma,NA,U-373MG,NA,SFA followed by Western Blotting,0.28,0.7582,29115404
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,FACs and SFA followed by Western blotting and qRT-PCR,0.6,0.7582,34408983
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,SFA and IF staining followed by qRT-PCR and FACs,0.6,0.7582,26030909
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting,0.6,0.7582,29115404
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting,0.6,0.7582,29115404
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting,0.6,0.7582,32578777
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,Temozolomide,SFA followed by Western Blotting,0.6,0.7582,33691197
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting and Sedimentation field flow fractionation(SdFFF) ,0.6,0.7582,31179686
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,Western Blotting and SFA,0.6,0.7582,31717924
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,SFA and Western Blotting,0.6,0.7582,28394339
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,SFA followed by IF staining,0.6,0.7582,25394756
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,SFA followed by IF staining,0.6,0.7582,33889875
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,IF staining followed by SFA,0.6,0.7582,21193962
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,SFA followed by RT-PCR,0.6,0.7582,31288857
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,SFA and qRT-PCR,0.6,0.7582,20082319
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,FACs followed by SFA and SP assay,0.6,0.7582,19232461
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,SFA followed by FACs,0.6,0.7582,29452949
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,SFA followed by FACs,0.6,0.7582,34235925
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,FACs followed by SFA,0.6,0.7582,28685346
PROM1,LTM,NA,9454,Glioblastoma,NA,U-87MG,NA,SFA followed by FACs,0.6,0.7582,19212677
PROM1,LTM,NA,9454,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,28870814
PROM1,LTM,NA,9454,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.7582,32661469
PROM1,LTM,NA,9454,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.7582,31180522
PROM1,LTM,NA,9454,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by FACs and RT-PCR,0.48,0.7582,30397177
PROM1,LTM,NA,9454,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,Benzidine,SFA followed by Western Blotting,0.48,0.7582,33552265
PROM1,LTM,NA,9454,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting,0.48,0.7582,33552265
PROM1,LTM,NA,9454,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,Cisplatin,qRT-PCR,0.48,0.7582,31239709
PROM1,LTM,NA,9454,Colon Cancer,Adenocarcinoma,WIDR,NA,FACs followed by SP assay and RT-PCR,0.32,0.7582,17932721
PROM1,LTM,NA,9454,Skin Cancer,NA,WM266-4,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.7582,31817719
PROM1,LTM,NA,9454,Skin Cancer,NA,WM266-4,NA,SFA followed by RT-PCR,0.48,0.7582,26554153
PROM1,LTM,NA,9454,Skin Cancer,NA,WM793,NA,FACs,0.12,0.7582,29049740
PROM1,LTM,NA,9454,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.7582,21618577
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN30,Deferoxamine,RT-PCR,0.2,0.7582,35313655
PROM1,LTM,NA,9454,Bladder Cancer,NA,Primary,NA,IHC staining,0.32,0.7582,31718471
PROM1,LTM,NA,9454,Bladder Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.7582,32424373
PROM1,LTM,NA,9454,Bladder Cancer,NA,Primary,NA,SFA followed by IF staining,0.32,0.7582,19961489
PROM1,LTM,NA,9454,Breast Cancer,NA,Primary,NA,qPCR followed by IHC staining,0.6,0.7582,29660692
PROM1,LTM,NA,9454,Breast Cancer,Adenocarcinoma,Primary,NA,IF staining,0.6,0.7582,31791269
PROM1,LTM,NA,9454,Breast Cancer,NA,Primary,NA,IHC staining,0.6,0.7582,27994520
PROM1,LTM,NA,9454,Breast Cancer,NA,Primary,NA,IHC staining,0.6,0.7582,30542507
PROM1,LTM,NA,9454,Breast Cancer,NA,Primary,NA,IHC staining,0.6,0.7582,31516750
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,qRT-PCR followed by IHC staining,0.6,0.7582,25625240
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,RT-PCR and IHC staining,0.6,0.7582,25625240
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,SFA followed by FACs and IF staining,0.6,0.7582,27077950
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,SFA and Western Blotting,0.6,0.7582,24833610
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,Western Blotting,0.6,0.7582,24833610
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,IHC staining,0.6,0.7582,19621338
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,IHC staining,0.6,0.7582,22740326
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,IHC staining,0.6,0.7582,22878609
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,IHC staining,0.6,0.7582,22964035
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,IHC staining,0.6,0.7582,29102042
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,IHC staining,0.6,0.7582,29328371
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,IHC staining,0.6,0.7582,31000786
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,SFA and IF staining,0.6,0.7582,24607406
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,SFA followed by IHC staining,0.6,0.7582,18371377
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,qRT-PCR,0.6,0.7582,24492635
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,RT-PCR,0.6,0.7582,23545848
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,FACs,0.6,0.7582,31057717
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,FACs,0.6,0.7582,31973205
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,FACs followed by CFA and Tumorigenicity assay,0.6,0.7582,18757407
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,FACs followed by SFA,0.6,0.7582,26745821
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,MACs,0.6,0.7582,22753241
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,MACs followed by CFA and Tumorigenicity assay ,0.6,0.7582,20530554
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,MACs followed by Tumorigenicity assay and SFA,0.6,0.7582,18371377
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,SFA and FACs,0.6,0.7582,24944672
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.6,0.7582,18765800
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.6,0.7582,20332776
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.6,0.7582,23642368
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.6,0.7582,25483065
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.6,0.7582,26383537
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,SFA followed by FACs,0.6,0.7582,23643941
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,SFA followed by FACs and Tumorigenicity assay,0.6,0.7582,19454726
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,ROCK inhibitor,SFA followed by FACs and Tumorigenicity assay,0.6,0.7582,23002207
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,Y-27632,SFA followed by FACs and Tumorigenicity assay,0.6,0.7582,23002207
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,SFA followed by FACs and Tumorigenicity assay,0.6,0.7582,29110645
PROM1,LTM,NA,9454,Gastric Cancer,Carcinoma,Primary,NA,IHC staining,0.68,0.7582,31217618
PROM1,LTM,NA,9454,Glioblastoma,NA,Primary,NA,MACs and IF staining followed by SFA,0.52,0.7582,26170223
PROM1,LTM,NA,9454,Glioblastoma,NA,Primary,NA,SFA followed by qRT-PCR and FACs,0.52,0.7582,19020659
PROM1,LTM,NA,9454,Glioblastoma,NA,Primary,NA,SFA followed by ICC staining,0.52,0.7582,23143002
PROM1,LTM,NA,9454,Glioblastoma,NA,Primary,NA,SFA followed by IF staining,0.52,0.7582,19956386
PROM1,LTM,NA,9454,Glioblastoma,NA,Primary,NA,FACs followed by SFA,0.52,0.7582,19427293
PROM1,LTM,NA,9454,Glioblastoma,NA,Primary,NA,SFA and FACs,0.52,0.7582,26683773
PROM1,LTM,NA,9454,Glioblastoma,NA,Primary,NA,SFA and FACs,0.52,0.7582,28881826
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IF staining,0.32,0.7582,32327629
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.32,0.7582,31811857
PROM1,LTM,NA,9454,Head and Neck Cancer,NA,Primary,NA,MACs followed by SFA,0.32,0.7582,22892238
PROM1,LTM,NA,9454,Hepatic Cancer,NA,Primary,NA,FACs,0.2,0.7582,26942873
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,Primary,NA,SFA and FACs followed by IHC staining,0.52,0.7582,28855609
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by FACs and qPCR,0.52,0.7582,26621583
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,Primary,NA,MACs followed by FACs and SFA,0.52,0.7582,25435932
PROM1,LTM,NA,9454,Lung Cancer,NA,Primary,Cisplatin,IHC staining,0.52,0.7582,19805294
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.52,0.7582,23252868
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.52,0.7582,26046383
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.52,0.7582,28476825
PROM1,LTM,NA,9454,Lung Cancer,NA,Primary,NA,SFA followed by IF staining,0.52,0.7582,25955492
PROM1,LTM,NA,9454,Lung Cancer,NA,Primary,NA,FACs,0.52,0.7582,30397852
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,Primary,NA,FACs followed by CFA,0.52,0.7582,33135338
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,Primary,NA,MACs followed by SFA and Tumorigenicity assay,0.52,0.7582,25738369
PROM1,LTM,NA,9454,Lung Cancer,Large Cell Neuroendocrine Carcinoma,Primary,NA,SFA and Tumorigenicity assay followed by  FACs,0.52,0.7582,25034785
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,Primary,NA,SFA and Tumorigenicity assay followed by FACs,0.52,0.7582,25034785
PROM1,LTM,NA,9454,Lung Cancer,Squamous Cell Carcinoma,Primary,NA,SFA and Tumorigenicity assay followed by FACs,0.52,0.7582,25034785
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by FACs,0.52,0.7582,29720480
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay followed by FACs and SFA,0.52,0.7582,22285547
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining followed by IF staining,0.64,0.7582,21293543
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining followed by qRT-PCR,0.64,0.7582,26770215
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by FACs and Western Blotting,0.64,0.7582,32552834
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining and FACs followed by SFA and Tumorigenicity assay,0.64,0.7582,18049477
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,Cisplatin,IHC staining followed by FACs and Tumorigenicity assay,0.64,0.7582,19805294
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,MACs and FACs followed by SFA,0.64,0.7582,21225866
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,MACs and FACs followed by SFA,0.64,0.7582,21225866
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,IF staining,0.64,0.7582,25806288
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.64,0.7582,22115706
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.64,0.7582,22199321
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.64,0.7582,23878161
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.64,0.7582,24346092
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.64,0.7582,29158791
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining followed by Tumorigenicity assay,0.64,0.7582,19676044
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,qRT-PCR followed by SFA,0.64,0.7582,29568370
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,FACs,0.64,0.7582,19464919
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,FACs,0.64,0.7582,22225612
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,MACs followed by SFA and Tumorigenicity assay,0.64,0.7582,18612434
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,MACs followed by SFA and Tumorigenicity assay,0.64,0.7582,18612434
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by FACs,0.64,0.7582,27343631
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by FACs,0.64,0.7582,27343631
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining followed by FACs,0.52,0.7582,27414409
PROM1,LTM,NA,9454,Pancreatic Cancer,Carcinoma,Primary,NA,IHC staining,0.52,0.7582,18349830
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.52,0.7582,21922151
PROM1,LTM,NA,9454,Pancreatic Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.52,0.7582,25240521
PROM1,LTM,NA,9454,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.52,0.7582,26840020
PROM1,LTM,NA,9454,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.52,0.7582,32197003
PROM1,LTM,NA,9454,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.52,0.7582,24839953
PROM1,LTM,NA,9454,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.52,0.7582,25081383
PROM1,LTM,NA,9454,Pancreatic Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.52,0.7582,26609473
PROM1,LTM,NA,9454,Pancreatic Cancer,NA,Primary,NA,FACs,0.52,0.7582,20564084
PROM1,LTM,NA,9454,Pancreatic Cancer,NA,Primary,NA,FACs,0.52,0.7582,23029396
PROM1,LTM,NA,9454,Skin Cancer,NA,Primary,NA,IHC staining followed by CFA and  FACs,0.52,0.7582,19221743
PROM1,LTM,NA,9454,Skin Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.52,0.7582,28617309
PROM1,LTM,NA,9454,Skin Cancer,NA,Primary,NA,IHC staining,0.52,0.7582,18727808
PROM1,LTM,NA,9454,Skin Cancer,NA,Primary,NA,IHC staining,0.52,0.7582,20062010
PROM1,LTM,NA,9454,Skin Cancer,NA,Primary,NA,IHC staining,0.52,0.7582,27870003
PROM1,LTM,NA,9454,Skin Cancer,NA,Primary,NA,FACs,0.52,0.7582,19491215
PROM1,LTM,NA,9454,Skin Cancer,Squamous Cell Carcinoma,Primary,NA,FACs followed by SFA,0.52,0.7582,29959199
PROM1,LTM,NA,9454,Skin Cancer,NA,Primary,NA,SFA followed by FACs,0.52,0.7582,20236249
PROM1,LTM,NA,9454,Small Cell Lung Cancer,NA,Primary,NA,IF staining followed by FACs,0.52,0.7582,31446534
PROM1,LTM,NA,9454,Small Cell Lung Cancer,NA,Primary,NA,IHC staining and FACs followed by SFA and Tumorigenicity assay,0.52,0.7582,18049477
PROM1,LTM,NA,9454,Breast Cancer,NA,Primary,NA,FACs followed by SFA,0.6,0.7582,34195201
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,IHC staining followed by qRT-PCR,0.6,0.7582,33819194
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,IHC staining,0.6,0.7582,34609414
PROM1,LTM,NA,9454,Colon Cancer,NA,Primary,NA,qRT-PCR,0.6,0.7582,35392530
PROM1,LTM,NA,9454,Gastric Cancer,NA,Primary,Cisplatin,IHC staining followed by Western Blotting,0.68,0.7582,33635343
PROM1,LTM,NA,9454,Gastric Cancer,NA,Primary,NA,Western Blotting followed by SFA,0.68,0.7582,31309567
PROM1,LTM,NA,9454,Gastric Cancer,Submucosal,Primary,NA,IHC staining,0.68,0.7582,33450435
PROM1,LTM,NA,9454,Gastric Cancer,NA,Primary,NA,IHC staining,0.68,0.7582,34160355
PROM1,LTM,NA,9454,Gastric Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.68,0.7582,34027868
PROM1,LTM,NA,9454,Gastric Cancer,NA,Primary,NA,IHC staining,0.68,0.7582,34532091
PROM1,LTM,NA,9454,Gastric Cancer,NA,Primary,NA,IHC staining,0.68,0.7582,33118117
PROM1,LTM,NA,9454,Gastric Cancer,NA,Primary,NA,IHC staining,0.68,0.7582,29422082
PROM1,LTM,NA,9454,Gastric Cancer,NA,Primary,NA,IHC staining,0.68,0.7582,30240769
PROM1,LTM,NA,9454,Gastric Cancer,NA,Primary,NA,IHC staining,0.68,0.7582,31611965
PROM1,LTM,NA,9454,Gastric Cancer,NA,Primary,NA,IHC staining,0.68,0.7582,28261336
PROM1,LTM,NA,9454,Gastric Cancer,NA,Primary,NA,FACs followed by SFA,0.68,0.7582,27620279
PROM1,LTM,NA,9454,Gastric Cancer,NA,Primary,NA,SFA followed by FACs,0.68,0.7582,32350414
PROM1,LTM,NA,9454,Glioblastoma,NA,Primary,NA,FACs,0.52,0.7582,31226325
PROM1,LTM,NA,9454,Glioblastoma,NA,Primary,NA,MAC followed by CFA,0.52,0.7582,31036696
PROM1,LTM,NA,9454,Glioblastoma Multiforme,NA,Primary,NA,FACs followed by IHC staining,0.52,0.7582,28454230
PROM1,LTM,NA,9454,Glioblastoma Multiforme,NA,Primary,NA,IHC staining,0.52,0.7582,19088037
PROM1,LTM,NA,9454,Glioblastoma Multiforme,NA,Primary,NA,SFA followed by qRT-PCR,0.52,0.7582,32131421
PROM1,LTM,NA,9454,Glioblastoma Multiforme,NA,Primary,NA,Isolation of autofluorescence cells followed by SFA and FACs,0.52,0.7582,33669350
PROM1,LTM,NA,9454,Glioblastoma Multiforme,NA,Primary,NA,SFA followed by FACs,0.52,0.7582,24311636
PROM1,LTM,NA,9454,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IF staining,0.32,0.7582,27619333
PROM1,LTM,NA,9454,Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining,0.52,0.7582,34803670
PROM1,LTM,NA,9454,Lung Cancer,NA,Primary,PD98059,SFA followed by qRT-PCR,0.52,0.7582,33867839
PROM1,LTM,NA,9454,Lung Cancer,NA,Primary,NA,FACs followed by SFA,0.52,0.7582,34929442
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,FACs followed by qRT-PCR and SFA,0.64,0.7582,28855609
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,IF staining,0.64,0.7582,33894494
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,IF staining,0.64,0.7582,27920206
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IF staining,0.64,0.7582,33925297
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by IF staining,0.64,0.7582,33925297
PROM1,LTM,NA,9454,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by FACs,0.64,0.7582,28416482
PROM1,LTM,NA,9454,Pancreatic Cancer,NA,Primary,NA,IHC staining,0.52,0.7582,33672734
PROM1,LTM,NA,9454,Pancreatic Cancer,NA,Primary,NA,FACs followed by SFA,0.52,0.7582,33067432
PROM1,LTM,NA,9454,Skin Cancer,NA,Primary,NA,IHC staining,0.52,0.7582,25339000
PROM1,LTM,NA,9454,Triple Negative Breast Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.36,0.7582,33924995
PROM1,LTM,NA,9454,Hepatic Cancer,NA,Primary,NA,SP assay followed by FACs,0.2,0.7582,23104270
PRPM1,LTM,NA,NA,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.2,0.0011,35017469
PRR11,LTM,NA,25619,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,30007956
PRR11,LTM,NA,25619,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,30007956
PRX,LTM,NA,13797,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by qRT-PCR and Western Blotting,0.48,0.0011,34798428
PRX,LTM,NA,13797,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker followed by qRT-PCR and Western Blotting,0.48,0.0011,34798428
PSCA,LTM,NA,9500,Gastric Cancer,NA,Primary,NA,qPCR,0.28,0.0032,26870231
PTBP3,LTM,NA,10253,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting and Migartion Invasion assay,0.28,0.0011,29187406
PTCH1,LTM,NA,9585,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.28,0.0032,29697746
PTEN,LTM,Down,9588,Colon Cancer,Carcinoma,HCT116,NA,SFA and Western Blotting,0.28,0.0053,23894315
PTEN,LTM,Down,9588,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and Western Blotting,0.28,0.0053,23894315
PTEN,LTM,NA,9588,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by RT-PCR,0.2,0.0053,30696080
PTEN,LTM,NA,9588,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR,0.2,0.0053,19232461
PTEN,LTM,NA,9588,Lung Cancer,NA,Primary,NA,RT-PCR,0.28,0.0053,19536353
PTK7,LTM,NA,9618,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,qRT-PCR and CFA followed by SFA and Migration assay,0.2,0.0032,30348980
PTPRC,LTM,NA,9666,Breast Cancer,NA,Primary,NA,FACs,0.2,0.0021,31555258
PTPRC,LTM,NA,9666,Breast Cancer,NA,Primary,NA,FACs,0.2,0.0021,18685093
PTPRC,LTM,NA,9666,Breast Cancer,NA,Primary,NA,FACs,0.2,0.0021,31555258
PTPRC,LTM,NA,9666,Breast Cancer,NA,Primary,NA,FACs followed by SFA,0.2,0.0021,31555258
RAB27A,LTM,NA,9766,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,27556511
RAB27A,LTM,NA,9766,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and qRT-PCR,0.48,0.0032,27556511
RAB27A,LTM,NA,9766,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,28928832
RAC1,LTM,NA,9801,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.28,0.0032,28461325
RAC1,LTM,NA,9801,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.28,0.0032,28461325
RAC1,LTM,NA,9801,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.0032,28461325
RAD50,LTM,NA,9816,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by Western Blotting,0.28,0.0021,33090711
RAD50,LTM,NA,9816,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Cyclophosphamide,Western Blotting,0.28,0.0021,33090711
RAD50,LTM,NA,9816,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0021,33090711
RAD50,LTM,NA,9816,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cyclophosphamide,Western Blotting,0.28,0.0021,33090711
RASSF1,LTM,NA,9882,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and Western Blotting,0.4,0.0021,25007054
REL,LTM,NA,9954,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IF staining,0.32,0.0021,33925297
REL,LTM,NA,9954,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by IF staining,0.32,0.0021,33925297
RELA,LTM,NA,9955,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0032,31497349
RELA,LTM,NA,9955,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0032,31497349
RELA,LTM,NA,9955,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Western Blotting,0.28,0.0032,31497349
RELA,LTM,NA,9955,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IF staining,0.32,0.0032,33925297
RELA,LTM,NA,9955,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by IF staining,0.32,0.0032,33925297
RELB,LTM,NA,9956,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IF staining,0.32,0.0032,33925297
RELB,LTM,NA,9956,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,SFA followed by IF staining,0.32,0.0032,33925297
RHOC,LTM,NA,669,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,SFA followed by qRT-PCR,0.2,0.0032,24533098
ROHA,LTM,NA,667,Pancreatic Cancer,Ductal Adenocarcinoma,PaCa-44,NA,Prolonged exposure to simulated microgravity followed by qRT-PCR,0.2,0.0011,35391557
RORA,LTM,NA,10258,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by qRT-PCR and IF staining,0.44,0.0021,27602437
RSPO2,LTM,NA,28583,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0011,27158331
RSPO2,LTM,NA,28583,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0011,27158331
RTCB,LTM,NA,26935,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,MACs followed by SFA and RT-PCR,0.32,0.0021,29187905
RXRA,LTM,NA,10477,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting followed by SFA,0.28,0.0021,30058740
RXRA,LTM,NA,10477,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by qPCR and Western Blotting,0.48,0.0021,29228308
RXRA,LTM,NA,10477,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Cisplatin,Western Blotting,0.48,0.0021,29228308
RXRA,LTM,NA,10477,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by qPCR and Western Blotting,0.48,0.0021,29228308
RXRA,LTM,NA,10477,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,Western Blotting,0.48,0.0021,29228308
S100A4,LTM,NA,10494,Pancreatic Cancer,Ductal Adenocarcinoma,PaCa-44,NA,Prolonged exposure to simulated microgravity followed by qRT-PCR,0.2,0.0074,35391557
S100A4,LTM,NA,10494,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by Western Blotting,0.36,0.0074,21169409
S1PR3,LTM,NA,3167,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.2,0.0021,33919234
SALL4,LTM,NA,15924,Glioblastoma Multiforme,NA,Primary,NA,IHC staining and IF staining followed by Western Blotting,1,0.0021,27617262
SATB2,LTM,NA,1681,Pancreatic Cancer,NA,Primary,NA,SFA followed by Western Blotting and qRT-PCR,0.64,0.0021,27472393
SCD,LTM,NA,10571,Skin Cancer,NA,A-375,NA,SFA followed by qRT-PCR,0.2,0.0127,30558661
SCD,LTM,NA,10571,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0127,24309934
SCD,LTM,NA,10571,Non Small Cell Lung Cancer,Carcinoma,H460,NA,qRT-PCR and SFA,0.48,0.0127,31717588
SCD,LTM,NA,10571,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.48,0.0127,31397494
SCD,LTM,NA,10571,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.28,0.0127,33430034
SCD,LTM,NA,10571,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SFA followed by Western Blotting,0.28,0.0127,33430034
SCD,LTM,NA,10571,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.28,0.0127,33430034
SCD,LTM,NA,10571,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.28,0.0127,31835579
SCD,LTM,NA,10571,Skin Cancer,NA,MA-MEL-66A,NA,SFA followed by qRT-PCR,0.2,0.0127,30558661
SCD,LTM,NA,10571,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0127,34486791
SCD,LTM,NA,10571,Skin Cancer,NA,SK-MEL-28,NA,SFA followed by qRT-PCR,0.2,0.0127,30558661
SCD,LTM,NA,10571,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by Western Blotting,0.28,0.0127,33430034
SCD,LTM,NA,10571,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by RT-PCR and Western Blotting,0.64,0.0127,24309934
SCUBE2,LTM,NA,30425,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0021,29981340
SH2D3A,LTM,NA,16885,Lung Cancer,NA,Primary,NA,qRT-PCR and Western Blotting followed by SFA,0.64,0.0021,34385181
SHH,LTM,NA,10848,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,CFA and Western Blotting,0.28,0.0201,29914183
SHH,LTM,NA,10848,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by qPCR and Western Blotting,0.48,0.0201,34424425
SHH,LTM,NA,10848,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0201,30555330
SHH,LTM,NA,10848,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs and qRT-PCR  followed by SFA and Tumorigenicity assay,0.48,0.0201,29262597
SHH,LTM,NA,10848,Gastric Cancer,Adenocarcinoma,BGC-823,NA,CFA followed by qPCR and Western Blotting,0.48,0.0201,26276718
SHH,LTM,NA,10848,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.48,0.0201,34350176
SHH,LTM,NA,10848,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by Western Blotting,0.48,0.0201,30624124
SHH,LTM,NA,10848,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by Western Blotting,0.28,0.0201,33552265
SHH,LTM,NA,10848,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,Cisplatin,SFA followed by IF staining and qRT-PCR,0.44,0.0201,32206093
SHH,LTM,NA,10848,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0201,30555330
SHH,LTM,NA,10848,Non Small Cell Lung Cancer,Adenocarcinoma,H322,NA,SFA followed by ELISA,0.28,0.0201,26088878
SHH,LTM,NA,10848,Non Small Cell Lung Cancer,Adenocarcinoma,H322,NA,SFA followed by ELISA,0.28,0.0201,26088878
SHH,LTM,NA,10848,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,SFA followed by ELISA,0.28,0.0201,26088878
SHH,LTM,NA,10848,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs for CSC marker followed by qPCR and Western Blotting,0.48,0.0201,34424425
SHH,LTM,NA,10848,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and RT-PCR,0.32,0.0201,19451087
SHH,LTM,NA,10848,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0201,34052833
SHH,LTM,NA,10848,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qPCR,0.28,0.0201,29846560
SHH,LTM,NA,10848,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.28,0.0201,29697746
SHH,LTM,NA,10848,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR,0.28,0.0201,26918054
SHH,LTM,NA,10848,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,CFA followed by qPCR and Western Blotting,0.48,0.0201,26276718
SHH,LTM,NA,10848,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.48,0.0201,34350176
SHH,LTM,NA,10848,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.0201,30624124
SHH,LTM,NA,10848,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting,0.28,0.0201,33288882
SHH,LTM,NA,10848,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting,0.28,0.0201,25003666
SHH,LTM,NA,10848,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,Western Blotting followed by CFA,0.28,0.0201,28423495
SHH,LTM,NA,10848,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-10B,NA,Western Blotting followed by CFA,0.28,0.0201,28423495
SHH,LTM,NA,10848,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting,0.28,0.0201,33552265
SHH,LTM,NA,10848,Skin Cancer,Squamous Cell Carcinoma,UW-BCC1,NA,CFA and Western Blotting,0.28,0.0201,29914183
SHH,LTM,NA,10848,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,Cisplatin,SFA followed by IF staining and qRT-PCR,0.6,0.0201,32206093
SIK2,LTM,NA,21680,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by qPCR and Western Blotting,0.48,0.0011,35277657
SIK2,LTM,NA,21680,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qPCR and Western Blotting,0.48,0.0011,35277657
SIRPG,LTM,NA,15757,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0021,35229723
SIRPG,LTM,NA,15757,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.04,0.0021,35229723
SIRT1,LTM,NA,14929,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting followed by SFA,0.28,0.0021,27312708
SIRT1,LTM,NA,14929,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,Western Blotting followed by SFA,0.28,0.0021,27312708
SKI,LTM,NA,10896,Pancreatic Cancer,Carcinoma,PANC-1,NA,qPCR followed by Western Blotting,0.48,0.0021,27734340
SKP2,LTM,NA,10901,Head and Neck Cancer,Squamous Cell Carcinoma,CNE2,NA,Western Blotting,0.28,0.0053,25015320
SKP2,LTM,NA,10901,Head and Neck Cancer,Squamous Cell Carcinoma,HONE1,NA,Western Blotting,0.28,0.0053,25015320
SKP2,LTM,NA,10901,Head and Neck Cancer,Esophageal Squamous Cell Carcinoma,KYSE180,NA,Western Blotting followed by CFA,0.28,0.0053,22533738
SKP2,LTM,NA,10901,Head and Neck Cancer,Esophageal Squamous Cell Carcinoma,KYSE30,NA,Western Blotting followed by CFA,0.28,0.0053,22533738
SKP2,LTM,NA,10901,Head and Neck Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.0053,21352698
SLC22A2,LTM,NA,10966,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR,0.2,0.0011,29651165
SLC2A1,LTM,NA,11005,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.2,0.0042,30639386
SLC2A3,LTM,NA,11007,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by Western Blotting,0.28,0.0042,30305725
SLC2A3,LTM,NA,11007,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,Cisplatin,FACs followed by SFA,0.12,0.0042,25217518
SLC34A2,LTM,NA,11020,Gastric Cancer,Adenocarcinoma,MKN28,NA,SFA followed by Western Blotting,0.28,0.0011,29178392
SLC34A2,LTM,NA,11020,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.28,0.0011,29178392
SLC34A2,LTM,NA,11020,Gastric Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.36,0.0011,29178392
SLC38A2,LTM,NA,13448,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA and Western Blotting,0.28,0.0011,34173116
SLC38A2,LTM,NA,13448,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.28,0.0011,34173116
SLC38A2,LTM,NA,13448,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting,0.28,0.0011,34173116
SLC38A2,LTM,NA,13448,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.28,0.0011,34173116
SLC3A2,LTM,NA,11026,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.32,0.0085,35140342
SLC3A2,LTM,NA,11026,Head and Neck Cancer,Oropharyngeal Squamous Cell Carcinoma,Primary,NA,IHC staining,0.32,0.0085,24315751
SLC3A2,LTM,NA,11026,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining and Tumorigenicity assay,0.32,0.0085,23523931
SLC7A11,LTM,NA,11059,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.2,0.0021,34385181
SLC7A11,LTM,NA,11059,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by qRT-PCR,0.2,0.0021,34385181
SLC7A5,LTM,NA,11063,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.2,0.0042,34681614
SLCO1B3,LTM,NA,10961,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR,0.2,0.0021,32065779
SLCO1B3,LTM,NA,10961,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.2,0.0021,32065779
SLCO4A1,LTM,NA,10953,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by qRT-PCR,0.2,0.0042,33958701
SMO,LTM,NA,11119,Skin Cancer,Squamous Cell Carcinoma,A-431,NA,CFA and Western Blotting,0.28,0.0212,29914183
SMO,LTM,NA,11119,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by qPCR and Western Blotting,0.48,0.0212,34424425
SMO,LTM,NA,11119,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA,0.48,0.0212,29225473
SMO,LTM,NA,11119,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.28,0.0212,34350176
SMO,LTM,NA,11119,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by Western Blotting,0.28,0.0212,30624124
SMO,LTM,NA,11119,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by RT-PCR,0.2,0.0212,28093940
SMO,LTM,NA,11119,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by Western Blotting,0.28,0.0212,33552265
SMO,LTM,NA,11119,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR,0.2,0.0212,28093940
SMO,LTM,NA,11119,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.2,0.0212,25669973
SMO,LTM,NA,11119,Non Small Cell Lung Cancer,Carcinoma,H460,NA,FACs for CSC marker followed by qPCR and Western Blotting,0.48,0.0212,34424425
SMO,LTM,NA,11119,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by qRT-PCR and SFA,0.2,0.0212,29792038
SMO,LTM,NA,11119,Hepatic Cancer,Carcinoma,Mahlavu,NA,SP assay followed by Western Blotting,0.28,0.0212,29792038
SMO,LTM,NA,11119,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.28,0.0212,34445421
SMO,LTM,NA,11119,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR followed by SFA,0.2,0.0212,30543303
SMO,LTM,NA,11119,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR and SFA,0.2,0.0212,28692437
SMO,LTM,NA,11119,Gastric Cancer,Carcinoma,NCI-N87,NA,RT-PCR followed by SFA,0.2,0.0212,30543303
SMO,LTM,NA,11119,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by RT-PCR,0.2,0.0212,30696080
SMO,LTM,NA,11119,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0212,22923052
SMO,LTM,NA,11119,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.48,0.0212,29697746
SMO,LTM,NA,11119,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by RT-PCR,0.48,0.0212,26918054
SMO,LTM,NA,11119,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.28,0.0212,34350176
SMO,LTM,NA,11119,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.28,0.0212,30624124
SMO,LTM,NA,11119,Hepatic Cancer,Adenocarcinoma,SK-Hep-1,NA,SP assay followed by Western Blotting,0.28,0.0212,29792038
SMO,LTM,NA,11119,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,qRT-PCR followed by SFA,0.2,0.0212,32773768
SMO,LTM,NA,11119,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,SFA followed by RT-PCR,0.2,0.0212,31742606
SMO,LTM,NA,11119,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,qRT-PCR followed by SFA,0.2,0.0212,32773768
SMO,LTM,NA,11119,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by Western Blotting,0.28,0.0212,33552265
SMO,LTM,NA,11119,Skin Cancer,Squamous Cell Carcinoma,UW-BCC1,NA,CFA and Western Blotting,0.28,0.0212,29914183
SMO,LTM,NA,11119,Pancreatic Cancer,NA,Primary,NA,qRT-PCR and Western Blotting,0.64,0.0212,23029396
SMURF1,LTM,NA,16807,Head and Neck Cancer,Squamous Cell Carcinoma,TR146,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0011,25471937
SMURF1,LTM,NA,16807,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-17B,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0011,25471937
SMURF1,LTM,NA,16807,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-58,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0011,25471937
SNAI1,LTM,NA,11128,Non Small Cell Lung Cancer,Carcinoma,A549,Irradiation,SFA and Western Blotting,0.28,0.0212,34163000
SNAI1,LTM,NA,11128,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by Western Blotting,0.28,0.0212,35267489
SNAI1,LTM,NA,11128,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR,0.28,0.0212,34400945
SNAI1,LTM,NA,11128,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.28,0.0212,32033067
SNAI1,LTM,NA,11128,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Western Blotting,0.28,0.0212,35267489
SNAI1,LTM,NA,11128,Colon Cancer,Carcinoma,HCT116,NA,SFA and Western Blotting,0.28,0.0212,24039918
SNAI1,LTM,NA,11128,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by qRT-PCR,0.2,0.0212,25104726
SNAI1,LTM,NA,11128,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.28,0.0212,33667839
SNAI1,LTM,NA,11128,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and Western Blotting,0.28,0.0212,24039918
SNAI1,LTM,NA,11128,Head and Neck Cancer,Carcinoma,KB,NA,SFA followed by qRT-PCR,0.2,0.0212,25104726
SNAI1,LTM,NA,11128,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Western Blotting,0.28,0.0212,34502547
SNAI1,LTM,NA,11128,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0212,34451892
SNAI1,LTM,NA,11128,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.28,0.0212,35017469
SNAI1,LTM,NA,11128,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qPCR and SFA,0.28,0.0212,31745977
SNAI1,LTM,NA,11128,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.28,0.0212,29197410
SNAI1,LTM,NA,11128,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA and qRT-PCR followed by Western Blotting ,0.48,0.0212,33608016
SNAI1,LTM,NA,11128,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and IF staining,0.24,0.0212,24719318
SNAI1,LTM,NA,11128,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.2,0.0212,26862521
SNAI1,LTM,NA,11128,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and qRT-PCR followed by Western Blotting ,0.48,0.0212,33608016
SNAI1,LTM,NA,11128,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-1,NA,qRT-PCR and SFA,0.2,0.0212,26323460
SNAI1,LTM,NA,11128,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-11B,NA,SFA followed by qRT-PCR,0.2,0.0212,26323460
SNAI1,LTM,NA,11128,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-9,NA,SFA followed by qRT-PCR,0.2,0.0212,26323460
SNAI1,LTM,NA,11128,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,SFA followed by qRT-PCR,0.2,0.0212,26323460
SNAI1,LTM,NA,11128,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0212,31506430
SNAI1,LTM,NA,11128,Pancreatic Cancer,NA,Primary,NA,qPCR followed by SFA,0.28,0.0212,24785258
SNAI2,LTM,NA,11094,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,SFA and Western Blotting,0.28,0.0159,33390847
SNAI2,LTM,NA,11094,Colon Cancer,Carcinoma,HCT116,NA,SFA and Western Blotting,0.28,0.0159,24039918
SNAI2,LTM,NA,11094,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.28,0.0159,33667839
SNAI2,LTM,NA,11094,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and Western Blotting,0.28,0.0159,24039918
SNAI2,LTM,NA,11094,Pancreatic Cancer,Ductal Carcinoma,KLM-1,NA,SFA followed by qRT-PCR,0.2,0.0159,34628696
SNAI2,LTM,NA,11094,Pancreatic Cancer,Adenocarcinoma,KMP5,NA,SFA followed by qRT-PCR,0.2,0.0159,34628696
SNAI2,LTM,NA,11094,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0159,31604679
SNAI2,LTM,NA,11094,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.28,0.0159,33390847
SNAI2,LTM,NA,11094,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0159,34451892
SNAI2,LTM,NA,11094,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.28,0.0159,29197410
SNAI2,LTM,NA,11094,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.28,0.0159,31604679
SNAI2,LTM,NA,11094,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA and qRT-PCR followed by Western Blotting ,0.48,0.0159,33608016
SNAI2,LTM,NA,11094,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and qRT-PCR followed by Western Blotting ,0.48,0.0159,33608016
SNAI2,LTM,NA,11094,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.0159,34532091
SNAI2,LTM,NA,11094,Pancreatic Cancer,NA,Primary,NA,SFA followed by IHC staining,0.32,0.0159,34628696
SOD2,LTM,NA,11180,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.28,0.0064,34195288
SOD2,LTM,NA,11180,Breast Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0064,31728117
SOX1,LTM,NA,11189,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay followed by FACs and Tumorigenicity assay,0.12,0.0042,20424609
SOX1,LTM,NA,11189,Head and Neck Cancer,Squamous Cell Carcinoma,LK0923,NA,qRT-PCR,0.2,0.0042,23049743
SOX10,LTM,NA,11190,Skin Cancer,NA,Primary,NA,IHC staining,0.32,0.0011,23958542
SOX2,LTM,NA,11195,Bladder Cancer,Carcinoma,5637,Paclitaxel,SFA followed by Western Blotting,0.28,0.5695,35008872
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by FACs and Western Blotting,0.4,0.5695,30628703
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by qRT-PCR,0.4,0.5695,27766570
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by RT-PCR,0.4,0.5695,27556038
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by SP assay and RT-PCR,0.4,0.5695,30477473
SOX2,LTM,NA,11195,Glioblastoma,NA,A-172,Temozolomide,Western Blotting and CFA,0.28,0.5695,34036375
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,A-253,NA,RT-PCR followed by CFA,0.2,0.5695,24612587
SOX2,LTM,NA,11195,Skin Cancer,NA,A-375,NA,SFA followed by qPCR and Western Blotting,0.48,0.5695,29693169
SOX2,LTM,NA,11195,Skin Cancer,NA,A-375,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,29693169
SOX2,LTM,NA,11195,Skin Cancer,NA,A-375,NA,SP assay followed by RT-PCR,0.48,0.5695,30522558
SOX2,LTM,NA,11195,Skin Cancer,Epidermoid Carcinoma,A3886,NA,RT-PCR followed by Western Blotting,0.48,0.5695,31928951
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,IF staining and Western Blotting followed by SFA,0.52,0.5695,35278461
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and Western Blotting,0.52,0.5695,34063628
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,qRT-PCR and Western Blotting,0.52,0.5695,34065942
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and Western Blotting followed by SFA,0.52,0.5695,33783940
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,34873829
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,35229723
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,CFA and SFA followed by RT-PCR and Western Blotting,0.52,0.5695,28406482
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR  followed by Western Blotting,0.52,0.5695,28179999
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by Western Blotting,0.52,0.5695,30878308
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA and qRT-PCR followed by Western Blotting,0.52,0.5695,32396269
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,25955300
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,29888108
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,30485693
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,32655789
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.52,0.5695,30555330
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR and Western Blotting,0.52,0.5695,22615765
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining and RT-PCR,0.52,0.5695,21520032
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and IF staining,0.52,0.5695,26239272
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,FACs followed by RT-PCR,0.52,0.5695,24356998
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and qRT-PCR,0.52,0.5695,30816208
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs for CSC marker followed by SFA and Western Blotting,0.52,0.5695,33707423
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Irradiation,SFA and Western Blotting,0.52,0.5695,34163000
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.5695,33980809
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.5695,34949193
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting followed by SFA,0.52,0.5695,33721187
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,SFA and Western Blotting,0.52,0.5695,26779808
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by CFA and Western Blotting,0.52,0.5695,32637578
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.5695,21425153
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.5695,21802163
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by Western Blotting,0.52,0.5695,22370645
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.5695,24013232
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,SFA followed by Western Blotting,0.52,0.5695,29299167
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.5695,29416721
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA followed by Western Blotting,0.52,0.5695,31207300
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.5695,31263095
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.5695,31658996
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.5695,31928533
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by Western Blotting,0.52,0.5695,33125096
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,Western Blotting,0.52,0.5695,23349823
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting,0.52,0.5695,29254164
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,Western Blotting,0.52,0.5695,30341415
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Paclitaxel,Western Blotting followed by SFA,0.52,0.5695,29299167
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by IF staining,0.52,0.5695,26261505
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Irradiation,CFA followed by qRT-PCR,0.52,0.5695,33924205
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR,0.52,0.5695,33995625
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR,0.52,0.5695,34400945
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,qRT-PCR and SFA,0.52,0.5695,33784109
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,qRT-PCR and SFA,0.52,0.5695,34246759
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by SFA,0.52,0.5695,33670440
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,33437165
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,34209829
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,34277782
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,34832951
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.52,0.5695,34681614
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,BME based 3D culture and SFA followed by qRT-PCR,0.52,0.5695,29017078
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Pemetrexed,qPCR,0.52,0.5695,26181204
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR,0.52,0.5695,24646078
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and SFA,0.52,0.5695,29144562
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR followed by SFA and SP assay,0.52,0.5695,26468775
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR,0.52,0.5695,25906011
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR,0.52,0.5695,26940223
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR,0.52,0.5695,31201845
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by CFA,0.52,0.5695,29995950
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA,0.52,0.5695,25003810
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,RT-PCR followed by SFA,0.52,0.5695,31368411
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Gefitinib,SFA and CFA followed by RT-PCR,0.52,0.5695,28850563
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Regorafenib,SFA and CFA followed by RT-PCR,0.52,0.5695,28850563
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Sorafenib,SFA and CFA followed by RT-PCR,0.52,0.5695,28850563
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qPCR,0.52,0.5695,26675547
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qPCR,0.52,0.5695,31796785
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,22900142
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,24101104
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,24101104
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,5-Fluorouracil,SFA followed by qRT-PCR,0.52,0.5695,25683371
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,25683371
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,27766570
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,28035349
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,29044153
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,29448000
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,31024010
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,32033067
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.52,0.5695,32401390
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by qRT-PCR,0.52,0.5695,32655321
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.52,0.5695,23370278
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.52,0.5695,26546046
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by RT-PCR,0.52,0.5695,27009878
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR,0.52,0.5695,29414668
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.52,0.5695,28456659
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay and SFA followed by qRT-PCR,0.52,0.5695,31871777
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by qRT-PCR,0.52,0.5695,23009336
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,Trichostatin,SP assay followed by qRT-PCR,0.52,0.5695,27418136
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by SFA and RT-PCR,0.52,0.5695,28440478
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs,0.52,0.5695,21947321
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting and IF staining,0.52,0.5695,33288885
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,AGS,NA,qRT-PCR followed by Western Blotting,0.52,0.5695,32093282
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA and Western Blotting,0.52,0.5695,34278502
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.52,0.5695,28461325
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.52,0.5695,32606358
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.52,0.5695,35117718
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.52,0.5695,29512256
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.52,0.5695,32633423
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.52,0.5695,34173116
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by qRT-PCR,0.52,0.5695,28822889
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Western Blotting and IF staining,0.52,0.5695,25811929
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qRT-PCR followed by Western Blotting,0.52,0.5695,28703793
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by qPCR and Western Blotting,0.52,0.5695,32575925
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,SFA followed by Western Blotting,0.52,0.5695,30853342
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,AsPC1,NA,qRT-PCR,0.52,0.5695,34163012
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,AsPC1,Gemcitabine,qRT-PCR,0.52,0.5695,26391180
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and qRT-PCR and Western Blotting ,0.48,0.5695,33731207
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and qRT-PCR followed by Western Blotting ,0.48,0.5695,34427968
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,BGC-823,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,33579380
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5695,28440445
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA and Western Blotting,0.48,0.5695,34350176
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,BGC-823,NA,Western Blotting followed by SFA,0.48,0.5695,31517391
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs for CSC marker followed by qRT-PCR,0.48,0.5695,33798550
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,BGC-823,NA,SFA followed by qRT-PCR,0.48,0.5695,34173116
SOX2,LTM,NA,11195,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by qRT-PCR,0.2,0.5695,35195687
SOX2,LTM,NA,11195,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,RT-PCR,0.2,0.5695,30206184
SOX2,LTM,NA,11195,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,Trastuzumab,SFA followed by qPCR,0.2,0.5695,28722778
SOX2,LTM,NA,11195,Luminal B Breast Cancer,Ductal Carcinoma,BT-474,NA,SFA followed by qPCR,0.2,0.5695,30224376
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,Western Blotting,0.28,0.5695,29100426
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Paclitaxel,Western Blotting and SFA,0.28,0.5695,31308076
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,IF staining followed by SFA,0.28,0.5695,34889737
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Cyclophosphamide,qRT-PCR,0.28,0.5695,33090711
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA and qRT-PCR,0.28,0.5695,35064101
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by qPCR,0.28,0.5695,35277657
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,SFA followed by qRT-PCR,0.28,0.5695,33090711
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,RT-PCR,0.28,0.5695,29262622
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.5695,27576197
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.5695,28703793
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by Western Blotting,0.48,0.5695,31713003
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,Western Blotting and SFA,0.48,0.5695,33082357
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by Western Blotting,0.48,0.5695,30853342
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by Western Blotting,0.48,0.5695,32766132
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,Western Blotting,0.48,0.5695,29970519
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,FACs,0.48,0.5695,31713003
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,FACs followed by SP assay,0.48,0.5695,22963768
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA followed by FACs,0.48,0.5695,29719602
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,CACO-2,NA,SP assay followed by qPCR and SFA,0.2,0.5695,32367652
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,Western Blotting followed by IF staining and SFA,0.52,0.5695,29575240
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Western Blotting,0.52,0.5695,34502158
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,Western Blotting and SFA,0.52,0.5695,25871396
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,Western Blotting followed by SFA,0.52,0.5695,34795388
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA and Western Blotting,0.52,0.5695,27108536
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.52,0.5695,27380877
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Cisplatin,qRT-PCR followed by SFA and CFA,0.52,0.5695,27380877
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,Docetaxel,qRT-PCR followed by SFA and CFA,0.52,0.5695,27380877
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.5695,29130098
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by Western Blotting and SFA,0.48,0.5695,32781084
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by SFA and qRT-PCR,0.48,0.5695,30466404
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,FACs followed by SP assay,0.48,0.5695,22963768
SOX2,LTM,NA,11195,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting and IF staining,0.52,0.5695,25811929
SOX2,LTM,NA,11195,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,33737813
SOX2,LTM,NA,11195,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.52,0.5695,30853342
SOX2,LTM,NA,11195,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.52,0.5695,29100320
SOX2,LTM,NA,11195,Lung Cancer,Adenocarcinoma,CL-1-1,NA,SFA followed by Western Blotting,0.28,0.5695,29416721
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,CL-141,NA,SFA followed by Western Blotting,0.28,0.5695,31638335
SOX2,LTM,NA,11195,Skin Cancer,NA,D10,NA,SFA and CFA followed by qRT-PCR,0.2,0.5695,26208390
SOX2,LTM,NA,11195,Glioblastoma,NA,DBTRG-05MG,NA,SFA and Western Blotting,0.28,0.5695,33317545
SOX2,LTM,NA,11195,Head and Neck Cancer,Carcinoma,Detroit-562,NA,Western Blotting followed by CFA,0.28,0.5695,34837170
SOX2,LTM,NA,11195,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.2,0.5695,23418515
SOX2,LTM,NA,11195,Small Cell Lung Cancer,Carcinoma,DMS53,NA,Western Blotting,0.28,0.5695,31446534
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by qPCR and Western Blotting,0.48,0.5695,29228308
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.5695,31382448
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by Western Blotting,0.48,0.5695,34502158
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,Western Blotting and SFA,0.48,0.5695,25871396
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,Western Blotting followed by CFA,0.48,0.5695,34837170
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR,0.48,0.5695,32708734
SOX2,LTM,NA,11195,Glioblastoma Multiforme,NA,GBM8401,NA,SFA followed by IF staining,0.24,0.5695,31035045
SOX2,LTM,NA,11195,Glioblastoma Multiforme,NA,GBM8401,NA,SP assay and SFA followed by RT-PCR,0.24,0.5695,25359730
SOX2,LTM,NA,11195,Small Cell Lung Cancer,Carcinoma,GLC14,NA,SFA followed by Western Blotting and IF staining,0.52,0.5695,33607458
SOX2,LTM,NA,11195,Small Cell Lung Cancer,Carcinoma,GLC16,NA,SFA followed by Western Blotting and IF staining,0.52,0.5695,33607458
SOX2,LTM,NA,11195,Small Cell Lung Cancer,Carcinoma,GLC19,NA,SFA  and qRT-PCR followed by Western Blotting and IF staining,0.72,0.5695,33607458
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,SFA followed by Western Blotting,0.28,0.5695,30717421
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,qRT-PCR,0.28,0.5695,24646078
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenosquamous Cell Carcinoma,H125,NA,SFA followed by RT-PCR,0.28,0.5695,23370278
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,IF staining and Western Blotting followed by SFA,0.52,0.5695,35278461
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,qRT-PCR and Western Blotting followed by SFA,0.52,0.5695,33783940
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,34873829
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR and Western Blotting,0.52,0.5695,30555330
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs and Western Blotting,0.52,0.5695,27542268
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,FACs followed by Western Blotting and SFA,0.52,0.5695,24838270
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,MACs followed by qPCR,0.52,0.5695,24008862
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by FACs and qRT-PCR,0.52,0.5695,30816208
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR and FACs,0.52,0.5695,25669973
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.52,0.5695,33980809
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by CFA and Western Blotting,0.52,0.5695,32637578
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by Western Blotting,0.52,0.5695,33125096
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,Cisplatin,FACs for CSC marker followed by qRT-PCR,0.52,0.5695,33550205
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,RT-PCR and SFA,0.52,0.5695,34681614
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.52,0.5695,34832951
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,qRT-PCR and SFA,0.52,0.5695,29144562
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,RT-PCR,0.52,0.5695,25906011
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,Gefitinib,SFA and CFA followed by RT-PCR,0.52,0.5695,28850563
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,Regorafenib,SFA and CFA followed by RT-PCR,0.52,0.5695,28850563
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,Sorafenib,SFA and CFA followed by RT-PCR,0.52,0.5695,28850563
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qPCR,0.52,0.5695,26675547
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,Docetaxel,SFA followed by qRT-PCR,0.52,0.5695,25279705
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.52,0.5695,32051483
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.52,0.5695,32401390
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,Cisplatin,SFA followed by qRT-PCR,0.52,0.5695,32655321
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR,0.52,0.5695,25735977
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR,0.52,0.5695,27556038
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by RT-PCR,0.52,0.5695,29651165
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SP assay and SFA followed by qRT-PCR,0.52,0.5695,31871777
SOX2,LTM,NA,11195,Small Cell Lung Cancer,NA,H1408,NA,SFA followed by FACs and RT-PCR,0.32,0.5695,29437792
SOX2,LTM,NA,11195,Small Cell Lung Cancer,Carcinoma,H146,NA,SP assay followed by FACs and Tumorigenicity assay,0.12,0.5695,20424609
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H157,NA,SFA followed by qPCR,0.2,0.5695,26675547
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H157,Cisplatin,SFA followed by RT-PCR,0.2,0.5695,27009878
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Giant Cell Carcinoma,H1581,NA,SFA followed by qRT-PCR,0.2,0.5695,26936993
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,FACs followed by SFA and qPCR,0.32,0.5695,24091605
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,NA,SP assay followed by SFA and Western Blotting,0.32,0.5695,30831275
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H1650,Erlotinib,qRT-PCR,0.32,0.5695,30480362
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H1658,Erlotinib,RT-PCR followed by CFA and SFA,0.2,0.5695,31069016
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H1703,NA,qRT-PCR followed by SFA and SP assay,0.2,0.5695,26468775
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,29888108
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,Western Blotting,0.48,0.5695,34475041
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA and Western Blotting,0.48,0.5695,29980786
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,Osimertinib,SFA followed by Western Blotting,0.48,0.5695,30910592
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,qRT-PCR followed by SFA,0.48,0.5695,32922547
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SP assay followed by qRT-PCR,0.48,0.5695,23009336
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,SFA and FACs for CSC marker followed by Transcriptomics,0.48,0.5695,35229723
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H1993,NA,RT-PCR followed by CFA,0.2,0.5695,29995950
SOX2,LTM,NA,11195,Small Cell Lung Cancer,Carcinoma,H209,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,32953511
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H2170,NA,qRT-PCR followed by SFA,0.2,0.5695,33670440
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H2228,NA,SFA followed by Western Blotting,0.28,0.5695,26517679
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H226,NA,SFA followed by qRT-PCR,0.2,0.5695,35006496
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,qRT-PCR and Western Blotting,0.48,0.5695,34063628
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H23,NA,SFA and qRT-PCR,0.48,0.5695,29980786
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H292,NA,SFA followed by qRT-PCR,0.2,0.5695,34209829
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H3122,NA,SFA followed by Western Blotting,0.28,0.5695,26517679
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H3122,NA,SFA followed by qRT-PCR,0.28,0.5695,29950868
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H322,NA,SFA followed by Western Blotting,0.28,0.5695,26837769
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,FACs for CSC marker followed by qRT-PCR,0.2,0.5695,34530236
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,SFA followed by RT-PCR and Tumorigenicity assay,0.2,0.5695,28456659
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,FACs,0.2,0.5695,21947321
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,SFA followed by RT-PCR,0.2,0.5695,29414668
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,H441,NA,SFA followed by FACs and SP assay,0.2,0.5695,30092824
SOX2,LTM,NA,11195,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,30254465
SOX2,LTM,NA,11195,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,32953511
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,NA,qRT-PCR and Western Blotting,0.48,0.5695,34063628
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,CFA and SFA followed by RT-PCR and Western Blotting,0.48,0.5695,28406482
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA and Western Blotting,0.48,0.5695,34635641
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by CFA and Western Blotting,0.48,0.5695,32637578
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.48,0.5695,26880969
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.48,0.5695,26885450
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.48,0.5695,30305725
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,Western Blotting,0.48,0.5695,23349823
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,NA,Western Blotting followed by SFA,0.48,0.5695,26901847
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,FACs for CSC marker followed by qRT-PCR,0.48,0.5695,33550205
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,qRT-PCR and SFA,0.48,0.5695,34246759
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.48,0.5695,34209829
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.48,0.5695,34349823
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,Pemetrexed,qPCR,0.48,0.5695,26181204
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,Sorafenib,qRT-PCR and SFA,0.48,0.5695,28850563
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,Gefitinib,SFA and CFA followed by RT-PCR,0.48,0.5695,28850563
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,Regorafenib,SFA and CFA followed by RT-PCR,0.48,0.5695,28850563
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qPCR and Tumorigenicity assay,0.48,0.5695,30305725
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.48,0.5695,31397494
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.48,0.5695,31658996
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by qRT-PCR,0.48,0.5695,31717588
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,FACs for CSC marker followed by SFA and Western Blotting,0.28,0.5695,33707423
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,Western Blotting followed by SFA,0.28,0.5695,33721187
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,SFA followed by qRT-PCR,0.28,0.5695,26936993
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,H520,NA,SFA followed by qRT-PCR,0.28,0.5695,32863772
SOX2,LTM,NA,11195,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA followed by qRT-PCR,0.2,0.5695,34832951
SOX2,LTM,NA,11195,Breast Cancer,Carcinoma,HCC1569,NA,IF staining followed by SFA,0.24,0.5695,34889737
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,HCC1588,NA,SFA followed by qRT-PCR,0.2,0.5695,26711929
SOX2,LTM,NA,11195,Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,IF staining followed by SFA,0.24,0.5695,34889737
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,SFA and Western Blotting,0.28,0.5695,33390847
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,IF staining followed by SFA,0.28,0.5695,34889737
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Ductal Carcinoma,HCC1937,NA,qRT-PCR,0.28,0.5695,31273285
SOX2,LTM,NA,11195,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,NA,Western Blotting followed by SFA,0.28,0.5695,30326469
SOX2,LTM,NA,11195,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,MK-0752,qRT-PCR,0.28,0.5695,29027990
SOX2,LTM,NA,11195,HER2 Positive Breast Cancer,Ductal Carcinoma,HCC1954,MK-0752,qRT-PCR,0.28,0.5695,29027990
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Ductal Carcinoma,HCC-38,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5695,30336071
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,FACs followed by SFA and qPCR,0.32,0.5695,24091605
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by Western Blotting,0.32,0.5695,33955683
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,NA,SFA followed by Western Blotting,0.32,0.5695,30305725
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,qPCR,0.32,0.5695,24489728
SOX2,LTM,NA,11195,Lung Cancer,Squamous Cell Carcinoma,HCC95,NA,SFA followed by qRT-PCR,0.2,0.5695,32863772
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,HCCLM3,NA,CFA followed by SFA and qRT-PCR,0.2,0.5695,27783993
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5695,30774996
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by SFA and Western Blotting,0.48,0.5695,33819194
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.48,0.5695,35392530
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,Oxaliplatin,SFA followed by Western Blotting,0.48,0.5695,24330852
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting,0.48,0.5695,27997180
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.48,0.5695,30305725
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,SFA and IF staining,0.48,0.5695,26745821
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.48,0.5695,35242031
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,qRT-PCR,0.48,0.5695,29426374
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,RT-PCR followed by SFA,0.48,0.5695,32037723
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,SFA and qRT-PCR,0.48,0.5695,33209130
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qPCR,0.48,0.5695,31349708
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by qRT-PCR,0.48,0.5695,29307822
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,SFA followed by RT-PCR,0.48,0.5695,21750907
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,HCT116,NA,FACs,0.48,0.5695,31641961
SOX2,LTM,NA,11195,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,qRT-PCR and Western Blotting,0.48,0.5695,24145190
SOX2,LTM,NA,11195,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SFA followed by Western Blotting,0.48,0.5695,27997180
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HCT-15,Cisplatin,SFA and qPCR,0.48,0.5695,34921482
SOX2,LTM,NA,11195,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,RT-PCR followed by SFA,0.48,0.5695,28946619
SOX2,LTM,NA,11195,Dukes Type C Colon Cancer,Adenocarcinoma,HCT-15,NA,SP assay followed by Tumorigenicity assay and RT-PCR,0.48,0.5695,21435460
SOX2,LTM,NA,11195,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by qPCR and Western Blotting,0.48,0.5695,29228308
SOX2,LTM,NA,11195,Head and Neck Cancer,Carcinoma,HEp-2,NA,Western Blotting followed by CFA,0.48,0.5695,34837170
SOX2,LTM,NA,11195,Head and Neck Cancer,Carcinoma,HEp-2,5-Fluorouracil,qRT-PCR followed by SFA and CFA,0.48,0.5695,27380877
SOX2,LTM,NA,11195,Head and Neck Cancer,Carcinoma,HEp-2,Cisplatin,qRT-PCR followed by SFA and CFA,0.48,0.5695,27380877
SOX2,LTM,NA,11195,Head and Neck Cancer,Carcinoma,HEp-2,Docetaxel,qRT-PCR followed by SFA and CFA,0.48,0.5695,27380877
SOX2,LTM,NA,11195,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by RT-PCR,0.48,0.5695,26021266
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by qRT-PCR,0.2,0.5695,27773936
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by qRT-PCR,0.2,0.5695,34405006
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,Hep3B,NA,CFA followed by SFA and qRT-PCR,0.2,0.5695,27783993
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,Hep3B,NA,FACs followed by CFA,0.2,0.5695,22194816
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,Hep-G2,NA,SFA followed by Western Blotting,0.28,0.5695,29033320
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,Hep-G2,NA,SFA followed by Western Blotting,0.28,0.5695,32626943
SOX2,LTM,NA,11195,Gastric Cancer,NA,HFE-145,NA,SFA followed by Western Blotting and IF staining,0.52,0.5695,33288885
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by Western Blotting,0.28,0.5695,28446252
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,HGC-27,NA,SFA followed by Western Blotting,0.28,0.5695,30007956
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,HGC-27,NA,Western Blotting,0.28,0.5695,32724313
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,HN-1,NA,SFA followed by RT-PCR,0.2,0.5695,25024430
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,HN4,Cisplatin,Western Blotting followed by SFA,0.28,0.5695,34795388
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.5695,29130098
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,HPAF-II,NA,SFA followed by Western Blotting,0.28,0.5695,30853342
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,IF staining followed by SFA,0.24,0.5695,34889737
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by qPCR,0.24,0.5695,30224376
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,SFA followed by Western Blotting,0.28,0.5695,27002147
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,qPCR and SFA,0.28,0.5695,26448762
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,HSC-3,NA,qRT-PCR followed by CFA,0.28,0.5695,22847005
SOX2,LTM,NA,11195,Bladder Cancer,Carcinoma,HT-1197,NA,Western Blotting,0.28,0.5695,35008872
SOX2,LTM,NA,11195,Bladder Cancer,Carcinoma,HT-1376,NA,SFA followed by qRT-PCR,0.2,0.5695,26452033
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs followed by Western Blotting and RT-PCR,0.6,0.5695,22384170
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR and Western Blotting,0.6,0.5695,30774996
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker followed by SFA and Western Blotting,0.6,0.5695,33819194
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.6,0.5695,35392530
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.6,0.5695,30944638
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and IF staining,0.6,0.5695,26745821
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by IHC staining,0.6,0.5695,26918725
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by qRT-PCR,0.6,0.5695,35267511
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,qRT-PCR followed by SFA,0.6,0.5695,32037723
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.6,0.5695,21130073
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by RT-PCR,0.6,0.5695,26634106
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by RT-PCR,0.6,0.5695,30209760
SOX2,LTM,NA,11195,Colon Cancer,Adenocarcinoma,HT-29,NA,SP assay followed by Tumorigenicity assay and RT-PCR,0.6,0.5695,21435460
SOX2,LTM,NA,11195,Bladder Cancer,Carcinoma,HTB-9,NA,ICC staining followed by SFA,0.24,0.5695,26054707
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by Western Blotting,0.28,0.5695,27312708
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting followed by SFA and CFA,0.28,0.5695,30908631
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.28,0.5695,27773936
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,Huh7,Zebularine,SP assay followed by SFA and qRT-PCR,0.28,0.5695,21618577
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.28,0.5695,32128906
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by CFA,0.28,0.5695,22194816
SOX2,LTM,NA,11195,Bladder Cancer,Carcinoma,J-82,NA,Western Blotting,0.28,0.5695,24649144
SOX2,LTM,NA,11195,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by RT-PCR,0.28,0.5695,30397177
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by Western Blotting and IF staining,0.52,0.5695,33288885
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,KATO-III,NA,qRT-PCR followed by Western Blotting,0.52,0.5695,32093282
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by Western Blotting,0.52,0.5695,32606358
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,KMCH-1,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.5695,21618577
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by IF staining and Western Blotting,0.52,0.5695,32457900
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,23917223
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenosquamous Cell Carcinoma,L3.6pl,NA,SFA followed by qRT-PCR,0.52,0.5695,26840266
SOX2,LTM,NA,11195,Lung Cancer,Large Cell Carcinoma,L9981,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,30485693
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,NA,LC31,NA,RT- PCR followed by SFA,0.2,0.5695,21738704
SOX2,LTM,NA,11195,Lung Cancer,NA,LC-42,NA,IHC staining and SFA followed by SP assay and RT-PCR,0.44,0.5695,23738757
SOX2,LTM,NA,11195,Lung Cancer,Adenocarcinoma,LHK2,NA,SP assay followed by qRT-PCR and CFA,0.2,0.5695,27418136
SOX2,LTM,NA,11195,Glioblastoma,NA,LN-229,NA,SFA and Western Blotting,0.28,0.5695,29228694
SOX2,LTM,NA,11195,Dukes Type C Colon Cancer,Adenocarcinoma,LoVo,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.28,0.5695,33109220
SOX2,LTM,NA,11195,Dukes Type B Colon Cancer,Adenocarcinoma,LS174T,NA,FACs followed by Western Blotting and RT-PCR,0.6,0.5695,22384170
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by IF staining and SFA,0.52,0.5695,29982992
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and Western Blotting followed by CFA,0.52,0.5695,35235236
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Adriamycin,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,33866606
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,34755264
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by qRT-PCR and SFA,0.52,0.5695,33791297
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR followed by Western Blotting and SFA,0.52,0.5695,31736268
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qPCR and Western Blotting,0.52,0.5695,29846560
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,30622340
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,30622340
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,31300015
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,31760402
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by RT-PCR and Western Blotting,0.52,0.5695,28703799
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and RT-PCR followed by SFA,0.52,0.5695,29601799
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and IF staining,0.52,0.5695,30188754
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and IF staining,0.52,0.5695,30188754
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by Western Blotting,0.52,0.5695,33731668
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,33305893
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,33419140
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,34830821
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.52,0.5695,34362383
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by SFA,0.52,0.5695,34528694
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,CFA followed by Western Blotting,0.52,0.5695,28839461
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,28802057
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,28823831
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,29100426
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,29383157
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,29434914
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,29749438
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,29797562
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,30080291
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,31308814
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,31501409
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,31604679
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,31672029
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,31695775
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.52,0.5695,31760908
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,Western Blotting,0.52,0.5695,31286834
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting,0.52,0.5695,31591207
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.52,0.5695,29287960
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.52,0.5695,29956731
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.52,0.5695,30482236
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by SFA,0.52,0.5695,29218545
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting followed by SFA,0.52,0.5695,30335523
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Cobalt Chloride,Western Blotting followed by SFA,0.52,0.5695,31584203
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,Western Blotting followed by SFA,0.52,0.5695,31690832
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR,0.52,0.5695,33634797
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and SFA,0.52,0.5695,34217266
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and SFA,0.52,0.5695,34298877
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR followed by SFA,0.52,0.5695,34830485
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5695,33511560
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5695,34486791
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5695,34680485
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5695,34803458
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5695,35029026
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,qRT-PCR and SFA,0.52,0.5695,30239174
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,MK-0752,qRT-PCR followed by SFA,0.52,0.5695,29027990
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR,0.52,0.5695,30206184
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,RT-PCR followed by SFA,0.52,0.5695,28929082
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5695,29044153
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5695,30175027
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.52,0.5695,30628646
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by RT-PCR,0.52,0.5695,30579251
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs,0.52,0.5695,29509055
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs followed by SFA,0.52,0.5695,29048610
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and Western Blotting,0.48,0.5695,35055160
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,33866606
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,35401817
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.5695,29848346
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5695,28703799
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5695,29601799
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5695,30336071
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR and IHC staining,0.48,0.5695,30131941
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs followed by qRT-PCR,0.48,0.5695,30255421
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Irradiation,CFA followed by Western Blotting,0.48,0.5695,34708581
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Western Blotting,0.48,0.5695,33731668
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and Western Blotting,0.48,0.5695,33390847
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5695,34178639
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5695,34789263
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.48,0.5695,34528694
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,CFA followed by Western Blotting,0.48,0.5695,28839461
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and SP assay followed by Western Blotting,0.48,0.5695,28903350
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5695,28823831
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5695,29137219
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5695,29383157
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5695,29422613
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5695,29797562
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5695,29981340
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5695,31308814
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.48,0.5695,31695775
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting,0.48,0.5695,29100426
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.48,0.5695,29956731
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.48,0.5695,30482236
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.48,0.5695,31501409
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting followed by SFA,0.48,0.5695,29218545
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,Western Blotting followed by SFA,0.48,0.5695,29880481
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cobalt Chloride,Western Blotting followed by SFA,0.48,0.5695,31584203
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Culture of cells in electrospun scaffolds followed by qRT-PCR,0.48,0.5695,34841239
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Culturing cells in Electrospun nanofiber scaffolds 3D model followed by qRT-PCR,0.48,0.5695,33634797
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qPCR followed by SFA,0.48,0.5695,35135840
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cyclophosphamide,qRT-PCR,0.48,0.5695,33090711
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and SFA,0.48,0.5695,34298877
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5695,33090711
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5695,33511560
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5695,34420298
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Lapatinib,SFA followed by qRT-PCR,0.48,0.5695,34435487
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5695,34445421
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5695,34990518
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5695,35017469
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5695,35029026
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5695,35195687
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5695,35326667
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qPCR and SFA,0.48,0.5695,31745977
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR,0.48,0.5695,30021199
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR,0.48,0.5695,30542507
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR and SFA,0.48,0.5695,30239174
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA,0.48,0.5695,30052635
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qRT-PCR followed by SFA,0.48,0.5695,31658701
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and qRT-PCR,0.48,0.5695,28991374
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and RT-PCR,0.48,0.5695,29964299
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by qPCR,0.48,0.5695,28703802
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Cisplatin,SFA followed by qRT-PCR,0.48,0.5695,28871147
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Paclitaxel,SFA followed by qRT-PCR,0.48,0.5695,28871147
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.48,0.5695,30587555
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR,0.48,0.5695,30149665
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,11 Gy Radiation,SFA followed by RT-PCR,0.48,0.5695,30579251
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,Irradiation,CFA followed by Western Blotting,0.28,0.5695,34708581
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-436,NA,SFA followed by qRT-PCR,0.28,0.5695,35326667
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5695,30336071
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,Irradiation,CFA followed by Western Blotting,0.48,0.5695,34708581
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.48,0.5695,34789263
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.48,0.5695,31604679
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,Culture of cells in electrospun scaffolds followed by qRT-PCR,0.48,0.5695,34841239
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,qPCR followed by SFA,0.48,0.5695,35135840
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by qPCR,0.48,0.5695,30224376
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by qRT-PCR,0.48,0.5695,30622340
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by qRT-PCR,0.48,0.5695,30628646
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,32189359
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MGC-803,NA,qRT-PCR and Western Blotting,0.48,0.5695,32638620
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.5695,28415621
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting,0.48,0.5695,28337375
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting,0.48,0.5695,28529558
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MGC-803,NA,Western Blotting,0.48,0.5695,32724313
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qPCR,0.48,0.5695,28428713
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.48,0.5695,28893318
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qRT-PCR,0.48,0.5695,32142918
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by qPCR,0.48,0.5695,28336807
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by RT-PCR,0.48,0.5695,24573253
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,32229502
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,MHCC97-H,NA,Western Blotting and SFA,0.48,0.5695,31888685
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,MHCC97-H,NA,Western Blotting followed by SFA and CFA,0.48,0.5695,30908631
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,MHCC97-H,NA,CFA followed by SFA and qRT-PCR,0.48,0.5695,27783993
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qPCR and Western Blotting,0.48,0.5695,34168259
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,35158144
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qPCR and Western Blotting,0.48,0.5695,32575925
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA and Western Blotting,0.48,0.5695,35428310
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,CFA followed by Western Blotting,0.48,0.5695,25015789
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by Western Blotting,0.48,0.5695,26458814
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by Western Blotting,0.48,0.5695,30341797
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,Gemcitabine,SFA followed by Western Blotting,0.48,0.5695,30341797
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,Western Blotting,0.48,0.5695,29179494
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.48,0.5695,24734907
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by qRT-PCR,0.48,0.5695,26840266
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by FACs,0.48,0.5695,29719602
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,MIA-PaCa-3,NA,SFA followed by qPCR and Western Blotting,0.48,0.5695,34168259
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN28,NA,SFA followed by Western Blotting,0.28,0.5695,28529558
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by IF staining and Western Blotting,0.52,0.5695,28430578
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting and IF staining,0.52,0.5695,33288885
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting and IF staining,0.52,0.5695,32160650
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by qRT-PCR and Western Blotting,0.52,0.5695,27602437
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,qRT-PCR and Western Blotting followed by SFA,0.52,0.5695,31037832
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting and qRT-PCR,0.52,0.5695,34173116
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,28959362
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,30843262
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR and Western Blotting,0.52,0.5695,31345097
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,qRT-PCR and Western Blotting,0.52,0.5695,32638620
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs for CSC marker followed by Western Blotting,0.52,0.5695,29212193
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting,0.52,0.5695,34278502
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.52,0.5695,27644439
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.52,0.5695,28337375
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.52,0.5695,28461325
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.5695,27157616
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.5695,27511210
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.5695,29512256
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.5695,32633423
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by RT-PCR,0.52,0.5695,33725258
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR,0.52,0.5695,25081334
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,Acetylcholine,SFA followed by qRT-PCR,0.52,0.5695,30207200
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.5695,26862521
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.5695,28822889
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.52,0.5695,32863948
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,MKN74,NA,SFA followed by qRT-PCR,0.2,0.5695,28822889
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,MOR,Cisplatin,Western Blotting,0.28,0.5695,23349823
SOX2,LTM,NA,11195,Small Cell Lung Cancer,Carcinoma,N417,NA,FACs,0.12,0.5695,21947321
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.5695,28446252
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.5695,28461325
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by Western Blotting,0.28,0.5695,32606358
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,OCUM-12,NA,SP assay followed by qRT-PCR,0.2,0.5695,34667215
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,OM-1,NA,RT-PCR followed by SFA,0.2,0.5695,26399460
SOX2,LTM,NA,11195,Pancreatic Cancer,Ductal Adenocarcinoma,PaCa-44,NA,SFA followed by qPCR and Western Blotting,0.48,0.5695,34168259
SOX2,LTM,NA,11195,Pancreatic Cancer,Ductal Adenocarcinoma,PaCa-44,NA,Prolonged exposure to simulated microgravity followed by qRT-PCR,0.48,0.5695,35391557
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,PAMC82,NA,Western Blotting and SFA,0.28,0.5695,33067426
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and qRT-PCR followed by Western Blotting and IF staining,0.72,0.5695,29975934
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR and Western Blotting,0.72,0.5695,35158144
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,qRT-PCR followed by Western Blotting,0.72,0.5695,28703793
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by qRT-PCR and Western Blotting,0.72,0.5695,31508487
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SP assay followed by qRT-PCR and Western Blotting,0.72,0.5695,24040121
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by qRT-PCR,0.72,0.5695,29444383
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA and qPCR,0.72,0.5695,30954649
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and Western Blotting,0.72,0.5695,35428310
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.72,0.5695,33115754
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.72,0.5695,34551785
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting,0.72,0.5695,33708436
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,CFA followed by Western Blotting,0.72,0.5695,25015789
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.72,0.5695,26458814
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by Western Blotting,0.72,0.5695,30341797
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,SFA followed by Western Blotting,0.72,0.5695,30341797
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.72,0.5695,30535490
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.72,0.5695,32766132
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,Western Blotting,0.72,0.5695,29179494
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,Western Blotting followed by SFA,0.72,0.5695,30486896
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR,0.72,0.5695,34163012
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5695,34446696
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,Migration and Invasion assay followed by RT-PCR and SFA,0.72,0.5695,30852389
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,qRT-PCR,0.72,0.5695,30272287
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,5-fluorouracil,qRT-PCR followed by SFA,0.72,0.5695,22993328
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qPCR,0.72,0.5695,32605166
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5695,26298849
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5695,26439804
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5695,26840266
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5695,27505247
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5695,28580169
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5695,29434962
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5695,30954649
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.72,0.5695,31027735
SOX2,LTM,NA,11195,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SP assay,0.72,0.5695,23815678
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.5695,27996162
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.5695,28244691
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.5695,28244691
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,qRT-PCR followed by Western Blotting,0.48,0.5695,31508487
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,Patu8988,Gemcitabine,Western Blotting followed by SFA,0.48,0.5695,30486896
SOX2,LTM,NA,11195,Pancreatic Cancer,Ductal Adenocarcinoma,PC1J,NA,SFA followed by qPCR and Western Blotting,0.48,0.5695,34168259
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by IF staining and qRT-PCR,0.44,0.5695,31966561
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,CFA and SFA followed by IF staining and RT-PCR,0.44,0.5695,25960639
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by IF staining and qPCR,0.44,0.5695,31966561
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Erlotinib,FACs followed by qRT-PCR,0.44,0.5695,28901474
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,FACs followed by SFA and RT-PCR,0.44,0.5695,22935675
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,SFA followed by Western Blotting,0.44,0.5695,33955683
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Osimertinib,SFA followed by Western Blotting,0.44,0.5695,30910592
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Osimertinib+Gefitinib,SFA followed by Western Blotting,0.44,0.5695,30910592
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,NA,Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR,0.44,0.5695,34771484
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,Culture on polycaprolactone electrospun (PCL-ES) scaffolds and SFA followed by qRT-PCR,0.44,0.5695,34771484
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qPCR followed by SFA and Tumorigenicity assay,0.44,0.5695,24489728
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qRT-PCR,0.44,0.5695,30480362
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,SP assay followed by RT-PCR and Tumorigenicity assay,0.44,0.5695,25871388
SOX2,LTM,NA,11195,Pancreatic Cancer,Ductal Adenocarcinoma,PK-1,NA,SFA followed by qRT-PCR,0.2,0.5695,31027735
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SFA followed by Western Blotting,0.28,0.5695,27312708
SOX2,LTM,NA,11195,Head and Neck Cancer,NA,QLL-1,NA,SFA followed by Western Blotting,0.28,0.5695,32327629
SOX2,LTM,NA,11195,Colon Cancer,Carcinoma,RKO,NA,SFA followed by qPCR,0.2,0.5695,29721049
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,SAS,NA,SP assay and Western Blotting,0.28,0.5695,23843890
SOX2,LTM,NA,11195,Small Cell Lung Cancer,Carcinoma,SBC-5,NA,SFA followed by qRT-PCR,0.2,0.5695,29448000
SOX2,LTM,NA,11195,Small Cell Lung Cancer,Carcinoma,SBC-5,NA,SFA followed by RT-PCR,0.2,0.5695,28248963
SOX2,LTM,NA,11195,Skin Cancer,Squamous Cell Carcinoma,SCC-13,NA,SFA followed by Western Blotting,0.28,0.5695,25969142
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-131,NA,Western Blotting followed by IF staining and SFA,0.52,0.5695,29575240
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-15,NA,Western Blotting followed by SFA,0.28,0.5695,35013621
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-15,NA,SFA followed by Western Blotting,0.28,0.5695,32327629
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,Cisplatin,Western Blotting followed by SFA,0.28,0.5695,34795388
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,Western Blotting followed by SFA,0.28,0.5695,35013621
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-25,NA,SFA followed by Western Blotting,0.28,0.5695,32327629
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,SCC-9,NA,Western Blotting followed by CFA,0.28,0.5695,34837170
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.5695,31037832
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and qRT-PCR and Western Blotting ,0.48,0.5695,33731207
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and qRT-PCR followed by Western Blotting ,0.48,0.5695,34427968
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting and qRT-PCR,0.48,0.5695,34173116
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,30843262
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,Cisplatin,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,33579380
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.5695,28415621
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.48,0.5695,34350176
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.48,0.5695,34657624
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.5695,27644439
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.5695,30007956
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting,0.48,0.5695,34802261
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,Western Blotting followed by SFA,0.48,0.5695,31517391
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by qRT-PCR,0.48,0.5695,32142918
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,qRT-PCR followed by SFA,0.48,0.5695,29662192
SOX2,LTM,NA,11195,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by Western Blotting,0.28,0.5695,29100426
SOX2,LTM,NA,11195,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by Western Blotting,0.28,0.5695,29100426
SOX2,LTM,NA,11195,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by qRT-PCR,0.28,0.5695,35326667
SOX2,LTM,NA,11195,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,qRT-PCR followed by SP assay and SFA,0.28,0.5695,30613295
SOX2,LTM,NA,11195,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,qRT-PCR followed by SP assay and SFA,0.28,0.5695,30613295
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,SK-MES-1,Cisplatin,FACs for CSC marker followed by qRT-PCR,0.2,0.5695,33550205
SOX2,LTM,NA,11195,Glioblastoma,NA,SNB-19,NA,SFA and qRT-PCR,0.2,0.5695,20082319
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,SNU16,NA,Western Blotting and SFA,0.28,0.5695,33067426
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,SNU16,NA,RT-PCR followed by SFA,0.28,0.5695,31073886
SOX2,LTM,NA,11195,Hepatic Cancer,Carcinoma,SNU-398,NA,Western Blotting and SFA,0.28,0.5695,31888685
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SNU484,NA,SFA followed by qPCR and Western Blotting,0.48,0.5695,30284938
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,SNU5,NA,FACs for CSC marker followed by Western Blotting and qRT-PCR,0.48,0.5695,33798550
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,SNU5,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5695,28440445
SOX2,LTM,NA,11195,Gastric Cancer,Carcinoma,SNU5,NA,RT-PCR followed by SFA,0.48,0.5695,31073886
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by qPCR and Western Blotting,0.48,0.5695,30284938
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by qRT-PCR,0.48,0.5695,32863948
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,SNU-668,NA,SFA followed by Western Blotting,0.28,0.5695,32606358
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,CFA and SFA followed by IF staining and RT-PCR,0.44,0.5695,25960639
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by Western Blotting,0.44,0.5695,34949193
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,Docetaxel,SFA followed by qRT-PCR,0.44,0.5695,25279705
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,NA,SFA followed by qRT-PCR,0.44,0.5695,28035349
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,SQ-1,Trichostatin,SP assay followed by ALDEFLUOR assay and SFA,0.12,0.5695,27418136
SOX2,LTM,NA,11195,Gastric Cancer,Adenocarcinoma,ST2957,NA,SFA followed by qRT-PCR,0.2,0.5695,32863948
SOX2,LTM,NA,11195,Pancreatic Cancer,Ductal Adenocarcinoma,Su86.86,NA,FACs followed by SP assay,0.12,0.5695,22963768
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,qRT-PCR and Western Blotting,0.48,0.5695,30542507
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,qPCR followed by SFA,0.48,0.5695,35135840
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Carcinoma,SUM149PT,MK-0752,qRT-PCR followed by SFA,0.48,0.5695,29027990
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Carcinoma,SUM149PT,NA,RT-PCR followed by SFA,0.48,0.5695,29471829
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Carcinoma,SUM149PT,Paclitaxel,SFA followed by qPCR,0.48,0.5695,28703802
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Carcinoma,SUM159,Paclitaxel,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,35401817
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs and RT-PCR,0.48,0.5695,29249663
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA and qRT-PCR,0.48,0.5695,35064101
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,qRT-PCR and SFA,0.48,0.5695,31850822
SOX2,LTM,NA,11195,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA and qRT-PCR,0.48,0.5695,28991374
SOX2,LTM,NA,11195,Breast Cancer,Carcinoma,SUM190PT,Paclitaxel,SFA followed by qPCR,0.2,0.5695,28703802
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,33737813
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR and Western Blotting followed by SFA,0.48,0.5695,27576197
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR followed by Western Blotting,0.48,0.5695,31508487
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,FACs followed by SFA and qPCR,0.48,0.5695,30954649
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting,0.48,0.5695,33288882
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting and SFA,0.48,0.5695,32781084
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,qRT-PCR,0.48,0.5695,26391180
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.48,0.5695,30954649
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.48,0.5695,28947139
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR,0.48,0.5695,26439804
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by SFA and qRT-PCR,0.48,0.5695,30466404
SOX2,LTM,NA,11195,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,FACs followed by SP assay,0.48,0.5695,22963768
SOX2,LTM,NA,11195,Dukes Type C Colon Cancer,Adenocarcinoma,SW48,NA,Western Blotting followed by SFA,0.28,0.5695,30802541
SOX2,LTM,NA,11195,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by qRT-PCR and Western Blotting,0.48,0.5695,24926880
SOX2,LTM,NA,11195,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,FACs followed by SFA and qRT-PCR,0.48,0.5695,29693155
SOX2,LTM,NA,11195,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by Western Blotting,0.48,0.5695,30774996
SOX2,LTM,NA,11195,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,Western Blotting followed by SFA,0.48,0.5695,30802541
SOX2,LTM,NA,11195,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by qRT-PCR,0.48,0.5695,35267511
SOX2,LTM,NA,11195,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,qRT-PCR,0.48,0.5695,29426374
SOX2,LTM,NA,11195,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by qPCR,0.48,0.5695,31349708
SOX2,LTM,NA,11195,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SFA followed by qRT-PCR,0.48,0.5695,29307822
SOX2,LTM,NA,11195,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,SP assay followed by Tumorigenicity assay and RT-PCR,0.48,0.5695,21435460
SOX2,LTM,NA,11195,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5695,30774996
SOX2,LTM,NA,11195,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by Western Blotting and Tumorigenicity assay,0.48,0.5695,33109220
SOX2,LTM,NA,11195,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by qRT-PCR,0.48,0.5695,35267511
SOX2,LTM,NA,11195,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by CFA and qRT-PCR,0.48,0.5695,30115896
SOX2,LTM,NA,11195,Dukes Type C Colon Cancer,Adenocarcinoma,SW620,NA,SFA followed by qPCR,0.48,0.5695,31349708
SOX2,LTM,NA,11195,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.2,0.5695,31187490
SOX2,LTM,NA,11195,Bladder Cancer,Carcinoma,T24,NA,SP assay followed by RT-PCR and SFA,0.2,0.5695,25020236
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,qRT-PCR and Western Blotting followed by CFA,0.48,0.5695,35235236
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.5695,30326469
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,qRT-PCR followed by Western Blotting and SFA,0.48,0.5695,31736268
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.5695,31300015
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5695,28703799
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by RT-PCR and IHC staining,0.48,0.5695,30131941
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,Western Blotting and SFA,0.48,0.5695,34362383
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Western Blotting,0.48,0.5695,28802057
SOX2,LTM,NA,11195,Glioblastoma,NA,T98G,NA,SFA and qRT-PCR,0.2,0.5695,20082319
SOX2,LTM,NA,11195,Glioblastoma,NA,U-251,BIX01294,SFA and Western Blotting,0.28,0.5695,24833465
SOX2,LTM,NA,11195,Glioblastoma,NA,U-251,NA,SFA followed by qRT-PCR,0.28,0.5695,33575080
SOX2,LTM,NA,11195,Glioblastoma,NA,U-251,NA,SFA followed by RT-PCR,0.28,0.5695,31288857
SOX2,LTM,NA,11195,Glioblastoma,NA,U-251,NA,CFA followed by qRT-PCR,0.28,0.5695,19324493
SOX2,LTM,NA,11195,Glioblastoma,NA,U-373MG,NA,SFA followed by Western Blotting,0.28,0.5695,29115404
SOX2,LTM,NA,11195,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.5695,34408983
SOX2,LTM,NA,11195,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting,0.48,0.5695,29115404
SOX2,LTM,NA,11195,Glioblastoma,NA,U-87MG,Temozolomide,SFA followed by Western Blotting,0.48,0.5695,33691197
SOX2,LTM,NA,11195,Glioblastoma,NA,U-87MG,NA,Western Blotting and SFA,0.48,0.5695,31717924
SOX2,LTM,NA,11195,Glioblastoma,NA,U-87MG,NA,SFA and Western Blotting,0.48,0.5695,28394339
SOX2,LTM,NA,11195,Glioblastoma,NA,U-87MG,NA,SFA and Western Blotting,0.48,0.5695,29228694
SOX2,LTM,NA,11195,Glioblastoma,NA,U-87MG,NA,SFA and Western Blotting,0.48,0.5695,32360621
SOX2,LTM,NA,11195,Glioblastoma,NA,U-87MG,NA,SFA followed by IF staining,0.48,0.5695,34235925
SOX2,LTM,NA,11195,Glioblastoma,NA,U-87MG,NA,SFA followed by qRT-PCR,0.48,0.5695,30175027
SOX2,LTM,NA,11195,Glioblastoma,NA,U-87MG,NA,SFA followed by RT-PCR,0.48,0.5695,31288857
SOX2,LTM,NA,11195,Glioblastoma,NA,U-87MG,NA,SFA and qRT-PCR,0.48,0.5695,20082319
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-1,NA,SFA followed by qPCR,0.2,0.5695,21304586
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-1,NA,SFA followed by qRT-PCR,0.2,0.5695,26323460
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,SFA followed by qRT-PCR,0.2,0.5695,24533098
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-103,NA,SFA followed by qRT-PCR,0.2,0.5695,25428916
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-11B,NA,SFA followed by qPCR,0.2,0.5695,21304586
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.5695,32773768
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-12,NA,SFA followed by RT-PCR,0.48,0.5695,31742606
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-14B,NA,SFA followed by qRT-PCR,0.2,0.5695,25428916
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,NA,Western Blotting,0.28,0.5695,25379016
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,NA,Western Blotting,0.28,0.5695,25379016
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,qRT-PCR and Western Blotting followed by SFA,0.48,0.5695,32773768
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-38,NA,Western Blotting,0.48,0.5695,25379016
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-46,NA,SP assay followed by Western Blotting and qRT-PCR,0.48,0.5695,25379016
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-47,NA,SFA followed by qRT-PCR,0.2,0.5695,24533098
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-9,NA,SFA followed by qRT-PCR,0.2,0.5695,26323460
SOX2,LTM,NA,11195,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by RT-PCR,0.2,0.5695,30397177
SOX2,LTM,NA,11195,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by qRT-PCR,0.2,0.5695,26452033
SOX2,LTM,NA,11195,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SP assay followed by RT-PCR and SFA,0.2,0.5695,25020236
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-22,NA,SFA followed by qPCR,0.2,0.5695,21304586
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,SFA followed by qRT-PCR,0.2,0.5695,26323460
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,SFA followed by qRT-PCR,0.2,0.5695,26323460
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-38,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.5695,31382448
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,qRT-PCR followed by SFA,0.2,0.5695,26323893
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,qRT-PCR followed by SFA,0.2,0.5695,26323893
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-9,NA,SFA followed by qPCR,0.2,0.5695,21304586
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,VU-1365,NA,RT-PCR followed by SFA,0.2,0.5695,25340704
SOX2,LTM,NA,11195,Skin Cancer,NA,WM115,NA,qRT-PCR,0.2,0.5695,23915418
SOX2,LTM,NA,11195,Skin Cancer,NA,WM266-4,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.5695,31817719
SOX2,LTM,NA,11195,Hepatic Cancer,NA,WRL68,Zebularine,SP assay followed by SFA and qRT-PCR,0.2,0.5695,21618577
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN19,NA,SFA followed by RT-PCR,0.2,0.5695,25024430
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN26,NA,SFA followed by RT-PCR,0.2,0.5695,25024430
SOX2,LTM,NA,11195,Gastric Cancer,NA,XN0422,NA,qRT-PCR followed by SFA,0.2,0.5695,29662192
SOX2,LTM,NA,11195,Luminal A Breast Cancer,Ductal Carcinoma,ZR-75-1,NA,qRT-PCR followed by SP assay and SFA,0.2,0.5695,30613295
SOX2,LTM,NA,11195,Bladder Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.5695,28765327
SOX2,LTM,NA,11195,Bladder Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.5695,32019566
SOX2,LTM,NA,11195,Breast Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.36,0.5695,33340428
SOX2,LTM,NA,11195,Breast Cancer,NA,Primary,Chemotherapy,SFA followed by Western Blotting,0.36,0.5695,28835684
SOX2,LTM,NA,11195,Breast Cancer,NA,Primary,NA,IF staining,0.36,0.5695,35402219
SOX2,LTM,NA,11195,Breast Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.36,0.5695,28746471
SOX2,LTM,NA,11195,Breast Cancer,NA,Primary,NA,SFA followed by FACs,0.36,0.5695,30359767
SOX2,LTM,NA,11195,Colon Cancer,NA,Primary,NA,qRT-PCR and Western Blotting followed by SFA,0.64,0.5695,34271345
SOX2,LTM,NA,11195,Colon Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.64,0.5695,33500430
SOX2,LTM,NA,11195,Colon Cancer,NA,Primary,NA,SFA followed by Western Blotting,0.64,0.5695,29110645
SOX2,LTM,NA,11195,Colon Cancer,NA,Primary,5-Fluorouracil,SFA followed by Western Blotting,0.64,0.5695,30091203
SOX2,LTM,NA,11195,Colon Cancer,NA,Primary,Oxaliplatin,SFA followed by Western Blotting,0.64,0.5695,30091203
SOX2,LTM,NA,11195,Colon Cancer,NA,Primary,NA,IHC staining,0.64,0.5695,29102042
SOX2,LTM,NA,11195,Colon Cancer,NA,Primary,NA,IHC staining,0.64,0.5695,31186779
SOX2,LTM,NA,11195,Colon Cancer,NA,Primary,NA,SFA and IF staining,0.64,0.5695,26745821
SOX2,LTM,NA,11195,Colon Cancer,NA,Primary,NA,RT-PCR,0.64,0.5695,23545848
SOX2,LTM,NA,11195,Colon Cancer,NA,Primary,5-Fluorouracil,SFA followed by FACs,0.64,0.5695,30091203
SOX2,LTM,NA,11195,Colon Cancer,NA,Primary,Oxaliplatin,SFA followed by FACs,0.64,0.5695,30091203
SOX2,LTM,NA,11195,Gastric Cancer,NA,Primary,NA,SFA and RT-PCR followed by Western Blotting and IHC ataining,0.96,0.5695,32788883
SOX2,LTM,NA,11195,Gastric Cancer,NA,Primary,NA,SFA followed by Western Blotting and IHC staining,0.96,0.5695,30745823
SOX2,LTM,NA,11195,Gastric Cancer,NA,Primary,NA,IHC staining,0.96,0.5695,28356964
SOX2,LTM,NA,11195,Gastric Cancer,NA,Primary,NA,IHC staining,0.96,0.5695,28046028
SOX2,LTM,NA,11195,Gastric Cancer,NA,Primary,NA,qRT-PCR,0.96,0.5695,30628031
SOX2,LTM,NA,11195,Gastric Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.96,0.5695,32350414
SOX2,LTM,NA,11195,Gastric Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.96,0.5695,26862521
SOX2,LTM,NA,11195,Glioblastoma,NA,Primary,NA,IHC staining and Western Blotting followed by SFA,0.68,0.5695,19427293
SOX2,LTM,NA,11195,Glioblastoma,NA,Primary,NA,SFA and Western Blotting,0.68,0.5695,30701538
SOX2,LTM,NA,11195,Glioblastoma,NA,Primary,NA,SFA followed by Western Blotting,0.68,0.5695,34298643
SOX2,LTM,NA,11195,Glioblastoma,NA,Primary,NA,SFA and IF staining,0.68,0.5695,26683773
SOX2,LTM,NA,11195,Glioblastoma,NA,Primary,NA,SFA and qRT-PCR,0.68,0.5695,30280197
SOX2,LTM,NA,11195,Glioblastoma,NA,Primary,NA,SFA followed by qRT-PCR,0.68,0.5695,21600039
SOX2,LTM,NA,11195,Glioblastoma Multiforme,NA,Primary,NA,IHC staining and IF staining followed by Western Blotting,1,0.5695,27617262
SOX2,LTM,NA,11195,Glioblastoma Multiforme,NA,Primary,NA,IHC staining and IF staining followed by Western Blotting,1,0.5695,27730123
SOX2,LTM,NA,11195,Glioblastoma Multiforme,NA,Primary,NA,SFA and qPCR followed by Western Blotting and IHC staining,1,0.5695,29963265
SOX2,LTM,NA,11195,Glioblastoma Multiforme,NA,Primary,NA,IF staining followed by SFA,1,0.5695,29137258
SOX2,LTM,NA,11195,Glioblastoma Multiforme,NA,Primary,NA,Isolation of autofluorescence cells followed by SFA and qRT-PCR,1,0.5695,33669350
SOX2,LTM,NA,11195,Head and Neck Cancer,Cutaneous Squamous Cell Carcinoma,Primary,NA,IHC staining and IF staining followed by qRT-PCR,0.92,0.5695,32850316
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining and IF staining followed by SFA,0.92,0.5695,32019273
SOX2,LTM,NA,11195,Head and Neck Cancer,NA,Primary,NA,IHC staining followed by IF staining and SFA,0.92,0.5695,32019273
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qPCR and Western Blotting,0.92,0.5695,23876835
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR and Western Blotting,0.92,0.5695,30651721
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR and IF staining,0.92,0.5695,21167769
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR and IF staining,0.92,0.5695,22426199
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by Western Blotting,0.92,0.5695,26239260
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IF staining,0.92,0.5695,32327629
SOX2,LTM,NA,11195,Head and Neck Cancer,NA,Primary,NA,IF staining and SFA,0.92,0.5695,32019273
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.92,0.5695,35140342
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.92,0.5695,33513805
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.92,0.5695,22847005
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.92,0.5695,25871396
SOX2,LTM,NA,11195,Head and Neck Cancer,NA,Primary,NA,IHC staining,0.92,0.5695,26556875
SOX2,LTM,NA,11195,Head and Neck Cancer,NA,Primary,NA,IHC staining,0.92,0.5695,32816856
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,IHC staining,0.92,0.5695,30528285
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by IHC staining,0.92,0.5695,22640830
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,qRT-PCR,0.92,0.5695,20036608
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by qRT-PCR,0.92,0.5695,19450560
SOX2,LTM,NA,11195,Head and Neck Cancer,Squamous Cell Carcinoma,Primary,NA,SFA followed by FACs,0.92,0.5695,27619333
SOX2,LTM,NA,11195,Hepatic Cancer,NA,Primary,NA,SP assay followed by qRT-PCR and SFA,0.28,0.5695,23104270
SOX2,LTM,NA,11195,Hepatic Cancer,NA,Primary,NA,FACs,0.28,0.5695,26942873
SOX2,LTM,NA,11195,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.5695,25963795
SOX2,LTM,NA,11195,Large Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.5695,25963795
SOX2,LTM,NA,11195,Lung Cancer,Adenocarcinoma,Primary,NA,IHC staining and IF staining followed by qRT-PCR,0.92,0.5695,31894290
SOX2,LTM,NA,11195,Lung Cancer,Adenocarcinoma,Primary,NA,SP assay followed by qRT-PCR and Western Blotting,0.92,0.5695,22285547
SOX2,LTM,NA,11195,Lung Cancer,NA,Primary,NA,IHC staining,0.92,0.5695,32500024
SOX2,LTM,NA,11195,Lung Cancer,NA,Primary,PD98059,SFA followed by qRT-PCR,0.92,0.5695,33867839
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.32,0.5695,24346092
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,qRT-PCR followed by SFA,0.32,0.5695,28855609
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Adenocarcinoma,Primary,NA,RT-PCR,0.32,0.5695,31921651
SOX2,LTM,NA,11195,Non Small Cell Lung Cancer,Squamous Cell Carcinoma,Primary,NA,RT-PCR,0.32,0.5695,31921651
SOX2,LTM,NA,11195,Pancreatic Cancer,NA,Primary,NA,SFA and qRT-PCR followed by Western Blotting and IHC staining,0.96,0.5695,26451606
SOX2,LTM,NA,11195,Pancreatic Cancer,NA,Primary,NA,SFA followed by qRT-PCR and IF staining,0.96,0.5695,26609473
SOX2,LTM,NA,11195,Pancreatic Cancer,NA,Primary,NA,qPCR followed by SFA,0.96,0.5695,24785258
SOX2,LTM,NA,11195,Pancreatic Cancer,NA,Primary,NA,qRT-PCR,0.96,0.5695,21796625
SOX2,LTM,NA,11195,Skin Cancer,NA,Primary,NA,IHC staining followed by IF staining,0.64,0.5695,30626524
SOX2,LTM,NA,11195,Small Cell Lung Cancer,Carcinoma,Primary,NA,IHC staining,0.32,0.5695,25963795
SOX2,LTM,NA,11195,Small Cell Lung Cancer,NA,Primary,NA,IHC staining,0.32,0.5695,27363902
SOX2-OT,LTM,NA,20209,Bladder Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0011,32019566
SOX4,LTM,NA,11200,Bladder Cancer,Carcinoma,5637,NA,Western Blotting,0.28,0.0042,26681916
SOX4,LTM,NA,11200,Bladder Cancer,Carcinoma,HT-1197,NA,Western Blotting,0.28,0.0042,26681916
SOX4,LTM,NA,11200,Bladder Cancer,Carcinoma,J-82,NA,Western Blotting,0.28,0.0042,26681916
SOX4,LTM,NA,11200,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Culture of cells in electrospun scaffolds followed by qRT-PCR,0.2,0.0042,34841239
SOX4,LTM,NA,11200,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,Culture of cells in electrospun scaffolds followed by qRT-PCR,0.2,0.0042,34841239
SOX4,LTM,NA,11200,Bladder Cancer,Carcinoma,RT-112,NA,Western Blotting followed by SFA,0.28,0.0042,26681916
SOX4,LTM,NA,11200,Bladder Cancer,Transitional Cell Carcinoma,SW780,NA,Western Blotting,0.28,0.0042,26681916
SOX5,LTM,NA,11201,Non Small Cell Lung Cancer,Carcinoma,A549,NA,qRT-PCR and Western Blotting followed by SFA and Migration Invasion assay,0.48,0.0011,29888108
SOX5,LTM,NA,11201,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,qRT-PCR and Western Blotting followed by SFA and Migration Invasion assay,0.48,0.0011,29888108
SOX9,LTM,NA,11204,Non Small Cell Lung Cancer,Carcinoma,A549,NA,IF staining and Western Blotting followed by SFA,0.52,0.0244,35278461
SOX9,LTM,NA,11204,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,RT-PCR and Western Blotting followed by SFA,0.48,0.0244,28984791
SOX9,LTM,NA,11204,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by Western Blotting and SFA,0.48,0.0244,32781084
SOX9,LTM,NA,11204,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SP assay followed by SFA and qRT-PCR,0.48,0.0244,30466404
SOX9,LTM,NA,11204,Dukes Type C Colon Cancer,Adenocarcinoma,DLD-1,NA,Western Blotting followed by SFA,0.28,0.0244,31964531
SOX9,LTM,NA,11204,Small Cell Lung Cancer,Carcinoma,GLC16,NA,SFA followed by Western Blotting,0.28,0.0244,33607458
SOX9,LTM,NA,11204,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,IF staining and Western Blotting followed by SFA,0.52,0.0244,35278461
SOX9,LTM,NA,11204,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA followed by Western Blotting,0.28,0.0244,31658996
SOX9,LTM,NA,11204,Triple Negative Breast Cancer,Squamous Cell Carcinoma,HCC1806,NA,Western Blotting and SFA,0.28,0.0244,35504883
SOX9,LTM,NA,11204,Colon Cancer,Carcinoma,HCT116,NA,Western Blotting,0.28,0.0244,22319203
SOX9,LTM,NA,11204,Pancreatic Cancer,Adenocarcinoma,HPAC,Gemcitabine,Migration and Invasion assay followed by qRT-PCR and SFA,0.2,0.0244,23592398
SOX9,LTM,NA,11204,Colon Cancer,Adenocarcinoma,HT-29,NA,Western Blotting followed by SFA,0.28,0.0244,31964531
SOX9,LTM,NA,11204,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0244,30622340
SOX9,LTM,NA,11204,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,SFA followed by qRT-PCR and Western Blotting,0.48,0.0244,30622340
SOX9,LTM,NA,11204,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,Western Blotting followed by SFA,0.48,0.0244,31690832
SOX9,LTM,NA,11204,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.28,0.0244,35504883
SOX9,LTM,NA,11204,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by qRT-PCR,0.2,0.0244,30622340
SOX9,LTM,NA,11204,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and Western Blotting,0.28,0.0244,34845198
SOX9,LTM,NA,11204,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.28,0.0244,28984791
SOX9,LTM,NA,11204,Pancreatic Cancer,Carcinoma,PANC-1,Gemcitabine,Migration and Invasion assay followed by qRT-PCR and SFA,0.28,0.0244,23592398
SOX9,LTM,NA,11204,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and Western Blotting,0.28,0.0244,34845198
SOX9,LTM,NA,11204,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs and RT-PCR,0.32,0.0244,29249663
SOX9,LTM,NA,11204,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting,0.28,0.0244,33288882
SOX9,LTM,NA,11204,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by Western Blotting and SFA,0.28,0.0244,32781084
SOX9,LTM,NA,11204,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SP assay followed by SFA and qRT-PCR,0.28,0.0244,30466404
SOX9,LTM,NA,11204,Dukes Type B Colon Cancer,Adenocarcinoma,SW480,NA,Western Blotting,0.28,0.0244,22319203
SOX9,LTM,NA,11204,Luminal A Breast Cancer,Ductal Carcinoma,T47D,Tamoxifen,Western Blotting followed by SFA,0.28,0.0244,31690832
SOX9,LTM,NA,11204,Breast Cancer,NA,Primary,NA,Western Blotting and IF staining followed by qRT-PCR,0.96,0.0244,30622340
SOX9,LTM,NA,11204,Breast Cancer,NA,Primary,Tamoxifen,SFA followed by qRT-PCR,0.96,0.0244,30622340
SPRY4?IT1,LTM,NA,42394,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.2,0.0011,31736268
SRC,LTM,NA,11283,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0032,34830821
SRC,LTM,NA,11283,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.2,0.0032,33530373
SRC,LTM,NA,11283,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by qRT-PCR,0.2,0.0032,33530373
SRXN1,LTM,NA,16132,Colon Cancer,Carcinoma,HCT116,NA,FACs for CSC marker followed by qRT-PCR and Western Blotting,0.48,0.0032,34798428
SRXN1,LTM,NA,16132,Colon Cancer,Adenocarcinoma,HT-29,NA,FACs for CSC marker followed by qRT-PCR and Western Blotting,0.48,0.0032,34798428
STAT3,LTM,NA,11364,Pancreatic Cancer,Adenocarcinoma,BxPC-3,NA,SFA and Western Blotting,0.28,0.0223,27748818
STAT3,LTM,NA,11364,Pancreatic Cancer,Adenocarcinoma,BxPC-3,Gemcitabine,Western Blotting followed by SFA,0.28,0.0223,27576197
STAT3,LTM,NA,11364,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,SFA followed by Western Blotting,0.28,0.0223,34502158
STAT3,LTM,NA,11364,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by RT-PCR,0.2,0.0223,29100320
STAT3,LTM,NA,11364,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by Western Blotting,0.28,0.0223,34502158
STAT3,LTM,NA,11364,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA and Western Blotting,0.28,0.0223,27748818
STAT3,LTM,NA,11364,Glioblastoma,NA,LN-18,NA,SFA and qRT-PCR,0.2,0.0223,29069805
STAT3,LTM,NA,11364,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.36,0.0223,31619923
STAT3,LTM,NA,11364,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Tamoxifen,SFA followed by Western Blotting,0.36,0.0223,31760402
STAT3,LTM,NA,11364,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,Western Blotting and SFA,0.36,0.0223,30214607
STAT3,LTM,NA,11364,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,FACs followed by Migration assay,0.36,0.0223,31286834
STAT3,LTM,NA,11364,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0223,34146553
STAT3,LTM,NA,11364,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0223,31619923
STAT3,LTM,NA,11364,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,Western Blotting and SFA,0.28,0.0223,31850822
STAT3,LTM,NA,11364,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA and FACs followed by Western Blotting,0.4,0.0223,26862521
STAT3,LTM,NA,11364,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA and Western Blotting,0.28,0.0223,27748818
STAT3,LTM,NA,11364,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by Western Blotting,0.28,0.0223,31619923
STAT3,LTM,NA,11364,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by Western Blotting,0.28,0.0223,31619923
STAT3,LTM,NA,11364,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,Western Blotting and SFA,0.28,0.0223,31850822
STAT3,LTM,NA,11364,Pancreatic Cancer,Adenocarcinoma,SW1990,Gemcitabine,Western Blotting followed by SFA,0.28,0.0223,27576197
STAT3,LTM,NA,11364,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Western Blotting,0.28,0.0223,31619923
STAT3,LTM,NA,11364,Glioblastoma,NA,U-373MG,NA,SFA followed by Western Blotting,0.28,0.0223,29115404
STAT3,LTM,NA,11364,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.0223,34408983
STAT3,LTM,NA,11364,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting,0.48,0.0223,29115404
STAT3,LTM,NA,11364,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,NA,Western Blotting followed by SFA,0.28,0.0223,34689150
STAT3,LTM,NA,11364,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-1,Cisplatin,Western Blotting followed by SFA,0.28,0.0223,34689150
STAT3,LTM,NA,11364,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,NA,Western Blotting followed by SFA,0.28,0.0223,34689150
STAT3,LTM,NA,11364,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22A,Cisplatin,Western Blotting followed by SFA,0.28,0.0223,34689150
STAT3,LTM,NA,11364,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,NA,Western Blotting followed by SFA,0.28,0.0223,34689150
STAT3,LTM,NA,11364,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,Cisplatin,Western Blotting followed by SFA,0.28,0.0223,34689150
STAT3,LTM,NA,11364,Bladder Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0223,28765327
STAT3,LTM,NA,11364,Gastric Cancer,NA,Primary,NA,SFA followed by FACs,0.2,0.0223,26862521
STAT3,LTM,NA,11364,Glioblastoma,NA,Primary,NA,SFA and Western Blotting,0.36,0.0223,30701538
STAT3,LTM,NA,11364,Glioblastoma Multiforme,NA,Primary,NA,IHC staining and IF staining followed by Western Blotting,1,0.0223,27617262
STK11,LTM,NA,11389,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR,0.2,0.0032,28507102
SUZ12,LTM,NA,17101,Non Small Cell Lung Cancer,Carcinoma,H1299,Docetaxel,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,25279705
SUZ12,LTM,NA,17101,Non Small Cell Lung Cancer,Adenocarcinoma,SPCA1,Docetaxel,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,25279705
SUZ12,LTM,NA,17101,Lung Cancer,NA,Primary,NA,RT-PCR,0.28,0.0032,19536353
SUZ12,LTM,NA,17101,Lung Cancer,NA,Primary,NA,SFA followed by RT-PCR,0.28,0.0032,24019906
TAFAZZIN,LTM,NA,11577,Head and Neck Cancer,Squamous Cell Carcinoma,CAL27,NA,Western Blotting followed by SFA,0.28,0.0011,31399556
TAFAZZIN,LTM,NA,11577,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,Western Blotting followed by SFA,0.28,0.0011,31399556
TAP1,LTM,NA,43,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.0021,34410967
TBL1XR1,LTM,NA,29529,Gastric Cancer,Adenocarcinoma,AGS,NA,SFA followed by Western Blotting,0.28,0.0011,33288885
TBL1XR1,LTM,NA,29529,Gastric Cancer,NA,HFE-145,NA,SFA followed by Western Blotting,0.28,0.0011,33288885
TBL1XR1,LTM,NA,29529,Gastric Cancer,Carcinoma,KATO-III,NA,SFA followed by Western Blotting,0.28,0.0011,33288885
TBL1XR1,LTM,NA,29529,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by Western Blotting,0.28,0.0011,33288885
TCF4,LTM,NA,11634,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen,SFA followed by qRT-PCR,0.28,0.0032,31693936
TCF4,LTM,NA,11634,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen+Fulvestrant,SFA followed by qRT-PCR,0.28,0.0032,31693936
TDO2,LTM,NA,11708,Bladder Cancer,Carcinoma,253JB-V,NA,qRT-PCR and SFA ,0.2,0.0011,34101386
TDO2,LTM,NA,11708,Bladder Cancer,Carcinoma,KMBC-2,NA,qRT-PCR and SFA ,0.2,0.0011,34101386
TDO2,LTM,NA,11708,Bladder Cancer,Carcinoma,RT-112,NA,qRT-PCR and SFA ,0.2,0.0011,34101386
TDO2,LTM,NA,11708,Bladder Cancer,Carcinoma,UM-UC-6,NA,qRT-PCR and SFA ,0.2,0.0011,34101386
TDO2,LTM,NA,11708,Bladder Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0011,34101386
TENM4,LTM,NA,29945,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0021,33672732
TENM4,LTM,NA,29945,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0021,33672732
TENM4,LTM,NA,29945,HER2 Positive Breast Cancer,Adenocarcinoma,SKBR3,NA,SFA followed by Western Blotting,0.28,0.0021,33672732
TERT,LTM,NA,11730,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by IF staining and Migration assay,0.24,0.0053,29907642
TERT,LTM,NA,11730,Lung Cancer,NA,Primary,NA,RT-PCR,0.28,0.0053,19536353
TERT,LTM,NA,11730,Lung Cancer,NA,Primary,NA,SFA followed by RT-PCR,0.28,0.0053,24019906
TERT,LTM,NA,11730,Pancreatic Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0053,26609473
TGFB1,LTM,NA,11766,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting followed by SFA and Migration Invasion assay,0.28,0.0138,32606331
TGFB1,LTM,NA,11766,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by Migration and Invasion assay,0.28,0.0138,28789457
TGFB1,LTM,NA,11766,Non Small Cell Lung Cancer,NA,LC006,NA,FACs followed by qRT-PCR and CFA,0.32,0.0138,29407170
TGFB1,LTM,NA,11766,Non Small Cell Lung Cancer,NA,LC021,NA,FACs followed by qRT-PCR and CFA,0.32,0.0138,29407170
TGFB1,LTM,NA,11766,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,qPCR followed by Western Blotting and SFA,0.48,0.0138,28054666
TGFB1,LTM,NA,11766,Dukes Type C Colon Cancer,Adenocarcinoma,SW48,Doxorubicin,Western Blotting,0.28,0.0138,27517620
TGFB1,LTM,NA,11766,Breast Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0138,31728117
TGFB1,LTM,NA,11766,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0138,28416482
TGFB2,LTM,NA,11768,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,RT-PCR and SFA,0.24,0.0074,35413424
TGFB2,LTM,NA,11768,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR and SFA,0.2,0.0074,35413424
TGIF2,LTM,NA,15764,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay and Western Blotting followed by qRT-PCR and SFA,0.48,0.0021,31871777
TGIF2,LTM,NA,15764,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SP assay and Western Blotting followed by qRT-PCR and SFA,0.48,0.0021,31871777
THRA,LTM,NA,11796,Luminal A Breast Cancer,Adenocarcinoma,MCF8,NA,SFA followed by qRT-PCR,0.2,0.0021,31760908
THRB,LTM,NA,11799,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.0021,31760908
THY1,LTM,NA,11801,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by IF staining and RT-PCR,0.56,0.0371,21738704
THY1,LTM,NA,11801,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,IF staining followed by FACs and SFA,0.56,0.0371,31781681
THY1,LTM,NA,11801,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by RT-PCR and SFA,0.56,0.0371,29576613
THY1,LTM,NA,11801,Non Small Cell Lung Cancer,Carcinoma,A549,NA,FACs followed by Tumorigenicity assay,0.56,0.0371,33707423
THY1,LTM,NA,11801,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs,0.56,0.0371,24101104
THY1,LTM,NA,11801,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by FACs and Tumorigenicity assay,0.56,0.0371,24101104
THY1,LTM,NA,11801,Gastric Cancer,Adenocarcinoma,BGC-823,NA,FACs followed by SFA,0.12,0.0371,31073886
THY1,LTM,NA,11801,Head and Neck Cancer,Squamous Cell Carcinoma,FaDu,NA,SFA followed by RT-PCR,0.2,0.0371,32708734
THY1,LTM,NA,11801,Non Small Cell Lung Cancer,Bronchioalveolar Carcinoma,H358,NA,FACs followed by RT-PCR and SFA,0.32,0.0371,29576613
THY1,LTM,NA,11801,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by FACs and qRT-PCR,0.32,0.0371,24101104
THY1,LTM,NA,11801,Small Cell Lung Cancer,Carcinoma,H446,NA,SFA followed by FACs,0.32,0.0371,24101104
THY1,LTM,NA,11801,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,IF staining followed by FACs and SFA,0.36,0.0371,31781681
THY1,LTM,NA,11801,Non Small Cell Lung Cancer,Giant Cell Carcinoma,H661,Cisplatin,IF staining followed by FACs and SFA,0.36,0.0371,31781681
THY1,LTM,NA,11801,Small Cell Lung Cancer,Carcinoma,H69,NA,SFA followed by FACs,0.12,0.0371,34228218
THY1,LTM,NA,11801,Small Cell Lung Cancer,Carcinoma,H82,NA,SFA followed by FACs,0.12,0.0371,34228218
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,HCCLM3,NA,CFA followed by SFA and qRT-PCR,0.2,0.0371,27783993
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,HCCLM3,NA,SFA followed by qRT-PCR,0.2,0.0371,25676692
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Hep3B,NA,CFA followed by SFA and qRT-PCR,0.2,0.0371,27783993
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Hep3B,NA,SFA followed by qRT-PCR,0.2,0.0371,25676692
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Hep3B,NA,FACs followed by CFA,0.2,0.0371,22194816
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Hep-G2,NA,SFA followed by qRT-PCR,0.2,0.0371,28554132
THY1,LTM,NA,11801,Bladder Cancer,Carcinoma,HTB-9,NA,FACs followed by SFA,0.12,0.0371,26054707
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by Western Blotting,0.4,0.0371,32221015
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting and SFA,0.4,0.0371,32229502
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting followed by SFA and CFA,0.4,0.0371,30908631
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.4,0.0371,28554132
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.4,0.0371,25676692
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Huh7,NA,SFA followed by qRT-PCR,0.4,0.0371,32128906
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Huh7,NA,FACs followed by CFA,0.4,0.0371,22194816
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by FACs and SFA,0.4,0.0371,25997710
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Huh7,NA,FACs,0.4,0.0371,21879266
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,Huh7,NA,SP assay followed by FACs,0.4,0.0371,25997710
THY1,LTM,NA,11801,Pancreatic Cancer,NA,Insulinoma,NA,FACs followed by Tumorigenicity assay,0.12,0.0371,27049037
THY1,LTM,NA,11801,Gastric Cancer,Carcinoma,KATO-III,NA,qRT-PCR and SFA,0.2,0.0371,31233198
THY1,LTM,NA,11801,Non Small Cell Lung Cancer,NA,LC006,NA,FACs,0.12,0.0371,29407170
THY1,LTM,NA,11801,Non Small Cell Lung Cancer,NA,LC021,NA,FACs,0.12,0.0371,29407170
THY1,LTM,NA,11801,Non Small Cell Lung Cancer,NA,LC31,NA,FACs followed by IF staining and RT-PCR,0.56,0.0371,21738704
THY1,LTM,NA,11801,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,qPCR followed by SFA,0.2,0.0371,29907642
THY1,LTM,NA,11801,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR,0.2,0.0371,29103027
THY1,LTM,NA,11801,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by FACs,0.2,0.0371,30564555
THY1,LTM,NA,11801,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by RT-PCR,0.2,0.0371,24573253
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0371,32229502
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,MHCC97-H,NA,Western Blotting followed by SFA and CFA,0.48,0.0371,30908631
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,MHCC97-H,NA,CFA followed by SFA and qRT-PCR,0.48,0.0371,27783993
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,MHCC97-H,NA,SFA followed by qRT-PCR,0.48,0.0371,25676692
THY1,LTM,NA,11801,Gastric Cancer,Adenocarcinoma,MKN45,NA,FACs followed by SFA,0.12,0.0371,31073886
THY1,LTM,NA,11801,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by FACs,0.12,0.0371,32863948
THY1,LTM,NA,11801,Gastric Cancer,Carcinoma,NCI-N87,NA,SFA followed by FACs,0.12,0.0371,28404967
THY1,LTM,NA,11801,Gastric Cancer,Carcinoma,NCI-N87,NA,FACs followed by SFA,0.12,0.0371,31073886
THY1,LTM,NA,11801,Gastric Cancer,Carcinoma,PAMC82,NA,FACs followed by SFA,0.12,0.0371,31073886
THY1,LTM,NA,11801,Pancreatic Cancer,Carcinoma,PANC-1,NA,FACs followed by SFA and qPCR,0.32,0.0371,30954649
THY1,LTM,NA,11801,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by qRT-PCR and FACs and Tumorigenicity assay,0.32,0.0371,30954649
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SP assay followed by FACs and SFA,0.12,0.0371,25997710
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,FACs,0.12,0.0371,21879266
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SP assay followed by FACs,0.12,0.0371,20697159
THY1,LTM,NA,11801,Hepatic Cancer,Carcinoma,PLC/PRF/5,NA,SP assay followed by FACs,0.12,0.0371,25997710
THY1,LTM,NA,11801,Gastric Cancer,Carcinoma,SNU16,NA,FACs followed by SFA,0.12,0.0371,31073886
THY1,LTM,NA,11801,Gastric Cancer,Carcinoma,SNU5,NA,FACs,0.12,0.0371,32661467
THY1,LTM,NA,11801,Gastric Cancer,Carcinoma,SNU5,NA,FACs followed by SFA,0.12,0.0371,31073886
THY1,LTM,NA,11801,Gastric Cancer,Adenocarcinoma,SNU638,NA,SFA followed by FACs,0.12,0.0371,32863948
THY1,LTM,NA,11801,Gastric Cancer,Adenocarcinoma,ST2957,NA,SFA followed by FACs,0.12,0.0371,32863948
THY1,LTM,NA,11801,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,FACs followed by SFA and qPCR,0.32,0.0371,30954649
THY1,LTM,NA,11801,Pancreatic Cancer,Adenocarcinoma,SW1990,NA,SFA followed by qRT-PCR and FACs,0.32,0.0371,30954649
THY1,LTM,NA,11801,Hepatic Cancer,NA,Primary,NA,SP assay followed by FACs,0.2,0.0371,23104270
THY1,LTM,NA,11801,Lung Cancer,NA,Primary,NA,SFA followed by IF staining,0.32,0.0371,25955492
THY1,LTM,NA,11801,Non Small Cell Lung Cancer,NA,Primary,NA,SFA followed by qRT-PCR,0.28,0.0371,31506430
TIMP1,LTM,NA,11820,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0053,30397177
TIMP1,LTM,NA,11820,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0053,30397177
TIMP2,LTM,NA,11821,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0032,30397177
TIMP2,LTM,NA,11821,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0032,30397177
TLR4,LTM,NA,11850,Hepatic Cancer,Carcinoma,Huh7,NA,Western Blotting and SFA,0.28,0.0021,29602239
TM4SF4,LTM,NA,11856,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting followed by SFA and Migration Invasion assay,0.28,0.0032,29254164
TMCC3,LTM,NA,29199,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0032,33742122
TMCC3,LTM,NA,29199,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0032,33742122
TMCC3,LTM,NA,29199,Breast Cancer,NA,Primary,NA,qRT-PCR,0.28,0.0032,33742122
TMPRSS4,LTM,NA,11878,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Migration Invasion assay,0.2,0.0042,26546046
TNF,LTM,NA,11892,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0021,30397177
TNF,LTM,NA,11892,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0021,30397177
TNFRSF1A,LTM,NA,11916,Bladder Cancer,Carcinoma,J-82,NA,SFA followed by ELISA,0.28,0.0021,30397177
TNFRSF1A,LTM,NA,11916,Bladder Cancer,Transitional Cell Carcinoma,UM-UC3,NA,SFA followed by ELISA,0.28,0.0021,30397177
TNFRSF4,LTM,NA,11918,Pancreatic Cancer,NA,Primary,NA,FACs followed by Tumorigenicity assay,0.2,0.0021,18371365
TNFSF13,LTM,NA,11928,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR followed by SFA,0.2,0.0021,30131941
TNFSF13,LTM,NA,11928,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,RT-PCR followed by SFA,0.2,0.0021,30131941
TNFSF13B,LTM,NA,11929,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR followed by SFA,0.2,0.0011,30131941
TNFSF13B,LTM,NA,11929,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,RT-PCR followed by SFA,0.2,0.0011,30131941
TPBG,LTM,NA,12004,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-11B,NA,FACs followed by SFA,0.12,0.0032,27780858
TPBG,LTM,NA,12004,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-22B,NA,FACs followed by SFA,0.12,0.0032,27780858
TRPM7,LTM,NA,17994,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95D,NA,SFA followed by RT-PCR and IF staining,0.44,0.0021,30477473
TRPM7,LTM,NA,17994,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by SFA and FACs,0.12,0.0021,30477473
TSPAN8,LTM,NA,11855,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.28,0.0032,32395477
TSPYL5,LTM,NA,29367,Non Small Cell Lung Cancer,Carcinoma,A549,Irradiation,SFA and Western Blotting,0.28,0.0032,34163000
TSPYL5,LTM,NA,29367,Non Small Cell Lung Cancer,Carcinoma,H460,Gefitinib,SFA and Western Blotting,0.28,0.0032,34163000
TWIST1,LTM,NA,12428,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,Western Blotting,0.28,0.0191,34277708
TWIST1,LTM,NA,12428,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,Paclitaxel,Western Blotting and SFA,0.28,0.0191,31308076
TWIST1,LTM,NA,12428,Head and Neck Cancer,Carcinoma,HEp-2,NA,SFA followed by qRT-PCR,0.2,0.0191,25104726
TWIST1,LTM,NA,12428,Triple Negative Breast Cancer,Carcinoma,Hs-578T,NA,SFA followed by qRT-PCR,0.2,0.0191,28976208
TWIST1,LTM,NA,12428,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.28,0.0191,33667839
TWIST1,LTM,NA,12428,Head and Neck Cancer,Carcinoma,KB,NA,SFA followed by qRT-PCR,0.2,0.0191,25104726
TWIST1,LTM,NA,12428,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by qRT-PCR,0.2,0.0191,33845139
TWIST1,LTM,NA,12428,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Lapatinib,SFA followed by qRT-PCR,0.2,0.0191,34435487
TWIST1,LTM,NA,12428,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA and qRT-PCR followed by Western Blotting ,0.48,0.0191,33608016
TWIST1,LTM,NA,12428,Gastric Cancer,Adenocarcinoma,MKN45,NA,Western Blotting,0.28,0.0191,27878307
TWIST1,LTM,NA,12428,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.28,0.0191,26862521
TWIST1,LTM,NA,12428,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA and qRT-PCR followed by Western Blotting ,0.48,0.0191,33608016
TWIST1,LTM,NA,12428,Triple Negative Breast Cancer,Carcinoma,SUM159,NA,SFA followed by FACs and RT-PCR,0.32,0.0191,29249663
TWIST1,LTM,NA,12428,Head and Neck Cancer,Squamous Cell Carcinoma,UD-SCC-1,NA,SFA followed by qRT-PCR,0.2,0.0191,26323460
TWIST1,LTM,NA,12428,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-11B,NA,SFA followed by qRT-PCR,0.2,0.0191,26323460
TWIST1,LTM,NA,12428,Head and Neck Cancer,Squamous Cell Carcinoma,UM-SCC-9,NA,SFA followed by qRT-PCR,0.2,0.0191,26323460
TWIST1,LTM,NA,12428,Head and Neck Cancer,Squamous Cell Carcinoma,UT-SCC-33,NA,SFA followed by qRT-PCR,0.2,0.0191,26323460
TWIST1,LTM,NA,12428,Breast Cancer,NA,Primary,NA,FACs for CSC marker followed by qRT-PCR,0.28,0.0191,33799422
TWIST1,LTM,NA,12428,Colon Cancer,NA,Primary,NA,RT-PCR,0.28,0.0191,23545848
TWIST1,LTM,NA,12428,Gastric Cancer,NA,Primary,NA,IHC staining followed by Western Blotting,0.68,0.0191,27878307
TWIST2,LTM,NA,20670,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qPCR,0.2,0.0011,33468994
UBE3C,LTM,NA,16803,Non Small Cell Lung Cancer,Giant Cell Carcinoma,95C,NA,Western Blotting and SFA followed by Migration and Invasion assay,0.28,0.0021,30503554
UBE3C,LTM,NA,16803,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting and SFA followed by Migration and Invasion assay,0.28,0.0021,30503554
UBQLN1,LTM,NA,12508,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by qRT-PCR and Western Blotting and SFA,0.48,0.0021,34528694
UBQLN1,LTM,NA,12508,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by qRT-PCR and Western Blotting and SFA,0.48,0.0021,34528694
UBQLN1,LTM,NA,12508,Breast Cancer,NA,Primary,NA,IHC staining,0.32,0.0021,34528694
ULBP2,LTM,NA,14894,Glioblastoma,NA,U-251,NA,SFA followed by FACs,0.12,0.0021,31288857
ULBP2,LTM,NA,14894,Glioblastoma,NA,U-87MG,NA,SFA followed by FACs,0.12,0.0021,31288857
USP22,LTM,NA,12621,Gastric Cancer,Adenocarcinoma,MGC-803,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.0032,28415621
USP22,LTM,NA,12621,Gastric Cancer,Adenocarcinoma,MKN45,NA,RT-PCR followed by SFA and Western Blotting,0.48,0.0032,30543303
USP22,LTM,NA,12621,Gastric Cancer,Carcinoma,NCI-N87,NA,RT-PCR followed by SFA and Western Blotting,0.48,0.0032,30543303
USP22,LTM,NA,12621,Gastric Cancer,Adenocarcinoma,SGC-7901,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.0032,28415621
USP29,LTM,NA,18563,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,RT-PCR followed by Tumorigenicity assay,0.2,0.0011,32968046
USP29,LTM,NA,18563,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,RT-PCR followed by Tumorigenicity assay,0.2,0.0011,32968046
USP37,LTM,NA,20063,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting and Migartion Invasion assay,0.28,0.0011,30482232
USP4,LTM,NA,12627,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting followed by SFA,0.28,0.0021,32549341
USP4,LTM,NA,12627,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,Western Blotting followed by SFA,0.28,0.0021,32549341
VCP,LTM,NA,12666,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,FACs for CSC marker followed by Western Blotting,0.28,0.0042,33731668
VCP,LTM,NA,12666,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,FACs for CSC marker followed by Western Blotting,0.28,0.0042,33731668
VCP,LTM,NA,12666,Breast Cancer,NA,Primary,NA,IHC staining,0.32,0.0042,33731668
VEGF,LTM,NA,12680,Pancreatic Cancer,Carcinoma,MIA-PaCa-2,NA,SFA followed by CFA and qRT-PCR,0.2,0.0042,24719318
VEGF,LTM,NA,12680,Glioblastoma,NA,U-373MG,NA,SFA followed by Western Blotting,0.28,0.0042,29115404
VEGF,LTM,NA,12680,Glioblastoma,NA,U-87MG,NA,SFA followed by Western Blotting,0.28,0.0042,29115404
VEGF,LTM,NA,12680,Head and Neck Cancer,Squamous Cell Carcinoma,WSU-HN30,Deferoxamine,RT-PCR,0.2,0.0042,35313655
VEGF,LTM,NA,12680,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen,SFA followed by qRT-PCR,0.28,0.0042,31693936
VEGF,LTM,NA,12680,Breast Cancer,Ductal Carcinoma,Primary,Tamoxifen+Fulvestrant,SFA followed by qRT-PCR,0.28,0.0042,31693936
VEGFA,LTM,NA,12680,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,29179185
VEGFA,LTM,NA,12680,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by qRT-PCR and Western Blotting,0.48,0.0032,29179185
VIM,LTM,NA,12692,Non Small Cell Lung Cancer,Carcinoma,A549,Irradiation,SFA and Western Blotting,0.28,0.0170,34163000
VIM,LTM,NA,12692,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,SFA followed by Western Blotting,0.28,0.0170,35267489
VIM,LTM,NA,12692,Non Small Cell Lung Cancer,Carcinoma,H460,Cisplatin,SFA followed by Western Blotting,0.28,0.0170,35267489
VIM,LTM,NA,12692,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting,0.28,0.0170,31604679
VIM,LTM,NA,12692,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by qRT-PCR,0.28,0.0170,33603536
VIM,LTM,NA,12692,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,Lapatinib,SFA followed by qRT-PCR,0.2,0.0170,34435487
VIM,LTM,NA,12692,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-468,NA,SFA followed by Western Blotting,0.28,0.0170,31604679
VIM,LTM,NA,12692,Gastric Cancer,Adenocarcinoma,MKN45,NA,SFA followed by qRT-PCR,0.2,0.0170,26862521
VTCN1,LTM,NA,28873,Non Small Cell Lung Cancer,Carcinoma,A549,NA,IF staining and Western Blotting followed by SFA,0.52,0.0021,35278461
VTCN1,LTM,NA,28873,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,IF staining and Western Blotting followed by SFA,0.52,0.0021,35278461
WASF3,LTM,NA,12734,Triple Negative Breast Cancer,Ductal Carcinoma,BT-549,NA,qRT-PCR followed by SFA and Migration assay,0.2,0.0011,29262622
WASF3,LTM,NA,12734,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,RT-PCR,0.2,0.0011,29262622
WNT1,LTM,NA,12774,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR and Western Blotting,0.48,0.0074,22615765
WNT1,LTM,NA,12774,Non Small Cell Lung Cancer,Carcinoma,A549,Cisplatin,Western Blotting,0.48,0.0074,31819528
WNT1,LTM,NA,12774,Non Small Cell Lung Cancer,Carcinoma,H1299,Cisplatin,Western Blotting,0.28,0.0074,31819528
WNT1,LTM,NA,12774,Colon Cancer,Carcinoma,HCT116,NA,FACs followed by SFA and RT-PCR,0.32,0.0074,19451087
WNT1,LTM,NA,12774,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA followed by Western Blotting,0.28,0.0074,30944638
WNT1,LTM,NA,12774,Luminal A Breast Cancer,Adenocarcinoma,MCF7,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.0074,31595560
WNT1,LTM,NA,12774,Luminal A Breast Cancer,Ductal Carcinoma,T47D,NA,SFA followed by Western Blotting and qRT-PCR,0.48,0.0074,31595560
WNT1,LTM,NA,12774,Breast Cancer,NA,Primary,Chemotherapy,SFA followed by Western Blotting,0.36,0.0074,28835684
WNT2,LTM,NA,12780,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by RT-PCR and Western Blotting,0.48,0.0032,22615765
WNT2,LTM,NA,12780,Colon Cancer,Adenocarcinoma,HT-29,NA,RT-PCR followed by SFA,0.2,0.0032,21130073
WNT7B,LTM,NA,12787,Pancreatic Cancer,Adenocarcinoma,Capan-2,NA,SFA followed by Western Blotting,0.28,0.0042,33934523
WNT7B,LTM,NA,12787,Pancreatic Cancer,Carcinoma,PANC-1,NA,SFA followed by Western Blotting,0.28,0.0042,33934523
WNT7B,LTM,NA,12787,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qRT-PCR,0.2,0.0042,31966561
WNT7B,LTM,NA,12787,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Cisplatin,SFA followed by qPCR,0.2,0.0042,31966561
XAGE5,LTM,NA,30930,Bladder Cancer,Carcinoma,EJ-28,NA,SFA followed by qRT-PCR,0.2,0.0011,32065779
XAGE5,LTM,NA,30930,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qRT-PCR,0.2,0.0011,32065779
XBP1,LTM,NA,12801,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by RT-PCR,0.2,0.0021,29601799
XIST,LTM,NA,12810,Bladder Cancer,Carcinoma,5637,NA,SFA followed by qPCR,0.2,0.0021,29559853
XIST,LTM,NA,12810,Bladder Cancer,Carcinoma,T24,NA,SFA followed by qPCR,0.2,0.0021,29559853
YAP1,LTM,NA,16262,Bladder Cancer,Carcinoma,5637,NA,Western Blotting,0.28,0.0117,30349299
YAP1,LTM,NA,16262,Bladder Cancer,Carcinoma,5637,NA,SFA followed by qRT-PCR,0.28,0.0117,30327565
YAP1,LTM,NA,16262,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by RT-PCR and Western Blotting,0.48,0.0117,30128013
YAP1,LTM,NA,16262,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SP assay followed by qRT-PCR,0.48,0.0117,27911857
YAP1,LTM,NA,16262,Bladder Cancer,Carcinoma,BFTC-905,NA,SFA followed by qRT-PCR,0.2,0.0117,30327565
YAP1,LTM,NA,16262,Bladder Cancer,Carcinoma,BFTC-909,NA,SFA followed by qRT-PCR,0.2,0.0117,30327565
YAP1,LTM,NA,16262,Colon Cancer,Adenocarcinoma,CACO-2,NA,SFA and CFA followed by FACs and Western Blotting,0.4,0.0117,29312609
YAP1,LTM,NA,16262,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SP assay followed by Western Blotting and qRT-PCR,0.48,0.0117,27911857
YAP1,LTM,NA,16262,Colon Cancer,Adenocarcinoma,HT-29,NA,SFA and CFA followed by FACs,0.12,0.0117,29312609
YAP1,LTM,NA,16262,Luminal A Breast Cancer,Adenocarcinoma,MCF7,Doxorubicin,Western Blotting,0.28,0.0117,29635751
YAP1,LTM,NA,16262,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0117,34146553
YAP1,LTM,NA,16262,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA followed by Western Blotting,0.28,0.0117,34445421
YAP1,LTM,NA,16262,Gastric Cancer,NA,Primary,NA,IHC staining,0.32,0.0117,31489619
YBX1,LTM,NA,8014,Non Small Cell Lung Cancer,Carcinoma,A549,NA,Western Blotting followed by Invasion assay and SFA,0.28,0.0021,28400280
YTHDF1,LTM,NA,15867,Glioblastoma,NA,DBTRG-05MG,NA,SFA and Western Blotting,0.28,0.0011,33317545
ZEB1,LTM,NA,11642,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qPCR,0.2,0.0074,33468994
ZEB1,LTM,NA,11642,Non Small Cell Lung Cancer,Adenocarcinoma,HCC827,Gefitinib,qRT-PCR,0.2,0.0074,33764690
ZEB1,LTM,NA,11642,Triple Negative Breast Cancer,Adenocarcinoma,MDA-MB-231,NA,SFA and SP assay followed by Western Blotting and Tumorigenicity assay,0.28,0.0074,28903350
ZEB1,LTM,NA,11642,Non Small Cell Lung Cancer,Adenocarcinoma,PC9,Gefitinib,qRT-PCR,0.2,0.0074,33764690
ZEB1,LTM,NA,11642,Head and Neck Cancer,NA,Primary,NA,SFA followed by FACs and SP assay,0.2,0.0074,22892238
ZEB2,LTM,NA,14881,Head and Neck Cancer,NA,Primary,NA,SFA followed by FACs and SP assay,0.2,0.0021,22892238
ZFP42,LTM,NA,30949,Glioblastoma,NA,DBTRG-05MG,NA,SFA and Western Blotting,0.28,0.0011,33317545
ZG16B,LTM,NA,30456,Pancreatic Cancer,Adenocarcinoma,Capan-1,NA,SFA followed by Western Blotting,0.28,0.0021,29100320
ZG16B,LTM,NA,30456,Pancreatic Cancer,Ductal Adenocarcinoma,CFPAC-1,NA,SFA followed by Western Blotting,0.28,0.0021,29100320
ZG16B,LTM,NA,30456,Pancreatic Cancer,Adenocarcinoma,HPAC,NA,SFA followed by Western Blotting,0.28,0.0021,29100320
ZIC2,LTM,NA,12873,Non Small Cell Lung Cancer,Adenocarcinoma,H1975,NA,qRT-PCR followed by SFA and Tumorigenicity assay,0.2,0.0011,32922547
ZNF32,LTM,NA,13095,Breast Cancer,Ductal Carcinoma,ZR-75-30,NA,FACs followed by SFA,0.12,0.0021,30478301
ZNF322,LTM,NA,23640,Non Small Cell Lung Cancer,Carcinoma,A549,NA,SFA followed by qRT-PCR,0.2,0.0011,30258097
ZNF322,LTM,NA,23640,Non Small Cell Lung Cancer,Carcinoma,H1299,NA,SFA followed by qRT-PCR,0.2,0.0011,30258097
ZNF322,LTM,NA,23640,Non Small Cell Lung Cancer,Carcinoma,H460,NA,SFA and qRT-PCR followed by Tumorigenicity assay,0.2,0.0011,30258097
